<SEC-DOCUMENT>0001564590-22-012325.txt : 20220330
<SEC-HEADER>0001564590-22-012325.hdr.sgml : 20220330
<ACCEPTANCE-DATETIME>20220330080924
ACCESSION NUMBER:		0001564590-22-012325
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		116
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220330
DATE AS OF CHANGE:		20220330

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Orchard Therapeutics plc
		CENTRAL INDEX KEY:			0001748907
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38722
		FILM NUMBER:		22783237

	BUSINESS ADDRESS:	
		STREET 1:		108 CANNON STREET
		CITY:			LONDON
		STATE:			X0
		ZIP:			EC4N 6EU
		BUSINESS PHONE:		011-44-0-203-3846700

	MAIL ADDRESS:	
		STREET 1:		108 CANNON STREET
		CITY:			LONDON
		STATE:			X0
		ZIP:			EC4N 6EU

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Orchard Rx Ltd
		DATE OF NAME CHANGE:	20180802
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>ortx-10k_20211231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml  version="1.0" encoding="utf-8"?>
<!-- DFIN ActiveDisclosure(SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-03-30T03:21:51.5007884+00:00 -->
<!-- Version            : 5.0.1.728 -->
<!-- Package ID         : 1b558024b59f49cabedb23f437fea13f -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ortx="http://www.orchard-tx.com/20211231" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta http-equiv="Content-Type" content="text/html" />
<title>
ortx-10k_20211231.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body><div style="display:none">
	<ix:header>
		<ix:hidden>
			<ix:nonNumeric id="F_000001" name="dei:AmendmentFlag" contextRef="C_0001748907_20210101_20211231">false</ix:nonNumeric>
			<ix:nonNumeric id="F_000004" name="dei:DocumentFiscalPeriodFocus" contextRef="C_0001748907_20210101_20211231">FY</ix:nonNumeric>
			<ix:nonNumeric id="F_000006" name="dei:CurrentFiscalYearEndDate" contextRef="C_0001748907_20210101_20211231">--12-31</ix:nonNumeric>
			<ix:nonNumeric id="F_000007" name="dei:EntityCentralIndexKey" contextRef="C_0001748907_20210101_20211231">0001748907</ix:nonNumeric>
			<ix:nonNumeric id="F_000027" name="dei:EntityTaxIdentificationNumber" contextRef="C_0001748907_20210101_20211231">00-0000000</ix:nonNumeric>
			<ix:nonNumeric id="F_000449" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" contextRef="C_0001748907_20211231">true</ix:nonNumeric>
			<ix:nonNumeric id="F_000658" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxGSKAgreementMember_20210101_20211231">true</ix:nonNumeric>
			<ix:nonNumeric id="F_000735" name="ortx:LineOfCreditFacilityAmortizationTerm" contextRef="C_0001748907_srtRangeAxis_srtMinimumMember_20210501_20210531">P18M</ix:nonNumeric>
			<ix:nonNumeric id="F_000736" name="ortx:LineOfCreditFacilityAmortizationTerm" contextRef="C_0001748907_srtRangeAxis_srtMaximumMember_20210501_20210531">P30M</ix:nonNumeric>
			<ix:nonNumeric id="F_000618" name="us-gaap:LeaseExpirationDate1" contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxOfficeSpaceMenloParkLeaseAgreementMember_20171101_20171130">2020-12-31</ix:nonNumeric>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000620" name="us-gaap:PaymentsForRent" contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxOfficeAndLaboratorySpaceMenloParkLeaseAgreementMember_20210101_20211231" xsi:nil="true"></ix:nonFraction>
			<ix:nonNumeric id="F_000623" name="us-gaap:LeaseExpirationDate1" contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxFiveYearsLeaseTermTerminatesInJanuaryTwoThousandTwentyThreeMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_ortxOfficeSpaceLondonUnitedKingdomLeaseAgreementMember_20180101_20180131">2023-01-31</ix:nonNumeric>
			<ix:nonNumeric id="F_000628" name="us-gaap:LeaseExpirationDate1" contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxLeaseTermTerminatesInSeptemberTwoThousandTwentyTwoMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_ortxOfficeSpaceBostonUnitedStatesLeaseAgreementMember_20180301_20180331">2022-09-30</ix:nonNumeric>
			<ix:nonNumeric id="F_000631" name="ortx:OperatingLeasesCommencedTerm" contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxLeaseTermTerminatesInSeptemberTwoThousandTwentySixMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_ortxOfficeSpaceBostonUnitedStatesLeaseAgreementMember_20190701_20190731">2020-01-31</ix:nonNumeric>
			<ix:nonNumeric id="F_000632" name="us-gaap:LeaseExpirationDate1" contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxLeaseTermTerminatesInSeptemberTwoThousandTwentySixMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_ortxOfficeSpaceBostonUnitedStatesLeaseAgreementMember_20190701_20190731">2026-09-30</ix:nonNumeric>
			<ix:nonNumeric id="F_000639" name="us-gaap:LeaseExpirationDate1" contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxFremontLeaseAgreementMember_20181201_20181231">2030-05-31</ix:nonNumeric>
			<ix:nonNumeric id="F_000710" name="us-gaap:LineOfCreditFacilityInitiationDate1" contextRef="C_0001748907_20190501_20190531">2019-05-31</ix:nonNumeric>
			<ix:nonNumeric id="F_000797" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="C_0001748907_20210101_20211231">P10Y</ix:nonNumeric>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000834" name="ortx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeEquityPlanProceedsReceivedAfterYearEnd" contextRef="C_0001748907_20211231" xsi:nil="true"></ix:nonFraction>
			<ix:nonNumeric id="F_000844" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_0001748907_us-gaapAwardTypeAxis_ortxTimeBasedRestrictedShareUnitsMember_20210101_20211231">P3Y</ix:nonNumeric>
			<ix:nonNumeric id="F_001050" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_0001748907_srtTitleOfIndividualAxis_ortxNonEmployeeAdvisorMember_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_ortxConsultingAgreementMember_20190101_20191231">P4Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000619" name="us-gaap:LeaseExpirationDate1" contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxLaboratorySpaceMenloParkLeaseAgreementMember_20190101_20190131">2020-12-31</ix:nonNumeric>
			<ix:nonNumeric id="F_000624" name="us-gaap:LeaseExpirationDate1" contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxFiveYearsLeaseTermTerminatesInJanuaryTwoThousandTwentyThreeMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_ortxOfficeSpaceLondonUnitedKingdomLeaseAgreementMember_20181201_20181231">2023-01-31</ix:nonNumeric>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000082" name="us-gaap:CommitmentsAndContingencies" contextRef="C_0001748907_20211231" xsi:nil="true"></ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000083" name="us-gaap:CommitmentsAndContingencies" contextRef="C_0001748907_20201231" xsi:nil="true"></ix:nonFraction>
			<ix:nonNumeric id="F_000111" name="us-gaap:TypeOfCostGoodOrServiceExtensibleList" contextRef="C_0001748907_20200101_20201231">http://fasb.org/us-gaap/2021-01-31#ProductMember</ix:nonNumeric>
			<ix:nonNumeric id="F_000409" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_0001748907_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_ortxLabEquipmentMember_20210101_20211231">P5Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000410" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_0001748907_srtRangeAxis_srtMaximumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_ortxLabEquipmentMember_20210101_20211231">P10Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000413" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_0001748907_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_ortxOfficeAndComputerEquipmentMember_20210101_20211231">P3Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000414" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_0001748907_srtRangeAxis_srtMaximumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_ortxOfficeAndComputerEquipmentMember_20210101_20211231">P5Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000677" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="C_0001748907_20211231">P6Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000678" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="C_0001748907_20201231">P6Y7M6D</ix:nonNumeric>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000798" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="C_0001748907_20210101_20211231" decimals="INF">0.005</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000799" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="C_0001748907_20200101_20201231" decimals="INF">0.003</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000806" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="C_0001748907_20210101_20211231" decimals="INF">0.742</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000807" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="C_0001748907_20200101_20201231" decimals="INF">0.707</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000800" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="C_0001748907_20210101_20211231" decimals="INF">0.013</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000801" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="C_0001748907_20200101_20201231" decimals="INF">0.017</ix:nonFraction>
			<ix:nonNumeric id="F_000802" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001748907_srtRangeAxis_srtMinimumMember_20210101_20211231">P5Y3M18D</ix:nonNumeric>
			<ix:nonNumeric id="F_000803" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001748907_srtRangeAxis_srtMinimumMember_20200101_20201231">P5Y6M</ix:nonNumeric>
			<ix:nonNumeric id="F_000804" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001748907_srtRangeAxis_srtMaximumMember_20210101_20211231">P6Y1M6D</ix:nonNumeric>
			<ix:nonNumeric id="F_000805" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001748907_srtRangeAxis_srtMaximumMember_20200101_20201231">P6Y1M6D</ix:nonNumeric>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000808" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="C_0001748907_20210101_20211231" decimals="INF">0.787</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000809" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="C_0001748907_20200101_20201231" decimals="INF">0.752</ix:nonFraction>
			<ix:nonNumeric id="F_000824" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_0001748907_20200101_20201231">P7Y1M28D</ix:nonNumeric>
			<ix:nonNumeric id="F_000825" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" contextRef="C_0001748907_20210101_20211231">P7Y9M29D</ix:nonNumeric>
			<ix:nonNumeric id="F_000826" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="C_0001748907_20210101_20211231">P6Y7M2D</ix:nonNumeric>
		</ix:hidden>
		<ix:references>
			<link:schemaRef xlink:type="simple" xlink:href="ortx-20211231.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef>
		</ix:references>
		<ix:resources>
			<xbrli:context id="C_0001748907_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_xbrlishares">
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001748907_20220315">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-03-15</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_iso4217USD">
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001748907_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_iso4217GBP_xbrlishares">
				<xbrli:divide>
					<xbrli:unitNumerator>
						<xbrli:measure>iso4217:GBP</xbrli:measure>
					</xbrli:unitNumerator>
					<xbrli:unitDenominator>
						<xbrli:measure>xbrli:shares</xbrli:measure>
					</xbrli:unitDenominator>
				</xbrli:divide>
			</xbrli:unit>
			<xbrli:unit id="U_iso4217GBP">
				<xbrli:measure>iso4217:GBP</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001748907_srtProductOrServiceAxis_us-gaapProductMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_srtProductOrServiceAxis_us-gaapProductMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_srtProductOrServiceAxis_ortxCollaborationMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ortx:CollaborationMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_iso4217USD_xbrlishares">
				<xbrli:divide>
					<xbrli:unitNumerator>
						<xbrli:measure>iso4217:USD</xbrli:measure>
					</xbrli:unitNumerator>
					<xbrli:unitDenominator>
						<xbrli:measure>xbrli:shares</xbrli:measure>
					</xbrli:unitDenominator>
				</xbrli:divide>
			</xbrli:unit>
			<xbrli:context id="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_us-gaapTypeOfArrangementAxis_ortxSecuritiesPurchaseAgreementMember_20210209_20210209">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-02-09</xbrli:startDate>
					<xbrli:endDate>2021-02-09</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_us-gaapTypeOfArrangementAxis_ortxSecuritiesPurchaseAgreementMember_20210209">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-02-09</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapStatementClassOfStockAxis_ortxNonVotingOrdinarySharesMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_us-gaapTypeOfArrangementAxis_ortxSecuritiesPurchaseAgreementMember_20210209_20210209">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ortx:NonVotingOrdinarySharesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-02-09</xbrli:startDate>
					<xbrli:endDate>2021-02-09</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapStatementClassOfStockAxis_ortxNonVotingOrdinarySharesMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_us-gaapTypeOfArrangementAxis_ortxSecuritiesPurchaseAgreementMember_20210209">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ortx:NonVotingOrdinarySharesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-02-09</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapTypeOfArrangementAxis_ortxSecuritiesPurchaseAgreementMember_20210209_20210209">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-02-09</xbrli:startDate>
					<xbrli:endDate>2021-02-09</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_srtStatementGeographicalAxis_countryGB_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_srtStatementGeographicalAxis_countryGB_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_srtStatementGeographicalAxis_countryUS_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_srtStatementGeographicalAxis_countryUS_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_srtStatementGeographicalAxis_ortxGBAndEuropeanUnionMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ortx:GBAndEuropeanUnionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_srtStatementGeographicalAxis_ortxGBAndEuropeanUnionMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ortx:GBAndEuropeanUnionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapLeaseContractualTermAxis_ortxFremontLeaseAgreementMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ortx:FremontLeaseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapLeaseContractualTermAxis_ortxFremontLeaseAgreementMember_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ortx:FremontLeaseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapLeaseContractualTermAxis_ortxFremontLeaseAgreementMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ortx:FremontLeaseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapBalanceSheetLocationAxis_us-gaapPrepaidExpensesAndOtherCurrentAssetsMember_us-gaapLeaseContractualTermAxis_ortxFremontLeaseAgreementMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ortx:FremontLeaseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_ortxLabEquipmentMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ortx:LabEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_srtRangeAxis_srtMaximumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_ortxLabEquipmentMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ortx:LabEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_ortxOfficeAndComputerEquipmentMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ortx:OfficeAndComputerEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_srtRangeAxis_srtMaximumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_ortxOfficeAndComputerEquipmentMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ortx:OfficeAndComputerEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_srtStatementGeographicalAxis_countryGB_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_srtStatementGeographicalAxis_countryGB_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_srtStatementGeographicalAxis_countryGB_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_srtStatementGeographicalAxis_countryGB_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_srtStatementGeographicalAxis_countryGB_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_xbrlipure">
				<xbrli:measure>xbrli:pure</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001748907_srtStatementGeographicalAxis_countryGB_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapAwardTypeAxis_ortxUnvestedSharesFromSharePlanAndConsultingAgreementMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ortx:UnvestedSharesFromSharePlanAndConsultingAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapAwardTypeAxis_ortxUnvestedSharesFromSharePlanAndConsultingAgreementMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ortx:UnvestedSharesFromSharePlanAndConsultingAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapCommercialPaperMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapCommercialPaperMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapUSTreasuryAndGovernmentMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapUSTreasuryAndGovernmentMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapCommercialPaperMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapCommercialPaperMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapPropertyPlantAndEquipmentByTypeAxis_ortxLabEquipmentMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ortx:LabEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapPropertyPlantAndEquipmentByTypeAxis_ortxLabEquipmentMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ortx:LabEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapPropertyPlantAndEquipmentByTypeAxis_ortxOfficeAndITEquipmentMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ortx:OfficeAndITEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapPropertyPlantAndEquipmentByTypeAxis_ortxOfficeAndITEquipmentMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ortx:OfficeAndITEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicenseMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicenseMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapRestructuringPlanAxis_ortxMenloParkCaliforniaMember_20200501_20200531">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ortx:MenloParkCaliforniaMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-05-01</xbrli:startDate>
					<xbrli:endDate>2020-05-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_20200401_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-04-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapRestructuringPlanAxis_ortxFremontCaliforniaMember_20200501_20200531">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ortx:FremontCaliforniaMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-05-01</xbrli:startDate>
					<xbrli:endDate>2020-05-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapRestructuringPlanAxis_ortxFremontCaliforniaMember_20200531">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ortx:FremontCaliforniaMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-05-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_srtRangeAxis_srtMinimumMember_us-gaapRestructuringPlanAxis_ortxFremontCaliforniaMember_20200531">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ortx:FremontCaliforniaMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-05-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_srtRangeAxis_srtMaximumMember_us-gaapRestructuringPlanAxis_ortxFremontCaliforniaMember_20200531">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ortx:FremontCaliforniaMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-05-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapRestructuringPlanAxis_ortxFremontCaliforniaMember_20201201_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ortx:FremontCaliforniaMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-12-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapLeaseContractualTermAxis_ortxOfficeSpaceMenloParkLeaseAgreementMember_20171101_20171130">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ortx:OfficeSpaceMenloParkLeaseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2017-11-01</xbrli:startDate>
					<xbrli:endDate>2017-11-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapLeaseContractualTermAxis_ortxLaboratorySpaceMenloParkLeaseAgreementMember_20190101_20190131">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ortx:LaboratorySpaceMenloParkLeaseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-01-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapLeaseContractualTermAxis_ortxOfficeAndLaboratorySpaceMenloParkLeaseAgreementMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ortx:OfficeAndLaboratorySpaceMenloParkLeaseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapLeaseContractualTermAxis_ortxOfficeAndLaboratorySpaceMenloParkLeaseAgreementMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ortx:OfficeAndLaboratorySpaceMenloParkLeaseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapLeaseContractualTermAxis_ortxFiveYearsLeaseTermTerminatesInJanuaryTwoThousandTwentyThreeMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_ortxOfficeSpaceLondonUnitedKingdomLeaseAgreementMember_20180101_20180131">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ortx:FiveYearsLeaseTermTerminatesInJanuaryTwoThousandTwentyThreeMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ortx:OfficeSpaceLondonUnitedKingdomLeaseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-01-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapLeaseContractualTermAxis_ortxFiveYearsLeaseTermTerminatesInJanuaryTwoThousandTwentyThreeMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_ortxOfficeSpaceLondonUnitedKingdomLeaseAgreementMember_20181201_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ortx:FiveYearsLeaseTermTerminatesInJanuaryTwoThousandTwentyThreeMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ortx:OfficeSpaceLondonUnitedKingdomLeaseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-12-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapLeaseContractualTermAxis_ortxFiveYearsLeaseTermTerminatesInJanuaryTwoThousandTwentyThreeMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_ortxOfficeSpaceLondonUnitedKingdomLeaseAgreementMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ortx:FiveYearsLeaseTermTerminatesInJanuaryTwoThousandTwentyThreeMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ortx:OfficeSpaceLondonUnitedKingdomLeaseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapLeaseContractualTermAxis_ortxFiveYearsLeaseTermTerminatesInJanuaryTwoThousandTwentyThreeMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_ortxOfficeSpaceLondonUnitedKingdomLeaseAgreementMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ortx:FiveYearsLeaseTermTerminatesInJanuaryTwoThousandTwentyThreeMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ortx:OfficeSpaceLondonUnitedKingdomLeaseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapPropertyPlantAndEquipmentByTypeAxis_ortxRentalLabSpaceMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ortx:RentalLabSpaceMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapLeaseContractualTermAxis_ortxLeaseTermTerminatesInSeptemberTwoThousandTwentyTwoMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_ortxOfficeSpaceBostonUnitedStatesLeaseAgreementMember_20180301_20180331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ortx:OfficeSpaceBostonUnitedStatesLeaseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ortx:LeaseTermTerminatesInSeptemberTwoThousandTwentyTwoMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-03-01</xbrli:startDate>
					<xbrli:endDate>2018-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapLeaseContractualTermAxis_ortxLeaseTermTerminatesInSeptemberTwoThousandTwentyTwoMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_ortxOfficeSpaceBostonUnitedStatesLeaseAgreementMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ortx:OfficeSpaceBostonUnitedStatesLeaseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ortx:LeaseTermTerminatesInSeptemberTwoThousandTwentyTwoMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapLeaseContractualTermAxis_ortxLeaseTermTerminatesInSeptemberTwoThousandTwentyTwoMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_ortxOfficeSpaceBostonUnitedStatesLeaseAgreementMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ortx:OfficeSpaceBostonUnitedStatesLeaseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ortx:LeaseTermTerminatesInSeptemberTwoThousandTwentyTwoMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapLeaseContractualTermAxis_ortxLeaseTermTerminatesInSeptemberTwoThousandTwentySixMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_ortxOfficeSpaceBostonUnitedStatesLeaseAgreementMember_20190701_20190731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ortx:LeaseTermTerminatesInSeptemberTwoThousandTwentySixMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ortx:OfficeSpaceBostonUnitedStatesLeaseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-07-01</xbrli:startDate>
					<xbrli:endDate>2019-07-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapLeaseContractualTermAxis_ortxLeaseTermTerminatesInSeptemberTwoThousandTwentySixMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_ortxOfficeSpaceBostonUnitedStatesLeaseAgreementMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ortx:LeaseTermTerminatesInSeptemberTwoThousandTwentySixMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ortx:OfficeSpaceBostonUnitedStatesLeaseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapLeaseContractualTermAxis_ortxLeaseTermTerminatesInSeptemberTwoThousandTwentySixMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_ortxOfficeSpaceBostonUnitedStatesLeaseAgreementMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ortx:LeaseTermTerminatesInSeptemberTwoThousandTwentySixMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ortx:OfficeSpaceBostonUnitedStatesLeaseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapLeaseContractualTermAxis_ortxBostonAndLondonOfficeSpaceLeaseAgreementsMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ortx:BostonAndLondonOfficeSpaceLeaseAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapLeaseContractualTermAxis_ortxBostonAndLondonOfficeSpaceLeaseAgreementsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ortx:BostonAndLondonOfficeSpaceLeaseAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapLeaseContractualTermAxis_ortxFremontLeaseAgreementMember_20181201_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ortx:FremontLeaseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-12-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapLeaseContractualTermAxis_ortxFremontLeaseAgreementMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ortx:FremontLeaseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_srtRangeAxis_srtMaximumMember_us-gaapLeaseContractualTermAxis_ortxFremontLeaseAgreementMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ortx:FremontLeaseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapLeaseContractualTermAxis_ortxFremontSubleaseAgreementMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ortx:FremontSubleaseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_srtRangeAxis_srtMaximumMember_us-gaapLeaseContractualTermAxis_ortxFremontSubleaseAgreementMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ortx:FremontSubleaseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapBalanceSheetLocationAxis_us-gaapOtherNoncurrentLiabilitiesMember_us-gaapLeaseContractualTermAxis_ortxFremontSubleaseAgreementMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ortx:FremontSubleaseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapLeaseContractualTermAxis_ortxFremontLeaseAgreementMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ortx:FremontLeaseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapLeaseContractualTermAxis_ortxGSKAgreementMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ortx:GSKAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapLeaseContractualTermAxis_ortxGSKAgreementMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ortx:GSKAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_iso4217EUR">
				<xbrli:measure>iso4217:EUR</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001748907_us-gaapLeaseContractualTermAxis_ortxGSKAgreementMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ortx:GSKAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapLeaseContractualTermAxis_ortxGSKAgreementMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ortx:GSKAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_srtCurrencyAxis_currencyGBP_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_srtCurrencyAxis_currencyEUR_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_20190501_20190531">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-05-01</xbrli:startDate>
					<xbrli:endDate>2019-05-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_20190531">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-05-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_20210531">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-05-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapDebtInstrumentAxis_ortxTheFirstTrancheTermLoanMember_20210531">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ortx:TheFirstTrancheTermLoanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-05-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapDebtInstrumentAxis_ortxTheFirstTrancheTermLoanMember_20190531">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ortx:TheFirstTrancheTermLoanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-05-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapDebtInstrumentAxis_ortxTheFirstTrancheTermLoanMember_20210501_20210531">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ortx:TheFirstTrancheTermLoanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-05-01</xbrli:startDate>
					<xbrli:endDate>2021-05-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapDebtInstrumentAxis_ortxTheSecondTrancheTermLoanMember_20210531">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ortx:TheSecondTrancheTermLoanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-05-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapDebtInstrumentAxis_ortxTheThirdTrancheTermLoanMember_20210531">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ortx:TheThirdTrancheTermLoanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-05-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_srtRangeAxis_srtMinimumMember_us-gaapDebtInstrumentAxis_ortxTheSecondTrancheTermLoanMember_20210531">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ortx:TheSecondTrancheTermLoanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-05-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_srtRangeAxis_srtMinimumMember_us-gaapDebtInstrumentAxis_ortxTheThirdTrancheTermLoanMember_20210531">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ortx:TheThirdTrancheTermLoanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-05-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapDebtInstrumentAxis_ortxTheSecondTrancheTermLoanMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ortx:TheSecondTrancheTermLoanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapDebtInstrumentAxis_ortxTheThirdTrancheTermLoanMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ortx:TheThirdTrancheTermLoanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapVariableRateAxis_ortxLondonInterbankOfferedRateFloorMember_20190501_20190531">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">ortx:LondonInterbankOfferedRateFloorMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-05-01</xbrli:startDate>
					<xbrli:endDate>2019-05-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapVariableRateAxis_ortxLondonInterbankOfferedRateFloorMember_20210501_20210531">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">ortx:LondonInterbankOfferedRateFloorMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-05-01</xbrli:startDate>
					<xbrli:endDate>2021-05-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_20210501_20210531">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-05-01</xbrli:startDate>
					<xbrli:endDate>2021-05-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapDebtInstrumentAxis_ortxTheSecondTrancheTermLoanMember_20210501_20210531">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ortx:TheSecondTrancheTermLoanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-05-01</xbrli:startDate>
					<xbrli:endDate>2021-05-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapDebtInstrumentAxis_ortxTheThirdTrancheTermLoanMember_20210501_20210531">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ortx:TheThirdTrancheTermLoanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-05-01</xbrli:startDate>
					<xbrli:endDate>2021-05-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_srtRangeAxis_srtMinimumMember_20210501_20210531">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-05-01</xbrli:startDate>
					<xbrli:endDate>2021-05-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_srtRangeAxis_srtMaximumMember_20210501_20210531">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-05-01</xbrli:startDate>
					<xbrli:endDate>2021-05-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_srtRangeAxis_srtMinimumMember_us-gaapDebtInstrumentRedemptionPeriodAxis_us-gaapDebtInstrumentRedemptionPeriodTwoMember_20210531">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-05-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_srtRangeAxis_srtMinimumMember_us-gaapDebtInstrumentRedemptionPeriodAxis_us-gaapDebtInstrumentRedemptionPeriodThreeMember_20210531">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-05-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapLongtermDebtTypeAxis_ortxTermLoanMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ortx:TermLoanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapLongtermDebtTypeAxis_ortxTermLoanMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ortx:TermLoanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_ortxVotingRight">
				<xbrli:measure>ortx:VotingRight</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001748907_srtRangeAxis_srtMaximumMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_srtRangeAxis_srtMaximumMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapTypeOfArrangementAxis_ortxOxfordBioMedicaLicenseDevelopmentAndSupplyAgreementMember_20200430">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:OxfordBioMedicaLicenseDevelopmentAndSupplyAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-04-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_srtTitleOfIndividualAxis_ortxNonEmployeeAdvisorMember_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_ortxConsultingAgreementMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ortx:NonEmployeeAdvisorMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ortx:ConsultingAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_srtTitleOfIndividualAxis_ortxNonEmployeeAdvisorMember_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_ortxConsultingAgreementMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ortx:NonEmployeeAdvisorMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ortx:ConsultingAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_us-gaapTypeOfArrangementAxis_ortxSecuritiesPurchaseAgreementMember_20210201_20210228">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-02-01</xbrli:startDate>
					<xbrli:endDate>2021-02-28</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_us-gaapTypeOfArrangementAxis_ortxSecuritiesPurchaseAgreementMember_20210228">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-02-28</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapStatementClassOfStockAxis_ortxNonVotingOrdinarySharesMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_us-gaapTypeOfArrangementAxis_ortxSecuritiesPurchaseAgreementMember_20210201_20210228">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ortx:NonVotingOrdinarySharesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-02-01</xbrli:startDate>
					<xbrli:endDate>2021-02-28</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapStatementClassOfStockAxis_ortxNonVotingOrdinarySharesMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_us-gaapTypeOfArrangementAxis_ortxSecuritiesPurchaseAgreementMember_20210228">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ortx:NonVotingOrdinarySharesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-02-28</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapTypeOfArrangementAxis_ortxSecuritiesPurchaseAgreementMember_20210201_20210228">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-02-01</xbrli:startDate>
					<xbrli:endDate>2021-02-28</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapTypeOfArrangementAxis_ortxSharePurchaseAgreementWithPharmingMember_20210701_20210731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:SharePurchaseAgreementWithPharmingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-07-01</xbrli:startDate>
					<xbrli:endDate>2021-07-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapPlanNameAxis_ortxTwoThousandAndEighteenShareOptionAndIncentivePlanMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ortx:TwoThousandAndEighteenShareOptionAndIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapPlanNameAxis_ortxTwoThousandAndEighteenEmployeeSharePurchasePlanMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ortx:TwoThousandAndEighteenEmployeeSharePurchasePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapPlanNameAxis_ortxTwoThousandAndTwentyInducementEquityPlanMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ortx:TwoThousandAndTwentyInducementEquityPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_srtRangeAxis_srtMinimumMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_srtRangeAxis_srtMinimumMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_srtRangeAxis_srtMaximumMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_srtRangeAxis_srtMaximumMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapAwardTypeAxis_us-gaapPerformanceSharesMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapAwardTypeAxis_us-gaapPerformanceSharesMember_us-gaapTypeOfArrangementAxis_ortxLibmeldyMember_20201001_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:LibmeldyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-10-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_srtTitleOfIndividualAxis_srtChiefExecutiveOfficerMember_us-gaapAwardTypeAxis_us-gaapPerformanceSharesMember_20200401_20200430">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-04-01</xbrli:startDate>
					<xbrli:endDate>2020-04-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_srtTitleOfIndividualAxis_srtChiefExecutiveOfficerMember_us-gaapAwardTypeAxis_us-gaapPerformanceSharesMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheOneMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapAwardTypeAxis_ortxTimeBasedRestrictedShareUnitsMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ortx:TimeBasedRestrictedShareUnitsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapAwardTypeAxis_us-gaapPerformanceSharesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapAwardTypeAxis_ortxTimeBasedRestrictedShareUnitsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ortx:TimeBasedRestrictedShareUnitsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapAwardTypeAxis_us-gaapPerformanceSharesMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapAwardTypeAxis_ortxTimeBasedRestrictedShareUnitsMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ortx:TimeBasedRestrictedShareUnitsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_ortxProgram">
				<xbrli:measure>ortx:Program</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001748907_us-gaapTypeOfArrangementAxis_ortxGSKAssetPurchaseAndLicenseAgreementMember_20180401_20180430">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:GSKAssetPurchaseAndLicenseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-04-01</xbrli:startDate>
					<xbrli:endDate>2018-04-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_us-gaapTypeOfArrangementAxis_ortxGSKAssetPurchaseAndLicenseAgreementMember_20180401_20180430">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:GSKAssetPurchaseAndLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-04-01</xbrli:startDate>
					<xbrli:endDate>2018-04-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_us-gaapTypeOfArrangementAxis_ortxGSKAssetPurchaseAndLicenseAgreementMember_20180430">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:GSKAssetPurchaseAndLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-04-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapTypeOfArrangementAxis_ortxGSKAssetPurchaseAndLicenseAgreementMember_20180430">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:GSKAssetPurchaseAndLicenseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-04-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapTypeOfArrangementAxis_ortxGSKAssetPurchaseAndLicenseAgreementMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:GSKAssetPurchaseAndLicenseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapTypeOfArrangementAxis_ortxGSKAssetPurchaseAndLicenseAgreementMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:GSKAssetPurchaseAndLicenseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapTypeOfArrangementAxis_ortxTelethonOSRLicenseAgreementsMember_20190501_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:TelethonOSRLicenseAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-05-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapTypeOfArrangementAxis_ortxTelethonOSRLicenseAgreementsMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:TelethonOSRLicenseAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapTypeOfArrangementAxis_ortxUCLBAndUCLATechnologyMember_20160101_20161231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:UCLBAndUCLATechnologyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2016-01-01</xbrli:startDate>
					<xbrli:endDate>2016-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapTypeOfArrangementAxis_ortxUCLBTechnologyAndManufacturingTechnologyMember_20160101_20161231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:UCLBTechnologyAndManufacturingTechnologyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2016-01-01</xbrli:startDate>
					<xbrli:endDate>2016-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapTypeOfArrangementAxis_ortxUCLBLicenseAgreementMember_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:UCLBLicenseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapTypeOfArrangementAxis_ortxUCLBLicenseAgreementMember_20171231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:UCLBLicenseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2017-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapTypeOfArrangementAxis_ortxUCLBLicenseAgreementMember_20161231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:UCLBLicenseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2016-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapTypeOfArrangementAxis_ortxUCLBAndUCLALicenseAgreementMember_20170101_20171231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:UCLBAndUCLALicenseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2017-01-01</xbrli:startDate>
					<xbrli:endDate>2017-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapTypeOfArrangementAxis_ortxUCLBAndUCLALicenseAgreementMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:UCLBAndUCLALicenseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapTypeOfArrangementAxis_ortxUCLBAndUCLALicenseAgreementMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:UCLBAndUCLALicenseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapTypeOfArrangementAxis_ortxOxfordBioMedicaLicenseDevelopmentAndSupplyAgreementMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:OxfordBioMedicaLicenseDevelopmentAndSupplyAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapTypeOfArrangementAxis_ortxOxfordBioMedicaLicenseDevelopmentAndSupplyAgreementMember_20181130">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:OxfordBioMedicaLicenseDevelopmentAndSupplyAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-11-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapTypeOfArrangementAxis_ortxOxfordBioMedicaLicenseDevelopmentAndSupplyAgreementMember_20180930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:OxfordBioMedicaLicenseDevelopmentAndSupplyAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapTypeOfArrangementAxis_ortxOxfordBioMedicaLicenseDevelopmentAndSupplyAgreementMember_20200430_20200430">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:OxfordBioMedicaLicenseDevelopmentAndSupplyAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-04-30</xbrli:startDate>
					<xbrli:endDate>2020-04-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_ortxMilestone">
				<xbrli:measure>ortx:Milestone</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001748907_us-gaapTypeOfArrangementAxis_ortxOxfordBioMedicaLicenseDevelopmentAndSupplyAgreementMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:OxfordBioMedicaLicenseDevelopmentAndSupplyAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapTypeOfArrangementAxis_ortxStrategicCollaborationAgreementWithPharmingMember_20210701_20210701">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:StrategicCollaborationAgreementWithPharmingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-07-01</xbrli:startDate>
					<xbrli:endDate>2021-07-01</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_ortxStrategicCollaborationAgreementWithPharmingMember_20210701">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:StrategicCollaborationAgreementWithPharmingMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-07-01</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapTypeOfArrangementAxis_ortxSharePurchaseAgreementWithPharmingMember_20210701_20210701">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:SharePurchaseAgreementWithPharmingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-07-01</xbrli:startDate>
					<xbrli:endDate>2021-07-01</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapTypeOfArrangementAxis_ortxPharmingAgreementsMember_20210701_20210701">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:PharmingAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-07-01</xbrli:startDate>
					<xbrli:endDate>2021-07-01</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_srtProductOrServiceAxis_ortxReimbursementRevenueMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ortx:ReimbursementRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_srtProductOrServiceAxis_ortxUpfrontAndMilestonePaymentRevenueMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ortx:UpfrontAndMilestonePaymentRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapBalanceSheetLocationAxis_us-gaapAccountsReceivableMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapBalanceSheetLocationAxis_us-gaapAccountsReceivableMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_srtStatementGeographicalAxis_countryUS_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_ortxOrphanDrugTaxCreditMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">ortx:OrphanDrugTaxCreditMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_srtStatementGeographicalAxis_countryUS_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_ortxOrphanDrugTaxCreditMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">ortx:OrphanDrugTaxCreditMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_srtStatementGeographicalAxis_countryUS_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_srtStatementGeographicalAxis_countryUS_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_srtStatementGeographicalAxis_countryUS_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapTaxPeriodAxis_us-gaapEarliestTaxYearMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:EarliestTaxYearMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapTaxPeriodAxis_us-gaapLatestTaxYearMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:LatestTaxYearMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapSupplyCommitmentAxis_ortxProductManufacturingCommitmentsMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">ortx:ProductManufacturingCommitmentsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapSupplyCommitmentAxis_ortxDedicatedManufacturingAndDevelopmentResourcesMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">ortx:DedicatedManufacturingAndDevelopmentResourcesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapSupplyCommitmentAxis_ortxExclusiveTransductionSuitesMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">ortx:ExclusiveTransductionSuitesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapTypeOfArrangementAxis_ortxManufacturingAndTechnologyDevelopmentMasterAgreementMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:ManufacturingAndTechnologyDevelopmentMasterAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_srtTitleOfIndividualAxis_ortxNonEmployeeAdvisorMember_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_ortxConsultingAgreementMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ortx:ConsultingAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ortx:NonEmployeeAdvisorMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_srtTitleOfIndividualAxis_ortxNonEmployeeAdvisorMember_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_ortxConsultingAgreementMember_us-gaapTypeOfArrangementAxis_ortxClinicalDevelopmentAndRegulatoryMilestoneMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ortx:ConsultingAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ortx:NonEmployeeAdvisorMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:ClinicalDevelopmentAndRegulatoryMilestoneMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_srtTitleOfIndividualAxis_ortxNonEmployeeAdvisorMember_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_ortxConsultingAgreementMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ortx:ConsultingAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ortx:NonEmployeeAdvisorMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_srtTitleOfIndividualAxis_ortxNonEmployeeAdvisorMember_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_ortxConsultingAgreementMember_us-gaapTypeOfArrangementAxis_ortxClinicalDevelopmentAndRegulatoryMilestoneMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ortx:ConsultingAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ortx:NonEmployeeAdvisorMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:ClinicalDevelopmentAndRegulatoryMilestoneMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_srtTitleOfIndividualAxis_ortxNonEmployeeAdvisorMember_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_ortxConsultingAgreementMember_us-gaapTypeOfArrangementAxis_ortxClinicalDevelopmentAndRegulatoryMilestoneMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ortx:ConsultingAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ortx:NonEmployeeAdvisorMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:ClinicalDevelopmentAndRegulatoryMilestoneMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_srtTitleOfIndividualAxis_ortxNonEmployeeAdvisorMember_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_ortxConsultingAgreementMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ortx:ConsultingAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ortx:NonEmployeeAdvisorMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_srtTitleOfIndividualAxis_ortxNonEmployeeAdvisorMember_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_ortxConsultingAgreementMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ortx:ConsultingAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ortx:NonEmployeeAdvisorMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ortxGSKMember_20180401_20180430">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ortx:GSKMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-04-01</xbrli:startDate>
					<xbrli:endDate>2018-04-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ortxGSKMember_20180430">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ortx:GSKMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-04-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ortxGSKMember_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20180430">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ortx:GSKMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-04-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ortxGSKMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ortx:GSKMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ortxGSKMember_us-gaapTypeOfArrangementAxis_ortxGSKAssetPurchaseAndLicenseAgreementMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ortx:GSKMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:GSKAssetPurchaseAndLicenseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ortxGSKMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ortx:GSKMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_srtStatementGeographicalAxis_countryGB_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220330_20220330">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-03-30</xbrli:startDate>
					<xbrli:endDate>2022-03-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001748907_srtStatementGeographicalAxis_countryGB_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220330">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001748907</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-03-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
		</ix:resources>
	</ix:header>
</div>

<p style="text-align:center;border-top:Double 2.25pt;padding-top:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;border-top:Double 2.25pt;padding-top:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Washington, D.C. 20549 </p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:42.86%;margin-right:42.86%;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM <ix:nonNumeric id="F_000000" name="dei:DocumentType" contextRef="C_0001748907_20210101_20211231">10-K</ix:nonNumeric><span style="font-weight:normal;"> </span></p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:42.86%;margin-right:42.86%;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> (Mark&#160;One) </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Segoe UI Symbol;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000023" name="dei:DocumentAnnualReport" contextRef="C_0001748907_20210101_20211231" format="ixt-sec:boolballotbox">
&#9746;</ix:nonNumeric></p></td>
<td valign="top" style="width:95.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934 </p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">For the fiscal year ended <ix:nonNumeric id="F_000002" name="dei:DocumentPeriodEndDate" contextRef="C_0001748907_20210101_20211231" format="ixt:datemonthdayyearen">December 31, <ix:nonNumeric id="F_000003" name="dei:DocumentFiscalYearFocus" contextRef="C_0001748907_20210101_20211231">2021</ix:nonNumeric></ix:nonNumeric></p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">OR </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Segoe UI Symbol;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000024" name="dei:DocumentTransitionReport" contextRef="C_0001748907_20210101_20211231" format="ixt-sec:boolballotbox">
&#9744;</ix:nonNumeric></p></td>
<td valign="top" style="width:95.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934 FOR THE TRANSITION PERIOD FROM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; TO &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Commission File Number&#160;<span style="Background-color:#FFFFFF;color:#000000;"><ix:nonNumeric id="F_000025" name="dei:EntityFileNumber" contextRef="C_0001748907_20210101_20211231">001-38722</ix:nonNumeric></span></p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:42.86%;margin-right:42.86%;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:24pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;"><ix:nonNumeric id="F_000005" name="dei:EntityRegistrantName" contextRef="C_0001748907_20210101_20211231">ORCHARD THERAPEUTICS PLC</ix:nonNumeric></span><span style="color:#000000;"> </span></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of Registrant as specified in its Charter) </p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:42.86%;margin-right:42.86%;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:49.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000017" name="dei:EntityIncorporationStateCountryCode" contextRef="C_0001748907_20210101_20211231" format="ixt-sec:edgarprovcountryen">England and Wales</ix:nonNumeric></p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:49.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Not Applicable</p></td>
</tr>
<tr>
<td valign="bottom" style="width:49.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or other jurisdiction of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">incorporation or organization)</p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:49.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(I.R.S. Employer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identification No.)</p></td>
</tr>
</table></div>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000018" name="dei:EntityAddressAddressLine1" contextRef="C_0001748907_20210101_20211231">108 Cannon Street</ix:nonNumeric></p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000019" name="dei:EntityAddressCityOrTown" contextRef="C_0001748907_20210101_20211231">London</ix:nonNumeric> <ix:nonNumeric id="F_000020" name="dei:EntityAddressPostalZipCode" contextRef="C_0001748907_20210101_20211231">EC4N 6EU</ix:nonNumeric></p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000028" name="dei:EntityAddressCountry" contextRef="C_0001748907_20210101_20211231" format="ixt-sec:countrynameen">United Kingdom</ix:nonNumeric></p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of principal executive offices)</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Registrant&#8217;s telephone number, including area code:<span style="color:#000000;font-size:8pt;"> </span><span style="color:#000000;">+<ix:nonNumeric id="F_000021" name="dei:CityAreaCode" contextRef="C_0001748907_20210101_20211231">44</ix:nonNumeric> <ix:nonNumeric id="F_000022" name="dei:LocalPhoneNumber" contextRef="C_0001748907_20210101_20211231">(0) 203 808-8286</ix:nonNumeric></span></p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:42.86%;margin-right:42.86%;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section&#160;12(b) of the Act:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:39%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title of each class</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:20%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Trading Symbol(s)</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:39%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name of each exchange on which registered</p></td>
</tr>
<tr>
<td valign="middle" style="width:39%; border-top:solid 0.75pt #000000;"><ix:nonNumeric id="F_000031" name="dei:Security12bTitle" contextRef="C_0001748907_20210101_20211231"><p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">American Depositary Shares, </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">each representing one ordinary share, nominal value &#163;0.10 per share</p></ix:nonNumeric></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;">&#160;</p></td>
<td valign="bottom" style="width:20%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000032" name="dei:TradingSymbol" contextRef="C_0001748907_20210101_20211231">ORTX</ix:nonNumeric></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;">&#160;</p></td>
<td valign="bottom" style="width:39%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000033" name="dei:SecurityExchangeName" contextRef="C_0001748907_20210101_20211231" format="ixt-sec:exchnameen">The Nasdaq Global Select Market</ix:nonNumeric></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:3pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section&#160;12(g) of the Act: <span style="font-weight:normal;">None</span></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.&#160;<span style="text-transform:uppercase;">Yes</span>&#160;<span style="font-family:Segoe UI Symbol;">&#9744; </span><span style="text-transform:uppercase;"><ix:nonNumeric id="F_000009" name="dei:EntityWellKnownSeasonedIssuer" contextRef="C_0001748907_20210101_20211231">No</ix:nonNumeric></span>&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the Registrant is not required to file reports pursuant to Section&#160;13 or 15(d) of the Act. &#160;<span style="text-transform:uppercase;">Yes</span>&#160;<span style="font-family:Segoe UI Symbol;">&#9744; </span><span style="text-transform:uppercase;"><ix:nonNumeric id="F_000014" name="dei:EntityVoluntaryFilers" contextRef="C_0001748907_20210101_20211231">No</ix:nonNumeric></span>&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the Registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the Registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. &#160;<span style="text-transform:uppercase;"><ix:nonNumeric id="F_000015" name="dei:EntityCurrentReportingStatus" contextRef="C_0001748907_20210101_20211231">Yes</ix:nonNumeric></span>&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span> <span style="text-transform:uppercase;">No</span>&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the Registrant was required to submit such files). &#160;<span style="text-transform:uppercase;"><ix:nonNumeric id="F_000016" name="dei:EntityInteractiveDataCurrent" contextRef="C_0001748907_20210101_20211231">Yes</ix:nonNumeric></span>&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span> <span style="text-transform:uppercase;">No</span>&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr style="height:10.8pt;">
<td valign="top" style="width:18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Large&#160;accelerated&#160;filer</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:55%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:20%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accelerated&#160;filer</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
</tr>
<tr style="height:1.9pt;">
<td valign="top" style="width:18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:21%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000008" name="dei:EntityFilerCategory" contextRef="C_0001748907_20210101_20211231" format="ixt-sec:entityfilercategoryen">Non-accelerated filer</ix:nonNumeric></p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:55%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:20%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Smaller&#160;reporting&#160;company</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000010" name="dei:EntitySmallBusiness" contextRef="C_0001748907_20210101_20211231" format="ixt-sec:boolballotbox">
&#9746;</ix:nonNumeric></p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr style="height:1.9pt;">
<td valign="top" style="width:18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="width:55%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="width:20%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:55%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000026" name="dei:EntityEmergingGrowthCompany" contextRef="C_0001748907_20210101_20211231" format="ixt-sec:boolballotbox">
&#9744;</ix:nonNumeric></p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:20%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the Registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.&#160;&#160;<span style="font-family:Segoe UI Symbol;"><ix:nonNumeric id="F_000029" name="dei:IcfrAuditorAttestationFlag" contextRef="C_0001748907_20210101_20211231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the Registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). &#160;<span style="text-transform:uppercase;">Yes</span>&#160;<span style="font-family:Segoe UI Symbol;"><ix:nonNumeric id="F_000013" name="dei:EntityShellCompany" contextRef="C_0001748907_20210101_20211231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span> <span style="text-transform:uppercase;">No</span>&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of the last business day of the Registrant&#8217;s most recently completed second fiscal quarter, the aggregate market value of the Registrant&#8217;s ordinary shares, nominal value &#163;0.10 per share, held by non-affiliates was approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000012" name="dei:EntityPublicFloat" contextRef="C_0001748907_20210630" decimals="-6" scale="6">544</ix:nonFraction> million. </p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 15, 2022, the Registrant had <ix:nonFraction unitRef="U_xbrlishares" id="F_000011" name="dei:EntityCommonStockSharesOutstanding" contextRef="C_0001748907_20220315" decimals="INF" format="ixt:numdotdecimal">125,834,611</ix:nonFraction> ordinary shares, nominal value &#163;0.10 per share, outstanding.&#160;&#160;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">DOCUMENTS INCORPORATED BY REFERENCE</p><ix:nonNumeric id="F_000293" name="dei:DocumentsIncorporatedByReferenceTextBlock" contextRef="C_0001748907_20210101_20211231" escape="true" continuedAt="F_000293_dcnt_fa6086ad-6207-4f1a-a45b-36ffb658c963">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Portions of the Registrant&#8217;s definitive proxy statement for its 2022 Annual General Meeting are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated.</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<p style="border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&#160;</p></ix:nonNumeric>
<hr style="page-break-after:always" /><ix:continuation id="F_000293_dcnt_fa6086ad-6207-4f1a-a45b-36ffb658c963">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Summary of the Material Risks Associated with Our Business<span style="font-style:italic;"> </span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business is subject to numerous risks and uncertainties that you should be aware of in evaluating our business. These risks include, but are not limited to, the following:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">We have incurred net losses since inception. We expect to incur net losses for the foreseeable future and may never achieve or maintain profitability.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#212529;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">We will need additional funding, which may not be available on acceptable terms or at all. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate our product development efforts or other operations.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.14%;text-indent:0%;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">Our gene therapy product candidates are based on a novel technology, which makes it difficult to predict the time and cost of product candidate development and of subsequently obtaining regulatory approval.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#212529;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">The results from our clinical trials for OTL-200 for metachromatic leukodystrophy, or MLD, and for any of our other product candidates may not be sufficiently robust to support marketing approval or the submission of marketing approval. Before we submit our product candidates for marketing approval, the U.S. Food and Drug Administration or the European Medicines Agency may require us to conduct additional clinical trials or evaluate patients for an additional follow-up period.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#212529;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">Interim data and ad hoc analyses are preliminary in nature.&#160;Success in preclinical studies or early clinical trials may not be indicative of results obtained in later trials.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#212529;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">Gene therapies are novel, complex and difficult to manufacture. We have limited manufacturing experience, and we rely on third-party manufacturers that are often our single source of supply. We could experience manufacturing problems that result in delays in the development or commercialization of our commercial products or our product candidates or otherwise harm our business.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#212529;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Libmeldy<sup style="font-size:85%;line-height:120%;vertical-align:top">&#8482;</sup>, Strimvelis<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> and our product candidates and the process for administering Libmeldy, Strimvelis and our product candidates may cause serious or undesirable side effects or adverse events or have other properties that could delay or prevent regulatory approval, limit commercial potential or result in significant negative consequences for our company. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">We may find it difficult to enroll patients in our clinical trials, which could delay or prevent us from proceeding with clinical trials of our product candidates.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">If we are unable to establish effective sales and marketing capabilities or enter into agreements with third parties to market, sell and gain reimbursement for Libmeldy and our product candidates that may be approved, we may be unable to generate product revenue.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#212529;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">If the size and value of the market opportunities for our commercial products or product candidates are smaller than our estimates, or if we have difficulty in finding patients that meet eligibility requirements for Libmeldy or any of our product candidates, if approved, our product revenues may be adversely affected and our business may suffer. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#212529;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">We face significant competition in our industry and there can be no assurance that our commercial products or our product candidates, if approved, will achieve acceptance in the market over existing established therapies. In addition, our competitors may develop therapies that are more advanced or effective than ours, which may adversely affect our ability to successfully market or commercialize any of our products or product candidates.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#212529;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">Business interruptions resulting from the ongoing COVID-19 pandemic have caused and may continue to cause a disruption to the development of our product candidates and adversely impact our business. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#212529;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">We may not be able to protect our intellectual property rights throughout the world.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#212529;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">We may become subject to claims that we are infringing certain third-party patents, for example, patents relating to lentiviral vectors, or other third-party intellectual property rights, any of which may prevent or delay our development and commercialization efforts and have a material effect on our business.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#212529;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">We have in the past, and in the future we may, enter into collaborations with third parties to develop or commercialize product candidates. If these collaborations are not successful, our business could be adversely affected. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">The market price of our ADSs may be highly volatile and may fluctuate due to factors beyond our control.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The summary risk factors described above should be read together with the text of the full risk factors below, in the section entitled &#8220;Risk Factors&#8221; in Part I, Item 1.A. and the other information set forth in this Annual Report on Form 10-K, including our consolidated financial statements and the related notes, as well as in other documents that we file with the U.S. Securities and Exchange Commission. The risks summarized above or described in full below are not the only risks that we face. Additional risks and uncertainties not precisely known to us, or that we currently deem to be immaterial may also materially adversely affect our business, financial condition, results of operations and future growth prospects.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Table of Contents</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Page</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_I"><span style="text-decoration:underline;">PART I</span></a></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1_BUSINESS"><span style="text-decoration:underline;">Business</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1A.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1A_RISK_FACTORS"><span style="text-decoration:underline;">Risk Factors</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1B.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1B_UNRESOLVED_STAFF_COMMENTS"><span style="text-decoration:underline;">Unresolved Staff Comments</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;2.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_2_PROPERTIES"><span style="text-decoration:underline;">Properties</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;3.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_3_LEGAL_PROCEEDINGS"><span style="text-decoration:underline;">Legal Proceedings</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;4.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_4_MINE_SAFETY_DISCLOSURES"><span style="text-decoration:underline;">Mine Safety Disclosures</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_II"><span style="text-decoration:underline;">PART&#160;II</span></a></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;5.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_5_MARKET_FOR_REGISTRANTS_COMMON_EQU"><span style="text-decoration:underline;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;6.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_6_SELECTED_FINANCIAL_DATA"><span style="text-decoration:underline;">Reserved</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;7.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_7_MANAGEMENTS_DISCUSSION_ANALYSIS_F"><span style="text-decoration:underline;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;7A.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_7A_QUANTITATIVE_QUALITATIVE_DISCLOS"><span style="text-decoration:underline;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;8.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_8_FINANCIAL_STATEMENTS_SUPPLEMENTAR"><span style="text-decoration:underline;">Financial Statements and Supplementary Data</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC"><span style="text-decoration:underline;">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9A.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9A_CONTROLS_PROCEDURES"><span style="text-decoration:underline;">Controls and Procedures</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9B.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9B_OR_INFORMATION"><span style="text-decoration:underline;">Other Information</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 9C</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Disclosure Regarding Foreign Jurisdiction that Prevents Inspections</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">129</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_III"><span style="text-decoration:underline;">PART&#160;III</span></a></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">130</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;10.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_10_DIRECTORS_EXECUTIVE_FICERS_CORPO"><span style="text-decoration:underline;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">130</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;11.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_11_EXECUTIVE_COMPENSATION"><span style="text-decoration:underline;">Executive Compensation</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">130</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;12.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF"><span style="text-decoration:underline;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">130</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;13.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_TR"><span style="text-decoration:underline;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">130</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;14.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_14_PRINCIPAL_ACCOUNTING_FEES_SERVIC"><span style="text-decoration:underline;">Principal Accounting Fees and Services</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">130</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_IV"><span style="text-decoration:underline;">PART&#160;IV</span></a></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">131</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;15.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_15_EXHIBITS_FINANCIAL_STATEMENT_SCH"><span style="text-decoration:underline;">Exhibits, Financial Statement Schedules</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">131</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;16</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_16_FORM_10K_SUMMARY"><span style="text-decoration:underline;">Form 10-K Summary</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;">
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">134</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Annual Report on Form 10-K, or Annual Report, contains express or implied forward-looking statements <span style="Background-color:#FFFFFF;">within the meaning of Section&#160;27A of the Securities Act of 1933, as amended, and Section&#160;21E of the Securities Exchange Act of 1934, as amended,</span>&#160;that involve substantial risks and uncertainties. In some cases, forward-looking statements may be identified by the words &#8220;may,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;objective,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;ongoing,&#8221; or the negative of these terms, or other comparable terminology intended to identify statements about the future. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. The forward-looking statements and opinions contained in this Annual Report are based upon information available to our management as of the date of this Annual Report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. Forward-looking statements contained in this Annual Report include, but are not limited to, statements about: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.14%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the timing, progress and results of clinical trials and preclinical studies for our programs and product candidates, including statements regarding the timing of initiation and completion of trials or studies and related preparatory work and the period during which the results of the trials or studies will become available&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.14%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the timing, scope and likelihood of regulatory submissions, filings and approvals&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.14%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>our ability to develop and advance product candidates into, and successfully complete, clinical trials&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.14%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>our expectations regarding the market opportunity for and size of the patient populations for Libmeldy (OTL-200) and our product candidates, if approved for commercial use&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.14%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the implementation of our business model and our strategic plans for our business, commercial products, product candidates and technology&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.14%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>our plans and ability to build out our commercial infrastructure and successfully identify eligible patients for Libmeldy in Europe and our product candidates, if approved for commercial use&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.14%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>our commercialization, marketing and manufacturing capabilities and strategy&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.14%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the pricing and reimbursement of Libmeldy and any of our product candidates, if approved, including reimbursement for patients treated in a country where they are not a resident&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.14%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the adequacy, scalability and commercial viability of our manufacturing capacity, methods and processes, including those of our manufacturing partners, and our plans for future development&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.14%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the rate and degree of market acceptance and clinical utility of our commercial products and product candidates and gene therapy in general&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.14%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>our ability to establish or maintain collaborations or strategic relationships or obtain additional funding&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.14%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the impact of the COVID-19 global pandemic on our business operations&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.14%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>our competitive position&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.14%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the scope of protection we and our licensors are able to establish and maintain for intellectual property rights covering our commercial products and product candidates&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.14%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>developments and projections relating to our competitors and our industry&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.14%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>our estimates regarding expenses, future revenue, capital requirements and needs for additional financing&#59; </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.14%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the impact of laws and regulations&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.14%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>our ability to attract and retain qualified employees and key personnel&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.14%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>our ability to contract with third-party suppliers, clinical sites and manufacturers and their ability to perform adequately&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.14%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>our projected financial condition, including the sufficiency of our cash, cash equivalents and investments to fund operations in future periods and future liquidity, working capital and capital requirements&#59; and </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.14%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>other risks and uncertainties, including those listed under the caption &#8220;Item 1A. Risk Factors.&#8221; </p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You should refer to the section titled &#8220;Item 1A. Risk Factors&#8221; for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. As a result of these factors, we cannot be assured that the forward-looking statements in this Annual Report will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, these statements should not be regarded as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You should read this Annual Report and the documents that we reference in this Annual Report and have filed as exhibits to this Annual Report completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;"><br /></span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="PART_I"><span style="Background-color:#FFFFFF;">PART I</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_1_BUSINESS">Item 1. Business. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a global gene therapy company dedicated to transforming the lives of people affected by rare diseases through the development of innovative, potentially curative gene therapies. Our <span style="font-style:italic;">ex vivo</span> autologous hematopoietic stem cell, or HSC, gene therapy approach harnesses the power of genetically modified blood stem cells and seeks to correct the underlying cause of disease in a single administration. We seek to achieve this outcome by utilizing a lentiviral vector to introduce a functional copy of a missing or faulty gene into the patient&#8217;s own, or autologous, HSCs through an <span style="font-style:italic;">ex vivo</span> process, resulting in a gene-modified cellular drug product that can then be administered to the patient at the bedside. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, over 160 patients have been treated with our current and former product candidates across seven different diseases, with follow-up periods of more than 11 years following a single administration. We believe the data observed across these development programs, in combination with our expertise in the development, manufacturing and commercialization of gene and cell therapies, position us to provide potentially curative therapies to people suffering from a broad range of diseases. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are currently focusing our <span style="font-style:italic;">ex vivo </span>autologous HSC gene therapy approach on severe neurometabolic diseases and early research programs. Our lead program is OTL-200, which was approved in the European Union, the United Kingdom, Iceland, Liechtenstein and Norway under the brand name Libmeldy for eligible patients with early-onset metachromatic leukodystrophy, or MLD. Three eligible patients have been treated in a commercial setting to date. Our planned BLA submission timeline for OTL-200 with the FDA is late 2022 to early 2023.<span style="font-weight:bold;font-style:italic;"> </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have a portfolio that includes a commercial-stage product and research and development-stage product candidates, and we believe our approach of using lentiviral vectors to genetically modify HSCs has wide-ranging applicability to a large number of indications. The ability of HSCs to differentiate into multiple cell types allows us to deliver gene-modified cells to multiple physiological systems, including the central nervous system, immune system and red blood cell and platelet lineage, thereby potentially enabling the correction of a wide range of diseases. By leveraging the innate self-renewing capability of HSCs that are engrafted in the bone marrow as well as the ability of lentiviral vectors to achieve stable integration of a modified gene into the chromosomes of HSCs, our gene therapies have the potential to provide a durable effect following a single administration. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="geajuovwk5do000001.jpg" title="" alt="" style="width:659px;height:250px;" /></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The diseases we are targeting affect patients around the world, requiring an infrastructure to deliver gene therapies globally. In order to meet anticipated demand for our pipeline of approved products and product candidates still in development, we are utilizing our existing network of contract development and manufacturing organizations, or CDMOs, to manufacture lentiviral vectors and drug product. In addition, we have established process development capabilities in London, UK, and are leveraging technologies that will allow us to deliver our gene therapies globally. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cryopreservation of our gene-modified HSCs is a key component of our commercialization strategy to deliver potentially curative gene therapies to patients worldwide, facilitating both local treatment and local or cross-border product </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reimbursement. In anticipation of commercialization, we developed</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> a</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> cryopreserved formulation of Libmeldy (OTL-200)</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and are collecting supportive clinical data from patients treated with cryopreserved formulations to support the analytical comparability to the fresh cell formulations used in our registrational clinical trials. The registrational trials for all our earlier stage product candidates are expected to be conducted using a cryopreserved formulation. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With the exception of OTL-105, our product candidate for the potential treatment of hereditary angioedema, or HAE, which we are pursuing in partnership with Pharming Group N.V., we have global commercial rights to all our clinical product candidates and plan to commercialize our gene therapies in key markets worldwide, including in Europe and the U.S. initially, subject to obtaining the necessary marketing approvals for these jurisdictions. We plan to deploy a focused commercial infrastructure to deliver Libmeldy and our product candidates, if approved, to patients and are focused on working closely with all relevant stakeholders, including patients, caregivers, specialist physicians and payors, to ensure the widest possible post-approval access for our product candidates. In addition, we may rely on third parties to assist with regulatory submissions, disease awareness, patient identification and reimbursement in countries where local expertise is required or where we do not have a direct presence. For example, in January 2021, we announced partnerships with two regional specialty pharmaceutical companies with experience in rare genetic diseases to support us in the Middle East and Turkey.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As we continue to develop our portfolio, we believe that the experience of our management team and our extensive academic relationships are key strategic strengths. Our management team has extensive experience in rare diseases and in the manufacturing, preclinical and clinical development and commercialization of gene and cell therapies. In addition, we partner with leading academic institutions around the world, which are pioneers in <span style="font-style:italic;">ex vivo </span>autologous HSC-based gene therapy. We plan to leverage our internal expertise combined with our relationships with leading academic institutions to transition our lead clinical-stage product candidates to commercialization and continue to expand our portfolio of <span style="font-style:italic;">ex vivo </span>autologous HSC gene therapy products. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our <span style="font-style:italic;">ex vivo </span>autologous HSC<span style="font-style:italic;"> </span>gene therapy approach </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our <span style="font-style:italic;">ex vivo </span>autologous HSC<span style="font-style:italic;"> </span>gene therapy approach seeks to transform a patient&#8217;s autologous HSCs into a gene-modified cellular drug product to treat the patient&#8217;s disease. HSCs are self-renewing cells that are capable of differentiating into all types of blood cells, including white blood cells, red blood cells, platelets and tissue resident macrophages, which include the microglia of the central nervous system. HSCs can be obtained directly from the bone marrow, which requires administration of a general anesthetic, or from the patient&#8217;s peripheral blood with the use of mobilizing agents, which are agents that can move HSCs from the bone marrow into the peripheral blood for easier collection. The HSCs collected are then manufactured to insert a functional copy of the missing or faulty gene. By delivering gene-modified HSCs back to patients, we seek to take advantage of the self-renewing capability of HSCs to enable a durable effect following a single administration, as has been seen in our commercial and development programs. Since these cells are recognized by the body as the patient&#8217;s own cells, the risks associated with using donor cells may be reduced. In addition, the ability of HSCs to differentiate into multiple different cell types has the potential to enable the delivery of gene-modified cells to different physiological systems and allow the correction of a broad range of different diseases. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical validation already exists for hematopoietic stem cell transplantation, or HSCT, an approach of treating a patient with a genetic disease with HSCs contributed by a healthy donor individual, thereby using HSCs that contain a functioning copy of the gene of interest. However, this approach has significant limitations, including difficulties in finding appropriate genetically matched donors and the risk of graft-versus-host disease, transplant-related rejection and mortality from these and other complications, and is therefore typically only offered on a limited basis. Furthermore, genetically modified cells can be used to express enzyme activity at supra-physiological levels, which we believe has the potential to overcome the limitations of HSCT (where enzyme expression is generally limited to normal levels) to treat some neurometabolic disorders and improve the metabolic correction in neuronal cells before irreversible degeneration occurs. Our approach is intended to address these significant limitations of HSCT. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In a preclinical study conducted by one of our scientific advisors and published in <span style="font-style:italic;">Proceedings of the National Academy of Sciences of the United States of America, </span>or <span style="font-style:italic;">PNAS</span>, a subpopulation of gene-modified HSCs has evidenced the potential to cross the blood-brain barrier, engraft in the brain as microglia and express genes and proteins within the central nervous system, one of the important physiological systems targeted by our HSC gene therapy approach. As published in <span style="font-style:italic;">PNAS</span>, images taken during the study show a cross-section of the brain of a mouse that was infused intravenously with HSCs, which had been genetically modified using a lentiviral vector carrying green fluorescent protein, or GFP. The GFP expression observed throughout the brain illustrates the potential of gene-modified HSCs to cross the blood-brain barrier, engraft in the brain and express the functional protein throughout the brain, thereby potentially addressing a range of diseases that affect the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">central nervous system. Libmeldy (OTL-200)</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, for instance,</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> leverages this same mechanism of action to deliver gene-modified HSCs that can cross the blood-brain barrier and deliver a therapeutic gene that can prevent neuronal degeneration. The </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">study demonstrated</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> widespread distribution and expression of GFP in the brain of a mouse model following intravenous administration of HSCs transduced with GFP encoding vector.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With respect to Libmeldy (OTL-200) and each of our product candidates, our <span style="font-style:italic;">ex vivo </span>gene therapy approach utilizes a self-inactivating, or SIN, lentiviral vector to introduce a functional copy of the missing or faulty gene into the patient&#8217;s autologous HSCs through an <span style="font-style:italic;">ex vivo</span> process called transduction, resulting in a cellular drug product that can then be re-introduced into the patient. Unlike some other viral vectors, such as adeno-associated viral, or AAV, vectors, lentiviral vectors integrate into the chromosomes of patients&#8217; HSCs. We believe this allows us to achieve stable integration of the functional gene into the HSCs and can lead to durable expression of the target protein by the gene-modified HSCs and their progeny after a single administration of gene therapy. In contrast, because AAV vectors rarely integrate into the genome, the transgene is not passed on to all progeny when the cell divides, resulting in rapid dilution and loss of the transgene among frequently dividing cells such as HSCs.&#160;Regarding immunogenicity, because <span style="font-style:italic;">in vivo</span> delivery of AAV places the vector into direct contact with the immune system and most individuals harbor some type of pre-existing immunity, including neutralizing antibodies, to one or more types of AAV vector, the incoming vector can be completely inactivated by the patient&#8217;s immune system. Furthermore, there have been reports that certain high dose applications of AAV have resulted in acute and severe innate immune responses that have proved lethal. With <span style="font-style:italic;">ex vivo</span> delivery, however, the vector is not introduced directly into the body and vector elements are washed away in the laboratory such that there is little to no vector element left to present to the immune system. Our HSC gene therapies and product candidates are all manufactured <span style="font-style:italic;">ex vivo</span>. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Strimvelis for adenosine deaminase severe combined immunodeficiency, or ADA-SCID, is the only gammaretroviral vector-based gene therapy in our portfolio. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The image below illustrates the steps in our approach to transform a patient&#8217;s autologous HSCs <span style="font-style:italic;">ex vivo</span> into therapeutic product. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="geajuovwk5do000002.jpg" title="" alt="" style="width:617px;height:249px;" /></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Initial clinical trials conducted using our product candidates utilized a fresh product formulation, resulting in a limited drug product shelf life. We market Libmeldy (OTL-200) and plan to market our current and any future product candidates, if approved, in a cryopreserved product formulation, which is designed to extend the drug product shelf life and enable the shipment of the drug product to specialized treatment centers, allowing patients to receive treatment closer to their home while leveraging more centralized manufacturing. Cryopreservation also allows us to conduct a number of quality control tests on the genetically modified HSCs prior to introducing them into the patient. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, certain of our clinical-stage product candidates have been evaluated in registrational trials using drug product derived from HSCs extracted from the patients&#8217; bone marrow. To optimize our potential product label and the number of patients that we may be able to treat, as part of any BLA or MAA submission for such product candidates, we plan to demonstrate comparability between drug product manufactured using HSCs derived from the patients&#8217; peripheral blood and drug product manufactured using HSCs derived from the patients&#8217; bone marrow. In cases where clinical trials were conducted using vector and/or drug product manufactured at academic centers, we plan to demonstrate comparability between vector and/or drug product manufactured by our third party commercial CDMOs with vector and drug product </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">manufactured at such academic centers. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are currently focused on employing our <span style="font-style:italic;">ex vivo </span>autologous HSC<span style="font-style:italic;"> </span>gene therapy approach in two therapeutic disease areas: neurodegenerative and immunological disorders. We also have a program focused on beta thalassemia, or TDT, a blood disorder, but new investments in this program are currently limited. Data from clinical trials suggest that <span style="font-style:italic;">ex vivo </span>autologous HSC<span style="font-style:italic;"> </span>gene therapy has the potential to provide generally well-tolerated, sustainable and improved outcomes over existing standards of care for diseases in these areas. We believe that we can apply our approach beyond our current target indications to treat an even broader range of diseases. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our strategy </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are building a leading, global, fully-integrated gene therapy company focused on transforming the lives of people affected by severe diseases. To achieve this, we are pursuing the following strategies:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:7.14%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Successfully commercialize Libmeldy (OTL-200) for the treatment of eligible patients with early-onset MLD in Europe and expand geographically into new markets as regulatory approvals are obtained</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:7.14%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Advance our clinical-stage product candidates towards marketing approvals </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:7.14%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Leverage the power of our therapeutic approach to investigate the potential of HSC gene therapy in larger indications </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:7.14%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Invest in new technologies and innovations to continue to improve our manufacturing processes for lentiviral vector and drug product and reduce costs of goods manufactured</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:7.14%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Establish end-to-end process development, manufacturing and supply chain capabilities, initially through third parties and internally over time</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:7.14%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Establish a patient-centric, global commercial infrastructure, including with third parties in certain regions where we do not have a direct presence&#160;&#160;&#160;&#160; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:7.14%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Execute a business development strategy to leverage our HSC gene therapy approach, expand geographically, accelerate time-to-market or attract disease-area expertise to optimize the value of our portfolio of product candidates or expand into new indications</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our pipeline </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our pipeline spans multiple therapeutic areas where the disease burden on children, families and caregivers is immense and current treatment options are limited or do not exist. </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Our programs focused on neurodegenerative disorders consist of our commercial program approved in Europe, Libmeldy (OTL-200) for MLD, two clinical proof of concept-stage programs, OTL-203 for MPS-I and OTL-201 for mucopolysaccharidosis type IIIA, or MPS-IIIA, and three preclinical programs, OTL-202 for mucopolysaccharidosis type IIIB, or MPS-IIIB, OTL-204 for frontotemporal dementia with progranulin mutations, or GRN-FTD, and OTL-205 for amyotrophic lateral sclerosis, or ALS. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Our programs in immunological disorders consist of two preclinical programs, OTL-104 for Crohn&#8217;s disease with mutations in the nucleotide-binding oligomerization domain-containing protein 2, or NOD2-CD, and OTL-105 for HAE. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.71%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">We also have a commercial program approved in Europe, Strimvelis for adenosine deaminase severe combined immunodeficiency, or ADA-SCID, an advanced registrational clinical program, OTL-103 for Wiskott Aldrich syndrome, or WAS, and one clinical proof of concept-stage program, OTL-102 for X-linked chronic granulomatous disease, or X-CGD. However, in March 2022, we announced that we would discontinue our investment in and seek alternatives for Strimvelis, OTL-103 and OTL-102. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.71%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">In July 2021, we entered into a collaboration with Pharming Group N.V., or Pharming, pursuant to which we granted Pharming worldwide rights to OTL-105. Under our agreement with Pharming, we will lead the completion of IND-enabling activities of OTL-105 and oversee its manufacturing during preclinical and clinical development, which will be funded by Pharming. Pharming will be responsible for clinical development, regulatory filings and commercialization of OTL-105, if approved, including associated costs.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">We have a program focused on blood disorders at the clinical proof of concept stage of development, OTL-300 for TDT. However, in May 2020, we announced that new investment in OTL-300 would be limited.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The nature of our autologous gene therapy product candidates precludes the conduct of Phase 1 safety studies in healthy volunteers. Moreover, considering the indications our product candidates are intended to treat, which are often fatal without treatment and which are rare indications with high unmet medical need, we believe our clinical programs will generally be eligible to proceed to registration based on a single pivotal study given the bioethical considerations regarding the conduct of randomized, double-blind and placebo-controlled clinical trials with gene therapies for such indications. For purposes of this Annual Report, we refer to an exploratory study, which is sometimes referred to as a Phase 1 or Phase 1/2 clinical trial, as a proof of concept trial, and a confirmatory efficacy and safety study to support submission of a potential marketing application with the applicable regulatory authorities, which is sometimes referred to as a Phase 2/3 or Phase 3 clinical trial or a pivotal trial, as a registrational trial. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Neurodegenerative Disorders </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Gene therapy for treatment of MLD </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Disease overview </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MLD is a rare and life-threatening inherited disease of the body&#8217;s metabolic system occurring in approximately one in every 100,000 live births in most regions of the world. Higher incidence rates are reported in geographies of higher consanguinity, such as Turkey and the Middle East. MLD is caused by a mutation in the&#160;arylsulfatase-A gene, or ARSA, that results in the accumulation of sulfatides in the brain and other areas of the body, including the liver, gallbladder, kidneys, and/or spleen. Over time, the nervous system is damaged, leading to neurological problems such as motor, behavioral and cognitive regression, severe spasticity and seizures. Patients with MLD gradually lose the ability to move, talk, swallow, eat and see. In its late infantile form, mortality at five years from onset is estimated at 50% and 44% at 10 years for juvenile patients.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Limitations of current therapies </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the approval of Libmeldy (OTL-200) in Europe, there were no effective treatments or approved therapies for MLD. Palliative care options involve medications for seizures and pain, antibiotics and sedatives, on a case-by-case basis, as well as physiotherapy, hydrotherapy and tube feeding or gastrostomy when patients can no longer eat without assistance. Palliative care addresses the symptoms of MLD but does not slow or reverse the progression of the underlying disease. HSCT has limited and variable efficacy in arresting disease progression and, as a result, HSCT is not considered to be a standard of care for this disease. MLD patients, their caregivers and families, and the healthcare system have faced significant burdens given the severity of the disease and the lack of effective treatments. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Our solution, Libmeldy (OTL-200) for treatment of MLD</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OTL-200 is designed as a one-time therapy that aims to correct the underlying genetic cause of MLD, offering eligible patients the potential for long-term positive effects on cognitive development and maintenance of motor function at ages at which untreated patients show severe motor and cognitive impairments. With OTL-200, a patient&#8217;s own HSCs are selected, and functional copies of the&#160;ARSA&#160;gene are inserted into the genome of the HSCs using a lentiviral vector before these genetically modified cells are infused back into the patient. The ability of the gene-corrected HSCs to migrate across the blood-brain barrier into the brain, engraft, and express the functional enzyme has the potential to persistently correct the underlying disease with a single treatment. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We obtained worldwide rights to this program through our asset purchase and license agreement with Glaxo Group Limited and GlaxoSmithKline Intellectual Property Development LTD, or, together, GSK. The clinical trials for this program have been conducted under a GSK-sponsored clinical trial authorization, which was transferred to us during the third quarter of 2018. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Libmeldy approval in Europe as Orphan Drug</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2020, the European Commission granted full, or standard, marketing authorization for Libmeldy (OTL-200) <span style="Background-color:#FFFFFF;color:#000000;">(autologous CD34+ cell enriched population that contains hematopoietic stem and progenitor cells transduced </span><span style="font-style:italic;Background-color:#FFFFFF;color:#000000;">ex vivo </span><span style="Background-color:#FFFFFF;color:#000000;">using a lentiviral vector encoding the human </span><span style="font-style:italic;Background-color:#FFFFFF;color:#000000;">arylsulfatase-A</span><span style="Background-color:#FFFFFF;color:#000000;"> (</span><span style="font-style:italic;Background-color:#FFFFFF;color:#000000;">ARSA</span><span style="Background-color:#FFFFFF;color:#000000;">) gene)</span> for the treatment of early-onset MLD characterized by biallelic mutations in the ARSA gene leading to a reduction of the ARSA enzymatic activity in children with (i) late infantile or early juvenile forms, without clinical manifestations of the disease, or (ii) the early juvenile form, with early clinical manifestations of the disease, who still have the ability to walk independently and before the onset of cognitive decline.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Libmeldy has received orphan drug designation from the EMA for the treatment of MLD and orphan drug status was maintained at the time of approval. We are continuing to follow patients in the clinical development program for up to 15 years as a post-marketing commitment, and data will be presented to regulators at agreed timepoints in order to further characterize the long-term efficacy and safety of Libmeldy, particularly in the early symptomatic early juvenile population. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Data Supporting the Clinical Profile of Libmeldy </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The European Commission approval is supported by clinical studies of Libmeldy in both pre- and early- symptomatic, early-onset MLD patients. Early-onset MLD encompasses the disease variants traditionally referred to as late infantile, or LI, and early juvenile, or EJ.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical efficacy was based on the integrated analysis of results from 29 patients with early-onset MLD who were all treated with Libmeldy prepared as a fresh formulation:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">20 patients were treated in a registrational study (median follow-up of 4 years)&#59; 9 patients were treated in expanded access programs (median follow-up of 1.5 years) </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">16 patients had a diagnosis of LI MLD&#59; 13 had a diagnosis of EJ MLD</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">At the time of treatment, 20 patients were deemed pre-symptomatic&#59; 9 were deemed early-symptomatic</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical safety was evaluated in 35 patients with early-onset MLD:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">29 patients from integrated efficacy analysis (described above)</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">6 patients treated with the cryopreserved formulation of Libmeldy</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Co-primary endpoints</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><br /><span style="font-style:normal;">The co-primary endpoints of the integrated efficacy analysis were Gross Motor Function Measure, or GMFM, total score and ARSA activity, both evaluated at two years post-treatment. Results of this analysis indicate that a single-dose intravenous administration of Libmeldy is effective in modifying the disease course of early-onset MLD in most patients.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pre-symptomatic LI and EJ patients treated with Libmeldy experienced significantly less deterioration in motor function at two years and three years post-treatment, as measured by GMFM total score, compared to age and disease subtype-matched untreated patients (p&#8804;0.008). The mean difference between treated pre-symptomatic LI patients and age-matched untreated LI patients was 71.0% at year 2 and 79.8% at year 3. Similarly, the mean difference between treated pre-symptomatic EJ patients and age-matched untreated EJ patients was 52.4% at year 2 and 74.9% at year 3. Although not statistically significant, a clear difference in GMFM total score was also noted between treated early-symptomatic EJ patients and age-matched untreated EJ patients (28.7% at year 2&#59; p&#61;0.350 and 43.9% at year 3&#59; p&#61;0.054).</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A statistically significant increase in ARSA activity in peripheral blood mononuclear cells was observed at 2 years post-treatment compared to pre-treatment in both pre-symptomatic patients (20.0-fold increase&#59; p&#60;0.001) and early-symptomatic patients (4.2-fold increase&#59; p&#61;0.004).</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the time of the integrated data analysis, all treated LI patients were alive with a follow-up post-treatment up to 7.5 years and 10 out of 13 treated EJ patients were alive with a follow-up post-treatment of up to 6.5 years. No treatment-related mortality has been reported in patients treated with Libmeldy.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Key secondary endpoints<br /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For EJ patients who were early-symptomatic when treated with Libmeldy, meaningful effects on motor development were demonstrated when these patients were treated before entering the rapidly progressive phase of the disease (IQ&#8805;85 and Gross Motor Function Classification, or GMFC, &#8804;1). By 4 years post-disease onset, an estimated 62.5% of treated, early-symptomatic EJ MLD patients survived and maintained locomotion and ability to sit without support compared with 26.3% of untreated early-symptomatic EJ MLD patients, representing a delay in disease progression following treatment with Libmeldy.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A secondary efficacy endpoint that measured cognitive and language abilities as quantified by Intelligence Quotient/Development Quotient, or IQ/DQ, found in the treated LI subgroup, 12 out of 15 assessed patients had a fairly constant IQ/DQ, within the normal range (IQ/DQ score of 100 +/- SD of 15) throughout follow-up. All but two of these patients (i.e., one pre-symptomatic and one early-symptomatic) remained above the threshold of severe mental disability (IQ/DQ&#62;55) at chronological ages at which all 14 untreated comparator LI patients showed evidence of severe cognitive impairment, which is defined as IQ/DQ below 55 and close to zero. Of the 10 surviving EJ patients, all 4 pre-symptomatic patients and 4 out of 6 early-symptomatic patients showed normal IQ/DQ throughout follow-up. In contrast, 11 out of 12 untreated EJ patients showed evidence of severe cognitive impairment during follow-up.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Clinical trial with cryopreserved drug formulation</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The cryopreserved formulation of OTL-200 is being studied in a clinical trial of pediatric patients with pre-symptomatic LI, or pre- to early-symptomatic EJ in Milan, Italy.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The primary goal of this clinical trial is to assess the safety and efficacy of a cryopreserved formulation of OTL-200 in early-onset MLD patients, as measured by improvement in gross motor function and ARSA activity levels in the patients&#8217; blood cells as well as overall survival. Secondary goals for this clinical trial include assessment of cognitive function through IQ. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ten patients were treated in this trial between April 2017 and April 2020. Data, which included six of these ten patients, was presented at WORLDSymposium in 2021. The median duration of follow up was 0.87 years as of November 2019. Administration was generally well tolerated in all patients, and for those with enough follow-up post-treatment, preliminary evidence of engraftment and restoration of ARSA activity in peripheral blood to supraphysiological levels and in cerebral spinal fluid, or CSF, to normal levels has been shown. The short-term safety profile was comparable between patients treated with the fresh formulation.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Data Supporting Safety Profile of Libmeldy</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The safety of Libmeldy was evaluated in 35 patients with MLD. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The median duration of follow-up in the integrated safety data set, which included 29 patients treated with the fresh (investigational) formulation was 4.51 years. Three patients died and a total of 26 patients remained in the follow-up phase. The median duration of follow-up in the 6 patients treated with the cryopreserved (commercial) formulation was 0.87 years.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All treated LI patients were alive with a follow-up post-treatment up to 7.5 years, and 10 out of 13 treated EJ patients were alive with a follow-up post-treatment of up to 6.5 years. No treatment-related mortality has been reported in patients treated with Libmeldy.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The most common adverse reaction attributed to Libmeldy was presence of anti-ARSA antibodies, or AAA. Five events of AAA were observed in four out of 35 patients and were related to treatment. Antibody titers were generally low and resolved either spontaneously or after a short course of rituximab. In all patients with positive AAA test results, no negative effects were observed in the post-treatment ARSA activity of peripheral blood or bone marrow cellular subpopulations nor in the ARSA activity within the cerebrospinal fluid. No impact on the clinical efficacy or safety outcomes were observed.in any of the subjects who reported AAA. In addition to the risk associated with the gene therapy, treatment with Libmeldy is preceded by other medical interventions, namely bone marrow harvest or peripheral blood mobilization and apheresis, followed by myeloablative conditioning, which carry their own risks. During the clinical studies, the safety profiles of these interventions were consistent with their known safety and tolerability.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For more details, please see the Summary of Product Characteristics, or SmPC, for Libmeldy.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">OTL-200 development in the U.S.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OTL-200 has received orphan drug designation for the treatment of MLD as well as Rare Pediatric Disease designation. In late 2020, the FDA cleared our IND application for OTL-200 in the U.S., and in January 2021, FDA granted regenerative medicine advanced therapy, or RMAT, designation for OTL-200. Based on feedback received from the FDA, we are preparing for a BLA filing for OTL-200 in pre-symptomatic, early-onset MLD patients in late 2022 or early 2023 using data from existing OTL-200 patients. This approach and timeline are subject to the successful completion of activities remaining in advance of an expected pre-BLA meeting with the FDA, including demonstration of the natural history data as a representative comparator for the treated population.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Gene therapy for treatment of MPS-I</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Disease overview </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mucopolysaccharidosis type I is a lysosomal storage disease caused by a deficiency of the lysosomal enzyme alpha-L-iduronidase, or IDUA. Inherited deficiency of IDUA is responsible for MPS-I. Without treatment, clinical manifestations of this severe disease include skeletal abnormalities with severe orthopedic manifestations, hepatosplenomegaly, neurodevelopmental decline, sight and hearing disturbances, cardiovascular and respiratory problems leading to death in early childhood. IDUA deficiency can result in a wide range of clinical severity, with 3 major recognized clinical entities: Hurler, or MPS-IH, Scheie, or MPS-IS, and Hurler-Scheie, or MPS-IH/S, syndromes. Hurler and Scheie syndromes represent phenotypes at the severe and attenuated ends of the MPS-I clinical spectrum, respectively.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The median age of diagnosis for MPS-IH is 12 months&#59; most affected children are diagnosed before 18 months of age. Infants affected by MPS-IH usually appear normal at birth, but may develop inguinal or umbilical hernias in the first six months, and develop the characteristic somatic phenotype over the first few years of life. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The approximate incidence of MPS-I is of one in 100,000 live births. Approximately 60 percent of children born with MPS-I have MPS-IH.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Limitations of current therapies </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:9pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Allogeneic-HSCT with pre- and peri-transplant enzyme replacement therapy, or ERT, from diagnosis to engraftment has been established as the standard of care for MPS-IH patients diagnosed before the age of 30 months and with presumed MPS-IH (presence of family history and/or clinical signs and symptoms compatible with MPS-IH, <span style="font-style:italic;">i.e</span>., phenotypic diagnosis based on clinical expertise), and/or homozygosity or compound heterozygosity for mutations associated with the severe phenotype. The recommendation that HSCT should be standard of care for MPS-IH patients is endorsed by the European Society for Blood and Marrow Transplantation and the American Society for Transplantation and Cellular Therapy.</p>
<p style="margin-bottom:9pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Despite its established position in treatment algorithms, allogeneic-HSCT can result in alloreactive complications, including potentially fatal graft versus host disease, or GvHD, particularly when the degree of matching between graft donor and recipient is low. Additionally, although it may stabilize cognitive decline, life-threatening or severely debilitating cognitive, neurological, orthopedic, cardiac, respiratory and ophthalmic manifestations of MPS-IH have been reported during long-term post-HSCT follow-up. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Our solution, OTL-203 for treatment of MPS-I </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Ex vivo<span style="font-style:normal;"> autologous HSC gene therapy strategies aimed at correcting the genetic defect in patients could represent a significant improvement for the treatment of MPS-I, notably MPS-IH the most severe and prevalent phenotype with the highest unmet medical need, when compared to current treatments.&#160;&#160;</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OTL-203 is a single administration, gene therapy product candidate consisting of autologous CD34+ enriched HSPCs, derived from mobilized peripheral blood, genetically modified <span style="font-style:italic;">ex vivo</span> with the lentiviral vector encoding for the IDUA complementary DNA, or cDNA. It is being developed as a cryopreserved formulation. <span style="font-style:italic;">Ex vivo</span> autologous gene therapies, such as OTL-203, are designed to correct the genetic defect in patients&#8217; own HSCs and their progeny by addition of corrective cDNA. The OTL-203 mechanism of action addresses the disease pathophysiology by restoring enzymatic IDUA expression in peripheral and central body compartments as well as restoring microglia homeostasis and its neuroprotective effects against the neurotoxic effects of glycosaminoglycan, or GAG, accumulation in affected cells. We have obtained worldwide development and commercialization rights to OTL-203 from Telethon Foundation and San Raffaele Hospital.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Autologous cells may be genetically modified to constitutively express supra-normal levels of the therapeutic enzyme and become a quantitatively more effective source of functional enzyme than wild-type cells, possibly also at the level of the nervous system and bone. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The therapeutic potential of this approach for addressing the extensive nervous system manifestations of MPS-IH is based on the contribution of HSCs to the turnover of CNS-resident microglia, demonstrated both in physiological and pathological conditions. Since microglia have been implicated in the pathogenesis of a number of neurodegenerative conditions, including LSDs. These cells should be considered a primary target cell type in therapeutic strategies for LSD with neurologic involvement such as MPS-IH. Moreover, compared to allogeneic transplantation, which is the current standard of care for MPS-IH treatment, the autologous nature of OTL-203 is associated with a significantly reduced transplant-related morbidity and mortality and avoids the risks of graft versus host disease.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OTL-203 has received orphan drug and PRIME designation from the EMA as well as orphan drug designation and rare pediatric disease designation from the FDA for the treatment of MPS-I.<span style="font-weight:bold;font-style:italic;"> </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Ongoing clinical trials</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OTL-203 is currently being investigated in an ongoing, academic-sponsored clinical trial at the San Raffaele Hospital in Milan, Italy to establish proof of concept. The study is a prospective, single dose, single center, non-randomized, open label study involving a single administration of OTL-203 in eight patients with a confirmed diagnosis of MPS-IH. The study is fully enrolled using a cryopreserved formulation of OTL-203. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The patients evaluated in this trial include pediatric MPS-IH patients from 14 to 35 months of age at the time of treatment and will be followed for at least five years post-treatment in the context of the proof of concept study and then continue to be evaluated in a long-term follow-up study. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2021, we announced data published in the <span style="font-style:italic;">New England Journal of Medicine</span> evaluating the safety and efficacy of OTL-203. For this publication&#8217;s last follow up of all patients (range between 12 and 24 months), interim data supporting clinical proof-of-concept illustrated that treatment with OTL-203 was generally well-tolerated with a safety profile consistent with the selected conditioning regimen.<sub style="font-size:85%; vertical-align:bottom"> </sub>IDUA antibodies present prior to gene therapy as a result of ERT were not seen in any patient within three months following treatment. In addition, ERT was discontinued at least three weeks prior to any patient receiving gene therapy treatment, and no patients had re-started ERT post-treatment.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In terms of biomarker data, treatment demonstrated rapid and sustained metabolic correction with all patients achieving supra-physiological IDUA expression in dried blood spot samples at 12 months (a primary efficacy endpoint). Associated with this, the results demonstrated increased IDUA expression in the CSF, with reduction of GAGs in CSF and normalization of GAG levels in urine.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All eight patients treated with OTL-203 showed stable cognitive function, motor function and growth within or near the normal range at multiple data points post-treatment. For instance, stable cognitive performance was shown in all patients post-treatment, with follow-up ranging from six months to two years. Longitudinal growth that was within age-appropriate reference ranges was seen in all patients post-treatment, with follow-up ranging from nine months to two years. Furthermore, stable motor function was seen in all patients compared to pre-treatment, with follow-up ranging from nine months to 1.5 years, and improved range of motion (less joint stiffness) was also shown in all patients compared to pre-treatment, with follow-up ranging from nine months to 1.5 years.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have been granted parallel scientific advice by the FDA and EMA on this program. We intend to seek the necessary regulatory clearance in mid-2022 to enable the initiation of the OTL-203 global registrational study by year end.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Gene therapy for treatment of MPS-IIIA and MPS-IIIB</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Disease overviews</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MPS-IIIA, also known as Sanfilippo syndrome type A, and MPS-IIIB, also known as Sanfilippo syndrome type B, are life-threatening metabolic diseases that cause accumulation of glycosaminoglycan in cells, tissues and organs, particularly in the brain. Within the first years after birth, MPS-IIIA and MPS-IIIB patients begin to experience progressive neurodevelopmental delay and decline, including speech delay and eventual loss of language, behavioral disturbances, and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">potentially severe dementia. Ultimately, most patients with MPS-IIIA progress to a vegetative state. Life expectancy for patients with MPS-IIIA and MPS-IIIB is between 10 to 25 years and 15 to 30 years, respectively. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The incidence of MPS-IIIA and MPS-IIIB are currently estimated to be one in 100,000 and one in 200,000 live births per year, respectively. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Limitations of current therapies </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Currently, there are no effective treatments or approved therapies for MPS-IIIA or MPS-IIIB. Palliative care options involve medications for seizures and pain, antibiotics and sedatives, on a case-by-case basis, as well as physiotherapy, hydrotherapy and tube feeding or gastrostomy when patients can no longer eat without assistance. Palliative care addresses the symptoms of MPS-IIIA and MPS-IIIB but does not slow or reverse the progression of the underlying disease. Systemic ERT is not an approved treatment option and HSCT is not considered to be an effective treatment option for these diseases. The severity of symptoms and lack of an effective treatment option to manage these symptoms is a significant burden to MPS-IIIA and MPS-IIIB patients, their caregivers and families and healthcare systems. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Our solutions, OTL-201 for treatment of MPS-IIIA and OTL-202 for treatment of MPS-IIIB</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are developing OTL-201 and OTL-202 as <span style="font-style:italic;">ex vivo</span><span style="font-size:12pt;"> </span>autologous HSC gene therapies for treatment of patients with MPS-IIIA and MPS-IIIB, respectively. In both indications we believe preclinical studies in mice have shown that <span style="font-style:italic;">ex vivo </span>autologous gene therapy has the potential to address the neurological manifestations of MPS-IIIA and MPS-IIIB. We have obtained worldwide development and commercialization rights to OTL-201 and OTL-202 from The University of Manchester. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OTL-201 has received orphan drug designation from the EMA and FDA for the treatment of MPS-IIIA and has received rare pediatric disease designation from the FDA. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Proof of concept trial in MPS-IIIA<span style="font-style:normal;"> </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are supporting a proof-of-concept trial for the treatment of MPS-IIIA, which started enrollment in January 2020. The trial, which is being conducted by the Royal Manchester Children&#8217;s Hospital and sponsored by the Manchester University NHS Foundation Trust, completed enrollment in 2021 with the fifth patient treated in September 2021. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interim results were presented at the WORLDSymposium in February 2022 through an oral presentation. The presentation featured supportive biomarker data from all five patients with evaluable results, with duration of follow-up ranging from three to 18 months. The treatment has been generally well-tolerated in all enrolled patients (n&#61;5) with no serious adverse events.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In terms of biomarker data, SGSH enzyme expression in leukocytes and CD15+ cells increased from below normal levels at baseline to supra-physiological levels at three months in all five patients. Furthermore, investigators reported that within three months, there was &#62;90% reduction in urinary GAGs (heparan sulfate) in all treated patients. Levels continue to decrease throughout the length of follow-up. CSF GAGs (heparan sulfate) decreased from baseline in the first three patients with available data. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We intend to report clinical data, including early clinical outcomes of cognitive function, from the OTL-201 proof-of-concept trial by year end.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Preclinical development of OTL-202 for treatment of MPS-IIIB</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We intend to use the same approach to development for OTL-202 as OTL-201. Lentivirus vector optimization for OTL-202 for treatment of MPS-IIIB is ongoing, and we plan to continue to progress preclinical development of OTL-202. We plan to leverage information gained from OTL-201 preclinical and clinical development to support the OTL-202 program.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research program in FTD </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Disease overview </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Frontotemporal Dementia, or FTD, is the second most common cause of dementia after Alzheimer Disease in people under the age of 65. FTD is due to the atrophy of the frontal and temporal lobes of the brain. The disease manifests with progressive changes in behavior and personality, starting with symptoms such as decline in social and personal interactions, depression, apathy, emotional blunting, disinhibition and language disorders, and then progressing to general cognitive impairment at a later stage. In ~5% of patients, FTD is caused by mutations in one copy (haploinsufficiency) of the gene that codes for progranulin, or GRN. GRN is a neurotrophic, anti-inflammatory factor that is produced and secreted among others by specialized cells in the brain called microglia cells. GRN produced by microglia cells can be taken up by neighboring neurons, helping them to be healthy and functional. Since GRN-FTD patients&#8217; cells do not produce enough GRN, brain inflammation develops with time and neurons become progressively dysfunctional until they eventually die, leading to brain atrophy and the aforementioned symptoms. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe there are currently up to 2,500 people affected by GRN-FTD in Europe/U.S., with approximately 800 new cases per year.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Limitations of current therapies </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are no treatments available for FTD and death occurs six to nine years after onset.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Our solution, OTL-204 for treatment of FTD</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OTL-204 is an <span style="font-style:italic;">ex vivo</span><span style="font-size:12pt;"> </span>autologous HSC gene therapy being developed to replace the defective microglia cells in the brain of GRN-FTD patients with genetically modified microglia cells that produce and secrete a corrective amount of GRN. These cells develop naturally from HSCs, which are collected from the patient and modified by using a viral vector that brings a functional copy of the GRN gene. When they are infused in the patient, the genetically modified HSCs naturally reach the brain and become resident microglia cells. OTL-204 is being developed in partnership with Professor Alessandra Biffi at the University of Padua in Italy. As part of the collaboration, we initiated a sponsored research agreement with the University of Padua and obtained an exclusive option with Boston Children&#8217;s Hospital to develop and exclusively license the program.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Preclinical development of OTL-204</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preliminary <span style="font-style:italic;">in vitro</span> data obtained in 2020 have demonstrated that human cell lines and mouse HSCs can be efficiently transduced to produce GRN. GRN is then secreted in the culture medium and can be taken up by other types of cells that do not produce GRN themselves.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preliminary <span style="font-style:italic;">in vivo</span> data from the preclinical proof-of-concept study showed that murine GRN-/- HSPCs, transduced with an LV expressing progranulin under the control of a novel promoter, are able to engraft and repopulate the brain myeloid compartment of FTD mice and to locally deliver the GRN enzyme.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We intend to report data from the preclinical proof-of-concept study by year end and file an IND in 2024.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research program in ALS</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Disease overview </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amyotrophic lateral sclerosis, or ALS, is a progressive neurodegenerative disease of the motor neurons. People affected by ALS develop muscular weakness, twitching and atrophy that cause difficulties in speaking, swallowing and eventually breathing. Mutations in many different genes have been linked to ALS and these generally lead to the malfunctioning of neurons and their degeneration, causing a strong inflammation in the brain that further worsen neuronal death. Microglia cells are a type of brain cells that are heavily involved in inflammation and can contribute to neuronal loss by promoting oxidative stress. In particular, the Nox2 gene expressed by microglia cells induces the production of reactive oxygen radical species, which cause oxidative stress, damage to molecules and inflammation. It is important to note that ALS patients who have lower levels of Nox2 have a much better survival.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The incidence of ALS is currently estimated at 2.1 to 3.8 per 100,000 live births in the EU and UK and 1.0 to 2.6 per 100,000 live births in the U.S., for a total of up to 12,000 to 15,000 new patients per year.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Limitations of current therapies </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is no effective treatment for ALS and the average survival is between two and four years from the onset of symptoms. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Our solution, OTL-205 for treatment of ALS</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OTL-205 is an <span style="font-style:italic;">ex vivo</span> autologous gene therapy being developed to genetically modify microglia cells so that they have a much lower level of Nox2 and therefore produce less oxidative stress and less local inflammation. Microglia cells can be derived from HSCs. In our approach, HSCs are extracted from the patient, modified in the laboratory with the lentiviral vector and then infused back into the patient. These modified HSCs then migrate into the brain, where they become microglia cells replacing the diseased cells and reducing inflammation. This approach has the potential to improve symptoms and prolong survival in all ALS patients irrespective of their genetic mutations. OTL-205 is being developed in partnership with Professor Alessandra Biffi at the University of Padua in Italy. As part of the collaboration, we initiated a sponsored research agreement with the University of Padua and obtained an exclusive option with Boston Children&#8217;s Hospital to develop and exclusively license the program.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Preclinical development of OTL-205</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preliminary <span style="font-style:italic;">in vitro</span> data have shown that reducing Nox2 levels by RNA interference in microglia cells efficiently reduces the inflammatory response in these cells and the production of oxygen radicals.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We plan to continue to progress <span style="font-style:italic;">in vitro</span> and <span style="font-style:italic;">in vivo</span> characterization of this therapeutic approach in relevant ALS mouse models.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Immunological Disorders </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research program in NOD2-Crohn&#8217;s Disease </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Disease overview </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Crohn&#8217;s Disease, or CD, is a form of Irritable Bowel Disease, or IBD, a condition affecting the gastrointestinal tract caused by an uncontrolled and chronic inflammatory process directed against intestinal bacteria. Mutations in a number of genes are known to confer susceptibility to the risk of CD, and amongst these the NOD2 gene (nucleotide-binding oligomerization domain-containing protein 2) is known to be the most common genetic factor, with 20-40% of Crohn&#8217;s patients carrying mutations causing defective NOD2 activity.&#160;&#160;NOD2 encodes a cell receptor which controls bacterial elimination by innate immune cells such as macrophages through recognition of bacterial peptide (MDP) and induction of a pro-inflammatory immune response. NOD2 deficiency results in an impaired detection and clearance of bacteria penetrating the gut during gastrointestinal infection, creating an unchecked and relapsing inflammation within the intestinal tissues characterized by intestinal granuloma formation. This leads to recurrent clinical symptoms of chronic abdominal pain, diarrhea, weight loss, fatigue, malnutrition and for some patients, more severe intestinal damage requiring surgical resection. NOD2-CD patients typically present with more severe symptoms and are reported to be more refractory to existing therapies.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The incidence of CD is high compared to our other indications, with estimates of 100 to 200 patients per million in Europe and North America.&#160;&#160;Epidemiological studies suggest NOD2 genetic variants causing functional defects are associated with 7 to 10% of all cases of CD, with up to 200,000 patients in the U.S. and Europe with two NOD2 mutated alleles.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Limitations of current therapies </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current clinical management for Crohn&#8217;s disease includes use of immune-suppressive medications, biological agents such as anti-TNF, steroids and surgical resection. There is currently no cure for Crohn's disease, and long-term, effective treatment options are limited.<span style="font-family:Calibri;"> </span>Several clinical trials have evaluated autologous HSCT in Crohn&#8217;s disease, although with limited success<span style="font-family:Calibri;">. </span>There remains a need for therapeutic modalities that target underlying causes of Crohn&#8217;s disease to achieve effective amelioration of symptoms and disease remission.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Our solution, OTL-104 for treatment of NOD2-CD</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are developing OTL-104 to evaluate its therapeutic efficacy as an <span style="font-style:italic;">ex vivo</span><span style="font-size:12pt;"> </span>autologous HSC gene therapy to treat patients with NOD2-CD through a single administration. As the pathogenesis of NOD2-CD is associated with the function of cells of the hematopoietic system, <span style="font-style:italic;">ex vivo</span> autologous HSC gene therapy may therefore be used restore NOD2 function to immune </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cells such as tissue resident macrophages within the gastrointestinal tract. Our OTL-104 program is being designed to introduce the NOD2 gene into cells of the hematopoietic system by lentiviral transduction of a patient&#8217;s own blood or bone marrow derived HSCs, and the gene-modified cells can then be infused back into the patient. </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We own</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> pending patent applications in the United States and other jurisdictions </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and all other intellectual property rights associated with t</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">he OTL-104 program</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Preclinical development of OTL-104</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OTL-104 preclinical work has shown that restoration of NOD2 gene expression in murine and human stem cells can rescue a defective myeloid immune response to microbial peptides. NOD2 defective inflammatory functions in primary human myeloid cells can be restored by both lentiviral and gene editing approaches. Preclinical studies to evaluate the safety of this approach show that NOD2-LV gene modification of human CD34<sup style="font-size:85%;line-height:120%;vertical-align:top">+</sup> stem cells does not affect HSC engraftment or immune subset development and differentiation following transplantation into NSG mice. Transplantation of NOD2-LV gene modified murine stem cells further demonstrates that HSC derived transgene<sup style="font-size:85%;line-height:120%;vertical-align:top">+</sup> cells can efficiently migrate and reconstitute the myeloid cell compartments of intestinal tissue.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development of an experimental colitis induction model is now in progress for OTL-104 preclinical proof-of-concept studies.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Other programs</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2022, we announced that we would discontinue our investment in and seek alternatives for Strimvelis, OTL-103 for treatment of WAS and OTL-102 for treatment of X-CGD. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Blood disorders</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Gene therapy for treatment of TDT </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2020, we announced that new investment in OTL-300 for treatment of beta-thalassemia would be limited.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Future applications of our <span style="font-style:normal;">ex vivo</span> autologous HSC gene therapy approach </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that our versatile <span style="font-style:italic;">ex vivo</span> autologous HSC gene therapy approach has the potential to deliver promising gene therapies to patients across a broad range of diseases. Although our near-term focus is on delivering our commercial and clinical-stage gene therapies to patients suffering from several rare diseases described above, we believe we can leverage our significant research and development experience and partnerships with academic institutions to identify other diseases in our target areas, including neurodegenerative, immunological and blood disorders, where <span style="font-style:italic;">ex vivo</span> gene therapy may have a comparably higher probability of success as compared to other approaches Our mid- to long-term strategy is to leverage our HSC gene therapy approach in additional larger indications, either on our own or with partners. We are building research capabilities to continue to explore additional indications in our laboratories.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our regulatory strategy </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The nature of our autologous gene therapy product candidates precludes the conduct of Phase 1 safety studies in healthy volunteers. Moreover, considering the indications our product candidates are intended to treat, which are often fatal without treatment and which are rare indications with high unmet medical need, we believe our clinical programs will generally be eligible to proceed to registration based on a single pivotal study given <span style="color:#000000;">the bioethical considerations regarding the conduct of randomized, double-blind and placebo-controlled clinical trials with gene therapies for such indications.</span> <span style="color:#000000;">Both the FDA and EMA provide expedited pathways for the development of drug product candidates for the treatment of rare diseases, particularly life-threatening diseases with high unmet medical need. Such drug product candidates may be eligible to proceed to registration following one or more clinical trials in a limited patient population, following review of the trial&#8217;s design, endpoints and clinical data by the applicable regulatory agencies. These determinations are based on the applicable regulatory agency&#8217;s scientific judgement and these determinations may differ in the United States and the European Union. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In some cases applicable regulatory agency may require us to perform analytical studies or conduct additional clinical trials to support analytical comparability of drug product, for example by demonstrating comparability of drug product manufactured using HSCs derived from a patient&#8217;s mobilized peripheral blood and drug product manufactured using HSCs derived from a patient&#8217;s bone marrow and/or comparability of drug product that has been cryopreserved and fresh drug </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product. For purposes of this Annual Report we refer to these clinical trials as supportive clinical trials. In addition, certain of our product candidates may be evaluated in clinical trials for which clinical data is not intended to be pooled with data from our registrational trials for purposes of a regulatory submission, but will be submitted to the applicable regulatory agencies for informational purposes. For purposes of this Annual Report we refer to these trials as additional clinical trials. In addition, in some cases patients may be ineligible for participation in our clinical trials and may receive treatment under a compassionate use program or an expanded access program. We expect that the available safety and efficacy results from all these trials would be included in any regulatory submission we may submit, and the applicable regulatory agency with respect to each clinical program will make a determination as to whether the available data is sufficient to support a regulatory submission. See</span><span style="font-style:italic;"> Item 1A. Risk Factor</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s&#8212;&#8220;The results from our clinical trials for OTL-200 for MLD and for any of our other product candidates may not be sufficiently robust to support</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> marketing approval or</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the submission of marketing approval,&#8221; &#8220;We may be unable to demonstrate comparability between drug product manufactured using HSCs derived from the patient&#8217;s mobilized peripheral blood and drug product manufactured using HSCs derived from the patient&#8217;s bone marrow and/or comparability between drug product that has been cryopreserved and fresh drug product</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and/or demonstrate comparability between the manufacturing process used at academic centers with the manufacturing process used at CDMOs</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,&#8221; and &#8220;To date, most of the clinical trials for our product candidates were conducted as investigator</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">sponsored clinical trials using drug product manufactured at academic sites.&#8221; </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The diseases we are targeting affect patients across the world. Therefore, we are implementing plans to enhance our partnerships with CDMOs and leverage technologies that will allow us to deliver our gene therapies globally. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Global supply network with experienced CDMOs </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently partner with a network of experienced CDMOs, including AGC Biologics S.p.A. (formerly MolMed S.p.A.) and Oxford BioMedica, for the supply of our vectors and/or drug products, including Libmeldy. We have established relationships with commercial CDMO partners with the resources and capacity to meet our clinical and existing and expected initial commercial needs. Our CDMO partners also provide us with access to their state-of-the art manufacturing technologies. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Manufacturing efficiencies and scalability </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are investing in human capital and advancing manufacturing technologies for HSC-based autologous <span style="font-style:italic;">ex vivo</span> gene therapies. We have licensed lentiviral vector stable cell line technologies from GSK, completed transduction enhancer screening processes, established a vector process development lab at a Catapult Network facility in the UK, and are in the process of building cell therapy and analytical development capabilities at our London, UK global headquarters. We seek to enhance our product and process understanding while actively exploring and developing innovative technologies for vector and drug product manufacturing to improve the efficiency and scalability of manufacturing processes with an ultimate goal to reliably manufacture high quality products for rare diseases and larger indications at lower cost. For example, we have identified and validated several transduction enhancing compounds in order to facilitate lentiviral vector entry into HSCs, showing a greater than 50% reduction in vector requirements. We continue to invest in our people to support the commercialization and lifecycle management of our pipeline products. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cryopreservation of our gene therapy programs </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cryopreservation of gene-modified cells is a key component of our strategy to deliver innovative, potentially curative gene therapies to patients worldwide. We have developed cryopreserved formulations of our OTL-200 and OTL-103 programs and expect to demonstrate comparability of our cryopreserved formulations to earlier manufactured fresh formulations in support of future submissions for marketing approval in the United States and Europe. Our programs in OTL-102, OTL-203 and OTL-201 have already started or will start with cryopreserved formulations. We plan to establish cryopreserved product formulations as the standard for all of our future gene therapy candidates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the cryopreservation process, a patient&#8217;s gene-modified HSCs are frozen at extremely low temperatures and then stored to allow quality control testing and release to be performed before introducing the gene-modified cells back into the patient. Our cryopreserved formulations are expected to have shelf-lives of months to years, enabling us to potentially distribute our products and product candidates from a few centralized manufacturing facilities to geographically dispersed treatment sites. Our ability to ultimately distribute our product candidates globally will facilitate access of the therapies to patients and reduce the logistical burden on patients and their families. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Commercial operations</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have commercially launched Libmeldy (OTL-200) for the treatment of early-onset MLD following receipt of full, or standard, marketing approval from the European Commission in December 2020. We have substantially completed our build-out of our commercial operations in Europe with the goal of delivering Libmeldy to patients through qualified treatment centers in the UK, France, Germany, Italy and the Netherlands. In addition, we expect to leverage cross-border and treatment abroad reimbursement pathways in both Europe and markets such as the Middle East and Turkey through third-party strategic partners and distributors. Subject to approval of OTL-200 from the FDA, we plan to also put in place commercial operations and quality treatment centers in the U.S. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have begun a phased build of commercial capabilities by employing individuals with broad experience in quality assurance and compliance, medical education, marketing, supply chain, sales, public policy, patient services, market access and product reimbursement. We will need to expand these capabilities as we continue to implement appropriate quality systems, compliance policies, systems and procedures, as well as internal systems and infrastructure in order to support our supply chain, qualify and train additional treatment centers, establish patient-focused programs, educate healthcare professionals, and secure reimbursement. The timing and conduct of these commercial activities will be dependent upon regulatory approvals and on agreements we have made or may make in the future with strategic collaborators. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of the commercialization process, we are engaged in discussions with stakeholders across the healthcare system, including public and private payors, patient advocates and organizations, and healthcare providers, to drive more timely patient identification through education, newborn screening, and diagnostic initiatives and to explore new payment models that we hope will enable broader patient access. We have initiated pilot studies for newborns in certain countries to screen for MLD and develop the necessary data package to enable universal newborn screening in various countries where we expect our products to be sold. Ultimately, we intend to utilize the commercial infrastructure that we are building to support the potential for multiple product launches, if approved, across multiple geographies. For many territories and countries, we may also elect to utilize strategic partners, distributors, or contract field-based teams to assist in the commercialization of our products. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We anticipate the list price of Libmeldy to be less than the average 10-year cumulative cost for some chronic or lifelong rare disease treatments, such as certain enzyme replacement therapies, which do not offer the potential for full genetic correction or a potentially positive impact on cognitive outcomes. We are engaging with European country- and regional-level payment authorities to negotiate reimbursement and access and are considering novel payment approaches, such as annuity payments, as part of these negotiation discussions. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intellectual property and barriers to entry </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial success depends, in part, upon our ability to protect commercially important and proprietary aspects of our business, defend and enforce our intellectual property rights, preserve the confidentiality of our know-how and trade secrets, and operate without infringing, misappropriating and otherwise violating valid and enforceable intellectual property rights of others. In particular, we strive to protect the proprietary aspects of our business and to develop barriers to entry that we believe are important to the development and commercialization of our gene therapies. For example, where appropriate, we develop, or acquire exclusive rights to, clinical data, patents, know-how and trade secrets associated with each of our products and product candidates. However, we do not own any patents or patent applications that cover Libmeldy, Strimvelis or any of our lead product candidates. We cannot guarantee that patents will issue from any of existing patent applications or from any patent applications that we or our licensors may file in the future, nor can we guarantee that any patents that may issue in the future from such patent applications will be commercially useful in protecting our products and product candidates. In addition, we plan to rely on regulatory protection based on orphan drug exclusivities, data exclusivities and market exclusivities. See &#8220;&#8212;Government regulation&#8221; for additional information. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently rely primarily on know-how and trade secret protection for aspects of our proprietary technologies that we or our licensors believe are not amenable to or appropriate for patent protection, including, for example, clinical data and production information for Libmeldy, Strimvelis and each of our product candidates. Nonetheless, know-how and trade secrets can be difficult to protect. Although we take steps to protect our know-how, trade secrets and other proprietary information, including restricting access to our premises and our confidential information, as well as entering into agreements with our employees, consultants, advisors and potential collaborators, third parties may independently develop the same or similar know-how, trade secrets or proprietary information or may otherwise gain access to such know-how, trade secrets and other proprietary information or such know-how, trade secrets or other proprietary information may otherwise become known. Moreover, we cannot guarantee that our confidentiality agreements will provide meaningful protection or that they </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">not be breached</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and we may not have an adequate remedy for any such breach. As a result, we may be unable to meaningfully protect our know-how, trade secrets and other proprietary information. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, with regard to patent protection, the scope of coverage being sought in a patent application may be reduced significantly before a patent is issued, and even after issuance the scope of coverage may be challenged. As a result, we cannot guarantee that any of our product candidates will be protectable or remain protected by enforceable patents. We cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient proprietary protection from competitors. Any patents that we hold may be challenged, circumvented or invalidated by third parties. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With regards to Strimvelis, OTL-103, OTL-200 and OTL-300, and as discussed in detail in &#8220;&#8212;License agreements&#8221;, we have exclusive, worldwide, sublicensable licenses pursuant to our asset purchase and license agreement with GSK, or the GSK Agreement, and the R&#38;D Agreement to anonymized patient-level data arising from the clinical trials of Strimvelis, OTL-103, OTL-200 and OTL-300 and know-how, including other clinical data and production information relating to Strimvelis, OTL-103, OTL-200, and OTL-300. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The term of individual patents depends upon the legal term of the patents in the countries in which they are obtained. In most countries in which we are seeking patent protection for our product candidates, the patent term is 20 years from the earliest date of filing a non-provisional patent application. In the United States, the term of a patent may be lengthened by a patent term adjustment to accommodate for administrative delays caused at the U.S. Patent and Trademark Office, or USPTO, or may be shortened if another patent has a terminal disclaimer with an earlier expiration date. Furthermore, in the United States, the term of a patent covering an FDA-approved drug may be eligible for a patent term extension under the Hatch-Waxman Amendments as compensation for the loss of patent term during the FDA regulatory review process. The period of extension may be up to five years beyond the expiration of the patent but cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval. Only one patent among those eligible for an extension may be extended. Similar provisions are available in Europe and in certain other jurisdictions to extend the term of a patent that covers an approved drug. In the future, if we obtain any additional issued U.S. patents covering one of our present or future product candidates, and if such product candidate receives FDA approval, we expect to apply for a patent term extension, if available, to extend the term of the patent covering such approved product candidate. We also expect to seek patent term extensions in any jurisdictions where they are available, but there is no guarantee that the applicable authorities, including the FDA, will agree with our assessment of whether such an extension should be granted, and even if granted, they may disagree with our assessment of the appropriate length of such an extension. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">License agreements </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">GSK asset purchase and license agreement </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2018, we entered into the GSK Agreement pursuant to which GSK transferred to us its portfolio of approved and investigational rare disease gene therapies, including Strimvelis, the first gene therapy approved by the EMA for ADA-SCID, two late-stage clinical gene therapy programs in ongoing registrational trials, OTL-200 for MLD and OTL-103 for WAS, and OTL-300, a clinical-stage gene therapy program for TDT. In addition, GSK novated to us their R&#38;D Agreement with Telethon-OSR. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the GSK Agreement, we are subject to certain obligations to develop and advance certain of the acquired product candidates. For example, we were required to use best endeavors to file an MAA for OTL-200 for MLD in either Europe or a BLA for MLD in the United States and to subsequently use commercially reasonable efforts to file an MAA or BLA, as applicable, in the other jurisdiction and to market, sell and promote OTL-200 in such jurisdictions. In December 2020, we received full, or standard, marketing authorization for Libmeldy in the European Union as well as the United Kingdom, Iceland, Liechtenstein and Norway. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are required to use commercially reasonable efforts to obtain a PRV from the FDA for each of Strimvelis, OTL-200, OTL-103 and OTL-300 and to transfer the first such PRV to GSK. GSK also has an option to acquire at a defined price any PRVs granted to us thereafter for Strimvelis, OTL-200, OTL-103 and OTL-300. In the event that GSK does not exercise this option with respect to any PRV, we may sell the PRV to a third party and must share any proceeds in excess of a specified sale price equally with GSK. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the GSK Agreement we are also obligated to pay non-refundable royalties and milestone payments in relation to the gene therapy programs acquired. We will pay a mid-single-digit percentage royalty on the annual net sales of Strimvelis. We </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will also pay tiered royalty rates at percentages from the mid-teens to the low twenties for the MLD and WAS products, upon marketing approval, calculated as percentages of aggregate cumulative net sales of the MLD and WAS products, respectively. We will pay a tiered royalty at percentages from the high single-digits to the low teens for the TDT product, upon marketing approval, calculated as percentages of aggregate annual net sales of the TDT product. These royalties owed to GSK are in addition to any royalties owed to other third parties under various license agreements for the GSK programs. In aggregate, we may pay up to &#163;90.0 million in milestone payments upon achievement of certain sales milestones. Our royalty obligations with respect to MLD and WAS may be deferred for a certain period in the interest of prioritizing available capital to develop each product. Our royalty obligations are subject to reduction on a product-by-product basis in the event of market control by biosimilars and will expire in April 2048. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may terminate our development or commercialization activities of any of the programs under the GSK Agreement upon the occurrence of an SAE, if we believe such program poses a safety risk to patients or in certain additional situations. GSK may require us to grant a third party a non-exclusive license under the intellectual property we have acquired from GSK under the GSK Agreement if we materially breach our obligations to use best endeavors or commercially reasonable efforts, as applicable, to develop and commercialize the acquired programs and fail to develop and implement a mutually agreeable plan to cure such material breach within a specified time period. The foregoing hypothetical license would only continue until such time as we cured our material breach, and we would be required to pay GSK all amounts we received from the third party in connection with such license. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Telethon-OSR research and development collaboration and license agreement </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2018, in connection with our entering into the GSK Agreement, we entered into a deed of novation with GSK, Telethon Foundation and San Raffaele Hospital, together referred to as Telethon-OSR, pursuant to which we acquired and assumed all of GSK&#8217;s rights and obligations under the R&#38;D Agreement with Telethon-OSR for the research, development and commercialization of <span style="font-style:italic;">ex vivo</span> HSC gene therapies for ADA-SCID, WAS, MLD and TDT and options on three additional earlier-stage development programs.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the R&#38;D Agreement, Telethon-OSR had granted to GSK an exclusive, worldwide, sublicensable license under certain intellectual property rights to develop and commercialize <span style="font-style:italic;">ex vivo</span> gene therapy products for the treatment of ADA-SCID. In addition, Telethon-OSR had granted to GSK an exclusive option for an exclusive, sublicensable, worldwide license under certain intellectual property rights to develop and commercialize certain vectors and gene therapy products from disease-specific development programs for the treatment of WAS, MLD and TDT. At the time we entered into the novation agreement, GSK had completed development, launched and commercialized Strimvelis for ADA-SCID in the European Union, and had exercised its exclusive option to obtain exclusive licenses from Telethon-OSR to the WAS, MLD and TDT programs. We acquired Strimvelis and GSK&#8217;s exclusive licenses relating to the ADA-SCID, WAS, MLD and TDT collaboration programs pursuant to the GSK Agreement and the deed of novation. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the R&#38;D Agreement, Telethon-OSR is required to use commercially reasonable efforts to conduct each of the collaboration programs in accordance with development plans approved by a joint steering committee. With respect to those programs in relation to which our option has been exercised, we are required to use commercially reasonable efforts to develop, obtain regulatory approval, launch and promote in both the European Union and the United States all licensed products and to commercialize and manufacture such products at levels sufficient to meet commercial demands. We are required to use best efforts to renew the European Union marketing authorization for Strimvelis to enable patients to be treated at the San Raffaele hospital from all referring centers globally, as permitted by applicable law. We are responsible for the costs and activities associated with the continued development of Strimvelis and each program for which an option under the R&#38;D Agreement is exercised. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As consideration for the licenses and options granted under the R&#38;D Agreement, we are required to make payments to Telethon-OSR upon achievement of certain product development milestones. We are obligated to pay up to an aggregate of &#8364;31.0 million ($35.0 million at December 31, 2021) in connection with product development milestones with respect to those programs for which we have exercised an option under this agreement (that is, our WAS, MLD and TDT programs). Additionally, we are required to pay to Telethon-OSR a tiered mid-single to low-double digit royalty percentage on net annual sales of licensed products on a country-by-country basis, as well as a low double-digit percentage of sublicense income received from any certain third party sublicensees of the collaboration programs. Our royalty obligation expires on a licensed product-by-licensed product and country-by-country basis upon the latest to occur of the expiration of the last valid claim under the licensed patent rights in such country, the 10th anniversary of the first commercial sale of such licensed product in such country, and the expiration of any applicable regulatory exclusivity in such country, provided that our royalty obligation will terminate immediately in the event significant generic or biosimilar competition to a licensed product achieves </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a certain threshold percentage of the market share. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless terminated earlier, the R&#38;D Agreement will expire (i)&#160;on a product-by-product and country-by-country basis upon the expiration of all payment obligations with respect to such product in such country, (ii)&#160;in its entirety upon the expiration of all payment obligations with respect to the last product in all countries in the world, and (iii) on a program-by-program basis when no vector or gene therapy product is being researched, developed or commercialized. Either we or Telethon-OSR may terminate the R&#38;D Agreement in its entirety or on a program-by-program basis if the other party commits a material breach and fails to cure such breach within a certain period of time. Additionally, either we or Telethon-OSR may terminate involvement in a collaboration program for compelling safety reasons, and either we or Telethon-OSR may terminate the R&#38;D Agreement if the other party becomes insolvent. We may also terminate the R&#38;D Agreement either in its entirety or on a program-by-program basis for any reason upon notice to Telethon-OSR. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Oxford BioMedica license and development agreement </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2016, we entered into a license and development agreement, or the Oxford Development Agreement, with Oxford BioMedica (UK) Limited, or Oxford BioMedica, for the development of gene therapies for ADA-SCID, MPS-IIIA and certain other diseases that we may request be included under the Oxford Development Agreement, such other diseases referred to as Subsequent Indications. The Oxford Development Agreement was amended on multiple occasions and most recently in April 2020.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the Oxford Development Agreement, Oxford BioMedica granted us an exclusive, worldwide license under certain intellectual property rights for the purposes of research, development and commercialization of <span style="font-style:italic;">ex vivo</span> gene therapy products for the treatment of ADA-SCID, MPS-IIIA and Subsequent Indications, except that such license is non-exclusive to the extent the treatment of a Subsequent Indication is the subject of a certain previous license granted by Oxford BioMedica. Oxford BioMedica also granted us a non-exclusive, worldwide license under certain intellectual property rights for the purposes of research, development, commercialization and manufacture of <span style="font-style:italic;">ex vivo </span>gene therapy products for the treatment of certain diseases other than ADA-SCID, MPS-IIIA and Subsequent Indications. Under the Oxford Development Agreement, Oxford BioMedica is required to use commercially reasonable efforts to perform the activities set forth in a collaboration plan approved by a joint steering committee, and we are responsible for certain costs of the activities set forth in such collaboration plan. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As consideration for the licenses granted under the agreement, we issued 588,220 of our ordinary shares to Oxford BioMedica. We are also obligated to issue additional equity upon the achievement of certain milestones, pursuant to which we issued 150,826 ordinary shares upon the achievement of the first milestone in November 2017 and 150,826 ordinary shares were issued upon the achievement of further milestones in August 2018. In April 2020, the fifth milestone was deemed to have been met upon execution of the amended agreement in April 2020, and the Company issued another 75,413 ordinary shares to Oxford BioMedica. Additionally, we are obligated to pay low single-digit percentage royalties on net sales of licensed products until January 31, 2039. The foregoing royalties are reduced by a mid-double digit percentage in the case of compassionate use of a licensed product in a country until the first commercial sale following marketing authorization in such country. We are also required to pay a set monthly fee to Oxford BioMedica in the event we use a certain Oxford BioMedica system for generating stable cell lines. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless terminated earlier, the Oxford Development Agreement will expire when no further payments are due to Oxford BioMedica. We may terminate the performance of the collaboration plan upon notice to Oxford BioMedica, and either party may terminate the performance of the collaboration plan or the Oxford Development Agreement if the other party commits a material breach that is not cured within a certain period of time. Either party may also terminate the Oxford Development Agreement in the event the other party becomes insolvent. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Telethon-OSR license agreement</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2019, we entered into a license agreement with Telethon-OSR under which Telethon-OSR granted us an exclusive worldwide license for the research, development, manufacture and commercialization of <span style="font-style:italic;">ex vivo</span> autologous HSC lentiviral based gene therapy products for the treatment of MPS-I, including MPS IH. Under the terms of the agreement, Telethon-OSR is entitled to receive an upfront payment, and we may be required to make milestone payments if certain development, regulatory and commercial milestones are achieved. Additionally, we will be required to pay Telethon-OSR a tiered mid-single to low-double digit royalty percentage on annual net sales of licensed products.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Competition</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The biotechnology and pharmaceutical industries are characterized by intense and rapidly changing competition to develop new technologies and proprietary products. While we believe that our portfolio of product candidates and scientific expertise in gene therapy provides us with competitive advantages, we face potential competition from many different sources. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We face competition not only from gene therapy companies, but also from companies that are developing novel, non-gene therapy approaches or improving existing treatment approaches. Depending on how successful these efforts are, it is possible they may increase the barriers to adoption and success for our product candidates, if approved. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are currently aware of the following competitive approaches among our products and clinical programs: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.14%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;color:#000000;">MLD</span><span style="color:#000000;">: To our knowledge, beyond Libmeldy in Europe, there is currently no other effective treatment option for patients with MLD. HSCT, for example, has demonstrated limited efficacy in halting disease progression and is therefore not considered a standard of care for this disease. A number of alternative approaches to HSCT are under investigation. For instance, Homology Medicines is at the preclinical stage of developing an </span><span style="font-style:italic;color:#000000;">in vivo</span><span style="color:#000000;"> AAV gene therapy for MLD delivered intravenously, Passage Bio has a preclinical development program for MLD, and Affinia has a preclinical program for </span><span style="font-style:italic;color:#000000;">in vivo</span><span style="color:#000000;"> AAV gene therapy for MLD through lumbar puncture (LP) administration. We are also aware that Takeda is investigating an ERT for MLD with a biweekly intrathecal infusion, and Denali Therapeutics is at the preclinical stage of developing a recombinant ARSA enzyme engineered to cross the blood-brain barrier.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.14%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;color:#000000;">MPS-I</span><span style="color:#000000;">: The current standard of care for MPS-IH patients is HSCT before the age of 30 months. We are aware that REGENXBIO is developing an AAV-based gene therapy, which is in Phase I trials and to be delivered intracisternally. bluebird bio and Immusoft have both reported that they are developing </span><span style="font-style:italic;color:#000000;">ex vivo</span><span style="color:#000000;"> cell therapies in the preclinical stage. For MPS-I patients that are not suitable candidates for HSCT because they lack a suitable donor, were diagnosed later in life, or have a less severe subtype of MPS-I, the current standard of care for the treatment of MPS-I involves regular intravenous injections of laronidase (Aldurazyme), an ERT commercialized by BioMarin and Sanofi Genzyme. A formulation of laronidase for intrathecal administration is currently under evaluation. JCR Pharmaceuticals is developing an ERT, which is in Phase I trials.&#160;Denali Therapeutics has an ERT program in the discovery stage.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.14%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;color:#000000;">MPS-IIIA</span><span style="color:#000000;">: There are currently no effective disease modifying treatment options for patients with MPS-IIIA. We are aware of three gene therapy candidates in clinical development. Lysogene is developing an AAV gene therapy product administered through intracerebral injections, in a collaboration with Sarepta Therapeutics that is set to terminate in July 2022&#59; Abeona Therapeutics is developing AAV gene therapy product administered intravenously&#59; and Esteve is developing an AAV gene therapy administered through intracerebroventricular injection. Amicus Therapeutics is at the preclinical stage of developing an AAV gene therapy for MPS-IIIA. We are aware that JCR Pharmaceuticals and Denali Therapeutics each has a preclinical stage ERT program for MPS-IIIA.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.14%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;color:#000000;">GRN-FTD</span><span style="color:#000000;">:</span><span style="font-weight:bold;color:#000000;"> </span><span style="color:#000000;">There are no approved disease modifying treatments for GRN-FTD. Each of Prevail Therapeutics (now owned by Eli Lilly &#38; Company) and Passage Bio is developing in early-stage clinical trials an AAV gene therapy to be delivered intra-cisterna magna. Alector is developing a monoclonal antibody designed to increase levels of GRN in the brain in late-stage clinical trials, and Denali Therapeutics is developing a modified protein designed to penetrate across the blood-brain barrier at the preclinical stage in collaboration with Takeda.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.14%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;color:#000000;">ALS</span><span style="color:#000000;">:</span><span style="font-weight:bold;color:#000000;"> </span><span style="color:#000000;">There are currently few approved treatment options for ALS, limited to riluzole and edaravone. Multiple companies are developing gene therapies for genetically defined populations of ALS. We are not aware of any companies developing therapies targeted to reduce expression of Nox2. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.14%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;color:#000000;">NOD2-Crohn&#8217;s</span><span style="color:#000000;">:</span><span style="font-weight:bold;color:#000000;"> </span><span style="color:#000000;">There are no approved treatment options specifically for the NOD-2 form of Crohn&#8217;s disease, and many patients with Crohn&#8217;s disease have uncontrolled symptoms despite treatment with standard of care, including multiple anti-inflammatory biologics and surgical interventions. We are not aware of any other treatments in development specifically for the NOD-2 form of Crohn&#8217;s disease. </span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many of our potential competitors, alone or with their strategic partners, have substantially greater financial, technical and other resources than we do, such as larger research and development, clinical, marketing and manufacturing organizations. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated among a smaller number of competitors. Our commercial opportunity could be reduced or eliminated if competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. Competitors also may obtain FDA, EMA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. Additionally, technologies developed by our competitors may render our potential product candidates uneconomical or obsolete, and we may not be successful in marketing our product candidates against competitors. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Government regulation </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;letter-spacing:-0.15pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, biological products, including gene therapy products, are subject to regulation under the Federal Food, Drug, and Cosmetic Act, or FD&#38;C Act, and the Public Health Service Act, or PHS Act, and other federal, state, local and foreign statutes and regulations. Both the FD&#38;C Act and the PHS Act and their corresponding regulations govern, among other things, the research, development, clinical trial, testing, manufacturing, safety, efficacy, labeling, packaging, storage, record keeping, distribution, reporting, advertising and other promotional practices involving biological products. Each clinical trial protocol for a gene therapy product must be reviewed by the FDA. FDA approval must be obtained before the marketing of biological products. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources and we may not be able to obtain the required regulatory approvals. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ethical, social and legal concerns about gene therapy, genetic testing and genetic research could result in additional laws and regulations restricting or prohibiting the processes we may use. Federal and state legislatures, agencies, congressional committees and foreign governments have expressed interest in further regulating biotechnology. More restrictive laws and regulations or interpretations of existing laws or regulations, or claims that our products are unsafe or pose a hazard, could prevent us from commercializing any products. New government requirements may be established that could delay or prevent regulatory approval of our product candidates under development. It is impossible to predict whether legislative changes will be enacted, regulations, policies or guidance changed, or interpretations by agencies or courts changed, or what the impact of such changes, if any, may be. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">U.S. biological products development process </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The process required by the FDA before a biological product may be marketed in the United States generally involves the following: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:7.14%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">completion of nonclinical laboratory tests and animal studies according to good laboratory practices, or GLPs, unless justified, and applicable requirements for the humane use of laboratory animals or other applicable regulations&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:7.14%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;letter-spacing:-0.15pt;color:#000000;">submission to the FDA of an application for an investigational new drug application, or IND, which must become effective before human clinical trials may begin&#59;</span><span style="font-size:10pt;color:#000000;"> </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:7.14%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">approval of the protocol and related documentation by an independent institutional review board, or IRB, or ethics committee at each clinical trial site before each study may be initiated&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:7.14%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">performance of adequate and well-controlled human clinical trials according to the FDA&#8217;s regulations commonly referred to as good clinical practices, or GCPs, and any additional requirements for the protection of human research subjects and their health information, to establish the safety and efficacy of the proposed biological product for its intended use&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:7.14%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">submission to the FDA of a biologics license application, or BLA, for marketing approval that includes sufficient evidence of establishing the safety, purity, and potency of the proposed biological product for its intended indication, including from results of nonclinical testing and clinical trials&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:7.14%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">satisfactory completion of an FDA inspection of the manufacturing facility or facilities where the biological product is produced to assess compliance with current good manufacturing practice, or cGMP, to assure that the facilities, methods and controls are adequate to preserve the biological product&#8217;s identity, strength, quality and </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:7.14%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="font-size:10pt;color:#000000;">purity and, if applicable, the FDA&#8217;s current good tissue practices, or CGTPs, for the use of human cellular and tissue products&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:7.14%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">potential FDA audit of the nonclinical study and clinical trial sites that generated the data in support of the BLA in accordance with any applicable expedited programs or designations&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:7.14%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">review of the product candidate by an FDA advisory committee, where appropriate or if applicable&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:7.14%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">payment of user fees for FDA review of the BLA (unless a fee waiver applies)&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:7.14%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">FDA review and approval, or licensure, of the BLA. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before testing any biological product candidate, including a gene therapy product, in humans, the product candidate enters the preclinical testing stage. Preclinical tests, also referred to as nonclinical studies, include laboratory evaluations of product biological characteristics, chemistry, toxicity and formulation, as well as animal studies to assess the potential safety and activity of the product candidate. The conduct of the preclinical tests must comply with federal regulations and requirements including GLPs. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An IND is an exemption from the FD&#38;C Act that allows an unapproved product candidate to be shipped in interstate commerce for use in an investigational clinical trial and a request for FDA authorization to administer such investigational product to humans. Such authorization must be secured prior to interstate shipment and administration of any product candidate that is not the subject of an approved BLA. In support of a request for an IND, applicants must submit a protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. In addition, the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and plans for clinical trials, among other things, must be submitted to the FDA as part of an IND. The FDA requires a 30-day waiting period after the filing of each IND before clinical trials may begin. This waiting period is designed to allow the FDA to review the IND to determine whether human research subjects will be exposed to unreasonable health risks. At any time during this 30-day period the FDA may raise concerns or questions about the conduct of the trials as outlined in the IND and impose a clinical hold or partial clinical hold. In this case, the IND sponsor and the FDA must resolve any outstanding concerns before clinical trials can begin. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Following commencement of a clinical trial, the FDA may also place a clinical hold or partial clinical hold on that trial. A clinical hold is an order issued by the FDA to the sponsor to delay a proposed clinical investigation or to suspend an ongoing investigation. A partial clinical hold is a delay or suspension of only part of the clinical work requested under the IND. No more than 30 days after imposition of a clinical hold or partial clinical hold, the FDA will provide the sponsor a written explanation of the basis for the hold. Following issuance of a clinical hold or partial clinical hold, an investigation may only resume after the FDA has notified the sponsor that the investigation may proceed. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A sponsor may choose, but is not required, to conduct a foreign clinical trial under an IND. When a foreign clinical trial is conducted under an IND, all FDA IND requirements must be met unless waived. When a foreign clinical trial is not conducted under an IND, the sponsor must ensure that the study complies with certain regulatory requirements of the FDA in order to use the study as support for an IND or application for marketing approval or licensing. In particular, such studies must be conducted in accordance with GCP, including review and approval by an independent ethics committee, or IEC, and informed consent from subjects. The FDA must be able to validate the data through an onsite inspection, if deemed necessary by the FDA. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An IRB representing each institution participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution, and the IRB must conduct continuing review and reapprove the study at least annually. The IRB must review and approve, among other things, the study protocol and informed consent information to be provided to study subjects. An IRB must operate in compliance with FDA regulations. An IRB can suspend or terminate approval of a clinical trial at its institution, or an institution it represents, if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the product candidate has been associated with unexpected serious harm to patients. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some trials are overseen by an independent group of qualified experts organized by the trial sponsor, known as a data safety monitoring board or committee, or DSMB. This group provides authorization as to whether or not a trial may move forward at designated check points based on access that only the group maintains to available data from the study. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the submission of an IND to the FDA before initiation of a clinical trial in the United States, certain human clinical trials involving recombinant or synthetic nucleic acid molecules are subject to oversight of institutional biosafety committees, or IBCs, as set forth in the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules, or NIH Guidelines. Under the NIH Guidelines, recombinant and synthetic nucleic acids are defined as: (i) molecules that are constructed by joining nucleic acid molecules and that can replicate in a living cell (i.e., recombinant nucleic acids)&#59; (ii) nucleic acid molecules that are chemically or by other means synthesized or amplified, including those that are chemically or otherwise modified but can base pair with naturally occurring nucleic acid molecules (i.e., synthetic nucleic acids)&#59; or (iii) molecules that result from the replication of those described in (i) or (ii). Specifically, under the NIH Guidelines, supervision of human gene transfer trials includes evaluation and assessment by an IBC, a local institutional committee that reviews and oversees research utilizing recombinant or synthetic nucleic acid molecules at that institution. The IBC assesses the safety of the research and identifies any potential risk to public health or the environment, and such review may result in some delay before initiation of a clinical trial. While the NIH Guidelines are not mandatory unless the research in question is being conducted at or sponsored by institutions receiving NIH funding of recombinant or synthetic nucleic acid molecule research, many companies and other institutions not otherwise subject to the NIH Guidelines voluntarily follow them.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Information about clinical trials must be submitted within specific timeframes to the NIH for public dissemination on its ClinicalTrials.gov website. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trials typically are conducted in three sequential phases that may overlap or be combined: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:7.14%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;font-size:10pt;color:#000000;">Phase&#160;1</span><span style="font-size:10pt;color:#000000;">. The biological product is initially introduced into healthy human subjects and tested for safety. In the case of some products for severe or life-threatening diseases, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:7.14%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;font-size:10pt;color:#000000;">Phase&#160;2</span><span style="font-size:10pt;color:#000000;">. The biological product is evaluated in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance, optimal dosage and dosing schedule. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:7.14%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;font-size:10pt;color:#000000;">Phase&#160;3</span><span style="font-size:10pt;color:#000000;">. Clinical trials are undertaken to further evaluate dosage, clinical efficacy, potency, and safety in an expanded patient population at geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the product and provide an adequate basis for approval and product labeling. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Post-approval clinical trials, sometimes referred to as Phase&#160;4 clinical trials, may be conducted after initial marketing approval. These clinical trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication, particularly for long-term safety follow-up. The FDA generally recommends that sponsors<span style="font-size:12pt;"> </span>of human gene therapy products integrating vectors such as gammaretroviral and lentiviral vectors and transposon elements observe subjects for potential gene therapy-related delayed adverse events for a 15-year period, including a minimum of five years of annual examinations followed by ten years of annual queries, either in person or by questionnaire, of study subjects. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Both the FDA and the EMA provide expedited pathways for the development of drug product candidates for treatment of rare diseases, particularly life-threatening diseases with high unmet medical need. Such drug product candidates may be eligible to proceed to registration following a single clinical trial in a limited patient population, sometimes referred to as a Phase 1/2 trial, but which may be deemed a pivotal or registrational trial following review of the trial&#8217;s design and primary endpoints by the applicable regulatory agencies. Determination of the requirements to be deemed a pivotal or registrational trial is subject to the applicable regulatory authority&#8217;s scientific judgement and these requirements may differ in the U.S. and the European Union. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During all phases of clinical development, regulatory agencies require extensive monitoring and auditing of all clinical activities, clinical data, and clinical trial investigators. Annual progress reports detailing the results of the clinical trials must be submitted to the FDA. Written IND safety reports must be promptly submitted to the FDA, the NIH and the investigators for serious and unexpected adverse events, any findings from other studies, tests in laboratory animals or <span style="font-style:italic;">in vitro</span> testing that suggest a significant risk for human subjects, or any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor must submit an IND safety report within 15 calendar days after the sponsor determines that the information qualifies for reporting. The sponsor also must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction within seven calendar days after the sponsor&#8217;s initial receipt of the information. Phase&#160;1, Phase&#160;2 and Phase&#160;3 clinical trials may not be completed successfully within any </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">specified period, if at all. The FDA or the sponsor, acting on its own or based on a recommendation from the sponsor&#8217;s data safety monitoring board may suspend a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the biological product has been associated with unexpected serious harm to patients. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Human gene therapy products are a new category of therapeutics. Because this is a relatively new and expanding area of novel therapeutic interventions, there can be no assurance as to the length of the study period, the number of patients the FDA will require to be enrolled in the studies in order to establish the safety, purity and potency of human gene therapy products, or that the data generated in these studies will be acceptable to the FDA to support marketing approval. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Concurrent with clinical trials, companies usually complete additional animal studies and also must develop additional information about the physical characteristics of the biological product as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. To help reduce the risk of the introduction of adventitious agents with use of biological products, the PHS Act emphasizes the importance of manufacturing control for products whose attributes cannot be precisely defined. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the sponsor must develop methods for testing the identity, strength, quality, potency and purity of the final biological product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the biological product candidate does not undergo unacceptable deterioration over its shelf life. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">U.S. review and approval processes </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After the completion of clinical trials of a biological product, FDA approval of a BLA must be obtained before commercial marketing of the biological product. The BLA must include results of product development, laboratory and animal studies, human studies, information on the manufacture and composition of the product, proposed labeling and other relevant information. The testing and approval processes require substantial time and effort and there can be no assurance that the FDA will accept the BLA for filing and, even if filed, that any approval will be granted on a timely basis, if at all. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Within 60 days following submission of the application, the FDA reviews a BLA submitted to determine if it is substantially complete before the FDA accepts it for filing. The FDA may refuse to file any BLA that it deems incomplete or not properly reviewable at the time of submission and may request additional information. In this event, the BLA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing. In most cases, the submission of a BLA is subject to a substantial application user fee, although the fee may be waived under certain circumstances. Under the performance goals and policies implemented by the FDA under the Prescription Drug User Fee Act, or PDUFA, for original BLAs, the FDA targets ten months from the filing date in which to complete its initial review of a standard application and respond to the applicant, and six months from the filing date for an application with priority review. The FDA does not always meet its PDUFA goal dates, and the review process is often significantly extended by FDA requests for additional information or clarification. This review typically takes twelve months from the date the BLA is submitted to the FDA because the FDA has approximately two months to make a &#8216;&#8216;filing&#8217;&#8217; decision. The review process and the PDUFA goal date may be extended by three months if the FDA requests or the BLA sponsor otherwise provides additional information or clarification regarding information already provided in the submission within the last three months before the PDUFA goal date. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once the submission is accepted for filing, the FDA begins an in-depth substantive review of the BLA. The FDA reviews the BLA to determine, among other things, whether the proposed product is safe, pure and potent, for its intended use, and whether the product is being manufactured in accordance with cGMP to ensure the continued safety, purity and potency of such product. The FDA may refer applications for novel biological products or biological products that present difficult or novel questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. During the biological product approval process, the FDA also will determine whether a Risk Evaluation and Mitigation Strategy, or REMS, is necessary to assure the safe use of the biological product. If the FDA concludes a REMS is needed, the sponsor of the BLA must submit a proposed REMS&#59; the FDA will not approve the BLA without a REMS, if required. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before approving a BLA, the FDA typically will inspect the facilities at which the product is manufactured. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">requirements and adequate to assure consistent production of the product within required specifications. For a gene therapy product, the FDA also will not approve the product if the manufacturer is not in compliance with the CGTPs. These are FDA regulations that govern the methods used in, and the facilities and controls used for, the manufacture of human cells, tissues, and cellular and tissue-based products, or HCT/Ps, which are human cells or tissue intended for implantation, transplant, infusion, or transfer into a human recipient. The primary intent of the CGTP requirements is to ensure that cell and tissue-based products are manufactured in a manner designed to prevent the introduction, transmission and spread of communicable disease. FDA regulations also require tissue establishments to register and list their HCT/Ps with the FDA and, when applicable, to evaluate donors through appropriate screening and testing. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to assure that the clinical trials were conducted in compliance with IND study requirements and GCP requirements. During the</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> ongoing</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> COVID-19 pandemic, restrictions preventing the conduct or completion of facility or clinical site inspections </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">have</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> led </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and may continue to lead </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to FDA deferred action on marketing applications or the issuance of complete response letters. To assure cGMP, CGTP and GCP compliance, an applicant must incur significant expenditure of time, money and effort in the areas of training, record keeping, production and quality control. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Pediatric Research Equity Act, or PREA, a BLA or supplement to a BLA for a novel product (e.g., new active ingredient, new indication, etc.) must contain data to assess the safety and effectiveness of the biological product for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may grant deferrals for submission of data or full or partial waivers. Unless otherwise required by regulation, PREA does not apply to any biological product for an indication for which orphan designation has been granted. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notwithstanding the submission of relevant data and information, the FDA may ultimately decide that the BLA does not satisfy its regulatory criteria for approval and deny approval. Data obtained from clinical trials are not always conclusive and the FDA may interpret data differently than we interpret the same data. If the FDA decides not to approve the BLA in its present form, the FDA will issue a complete response letter that usually describes all of the specific deficiencies in the BLA identified by the FDA. The deficiencies identified may be minor, for example, requiring labeling changes, or major, for example, requiring additional clinical trials. Additionally, the complete response letter may include recommended actions that the applicant might take to place the application in a condition for approval. If a complete response letter is issued, the applicant may either resubmit the BLA, addressing all of the deficiencies identified in the letter, or withdraw the application. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a product receives regulatory approval, the approval may be significantly limited to specific diseases and dosages or the indications for use may otherwise be limited, including to subpopulations of patients, which could restrict the commercial value of the product. Further, the FDA may require that certain contraindications, warnings precautions or interactions be included in the product labeling. The FDA may impose restrictions and conditions on product distribution, prescribing, or dispensing in the form of a REMS, or otherwise limit the scope of any approval. In addition, the FDA may require post-marketing clinical trials, sometimes referred to as Phase&#160;4 clinical trials, designed to further assess a biological product&#8217;s safety and effectiveness, and testing and surveillance programs to monitor the safety of approved products that have been commercialized. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Orphan drug designation </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biological product intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making a drug or biological product available in the United States for this type of disease or condition will be recovered from sales of the product. Orphan product designation must be requested before submitting a BLA. After the FDA grants orphan product designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan product designation does not convey any advantage in or shorten the duration of the regulatory review and approval process. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers. If a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications to market the same drug or biological product for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity. Competitors, however, may receive approval of different products for the indication for which the orphan product has exclusivity or obtain approval for the same product but for a different indication for which the orphan product </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">has exclusivity. Orphan product exclusivity also could block the approval of one of our products for seven years if a competitor obtains approval of the same biological product for the same use or indication, and we are unable to demonstrate that our product is clinically superior to the previously approved drug for the same use or indication. If a drug or biological product designated as an orphan product receives marketing approval for an indication broader than what is designated, it may not be entitled to orphan product exclusivity. Orphan drug status in the European Union has similar, but not identical, benefits.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Rare Pediatric Disease Designation and Priority Review Vouchers </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the FD&#38;C Act, the FDA incentivizes the development of drugs and biological products that meet the definition of a &#8220;rare pediatric disease,&#8221; defined to mean a serious or life-threatening disease in which the serious of life-threatening manifestations primarily affect individuals aged from birth to 18 years and the disease affects fewer than 200,000 individuals in the United States or affects more than 200,000 in the United States and for which there is no reasonable expectation that the cost of developing and making in the United States a drug or biological product for such disease or condition will be received from sales in the United States of such drug or biological product. The sponsor of a product candidate for a rare pediatric disease may be eligible for a voucher that can be used to obtain a priority review for a subsequent human drug or biological product application after the date of approval of the rare pediatric disease drug or biological product, referred to as a priority review voucher, or PRV. A sponsor may request rare pediatric disease designation from the FDA prior to the submission of its BLA. A rare pediatric disease designation does not guarantee that a sponsor will receive a PRV upon approval of its BLA. Moreover, a sponsor who chooses not to submit a rare pediatric disease designation request may nonetheless receive a PRV upon approval of their marketing application if they request such a voucher in their original marketing application and meet all of the eligibility criteria. If a PRV is received, it may be sold or transferred an unlimited number of times. Congress has extended the PRV program through September 30, 2024, with the potential for PRVs to be granted through September 30, 2026.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Expedited development and review programs </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA has various programs, including Fast Track designation, breakthrough therapy designation, accelerated approval and priority review, that are intended to expedite or simplify the process for the development and FDA review of drugs and biologics that are intended for the treatment of serious or life-threatening diseases or conditions. These programs do not change the standards for approval but may help expedite the development or approval process. To be eligible for fast track designation, new drugs and biological products must be intended to treat a serious or life-threatening condition and demonstrate the potential to address unmet medical needs for the condition. Fast Track designation applies to the combination of the product and the specific indication for which it is being studied. The sponsor of a new drug or biologic may request the FDA to designate the drug or biologic as a Fast Track product at any time during the clinical development of the product. One benefit of fast track designation, for example, is that the FDA may consider for review sections of the marketing application for a product that has received Fast Track designation on a rolling basis before the complete application is submitted. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the FDA&#8217;s breakthrough therapy program, products intended to treat a serious or life-threatening disease or condition may be eligible for the benefits of the Fast Track program when preliminary clinical evidence demonstrates that such product may have substantial improvement on one or more clinically significant endpoints over existing therapies. Additionally, the FDA will seek to ensure the sponsor of a breakthrough therapy product receives timely advice and interactive communications to help the sponsor design and conduct a development program as efficiently as possible. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any product is eligible for priority review if it has the potential to provide safe and effective therapy where no satisfactory alternative therapy exists or a significant improvement in the treatment, diagnosis or prevention of a disease compared to marketed products. The FDA will attempt to direct additional resources to the evaluation of an application for a new drug or biological product designated for priority review in an effort to facilitate the review. Under priority review, the FDA&#8217;s goal is to review an application in six months once it is filed, compared to ten months for a standard review. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, a product may be eligible for accelerated approval. Drug or biological products studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may receive accelerated approval, which means that they may be approved on the basis of adequate and well-controlled clinical trials establishing that the product has an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit, or on the basis of an effect on an intermediate clinical endpoint other than survival or irreversible morbidity. As a condition of approval, the FDA may require that a sponsor of a drug or biological product receiving accelerated approval perform adequate and well-controlled post-marketing clinical trials. In addition, for products being </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">considered for accelerated approval, the FDA generally requires, unless otherwise informed by the agency, that all advertising and promotional materials intended for dissemination or publication within 120 days of marketing approval be submitted to the agency for review during the pre-approval review period. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">RMAT designation </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of the 21st Century Cures Act, enacted in December 2016, Congress amended the FD&#38;C Act to facilitate an efficient development program for, and expedite review of RMAT, which include cell and gene therapies, therapeutic tissue engineering products, human cell and tissue products, and combination products using any such therapies or products. RMAT do not include those HCT/Ps regulated solely under section&#160;361 of the PHS Act and 21&#160;CFR Part&#160;1271. This program is intended to facilitate efficient development and expedite review of regenerative medicine therapies, which are intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition and qualify for RMAT designation. A drug sponsor may request that FDA designate a drug as a RMAT concurrently with or at any time after submission of an IND. FDA has 60 calendar days to determine whether the drug meets the criteria, including whether there is preliminary clinical evidence indicating that the drug has the potential to address unmet medical needs for a serious or life-threatening disease or condition. A BLA for a regenerative medicine therapy that has received RMAT designation may be eligible for priority review or accelerated approval through use of surrogate or intermediate endpoints reasonably likely to predict long-term clinical benefit, or reliance upon data obtained from a meaningful number of sites.&#160;Benefits of RMAT designation also include early interactions with FDA to discuss any potential surrogate or intermediate endpoint to be used to support accelerated approval.&#160;A regenerative medicine therapy with RMAT designation that is granted accelerated approval and is subject to post-approval requirements may fulfill such requirements through the submission of clinical evidence from clinical trials, patient registries, or other sources of real world evidence, such as electronic health records&#59; the collection of larger confirmatory data sets&#59; or post-approval monitoring of all patients treated with such therapy prior to its approval. Like some of FDA&#8217;s other expedited development programs, RMAT designation does not change the standards for approval but may help expedite the development or approval process. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Post-approval requirements </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maintaining substantial compliance with applicable federal, state, and local statutes and regulations requires the expenditure of substantial time and financial resources. Rigorous and extensive FDA regulation of biological products continues after approval, particularly with respect to cGMP. We currently rely, and may continue to rely, on third parties for the production of clinical and commercial quantities of any products that we may commercialize. Manufacturers of our products are required to comply with applicable requirements in the cGMP regulations, including quality control and quality assurance and maintenance of records and documentation. Other post-approval requirements applicable to biological products, include reporting of cGMP deviations that may affect the identity, potency, purity and overall safety of a distributed product, record-keeping requirements, reporting of adverse effects, reporting updated safety and efficacy information, and complying with electronic record and signature requirements. After a BLA is approved, the product also may be subject to official lot release. As part of the manufacturing process, the manufacturer is required to perform certain tests on each lot of the product before it is released for distribution. If the product is subject to official release by the FDA, the manufacturer submits samples of each lot of product to the FDA together with a release protocol showing a summary of the history of manufacture of the lot and the results of all of the manufacturer&#8217;s tests performed on the lot. The FDA also may perform certain confirmatory tests on lots of some products, such as viral vaccines, before releasing the lots for distribution by the manufacturer. In addition, the FDA conducts laboratory research related to the regulatory standards on the safety, purity, potency, and effectiveness of biological products. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also must comply with the FDA&#8217;s advertising and promotion requirements, such as those related to direct-to-consumer advertising, the prohibition on promoting products for uses or in patient populations that are not described in the product&#8217;s approved labeling (known as &#8220;off-label use&#8221;), industry-sponsored scientific and educational activities, and promotional activities involving the internet. Discovery of previously unknown problems or the failure to comply with the applicable regulatory requirements may result in restrictions on the marketing of a product or withdrawal of the product from the market as well as possible civil or criminal sanctions. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant or manufacturer to administrative or judicial civil or criminal sanctions and adverse publicity. FDA sanctions could include refusal to approve pending applications, withdrawal of an approval, clinical holds, warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, mandated corrective advertising or communications with doctors or other stakeholders, debarment, restitution, disgorgement of profits, or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Biological product manufacturers and other entities involved in the manufacture and distribution of approved biological products are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP and other laws. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance. Discovery of problems with a product after approval may result in restrictions on a product, manufacturer, or holder of an approved BLA, including withdrawal of the product from the market. In addition, changes to the manufacturing process or facility generally require prior FDA approval before being implemented and other types of changes to the approved product, such as adding new indications and additional labeling claims, are also subject to further FDA review and approval. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">U.S. patent term restoration and marketing exclusivity </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depending upon the timing, duration and specifics of the FDA approval of the use of our product candidates, some of our U.S. patents may be eligible for limited patent term extension under the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the product&#8217;s approval date. The patent term restoration period is generally one-half the time between the effective date of an IND and the submission date of a BLA plus the time between the submission date of a BLA and the approval of that application. Only one patent applicable to an approved biological product is eligible for the extension and the application for the extension must be submitted prior to the expiration of the patent. In addition, a patent can only be extended once and only for a single product. The USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we may intend to apply for restoration of patent term for one of our patents, if and as applicable, to add patent life beyond its current expiration date, depending on the expected length of the clinical trials and other factors involved in the filing of the relevant BLA. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A biological product can obtain pediatric market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity periods, including some regulatory exclusivity periods tied to patent terms. This six-month exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of a pediatric study in accordance with an FDA-issued &#8220;Written Request&#8221; for such a study. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ACA, signed into law on March&#160;23, 2010, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009 which created an abbreviated approval pathway for biological products shown to be similar to, or interchangeable with, an FDA-licensed reference biological product. This amendment to the PHS Act attempts to minimize duplicative testing. Biosimilarity, which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency, can be shown through analytical studies, animal studies, and a clinical trial or trials. Interchangeability requires that a product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same clinical results as the reference product and, for products administered multiple times, the biologic and the reference biologic may be switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reference biological product is granted four- and 12-year exclusivity periods from the time of first licensure of the product. FDA will not accept an application for a biosimilar or interchangeable product based on the reference biological product until four years after the date of first licensure of the reference product, and FDA will not approve an application for a biosimilar or interchangeable product based on the reference biological product until twelve years after the date of first licensure of the reference product. &#8220;First licensure&#8221; typically means the initial date the particular product at issue was licensed in the United States. Date of first licensure does not include the date of licensure of (and a new period of exclusivity is not available for) a biological product if the licensure is for a supplement for the biological product or for a subsequent application by the same sponsor or manufacturer of the biological product (or licensor, predecessor in interest, or other related entity) for a change (not including a modification to the structure of the biological product) that results in a new indication, route of administration, dosing schedule, dosage form, delivery system, delivery device or strength, or for a modification to the structure of the biological product that does not result in a change in safety, purity, or potency. Therefore, one must determine whether a new product includes a modification to the structure of a previously licensed product that results in a change in safety, purity, or potency to assess whether the licensure of the new product is a first licensure that triggers its own period of exclusivity. Whether a subsequent application, if approved, warrants exclusivity as the &#8220;first licensure&#8221; of a biological product is determined on a case-by-case basis with data submitted by the sponsor. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Additional regulation </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the foregoing, state and federal laws regarding environmental protection and hazardous substances, including the Occupational Safety and Health Act, the Resource Conservancy and Recovery Act and the Toxic Substances Control Act, affect our business. These and other laws govern our use, handling and disposal of various biological, chemical and radioactive substances used in, and wastes generated by, our operations. If our operations result in contamination of the environment or expose individuals to hazardous substances, we could be liable for damages and governmental fines. We believe that we are in material compliance with applicable environmental laws and that continued compliance therewith will not have a material adverse effect on our business. We cannot predict, however, how changes in these laws may affect our future operations. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">U.S. Foreign Corrupt Practices Act </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The U.S. Foreign Corrupt Practices Act, to which we are subject, prohibits corporations and individuals from engaging in certain activities to obtain or retain business or to influence a person working in an official capacity. It is illegal to pay, offer to pay or authorize the payment of anything of value to any foreign government official, government staff member, political party or political candidate in an attempt to obtain or retain business or to otherwise influence a person working in an official capacity. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Government regulation outside of the United States </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to regulations in the United States, we are subject to a variety of regulations in other jurisdictions governing, among other things, research and development, clinical trials, testing, manufacturing, safety, efficacy, labeling, packaging, storage, record keeping, distribution, reporting, advertising and other promotional practices involving biological products as well as authorization and approval of our products. Because biologically sourced raw materials are subject to unique contamination risks, their use may be restricted in some countries. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The requirements and process governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, the clinical trials must be conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki. If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension of clinical trials, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Clinical trials regulation</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Whether or not we obtain FDA approval for a product, we must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of the product in those countries. Certain countries outside of the United States have a similar process that requires the submission of a clinical trial application much like the IND prior to the commencement of human clinical trials. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2014, the EU adopted the new Clinical Trials Regulation (EU) No 536/2014, or Regulation, which replaced the Clinical Trials Directive 2001/20/EC, or Directive, on January 31, 2022.<span style="font-size:12pt;"> </span>The transitory provisions of the new Regulation offer sponsors the possibility to choose between the requirements of the previous Directive and the new Regulation if the request for authorization of a clinical trial is submitted in the year after the new Regulation became applicable. If the sponsor chooses to submit under the previous Directive, the clinical trial continues to be governed by the Directive until three years after the new Regulation became applicable. If a clinical trial continues for more than three years after the Clinical Trials Regulation became applicable, the Clinical Trials Regulation will at that time begin to apply to the clinical trial. The new Regulation overhauls the current system of approvals for clinical trials in the EU. Specifically, the new Regulation, which is directly applicable in all Member States (meaning that no national implementing legislation in each EU Member State is required), aims at simplifying and streamlining the approval of clinical trials in the EU. The main characteristics of the regulation include: a streamlined application procedure via a single-entry point through the Clinical Trials Information System, or CTIS&#59; a single set of documents to be prepared and submitted for the application as well as simplified reporting procedures for clinical trial sponsors&#59; and a harmonized procedure for the assessment of applications for clinical trials, which is divided in two parts (Part I contains scientific and medicinal product documentation and Part II contains the national and patient-level documentation). Part&#160;I is assessed by a coordinated review by the competent authorities of all EU Member States in which an application for authorization of a clinical trial has been submitted (Member States concerned) of a draft report prepared by a Reference Member State. Part&#160;II is assessed separately by each Member State concerned. Strict deadlines have been established for the assessment of clinical trial applications. The role of the relevant ethics committees in </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the assessment procedure will continue to be governed by the national law of the concerned EU Member State. However, overall related timelines will be defined by the Clinical Trials Regulation.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Drug review and approval </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the <span style="color:#000000;">EU</span>, medicinal products, including advanced therapy medicinal products, or ATMPs, are subject to extensive pre- and post-market regulation by regulatory authorities at both the EU and national levels. ATMPs comprise gene therapy products, somatic cell therapy products and tissue engineered products. Gene therapy products deliver genes into the body that lead to a therapeutic, prophylactic or diagnostic effect. Libmeldy is authorized as a gene therapy product in the EU, and we anticipate that our gene therapy development products would also be regulated as ATMPs in the EU. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To obtain regulatory approval of an ATMP under EU regulatory systems, we must submit an MAA <span style="color:#000000;">under the centralized procedure administered by the EMA</span>. The application used to submit the BLA in the United States is similar to that required in the EU, with the exception of, among other things, <span style="color:#000000;">certain specific requirements set out in Regulation (EC) No 1394/2007 on advanced therapy medicinal products, or the ATMP Regulation, for example certain particulars to be contained in the summary of product characteristics</span>. <span style="color:#000000;">The centralized procedure provides for the grant of a single marketing authorization by the European Commission that is valid across all of the EU, and in the additional Member States of the European Economic Area (Iceland, Liechtenstein and Norway). As provided for in the ATMP Regulation, the scientific evaluation of MAAs for ATMPs is primarily performed by a specialized scientific committee called the Committee for Advanced Therapies, or CAT. The CAT prepares a draft opinion on the quality, safety and efficacy of the ATMP which is the subject of the MAA, which is sent for final approval to the Committee for Medicinal Products for Human Use, or CHMP. The CHMP recommendation is then sent to the European Commission, which adopts a decision binding in all EU Member States. The maximum timeframe for the evaluation of an MAA for an ATMP is 210 days from receipt of a valid MAA, excluding clock stops when additional information or written or oral explanation is to be provided by the applicant in response to questions asked by the CAT and/or CHMP. Clock stops may extend the timeframe of evaluation of an MAA considerably beyond 210 days. Where the CHMP gives a positive opinion, the EMA provides the opinion together with supporting documentation to the European Commission, who make the final decision to grant a marketing authorization, which is issued within 67 days of receipt of the EMA&#8217;s recommendation. Accelerated assessment may be granted by the CHMP in exceptional cases, when a medicinal product is of major public health interest, particularly from the viewpoint of therapeutic innovation. If the CHMP accepts such a request, the timeframe of 210 days for assessment will be reduced to 150 days (excluding clock stops), but it is possible that the CHMP may revert to the standard time limit for the centralized procedure if it determines that the application is no longer appropriate to conduct an accelerated assessment.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Now that the UK (which comprises Great Britain and Northern Ireland) has left the European Union, Great Britain will no longer be covered by centralized marketing authorizations (under the Northern Ireland Protocol, centralized marketing authorizations will continue to be recognized in Northern Ireland). All medicinal products with a current centralized marketing authorization were automatically converted to Great Britain marketing authorizations on January 1, 2021. For a period of two years from January 1, 2021, the Medicines and Healthcare products Regulatory Agency, or MHRA, the UK medicines regulator, may rely on a decision taken by the European Commission on the approval of a new marketing authorization in the centralized procedure, in order to more quickly grant a new Great Britain marketing authorization. A separate application will, however, still be required.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Data and marketing exclusivity</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The EEA also provides opportunities for market exclusivity. Upon receiving marketing authorization in the EEA, innovative medicinal products generally receive eight years of data exclusivity and an additional two years of market exclusivity. If granted, data exclusivity prevents generic or biosimilar applicants from referencing the innovator&#8217;s preclinical and clinical trial data contained in the dossier of the reference product when applying for a generic or biosimilar marketing authorization during a period of eight years from the date on which the reference product was first authorized in the EEA. During the additional two-year period of market exclusivity, a generic or biosimilar marketing authorization can be submitted, and the innovator&#8217;s data may be referenced, but no generic or biosimilar product can be marketed until the expiration of the market exclusivity period. <span style="color:#000000;">The overall ten-year period will be extended to a maximum of eleven years if, during the first eight years of those ten years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to authorization, is held to bring a significant clinical benefit in comparison with existing therapies. Even if an innovative medicinal product gains the prescribed period of data exclusivity, another company may market another version of the product if such company obtained marketing authorization based on a MAA with a complete independent data package of pharmaceutical tests, preclinical tests and clinical trials. </span>There is, however, no </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">guarantee that a product will be considered by the European Union&#8217;s regulatory authorities to be an innovative medicinal product, and products may therefore not qualify for data exclusivity. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Orphan designation and exclusivity</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Products with an orphan designation in the EU can receive ten years of market exclusivity, during which time &#8220;no similar medicinal product&#8221; for the same indication may be placed on the market. A &#8220;similar medicinal product&#8221; is defined as a medicinal product containing a similar active substance or substances as contained in an authorized orphan medicinal product, and which is intended for the same therapeutic indication. An orphan product can also obtain an additional two years of market exclusivity in the EU where an agreed pediatric investigation plan for pediatric studies has been complied with. No extension to any supplementary protection certificate can be granted on the basis of pediatric studies for orphan indications. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The criteria for designating an &#8220;orphan medicinal product&#8221; in the EU are similar in principle to those in the United States. Under Article 3 of Regulation (EC) 141/2000, a medicinal product may be designated as an orphan medicinal product if&#160;it meets the following criteria: (1) it is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition&#59; and (2) either (i) the prevalence of such condition must not be more than five&#160;in 10,000 persons in the EU when the application is made, or (ii) without the benefits derived from orphan status, it must be unlikely that the marketing of the medicine would generate sufficient return in the EU to justify the investment needed for its development&#59; and (3)&#160;there exists no satisfactory method of diagnosis, prevention or treatment of such condition authorized for marketing in the EU, or if such a method exists, the product will be of significant benefit to those affected by the condition, as defined in Regulation (EC) 847/2000. Orphan medicinal products are eligible for financial incentives such as reduction of fees or fee waivers and are, upon grant of a marketing authorization, entitled to ten years of market exclusivity for the approved therapeutic indication. The application for orphan designation must be submitted before the application for marketing authorization. The applicant will receive a fee reduction for the MAA if the orphan designation has been granted, but not if the designation is still pending at the time the marketing authorization is submitted. Orphan designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:7.14%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">a second applicant can establish that its product, although similar, is safer, more effective or otherwise clinically superior&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:7.14%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the marketing authorization holder of the authorized orphan product consents to a second orphan medicinal product application&#59; or </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:7.14%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the marketing authorization holder of the authorized orphan product cannot supply enough orphan medicinal product. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since January 1, 2021, a separate process for orphan designation has applied in Great Britain. There is now no pre-marketing authorization orphan designation (as there is in the EU) in Great Britain and the application for orphan designation will be reviewed by the MHRA at the time of an MAA for a UK or Great Britain MA. The criteria for orphan designation are the same as in the EU, save that they apply to Great Britain only (e.g., there must be no satisfactory method of diagnosis, prevention or treatment of the condition concerned in Great Britain, as opposed to the EU, and the prevalence of the condition must not be more than five in 10,000 persons in the EU).</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Pediatric development </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the EU, companies developing a new medicinal product must agree upon a pediatric investigation plan, or PIP, with the EMA&#8217;s Pediatric Committee, or PDCO, and must conduct pediatric clinical trials in accordance with that PIP, unless a waiver applies, (e.g., because the relevant disease or condition occurs only in adults). <span style="color:#000000;">The PIP sets out the timing and measures proposed to generate data to support a pediatric indication of the drug for which marketing authorization is being sought.</span> The MAA for the product must include the results of pediatric clinical trials conducted in accordance with the PIP, unless a waiver applies, or a deferral has been granted <span style="color:#000000;">by the PDCO of the obligation to implement some or all of the measures of the PIP until there are sufficient data to demonstrate the efficacy and safety of the product in adults</span>, in which case the pediatric clinical trials must be completed at a later date. Products that are granted a marketing authorization with the results of the pediatric clinical trials conducted in accordance with the PIP are eligible for a six-month extension of the protection under a supplementary protection certificate (if any is in effect at the time of approval) even where the trial results are negative. In the case of orphan medicinal products, a two-year extension of the orphan market exclusivity may be available. This pediatric reward is subject to specific conditions and is not automatically available when data in compliance with the PIP are developed and submitted. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">PRIME Designation </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2016, the EMA launched an initiative to facilitate development of product candidates in indications, often rare, for which few or no therapies currently exist. The PRIority MEdicines, or PRIME, scheme is intended to encourage drug development in areas of unmet medical need and provides accelerated assessment of products representing substantial innovation, where the MAA will be made through the centralized procedure. Eligible products must target conditions for which where is an unmet medical need (there is no satisfactory method of diagnosis, prevention or treatment in the EEA or, if there is, the new medicine will bring a major therapeutic advantage) and they must demonstrate the potential to address the unmet medical need by introducing new methods of therapy or improving existing ones. Products from small- and medium-sized enterprises may qualify for earlier entry into the PRIME scheme than larger companies. Many benefits accrue to sponsors of product candidates with PRIME designation, including but not limited to, early and proactive regulatory dialogue with the EMA, frequent discussions on clinical trial designs and other development program elements, and accelerated MAA assessment once a dossier has been submitted. Importantly, a dedicated EMA contact and rapporteur from the CHMP or CAT are appointed early in the PRIME scheme facilitating increased understanding of the product at EMA&#8217;s Committee level. A kick-off meeting initiates these relationships and includes a team of multidisciplinary experts at the EMA to provide guidance on the overall development and regulatory strategies. Where, during the course of development, a medicine no longer meets the eligibility criteria, support under the PRIME scheme may be withdrawn.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Post-approval controls </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Following approval, the holder of the marketing authorization is required to comply with a range of requirements applicable to the manufacturing, marketing, promotion and sale of the medicinal product. These include the following:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">The holder of a marketing authorization must establish and maintain a pharmacovigilance system and appoint an individual qualified person for pharmacovigilance, who is responsible for oversight of that system. Key obligations include expedited reporting of suspected serious adverse reactions and submission of periodic safety update reports, or PSURs. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">All new MAAs must include a risk management plan, or RMP, describing the risk management system that the company will put in place and documenting measures to prevent or minimize the risks associated with the product. The regulatory authorities may also impose specific obligations as a condition of the marketing authorization. Such risk-minimization measures or post-authorization obligations may include additional safety monitoring, more frequent submission of PSURs, or the conduct of additional clinical trials or post-authorization safety studies. RMPs and PSURs are routinely available to third parties requesting access, subject to limited redactions. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">All advertising and promotional activities for the product must be consistent with the approved SmPC and therefore all off-label promotion is prohibited. Direct-to-consumer advertising of prescription medicines is also prohibited in the European Union. Although general requirements for advertising and promotion of medicinal products are established under European Union directives, the details are governed by regulations in each European Union Member State and can differ from one country to another. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Brexit and the Regulatory Framework in the UK </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the electorate in the UK voted in favor of leaving the EU (commonly referred to as &#8220;Brexit&#8221;), and the UK formally left the EU on January 31, 2020. There was a transition period during which EU pharmaceutical laws continued to apply to the UK, which expired on December 31, 2020. However, the EU and the UK have concluded a trade and cooperation agreement, or TCA, which was provisionally applicable since January 1, 2021 and has been formally applicable since May 1, 2021. The TCA includes specific provisions concerning pharmaceuticals, which include the mutual recognition of GMP, inspections of manufacturing facilities for medicinal products and GMP documents issued, but does not foresee wholesale mutual recognition of UK and EU pharmaceutical regulations. At present, Great Britain has implemented EU legislation on the marketing, promotion and sale of medicinal products through the Human Medicines Regulations 2012 (as amended) (under the Northern Ireland Protocol, the EU regulatory framework will continue to apply in Northern Ireland). The regulatory regime in Great Britain therefore largely aligns with current EU regulations, however it is possible that these regimes will diverge in future now that Great Britain&#8217;s regulatory system is independent from the EU and the TCA does not provide for mutual recognition of UK and EU pharmaceutical legislation. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Other healthcare laws and compliance requirements </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, our current and future operations are subject to regulation by various federal, state and local authorities in addition to the FDA, including but not limited to, the Centers for Medicare and Medicaid Services, or CMS, other divisions of the U.S. Department of Health and Human Services, or HHS (such as the Office of Inspector General, Office for Civil Rights and the Health Resources and Service Administration), the U.S. Department of Justice, or DOJ, and individual U.S. Attorney offices within the DOJ, and state and local governments. For example, our clinical research, sales, marketing and scientific/educational grant programs may have to comply with the anti-fraud and abuse provisions of the Social Security Act, the false claims laws, the privacy and security provisions of the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, and similar state laws, each as amended, as applicable:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:7.14%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the federal Anti-Kickback Statute, which prohibits, among other things, knowingly and willfully soliciting, receiving, offering or paying any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, either the referral of an individual, or the purchase, lease, order, arrangement or recommendation of any good, facility, item or service for which payment may be made, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs&#59; a person or entity does not need to have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it to have committed a violation. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act or federal civil money penalties statute&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:7.14%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the federal civil and criminal false claims laws and civil monetary penalty laws, including the False Claims Act, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, false or fraudulent claims for payment to, or approval by Medicare, Medicaid, or other federal healthcare programs, knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim or an obligation to pay or transmit money to the federal government, or knowingly concealing or knowingly and improperly avoiding or decreasing or concealing an obligation to pay money to the federal government. Manufacturers can be held liable under the False Claims Act even when they do not submit claims directly to government payers if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims. The False Claims Act also permits a private individual acting as a &#8220;whistleblower&#8221; to bring actions on behalf of the federal government alleging violations of the False Claims Act and to share in any monetary recovery&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:7.14%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the anti-inducement law, which prohibits, among other things, the offering or giving of remuneration, which includes, without limitation, any transfer of items or services for free or for less than fair market value (with limited exceptions), to a Medicare or Medicaid beneficiary that the person knows or should know is likely to influence the beneficiary&#8217;s selection of a particular supplier of items or services reimbursable by a federal or state governmental program&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:7.14%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">HIPAA, which created new federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g.,&#160;public or private) and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false, fictitious, or fraudulent statements or representations in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters&#59; similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:7.14%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, and their respective implementing regulations, which impose requirements on certain covered healthcare providers, health plans, and healthcare clearinghouses as well as their respective business associates that perform services for them that involve the use, or disclosure of, individually identifiable health information, relating to the privacy, security and transmission of individually identifiable health information&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:7.14%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the federal transparency requirements under the ACA, including the provision commonly referred to as the Physician Payments Sunshine Act, and its implementing regulations, which requires applicable manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program to report annually to the U.S. Department of Health and Human Services, CMS, information related to payments or other transfers of value made to physicians (defined to </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:7.14%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="font-size:10pt;color:#000000;">include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as ownership and investment interests held by the physicians described above and their immediate family members. Effective January 1, 2022, these reporting obligations extend to include transfers of value made to certain non-physician providers such as physician assistants and nurse practitioners&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:7.14%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">federal government price reporting laws, which require us to calculate and report complex pricing metrics in an accurate and timely manner to government programs&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:7.14%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, we are subject to state and foreign equivalents of each of the healthcare laws and regulations described above, among others, some of which may be broader in scope and may apply regardless of the payor. Many U.S. states have adopted laws similar to the federal Anti-Kickback Statute and False Claims Act, and may apply to our business practices, including, but not limited to, research, distribution, sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental payors, including private insurers. In addition, some states have passed laws that require pharmaceutical companies to comply with the April&#160;2003 Office of Inspector General Compliance Program Guidance for Pharmaceutical Manufacturers and/or the Pharmaceutical Research and Manufacturers of America&#8217;s Code on Interactions with Healthcare Professionals. Several states also impose other marketing restrictions or require pharmaceutical companies to make marketing or price disclosures to the state. There are ambiguities as to what is required to comply with these state requirements and if we fail to comply with an applicable state law requirement, we could be subject to penalties. Finally, there are state and&#160;foreign laws governing the privacy and security of health information (e.g., the California Consumer Privacy Act), many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may also be subject to additional privacy restrictions. The collection, use, storage, disclosure, transfer, or other processing of personal data regarding individuals in the European Economic Area, or EEA, including personal health data, is subject to the General Data Protection Regulation 2016/679 (EU GDPR), which became effective on May 25, 2018. Further to Brexit on January 31, 2020 and the expiry of the subsequent transition period on December 31, 2020, the EU GDPR has been brought into UK law as the &#8220;UK GDPR&#8221;. In the present document, references to &#8220;GDPR&#8221; are meant to include both the EU and the UK GDPR, unless specified. The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal data. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Violations of fraud and abuse laws may be punishable by criminal and/or civil sanctions, including penalties, fines, imprisonment and/or exclusion or suspension from federal and state healthcare programs such as Medicare and Medicaid and debarment from contracting with the U.S. government. In addition, private individuals have the ability to bring actions on behalf of the U.S. government under the federal False Claims Act as well as under the false claims laws of several states. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Law enforcement authorities are increasingly focused on enforcing fraud and abuse laws, and it is possible that some of our practices may be challenged under these laws. Efforts to ensure that our current and future business arrangements with third parties, and our business generally, will comply with applicable healthcare laws and regulations will involve substantial costs. If our operations, including our arrangements with physicians and other healthcare providers<span style="font-weight:bold;font-style:italic;"> </span>are found to be in violation of any of such laws or any other governmental regulations that apply to us, we may be subject to penalties, including, without limitation, administrative, civil and criminal penalties, damages, fines, disgorgement, contractual damages, reputational harm, diminished profits and future earnings, the curtailment or restructuring of our operations, exclusion from participation in federal and state healthcare programs (such as Medicare and Medicaid), and imprisonment, any of which could adversely affect our ability to operate our business and our financial results. In addition, our gene therapy programs for Strimvelis and Libmeldy were approved by the EMA in 2016 and 2020, respectively, and the approval and commercialization of Strimvelis and Libmeldy subjects us to foreign equivalents of the healthcare laws mentioned above, among other foreign laws. The approval and commercialization of any of our other gene therapies outside the United States will also likely subject us to foreign equivalents of the healthcare laws mentioned above, among other foreign laws. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any of the physicians or other healthcare providers or entities with whom we expect to do business are found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs, which may also adversely affect our business. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The risk of our being found in violation of these laws is increased by the fact that many of these laws have not been fully interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of interpretations. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. The shifting compliance environment and the need to build and maintain a robust system to comply with multiple jurisdictions with different compliance and reporting requirements increases the possibility that a healthcare company may violate one or more of the requirements. Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial cost. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Healthcare reform</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and other payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medical products. For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or ACA, was enacted, which, among other things, increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate Program&#59; introduced a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected&#59; extended the Medicaid Drug Rebate Program to utilization of prescriptions of individuals enrolled in Medicaid managed care plans&#59; imposed mandatory discounts for certain Medicare Part D beneficiaries as a condition for manufacturers&#8217; outpatient drugs coverage under Medicare Part D&#59; subjected drug manufacturers to new annual, nondeductible fees based on pharmaceutical companies&#8217; share of sales to federal healthcare programs&#59; imposed a new federal excise tax on the sale of certain medical devices&#59; expanded healthcare fraud and abuse laws, including the False Claims Act and the Anti-Kickback Statute, new government investigative powers and enhanced penalties for non-compliance&#59; expanded eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals with income at or below 133% of the federal poverty level, thereby potentially increasing manufacturers&#8217; Medicaid rebate liability&#59; expanded the entities eligible for discounts under the PHS Act&#8217;s pharmaceutical pricing program, also known as the 340B Drug Pricing Program&#59; created new requirements to report financial arrangements with physicians and teaching hospitals, commonly referred to as the Physician Payments Sunshine Act&#59; created a new requirement to annually report the identity and quantity of drug samples that manufacturers and authorized distributors of record provide to physicians&#59; created a new Patient Centered Outcomes Research Institute to oversee, identify priorities in and conduct comparative clinical effectiveness research, along with funding for such research&#59; and established the Center for Medicare Innovation at the CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some of the provisions of the ACA have yet to be implemented, and there have been legal and political challenges to certain aspects of the ACA. Since its enactment, there have been judicial, Congressional and executive challenges to certain aspects of the ACA. In June 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. Prior to the Supreme Court&#8217;s decision, President Biden issued an executive order to initiate a special enrollment period from February 15, 2021 through August 15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is unclear how other healthcare reform measures of the Biden administration or other efforts, if any, to challenge, repeal or replace the ACA will impact our business.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the Biden administration, in October 2017, former President Trump signed an Executive Order terminating the cost-sharing subsidies that reimburse insurers under the ACA. The former Trump administration concluded that cost-sharing reduction, or CSR, payments to insurance companies required under the ACA have not received necessary appropriations from Congress and announced that it will discontinue these payments immediately until those appropriations are made. Several state Attorneys General filed suit to stop the administration from terminating the subsidies, but their request for a restraining order was denied by a federal judge in California on October 25, 2017. On August 14, 2020, the U.S. Court of Appeals for the Federal Circuit ruled in two separate cases that the federal government is liable for the full amount of unpaid CSRs for the years preceding and including 2017. For CSR claims made by health insurance companies for years 2018 and later, further litigation will be required to determine the amounts due, if any. Further, on June 14, 2018, the U.S. Court of Appeals for the Federal Circuit ruled that the federal government was not required to pay more than $12 billion in ACA risk corridor payments to third-party payors who argued the payments were owed to them. On April 27, 2020, the United States Supreme Court reversed the U.S. Court of Appeals for the Federal Circuit's decision and remanded the case to the U.S. Court of Federal Claims, concluding the government has an obligation to pay these risk corridor payments under the relevant </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">formula. It is unclear what impact these rulings will have on our business.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, CMS published a final rule that would give states greater flexibility as of 2020 in setting benchmarks for insurers in the individual and small group marketplaces, which may have the effect of relaxing the essential health benefits required under the ACA for plans sold through such marketplaces.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 20, 2019, former President Trump signed into law the Further Consolidated Appropriations Act (H.R. 1865), which repeals the Cadillac tax, the health insurance provider tax, and the medical device excise tax.&#160; It is impossible to determine whether similar taxes could be instated in the future. Other legislative changes have been proposed and adopted since the ACA was enacted: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">In August 2011, President Obama signed into law the Budget Control Act of 2011, which, among other things, created the Joint Select Committee on Deficit Reduction to recommend to Congress proposals in spending reductions. The Joint Select Committee on Deficit Reduction did not achieve a targeted deficit reduction of at least $1.2 trillion for fiscal years 2012 through 2021, triggering the legislation&#8217;s automatic reduction to several government programs. This includes aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, which went into effect beginning on April&#160;1, 2013 and, due to legislation amendments to the statute, including the BBA, will stay in effect through 2030 unless additional Congressional action is taken. However, pursuant to the Coronavirus Aid, Relief and Economic Security Act, or CARES Act, and subsequent legislation, these Medicare sequester reductions are suspended from May 1, 2020 through March 31, 2022 due to the COVID-19 pandemic. Following the temporary suspension, a&#160;1% payment reduction will occur beginning&#160;April 1, 2022&#160;through June 30, 2022, and the 2% payment reduction&#160;will resume on July 1, 2022.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">In January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">On April 13, 2017, CMS published a final rule that gives states greater flexibility in setting benchmarks for insurers in the individual and small group marketplaces, which may have the effect of relaxing the essential health benefits required under the ACA for plans sold through such marketplaces.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">On May 30, 2018, the Right to Try Act, was signed into law. The law, among other things, provides a federal framework for certain patients to access certain investigational new drug products that have completed a Phase 1 clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA permission under the FDA expanded access program. There is no obligation for a pharmaceutical manufacturer to make its drug products available to eligible patients as a result of the Right to Try Act. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">On&#8239;May 23, 2019, CMS published a final rule to allow Medicare Advantage Plans the option of using step therapy for Part B drugs beginning January 1, 2020. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">On December 20, 2019, former President Trump signed into law the Further Consolidated Appropriations Act (H.R. 1865), which repealed the Cadillac tax, the health insurance provider tax, and the medical device excise tax.&#160;&#160;It is impossible to determine whether similar taxes could be instated in the future.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. At the federal level, the Trump administration&#8217;s budget proposal for fiscal year 2021 includes a $135 billion allowance to support legislative proposals seeking to reduce drug prices, increase competition, lower out-of-pocket drug costs for patients, and increase patient access to lower-cost generic and biosimilar drugs. On March 10, 2020, the Trump administration sent &#8220;principles&#8221; for drug pricing to Congress, calling for legislation that would, among other things, cap Medicare Part D beneficiary out-of-pocket pharmacy expenses, provide an option to cap Medicare Part D beneficiary monthly out-of-pocket expenses, and place limits on pharmaceutical price increases. . Further, the Trump administration also previously released a &#8220;Blueprint&#8221;, or plan, to lower drug prices and reduce out of pocket costs of drugs that contains additional proposals to increase drug manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products, and reduce the out of pocket costs of drug products paid by consumers. HHS has already started the process of soliciting feedback on some of these measures and, at the same, is immediately implementing others under its existing authority. For example, in May 2019, CMS issued a final rule to allow Medicare Advantage Plans the option of using step therapy, a type of prior authorization, for Part B drugs beginning January 1, 2020. This final rule codified CMS&#8217;s policy change that became effective January 1, 2019. In </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">addition, there has been several changes to the 340B drug pricing program, which imposes ceilings on prices that drug manufacturers can charge for medications sold to certain health care facilities. On December 27, 2018, the District Court for the District of Columbia invalidated a reimbursement formula change under the 340B drug pricing program, and CMS subsequently altered the FYs 2019 and 2018 reimbursement formula on specified covered outpatient drugs (&#8220;"SCODs&#8221;"). The court ruled this change was not an &#8220;adjustment&#8221; which was within the Secretary&#8217;s discretion to make but was instead a fundamental change in the reimbursement calculation. However, most recently, on July 31, 2020, the U.S. Court of Appeals for the District of Columbia Circuit overturned the district court&#8217;s decision and found that the changes were within the Secretary&#8217;s authority. On September 14, 2020, the plaintiffs-appellees filed a Petition for Rehearing En Banc (i.e., before the full court), but was denied on October 16, 2020.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> P</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">laintiffs-appellees filed a petition for a writ of certiorari at the Supreme Court on February 10, 2021. On Friday July 2, 2021, the Supreme Court granted the petition.&#160;&#160;It is unclear how these developments could affect covered hospitals who might purchase our future products and affect the rates we may charge such facilities for our approved products in the future, if any. While a number of these and other proposed measures will require authorization through additional legislation to become effective, Congress and has indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, there has been increasing legislative and enforcement interest in the United States with respect to drug pricing practices.&#160;&#160;Specifically, there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, and review the relationship between pricing and manufacturer patient programs.&#160;&#160;At a federal level, President Biden signed an Executive Order on July 9, 2021 affirming the administration&#8217;s policy to (i) support legislative reforms that would lower the prices of prescription drug and biologics, including by allowing Medicare to negotiate drug prices, by imposing inflation caps, and, by supporting the development and market entry of lower-cost generic drugs and biosimilars&#59; and (ii) support the enactment of a public health insurance option. Among other things, the Executive Order also directs HHS to provide a report on actions to combat excessive pricing of prescription drugs, enhance the domestic drug supply chain, reduce the price that the Federal government pays for drugs, and address price gouging in the industry&#59; and directs the FDA to work with states and Indian Tribes that propose to develop section 804 Importation Programs in accordance with the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, and the FDA&#8217;s implementing regulations. FDA released such implementing regulations on September 24, 2020, which went into effect on November 30, 2020, providing guidance for states to build and submit importation plans for drugs from Canada. On September 25, 2020, CMS stated drugs imported by states under this rule will not be eligible for federal rebates under Section 1927 of the Social Security Act and manufacturers would not report these drugs for &#8220;best price&#8221; or Average Manufacturer Price purposes. Since these drugs are not considered covered outpatient drugs, CMS further stated it will not publish a National Average Drug Acquisition Cost for these drugs. If implemented, importation of drugs from Canada may materially and adversely affect the price we receive for any of our product candidates. Further, on November 20, 2020 CMS issued an Interim Final Rule implementing the Most Favored Nation, or MFN, Model under which Medicare Part B reimbursement rates would have been be calculated for certain drugs and biologicals based on the lowest price drug manufacturers receive in Organization for Economic Cooperation and Development countries with a similar gross domestic product per capita.&#160;&#160;However, on December 29, 2021 CMS rescinded the Most Favored Nations rule. Additionally, on November 30, 2020, HHS published a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. Pursuant to court order, the removal and addition of the aforementioned safe harbors were delayed and recent legislation imposed a moratorium on implementation of the rule until January 1, 2026. Although a number of these and other proposed measures may require authorization through additional legislation to become effective, and the Biden administration may reverse or otherwise change these measures, both the Biden administration and Congress have indicated that they will continue to seek new legislative measures to control drug costs.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Individual states in the United States have also increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Coverage and reimbursement </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant uncertainty exists as to the coverage and reimbursement status of any gene therapies for which we obtain regulatory approval. In the United States and markets in other countries, sales of any gene therapies for which we receive </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regulatory approval for commercial sale will depend, in part, on the availability of coverage and reimbursement from payors. Payors include government authorities, managed care providers, private health insurers and other organizations. Patients who are prescribed treatments for their conditions and providers generally rely on these third-party payors to reimburse all or part of the associated healthcare. The process for determining whether a payor will provide coverage for a product may be separate from the process for setting the reimbursement rate that the payor will pay for the product. Payors may limit coverage to specific products on an approved list, or formulary, which might not include all of the FDA-approved products for a particular indication. A decision by a payor not to cover our gene therapies could reduce physician utilization of our products once approved and have a material adverse effect on our sales, results of operations and financial condition. Moreover, a payor&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development and manufacturing costs. Further, due to the COVID-19 pandemic, millions of individuals have lost or may lose employer-based insurance coverage, which may adversely affect our ability to commercialize our products in certain jurisdictions.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, coverage and reimbursement for products can differ significantly from payor to payor. One payor&#8217;s decision to cover a particular medical product or service does not ensure that other payors will also provide coverage for the medical product or service, or will provide coverage at an adequate reimbursement rate. In the United States, the principal decisions about reimbursement for new medicines are typically made by the Centers for Medicare &#38; Medicaid Services, or CMS, an agency within the U.S. Department of Health and Human Services. CMS decides whether and to what extent a new medicine will be covered and reimbursed under Medicare and private payors tend to follow CMS to a substantial degree.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, the coverage determination process will require us to provide scientific and clinical support for the use of our products to each payor separately and will be a time-consuming process. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payors are increasingly challenging the price and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. In order to obtain and maintain coverage and reimbursement for any product, we may need to conduct expensive evidence generation studies in order to demonstrate the medical necessity and cost-effectiveness of such a product, in addition to the costs required to obtain regulatory approvals. If payors do not consider a product to be cost-effective compared to current standards of care, they may not cover the product as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow a company to cover its costs or make a profit. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outside of the United States, the pricing of pharmaceutical products is subject to governmental control in many countries. For example, in the EU, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only after a reimbursement price has been agreed with the government authority. Furthermore, some countries may require the completion of additional studies that compare the effectiveness and/or cost-effectiveness of a particular therapy to current standards of care as part of so-called health technology assessments, or HTAs, in order to obtain reimbursement or pricing approval. Additionally, there may be a need for activities to secure reimbursement for procedures associated with products administered in a hospital setting, such as Libmeldy, under the diagnosis-related group, or DRG, system, whereby a billing code may not exist or may be currently insufficient to cover the cost of the procedure. In other instances, countries may monitor and control product volumes and issue guidance to physicians to limit prescriptions in the form of treatment policies. Efforts to control prices and utilization of pharmaceutical products and medical devices will likely continue as countries attempt to manage healthcare expenditures.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Employees and Human Capital Resources</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, we had 259 full-time employees. We have no collective bargaining agreements with our employees, and we have not experienced any work stoppages. We consider our relationship with our employees to be positive.<span style="font-size:12pt;"> </span>We monitor employee engagement through an annual survey and develop a prioritized action plan on an annual basis to address any areas in need of attention. Our human capital objectives include, as applicable, identifying, recruiting, developing, retaining, and incentivizing our existing and prospective employees, as well as optimizing the overall employee experience. The principal purposes of our incentive plans are to attract, retain and motivate our employees. The granting of share-based compensation awards is designed to reward selected employees for long-term shareholder value creation and our cash-based performance bonus awards reward the achievement of annual performance goals. The health and safety of our employees, customers and communities are of primary concern. During the COVID-19 pandemic, we have taken significant steps to protect our workforce, including, but not limited to, working remotely and implementing social distancing protocols consistent with guidelines issued by federal, state and local laws. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Corporate Information</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We were originally incorporated under the laws of England and Wales in August 2018 as Orchard Rx Limited (now known as Orchard Therapeutics plc) to become a holding company for Orchard Therapeutics (Europe) Limited (previously known as Orchard Therapeutics Limited). Orchard Rx Limited subsequently re-registered as a public limited company and its name was changed from Orchard Rx Limited to Orchard Therapeutics plc in October 2018. Orchard Therapeutics (Europe) Limited was originally incorporated under the laws of England and Wales in September 2015 as Newincco 1387 Limited and subsequently changed its name to Orchard Therapeutics Limited in November 2015 and to Orchard Therapeutics (Europe) Limited in October 2018. Our registered office is located at 108 Cannon Street, London EC4N 6EU, United Kingdom, and our telephone number is +44 (0) 203 808 8286. Our website address is www.orchard-tx.com. We do not incorporate the information on or accessible through our website into this Annual Report, and you should not consider any information on, or that can be accessed through, our website as part of this Annual Report. We make available free of charge through our website our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to these reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, as soon as reasonably practicable after we electronically file or furnish such materials to the U.S. Securities and Exchange Commission.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_1A_RISK_FACTORS">Item 1A. Risk Factors. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Our business faces significant risks. This section of the Annual Report highlights some of the risks that may affect our future operating results. You should carefully consider the risks described below, as well as in our consolidated financial statements and the related notes included elsewhere in this Annual Report and in our other SEC filings. The occurrence of any of the events or developments described below could harm our business, financial condition, results of operations and prospects. This Annual Report also contains forward-looking statements that involve risks and uncertainties. Our results could materially differ from those anticipated in forward-looking statements as a result of certain factors, including the risks described below and elsewhere in this Annual Report and our other SEC filings. See &#8220;Special Note Regarding Forward-Looking Statements&#8221; above. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks related to our financial position and need for additional capital</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have incurred net losses since inception. We expect to incur net losses for the foreseeable future and may never achieve or maintain profitability.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since inception, we have incurred net losses. We incurred net losses of $144.6 million and $152.0 million for the years ended December 31, 2021 and 2020, respectively. We historically have financed our operations primarily through private placements of our convertible preferred shares and through sales of our ADSs in our initial public offering and follow-on offering. We have devoted substantially all of our efforts to research and development, including clinical and preclinical development and arranging the manufacturing of our product candidates, establishing a commercial infrastructure to support the commercialization of Libmeldy in the European Union, building a global commercial infrastructure to support commercialization of Libmeldy (OTL-200) and our product candidates, if approved, as well as expanding our team. Prior to the approval of Libmeldy in Europe in December 2020, Strimvelis was our only product approved for sale, and in March 2022, we announced our decision to discontinue our investment in and seek alternatives for Strimvelis. Absent the realization of sufficient revenues from product sales of Libmeldy and Strimvelis, and from sales of our current or future product candidates, if approved, we may never attain profitability.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> We expect to continue to incur significant expenses and operating losses for the foreseeable future, particularly if, and as, we:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>seek marketing approvals for our product candidates that successfully complete clinical trials or meet primary endpoints, if any&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>market and sell Libmeldy in Europe and grow our commercial infrastructure for the commercialization (or anticipated commercialization) of any product candidates that we may submit for and obtain marketing approval anywhere in the world&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>continue the development of our product candidates&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>continue our ongoing clinical trials and any required regulatory updates for certain deprioritized programs&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>conduct investigational new drug application, or IND, or clinical trial application, or CTA, enabling studies for our preclinical programs&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>initiate additional clinical trials and preclinical studies for our other product candidates or future product candidates, including new research programs in genetic subsets of frontotemporal dementia, or FTD, and Crohn&#8217;s disease&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>seek to identify and develop, acquire or in-license additional product candidates or technologies&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>develop the necessary processes, controls and manufacturing data to obtain marketing approval for our product candidates, to support technology and process innovation, and to support manufacturing of product to commercial scale&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>establish partnerships with contract development and manufacturing organizations, or CDMOs&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">develop and implement plans to establish and operate our own in-house manufacturing operations and facility in the long-term&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>hire and retain personnel, such as non-clinical, clinical, pharmacovigilance, quality, regulatory affairs, process development and control, manufacturing, supply chain, legal, compliance, medical affairs, finance, general and administrative, commercial and scientific personnel&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>encounter delays or setbacks in the preclinical testing, enrollment or conduct of our clinical trials for our product candidates, encounter delays in regulatory review timelines, or experience high levels of absenteeism due to the COVID-19 pandemic&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>develop, maintain, expand and protect our intellectual property portfolio&#59; and</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>comply with our obligations as a public company.</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since receiving marketing authorization, only a limited number of patients have been treated with Strimvelis and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Libmeldy. There is no assurance that revenue from sales of Libmeldy and Strimvelis alone will be sufficient for us to become profitable. To become and remain profitable, we must </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">develop and eventually commercialize product candidates with greater market potential. This will require us to be successful in a range of challenging activities, and our expenses will increase as we seek to complete necessary preclinical studies and clinical trials of our product candidates, and manufacture, market and sell Libmeldy or any future product candidates for which we may obtain marketing approval, if any, and satisfy any post-marketing requirements. We may never succeed in any or all of these activities and, even if we do, we may never generate revenues that are significant or large enough to achieve profitability. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of our company and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have only generated limited sales revenue to date, and we may never be profitable. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our ability to generate revenue from product sales and achieve profitability depends on our ability, alone or with collaborative partners, to successfully develop and commercialize products. Although we have generated revenue from the sale of Libmeldy and Strimvelis in Europe, we will not achieve profitability unless and until we <span style="color:#000000;">complete the development of, and obtain the regulatory approvals necessary to commercialize, additional product candidates. </span>Our ability to generate future revenues from product sales depends heavily on our and or our collaborators&#8217; success in: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>completing research and preclinical development of our product candidates and identifying attractive new gene therapy product candidates&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>conducting and fully enrolling clinical trials in the development of our product candidates, including maintaining or reaching target enrollment levels and collecting the necessary follow-up data during the COVID-19 pandemic&#59;<span style="font-weight:bold;font-style:italic;"> </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>seeking and obtaining regulatory and marketing approvals for product candidates for which we complete registrational clinical trials that achieve their primary endpoints&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>successfully commercializing Libmeldy in Europe and other product candidates for which we obtain regulatory and marketing approval by expanding our existing sales force, marketing and distribution infrastructure or, alternatively, collaborating with a commercialization partner&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>maintaining marketing authorization and related post-marketing commitments for regulatory compliance for Libmeldy and Strimvelis in the European Union&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>qualifying for, and maintaining, adequate coverage and reimbursement by government and payors for Libmeldy and Strimvelis and any product candidate for which we obtain marketing approval&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>establishing and maintaining supply and manufacturing processes and relationships with third parties that can provide adequate, in both amount and quality, products and services to support clinical development of our product candidates and the market demand for Libmeldy and Strimvelis, if sales are resumed, and any of our product candidates for which we obtain marketing approval&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>obtaining market acceptance of Libmeldy, Strimvelis and our product candidates, if approved, as viable treatment options with acceptable safety profiles&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>addressing any competing technological and market developments&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>implementing additional internal systems and infrastructure, as needed, including robust quality systems and manufacturing capabilities&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>negotiating favorable terms in any collaboration, licensing or other arrangements into which we may enter and performing our obligations under such arrangements&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>maintaining, protecting and expanding our portfolio of intellectual property rights, including patents, trade secrets and know-how&#59; and</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>attracting, hiring and retaining qualified personnel.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect that we will continue to incur significant costs associated with commercializing Libmeldy in Europe and any other products for which we obtain marketing approval. Our expenses could increase beyond expectations if we are required by the United States Food and Drug Administration, or the FDA, or the EMA or other regulatory authorities to perform clinical and other studies in addition to those that we currently anticipate or if we encounter delays or clinical holds in the development of our product candidates. <span style="color:#000000;">Even if we generate more significant revenue from sales of Strimvelis and Libmeldy in Europe and are able to generate revenues from the sale of any other approved products, we </span>may not become profitable and may need to obtain additional funding to continue operations.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We will need additional funding, which may not be available on acceptable terms or at all. Failure to obtain necessary capital when needed may force us to delay, limit or terminate our product development efforts or other operations.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our operations have consumed a substantial amount of cash since our inception. We recorded negative cash flows from operating activities in 2021, primarily due to our net loss of $144.6 million for that year. We expect to continue to incur substantial expenses in connection with our ongoing activities, which may increase over time, particularly as we (i) continue to commercialize Libmeldy in Europe, (ii) continue the research and development of, initiate further clinical trials of and seek marketing approval for, our product candidates and (iii) continue to enhance and optimize our vector technology and manufacturing processes. In addition, we expect to incur significant expenses related to product sales, post-marketing regulatory commitments, medical affairs, marketing, manufacturing, distribution and quality systems to support Libmeldy and any other products for which we obtain marketing approval. Furthermore, we will continue to incur costs associated with operating as a public company, including with respect to the system and process evaluations and testing of our internal controls and financial reporting. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on reasonable terms, or at all, we would be forced to delay, reduce or eliminate certain of our ongoing activities, such as research and development programs and commercialization efforts. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our future capital requirements will depend on many factors, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the success of our commercialization efforts and market acceptance of Libmeldy in Europe&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the cost and our ability to maintain the commercial infrastructure and manufacturing capabilities to support Libmeldy in Europe and any other products for which we obtain marketing approval, including costs relating to quality systems, regulatory affairs, compliance, product sales, medical affairs, commercial marketing, manufacturing and distribution&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>qualifying for, and maintaining, adequate coverage and reimbursement by government and payors on a timely basis for Libmeldy and any other products for which we obtain marketing approval&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the costs of preparing and submitting marketing approvals for any of our product candidates that successfully complete clinical trials, and the costs of maintaining marketing authorization and related post-marketing commitments for regulatory compliance for any products for which we obtain marketing approval&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the scope, progress, results and costs of drug discovery, laboratory testing, preclinical development and clinical trials for our product candidates or future product candidates, including the need to conduct long-term follow-up for up to 15 years for our development programs and additional clinical trials to support marketing approvals for our product candidates&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>our ability to enroll clinical trials in a timely manner and to quickly resolve any delays or clinical holds that may be imposed on our development programs, including our ability to resolve delays in trial enrollment as a result of the COVID-19 pandemic&#59;<span style="color:#968983;font-size:14.5pt;"> </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the costs associated with our manufacturing process development and evaluation of third-party manufacturers and suppliers&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the costs, timing and outcome of regulatory review of our product candidates&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>revenue, if any, received from commercial sales of Libmeldy, Strimvelis and any other products for which we may obtain marketing approval, including amounts reimbursed by government and third-party payors&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the terms of our current and any future license agreements and collaborations&#59; and</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the extent to which we acquire or in-license other product candidates, technologies and intellectual property.</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Identifying potential product candidates and conducting preclinical testing and clinical trials, as well as preparing for the potential commercialization of these product candidates, is a time-consuming, expensive and uncertain process that takes years to complete. We may never generate the necessary data or results required to obtain marketing approval and achieve product sales for any products other than Strimvelis. In addition, Libmeldy, Strimvelis and any other products for which we obtain and maintain marketing approval may not achieve commercial success. Any product revenues from our product candidates, if any, will be derived from or based on sales of products that may not be commercially available for many years, if at all. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Raising additional capital may cause dilution to our existing shareholders, restrict our operations or cause us to relinquish valuable rights.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may seek to raise capital through a combination of public and private equity offerings, debt financings, strategic partnerships and alliances and licensing arrangements. To the extent that we raise capital through the sale of equity, convertible debt securities or other equity-based derivative securities, ownership percentages of all our shareholders may be diluted and the terms may include liquidation or other preferences that adversely affect their rights as shareholders. Any additional indebtedness we incur would result in additional increased fixed payment obligations and could involve restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. Furthermore, the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our ADSs to decline and existing shareholders may not agree with our financing plans or the terms of such financings. If we raise funds through strategic partnerships, alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, or our product candidates, or grant licenses on terms unfavorable to us. Adequate financing may not be available to us on acceptable terms, or at all. The significant volatility in public equity markets <span style="color:#000000;">and the disruptions to the U.S. and global economies</span> caused by the COVID-19 pandemic may make it more difficult to raise capital through sales of our ADSs on favorable terms, or at all.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our limited operating history may make it difficult to evaluate the success of our business to date and to assess our future viability.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We were incorporated in August 2018 to become a holding company for Orchard Therapeutics (Europe) Limited, which was founded in 2015, and its subsidiaries. Our operations, to date, have been limited to corporate organization, recruiting key personnel, business planning, raising capital, acquiring certain of our product candidate portfolios and rights to our technology, identifying potential product candidates, undertaking preclinical studies and planning and supporting clinical trials of our product candidates, establishing research and development and manufacturing capabilities, establishing a quality management system, establishing a commercial infrastructure to support the commercialization of Strimvelis in the European Union and building a global commercial infrastructure to support commercialization of Libmeldy. We have not yet demonstrated the ability to manufacture products on a commercial scale or conduct sales and marketing activities necessary for successful commercialization. Consequently, any predictions about our future success or viability may not be as accurate as they might be if we had a longer operating history. In addition, as a new business, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors and setbacks.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks related to the discovery, development and regulatory approval of our product candidates</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our gene therapy product candidates are based on a novel technology, which makes it difficult to predict the time and cost of product candidate development and of subsequently obtaining regulatory approval.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;letter-spacing:-0.15pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have concentrated our research and development efforts on our autologous&#160;<span style="font-style:italic;">ex vivo</span>&#160;gene therapy approach, and our future success depends on our successful development of commercially viable gene therapy products. There can be no assurance that we will not experience problems or delays in developing new products and that such problems or delays will not cause unanticipated costs or that any such development problems can be solved. Although we have established a commercial infrastructure for the production of Strimvelis in the European Union and we are building a global commercial infrastructure to support commercialization of Libmeldy, we may experience delays in establishing a sustainable, reproducible and scalable manufacturing capability with commercial CDMO partners, which may prevent us from commercializing our product candidates for which we obtain marketing approval on a timely or profitable basis, if at all. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the clinical trial requirements of the FDA, EMA and other foreign regulatory authorities and the criteria these regulators use to determine the safety and efficacy of a product candidate can vary substantially, for example, based upon the type, complexity, novelty and intended use and market of such product candidates. The regulatory approval process </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for novel product candidates such as ours can be more expensive and take longer than</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the process</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> for other, better known or more extensively studied product candidates. To date, only a limited number of gene therapies have received marketing authorization from the FDA or EMA. We have limited experience in preparing, submitting and maintaining regulatory submissions. It is difficult to determine how long it will take or how much it will cost to obtain regulatory approvals for our product candidates in the United States</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, Europe</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">other jurisdictions</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or how long it will take to commercialize Libmeldy in </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Europe</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or any other product candidates for which we obtain marketing approval. Approvals by the EMA may not be indicative of what the FDA may require for approval, and vice versa.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The results from our clinical trials for OTL-200 for MLD and for any of our other product candidates may not be sufficiently robust to support marketing approval or the submission of marketing approval. Before we submit our product candidates for marketing approval, the FDA or the EMA may require us to conduct additional clinical trials or evaluate patients for an additional follow-up period.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The results from our clinical trials may not be sufficiently robust to support the approval of or submission of marketing approval for our product candidates, including by the FDA for OTL-200. The FDA and EMA normally require two registrational trials to approve a drug or biologic product, and therefore either the FDA or EMA might require that we conduct additional clinical trials of our product candidates prior to a BLA or MAA submission, respectively. The FDA and EMA typically do not consider a single registrational clinical trial to be adequate to serve as sufficient evidence to support a marketing authorization unless, among other things, (i) the trial is well-controlled and demonstrates a clinically meaningful effect on mortality, irreversible morbidity, or prevention of a disease with a potentially serious outcome and (ii) a confirmatory study would be practically or ethically impossible. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due to the nature of the indications our product candidates are designed to treat, and the limited number of patients with these conditions, a placebo-controlled and blinded study is not always practicable for ethical and other reasons.&#160;&#160;Accordingly, in some cases our registrational programs rely on natural history models to demonstrate clinical efficacy.&#160;&#160;While the FDA recognizes the potential for natural history models to alleviate the need for placebo arms in trials for drugs that target very rare diseases, where trial recruitment can be especially challenging, the FDA has found the use of natural history data as a historical comparator to be unsuitable for adequate and well-controlled trials in many circumstances. The FDA generally finds trials using historical controls to be credible only when the observed effect is large in comparison to variability in disease course. It is possible the FDA will not consider our comparisons to natural history data and, where available, historical transplant data or intra-subject comparison between before gene therapy and after gene therapy, to provide clinically meaningful results. Additionally, even though OTL-200 for MLD has achieved the primary endpoints in its ongoing registrational clinical trial, the FDA has not yet approved the clinical meaningfulness of the trial results and their sufficiency to support a marketing authorization. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, although the FDA cleared our IND application for OTL-200 in 2020 and we received Regenerative Medicine Advanced Therapy, or RMAT, designation in 2021, there can be no guarantee we will be successful in resolving open matters to the FDA&#8217;s satisfaction before the intended BLA submission, in which case the adequacy of our clinical endpoints, natural history analysis and CMC data package to support a potential BLA submission and approval will be review issues. We continue to engage with the FDA as we seek to address its recommendations <span style="color:#000000;">and identify expeditious paths to market for our product candidates</span>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> It is possible that the FDA or EMA may recommend or require us to conduct further studies, analyses or registrational trials with respect to our product candidates, possibly involving a larger sample size or a different clinical trial design. The FDA or EMA may also require that we conduct a longer follow-up period of patients treated with our product candidates prior to accepting a BLA or MAA submission, as applicable.<span style="color:#000000;"> </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, data obtained from preclinical and clinical activities are subject to varying interpretations, which may delay, limit or prevent regulatory approval. There can be no assurance that the FDA, EMA or other foreign regulatory bodies will find the efficacy endpoints in our registrational trials or any efficacy endpoint we propose in future registrational trials to be sufficiently validated and clinically meaningful, or that our product candidates will achieve the pre-specified endpoints in current or future registrational trials to a degree of statistical significance, and with acceptable safety profiles. The FDA may further refer any future BLA submission to an advisory committee for review, evaluation, and recommendation as to whether the application should be approved. This review may add to the time for approval, and although the FDA is not bound by the recommendation of an advisory committee, objections or concerns expressed by the advisory committee may cause the FDA to delay or deny approval. We also may experience regulatory delays or rejections as a result of many factors, including serious adverse events, or SAEs, involving our product candidates, changes in regulatory policy or changes in requirements </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">during the period of our product candidate development. Any such delays could materially and adversely affect our business, financial condition, results of operations and prospects.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect that the FDA and EMA will assess the totality of the safety and efficacy data from our product candidates in reviewing any future BLA or MAA submissions. Based on this assessment, the FDA or EMA may require that we conduct additional preclinical studies or clinical trials prior to submitting or approving a BLA or MAA for our target indications.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">It is possible that the FDA or EMA may not consider the results of our clinical trials, including reliance on foreign clinical data, to be sufficient for approval of our product candidates. If the FDA or EMA require additional trials, we would incur increased costs and delays in the marketing approval process, which may require us to expend more resources than we have available. In addition, it is possible that the FDA and EMA may have divergent opinions on the elements necessary for a successful BLA and MAA submission, respectively, which may cause us to alter our development, regulatory and/or commercialization strategies.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Regulatory requirements governing gene and cell therapy products have evolved and may continue to change in the future. Such requirements may lengthen the regulatory review process, require us to perform additional studies and increase our development costs or may force us to delay, limit or terminate certain of our programs.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regulatory requirements governing gene and cell therapy products have evolved and may continue to change in the future. The FDA has established the Office of Tissues and Advanced Therapies within its Center for Biologics Evaluation and Research, or CBER, to consolidate the review of gene therapy and related products, and has established the Cellular, Tissue and Gene Therapies Advisory Committee to advise CBER in its review when called upon. The NIH has refocused the NIH Recombinant DNA Advisory Committee and changed its name to the Novel and Exceptional Technology and Research Advisory Committee, or NExTRAC. NExTRAC is a federal advisory committee that provides recommendations to the NIH Director and a public forum for the discussion of the scientific, safety, and ethical issues associated with emerging biotechnologies, which include, but are not restricted to, technologies surrounding advances in recombinant or synthetic nucleic acid research such as human gene transfer. These regulatory review committees and advisory groups and any new guidelines they promulgate may lengthen the regulatory review process, require us to perform additional studies, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of these product candidates or lead to significant post-approval limitations or restrictions. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA and EMA have each expressed interest in further regulating biotechnology, including gene therapy and genetic testing. For example, the EMA advocates a risk-based approach to the development of a gene therapy product. Agencies at both the federal and state level in the United States, as well as U.S. congressional committees and other governments or governing agencies, have also expressed interest in further regulating the biotechnology industry. Such action may delay or prevent commercialization of some or all of our product candidates. Adverse events in clinical trials of gene therapy products conducted by others may cause the FDA or other oversight bodies to change the requirements for approval of any of our product candidates, which could require additional preclinical studies or clinical trials to support the marketing approval of our product candidates or which could make our product candidates unable to successfully obtain approval. Similarly, the European Commission may issue new guidelines concerning the development and marketing authorization for gene therapies and require that we comply with these new guidelines, which could require additional preclinical studies or clinical trials to support the marketing approval of our product candidates or which could make our product candidates unable to successfully obtain approval.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As we advance our product candidates, we are required to consult with these regulatory and advisory groups and comply with applicable guidelines. If we fail to do so, we may be required to delay or discontinue development of certain of our product candidates. These additional processes may result in a review and approval process that is longer than we otherwise would have expected. Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring a potential product to market could decrease our ability to generate sufficient product revenue, and our business, financial condition, results of operations and prospects might be materially and adversely affected.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA<span style="color:#000000;"> </span>and EMA have released a series of final guidance documents and a draft guidance document for consultation, which amongst other topics, included various aspects of gene therapy product development, review and approval, including aspects relating to clinical and manufacturing issues related to gene therapy products. We cannot be certain whether future guidance will be issued and be relevant to, or have an impact on, our gene therapy programs or the duration or expense of any applicable regulatory development and review processes.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Libmeldy</span><span style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">, Strimvelis</span><span style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> and our product candidates and the process for administering Libmeldy</span><span style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">, Strimvelis</span><span style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> and our product candidates may cause serious or undesirable side effects or adverse events or have other properties that could delay or prevent regulatory approval, limit commercial potential or result in significant negative consequences for our company. </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Following treatment with our gene therapies, patients may experience changes in their health, including illnesses, injuries, discomforts or a fatal outcome. It is possible that as we test our product candidates in larger, longer and more extensive clinical programs, or as use of our product candidates becomes more widespread if they receive regulatory approval, illnesses, injuries, discomforts and other adverse events that were observed in previous clinical trials, as well as conditions that did not occur or went undetected in previous clinical trials, will be reported by patients. Gene therapies are also subject to the potential risk that occurrence of adverse events will be delayed following administration of the gene therapy due to persistent biological activity of the genetic material or other components of the vectors used to carry the genetic material. Many times, additional safety risks, contraindications, drug interactions, adverse events and side effects are only detectable after investigational products are tested in larger scale registrational trials or, in some cases, after they are made available to patients on a commercial scale after approval. The FDA generally requires long-term follow-up of study subjects. Although the risk profile of a gene therapy candidate is a factor in determining the adequacy of such long-term follow-up, the FDA currently recommends that sponsors observe study subjects for potential gene therapy-related adverse events for a 15-year period, including a minimum of five years of annual examinations followed by ten years of annual queries, either in person or by questionnaire, of study subjects. If additional experience indicates that any of our product candidates -- or similar products developed by other companies -- have side effects or causes serious or life-threatening side effects, the development of such product candidate may fail or be delayed, or, if the product has received regulatory approval, such approval may be revoked or limited.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gene therapy is still a relatively new approach to disease treatment and additional adverse side effects could develop. Possible adverse side effects and adverse events that may occur with treatment with gene therapy products include an immunologic reaction early after administration that could substantially limit the effectiveness of the treatment or represent safety risks for patients. Another traditional safety concern for gene therapies using viral vectors has been the possibility of insertional mutagenesis (or oncogenesis) by the vectors, leading to malignant transformation of transduced cells. There have been several adverse events and SAEs attributed to gene therapy treatments in the past, including reported cases of leukemia with the use of gammaretrovirus vector and death seen in other clinical trials. In October 2020, we were notified that a patient treated with Strimvelis under a compassionate use program in 2016 had been diagnosed with <span style="color:#000000;">lymphoid T cell </span>leukemia. Subsequent findings confirmed that the patient&#8217;s leukemia was due to insertional oncogenesis attributable to treatment with Strimvelis. The EMA&#8217;s Committee for Medicinal Products for Human Use, or CHMP, concluded that the risk-benefit balance remains favorable and requested that the Strimvelis product information identify insertional mutagenesis (or oncogenesis) as an &#8220;important identified risk&#8221; instead of an &#8220;important potential risk&#8221; in light of this event. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Strimvelis is the only gammaretroviral vector-based gene therapy in our portfolio. Libmeldy and all of our pipeline therapies employ the self-inactivating (SIN) lentiviral vector-based approach, which has been specifically designed to avoid insertional oncogenesis after administration. Although to our knowledge and as of the date of this report no evidence of insertional oncogenesis has been observed with lentiviral vector-based HSC gene therapy in any of our programs, there can be no assurance that this will continue to be the case. Moreover, while our gene therapy approach is designed to avoid immunogenicity after administration, there can be no assurance that patients would not develop antibodies that may impair treatment. Our approach involves the use of integrating vectors, which have the potential for genomic disruption and therefore could interfere with other genes with adverse clinical effects. If any of our gene therapy product candidates demonstrates adverse side effects or adverse events at unacceptable rates or degrees of severity, we may decide or be required to halt or delay clinical development of such product candidates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to side effects and adverse events caused by our product candidates, the conditioning, administration process or related procedures also can cause adverse side effects and adverse events. A gene therapy patient is generally administered cytotoxic drugs to remove stem cells from the bone marrow to create sufficient space in the bone marrow for the modified stem cells to engraft and produce new cells. This procedure compromises the patient&#8217;s immune system. While certain of our product candidates are designed to utilize milder conditioning regimens that are intended to require only limited removal of a patient&#8217;s bone marrow cells, the conditioning regimens may not be successful or may nevertheless result in adverse side effects and adverse events. If in the future we are unable to demonstrate that such adverse events were caused by the conditioning regimens used, or administration process or related procedure, the FDA, the European Commission, EMA or other regulatory authorities could order us to cease further development of, or deny approval of, our product candidates for any or all target indications. Even if we are able to demonstrate that adverse events are not related to the drug product or the administration of such drug product, such occurrences could affect patient recruitment, the ability of enrolled patients to complete the clinical trial, or the commercial viability of any product candidates that obtain regulatory approval.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, the FDA could require us to adopt a Risk Evaluation and Mitigation Strategy, or REMS</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> as a condition of approval to ensure that the benefits of our product candidates outweigh their risks, which may include, among other things, a medication guide outlining the risks of the product for distribution to patients, a communication plan to health care practitioners, and restrictions on how or where the product can be distributed, dispensed or used. Other non-U.S. regulatory authorities could impose other specific obligations, such as through a risk management plan, or RMP, submitted to the EMA. Furthermore, if we or others later identify undesirable side effects caused by Strimvelis, Libmeldy or our product candidates, several potentially significant negative consequences could result, including:</span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>regulatory authorities may suspend or withdraw approvals of such product or product candidate&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>regulatory authorities may require additional warnings or limitations of use in product labeling&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>we may be required to change the way a product candidate is distributed, dispensed, or administered or conduct additional clinical trials&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>we could be sued and held liable for harm caused to patients&#59; and</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>our reputation may suffer.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any of these events could prevent us from achieving or maintaining market acceptance of Libmeldy, Strimvelis and any other products for which we obtain marketing approval and could significantly harm our business, prospects, financial condition and results of operations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">To date, most of the clinical trials for our product candidates were conducted as investigator-sponsored clinical trials using drug product manufactured at academic sites. Regulatory authorities may closely scrutinize the data collected from these trials and may require that we conduct additional clinical trials prior to any marketing approval.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have limited experience conducting company-sponsored clinical trials and to date most of our product candidates have been evaluated under investigator-sponsored clinical trials using drug product manufactured at the applicable or relevant academic site. We did not control the design or administration of these investigator-sponsored trials, nor the submission or approval of any IND or foreign equivalent required to conduct these clinical trials. Investigator-sponsored clinical trials are often conducted under less rigorous clinical and manufacturing standards than those used in company-sponsored clinical trials. For example, the drug product used in our company-sponsored clinical trials is manufactured by third party CDMOs using current good manufacturing practices, or cGMP, standards. Accordingly, regulatory authorities may closely scrutinize the data collected from these investigator-sponsored clinical trials and may require us to obtain and submit additional clinical data prior to granting any marketing approval, which could delay clinical development or marketing approval of our product candidates. We will be required to demonstrate comparability between the manufacturing process used at academic centers with the manufacturing process used at CDMOs, and we cannot provide assurances that we will satisfy such comparability requirements. We may also be required to demonstrate improved quality and drug product manufacturing state of control in accordance with cGMP standards. For example, in the compassionate use program conducted by Great Osmond Street Hospital, or GOSH, one patient experienced an SAE, staphylococcal infection, possibly resulting from a bacterial growth noted in samples of the fresh drug product during the transduction procedure at this academic facility. A similar SAE, bacteremia, was observed in the clinical trial conducted at University of California Los Angeles, or UCLA, for our since-returned program OTL-101 for ADA-SCID with the fresh drug product manufactured at the academic facility, also possibly due to contamination of the drug product. The bacteremia resolved on day three without sequelae. We believe that our commercial manufacturing processes for our product candidates, together with cryopreserved formulation, which allows for safety/microbiological testing to be completed prior to drug infusion to the patient, could mitigate the risk of contamination of products that might have resulted in such infections, but there can be no assurance that this will be the case. To the extent that the results of our current company-sponsored trials are inconsistent with, or different from, the results of any investigator-sponsored trials or raise concerns regarding our product candidates, the regulatory authorities may question the results from some or all of these trials, and may require us to obtain and submit additional clinical data from drug product manufactured by CDMOs prior to granting any marketing approval, which could delay clinical development or marketing approval of our product candidates.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.86%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">We may be unable to demonstrate comparability between (i) drug product manufactured using HSCs derived from a patient&#8217;s mobilized peripheral blood and drug product manufactured using HSCs derived from a patient&#8217;s bone marrow, (ii) drug product that has been cryopreserved and fresh drug product, and (iii) the manufacturing process used at academic centers with the manufacturing process used at CDMOs. Failure to demonstrate such comparability could affect our ability to secure regulatory approval for our product candidates or could affect the commercial viability of our product candidates if approved for use using only HSCs derived from bone marrow or using only fresh drug product.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, most of the patients who have been treated in clinical trials involving our product candidates received fresh drug product manufactured using HSCs derived from the patient&#8217;s bone marrow at academic centers. We are currently evaluating our product candidates and plan to seek marketing approval using drug product that is manufactured at CDMOs using HSCs derived from either the patient&#8217;s bone marrow or mobilized peripheral blood and using a procedure by which the gene-modified HSCs are cryopreserved in order to maintain the cellular material in suitable condition until it is thawed prior to being infused into the patient.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In those cases where clinical trials were conducted using vector and/or drug product manufactured at academic research centers, we will need to demonstrate comparability between vector and drug product manufactured by our CDMOs with vector and/or drug product manufactured at such academic centers. Similarly, in those cases where clinical trials were conducted using fresh drug product, we will need to demonstrate comparability between drug product that has been cryopreserved and fresh drug product. In some cases, clinical trials were conducted using drug product using bone marrow or mobilized peripheral blood, or both, as the cellular source. In some cases, we may seek to demonstrate comparability between drug product manufactured using one cellular source and another. In other cases, we may elect to initially seek approval of our product candidate using one cellular source only and subsequently seek approval for the use of the other cellular source. We cannot be assured that the FDA, EMA or other regulatory authority will not require us to conduct additional analytical studies (including comparability analyses), preclinical studies and/or<span style="color:#2E2E2E;font-family:Arial;"> </span><span style="Background-color:#FFFFFF;">clinical trials before approving our product candidates using these intended commercial production methods and processes. Moreover, we cannot be assured that our analytical comparability analyses or clinical trials will be sufficiently robust to support approval of our product candidates using these production methods and processes. For example, in connection with our OTL-200 (Libmeldy) program, the FDA has noted that we may have challenges demonstrating comparability between data collected at one manufacturing facility using bone marrow and data collected at another manufacturing facility using bone marrow or peripheral blood as source cells material. </span></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any of the FDA, EMA or other regulatory authority does not accept our comparability data or if an adequate potency assay for a product candidate is not available or supported by such regulatory authority, our regulatory approval for such product candidate, if any, will be limited or delayed. For example, if one or more of these regulatory authorities does not accept that our cryopreservation process produces a product candidate that is comparable to our fresh drug product, our regulatory approval, if any, would be limited to our fresh product candidate until we are able to provide the regulators with satisfactory comparability data, which may include data from additional clinical trials or require additional test method development. Potency assays that measure strength (<span style="font-style:italic;">e.g.</span>, enzymatic activity, or other relevant function) of each active ingredient are required for release testing of licensed biological drug products, comparability and stability analysis. </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In certain conditions, such as MLD and ADA-SCID, the potency of a product candidate may be directly measured through enzymatic activity&#59; however, for an intracellular protein such as WAS, developing an assay is more complex. Based on written feedback from the FDA, we believe that development of a functional potency assay for OTL-103 may require additional time and further investment. If an adequate potency assay for a product candidate is not available, if we face delays (including delays related to the COVID-19 pandemic), or if the FDA or EMA require additional tests or recommend a different approach to support the potency of any of our product candidates, regulatory approval for any such product candidates will be delayed and such regulators might request additional clinical data to support comparability analysis. Similarly, if one or more of these regulatory authorities does not accept that our drug product manufactured with HSCs derived from the patient&#8217;s mobilized peripheral blood is comparable to drug product manufactured with HSCs derived from the patient&#8217;s bone marrow, any regulatory approval would be limited to drug product manufactured with HSCs derived from the patient&#8217;s bone marrow until we are able to provide the regulators with satisfactory comparability data, which may include data from additional clinical trials. In April 2020, the FDA advised us that we may need to generate additional data to demonstrate the comparability of our OTL-200 drug product derived from the patient&#8217;s mobilized peripheral blood and the OTL-200 drug product derived from the patient&#8217;s bone marrow, and that the data provided to date are inadequate to determine if the two materials are comparable. Further, the FDA requested that we provide data that demonstrates the comparability of the different OTL-200 product formulations used across our trials. Failure to demonstrate such comparability, or if we are required to conduct additional testing or additional clinical trials, potentially at additional sites, would delay any marketing authorization and adversely affect the commercial viability of our product candidates and may adversely affect our ability to generate revenue, as a result of which our business, prospects, financial condition and results of operations may suffer.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our focus on developing our current product candidates may not yield any commercially viable products, and our failure to successfully identify and develop additional product candidates could impair our ability to grow.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of our strategy, we intend to identify, develop and market additional product candidates beyond our existing product candidates. We may spend several years completing our development of any particular current or future product </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidates, and failure can occur at any stage. Even if we receive approval of a product candidate, we may not achieve commercial success for a variety of factors, including failure to achieve market acceptance </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in the medical community and </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the availability of third-party insurance coverage or reimbursement. For example, we received</span><span style="color:#000000;"> standard</span><span style="color:#000000;"> </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">marketing authorization for Libmeldy in December 2020 from the European Commission and </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">launched</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the commercialization of Libmeldy in Europe</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in early 2022</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, but there is no assurance that our commercialization efforts will be successful or that our pricing assumptions or our assumptions about the size of the anticipated patient population will prove to be accurate. The product candidates to which we allocate our resources may not end up being successful. Because we have limited resources, we may forego or delay pursuit of opportunities with certain programs or product candidates or for indications that later prove to have greater commercial </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">potential. For example, in </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">May 2020, we announced our decision to reduce investment in the development of OTL-101 for ADA-SCID (for which we subsequently terminated our license) and OTL-300 for TDT to focus on other product candidates in our pipeline and new research and development efforts in less rare diseases. </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, in March 2022 we announced </span><span style="color:#000000;">our decision to focus </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on severe neurometabolic diseases and early research program</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s,</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and </span><span style="color:#000000;">to discontinue our investment in and seek strategic alternatives for our </span><span style="color:#000000;">programs in rare primary immune deficiencies, including</span><span style="color:#000000;"> OTL-103 for treatment of WAS, OTL-102 for treatment of X-CGD and Strimvelis</span><span style="color:#000000;">. </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> focus on the</span><span style="color:#000000;"> advancement of our other product candidates may ultimately prove to be unsuccessful or less successful than if we had </span><span style="color:#000000;">continued to prioritize such deprioritized product candidates</span><span style="color:#000000;">, and if we choose to reprioritize </span><span style="color:#000000;">such deprioritized product candidates</span><span style="color:#000000;"> in the future, we may experience delays that would not have otherwise occurred, due to inefficiencies from loss of organizational knowledge and ramp up costs.</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Our spending on current and future research and development programs may not yield any commercially viable product candidates. If we do not accurately evaluate the commercial potential for a particular product candidate, we may relinquish valuable rights to that product candidate through strategic collaborations, licensing or other arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. If any of these events occur, we may be forced to abandon our development efforts with respect to a particular product candidate or fail to develop a potentially successful product candidate.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because our internal research capabilities are limited, we may be dependent upon biotechnology companies, academic scientists and other researchers to sell or license product candidates, approved products or the underlying technology to us. The success of this strategy depends partly upon our ability to identify, select, discover and acquire promising product candidates and products.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, certain of our current or future product candidates may not demonstrate in patients any or all of the pharmacological benefits we believe they may possess or compare favorably to existing, approved therapies, such as bone marrow transplantation or enzyme replacement therapy. We may never succeed in demonstrating efficacy and safety of our product candidates or any future product candidates in clinical trials or in obtaining marketing approval thereafter. Accordingly, our focus on treating rare diseases may not always result in the discovery and development of commercially viable products.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are unsuccessful in our development efforts, we may not be able to advance the development of our product candidates, commercialize products other than Strimvelis and Libmeldy, raise capital, expand our business or continue our operations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Interim data and ad hoc analyses are preliminary in nature. Success in preclinical studies or early clinical trials may not be indicative of results obtained in later trials. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, we may publish interim data and/or ad hoc analyses from investigator-sponsored or company-sponsored clinical trials of our product candidates. Preliminary data and ad hoc analyses from these clinical trials may change as longer-term patient data become available. In general, we seek to conduct interim analyses at times we pre-specify with the applicable regulators prior to commencement of the trial, at which time we lock and reconcile the database. We may occasionally elect not to conduct subsequent interim analyses so as not to compromise the statistical analysis plan for the trial. Accordingly, our interim analyses do not include data subsequent to the cut-off date and may not be available until the next planned interim analysis. From time to time, preliminary data and ad hoc analyses might be presented, typically by academic investigators at scientific conferences or in scientific publications.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With respect to clinical trials conducted by our academic or other collaborators, such as University College London, UCLA, Telethon-OSR and GSK, we may not have access to the most recent clinical data or the clinical data available to us may otherwise be limited or incomplete. Interim data or ad hoc analyses from these clinical trials are not necessarily predictive of final results. Interim data or ad hoc analyses are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and/or more patient data become available to us. Interim, topline and preliminary data and ad hoc analyses also remain subject to audit and verification procedures that may result in the final data </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">being materially different from the preliminary data available to us or that we previously published. As a result, preliminary and interim data and ad hoc analyses should be viewed with caution until the final data are available. Material adverse changes in the final data compared to the preliminary or interim data or ad hoc analyses could significantly harm our business prospects.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Similarly, the results of preclinical studies and previous clinical trials<span style="font-weight:bold;font-style:italic;">&#160;</span>should not be relied upon as evidence that our ongoing or future clinical trials will succeed. Trial designs and results from preclinical studies or previous clinical trials are not necessarily predictive of future clinical trial results or the ability to obtain marketing approval for our product candidates. Our product candidates may fail to show the desired safety and efficacy in clinical development despite demonstrating positive results in preclinical studies or having successfully advanced through initial clinical trials or preliminary stages of registrational clinical trials.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, although sustained clinical activity has been observed in clinical trials to date for Libmeldy (OTL-200), follow-up in these clinical trials is ongoing and there can be no assurance that the results, in each case as of the applicable primary endpoint measurement date, seen in clinical trials of any of our product candidates ultimately will result in success in clinical trials or provide adequate support for marketing approvals by the FDA, in the case of Libmeldy, without conducting further clinical trials. These data, or other positive data, may not continue or occur for these patients or for any future patients in our ongoing or future clinical trials, and may not be repeated or observed in ongoing or future trials involving our product candidates. There are limited data concerning long-term safety and efficacy following treatment with our product candidates. Our product candidates may fail to adequately demonstrate safety and efficacy in clinical development despite positive results in preclinical studies. Our product candidates may fail to show the desired safety and efficacy in later stages of clinical development despite having successfully advanced through initial clinical trials. There can be no assurance that any of these trials will ultimately be successful or support further clinical advancement or regulatory approval of our product candidates. In addition, there can be no assurance that we will be able to achieve the same or similar success in our preclinical studies and clinical trials of our other product candidates. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Favorable results from compassionate use programs may not establish proof of concept, and the FDA or other regulatory authorities may not accept compassionate use data as sufficient clinical validation in support of our regulatory approval efforts.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A number of patients have been administered our autologous&#160;<span style="font-style:italic;">ex vivo</span>&#160;gene therapies through compassionate use programs. Compassionate use is a term that is used to refer to the use of an investigational drug outside of a clinical trial to treat a patient with a serious or immediately life-threatening disease or condition who has no comparable or satisfactory alternative treatment options. Regulators often allow compassionate use on a case-by-case basis for an individual patient or for defined groups of patients with similar treatment needs. Caution should be given when reviewing and interpreting compassionate use data. While results from treating patients through compassionate use have in certain cases been encouraging, we cannot be assured that the results observed in these cases will be observed in our ongoing or future clinical trials or that our ongoing and future clinical trials will ultimately be successful.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We plan to submit any data available to us from compassionate use cases as part of any regulatory submission for the applicable product candidate. However, because these patients were not treated as part of a clinical trial regulatory framework and related requirements, regulatory authorities may not accept compassionate use data as sufficiently robust clinical evidence in support of our regulatory approval efforts, or they may find that the data submitted from our clinical trials are insufficient to support approval. Such decisions could materially and adversely affect our business, financial condition, results of operations and prospects.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may find it difficult to enroll patients in our clinical trials, which could delay or prevent us from proceeding with clinical trials of our product candidates.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Identifying and qualifying patients to participate in clinical trials of our product candidates is critical to our success. The timing of our clinical trials depends on our ability to recruit patients to participate as well as the completion of required follow-up periods. Patients may be unwilling to participate in our gene therapy clinical trials because of negative publicity from adverse events related to the biotechnology or gene therapy fields generally, competitive clinical trials for similar patient populations, clinical trials in product candidates employing our vectors, the existence of current treatments or for other reasons. Additionally, the ongoing COVID-19 global pandemic has had and may continue to have a sustained impact on our ability to recruit and follow-up with patients either due to continued or renewed restrictions on travel or shelter-in-place orders or policies or due to changes in patient willingness to participate in trials or travel to study sites in the wake of the pandemic. Additionally, COVID-19 related study site policies may create delays or setbacks in our ability to continue to </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">enroll or to dose patients</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. In addition, the indications that we are currently targeting and may in the future target are rare diseases, which may limit the pool of patients that may be enrolled in our ongoing or planned clinical trials. The timeline for recruiting patients, conducting trials and obtaining regulatory approval of our product candidates may be delayed, which could result in increased costs, delays in advancing our product candidates, delays in testing the effectiveness of our product candidates or termination of the clinical trials altogether.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may not be able to identify, recruit and enroll a sufficient number of patients, or those with the required or desired characteristics, to complete our clinical trials in a timely manner. For example, due to the nature of the indications that we are initially targeting, patients with advanced disease progression may not be suitable candidates for treatment with our product candidates and may be ineligible for enrollment in our clinical trials. Therefore, early diagnosis in patients with our target diseases is critical to our success. Patient enrollment and trial completion is affected by factors including the:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>size of the patient population and process for identifying subjects&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>design of the trial protocol&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>eligibility and exclusion criteria&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>safety profile, to date, of the product candidate under study&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>perceived risks and benefits of the product candidate under study&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>perceived risks and benefits of gene therapy-based approaches to treatment of diseases, including any required pretreatment conditioning regimens&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>availability of competing therapies and clinical trials&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>severity of the disease under investigation&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>degree of progression of the subject&#8217;s disease at the time of enrollment&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>availability of genetic testing for potential patients&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>proximity and availability of clinical trial sites for prospective subjects&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the impact of the COVID-19 global pandemic or future pandemics or similar events on patients&#8217; willingness and ability to participate in clinical trials or on study site policies&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>ability to obtain and maintain subject consent&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>risk that enrolled subjects will drop out before completion of the trial&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>patient referral practices of physicians&#59; and</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>ability to monitor subjects adequately during and after treatment.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our current product candidates are being developed to treat rare conditions. We plan to seek initial marketing approvals in the United States and the European Union. We may not be able to initiate or continue clinical trials if we cannot enroll a sufficient number of eligible patients to participate in the clinical trials required by the FDA or EMA. Our ability to successfully initiate, enroll and complete a clinical trial in any foreign country is subject to numerous risks unique to conducting business in foreign countries, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>difficulty in establishing or managing relationships with academic partners or contract research organizations, or CROs, and physicians&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>different standards for the conduct of clinical trials&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the absence in some countries of established groups with sufficient regulatory expertise for review of gene therapy protocols&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>our inability to locate qualified local consultants, physicians and partners&#59; and</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the potential burden of complying with a variety of foreign laws, medical standards and regulatory requirements, including the regulation of pharmaceutical and biotechnology products and treatment.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we have difficulty enrolling a sufficient number of patients to conduct our clinical trials as planned, we may need to delay, limit or terminate ongoing or planned clinical trials, any of which would have an adverse effect on our business, financial condition, results of operations and prospects.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may encounter substantial delays in our clinical trials, or we may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must conduct extensive clinical trials to demonstrate the safety and efficacy of the product candidates in humans. Clinical testing is expensive, time-consuming and the outcome is uncertain. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all.<span style="font-weight:bold;font-style:italic;"> </span>As a result of the COVID-19 global pandemic, certain of our clinical sites have partially shifted and may continue to shift significant resources to patients with COVID-19, which creates challenges for </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patient follow-up visits for all programs.</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> A failure of one or more clinical trials can occur at any stage of testing. Events that may prevent successful or timely completion of clinical development include:</span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>delays in reaching a consensus with regulatory agencies on study design&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>delays in reaching agreement on acceptable terms with prospective CROs and clinical trial sites&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>delays in obtaining required Institutional Review Board, or IRB, approval at each clinical trial site&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>delays in recruiting suitable patients and in sufficient volume to participate in our clinical trials&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>imposition of a clinical hold by regulatory agencies&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>failure by our academic partners, CROs, other third parties or us to adhere to clinical trial protocol and recordkeeping requirements&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>failure to perform in accordance with the FDA&#8217;s good clinical practices, or GCP, or applicable regulatory guidelines in other countries&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>delays in the testing, validation, manufacturing and delivery of our product candidates to the clinical sites&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>delays in having patients complete participation in a study or return for post-treatment follow-up&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>clinical trial sites or patients dropping out of a study&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>delays in patient enrollment, missed assessments resulting from remote follow-up visits, or delays in completion of participation as a result of the impact of the COVID-19 global pandemic or future pandemics or similar events&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the occurrence of SAEs associated with the product candidate that are viewed to outweigh its potential benefits&#59; or</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>changes in regulatory requirements and guidance that require amending or submitting new clinical protocols.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any inability to successfully complete preclinical and clinical development could result in additional costs to us or impair our ability to generate revenues. In addition, if we make changes to our product candidates, we may need to conduct additional studies to bridge our modified product candidates to earlier versions, which could delay our clinical development plan or marketing approval for our product candidates. Clinical trial delays could also shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do, which could impair our ability to successfully commercialize our product candidates and may harm our business and results of operations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the results of our clinical trials are inconclusive or if there are safety concerns or adverse events associated with our product candidates, we may:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>be delayed in obtaining marketing approval for our product candidates, if at all&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>obtain approval for indications or patient populations that are not as broad as intended or desired&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>obtain approval with, or later become subject to, labeling or a REMS (or equivalent requirement from a non-U.S. regulatory authority) that includes significant use or distribution restrictions or safety warnings, precautions, contraindications, drug interactions, or adverse events&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>be subject to changes with the way the product is administered&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>be required to perform additional clinical trials to support comparability or approval or be subject to additional post-marketing testing requirements&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>have regulatory authorities withdraw their approval of the product or impose restrictions on its distribution in the form of a REMS (or equivalent requirement from a non-U.S. regulatory authority)&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>be sued by competitors, patent holders, patients, or third parties&#59; or</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>experience damage to our reputation.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any of these events could prevent us from achieving or maintaining market acceptance of our product candidates and impair our ability to commercialize our products.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may elect to initiate a rolling BLA for our product candidates, in which case the FDA will not complete, and may delay initiating, its review of the BLA until we submit all of the required information.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A rolling BLA is an application process that allows us to submit the information required by the BLA in sections. The FDA will not complete, and may delay initiating, its review of our BLA until we submit all of the required information for a full BLA. If we are delayed or unable to provide this required information it could delay or prevent our ability to obtain regulatory approvals, as a result of which our business, prospects, financial condition and results of operations may suffer.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Even if we complete the necessary preclinical studies and clinical trials, we cannot predict when or if we will obtain regulatory approval to commercialize a product candidate, and the approval may be for a narrower indication than we seek. </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.14%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot commercialize a product until the appropriate regulatory authorities have reviewed and approved such product candidate. Even if a product candidate demonstrates safety and efficacy in clinical trials, the regulatory agencies may not complete their review processes in a timely manner, or we may not be able to obtain regulatory approval. Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials even after achieving promising results in preclinical testing and earlier-stage clinical trials. Additional delays may result if an FDA Advisory Committee or other regulatory authority recommends non-approval or restrictions on approval. In addition, we may experience delays or rejections based upon additional government regulation from future legislation or administrative action or changes in regulatory agency policy during the period of product development, clinical trials and the review process. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of May 26, 2021, the FDA noted it was continuing to ensure timely reviews of applications for medical products during the COVID-19 pandemic in line with its user fee performance goals and conducting mission critical domestic and foreign inspections to ensure compliance of manufacturing facilities with FDA quality standards. However, the FDA may not be able to maintain this pace and delays or setbacks are possible in the future, including where a pre-approval inspection or an inspection of clinical sites is required and, due to the ongoing COVID-19 pandemic and travel restrictions, the FDA is unable to complete such required inspection during the review period. In 2020 and 2021, a number of companies announced receipt of complete response letters due to the FDA&#8217;s inability to complete required inspections for their applications. Regulatory authorities outside the U.S. may similarly experience delays in their regulatory activities due to the COVID-19 pandemic.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, regulatory agencies may not approve the labeling claims that are necessary or desirable for the successful commercialization of our product candidates. For example, regulatory agencies may approve a product candidate for fewer or more limited indications than requested or may grant approval subject to the performance of post-marketing studies. Regulators may approve a product candidate for a smaller patient population, drug formulation (such as drug product using HSCs derived from bone marrow as opposed to mobilized peripheral blood or vice versa) or manufacturing processes (such as fresh drug product as opposed to cryopreserved or use of different manufacturing facilities) than we are seeking. If we are delayed in obtaining or unable to obtain necessary regulatory approvals, or if we obtain more limited regulatory approvals than we expect, our business, prospects, financial condition and results of operations may suffer. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Even if we complete the necessary preclinical studies and clinical trials, the marketing approval process is expensive, time-consuming and uncertain and may prevent us from obtaining approvals for the commercialization of some or all of our product candidates. If we or any future collaborators are not able to obtain, or if there are delays in obtaining, required regulatory approvals, we or they will not be able to commercialize our product candidates, and our ability to generate revenue will be materially impaired. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our product candidates and the activities associated with their development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale and distribution, export and import, are subject to comprehensive regulation by the FDA and other regulatory agencies in the United States and by the EMA and comparable regulatory authorities in other countries. Failure to obtain marketing approval for a product candidate will prevent us from commercializing such product candidate. We have only limited experience in submitting and supporting the applications necessary to gain marketing approvals and expect to rely on third-party CROs to assist us in this process.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securing marketing approval requires the submission of extensive preclinical and clinical data and supporting information to the various regulatory authorities for each therapeutic indication to establish the product candidate&#8217;s safety and efficacy. Securing regulatory approval also requires the submission of extensive information about the product manufacturing process and controls up to and including inspection of manufacturing facilities by, the relevant regulatory authority. Our product candidates may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The process of obtaining marketing approvals, both in the United States and abroad, is expensive (the submission fee in the United States can be more than $2.0&#160;million and may be higher in the future), may take many years if additional clinical trials are required, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">complexity and novelty of the product candidates involved. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted product application, may cause delays in the approval or rejection of an application. The FDA and comparable authorities in other countries have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical or other studies. In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent marketing approval of a drug candidate. Any marketing approval of our product candidates that we, or any future collaborators, ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accordingly, if we or any future collaborators experience delays in obtaining approval or if we or they fail to obtain approval of our product candidates, the commercial prospects for our product candidates may be harmed and our ability to generate revenues will be materially impaired.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Even if we obtain and maintain approval for our product candidates in one jurisdiction, we may never obtain approval for our product candidates in other jurisdictions, which would limit our market opportunities and adversely affect our business. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Approval of a product candidate in the United States by the FDA does not ensure approval of such product candidate by the EMA or other regulatory authorities in other countries or jurisdictions, and approval by the EMA or another regulatory authority does not ensure approval by regulatory authorities in other foreign countries or by the FDA. For example, though we received <span style="color:#000000;">standard</span> marketing authorization of Libmeldy (OTL-200) from the European Commission in December 2020, there is no guarantee that we will receive approval from the FDA. Sales of our product candidates outside of the United States will be subject to foreign regulatory requirements governing clinical trials and marketing approval. Even if the FDA grants marketing approval for a product candidate, comparable regulatory authorities of foreign countries also must approve the manufacturing and marketing of the product candidates in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and more onerous than, those in the United States, including additional preclinical studies or clinical trials. In many countries outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that country. In some cases, the price that we intend to charge for our products, if approved, is also subject to approval. We intend to submit an MAA to the EMA for approval of our product candidates in the European Union but obtaining such approval from the European Commission following the opinion of EMA is a lengthy and expensive process. Even if a product candidate is approved, the FDA or the European Commission may limit the indications for which the product may be marketed, require extensive warnings on the product labeling or require expensive and time-consuming additional clinical trials or reporting as conditions of approval. Regulatory authorities in countries outside of the United States and the European Union also have requirements for approval of product candidates with which we must comply prior to marketing in those countries. Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our product candidates in certain countries.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries. Also, regulatory approval for any of our product candidates may be withdrawn. If we fail to comply with the regulatory requirements, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed and our business, financial condition, results of operations and prospects may be harmed.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, in June 2016, the UK held a referendum in which a majority of voters approved an exit from the EU, or Brexit, and the UK formally left the EU on January 31, 2020. There was a transition period during which EU pharmaceutical laws continued to apply to the UK, which expired on December 31, 2020. However, the EU and the UK have concluded a trade and cooperation agreement, or TCA, which was provisionally applicable since January 1, 2021 and has been formally applicable since May 1, 2021. The TCA includes specific provisions concerning pharmaceuticals, which include the mutual recognition of GMP, inspections of manufacturing facilities for medicinal products and GMP documents issued, but does not foresee wholesale mutual recognition of UK and EU pharmaceutical regulations. At present, Great Britain has implemented EU legislation on the marketing, promotion and sale of medicinal products through the Human Medicines Regulations 2012 (as amended) (under the Northern Ireland Protocol, the EU regulatory framework will continue to apply in Northern Ireland). The regulatory regime in Great Britain therefore currently aligns in the most part with EU regulations, however it is possible that these regimes will diverge in future now that Great Britain&#8217;s regulatory system is independent from the EU and the TCA does not provide for mutual recognition of UK and EU pharmaceutical legislation. For example, the new Clinical Trials Regulation, which became effective in the EU on January 31, 2022, and provides for a streamlined clinical trial application and assessment procedure covering multiple EU Member States, has not been implemented into UK law, and a separate application will need to be submitted for clinical trial authorization in the UK. The separate, and potentially diverging, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regulatory regimes between Great Britain and the EU may increase our regulatory burden of applying for and obtaining authorization in Great Britain and the EU.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Most of the clinical trials for our product candidates conducted to date were conducted at sites outside the United States, and the FDA may not accept data from trials conducted in such locations.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, most of the clinical trials conducted on our product candidates have been conducted outside the United States. For example, we do not yet have an IND open in the United States for OTL-203 for MPS-IH or OTL-201 for MPS-IIIA. Although the FDA may accept data from clinical trials conducted outside the United States, acceptance of these data is subject to conditions imposed by the FDA, as noted in the risk factor immediately above. For example, the clinical trial must be well designed and conducted and performed by qualified investigators in accordance with ethical principles. The trial population must also adequately represent the U.S. population, and the data must be applicable to the U.S. population and U.S. medical practice in ways that the FDA deems clinically meaningful. In addition, while these clinical trials are subject to the applicable local laws, FDA acceptance of the data will depend on its determination that the trials also complied with all applicable U.S. laws and regulations. If the FDA does not accept the data from any trial that we conduct outside the United States, due to study design or otherwise, it would likely result in the need for additional trials, which would be costly and time-consuming and would delay or permanently halt our development of the applicable product candidates. <span style="color:#000000;">Further, without an IND open in the United States, we forego more frequent interactions and dialogue with FDA regarding the design and conduct of our trials as well as product comparability, which may delay or halt the development of our product candidates later in development should FDA later disagree with the design or conduct of our trials or product comparability approach.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, in order to commence a clinical trial in the United States, we are required to seek FDA acceptance of an IND for each of our product candidates. We cannot be sure any IND we submit to the FDA, or any similar CTA we submit in other countries, will be accepted. We may also be required to conduct additional preclinical testing prior to submitting an IND for any of our product candidates, and the results of any such testing may not be positive. Consequently, we may be unable to successfully and efficiently execute and complete necessary clinical trials in a way that leads to a BLA submission and approval of our product candidates. We may require more time and incur greater costs than our competitors and may not succeed in obtaining regulatory approvals of product candidates that we develop. Failure to commence or complete, or delays in, our planned clinical trials, could prevent us from or delay us in commercializing our product candidates.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">While we intend to seek designations for our product candidates with the FDA and other comparable regulatory authorities that are intended to confer benefits such as a faster development process or an accelerated regulatory pathway, there can be no assurance that we will successfully obtain such designations. In addition, even if one or more of our product candidates are granted such designations, we may not be able to realize the intended benefits of such designations.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA and comparable other regulatory authorities offer certain designations for product candidates that are designed to encourage the research and development of product candidates that are intended to address conditions with significant unmet medical need. These designations may confer benefits such as additional interaction with regulatory authorities, a potentially accelerated regulatory pathway and priority review. <span style="color:#000000;">OTL-200 for MLD and </span>OTL-103 for WAS received RMAT designation from the FDA, and both OTL-300 for TDT and OTL-203 for MPS-IH received a Priority Medicines, or PRIME, designation from EMA. Despite these designations, there can be no assurance that we will successfully obtain these or other designations for any of our other product candidates. In addition, while such designations could expedite the development or review process, they generally do not change the standards for approval. Even if we obtain such designations for one or more of our product candidates, there can be no assurance that we will realize their intended benefits. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, we may seek a Breakthrough Therapy designation for some of our other product candidates. A breakthrough therapy is defined as a therapy that is intended, alone or in combination with one or more other therapies, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the therapy may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For therapies that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Therapies designated as breakthrough therapies by the FDA are also eligible for accelerated approval. Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe one of our product candidates meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a Breakthrough Therapy designation for a product candidate may not result in a faster development </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">process, review or approval compared to therapies considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify as breakthrough therapies, the FDA may later decide that such product candidates no longer meet the conditions for qualification.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we may seek RMAT designation for some of our other product candidates. An RMAT is defined as cell therapies, therapeutic tissue engineering products, human cell and tissue products, and combination products using any such therapies or products. Gene therapies, including genetically modified cells that lead to a durable modification of cells or tissues may meet the definition of a regenerative medicine therapy. The RMAT program is intended to facilitate efficient development and expedite review of RMATs, which are intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition and for which preliminary clinical evidence indicates that the drug has the potential to address unmet medical needs for such disease or condition. A BLA for an RMAT may be eligible for priority review or accelerated approval. An RMAT may be eligible for priority review if it treats a serious condition, and, if approved, would provide a significant improvement in the safety or effectiveness of the treatment of the condition. An RMAT may be eligible for accelerated approval through (1)&#160;surrogate or intermediate endpoints reasonably likely to predict long-term clinical benefit or (2)&#160;reliance upon data obtained from a meaningful number of sites. Benefits of such designation also include early interactions with FDA to discuss any potential surrogate or intermediate endpoint to be used to support accelerated approval. A regenerative medicine therapy that is granted accelerated approval and is subject to post-approval requirements may fulfill such requirements through the submission of clinical evidence, clinical trials, patient registries, or other sources of real-world evidence, such as electronic health records, the collection of larger confirmatory data sets, or post-approval monitoring of all patients treated with such therapy prior to its approval. RMAT designation is within the discretion of the FDA. Accordingly, even if we believe one of our product candidates meets the criteria for designation as a RMAT, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of RMAT designation for a product candidate may not result in a faster development process, review or approval compared to drugs considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify as for RMAT designation, the FDA may later decide that the biological products no longer meet the conditions for qualification.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the FDA has granted Rare Pediatric Disease designation to Strimvelis, OTL-200 for MLD, OTL-103 for WAS, OTL-201 for MPS-IIIA and OTL-203 for MPS-IH, and we may seek Rare Pediatric Disease designation for some of our other product candidates. The FDA defines a &#8220;rare pediatric disease&#8221; as a serious or life-threatening disease in which the serious of life-threatening manifestations primarily affect individuals aged from birth to 18 years and the disease affects fewer than 200,000 individuals in the U.S. or affects more than 200,000 in the U.S. and for which there is no reasonable expectation that the cost of developing and making in the U.S. a drug for such disease or condition will be received from sales in the U.S. of such drug. Under the FDA&#8217;s Rare Pediatric Disease Priority Review Voucher, or PRV, program, upon the approval of a BLA for the treatment of a rare pediatric disease, the sponsor of such application would be eligible for a Rare Pediatric Disease PRV that can be used to obtain priority review for a subsequent new drug application or BLA. The PRV may be sold or transferred an unlimited number of times. Congress has extended the PRV program through September 30, 2024, with potential for PRVs to be granted through September 30, 2026. This program has been subject to criticism, including by the FDA, and it is possible that even if we obtain approval for Libmeldy (OTL-200), OTL-103 for WAS, OTL-201 for MPS-IIIA and OTL-203 for MPS-IH and qualify for such a PRV, the program may no longer be in effect at the time or the value of any such PRV may decrease such that we are may not be able to realize the benefits of such PRV. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;letter-spacing:-0.15pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we may seek Fast Track Designation for some of our product candidates. If a therapy is intended for the treatment of a serious or life-threatening condition and the therapy demonstrates the potential to address unmet medical needs for this condition, the therapy sponsor may apply for Fast Track Designation. The FDA has broad discretion whether or not to grant this designation, so even if we believe a particular product candidate is eligible for this designation, there can be no assurance that the FDA would decide to grant it. Even if we do receive Fast Track Designation, we may not experience a faster development process, review or approval compared to conventional FDA procedures, and receiving a Fast Track Designation does not provide assurance of ultimate FDA approval. In addition, the FDA may withdraw Fast Track Designation if it believes that the designation is no longer supported by data from our clinical development program.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may seek priority review designation for one or more of our product candidates, but we might not receive such designation, and even if we do, such designation may not lead to a faster regulatory review or approval process. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;letter-spacing:-0.15pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the FDA determines that a product candidate offers a treatment for a serious condition and, if approved, the product would provide a significant improvement in safety or effectiveness, the FDA may designate the product candidate for priority review. A priority review designation means that the goal for the FDA to review an application is six months, rather than the standard review period of ten months. We may request priority review for our product candidates. The FDA has broad discretion </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;letter-spacing:-0.15pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;letter-spacing:-0.15pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with respect to whether or not to grant priority review status to a product candidate, so even if we believe a particular product candidate is eligible for such designation or status, in particular if such product candidate has received a Breakthrough Therapy designation or RMAT designation, the FDA may decide not to grant it. Moreover, a priority review designation does not result in expedited development and does not necessarily result in expedited regulatory review or approval process or necessarily confer any advantage with respect to approval compared to conventional FDA procedures. Receiving priority review from the FDA does not guarantee approval within the six-month review cycle or at all.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the GSK Agreement, we are required to use commercially reasonable efforts to obtain a PRV from the FDA for each of Libmeldy, OTL-103 for WAS and OTL-300 for TDT and to transfer the first such PRV to GSK. GSK also has an option to acquire at a defined price any PRV granted to us thereafter for Libmeldy, OTL-103 for WAS and OTL-300 for TDT. In the event that GSK does not exercise this option with respect to any PRV, we may sell the PRV to a third party and must share any proceeds in excess of a specified sale price equally with GSK.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have sought and received orphan drug designation for Libmeldy (OTL-200), OTL-103 for WAS, OTL-102 for X-CGD and OTL-201 for MPS-IIIA from the FDA and EMA, for OTL-203 for MPS-IH from the FDA, and for OTL-300 for TDT from the EMA, but we may be unable to obtain orphan drug designation for our other product candidates, and, even if we obtain such designation, we may not be able to realize the benefits of such designation, including potential marketing exclusivity of our product candidates, if approved.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regulatory authorities in some jurisdictions, including the United States and other major markets, may designate drugs intended to treat conditions or diseases affecting relatively small patient populations as orphan drugs. Under the Orphan Drug Act of 1983, the FDA may designate a product candidate as an orphan drug if it is intended to treat a rare disease or condition, which is generally defined as having a patient population of fewer than 200,000 individuals in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. In the EU, the EMA&#8217;s Committee for Orphan Medicinal Products grants orphan designation to promote the development of products that are intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition affecting not more than 5 in 10,000 persons in the EU. Additionally, orphan designation is granted for products intended for the diagnosis, prevention or treatment of a life-threatening, seriously debilitating or serious and chronic condition and when, without incentives, it is unlikely such products would generate sufficient return in the EU to justify the necessary investment their development. In either case, the applicant for orphan designation must also demonstrate that no satisfactory method of diagnosis, prevention, or treatment for the condition has been authorized for marketing in the EU (or, if a method exists, the new product would be a significant benefit to those affected by the condition).</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have sought and received orphan drug designation for Libmeldy, OTL-103 for WAS, OTL-102 for X-CGD and OTL-201 for MPS-IIIA from the FDA and EMA, for OTL-203 for MPS-IH from the FDA, and for OTL-300 for TDT from the EMA. If we request orphan drug designation for any of our other product candidates, there can be no assurances that the FDA or EMA will grant any of our other product candidates such designation. Additionally, the designation of any of our product candidates as an orphan product does not mean that any regulatory agency will accelerate regulatory review of, or ultimately approve, that product candidate, nor does it limit the ability of any regulatory agency to grant orphan drug designation to product candidates of other companies that treat the same indications as our product candidates prior to our product candidates receiving exclusive marketing approval.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Generally, if a product candidate with an orphan drug designation receives the first marketing approval for the indication for which it has such designation, the product is entitled to a period of marketing exclusivity, which precludes the FDA or EMA from approving another marketing application for a product that constitutes the same drug treating the same indication for that marketing exclusivity period, except in limited circumstances. If another sponsor receives such approval before we do (regardless of our orphan drug designation), we will be precluded from receiving marketing approval for our product for the applicable exclusivity period. The applicable period is seven years in the United States and 10 years in the EU. The exclusivity period in the EU can be reduced to six years if a product no longer meets the criteria for orphan designation or if the product is sufficiently profitable so that market exclusivity is no longer justified. Orphan drug exclusivity may be revoked if any regulatory agency determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the product to meet the needs of patients with the rare disease or condition.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we obtain orphan drug exclusivity for a product candidate, that exclusivity may not effectively protect the product candidate from competition because different drugs can be approved for the same condition. In the United States, even after an orphan drug is approved, the FDA may subsequently approve another drug for the same condition if the FDA </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">concludes that the latter drug is not the same drug or is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care. In the EEA, marketing authorization may be granted to a similar medicinal product for the same orphan indication if:</span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the second applicant can establish in its application that its medicinal product, although similar to the orphan medicinal product already authorized, is safer, more effective or otherwise clinically superior&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the holder of the marketing authorization for the original orphan medicinal product consents to a second orphan medicinal product application&#59; or</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the holder of the marketing authorization for the original orphan medicinal product cannot supply sufficient quantities of orphan medicinal product.</p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may seek a conditional marketing authorization in Europe for some or all of our current product candidates, but we may not be able to obtain or maintain such designation.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of its marketing authorization process, the EMA may grant marketing authorizations for certain categories of medicinal products on the basis of less complete data than is normally required, where the benefit of immediate availability of the medicine outweighs the risk inherent in the fact that additional data are still required or in the interests of public health. In such cases, it is possible for the CHMP to recommend the granting of a marketing authorization, subject to certain specific obligations to be reviewed annually, which is referred to as a conditional marketing authorization. This may apply to medicinal products for human use that fall under the jurisdiction of the EMA, including those that aim at the treatment, the prevention, or the medical diagnosis of seriously debilitating or life-threatening diseases and those designated as orphan medicinal products.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A conditional marketing authorization may be granted when the CHMP finds that, although comprehensive clinical data referring to the safety and efficacy of the medicinal product have not been supplied, all the following requirements are met:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the risk-benefit balance of the medicinal product is positive&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>it is likely that the applicant will be in a position to provide the comprehensive clinical data post-authorization&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>unmet medical needs will be fulfilled&#59; and</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the benefit to public health of the immediate availability on the market of the medicinal product concerned outweighs the risk inherent in the fact that additional data is still required.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The granting of a conditional marketing authorization is restricted to situations in which only the clinical part of the application is not yet fully complete. Incomplete preclinical or quality data may only be accepted if duly justified and only in the case of a product intended to be used in emergency situations in response to public health threats. Conditional marketing authorizations are valid for one year, on a renewable basis. The holder will be required to complete ongoing trials or to conduct new trials with a view to confirming that the benefit-risk balance is positive. In addition, specific obligations may be imposed in relation to the collection of pharmacovigilance data.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granting a conditional marketing authorization allows medicines to reach patients with unmet medical needs earlier than might otherwise be the case and will ensure that additional data on a product is generated, submitted, assessed and acted upon. Although we may seek a conditional marketing authorization for one or more of our product candidates by the EMA, the CHMP may ultimately not agree that the requirements for such conditional marketing authorization have been satisfied and hence delay the commercialization of our product candidates.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Even if we obtain regulatory approval for a product candidate, our products will remain subject to regulatory oversight. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Libmeldy, Strimvelis and any of our product candidates for which we obtain regulatory approval will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping and submission of safety and other post-market information. <span style="color:#000000;">For example, as a post-marketing commitment, we are continuing to follow patients in the OTL-200 clinical development program for up to 15 years, and data will be presented to regulators at agreed points in order to further characterize the long-term efficacy and safety of Libmeldy, particularly in the early symptomatic early juvenile population. </span>For an example of adverse event reporting, in October 2020 we notified the EMA and relevant local European regulatory authorities after we became aware that a patient treated with Strimvelis under a compassionate use program in 2016 had been diagnosed with leukemia. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any regulatory approvals that we receive for our product candidates also may be subject to a REMS or equivalent requirement from a non-U.S. regulatory authority, limitations on the approved indicated uses for which the product may be </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase 4 clinical trials, and surveillance to monitor the quality, safety and efficacy of the product. For example, in the United States, the holder of an approved BLA is obligated to monitor and report adverse events and any failure of a product to meet the specifications in the BLA. FDA guidance advises that patients treated with some types of gene therapy undergo long-term safety and efficacy follow-up for as long as 15 years post therapy. The holder of an approved BLA must also submit new or supplemental applications and obtain FDA approval for certain changes to the approved product, product labeling or manufacturing process. Advertising and promotional materials must comply with FDA rules and are subject to FDA review, in addition to other potentially applicable federal and state laws.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the EU, the advertising and promotion of our products are subject to EU laws governing promotion of medicinal products, interactions with physicians, misleading and comparative advertising and unfair commercial practices. In addition, other legislation adopted by individual EU Member States may apply to the advertising and promotion of medicinal products. These laws require that promotional materials and advertising for medicinal products are consistent with the product&#8217;s Summary of Product Characteristics, or SmPC, as approved by the competent authorities. The SmPC is the document that provides information to physicians concerning the safe and effective use of the medicinal product. It forms an intrinsic and integral part of the marketing authorization granted for the medicinal product. Promotion of a medicinal product that does not comply with the SmPC is considered to constitute off-label promotion. The off-label promotion of medicinal products is prohibited in the EU. The applicable laws at EU level and in the individual EU Member States also prohibit the direct-to-consumer advertising of prescription-only medicinal products. Violations of the rules governing the promotion of medicinal products in the EU could be penalized by administrative measures, fines and imprisonment. These laws may further limit or restrict the advertising and promotion of our products to the general public and may also impose limitations on our promotional activities with health care professionals.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, product manufacturers and their facilities are subject to payment of user fees and continual review and periodic inspections by the FDA and other regulatory authorities for compliance cGMP requirements and adherence to commitments made in the BLA or foreign marketing application. If we, or a regulatory authority, discover previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured or disagrees with the promotion, marketing or labeling of that product, a regulatory authority may impose restrictions relative to that product, the manufacturing facility or us, including requiring recall or withdrawal of the product from the market or suspension of manufacturing.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we fail to comply with applicable regulatory requirements following approval of any of our product candidates, a regulatory authority may:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>issue a warning letter asserting that we are in violation of the law&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>seek an injunction or impose administrative, civil or criminal penalties or monetary fines&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>suspend or withdraw regulatory approval&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>suspend any ongoing clinical trials&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>refuse to approve a pending BLA or comparable foreign marketing application (or any supplements thereto) submitted by us or our strategic partners&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>restrict the marketing or manufacturing of the product&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>seize or detain the product or otherwise require the withdrawal of the product from the market&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>refuse to permit the import or export of products&#59; or</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>refuse to allow us to enter into supply contracts, including government contracts.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and adversely affect our business, financial condition, results of operations and prospects.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the FDA&#8217;s policies, and those of the EMA and other regulatory authorities, may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability, which would materially and adversely affect our business, financial condition, results of operations and prospects.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Both marketing authorization holders and manufacturers of medicinal products are subject to comprehensive regulatory oversight by the EMA and the competent authorities of the individual EU Member States both before and after grant of the manufacturing and marketing authorizations. This includes compliance with cGMP rules, which govern quality control of the manufacturing process and require documentation policies and procedures. We and our third-party manufacturers would be required to ensure that all of our processes, quality systems, methods, and equipment are compliant with cGMP. Failure by us or by any of our third-party partners, including suppliers, manufacturers, and distributors to comply with EU laws and the related national laws of individual EU Member States governing the conduct of clinical trials, manufacturing approval, marketing authorization of medicinal products, both before and after grant of marketing authorization, and marketing of such products following grant of authorization may result in administrative, civil, or criminal penalties. These penalties could include delays in or refusal to authorize the conduct of clinical trials or to grant marketing authorization, product withdrawals and recalls, product seizures, suspension, or variation of the marketing authorization, total or partial suspension of production, distribution, manufacturing, or clinical trials, operating restrictions, injunctions, suspension of licenses, fines, and criminal penalties.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, EU legislation related to pharmacovigilance, or the assessment and monitoring of the safety of medicinal products, provides that EMA and the competent authorities of the EU Member States have the authority to require companies to conduct additional post-approval clinical efficacy and safety studies. The legislation also governs the obligations of marketing authorization holders with respect to additional monitoring, adverse event management and reporting. Under the pharmacovigilance legislation and its related regulations and guidelines, we may be required to conduct a burdensome collection of data regarding the risks and benefits of marketed products and may be required to engage in ongoing assessments of those risks and benefits, including the possible requirement to conduct additional clinical trials, which may be time-consuming and expensive and could impact our profitability. Non-compliance with such obligations can lead to the variation, suspension or withdrawal of marketing authorization or imposition of financial penalties or other enforcement measures.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks related to manufacturing and supply</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Gene therapies are novel, complex and difficult to manufacture. We have limited manufacturing experience and we rely on third party manufacturers that are often our single source of supply. We could experience manufacturing problems that result in delays in the development or commercialization of our commercial products or our product candidates or otherwise harm our business.<span style="font-weight:normal;font-style:normal;"> </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Biological products are inherently difficult to manufacture, and gene therapy products are complex biological products, the development and manufacture of which necessitates substantial expertise and capital investment. Libmeldy, Strimvelis and our product candidates are individually manufactured for each patient using complex processes in specialized facilities. Our production process requires a variety of raw materials, some of which are highly specialized, including the viral vector that encodes for the functional copy of the missing or faulty gene to treat a specific disease. Some of these raw materials have limited and, in some cases, sole suppliers. Even though we plan to have back-up supplies of raw materials whenever possible, we cannot be certain such supplies will be sufficient if our primary sources are unavailable. A shortage of a critical raw material or a technical issue during manufacturing may lead to delays in clinical development or commercialization of our product candidates. Additionally, each manufacturing batch must meet certain analytical specifications to be released and production difficulties caused by unforeseen events may delay the availability of one or more of the necessary raw materials or delay the manufacture of our product candidates for use in clinical trials or for commercial supply. As a result of the COVID-19 global pandemic, some of our CDMOs have experienced, and may continue to experience, delays and other direct impacts at their manufacturing sites as a result of travel restrictions, shelter-in-place policies or restrictions and other disruptions caused by the pandemic. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have contracted with third party CDMOs for the manufacture of our viral vectors and drug product. We expect these CDMOs will be capable of providing sufficient quantities of our viral vectors and gene therapy products to meet the anticipated scale of our clinical trials and current and initial commercial demands, if any additional products are approved. However, to meet our projected needs for further commercial manufacturing and clinical trials of new product candidates, third parties with whom we currently work might need to increase their scale and frequency of production or we will need to secure alternate suppliers or develop in-house capabilities. We believe that there are alternate sources of supply that can satisfy our clinical and commercial requirements&#59; however, identifying and establishing relationships with such sources, if necessary, could result in significant delays or material additional costs, which could delay or prevent the development of our product candidates and would have a negative impact on our business, financial condition and results of operations.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, the manufacturers of pharmaceutical products must comply with strictly enforced cGMP requirements, state and federal regulations, as well as foreign requirements when applicable. Any failure of our CDMOs to adhere to or document compliance to such regulatory requirements could lead to a delay or interruption in the availability of our program materials for clinical trials. If our manufacturers were to fail to comply with the FDA, EMA, or other regulatory authority, it could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of raw materials, product candidates or products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our product candidates. Our dependence upon others for the manufacture of our gene therapies may also adversely affect our future profit margins and our ability to commercialize any product candidates that receive regulatory approval on a timely and competitive basis.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Delays in obtaining regulatory approval of our or our CDMOs&#8217; manufacturing process and facility or disruptions in our manufacturing process may delay or disrupt our commercialization efforts. Until recently, no cGMP gene therapy manufacturing facility in the United States had received approval from the FDA for the manufacture of an approved gene therapy product.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before we can begin to commercially manufacture our viral vector or product candidates in a CDMO facility, we must obtain regulatory approval from the FDA for our manufacturing processes and for the facility in which manufacturing is performed. A manufacturing authorization must also be obtained from the appropriate European Union regulatory authorities. Until recently, no cGMP gene therapy manufacturing facility in the United States had received approval from the FDA for the manufacture of an approved gene therapy product&#59; therefore, the timeframe required for us to obtain such approval is uncertain. In addition, we must pass a pre-approval inspection of our CDMOs manufacturing facility by the FDA and other relevant regulatory&#160;authorities before any of our gene therapy product candidates can obtain marketing approval. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since March 2020 when foreign and domestic inspections of facilities were largely placed on hold, the FDA has been working to resume routine surveillance, bioresearch monitoring and pre-approval inspections on a prioritized basis. Since April 2021, the FDA has conducted limited inspections and employed remote interactive evaluations, using risk management methods, to meet user fee commitments and goal dates. Ongoing travel restrictions and other uncertainties continue to impact oversight operations both domestic and abroad and it is unclear when standard operational levels will resume. The FDA is continuing to complete mission-critical work, prioritize other higher-tiered inspectional needs (e.g., for-cause inspections), and carry out surveillance inspections using risk-based approaches for evaluating public health. Should FDA determine that an inspection is necessary for approval and an inspection cannot be completed during the review cycle due to restrictions on travel, and the FDA does not determine a remote interactive evaluation to be adequate, the agency has stated that it generally intends to issue, depending on the circumstances, a complete response letter or defer action on the application until an inspection can be completed. During the COVID-19 public health emergency, a number of companies announced receipt of complete response letters due to the FDA&#8217;s inability to complete required inspections for their applications. Regulatory authorities outside the U.S. may adopt similar restrictions or other policy measures in response to the ongoing COVID-19 pandemic and may experience delays in their regulatory activities.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order to obtain approval, we will need to ensure that all of our processes, quality systems, methods, equipment, policies and procedures are compliant with cGMP, and perform extensive audits of vendors, contract laboratories, CDMOs and suppliers. If any of our vendors, contract laboratories, CDMOs or suppliers is found to be out of compliance with cGMP, we may experience delays or disruptions in manufacturing while we work with these third parties to remedy the violation or while we work to identify suitable replacement vendors. The cGMP requirements govern quality control of the manufacturing process and documentation policies and procedures. In complying with cGMP, we will be obligated to spend time, money and effort in production, record keeping and quality control to assure that the product meets applicable specifications and other requirements. If we fail to comply with these requirements, we would be subject to possible regulatory action and may not be permitted to sell any products that we may develop. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any problems in our manufacturing process or facilities could make us a less attractive collaborator for potential partners, including larger pharmaceutical companies and academic research institutions, which could limit our access to additional attractive development programs.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We do not have experience as a company managing a complex supply chain or satisfying manufacturing-related regulatory requirements. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA, EMA and other foreign regulatory authorities may require us to submit samples of any lot of any approved product together with the protocols showing the results of applicable tests at any time. Under some circumstances, the FDA, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EMA or other foreign regulatory authorities may require that we not distribute a product lot until the relevant agency authorizes its release. Slight deviations in the manufacturing process, including those affecting quality attributes and stability, may result in unacceptable changes in a viral vector or a gene therapy product that could result in lot failures or product recalls. Lot failures or product recalls could cause us to delay product launches or clinical trials, which could be costly to us and otherwise harm our business, financial condition, results of operations and prospects. Problems in our manufacturing processes could restrict our ability to meet market demand for our products. </span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Managing an autologous ex vivo gene therapy supply chain is highly complex. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We must identify, engage and coordinate with treatment centers where a patient&#8217;s cellular source material must be collected, prepared, stored and transported to the manufacturing facility, and the cryopreserved drug product must be returned to the treatment center for administration into the patient using controlled temperature shipping containers. Once collected from the patient, the cellular source material must be prepared and stored according to specified procedures. While we intend to standardize the processes at treatment centers, if there is a deviation of the processes, the cellular source material from a patient could be adversely impacted and potentially result in manufacturing failures. The patient&#8217;s cellular materials must be transported to the manufacturing facility using a shipping container that maintains the material at a cool temperature and must typically be delivered and processed within three days of collection. While we intend to use reputable couriers and agents for the transport of such materials, if the shipping container is opened or damaged such that the cool temperature is not maintained, the cellular source material may be adversely impacted, and it may not be feasible to manufacture a drug product for the patient. Similarly, if a shipment is delayed due to adverse weather, misrouting, being held up at a customs point, COVID-19 impacts or other events, the cellular source material may not be delivered within a time window that will allow for its use for the successful manufacture of a drug product. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Similarly, the patient&#8217;s autologous drug product must be returned to the clinical site for administration into the patient using a specialized shipping container that maintains the material at a very low temperature for a period of typically up to ten days. While we intend to use reputable couriers and agents for the transport of our drug products, if the shipping container is opened or damaged such that the very low temperature is not maintained, the drug product may be adversely impacted and it may not be feasible to administer it to the patient or, if administered, it could cause harm to the patient. Similarly, if a shipment is delayed due to adverse weather, misrouting, being held up at a customs point, COVID-19 impacts or other events, and is not delivered to the clinical site within the time period that the very low temperature is maintained, the drug product may be adversely affected and be unable to be administered or, if administered, could cause harm to the patient.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;letter-spacing:-0.15pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may be delayed or unable to identify, engage, successfully coordinate or qualify with treatment centers in the regions we are targeting as part of our commercial launch strategy, which could delay or prevent patients from receiving gene therapy treatments, if approved. For example, due to COVID-19-related travel restrictions, some in-person visits to qualify certain potential treatment centers were postponed or required to take place remotely. If our treatment centers fail to perform satisfactorily, we may suffer reputational, operational, and business harm. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any of the above events, should they happen, could adversely affect our development timelines and our business, financial condition, results of operations and prospects.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our gene therapies are for autologous use only. Therefore, if a drug product is administered to the wrong patient, the patient could suffer harm.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our gene therapies are autologous, so they must be administered back only to the patient from which the cellular source material was collected. While we implement specific identifiers, lot numbers and labels with cross checks for our products and operations from collection of cellular source material, through manufacture of drug product, transport of product to the clinical site up to thawing and administration of the product, it is possible that a product may be administered into the wrong patient. If an autologous gene therapies were to be administered into the wrong patient, the patient could suffer harm, including experiencing a severe adverse immune reaction and this event, should it happen, could adversely affect our business, financial condition, results of operations and prospects.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Any microbial contamination in the manufacturing process for our viral vectors or drug product, shortages of raw materials or failure of any of our key suppliers to deliver necessary components could result in delays in our clinical development or marketing schedules.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;letter-spacing:-0.15pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Given the nature of biologics manufacturing, there is a risk of microbial contamination. Any microbial contamination could adversely affect our ability to produce, release or administer our gene therapies on schedule and could, therefore, harm our results </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;letter-spacing:-0.15pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;letter-spacing:-0.15pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of operations and cause reputational damage. Additionally, although our gene therapies are tested for microbial contamination prior to release, if a contaminated product was administered to a patient, it could result in harm to the patient.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some of the raw materials required in our manufacturing processes are derived from biologic sources. Such raw materials are difficult to procure and may be subject to contamination or recall. A material shortage, contamination, recall or restriction on the use of biologically derived substances in the manufacture of our vectors or drug product could adversely impact or disrupt the commercial manufacturing or the production of clinical material, which could adversely affect our development timelines and our business, financial condition, results of operations and prospects.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Interruptions in the supply of viral vectors or drug products or inventory loss may harm our operating results and financial condition. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our viral vectors and drug products are manufactured using technically complex processes in specialized facilities, sometimes using specialized equipment with highly specific raw materials and other production constraints. The complexity of these processes, as well as strict government standards for the manufacture and storage of our gene therapies, subjects us to manufacturing risks. While viral vectors and drug product released for use in clinical trials or for commercialization undergo sample testing, some defects may only be identified following their release. In addition, process deviations or unanticipated effects of approved process changes may result in viral vector and/or drug product not complying with stability requirements or specifications. Our viral vectors and drug product must be stored and transported at temperatures within a certain range. If these environmental conditions deviate, our viral vectors and drug products&#8217; remaining shelf-lives could be impaired or their efficacy and safety could be negatively impacted, making them no longer suitable for use. For example, patients&#8217; cellular material must be received by the manufacturing facility typically within three days after collection, and our gene therapy must be received by the clinical site typically within ten days after shipping from the manufacturing facility. The occurrence, or suspected occurrence, of manufacturing and distribution difficulties can lead to lost inventories and, in some cases, product recalls, with consequential reputational damage and the risk of product liability. The investigation and remediation of any identified problems can cause production delays, substantial expense, lost sales and delays of new product launches. Any interruption in the supply of finished products, due to transportation or other delays, including delays or disruptions resulting from the impact of the COVID-19 pandemic, or the loss thereof could hinder our ability to timely distribute our products and satisfy customer demand. Any unforeseen failure in the storage of the viral vectors or drug products or loss in supply could delay our clinical trials and result in a loss of our market share for our commercial products or our product candidates, if approved, and negatively affect our business, financial condition, results of operations and prospects.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our cryopreserved product candidates require specific storage, handling and administration at the clinical sites. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our cryopreserved product candidates must be stored at very low temperatures in specialized freezers or specialized shipping containers until immediately prior to use. For administration, the cryopreserved drug product container must be carefully removed from storage, and rapidly thawed under controlled temperature conditions in an area proximal to the patient&#8217;s bedside and administered into the patient. The handling, thawing and administration of the cryopreserved gene therapy product must be performed according to specific instructions, typically using specific disposables and in some steps within specific time periods. Failure to correctly handle the product, follow the instructions for thawing and administration and or failure to administer the product within the specified period post-thaw could negatively impact the efficacy and or safety of the product. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks related to our reliance on third parties</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have in the past, and in the future we may, enter into collaborations with third parties to develop or commercialize product candidates. If these collaborations are not successful, our business could be adversely affected.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have entered into licensing and collaboration agreements with third parties, including the GSK Agreement, pursuant to which GSK transferred to us Strimvelis, Libmeldy (OTL-200), OTL-103 for WAS and OTL-300 for TDT. In addition, GSK novated to us their R&#38;D and collaboration and license agreement, or the R&#38;D Agreement, with Telethon-OSR. These agreements impose, and we expect that future license agreements will impose, various due diligence, milestone payment, royalty, insurance and other obligations on us. The termination of these agreements could result in our loss of rights to practice the intellectual property licensed to us under these agreements and could compromise our development and commercialization efforts for our current or any future product candidates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also entered into a collaboration with <span style="color:#000000;">Pharming Group N.V., or Pharming, pursuant to which Pharming was granted worldwide rights to OTL-105, an investigational </span><span style="font-style:italic;color:#000000;">ex vivo</span><span style="color:#000000;"> autologous hematopoietic stem cell gene therapy for the </span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;">treatment of hereditary angioedema</span><span style="color:#000000;">.</span><span style="color:#000000;"> The Company will lead the completion of IND-enabling activities and oversee manufacturing of OTL-105 during preclinical and clinical development, which will be funded by Pharming.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may enter into additional collaborations in the future. We have limited control over the amount and timing of resources that our current and future collaborators dedicate to the development or commercialization of our product candidates. Our ability to generate revenues from these arrangements will depend on our and our collaborators&#8217; abilities to successfully perform the functions assigned to each of us in these arrangements. Moreover, an unsuccessful outcome in any clinical trial for which our collaborator is responsible could be harmful to the public perception and prospects of our gene therapy platform.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any collaborations we enter into in the future may pose several risks, including the following:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>collaborators may not perform their obligations as expected&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>we may not achieve any milestones, or receive any payments, under our collaborations, including milestones or payments that we expect to achieve or receive&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the clinical trials conducted as part of these collaborations may not be successful&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>collaborators may not pursue development and commercialization of any product candidates that achieve regulatory approval or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborators&#8217; strategic focus or available funding or external factors, such as an acquisition, that divert resources or create competing priorities&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>collaborators may delay clinical trials, provide insufficient funding for clinical trials, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>we may not have access to, or may be restricted from disclosing, certain information regarding product candidates being developed or commercialized under a collaboration and, consequently, may have limited ability to inform our shareholders about the status of such product candidates&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>product candidates developed in collaboration with us may be viewed by our collaborators as competitive with their own product candidates or products, which may cause collaborators to cease to devote resources to the commercialization of our product candidates&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>a collaborator with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of any such product candidate&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development of any product candidates, may cause delays or termination of the research, development or commercialization of such product candidates, may lead to additional responsibilities for us with respect to such product candidates or may result in litigation or arbitration, any of which would be time-consuming and expensive&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>disputes may arise with respect to the ownership of intellectual property developed pursuant to our collaborations&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability&#59; and</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>collaborations may be terminated for the convenience of the collaborator and, if terminated, we could be required to raise additional capital to pursue further development or commercialization of the applicable product candidates.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If our collaborations do not result in the successful development and commercialization of products or if one of our collaborators terminates its agreement with us, we may not receive any future research funding or milestone or royalty payments under such collaborations. If we do not receive the funding we expect under these agreements, our development of product candidates could be delayed, and we may need additional resources to develop our product candidates. In addition, if one of our collaborators terminates its agreement with us, we may find it more difficult to attract new collaborators and the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">perception of us in the business and financial communities could be adversely affected. All of the risks relating to product development, regulatory approval and commercialization described in this Annual Report apply to the activities of our collaborators.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may in the future decide to collaborate with other pharmaceutical and biotechnology companies for the development and potential commercialization of additional product candidates. These relationships, or those like them, may require us to incur non-recurring and other charges, increase our near- and long-term expenditures, issue securities that dilute our existing shareholders or disrupt our management and business. In addition, we could face significant competition in seeking appropriate collaborators and the negotiation process will likely be time-consuming and complex. Our ability to reach a definitive collaboration agreement in such instances will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of several factors. If we license rights to additional product candidates, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company culture.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We utilize, and expect to continue to utilize, third parties to conduct some or all aspects of our vector production and product manufacturing for the foreseeable future, and these third parties may not perform satisfactorily. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are not able to independently manufacture material for our planned clinical programs or our commercial supply of Libmeldy, Strimvelis or any other product for which we obtain marketing approval, if any, and we do not expect to be able to in the foreseeable future. We currently rely on our CDMOs and in some cases academic partners for the production of our viral vectors and product candidates for our ongoing registrational and clinical trials and preclinical studies. For future clinical trials and for Libmeldy and other products for which we obtain marketing approval, if any, we intend to utilize materials manufactured by CDMOs. If our academic partners or these CDMOs do not successfully carry out their contractual duties, meet expected deadlines or manufacture our viral vector and product candidates in accordance with regulatory requirements or if there are disagreements between us and our academic partners or these CDMOs, we will not be able to complete, or may be delayed in completing, the preclinical studies and clinical trials required to support approval of our product candidates or the FDA, EMA or other regulatory agencies may refuse to accept our clinical or preclinical data. In such instances, we may need to enter into an appropriate third-party relationship, which may not be readily available or available on acceptable terms. This could cause additional delay or increased expense prior to the approval of our product candidates and could have a negative impact on our business, financial condition, results of operations and prospects.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We partner with CDMOs and intend to utilize viral vectors and gene therapy products manufactured by CDMOs for our future clinical trials and products for which we obtain marketing approval. In some cases, we may need to perform clinical or analytical or other animal or cell-based testing to demonstrate that materials produced by these CDMOs, or any other third-party manufacturer that we engage, is comparable to the material produced by our academic partners and utilized in our registrational and clinical trials of our product candidates. There is no assurance that these CDMOs, or any other future third-party manufacturer that we engage, will be successful in producing any or all of our viral vector or product candidates, that any such product will, if required, pass the required comparability testing, or that any materials produced by these CDMOs or any other third-party manufacturer that we engage will have the same effect in patients that we have observed to date with respect to materials produced by our academic partners. We believe that our manufacturing network will have sufficient capacity to meet demand for our clinical and existing and expected initial commercial needs, but there is a risk that if supplies are interrupted or result in poor yield or quality, it would materially harm our business. Additionally, if the gene therapy industry were to grow, we may encounter increasing competition for the raw materials and consumables necessary to produce our product candidates. Furthermore, demand for CDMO cGMP manufacturing capabilities may grow at a faster rate than existing manufacturing capacity, which could disrupt our ability to find and retain third-party manufacturers capable of producing sufficient quantities of our viral vectors or product candidates for future clinical trials or to meet expected initial commercial demand.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under certain circumstances, our current CDMOs may terminate their engagements with us. If we need to enter into alternative arrangements, it could delay our development activities. Our reliance on our CDMOs for certain manufacturing activities will reduce our control over these activities but will not relieve us of our responsibility to ensure compliance with all required regulations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to our current CDMOs, we may rely on additional third parties to manufacture our viral vectors and/or drug products in the future and to perform quality testing. Reliance on these third parties entails risks that we would not be subject to if we manufactured the product candidates ourselves, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>reduced control for certain aspects of manufacturing activities&#59;</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>termination or nonrenewal of manufacturing and service agreements with third parties in a manner or at a time that is costly or damaging to us&#59; and</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>disruptions to the operations of our third-party manufacturers and service providers caused by conditions unrelated to our business or operations, including the bankruptcy of the manufacturer or service provider or the COVID-19 global pandemic or similar future pandemics or disruptions.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any of these events could lead to clinical trial delays, failure to obtain regulatory approval or impact our ability to successfully commercialize any of our product candidates. Some of these events could be the basis for FDA, EMA or other regulatory authority action, including injunction, recall, seizure or total or partial suspension of product manufacture.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We rely on third parties, including independent clinical investigators and CROs, to conduct and sponsor some of the clinical trials of our product candidates. Any failure by a third party to meet its obligations with respect to the clinical development of our product candidates may delay or impair our ability to obtain regulatory approval for our product candidates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have relied upon and plan to continue to rely upon third parties, including independent clinical investigators and third-party CROs, to conduct our preclinical studies and clinical trials, including in some instances sponsoring such clinical trials, and to monitor and manage data for our ongoing preclinical and clinical programs. For example, OTL-102 for X-CGD is currently being investigated in ongoing academic-sponsored clinical trials at Boston Children&#8217;s Hospital, the NIH and UCLA in the United States, and GOSH in Europe. While we will have agreements governing the activities of our academic partners and CROs, we will control only certain aspects of their activities and have limited influence over their actual performance.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nevertheless, we are responsible for ensuring that each of our preclinical studies and clinical trials is conducted in accordance with the applicable protocol and legal, regulatory and scientific standards, and our reliance on these third parties does not relieve us of our regulatory responsibilities. We and our third-party contractors and CROs are required to comply with GLP and GCP requirements, which are regulations and guidelines enforced by the FDA, the Competent Authorities of the Member States of the EEA, and comparable foreign regulatory authorities for all of our products in clinical development. Regulatory authorities enforce these GCP requirements through periodic inspections of trial sponsors, principal investigators and trial sites. The FDA, EMA or comparable foreign regulatory authorities may deem the clinical data generated in our clinical trials unreliable and may require us to perform additional clinical trials before approving our marketing applications if, among other things, we fail to exercise adequate oversight over any of our academic partners or CROs or if our academic partners or CROs do not successfully carry out their respective contractual duties or obligations, fail to meet expected deadlines or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements. We cannot assure that upon a regulatory inspection of us, our academic partners or our CROs or other third parties performing services in connection with our clinical trials, such regulatory authority will determine that any of our clinical trials complies with GCP regulations. In addition, our clinical trials must be conducted with product produced under applicable cGMP regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process. As a result, our financial results and the commercial prospects for our product candidates would be harmed, our costs could increase, and our ability to generate revenues could be delayed.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not control the design or conduct of the academic-sponsored trials, and it is possible that the FDA or EMA will not view these academic-sponsored trials as providing adequate support for future clinical trials or market approval, whether controlled by us or third parties, for any one or more reasons, including elements of the design or execution of the trials or safety concerns or other trial results. Such arrangements provide us certain information rights with respect to the academic-sponsored trials, including access to and the ability to use and reference the data, including for our own regulatory submissions, resulting from the academic-sponsored trials. However, we do not have control over the timing and reporting of the data from academic-sponsored trials, nor do we own the data from the academic-sponsored trials. If we are unable to confirm or replicate the results from the academic-sponsored trials or if negative results are obtained, we would likely be further delayed or prevented from advancing further clinical development of OTL-201 for MPS-IIIA and OTL-203 for MPS-IH or any other product candidate investigated in an academic-sponsored clinical trial. Further, if investigators or institutions breach their obligations with respect to the clinical development of our product candidates or if the data proves to be inadequate compared to the first-hand knowledge we might have gained had the academic-sponsored trials been sponsored and conducted by us, then our ability to design and conduct any future clinical trials ourselves may be adversely affected.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, the FDA or EMA may disagree with the sufficiency of our right of reference to the preclinical, manufacturing or clinical data generated by these academic-sponsored trials or our interpretation of preclinical, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">manufacturing or clinical data from these academic-sponsored trials. If so, the FDA or EMA may require us to obtain and submit additional preclinical, manufacturing or clinical data.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We and our contract manufacturers are subject to significant regulation with respect to manufacturing our viral vectors and drug products. The manufacturing facilities on which we rely may not continue to meet regulatory requirements and have limited capacity.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently have relationships with a limited number of suppliers for the manufacturing of our viral vectors and drug products. Each supplier may require licenses to manufacture such components if such processes are not owned by the supplier or in the public domain, and we may be unable to transfer or sublicense the intellectual property rights we may have with respect to such activities.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All entities involved in the preparation of therapeutics for clinical trials or commercial sale, including our existing CDMOs for our viral vectors and drug product, are subject to extensive regulation. Components of a finished therapeutic product approved for commercial sale or used in clinical trials, including in some cases critical raw materials used in the manufacture thereof, must be manufactured in accordance with cGMP. Poor control of production processes can lead to the introduction of adventitious agents or other contaminants, or to inadvertent changes in the properties or stability of our viral vectors or product candidates that may not be detectable in final product testing. We or our CDMOs must supply all necessary documentation in support of a BLA or MAA on a timely basis and must adhere to the FDA&#8217;s and EMA&#8217;s cGMP and other applicable regulations that are enforced through facilities inspection programs. Some of our CDMOs have not produced a commercially-approved product and have never been inspected by the FDA or other regulatory body. Our quality systems and the facilities and quality systems of some or all of our CDMOs must pass a pre-approval inspection for compliance with the applicable regulations as a condition of regulatory approval of our product candidates or any of our other potential products. In addition, the regulatory authorities may, at any time, audit or inspect a manufacturing facility involved with the preparation of our viral vector or drug product or our other potential products or the associated quality systems for compliance with the regulations applicable to the activities being conducted.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any such inspection or audit identifies a failure to comply with applicable regulations or if a violation of our product specifications or applicable regulations occurs independent of such an inspection or audit, we or the relevant regulatory authority may require remedial measures that may be costly and/or time-consuming for us or a third party to implement and that may include the temporary or permanent suspension of a clinical trial or commercial sales or the temporary or permanent closure of a facility. Any such remedial measures imposed upon us or third parties with whom we contract could materially harm our business.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we or any of our CDMOs fail to maintain regulatory compliance, the FDA can impose regulatory sanctions including, among other things, refusal to approve a pending application for a new product or biologic product, or revocation of a pre-existing approval. As a result, our business, financial condition and results of operations may be materially harmed.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These factors could cause the delay of clinical trials, regulatory submissions, required approvals of our product candidates or commercialization of our commercial products or product candidates, if approved, and cause us to incur higher costs and prevent us from commercializing our products successfully. Furthermore, if our suppliers fail to meet contractual requirements, and we are unable to secure one or more replacement suppliers capable of production at a substantially equivalent cost, our preclinical studies and clinical trials may be delayed.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We are dependent on a limited number of suppliers and, in some instances, a sole supplier, for some of our components and materials used in our product candidates. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently depend on a limited number of suppliers and, in some instances, a sole supplier, for some of the components and equipment necessary for the production of our viral vectors and drug product. We cannot be sure that these suppliers will remain in business, or that they will not be purchased by one of our competitors or another company that is not interested in continuing to produce these materials for our intended purpose. Our use of a sole or a limited number of suppliers of raw materials, components and finished goods exposes us to several risks, including disruptions in supply, price increases, late deliveries and an inability to meet customer demand. There are, in general, relatively few alternative sources of supply for these components, and, in some cases, no alternatives. These vendors may be unable or unwilling to meet our future demands for our clinical trials or commercial sale. Establishing additional or replacement suppliers for these components could take a substantial amount of time and it may be difficult to establish replacement suppliers who meet regulatory requirements. As a result of the COVID-19 pandemic, we may experience supply shortages from some of our suppliers. Any disruption in supply from any supplier or manufacturing location could lead to supply delays or interruptions which would damage our business, financial condition, results of operations and prospects.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are required to switch to a replacement supplier, the manufacture and delivery of our viral vectors and product candidates could be interrupted for an extended period, adversely affecting our business. Establishing additional or replacement suppliers may not be accomplished quickly. If we are able to find a replacement supplier, the replacement supplier would need to be qualified and may require additional regulatory authority approval, which could result in further delay.&#160;For example, the FDA or EMA could require additional supplemental data, manufacturing data and comparability data up to and including clinical trial data if we rely upon a new supplier. </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While we seek to maintain adequate inventory of the components and materials used in our product candidates, any interruption or delay in the supply of components or materials, or our inability to obtain components or materials from alternate sources at acceptable prices in a timely manner, could impair our ability to conduct our clinical trials and, if our product candidates are approved, to meet the demand of our customers and cause them to cancel orders.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, as part of the FDA&#8217;s approval of our product candidates, the FDA must review and approve the individual components of our production process, which includes raw materials, the manufacturing processes and facilities of our suppliers. Some of our current suppliers have not undergone this process nor have they had any components included in any product approved by the FDA.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our reliance on these suppliers subjects us to a number of risks that could harm our reputation, business, and financial condition, including, among other things:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the interruption of supply resulting from modifications to or discontinuation of a supplier&#8217;s operations&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>delays in product shipments resulting from uncorrected defects, reliability issues, or a supplier&#8217;s variation in a component&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>a lack of long-term supply arrangements for key components with our suppliers&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the inability to obtain adequate supply in a timely manner, or to obtain adequate supply on commercially reasonable terms&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>difficulty and cost associated with locating and qualifying alternative suppliers for our components in a timely manner&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>production delays related to the evaluation and testing of products from alternative suppliers, and corresponding regulatory qualifications&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>a delay in delivery due to our suppliers prioritizing other customer orders over ours&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>damage to our reputation caused by defective components produced by our suppliers&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>increased cost of our warranty program due to product repair or replacement based upon defects in components produced by our suppliers&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>interruptions, shortages, delivery delays and potential discontinuation of supply as a result of the ongoing COVID-19 global pandemic, or any recurrence of the pandemic or future pandemics&#59; and</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>fluctuation in delivery by our suppliers due to changes in demand from us or their other customers.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any of these risks materialize, costs could significantly increase and our ability to conduct our clinical trials and, if our product candidates are approved, to meet demand for our products could be impacted.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because we currently rely on third parties to manufacture our vectors and our commercial products and product candidates, and because we collaborate with various organizations and academic institutions on the advancement of our gene therapy approach, we must, at times, share trade secrets with such third parties. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, collaborative research agreements, consulting agreements or other similar agreements with our collaborators, advisors, employees and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, such as trade secrets.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor&#8217;s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have a material adverse effect on our business.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, these agreements typically restrict the ability of our collaborators, advisors, employees and consultants to publish data potentially relating to our trade secrets. Our academic collaborators typically have rights to publish data, provided that we are notified in advance and may delay publication for a specified time in order to secure our intellectual property rights arising from the collaboration. In other cases, publication rights are controlled exclusively by us, although in some cases we may share these rights with other parties. Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of these agreements, independent development or publication of information including our trade secrets in cases where we do not have proprietary or otherwise protected rights at the time of publication. A competitor&#8217;s discovery of our trade secrets would impair our competitive position and have an adverse impact on our business.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks related to commercialization of our product candidates </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we are unable to either establish effective sales and marketing capabilities or enter into agreements with third parties for such services, we may be unable to generate product revenue.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-size:6pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are working to successfully commercialize Libmeldy in Europe, and we intend to commercialize our product candidates, if approved, in the United States, Europe and other markets. Given the relative rarity of the indications that we are targeting, we are commercializing Libmeldy and we currently intend to commercialize any product candidates that are approved directly with specialized teams. We are building out our commercial infrastructure for the commercialization of Libmeldy in Europe, but we have a limited marketing and sales team. In order to commercialize Libmeldy, Strimvelis and any other product candidates that may be approved, we must continue to build and expand<span style="color:#000000;">, on a territory-by-territory basis, marketing, sales, distribution, managerial and other capabilities or make arrangements with third parties to perform these services. If we are unable to do so, we may be unable to generate sufficient revenue to sustain our business.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regardless of whether we establish our own sales and marketing capabilities or enter into third-party arrangements, there are risks involved. On the one hand, recruiting and training a commercial organization is both expensive and time consuming, and we could face delays in any product launch. If a product launch is delayed or does not occur, we may be unable to recoup our investment if we cannot retain or reposition our sales and marketing personnel. There are several factors that could inhibit our efforts to commercialize Libmeldy and our product candidates, if approved, on our own. These include, but are not limited to:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>we may be unable to recruit, train and retain adequate numbers of effective sales and marketing personnel&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>our sales personnel may be unable to obtain access to physicians or may be unable to persuade adequate numbers of physicians to prescribe Libmeldy and any future products that we may develop&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>we may face changes or setbacks at treatment centers contracted for the administration of any approved treatments&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>adverse events could occur&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>we are unable to offer complementary treatments, which may put us at a competitive disadvantage relative to companies with more extensive product lines&#59; and</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>we may experience unforeseen costs and expenses associated with creating an independent sales and marketing organization.</p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;color:#212529;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we will need to commit significant additional management and other resources to maintain and grow our sales organization. We may not be able to achieve the necessary development and growth in a cost-effective manner or realize a positive return on our investment. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On the other hand, there are risks with entering into third party arrangements for the performance of sales, marketing and distribution services. These include, but are not limited to:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>our product revenue or the profitability to us from these revenue streams may be lower than if we were to perform these services ourselves&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>we may be unable to enter into suitable third-party arrangements or we may only be able to do so on unfavorable terms, particularly given that we face competition in any search for third party assistance&#59; and</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>we will likely have limited control over third parties, and they may fail to devote the necessary resources and attention to market and sell our products or product candidates, if approved, effectively.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we do not establish sales and marketing capabilities successfully, either on our own or in collaboration with third parties, we may be unable to generate product revenue.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We face significant competition in our industry and there can be no assurance that our commercial products or our product candidates, if approved, will achieve acceptance in the market over existing established therapies. In addition, our competitors may develop therapies that are more advanced or effective than ours, which may adversely affect our ability to successfully market or commercialize any of our product candidates.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We operate in a highly competitive segment of the biopharmaceutical market. We face competition from many different sources, including larger pharmaceutical, specialty pharmaceutical and biotechnology companies, as well as from academic institutions, government agencies and private and public research institutions. Our product candidates, if successfully developed and approved, will compete with established therapies, some of which are being marketed by large and international companies. In addition, we expect to compete with new treatments that are under development or may be advanced into the clinic by our competitors. There are a variety of product candidates, including gene therapies, in development for the indications that we are targeting, including new areas that we may target as part of our strategic initiatives.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We rely primarily on know-how and trade secret protection for aspects of our proprietary technologies, Libmeldy, Strimvelis and our product candidates. We do not have any issued patents covering Libmeldy, Strimvelis or our product candidates.&#160;This means that barriers to entry that typically apply in the case of pharmaceutical and biopharmaceutical companies with issued patents covering aspects of their proprietary technologies, products and product candidates, such as composition of matter claims, will generally not apply to our commercial products or our product candidates, and this may expose us to competition from other biopharmaceutical companies, particularly those companies that possess greater financial resources and more mature product candidate development, manufacturing, marketing and distribution resources than we do.&#160;Although our product candidates, if approved, may be eligible for marketing and/or data exclusivities in, for example, the United States and Europe, these exclusivities would not prevent another biopharmaceutical company from conducting its own clinical trials to develop and seek regulatory approval of a competitive product.&#160;We are not the only company that is developing and commercializing products using a lentiviral-based autologous&#160;<span style="font-style:italic;">ex vivo</span>&#160;gene therapy approach, and these competitive approaches may be comparable or superior to our approach. One or more of these companies may seek to develop products that compete directly with our commercial products or one or more of our product candidates, the result of which could have a material adverse effect on our business. In addition, many universities and private and public research institutes are active in our target disease areas.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many of our competitors have significantly greater financial, product candidate development, manufacturing and marketing resources than we do. Large pharmaceutical and biotechnology companies have extensive experience in clinical testing and obtaining regulatory approval for their products, and mergers and acquisitions within these industries may result in even more resources being concentrated among a smaller number of larger competitors. Established pharmaceutical companies may also invest heavily to accelerate discovery and development of novel therapeutics or to in-license novel therapeutics that could make the product candidates that we develop obsolete. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries. Our business would be materially and adversely affected if competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, have broader market acceptance, are more convenient or are less expensive than any product candidate that we may develop.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we obtain regulatory approval of our product candidates, the availability and price of our competitors&#8217; products could limit the demand and the price we are able to charge for our product candidates. We may not be able to implement our business plan if the acceptance of our product candidates is inhibited by price competition or the reluctance of physicians to switch from existing methods of treatment to our product candidates, or if physicians switch to other new drug or biologic products or choose to reserve our product candidates for use in limited circumstances.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If the size and value of the market opportunities for our commercial products or product candidates are smaller than our estimates, or if we have difficulty in finding patients that meet eligibility requirements for Libmeldy, Strimvelis or any of our product candidates, if approved, our product revenues may be adversely affected and our business may suffer. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.14%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We focus our research and product development on treatments for immunological disorders and inherited neurometabolic and neurodegenerative genetic disorders. We base our market opportunity estimates on a variety of factors, including our estimates of the number of people who have these diseases, the potential scope of our approved product labels, the subset of people with these diseases who have the potential to benefit from treatment with our product candidates, various pricing scenarios, and our understanding of reimbursement policies for rare diseases in particular countries. These estimates are based on many assumptions and may prove to be incorrect, and new studies may reduce the estimated incidence or prevalence of these diseases. Estimating market opportunities can be particularly challenging for ultra-rare indications, such </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as the ones we currently address, as epidemiological data is often more limited than for more prevalent indications and can require additional assumptions to assess potential patient populations. </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, as we advance our product candidates towards commercialization, learn more about market dynamics and engage with regulators on potential marketing approvals, our view of the initial potential market opportunity for our products will become more refined. In some cases</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the approved label may initially be directed to a narrower patient population with the opportunity to expand the label upon submission of additional clinical data. </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, in the case of Libmeldy,</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> we are initially focused primarily on annual incidence of the disease. </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> means the initial market opportunity for </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Libmeldy</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> may be smaller than the total addressable market opportunity that could be achieved over time. </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are unable to advance</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> product candidates with attractive market opportunities, our future product revenues may be smaller than anticipated and our business may suffer.</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Patient identification efforts also influence the ability to address a patient population. If efforts in patient identification are unsuccessful or less impactful than anticipated, </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for instance, because of a lack of newborn screening or diagnostic initiatives, inadequate disease awareness among healthcare providers, or otherwise, </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we may not address the entirety of the opportunity we are seeking. </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result, patients may be difficult to identify and access, the addressable patient population in the United States, Europe and elsewhere may turn out to be lower than expected, or patients may not be otherwise amenable to treatment with our products, all of which would adversely affect our business, financial condition, results of operations and prospects. </span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The commercial success of any current or future product candidate will depend upon the degree of market acceptance by physicians, patients, payors and others in the medical community.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we obtain any regulatory approval for our product candidates, the commercial success of our product candidates will depend in part on the medical community, patients, and payors accepting gene therapy products in general, and our product candidates in particular, as effective, safe and cost-effective. Any product that we bring to the market may not gain market acceptance by physicians, patients, payors and others in the medical community. The degree of market acceptance of these product candidates, if approved for commercial sale, will depend on a number of factors, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the potential efficacy and potential advantages over alternative treatments&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the frequency and severity of any side effects, including any limitations or warnings contained in a product&#8217;s approved labeling&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the frequency and severity of any side effects resulting from the conditioning regimen or follow-up requirements for the administration of our product candidates&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the relative convenience and ease of administration&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the strength of marketing and distribution support and timing of market introduction of competitive products&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>publicity concerning our products or competing products and treatments&#59; and</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>sufficient third-party insurance coverage or reimbursement.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if a product candidate displays a favorable efficacy and safety profile in preclinical studies and clinical trials, market acceptance of the product, if approved for commercial sale, will not be known until after it is launched. Our efforts to educate the medical community and payors on the benefits of our product candidates may require significant resources and may never be successful. Such efforts to educate the marketplace may require more resources than are required by the conventional technologies marketed by our competitors. If these products do not achieve an adequate level of acceptance, we may not generate significant product revenue and may not become profitable.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The insurance coverage and reimbursement status of newly-approved products is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for any of our product candidates, if approved, could limit our ability to market those products and decrease our ability to generate revenue.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect the cost of a single administration of gene therapy products, such as those we are developing, to be substantial, when and if they achieve market approval. In the United States and markets in other countries, patients generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. The availability and extent of reimbursement by governmental and private payors is essential for most patients to be able to afford expensive treatments, such as stem cell transplants. Sales of our product candidates will depend substantially, both domestically and abroad, on the extent to which the costs of our product candidates will be covered and paid by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or reimbursed by government health administration authorities, private health coverage insurers and other payors. If coverage and adequate reimbursement are not available, or are available only to limited levels, we may not be able to successfully commercialize our product candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a sufficient return on our investment. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may not be able to provide data sufficient to gain acceptance with respect to coverage and reimbursement. If reimbursement is not available, or is available only at limited levels, we may not be able to successfully commercialize our product candidates, if approved. The process for determining whether a payor will provide coverage for a product may be separate from the process for setting the reimbursement rate that the payor will pay for the product. Payors may limit coverage to specific products on an approved list, or formulary, which might not include all of the FDA-approved products for a particular indication. A decision by a payor not to cover our gene therapies could reduce physician utilization of our products once approved and have a material adverse effect on our sales, results of operations and financial condition. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the United States, the principal decisions about coverage and reimbursement for new medicines are typically made by the Centers for Medicare&#160;&#38; Medicaid Services, or CMS, an agency within the U.S. Department of Health and Human Services, or HHS. CMS decides whether and to what extent a new medicine will be covered and reimbursed under Medicare. Private payors tend to follow the CMS to a substantial degree. It is difficult to predict what the CMS will decide with respect to reimbursement for fundamentally novel products such as ours, as there is no body of established practices and precedents for these new products. Factors payors consider in determining reimbursement are based on whether the product is:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>a covered benefit under its health plan&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>safe, effective and medically necessary&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>appropriate for the specific patient&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>cost-effective&#59; and </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>neither experimental nor investigational.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outside the United States, certain countries, including a number of member states of the European Union, set prices and reimbursement for pharmaceutical products, or medicinal products, as they are commonly referred to in the European Union, with limited participation from the marketing authorization holders. We cannot be sure that such prices and reimbursement will be acceptable to us or our collaborators. If the regulatory authorities in these jurisdictions set prices or reimbursement levels that are not commercially attractive for us or our collaborators, our revenues from sales by us or our collaborators, and the potential profitability of our drug products, in those countries would be negatively affected. Some countries may also require the completion<span style="color:#000000;"> </span>of clinical trials that compare the cost effectiveness of a particular product candidate to currently available therapies. An increasing number of countries are taking initiatives to attempt to reduce large budget deficits by focusing cost-cutting efforts on pharmaceuticals for their state-run health care systems. These international price control efforts have impacted all regions of the world, but have been most drastic in the European Union. Additionally, some countries require approval of the sale price of a product before it can be marketed.&#160;In many countries, the pricing review period begins after marketing or product licensing approval is granted.&#160;As a result, we might obtain marketing approval for a product in a particular country, but then may experience delays in the reimbursement approval of our product or be subject to price regulations that would delay our commercial launch of the product, possibly for lengthy time periods, which could negatively impact the revenues we are able to generate from the sale of the product in that particular country. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our product candidates. Historically, products launched in the European Union do not follow price structures of the U.S. and generally prices tend to be significantly lower.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, efforts by governmental and payors, in the United States and abroad, to cap or reduce healthcare costs may cause such organizations to limit both coverage and level of reimbursement for new products approved, and, as a result, they may not cover or provide adequate payment for our product candidates. We expect to experience pricing pressures in connection with the sale of any of our product candidates, due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Due to the novel nature of our technology and the potential for our product candidates to offer therapeutic benefit in a single administration, we face uncertainty related to pricing and reimbursement for these product candidates.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are targeting rare diseases for which the patient populations are relatively small. In addition, treatment with any of our product candidates involves only a single administration. As a result, the pricing and reimbursement of our product candidates, if approved, must be adequate to support commercial infrastructure. It is possible that commercially available products may serve as a reference price that, for various reasons, may be lower than the price we need to obtain for our product candidates. If we are unable to obtain adequate levels of reimbursement, our ability to successfully market and sell our product candidates will be adversely affected. The manner and level at which reimbursement is provided for services </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">related to our product candidates (</span><span style="font-style:italic;">e.g.</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, for administration of our product to patients) is also important. Inadequate reimbursement for such services may lead to physician resistance and adversely affect our ability to market or sell our product candidates, if approved.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks related to the impact of COVID-19</p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Business interruptions resulting from the COVID-19 pandemic or similar public health crises have caused and may cause or continue to cause a disruption to the development of our product candidates and adversely impact our business. </p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Public health crises such as pandemics or similar outbreaks can adversely impact our business. The COVID-19 global pandemic has caused significant disruptions to the U.S. and global economies, has contributed to significant volatility and negative pressure in financial markets, and has led to the implementation of various responses, including government-imposed quarantines, travel restrictions and other public health safety measures, which have impacted various aspects of our business and our operations and are likely to continue to impact our operations. The extent to which the COVID-19 global pandemic impacts our operations, or those of our third-party partners, will depend on future developments, which are highly uncertain and cannot be predicted with confidence. Such developments include the duration of the pandemic and related disruptions, renewed outbreaks in the future, including different variants of the virus, the ability to distribute and deliver approved vaccines and boosters on a timely basis and the uptake and effectiveness of such vaccines, new information that may emerge concerning the severity of the pandemic and other actions to contain the coronavirus or treat its impact, among others.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In response to the pandemic, we implemented a work from home policy. Most of our administrative employees continue to work outside of our offices, and we have reduced on-site staff significantly and, in some cases, restricted on-site staff to only those required to execute certain laboratory and related support activities. Continued remote working could have a variety of impacts on our business, including increasing our cyber security risk, creating data accessibility concerns, and making us more susceptible to communication disruptions, any of which could adversely impact our business operations or delay necessary interactions with regulators, manufacturing sites and clinical trial sites. We may also experience difficulty in recruiting and onboarding new employees. In addition, as a result of continued or renewed restrictions, our on-site staff conducting research and development, preclinical studies, and manufacturing activities may not be able to access our laboratories or manufacturing space, and these core activities may be significantly limited or curtailed, possibly for an extended period of time.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are conducting clinical trials for our product candidates in the United States and Europe, which are currently being affected by the COVID-19 pandemic and will likely continue to be affected. Our clinical sites have devoted significant resources to patients with COVID-19, <span style="color:#000000;">which could limit their ability to enroll additional patients in ongoing clinical trials or follow-up with existing patients.&#160;Some </span>factors from the COVID-19 pandemic that have delayed and may continue to delay or otherwise adversely affect enrollment in or the progress of our clinical trials for some or all of our product candidates, as well as our business generally, include:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the potential diversion of healthcare resources away from the conduct of clinical trials to focus on pandemic concerns, including the attention of physicians serving as our clinical trial investigators, hospitals or academic centers serving as our clinical trial sites and staff supporting the conduct of our clinical trials&#59;</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">limitations on travel that could interrupt treatment center qualification, key trial activities, such as clinical trial site initiations and monitoring, domestic and international travel by employees, contractors or patients to clinical trial sites, including any government-imposed travel restrictions or quarantines that may impact the ability or willingness of patients, employees or contractors to travel to our clinical trial sites or secure visas or entry permissions, any of which could delay or adversely impact the conduct or progress of our clinical trials&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">interruption in global shipping affecting the transport of clinical trial materials, such as patient samples, investigational drug product and conditioning drugs and other supplies used in our clinical trials&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">business disruptions caused by potential workplace, laboratory and office closures and an increased reliance on employees working from home, disruptions to or delays in ongoing laboratory experiments and operations, disruptions or delays in subleasing any leased facilities no longer required for our business operations, staffing shortages, travel limitations or mass transit disruptions, any of which could adversely impact our business operations or delay necessary interactions with local regulators, ethics committees and other important agencies and contractors&#59; </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">business disruptions involving our third parties on whom we rely, including CROs and other collaborators for the conduct of our clinical trials or our third</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">party suppliers or CDMOs, which could impact their ability to perform adequately or disrupt our supply chain&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">changes in hospital or research institution policies or government regulations, which could delay or adversely impact our ability to conduct our clinical trials.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Trial procedures (particularly any procedures that may be deemed non-essential), patient dosing, shipment of our product candidates, distribution of clinical trial materials, study monitoring, site inspections and data analysis may be paused or delayed due to the above factors or other reasons related to the pandemic. Furthermore, if the coronavirus, including new variants of the virus, continues to spread, or recurs in the future, or if approved vaccines are not as effective as anticipated or are significantly delayed in being administered, some patients and clinical investigators may not be able to comply with clinical trial protocols or we may see increased rates of patients withdrawing from any planned clinical trial following enrollment, including as a result of contracting COVID-19 or travel limitations (whether voluntary or required), which may impede patient movement, affect access to trial sites, or interrupt healthcare services. Moreover, follow-up visits associated with our active clinical trials are in most cases being conducted using alternative data collection approaches due to COVID-19 travel and other trial site limitations. Though we are following the FDA, EMA and certain country-specific guidance on the management of clinical trials during the COVID-19 pandemic, we may also utilize other alternative approaches that may not be as effective as traditional approaches, and regulatory bodies, such as the FDA and EMA, may not approve such data collection techniques and may consider the data collected during the COVID-19 pandemic insufficient support for the relevant regulatory filings. Additionally, we have experienced and anticipate that the COVID-19 pandemic may continue to result in regulatory delays, such as delays in receiving regulatory advice, reviews of applications, or performance of inspections required for approvals. The pandemic may also result in greater regulatory uncertainty. For example, while the FDA and EMA have issued guidance to provide biopharmaceutical manufacturers greater flexibility in certain regulatory areas, including remote monitoring, protocol deviations and adverse event reporting, such flexibility may result in greater uncertainty regarding the expectations of such health authorities in relation to this guidance and the adequacy of the data collected during the COVID-19 pandemic to support regulatory filings. Any disruption or delay in our ability to complete preclinical and clinical development of our product candidates could <span style="color:#000000;">impair our ability to successfully gain regulatory approval for and ultimately commercialize our product candidates and may harm our business and results of operations.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The extent and impact of such disruptions are currently unpredictable. Any prolongation or de-prioritization of our clinical trials or delay in regulatory review resulting from such disruptions could materially affect the development, study and regulatory submissions of our product candidates. The COVID-19 global pandemic may also result in interruption or delays in the operations of the FDA and EMA and other regulatory agencies, which could further delay our anticipated regulatory submissions and any potential approval of our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.9%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the COVID-19 pandemic initially impacted our ability to generate revenue <span style="color:#000000;">from the sale of Strimvelis, as</span> <span style="Background-color:#FFFFFF;color:#000000;">Ospedale San Raffaele</span><span style="color:#000000;">, Milan, Italy, the treatment site for Strimvelis, postponed scheduling and treating non-urgent patients with the therapy for approximately three months. Although we derive limited revenue from sales of Strimvelis,</span> <span style="color:#000000;">a prolonged postponement of treatments would significantly reduce our sole source of product revenue. The COVID-19 pandemic may also result in a diversion of payor or government resources away from health technology assessment, reimbursement or market access activities, which could delay our efforts to commercialize Libmeldy in the EU. </span></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The extent to which the COVID-19 pandemic impacts our business, and our clinical development and regulatory efforts, as well as our supply chain, will depend on future developments that are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the duration of the outbreak, government actions, such as travel restrictions, quarantines and social distancing requirements in the U.S. and in other countries, business closures or business disruptions and the effectiveness of actions taken in the U.S. and in other countries to contain and treat the disease. Accordingly, we do not yet know the full extent of potential delays or impacts on our business, our clinical and regulatory activities, our research programs, healthcare systems or the global economy as a whole. However, these effects could materially and adversely affect our business, financial condition, results of operations and growth prospects, which may in turn also have the effect of heightening many of the other risks and uncertainties described elsewhere in this &#8220;Risk Factors&#8221; section.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks related to our business operations</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our gene therapy approach utilizes vectors derived from viruses, which may be perceived as unsafe or may result in unforeseen adverse events. Negative public opinion and increased regulatory scrutiny of gene therapy and genetic </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">research may damage public perception of our product candidates or adversely affect our ability to conduct our business or obtain regulatory approvals for our product candidates.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gene therapy remains a novel technology, with only a limited number of gene therapy products approved to date. Public perception may be influenced by claims that gene therapy is unsafe, and gene therapy may not gain the acceptance of the public or the medical community. Adverse events in other lentiviral gene therapy trials unrelated to our product candidates could negatively impact our business. Our success will depend upon physicians specializing in the treatment of those diseases that our product candidates target prescribing treatments that involve the use of our product candidates in lieu of, or in addition to, existing treatments they are already familiar with and for which greater clinical data may be available. More restrictive government regulations or negative public opinion would have a negative effect on our business or financial condition and may delay or impair the development and commercialization of our product candidates or demand for any products we may develop. Adverse events in our clinical trials, even if not ultimately attributable to our product candidates (such as the many adverse events that typically arise from the conditioning process), or adverse events in other lentiviral gene therapy trials, and the resulting publicity could result in increased governmental regulation, unfavorable public perception, potential regulatory delays in the testing or approval of our potential product candidates, stricter labeling requirements for those product candidates that are approved and a decrease in demand for any such product candidates.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Increasing demand for compassionate use of our unapproved therapies could result in losses.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are developing our autologous&#160;<span style="font-style:italic;">ex vivo</span>&#160;gene therapies to address rare diseases for which there are currently limited or no available therapeutic options. Media attention to individual patients&#8217; expanded access requests has resulted in the introduction and passage of legislation at the local and national level referred to as &#8220;Right to Try&#8221; laws, which are intended to help enable patient access to unapproved therapies. Such legislation includes the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017, which was signed into law in May 2018. New and emerging legislation regarding expanded access to unapproved drugs for life-threatening illnesses could negatively impact our business in the future.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A possible consequence of both activism and legislation in this area is the need for us to initiate an unanticipated expanded access program or to make our product candidates more widely available sooner than anticipated. We have limited resources and unanticipated trials or access programs could result in diversion of resources from our primary goals.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, patients who receive access to unapproved drugs through compassionate use or expanded access programs have life-threatening illnesses and have exhausted all other available therapies. The risk for SAEs in this patient population is high, which could have a negative impact on the safety profile of our product candidates. This could cause significant delays or an inability to successfully commercialize our product candidates, which could materially harm our business.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have acquired rights to several programs and we may in the future acquire rights to additional programs. If we are unable to effectively manage these programs, our future results may suffer. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2018, we acquired worldwide rights to Libmeldy (OTL-200), Strimvelis, OTL-103 for WAS and OTL-300 for TDT pursuant to the GSK Agreement. We further acquired worldwide rights to OTL-203 for MPS-IH in May 2019 pursuant to an exclusive licensing agreement with Telethon-OSR. These acquisitions significantly changed the composition of our operations, markets and product candidate mix, and we are continuing to adapt our organization to manage these programs. As an example, we have since announced the reduction of the investment in and scope of certain of these programs. Our future success depends, in part, on our ability to continue to address these changes, and, where necessary, to attract and retain new personnel that possess the requisite skills called for by these changes. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our failure to adequately address the financial, operational or legal risks of any of our acquisitions could harm our business. Financial aspects of such future transactions that could alter our financial position or operating results include:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>use of cash resources&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>higher than anticipated acquisition costs and expenses&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>potentially dilutive issuances of equity securities&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the incurrence of debt and contingent liabilities, impairment losses or restructuring charges&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>large write-offs and difficulties in assessing the relative percentages of in-process research and development expense that can be immediately written off as compared to the amount that must be amortized over the appropriate life of the asset&#59; and</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>amortization expenses related to other intangible assets.</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operational risks that could harm our existing operations or prevent realization of anticipated benefits from these transactions include:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>challenges associated with managing an increasingly diversified business&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>disruption of our ongoing business&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>difficulty and expense in assimilating the operations, products, technology, information systems or personnel of the acquired company&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>entry into a geographic or business market in which we have little or no prior experience&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>inability to maintain uniform standards, controls, procedures and policies&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the assumption of known and unknown liabilities of the acquired business or asset, including intellectual property claims&#59; and</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>subsequent loss of key personnel.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our future success depends, in part, upon our ability to manage our expansion opportunities. Integrating new operations into our existing business in an efficient and timely manner, successfully monitoring our operations, costs, regulatory compliance and customer relationships, and maintaining other necessary internal controls pose substantial challenges for us. As a result, we cannot assure that our expansion or acquisition opportunities will be successful or that we will realize our expected operating efficiencies, cost savings, revenue enhancements, synergies or other benefits.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We face potential product liability and if successful claims are brought against us we may incur substantial liability and costs. If the use of Libmeldy, Strimvelis or any of our product candidates harms patients, or is perceived to harm patients even when such harm is unrelated to our products or product candidates, our regulatory approvals could be revoked or otherwise negatively impacted and we could be subject to costly and damaging product liability claims.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The use of our product candidates in clinical trials and the sale of Strimvelis and Libmeldy or any products for which we obtain marketing approval exposes us to the risk of product liability claims. Product liability claims might be brought against us by consumers, healthcare providers, pharmaceutical companies or others selling or otherwise coming into contact with our products. There is a risk that our product candidates may induce adverse events. For example, in October 2020, we were notified that a patient treated with Strimvelis under a compassionate use program in 2016 had been diagnosed with leukemia. Subsequent findings confirmed that the patient&#8217;s leukemia was due to insertional oncogenesis attributable to treatment with Strimvelis, though the CHMP concluded that the risk-benefit balance remains favorable. If we cannot successfully defend against product liability claims, including any claims related to treatment with Strimvelis, we could incur substantial liability and costs. In addition, regardless of merit or eventual outcome, product liability claims may result in:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the impairment of our business reputation&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the withdrawal of clinical trial participants&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>costs due to related litigation&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the distraction of management&#8217;s attention from our primary business&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>substantial monetary awards to patients or other claimants&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the inability to commercialize our product candidates&#59; and</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>decreased demand for our product candidates, if approved for commercial sale.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe our product liability insurance coverage is sufficient in light of our current commercial and clinical programs&#59; however, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. We intend to expand our insurance coverage each time we commercialize an additional product, but we may be unable to obtain product liability insurance on commercially reasonable terms or in adequate amounts. On occasion, large judgments have been awarded in class action lawsuits based on drugs or medical treatments that had unanticipated adverse effects. A successful product liability claim or series of claims brought against us could adversely affect our results of operations and business.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patients with the diseases targeted by certain of our product candidates are often already in severe and advanced stages of disease and have both known and unknown significant pre-existing and potentially life- threatening health risks. During the course of treatment, patients may suffer adverse events, including death, for reasons that may be related to our product candidates. Such events could subject us to costly litigation, require us to pay substantial amounts of money to injured patients, delay, negatively impact or end our opportunity to receive or maintain regulatory approval to market our products, or require us to suspend or abandon our commercialization efforts. Even in a circumstance in which we do not believe that an adverse event is related to our products, the investigation into the circumstance may be time-consuming or inconclusive. These investigations may interrupt our sales efforts, delay our regulatory approval process in other countries, or impact and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">limit the type of regulatory approvals our product candidates receive or maintain. As a result of these factors, a product liability claim, even if successfully defended, could have a material adverse effect on our business, financial condition or results of operations.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">An information security incident, including a cybersecurity breach, could have a negative impact to the Company&#8217;s business or reputation.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Security incidents have become more prevalent across industries and may occur on our systems or on the systems of our third-party service providers. These security incidents may be caused by, or result in, security breaches, computer malware or malicious software, ransomware, computer hacking, denial of service attacks, security system control failures in our own systems or from service providers we use, email phishing, software vulnerabilities, social engineering, sabotage, drive-by downloads and the malfeasance of our or our service providers&#8217; employees, among other things. We have taken measures to detect, remediate and prevent future attacks and security threats. However, we may be affected, particularly given that such attacks are increasing in volume and sophistication and attack techniques frequently change.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Despite our security measures, our internal computer systems and those of our current and any future collaborators and other contractors or consultants are vulnerable to, among other things, damage from computer viruses, unauthorized access, ransomware, natural disasters, terrorism, war and telecommunication and electrical failures. Furthermore, the ongoing COVID-19 pandemic and the related disruptions to our business and our collaborators&#8217;, contractors&#8217; and consultants&#8217; businesses may increase the risk of security incidents. If any cyberattack or data breach were to occur in the future and cause interruptions in our or our collaborators&#8217;, contractors&#8217; or consultants&#8217; operations, it could result in a material disruption of our development programs and our business operations, whether due to a loss of our trade secrets or other proprietary information or other similar disruptions. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or the inappropriate disclosure of confidential or proprietary information, we could incur liability, our competitive position could be harmed and the further development and commercialization of our product candidates could be delayed.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our future success depends on our ability to retain key employees, consultants and advisors and to attract, retain and motivate qualified personnel.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are highly dependent on principal members of our executive team and key employees, including our Chief Executive Officer. If we lost any such person&#8217;s services, our business may suffer. While we have entered into employment agreements with each of our executive officers, any of them could leave our employment at any time. We do not maintain &#8220;key person&#8221; insurance policies on the lives of these individuals or the lives of any of our other employees. The loss of the services of one or more of our current employees might impede the achievement of our research, development and commercialization objectives. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recruiting and retaining other qualified employees, consultants and advisors for our business, including scientific and technical personnel, will also be critical to our success. There is currently a shortage of skilled executives in our industry, which is likely to continue. As a result, competition for skilled personnel, including in gene therapy research and vector manufacturing, is intense and the turnover rate can be high. We may not be able to attract and retain personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for individuals with similar skill sets. In addition, failure to succeed in preclinical or clinical trials may make it more challenging to recruit and retain qualified personnel. The inability to recruit or the loss of the services of any executive, key employee, consultant or advisor may impede the progress of our research, development and commercialization objectives. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our corporate restructuring and the associated proposed headcount reduction may not result in anticipated savings, could result in total costs and expenses that are greater than expected and could disrupt our business,<span style="color:#000000;"> and we may experience difficulties in managing our current and any future restructurings. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 30, 2022, we announced a proposed reduction of our workforce of approximately 30%, subject to a consultation process with certain employees in the United Kingdom. <span style="color:#000000;">In March 2022, we announced that we would discontinue </span>our investment in <span style="color:#000000;">and seek alternatives for Strimvelis, OTL-103 for treatment of WAS and OTL-102 for treatment of X-CGD. </span>Future growth would impose significant added responsibilities on members of management, including the need to identify, recruit, maintain and integrate additional employees. Due to our limited resources, we may not be able to effectively manage our operations or recruit and retain qualified personnel, which may result in weaknesses in our infrastructure and operations, risks that we may not be able to comply with legal and regulatory requirements, and loss of </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">employees and reduced productivity among remaining employees. For example, the </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">proposed </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">workforce reduction may negatively impact our clinical, regulatory, technical operations, and commercial functions, which would have a negative impact on our ability to successfully develop, and ultimately, commercialize our product candidates. Our future financial performance and our ability to develop our product candidates or additional assets will depend, in part, on our ability to effectively manage any future growth or restructuring, as the case may be.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our employees, principal investigators, consultants and commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are exposed to the risk of fraud or other misconduct by our employees, principal investigators, consultants and commercial partners, CROs and CDMOs. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. Misconduct by these parties could include intentional failures to (i) comply with the regulations of the FDA, EMA or of other foreign regulatory authorities, (ii) provide accurate information to the FDA, EMA and other foreign regulatory authorities, (iii) comply with healthcare fraud and abuse laws and regulations in the United States and abroad, (iv) report financial information or data accurately or (v) disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Such misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation. We have adopted a code of conduct applicable to all of our employees, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions such as criminal and administrative penalties, damages, imprisonment, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of noncompliance with these laws, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.86%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Healthcare legislative reform measures and constraints on national budget social security systems may have a material adverse effect on our business and results of operations.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payors, whether domestic or foreign, or governmental or private, are developing increasingly sophisticated methods of controlling healthcare costs and those methods are not always specifically adapted for new technologies such as gene therapy and therapies addressing rare diseases such as those we are developing. In both the United States and certain foreign jurisdictions, there have been a number of legislative and regulatory changes to the health care system that could impact our ability to sell our products profitably. In particular, in 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively, the ACA, was enacted, which, among other things: (i) subjected biologic products to potential competition by lower-cost biosimilars&#59; (ii) addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected&#59; (iii) increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate Program&#59; (iv) extended the Medicaid Drug Rebate program to utilization of prescriptions of individuals enrolled in Medicaid managed care organizations&#59; (v) subjected manufacturers to new annual fees and taxes for certain branded prescription drugs&#59; (vi) created a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% (increased to 70% pursuant to the Bipartisan Budget Act of 2018, effective as of January 1, 2019, or the BBA, point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D&#59; and (vii) provided incentives to programs that increase the federal government&#8217;s comparative effectiveness research. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some of the provisions of the ACA have yet to be fully implemented, while certain provisions have been subject to judicial and Congressional challenges. While Congress has not passed comprehensive repeal legislation, two bills affecting the implementation of certain taxes under the ACA have been signed into law. First, the Tax Cuts and Jobs Act of 2017, or the Tax Act, decreased the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year, commonly referred to as the &#8220;individual mandate,&#8221; to $0, effective January 1, 2019. Second, the BBA repealed the so-called &#8220;Cadillac&#8221; tax on certain high-cost employer-sponsored </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">insurance plans, the annual fee imposed on certain health insurance providers, and the medical device excise tax on non-exempt medical devices. The BBA also closed the coverage gap in most Medicare drug plans, commonly referred to as the &#8220;donut hole.&#8221;</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2021, the U.S. Supreme Court, or Supreme Court, dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. Prior to the Supreme Court's decision, President Biden issued an Executive Order to initiate a special enrollment period from February 15, 2021 through August 15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The Executive Order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2018, the U.S. Court of Appeals for the Federal Circuit ruled that the federal government was not required to pay in excess of $12.0 billion in ACA risk corridor payments to third-party payors. This decision was appealed to the Supreme Court, which in April 2020 reversed the U.S. Court of Appeals and remanded the case, concluding that the government had an obligation to pay these risk corridor payments under the relevant formula. The effects of this gap in reimbursement on third-party payors, the viability of the ACA marketplace, providers, and potentially our business are not yet known. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, in December 2018, CMS published a final rule permitting further collections and payments to and from certain ACA-qualified health plans and health insurance issuers under the ACA risk adjustment program in response to the outcome of federal district court litigation regarding the method CMS uses to determine this risk adjustment. Since then, the ACA risk adjustment program payment parameters have been updated annually. In addition, CMS published a final rule that would give states greater flexibility in setting benchmarks for insurers in the individual and small group marketplaces, which may have the effect of relaxing the essential health benefits required under the ACA for plans sold through such marketplaces. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">It is unclear how other healthcare reform measures of the Biden administrations or other efforts, if any, to challenge repeal or replace the ACA, will impact our business.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other legislative changes potentially affecting our business have been proposed and adopted in the United States since the ACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.5 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. This included aggregate reductions of Medicare payments to providers of 2%&#160;per fiscal year, which went into effect in April 2013 and will remain in effect through 2030 unless additional Congressional action is taken. Pursuant to the CARES Act and subsequent legislation, however, these reductions were suspended from May 2020 through March 31, 2022 due to the COVID-19 pandemic. Then, a 1% payment reduction will occur beginning April 1, 2022 through June 30, 2022, and the 2% payment reduction will resume on July 1, 2022.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2013, the American Taxpayer Relief Act of 2012, was signed into law, which, among other things, further reduced Medicare payments to several providers, including hospitals and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, there have been several changes to the 340B drug pricing program, which imposes ceilings on prices that drug manufacturers can charge for medications sold to certain health care facilities. On December 27, 2018, the District Court for the District of Columbia invalidated a reimbursement formula change under the 340B drug pricing program, and CMS subsequently altered the FYs 2019 and 2018 reimbursement formula on specified covered outpatient drugs (&#8220;SCODs&#8221;). The court ruled this change was not an &#8220;adjustment&#8221; which was within the Secretary&#8217;s discretion to make but was instead a fundamental change in the reimbursement calculation. However, most recently, on July 31, 2020, the U.S. Court of Appeals for the District of Columbia Circuit overturned the district court&#8217;s decision and found that the changes were within the Secretary&#8217;s authority. On September 14, 2020, the plaintiffs-appellees filed a Petition for Rehearing En Banc (i.e., before the full court), but was denied on October 16, 2020. Plaintiffs-appellees filed a petition for a writ of certiorari at the Supreme Court on February 10, 2021. On Friday July 2, 2021, the Supreme Court granted the petition. It is unclear how these developments could affect covered hospitals who might purchase our future products and affect the rates we may charge such facilities for our approved products in the future, if any.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There have been several other actions taken at a federal level seeking to lower drug prices. At a federal level, President Biden signed an Executive Order in July 2021 affirming the administration&#8217;s policy to (i) support legislative reforms that would lower the prices of prescription drug and biologics, including by allowing Medicare to negotiate drug prices, by imposing inflation caps, and, by supporting the development and market entry of lower-cost generic drugs and biosimilars and (ii) support the enactment of a public health insurance option. Among other things, the Executive Order directs HHS to </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">provide a report on actions to combat excessive pricing of prescription drugs, enhance the domestic drug supply chain, reduce the price that the U.S. federal government pays for drugs, and address price gouging in the industry. The Executive Order also directs the FDA to work with states and Indian Tribes that propose to develop section 804 Importation Programs in accordance with the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, and the FDA&#8217;s implementing regulations. The FDA released such implementing regulations in September 2020, which went into effect in November 2020, providing guidance for states to build and submit importation plans for drugs from Canada. Further, in November 2020, CMS issued an Interim Final Rule implementing the Most Favored Nation, or MFN, Model under which Medicare Part B reimbursement rates would have been calculated for certain drugs and biologicals based on the lowest price drug manufacturers receive in Organization for Economic Cooperation and Development countries with a similar gross domestic product per capita. The MFN Model regulations mandate participation by identified Part B providers and would have applied to all U.S. states and territories for a seven-year period beginning January 1, 2021 and ending December 31, 2027. However, on December 29, 2021 CMS rescinded the Most Favored Nations rule.. Further, authorities in Canada have passed rules designed to safeguard the Canadian drug supply from shortages. If implemented, importation of drugs from Canada may materially and adversely affect the price we receive for any of our product candidates. Additionally, in December 2020, HHS published a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. Pursuant to court order, the removal and addition of the aforementioned safe harbors have been delayed until January 1, 2026. Although a number of these and other proposed measures may require authorization through additional legislation to become effective, and the Biden administration may reverse or otherwise change these measures, both the Biden administration and Congress have indicated that it will continue to seek new legislative measures to control drug costs.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the state level, legislatures are increasingly passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, or restrictions on certain product access, and marketing cost disclosure and transparency measures, which, in some cases, are designed to encourage importation from other countries and bulk purchasing. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal and state levels directed at broadening the availability of healthcare and containing or lowering the cost of healthcare. We cannot predict the initiatives that may be adopted in the future. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.43%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the demand for our product candidates, if we obtain regulatory approval&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.43%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>our ability to set a price that we believe is fair for our products&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.43%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>our ability to generate revenue and achieve or maintain profitability&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.43%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the level of taxes that we are required to pay&#59; and</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.43%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the availability of capital.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any denial in coverage or reduction in reimbursement from Medicare or other government programs may result in a similar denial or reduction in payments from private payors, which may adversely affect our future profitability.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We are subject to the UK Bribery Act 2010, or the Bribery Act, the U.S. Foreign Corrupt Practices Act of 1977, as amended, or the FCPA, and other anti-corruption laws, as well as export control laws, import and customs laws, trade and economic sanctions laws and other laws governing our operations.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our operations are subject to anti-corruption laws, including the Bribery Act, the FCPA, the U.S. domestic bribery statute contained in 18 U.S.C. &#167;201, the U.S. Travel Act, and other anti-corruption laws that apply in countries where we do business. The Bribery Act, the FCPA and these other laws generally prohibit us and our employees and intermediaries from authorizing, promising, offering, or providing, directly or indirectly, improper or prohibited payments, or anything else of value, to government officials or other persons to obtain or retain business or gain some other business advantage. Under the Bribery Act, we may also be liable for failing to prevent a person associated with us from committing a bribery offense. We and our commercial partners operate in a number of jurisdictions that pose a high risk of potential Bribery Act or FCPA violations, and we participate in collaborations and relationships with third parties whose corrupt or illegal activities could potentially subject us to liability under the Bribery Act, FCPA or local anti-corruption laws, even if we do not explicitly authorize or have actual knowledge of such activities. In addition, we cannot predict the nature, scope or effect of future </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regulatory requirements to which our international operations might be subject or the manner in which existing laws might be administered or interpreted.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are also subject to other laws and regulations governing our international operations, including regulations administered by the governments of the United Kingdom and the United States, and authorities in the European Union, including applicable export control regulations, economic sanctions and embargoes on certain countries and persons, anti-money laundering laws, import and customs requirements and currency exchange regulations, collectively referred to as the Trade Control laws.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is no assurance that we will be completely effective in ensuring our compliance with all applicable anti-corruption laws, including the Bribery Act, the FCPA or other legal requirements, including Trade Control laws. If we are not in compliance with the Bribery Act, the FCPA and other anti-corruption laws or Trade Control laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures, and legal expenses, which could have an adverse impact on our business, financial condition, results of operations and liquidity. Likewise, any investigation of any potential violations of the Bribery Act, the FCPA, other anti-corruption laws or Trade Control laws by United Kingdom, United States or other authorities could also have an adverse impact on our reputation, our business, results of operations and financial condition.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws health information privacy and security laws, and other health care laws and regulations. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we obtain FDA approval for any of our product candidates and begin commercializing those products in the United States, our operations will be directly, or indirectly through our prescribers, customers and purchasers, subject to various federal and state fraud and abuse laws and regulations, including, without limitation, the federal Health Care Program Anti-Kickback Statute, the federal civil and criminal False Claims Act and Physician Payments Sunshine Act and regulations. These laws will impact, among other things, our proposed sales, marketing and educational programs. In addition, we may be subject to patient privacy laws by both the federal government and the states in which we conduct our business. The laws that will affect our operations include, but are not limited to, the below:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>The federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, receiving, offering or paying any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, the purchase, lease, order, arrangement, or recommendation of any good, facility, item or service for which payment may be made, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. A person or entity does not need to have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it to have committed a violation. Violations are subject to civil and criminal fines and penalties for each violation, plus up to three times the remuneration involved, imprisonment, and exclusion from government healthcare programs. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act or federal civil money penalties.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>The federal civil and criminal false claims laws and civil monetary penalty laws, such as the federal False Claims Act, which impose criminal and civil penalties and authorize civil whistleblower or qui tam actions, against individuals or entities for, among other things: knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent&#59; knowingly making, using or causing to be made or used, a false statement of record material to a false or fraudulent claim or obligation to pay or transmit money or property to the federal government or knowingly concealing or knowingly and improperly avoiding or decreasing an obligation to pay money to the federal government. Manufacturers can be held liable under the federal False Claims Act even when they do not submit claims directly to government payors if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims. The federal False Claims Act also permits a private individual acting as a &#8220;whistleblower&#8221; to bring actions on behalf of the federal government alleging violations of the federal False Claims Act and to share in any monetary recovery.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>The anti-inducement law, which prohibits, among other things, the offering or giving of remuneration, which includes, without limitation, any transfer of items or services for free or for less than fair market value (with limited exceptions), to a Medicare or Medicaid beneficiary that the person knows or should know is likely to influence the beneficiary&#8217;s selection of a particular supplier of items or services reimbursable by a federal or state governmental program.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created new federal criminal statutes that prohibit a person from knowingly and willfully executing, or attempting to execute, a </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (</span><span style="font-style:italic;">e.g.</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, public or private) and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false, fictitious, or fraudulent statements or representations in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters&#59; similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH and their respective implementing regulations, including the Final Omnibus Rule published in January 2013, which impose requirements on certain covered healthcare providers, health plans, and healthcare clearinghouses as well as their respective business associates,<span style="color:#000000;"> </span>independent contractors or agents of covered entities, that perform services for them that involve the creation, maintenance, receipt, use, or disclosure of, individually identifiable health information relating to the privacy, security and transmission of individually identifiable health information. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions. In addition, there may be additional federal, state and non-U.S. laws which govern the privacy and security of health and other personal information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>The U.S. federal transparency requirements under the ACA, including the provision commonly referred to as the Physician Payments Sunshine Act, and its implementing regulations, which requires applicable manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program to report annually to CMS, information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as ownership and investment interests held by the physicians described above and their immediate family members. <span style="color:#000000;">Effective January 1, 2022, these reporting obligations extend to include transfers of value made to certain non-physician providers such as physician assistants and nurse practitioners</span>.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>The federal government price reporting laws, which require us to calculate and report complex pricing metrics in an accurate and timely manner to government programs.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>The federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers. </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="color:#000000;">Many state</span><span style="color:#000000;">s in the United States have enacted</span><span style="color:#000000;"> laws </span><span style="color:#000000;">that regulate</span><span style="color:#000000;"> the privacy</span><span style="color:#000000;"> and/or security</span><span style="color:#000000;"> of</span><span style="color:#000000;"> certain types of</span><span style="color:#000000;"> personal information. For example, in California the California Consumer Protection Act (CCPA), which went into effect on January 1, 2020, establishes a new privacy framework for covered businesses by creating an expanded definition of personal information, establishing new data privacy rights for consumers in the State of California, imposing special rules on the collection of consumer data from minors, and creating a new and potentially severe statutory damages framework for violations of the CCPA and for businesses that fail to implement reasonable security procedures and practices to prevent data breaches. </span><span style="color:#000000;">After a delay, the CCPA became subject to enforcement as of </span><span style="color:#000000;">July 1, 2020. </span><span style="color:#000000;">Although </span><span style="color:#000000;">clinical trial data and </span><span style="color:#000000;">protected health information subject to </span><span style="color:#000000;">HIPAA are currently exempt from CCPA</span><span style="color:#000000;">, we may be subject to the CCPA with respect to other personal information regarding California residents. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The CCPA may increase our compliance costs and potential liability. Some observers have noted that the CCPA could mark the beginning of a trend toward more stringent privacy legislation in the U.S., which could increase our potential liability and adversely affect our business.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Additionally, a new California ballot initiative, the California Privacy Rights Act, or &#8220;CPRA,&#8221; was passed in November 2020. Effective starting on January 1, 2023, the CPRA imposes additional obligations on companies covered by the legislation and will significantly modify the CCPA, including by expanding consumers&#8217; rights with respect to certain sensitive personal information. The CPRA also creates a new state agency that will be vested with authority to implement and enforce the CCPA and the CPRA. The effects of the CCPA and the CPRA are potentially significant and may require us to modify our data collection or processing practices and policies and to incur substantial costs and expenses in an effort to comply and increase our potential exposure to regulatory enforcement and/or litigation. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Certain other state laws impose similar privacy obligations, and we also expect anticipate that more states to may enact legislation similar to the CCPA, which provides consumers with new privacy rights and increases the </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="color:#000000;">privacy and security obligations of entities handling certain personal information of such consumers. The CCPA has prompted a number of proposals for new federal and state-level privacy legislation. Such proposed legislation, if enacted, may add additional complexity, variation in requirements, restrictions and potential legal risk, require additional investment of resources in compliance programs, impact strategies and the availability of previously useful data and could result in increased compliance costs and/or changes in business practices and policies.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Following the UK&#8217;s withdrawal from the EU on January 31, 2020 and the end of the transitional arrangements agreed between the UK and EU, as of January 1, 2021, the GDPR has been incorporated into UK domestic. UK-based organizations doing business in the EU will need to continue to comply with the GDPR. The UK is now regarded as a third country under the EU GDPR, but the European Commission has issued a decision recognizing the UK as providing adequate protection under the EU GDPR. Therefore, transfers of personal data originating in the EU to the UK remain unrestricted. The UK Government has also confirmed that transfers of personal data originating in the UK to the EU may continue to flow freely.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, we are subject to state and foreign equivalents of each of the healthcare laws and regulations described above, among others, some of which may be broader in scope and may apply regardless of the payor. Many U.S. states have adopted laws similar to the federal Anti-Kickback Statute and False Claims Act and may apply to our business practices, including, but not limited to, research, distribution, sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental payors, including private insurers. In addition, some states have passed laws that require pharmaceutical companies to comply with the April 2003 Office of Inspector General Compliance Program Guidance for Pharmaceutical Manufacturers and/or the Pharmaceutical Research and Manufacturers of America&#8217;s Code on Interactions with Healthcare Professionals. Several states also impose other marketing restrictions or require pharmaceutical companies to make marketing or price disclosures to the state and require the registration of pharmaceutical sales representatives. State and foreign laws, including for example the GDPR, which became effective May 2018 also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. There are ambiguities as to what is required to comply with these state requirements, and if we fail to comply with an applicable state law requirement we could be subject to penalties. Finally, there are state and foreign laws governing the privacy and security of health information, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event we decide to conduct clinical trials or continue to enroll subjects in our ongoing or future clinical trials, we may be subject to additional privacy restrictions. The collection, use, storage, disclosure, transfer, or other processing of personal data regarding individuals in the EEA or the UK, including personal health data, is subject to the GDPR. The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal data, including requirements relating to processing health and other sensitive data, where required obtaining consent of the individuals to whom the personal data relates, providing information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data, where required providing notification of data breaches, and taking certain measures when engaging third-party processors, including concluding data processing agreements, <span style="color:#000000;">where required appointing data protection officers, where required conducting data protection impact assessments, and record-keeping</span>. The GDPR also imposes strict rules and restrictions on the transfer of personal data to countries outside the EEA or the UK, including the United States (see below), and permits data protection authorities to impose large penalties for violations of the GDPR, including potential fines of up to &#8364;20.0 million (&#163;17.5 million) or 4% of annual global revenues, whichever is greater. The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. The GDPR may increase our responsibility and liability in relation to personal data that we process where such processing is subject to the GDPR, and we may be required to put in place additional mechanisms to ensure compliance with the GDPR, including as implemented by individual countries. Compliance with the GDPR will be a rigorous and time-intensive process that may increase our cost of doing business or require us to change our business practices, and despite those efforts, there is a risk that we may be subject to fines and penalties, litigation, and reputational harm in connection with our European activities. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significantly, adequate safeguards must be implemented to enable the transfer of personal data outside of the EEA or the UK, in particular to the United States, in compliance with European and UK data protection laws. In June 2021, the European Commission issued new forms of standard contractual clauses for data transfers from controllers or processors in the EU/EEA (or otherwise subject to the EU GDPR) to controllers or processors established outside the EU/EEA (and not subject to the EU GDPR). The new standard contractual clauses replace the standard contractual clauses that were adopted previously under the Data Protection Directive. The UK is not subject to the European Commission&#8217;s new standard contractual clauses but has published its own version of standard clauses, referred to as International Data Transfer </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Agreement, which was laid before Parliament in February 2022, and, unless objections are raised, will enter into force in March 2022 to enable transfers originating from the UK. We will be required to implement these new safeguards when conducting restricted data transfers under the GDPR and doing so will require significant effort and cost.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge and may not comply under one or more of such laws, regulations, and guidance. Law enforcement authorities are increasingly focused on enforcing fraud and abuse laws, and it is possible that some of our practices may be challenged under these laws. Efforts to ensure that our current and future business arrangements with third parties, and our business generally, will comply with applicable healthcare laws and regulations will involve substantial costs. If our operations, including our arrangements with physicians and other healthcare providers, some of whom receive share options as compensation for services provided, are found to be in violation of any of such laws or any other governmental regulations that apply to us, we may be subject to penalties, including, without limitation, administrative, civil and criminal penalties, damages, fines, disgorgement, contractual damages, reputational harm, diminished profits and future earnings, the curtailment or restructuring of our operations, exclusion from participation in federal and state healthcare programs (such as Medicare and Medicaid), and imprisonment, as well as additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, any of which could adversely affect our ability to operate our business and our financial results.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we or our CDMOs and CROs fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We and third parties such as our CDMOs and CROs are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties. Furthermore, environmental laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance. In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials or other work-related injuries, this insurance may not provide adequate coverage against potential liabilities. In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions or liabilities, which could materially adversely affect our business, financial condition, results of operations and prospects.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">As a company based outside of the United States, our business is subject to economic, political, regulatory and other risks associated with international operations.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a company based partly in the United Kingdom and EU countries, our business is subject to risks associated with conducting business outside of the United States. Many of our suppliers and clinical trial relationships are located outside the United States. Accordingly, our future results could be harmed by a variety of factors, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>economic weakness, including inflation, or political instability in the United Kingdom and other non-U.S. economies and markets, including the substantial economic dislocation that has occurred and is likely to persist as a result of the impact of the COVID-19 global pandemic&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>differing and changing regulatory requirements for product approvals&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>differing jurisdictions could present different issues for securing, maintaining or obtaining freedom to operate in such jurisdictions&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>potentially reduced protection for intellectual property rights&#59;</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>difficulties in compliance with different, complex and changing laws, regulations and court systems of multiple jurisdictions and compliance with a wide variety of foreign laws, treaties and regulations&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>changes in non-U.S. regulations and customs, tariffs and trade barriers&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>changes in non-U.S. currency exchange rates of the pound sterling, U.S. Dollar, euro and currency controls&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>changes in a specific country&#8217;s or region&#8217;s political or economic environment, including the implications of the recent decision of the eligible members of the UK electorate for the United Kingdom to withdraw from the European Union&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>trade protection measures, import or export licensing requirements or other restrictive actions by governments&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>differing reimbursement regimes and price controls in certain non-U.S. markets&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>negative consequences from changes in tax laws or practice&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>compliance with tax, employment, immigration and labor laws for employees living or traveling abroad, including, for example, the variable tax treatment in different jurisdictions of options granted under our share option schemes or equity incentive plans&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>workforce uncertainty in countries where labor unrest is more common than in the United States&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>litigation or administrative actions resulting from claims against us by current or former employees or consultants individually or as part of class actions, including claims of wrongful terminations, discrimination, misclassification or other violations of labor law or other alleged conduct&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>difficulties associated with staffing and managing international operations, including differing labor relations&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad&#59; and</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>business interruptions resulting from geo-political actions, including war and terrorism, or natural disasters including earthquakes, typhoons, floods, fires and public health epidemics and pandemics, including the current COVID-19 global pandemic.</p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks related to our intellectual property</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may become subject to claims that we are infringing certain third-party patents, for example, patents relating to lentiviral vectors, or other third-party intellectual property rights, any of which may prevent or delay our development and commercialization efforts and have a material adverse effect on our business.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial success depends in part on avoiding infringing, misappropriating and otherwise violating the patents and other intellectual property and proprietary rights of third parties. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, and administrative proceedings such as interferences,&#160;<span style="font-style:italic;">inter partes</span>&#160;review and post grant review proceedings before the U.S. Patent and Trademark Office, or USPTO, and opposition proceedings before foreign patent offices. Numerous U.S. and foreign issued patents and pending patent applications, which are owned or controlled by third parties, including our competitors, exist in the fields in which we are pursuing products and product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our products and product candidates may be subject to claims of infringement of the patent rights of third parties.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third parties may assert that we or our licensors are employing their proprietary technology without authorization. There may be third party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment relating to our products and product candidates and, because patent applications can take many years to issue, there may be currently pending third party patent applications which may later result in issued patents, in each case that our products and product candidates, their manufacture or use may infringe or be alleged to infringe.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Parties making patent infringement claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our products or product candidates. Defense of these claims, including demonstrating non-infringement, invalidity or unenforceability of the respective patent rights in question, regardless of their merit, is time-consuming, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. For example, in order to successfully challenge the validity of any U.S. patent in federal court, we would need to overcome a presumption of validity. This is a high burden requiring us to present clear and convincing evidence as to the invalidity of any such U.S. patent claim, and we can provide no assurance that a court of competent jurisdiction would invalidate the claims of any such U.S. patent. We may not have sufficient resources to bring these actions to a successful conclusion. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event that a holder of any such patents seeks to enforce its patent rights against us with respect to one or more of our products or product candidates, and our defenses against the infringement of such patent rights are unsuccessful, we may be precluded from commercializing such products and product candidates, even if approved, without first obtaining a license to some or all of these patents, which may not be available on commercially reasonable terms or at all. Moreover, we may be required to pay significant fees and royalties to secure a license to the applicable patents. Such a license may only be non-exclusive, in which case our ability to stop others from using or commercializing technology and products similar or identical to ours may be limited. Furthermore, we could be liable for damages to the holders of these patents, which may be significant and could include treble damages if we are found to have willfully infringed such patents. In the event that a challenge to these patents were to be unsuccessful or we were to become subject to litigation or unable to obtain a license on commercially reasonable terms with respect to these patents, it could harm our business, financial condition, results of operations and prospects.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are aware of third-party issued patents and patent applications relating to the lentiviral vectors used in the manufacture or use of one or more our product candidates and/or relating to one or more of our product candidates. <span style="color:#000000;">I</span>f these patent rights were enforced against us, we believe that we have defenses against any such action, including that these patents would not be infringed by our product candidates and/or that these patents are not valid. However, if these patents were enforced against us and defenses to such enforcement were unsuccessful, unless we obtain a license to these patents, which may not be available on commercially reasonable terms, or at all, we could be liable for damages and precluded from commercializing any products and product candidates that were ultimately held to infringe these patents, which could have a material adverse effect on our business, financial condition, results of operations and prospects.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even in the absence of a finding of infringement, we may need to obtain licenses from third parties to advance our research or allow commercialization of our products and product candidates. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, or at all. In that event, we would be unable to further develop and commercialize our products and product candidates. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business. Any of the foregoing could materially adversely affect our business, results of operations and financial condition.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, our trade secrets may otherwise become known or be independently discovered by competitors. Competitors and other third parties could purchase our products and product candidates and attempt to replicate some or all of the competitive advantages we derive from our development efforts, willfully infringe, misappropriate or otherwise violate our intellectual property rights, design around our protected technology or develop their own competitive technologies that fall outside of our intellectual property rights. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If our trade secrets are not adequately protected or sufficient to provide an advantage over our competitors, our competitive position could be adversely affected, as could our business. Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating our trade secrets.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We are highly dependent on intellectual property and data licensed from third parties to develop and commercialize our products and product candidates, and our development and commercialization abilities are subject, in part, to the terms and conditions of licenses granted to us by such third parties.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are highly dependent on the intellectual property and data licensed to us by third parties that are important or necessary to the development of our technology and products and product candidates, including technology related to the manufacture and use of our products and product candidates. In particular, we do not own any patents or patent applications and have not in-licensed any issued patents related to Strimvelis, Libmeldy or any of our lead product candidates. We have in-licensed certain know-how and data from GSK and Telethon-OSR, relating to Strimvelis, OTL-103 for WAS, Libmeldy, and OTL-300 for TDT, certain know-how and data from Telethon-OSR relating to OTL-203 for MPS-IH, and certain other intellectual property for our clinical and preclinical programs. Any termination of these license rights could result in the loss of significant rights and could harm or prevent our ability to commercialize our products and product candidates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although our license rights from The Regents of the University of California, University College London, GSK, and Telethon-OSR, are exclusive, they are limited to particular fields, such as MLD, WAS or TDT, and are subject to certain retained rights. Absent an amendment or additional agreement, we may not have the right to use the in-licensed intellectual property, data, or know-how for one of our programs in another program. Furthermore, the licenses (including sublicenses) that we have or may enter into in the future may not provide rights to use such intellectual property and technology in all relevant fields of use and in all territories in which we may wish to develop or commercialize our technology, products and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product candidates. As a result, we may not be free to commercialize certain of our products or product candidates in fields or territories of interest to us. Furthermore, if the licenses are not exclusive in territories of interest to us, we may be unable to prevent competitors from developing and commercializing competitive products in territories included in our licenses. Licenses (including sublicenses) to additional third-party technology that may be required for our development programs may not be available in the future or may not be available on commercially reasonable terms, or at all, which could have a material adverse effect on our business.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In some circumstances, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology that we license from third parties. Therefore, we cannot be certain that these patents and applications will be prosecuted, maintained and enforced in a manner consistent with the best interests of our business. If our licensors fail to maintain such patents, or lose rights to those patents or patent applications, the rights we have licensed may be reduced or eliminated and our right to develop and commercialize any of our products and product candidates that are the subject of such licensed rights could be adversely affected.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our current license agreements impose, and we expect that future license agreements that we may enter into will impose, various obligations, including diligence and certain payment obligations. If we fail to satisfy our obligations, the particular licensor may have the right to terminate such agreements. Disputes may arise between us and any of our licensors regarding intellectual property subject to such agreements and other issues. Such disputes over intellectual property that we have licensed or the terms of our license agreements may prevent or impair our ability to maintain our current arrangements on acceptable terms, or at all, or may impair the value of the arrangement to us. Any such dispute could have a material adverse effect on our business. If we cannot maintain a necessary license agreement or if the agreement is terminated, we may be unable to successfully develop and commercialize the affected products and product candidates. Termination of our license agreements or reduction or elimination of our rights under them may result in our having to negotiate a new or reinstated agreement, which may not be available to us on equally favorable terms, or at all, which may mean we are unable to develop or commercialize the affected product or product candidate or cause us to lose our rights under the agreement. Any of the foregoing could have a material adverse effect on our business.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we are unable to obtain and maintain patent and other intellectual property protection for our products and product candidates, or if the scope of the patent and other intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize our products and product candidates may be adversely affected.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our ability to compete effectively will depend, in part, on our ability to maintain the proprietary nature of our technology and manufacturing processes. We rely on manufacturing and other know-how, patents, trade secrets, license agreements and contractual provisions to establish our intellectual property rights and protect our products and product candidates. These legal means, however, afford only limited protection and may not adequately protect our rights. We currently do not own any patents or patent applications and have not in-licensed any issued patents related to Strimvelis, Libmeldy or OTL-103. Many of our products and product candidates are in-licensed from third parties. Accordingly, in some cases, the availability and scope of potential patent protection is limited based on prior decisions by our licensors or the inventors, such as decisions on when to file patent applications or whether to file patent applications at all. Our or our licensors&#8217; failure to obtain, maintain, enforce or defend such intellectual property rights, for any reason, could allow third parties, in particular, other established and better-financed gene therapy companies having established development, manufacturing and distribution capabilities, to make competing products or impact our ability to develop, manufacture and market our products and product candidates, even if approved, on a commercially viable basis, if at all, which could have a material adverse effect on our business.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In particular, we rely primarily on trade secrets, know-how and other unpatented technology, which are difficult to protect. Although we seek such protection in part by entering into confidentiality agreements with our vendors, employees, consultants and others who may have access to proprietary information, we cannot be certain that these agreements will not be breached, adequate remedies for any breach would be available, or our trade secrets, know-how and other unpatented proprietary technology will not otherwise become known to or be independently developed by our competitors. If we are unsuccessful in protecting our intellectual property rights, sales of our products may suffer and our ability to generate revenue could be severely impacted.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently do not own any issued patents related to Strimvelis, Libmeldy or our lead product candidates. Certain intellectual property related to Strimvelis, Libmeldy and all of our product candidates are in-licensed from third parties, but we have not in-licensed any issued patents related to Strimvelis, Libmeldy or any of our product candidates. In certain situations and as considered appropriate, we and our licensors have sought, and we intend to continue to seek to protect our proprietary position by filing patent applications in the United States and, in at least some cases, one or more countries </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">outside the United States relating to current and future products and product candidates that are important to our business. However, we cannot predict whether the patent applications currently being pursued will issue as patents, whether the claims of any resulting patents will provide us with a competitive advantage or prevent competitors from designing around our claims to develop competing technologies in a non-infringing manner, or whether we will be able to successfully pursue patent applications in the future relating to our current or future products and product candidates. Moreover, the patent application and approval process is expensive and time-consuming. We may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. Furthermore, we, or any future partners, collaborators, or licensees, may fail to identify patentable aspects of inventions made in the course of development and commercialization activities before it is too late to obtain patent protection on them. Therefore, we may miss potential opportunities to seek additional patent protection.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">It is possible that defects of form in the preparation or filing of patent applications may exist, or may arise in the future, for example with respect to proper priority claims, inventorship, claim scope, or requests for patent term adjustments. If we fail to establish, maintain or protect such patents and other intellectual property rights, such rights may be reduced or eliminated. If there are material defects in the form, preparation, prosecution or enforcement of our patents or patent applications, such patents may be invalid and/or unenforceable, and such applications may never result in valid, enforceable patents. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other parties, many of whom have substantially greater resources and have made significant investments in competing technologies, have developed or may develop technologies that may be related or competitive with our approach, and may have filed or may file patent applications and may have been issued or may be issued patents with claims that overlap or conflict with our patent applications, either by claiming the same compositions, formulations or methods or by claiming subject matter that could dominate our patent position. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. As a result, any patents we may obtain in the future may not provide us with adequate and continuing patent protection sufficient to exclude others from commercializing products similar to our products and product candidates.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may not be able to protect our intellectual property rights throughout the world.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Filing, prosecuting, maintaining, defending and enforcing patents on products and product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States could be less extensive than those in the United States. There<span style="font-weight:bold;font-style:italic;"> </span>can be no assurance that we will obtain or maintain patent rights in or outside the United States under any future license agreements. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States even in jurisdictions where we and our licensors may pursue patent protection. Consequently, we and our licensors may not be able to prevent third parties from practicing our inventions in all countries outside the United States (even in jurisdictions where we and our licensors pursue patent protection) or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we and our licensors have not pursued and obtained patent protection to develop their own products, and they may export otherwise infringing products to territories where we have patent protection but enforcement is not as strong as that in the United States. These products may compete with our products and product candidates and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights, even if obtained, in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Issued patents covering our products and product candidates could be found invalid or unenforceable if challenged in court or in administrative proceedings. We may not be able to protect our trade secrets in court.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we or one of our licensing partners initiate legal proceedings against a third party to enforce a patent covering one of our products or product candidates, should such a patent issue, the defendant could counterclaim that the patent covering our product or product candidate is invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, written description or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld information material to patentability from the USPTO, or made a misleading statement, during prosecution. Third parties also may raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, post grant review,&#160;<span style="font-style:italic;">inter partes</span>&#160;review and equivalent proceedings in foreign jurisdictions. An adverse determination in any of the foregoing proceedings could result in the revocation or cancellation of, or amendment to, our patents in such a way that they no longer cover our products or product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which the patent examiner and we or our licensing partners were unaware during prosecution. If a defendant or third party were to prevail on a legal assertion of invalidity or unenforceability, we could lose at least part, and perhaps all, of the patent protection on one or more of our products and product candidates. Such a loss of patent protection could have a material adverse impact on our business.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable or that we elect not to patent, processes for which patents are difficult to enforce and any other elements of our product candidate discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents. However, trade secrets can be difficult to protect and some courts inside and outside the United States are less willing or unwilling to protect trade secrets. We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with our employees, consultants, scientific advisors, and contractors. We cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary technology and processes. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached, and we may not have adequate remedies for any breach.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we do not obtain patent term extension and data exclusivity for our products and product candidates, our business may be materially harmed.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our products and product candidates are obtained, once the patent life has expired for a product or product candidate, we may be open to competition from competitive products. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products and product candidates similar or identical to ours.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the future, if we obtain an issued patent covering one of our present or future product candidates, depending upon the timing, duration and specifics of any FDA marketing approval of such product candidates, such patent may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, or Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent extension term of up to five years as compensation for patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent may be extended and only those claims covering the approved drug, a method for using it or a method for manufacturing it may be extended. A patent may only be extended once and only based on a single approved product. However, we may not be granted an extension because of, for example, failure to obtain a granted patent before approval of a product candidate, failure to exercise due diligence during the testing phase or regulatory review process, failure to apply within applicable deadlines, failure to apply prior to expiration of relevant patents or otherwise our failure to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than we request, our competitors may obtain approval of competing products following our patent expiration, and our revenue could be reduced, possibly materially. In addition, we do not control the efforts of our licensors to obtain a patent term extension, and there can be no assurance that they will pursue or obtain such extensions to patents that we may license from them.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Some intellectual property which we have in-licensed may have been discovered through government funded programs and thus may be subject to federal regulations such as &#8220;march-in&#8221; rights, certain reporting requirements, and a preference for U.S. industry. Compliance with such regulations may limit our exclusive rights and limit our ability to contract with non-U.S. manufacturers.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some of the intellectual property rights we have licensed may have been generated through the use of U.S. government and state funding and may therefore be subject to certain federal and state laws and regulations. As a result, the U.S. government may have certain rights to intellectual property embodied in our current or future products and product candidates pursuant to the Bayh-Dole Act of 1980. These U.S. government rights in certain inventions developed under a government-funded program include a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S. government has the right to require us to grant exclusive, partially exclusive, or non-exclusive licenses to any of these inventions to a third party if it determines that: (i)&#160;adequate steps have not been taken to commercialize the invention&#59; (ii)&#160;government action is necessary to meet public health or safety needs&#59; or (iii)&#160;government action is necessary to meet requirements for public use under federal regulations (also referred to as &#8220;march-in rights&#8221;). The U.S. government also has the right to take title to these inventions if we, or the applicable licensor, fail to disclose the invention to the government and fail to file an application to register the intellectual property within specified time limits. Intellectual property generated under a government-funded program is also subject to certain reporting requirements, compliance with which may require us or the applicable licensor to expend substantial resources. In addition, the U.S. government requires that products embodying the subject invention or produced through the use of the subject invention be manufactured substantially in the United States. The manufacturing preference requirement can be waived if the owner of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible. This preference for U.S. manufacturers may limit our ability to contract with non-U.S. product manufacturers for products covered by such intellectual property. With respect to state funding, specifically funding via the California Institute of Regenerative Medicine, or CIRM, the grantee has certain obligations and the state or CIRM has certain rights. For example, the grantee has an obligation to share intellectual property, including research results, generated by CIRM-funded research, for research use in California.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Intellectual property rights and regulatory exclusivity rights do not necessarily address all potential threats.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;letter-spacing:-0.15pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and they may not adequately protect our business or permit us to maintain our competitive advantage. For example:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the patents of others may have an adverse effect on our business&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>others, including one or more of our competitors, may reverse engineer or independently develop the know-how or data, including clinical data, that we rely on for a competitive advantage&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>others may be able to make gene therapy products that are similar to our products or product candidates but that are not covered by the claims of the patents that we license or may own or license in the future or by our other intellectual property rights&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>we, our license partners or current or future collaborators, might not have been the first to make the inventions covered by the issued patents or pending patent applications that we license or may own or license in the future&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>we, our license partners or current or future collaborators, might not have been the first to file patent applications covering certain of our or their inventions&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing, misappropriating or otherwise violating our owned or licensed intellectual property rights&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>it is possible that our pending licensed patent applications or those that we may own or license in the future will not lead to issued patents&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>issued patents that we hold rights to or may hold rights to in the future may be held invalid or unenforceable, including as a result of legal challenges by our competitors&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>one or more of our products or product candidates may never be protected by patents&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>we may not develop additional proprietary technologies that are patentable&#59; and</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>we or our licensors or collaborators may choose not to file a patent application for certain trade secrets or know-how, and a third party may subsequently file a patent application or obtain a patent covering such intellectual property.</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap"></td>
<td valign="top">
</td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Should any of these events occur, they could significantly harm our business, financial condition, results of operations and prospects.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may become involved in lawsuits to protect or enforce our patents, if issued, or other intellectual property, which could be expensive, time consuming and unsuccessful.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Competitors may infringe, misappropriate or otherwise violate patents, trademarks, copyrights or other intellectual property that we own or in-license. To counter infringement, misappropriation or other unauthorized use, we may be required to file claims, which can be expensive and time consuming and divert the time and attention of our management and scientific personnel. Any claims we assert against perceived violators could provoke these parties to assert counterclaims against us alleging that we infringe, misappropriate or otherwise violate their intellectual property, in addition to counterclaims asserting that our patents are invalid or unenforceable, or both. In any future patent infringement proceeding, there is a risk that a court will decide that a patent of ours is invalid or unenforceable, in whole or in part, and that we do not have the right to stop the other party from using the invention at issue. There is also a risk that, even if the validity of such patents is upheld, the court will construe the patent&#8217;s claims narrowly or decide that we do not have the right to stop the other party from using the invention at issue on the grounds that our patent claims do not cover the invention. An adverse outcome in a litigation or proceeding involving our patents could limit our ability to assert our patents against those parties or other competitors and may curtail or preclude our ability to exclude third parties from making and selling similar or competitive products. Any of these occurrences could adversely affect our competitive business position, business prospects and financial condition.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we establish infringement, misappropriation or another violation of our intellectual property rights, a court may decide not to grant an injunction against the offender and instead award only monetary damages, which may not be an adequate remedy. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of shares of our ADSs. Moreover, there can be no assurance that we will have sufficient financial or other resources to file and pursue such claims, which typically last for years before they are concluded. Even if we ultimately prevail in such claims, the monetary cost of such litigation and the diversion of the attention of our management and scientific personnel could outweigh any benefit we receive as a result of the proceedings. Any of the foregoing may have a material adverse effect on our business, financial condition, results of operations and prospects.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may be subject to claims asserting that our employees, consultants or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain of our employees, consultants or advisors are currently, or were previously, employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and advisors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that these individuals or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#8217;s current or former employer. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management. Our licensors may face similar risks, which could have an adverse impact on intellectual property that is licensed to us.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may be subject to claims challenging the inventorship or ownership of the patents and other intellectual property that we own or license.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We or our licensors may be subject to claims that former employees, collaborators or other third parties have an ownership interest in the patents and intellectual property that we own or license or that we may own or license in the future. While it is our policy to require our employees and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own or such assignments may not be self-executing or may be breached. Our licensors may face similar obstacles. We could be subject to ownership disputes arising, for example, from conflicting obligations of employees, consultants or others who are involved in developing our products or product candidates. Litigation may be necessary to defend against any claims challenging inventorship or </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ownership. If we or our licensors fail in defending any such claims, we may have to pay monetary damages and may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property, which could adversely impact our business, results of operations and financial condition.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Changes in patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products and product candidates.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in either the patent laws or the interpretation of the patent laws in the United States or other jurisdictions could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. In September 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law. When implemented, the Leahy-Smith Act included several significant changes to U.S. patent law that impacted how patent rights could be prosecuted, enforced and defended. In particular, the Leahy-Smith Act also included provisions that switched the United States from a &#8220;first-to-invent&#8221; system to a &#8220;first-to-file&#8221; system, allowed third-party submission of prior art to the USPTO during patent prosecution and set forth additional procedures to attack the validity of a patent by the USPTO administered post grant proceedings. Under a first-to-file system, assuming the other requirements for patentability are met, the first inventor to file a patent application generally will be entitled to the patent on an invention regardless of whether another inventor had made the invention earlier. The USPTO developed new regulations and procedures governing the administration of the Leahy-Smith Act, and many of the substantive changes to patent law associated with the Leahy-Smith Act, and in particular, the first to file provisions, only became effective in March 2013. It remains unclear what, if any, impact the Leahy-Smith Act will have on the operation of our business. However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The patent positions of companies engaged in the development and commercialization of biologics are particularly uncertain. Two cases involving diagnostic method claims and &#8220;gene patents&#8221; have been decided by the Supreme Court. The Supreme Court issued a decision in <span style="font-style:italic;">Mayo Collaborative Services v. Prometheus Laboratories, Inc.</span>, or <span style="font-style:italic;">Prometheus</span>, a case involving patent claims directed to a process of measuring a metabolic product in a patient to optimize a drug dosage for the patient. According to the Supreme Court, the addition of well-understood, routine or conventional activity such as &#8220;administering&#8221; or &#8220;determining&#8221; steps was not enough to transform an otherwise patent-ineligible natural phenomenon into patent-eligible subject matter. Thereafter, the USPTO issued a guidance memo to patent examiners indicating that process claims directed to a law of nature, a natural phenomenon or a naturally occurring relation or correlation that do not include additional elements or steps that integrate the natural principle into the claimed invention such that the natural principle is practically applied and the claim amounts to significantly more than the natural principle itself should be rejected as directed to not patent-eligible subject matter. Subsequently, the Supreme Court issued its decision in <span style="font-style:italic;">Association for Molecular Pathology v. Myriad Genetics, Inc.</span>, or <span style="font-style:italic;">Myriad</span>, a case involving patent claims held by Myriad Genetics, Inc. relating to the breast cancer susceptibility genes BRCA1 and BRCA2. <span style="font-style:italic;">Myriad</span> held that an isolated segment of naturally occurring DNA, such as the DNA constituting the BRCA1 and BRCA2 genes, is not patent-eligible subject matter, but that complementary DNA, which is an artificial construct that may be created from RNA transcripts of genes, may be patent-eligible. Thereafter, the USPTO issued a guidance memorandum instructing USPTO examiners on the ramifications of the <span style="font-style:italic;">Prometheus</span> and <span style="font-style:italic;">Myriad</span> rulings and apply the <span style="font-style:italic;">Myriad</span> ruling to natural products and principles including all naturally occurring nucleic acids.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain claims of our in-licensed patent applications contain, and any future patents we may obtain may contain, claims that relate to specific recombinant DNA sequences that are naturally occurring at least in part and, therefore, could be the subject of future challenges made by third parties.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot assure that our efforts to seek patent protection for one or more of our products and product candidates will not be negatively impacted by the decisions described above, rulings in other cases or changes in guidance or procedures issued by the USPTO. We cannot fully predict what impact the Supreme Court&#8217;s decisions in <span style="font-style:italic;">Prometheus</span> and <span style="font-style:italic;">Myriad</span> may have on the ability of life science companies to obtain or enforce patents relating to their products in the future. These decisions, the guidance issued by the USPTO and rulings in other cases or changes in USPTO guidance or procedures could have a material adverse effect on our existing patent rights and our ability to protect and enforce our intellectual property in the future.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, although the Supreme Court held in <span style="font-style:italic;">Myriad</span> that isolated segments of naturally occurring DNA are not patent-eligible subject matter, certain third parties could allege that activities that we may undertake infringe other gene-related patent claims, and we may deem it necessary to defend ourselves against these claims by asserting non-infringement and/or invalidity positions, or paying to obtain a license to these claims. In any of the foregoing or in other situations involving third-party intellectual property rights, if we are unsuccessful in defending against claims of patent infringement, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we could be forced to pay damages or be subjected to an injunction that would prevent us from utilizing the patented subject matter, the result of which could have a material adverse effect on our business.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks related to ownership of our securities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The market price of our ADSs may be highly volatile and may fluctuate due to factors beyond our control. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The trading price of our ADSs has fluctuated and is likely to continue to fluctuate significantly. The market price of our ADSs depends on a number of factors, some of which are beyond our control. In addition to the factors discussed in this &#8220;Item 1.A.&#8212;Risk Factors&#8221; and elsewhere in this Annual Report, these factors include:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>adverse results or delays in preclinical studies or clinical trials&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>reports of adverse events in other gene therapy products or clinical trials of such products&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>an inability to obtain additional funding&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>failure by us to successfully develop and commercialize our product candidates&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>failure by our current or future collaborators to successfully develop and commercialize product candidates for which we are eligible to receive milestone and royalty payments&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>failure by us to adequately scale our manufacturing capabilities and commercial and sales organization to succeed in our commercialization efforts of Libmeldy&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>failure by us to succeed in our ongoing commercialization of Strimvelis&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>failure by us to gain broad insurance coverage and reimbursement for our product candidates, if approved&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>failure by us to maintain our existing strategic collaborations or enter into new collaborations&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>failure by us or our licensors and strategic partners to prosecute, maintain or enforce our intellectual property rights&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>changes in laws or regulations applicable to future products&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>an inability to obtain adequate product supply for our product candidates or the inability to do so at acceptable prices&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>adverse regulatory decisions&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the introduction of new products, services or technologies by our competitors&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>failure by us to meet or exceed financial or other projections we may provide to the public&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>failure by us to meet or exceed the financial or other projections of the investment community&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the perception of the pharmaceutical industry by the public, legislatures, regulators and the investment community&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us, our strategic partner or our competitors&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>additions or departures of key scientific or management personnel&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>significant lawsuits, including patent or shareholder litigation&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>changes in the market valuations of similar companies&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>general economic and market conditions, including the <span style="color:#000000;">significant disruptions to the U.S. and global economies and the related significant volatility and negative pressure in financial markets caused by the COVID-19 global pandemic&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>sales of our ADSs by us or our shareholders in the future&#59; and</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the trading volume of our ADSs.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, companies trading in the stock market in general, and The Nasdaq Global Select Market in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our ADSs, regardless of our actual operating performance.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If securities or industry analysts do not continue to publish research or publish inaccurate or unfavorable research about our business, our ADS price and trading volume could decline. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The trading market for our ADSs depends in part on the research and reports that securities or industry analysts publish about us or our business. We do not have any control over these analysts. In the event one or more analysts downgrade our ADSs or change their opinion of our ADSs, our ADS price would likely decline. In addition, if one or more analysts cease </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">coverage of our company or fail to regularly publish reports on us, we could lose visibility in the financial markets, which could cause our ADS price or trading volume to decline.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of ownership of our ordinary shares (including ordinary shares in the form of ADSs) among our existing executive officers, directors and principal shareholders may prevent new investors from influencing significant corporate decisions.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based upon our ordinary shares outstanding as of December 31, 2021, our executive officers, directors, greater than five percent shareholders and their affiliates beneficially own approximately 51% of our ordinary shares and ADSs. Depending on the level of attendance at our meetings of shareholders, these shareholders either alone or voting together as a group may be in a position to determine or significantly influence the outcome of decisions taken at any such meeting. Any shareholder or group of shareholders controlling more than 50% of the share capital present and voting at our meetings of shareholders may control any shareholder resolution requiring a simple majority, including the appointment of board members, certain decisions relating to our capital structure and the approval of certain significant corporate transactions. Among other consequences, this concentration of ownership may prevent or discourage unsolicited acquisition proposals that our shareholders may believe are in their best interest as shareholders. Some of these persons or entities may have interests that are different than those of our other shareholders. For example, because many of these shareholders purchased their ordinary shares at prices substantially below the price at which ADSs were sold in our initial public offering and have held their ordinary shares for a longer period, they may be more interested in selling our company to an acquirer than other investors or they may want us to pursue strategies that deviate from the interests of other shareholders.<span style="font-weight:bold;font-style:italic;"> </span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Future sales, or the possibility of future sales, of a substantial number of our securities could adversely affect the price of the shares and dilute shareholders. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional sales of our ADSs, or the perception that these sales could occur, could cause the market price of our ADSs to decline. If&#160;any of our large shareholders or members of our management team&#160;sell substantial amounts of ADSs in the public market, or the market perceives that such sales may occur, the market price of our ADSs and our ability to raise capital through an issue of equity securities in the future could be adversely affected.<span style="color:#000000;"> </span>Additionally, we filed a registration statement with the SEC and may issue securities in one or more underwritten transactions, in &#8220;at-the-market&#8221; offerings or in other transactions from time to time. If we were to issue such securities in the public market, the trading price of our ADSs could decline.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Holders of ADSs are not treated as holders of our ordinary shares</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Holders of our publicly traded securities are holders of ADSs with underlying ordinary shares in a company incorporated under English law. Holders of ADSs are not treated as holders of our ordinary shares, unless they withdraw the ordinary shares underlying their ADSs in accordance with the deposit agreement and applicable laws and regulations. The depositary is the holder of the ordinary shares underlying the ADSs. Holders of ADSs therefore do not have any rights as holders of our ordinary shares, other than the rights that they have pursuant to the deposit agreement.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Holders of ADSs may be subject to limitations on the transfer of their ADSs and the withdrawal of the underlying ordinary shares. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ADSs are transferable on the books of the depositary. However, the depositary may close its books at any time or from time to time when it deems expedient in connection with the performance of its duties. The depositary may refuse to deliver, transfer or register transfers of ADSs generally when our books or the books of the depositary are closed, or at any time if we or the depositary think it is advisable to do so because of any requirement of law, government or governmental body, or under any provision of the deposit agreement, or for any other reason, subject to the right of ADS holders to cancel their ADSs and withdraw the underlying ordinary shares. Temporary delays in the cancellation of the holder&#8217;s ADSs and withdrawal of the underlying ordinary shares may arise because the depositary has closed its transfer books or we have closed our transfer books, the transfer of ordinary shares is blocked to permit voting at a shareholders&#8217; meeting or we are paying a dividend on our ordinary shares. In addition, ADS holders may not be able to cancel their ADSs and withdraw the underlying ordinary shares when they owe money for fees, taxes and similar charges and when it is necessary to prohibit withdrawals in order to comply with any laws or governmental regulations that apply to ADSs or to the withdrawal of ordinary shares or other deposited securities.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We are entitled to amend the deposit agreement and to change the rights of ADS holders under the terms of such agreement, or to terminate the deposit agreement, without the prior consent of the ADS holders.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are entitled to amend the deposit agreement and to change the rights of the ADS holders under the terms of such agreement, without the prior consent of the ADS holders. We and the depositary may agree to amend the deposit agreement in any way we decide is necessary or advantageous to us or to the depositary. Amendments may reflect, among other things, operational changes in the ADS program, legal developments affecting ADSs or changes in the terms of our business relationship with the depositary. In the event that the terms of an amendment are materially disadvantageous to ADS holders, ADS holders will only receive 30 days&#8217; advance notice of the amendment, and no prior consent of the ADS holders is required under the deposit agreement. Furthermore, we may decide to direct the depositary to terminate the ADS facility at any time for any reason. For example, terminations may occur when we decide to list our ordinary shares on a non-U.S. securities exchange and determine not to continue to sponsor an ADS facility or when we become the subject of a takeover or a going-private transaction. If the ADS facility will terminate, ADS holders will receive at least 30 days&#8217; prior notice, but no prior consent is required from them. Under the circumstances that we decide to make an amendment to the deposit agreement that is disadvantageous to ADS holders or terminate the deposit agreement, the ADS holders may choose to sell their ADSs or surrender their ADSs and become direct holders of the underlying ordinary shares, but they will have no right to any compensation whatsoever.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ADSs holders may not be entitled to a jury trial with respect to claims arising under the deposit agreement, which could result in less favorable outcomes to the plaintiff(s) in any such action. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The deposit agreement governing the ADSs representing our ordinary shares provides that, to the fullest extent permitted by law, holders and beneficial owners of ADSs irrevocably waive the right to a jury trial of any claim they may have against us or the depositary arising out of or relating to the ADSs or the deposit agreement.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If this jury trial waiver provision is not permitted by applicable law, an action could proceed under the terms of the deposit agreement with a jury trial. If we or the depositary opposed a jury trial demand based on the waiver, the court would determine whether the waiver was enforceable based on the facts and circumstances of that case in accordance with the applicable state and federal law. To our knowledge, the enforceability of a contractual pre-dispute jury trial waiver in connection with claims arising under the federal securities laws has not been finally adjudicated by the Supreme Court. However, we believe that a contractual pre-dispute jury trial waiver provision is generally enforceable, including under the laws of the State of New York, which govern the deposit agreement, by a federal or state court in the City of New York, which has non-exclusive jurisdiction over matters arising under the deposit agreement. In determining whether to enforce a contractual pre-dispute jury trial waiver provision, courts will generally consider whether a party knowingly, intelligently and voluntarily waived the right to a jury trial. We believe that this is the case with respect to the deposit agreement and the ADSs.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any holders or beneficial owners of ADSs bring a claim against us or the depositary in connection with matters arising under the deposit agreement or the ADSs, including claims under federal securities laws, such holder or beneficial owner may not be entitled to a jury trial with respect to such claims, which may have the effect of limiting and discouraging lawsuits against us and/or the depositary. If a lawsuit is brought against us and/or the depositary under the deposit agreement, it may be heard only by a judge or justice of the applicable trial court, which would be conducted according to different civil procedures and may result in different outcomes than a trial by jury would have had, including results that could be less favorable to the plaintiff(s) in any such action, depending on, among other things, the nature of the claims, the judge or justice hearing such claims, and the venue of the hearing.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No condition, stipulation or provision of the deposit agreement or ADSs serves as a waiver by any holder or beneficial owner of ADSs or by us or the depositary of compliance with any substantive provision of the U.S. federal securities laws and the rules and regulations promulgated thereunder.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Holders of our ADSs do not have the same voting rights as the holders of our ordinary shares and may not receive voting materials in time to be able to exercise the holder&#8217;s right to vote.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Except as described in this Annual Report and our Quarterly Reports and in the deposit agreement, holders of the ADSs will not be able to exercise voting rights attaching to the ordinary shares represented by the ADSs. Under the terms of the deposit agreement, holders of the ADSs may instruct the depositary to vote the ordinary shares underlying their ADSs. Otherwise, holders of ADSs will not be able to exercise their right to vote unless they withdraw the ordinary shares underlying their ADSs to vote them in person or by proxy in accordance with applicable laws and regulations and our Articles of Association. Even so, ADS holders may not know about a meeting far enough in advance to withdraw those ordinary shares. If we ask for the instructions of holders of the ADSs, the depositary, upon timely notice from us, will notify ADS holders of the upcoming vote and arrange to deliver our voting materials to them. Upon our request, the depositary will </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">mail to holders a shareholder meeting notice that contains, among other things, a statement as to the manner in which voting instructions may be given. We cannot guarantee that ADS holders will receive the voting materials in time to ensure that they can instruct the depositary to vote the ordinary shares underlying their ADSs. A shareholder is only entitled to participate in, and vote at, the meeting of shareholders, provided that it holds our ordinary shares as of the record date set for such meeting and otherwise complies with our Articles of Association. In addition, the depositary&#8217;s liability to ADS holders for failing to execute voting instructions or for the manner of executing voting instructions is limited by the deposit agreement. As a result, holders of ADSs may not be able to exercise their right to give voting instructions or to vote in person or by proxy and they may not have any recourse against the depositary or us if their ordinary shares are not voted as they have requested or if their shares cannot be voted.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Holders of our ADSs may not receive distributions on our ordinary shares represented by the ADSs or any value for them if it is illegal or impractical to make them available to holders of ADSs.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The depositary for the ADSs has agreed to pay to the holders of our ADSs the cash dividends or other distributions it or the custodian receives on our ordinary shares or other deposited securities after deducting its fees and expenses. Holders of our ADSs will receive these distributions in proportion to the number of our ordinary shares such holder&#8217;s ADSs represent. However, in accordance with the limitations set forth in the deposit agreement, it may be unlawful or impractical to make a distribution available to holders of ADSs. We have no obligation to take any other action to permit distribution on the ADSs, ordinary shares, rights or anything else to holders of the ADSs. This means that holders of our ADSs may not receive the distributions we make on our ordinary shares or any value from them if it is unlawful or impractical to make them available. These restrictions may have an adverse effect on the value of our ADSs.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Because we do not anticipate paying any cash dividends on our ADSs in the foreseeable future, capital appreciation, if any, will be the sole source of gains to the holders of our ADSs and such holders may never receive a return on their investment.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under current English law, a company&#8217;s accumulated realized profits must exceed its accumulated realized losses (on a non-consolidated basis) before dividends can be declared and paid. Therefore, we must have distributable profits before declaring and paying a dividend. We have not paid dividends in the past on our ordinary shares. We intend to retain earnings, if any, for use in our business and do not anticipate paying any cash dividends in the foreseeable future. As a result, capital appreciation, if any, on our ADSs will be the sole source of gains to the holders of our ADSs for the foreseeable future, and such holders may suffer a loss on their investment if they are unable to sell their ADSs at or above the price at which such holders purchased the ADSs.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Sales of a substantial number of our ADSs <span style="color:#000000;">in the public market by our existing shareholders </span>could cause the market price of our ADSs to drop significantly.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales of a substantial number of our ADS in the public market, or the perception that holders of a large number of ADSs intend to sell, could reduce the market price of our ADSs. As of December 31, 2021, we had outstanding 125,674,095 voting shares. The holders of 8,611,375 shares of our ordinary shares are entitled to rights with respect to the registration of their ordinary shares under the Securities Act of 1933, as amended, or the Securities Act. Registration of these ordinary shares under the Securities Act would result in the ADSs representing them becoming freely tradable without restriction, except for ADSs purchased by affiliates. In addition, our directors, executive officers and other affiliates may establish, and certain executive officers, directors and affiliates have established, programmatic selling plans under Rule 10b5-1 of the Exchange Act, for the purpose of effecting sales of our ADSs. <span style="color:#000000;">Generally, sales under such plans by our executive officers and directors require public filings.</span> Any sales of securities by these shareholders, or the perception that those sales may occur, under such programmed selling plans, could have a material adverse effect on the trading price of our ADSs. In addition, as of December 31, 2021, 17,619,073 ordinary shares reserved for issuance upon the exercise of existing options outstanding and issuance of performance-based and time-based restricted shares under our current equity incentive plans will become eligible for sale in the public market in the future, subject to certain legal and contractual limitations. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We will continue to incur increased costs as a result of operating as a company whose ADSs are publicly traded in the United States, and our management is required to devote substantial time to new compliance initiatives.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a public company listed on a U.S. exchange, we have incurred and will continue to incur significant legal, accounting and other expenses that we did not incur as a private company. In addition, the Sarbanes-Oxley Act and rules subsequently implemented by the SEC and Nasdaq have imposed various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">management and other personnel are required to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations have increased and will continue to increase our legal and financial compliance costs and make some activities more time-consuming and costly.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Section&#160;404 of the Sarbanes-Oxley Act, or Section 404, we are required to furnish a report by our management on our internal control over financial reporting <span style="color:#000000;">and, once we are no longer a &#8220;smaller reporting company&#8221;, we will be required to furnish an attestation report on internal control over financial reporting issued by our independent registered public accounting firm</span>. In order to achieve and maintain compliance with Section&#160;404, we have documented and evaluated our internal control over financial reporting, which is both costly and challenging. In this regard, we continue to dedicate internal resources, have engaged outside consultants and adopted a detailed work plan to continually assess and document the adequacy of internal control over financial reporting, taken steps to improve control processes as appropriate, validated through testing that controls are functioning as documented and have implemented a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk in any given year that we will not be able to conclude within the prescribed timeframe that our internal control over financial reporting is effective as required by Section&#160;404. This could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements.<span style="color:#000000;"> </span>Moreover, if in the future we are required to obtain an opinion as to the effectiveness of our internal control over financial reporting and if our independent registered public accounting firm is unable to express an opinion as to the effectiveness of our internal control over financial reporting, investors may lose confidence in the accuracy and completeness of our financial reports and the market price of our ADSs could be negatively affected, and we could become subject to investigations by the SEC or other regulatory authorities or to shareholder litigation, which could have an adverse impact on the market price or our ADSs and cause us to incur additional expenses.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Shareholder protections and restrictions found in provisions under The City Code on Takeovers and Mergers do not apply to us.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2020, the UK Takeover Panel confirmed that we are not considered to be subject to The City Code on Takeovers and Mergers, or The Takeover Code, and, as a result, our shareholders are not entitled to the benefit of certain takeover offer protections provided under The Takeover Code. The Takeover Code provides a framework within which takeovers of companies are regulated and conducted and which may operate to prohibit certain arrangements and courses of conduct considered customary in the United States. There are no provisions in our Articles of Association that replicate the provisions of The Takeover Code.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that this position is unlikely to change at any time in the near future, but in accordance with good practice, we will review the situation on a regular basis and cooperate and consult with the UK Takeover Panel if there is any material change in our circumstances with respect to matters which the UK Takeover Panel might consider relevant in their determination of jurisdiction over us.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The rights of our shareholders may differ from the rights typically offered to shareholders of a U.S. corporation.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are incorporated under English law. The rights of holders of ordinary shares and, therefore, certain of the rights of holders of ADSs, are governed by English law, including the provisions of the UK Companies Act 2006, and by our Articles of Association. These rights differ in certain respects from the rights of shareholders in typical U.S. corporations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The principal differences include the following:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>Under English law and our Articles of Association, each shareholder present at a meeting has only one vote unless demand is made for a vote on a poll, in which case each holder gets one vote per share owned. Under U.S. law, each shareholder typically is entitled to one vote per share at all meetings.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>Under English law, it is only on a poll that the number of shares determines the number of votes a holder may cast. The voting rights of ADSs are also governed by the provisions of a deposit agreement with our depositary bank.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>Under English law, subject to certain exceptions and disapplications, each shareholder generally has preemptive rights to subscribe on a proportionate basis to any issuance of ordinary shares or rights to subscribe for, or to convert securities into, ordinary shares for cash. Under U.S. law, shareholders generally do not have preemptive rights unless specifically granted in the certificate of incorporation or otherwise.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>Under English law and our Articles of Association, certain matters require the approval of 75% of the shareholders who vote (in person or by proxy) on the relevant resolution (or on a poll of shareholders representing 75% of the ordinary shares voting (in person or by proxy)), including amendments to the Articles of </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Association. This may make it more difficult for us to complete corporate transactions deemed advisable by our board of directors. Under U.S. law, generally only majority shareholder approval is required to amend the certificate of incorporation or to approve certain significant transactions.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>In the United Kingdom, takeovers may be structured as takeover offers or as schemes of arrangement. Under English law, a bidder seeking to acquire us by means of a takeover offer would need to make an offer for all of our outstanding ordinary shares/ADSs. If acceptances are not received for 90% or more of the ordinary shares/ADSs under the offer, under English law, the bidder cannot complete a &#8220;squeeze out&#8221; to obtain 100% control of us. Accordingly, acceptances of 90% of our outstanding ordinary shares/ADSs will likely be a condition in any takeover offer to acquire us, not 50% as is more common in tender offers for corporations organized under Delaware law. By contrast, a scheme of arrangement, the successful completion of which would result in a bidder obtaining 100% control of us, requires the approval of a majority of shareholders voting at the meeting and representing 75% of the ordinary shares voting for approval.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>Under English law and our Articles of Association, shareholders and other persons whom we know or have reasonable cause to believe are, or have been, interested in our shares may be required to disclose information regarding their interests in our shares upon our request, and the failure to provide the required information could result in the loss or restriction of rights attaching to the shares, including prohibitions on certain transfers of the shares, withholding of dividends and loss of voting rights. Comparable provisions generally do not exist under U.S. law.</p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, shareholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our ADSs.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective internal controls over financial reporting are necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures, are designed to prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered in their implementation could cause us to fail to meet our reporting obligations. In addition, testing required to be conducted by us in connection with Section&#160;404, and subsequent testing by our independent registered public accounting firm, may reveal deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses or that may require prospective or retroactive changes to our financial statements or identify other areas for further attention or improvement. Inferior internal controls could also cause investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of our ADSs.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are required to disclose changes made in our internal controls and procedures on a quarterly basis, and our management is required to assess the effectiveness of these controls annually. However, for as long as we are a &#8220;smaller reporting company,&#8221; our independent registered public accounting firm will not be required to attest to the effectiveness of our internal control over financial reporting pursuant to Section&#160;404. We will qualify as a &#8220;smaller reporting company&#8221; if the market value of our ADSs held by non-affiliates is below $250&#160;million (or $700&#160;million if our annual revenue is less than $100 million) as of the last business day of our most recently completed second fiscal quarter. An independent assessment of the effectiveness of our internal control over financial reporting could detect problems that our management&#8217;s assessment might not. Undetected material weaknesses in our internal control over financial reporting could lead to financial statement restatements and require us to incur the expense of remediation.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to certain reporting requirements of the Exchange Act. Our disclosure controls and procedures are designed to reasonably assure that information required to be disclosed by us in reports we file or submit under the Exchange Act is accumulated and communicated to management, recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements or insufficient disclosures due to error or fraud may occur and not be detected.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks related to taxation</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Changes in tax law could adversely affect our business and financial condition.</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We conduct business globally. The tax treatment of the company or any of the group companies could be materially adversely affected by several factors, including, but not limited to: (i) changing tax laws, regulations and treaties, or the interpretation thereof&#59; (ii) tax policy initiatives and reforms under consideration (such as those related to the Organization for Economic Co-Operation and Development&#8217;s, or OECD, Base Erosion and Profit Shifting, or BEPS, Project, the European Commission&#8217;s state aid investigations and other initiatives)&#59; (iii) the practices of tax authorities in jurisdictions in which we operate&#59; and (iv) the resolution of issues arising from tax audits or examinations and any related interest or penalties. Such changes may include (but are not limited to) the taxation of operating income, investment income, dividends received or (in the specific context of withholding tax) dividends paid.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are unable to predict what tax reform may be proposed or enacted in the future or what effect such changes would have on our business, but such changes, to the extent they are brought into tax legislation, regulations, policies or practices in jurisdictions in which we operate, could affect our financial position, future results of operations, cash flows in a particular period and overall or effective tax rates in the future in countries where we have operations, reduce post-tax returns to our shareholders and increase the complexity, burden and cost of tax compliance.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Taxing authorities could challenge our historical and future tax positions or our allocation of taxable income among our subsidiaries, and tax laws to which we are subject could change in a manner adverse to us.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We operate through various subsidiaries in a number of countries throughout the world. Consequently, we are subject to tax laws, treaties, and regulations in the countries in which we operate, and these laws and treaties are subject to interpretation. We have taken, and will continue to take, tax positions based on our interpretation of such tax laws. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our transfer pricing arrangements are not generally binding on applicable tax authorities. The price charged for products, services, or the royalty rates and other amounts paid for intellectual property rights, could be challenged by the various tax authorities, resulting in additional tax liability, interest, and/or penalties. There can be no assurance that a taxing authority will not have a different interpretation of applicable law and assess us with additional taxes. Similarly, a tax authority could assert that we are subject to tax in a jurisdiction where we believe we have not established a taxable connection, often referred to as a &#8216;&#8216;permanent establishment&#8217;&#8217; under international tax treaties, and such an assertion, if successful, could increase our expected tax liability in one or more jurisdictions. If we are assessed with additional taxes, this may result in a material adverse effect on our results of operations and/or financial condition. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A tax authority may take the position that material income tax liabilities, interest and penalties are payable by us, for example where there has been a technical violation of contradictory laws and regulations that are relatively new and have not been subject to extensive review or interpretation, in which case we expect that we might contest such assessment. Contesting such an assessment may be lengthy and costly and if we were unsuccessful in disputing the assessment, the implications could increase our anticipated effective tax rate, where applicable, or result in other liabilities. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we are a controlled foreign corporation, there could be adverse U.S. federal income tax consequences to certain U.S. holders.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:7.14%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each &#8220;Ten Percent Shareholder&#8221; (as defined below) in a non-U.S. corporation that is classified as a &#8220;controlled foreign corporation,&#8221; or a CFC, for U.S. federal income tax purposes generally is required to include in income for U.S. federal tax purposes such Ten Percent Shareholder&#8217;s pro rata share of the CFC&#8217;s &#8220;Subpart F income&#8221; and investment of earnings in U.S. property, even if the CFC has made no distributions to its shareholders. Subpart F income generally includes dividends, interest, rents, royalties, global intangible low-taxed income, gains from the sale of securities and income from certain transactions with related parties. In addition, a Ten Percent Shareholder that realizes gain from the sale or exchange of shares in a CFC may be required to classify a portion of such gain as dividend income rather than capital gain. A non-U.S. corporation generally will be classified as a CFC for U.S. federal income tax purposes if Ten Percent Shareholders own, directly or indirectly, more than 50% of either the total combined voting power of all classes of stock of such corporation entitled to vote or of the total value of the stock of such corporation. A &#8220;Ten Percent Shareholder&#8221; is a United States person (as defined by the Code) who owns or is considered to own 10% or more of the total combined voting power of all classes of stock entitled to vote of such corporation. The determination of CFC status is complex and includes attribution rules, the application of which is not entirely certain.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:7.14%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that we were not a CFC in the 2021 taxable year, but we may become a CFC in a subsequent taxable year. If we are classified as both a CFC and a passive foreign investment company, or PFIC (as discussed below), we </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">generally will not be treated as a PFIC with respect to those U.S. holders that meet the definition of a Ten Percent Shareholder during the period in which we are a CFC. </span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we are a PFIC there could be adverse U.S. federal income tax consequences to U.S. holders.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Code, we will be a PFIC, for any taxable year in which (i) 75% or more of our gross income consists of passive income or (ii) 50% or more of the average quarterly value of our assets consists of assets that produce, or are held for the production of, passive income. For purposes of these tests, passive income includes dividends, interest, gains from the sale or exchange of investment property and certain rents and royalties. In addition, for purposes of the above calculations, a non-U.S. corporation that directly or indirectly owns at least 25% by value of the shares of another corporation is treated as holding and receiving directly its proportionate share of assets and income of such corporation. If we are a PFIC for any taxable year during which a U.S. holder holds our ordinary shares or ADSs, the U.S. holder may be subject to adverse tax consequences regardless of whether we continue to qualify as a PFIC, including ineligibility for any preferred tax rates on capital gains or on actual or deemed dividends, interest charges on certain taxes treated as deferred and additional reporting requirements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not believe that we were a PFIC in the 2021 taxable year. The determination of whether we are a PFIC is a fact-intensive determination made on an annual basis applying principles and methodologies that in some circumstances are unclear and subject to varying interpretation. The value of our assets would also be determined differently for the purposes of this determination if we were treated as a CFC, as discussed above. As a result, there can be no assurance regarding if we currently are treated as a PFIC or may be treated as a PFIC in the future. In addition, for our current and future taxable years, the total value of our assets for PFIC testing purposes may be determined in part by reference to the market price of our ordinary shares or ADSs from time to time, which may fluctuate considerably. Under the income test, our status as a PFIC depends on the composition of our income which will depend on the transactions we enter into in the future and our corporate structure. The composition of our income and assets is also affected by the spending of the cash we raise in any offering.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In certain circumstances, a U.S. holder of shares in a PFIC may alleviate some of the adverse tax consequences described above by making either a &#8220;qualified electing fund,&#8221; or QEF, election or a mark-to-market election (if our ordinary shares or ADSs constitute &#8220;marketable&#8221; securities under the Code), which each require the inclusion of a pro rata share of our income on a current basis. If we determine that we are a PFIC for any taxable year, we currently expect that we would provide the information necessary for U.S. holders to make a QEF election. A U.S. holder would also be able to make a mark-to-market election with respect to our ordinary shares or ADSs as long as those shares or ADSs constitute marketable securities under the Code.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may be unable to use UK net operating loss and tax credit carryforwards and certain built-in losses to reduce future tax payments or benefit from favorable UK tax legislation.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a UK incorporated and tax resident entity, we are subject to UK corporate taxation on tax-adjusted trading profits. Due to the nature of our business, we have generated losses since inception and therefore have not paid any UK corporation tax. As of December 31, 2021, we had cumulative carryforward tax losses of $506.2 million. Subject to numerous utilization criteria and restrictions (including those that limit the percentage of profits that can be reduced by carried forward losses and those that can restrict the use of carried forward losses where there is a change of ownership of more than half the ordinary shares of the Company and a major change in the nature, conduct or scale of the trade), we expect these to be eligible for carry forward and utilization against future operating profits. The use of loss carryforwards in relation to UK profits incurred on or after April&#160;1, 2017 will be limited each year to &#163;5.0&#160;million plus, broadly, an incremental 50% of UK taxable profits. In addition, if we were to have a major change in the nature of the conduct of our trade, loss carryforwards may be restricted or extinguished.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a company that carries out extensive research and development activities, we seek to benefit from two UK research and development tax relief programs, the Small and Medium-sized Enterprises R&#38;D Tax Credit Program, or SME Program, and the Research and Development Expenditure Credit program, or RDEC Program. Where available, we may be able to surrender the trading losses that arise from our qualifying research and development activities for cash or carried forward for potential offset against future profits (subject to relevant restrictions). The majority of our pipeline research, clinical trials management and manufacturing development activities are eligible for inclusion within these tax credit cash rebate claims. Our eligibility to claim payable research and development tax credits may be limited or eliminated because we may no longer qualify as a small or medium-sized company. The U.K. Finance Act of 2021 introduced a cap on payable credit claims under the SME Program in excess of &#163;20,000 with effect from April 2021 by reference to, broadly, three times the total PAYE and NICs liability of the company, subject to an exception which prevents the cap from applying. That exception requires the company to be creating, taking steps to create or managing intellectual property, as well as having qualifying research and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">development expenditure in respect of connected parties, which does not exceed 15% of the total claimed. If such exception does not apply, this could restrict the amount of payable credit that we claim.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may benefit in the future from the United Kingdom&#8217;s &#8220;patent box&#8221; regime, which allows certain profits attributable to revenues from patented products (and other qualifying income) to be taxed at an effective rate of 10%. We are the exclusive licensee or owner of several patent applications which, if issued, would cover our product candidates, and accordingly, future upfront fees, milestone fees, product revenues and royalties could be taxed at this tax rate. When taken in combination with the enhanced relief available on our research and development expenditures, we expect a long-term lower rate of corporation tax to apply to us. If, however, there are unexpected adverse changes to the UK research and development tax credit regime or the &#8220;patent box&#8221; regime, or for any reason we are unable to qualify for such advantageous tax legislation, or we are unable to use net operating loss and tax credit carryforwards and certain built-in losses to reduce future tax payments then our business, results of operations and financial condition may be adversely affected.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our ability to use our U.S. tax attributes may be limited.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under Section 382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code, if a corporation undergoes an &#8220;ownership change,&#8221; generally defined as a greater than 50% change (by value) in its equity ownership by certain stockholders over a three-year period, the corporation&#8217;s ability to use its pre-change tax attributes (such as research and development tax credits) to offset its post-change tax liabilities may be limited. We have completed several financings since our inception, which we believe have resulted in an ownership change as defined by Section 382 of the Code. We may also experience ownership changes in the future as a result of subsequent shifts in our share ownership. As a result, if we incur U.S. federal tax liability, our ability to use our pre-change tax attributes to offset U.S. federal tax liability may be subject to limitations, which could potentially result in increased future tax liability to us. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks related to our Domicile</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Exchange rate fluctuations may materially affect our results of operations and financial condition.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Owing to the international scope of our operations, fluctuations in exchange rates, particularly between the pound sterling and the U.S. Dollar, may adversely affect us. These adverse impacts may be exacerbated by the ongoing economic disruption caused by the COVID-19 global pandemic. Although we are based in the United Kingdom, we source research and development, manufacturing, consulting and other services from the United States and the European Union. Further, potential future revenue may be derived from abroad, particularly from the United States. As a result, our business and the price of our ADSs may be affected by fluctuations in foreign exchange rates not only between the pound sterling and the U.S. Dollar, but also the Euro, which may have a significant impact on our results of operations and cash flows from period to period. Currently, we do not have any exchange rate hedging arrangements in place.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Claims of U.S. civil liabilities may not be enforceable against us.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are incorporated under English law. Certain members of our board of directors and senior management are non-residents of the United States, and a substantial portion of our assets and the assets of such persons are located outside the United States. As a result, it may not be possible to serve process on such persons or us in the United States or to enforce judgments obtained in U.S. courts against them or us based on civil liability provisions of the securities laws of the United States. As a result, it may not be possible for investors to effect service of process within the United States upon such persons or to enforce judgments obtained in U.S. courts against them or us, including judgments predicated upon the civil liability provisions of the U.S. federal securities laws. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The United States and the United Kingdom do not currently have a treaty providing for recognition and enforcement of judgments (other than arbitration awards) in civil and commercial matters. Consequently, a final judgment for payment given by a court in the United States, whether or not predicated solely upon U.S. securities laws, would not automatically be recognized or enforceable in the United Kingdom. In addition, uncertainty exists as to whether U.K. courts would entertain original actions brought in the United Kingdom against us or our directors or senior management predicated upon the securities laws of the United States or any state in the United States. Any final and conclusive monetary judgment for a definite sum obtained against us in U.S. courts would be treated by the courts of the United Kingdom as a cause of action in itself and sued upon as a debt at common law so that no retrial of the issues would be necessary, provided that certain requirements are met. Whether these requirements are met in respect of a judgment based upon the civil liability provisions of the U.S. securities laws, including whether the award of monetary damages under such laws would constitute a penalty, is an issue for the court making such decision. If an English court gives judgment for the sum payable under a U.S. judgment, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the English judgment will be enforceable by methods generally available for this purpose. These methods generally permit the English court discretion to prescribe the manner of enforcement.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result, U.S. investors may not be able to enforce against us or our senior management, board of directors or certain experts named herein who are residents of the United Kingdom or countries other than the United States any judgments obtained in U.S. courts in civil and commercial matters, including judgments under the U.S. federal securities laws.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">General Risk Factors</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have debt service obligations and may incur additional indebtedness in the future, which could adversely affect our financial condition, our results of operations and our ability to react to changes in our business.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently have $33.0 million of principal indebtedness outstanding under our senior term facilities agreement, or the Amended Credit Facility, with MidCap Financial (Ireland) Limited. We have the ability to borrow up to an additional $67.0 million in the future under the Amended Credit Facility upon satisfaction of certain conditions. Our existing indebtedness and any additional indebtedness we may incur could require us to divert funds identified for other purposes for debt service and impair our liquidity position.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fact that a portion of our cash, cash equivalents, and marketable securities could be needed to make payments on our indebtedness could have important consequences, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>increasing our vulnerability to general adverse economic and industry conditions or increased interest rates&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>restricting our ability to use our cash, cash equivalents and marketable securities for other purposes&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>limiting our flexibility in planning for or reacting to changes in our business and the markets in which we operate, which would place us at a competitive disadvantage compared to our competitors that may have less debt&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>limiting our ability to borrow additional funds for working capital, capital expenditures and other investments&#59; and</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>failing to comply with the covenants in our debt agreements could result in all of our indebtedness becoming immediately due and payable.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If our business does not generate sufficient cash flow from operations or if future borrowings are not available to us under the Amended Credit Facility or otherwise in amounts sufficient to enable us to fund our liquidity needs, our financial condition and results of operations may be adversely affected. Our inability to make scheduled payments on our debt obligations in the future would require us to refinance all or a portion of our indebtedness on or before maturity, sell assets or seek additional equity investment. We may not be able to take any of such actions on a timely basis on terms satisfactory to us or at all.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Amended Credit Facility contains usual and customary restrictive covenants relating to the operation of our business, including restrictions on our ability to:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>incur or guarantee additional indebtedness&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>incur or permit to exist certain liens&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>undergo a change in control&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>amend material agreements and organizational documents&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>effect certain mergers, consolidations, asset sales and acquisitions&#59; and</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>pay dividends on, or redeem or repurchase, share capital, enter into transactions with affiliates, or materially change our business.</p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may be adversely affected by natural disasters, and our business continuity and disaster recovery plans may not adequately protect us.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Natural disasters, including earthquakes, fires, flooding and health epidemics and pandemics, could severely disrupt our business. If a natural disaster occurred, we could be prevented from using all or a significant portion of our facilities, which could make it difficult or impossible for us to continue our business or a portion of our business for a substantial period of time. A natural disaster could also damage critical infrastructure and affect our third-party contract manufacturers. Our disaster recovery and business continuity plans are currently limited and may not prove adequate in the event of a serious </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">natural disaster or similar event. As such, </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> could incur substantial expenses if a natural disaster occurs, which could have a material impact on </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> business, financial condition, results of operations and prospects. </span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The anticipated phasing out of&#160;LIBOR may adversely affect the value of any outstanding debt instruments.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">National and international regulators and law enforcement agencies have conducted investigations into a number of rates or indices known as &#8220;reference rates.&#8221; Actions by such regulators and law enforcement agencies may result in changes to the manner in which certain reference rates are determined, their discontinuance, or the establishment of alternative reference rates. In particular, in July 2017, the Chief Executive of the UK Financial Conduct Authority, or FCA, which regulates LIBOR, announced that the FCA will no longer persuade or compel banks to submit rates for the calculation of LIBOR after 2021. This deadline was extended until June 2023 for a number of key U.S. dollar benchmark maturities.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At this time, it is not possible to predict the effect that these developments, any discontinuance, modification or other reforms to LIBOR or any other reference rate, or the establishment of alternative reference rates may have on LIBOR, other benchmarks, or LIBOR-based debt instruments. Uncertainty as to the nature of such potential discontinuance, modification, alternative reference rates or other reforms may materially adversely affect the trading market for securities linked to such benchmarks. Furthermore, the use of alternative reference rates or other reforms could cause the interest rate calculated for the LIBOR-based debt instruments to be materially different than expected.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Any changes to existing accounting pronouncements or taxation rules or practices may cause adverse fluctuations in our reported results of operations or affect how we conduct our business.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A change in accounting pronouncements or taxation rules or practices could have a significant effect on our reported results and may affect our reporting of transactions completed before the change is effective. New accounting pronouncements, taxation rules and varying interpretations of accounting pronouncements or taxation rules have occurred in the past and may occur in the future. We could be required to modify a current tax or accounting position as a result of any such change, and this could adversely affect our reported financial results and could change the way we conduct our business.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We could be subject to securities class action litigation.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We could be the subject of a securities class action litigation. The risk is especially relevant to us because such litigations are often brought against companies following a decline in the market price of its securities, and biotechnology and pharmaceutical companies have experienced significant securities price volatility in recent years. If such a litigation were brought against us, it could result in substantial costs and could divert management&#8217;s attention and resources, which would be harmful to our business.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_1B_UNRESOLVED_STAFF_COMMENTS">Item 1B. Unresolved Staff Comments. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_2_PROPERTIES">Item 2. Properties. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Facilities </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our principal office is located at 108 Cannon Street, London EC4N 6EU, United Kingdom. We lease approximately 14,000 square feet of office space at this location and our lease for this location extends through January 2023. We also lease approximately 14,000 square feet of office space in Boston, Massachusetts, our U.S. Headquarters. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2018, we entered into an agreement to lease approximately 153,000 square feet of manufacturing and office space in Fremont, California. This lease extends through May 2030. We have abandoned plans to build-out the facility and have subleased the facility to a third-party for the remainder of the lease term. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that suitable additional or substitute space will be available as needed to accommodate any future expansion of our operations.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_3_LEGAL_PROCEEDINGS">Item 3. Legal Proceedings. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, we may be a party to litigation or subject to claims incident to the ordinary course of business. Although the results of litigation and claims cannot be predicted with certainty, we currently believe that the final outcome of these ordinary course matters will not have a material adverse effect on our business. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors. As of December 31, 2021, we were not a party to any material legal proceedings.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_4_MINE_SAFETY_DISCLOSURES">Item 4. Mine Safety Disclosures.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="PART_II">PART II</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_5_MARKET_FOR_REGISTRANTS_COMMON_EQU">Item 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Market Information and Holders of Ordinary Shares and ADSs</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our American Depositary Shares, or ADSs, each represent one ordinary share, nominal value &#163;0.10 per share, of Orchard Therapeutics plc. An ADS may be evidenced by an American Depositary Receipt issued by Citibank, N.A. as depositary bank. Our ADSs have been listed and traded on The Nasdaq Global Select Market under the symbol &#8220;ORTX&#8221; since October 31, 2018. As of March 15, 2022, there were approximately 53 holders of record of our ordinary shares, nominal value &#163;0.10 per share and one holder of record of our ADSs. The closing sale price per ADS on The Nasdaq Global Select Market on March 15, 2022 was $0.71. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sales of Unregistered Securities</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 6, 2021, we issued 22,758 ordinary shares to Gene Therapy Consulting S.r.l. in connection with milestones that were deemed to have been met pursuant to a consulting agreement. The offer, sale, and issuance of the shares is exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, as a transaction by an issuer not involving a public offering.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Dividends</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since our inception, we have not declared or paid any dividends on our ordinary shares. We intend to retain any earnings for use in our business and do not currently intend to pay dividends on our ordinary shares.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The payment of dividends by us is governed by English law. The declaration and payment of any future dividends will be at the discretion of our board of directors and will depend upon our results of operations, cash requirements, financial condition, contractual restrictions, restrictions imposed by our indebtedness, any future debt agreements or applicable laws and other factors that our board of directors may deem relevant.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Information about Our Equity Compensation Plans</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Information regarding our equity compensation plans is incorporated by reference in Item&#160;12 of Part III of this Annual Report.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item 6. Reserved. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_7_MANAGEMENTS_DISCUSSION_ANALYSIS_F">Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The following discussion of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and related notes included elsewhere in this report. Some of the information contained in this discussion and analysis and set forth elsewhere in this report, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. You should review the section titled &#8220;Risk Factors&#8221; in Part&#160;I&#8212;Item&#160;1A of this report for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. </span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Business Overview </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Orchard Therapeutics is a global gene therapy company dedicated to transforming the lives of people affected by severe diseases through the development of innovative, potentially curative gene therapies. Our&#160;<span style="font-style:italic;">ex vivo&#160;</span>autologous hematopoietic stem cell (&#8220;HSC&#8221;) gene therapy approach harnesses the power of genetically modified blood stem cells and seeks to correct the underlying cause of disease in a single administration. We have one of the deepest and most advanced gene therapy pipelines in the industry spanning multiple therapeutic areas where the disease burden on children, families and caregivers is immense and current treatment options are limited or do not exist. </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since our inception in 2015, we have devoted substantially all of our resources to conducting research and development of our product candidates, in-licensing and acquiring rights to our product candidates, business planning, raising capital and providing general and administrative support for our operations. To date, we have financed our operations primarily with proceeds from the sale of equity securities, including American Depositary Shares (&#8220;ADSs&#8221;) in our initial public offering (&#8220;IPO&#8221;) and follow-on offering, ordinary shares in our private placement, and convertible preferred shares. We have also financed our operations through proceeds from our senior term facilities agreement (the &#8220;Amended Credit Facility&#8221;) with MidCap Financial (Ireland) Limited (&#8220;MidCap Financial&#8221;), research grants from the California Institute of Regenerative Medicine (&#8220;CIRM&#8221;), upfront payments from our collaboration agreement with Pharming Group N.V., and proceeds associated&#160;<span style="Background-color:#FFFFFF;">two UK research and development tax relief programs, the Small and Medium-sized Enterprises research and development tax credit (&#8220;SME&#8221;) program and the Research and Development Expenditure (&#8220;RDEC&#8221;) program.</span></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have incurred significant operating losses since our inception. With the approval of Libmeldy in Europe, we are now focused on our transition from a primarily clinical development stage company to a commercial stage company. We plan to continue the implementation of our commercialization plan for Libmeldy and our near-term plans for commercialization include: </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Enabling patient identification via multi-pronged diagnostics initiatives and newborn screening in Europe and the U.S.&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Expanding global footprint by qualifying leading centers with transplant and disease area expertise&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Leveraging cross-border and treatment abroad reimbursement pathways in Europe, Middle East, and Turkey&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Securing market access via multi-stakeholder engagement with various payment models.</span></p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our net losses were $144.6 million for the year ended December 31, 2021. As of December 31, 2021, we had an accumulated deficit of $750.2 million. As of December 31, 2021, we had cash, cash equivalents and marketable securities of $220.1 million, excluding amounts held in escrow deposits. Our losses have resulted primarily from costs incurred in connection with research and development activities and general and administrative costs associated with our operations. We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future. </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through a combination of equity offerings, debt financings, collaborations, government contracts or other strategic transactions. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on favorable terms, or at all.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Recent Developments</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February 9, 2021, we issued and sold (i) 20,900,321 ordinary shares, nominal value &#163;0.10 per share, at a purchase price of $6.22 per share (the &#8220;Purchase Price&#8221;), which was the closing sale price of our ADSs on the Nasdaq Global Select Market on February 4, 2021, and (ii) 3,215,434 non-voting ordinary shares, nominal value &#163;0.10 per share, at the Purchase Price </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(together (i) and (ii) the &#8220;Private Placement&#8221;). The Private Placement resulted in net proceeds to us of $143.7 million after deducting placement agent fees of $6.0 million and other offering-related costs of $0.3 million. The ordinary shares and non-voting ordinary shares were sold pursuant to a securities purchase agreement we entered into with the purchasers named therein on February 4, 2021. </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All non-voting ordinary shares have been converted to ordinary shares as of December 31, 2021.</span></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The ADSs representing the ordinary shares issued in the Private Placement were registered for resale on an automatic shelf registration statement on Form S-3 filed with the SEC on April 8, 2021.</span></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">On May 28, 2021, we notified UCL Business Plc (&#8220;UCLB&#8221;) and The Regents of the University of California (&#8220;UCLA&#8221;) that we were terminating the license relating to our OTL-101 program for ADA-SCID, which was granted to us pursuant to the license agreement, dated February 6, 2016, among us, UCLB and UCLA, as amended (the &#8220;License Agreement&#8221;), such termination to be effective 30 days after the date of such notice. Except for the termination of such license, the License Agreement continues in full force and effect.</span></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 1, 2021, the Company announced a strategic collaboration with Pharming to research, develop, manufacture and commercialize OTL-105, an investigational&#160;<span style="font-style:italic;">ex vivo</span>&#160;autologous HSC gene therapy for the treatment of hereditary angioedema (HAE), a life-threatening rare disorder that causes recurring swelling attacks in the face, throat, extremities and abdomen.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the collaboration, Pharming has been granted worldwide rights to OTL-105 and will be responsible for clinical development, regulatory filings and commercialization of the investigational gene therapy, including associated costs. The Company will lead the completion of IND-enabling activities and oversee manufacturing of OTL-105 during preclinical and clinical development, which will be funded by Pharming. In addition, both the Company and Pharming will explore the application of non-toxic conditioning regimen for use with OTL-105 administration.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company received an upfront payment of $17.5 million comprising $10.0 million in cash and a $7.5 million equity investment from Pharming at a premium to the Company&#8217;s then recent share price, resulting in the issuance of 1,227,738 ordinary shares subject to resale restrictions. The Company is also eligible to receive up to $189.5 million in development, regulatory and sales milestones as well as mid-single to low double-digit percentage royalty payments on future worldwide sales.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2022, we announced our decision to focus on severe neurometabolic diseases and early research programs, and to discontinue our investment in and seek strategic alternatives for our programs in rare primary immune deficiencies, including OTL-103 for treatment of WAS, OTL-102 for treatment of X-CGD and Strimvelis. In connection with our new strategic focus, we plan to reduce our workforce by approximately 30%. We expect to recognize employee-related termination costs related to the restructuring of approximately $2.5 million during the first and second quarter of 2022. We also expect to incur discontinuation costs relating to OTL-102, OTL-103 and Strimvelis, such as contract termination fees and non-cancellable commitments. At the time of the filing of this Annual Report on Form 10-K, we are unable to determine the estimated discontinuation costs in good faith because such costs are subject to a number of variables that are not entirely within our control.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Business update regarding COVID-19</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The current COVID-19 pandemic has presented substantial public health and economic challenges around the world and is affecting our employees, patients, communities and business operations, as well as the U.S. and global economies and financial markets.&#160;The impact of this pandemic has been and will likely continue to be extensive in many aspects of society and will likely continue to result in significant disruptions to the global economy, as well as businesses and capital markets around the world.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In an effort to halt the outbreak of COVID-19, a number of countries, including the United States, United Kingdom and Italy, have placed significant restrictions on travel. While some restrictions have been relaxed since the beginning of the pandemic, many restrictions are still in place. In the U.S. and UK, our office-based employees have been primarily working from home since March 2020. Limitations on travel and other social distancing measures may have an effect on our preclinical and clinical activities and regulatory timelines.&#160;While our clinical sites are still treating and following up with patients in clinical trials, these centers are also devoting significant resources to patients with COVID-19 and may need to devote additional resources as variants of COVID-19 lead to a potential rise in hospitalizations, which could limit their ability to enroll additional patients in ongoing clinical studies.&#160;While we believe we have enrolled and treated enough patients to support a first regulatory filing for OTL-200 in the U.S., COVID-19-related impacts shifted the enrollment timeline for our OTL-201 trial for the treatment of MPS-IIIA by three months. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As additional variants of the virus proliferate, potential renewed travel </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and stay-at-home orders could adversely affect our contract manufacturers and third-party logistics providers. To date, our&#160;third-party contract development and manufacturing organization (CDMO) partners have continued to operate at or near normal levels. While we currently do not anticipate any interruptions, it is possible that the COVID-19 pandemic and response efforts may have an impact in the future on our or our third-party suppliers&#8217; and CDMO partners&#8217; ability to manufacture our products in development.&#160;Any prolonged material disruptions to our employees, suppliers, CDMOs, vendors or patients could impact our operating results and could lead to impairments. To date</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, we have</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> recorded impairments on long-lived assets that are due to a combination of a corporate restructuring and COVID-19 market impacts.</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, our ability to access the capital markets could be impacted if there are future disruptions to capital markets that result from the COVID-19 pandemic.&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For additional information on the various risks posed by the COVID-19 pandemic, please see the section titled &#8220;Item 1A. Risk Factors&#8221; included in this Annual Report.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Components of our results of operations </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Product Sales </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the years ended December 31, 2021 and 2020, we recognized $0.7 million and $2.6 million revenue from sales of Strimvelis, respectively. <span style="Background-color:#FFFFFF;color:#000000;">Libmeldy received approval from the European Commission in December 2020 and, if we are able to identify patients and secure reimbursement for our treatment, we may begin to generate revenue from the sale of Libmeldy in Europe in early 2022</span>. Strimvelis is distributed exclusively at the San Raffaele Hospital in Milan, Italy. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Collaboration revenue</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31, 2021, we recognized $1.0 million under our collaboration agreement with Pharming. <span style="Background-color:#FFFFFF;color:#000000;">Under revenue recognition guidance, we account&#160;for our obligations to provide the license and research, development, and manufacturing services under the agreement </span><span style="color:#000000;">as a series of distinct services that are accounted for as a single performance obligation</span><span style="Background-color:#FFFFFF;color:#000000;">.</span><span style="color:#000000;"> </span><span style="Background-color:#FFFFFF;color:#000000;">We&#160;recognize revenue using the&#160;</span><span style="color:#000000;">cost-to-cost </span><span style="Background-color:#FFFFFF;color:#000000;">input method, which&#160;we&#160;believe best depicts the transfer of control to the customer. Under the&#160;</span><span style="color:#000000;">cost-to-cost</span><span style="Background-color:#FFFFFF;color:#000000;">&#160;input method, the extent of progress towards completion is measured based on the ratio of actual costs incurred to the total estimated costs expected upon satisfying the identified performance obligation. Under this method, revenue is recorded as a percentage of the estimated transaction price based on the extent of progress towards completion. Under this method, the impact of this adjustment on revenue recorded to date is recognized in the period the adjustment is identified. Reimbursement for research, development, and manufacturing services are recognized as the costs are incurred.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cost of product sales</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of sales consists of costs to manufacture, including raw materials, distribute and administer Strimvelis, and royalty payments due to third parties that are tied to sales. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Operating expenses </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Research and development expenses </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses consist primarily of costs incurred for our research activities, including our discovery efforts and the development of our product candidates, and include: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">expenses incurred under agreements with third parties, including contract research organizations (CROs) that conduct research, preclinical activities and clinical trials on our behalf as well as contract manufacturing organizations that manufacture lentiviral vectors and cell-based drug products for use in our preclinical and clinical trials&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">expenses to acquire technologies to be used in research and development&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">salaries, benefits and other related costs, including share-based compensation expense, for personnel engaged in research and development functions&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">costs related to research and development performed associated with the Company&#8217;s collaboration arrangement&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">costs of outside consultants, including their fees, share-based compensation and related travel expenses&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the costs of laboratory supplies and acquiring, developing and manufacturing preclinical study and clinical trial materials&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">costs related to compliance with regulatory requirements&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">facility-related expenses, which include direct depreciation costs and allocated expenses for rent and maintenance of facilities, costs related to our collaboration agreements, and other operating costs&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">upfront, milestone and management fees for maintaining licenses under our third-party licensing agreements&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">grant awards or other government incentives unrelated to income taxes that we earn that are recorded as an offset to the related research and development costs incurred.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expense research and development costs as incurred. We recognize external development costs based on an evaluation of the progress to completion of specific tasks using information provided to us by our service providers. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and are reflected in our financial statements as prepaid expenses or accrued research and development expenses. United Kingdom research and development tax credits are recorded as an offset to research and development expense. Amortization of the Strimvelis loss provision is also recorded as an offset to research and development expense (see Note 2 of our consolidated financial statements). </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our direct external research and development expenses are tracked on a program-by-program basis and consist of costs, such as fees paid to consultants, contractors and contract manufacturing organizations in connection with our preclinical and clinical development activities. License fees and other costs incurred after a product candidate has been designated and that are directly related to the product candidate are included in direct research and development expenses for that program. License fees and other costs incurred prior to designating a product candidate for development are included in unallocated costs. We do not allocate employee costs, costs associated with our early-stage discovery efforts, laboratory supplies, and facilities, including depreciation or other indirect costs, to specific product development programs because these costs are deployed across multiple product development programs and, as such, are not separately classified. </p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials or the manufacturing requirements to conduct those clinical trials. We expect that our research and development expenses will remain consistent quarter over quarter for the near term as we continue to: (i)&#160;expedite the clinical development and seek to obtain marketing approval for our product candidates, including OTL-200 in the U.S. for MLD<span style="color:#000000;">&#59; (ii) work towards the clinical development of our early clinical phase product candidates, which may include initiating pivotal clinical trials for OTL-203 in MPS-IH and expanding the Phase I/II study for OTL-201 in MPS-IIIA&#59; (iii) </span>reduce our investment in and development expenses for OTL-300 for TDT and reallocate these financial resources to other programs&#59; (iv)<span style="color:#000000;"> seek to&#160;improve the efficiency and scalability of our outsourced manufacturing processes and supply chain&#59; (v)&#160;build process development and analytical capabilities in the near term, and potential manufacturing capabilities in the longer term&#59; and (vi) continue to discover and develop additional product candidates. For example, in April 2020, we announced our intention to accelerate our research and development efforts for projects in less rare indications, including two new research programs in genetic subsets of frontotemporal dementia (FTD) and Crohn&#8217;s disease, and in November 2020 we announced a new program in amyotrophic lateral sclerosis (ALS). We also expect to incur additional expenses related to milestone, royalty payments and maintenance fees payable to third parties with whom we have entered into license agreements&#160;to acquire the rights related to our product candidates. </span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Selling, general and administrative expenses </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative expenses consist primarily of salaries and other related costs, including share-based compensation, for personnel in our executive, finance, commercial, corporate and business development, and administrative functions. Selling, general and administrative expenses also include professional fees for legal, patent, accounting, auditing, tax and consulting services, travel expenses and facility-related expenses, which include direct depreciation costs and allocated expenses for rent and maintenance of facilities and other operating costs. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Other income (expense), net </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Interest income</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income consists of income earned on our cash and cash equivalents and marketable securities.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Interest expense</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense consists of interest associated with our credit facility with MidCap Financial, which we entered into in May 2019, and amended and restated in May 2021. The Amended Credit Facility bears a variable interest rate at a rate of 5.95% above LIBOR, plus a final payment equal to 3.5% of the principal borrowed under the Amended Credit Facility. LIBOR phases out in June 2023, at which point the Company and MidCap will agree on a new reference rate.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Other income (expense)</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense), net consists primarily of realized and unrealized foreign currency transaction gains and losses.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Results of operations </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Information pertaining to fiscal year 2020 was included in our Annual Report on Form 10-K for the year ended December 31, 2020 on page 120 under Item 7, &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; which was filed with the U.S. Securities and Exchange Commission on March 2, 2021.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Comparison of the years ended December 31, 2021 and 2020</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our results of operations for the years ended December&#160;31, 2021 and 2020: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product sales, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">700</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,595</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,895</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Collaboration revenue</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">975</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">975</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenues</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,675</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,595</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(920</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Costs and operating expenses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of product sales</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">226</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">857</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(631</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86,977</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93,730</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,753</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,905</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64,986</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,081</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total costs and operating expenses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">142,108</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">159,573</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,465</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(140,433</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(156,978</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,545</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other (expense) income:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">412</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,185</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,773</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,497</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,328</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(169</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other (expense) income, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,238</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,411</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,649</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other (expense) income, net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,323</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,268</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,591</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss before income tax</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(143,756</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(152,710</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,954</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax (expense) benefit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(828</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">731</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,559</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to ordinary shareholders</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(144,584</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(151,979</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,395</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Research and development expenses</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The table below summarizes our research and development expenses by therapeutic area: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Direct research and development expenses by therapeutic area:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Neurometabolic disorders</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,443</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,714</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,729</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Primary immune deficiencies</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,801</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,073</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,272</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Blood disorders</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">743</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,255</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,512</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other research and preclinical programs under development</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,636</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,479</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,157</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total direct research and development expenses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46,623</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,521</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,102</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and discovery and unallocated costs</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Personnel related (excluding share-based compensation)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,421</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,949</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,528</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share-based compensation</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,214</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,679</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,465</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accretion of Strimvelis loss provision</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,037</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,413</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,376</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development tax credit</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,920</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21,130</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,210</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Impairment of long-lived assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,650</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,650</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Facility and other</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,676</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,474</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,798</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> Total indirect research and development expenses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,354</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,209</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,855</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total research and development expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86,977</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93,730</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,753</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Direct research and development expenses for neurometabolic programs increased by $4.7 million. The increase is primarily driven by a <span style="letter-spacing:-0.15pt;">$3.3 million increase in OTL-203 for MPS-I, and a $2.3 million increase for OTL-200 for MLD/Libmeldy, offset by a $0.9 million decline in OTL-201 for MPS-IIIA.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Direct research and development expenses for primary immune deficiencies declined by $3.3 million. The decline is primarily driven by a <span style="letter-spacing:-0.15pt;">$3.8 million decline in OTL-101 for ADA-SCID, and a $1.9 million decline in OTL-102 for X-CGD, offset by a $1.8 million increase in OTL-103 for WAS, and $0.6 million increase in Strimvelis. The primary decline in primary immune deficiencies was for OTL-101, and is due to the termination of the license for this program with UCLA/UCLB.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Direct research and development expenses for our blood disorder programs declined by $1.5 million, as a result of incurring lower expenses for OTL-300 for TDT following our reduction in investment in that product candidate in connection with our strategic reprioritization in 2020. The decrease in expenses was due to a decline in manufacturing expenses.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Direct expenses associated with other research and preclinical programs increased by $2.2 million. This was primarily due to increased costs for preclinical programs in hereditary angioedema (HAE), </span><span style="Background-color:#FFFFFF;color:#1D2228;">frontotemporal dementia with progranulin mutations (GRN-FTD) and Crohn&#8217;s disease with mutations in the nucleotide-binding oligomerization domain-containing protein 2 (NOD2-CD), as well as other undisclosed discovery programs.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unallocated research and development costs and offsets to research and development expenses declined by $8.9 million. This was primarily due to a decline in personnel related costs of $3.6 million and share-based compensation of $2.5 million. The decline in personnel costs is due to $3.6 million in severance associated with the consolidation and closure of our research and development and manufacturing facilities in California in 2020, which did not recur in 2021, as well as lower compensation costs. We also took a $5.7 million non-cash asset impairment charge associated with assets at our former California research facilities in 2020 that did not recur in 2021. Other facility, travel, and unallocated platform-related research and development costs have declined by $5.7 million. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Research and development expenses were further offset by $13.9 million as a result of the benefits of the UK research and development tax credit that is recorded as an offset to research and development expense. Tax credit benefits decreased by $7.2 million primarily due expenses qualifying for credit under a less favorable credit regime as a result of EU State Aid Cap thresholds being met for certain programs.&#160;Accretion of the Strimvelis loss provision, which is also accounted for as an offset to research and development expense, declined by $1.4 million as we have adjusted our ongoing estimate due to our </span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">reduction of investment in</span><span style="Background-color:#FFFFFF;"> OTL-101 and have extended out the expected period of losses for Strimvelis, which results in lower amortization of the loss provision in a given period.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Selling, general and administrative expenses </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The table below summarizes our selling, general and administrative expenses by functional area:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.26%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.28%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.28%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative expenses:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Personnel (excluding share-based compensation)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,711</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,890</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,179</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share-based compensation</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,322</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,283</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,961</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Consulting, professional, and insurance-related costs</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,679</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,315</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,364</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketing, promotions, and advocacy</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,259</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,093</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,834</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Facilities and IT-related costs</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,539</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,422</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(883</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">395</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">983</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.28%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(588</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total selling, general, and administrative expenses:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.28%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,905</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.28%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64,986</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.28%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,081</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative expenses were $54.9 million in 2021, compared to $65.0&#160;million in 2020. The decline of $10.1 million was primarily due to lower personnel and share-based compensation. Personnel costs declined by $4.2&#160;million, generally due to $1.3 million in severance charges associated with our corporate restructuring and CEO transition 2020 that did not recur in 2021, and a decline in salary and bonus charges associated with our selling, general, and administrative staff. Share-based compensation expense declined by $3.0 million in 2021 compared to 2020 due to a $2.7 million charge associated with the modification of our former CEO&#8217;s share options in 2020 that did not recur in 2021. Consulting, professional, and insurance-related costs increased by of $1.4 million primarily due to an increase in directors&#8217; and officers&#8217; insurance.<span style="color:#000000;"> Expenses associated with marketing and commercialization of Strimvelis, and costs associated with preparing for the potential future commercialization of our product candidates, if approved, declined by $2.8 million. Facilities and IT costs and other expenses also declined, as we have realized savings from our 2020 corporate restructuring.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Other (expense) income, net </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other (expense) income, net for 2021 and 2020 was a loss of $3.3 million and a gain of $4.3 million, respectively. During 2021, we had realized and unrealized losses on foreign currency transactions of $1.2 million, compared to $3.4 million in gains for 2020. These gains and losses are primarily due to fluctuations in the exchange rate between British Pound and U.S. Dollars as it relates to our foreign currency denominated monetary assets and liabilities. Interest income declined by $2.8 million due to lower investment portfolio balances as a result of cash used for operations. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liquidity and capital resources</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From our inception through December 31, 2021, we have not generated significant revenue from product sales and incurred significant operating losses and negative cash flows from our operations. We acquired our commercial product Strimvelis and the program that is now Libmeldy from GSK in April 2018, and our product candidates are in various phases of preclinical and clinical development. In December 2020,<span style="color:#000000;"> the European Commission granted standard marketing authorization for Libmeldy. We expect to launch Libmeldy in Europe and generate product sales in early 2022. </span>To date, we have financed our operations primarily with proceeds from the sale of ADSs in our IPO and follow-on offering, proceeds from the sale of ordinary shares in our private placement, proceeds from the sale of convertible preferred shares, proceeds associated&#160;with <span style="Background-color:#FFFFFF;">two UK research and development tax relief programs, the Small and Medium-sized Enterprises research and development tax credit (&#8220;SME&#8221;) program and the Research and Development Expenditure (&#8220;RDEC&#8221;) program, </span>reimbursements from our research agreement with UCLA and, following transfer of the ADA-SCID research program sponsorship from UCLA to us in July 2018, a grant from the California Institute of Regenerative Medicine (&#8220;CIRM&#8221;), upfront payments from our collaboration agreement with Pharming Group N.V., and our Original Credit Facility and our Amended Credit Facility. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February 27, 2020, we entered into a Sales Agreement with Cowen and Company, LLC (&#8220;Cowen&#8221;), as agent, relating to an &#8220;at the market offering,&#8221; pursuant to which we may issue and sell ADSs representing our ordinary shares, having an aggregate offering price of up to $100.0 million. As of December 31, 2021, we have not sold any shares under the Sales Agreement. On March 24, 2022, we delivered written notice to Cowen to terminate the Sales Agreement, effective as of </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 30, 2022, pursuant to Section 11(b) thereof. Prior to termination, we had not sold any ADSs pursuant to the Sales Agreement. As a result of the termination of the Sales Agreement, we will not offer or sell any ADSs under the Sales Agreement.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently have no ongoing material financing commitments, such as lines of credit or guarantees, that are expected to affect our liquidity over the next five years, other than our manufacturing, lease, and debt obligations described below. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Cash flows </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Information pertaining to fiscal year 2020 was included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020 beginning on page 120 under Item 7, &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; which was filed with the U.S. Securities and Exchange Commission on March 2, 2021.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our cash flows for each of the periods presented: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Year Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(125,097</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(126,274</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash from investing activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(32,165</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">157,379</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">158,066</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,936</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effect of exchange rate changes on cash</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,043</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net increase in cash, cash equivalents, and restricted cash</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">777</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,084</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Operating activities </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During 2021, operating activities used $125.1 million of cash, primarily resulting from our net loss of $144.6 million. Cash usage from changes in our operating assets and liabilities was $17.1 million. There was cash usage of $13.9 million from our UK research and development tax credit receivable, consisting of claims that were filed in December 2021 that we expect to receive in 2022. Further, payment of accruals and accounts payable resulted in cash outflows of $9.5 million. These were offset by a $13.1 million increase in deferred revenue associated with our strategic collaboration with Pharming. Non-cash adjustments to operating activities of $36.6 million was primarily due to $22.5 million in non-cash share-based compensation expense, offset by $1.0 million in amortization of the Strimvelis loss provision as an offset to research and development expense. There were also unrealized foreign currency transaction losses on investments, intercompany accounts, and foreign-currency denominated payables and receivables held by our UK subsidiary of $9.7 million. Finally, we had $1.1 million in deferred income tax expense during 2021.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During 2020, operating activities used $126.3 million of cash, primarily resulting from our net loss of $152.0 million. Cash usage from changes in our operating assets and liabilities was $3.6 million. There was an $11.7 million increase from our UK research and development tax credit receivable, for which we received $33.8 million during 2020 (which was associated with our 2018 and 2019 tax credit claims), offset by $21.1 million taken as an offset to research and development expense that will be included in our 2020 claim. Further, payment of accruals and accounts payable resulted in cash outflows of $12.3 million. The decline in these accounts is primarily due to timing of payments in comparison with the prior year-end. Non-cash adjustments to operating activities of $29.3 million was primarily due to $28.0 million in non-cash share-based compensation expense, offset by $2.4 million in amortization of the Strimvelis loss provision as an offset to research and development expense. Additionally, we took $5.7 million in asset impairments associated with our restructuring. There were also unrealized foreign currency transaction gains on investments, intercompany accounts, and foreign-currency denominated payables and receivables held by our UK subsidiary of $3.9 million. Finally, we had $2.3 million in deferred income tax benefits during 2020.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Investing activities </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During 2021 and 2020, we used $32.2 million and generated $157.4 million, respectively, of cash in investing activities. The change in cash from investing activity is primarily due to proceeds from sales and maturities of marketable debt securities that we utilize for operating activities. Further, in 2020 we made $10 million construction deposit associated with our Fremont lease, and we received $1.9 million in receipts from the escrow account, as compared to receiving $0.2 million in 2021.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Financing activities</span><span style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"> </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">During 2021, we generated $158.1 million in cash from financing activities. This is primarily due to $143.6 million in proceeds from the issuance of ordinary shares in our private placement, after payment of $6.4 million in offering costs. We also generated $7.4 million associated with&#160;our entrance into&#160;the Amended Credit Facility.&#160;Further, we generated $4.1 million in proceeds associated with the Securities Purchase Agreement with Pharming that was entered into as part of our collaboration agreement.&#160; We generated $2.9 million in proceeds from the exercise of share options and issuance of ordinary shares as part of our ESPP.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During 2020, we received proceeds of $3.9 million from the exercise of share options and the issuance of ordinary shares as part of our 2018 Employee Share Purchase Plan, or ESPP.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Funding requirements </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect our expenses and capital expenditures will remain consistent in the near term in connection with our ongoing activities as we advance the preclinical activities and clinical trials of our product candidates and as we: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">seek marketing approvals for our product candidates that successfully complete clinical trials, if any&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">continue to grow a sales, marketing and distribution infrastructure for our commercialization of Libmeldy in Europe, and for any product candidates for which we may submit for and obtain marketing approval anywhere in the world&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">continue our development of our product candidates, including continuing our ongoing advanced registrational trials and supporting studies, and any other clinical trials that may be required to obtain marketing approval for our product candidates&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">perform research and development activities with respect to potential new product candidates&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">conduct </span><span style="color:#000000;">investigational new drug application, or </span><span style="color:#000000;">IND, and </span><span style="color:#000000;">or clinical trial application, or </span><span style="color:#000000;">CTA-enabling studies for our preclinical programs&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">initiate additional clinical trials and preclinical studies for our other product candidates&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">seek to identify and develop, acquire or in-license additional product candidates&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">develop the necessary processes, controls and manufacturing data to obtain marketing approval for our product candidates, to support technology and process innovations and to support manufacturing of product to commercial scale&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">develop and implement plans to establish and operate our own in-house manufacturing operations and facility&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">hire and retain additional personnel, such as non-clinical, clinical, pharmacovigilance, quality assurance, regulatory affairs, manufacturing, distribution, legal, compliance, medical affairs, finance, general and administrative, commercial and scientific personnel&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">develop, maintain, expand and protect our intellectual property portfolio&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">comply with our obligations as a public company. </span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because of the numerous risks and uncertainties associated with biopharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve or maintain profitability. Even if we are able to generate product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe our existing cash will enable us to fund our operating expenses and capital expenditure requirements into 2024. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Critical Accounting Policies and Estimates</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management&#8217;s discussion and analysis of financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of our consolidated financial </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">statements and related disclosures requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, costs and expenses and the disclosure of contingent assets and liabilities in our consolidated financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.</span></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While our significant accounting policies are described in greater detail in Note 2 to our consolidated financial statements in this Annual Report, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our consolidated financial statements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">United Kingdom research and development tax credit </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a company that carries out research and development activities, we are able to submit tax credit claims from two UK research and development tax relief programs, the Small and Medium-sized Enterprises research and development tax credit (&#8220;SME&#8221;) program and the Research and Development Expenditure Credit (&#8220;RDEC&#8221;) program depending on eligibility. Qualifying expenditures largely comprise employment costs for research staff, consumables and certain internal overhead costs incurred as part of research projects for which we do not receive income.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each reporting period, we evaluate which tax relief programs we are expected to be eligible for and record a reduction to research and development expense for the portion of the expense that we expect to qualify under the programs, that we plan to submit a claim for, and we have reasonable assurance that the amount will ultimately be realized. <span style="color:#000000;">Based on criteria established by HM Revenue and Customs (&#8220;HMRC&#8221;), we expect a proportion of expenditures being carried in relation to our pipeline research, clinical trials management and manufacturing development activities to be eligible for the research and development tax relief programs for the years ended December 31, 2021 and 2020. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The RDEC and SME credits are not dependent on us generating future taxable income or on our ongoing tax status or tax position. We have assessed our research and development activities and expenditures to determine whether the nature of the activities and expenditures will qualify for credit under the tax relief programs and whether the claims will ultimately be realized based on the allowable reimbursable expense criteria established by the UK government which are subject to interpretation. At each period end, we estimate the reimbursement available to us based on available information at the time.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We recognize credits from the research and development incentives when the relevant expenditure has been incurred and there is reasonable assurance that the reimbursement will be received.&#160;Such credits are accounted for as reductions in research and development expense. We make estimates of the research and development tax credit receivable as of each balance sheet date, based upon facts and circumstances known to us at the time. Although we do not expect our estimates to be materially different from amounts actually recognized, our estimates could differ from actual results. To date, there have not been any material adjustments to our prior estimates of the research and development tax credit receivable.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Accrued research and development expenses</span></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of the process of preparing our consolidated financial statements, we are required to estimate our accrued research and development expenses. This process involves reviewing open contracts and purchase orders, communicating with our personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of actual costs. The majority of our service providers invoice us in arrears for services performed, on a&#160;pre-determined&#160;schedule or when contractual milestones are met&#59; however, some require advanced payments. We make estimates of our prepaid and accrued expenses as of each balance sheet date in the consolidated financial statements based on facts and circumstances known to us at that time. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the expense.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">117</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We base our expenses related to preclinical studies and clinical trials on our estimates of the services received and efforts expended pursuant to quotes and contracts with multiple CROs, research institutions and other vendors that supply, conduct and manage preclinical studies and clinical trials on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the expense. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, we adjust the accrual or the amount of prepaid expenses accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period. To date, there have not been any material adjustments to our prior estimates of accrued research and development expenses.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Valuation of share-based compensation</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We measure share-based awards granted to employees,&#160;non-employees&#160;and directors based on the fair value on the date of the grant and recognize compensation expense for those awards over the requisite service period, which is generally the vesting period of the respective award. Forfeitures are accounted for as they occur. Generally, we issue share-based awards in the form of stock options with only service-based vesting conditions and record the expense for these awards using the straight-line method. We have also issued share-based awards with performance-based vesting conditions for which the expense is recognized when achievement of such performance conditions becomes probable.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of each share option is estimated on the date of grant using the Black-Scholes option pricing model. Until the completion of our initial public offering in November 2018, we had been a private company and lacked company-specific historical and implied volatility information for our shares. Therefore, we estimate our expected share price volatility based on the historical volatility of publicly traded peer companies and expect to continue to do so until such time as we have adequate historical data regarding the volatility of our own traded share price. The expected term of our share options has been determined utilizing the &#8220;simplified method&#8221; for awards that qualify as &#8220;plain-vanilla&#8221; options. Prior to the adoption of ASU&#160;2018-07,&#160;the expected term of share options granted to&#160;non-employees&#160;was the contractual term. After adoption of ASU&#160;2018-07,&#160;the expected term of share options granted to&#160;non-employees&#160;is determined in the same manner as share options granted to employees. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that we have never paid cash dividends on our ordinary shares and do not expect to pay any cash dividends in the foreseeable future.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Off-balance sheet arrangements. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_7A_QUANTITATIVE_QUALITATIVE_DISCLOS">Item 7A. Quantitative and Qualitative Disclosures About Market Risk. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Interest rate sensitivity </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, we had cash, cash equivalents, marketable securities, and restricted cash of $224.4&#160;million. Our exposure to interest rate sensitivity is impacted by changes in the underlying UK and U.S. bank interest rates. Our surplus cash has been invested in corporate bonds, commercial paper, U.S. treasuries, and money market accounts. We have not entered into investments for trading or speculative purposes. Due to the conservative nature of our investment portfolio, which is predicated on capital preservation of investments with short-term maturities, we do not believe an immediate one percentage point change in interest rates would have a material effect on the fair market value of our portfolio, and therefore we do not expect our operating results or cash flows to be significantly affected by changes in market interest rates. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have borrowed $</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33.0</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million under our credit facility. Amounts outstanding under the credit facility bear interest at a variable interest rate of </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.95</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">% plus LIBOR. As of December 31, 20</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, the carrying value of the term loans under the credit facility was $</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32.9</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2017, the United Kingdom&#8217;s Financial Conduct Authority announced that after 2021 it would no longer compel banks to submit the rates required to calculate the London Interbank Offered Rate (LIBOR) and other interbank offered rates, which have been widely used as reference rates for various securities and financial contracts, including loans, debt and derivatives. This announcement indicates that the continuation of LIBOR on the current basis is not guaranteed after 2021. Regulators in the U.S. and other jurisdictions have been working to replace these rates with alternative reference interest rates that are supported by transactions in liquid and observable markets, such as the Secured Overnight Financing Rate (SOFR). Currently, our credit facilities reference LIBOR-based rates. The discontinuation of LIBOR will require these arrangements to be modified in order to replace LIBOR with an alternative reference interest rate, which could impact our cost of funds. Our credit facilities include a provision for the determination of a successor LIBOR rate.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Foreign currency exchange risk </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is exposed to foreign currency exchange risk because it currently operates in the United Kingdom and the United States. The reporting currency of the Company is the U.S. dollar. The Company has determined the functional currency of the ultimate parent company, Orchard Therapeutics plc, is U.S. dollars because it predominantly raises finance and expends cash in U.S. dollars and expects to continue to do so in the future. Monetary assets and liabilities denominated in currencies other than the functional currency are translated into the functional currency of the relevant entity at rates of exchange prevailing at the balance sheet dates. Non-monetary assets and liabilities denominated in foreign currencies are translated into the functional currency at the exchange rates prevailing at the date of the transaction. Exchange gains or losses arising from foreign currency transactions are included in the determination of net income (loss) for the respective periods. We recorded realized and unrealized foreign currency losses of $1.2 million and gains of $3.4 million for the years ended December&#160;31, 2021 and 2020. These foreign currency transaction gains and losses are included in other (expense) income in our consolidated statements of operations and comprehensive loss. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets and liabilities have been translated at the exchange rates at the balance sheet dates, while revenue and expenses are translated at the average exchange rates over the reporting period and shareholders&#8217; equity amounts are translated based on historical exchange rates as of the date of each transaction. Translation adjustments are not included in determining net loss but are included in our foreign currency translation adjustment to other comprehensive loss, a component of shareholders&#8217; equity. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not currently engage in currency hedging activities in order to reduce our currency exposure, but we may begin to do so in the future. Instruments that may be used to hedge future risks include foreign currency forward and swap contracts. These instruments may be used to selectively manage risks, but there can be no assurance that we will be fully protected against material foreign currency fluctuations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_8_FINANCIAL_STATEMENTS_SUPPLEMENTAR">Item 8. Financial Statements and Supplementary Data. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Our consolidated financial statements are appended at the end of this Annual Report, starting at page F-1, and incorporated herein by reference</span>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC">Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_9A_CONTROLS_PROCEDURES">Item 9A. Controls and Procedures. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Evaluation of Disclosure Controls and Procedures</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We maintain disclosure controls and procedures (as defined in Rules&#160;13a-15(e) or 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act) that are designed to ensure that information required to be disclosed in reports that we file or submit under the Exchange Act is (1)&#160;recorded, processed, summarized, and reported within the time periods specified in the SEC&#8217;s rules and forms and (2)&#160;accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:11pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report. In designing and evaluating our disclosure controls and procedures, our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our principal executive officer and principal financial officer have concluded based upon the evaluation described above that, as of </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 3</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, 2021, our disclosure controls and procedures were effective at the reasonable assurance level.</span></p>
<p style="margin-bottom:0pt;margin-top:11pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We continue to review and document our disclosure controls and procedures, including our internal controls and procedures for financial reporting, and may from time to time make changes aimed at enhancing their effectiveness and to ensure that our systems evolve with our business in accordance with the Exchange Act.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Management&#8217;s Annual Report on Internal Control Over Financial Reporting</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with general accepted accounting principles. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the supervision and with the participation of our management, including our&#160;principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting based on the 2013 framework in Internal Control &#8211; Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on our evaluation under that framework, our management concluded that our internal control over financial reporting was&#160;effective as of&#160;December&#160;31, 2021.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Changes in Internal Control Over Financial Reporting</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were no changes in our internal control over financial reporting (as defined in Rules&#160;13a&#8209;15(f)&#160;and 15d&#8209;15(f)&#160;under the Exchange Act) during the quarter ended December 31, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_9B_OR_INFORMATION">Item 9B. Other Information. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Costs Associated with Exit or Disposal Activities</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 25, 2022, we approved a restructuring, pursuant to which the Company proposed to reduce its workforce by approximately 30%. The workforce reduction is subject to a consultation process with certain employees in the United Kingdom. The proposed reduction in force is expected to take place during, and be substantially completed by, the end of the second quarter 2022. <span style="color:#000000;">In March 2022, we announced that we would discontinue </span>our investment in <span style="color:#000000;">and seek alternatives for Strimvelis, OTL-103 for treatment of WAS and OTL-102 for treatment of X-CGD.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The restructuring is expected to extend our cash runway into 2024. As part of the restructuring, we expect to recognize employee-related termination costs of approximately $2.5 million during the first and second quarters of 2022. We also expect to incur discontinuation costs relating to OTL-102, OTL-103 and Strimvelis, such as contract termination fees and non-cancellable commitments. At the time of the filing of this Annual Report on Form 10-K, we are unable to make a determination of the discontinuation costs in good faith because such costs are subject to a number of variables that are not entirely within the Company&#8217;s control. <span style="Background-color:#FFFFFF;color:#000000;">These estimates of the expenses that the Company expects to incur and potential cost savings in connection with the proposed restructuring, and the timing thereof, are subject to a number of assumptions and actual results may differ. The Company may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, the restructuring.</span> </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&#8220;At the Market&#8221; Equity Offering Program</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As previously disclosed, in February 2020 we entered into a sales agreement (the &#8220;Sales Agreement&#8221;) with Cowen and Company, LLC (&#8220;Cowen&#8221;), pursuant to which <span style="Background-color:#FFFFFF;">we had the ability to issue and sell, from time to time at our option, ADSs </span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">representing our ordinary shares having an aggregate offering price of up to $100 million</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, through an &#8220;at the market&#8221; equity offering program under which Cowen acted as sales agent. On March 24, 2022, we delivered written notice to Cowen to terminate the Sales Agreement, effective as of March 30, 2022, pursuant to Section&#160;11(b) thereof. We are not subject to any termination penalties related to the termination of the Sales Agreement. Prior to termination, we had not sold any ADSs pursuant to the Sales Agreement. As a result of the termination of the Sales Agreement, we will not offer or sell any ADSs under the Sales Agreement. A copy of the Sales Agreement was filed as Exhibit 1.2 to the post-effective amendment to our Registration Statement on Form S-3, filed with the SEC on February 27, 2020 (the &#8220;Form S-3&#8221;). The description of the Sales Agreement contained in this Annual Report does not purport to be complete and is qualified in its entirety by reference to the copy of the Sales Agreement filed as Exhibit 1.2 to the Form S-3.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Frank Thomas Transitional Services Agreement</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 30, 2022, the Company and Frank Thomas entered into an amendment (the &#8220;Amendment&#8221;) to his <span style="Background-color:#FFFFFF;color:#000000;">Transitional Services Agreement, dated November 3, 2021 (as amended by the Amendment, the &#8220;Agreement&#8221;). Pursuant to the Amendment, Mr. Thomas will continue to serve as President and Chief Operating Officer of the Company and provide services for the Company on a full-time basis until&#160;December 31, 2022, unless his employment ends earlier or the Company and Mr. Thomas agree to an extension (such period, the &#8220;Transition Period&#8221;). During the Transition Period, the Amendment provides, among other things, that in exchange for entering into and complying with the Agreement, which includes a customary release of claims,&#160;Mr. Thomas will (i) continue to receive his base salary, subject to an increase in the base salary rate in an amount determined by the Board of Directors of the Company (or the Compensation Committee thereof) to be effective at the time that other executive team members of the Company receive base salary rate increases, (ii) remain eligible to participate in the Company&#8217;s group employee benefit plans, (iii) continue to vest in his stock options, and (iv) subject to the approval of the Company&#8217;s Board of Directors (or the Compensation Committee thereof), receive an award of stock options to purchase shares of the Company and/or other form of equity. </span><span style="Background-color:#FFFFFF;">Further, if Mr. Thomas remains employed by the Company on October 1, 2022, or in the event that he is terminated without &#8220;Cause&#8221; (as defined in the Agreement) prior to October 1, 2022 but has, among other things, executed an updated release of claims, then Mr. Thomas will be eligible to receive a cash incentive compensation in an amount equal to 25% of Mr. Thomas&#8217; then current base salary, to be paid no later than October 31, 2022.&#160;</span><span style="Background-color:#FFFFFF;color:#000000;">In addition, at the conclusion of his employment with the Company, provided that, among other things, Mr. Thomas&#8217; employment is not terminated by the Company for &#8220;Cause&#8221; and subject to the execution and effectiveness of an updated release, Mr. Thomas will be entitled to the following benefits (a) for up to six months, the Company shall pay the monthly employer COBRA premium for the same level of group health coverage as in effect at the conclusion of Mr. Thomas&#8217; employment, (b) be eligible t</span>o receive a cash incentive compensation in an amount equal to 25% of Mr. Thomas&#8217; then current base salary, to be paid at the time that the Company pays it executives their annual incentive compensation for 2022, which will be no later than March 15, 2023<span style="Background-color:#FFFFFF;color:#000000;">, and (</span>c) subject to approval by the Company&#8217;s Board of Directors (or the Compensation Committee thereof)<span style="Background-color:#FFFFFF;color:#000000;"> (x) continued vesting of all equity awards until April 1, 2023 and (y) an extension of the exercise period with respect to the vested shares of his stock options as of the date that the Company receives Mr. Thomas&#8217; executed updated release of claims, until the earlier of (A) April 1, 2024 or (B) the expiration date of the applicable share option.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The following summary contains a description of material U.S. federal income tax and UK tax consequences of the acquisition, ownership and disposition of our ordinary shares or ADSs. This summary should not be considered a comprehensive description of all the tax considerations that may be relevant to beneficial owners of ADSs.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Material U.S. federal income tax considerations for U.S. holders</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a description of the material U.S. federal income tax consequences to the U.S. Holders described below of owning and disposing of our ordinary shares or ADSs. It is not a comprehensive description of all tax considerations that may be relevant to a particular person&#8217;s decision to acquire securities. This discussion applies only to a U.S. Holder that holds our ordinary shares or ADSs as a capital asset for tax purposes (generally, property held for investment). In addition, it does not describe all of the tax consequences that may be relevant in light of a U.S. Holder&#8217;s particular circumstances, including state and local tax consequences, estate tax consequences, alternative minimum tax consequences, the potential application of the Medicare contribution tax, and tax consequences applicable to U.S. Holders subject to special rules, such as: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.8%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">banks, insurance companies, and certain other financial institutions&#59; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.8%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. expatriates and certain former citizens or long-term residents of the United States&#59; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.8%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">dealers or traders in securities who use a mark-to-market method of tax accounting&#59; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.8%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">persons holding ordinary shares or ADSs as part of a hedging transaction, &#8220;straddle,&#8221; wash sale, conversion transaction or integrated transaction or persons entering into a constructive sale with respect to ordinary shares or ADSs&#59; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">121</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.8%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">persons whose &#8220;functional currency&#8221; for U.S. federal income tax purposes is not the U.S. dollar&#59; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.8%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">brokers, dealers or traders in securities, commodities or currencies&#59; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.8%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tax-exempt entities or government organizations&#59; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.8%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S corporations, partnerships, or other entities or arrangements classified as partnerships for U.S. federal income tax purposes&#59; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.8%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regulated investment companies or real estate investment trusts&#59; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.8%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">persons who acquired our ordinary shares or ADSs pursuant to the exercise of any employee stock option or otherwise as compensation&#59; and </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.8%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">persons holding our ordinary shares or ADSs in connection with a trade or business, permanent establishment, or fixed base outside the United States. </p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an entity that is classified as a partnership for U.S. federal income tax purposes holds ordinary shares or ADSs, the U.S. federal income tax treatment of a partner will generally depend on the status of the partner and the activities of the partnership. Partnerships holding ordinary shares or ADSs and partners in such partnerships are encouraged to consult their tax advisers as to the particular U.S. federal income tax consequences of holding and disposing of ordinary shares or ADSs. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The discussion is based on the Code, administrative pronouncements, judicial decisions, final, temporary and proposed Treasury Regulations, and the income tax treaty between the United Kingdom and the United States, or the Treaty, all as of the date hereof, changes to any of which may affect the tax consequences described herein&#8212;possibly with retroactive effect. &#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A &#8220;U.S. Holder&#8221; is a holder who, for U.S. federal income tax purposes, is a beneficial owner of ordinary shares or ADSs and is: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.8%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)</p></td>
<td valign="top" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An individual who is a citizen or individual resident of the United States&#59; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.8%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)</p></td>
<td valign="top" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a corporation, or other entity taxable as a corporation, created or organized in or under the laws of the United States, any state therein or the District of Columbia&#59; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.8%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii)</p></td>
<td valign="top" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">an estate the income of which is subject to U.S. federal income taxation regardless of its source&#59; or </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.8%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iv)</p></td>
<td valign="top" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a trust if (1)&#160;a U.S. court is able to exercise primary supervision over the administration of the trust and one or more U.S. persons have authority to control all substantial decisions of the trust or (2)&#160;the trust has a valid election to be treated as a U.S. person under applicable U.S. Treasury Regulations. </p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The discussion below assumes that the representations contained in the deposit agreement are true and that the obligations in the deposit agreement and any related agreement will be complied with in accordance with their terms. Generally, a holder of an ADS should be treated for U.S. federal income tax purposes as holding the ordinary shares represented by the ADS. Accordingly, no gain or loss will be recognized upon an exchange of ADSs for ordinary shares. The U.S. Treasury has expressed concerns that intermediaries in the chain of ownership between the holder of an ADS and the issuer of the security underlying the ADS may be taking actions that are inconsistent with the beneficial ownership of the underlying security. Accordingly, the creditability of foreign taxes, if any, as described below, could be affected by actions taken by intermediaries in the chain of ownership between the holders of ADSs and our company if as a result of such actions the holders of ADSs are not properly treated as beneficial owners of the underlying ordinary shares. These actions would also be inconsistent with the claiming of the reduced tax rate, described below, applicable to dividends received by certain non-corporate holders. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PERSONS CONSIDERING AN INVESTMENT IN ORDINARY SHARES OR ADSs SHOULD CONSULT THEIR OWN TAX ADVISORS AS TO THE PARTICULAR TAX CONSEQUENCES APPLICABLE TO THEM RELATING TO THE ACQUISITION, OWNERSHIP AND DISPOSITION OF THE ORDINARY SHARES OR ADSs, INCLUDING THE APPLICABILITY OF U.S. FEDERAL, STATE AND LOCAL TAX LAWS. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">PFIC Rules </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are classified as a PFIC in any taxable year, a U.S. Holder will be subject to special rules generally intended to reduce or eliminate any benefits from the deferral of U.S. federal income tax that a U.S. Holder could derive from investing in a non-U.S. company that does not distribute all of its earnings on a current basis. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">122</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A non-U.S. corporation will be classified as a PFIC for any taxable year in which, after applying certain look-through rules, either: </span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.8%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">at least 75% of its gross income is passive income (such as interest income)&#59; or </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.8%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">at least 50% of its gross assets (determined on the basis of a quarterly average) is attributable to assets that produce passive income or are held for the production of passive income. </p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will be treated as owning our proportionate share of the assets and earning our proportionate share of the income of any other corporation, the equity of which we own, directly or indirectly, 25% or more (by value). &#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not believe that we were a PFIC in the 2021 taxable year, though we have not made a determination regarding our PFIC status in the current taxable year. However, a separate determination must be made after the close of each taxable year as to whether we are a PFIC for that year. As a result, our PFIC status may change from year to year, and we may be classified as a PFIC currently or in the future. The total value of our assets for purposes of the asset test generally will be calculated using the market price of the ordinary shares or ADSs, which may fluctuate considerably. Fluctuations in the market price of the ordinary shares or ADSs may result in our being a PFIC for any taxable year. However, if we are a &#8220;controlled foreign corporation&#8221; for any taxable year (see discussion below in &#8220;Controlled foreign corporation considerations&#8221;), the value of our assets for purposes of the asset test will be determined based on the tax basis of such assets which could increase the likelihood that we are treated as a PFIC. Because of the uncertainties involved in establishing our PFIC status, there can be no assurance regarding if we currently are treated as a PFIC or may be treated as a PFIC in the future. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are classified as a PFIC in any year with respect to which a U.S. Holder owns the ordinary shares or ADSs, we will continue to be treated as a PFIC with respect to such U.S. Holder in all succeeding years during which the U.S. Holder owns the ordinary shares or ADSs, regardless of whether we continue to meet the tests described above unless (i)&#160;we cease to be a PFIC and the U.S. Holder has made a &#8220;deemed sale&#8221; election under the PFIC rules, or (ii)&#160;the U.S. Holder makes a Qualified Electing Fund Election, or QEF Election, with respect to all taxable years during such U.S. Holders holding period in which we are a PFIC. If the &#8220;deemed sale&#8221; election is made, a U.S. Holder will be deemed to have sold the ordinary shares or ADSs the U.S. Holder holds at their fair market value and any gain from such deemed sale would be subject to the rules described below. After the deemed sale election, so long as we do not become a PFIC in a subsequent taxable year, the U.S. Holder&#8217;s ordinary shares or ADSs with respect to which such election was made will not be treated as shares in a PFIC and the U.S. Holder will not be subject to the rules described below with respect to any &#8220;excess distribution&#8221; the U.S. Holder receives from us or any gain from an actual sale or other disposition of the ordinary shares or ADSs. U.S. Holders should consult their tax advisors as to the possibility and consequences of making a deemed sale election if we cease to be a PFIC and such election becomes available. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For each taxable year we are treated as a PFIC with respect to U.S. Holders, U.S. Holders will be subject to special tax rules with respect to any &#8220;excess distribution&#8221; such U.S. Holder receives and any gain such U.S. Holder recognizes from a sale or other disposition (including, under certain circumstances, a pledge) of ordinary shares or ADSs, unless (i)&#160;such U.S. Holder makes a QEF Election or (ii)&#160;our ordinary shares or ADSs constitute &#8220;marketable&#8220; securities, and such U.S. Holder makes a mark-to-market election as discussed below. Distributions a U.S. Holder receives in a taxable year that are greater than 125% of the average annual distributions a U.S. Holder received during the shorter of the three preceding taxable years or the U.S. Holder&#8217;s holding period for the ordinary shares or ADSs will be treated as an excess distribution. Under these special tax rules: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.8%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the excess distribution or gain will be allocated ratably over a U.S. Holder&#8217;s holding period for the ordinary shares or ADSs&#59; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.8%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the amount allocated to the current taxable year, and any taxable year prior to the first taxable year in which we became a PFIC, will be treated as ordinary income&#59; and </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.8%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the amount allocated to each other year will be subject to the highest tax rate in effect for that year and the interest charge generally applicable to underpayments of tax will be imposed on the resulting tax attributable to each such year. &#160;</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The tax liability for amounts allocated to years prior to the year of disposition or &#8220;excess distribution&#8221; cannot be offset by any net operating losses for such years, and gains (but not losses) realized on the sale of the ordinary shares or ADSs cannot be treated as capital, even if a U.S. Holder holds the ordinary shares or ADSs as capital assets. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we determine that we are a PFIC for any taxable year, we currently expect that we would provide the information </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">123</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">necessary for U.S. holders to make a QEF Election. In addition, if we are a PFIC, a U.S. Holder will generally be subject to similar rules with respect to distributions we receive from, and our dispositions of the stock of, any of our direct or indirect subsidiaries that also are PFICs, as if such distributions were indirectly received by, and/or dispositions were indirectly carried out by, such U.S. Holder. U.S. Holders should consult their tax advisors regarding the application of the PFIC rules to our subsidiaries. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. Holders can avoid the interest charge on excess distributions or gain relating to the ordinary shares or ADSs by making a mark-to-market election with respect to the ordinary shares or ADSs, provided that the ordinary shares or ADSs are &#8220;marketable.&#8221; Ordinary shares or ADSs will be marketable if they are &#8220;regularly traded&#8221; on certain U.S. stock exchanges or on a foreign stock exchange that meets certain conditions. For these purposes, the ordinary shares or ADSs will be considered regularly traded during any calendar year during which they are traded, other than in de minimis quantities, on at least 15&#160;days during each calendar quarter. Any trades that have as their principal purpose meeting this requirement will be disregarded. Our ADSs will be listed on Nasdaq, which is a qualified exchange for these purposes. Consequently, if our ADSs remain listed on Nasdaq and are regularly traded, we expect the mark-to-market election would be available to U.S. Holders if we are a PFIC. Each U.S. Holder should consult its tax advisor as to the whether a mark-to-market election is available or advisable with respect to the ordinary shares or ADSs. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A U.S. Holder that makes a mark-to-market election must include in ordinary income for each year an amount equal to the excess, if any, of the fair market value of the ordinary shares or ADSs at the close of the taxable year over the U.S. Holder&#8217;s adjusted tax basis in the ordinary shares or ADSs. An electing holder may also claim an ordinary loss deduction for the excess, if any, of the U.S. Holder&#8217;s adjusted basis in the ordinary shares or ADSs over the fair market value of the ordinary shares or ADSs at the close of the taxable year, but this deduction is allowable only to the extent of any net mark-to-market gains for prior years. Gains from an actual sale or other disposition of the ordinary shares or ADSs will be treated as ordinary income, and any losses incurred on a sale or other disposition of the shares will be treated as an ordinary loss to the extent of any net mark-to-market gains for prior years. Once made, the election cannot be revoked without the consent of the Internal Revenue Service, or the IRS, unless the ordinary shares or ADSs cease to be marketable. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">However, a mark-to-market election generally cannot be made for equity interests in any lower-tier PFICs that we own, unless shares of such lower-tier PFIC are themselves &#8220;marketable.&#8221; As a result, even if a U.S. Holder validly makes a mark-to-market election with respect to our ordinary shares or ADSs, the U.S. Holder may continue to be subject to the PFIC rules (described above) with respect to its indirect interest in any of our investments that are treated as an equity interest in a PFIC for U.S. federal income tax purposes. U.S. Holders should consult their tax advisors to determine whether any of these elections would be available and if so, what the consequences of the alternative treatments would be in their particular circumstances. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless otherwise provided by the U.S. Treasury, each U.S. shareholder of a PFIC is required to file an Annual Report containing such information as the U.S. Treasury may require. A U.S. Holder&#8217;s failure to file the Annual Report will cause the statute of limitations for such U.S. Holder&#8217;s U.S. federal income tax return to remain open with regard to the items required to be included in such report until three years after the U.S. Holder files the Annual Report, and, unless such failure is due to reasonable cause and not willful neglect, the statute of limitations for the U.S. Holder&#8217;s entire U.S. federal income tax return will remain open during such period. U.S. Holders should consult their tax advisors regarding the requirements of filing such information returns under these rules. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WE STRONGLY URGE OUR INVESTORS TO CONSULT THEIR TAX ADVISOR REGARDING THE IMPACT OF OUR PFIC STATUS ON THEIR INVESTMENTS IN OUR ORDINARY SHARES OR ADSs AS WELL AS THE APPLICATION OF THE PFIC RULES TO THEIR INVESTMENT IN OUR ORDINARY SHARES OR ADSs. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Controlled foreign corporation considerations </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each &#8220;Ten Percent Shareholder&#8221; (as defined below) in a non-U.S. corporation that is classified as a &#8220;controlled foreign corporation,&#8221; or a CFC, for U.S. federal income tax purposes generally is required to include in income each year for U.S. federal tax purposes such Ten Percent Shareholder&#8217;s pro rata share of certain types of income earned by the CFC, including &#8220;Subpart F income,&#8221; &#8220;global intangible low-taxed income&#8221; and certain other income generated by the CFC, even if the CFC has made no distributions to its shareholders. In addition, a Ten Percent Shareholder that realizes gain from the sale or exchange of shares in the CFC may be required to classify a portion of such gain as dividend income rather than capital gain (see discussion below in &#8220;Taxation of distributions&#8221; regarding the tax treatment of dividend income). A non-U.S. corporation generally will be classified as a CFC for U.S. federal income tax purposes if Ten Percent Shareholders own, directly or indirectly, more than 50% of either the total combined voting power of all classes of stock of such corporation entitled to vote </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">124</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or of the total value of the stock of such corporation. A &#8220;Ten Percent Shareholder&#8221; is a United States person (as defined by the Code) who owns or is considered to own 10% or more of either the total combined voting power of all classes of stock of such corporation entitled to vote or of the total value of the stock of such corporation. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that we were not a CFC in the 2021 taxable year, though we have not made a determination regarding our CFC status in the current taxable year, and we may become a CFC in a subsequent taxable year. The determination of CFC status is complex and includes attribution rules, the application of which is not entirely certain. In addition, recent changes to the attribution rules relating to the determination of CFC status may make it difficult to determine our CFC status for any taxable year. It is possible that a shareholder treated as a U.S. person for U.S. federal income tax purposes will acquire, directly or indirectly, enough shares to be treated as a Ten Percent Shareholder. U.S. Holders should consult their own tax advisors with respect to the potential adverse U.S. tax consequences of becoming a Ten Percent Shareholder in a CFC. If we are classified as both a CFC and a PFIC, we generally will not be treated as a PFIC with respect to those U.S. Holders that meet the definition of a Ten Percent Shareholder during the period in which we are a CFC. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Taxation of distributions </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subject to the discussion above under &#8220;PFIC rules,&#8221; distributions paid on ordinary shares or ADSs, other than certain pro rata distributions of ordinary shares or ADSs, will generally be treated as dividends to the extent paid out of our current or accumulated earnings and profits (as determined under U.S. federal income tax principles). Because we may not calculate our earnings and profits under U.S. federal income tax principles, we expect that distributions generally will be reported to U.S. Holders as dividends. Subject to applicable limitations and the discussions above regarding concerns expressed by the U.S. Treasury, dividends paid to certain non-corporate U.S. Holders may be taxable at preferential rates applicable to &#8220;qualified dividend income&#8221; if we are a &#8220;qualified foreign corporation&#8221; and certain other requirements are met. However, the qualified dividend income treatment may not apply if we are treated as a PFIC with respect to the U.S. Holder. The amount of the dividend will be treated as foreign-source dividend income to U.S. Holders and will not be eligible for the dividends-received deduction generally available to U.S. corporations under the Code. Dividends will generally be included in a U.S. Holder&#8217;s income on the date of the U.S. Holder&#8217;s receipt of the dividend. The amount of any dividend income paid in foreign currency will be the U.S. dollar amount calculated by reference to the exchange rate in effect on the date of actual or constructive receipt, regardless of whether the payment is in fact converted into U.S. dollars. If the dividend is converted into U.S. dollars on the date of receipt, a U.S. Holder should not be required to recognize foreign currency gain or loss in respect of the dividend income. A U.S. Holder may have foreign currency gain or loss if the dividend is converted into U.S. dollars after the date of receipt. Such gain or loss would generally be treated as U.S.-source ordinary income or loss. The amount of any distribution of property other than cash (and other than certain pro rata distributions of ordinary shares or ADSs or rights to acquire ordinary shares or ADSs) will be the fair market value of such property on the date of distribution. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For foreign tax credit limitation purposes, our dividends will generally be treated as passive category income. Because no UK income taxes will be withheld from dividends on ordinary shares or ADSs, there will be no creditable foreign taxes associated with any dividends that a U.S. Holder will receive. The rules governing foreign tax credits are complex and U.S. Holders should therefore consult their tax advisers regarding the effect of the receipt of dividends for foreign tax credit limitation purposes. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Sale or other taxable disposition of ordinary shares and ADSs </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subject to the discussion above under &#8220;PFIC rules,&#8221; gain or loss realized on the sale or other taxable disposition of ordinary shares or ADSs will be capital gain or loss and will be long-term capital gain or loss if the U.S. Holder held the ordinary shares or ADSs for more than one year. The amount of the gain or loss will equal the difference between the U.S. Holder&#8217;s tax basis in the ordinary shares or ADSs disposed of and the amount realized on the disposition, in each case as determined in U.S. dollars. This gain or loss will generally be U.S.-source gain or loss for foreign tax credit purposes. The deductibility of capital losses is subject to limitations. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the consideration received by a U.S. Holder is not paid in U.S. dollars, the amount realized will be the U.S. dollar value of the payment received determined by reference to the spot rate of exchange on the date of the sale or other disposition. However, if the ordinary shares or ADSs are treated as traded on an &#8220;established securities market&#8221; and you are either a cash basis taxpayer or an accrual basis taxpayer that has made a special election (which must be applied consistently from year to year and cannot be changed without the consent of the IRS), you will determine the U.S. dollar value of the amount realized in a non-U.S. dollar currency by translating the amount received at the spot rate of exchange on the settlement date of the sale. If you are an accrual basis taxpayer that is not eligible to or does not elect to determine the amount realized using the spot rate on the settlement date, you will recognize foreign currency gain or loss to the extent of any difference between the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">125</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. dollar amount realized on the date of sale or disposition and the U.S. dollar value of the currency received at the spot rate on the settlement date. </span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Information reporting and backup withholding </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payments of dividends and sales proceeds that are made within the United States or through certain U.S.-related financial intermediaries generally are subject to information reporting, and may be subject to backup withholding, unless (i)&#160;the U.S. Holder is a corporation or other exempt recipient or (ii)&#160;in the case of backup withholding, the U.S. Holder provides a correct taxpayer identification number and certifies that it is not subject to backup withholding on a duly executed Form W-9 or otherwise establishes an exemption. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Backup withholding is not an additional tax. The amount of any backup withholding from a payment to a U.S. Holder will be allowed as a credit against the U.S. Holder&#8217;s U.S. federal income tax liability and may entitle the U.S. Holder to a refund, provided that the required information is timely furnished to the IRS. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Information with respect to foreign financial assets </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain U.S. Holders who are individuals (and, under regulations, certain entities) may be required to report information relating to the ordinary shares or ADSs, subject to certain exceptions (including an exception for ordinary shares or ADSs held in accounts maintained by certain U.S. financial institutions), by filing IRS Form 8938 (Statement of Specified Foreign Financial Assets) with their federal income tax return. Such U.S. Holders who fail to timely furnish the required information may be subject to a penalty. Additionally, if a U.S. Holder does not file the required information, the statute of limitations with respect to tax returns of the U.S. Holder to which the information relates may not close until three years after such information is filed. U.S. Holders should consult their tax advisers regarding their reporting obligations with respect to their ownership and disposition of the ordinary shares or ADSs. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">UK Taxation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is intended as a general guide to current UK tax law and HMRC published practice (which is not binding) applying as at the date of this Annual Report on Form 10-K (both of which are subject to change at any time, possibly with retrospective effect) relating to the holding of ADSs. It does not constitute legal or tax advice and does not purport to be a complete analysis of all UK tax considerations relating to the holding of ADSs, or all of the circumstances in which holders of ADSs may benefit from an exemption or relief from UK taxation. It is written on the basis that the company is not (and will not) directly or indirectly at any time derive 75% or more of our qualifying asset value from UK land, and that it is and remains solely resident in the UK for tax purposes and will therefore be subject to the UK tax regime and not the U.S. tax regime save as set out above under &#8220;Material U.S. federal income tax considerations for U.S. Holders.&#8221;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Except to the extent that the position of non-UK resident persons is expressly referred to, this guide relates only to persons who are resident (and in the case of individuals, domiciled or deemed domiciled) for tax purposes solely in the UK and do not have a permanent establishment, branch or agency (or equivalent) in any other jurisdiction with which the holding of the ADSs is connected, or UK Holders, who are absolute beneficial owners of the ADSs (and do not hold the ADSs through an Individual Savings Account or a Self-Invested Personal Pension) and any dividends paid in respect of the ADSs or underlying ordinary shares (where the dividends are regarded for UK tax purposes as that person&#8217;s own income). It is assumed that for the purposes of this guide that a holder of an ADS is the beneficial owner of the underlying ordinary share and any dividend income for UK direct tax purposes. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This guide may not relate to certain classes of UK Holders, such as (but not limited to): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">persons who are connected with the company&#59; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">financial institutions&#59; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">insurance companies&#59; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">charities or tax-exempt organizations&#59; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">collective investment schemes&#59; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pension schemes&#59; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">brokers or dealers in securities or persons who hold ADSs otherwise than as an investment&#59; </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">persons who have (or are deemed to have) acquired their ADSs by virtue of an office or employment or who are or have been officers or employees of the company or any of its affiliates&#59; and </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">individuals who are subject to UK taxation on a remittance basis or to whom split year treatment applies. </p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">126</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">THESE PARAGRAPHS ARE A SUMMARY OF CERTAIN UK TAX CONSIDERATIONS AND ARE INTENDED AS A GENERAL GUIDE ONLY. IT IS RECOMMENDED THAT ALL HOLDERS OF ADSs OBTAIN ADVICE AS TO THE CONSEQUENCES OF THE ACQUISITION, OWNERSHIP AND DISPOSAL OF THE ADSs IN THEIR OWN PARTICULAR CIRCUMSTANCES FROM THEIR OWN TAX ADVISORS. IN PARTICULAR, NON-UK RESIDENT OR DOMICILED PERSONS OR PERSONS SUBJECT TO TAXATION IN ANY JURISDICTION OTHER THAN THE UK ARE ADVISED TO CONSIDER THE POTENTIAL IMPACT OF ANY RELEVANT DOUBLE TAXATION AGREEMENTS. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Dividends </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Withholding Tax </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividends paid by the company will not be subject to any withholding or deduction for or on account of UK tax. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Income Tax </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An individual UK Holder may, depending on his or her particular circumstances, be subject to UK tax on dividends received from the company. An individual holder of ADSs who is not resident for tax purposes in the United Kingdom should not be chargeable to UK income tax on dividends received from the company unless he or she carries on (whether solely or in partnership) a trade, profession or vocation in the UK through a permanent establishment, branch or agency to which the ADSs are attributable. There are certain exceptions for trading in the UK through independent agent, such as some brokers and investment managers.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend income is treated as the top slice of the total income chargeable to UK income tax for an individual UK Holder. An individual UK Holder who receives a dividend in the 2020/2021 tax year will be entitled to a tax-free allowance of &#163;2,000. Income within the dividend allowance counts towards an individual&#8217;s basic or higher rate limits and may, therefore, affect the level of personal allowance to which they are entitled. Dividend income in excess of this tax-free allowance will (subject to the availability of any income tax personal allowance) be charged at 7.5% to the extent the excess amount falls within the basic rate band, 32.5% to the extent the excess amount falls within the higher rate band, and 38.1% to the extent the excess amount falls within the additional rate band. &#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Corporation tax </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A corporate holder of ADSs who is not resident for tax purposes in the United Kingdom should not be chargeable to UK corporation tax on dividends received from the company unless it carries on (whether solely or in partnership) a trade in the United Kingdom through a permanent establishment to which the ADSs are attributable. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate UK Holders should not be subject to UK corporation tax on any dividend received from the company so long as the dividends qualify for exemption, which should be the case, although certain conditions must be met. It should be noted that the exemptions, whilst of wide application, are not comprehensive and are subject to anti-avoidance rules in relation to a dividend. If the conditions for the exemption are not satisfied, or such anti-avoidance provisions apply, or such UK Holder elects for an otherwise exempt dividend to be taxable, UK corporation tax will be chargeable on the amount of any dividends (at the current rate of 19% for the tax year 2020/2021). </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">127</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Chargeable gains </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A disposal or deemed disposal of ADSs by a UK Holder may, depending on the UK Holder&#8217;s circumstances and subject to any available exemptions or reliefs (such as the annual exemption), give rise to a chargeable gain or an allowable loss for the purposes of UK capital gains tax and corporation tax on chargeable gains. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an individual UK Holder who is subject to UK income tax at either the higher or the additional rate is liable to UK capital gains tax on the disposal of ADSs, the applicable rate will be 20% (for the tax year 2020/2021). For an individual UK Holder who is subject to UK income tax at the basic rate and liable to UK capital gains tax on such disposal, the applicable rate would be 10% (for the tax year 2020/2021), save to the extent that any capital gains when aggregated with the UK Holder&#8217;s other taxable income and gains in the relevant tax year exceed the unused basic rate tax band. In that case, the rate applicable to the excess would be 20% (for the tax year 2020/2021). </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a corporate UK Holder becomes liable to UK corporation tax on the disposal (or deemed disposal) of ADSs, the main rate of UK corporation tax (currently 19% for the tax year 2020/2021) would apply. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A holder of ADSs which is not resident for tax purposes in the UK should not normally be liable to UK capital gains tax or corporation tax on chargeable gains on a disposal (or deemed disposal) of ADSs, unless the person is carrying on (whether solely or in partnership) a trade, profession or vocation UK through a branch or agency (or, in the case of a corporate holder of ADSs, through a permanent establishment) to which the ADSs are attributable. However, an individual holder of ADSs who has ceased to be resident for tax purposes in the UK for a period of less than five years and who disposes of ADSs during that period of temporary non-residence may be liable on his or her return to the UK (or upon ceasing to be regarded as resident outside the UK for the purposes of double taxation treaty) to UK tax on any capital gain realized (subject to any available exemption or relief). </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stamp duty and stamp duty reserve tax </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The discussion below relates to the holders of our ordinary shares or ADSs wherever resident, however it should be noted that special rules may apply to certain persons such as market makers, brokers, dealers or intermediaries. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Issue of Ordinary Shares <span style="font-style:normal;">&#160;</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a general rule, no UK stamp duty or stamp duty reserve tax (or SDRT) is payable on the issue of underlying ordinary shares in the company. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Transfers of Ordinary Shares </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An unconditional agreement to transfer ordinary shares will normally give rise to a charge to SDRT at the rate of 0.5% of the amount or value of the consideration payable for the transfer. The purchaser of the shares is liable for the SDRT. Transfers of ordinary shares in certificated form are generally also subject to stamp duty at the rate of 0.5% of the amount or value of the consideration given for the transfer (rounded up to the next &#163;5.00). Stamp duty is normally paid by the purchaser. The charge to SDRT will be cancelled or, if already paid, repaid (generally with interest), where a transfer instrument has been duly stamped within six years of the charge arising, (either by paying the stamp duty or by claiming an appropriate relief) or if the instrument is otherwise exempt from stamp duty. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Clearance Services and Depositary Receipts</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under current UK legislation, an issue or transfer of ordinary shares or an unconditional agreement to transfer ordinary shares to a clearance service or a depositary receipt system (including, to a nominee or agent for, a person whose business is or includes the issue of depositary receipts or the provision of clearance services) will generally be subject to SDRT (and, in the case of transfers, where the transfer is effected by a written instrument, stamp duty) at a higher rate of 1.5% of the amount or value of the consideration given for the transfer unless the clearance service has made and maintained an election under section 97A of the UK Finance Act 1986, or a section 97A election. It is understood that HMRC regards the facilities of DTC as a clearance service for these purposes and we are not aware of any section 97A election having been made by the DTC. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">However, based on current published HMRC practice following European Union case law in respect of the European Council Directives 69/335/EEC and 2009/7/EC, or the Capital Duties Directives, no SDRT is generally payable in respect of such an issue of ordinary shares and no SDRT or stamp duty is generally payable in respect of such a transfer of ordinary shares </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">128</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">where such transfer is an integral part of an issue of share capital. This position was reaffirmed by HMRC in their January 2021 Newsletter where they confirmed that the SDRT 1.5% charge on issues (or transfers integral to capital raising) remained disapplied under the terms of the European Union (Withdrawal) Act 2018 following the end of the transition period and that this would remain the position unless stamp taxes on shares legislation was amended. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Any stamp duty or SDRT payable on a transfer of ordinary shares to a depositary receipt system or clearance service will in practice generally be paid by the transferors or participants in the clearance service or depositary receipt system. Specific professional advice should be sought before incurring or reimbursing the costs of a 1.5% charge.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Transfers of ADSs </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No UK SDRT or stamp duty is required to be paid in respect of the issue of or an agreement to transfer ADS (including by way of a paperless transfer of ADSs through the facilities of DTC). </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item 9C. <span style="color:#000000;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</span></p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">129</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="PART_III">PART III </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_10_DIRECTORS_EXECUTIVE_FICERS_CORPO">Item 10. Directors, Executive Officers and Corporate Governance. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required under this item is incorporated herein by reference to our definitive proxy statement for our 2022 annual general meeting to be filed with the U.S. Securities and Exchange Commission. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_11_EXECUTIVE_COMPENSATION">Item 11. Executive Compensation. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required under this item is incorporated herein by reference to our definitive proxy statement for our 2022 annual general meeting to be filed with the U.S. Securities and Exchange Commission.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required under this item is incorporated herein by reference to our definitive proxy statement for our 2022 annual general meeting to be filed with the U.S. Securities and Exchange Commission.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_TR">Item 13. Certain Relationships and Related Transactions, and Director Independence. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required under this item is incorporated herein by reference to our definitive proxy statement for our 2022 annual general meeting to be filed with the U.S. Securities and Exchange Commission.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_14_PRINCIPAL_ACCOUNTING_FEES_SERVIC">Item 14. Principal Accounting Fees and Services. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required under this item is incorporated herein by reference to our definitive proxy statement for our 2022 annual general meeting to be filed with the U.S. Securities and Exchange Commission.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">130</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="PART_IV">PART IV </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_15_EXHIBITS_FINANCIAL_STATEMENT_SCH">Item 15. Exhibits, Financial Statement Schedules. </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following documents are filed as part of this Annual Report on Form&#160;10-K:</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) (1)<span style="font-style:italic;">&#160;Financial Statements</span>:</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The financial statements required by this item are submitted in a separate section beginning on page F-1 of this Report, as follows:</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="width:85.21%;"></td>
<td style="width:4.79%;"></td>
<td style="width:10%;"></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Page</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC"><span style="text-decoration:underline;">Report of Independent Registered Public Accounting Firm</span></a></p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-2</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_BALANCE_SHEETS"><span style="text-decoration:underline;">Consolidated Balance Sheets</span></a></p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-4</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_OPERATIONS_COMPR"><span style="text-decoration:underline;">Consolidated Statements of Operations and Comprehensive Loss</span></a></p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-5</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_SHAREHOLDERS_EQU"><span style="text-decoration:underline;">Consolidated Statements of Shareholders&#8217; Equity</span></a></p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-6</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_CASH_FLOWS"><span style="text-decoration:underline;">Consolidated Statements of Cash Flows</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-7</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#NOTES_TO_CONSOLIDATED_FINANCIAL_STATEMEN"><span style="text-decoration:underline;">Notes to Consolidated Financial Statements</span></a></p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-8</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:2pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) (2)<span style="font-style:italic;">&#160;Financial Statement Schedules</span>:</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) (3)<span style="font-style:italic;">&#160;Exhibits</span>:</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Exhibits which are filed as part of this Annual Report or which are incorporated by reference are set forth in the Exhibit Index hereto.</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="EXHIBIT_INDEX">EXHIBIT INDEX</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.64%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:12.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Incorporated by Reference herein from Form or Schedule</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:5.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:2.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:12.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">File Date</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:10.58%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">File Number</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.64%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.82%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:5.82%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.24%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.58%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">2.1</span>&#8224;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1748907/000119312518293354/d566761dex21.htm"><span style="text-decoration:underline;">Asset Purchase and License Agreement, by and among the registrant, Glaxo Group Limited and GlaxoSmithKline Intellectual Property Development Ltd., dated April&#160;11, 2018 (Schedules, exhibits, and similar supporting attachments are omitted pursuant to Item&#160;601(b)(2)&#160;of&#160;Regulation&#160;S-K.&#160;The&#160;registrant agrees to furnish a supplemental copy of any omitted schedule or similar attachment to the Securities and Exchange Commission upon request).</span></a></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">Form F-1</span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:5.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">2.1</span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">Oct. 4, 2018</span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">333-227698</span></p></td>
</tr>
<tr style="height:1pt;">
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:5.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">3.1</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1748907/000156459020029938/ortx-ex31_7.htm"><span style="text-decoration:underline;">A</span><span style="text-decoration:underline;">rticles of Association of Orchard Therapeutics plc</span></a></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">Form 8-K</span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:5.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">3.1</span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">Jun. 19, 2020</span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">001-38722</span></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:5.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">4.1</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1748907/000156459019008892/ortx-ex21_206.htm"><span style="text-decoration:underline;">D</span><span style="text-decoration:underline;">eposit Agreement</span></a></p></td>
<td valign="top" style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:12.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">Form 20-F</span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:5.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">2.1</span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">Mar. 22, 2019</span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">001-38722</span></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:5.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">4.2</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1748907/000156459019008892/ortx-ex21_206.htm"><span style="text-decoration:underline;">Form of American Depositary Receipt (included in Exhibit 4.1)</span></a></p></td>
<td valign="top" style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:12.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">Form 20-F</span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:5.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">2.2</span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">Mar. 22, 2019</span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">001-38722</span></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:5.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">4.3</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1748907/000119312519164149/d708154dex101.htm"><span style="text-decoration:underline;">Investment and shareholders&#8217; agreement by and between the registrant and the shareholders named therein, dated August&#160;2, 2018, as amended</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top" style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:12.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">Form F-1</span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:5.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">10.1</span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">Jun. 3, 2019</span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">333-231916</span></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:5.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">4.4</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1748907/000156459020007353/ortx-ex44_422.htm"><span style="text-decoration:underline;">Description of the registrant&#8217;s securities</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top" style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:12.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">Form 10-K</span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:5.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">4.4</span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">Feb. 27, 2020</span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">001-38722</span></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:5.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">131</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">10.1#</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1748907/000119312518293354/d566761dex102.htm"><span style="text-decoration:underline;">2016 Employee Share Option Plan with&#160;Non-Employee&#160;Sub-Plan&#160;and U.S.&#160;Sub-Plan,&#160;as amended.</span></a></p></td>
<td valign="top" style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:12.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">Form F-1</span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:5.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">10.2</span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">Oct. 4, 2018</span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">333-227698</span></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:5.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">10.2#</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1748907/000156459019008892/ortx-ex43_468.htm"><span style="text-decoration:underline;">2018 Share Option and Incentive Plan</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top" style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:12.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">Form 20-F</span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:5.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">4.3</span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">Mar. 22, 2019</span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">001-38722</span></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:5.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">10.3#</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1748907/000119312518304629/d566761dex1010.htm"><span style="text-decoration:underline;">2018 Employee Share Purchase Plan</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top" style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">Form F-1/A</span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:5.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">10.10</span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">Oct. 23, 2018</span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">333-227698</span></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:5.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">10.4#</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1748907/000156459020007353/ortx-ex1013_420.htm"><span style="text-decoration:underline;">Forms of aw</span><span style="text-decoration:underline;">ard agreements under the 2018 Share Option and Incentive Plan</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top" style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">Form 10-K</span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:5.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">10.13</span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">Feb. 27, 2020</span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">001-38722</span></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:5.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">10.5#</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1748907/000156459020022822/ortx-ex101_170.htm"><span style="text-decoration:underline;">2019 Short-Term Incentive Plan</span></a><span style="text-decoration:none;">.</span></p></td>
<td valign="top" style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">Form 10-Q</span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:5.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">10.1</span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">May 7, 2020</span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">001-38722</span></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:5.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">10.6#</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1748907/000119312520211883/d947729dex992.htm"><span style="text-decoration:underline;">2020 Inducement Equity Plan and forms of award agreements thereunder</span></a><span style="text-decoration:none;">.</span></p></td>
<td valign="top" style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form S-8</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:5.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.2</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Aug. 6 2020</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-241646</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:5.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">10.7#</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1748907/000119312518293354/d566761dex106.htm"><span style="text-decoration:underline;">Form of Deed of Indemnity between the registrant and each of its directors and executive officers.</span></a></p></td>
<td valign="top" style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">Form F-1</span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:5.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">10.6</span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">Oct. 4, 2018</span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">333-227698</span></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:5.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">10.8</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1748907/000119312518293354/d566761dex104.htm"><span style="text-decoration:underline;">Deed of Novation, by and among the registrant, Glaxo Group Limited, GlaxoSmithKline Intellectual Property Development Limited, GlaxoSmithKline S.p.A., Fondazione Telethon and Ospedale San Raffaele (in its own capacity and as successor in interest to Fondazione Centro San Raffaele Del Monte Tabor), dated April&#160;5, 2018</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top" style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:12.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">Form F-1</span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:5.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">10.4</span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">Oct. 4, 2018</span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">333-227698</span></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:5.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">10.9</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1748907/000119312518293354/d566761dex105.htm"><span style="text-decoration:underline;">Research and Development Collaboration and License Agreement, by and among Glaxo Group Limited, Fondazione Telethon and Fondazione Centro San Raffaele del Monte Tabor, dated October&#160;15, 2010, as amended</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top" style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:12.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">Form F-1</span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:5.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">10.5</span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">Oct. 4, 2018</span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">333-227698</span></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:5.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">10.10</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1748907/000119312521033294/d100234dex101.htm"><span style="text-decoration:underline;">Securities Purchase Agreement dated February 4, 2021, by and among Orchard Therapeutics plc and the Purchasers named therein</span></a></p></td>
<td valign="top" style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">Form 10-Q</span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:5.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">10.1</span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">May 13, 2021</span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">001-38722</span></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:5.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">10.11</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1748907/000119312518293354/d566761dex107.htm"><span style="text-decoration:underline;">Lease Agreement, dated as of January&#160;19, 2018, by and between the Registrant and New Connect Investments Limited</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top" style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:12.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">Form F-1</span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:5.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">10.7</span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">Oct. 4, 2018</span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">333-227698</span></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:5.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">10.12</span>&#8224;&#8224;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1748907/000156459019013383/ortx-ex412_7.htm"><span style="text-decoration:underline;">Lease Agreement, dated as of December 11, 2018, by and between BPP Pacific Industrial CA Non-REIT Owner 2 LLC and Orchard Therapeutics North America.</span></a></p></td>
<td valign="top" style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">Form 20-F/A</span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:5.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">4.12</span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">Apr. 26, 2019</span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">001-38722</span></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:5.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">10.13</span>&#8224;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1748907/000119312518293354/d566761dex108.htm"><span style="text-decoration:underline;">License and Development Agreement, by and between the registrant and Oxford BioMedica (UK) Limited, dated November&#160;28, 2016, as amended</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top" style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:12.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">Form F-1</span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:5.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">10.8</span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">Oct. 4, 2018</span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">333-227698</span></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:5.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">10.14</span>&#8224;&#8224;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1748907/000156459020022822/ortx-ex102_168.htm"><span style="text-decoration:underline;">Amendment Nos. 5 and 6 to License and Development Agreement, by and between the registrant and Oxford BioMedica (UK) Limited, dated November 28, 2016.</span></a></p></td>
<td valign="top" style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:12.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">Form 10-Q</span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:5.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">10.2</span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">May 7, 2020</span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">001-38722</span></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:5.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">10.15</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001748907/000156459021040496/ortx-ex101_12.htm"><span style="Background-color:#FFFFFF;text-decoration:underline;">Senior Term Facilities Agreement, dated May 24, 2019, as amended and restated on May 28, 2021, among Orchard Therapeutics plc, the entities listed as original guarantors therein,&#160;MidCap Financial (Ireland) Limited, and the additional lenders party thereto from time to time.</span></a></p></td>
<td valign="top" style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:12.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">Form 10-Q</span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:5.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">10.1</span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">Aug. 4, 2021</span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">001-38722</span></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:5.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">10.</span><span style="Background-color:#FFFFFF;">1</span><span style="Background-color:#FFFFFF;">6</span><span style="Background-color:#FFFFFF;">#</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1748907/000156459020007353/ortx-ex1015_424.htm"><span style="text-decoration:underline;">Employment Agreement between the registrant, Orchard Therapeutics North America, and Frank Thomas, effective September 1, 2019</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top" style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:12.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">Form 10-K</span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:5.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">10.15</span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">Feb. 27, 2020</span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">001-38722</span></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:5.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">10.17#</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1748907/000119312520080654/d901945dex104.htm"><span style="text-decoration:underline;">First Amendment to Employment Agreement, dated March 18, 2020, by and among the Company, Orchard Therapeutics North America and Frank Thomas.</span></a></p></td>
<td valign="top" style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:12.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">Form 8-K</span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:5.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">10.4</span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">Mar. 20, 2020</span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">001-38722</span></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:12.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:5.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">10.18#</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001748907/000156459021054252/ortx-ex101_194.htm"><span style="Background-color:#FFFFFF;text-decoration:underline;">Transitional Services Agreement, dated November 3, 2021, between the Company, Orchard Therapeutics North America and Frank Thomas.</span></a></p></td>
<td valign="top" style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:12.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">Form 10-Q</span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:5.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">10.1</span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">Nov. 4, 2021</span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">001-38722</span></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:5.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">10.19*#</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="ortx-ex1019_562.htm"><span style="Background-color:#FFFFFF;text-decoration:underline;">Amendment to the Transitional Services Agreement, dated March 30, 2022, between the Company, Orchard Therapeutics North America and Frank Thomas.</span></a></p></td>
<td valign="top" style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:12.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:5.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:5.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">10.20#</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1748907/000156459020007353/ortx-ex1016_421.htm"><span style="text-decoration:underline;">Contract of Employment between Orchard Therapeutics (Europe) Limited and Hubert Gaspar, dated January 8, 2018, as amended, effective May 24, 2019</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top" style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:12.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">Form 10-K</span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:5.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">10.16</span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">Feb. 27, 2020</span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">001-38722</span></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:5.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">10.21#</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1748907/000119312520080654/d901945dex103.htm"><span style="text-decoration:underline;">Variation to Contract of Employment, dated March 18, 2020, by and between Orchard Therapeutics (Europe) Limited and Hubert Gaspar, M.D., Ph.D.</span></a></p></td>
<td valign="top" style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:12.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">Form 8-K</span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:5.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">10.3</span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">Mar. 20, 2020</span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">001-38722</span></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:5.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">10.22</span>&#8224;&#8224;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1748907/000156459020037239/ortx-ex101_173.htm"><span style="text-decoration:underline;">Manufacturing and Technology Development Master Agreement, by and between Orchard Therapeutics (Europe) Limited, a wholly-owned subsidiary of the registrant, and MolMed S.p.A., dated July 2, 2020</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top" style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:12.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">Form 10-Q</span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:5.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">10.1</span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">Aug. 6, 2020</span></p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">001-38722</span></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:12.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:5.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">21.1*</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="ortx-ex211_7.htm"><span style="text-decoration:underline;">List of Subsidiaries.</span></a></p></td>
<td valign="top" style="width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:12.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:5.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:5.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">23.1*</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="ortx-ex231_6.htm"><span style="text-decoration:underline;">Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm</span></a></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:5.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:5.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31.1*</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="ortx-ex311_8.htm"><span style="Background-color:#FFFFFF;text-decoration:underline;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span><span style="Background-color:#FFFFFF;font-family:Arial;text-decoration:underline;">.</span></a></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:5.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:5.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">31.2*</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="ortx-ex312_10.htm"><span style="Background-color:#FFFFFF;text-decoration:underline;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:5.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:5.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">32.1*</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="ortx-ex321_9.htm"><span style="Background-color:#FFFFFF;text-decoration:underline;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:5.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:5.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">32.2*</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="ortx-ex322_11.htm"><span style="Background-color:#FFFFFF;text-decoration:underline;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:5.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:5.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">101.INS*</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Instance Document</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:5.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr style="height:4.65pt;">
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:5.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">133</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">101.SCH*</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Schema Document</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:5.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:5.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">101.CAL*</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:5.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:5.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">101.DEF*</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Definition Linkbase Document</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:5.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:5.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">101.LAB*</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Label Linkbase Document</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:5.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:5.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:2.75pt;">
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">101.PRE*</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:5.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr style="height:2.75pt;">
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:5.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr style="height:2.75pt;">
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">104</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cover Page Interactive Data File (formatted as Inline XBRL with applicable taxonomy extension information contained in Exhibits 101).</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:5.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:12.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:2.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:10.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
</table></div>
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:89.29%;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</span></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Filed herewith.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8224;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Confidential treatment has been granted for portions of this exhibit. These portions have been omitted from the registration statement and filed separately with the United States Securities and Exchange Commission.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8224;&#8224;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Portions of this exhibit (indicated by asterisks) were omitted in accordance with the rules of the Securities and Exchange Commission</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">#</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Indicates a management contract or any compensatory plan, contract or arrangement.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:-4.86%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_16_FORM_10K_SUMMARY">Item 16. Form 10-K Summary</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable.<span style="font-weight:bold;"> </span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">134</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="SIGNATURES">SIGNATURES</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ORCHARD THERAPEUTICS PLC</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 30, 2022</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Bobby Gaspar</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bobby Gaspar</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">POWER OF ATTORNEY</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We, the undersigned officers and directors of Orchard Therapeutics plc, hereby severally constitute and appoint Bobby Gaspar and Frank E. Thomas, and each of them singly (with full power to each of them to act alone), our true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution in each of them for him and in his name, place and stead, and in any and all capacities, to sign for us and in our names in the capacities indicated below any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto and other documents in connection therewith, with the U.S. Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as full to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Annual Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.66%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Signature</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Title</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.66%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.94%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.82%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.66%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Bobby Gaspar</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer and Director </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 30, 2022</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.66%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bobby Gaspar</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.66%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Frank E. Thomas</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Operating Officer </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Financial Officer and Principal Accounting Officer)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 30, 2022</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.66%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Frank E. Thomas</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.66%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;James A. Geraghty</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chairman of the Board of Directors</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 30, 2022</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.66%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">James A. Geraghty</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.66%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Steven M. Altschuler</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 30, 2022</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.66%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Steven M. Altschuler, M.D.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.66%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Joanne T. Beck</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 30, 2022</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.66%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Joanne T. Beck, Ph.D.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.66%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;John Curnutte</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 30, 2022</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.66%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">John Curnutte, M.D., Ph.D.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.66%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Marc Dunoyer</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 30, 2022</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.66%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marc Dunoyer</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.66%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Charles A. Rowland, Jr.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 30, 2022</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.66%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Charles A. Rowland, Jr.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.66%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Alicia Secor</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 30, 2022</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.66%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Alicia Secor</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">135</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="Auditor_Report">INDEX TO THE FINANCIAL STATEMENTS</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="width:89%;"></td>
<td style="width:1%;"></td>
<td style="width:10%;"></td>
</tr>
<tr style="height:1pt;">
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Page</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC"><span style="text-decoration:underline;">Report of Independent Registered Public Accounting Firm</span></a><span style="text-decoration:underline;"> (PCAOB ID <ix:nonNumeric id="F_000030" name="dei:AuditorFirmId" contextRef="C_0001748907_20210101_20211231">238</ix:nonNumeric>)</span></p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-2</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_BALANCE_SHEETS"><span style="text-decoration:underline;">Consolidated Balance Sheets</span></a></p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-4</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_OPERATIONS_COMPR"><span style="text-decoration:underline;">Consolidated Statements of Operations and Comprehensive Loss</span></a></p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-5</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_SHAREHOLDERS_EQU"><span style="text-decoration:underline;">Consolidated Statements of Shareholders&#8217; Equity</span></a></p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-6</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_CASH_FLOWS"><span style="text-decoration:underline;">Consolidated Statements of Cash Flows</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-7</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#NOTES_TO_CONSOLIDATED_FINANCIAL_STATEMEN"><span style="text-decoration:underline;">Notes to Consolidated Financial Statements</span></a></p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-8</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-1</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;" id="eXC_Paragraph_10">&#160;</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the Board of Directors and Shareholders of Orchard Therapeutics plc</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;" id="eXC_Paragraph_11">Opinion on the Financial Statements</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;" id="eXC_Paragraph_12">We have audited the accompanying consolidated balance sheets of Orchard Therapeutics plc and its subsidiaries (the &#8220;Company&#8221;) as of December 31, 2021 and 2020, and the related consolidated statements of operations and comprehensive loss, of shareholders' equity and of cash flows for the years then ended, including the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2021 and 2020, and the results of its operations and its cash flows for the years then ended in conformity with accounting principles generally accepted in the United States of America.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;text-transform:none;font-variant: normal;" id="eXC_Paragraph_16">Basis for Opinion</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;" id="Paragraph_13">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;" id="Paragraph_14">We conducted our audits of these consolidated financial statements in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;" id="Paragraph_18">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Critical Audit Matters</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that (i) relates to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">United Kingdom (U.K.) Research and Development Tax Credits </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As described in Note 2 to the consolidated financial statements,<span style="font-weight:bold;font-style:italic;"> </span>the Company carries out research and development activities and is able to submit tax credit claims under two U.K. research and development tax relief programs, the Small and Medium-sized Enterprises research and development tax credit (&#8220;SME&#8221;) <span style="color:#000000;">program and </span>the Research and Development Expenditure Credit (&#8220;RDEC&#8221;) program, depending on eligibility. Each reporting period, management evaluates the tax relief programs the Company is expected to be eligible for and records a reduction to research and development expense for the portion of the expense that it expects to qualify under the programs, that it plans to submit a claim for, and it has reasonable assurance that the amount will ultimately be realized. <span style="color:#000000;"> Management assesses its research and development activities and expenditures to determine </span>whether the nature of the activities and expenditures will qualify for credit under the tax relief programs and whether the claims will ultimately be realized based on the allowable reimbursable expense criteria established by the U.K. government, which are subject to interpretation. For the year ended December 31, 2021, the Company <span style="color:#000000;">recorded $13.9 million </span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-2</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;">as a reduction of research and development expense related to these programs and has a related tax credit receivable of $</span><span style="color:#000000;">30.7</span><span style="color:#000000;"> million</span><span style="color:#000000;"> </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as of December 31, 2021. </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The principal considerations for our determination that performing procedures relating to the U.K. research and development tax credits is a critical audit matter are (i)<span style="font-style:italic;"> </span>the significant judgment by management when determining the nature and amount of expenses that qualify under the tax relief programs and estimating the amount of tax credit claims that will ultimately be realized based on the criteria established by the U.K. government&#59; (ii) a high degree of auditor judgment, subjectivity, and effort in performing procedures and evaluating audit evidence relating to the U.K. research and development tax credits&#59; and (iii) the audit effort involved the use of professionals with specialized skill and knowledge.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included, among others (i) testing management&#8217;s process for determining the programs the Company expects to qualify for and file tax credit claims under and the total qualifying expenses claimed or to be claimed, (ii) evaluating the reasonableness of management&#8217;s assessment of the amount expected to be realized considering the relevant criteria outlined in the tax relief programs, and (iii) testing the completeness and accuracy of the data underlying the tax credit calculations. Professionals with specialized skill and knowledge were used to assist in evaluating management&#8217;s assessment of the U.K. research and development tax relief programs the Company expects to qualify for and file tax credit claims under, testing management&#8217;s research and development tax credit calculations, and evaluating the reasonableness of management&#8217;s assessment of the amount expected to be realized.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;" id="eXC_Paragraph_30">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ <ix:nonNumeric id="F_000034" name="dei:AuditorName" contextRef="C_0001748907_20210101_20211231">PricewaterhouseCoopers LLP</ix:nonNumeric></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000035" name="dei:AuditorLocation" contextRef="C_0001748907_20210101_20211231">Boston, Massachusetts</ix:nonNumeric></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;" id="eXC_Paragraph_31">March 30, 2022</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;" id="Paragraph_26">We have served as the Company&#8217;s auditor since 2019.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-3</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Orchard Therapeutics plc </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="CONSOLIDATED_BALANCE_SHEETS">Consolidated Balance Sheets </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(In&#160;thousands, except share and per share amounts) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current assets:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000036" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">55,912</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000037" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001748907_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">55,135</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000038" name="us-gaap:MarketableSecurities" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">164,195</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000039" name="us-gaap:MarketableSecurities" contextRef="C_0001748907_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">136,813</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000040" name="us-gaap:AccountsReceivableNetCurrent" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,480</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000041" name="us-gaap:AccountsReceivableNetCurrent" contextRef="C_0001748907_20201231" decimals="-3" scale="3">878</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000042" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">23,011</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000043" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_0001748907_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">13,365</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development tax credit receivable</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000044" name="ortx:ResearchAndDevelopmentTaxCreditReceivableCurrent" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">30,723</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000045" name="ortx:ResearchAndDevelopmentTaxCreditReceivableCurrent" contextRef="C_0001748907_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">17,344</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000046" name="us-gaap:AssetsCurrent" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">275,321</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000047" name="us-gaap:AssetsCurrent" contextRef="C_0001748907_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">223,535</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-current assets:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease right-of-use-assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000048" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">24,316</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000049" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0001748907_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">29,815</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000050" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,767</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000051" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001748907_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,781</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000052" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,266</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000053" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" contextRef="C_0001748907_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,266</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000054" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,149</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000055" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="C_0001748907_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,076</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000056" name="us-gaap:OtherAssetsNoncurrent" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,590</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000057" name="us-gaap:OtherAssetsNoncurrent" contextRef="C_0001748907_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">15,464</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total non-current assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000058" name="us-gaap:AssetsNoncurrent" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">47,088</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000059" name="us-gaap:AssetsNoncurrent" contextRef="C_0001748907_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">57,402</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000060" name="us-gaap:Assets" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">322,409</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000061" name="us-gaap:Assets" contextRef="C_0001748907_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">280,937</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liabilities and shareholders&#8217; equity</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current liabilities:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000062" name="us-gaap:AccountsPayableCurrent" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">10,008</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000063" name="us-gaap:AccountsPayableCurrent" contextRef="C_0001748907_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,823</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses and other current liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000064" name="ortx:AccruedExpensesAndOtherCurrentLiabilities" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">24,318</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000065" name="ortx:AccruedExpensesAndOtherCurrentLiabilities" contextRef="C_0001748907_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">28,943</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000066" name="us-gaap:DeferredRevenueCurrent" contextRef="C_0001748907_20211231" decimals="-3" scale="3">346</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000067" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,335</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000068" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_0001748907_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,934</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notes payable, current</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000069" name="us-gaap:NotesPayableCurrent" contextRef="C_0001748907_20211231" decimals="-3" scale="3">786</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000070" name="us-gaap:NotesPayableCurrent" contextRef="C_0001748907_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,861</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000071" name="us-gaap:LiabilitiesCurrent" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">42,793</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000072" name="us-gaap:LiabilitiesCurrent" contextRef="C_0001748907_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">51,561</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notes payable, long-term</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000073" name="us-gaap:LongTermNotesPayable" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">32,086</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000074" name="us-gaap:LongTermNotesPayable" contextRef="C_0001748907_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">20,204</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue, net of current portion</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000075" name="us-gaap:DeferredRevenueNoncurrent" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">12,519</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities, net of current portion</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000076" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">19,278</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000077" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_0001748907_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">24,168</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other long-term liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000078" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,783</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000079" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="C_0001748907_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,570</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000080" name="us-gaap:Liabilities" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">112,459</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000081" name="us-gaap:Liabilities" contextRef="C_0001748907_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">102,503</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commitments and contingencies (Note 18)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000082">&#160;</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000083">&#160;</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shareholders&#8217; equity:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ordinary shares, &#163;<ix:nonFraction unitRef="U_iso4217GBP_xbrlishares" id="F_000096" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001748907_20211231" decimals="INF"><ix:nonFraction unitRef="U_iso4217GBP_xbrlishares" id="F_000097" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001748907_20201231" decimals="INF">0.10</ix:nonFraction></ix:nonFraction> par value, authority to allot up to a maximum nominal</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; value of &#163;<ix:nonFraction unitRef="U_iso4217GBP" id="F_000098" name="ortx:CommonStockSharesAuthorizedNominalAmount" contextRef="C_0001748907_20211231" decimals="2" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_iso4217GBP" id="F_000099" name="ortx:CommonStockSharesAuthorizedNominalAmount" contextRef="C_0001748907_20201231" decimals="2" format="ixt:numdotdecimal">13,023,851.50</ix:nonFraction></ix:nonFraction> of shares at December 31, 2021 and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; 2020, respectively&#59; <ix:nonFraction unitRef="U_xbrlishares" id="F_000100" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001748907_20211231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000102" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001748907_20211231" decimals="INF" format="ixt:numdotdecimal">125,674,095</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="U_xbrlishares" id="F_000101" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001748907_20201231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000103" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001748907_20201231" decimals="INF" format="ixt:numdotdecimal">98,283,603</ix:nonFraction></ix:nonFraction> shares issued and outstanding</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; at December 31, 2021 and 2020, respectively.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000084" name="us-gaap:CommonStockValue" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">16,253</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000085" name="us-gaap:CommonStockValue" contextRef="C_0001748907_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">12,507</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional paid-in capital</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000086" name="us-gaap:AdditionalPaidInCapital" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">940,675</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000087" name="us-gaap:AdditionalPaidInCapital" contextRef="C_0001748907_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">771,194</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated other comprehensive income</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000088" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,246</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000089" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001748907_20201231" decimals="-3" scale="3">373</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000090" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0001748907_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">750,224</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000091" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0001748907_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">605,640</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total shareholders&#8217; equity</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000092" name="us-gaap:StockholdersEquity" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">209,950</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000093" name="us-gaap:StockholdersEquity" contextRef="C_0001748907_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">178,434</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities and shareholders&#8217; equity</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000094" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">322,409</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000095" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_0001748907_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">280,937</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these consolidated financial statements.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-4</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Orchard Therapeutics plc </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="CONSOLIDATED_STATEMENTS_OPERATIONS_COMPR">Consolidated Statements of Operations and Comprehensive Loss </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(In&#160;thousands, except share and per share amounts) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Year Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product sales, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000104" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001748907_srtProductOrServiceAxis_us-gaapProductMember_20210101_20211231" decimals="-3" scale="3">700</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000105" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001748907_srtProductOrServiceAxis_us-gaapProductMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,595</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Collaboration revenue</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000106" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001748907_srtProductOrServiceAxis_ortxCollaborationMember_20210101_20211231" decimals="-3" scale="3">975</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenues</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000107" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001748907_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,675</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000108" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001748907_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,595</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Costs and operating expenses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of product sales</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000109" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="C_0001748907_20210101_20211231" decimals="-3" scale="3">226</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000110" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="C_0001748907_20200101_20201231" decimals="-3" scale="3">857</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000112" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001748907_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">86,977</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000113" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001748907_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">93,730</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000114" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="C_0001748907_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">54,905</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000115" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="C_0001748907_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">64,986</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total costs and operating expenses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000116" name="us-gaap:CostsAndExpenses" contextRef="C_0001748907_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">142,108</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000117" name="us-gaap:CostsAndExpenses" contextRef="C_0001748907_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">159,573</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000118" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001748907_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">140,433</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000119" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001748907_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">156,978</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other (expense) income:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000120" name="us-gaap:InvestmentIncomeInterest" contextRef="C_0001748907_20210101_20211231" decimals="-3" scale="3">412</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000121" name="us-gaap:InvestmentIncomeInterest" contextRef="C_0001748907_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,185</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000122" name="us-gaap:InterestExpense" contextRef="C_0001748907_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,497</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000123" name="us-gaap:InterestExpense" contextRef="C_0001748907_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,328</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other (expense) income, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000124" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="C_0001748907_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,238</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000125" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="C_0001748907_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,411</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other (expense) income, net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000126" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_0001748907_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">3,323</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000127" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_0001748907_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,268</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss before income tax</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000128" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_0001748907_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">143,756</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000129" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_0001748907_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">152,710</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax (expense) benefit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000130" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0001748907_20210101_20211231" decimals="-3" scale="3">828</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000131" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0001748907_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">731</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to ordinary shareholders</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000132" name="us-gaap:NetIncomeLoss" contextRef="C_0001748907_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">144,584</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000133" name="us-gaap:NetIncomeLoss" contextRef="C_0001748907_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">151,979</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributable to ordinary shareholders, basic and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; diluted</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000134" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0001748907_20210101_20211231" decimals="2" sign="-">1.17</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000135" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0001748907_20200101_20201231" decimals="2" sign="-">1.53</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average number of ordinary shares outstanding, basic and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; diluted</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000136" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001748907_20210101_20211231" decimals="0" format="ixt:numdotdecimal">123,963,762</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000137" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001748907_20200101_20201231" decimals="0" format="ixt:numdotdecimal">99,445,874</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other comprehensive income (loss)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign currency translation adjustment</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000138" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0001748907_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,124</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000139" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0001748907_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,485</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized loss on marketable debt securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000140" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_0001748907_20210101_20211231" decimals="-3" sign="-" scale="3">251</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000141" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_0001748907_20200101_20201231" decimals="-3" sign="-" scale="3">184</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other comprehensive income (loss)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000142" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001748907_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,873</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000143" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001748907_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,669</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total comprehensive loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000144" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="C_0001748907_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">141,711</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000145" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="C_0001748907_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">153,648</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these consolidated financial statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-5</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Orchard Therapeutics plc </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="CONSOLIDATED_STATEMENTS_SHAREHOLDERS_EQU">Consolidated Statements of Shareholders&#8217; Equity </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(In&#160;thousands, except share amounts) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:26.74%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ordinary shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.8%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.6%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">other</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.8%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.8%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:26.74%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additional</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">paid-in capital</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.6%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">comprehensive</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">income (loss)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">deficit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:26.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2019</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000146" name="us-gaap:SharesOutstanding" contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231" decimals="INF" format="ixt:numdotdecimal">96,923,729</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000147" name="us-gaap:StockholdersEquity" contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">12,331</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000148" name="us-gaap:StockholdersEquity" contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">738,481</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.6%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000149" name="us-gaap:StockholdersEquity" contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,042</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000150" name="us-gaap:StockholdersEquity" contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">453,661</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000151" name="us-gaap:StockholdersEquity" contextRef="C_0001748907_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">299,193</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share-based compensation expense</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000152" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">27,962</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.6%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000153" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_0001748907_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">27,962</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise of share options</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000154" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">1,154,441</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000155" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="-3" scale="3">149</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000156" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,316</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000157" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001748907_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,465</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of ESPP shares</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000158" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">107,262</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000159" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="-3" scale="3">14</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000160" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" scale="3">657</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000161" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="C_0001748907_20200101_20201231" decimals="-3" scale="3">671</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ordinary shares issued as part of consulting agreement</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000162" name="ortx:StockIssuedDuringPeriodSharesAsPartOfConsultingAgreement" contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">22,758</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000163" name="ortx:StockIssuedDuringPeriodValueAsPartOfConsultingAgreement" contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="-3" scale="3">3</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000164" name="ortx:StockIssuedDuringPeriodValueAsPartOfConsultingAgreement" contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" sign="-" scale="3">3</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ordinary shares issued as part of license agreement</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000165" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">75,413</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000166" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="-3" scale="3">10</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000167" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" scale="3">781</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000168" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="C_0001748907_20200101_20201231" decimals="-3" scale="3">791</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign currency translation</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000169" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,485</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000170" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0001748907_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,485</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized gain on marketable debt securities</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000171" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231" decimals="-3" sign="-" scale="3">184</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000172" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" contextRef="C_0001748907_20200101_20201231" decimals="-3" sign="-" scale="3">184</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:26.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000173" name="us-gaap:NetIncomeLoss" contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">151,979</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000174" name="us-gaap:NetIncomeLoss" contextRef="C_0001748907_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">151,979</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:26.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2020</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000175" name="us-gaap:SharesOutstanding" contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="INF" format="ixt:numdotdecimal">98,283,603</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000176" name="us-gaap:StockholdersEquity" contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">12,507</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000177" name="us-gaap:StockholdersEquity" contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">771,194</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.6%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000178" name="us-gaap:StockholdersEquity" contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231" decimals="-3" scale="3">373</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000179" name="us-gaap:StockholdersEquity" contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">605,640</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000180" name="us-gaap:StockholdersEquity" contextRef="C_0001748907_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">178,434</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share-based compensation expense</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000181" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">22,536</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.6%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000182" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_0001748907_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">22,536</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise of share options</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000183" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">1,727,254</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000184" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231" decimals="-3" scale="3">224</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000185" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,515</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000186" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001748907_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,739</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of ESPP shares</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000187" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">232,340</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000188" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231" decimals="-3" scale="3">30</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000189" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231" decimals="-3" scale="3">534</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000190" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="C_0001748907_20210101_20211231" decimals="-3" scale="3">564</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vesting of restricted share units, net of shares withheld for taxes</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000191" name="us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">64,647</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000192" name="us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings" contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231" decimals="-3" scale="3">9</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000193" name="us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings" contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231" decimals="-3" sign="-" scale="3">401</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000194" name="us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings" contextRef="C_0001748907_20210101_20211231" decimals="-3" sign="-" scale="3">392</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sale of voting and non-voting ordinary shares, net of issuance costs of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000218" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="C_0001748907_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,355</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000195" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">24,115,755</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000196" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,310</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000197" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">140,335</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000198" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001748907_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">143,645</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ordinary shares issued as part of consulting agreement</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000199" name="ortx:StockIssuedDuringPeriodSharesAsPartOfConsultingAgreement" contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">22,758</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000200" name="ortx:StockIssuedDuringPeriodValueAsPartOfConsultingAgreement" contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231" decimals="-3" scale="3">3</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000201" name="ortx:StockIssuedDuringPeriodValueAsPartOfConsultingAgreement" contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231" decimals="-3" sign="-" scale="3">3</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ordinary shares issued as part of collaboration agreement</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000202" name="ortx:StockIssuedDuringPeriodSharesAsPartOfCollaborationAgreement" contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">1,227,738</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000203" name="ortx:StockIssuedDuringPeriodValueAsPartOfCollaborationAgreement" contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231" decimals="-3" scale="3">170</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000204" name="ortx:StockIssuedDuringPeriodValueAsPartOfCollaborationAgreement" contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,965</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000205" name="ortx:StockIssuedDuringPeriodValueAsPartOfCollaborationAgreement" contextRef="C_0001748907_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,135</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign currency translation</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000206" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,124</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000207" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0001748907_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,124</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized loss on marketable debt securities</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000208" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210101_20211231" decimals="-3" sign="-" scale="3">251</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000209" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" contextRef="C_0001748907_20210101_20211231" decimals="-3" sign="-" scale="3">251</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:26.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000210" name="us-gaap:NetIncomeLoss" contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">144,584</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000211" name="us-gaap:NetIncomeLoss" contextRef="C_0001748907_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">144,584</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:26.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2021</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000212" name="us-gaap:SharesOutstanding" contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231" decimals="INF" format="ixt:numdotdecimal">125,674,095</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000213" name="us-gaap:StockholdersEquity" contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">16,253</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000214" name="us-gaap:StockholdersEquity" contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">940,675</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.6%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000215" name="us-gaap:StockholdersEquity" contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,246</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000216" name="us-gaap:StockholdersEquity" contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">750,224</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000217" name="us-gaap:StockholdersEquity" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">209,950</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these consolidated financial statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-6</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Orchard Therapeutics plc </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="CONSOLIDATED_STATEMENTS_CASH_FLOWS">Consolidated Statements of Cash Flows </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(In&#160;thousands) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.06%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.06%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from operating activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to ordinary shareholders</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000219" name="us-gaap:ProfitLoss" contextRef="C_0001748907_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">144,584</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000220" name="us-gaap:ProfitLoss" contextRef="C_0001748907_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">151,979</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000221" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="C_0001748907_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,327</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000222" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="C_0001748907_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,004</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share-based compensation</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000223" name="us-gaap:ShareBasedCompensation" contextRef="C_0001748907_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">22,536</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000224" name="us-gaap:ShareBasedCompensation" contextRef="C_0001748907_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">27,962</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Impairment of long-lived assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000225" name="us-gaap:AssetImpairmentCharges" contextRef="C_0001748907_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,650</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-cash interest expense</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000226" name="ortx:NonCashInterestExpense" contextRef="C_0001748907_20210101_20211231" decimals="-3" scale="3">392</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000227" name="ortx:NonCashInterestExpense" contextRef="C_0001748907_20200101_20201231" decimals="-3" scale="3">500</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization of provision on loss contract</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000228" name="ortx:AmortizationOfProvisionOnLossContract" contextRef="C_0001748907_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,037</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000229" name="ortx:AmortizationOfProvisionOnLossContract" contextRef="C_0001748907_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">2,413</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-cash consideration for licenses and milestones</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000230" name="ortx:NonCashConsiderationForLicensesAndMilestones" contextRef="C_0001748907_20200101_20201231" decimals="-3" scale="3">791</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred income taxes</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000231" name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="C_0001748907_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,131</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000232" name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="C_0001748907_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">2,257</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization of premium on marketable securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000233" name="ortx:AmortizationOfPremiumOnMarketableSecurities" contextRef="C_0001748907_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,514</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000234" name="ortx:AmortizationOfPremiumOnMarketableSecurities" contextRef="C_0001748907_20200101_20201231" decimals="-3" scale="3">770</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized foreign currency and other non-cash adjustments</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000235" name="ortx:UnrealizedForeignCurrencyAndOtherNonCashAdjustments" contextRef="C_0001748907_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">9,687</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000236" name="ortx:UnrealizedForeignCurrencyAndOtherNonCashAdjustments" contextRef="C_0001748907_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,674</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in operating assets and liabilities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000237" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="C_0001748907_20210101_20211231" decimals="-3" scale="3">624</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000238" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="C_0001748907_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">582</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development tax credit receivable</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000239" name="ortx:IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable" contextRef="C_0001748907_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">13,920</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000240" name="ortx:IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable" contextRef="C_0001748907_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">11,674</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses, other current assets, and other assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000241" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_0001748907_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,209</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000242" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_0001748907_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,070</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating leases, right-of-use-assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000243" name="ortx:IncreaseDecreaseInOperatingRightOfUseAssets" contextRef="C_0001748907_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,938</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000244" name="ortx:IncreaseDecreaseInOperatingRightOfUseAssets" contextRef="C_0001748907_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,863</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable, accrued expenses, and other current liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000245" name="ortx:IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesAndOtherOperatingLiabilities" contextRef="C_0001748907_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">9,452</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000246" name="ortx:IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesAndOtherOperatingLiabilities" contextRef="C_0001748907_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">12,278</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000247" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="C_0001748907_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">13,122</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other long-term liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000248" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" contextRef="C_0001748907_20210101_20211231" decimals="-3" scale="3">34</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000249" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" contextRef="C_0001748907_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,570</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000250" name="ortx:IncreaseDecreaseInOperatingLeaseLiabilities" contextRef="C_0001748907_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">6,952</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000251" name="ortx:IncreaseDecreaseInOperatingLeaseLiabilities" contextRef="C_0001748907_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">6,969</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000252" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_0001748907_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">125,097</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000253" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_0001748907_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">126,274</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from investing activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from sales and maturities of marketable securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000254" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="C_0001748907_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">234,732</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000255" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="C_0001748907_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">281,433</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of marketable securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000256" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" contextRef="C_0001748907_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">263,878</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000257" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" contextRef="C_0001748907_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">113,262</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payment of construction deposit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000258" name="us-gaap:PaymentsToAcquireRestrictedCertificatesOfDeposit" contextRef="C_0001748907_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">10,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Receipt of funds from construction deposit</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000259" name="ortx:ReceiptOfFundsFromConstructionDeposit" contextRef="C_0001748907_20210101_20211231" decimals="-3" scale="3">216</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000260" name="ortx:ReceiptOfFundsFromConstructionDeposit" contextRef="C_0001748907_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,876</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payments on intangible assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000261" name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="C_0001748907_20210101_20211231" decimals="-3" scale="3">887</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of property and equipment</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000262" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_0001748907_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,348</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000263" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_0001748907_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,668</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash (used in) provided by investing activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000264" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_0001748907_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">32,165</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000265" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_0001748907_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">157,379</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from financing activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from modification of credit facility, net of debt issuance costs paid</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000266" name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="C_0001748907_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,375</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from employee equity plans</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000267" name="us-gaap:ProceedsFromStockPlans" contextRef="C_0001748907_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,303</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000268" name="us-gaap:ProceedsFromStockPlans" contextRef="C_0001748907_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,936</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payment of taxes on restricted stock vesting</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000269" name="ortx:PaymentOfTaxesOnRestrictedStockVesting" contextRef="C_0001748907_20210101_20211231" decimals="-3" scale="3">392</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of shares as part of collaboration agreement</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000270" name="ortx:ProceedsFromIssuanceOfSharesAsPartOfCollaborationAgreement" contextRef="C_0001748907_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,135</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from the issuance of ordinary shares in private placement</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000271" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="C_0001748907_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">150,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payment of placement agent fees and offering costs</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000272" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="C_0001748907_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,355</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000273" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_0001748907_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">158,066</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000274" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_0001748907_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,936</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effect of exchange rate changes on cash</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000275" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001748907_20210101_20211231" decimals="-3" sign="-" scale="3">27</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000276" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001748907_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,043</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net increase in cash, cash equivalents and restricted cash</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000277" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_0001748907_20210101_20211231" decimals="-3" scale="3">777</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000278" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_0001748907_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">36,084</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash, cash equivalents, and restricted cash &#8212;beginning of year</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000279" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001748907_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">59,401</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000280" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001748907_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">23,317</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash, cash equivalents, and restricted cash &#8212;end of year</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000281" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">60,178</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000282" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001748907_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">59,401</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Supplemental disclosure of non-cash investing and financing</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets and property and equipment in accounts payable and accrued expenses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000283" name="ortx:IntangibleAssetsAndPropertyAndEquipmentInAccountsPayableAndAccruedExpenses" contextRef="C_0001748907_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,589</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000284" name="ortx:IntangibleAssetsAndPropertyAndEquipmentInAccountsPayableAndAccruedExpenses" contextRef="C_0001748907_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,096</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares issued in consideration of license agreements</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000285" name="us-gaap:StockIssued1" contextRef="C_0001748907_20200101_20201231" decimals="-3" scale="3">791</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee equity plan proceeds received after year-end</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000286" name="ortx:EmployeeEquityPlanProceedsReceived" contextRef="C_0001748907_20200101_20201231" decimals="-3" scale="3">200</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Supplemental disclosure of cash flow information</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease assets obtained in exchange for new operating lease liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000287" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="C_0001748907_20210101_20211231" decimals="-3" scale="3">552</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000288" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="C_0001748907_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">17,486</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid for interest</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000289" name="us-gaap:InterestPaidNet" contextRef="C_0001748907_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,103</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000290" name="us-gaap:InterestPaidNet" contextRef="C_0001748907_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,828</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid for taxes</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000291" name="us-gaap:IncomeTaxesPaidNet" contextRef="C_0001748907_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,651</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000292" name="us-gaap:IncomeTaxesPaidNet" contextRef="C_0001748907_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,007</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these consolidated financial statements.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-7</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Orchard Therapeutics plc</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="NOTES_TO_CONSOLIDATED_FINANCIAL_STATEMEN">Notes to Consolidated Financial Statements</p><ix:nonNumeric id="F_000294" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" contextRef="C_0001748907_20210101_20211231" escape="true" continuedAt="F_000294_dcnt_b19aec82-34ff-4d7c-8144-718032199091">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1. Nature of Business and Basis of Presentation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Orchard Therapeutics plc (the &#8220;Company&#8221;) is a global gene therapy company dedicated to transforming the lives of people affected by severe diseases through the development of innovative, potentially curative gene therapies. The Company&#8217;s&#160;<span style="font-style:italic;">ex vivo</span>&#160;autologous hematopoietic stem cell (&#8220;HSC&#8221;) gene therapy approach utilizes genetically modified blood stem cells and seeks to correct the underlying cause of disease in a single administration. The Company&#8217;s gene therapy product candidate pipeline spans multiple therapeutic areas where the disease burden on children, families and caregivers is immense and current treatment options are limited or do not exist.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is a public limited company incorporated pursuant to the laws of England and Wales. The Company has American Depositary Shares (&#8220;ADSs&#8221;) registered with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) and has been listed on the Nasdaq Global Select Market since October 31, 2018. The Company&#8217;s ADSs each represent one ordinary share of the Company.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2020, the Company received standard marketing authorization from the European Commission for Libmeldy&#8482; (<span style="color:#000000;">atidarsagene autotemcel</span>), for the treatment of early onset metachromatic leukodystrophy (&#8220;MLD&#8221;), characterized by biallelic mutations in the&#160;<span style="font-style:italic;">arylsulfatase-A</span>&#160;(<span style="font-style:italic;">ARSA</span>) gene leading to a reduction of the ARSA enzymatic activity in children with (i) late infantile or early juvenile forms, without clinical manifestations of the disease, or (ii) the early juvenile form, with early clinical manifestations of the disease, who still have the ability to walk independently and before the onset of cognitive decline.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February 9, 2021, the Company issued and sold (i) <ix:nonFraction unitRef="U_xbrlishares" id="F_000370" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001748907_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_us-gaapTypeOfArrangementAxis_ortxSecuritiesPurchaseAgreementMember_20210209_20210209" decimals="INF" format="ixt:numdotdecimal">20,900,321</ix:nonFraction> ordinary shares, nominal value &#163;<ix:nonFraction unitRef="U_iso4217GBP_xbrlishares" id="F_000371" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001748907_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_us-gaapTypeOfArrangementAxis_ortxSecuritiesPurchaseAgreementMember_20210209" decimals="INF">0.10</ix:nonFraction> per share, at a purchase price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000372" name="us-gaap:SaleOfStockPricePerShare" contextRef="C_0001748907_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_us-gaapTypeOfArrangementAxis_ortxSecuritiesPurchaseAgreementMember_20210209" decimals="2">6.22</ix:nonFraction> per share (the &#8220;Purchase Price&#8221;), which was the closing sale price of the Company&#8217;s ADSs on the Nasdaq Global Select Market on <ix:nonNumeric id="F_000373" name="ortx:ClosingPriceOfShareDate" contextRef="C_0001748907_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_us-gaapTypeOfArrangementAxis_ortxSecuritiesPurchaseAgreementMember_20210209_20210209" format="ixt:datemonthdayyearen">February 4, 2021</ix:nonNumeric>, and (ii) <ix:nonFraction unitRef="U_xbrlishares" id="F_000374" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001748907_us-gaapStatementClassOfStockAxis_ortxNonVotingOrdinarySharesMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_us-gaapTypeOfArrangementAxis_ortxSecuritiesPurchaseAgreementMember_20210209_20210209" decimals="INF" format="ixt:numdotdecimal">3,215,434</ix:nonFraction> non-voting ordinary shares, nominal value &#163;<ix:nonFraction unitRef="U_iso4217GBP_xbrlishares" id="F_000375" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001748907_us-gaapStatementClassOfStockAxis_ortxNonVotingOrdinarySharesMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_us-gaapTypeOfArrangementAxis_ortxSecuritiesPurchaseAgreementMember_20210209" decimals="INF">0.10</ix:nonFraction> per share, at the Purchase Price (together (i) and (ii) the &#8220;Private Placement&#8221;). The Private Placement resulted in net proceeds to the Company of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000379" name="ortx:NetProceedsFromIssuanceOfPrivatePlacement" contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxSecuritiesPurchaseAgreementMember_20210209_20210209" decimals="-5" scale="6">143.6</ix:nonFraction> million after deducting placement agent fees of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000376" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="C_0001748907_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_us-gaapTypeOfArrangementAxis_ortxSecuritiesPurchaseAgreementMember_20210209_20210209" decimals="-5" scale="6">6.0</ix:nonFraction> million and other issuance costs of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000377" name="ortx:PaymentsOfOtherIssuanceCosts" contextRef="C_0001748907_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_us-gaapTypeOfArrangementAxis_ortxSecuritiesPurchaseAgreementMember_20210209_20210209" decimals="-5" scale="6">0.4</ix:nonFraction> million. The ordinary shares and non-voting ordinary shares were sold pursuant to a securities purchase agreement entered into between the Company and the purchasers named therein on <ix:nonNumeric id="F_000378" name="us-gaap:SaleOfStockTransactionDate" contextRef="C_0001748907_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_us-gaapTypeOfArrangementAxis_ortxSecuritiesPurchaseAgreementMember_20210209_20210209" format="ixt:datemonthdayyearen">February 4, 2021</ix:nonNumeric>.&#160;&#160;At December 31, 2021, all outstanding non-voting shares have been converted to voting ordinary shares.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s business is subject to risks and uncertainties common to development-stage companies in the biotechnology industry. There can be no assurance that the Company&#8217;s research and development will be successfully completed, that adequate protection for the Company&#8217;s technology will be obtained, that any products developed will obtain necessary government regulatory approval or that any products, if approved, will be commercially viable. The Company operates in an environment of rapid technological innovation and substantial competition from pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees, consultants and service providers. Even if the Company&#8217;s product development efforts are successful in gaining regulatory approval, it is uncertain when, if ever, the Company will realize significant revenue from product sales. &#160;<span style="Background-color:#FFFFFF;">The future developments of the COVID-19 pandemic may also directly or indirectly impact the Company&#8217;s business, including impacts due to&#160;quarantines, border closures, increased border controls, travel restrictions, shelter-in-place orders and shutdowns, business closures, cancellations of public gatherings and other measures.</span> </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. Through December&#160;31, 2021, the Company funded its operations primarily with proceeds from the sale of convertible preferred shares, and ADSs in the IPO and follow-on offering. The Company has incurred recurring losses since its inception, including net losses of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000380" name="us-gaap:NetIncomeLoss" contextRef="C_0001748907_20210101_20211231" decimals="-5" sign="-" scale="6">144.6</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000381" name="us-gaap:NetIncomeLoss" contextRef="C_0001748907_20200101_20201231" decimals="-5" sign="-" scale="6">152.0</ix:nonFraction> million for the years ended December&#160;31, 2021 and 2020, respectively. As of December&#160;31, 2021, the Company had an accumulated deficit of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000382" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0001748907_20211231" decimals="-5" sign="-" format="ixt:numdotdecimal" scale="6">750.2</ix:nonFraction> million. The Company expects to continue to generate operating losses for the foreseeable future. The Company expects that its cash, cash equivalents, and marketable securities on hand as of December&#160;31, 2021 of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000383" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" contextRef="C_0001748907_20211231" decimals="-5" scale="6">220.1</ix:nonFraction> million will be sufficient to fund its operations and capital expenditure requirements for at least the next twelve months. <span style="Background-color:#FFFFFF;">The Company will seek additional funding through private or public equity financings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into collaborations or other arrangements. The terms of any financing may adversely affect the holdings or the rights of the Company's stockholders.&#160;</span>The future viability of the Company is dependent on its ability to raise additional capital to finance its </p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-8</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000294_dcnt_b19aec82-34ff-4d7c-8144-718032199091">
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">operations. If the Company is unable to obtain funding, the Company will be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects, or the Company may be unable to continue operations. Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Basis of presentation </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and include the accounts of the Company and its wholly owned subsidiaries, after elimination of all intercompany accounts and transactions. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts reported are based in thousands, except percentages, per share amounts or as otherwise noted. As a result, certain totals may not sum due to rounding.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p></ix:continuation><ix:nonNumeric id="F_000295" name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="C_0001748907_20210101_20211231" escape="true" continuedAt="F_000295_dcnt_b41e1a09-ab1f-4eb6-ac97-fe1427bd1217">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2. Summary of Significant Accounting Policies </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000315" name="us-gaap:ConsolidationPolicyTextBlock" contextRef="C_0001748907_20210101_20211231" escape="true">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Principles of consolidation</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.</p></ix:nonNumeric><ix:nonNumeric id="F_000316" name="us-gaap:UseOfEstimates" contextRef="C_0001748907_20210101_20211231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of estimates </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual for research and development expenses, the research and development tax credit receivable, share-based compensation, collaboration agreement milestones, operating lease assets and liabilities, and income taxes. Estimates are periodically reviewed in light of changes in circumstances, facts and experience.<span style="Background-color:#FFFFFF;"> Actual results could differ from the Company&#8217;s estimates.</span>&#160;</p></ix:nonNumeric><ix:nonNumeric id="F_000317" name="us-gaap:ConcentrationRiskCreditRisk" contextRef="C_0001748907_20210101_20211231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of credit risk </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000384" name="us-gaap:ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk" contextRef="C_0001748907_20210101_20211231">The Company has no significant off-balance sheet risk, such as foreign currency contracts, options contracts, or other foreign hedging arrangements.</ix:nonNumeric> Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents, marketable securities, and receivables. The Company maintains deposits in accredited financial institutions in excess of federally insured limits. The Company deposits its cash in financial institutions that it believes have high credit quality and has not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships or entities for which it has a receivable. </p></ix:nonNumeric><ix:nonNumeric id="F_000318" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" contextRef="C_0001748907_20210101_20211231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Foreign currency</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The financial statements of the Company&#8217;s subsidiaries with functional currencies other than the U.S. Dollar are translated into U.S. Dollars using period-end exchange rates for assets and liabilities, historical exchange rates for shareholders&#8217; equity and weighted average exchange rates for operating results. Translation gains and losses are included in accumulated other comprehensive income (loss) in shareholders&#8217; equity. Foreign currency transaction gains and losses are included in other income (expense), net in the results of operations.</span><span style="color:#000000;">  The Company recorded realized and unrealized foreign currency transaction losses of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000385" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="C_0001748907_20210101_20211231" decimals="-5" sign="-" scale="6">1.2</ix:nonFraction> million, and gains of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000386" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="C_0001748907_20200101_20201231" decimals="-5" scale="6">3.4</ix:nonFraction> million for the years ended December 31, 2021, and 2020, respectively, which is included in other income (expense) in the statements of operations and comprehensive loss. </span></p></ix:nonNumeric></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-9</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000295_dcnt_b41e1a09-ab1f-4eb6-ac97-fe1427bd1217" continuedAt="F_000295_dcnt_b2529db5-87e5-4348-b47a-bbe8fac15822"><ix:nonNumeric id="F_000319" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" contextRef="C_0001748907_20210101_20211231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Segment information</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company operates in a single segment, focusing on researching, developing and commercializing potentially curative gene therapies.&#160;&#160;Consistent with its operational structure, its chief operating decision maker manages and allocates resources at a global, consolidated level. Therefore, results of the Company's operations are reported on a consolidated basis for purposes of segment reporting.&#160;&#160;All material long-lived assets of the Company reside in the United States or United Kingdom. The Company had property and equipment of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000387" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001748907_srtStatementGeographicalAxis_countryGB_20211231" decimals="-5" scale="6">3.6</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000389" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001748907_srtStatementGeographicalAxis_countryUS_20211231" decimals="-5" scale="6">1.2</ix:nonFraction> million located in the United Kingdom and United States, respectively, as of December 31, 2021. </span>The Company had property and equipment of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000388" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001748907_srtStatementGeographicalAxis_countryGB_20201231" decimals="-5" scale="6">3.7</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000390" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001748907_srtStatementGeographicalAxis_countryUS_20201231" decimals="-5" scale="6">1.1</ix:nonFraction> million located in the United Kingdom and United States, respectively, as of December 31, 2020.&#160;The Company had right-of-use assets in the United States and United Kingdom and European Union of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000391" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0001748907_srtStatementGeographicalAxis_countryUS_20211231" decimals="-5" scale="6">12.5</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000393" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0001748907_srtStatementGeographicalAxis_ortxGBAndEuropeanUnionMember_20211231" decimals="-5" scale="6">11.8</ix:nonFraction> million, respectively, as of December 31, 2021. The Company had right-of-use assets in the United States and United Kingdom and European Union of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000392" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0001748907_srtStatementGeographicalAxis_countryUS_20201231" decimals="-5" scale="6">14.2</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000394" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0001748907_srtStatementGeographicalAxis_ortxGBAndEuropeanUnionMember_20201231" decimals="-5" scale="6">15.6</ix:nonFraction> million, respectively, as of December 31, 2020.</p></ix:nonNumeric><ix:nonNumeric id="F_000320" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" contextRef="C_0001748907_20210101_20211231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash equivalents </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid investments purchased with original maturities of 90 days or less at the date of acquisition to be cash equivalents. </p></ix:nonNumeric><ix:nonNumeric id="F_000321" name="us-gaap:MarketableSecuritiesPolicy" contextRef="C_0001748907_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Marketable securities</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities consist of investments with original maturities greater than ninety days at the date of acquisition. The Company has classified its investments with maturities beyond one year as short term, based on their highly liquid nature and because such marketable securities represent the investment of cash that is available for current operations. The Company considers its investment portfolio of investments as&#160;available-for-sale.&#160;Accordingly, these investments are recorded at fair value, which is based on quoted market prices or other observable inputs. Unrealized gains and losses are recorded as a component of other comprehensive income (loss). Realized gains and losses are determined on a specific identification basis and are included in other income (loss). Amortization and accretion of discounts and premiums is also recorded in other income (loss).</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">When the fair value is below the amortized cost of the asset an estimate of expected credit losses is made, the estimate is limited to the amount by which fair value is less than amortized cost. The credit-related impairment amount is recognized in the consolidated statements of operations&#59; the remaining impairment amount and unrealized gains are reported as a component of accumulated other comprehensive income (loss) in shareholders&#8217; equity. Credit losses are recognized through the use of an allowance for credit losses account and subsequent improvements in expected credit losses are recognized as a reversal of the allowance account. If the Company has the intent to sell the security or it is more likely than not that the Company will be required to sell the security prior to recovery of its amortized cost basis the allowance for credit loss is written off and the excess of the amortized cost basis of the asset over its fair value is recorded in the consolidated statements of operation.</span></p></ix:nonNumeric><ix:nonNumeric id="F_000322" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" contextRef="C_0001748907_20210101_20211231" escape="true" continuedAt="F_000322_dcnt_98b8632e-7985-4552-910a-823c408b720a">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Restricted cash and construction deposits</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents that are restricted as to withdrawal or use under the terms of certain contractual agreements are recorded as restricted cash on our consolidated balance sheet. The Company has an outstanding letter of credit for $<ix:nonFraction unitRef="U_iso4217USD" id="F_000395" name="us-gaap:ProceedsFromLinesOfCredit" contextRef="C_0001748907_20210101_20211231" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000396" name="us-gaap:ProceedsFromLinesOfCredit" contextRef="C_0001748907_20200101_20201231" decimals="-5" scale="6">3.0</ix:nonFraction></ix:nonFraction> million associated with a lease, and is required to hold this amount in a standalone bank account at December 31, 2021 and 2020. The Company is also contractually required to maintain a cash collateral account associated with corporate credit cards and other leases in the amount of <span>$<ix:nonFraction unitRef="U_iso4217USD" id="F_000397" name="us-gaap:CashCollateralForBorrowedSecurities" contextRef="C_0001748907_20211231" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000398" name="us-gaap:CashCollateralForBorrowedSecurities" contextRef="C_0001748907_20201231" decimals="-5" scale="6">1.3</ix:nonFraction></ix:nonFraction></span> million at December 31, 2021 and 2020. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company includes the restricted cash balance in cash and cash equivalents when reconciling beginning-of-period and end-of-period total amounts shown on the consolidated statements of cash flows. <ix:nonNumeric id="F_000339" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" contextRef="C_0001748907_20210101_20211231" escape="true" continuedAt="F_000339_cnt_1">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported in the consolidated balance sheet that sum to the total of the amounts reported in the consolidated statement of cash flows:</ix:nonNumeric></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000339_cnt_1">
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000399" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">55,912</ix:nonFraction></p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000400" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001748907_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">55,135</ix:nonFraction></p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000401" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,266</ix:nonFraction></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000402" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" contextRef="C_0001748907_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,266</ix:nonFraction></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash, cash equivalents and restricted cash shown in the statement of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; cash flows</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000403" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">60,178</ix:nonFraction></p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000404" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001748907_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">59,401</ix:nonFraction></p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:continuation></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-10</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000295_dcnt_b2529db5-87e5-4348-b47a-bbe8fac15822" continuedAt="F_000295_dcnt_7c5a89c6-2e64-461c-a7b0-e228895c0afd"><ix:continuation id="F_000322_dcnt_98b8632e-7985-4552-910a-823c408b720a">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company also has <span style="color:#000000;">$<ix:nonFraction unitRef="U_iso4217USD" id="F_000405" name="us-gaap:EscrowDeposit" contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxFremontLeaseAgreementMember_20211231" decimals="-5" scale="6">7.9</ix:nonFraction> million in an escrow account associated with the construction of the Company&#8217;s leased facility in Fremont, California, which the Company has ceased construction and build-out, and has subleased the facility to a third-party who intends to perform construction and build-out of the facility. </span>Subject to the terms of the lease and reduction provisions, this escrow amount may be decreased to nil over time upon qualifying construction expenditures, or will be returned in late 2022 to the extent funds are not used. The Company deposited $<ix:nonFraction unitRef="U_iso4217USD" id="F_000406" name="us-gaap:EscrowDeposit" contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxFremontLeaseAgreementMember_20200331" decimals="-5" scale="6">10.0</ix:nonFraction> million into the account in the first quarter of 2020 and has received $<ix:nonFraction unitRef="U_iso4217USD" id="F_000407" name="ortx:IncreaseDecreaseInEscrowDeposit" contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxFremontLeaseAgreementMember_20210101_20211231" decimals="-5" scale="6">2.1</ix:nonFraction> million in receipts from the escrow funds for work performed to date. Of the $<ix:nonFraction unitRef="U_iso4217USD" id="F_000408" name="us-gaap:EscrowDeposit" contextRef="C_0001748907_us-gaapBalanceSheetLocationAxis_us-gaapPrepaidExpensesAndOtherCurrentAssetsMember_us-gaapLeaseContractualTermAxis_ortxFremontLeaseAgreementMember_20211231" decimals="-5" scale="6">7.9</ix:nonFraction> million remaining in the escrow account, the entire balance is classified within other prepaid expenses and other current assets on the consolidated balance sheets based on the timing of when the Company expects to receive the cash from the escrow agent.</p></ix:continuation><ix:nonNumeric id="F_000323" name="us-gaap:InventoryPolicyTextBlock" contextRef="C_0001748907_20210101_20211231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Inventory</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventory is stated at the lower of cost or estimated net realizable value with cost determined on a first-in, first-out basis. Inventory costs include raw materials, third-party contract manufacturing, third-party packaging services, and freight. Raw and intermediate materials that may be utilized for either research and development or commercial purposes are classified as inventory. Amounts in inventory that are used for research and development purposes are charged to research and development expense when the product enters the research and development process and can no longer be used for commercial purposes and, therefore, does not have an &#8220;alternative future use&#8221; as defined in authoritative guidance. The Company performs an assessment of the recoverability of capitalized inventory during each reporting period and, if needed, writes down any excess and obsolete inventory to its estimated net realizable value in the period it is identified. If they occur, such impairment charges are recorded as a component of cost of goods sold in the consolidated statements of operations and comprehensive income (loss). Inventory is included in prepaid expenses and other current assets on the consolidated balance sheets and the amount was not significant as of December&#160;31, 2021.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the initial date that regulatory approval is received, costs related to the production of inventory are recorded as research and development expense on the Company&#8217;s consolidated statements of operations and comprehensive income (loss) in the period incurred. In connection with the acquisition of Strimvelis in April 2018, and with the EMA approval of Libmeldy in December 2020, the Company subsequently began capitalizing inventory manufactured or purchased after these dates.</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000324" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" contextRef="C_0001748907_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Intangible assets, net</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Intangible assets, net consist milestones associated with the Company&#8217;s approved products, net of accumulated amortization. The Company amortizes its intangible assets using the straight-line method over their estimated economic lives and periodically reviews for impairment. The Company has not recognized any impairment charges related to intangible assets to date.</span></p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000325" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" contextRef="C_0001748907_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Property and equipment </p><ix:nonNumeric id="F_000340" name="ortx:PropertyPlantAndEquipmentUsefulLifeTableTextBlock" contextRef="C_0001748907_20210101_20211231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are recorded at cost and depreciated or amortized using the straight-line method over the following estimated useful lives. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated useful&#160;&#160;life</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lab equipment</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5-10 years</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000411" name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives" contextRef="C_0001748907_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20210101_20211231">Shorter of lease term or estimated useful life</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000412" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_0001748907_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20210101_20211231" format="ixt-sec:duryear">4</ix:nonNumeric> years</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Office and computer equipment</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3-5 years</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Repairs and maintenance expenditures, which are not considered improvements and do not extend the useful life of property and equipment, are expensed as incurred. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts, and any resulting gain or loss is included in the consolidated statements of operations and other comprehensive loss. </p></ix:nonNumeric><ix:nonNumeric id="F_000326" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" contextRef="C_0001748907_20210101_20211231" escape="true" continuedAt="F_000326_dcnt_f3c22128-8f53-4c62-91f0-3d38afe52e41">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Impairment of long-lived assets </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-lived assets consist of property and equipment and operating lease right-of-use assets. Long-lived assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or </p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-11</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000295_dcnt_7c5a89c6-2e64-461c-a7b0-e228895c0afd" continuedAt="F_000295_dcnt_d9ea0972-54c1-43c3-afac-4985f09859be"><ix:continuation id="F_000326_dcnt_f3c22128-8f53-4c62-91f0-3d38afe52e41">
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">economic trends and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset group for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset group to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of an asset group are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset group over its fair value, as determined in accordance with the related accounting literature</span><span style="color:#000000;">. </span></p></ix:continuation><ix:nonNumeric id="F_000327" name="us-gaap:ResearchAndDevelopmentExpensePolicy" contextRef="C_0001748907_20210101_20211231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research and development costs </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including salaries, share-based compensation and benefits, facilities costs, depreciation, third-party license fees, certain milestone payments, and external costs of outside vendors engaged to conduct clinical development activities and clinical trials, the purchase of in-process research and development assets, as well as costs to develop a manufacturing process, perform analytical testing and manufacture clinical trial materials. Non-refundable prepayments for goods or services that will be used or rendered for future research and development activities are recorded as prepaid expenses. Such amounts are recognized as an expense as the goods are delivered or the related services are performed, or until it is no longer expected that the goods will be delivered, or the services rendered. In addition, funding from research grants is recognized as an offset to research and development expense on the basis of costs incurred on the research program. Royalties to third parties associated with our research grants will be accrued when they become probable.</p></ix:nonNumeric><ix:nonNumeric id="F_000328" name="ortx:ResearchContractCostsAndAccrualsPolicyTextBlock" contextRef="C_0001748907_20210101_20211231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research contract costs and accruals </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has entered into various research and development contracts. These agreements are cancelable, and related costs are recorded as research and development expenses as incurred. When billing terms under these contracts do not coincide with the timing of when the work is performed, the Company is required to make estimates of outstanding obligations as of period end to those third parties. Any accrual estimates are based on a number of factors, including the Company&#8217;s knowledge of the progress towards completion of the research and development activities, invoicing to date under the contracts, communication from the research institution or other companies of any actual costs incurred during the period that have not yet been invoiced, and the costs included in the contracts. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the expense. Actual results could differ from the estimates made by the Company. The historical accrual estimates made by the Company have not been materially different from the actual costs.</p></ix:nonNumeric><ix:nonNumeric id="F_000329" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" contextRef="C_0001748907_20210101_20211231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Share-based compensation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company measures share-based awards granted to employees, consultants and directors based on the fair value of the shares and options on the date of the grant and recognizes compensation expense for those awards over the requisite service period, which is the vesting period of the respective award. Forfeitures are accounted for as they occur. </p></ix:nonNumeric><ix:nonNumeric id="F_000330" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" contextRef="C_0001748907_20210101_20211231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Comprehensive loss </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Comprehensive loss is composed of net loss and other comprehensive income (loss). Other comprehensive income (loss) consists of unrealized gains and losses on marketable securities and foreign currency translation gains and losses.</span><span style="color:#000000;"> &#160;&#160;</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric><ix:nonNumeric id="F_000331" name="us-gaap:LesseeLeasesPolicyTextBlock" contextRef="C_0001748907_20210101_20211231" escape="true" continuedAt="F_000331_dcnt_6d04d95c-8983-4fb5-a9cd-b4259448c32a">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Leases</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determines if an arrangement is a lease at contract inception. Operating lease assets represent a right to use an underlying asset for the lease term and operating lease liabilities represent an obligation to make lease payments arising from the lease. Operating lease liabilities with a term greater than one year and their corresponding right-of-use assets are recognized on the balance sheet at the commencement date of the lease based on the present value of lease payments over the expected lease term. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received. The Company made an accounting policy election to not record a right-of-use asset or lease liability for leases with a term of one year or less. To date, the Company has not identified any material short-term leases, either individually or in the aggregate.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">As&#160;the Company&#8217;s&#160;leases do not provide an implicit rate,&#160;the Company utilized the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term as the lease an amount equal to the lease payments in a similar economic environment. The Company estimated the incremental borrowing rate based on the </span></p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-12</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000295_dcnt_d9ea0972-54c1-43c3-afac-4985f09859be" continuedAt="F_000295_dcnt_e3027ac7-ea89-43c6-9caa-a41d31db66a7"><ix:continuation id="F_000331_dcnt_6d04d95c-8983-4fb5-a9cd-b4259448c32a">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Company&#8217;s currently outstanding credit facility as inputs to the analysis to calculate a spread, adjusted for factors that reflect the profile of secured borrowing over the expected term of the lease.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The components of a lease should be split into three categories: lease components (e.g., land, building, etc.), non-lease components (e.g., common area maintenance, utilities, performance of manufacturing services, purchase of inventory, etc.), and non-components (e.g., property taxes, insurance, etc.). Then the fixed contract consideration (including any related to non-components) must be allocated based on fair values to the lease components and non-lease components. Although separation of lease and non-lease components is required, certain accounting policy elections are available to entities. Entities can elect accounting policies that would not separate lease and non-lease components. Rather, they would account for each lease component and the related non-lease&#160;component together as a single component. The Company has elected&#160;not to apply the accounting policy with respect to its lease of manufacturing space at a contract manufacturing organization, the Company has allocated the consideration between the lease and non-lease components of the contract&#160;based on the respective fair values of the lease and non-lease components.&#160;The&#160;Company calculated the fair value of the lease&#160;and non-lease&#160;components&#160;using financial information readily available as part of its master services arrangement&#160;and other representative data&#160;indicative of fair value.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company accounts for sublease income on a straight-line basis over the respective lease period and records an unbilled rent receivable for sublease income incurred but not yet paid. The Company periodically performs a collectability assessment associated with any unbilled rent receivables. The Company recognizes the sublease income as a reduction to the related operating expense associated with the head lease.</span></p></ix:continuation><ix:nonNumeric id="F_000332" name="ortx:StrimvelisLossProvisionPolicyTextBlock" contextRef="C_0001748907_20210101_20211231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Strimvelis loss provision</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of the GSK transaction, the Company is required to maintain commercial availability of Strimvelis in the European Union until such time that an alternative gene therapy is available (see Note 15). Strimvelis is not currently expected to generate sufficient cash flows to overcome the costs of maintaining the product and certain regulatory commitments&#59; therefore, the Company initially recorded a liability associated with the loss contract of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000415" name="us-gaap:ProvisionForLossOnContracts" contextRef="C_0001748907_20181231" decimals="-5" scale="6">18.4</ix:nonFraction>&#160;million in 2018. The Company recognizes the amortization of the loss provision on a diminishing balance basis based on the actual net loss incurred associated with the Strimvelis program and the expected future net losses to be generated until such time as Strimvelis is no longer commercially available. The amortization of the provision is recorded as a credit to research and development expense. The Company has made an estimate of the expected future losses associated with Strimvelis and will adjust this estimate as facts and circumstances change regarding the commercial availability and costs of maintaining and selling Strimvelis. The Company does not update the accrued loss provision for any subsequent adjustment of the future losses, however, the timing of recognizing the amortization of what was originally recorded is adjusted for the updated future losses. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000341" name="ortx:ScheduleOfChangesInLossProvisionTableTextBlock" contextRef="C_0001748907_20210101_20211231" escape="true" continuedAt="F_000341_cnt_1">The following table below outlines the changes to the Strimvelis loss provision for the periods ended December 31, 2021 and 2020:</ix:nonNumeric></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000341_cnt_1">
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at beginning of period</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000416" name="ortx:AssetAcquisitionLiabilityAssumed" contextRef="C_0001748907_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,482</ix:nonFraction></p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000417" name="ortx:AssetAcquisitionLiabilityAssumed" contextRef="C_0001748907_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,790</ix:nonFraction></p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provisions</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization of loss provision</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000418" name="ortx:AssetAcquisitionLiabilityAmortizationOfLossProvision" contextRef="C_0001748907_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,037</ix:nonFraction></p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000419" name="ortx:AssetAcquisitionLiabilityAmortizationOfLossProvision" contextRef="C_0001748907_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,413</ix:nonFraction></p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign currency translation</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000420" name="ortx:IncreaseDecreaseInAssetAcquisitionLiabilityEffectOfForeignExchangeTranslation" contextRef="C_0001748907_20210101_20211231" decimals="-3" sign="-" scale="3">26</ix:nonFraction></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000421" name="ortx:IncreaseDecreaseInAssetAcquisitionLiabilityEffectOfForeignExchangeTranslation" contextRef="C_0001748907_20200101_20201231" decimals="-3" scale="3">105</ix:nonFraction></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at end of period</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000422" name="ortx:AssetAcquisitionLiabilityAssumed" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,419</ix:nonFraction></p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.84%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000423" name="ortx:AssetAcquisitionLiabilityAssumed" contextRef="C_0001748907_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,482</ix:nonFraction></p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000424" name="ortx:AssetAcquisitionLiabilityAssumedCurrent" contextRef="C_0001748907_20211231" decimals="-5" scale="6">0.7</ix:nonFraction> million of the Strimvelis loss provision was classified as current, and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000426" name="ortx:AssetAcquisitionLiabilityAssumedNonCurrent" contextRef="C_0001748907_20211231" decimals="-5" scale="6">2.7</ix:nonFraction> million was classified as non-current. As of December 31, 2020, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000425" name="ortx:AssetAcquisitionLiabilityAssumedCurrent" contextRef="C_0001748907_20201231" decimals="-5" scale="6">0.9</ix:nonFraction> million of the Strimvelis loss provision was classified as current, and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000427" name="ortx:AssetAcquisitionLiabilityAssumedNonCurrent" contextRef="C_0001748907_20201231" decimals="-5" scale="6">3.6</ix:nonFraction> million was classified as non-current.</p></ix:nonNumeric><ix:nonNumeric id="F_000333" name="ortx:ResearchAndDevelopmentIncomeTaxCreditsPolicyTextBlock" contextRef="C_0001748907_20210101_20211231" escape="true" continuedAt="F_000333_dcnt_8861e00d-85c7-47d1-a5c7-97ef7f350bae">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">United Kingdom Research and development income tax credits </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a company that carries out research and development activities, the Company is able to submit tax credit claims from two UK research and development tax relief programs, the SME program and the RDEC program depending on eligibility. Qualifying expenditures largely comprise employment costs for research staff, consumables and certain internal overhead costs incurred as part of research projects for which the Company does not receive income.<span style="color:#000000;"> </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each reporting period, management evaluates which tax relief programs the Company is expected to be eligible for and records a reduction to research and development expense for the portion of the expense that it expects to qualify under the </p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-13</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000295_dcnt_e3027ac7-ea89-43c6-9caa-a41d31db66a7" continuedAt="F_000295_dcnt_5c0cae35-12d8-48e7-b682-e1497c8377cb"><ix:continuation id="F_000333_dcnt_8861e00d-85c7-47d1-a5c7-97ef7f350bae">
<p style="margin-bottom:0pt;margin-top:12pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">programs, that it plans to submit a claim for, and it has reasonable assurance that the amount will ultimately be realized. </span><span style="color:#000000;">Based on criteria established by HM Revenue and Customs (&#8220;HMRC&#8221;), management of the Company expects a proportion of expenditures being undertaken in relation to its pipeline research, clinical trials management and manufacturing development activities to be eligible for the research and development tax relief programs for the year ended December 31, 2021. </span><span style="Background-color:#FFFFFF;">The Company has qualified under the more favorable SME regime for the year ended December 31, 2020 and expects to qualify under the SME regime for the year ending December 31, 2021.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The RDEC and SME credits are not dependent on the Company generating future taxable income or on the ongoing tax status or tax position of the Company. The Company has assessed its research and development activities and expenditures to determine whether the nature of the activities and expenditures will qualify for credit under the tax relief programs and whether the claims will ultimately be realized based on the allowable reimbursable expense criteria established by the UK government which are subject to interpretation. At each period end, the Company estimates the reimbursement available to the Company based on available information at the time.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes credits from the research and development incentives when the relevant expenditure has been incurred and there is reasonable assurance that the reimbursement will be received.&#160;Such credits are accounted for as reductions in research and development expense. <ix:nonNumeric id="F_000342" name="us-gaap:SummaryOfTaxCreditCarryforwardsTextBlock" contextRef="C_0001748907_20210101_20211231" escape="true" continuedAt="F_000342_cnt_1">The following table outlines the changes to the research and development tax credit receivable, including amount recognized as an offset to research and development expense during the years ended December 31, 2021 and 2020:</ix:nonNumeric></p><ix:continuation id="F_000342_cnt_1">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.98%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at beginning of period</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000428" name="us-gaap:TaxCreditCarryforwardAmount" contextRef="C_0001748907_srtStatementGeographicalAxis_countryGB_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">17,344</ix:nonFraction></p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000429" name="us-gaap:TaxCreditCarryforwardAmount" contextRef="C_0001748907_srtStatementGeographicalAxis_countryGB_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">28,644</ix:nonFraction></p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recognition of credit claims as offset to research and development expense</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000430" name="us-gaap:IncomeTaxCreditsAndAdjustments" contextRef="C_0001748907_srtStatementGeographicalAxis_countryGB_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">13,920</ix:nonFraction></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000431" name="us-gaap:IncomeTaxCreditsAndAdjustments" contextRef="C_0001748907_srtStatementGeographicalAxis_countryGB_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">21,130</ix:nonFraction></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Receipt of credit claims</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000432" name="us-gaap:IncomeTaxReconciliationTaxCredits" contextRef="C_0001748907_srtStatementGeographicalAxis_countryGB_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">33,771</ix:nonFraction></p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign currency translation</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000433" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="C_0001748907_srtStatementGeographicalAxis_countryGB_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20211231" decimals="-3" sign="-" scale="3">541</ix:nonFraction></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000434" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="C_0001748907_srtStatementGeographicalAxis_countryGB_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,341</ix:nonFraction></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.18%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at end of period</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000435" name="us-gaap:TaxCreditCarryforwardAmount" contextRef="C_0001748907_srtStatementGeographicalAxis_countryGB_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">30,723</ix:nonFraction></p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000436" name="us-gaap:TaxCreditCarryforwardAmount" contextRef="C_0001748907_srtStatementGeographicalAxis_countryGB_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">17,344</ix:nonFraction></p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">During the year ended December 31, 2020, the Company recorded $<ix:nonFraction unitRef="U_iso4217USD" id="F_000437" name="ortx:AdditionalIncomeTaxCredits" contextRef="C_0001748907_srtStatementGeographicalAxis_countryGB_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231" decimals="-5" scale="6">4.8</ix:nonFraction>&#160;million of additional tax credits related to a change in estimate associated with its UK research and development tax credit receivable claim for fiscal year 2019. The change in estimate was based on the results of a tax credit&#160;analysis&#160;associated with the Company&#8217;s qualified projects and research and development expenditures completed during the third quarter to finalize the 2019 UK tax return.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, the Company&#8217;s tax credit receivable from the UK was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000439" name="ortx:ResearchAndDevelopmentTaxCreditReceivableCurrent" contextRef="C_0001748907_srtStatementGeographicalAxis_countryGB_20211231" decimals="-5" scale="6">30.7</ix:nonFraction> million, all of which was classified as current. As of December&#160;31, 2020, the Company&#8217;s tax incentive receivable from the UK was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000438" name="ortx:ResearchAndDevelopmentTaxCreditReceivable" contextRef="C_0001748907_srtStatementGeographicalAxis_countryGB_20201231" decimals="-5" scale="6">17.3</ix:nonFraction> million, all of which was classified as current.</p></ix:continuation><ix:nonNumeric id="F_000334" name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="C_0001748907_20210101_20211231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Income taxes </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is primarily subject to corporation taxes in the United Kingdom and the United States. The calculation of the Company&#8217;s tax provision involves the application of both United Kingdom and United States tax law and requires judgement and estimates. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for income taxes in accordance with ASC Topic 740, <span style="font-style:italic;">Accounting for Income Taxes</span>, which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. The Company determines its deferred tax assets and liabilities based on differences between financial reporting and tax bases of assets and liabilities, which are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are provided if, based upon the weight of available evidence, it is more likely than not that some or all of the net deferred tax assets will not be realized. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for uncertainty in income taxes by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed as the amount of benefit to recognize in the consolidated financial statements. The amount of benefits that may be used is the largest amount that has a greater than <ix:nonFraction unitRef="U_xbrlipure" id="F_000440" name="ortx:IncrementalPercentageOfTaxableProfits" contextRef="C_0001748907_srtStatementGeographicalAxis_countryGB_20210101_20211231" decimals="2" scale="-2">50</ix:nonFraction>% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate, as well as the related net interest and penalties. </p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-14</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000295_dcnt_5c0cae35-12d8-48e7-b682-e1497c8377cb" continuedAt="F_000295_dcnt_572c251e-b95e-493a-b567-7249cadf522a"><ix:nonNumeric id="F_000335" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" contextRef="C_0001748907_20210101_20211231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Product sales</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s product sales in 2021 and 2020 consist of sales of Strimvelis, which is distributed exclusively at the San Raffaele Hospital in Milan, Italy. San Raffaele Hospital will purchase and pay for Strimvelis and submit a claim to the payer. The Company&#8217;s contracted sales with San Raffaele Hospital contain a single performance obligation and the Company recognizes revenue from product sales when the Company has satisfied its performance obligation by transferring control of Strimvelis to San Raffaele Hospital. Control of the product generally transfers upon the completion of the scheduled Strimvelis treatment. The Company&#8217;s product sales represent total net product sales of Strimvelis. The Company evaluated the variable consideration under Accounting Standards Codification (ASC) 606,&#160;<span style="font-style:italic;">Revenue from Contracts with Customers</span>, and there is currently no variable consideration included in the transaction price for Strimvelis. Costs to manufacture and deliver the product and those associated with administering the therapy are included in cost of product sales. As the product is sold in direct relation to a scheduled treatment, the Company estimates that there is limited risk of product return, including the risk of product expiration. During the years ended December 31, 2021 and 2020, the Company has $<ix:nonFraction unitRef="U_iso4217USD" id="F_000441" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001748907_srtProductOrServiceAxis_us-gaapProductMember_20210101_20211231" decimals="-5" scale="6">0.7</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000442" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001748907_srtProductOrServiceAxis_us-gaapProductMember_20200101_20201231" decimals="-5" scale="6">2.6</ix:nonFraction> million in sales of Strimvelis, respectively.</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000336" name="us-gaap:RevenueRecognitionPolicyTextBlock" contextRef="C_0001748907_20210101_20211231" escape="true" continuedAt="F_000336_dcnt_3f64950d-fcd3-4ab6-a645-95c7dc56c438">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Collaboration revenue</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The terms of the Company&#8217;s collaboration agreements may include consideration such as&#160;non-refundable license fees, funding of research and development services, payments due upon the achievement of clinical and preclinical performance-<span style="color:#000000;">based development milestones, regulatory milestones, manufacturing services, sales-based milestones and royalties on product sales.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company first evaluates collaboration arrangements to determine whether the arrangement (or part of the arrangement) represents a collaborative arrangement pursuant to ASC Topic 808,&#160;<span style="font-style:italic;">Collaborative Arrangements</span>, based on the risks and rewards and activities of the parties pursuant to the contractual arrangement. The Company accounts for any collaborative arrangement or elements within the contract that are deemed to be a collaborative arrangement, and not<span style="font-size:12pt;"> </span>a customer relationship, in accordance with ASC&#160;808. Through December&#160;31, 2021, the Company entered into one agreement with Pharming Group N.V. (the &#8220;Pharming Agreement&#8221;, see Note 16) that is accounted for pursuant to ASC 606.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:9pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine the appropriate amount of revenue to be recognized for arrangements determined to be within the scope of ASC&#160;606, the Company performs the following five steps: (i)&#160;identification of the contract(s) with the customer, (ii)&#160;identification of the promised goods or services in the contract and determination of whether the promised goods or services are performance obligations, (iii)&#160;measurement of the transaction price, (iv)&#160;allocation of the transaction price to the performance obligations, and (v)&#160;recognition of revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect consideration it is entitled to in exchange for the goods or services it transfers to the customer.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company recognizes the&#160;</span>transaction&#160;<span style="Background-color:#FFFFFF;">price allocated to upfront license payments as revenue upon delivery of the license to the customer and resulting ability of the customer to use and benefit from the license, if the license is determined to be distinct from the other performance obligations identified in the contract. If the license is considered to not be distinct from other performance obligations, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied (i)&#160;at a point in time, but only for licenses determined to be distinct from other performance obligations in the contract, or (ii)&#160;over time, and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from license payments. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Pharming Agreement entitles the Company to additional payments upon the achievement of performance-based milestones. These milestones are generally categorized into three types: development milestones, regulatory milestones, and sales-based milestones.&#160;The Company is also eligible to receive from Pharming tiered royalty payments on worldwide net sales. The Company evaluates whether it is probable that the consideration associated with each milestone will not be subject to a significant reversal in the cumulative amount of revenue recognized. Amounts that meet this threshold are included in the transaction price using the most likely amount method, whereas amounts that do not meet this threshold are considered constrained and excluded from the transaction price until they meet this threshold.&#160;Milestones tied to regulatory approval, and therefore not within the Company&#8217;s control, are considered constrained until such approval is received. Upfront and ongoing development milestones per the collaboration agreements are not subject to refund if the development activities are not successful. At the end of each subsequent reporting period, the Company&#160;</span>re-evaluates<span style="Background-color:#FFFFFF;">&#160;the probability of a significant reversal of the cumulative revenue recognized for the milestones, and, if necessary, adjusts the estimate of the overall transaction price. Any such adjustments are recorded on a cumulative&#160;</span>catch-up <span style="Background-color:#FFFFFF;">basis, which would affect revenues from collaborators in </span></p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-15</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000295_dcnt_572c251e-b95e-493a-b567-7249cadf522a" continuedAt="F_000295_dcnt_1225ed24-7206-405b-884a-7544685c00bd"><ix:continuation id="F_000336_dcnt_3f64950d-fcd3-4ab6-a645-95c7dc56c438">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">the period of adjustment. The Company may enter into an agreement that includes sales-based milestone payments and royalties in exchange for a license of intellectual property. The Company considers the underlying facts and circumstances of these agreements, noting whether the future payments are contingent upon future sales and whether they are dependent on a third party&#8217;s ability to successfully commercialize a product using the licensed intellectual property. The Company also considers whether the license is the only, or predominant, item to which the milestone payments and royalties relate. If the Company concludes the license is the predominant item in the agreement, therefore the primary driver of value, the Company excludes sales-based milestone payments and royalties from the transaction price until the sale occurs (or, if later, until the underlying performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied). Currently, the Company has not recognized any royalty revenue resulting from the </span><span style="Background-color:#FFFFFF;">Pharming </span><span style="Background-color:#FFFFFF;">Agreement.</span></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ASC 606 requires the Company to allocate the arrangement consideration on a relative standalone selling price basis for each performance obligation after determining the transaction price of the contract and identifying the performance obligations to which that amount should be allocated. The relative standalone selling price is defined in ASC 606 as the price at which an entity would sell a promised good or service separately to a customer. If other observable transactions in which the Company has sold the same performance obligation separately are not available, the Company is required to estimate the standalone selling price of each performance obligation. Key assumptions to determine the standalone selling price may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Whenever the Company determines that a contract should be accounted for as a combined performance obligation, which is recognized over time, it will utilize the&#160;cost-to-cost&#160;input method. Revenue will be recognized over time using the&#160;cost-to-cost&#160;input method, based on the total estimated costs to fulfill the obligations. The Company will recognize revenue as services are delivered. Significant management judgment is required in determining the estimate of total costs required under an arrangement and the period over which the Company is expected to complete its performance obligations under an arrangement.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Consideration that does not meet the requirements to satisfy the above revenue recognition criteria is a contract liability and is recorded as deferred revenue in the consolidated balance sheets. Short-term deferred revenue consists of amounts that are expected to be recognized as revenue in the next 12 months. Amounts that the Company expects will not be recognized within the next 12 months are classified as long-term deferred revenue.</span></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied, either at a point in time or over time. In particular, for the Company&#8217;s collaborations with Pharming, revenue attributable to research services is recognized as those services are provided, based on the costs incurred to date.</p></ix:continuation><ix:nonNumeric id="F_000337" name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="C_0001748907_20210101_20211231" escape="true" continuedAt="F_000337_dcnt_b600c47a-1ea2-4d9f-96b2-3bc9b326771f">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Net loss per share </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share is computed by dividing the net loss by the weighted average number of ordinary shares outstanding for the period. Diluted net loss is computed by adjusting net loss based on the potential impact of dilutive securities. Diluted net loss per share is computed by dividing the diluted net loss by the weighted average number of ordinary shares outstanding for the period, including potential dilutive ordinary shares. For purpose of this calculation, outstanding options and unvested restricted shares are considered potential dilutive ordinary shares. Since the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share for all periods as the inclusion of all potential ordinary share equivalents outstanding would have been anti-dilutive. </p><ix:nonNumeric id="F_000343" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" contextRef="C_0001748907_20210101_20211231" escape="true" continuedAt="F_000343_dcnt_b286974e-bdc5-48d6-a0b4-5caf5d1312bb">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following securities, presented based on amounts outstanding at each period end, are considered to be ordinary share equivalents, but were not included in the computation of diluted net loss per ordinary share because to do so would have been anti-dilutive: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share options</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000443" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001748907_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">14,042,781</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000444" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001748907_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">11,071,555</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested shares from share plan and consulting agreement</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000445" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001748907_us-gaapAwardTypeAxis_ortxUnvestedSharesFromSharePlanAndConsultingAgreementMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">512,908</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000446" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001748907_us-gaapAwardTypeAxis_ortxUnvestedSharesFromSharePlanAndConsultingAgreementMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">816,316</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000447" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001748907_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">14,555,689</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000448" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001748907_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">11,887,871</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-16</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000295_dcnt_1225ed24-7206-405b-884a-7544685c00bd"><ix:continuation id="F_000337_dcnt_b600c47a-1ea2-4d9f-96b2-3bc9b326771f"><ix:continuation id="F_000343_dcnt_b286974e-bdc5-48d6-a0b4-5caf5d1312bb">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation></ix:continuation><ix:nonNumeric id="F_000338" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="C_0001748907_20210101_20211231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recent accounting pronouncements</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<span style="color:#000000;">In November 2021, the FASB issued <ix:nonNumeric id="F_000451" name="us-gaap:NewAccountingPronouncementOrChangeInAccountingPrincipleDescription" contextRef="C_0001748907_20210101_20211231">ASU No. 2020-10</ix:nonNumeric>,&#160;</span><span style="font-style:italic;color:#000000;">Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance</span><span style="color:#000000;">, which requires increased transparency in the disclosures about government assistant in the notes to the financial statements. This ASU is effective for the Company beginning <ix:nonNumeric id="F_000450" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" contextRef="C_0001748907_20211231" format="ixt:datemonthdayyearen">January 1, 2022</ix:nonNumeric>, and interim periods within that year, with early adoption permitted. The Company does not expect this amendment to have a significant effect on its financial statement disclosures. </span></p></ix:nonNumeric></ix:continuation><ix:nonNumeric id="F_000296" name="us-gaap:FairValueDisclosuresTextBlock" contextRef="C_0001748907_20210101_20211231" escape="true" continuedAt="F_000296_dcnt_32dce6f6-c954-4e20-b100-e33e7f6654e7">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3. Fair Value Measurements and Marketable Securities</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables present information about the Company&#8217;s financial assets that have been measured at fair value as of December 31, 2021 and 2020, and indicate the fair value of the hierarchy of the valuation inputs utilized to determine such fair value. In general, fair values determined by Level&#160;1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Fair value determined by Level&#160;2 inputs utilize observable inputs other than Level&#160;1 prices, such as quoted prices for similar assets or liabilities, quoted market prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities. Fair values determined by Level&#160;3 inputs are unobservable data points for the asset or liability, and include situations where there is little, if any, market activity for the asset or liability. During the years ended December 31, 2021 and 2020, there were <ix:nonFraction unitRef="U_iso4217USD" id="F_000453" name="us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount" contextRef="C_0001748907_20201231" decimals="-3" format="ixt-sec:numwordsen" scale="3"><ix:nonFraction unitRef="U_iso4217USD" id="F_000455" name="us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount" contextRef="C_0001748907_20201231" decimals="-3" format="ixt-sec:numwordsen" scale="3"><ix:nonFraction unitRef="U_iso4217USD" id="F_000452" name="us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount" contextRef="C_0001748907_20211231" decimals="-3" format="ixt-sec:numwordsen" scale="3"><ix:nonFraction unitRef="U_iso4217USD" id="F_000454" name="us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount" contextRef="C_0001748907_20211231" decimals="-3" format="ixt-sec:numwordsen" scale="3">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> transfers between Level&#160;1 and Level&#160;2 financial assets.</p><ix:nonNumeric id="F_000344" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" contextRef="C_0001748907_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the Company&#8217;s cash equivalents and marketable securities as of December 31, 2021:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements as of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021 Using:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000456" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">21,085</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000457" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">21,085</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000458" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,321</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000459" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,321</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000460" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapCommercialPaperMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">13,198</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000461" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapCommercialPaperMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">13,198</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash equivalents</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000462" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="C_0001748907_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">21,085</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000463" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="C_0001748907_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">20,519</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000464" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">41,604</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000465" name="ortx:MarketableSecuritiesFairValueDisclosure" contextRef="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">94,794</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000466" name="ortx:MarketableSecuritiesFairValueDisclosure" contextRef="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">94,794</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000467" name="ortx:MarketableSecuritiesFairValueDisclosure" contextRef="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapCommercialPaperMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">69,401</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000468" name="ortx:MarketableSecuritiesFairValueDisclosure" contextRef="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapCommercialPaperMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">69,401</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total marketable securities</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000469" name="ortx:MarketableSecuritiesFairValueDisclosure" contextRef="C_0001748907_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">164,195</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000470" name="ortx:MarketableSecuritiesFairValueDisclosure" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">164,195</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000471" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001748907_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">21,085</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000472" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001748907_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">184,714</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000473" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">205,799</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the Company&#8217;s cash equivalents and marketable securities as of December 31, 2020:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements as of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020 Using:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000474" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,650</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000475" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,650</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government securities</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000476" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapUSTreasuryAndGovernmentMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,001</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000477" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapUSTreasuryAndGovernmentMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,001</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000478" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapCommercialPaperMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,999</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000479" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapCommercialPaperMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,999</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash equivalents</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000480" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="C_0001748907_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,650</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000481" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="C_0001748907_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000482" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="C_0001748907_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">12,650</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US government securities</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000483" name="ortx:MarketableSecuritiesFairValueDisclosure" contextRef="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapUSTreasuryAndGovernmentMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,997</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000484" name="ortx:MarketableSecuritiesFairValueDisclosure" contextRef="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapUSTreasuryAndGovernmentMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,997</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000485" name="ortx:MarketableSecuritiesFairValueDisclosure" contextRef="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">93,358</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000486" name="ortx:MarketableSecuritiesFairValueDisclosure" contextRef="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">93,358</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000487" name="ortx:MarketableSecuritiesFairValueDisclosure" contextRef="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapCommercialPaperMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">40,458</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000488" name="ortx:MarketableSecuritiesFairValueDisclosure" contextRef="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapCommercialPaperMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">40,458</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total marketable securities</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000489" name="ortx:MarketableSecuritiesFairValueDisclosure" contextRef="C_0001748907_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">136,813</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000490" name="ortx:MarketableSecuritiesFairValueDisclosure" contextRef="C_0001748907_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">136,813</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000491" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001748907_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,650</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000492" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001748907_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">142,813</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000493" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001748907_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">149,463</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying amount reflected in the consolidated balance sheets for research and development tax incentive receivable, trade receivables, other receivables, accounts payable, and accrued expenses approximate fair value due to their short-term maturities. The carrying value of the Company&#8217;s outstanding notes payable approximates fair value (a Level 2 fair value measurement), reflecting interest rates currently available to the Company.</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-17</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000296_dcnt_32dce6f6-c954-4e20-b100-e33e7f6654e7">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Marketable Securities</span></p><ix:nonNumeric id="F_000345" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" contextRef="C_0001748907_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the Company&#8217;s cash equivalents and marketable securities as of December 31, 2021:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="18" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements as of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021 Using:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Credit Losses</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000494" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">102,224</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000497" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20211231" decimals="-3" scale="3">109</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000500" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">102,115</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000495" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapCommercialPaperMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">82,657</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000498" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapCommercialPaperMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20211231" decimals="-3" scale="3">58</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000501" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapCommercialPaperMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">82,599</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.58%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000496" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001748907_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">184,881</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000499" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0001748907_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20211231" decimals="-3" scale="3">167</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000502" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001748907_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">184,714</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the Company&#8217;s cash equivalents and marketable securities as of December 31, 2020:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="18" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.36%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements as of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020 Using:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Credit Losses</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government securities</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000503" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapUSTreasuryAndGovernmentMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000510" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapUSTreasuryAndGovernmentMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231" decimals="-3" scale="3">4</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000514" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapUSTreasuryAndGovernmentMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,996</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000504" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">96,259</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000507" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231" decimals="-3" scale="3">133</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000511" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231" decimals="-3" scale="3">32</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000515" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">96,360</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000505" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapCommercialPaperMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">43,469</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000508" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapCommercialPaperMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231" decimals="-3" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000512" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapCommercialPaperMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231" decimals="-3" scale="3">13</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000516" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapCommercialPaperMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">43,457</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000506" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001748907_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">142,728</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000509" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001748907_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231" decimals="-3" scale="3">134</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000513" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0001748907_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231" decimals="-3" scale="3">49</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000517" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001748907_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">142,813</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric><ix:nonNumeric id="F_000346" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" contextRef="C_0001748907_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the Company&#8217;s available-for-sale marketable debt securities by contractual maturity, as of December 31, 2021 and 2020:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maturities in one year or less</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000518" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">172,575</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000519" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" contextRef="C_0001748907_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">132,056</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maturities between one and three years</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000520" name="ortx:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsAmortizedCost" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">12,139</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000521" name="ortx:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsAmortizedCost" contextRef="C_0001748907_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">10,757</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000522" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">184,714</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000523" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" contextRef="C_0001748907_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">142,813</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:4pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;">&#160;</p><ix:nonNumeric id="F_000297" name="us-gaap:RevenueFromContractWithCustomerTextBlock" contextRef="C_0001748907_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4. Product sales</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the years ended December 31, 2021 and 2020, the Company recorded sales for one commercial-stage therapy, Strimvelis, for the treatment of ADA-SCID. Strimvelis is c<span style="Background-color:#FFFFFF;color:#000000;">urrently distributed exclusively at the San Raffaele Hospital in Milan, Italy. San Raffaele Hospital will purchase and pay for Strimvelis and submit a claim to the payer. The Company&#8217;s contracted sales with San Raffaele Hospital contain a single performance obligation and the Company recognizes revenue from product sales when the Company has satisfied its performance obligation by transferring control of Strimvelis to San Raffaele Hospital. Control of the product generally transfers upon the completion of the scheduled Strimvelis treatment. The Company&#8217;s product sales represent total net product sales of Strimvelis. The Company evaluated the variable consideration under Accounting Standards Codification (ASC) 606,&#160;</span><span style="font-style:italic;Background-color:#FFFFFF;color:#000000;">Revenue from Contracts with Customers</span><span style="Background-color:#FFFFFF;color:#000000;">, and there is currently no variable consideration included in the transaction price for Strimvelis. Costs to manufacture and deliver the product and those associated with administering the therapy are included in cost of product sales. As the product is sold in direct relation to a scheduled treatment, the Company estimates that there is limited risk of product return, including the risk of product expiration.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payment terms and conditions generally require payment for Strimvelis sales within <ix:nonNumeric id="F_000524" name="ortx:GeneralPaymentTermsMaximum" contextRef="C_0001748907_20210101_20211231" format="ixt-sec:durday">60</ix:nonNumeric> days of treatment. Strimvelis is currently distributed exclusively at the San Raffaele Hospital, and there is currently no variable consideration included in the transaction price of Strimvelis.</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-18</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000298" name="ortx:PrepaidExpensesAndOtherCurrentAssetsTextBlock" contextRef="C_0001748907_20210101_20211231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5. Prepaid expenses and other current assets</p><ix:nonNumeric id="F_000347" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" contextRef="C_0001748907_20210101_20211231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets consist of the following:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.32%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid external research and development expenses</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000525" name="ortx:PrepaidExternalResearchAndDevelopmentExpenses" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,438</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000526" name="ortx:PrepaidExternalResearchAndDevelopmentExpenses" contextRef="C_0001748907_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,421</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventories</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000527" name="us-gaap:InventoryNet" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,016</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000528" name="us-gaap:InventoryNet" contextRef="C_0001748907_20201231" decimals="-3" scale="3">665</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other prepayments</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000529" name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,128</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000530" name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="C_0001748907_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,930</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">VAT receivable</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000531" name="us-gaap:ValueAddedTaxReceivableCurrent" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,169</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000532" name="us-gaap:ValueAddedTaxReceivableCurrent" contextRef="C_0001748907_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,780</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction deposit - current</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000533" name="ortx:ConstructionDepositsCurrent" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,909</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000534" name="ortx:ConstructionDepositsCurrent" contextRef="C_0001748907_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,552</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-trade receivables</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000535" name="us-gaap:NontradeReceivablesCurrent" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,351</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000536" name="us-gaap:NontradeReceivablesCurrent" contextRef="C_0001748907_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,017</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total prepaid expenses and other current assets</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000537" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">23,011</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000538" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_0001748907_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">13,365</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000299" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" contextRef="C_0001748907_20210101_20211231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">6. Property and equipment </p><ix:nonNumeric id="F_000348" name="us-gaap:PropertyPlantAndEquipmentTextBlock" contextRef="C_0001748907_20210101_20211231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment consist of the following: </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.32%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment:</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lab equipment</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000539" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001748907_us-gaapPropertyPlantAndEquipmentByTypeAxis_ortxLabEquipmentMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,937</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000540" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001748907_us-gaapPropertyPlantAndEquipmentByTypeAxis_ortxLabEquipmentMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,114</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000541" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001748907_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,450</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000542" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001748907_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,522</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000543" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001748907_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20211231" decimals="-3" scale="3">303</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000544" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001748907_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20201231" decimals="-3" scale="3">304</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Office and IT equipment</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000545" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001748907_us-gaapPropertyPlantAndEquipmentByTypeAxis_ortxOfficeAndITEquipmentMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,023</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000546" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001748907_us-gaapPropertyPlantAndEquipmentByTypeAxis_ortxOfficeAndITEquipmentMember_20201231" decimals="-3" scale="3">763</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction-in-progress</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000547" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001748907_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20211231" decimals="-3" scale="3">211</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000548" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001748907_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20201231" decimals="-3" scale="3">302</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000549" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">10,924</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000550" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001748907_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,005</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: accumulated depreciation</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000551" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,157</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000552" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_0001748907_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,224</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000553" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,767</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000554" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001748907_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,781</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation expense for the years ended December&#160;31, 2021 and 2020 was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000555" name="us-gaap:Depreciation" contextRef="C_0001748907_20210101_20211231" decimals="-5" scale="6">2.2</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000556" name="us-gaap:Depreciation" contextRef="C_0001748907_20200101_20201231" decimals="-5" scale="6">2.0</ix:nonFraction> million, respectively.</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000300" name="us-gaap:IntangibleAssetsDisclosureTextBlock" contextRef="C_0001748907_20210101_20211231" escape="true" continuedAt="F_000300_dcnt_abb2b3a1-7e84-4a35-b1da-e68be318f3ef">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7. Intangible assets, net</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000349" name="ortx:ScheduleOfIntangibleAssetsNetOfAccumulatedAmortizationTableTextBlock" contextRef="C_0001748907_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets, net of accumulated amortization, consisted of the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.06%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.32%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated Amortization</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Net</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated Amortization</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Net</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License intangibles</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000557" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="C_0001748907_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicenseMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,329</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000559" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="C_0001748907_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicenseMember_20211231" decimals="-3" scale="3">180</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000561" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="C_0001748907_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicenseMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,149</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000563" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="C_0001748907_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicenseMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,076</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000565" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="C_0001748907_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicenseMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,076</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000558" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,329</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000560" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="C_0001748907_20211231" decimals="-3" scale="3">180</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000562" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,149</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000564" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="C_0001748907_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,076</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000566" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="C_0001748907_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,076</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License intangibles consist of capitalized milestone payments or accruals of payments the Company has deemed probable upon receiving regulatory approval of Libmeldy in the EU. The license intangibles are being amortized on a straight-line basis over the remaining useful life of the related patents of approximately <ix:nonNumeric id="F_000567" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" contextRef="C_0001748907_20210101_20211231" format="ixt-sec:durwordsen">twelve years</ix:nonNumeric>. For year ended December 31, 2021, amortization of intangible assets totaled $<ix:nonFraction unitRef="U_iso4217USD" id="F_000568" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="C_0001748907_20211231" decimals="-5" scale="6">0.2</ix:nonFraction> million. For the year ended December 31, 2020, amortization of intangible assets was nil. The effect of foreign currency translation on the net carrying value of intangible assets during 2021 was not material.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000350" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" contextRef="C_0001748907_20210101_20211231" escape="true" continuedAt="F_000350_dcnt_7511533f-fc3e-4121-96d3-53d26ed2ffba">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the estimated future amortization for intangible assets for the next five years and thereafter:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-19</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000300_dcnt_abb2b3a1-7e84-4a35-b1da-e68be318f3ef"><ix:continuation id="F_000350_dcnt_7511533f-fc3e-4121-96d3-53d26ed2ffba">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000569" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" contextRef="C_0001748907_20211231" decimals="-3" scale="3">364</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000570" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" contextRef="C_0001748907_20211231" decimals="-3" scale="3">364</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000571" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" contextRef="C_0001748907_20211231" decimals="-3" scale="3">364</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000572" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" contextRef="C_0001748907_20211231" decimals="-3" scale="3">364</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2026</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000573" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" contextRef="C_0001748907_20211231" decimals="-3" scale="3">364</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000574" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,329</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000575" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,149</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation></ix:continuation><ix:nonNumeric id="F_000301" name="us-gaap:OtherAssetsDisclosureTextBlock" contextRef="C_0001748907_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">8. Other assets</p><ix:nonNumeric id="F_000351" name="us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock" contextRef="C_0001748907_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets consist of the following:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000576" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,086</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000577" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="C_0001748907_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,219</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deposits</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000578" name="us-gaap:DepositsAssetsNoncurrent" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,404</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000579" name="us-gaap:DepositsAssetsNoncurrent" contextRef="C_0001748907_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,144</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred financing costs</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000580" name="us-gaap:DeferredFinanceCostsNoncurrentNet" contextRef="C_0001748907_20211231" decimals="-3" scale="3">693</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000581" name="us-gaap:DeferredFinanceCostsNoncurrentNet" contextRef="C_0001748907_20201231" decimals="-3" scale="3">975</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other non-current assets</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000582" name="ortx:OtherNonCurrentAssets" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,407</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000583" name="ortx:OtherNonCurrentAssets" contextRef="C_0001748907_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,554</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction deposits - long-term</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000584" name="ortx:ConstructionDepositsLongTerm" contextRef="C_0001748907_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,572</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other assets</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000585" name="us-gaap:OtherAssetsNoncurrent" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,590</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000586" name="us-gaap:OtherAssetsNoncurrent" contextRef="C_0001748907_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">15,464</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000302" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" contextRef="C_0001748907_20210101_20211231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9. Accrued expenses and other liabilities </p><ix:nonNumeric id="F_000352" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" contextRef="C_0001748907_20210101_20211231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses and other current liabilities consisted of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued external research and development expenses</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000587" name="ortx:AccruedExternalResearchAndDevelopmentExpensesCurrent" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,273</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000588" name="ortx:AccruedExternalResearchAndDevelopmentExpensesCurrent" contextRef="C_0001748907_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,878</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued payroll and related expenses</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000589" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,521</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000590" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="C_0001748907_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">11,881</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued milestone payments</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000591" name="ortx:AccruedMilestonePaymentsCurrent" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,058</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000592" name="ortx:AccruedMilestonePaymentsCurrent" contextRef="C_0001748907_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,252</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued professional fees</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000593" name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="C_0001748907_20211231" decimals="-3" scale="3">854</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000594" name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="C_0001748907_20201231" decimals="-3" scale="3">791</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued other</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000595" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,941</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000596" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="C_0001748907_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,225</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Strimvelis liability - current portion</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000597" name="ortx:ProductLiabilityCurrentPortion" contextRef="C_0001748907_20211231" decimals="-3" scale="3">671</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000598" name="ortx:ProductLiabilityCurrentPortion" contextRef="C_0001748907_20201231" decimals="-3" scale="3">916</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accrued expenses and other current liabilities</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000599" name="ortx:AccruedExpensesAndOtherCurrentLiabilities" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">24,318</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000600" name="ortx:AccruedExpensesAndOtherCurrentLiabilities" contextRef="C_0001748907_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">28,943</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000303" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" contextRef="C_0001748907_20210101_20211231" escape="true" continuedAt="F_000303_dcnt_49aa5edf-d3b2-420e-b3c1-77d97382be7a">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">10. Restructuring charges</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2020<span style="Background-color:#FFFFFF;color:#000000;">, the Company committed to a new strategic plan and restructuring intended to enable the Company to advance its corporate strategy while reducing overall operating expenses, including ceasing construction and build-out of its Fremont, California manufacturing facility, closing its office in Menlo Park, California, reducing its workforce by approximately&#160;<ix:nonFraction unitRef="U_xbrlipure" id="F_000601" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" contextRef="C_0001748907_us-gaapRestructuringPlanAxis_ortxMenloParkCaliforniaMember_20200501_20200531" decimals="2" scale="-2">25</ix:nonFraction>% across the Company, eliminating a number of future positions expected to be recruited in 2020 and 2021, reducing its investment in the future development for certain programs, and other cost-saving measures (collectively, the &#8220;Restructuring&#8221;). The workforce reductions took place primarily during the second and third quarters of 2020, and concluded in the fourth quarter of 2020.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Cash restructuring charges</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000353" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" contextRef="C_0001748907_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Accrued restructuring and severance costs are included in Accrued expenses and other current liabilities in the consolidated balance sheet. Activity for the fiscal year is summarized as follows:</span></p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.06%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at beginning of period</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Charged to expense</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000602" name="us-gaap:RestructuringCharges" contextRef="C_0001748907_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,854</ix:nonFraction></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payments made</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000603" name="us-gaap:PaymentsForRestructuring" contextRef="C_0001748907_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,848</ix:nonFraction></p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at end of period</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000604" name="us-gaap:RestructuringReserve" contextRef="C_0001748907_20201231" decimals="-3" scale="3">6</ix:nonFraction></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-20</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000303_dcnt_49aa5edf-d3b2-420e-b3c1-77d97382be7a">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">There were <ix:nonFraction unitRef="U_iso4217USD" id="F_000605" name="us-gaap:RestructuringCharges" contextRef="C_0001748907_20210101_20211231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction> restructuring costs during the year ended December 31, 2021.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Impairment of long-lived assets</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000354" name="us-gaap:DetailsOfImpairmentOfLongLivedAssetsHeldAndUsedByAssetTextBlock" contextRef="C_0001748907_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">During the second quarter of 2020, the Company also took the following non-cash charges to research and development expense associated with the impairment of construction-in-process associated with the Fremont manufacturing facility, partial impairment of the right-of-use asset for the Fremont manufacturing facility lease (the &#8220;Fremont ROU asset&#8221;), and a write-down of laboratory equipment from the Company&#8217;s Menlo Park, CA facility:</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Asset write-down</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease right-of-use asset</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000606" name="us-gaap:OperatingLeaseImpairmentLoss" contextRef="C_0001748907_20200401_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">2,605</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction-in-progress</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000607" name="ortx:ImpairmentOfConstructionInProcess" contextRef="C_0001748907_20200401_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">2,285</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000608" name="ortx:ImpairmentOfLaboratoryEquipment" contextRef="C_0001748907_20200401_20200630" decimals="-3" scale="3">760</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Charge included in research and development expense</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000609" name="us-gaap:AssetImpairmentCharges" contextRef="C_0001748907_20200401_20200630" decimals="-3" format="ixt:numdotdecimal" scale="3">5,650</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company assessed the Fremont construction-in-process for impairment in May 2020 upon the Restructuring. The construction-in-process related to design costs, and was determined to have no potential future value, and an impairment charge of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000610" name="ortx:ImpairmentOfConstructionInProcess" contextRef="C_0001748907_us-gaapRestructuringPlanAxis_ortxFremontCaliforniaMember_20200501_20200531" decimals="-5" scale="6">2.3</ix:nonFraction>&#160;million was taken for the full value of the construction-in-process asset.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">&#160;</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company assessed the Fremont ROU asset for impairment in May 2020 upon the Restructuring when the carrying value of the asset was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000611" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0001748907_us-gaapRestructuringPlanAxis_ortxFremontCaliforniaMember_20200531" decimals="-5" scale="6">13.8</ix:nonFraction>&#160;million. The Fremont ROU asset represented the asset group for the impairment assessment. Upon failing the first step of the long-lived asset impairment model where the undiscounted cash flows were less than the carrying value of the Fremont ROU asset, the Company performed the second step by comparing the fair value of the Fremont ROU asset to its carrying value. The fair value of the Fremont ROU asset is a non-recurring fair value measurement that was measured using a probability-weighted discounted cash flow approach, which estimated the present value of potential sublease income to be generated by the facility, less costs incurred to sublease the facility. The significant assumptions inherent in estimating the various probability weighted scenarios included the undiscounted forecasted sublease income less costs incurred, which included assumptions of the expected income and timing of entering into a future sublease, and a market-participant discount rate that reflects a potential discount rate. The Company selected the assumptions used in the fair value estimate using current market data associated with the potential sublease income and market participant discount rates. The undiscounted cash flows utilized in the fair value estimate ranged from $<ix:nonFraction unitRef="U_iso4217USD" id="F_000612" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="C_0001748907_srtRangeAxis_srtMinimumMember_us-gaapRestructuringPlanAxis_ortxFremontCaliforniaMember_20200531" decimals="-5" scale="6">11.7</ix:nonFraction>&#160;million to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000613" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="C_0001748907_srtRangeAxis_srtMaximumMember_us-gaapRestructuringPlanAxis_ortxFremontCaliforniaMember_20200531" decimals="-5" scale="6">19.1</ix:nonFraction>&#160;million to be generated over the remainder of the lease term. The market-participant discount rate utilized in the fair value estimate was&#160;<ix:nonFraction unitRef="U_xbrlipure" id="F_000614" name="us-gaap:LesseeOperatingLeaseDiscountRate" contextRef="C_0001748907_us-gaapRestructuringPlanAxis_ortxFremontCaliforniaMember_20200531" decimals="3" scale="-2">4.6</ix:nonFraction>%. These assumptions represent level 3 inputs of the fair value hierarchy (see Note 3).</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">&#160;</span></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">As of the assessment date, the fair value of the Fremont ROU asset was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000615" name="ortx:OperatingLeaseRightOfUseAssetFairValue" contextRef="C_0001748907_us-gaapRestructuringPlanAxis_ortxFremontCaliforniaMember_20200531" decimals="-5" scale="6">11.2</ix:nonFraction>&#160;million, and the Company recorded a $<ix:nonFraction unitRef="U_iso4217USD" id="F_000616" name="us-gaap:OperatingLeaseImpairmentLoss" contextRef="C_0001748907_us-gaapRestructuringPlanAxis_ortxFremontCaliforniaMember_20200501_20200531" decimals="-5" scale="6">2.6</ix:nonFraction>&#160;million impairment charge related to the asset. The remaining carrying value of the Fremont ROU asset is being amortized over the remaining lease term on a straight-line basis. In December 2020, the Company executed a sublease for the Fremont manufacturing facility with an unrelated third-party for the remaining lease term (see Note 11). <ix:nonFraction unitRef="U_iso4217USD" id="F_000617" name="us-gaap:OperatingLeaseImpairmentLoss" contextRef="C_0001748907_us-gaapRestructuringPlanAxis_ortxFremontCaliforniaMember_20201201_20201231" decimals="-6" format="ixt-sec:numwordsen" scale="6">No</ix:nonFraction> further impairment was necessary as a result of the sublease. The occurrence of a triggering event for the Fremont ROU asset in future periods could result in additional impairment charges if the estimated fair value of the asset is determined to be lower than the carrying value.</span></p></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:9pt;">&#160;</p><ix:nonNumeric id="F_000304" name="us-gaap:LesseeOperatingLeasesTextBlock" contextRef="C_0001748907_20210101_20211231" escape="true" continuedAt="F_000304_dcnt_2b0833d3-0038-4281-90cc-ef1d09ff17a7">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">11. Leases</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Operating leases</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2017 and January 2019, the Company entered into lease agreements for office and laboratory space in Menlo Park, California, United States. The leases terminated in <span style="-sec-ix-hidden:F_000618"><span style="-sec-ix-hidden:F_000619">December 2020</span></span>. The combined annual rental payments, including variable payments, under both leases with the same landlord were <span style="-sec-ix-hidden:F_000620">nil</span> in 2021 and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000621" name="us-gaap:PaymentsForRent" contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxOfficeAndLaboratorySpaceMenloParkLeaseAgreementMember_20200101_20201231" decimals="-5" scale="6">1.9</ix:nonFraction> million in 2020. The Company was provided with <ix:nonNumeric id="F_000622" name="ortx:OperatingLeaseDurationForFreeRent" contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxOfficeSpaceMenloParkLeaseAgreementMember_20171101_20171130" format="ixt-sec:durwordsen">one month</ix:nonNumeric> of free rent in connection with the first lease. The lease agreement included annual rent escalation provisions. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2018 and December 2018, the Company entered into lease agreements for office space in London, United Kingdom, both of which terminate in <span style="-sec-ix-hidden:F_000623"><span style="-sec-ix-hidden:F_000624">January 2023</span></span>. The combined annual rental payments, including variable payments, under the lease agreements were $<ix:nonFraction unitRef="U_iso4217USD" id="F_000625" name="us-gaap:PaymentsForRent" contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxFiveYearsLeaseTermTerminatesInJanuaryTwoThousandTwentyThreeMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_ortxOfficeSpaceLondonUnitedKingdomLeaseAgreementMember_20210101_20211231" decimals="-5" scale="6">1.8</ix:nonFraction> million in 2021 and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000626" name="us-gaap:PaymentsForRent" contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxFiveYearsLeaseTermTerminatesInJanuaryTwoThousandTwentyThreeMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_ortxOfficeSpaceLondonUnitedKingdomLeaseAgreementMember_20200101_20201231" decimals="-5" scale="6">1.7</ix:nonFraction> million in 2020. The Company also rented lab spaces in London in 2021, for which it made $<ix:nonFraction unitRef="U_iso4217USD" id="F_000627" name="us-gaap:PaymentsForRent" contextRef="C_0001748907_us-gaapPropertyPlantAndEquipmentByTypeAxis_ortxRentalLabSpaceMember_20210101_20211231" decimals="-5" scale="6">0.2</ix:nonFraction> million in payments in 2021.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2018, the Company entered into a lease agreement for office space in Boston, Massachusetts, United States, which terminates in <span style="-sec-ix-hidden:F_000628">September 2022</span>. The annual rental payments, including variable payments, were $<ix:nonFraction unitRef="U_iso4217USD" id="F_000629" name="us-gaap:PaymentsForRent" contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxLeaseTermTerminatesInSeptemberTwoThousandTwentyTwoMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_ortxOfficeSpaceBostonUnitedStatesLeaseAgreementMember_20200101_20201231" decimals="-5" scale="6">0.4</ix:nonFraction> million in 2021 and </p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-21</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000304_dcnt_2b0833d3-0038-4281-90cc-ef1d09ff17a7" continuedAt="F_000304_dcnt_8a149260-835c-4ed6-b077-6bb4d2238215">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020. The lease agreement includes annual rent escalation provisions.</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> The Company has subleased the space in</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> August 2021, and rec</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ognized</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> $</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000630" name="us-gaap:SubleaseIncome" contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxLeaseTermTerminatesInSeptemberTwoThousandTwentyTwoMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_ortxOfficeSpaceBostonUnitedStatesLeaseAgreementMember_20210101_20211231" decimals="-5" scale="6">0.1</ix:nonFraction></span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million in sublease income in 2021.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2019, the Company entered into a lease agreement for office space in Boston, Massachusetts, United States, which commences for accounting purposes in <span style="-sec-ix-hidden:F_000631">January 2020</span>. The lease terminates in <span style="-sec-ix-hidden:F_000632">September 2026</span>. The annual rental payments, including variable payments, were $<ix:nonFraction unitRef="U_iso4217USD" id="F_000633" name="us-gaap:PaymentsForRent" contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxLeaseTermTerminatesInSeptemberTwoThousandTwentySixMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_ortxOfficeSpaceBostonUnitedStatesLeaseAgreementMember_20210101_20211231" decimals="-5" scale="6">1.1</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000634" name="us-gaap:PaymentsForRent" contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxLeaseTermTerminatesInSeptemberTwoThousandTwentySixMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_ortxOfficeSpaceBostonUnitedStatesLeaseAgreementMember_20200101_20201231" decimals="-5" scale="6">0.9</ix:nonFraction> million in 2021 and 2020, respectively. The lease agreement includes annual rent escalation provisions.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, the carrying value of the operating lease right-of-use assets in Boston and London was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000635" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxBostonAndLondonOfficeSpaceLeaseAgreementsMember_20211231" decimals="-5" scale="6">4.1</ix:nonFraction> million and the lease liabilities was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000636" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxBostonAndLondonOfficeSpaceLeaseAgreementsMember_20201231" decimals="-5" scale="6">4.3</ix:nonFraction> million. As of December 31, 2020, the carrying value of the operating lease right-of-use assets in Boston and London was $<span style="color:#000000;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000637" name="us-gaap:OperatingLeaseLiability" contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxBostonAndLondonOfficeSpaceLeaseAgreementsMember_20211231" decimals="-5" scale="6">5.4</ix:nonFraction></span> million and the lease liabilities was $<span style="color:#000000;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000638" name="us-gaap:OperatingLeaseLiability" contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxBostonAndLondonOfficeSpaceLeaseAgreementsMember_20201231" decimals="-5" scale="6">5.7</ix:nonFraction></span> million.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Fremont operating lease and sublease agreements</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2018, the Company leased manufacturing, laboratory, and office space in Fremont, California (the &#8220;Fremont facility&#8221; and the &#8220;Head Lease&#8221;) which terminates in <span style="-sec-ix-hidden:F_000639">May 2030</span>. In May 2020, the Company committed to a restructuring plan (see Note 10) whereby we ceased construction and build-out of the Fremont facility. I<span style="color:#000000;">n December 2020, the Company entered into a sublease agreement (the &#8220;Sublease&#8221;) with an unrelated third-party (the &#8220;subtenant&#8221;) whereby the Company subleased the entire Fremont facility to the subtenant. The Company accounts for the Head Lease and Sublease as two separate contracts. Both the Head Lease and Sublease were determined to be operating leases.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Head Lease annual rental payments, including variable payments, were $<ix:nonFraction unitRef="U_iso4217USD" id="F_000643" name="us-gaap:PaymentsForRent" contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxFremontLeaseAgreementMember_20200101_20201231" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000644" name="us-gaap:PaymentsForRent" contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxFremontLeaseAgreementMember_20210101_20211231" decimals="-5" scale="6">3.1</ix:nonFraction></ix:nonFraction> million in 2021 and 2020. The Head Lease includes annual rent escalation provisions. The Company was provided with <ix:nonNumeric id="F_000640" name="ortx:OperatingLeaseDurationForFreeRent" contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxFremontLeaseAgreementMember_20181201_20181231" format="ixt-sec:durmonth">8</ix:nonNumeric> months of free rent. Subject to the terms of the Head Lease agreement, the Company executed a $<ix:nonFraction unitRef="U_iso4217USD" id="F_000642" name="us-gaap:ProceedsFromLinesOfCredit" contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxFremontLeaseAgreementMember_20181201_20181231" decimals="-5" scale="6">3.0</ix:nonFraction> million letter of credit upon signing the lease, which may be reduced by <ix:nonFraction unitRef="U_xbrlipure" id="F_000641" name="ortx:ReductionOfStandbyLetterOfCreditAmountPercentage" contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxFremontLeaseAgreementMember_20181201_20181231" decimals="2" scale="-2">25</ix:nonFraction>% subject to reduction requirements specified therein. This amount is classified as restricted cash on the consolidated balance sheets. <span style="color:#808080;"> </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, the carrying value of the Fremont Head Lease right-of-use asset was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000645" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxFremontLeaseAgreementMember_20211231" decimals="-5" scale="6">9.5</ix:nonFraction> million and the lease liability was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000646" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxFremontLeaseAgreementMember_20211231" decimals="-5" scale="6">13.1</ix:nonFraction> million. <span style="color:#000000;">The Head Lease provides for up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000647" name="ortx:TenantImprovementAllowance" contextRef="C_0001748907_srtRangeAxis_srtMaximumMember_us-gaapLeaseContractualTermAxis_ortxFremontLeaseAgreementMember_20210101_20211231" decimals="-5" scale="6">5.3</ix:nonFraction> million in tenant improvement allowances to be reimbursed to the Company by the landlord. These tenant improvement allowances have been included in the calculation of the operating lease liability and is currently expected to be received in 2022. The Company continues to assess the expected receipt of the tenant improvement allowances and may remeasure the right-of-use asset and liability from time to time as facts and circumstances may change</span>.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Sublease commenced in December 2020 and is in force for the remainder of the Head Lease term, through May 2030. The Sublease provides for <ix:nonNumeric id="F_000648" name="ortx:OperatingLeaseDurationForFreeRent" contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxFremontSubleaseAgreementMember_20200101_20201231" format="ixt-sec:durmonth">12</ix:nonNumeric> months of free rent until December 2021. The sublease provides for an initial annual cash base rent of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000649" name="us-gaap:PaymentsForRent" contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxFremontSubleaseAgreementMember_20200101_20201231" decimals="-5" scale="6">2.2</ix:nonFraction> million, with annual rent escalation provisions. The subtenant is also responsible for paying all operating expenses associated with the Head Lease. The Sublease also includes pass-through of up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000650" name="ortx:TenantImprovementAllowance" contextRef="C_0001748907_srtRangeAxis_srtMaximumMember_us-gaapLeaseContractualTermAxis_ortxFremontSubleaseAgreementMember_20200101_20201231" decimals="-5" scale="6">5.3</ix:nonFraction> million in tenant improvement allowances to the subtenant, subject to the Company being reimbursed for the allowances per the terms of the Head Lease. The Subtenant provided the Company with a $<ix:nonFraction unitRef="U_iso4217USD" id="F_000651" name="us-gaap:SecurityDeposit" contextRef="C_0001748907_us-gaapBalanceSheetLocationAxis_us-gaapOtherNoncurrentLiabilitiesMember_us-gaapLeaseContractualTermAxis_ortxFremontSubleaseAgreementMember_20201231" decimals="-5" scale="6">2.6</ix:nonFraction> million security deposit, which may be converted to a letter of credit upon providing evidence of $2.6 million in construction expenditures. The Company accounts for the security deposit within other long-term liabilities.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has $<ix:nonFraction unitRef="U_iso4217USD" id="F_000653" name="us-gaap:EscrowDeposit" contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxFremontLeaseAgreementMember_20201231" decimals="-5" scale="6">7.9</ix:nonFraction> million in an escrow account associated with construction on the Fremont facility, for which the Company has ceased construction and build-out. Subject to the terms of the Head Lease and reduction provisions, this amount may be returned to the Company upon qualifying construction expenditure, or will be returned in late 2022 (the &#8220;Sunset Date&#8221;) to the extent construction expenses have not been incurred. The Company deposited $<ix:nonFraction unitRef="U_iso4217USD" id="F_000652" name="us-gaap:EscrowDeposit" contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxFremontLeaseAgreementMember_20200331" decimals="-5" scale="6">10.0</ix:nonFraction> million into the account in the first quarter of 2020 and has received $<ix:nonFraction unitRef="U_iso4217USD" id="F_000654" name="ortx:IncreaseDecreaseInEscrowDeposit" contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxFremontLeaseAgreementMember_20200101_20201231" decimals="-5" sign="-" format="ixt:numdotdecimal" scale="6">2.1</ix:nonFraction> million in receipts from the escrow funds for costs incurred to date. The escrow balance is all classified within other current assets on the consolidated balance sheets based on the timing of when the Company expects funds to be returned from the escrow agent. Future receipts from the escrow deposit will be dependent upon the timing of the subtenant construction spend through the Sunset Date.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-22</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000304_dcnt_8a149260-835c-4ed6-b077-6bb4d2238215" continuedAt="F_000304_dcnt_4dfb78bf-9dce-4907-8651-23081b52d5f0">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Embedded operating lease arrangement</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company is party to a manufacturing agreement for research and development and commercial production&#160;with AGC Biologics, S.p.A. (formerly MolMed S.p.A.) (&#8220;AGC&#8221;) pursuant to which AGC will develop, manufacture and supply certain viral vectors and conduct cell processing activities for certain Company development and commercial programs.&#160;&#160;A manufacturing agreement with AGC was novated to the Company as part of the GSK Agreement (see Note 15).&#160;&#160;On July 2, 2020 (the &#8220;Effective Date&#8221;), the Company entered into a new manufacturing and technology development master agreement with AGC (the &#8220;AGC Agreement&#8221;) which superseded the novated agreement.</span><span style="color:#000000;"> </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determined that the AGC Agreement contains an embedded lease as it includes provision of manufacturing suites designated for the Company&#8217;s exclusive use during the term of the agreement.&#160;<span style="Background-color:#FFFFFF;">The AGC Agreement has an initial term of&#160;<ix:nonNumeric id="F_000655" name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxGSKAgreementMember_20211231" format="ixt-sec:durwordsen">five years</ix:nonNumeric>, beginning on the Effective Date and ending <ix:nonNumeric id="F_000656" name="us-gaap:LeaseExpirationDate1" contextRef="C_0001748907_20210101_20211231" format="ixt:datemonthdayyearen">July 2, 2025</ix:nonNumeric>.&#160;<ix:nonNumeric id="F_000657" name="us-gaap:LesseeOperatingLeaseOptionToExtend" contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxGSKAgreementMember_20210101_20211231">The agreement may be extended for an additional&#160;<ix:nonNumeric id="F_000659" name="ortx:LesseeOperatingLeaseExtendedTerm" contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxGSKAgreementMember_20210101_20211231" format="ixt-sec:durwordsen">two years</ix:nonNumeric>&#160;by mutual agreement of the Company and AGC</ix:nonNumeric></span>. The AGC Agreement contains payments associated with lease and non-lease components. The contractual annual rental payments associated with the lease that are considered a lease component amount to &#8364;<ix:nonFraction unitRef="U_iso4217EUR" id="F_000660" name="ortx:LeaseComponentManufacturingCommitmentAmount" contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxGSKAgreementMember_20211231" decimals="-5" scale="6">2.7</ix:nonFraction>&#160;million per contract year. The non-lease components of the agreement consist of minimum manufacturing purchase requirements and dedicated manufacturing and development services (see Note 18).</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, the carrying value of the embedded operating lease right-of-use asset was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000661" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxGSKAgreementMember_20211231" decimals="-5" scale="6">10.7</ix:nonFraction> million and the lease liability was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000663" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxGSKAgreementMember_20211231" decimals="-5" scale="6">9.3</ix:nonFraction> million. <span style="color:#000000;">As of December 31, 2020, the carrying value of the embedded operating lease right-of-use asset was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000662" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxGSKAgreementMember_20201231" decimals="-5" scale="6">13.9</ix:nonFraction> million and the lease liability was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000664" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxGSKAgreementMember_20201231" decimals="-5" scale="6">13.1</ix:nonFraction> million. </span><span style="Background-color:#FFFFFF;color:#000000;">The Company may terminate the AGC Agreement and the use of the exclusive manufacturing suites, with 12-months&#8217; notice, and beginning no earlier than July 2, 2022. AGC may terminate the AGC Agreement with 24-months&#8217; notice. The AGC Agreement provides for an option to reserve one additional exclusive manufacturing suite any time prior to January 1, 2022 for a one-time option fee plus annual rental fee. The AGC Agreement extends until&#160;<ix:nonNumeric id="F_000665" name="us-gaap:LeaseExpirationDate1" contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxGSKAgreementMember_20200101_20201231" format="ixt:datemonthdayyearen">July 2, 2025</ix:nonNumeric>.</span></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Summary of all lease costs recognized under ASC 842</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our facility leases described above generally contain customary provisions allowing the landlords to terminate the leases if we fail to remedy a breach of any of our obligations under any such lease within specified time periods, or upon our bankruptcy or insolvency. The leases do not include any restrictions or covenants that had to be accounted for under the lease guidance. <ix:nonNumeric id="F_000355" name="us-gaap:LeaseCostTableTextBlock" contextRef="C_0001748907_20210101_20211231" escape="true" continuedAt="F_000355_cnt_1">The following table contains a summary of the lease-related costs recognized within operating expenses, and other information pertaining to the Company&#8217;s operating leases as of December 31, 2021 and 2020:</ix:nonNumeric></p><ix:continuation id="F_000355_cnt_1">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fixed lease cost</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000666" name="ortx:FixedLeaseCost" contextRef="C_0001748907_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,701</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000667" name="ortx:FixedLeaseCost" contextRef="C_0001748907_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,593</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Impairment of right-of-use assets</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000668" name="us-gaap:OperatingLeaseImpairmentLoss" contextRef="C_0001748907_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,781</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Variable lease cost</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000669" name="us-gaap:VariableLeaseCost" contextRef="C_0001748907_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,696</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000670" name="us-gaap:VariableLeaseCost" contextRef="C_0001748907_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,131</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sublease income</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000671" name="us-gaap:SubleaseIncome" contextRef="C_0001748907_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,746</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000672" name="us-gaap:SubleaseIncome" contextRef="C_0001748907_20200101_20201231" decimals="-3" scale="3">181</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.24%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease cost</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000673" name="us-gaap:LeaseCost" contextRef="C_0001748907_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,651</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000674" name="us-gaap:LeaseCost" contextRef="C_0001748907_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">12,324</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other information</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; Operating cash flows used for operating leases</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000675" name="us-gaap:OperatingLeasePayments" contextRef="C_0001748907_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,989</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000676" name="us-gaap:OperatingLeasePayments" contextRef="C_0001748907_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,447</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; Weighted-average remaining lease term (years)</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000677">6.0</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000678">6.6</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; Weighted-average discount rate</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000679" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="C_0001748907_20211231" decimals="3" scale="-2">8.7</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000680" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="C_0001748907_20201231" decimals="3" scale="-2">8.6</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fixed lease cost represents the ASC 842 rent expense associated with the amortization of our right-of-use assets and lease liabilities. Impairment of right-of-use assets relates to discrete impairment charges taken when, in the Company&#8217;s estimation, the fair value of a right-of-use asset is below the carrying value. Variable lease cost are the amounts owed by the Company to a lessor that are not fixed, such as reimbursement for common area maintenance and utilities costs, and are not included in the calculation of the Company&#8217;s operating lease right of use assets or operating lease liabilities and are expensed when incurred. Sublease income represents the straight-line recognition of base rent sublease income over the term of the Sublease, and recognition of pass-through operating expense costs per the terms of the Sublease.</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31, 2021, the Company obtained right of use assets valued at $<ix:nonFraction unitRef="U_iso4217USD" id="F_000681" name="ortx:OperatingLeaseRightOfUseAssetValueExchangeForLeaseLiabilities" contextRef="C_0001748907_20211231" decimals="-5" scale="6">0.6</ix:nonFraction> million in exchange for </p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">lease liabilities of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000683" name="ortx:OperatingLeaseRightOfUseAssetValueExchangeForLeaseLiabilities" contextRef="C_0001748907_20211231" decimals="-5" scale="6">0.6</ix:nonFraction> million. During the year ended December 31, 2020 the Company obtained $<ix:nonFraction unitRef="U_iso4217USD" id="F_000682" name="ortx:OperatingLeaseRightOfUseAssetValueExchangeForLeaseLiabilities" contextRef="C_0001748907_20201231" decimals="-5" scale="6">17.5</ix:nonFraction> million in right of use assets in exchange for $<ix:nonFraction unitRef="U_iso4217USD" id="F_000684" name="ortx:OperatingLeaseRightOfUseAssetValueExchangeForLeaseLiabilities" contextRef="C_0001748907_20201231" decimals="-5" scale="6">17.5</ix:nonFraction> million in lease liabilities.</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-23</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000304_dcnt_4dfb78bf-9dce-4907-8651-23081b52d5f0">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000356" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" contextRef="C_0001748907_20210101_20211231" escape="true">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, future minimum base rent commitments under ASC 842 under the Company&#8217;s property leases were as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Due in:</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross lease payments</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross sublease receipts</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Net lease payments</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000685" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,326</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000694" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,334</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000701" name="ortx:OperatingLeaseLiabilityPaymentsDueYearOne" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,992</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000686" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,773</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000695" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedTwoYears" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,246</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000702" name="ortx:OperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,527</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000687" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,799</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000696" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedThreeYears" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,313</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000703" name="ortx:OperatingLeaseLiabilityPaymentsDueYearThree" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,486</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000688" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,361</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000697" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedFourYears" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,382</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000704" name="ortx:OperatingLeaseLiabilityPaymentsDueYearFour" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,979</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2026</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000689" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,720</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000698" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedFiveYears" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,454</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000705" name="ortx:OperatingLeaseLiabilityPaymentsDueYearFive" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,266</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000690" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">11,332</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000699" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedThereafter" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,960</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000706" name="ortx:OperatingLeaseLiabilityPaymentsDueAfterYearFive" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,372</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total future minimum lease payments</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000691" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">41,311</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000700" name="us-gaap:LessorOperatingLeasePaymentsToBeReceived" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">20,689</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000707" name="ortx:OperatingLeaseLiabilityPaymentsDueNet" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">20,622</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: imputed interest</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000692" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">14,698</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.84%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.84%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating lease payments</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000693" name="us-gaap:OperatingLeaseLiability" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">26,613</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.84%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.84%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*Tabular disclosure above for leases denominated in GBP have been translated at a rate of &#163;1.00 to $<ix:nonFraction unitRef="U_xbrlipure" id="F_000708" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" contextRef="C_0001748907_srtCurrencyAxis_currencyGBP_20211231" decimals="2">1.35</ix:nonFraction>, and leases denominated in Euro have been translated at a rate of &#8364;1.00 to $<ix:nonFraction unitRef="U_xbrlipure" id="F_000709" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" contextRef="C_0001748907_srtCurrencyAxis_currencyEUR_20211231" decimals="2">1.13</ix:nonFraction>. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000305" name="us-gaap:DebtDisclosureTextBlock" contextRef="C_0001748907_20210101_20211231" escape="true" continuedAt="F_000305_dcnt_c9a66364-9512-4e45-b335-155c66bbe940">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">12. Notes Payable</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In<span style="color:#000000;"> <span style="-sec-ix-hidden:F_000710">May 2019</span>, the Company entered into a senior term facilities agreement, which was amended in April 2020 (the &#8220;Original Credit Facility&#8221;) with MidCap Financial (Ireland) Limited (&#8220;MidCap Financial&#8221;), as agent, and additional lenders from time to time (together with MidCap Financial, the &#8220;Lenders&#8221;), to borrow up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000711" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="C_0001748907_20190531" decimals="INF" scale="6">75.0</ix:nonFraction> million in term loans.</span> </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2021, the Company amended and restated the Original Credit Facility (the &#8220;Amended Credit Facility&#8221;). Under the Amended Credit Facility, the Lenders agreed to make term loans available to the Company in the aggregate amount of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000712" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="C_0001748907_20210531" decimals="INF" scale="6">100.0</ix:nonFraction> million, including increasing the principal on the initial term loan to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000713" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="C_0001748907_us-gaapDebtInstrumentAxis_ortxTheFirstTrancheTermLoanMember_20210531" decimals="INF" scale="6">33.0</ix:nonFraction> million, from $<ix:nonFraction unitRef="U_iso4217USD" id="F_000714" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="C_0001748907_us-gaapDebtInstrumentAxis_ortxTheFirstTrancheTermLoanMember_20190531" decimals="INF" scale="6">25.0</ix:nonFraction> million. To date, the Company has borrowed $<ix:nonFraction unitRef="U_iso4217USD" id="F_000715" name="us-gaap:ProceedsFromLinesOfCredit" contextRef="C_0001748907_us-gaapDebtInstrumentAxis_ortxTheFirstTrancheTermLoanMember_20210501_20210531" decimals="-5" scale="6">33.0</ix:nonFraction> million under the amended initial term loan. The remaining $<ix:nonFraction unitRef="U_iso4217USD" id="F_000716" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" contextRef="C_0001748907_20210531" decimals="-5" scale="6">67.0</ix:nonFraction> million under the Amended Credit Facility may be drawn down in the form of a second and third term loan, <span style="Background-color:#FFFFFF;">the second term loan being a $<ix:nonFraction unitRef="U_iso4217USD" id="F_000717" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="C_0001748907_us-gaapDebtInstrumentAxis_ortxTheSecondTrancheTermLoanMember_20210531" decimals="INF" scale="6">33.0</ix:nonFraction>&#160;million term loan available no earlier than July 1, 2022&#160;&#160;and no later than July 1, 2023 <ix:nonNumeric id="F_000721" name="us-gaap:LineOfCreditFacilityCovenantTerms" contextRef="C_0001748907_us-gaapDebtInstrumentAxis_ortxTheSecondTrancheTermLoanMember_20210101_20211231">upon certain regulatory approvals and evidence of the Company having $<ix:nonFraction unitRef="U_iso4217USD" id="F_000719" name="us-gaap:InvestmentsAndCash" contextRef="C_0001748907_srtRangeAxis_srtMinimumMember_us-gaapDebtInstrumentAxis_ortxTheSecondTrancheTermLoanMember_20210531" decimals="-6" scale="6">100</ix:nonFraction>&#160;million in cash and cash equivalent investments</ix:nonNumeric>&#59; and the third term loan being a $<ix:nonFraction unitRef="U_iso4217USD" id="F_000718" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="C_0001748907_us-gaapDebtInstrumentAxis_ortxTheThirdTrancheTermLoanMember_20210531" decimals="INF" scale="6">34.0</ix:nonFraction>&#160;million term loan available no earlier than July 1, 2023 and no later than July 1, 2024 <ix:nonNumeric id="F_000722" name="us-gaap:LineOfCreditFacilityCovenantTerms" contextRef="C_0001748907_us-gaapDebtInstrumentAxis_ortxTheThirdTrancheTermLoanMember_20210101_20211231">upon evidence of the Company having $<ix:nonFraction unitRef="U_iso4217USD" id="F_000720" name="us-gaap:InvestmentsAndCash" contextRef="C_0001748907_srtRangeAxis_srtMinimumMember_us-gaapDebtInstrumentAxis_ortxTheThirdTrancheTermLoanMember_20210531" decimals="-6" scale="6">100</ix:nonFraction>&#160;million in cash and cash equivalent investments and attaining a pre-specified trailing 12-month revenue target</ix:nonNumeric>.</span><span style="color:#000000;">&#160;&#160;&#160;&#160;&#160;</span><span style="Background-color:#FFFFFF;"> </span><span style="color:#000000;">&#160;&#160;&#160;&#160;</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000730" name="us-gaap:LineOfCreditFacilityInterestRateDescription" contextRef="C_0001748907_20210101_20211231">Prior to execution of the Amended Credit Facility, each term loan under the Original Credit Facility bore interest at an annual rate equal to <ix:nonFraction unitRef="U_xbrlipure" id="F_000723" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="C_0001748907_us-gaapVariableRateAxis_ortxLondonInterbankOfferedRateFloorMember_20190501_20190531" decimals="3" scale="-2">6.0</ix:nonFraction>% plus LIBOR. The Company was required to make interest-only payments on the term loan for all payment dates prior to <ix:nonNumeric id="F_000724" name="ortx:LineOfCreditFacilityInterestPaymentsTerm" contextRef="C_0001748907_20190501_20190531" format="ixt-sec:durmonth">24</ix:nonNumeric> months following the date of the Original Credit Facility, unless the third tranche was drawn, in which case for all payment dates prior to <ix:nonNumeric id="F_000725" name="ortx:LineOfCreditFacilityAmortizationTerm" contextRef="C_0001748907_20190501_20190531" format="ixt-sec:durmonth">36</ix:nonNumeric> months following the date of the Original Credit Facility. The term loans prior to the Amended Credit Facility were to begin amortizing on either the&#160;24-month&#160;or the&#160;36-month&#160;anniversary of the Original Credit Facility (as applicable), with equal <ix:nonNumeric id="F_000726" name="us-gaap:LineOfCreditFacilityFrequencyOfPayments" contextRef="C_0001748907_20210101_20211231">monthly payments</ix:nonNumeric> of principal plus interest to be made by the Borrower to the Lenders in consecutive monthly installments until the loan maturity date. In addition, a final payment of <ix:nonFraction unitRef="U_xbrlipure" id="F_000727" name="ortx:LineOfCreditFacilityPercentageOfFinalPayment" contextRef="C_0001748907_20190501_20190531" decimals="3" scale="-2">4.5</ix:nonFraction>% was due on the loan maturity date.</ix:nonNumeric> The Company accrued the final payment amount of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000728" name="us-gaap:LineOfCreditFacilityPeriodicPaymentInterest" contextRef="C_0001748907_20190501_20190531" decimals="-5" scale="6">1.1</ix:nonFraction> million associated with the first term loan of the Original Credit Facility, to outstanding debt by charges to interest expense using the effective-interest method from the date of issuance through the date of the Amended Credit Facility. Upon execution of the Amended Credit Facility, the Company was required to make a payment of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000729" name="us-gaap:RepaymentsOfLinesOfCredit" contextRef="C_0001748907_20190501_20190531" decimals="-5" scale="6">0.5</ix:nonFraction> million for the accrued final payment associated with the Original Credit Facility, which was netted against proceeds from the additional initial term loan.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each term loan under the Amended Credit Facility bears interest at an annual rate equal to <ix:nonFraction unitRef="U_xbrlipure" id="F_000731" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="C_0001748907_us-gaapVariableRateAxis_ortxLondonInterbankOfferedRateFloorMember_20210501_20210531" decimals="4" scale="-2">5.95</ix:nonFraction>% plus LIBOR. The Company is required to make interest-only payments on the term loan for <ix:nonNumeric id="F_000732" name="ortx:LineOfCreditFacilityInterestPaymentsTerm" contextRef="C_0001748907_20210501_20210531" format="ixt-sec:durmonth">18</ix:nonNumeric> months following the date of the Amended Credit Facility, unless the Company is eligible for the second tranche, in which case the Company may elect to make interest-only payments for <span><ix:nonNumeric id="F_000733" name="ortx:LineOfCreditFacilityInterestPaymentsTerm" contextRef="C_0001748907_us-gaapDebtInstrumentAxis_ortxTheSecondTrancheTermLoanMember_20210501_20210531" format="ixt-sec:durmonth"><ix:nonNumeric id="F_000734" name="ortx:LineOfCreditFacilityInterestPaymentsTerm" contextRef="C_0001748907_us-gaapDebtInstrumentAxis_ortxTheThirdTrancheTermLoanMember_20210501_20210531" format="ixt-sec:durmonth">30</ix:nonNumeric></ix:nonNumeric> months</span> following the date of the Amended Credit Facility. The term loans under to the Amended Credit Facility begin amortizing on either the&#160;18-month&#160;or the&#160;30-month&#160;anniversary of the Amended Credit Facility (as applicable), with equal <ix:nonNumeric id="F_000737" name="us-gaap:LineOfCreditFacilityFrequencyOfPayments" contextRef="C_0001748907_20210101_20211231">monthly payments</ix:nonNumeric> of principal plus interest to be made by the Company to the Lenders in consecutive monthly installments until the loan maturity date. In addition, a final payment of <ix:nonFraction unitRef="U_xbrlipure" id="F_000738" name="ortx:LineOfCreditFacilityPercentageOfFinalPayment" contextRef="C_0001748907_20210501_20210531" decimals="3" scale="-2">3.5</ix:nonFraction>% is due on the loan maturity date. The Company is accruing the final payment amount of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000739" name="us-gaap:LineOfCreditFacilityPeriodicPaymentInterest" contextRef="C_0001748907_20210501_20210531" decimals="-5" scale="6">1.2</ix:nonFraction> million associated with the first term loan of the Amended Credit Facility, to outstanding </p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-24</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000305_dcnt_c9a66364-9512-4e45-b335-155c66bbe940">
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">debt by charges to interest expense using the effective-interest method from the date of issuance through the loan maturity date.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Amended Credit Facility includes affirmative and negative covenants. The affirmative covenants include, among others, covenants requiring the Company to maintain their legal existence and governmental approvals, deliver certain financial reports, maintain insurance coverage, maintain property, pay taxes, satisfy certain requirements regarding accounts and comply with laws and regulations. The negative covenants include, among others, restrictions on the Company transferring collateral, incurring additional indebtedness, engaging in mergers or acquisitions, paying dividends or making other distributions, making investments, creating liens, amending material agreements and organizational documents, selling assets, changing the nature of the business and undergoing a change in control, in some cases subject to certain exceptions. <ix:nonNumeric id="F_000742" name="us-gaap:DebtInstrumentCovenantDescription" contextRef="C_0001748907_20210101_20211231">The Company is also subject to an ongoing minimum cash financial covenant in which the Company must maintain unrestricted cash in an amount not less than $<ix:nonFraction unitRef="U_iso4217USD" id="F_000740" name="ortx:LineOfCreditFacilityCovenantsMinimumCashAllowed" contextRef="C_0001748907_srtRangeAxis_srtMinimumMember_us-gaapDebtInstrumentRedemptionPeriodAxis_us-gaapDebtInstrumentRedemptionPeriodTwoMember_20210531" decimals="-5" scale="6">20.0</ix:nonFraction>&#160;million following the utilization of the second term loan and not less than $<ix:nonFraction unitRef="U_iso4217USD" id="F_000741" name="ortx:LineOfCreditFacilityCovenantsMinimumCashAllowed" contextRef="C_0001748907_srtRangeAxis_srtMinimumMember_us-gaapDebtInstrumentRedemptionPeriodAxis_us-gaapDebtInstrumentRedemptionPeriodThreeMember_20210531" decimals="-5" scale="6">35.0</ix:nonFraction>&#160;million following the utilization of the third term loan</ix:nonNumeric>.</span></p><ix:nonNumeric id="F_000357" name="us-gaap:ScheduleOfDebtTableTextBlock" contextRef="C_0001748907_20210101_20211231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, and December 31, 2020, notes payable consist of the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notes payable, net of issuance costs</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000743" name="ortx:LongTermDebtBeforeAccretionIssuanceCostsNet" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">32,669</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000744" name="ortx:LongTermDebtBeforeAccretionIssuanceCostsNet" contextRef="C_0001748907_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">24,659</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: current portion</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000745" name="ortx:LongTermDebtBeforeAccretionIssuanceCostsNetCurrent" contextRef="C_0001748907_20211231" decimals="-3" scale="3">786</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000746" name="ortx:LongTermDebtBeforeAccretionIssuanceCostsNetCurrent" contextRef="C_0001748907_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,861</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notes payable, net of current portion</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000747" name="ortx:LongTermDebtBeforeAccretionIssuanceCostsNetNoncurrent" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">31,883</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000748" name="ortx:LongTermDebtBeforeAccretionIssuanceCostsNetNoncurrent" contextRef="C_0001748907_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">19,798</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accretion related to final payment</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000749" name="ortx:AccretionRelatedToFinalPayment" contextRef="C_0001748907_20211231" decimals="-3" scale="3">203</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000750" name="ortx:AccretionRelatedToFinalPayment" contextRef="C_0001748907_20201231" decimals="-3" scale="3">406</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notes payable, long term</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000751" name="us-gaap:LongTermDebtNoncurrent" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">32,086</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000752" name="us-gaap:LongTermDebtNoncurrent" contextRef="C_0001748907_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">20,204</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric><ix:nonNumeric id="F_000358" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" contextRef="C_0001748907_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, the future principal payments due are as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Minimum</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Payments</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000753" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" contextRef="C_0001748907_20211231" decimals="-3" scale="3">786</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000754" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,429</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000755" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,429</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000756" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,429</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2026</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000757" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,082</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000758" name="us-gaap:DebtInstrumentCarryingAmount" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">34,155</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less current portion</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000759" name="us-gaap:LongTermDebtCurrent" contextRef="C_0001748907_20211231" decimals="-3" scale="3">786</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less unamortized portion of final payment</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000760" name="ortx:UnamortizedPortionOfFinalPayment" contextRef="C_0001748907_20211231" decimals="-3" scale="3">952</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less unamortized debt issuance costs</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000761" name="us-gaap:UnamortizedDebtIssuanceExpense" contextRef="C_0001748907_20211231" decimals="-3" scale="3">331</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notes payable, long term</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000762" name="us-gaap:LongTermDebtNoncurrent" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">32,086</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the years ended December 31, 2021 and 2020, the Company recognized $<ix:nonFraction unitRef="U_iso4217USD" id="F_000763" name="us-gaap:InterestExpenseDebt" contextRef="C_0001748907_us-gaapLongtermDebtTypeAxis_ortxTermLoanMember_20210101_20211231" decimals="-5" scale="6">2.5</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000764" name="us-gaap:InterestExpenseDebt" contextRef="C_0001748907_us-gaapLongtermDebtTypeAxis_ortxTermLoanMember_20200101_20201231" decimals="-5" scale="6">2.3</ix:nonFraction> million of interest expense related to the term loan, respectively. The effective annual interest rate as of December 31, 2021 on the outstanding debt under the Term Loan was approximately <ix:nonFraction unitRef="U_xbrlipure" id="F_000765" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="C_0001748907_us-gaapLongtermDebtTypeAxis_ortxTermLoanMember_20210101_20211231" decimals="3" scale="-2">8.4</ix:nonFraction>%.</p></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000306" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="C_0001748907_20210101_20211231" escape="true" continuedAt="F_000306_dcnt_33d519ae-ec4e-4c47-8adb-fef241afbcbf">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">13. Shareholders&#8217; Equity and Convertible Preferred Shares </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Ordinary shares </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, and 2020, <ix:nonNumeric id="F_000766" name="us-gaap:CommonStockVotingRights" contextRef="C_0001748907_20210101_20211231">each holder of ordinary shares and ADSs is entitled to <ix:nonFraction unitRef="U_ortxVotingRight" id="F_000769" name="ortx:NumberOfOrdinaryVotingRights" contextRef="C_0001748907_20210101_20211231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_ortxVotingRight" id="F_000770" name="ortx:NumberOfOrdinaryVotingRights" contextRef="C_0001748907_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></ix:nonFraction> vote per ordinary share</ix:nonNumeric> and to receive dividends when and if such dividends are recommended by the board of directors and declared by the shareholders.&#160;&#160;As of&#160;December 31, 2021, and 2020, the Company has <ix:nonFraction unitRef="U_iso4217USD" id="F_000767" name="us-gaap:DividendsCommonStock" contextRef="C_0001748907_20210101_20211231" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000768" name="us-gaap:DividendsCommonStock" contextRef="C_0001748907_20200101_20201231" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction>t declared any dividends.</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-25</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000306_dcnt_33d519ae-ec4e-4c47-8adb-fef241afbcbf">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 20</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, and 20</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, the Company had authority to allot ordinary shares up to a maximum nominal value of &#163;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217GBP" id="F_000771" name="us-gaap:CommonStockValueOutstanding" contextRef="C_0001748907_srtRangeAxis_srtMaximumMember_20211231" decimals="2" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_iso4217GBP" id="F_000772" name="us-gaap:CommonStockValueOutstanding" contextRef="C_0001748907_srtRangeAxis_srtMaximumMember_20201231" decimals="2" format="ixt:numdotdecimal">13,023,851.50</ix:nonFraction></ix:nonFraction></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> with a nominal value of &#163;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217GBP_xbrlishares" id="F_000773" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001748907_20211231" decimals="INF"><ix:nonFraction unitRef="U_iso4217GBP_xbrlishares" id="F_000774" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001748907_20201231" decimals="INF">0.10</ix:nonFraction></ix:nonFraction></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> per share.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Ordinary share issuances</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2020, the Company issued <ix:nonFraction unitRef="U_xbrlishares" id="F_000775" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxOxfordBioMedicaLicenseDevelopmentAndSupplyAgreementMember_20200430" decimals="INF" format="ixt:numdotdecimal">75,413</ix:nonFraction> ordinary shares to Oxford BioMedica pursuant to the terms of our license agreement (see Note 15).</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2020, the Company issued <ix:nonFraction unitRef="U_xbrlishares" id="F_000776" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001748907_srtTitleOfIndividualAxis_ortxNonEmployeeAdvisorMember_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_ortxConsultingAgreementMember_20201231" decimals="INF" format="ixt:numdotdecimal">22,758</ix:nonFraction> ordinary shares pursuant to a consulting agreement (see Note 18) with a non-employee advisor.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2021, the Company issued and sold (i) <ix:nonFraction unitRef="U_xbrlishares" id="F_000778" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001748907_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_us-gaapTypeOfArrangementAxis_ortxSecuritiesPurchaseAgreementMember_20210201_20210228" decimals="INF" format="ixt:numdotdecimal">20,900,321</ix:nonFraction> ordinary shares, nominal value &#163;<ix:nonFraction unitRef="U_iso4217GBP_xbrlishares" id="F_000779" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001748907_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_us-gaapTypeOfArrangementAxis_ortxSecuritiesPurchaseAgreementMember_20210228" decimals="2">0.10</ix:nonFraction> per share, at a purchase price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000780" name="us-gaap:SaleOfStockPricePerShare" contextRef="C_0001748907_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_us-gaapTypeOfArrangementAxis_ortxSecuritiesPurchaseAgreementMember_20210228" decimals="2">6.22</ix:nonFraction> per share (the &#8220;Purchase Price&#8221;), which was the closing sale price of the Company&#8217;s ADSs on the Nasdaq Global Select Market on <ix:nonNumeric id="F_000781" name="ortx:ClosingPriceOfShareDate" contextRef="C_0001748907_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_us-gaapTypeOfArrangementAxis_ortxSecuritiesPurchaseAgreementMember_20210201_20210228" format="ixt:datemonthdayyearen">February 4, 2021</ix:nonNumeric>, and (ii) <ix:nonFraction unitRef="U_xbrlishares" id="F_000782" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001748907_us-gaapStatementClassOfStockAxis_ortxNonVotingOrdinarySharesMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_us-gaapTypeOfArrangementAxis_ortxSecuritiesPurchaseAgreementMember_20210201_20210228" decimals="INF" format="ixt:numdotdecimal">3,215,434</ix:nonFraction> non-voting ordinary shares, nominal value &#163;<ix:nonFraction unitRef="U_iso4217GBP_xbrlishares" id="F_000783" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001748907_us-gaapStatementClassOfStockAxis_ortxNonVotingOrdinarySharesMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_us-gaapTypeOfArrangementAxis_ortxSecuritiesPurchaseAgreementMember_20210228" decimals="INF">0.10</ix:nonFraction> per share, at the Purchase Price (together (i) and (ii) the &#8220;Private Placement&#8221;). The Private Placement resulted in net proceeds to the Company of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000787" name="ortx:NetProceedsFromIssuanceOfPrivatePlacement" contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxSecuritiesPurchaseAgreementMember_20210201_20210228" decimals="-5" scale="6">143.6</ix:nonFraction> million after deducting placement agent fees of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000784" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="C_0001748907_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_us-gaapTypeOfArrangementAxis_ortxSecuritiesPurchaseAgreementMember_20210201_20210228" decimals="-5" scale="6">6.0</ix:nonFraction> million and other issuance costs of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000785" name="ortx:PaymentsOfOtherIssuanceCosts" contextRef="C_0001748907_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_us-gaapTypeOfArrangementAxis_ortxSecuritiesPurchaseAgreementMember_20210201_20210228" decimals="-5" scale="6">0.4</ix:nonFraction> million. The ordinary shares and non-voting ordinary shares were sold pursuant to a securities purchase agreement entered into between the Company and the purchasers named therein on <ix:nonNumeric id="F_000786" name="us-gaap:SaleOfStockTransactionDate" contextRef="C_0001748907_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_us-gaapTypeOfArrangementAxis_ortxSecuritiesPurchaseAgreementMember_20210201_20210228" format="ixt:datemonthdayyearen">February 4, 2021</ix:nonNumeric>. All non-voting ordinary shares have been converted to ordinary shares as of December 31, 2021.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In July 2021 the Company issued <ix:nonFraction unitRef="U_xbrlishares" id="F_000789" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxSharePurchaseAgreementWithPharmingMember_20210701_20210731" decimals="INF" format="ixt:numdotdecimal">1,227,738</ix:nonFraction> ordinary shares to Pharming Group N.V. for total consideration of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000788" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxSharePurchaseAgreementWithPharmingMember_20210701_20210731" decimals="-5" scale="6">7.5</ix:nonFraction> million. The consideration is payment for the fair value of ordinary shares with a fair value of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000790" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxSharePurchaseAgreementWithPharmingMember_20210701_20210731" decimals="-5" scale="6">4.1</ix:nonFraction> million plus a $<ix:nonFraction unitRef="U_iso4217USD" id="F_000791" name="ortx:ProceedsFromPremiumSharesIssued" contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxSharePurchaseAgreementWithPharmingMember_20210701_20210731" decimals="-5" scale="6">3.4</ix:nonFraction> million premium on the fair value of the Company&#8217;s ordinary shares, which was allocated to the license and collaboration agreement (see Note 16).</span></p>
<p style="Background-color:#FFFFFF;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In December 2021, the Company issued <ix:nonFraction unitRef="U_xbrlishares" id="F_000777" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001748907_srtTitleOfIndividualAxis_ortxNonEmployeeAdvisorMember_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_ortxConsultingAgreementMember_20211231" decimals="INF" format="ixt:numdotdecimal">22,758</ix:nonFraction> ordinary shares pursuant to a consulting agreement (see Note 18) with a non-employee advisor</span></p></ix:continuation><ix:nonNumeric id="F_000307" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" contextRef="C_0001748907_20210101_20211231" escape="true" continuedAt="F_000307_dcnt_5590523c-e156-42fe-ad80-0fa687519e73">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">14. Share-based Compensation </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company maintains&#160;four&#160;equity compensation plans&#59; the Orchard Therapeutics Limited Employee Share Option Plan with Non-Employee Sub-Plan and U.S. Sub-Plan (the &#8220;2016 Plan&#8221;), the Orchard Therapeutics plc 2018 Share Option and Incentive Plan (the &#8220;2018 Plan&#8221;), the 2018 Employee Share Purchase Plan (the &#8220;ESPP&#8221;), and the 2020 Inducement Equity Plan (the &#8220;Inducement Plan&#8221;). <span style="color:#000000;">The number of shares of common stock that may be issued under the 2018 Plan is subject to increase by the number of shares forfeited under any options forfeited and not exercised under the 2018 Plan or 2016 Plan. </span>The board of directors has determined not to make any further awards under the 2016 plan. As of December 31, 2021, <ix:nonFraction unitRef="U_xbrlishares" id="F_000792" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="C_0001748907_us-gaapPlanNameAxis_ortxTwoThousandAndEighteenShareOptionAndIncentivePlanMember_20211231" decimals="INF" format="ixt:numdotdecimal">6,934,474</ix:nonFraction> shares remained available for grant under the 2018 Plan, <ix:nonFraction unitRef="U_xbrlishares" id="F_000794" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="C_0001748907_us-gaapPlanNameAxis_ortxTwoThousandAndTwentyInducementEquityPlanMember_20211231" decimals="INF" format="ixt:numdotdecimal">721,500</ix:nonFraction> remained available under the Inducement Plan, and <ix:nonFraction unitRef="U_xbrlishares" id="F_000793" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="C_0001748907_us-gaapPlanNameAxis_ortxTwoThousandAndEighteenEmployeeSharePurchasePlanMember_20211231" decimals="INF" format="ixt:numdotdecimal">1,197,399</ix:nonFraction> shares remained available for grant under the ESPP.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the Company&#8217;s IPO, the Company granted options to United States employees and non-employees at exercise prices deemed by the board of directors to be equal to the fair value of the ordinary share at the time of grant, and granted options to United Kingdom and European Union employees and non-employees at an exercise price equal to the par value of the ordinary shares of &#163;<ix:nonFraction unitRef="U_iso4217GBP_xbrlishares" id="F_000795" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" contextRef="C_0001748907_20211231" decimals="5">0.00001</ix:nonFraction>. After the IPO, options are now granted at exercise prices equal to the fair value of the Company&#8217;s ordinary shares on the grant date for all employees. The vesting period is determined by the board of directors, which is generally <ix:nonNumeric id="F_000796" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_0001748907_20210101_20211231" format="ixt-sec:durwordsen">four years</ix:nonNumeric>. An option&#8217;s maximum term is <span style="-sec-ix-hidden:F_000797">ten&#160;years</span>. </p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-26</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000307_dcnt_5590523c-e156-42fe-ad80-0fa687519e73" continuedAt="F_000307_dcnt_2a30d8cd-ebd7-4f93-b850-8dbeee613013">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Share options</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of each stock option award is determined on the date of grant using the Black-Scholes option-pricing model. <span style="Background-color:#FFFFFF;color:#000000;">The risk-free interest rate is based on a U.S. treasury instrument whose term is consistent with the expected term of the stock options. The expected term of the Company&#8217;s options has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain-vanilla&#8221; options. The expected volatility is based on the historical volatility of a representative group of companies with similar characteristics to the Company, including those in the early stages of product development with a similar and therapeutic focus. For these analyses, the Company selects companies with comparable characteristics to its own including enterprise value, risk profiles, position within the industry, and with historical share price information sufficient to meet the expected term of the options. </span><ix:nonNumeric id="F_000359" name="us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" contextRef="C_0001748907_20210101_20211231" escape="true" continuedAt="F_000359_cnt_1">The relevant data used to determine the value of stock option awards are as follows:</ix:nonNumeric></p><ix:continuation id="F_000359_cnt_1">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="4" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.12%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000798">0.5 - 1.3%</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000799">0.3 - 1.7%</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.3 - 6.1</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.5 - 6.1</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000806">74.2 - 78.7%</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000807">70.7 - 75.2%</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend rate</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000810" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_0001748907_20210101_20211231" decimals="4" scale="-2">0.00</ix:nonFraction>%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000811" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_0001748907_20200101_20201231" decimals="4" scale="-2">0.00</ix:nonFraction>%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p></ix:continuation><ix:nonNumeric id="F_000360" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" contextRef="C_0001748907_20210101_20211231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes option activity under the plans for the year ended December 31, 2021:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise Price</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">per Share</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Life (Years)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2020</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000812" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_0001748907_20201231" decimals="INF" format="ixt:numdotdecimal">13,895,643</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000818" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_0001748907_20201231" decimals="2">7.96</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000824">7.16</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000827" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="C_0001748907_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">91,133</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000813" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_0001748907_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">8,489,856</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000819" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_0001748907_20210101_20211231" decimals="2">4.75</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000814" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0001748907_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">1,727,254</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000820" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="C_0001748907_20210101_20211231" decimals="2">1.59</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000815" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="C_0001748907_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">3,357,505</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000821" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="C_0001748907_20210101_20211231" decimals="2">10.30</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding and expected to vest at December 31, 2021</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000816" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_0001748907_20211231" decimals="INF" format="ixt:numdotdecimal">17,300,740</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000822" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_0001748907_20211231" decimals="2">6.57</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000825">7.83</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000828" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,842</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable, as of December 31, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000817" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="C_0001748907_20211231" decimals="INF" format="ixt:numdotdecimal">7,880,668</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000823" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="C_0001748907_20211231" decimals="2">6.90</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000826">6.59</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000829" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,685</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate intrinsic value of options is calculated as the difference between the exercise price of the options and the fair value of the Company&#8217;s ordinary shares for those options that had exercise prices lower than the fair value of the Company&#8217;s ordinary shares. During the years ended December 31, 2021 and 2020, the total intrinsic value of share options exercised was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000830" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="C_0001748907_20210101_20211231" decimals="-5" scale="6">7.4</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000831" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="C_0001748907_20200101_20201231" decimals="-5" scale="6">5.0</ix:nonFraction> million, respectively. During the years ended December 31, 2021 and 2020, the total proceeds to the Company from share options exercised was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000832" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_0001748907_20210101_20211231" decimals="-5" scale="6">2.7</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000833" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_0001748907_20200101_20201231" decimals="-5" scale="6">3.9</ix:nonFraction> million, respectively. As of December 31, 2021, and 2020, there was $<span style="-sec-ix-hidden:F_000834">nil</span> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000835" name="ortx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeEquityPlanProceedsReceivedAfterYearEnd" contextRef="C_0001748907_20201231" decimals="-5" scale="6">0.2</ix:nonFraction> million in employee equity plan proceeds received after year-end, respectively.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted average grant date fair value of the options granted during the years ended December&#160;31, 2021 and 2020 was $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000836" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001748907_20210101_20211231" decimals="2">3.10</ix:nonFraction> per share and $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000837" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001748907_20200101_20201231" decimals="2">7.22</ix:nonFraction> per share, respectively.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Restricted Share Units</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Performance-based share units</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company has issued performance-based restricted share units (&#8220;RSUs&#8221;) to certain executives and members of its senior management, with vesting linked to the achievement of three specific regulatory and research and development milestones and one market condition based upon the volume weighted-average price (&#8220;VWAP&#8221;) of the Company&#8217;s ADSs for a certain period. Upon achievement of any of the aforementioned milestones, one third of the RSUs will vest, and the award will become fully vested upon achievement of three of the four performance conditions.&#160; <ix:nonFraction unitRef="U_xbrlishares" id="F_000838" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="C_0001748907_us-gaapAwardTypeAxis_us-gaapPerformanceSharesMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">89,667</ix:nonFraction> performance-based share units vested during the years ended December 31, 2021. At December 31, 2021, the remaining <ix:nonFraction unitRef="U_xbrlishares" id="F_000839" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="C_0001748907_us-gaapAwardTypeAxis_us-gaapPerformanceSharesMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">179,333</ix:nonFraction> performance-based share units outstanding under the scheme were cancelled.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The fair value associated with the performance-based conditions is recognized when achievement of the milestones becomes probable, if at all. In the fourth quarter of 2020, the Company determined that a performance milestone was probable upon </span></p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-27</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000307_dcnt_2a30d8cd-ebd7-4f93-b850-8dbeee613013">
<p style="margin-bottom:0pt;margin-top:12pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">approval of Libmeldy by the E</span><span style="Background-color:#FFFFFF;">uropean </span><span style="Background-color:#FFFFFF;">C</span><span style="Background-color:#FFFFFF;">ommission in December 2020</span><span style="Background-color:#FFFFFF;">, and recognized $</span><span style="Background-color:#FFFFFF;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000840" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001748907_us-gaapAwardTypeAxis_us-gaapPerformanceSharesMember_us-gaapTypeOfArrangementAxis_ortxLibmeldyMember_20201001_20201231" decimals="-5" scale="6">1.2</ix:nonFraction></span><span style="Background-color:#FFFFFF;"> million in compensation cost. </span><span style="Background-color:#FFFFFF;">The shares associated with recognition of this performance milestone vested and were issued in January 2021.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">CEO Award</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company granted&#160;<ix:nonFraction unitRef="U_xbrlishares" id="F_000841" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="C_0001748907_srtTitleOfIndividualAxis_srtChiefExecutiveOfficerMember_us-gaapAwardTypeAxis_us-gaapPerformanceSharesMember_20200401_20200430" decimals="INF" format="ixt:numdotdecimal">195,000</ix:nonFraction>&#160;performance-based RSUs with a total grant date fair value of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000842" name="ortx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" contextRef="C_0001748907_srtTitleOfIndividualAxis_srtChiefExecutiveOfficerMember_us-gaapAwardTypeAxis_us-gaapPerformanceSharesMember_20200401_20200430" decimals="-5" scale="6">1.4</ix:nonFraction> million to its Chief Executive Officer, Bobby Gaspar, M.D., Ph.D., in April 2020.&#160;&#160;<ix:nonNumeric id="F_000843" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" contextRef="C_0001748907_srtTitleOfIndividualAxis_srtChiefExecutiveOfficerMember_us-gaapAwardTypeAxis_us-gaapPerformanceSharesMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheOneMember_20210101_20211231">The award vests on January 2, 2024 as to 1/3 of the award for each of the first three to occur of four milestones, if each such milestone is achieved by the Company on or before December 31, 2023</ix:nonNumeric>&#160;and Dr. Gaspar remains continuously employed with the Company through January 2, 2024. The milestones relate to achievement of specific clinical and regulatory milestones. No performance-based share unit performance conditions associated with the CEO award were deemed probable and none vested during the year ended December 31, 2021. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Time-based restricted share units</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Time-based restricted share units vest in equal annual installments over a <span style="-sec-ix-hidden:F_000844">three-year</span> period.</span></p><ix:nonNumeric id="F_000361" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" contextRef="C_0001748907_20210101_20211231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes restricted share unit award activity for the year-end December 31, 2021:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Performance-based RSUs</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Time-based RSUs</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted Average Grant Date Fair Value per Share</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested at December 31, 2020</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000845" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="C_0001748907_us-gaapAwardTypeAxis_us-gaapPerformanceSharesMember_20201231" decimals="INF" format="ixt:numdotdecimal">464,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000846" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="C_0001748907_us-gaapAwardTypeAxis_ortxTimeBasedRestrictedShareUnitsMember_20201231" decimals="INF" format="ixt:numdotdecimal">180,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000854" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="C_0001748907_20201231" decimals="2">8.75</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000847" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="C_0001748907_us-gaapAwardTypeAxis_ortxTimeBasedRestrictedShareUnitsMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">47,500</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000855" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001748907_20210101_20211231" decimals="2">4.94</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000848" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="C_0001748907_us-gaapAwardTypeAxis_us-gaapPerformanceSharesMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">89,667</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000849" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="C_0001748907_us-gaapAwardTypeAxis_ortxTimeBasedRestrictedShareUnitsMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">41,667</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000856" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001748907_20210101_20211231" decimals="2">9.94</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000850" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="C_0001748907_us-gaapAwardTypeAxis_us-gaapPerformanceSharesMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">179,333</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000851" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="C_0001748907_us-gaapAwardTypeAxis_ortxTimeBasedRestrictedShareUnitsMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">62,500</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000857" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="C_0001748907_20210101_20211231" decimals="2">10.32</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested at December 31, 2021</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000852" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="C_0001748907_us-gaapAwardTypeAxis_us-gaapPerformanceSharesMember_20211231" decimals="INF" format="ixt:numdotdecimal">195,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000853" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="C_0001748907_us-gaapAwardTypeAxis_ortxTimeBasedRestrictedShareUnitsMember_20211231" decimals="INF" format="ixt:numdotdecimal">123,333</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000858" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="C_0001748907_20211231" decimals="2">6.41</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Share-based compensation </p><ix:nonNumeric id="F_000362" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" contextRef="C_0001748907_20210101_20211231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share-based compensation expense related to share options, restricted share unit awards, and the employee stock purchase plan was classified in the consolidated statements of operations and comprehensive loss as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000859" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001748907_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,214</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000860" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001748907_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">11,679</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000861" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001748907_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">13,322</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000862" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001748907_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">16,283</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000863" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001748907_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">22,536</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000864" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001748907_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">27,962</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had <ix:nonFraction unitRef="U_xbrlishares" id="F_000865" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" contextRef="C_0001748907_20211231" decimals="INF" format="ixt:numdotdecimal">9,420,072</ix:nonFraction> unvested options outstanding as of December&#160;31, 2021. As of December 31, 2021, total unrecognized compensation cost related to unvested stock option grants and time-based RSUs was approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000866" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="C_0001748907_20211231" decimals="-5" scale="6">37.1</ix:nonFraction> million. This amount is expected to be recognized over a weighted average period of approximately <ix:nonNumeric id="F_000867" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="C_0001748907_20210101_20211231" format="ixt-sec:duryear">2.77</ix:nonNumeric> years. As of December 31, 2021, the total unrecognized compensation cost related to performance-based RSUs is a maximum of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000868" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" contextRef="C_0001748907_20211231" decimals="-5" scale="6">1.4</ix:nonFraction> million, the timing of recognition will be dependent upon achievement of milestones. </p></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000308" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" contextRef="C_0001748907_20210101_20211231" escape="true" continuedAt="F_000308_dcnt_01e03978-4ab6-46f8-b677-ad912eb4d42c">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">15. License and Research Arrangements </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GSK asset purchase and license agreement </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2018, the Company completed an asset purchase and license agreement (the &#8220;GSK Agreement&#8221;) with subsidiaries of GSK to acquire a portfolio of autologous <span style="font-style:italic;">ex vivo</span> gene therapy assets and licenses, for rare diseases and option rights on three additional programs in preclinical development from Telethon Foundation and San Raffaele Hospital (&#8220;Telethon-OSR&#8221;). The portfolio of programs and options acquired consisted of: </p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-28</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000308_dcnt_01e03978-4ab6-46f8-b677-ad912eb4d42c" continuedAt="F_000308_dcnt_731bc985-7ea2-4908-8a78-fd2d782bd9c0">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:2.63%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.26%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;"><ix:nonFraction unitRef="U_ortxProgram" id="F_000869" name="ortx:NumberOfLateStageClinicalGeneTherapyPrograms" contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxGSKAssetPurchaseAndLicenseAgreementMember_20180401_20180430" decimals="INF" format="ixt-sec:numwordsen">Two</ix:nonFraction></span> late-stage clinical gene therapy programs in ongoing registrational trials for MLD and WAS&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:2.63%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.26%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;"><ix:nonFraction unitRef="U_ortxProgram" id="F_000870" name="ortx:NumberOfEarlierStageClinicalGeneTherapyProgram" contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxGSKAssetPurchaseAndLicenseAgreementMember_20180401_20180430" decimals="INF" format="ixt-sec:numwordsen">One</ix:nonFraction></span> earlier stage clinical gene therapy program for TDT&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:2.63%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.26%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Strimvelis, the first autologous </span><span style="font-style:italic;font-size:10pt;color:#000000;">ex vivo</span><span style="font-size:10pt;color:#000000;"> gene therapy for ADA-SCID which was approved for marketing by the European Medicines Agency in 2016&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:2.63%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.26%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Option rights exercisable upon completion of clinical proof of concept studies for <ix:nonFraction unitRef="U_ortxProgram" id="F_000871" name="ortx:NumberOfAdditionalEarlierStageDevelopmentPrograms" contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxGSKAssetPurchaseAndLicenseAgreementMember_20180401_20180430" decimals="INF" format="ixt-sec:numwordsen">three</ix:nonFraction> additional earlier-stage development programs, which option rights have all subsequently lapsed. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounted for the GSK Agreement as an asset acquisition, since the asset purchase and licensing arrangement did not meet the definition of a business pursuant to ASC&#160;805, Business Combinations. Total consideration was &#163;<ix:nonFraction unitRef="U_iso4217GBP" id="F_000872" name="us-gaap:AssetAcquisitionConsiderationTransferred" contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxGSKAssetPurchaseAndLicenseAgreementMember_20180401_20180430" decimals="-5" scale="6">94.2</ix:nonFraction>&#160;million ($<ix:nonFraction unitRef="U_iso4217USD" id="F_000873" name="us-gaap:AssetAcquisitionConsiderationTransferred" contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxGSKAssetPurchaseAndLicenseAgreementMember_20180401_20180430" decimals="-5" scale="6">133.6</ix:nonFraction>&#160;million at the acquisition date), which included an upfront payment of &#163;<ix:nonFraction unitRef="U_iso4217GBP" id="F_000874" name="ortx:AssetAcquisitionUpfrontPayment" contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxGSKAssetPurchaseAndLicenseAgreementMember_20180401_20180430" decimals="-5" scale="6">10.0</ix:nonFraction>&#160;million ($<ix:nonFraction unitRef="U_iso4217USD" id="F_000875" name="ortx:AssetAcquisitionUpfrontPayment" contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxGSKAssetPurchaseAndLicenseAgreementMember_20180401_20180430" decimals="-5" scale="6">14.2</ix:nonFraction>&#160;million at the acquisition date) and <ix:nonFraction unitRef="U_xbrlishares" id="F_000876" name="ortx:AssetAcquisitionNumberOfSharesIssuedForAcquisition" contextRef="C_0001748907_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_us-gaapTypeOfArrangementAxis_ortxGSKAssetPurchaseAndLicenseAgreementMember_20180401_20180430" decimals="INF" format="ixt:numdotdecimal">12,455,252</ix:nonFraction> convertible preferred shares of the Company issued to GSK at an aggregate value of &#163;<ix:nonFraction unitRef="U_iso4217GBP" id="F_000877" name="ortx:AssetAcquisitionValueOfEquityInstrumentsIssued" contextRef="C_0001748907_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_us-gaapTypeOfArrangementAxis_ortxGSKAssetPurchaseAndLicenseAgreementMember_20180430" decimals="-5" scale="6">65.8</ix:nonFraction>&#160;million ($<ix:nonFraction unitRef="U_iso4217USD" id="F_000878" name="ortx:AssetAcquisitionValueOfEquityInstrumentsIssued" contextRef="C_0001748907_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_us-gaapTypeOfArrangementAxis_ortxGSKAssetPurchaseAndLicenseAgreementMember_20180430" decimals="-5" scale="6">93.4</ix:nonFraction>&#160;million at the acquisition date), a loss contract on the Strimvelis program valued at &#163;<ix:nonFraction unitRef="U_iso4217GBP" id="F_000879" name="ortx:AssetAcquisitionLiabilityAssumed" contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxGSKAssetPurchaseAndLicenseAgreementMember_20180430" decimals="-5" scale="6">12.9</ix:nonFraction> million ($<ix:nonFraction unitRef="U_iso4217USD" id="F_000880" name="ortx:AssetAcquisitionLiabilityAssumed" contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxGSKAssetPurchaseAndLicenseAgreementMember_20180430" decimals="-5" scale="6">18.4</ix:nonFraction> million), an inventory purchase liability valued at &#163;<ix:nonFraction unitRef="U_iso4217GBP" id="F_000881" name="ortx:AssetAcquisitionInventoryPurchaseLiability" contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxGSKAssetPurchaseAndLicenseAgreementMember_20180430" decimals="-5" scale="6">4.9</ix:nonFraction>&#160;million ($<ix:nonFraction unitRef="U_iso4217USD" id="F_000882" name="ortx:AssetAcquisitionInventoryPurchaseLiability" contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxGSKAssetPurchaseAndLicenseAgreementMember_20180430" decimals="-5" scale="6">6.9</ix:nonFraction>&#160;million) and transaction costs of &#163;<ix:nonFraction unitRef="U_iso4217GBP" id="F_000883" name="ortx:AssetAcquisitionTransactionCosts" contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxGSKAssetPurchaseAndLicenseAgreementMember_20180401_20180430" decimals="-5" scale="6">0.6</ix:nonFraction> million ($<ix:nonFraction unitRef="U_iso4217USD" id="F_000884" name="ortx:AssetAcquisitionTransactionCosts" contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxGSKAssetPurchaseAndLicenseAgreementMember_20180401_20180430" decimals="-5" scale="6">0.8</ix:nonFraction> million). The Company allocated &#163;<ix:nonFraction unitRef="U_iso4217GBP" id="F_000885" name="ortx:AssetAcquisitionInProcessResearchAndDevelopmentExpense" contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxGSKAssetPurchaseAndLicenseAgreementMember_20180401_20180430" decimals="-5" scale="6">94.2</ix:nonFraction>&#160;million ($<ix:nonFraction unitRef="U_iso4217USD" id="F_000886" name="ortx:AssetAcquisitionInProcessResearchAndDevelopmentExpense" contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxGSKAssetPurchaseAndLicenseAgreementMember_20180401_20180430" decimals="-5" scale="6">133.6</ix:nonFraction>&#160;million) to in-process research and development expense (based on the fair value of the underlying programs in development). The convertible preferred shares were converted to ordinary shares as part of our IPO in November 2018.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is required to use commercially reasonable efforts to obtain a Priority Review Voucher (&#8220;PRV&#8221;) from the United States Food and Drug Administration for each of the programs for MLD, WAS and TDT, the first of which GSK retained beneficial ownership over. GSK also has an option to acquire, at a price pursuant to an agreed upon formula, any PRV granted to the Company thereafter for MLD, WAS and TDT. If GSK does not exercise this option to purchase any PRV, the Company may sell the PRV to a third party and must share any proceeds in excess of a specified sale price equally with GSK. For accounting purposes, as of December 31, 2021, the Company does not consider the attainment of a PRV from the United States Food and Drug Administration to be probable.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of the GSK Agreement the Company is required to use its best endeavors to make Strimvelis commercially available in the European Union until such time as an alternative gene therapy is commercially available for patients in Italy, and at all times at the San Raffaele Hospital in Milan, provided that a minimum number of patients continue to be treated at this site. Strimvelis is not currently expected to generate sufficient cash flows to overcome the costs of maintaining the product and certain regulatory commitments&#59; therefore, the Company recorded a liability associated with the loss contract of &#163;<ix:nonFraction unitRef="U_iso4217GBP" id="F_000887" name="ortx:AssetAcquisitionLiabilityAssumed" contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxGSKAssetPurchaseAndLicenseAgreementMember_20180430" decimals="-5" scale="6">12.9</ix:nonFraction> million ($<ix:nonFraction unitRef="U_iso4217USD" id="F_000888" name="ortx:AssetAcquisitionLiabilityAssumed" contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxGSKAssetPurchaseAndLicenseAgreementMember_20180430" decimals="-5" scale="6">18.4</ix:nonFraction> million at the acquisition date) associated with the loss expected due to this obligation. This liability is being amortized over the remaining period of expected sales of Strimvelis as a credit to research and development expenses (see Note 2).</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company will pay GSK non-refundable royalties and milestone payments in relation to the gene therapy programs. The Company will pay a flat mid-single digit percentage royalty on the combined annual net sales of ADA-SCID products, which includes Strimvelis. The Company will also pay tiered royalty rates at a percentage beginning in the mid-teens up to <ix:nonFraction unitRef="U_xbrlipure" id="F_000889" name="ortx:PaymentOfTieredRoyaltyMaximumPercentage" contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxGSKAssetPurchaseAndLicenseAgreementMember_20211231" decimals="2" format="ixt-sec:numwordsen" scale="-2">twenty</ix:nonFraction> percent for the MLD and WAS products, upon marketing approval, calculated as percentages of aggregate cumulative net sales of the MLD and WAS products, respectively. The Company will pay a tiered royalty at a percentage from the high single-digits to low double-digit for the TDT product, upon marketing approval, calculated as percentages of aggregate annual net sales of the TDT product. These royalties owed to GSK are in addition to any royalties owed to other third parties under various license agreements for the GSK programs. In aggregate, the Company may pay up to &#163;<ix:nonFraction unitRef="U_iso4217GBP" id="F_000890" name="ortx:MilestonePaymentsPayableUponAchievementOfCertainSalesMilestones" contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxGSKAssetPurchaseAndLicenseAgreementMember_20211231" decimals="-5" scale="6">90.0</ix:nonFraction> million in milestone payments upon achievement of certain sales milestones applicable to GSK. The Company&#8217;s royalty obligations with respect to MLD and WAS may be deferred for a certain period in the interest of prioritizing available capital to develop each product. The Company&#8217;s royalty obligations are subject to reduction on a product-by-product basis in the event of market control by biosimilars and will expire in April 2048. Other than Strimvelis, these royalty and milestone payments were not determined to be probable and estimable at the date of the acquisition and are not included as part of consideration. </p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-29</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000308_dcnt_731bc985-7ea2-4908-8a78-fd2d782bd9c0" continuedAt="F_000308_dcnt_54e654b8-d176-4064-9871-54b820182983">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company and GSK also separately executed a Transition Services Agreement (&#8220;TSA&#8221;) as well as an Inventory Sale Agreement, in April 2018. The TSA outlined several activities that the Company had requested GSK to assist with during the transition period, including but not limited to utilizing GSK to sell, market and distribute Strimvelis, and assist with regulatory, clinical and non-clinical activities for the other non-commercialized products which were ongoing at the date of the GSK Agreement. The TSA expired in December 2018. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Company&#8217;s entering into the GSK Agreement, GSK assigned rights and obligations to certain contracts, which include among others, the original license agreement with Telethon-OSR and an ongoing manufacturing agreement (see Note 18). </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Telethon-OSR research and development collaboration and license agreements</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Company&#8217;s entering into the GSK Agreement, the Company also&#160;acquired and assumed agreements with Telethon Foundation and San Raffaele Hospital, together referred to as Telethon-OSR, for the research, development and commercialization of autologous <span style="font-style:italic;">ex vivo</span> gene therapies for ADA-SCID, WAS, MLD, TDT, as well as options over three additional earlier-stage development programs. The Company&#8217;s options under the agreement with Telethon-OSR with respect to the earlier-stage programs have lapsed.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As consideration for the licenses, the Company will be required to make payments to Telethon-OSR upon achievement of certain product development milestones. Additionally, the Company will be required to pay to Telethon-OSR a tiered mid-single to low-double digit royalty percentage on annual sales of licensed products covered by patent rights on a country-by-country basis, as well as a low double-digit percentage of sublicense income received from any certain third-party sublicenses of the collaboration programs. These royalties are in addition to those payable to GSK under the GSK Agreement. The Company may pay up to an aggregate of approximately &#8364;<ix:nonFraction unitRef="U_iso4217EUR" id="F_000891" name="ortx:MilestonePaymentsPayableUponAchievementOfCertainSalesMilestones" contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxGSKAssetPurchaseAndLicenseAgreementMember_20211231" decimals="-5" scale="6">31.0</ix:nonFraction> million ($<ix:nonFraction unitRef="U_iso4217USD" id="F_000892" name="ortx:MilestonePaymentsPayableUponAchievementOfCertainSalesMilestones" contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxGSKAssetPurchaseAndLicenseAgreementMember_20211231" decimals="-5" scale="6">35.0</ix:nonFraction> million at December 31, 2021) in milestone payments upon achievement of certain product development milestones for the program.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000893" name="ortx:UpfrontPaymentDescription" contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxGSKAssetPurchaseAndLicenseAgreementMember_20210101_20211231">In May 2019, the Company entered into a license agreement with Telethon-OSR, under which Telethon-OSR granted to the Company an exclusive worldwide license for the research, development, manufacture and commercialization of Telethon-OSR&#8217;s <span style="font-style:italic;">ex vivo</span> autologous HSC lentiviral based gene therapy for the treatment of mucopolysaccharidosis type I (&#8220;MPS-I&#8221;), including the Hurler variant. To date, Telethon-OSR received &#8364;<ix:nonFraction unitRef="U_iso4217EUR" id="F_000894" name="ortx:UpfrontAndMilestonePayments" contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxTelethonOSRLicenseAgreementsMember_20190501_20211231" decimals="-5" scale="6">17.0</ix:nonFraction> million in upfront and milestone payments from the Company upon entering into the agreement and shortly thereafter, resulting in $<ix:nonFraction unitRef="U_iso4217USD" id="F_000895" name="ortx:InProcessResearchAndDevelopmentExpenseForUpfrontAndMilestonePayments" contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxTelethonOSRLicenseAgreementsMember_20190501_20211231" decimals="-5" scale="6">19.4</ix:nonFraction> million in in-process research and development expense.</ix:nonNumeric> The Company is also required to make milestone payments contingent upon certain development, regulatory and commercial milestones are achieved and may pay up to &#8364;<ix:nonFraction unitRef="U_iso4217EUR" id="F_000896" name="ortx:MilestonePaymentsPayableUponAchievementOfCertainDevelopmentRegulatoryAndCommercialMilestones" contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxTelethonOSRLicenseAgreementsMember_20211231" decimals="-5" scale="6">28.0</ix:nonFraction> million ($<ix:nonFraction unitRef="U_iso4217USD" id="F_000897" name="ortx:MilestonePaymentsPayableUponAchievementOfCertainDevelopmentRegulatoryAndCommercialMilestones" contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxTelethonOSRLicenseAgreementsMember_20211231" decimals="-5" scale="6">31.7</ix:nonFraction> million at December 31, 2021). Additionally, the Company will be required to pay Telethon a tiered mid-single to low-double digit royalty percentage on annual net sales of licensed products. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">UCLB/UCLA License Agreement </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, and amended in July 2017, the Company completed the UCLB/UCLA license agreement, under which the Company has been granted exclusive and non-exclusive, sublicensable licenses under certain intellectual property rights controlled by UCLB and UCLA to develop and commercialize gene therapy products in certain fields and territories. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In exchange for these rights, in 2016, the Company made upfront cash payments consisting of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000898" name="ortx:UpfrontCashPayment" contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxUCLBAndUCLATechnologyMember_20160101_20161231" decimals="-5" scale="6">0.8</ix:nonFraction> million for the license to the joint UCLB/UCLA technology and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000899" name="ortx:UpfrontCashPayment" contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxUCLBTechnologyAndManufacturingTechnologyMember_20160101_20161231" decimals="-5" scale="6">1.1</ix:nonFraction> million for the license to the UCLB technology and manufacturing technology. The Company also issued an aggregate of <ix:nonFraction unitRef="U_xbrlishares" id="F_000900" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxUCLBLicenseAgreementMember_20181231" decimals="INF" format="ixt:numdotdecimal">4,665,384</ix:nonFraction> ordinary shares to UCLB, of which <ix:nonFraction unitRef="U_xbrlishares" id="F_000901" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxUCLBLicenseAgreementMember_20171231" decimals="INF" format="ixt:numdotdecimal">1,224,094</ix:nonFraction>, and <ix:nonFraction unitRef="U_xbrlishares" id="F_000902" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxUCLBLicenseAgreementMember_20161231" decimals="INF" format="ixt:numdotdecimal">3,441,290</ix:nonFraction> ordinary shares were issued in 2017 and 2016, respectively. The Company recorded research and development expense based on the fair value of the ordinary shares as of the time the agreement was executed or modified. The Company was also obligated to make an additional cash payment for clinical data. In 2017, the Company paid $<ix:nonFraction unitRef="U_iso4217USD" id="F_000903" name="ortx:PaymentsToAcquireClinicalData" contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxUCLBAndUCLALicenseAgreementMember_20170101_20171231" decimals="-5" scale="6">0.8</ix:nonFraction> million in relation to clinical data acquired. The Company recorded the payments to research and development expense. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the UCLB/UCLA License Agreement, the Company is also obligated to pay an annual administration fee of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000904" name="us-gaap:PaymentForAdministrativeFees" contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxUCLBAndUCLALicenseAgreementMember_20210101_20211231" decimals="-5" scale="6">0.1</ix:nonFraction> million on the first, second and third anniversary of the agreement date. Additionally, the Company may become obligated to make payments to the parties of up to an aggregate of &#163;<ix:nonFraction unitRef="U_iso4217GBP" id="F_000905" name="ortx:PotentialPaymentForAchievementOfSpecifiedMilestones" contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxUCLBAndUCLALicenseAgreementMember_20210101_20211231" decimals="INF" scale="6">19.9</ix:nonFraction> million ($<ix:nonFraction unitRef="U_iso4217USD" id="F_000906" name="ortx:PotentialPaymentForAchievementOfSpecifiedMilestones" contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxUCLBAndUCLALicenseAgreementMember_20210101_20211231" decimals="INF" scale="6">26.8</ix:nonFraction> million at December 31, 2021) upon the achievement of specified regulatory milestones as well as royalties ranging from low to mid-single-digit percentage on net sales of the applicable gene therapy product. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recorded nil and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000907" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxUCLBAndUCLALicenseAgreementMember_20200101_20201231" decimals="-5" scale="6">0.1</ix:nonFraction> million of research and development costs in respect of the UCLB/UCLA license agreement associated with the annual administrative fee for the years ended December 31, 2021 and 2020.</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-30</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000308_dcnt_54e654b8-d176-4064-9871-54b820182983" continuedAt="F_000308_dcnt_4e9453ed-d512-4934-b142-78017951d92f">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2021, the Company terminated the license to its OTL-101 program for ADA-SCID, which was granted pursuant to the UCLB/UCLA license agreement. <span style="color:#000000;">Except for the termination of such license, the UCLB/UCLA license agreement continues in full force and effect.</span> </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless terminated earlier by either party, the UCLB/UCLA license agreement will expire on the 25<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup> anniversary of the agreement. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Oxford BioMedica license, development and supply agreement </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In November 2016, and as amended in June 2017, May&#160;2018, July 2018, September 2018, May 2019 and April 2020</span><span style="color:#000000;">, the Company entered into an arrangement with Oxford BioMedica whereby Oxford BioMedica granted an exclusive intellectual property license to the Company for the purposes of research, development, and commercialization of collaboration products, and will provide process development services, and manufacture clinical and commercial GMP-grade lentiviral vectors to the Company (&#8220;Oxford BioMedica Agreement&#8221;). As part of the consideration to rights and licenses granted under the Oxford BioMedica Agreement, the Company issued <ix:nonFraction unitRef="U_xbrlishares" id="F_000908" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxOxfordBioMedicaLicenseDevelopmentAndSupplyAgreementMember_20211231" decimals="INF" format="ixt:numdotdecimal">588,220</ix:nonFraction> ordinary shares to Oxford BioMedica. The Company is also obligated to make certain development milestone payments in the form of issuance of additional ordinary shares if the milestones are achieved. In November 2017, the first milestone was achieved, and the Company was committed to issue another <ix:nonFraction unitRef="U_xbrlishares" id="F_000909" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxOxfordBioMedicaLicenseDevelopmentAndSupplyAgreementMember_20181130" decimals="INF" format="ixt:numdotdecimal">150,826</ix:nonFraction> ordinary shares, and issued these shares in 2018. In September 2018, the second and fourth milestones were achieved, and the Company issued <ix:nonFraction unitRef="U_xbrlishares" id="F_000910" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxOxfordBioMedicaLicenseDevelopmentAndSupplyAgreementMember_20180930" decimals="INF" format="ixt:numdotdecimal">150,826</ix:nonFraction> ordinary shares. In April 2020, the fifth milestone was deemed to have been met upon execution of the amended agreement in April 2020, and the Company issued <ix:nonFraction unitRef="U_xbrlishares" id="F_000911" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxOxfordBioMedicaLicenseDevelopmentAndSupplyAgreementMember_20200430" decimals="INF" format="ixt:numdotdecimal">75,413</ix:nonFraction> ordinary shares to Oxford BioMedica with a total value of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000912" name="ortx:MilestonePayment" contextRef="C_0001748907_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapTypeOfArrangementAxis_ortxOxfordBioMedicaLicenseDevelopmentAndSupplyAgreementMember_20200430_20200430" decimals="-5" scale="6">0.8</ix:nonFraction> million, which was expensed to research and development expense. <ix:nonFraction unitRef="U_ortxMilestone" id="F_000913" name="ortx:NumberOfMilestonesMet" contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxOxfordBioMedicaLicenseDevelopmentAndSupplyAgreementMember_20190101_20191231" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction> milestones were met during the year ended December 31, 2021.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company may also pay low single-digit percentage royalties on annual net sales of collaborated product generated under the Oxford BioMedica Agreement. <span style="font-size:12pt;">&#160;</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">16. Collaboration agreement with Pharming Group N.V.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Overview</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 1, 2021, the Company entered into a strategic collaboration with Pharming Group N.V. (&#8220;Pharming&#8221;) to research, develop, manufacture, and commercialize OTL-105, an investigational&#160;<span style="font-style:italic;">ex vivo</span>&#160;autologous HSC gene therapy for the treatment of hereditary angioedema (HAE), a life-threatening rare disorder that causes recurring swelling attacks in the face, throat, extremities and abdomen (the &#8220;Collaboration Agreement&#8221;).</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the Collaboration Agreement, Pharming was granted worldwide rights to OTL-105 and will be responsible for clinical development, regulatory filings and commercialization of the investigational gene therapy, including associated costs. The Company will lead the completion of IND-enabling activities and oversee manufacturing of OTL-105 during preclinical and clinical development, which will be funded by Pharming. In addition, both the Company and Pharming will explore the application of non-toxic conditioning regimen for use with OTL-105 administration.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company received an upfront payment of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000914" name="us-gaap:ProceedsFromCollaborators" contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxStrategicCollaborationAgreementWithPharmingMember_20210701_20210701" decimals="-5" scale="6">10.0</ix:nonFraction>&#160;million in cash from Pharming. The Company is also eligible to receive up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000915" name="ortx:MilestonePaymentsReceivable" contextRef="C_0001748907_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_ortxStrategicCollaborationAgreementWithPharmingMember_20210701" decimals="INF" scale="6">189.5</ix:nonFraction>&#160;million in development, regulatory and sales milestones as well as mid-single to low double-digit percentage royalty payments on future worldwide sales.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Share Purchase Agreement</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company also entered into a Share Purchase Agreement with Pharming on July 1, 2021 (the &#8220;SPA&#8221;), pursuant to which the Company issued <ix:nonFraction unitRef="U_xbrlishares" id="F_000917" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxSharePurchaseAgreementWithPharmingMember_20210701_20210701" decimals="INF" format="ixt:numdotdecimal">1,227,738</ix:nonFraction> ordinary shares to Pharming for total consideration of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000916" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxSharePurchaseAgreementWithPharmingMember_20210701_20210701" decimals="-5" scale="6">7.5</ix:nonFraction> million. The consideration is payment for the fair value of ordinary shares with a fair value of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000918" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxSharePurchaseAgreementWithPharmingMember_20210701_20210701" decimals="-5" scale="6">4.1</ix:nonFraction> million plus a $<ix:nonFraction unitRef="U_iso4217USD" id="F_000919" name="ortx:ProceedsFromPremiumSharesIssued" contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxSharePurchaseAgreementWithPharmingMember_20210701_20210701" decimals="-5" scale="6">3.4</ix:nonFraction> million premium on the fair value of the Company&#8217;s ordinary shares</span>.</p>
<p style="Background-color:#FFFFFF;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The &#8220;Collaboration Agreement&#8221; and the &#8220;SPA&#8221; are referred to together as the &#8220;Pharming Agreements.&#8221;</span></p>
<p style="Background-color:#FFFFFF;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Accounting Analysis</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">At the commencement of the arrangement, two units of accounting were identified, which are the issuance of&#160;<ix:nonFraction unitRef="U_xbrlishares" id="F_000920" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxSharePurchaseAgreementWithPharmingMember_20210701_20210701" decimals="INF" format="ixt:numdotdecimal">1,227,738</ix:nonFraction> of the Company&#8217;s ordinary shares as part of the SPA, and the license and collaboration agreement, which conveys the license and provides for the Company to provide research, development, manufacturing services for OTL-105. The Pharming Agreements were entered into concurrently as part of a single commercial objective, and the Company considers them a </span></p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-31</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000308_dcnt_4e9453ed-d512-4934-b142-78017951d92f" continuedAt="F_000308_dcnt_34cb226a-9fd9-46dc-b82c-bba42afbd1b3">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">single arrangement for accounting purposes. The total upfront payments of $</span><span style="Background-color:#FFFFFF;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000921" name="ortx:ProceedsFromUpfrontPayment" contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxPharmingAgreementsMember_20210701_20210701" decimals="-5" scale="6">17.5</ix:nonFraction></span><span style="Background-color:#FFFFFF;"> million </span><span style="Background-color:#FFFFFF;">are</span><span style="Background-color:#FFFFFF;"> </span><span style="Background-color:#FFFFFF;">comprise</span><span style="Background-color:#FFFFFF;">d of</span><span style="Background-color:#FFFFFF;"> $</span><span style="Background-color:#FFFFFF;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000922" name="ortx:ProceedsFromUpfrontPaymentsAttributedToEquitySold" contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxPharmingAgreementsMember_20210701_20210701" decimals="-5" scale="6">4.1</ix:nonFraction>&#160;</span><span style="Background-color:#FFFFFF;">million attributed to the equity sold to Pharming and $</span><span style="Background-color:#FFFFFF;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000923" name="ortx:ProceedsFromUpfrontPaymentsAttributedToResearchActivities" contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxPharmingAgreementsMember_20210701_20210701" decimals="-5" scale="6">13.4</ix:nonFraction>&#160;</span><span style="Background-color:#FFFFFF;">million attributed to the Collaboration Agreement. In determining the fair value of the common stock issued to Pharming as part of the SPA, the Company used an option pricing valuation model to take into consideration certain holding period restrictions on the shares. The fair value of the Company&#8217;s common shares was considered a level 2 fair value measurement within the fair value hierarchy. </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The most significant assumptions within the model are the Company&#8217;s stock price, the term of the restrictions and the stock price volatility, which is based upon historical volatility of the Company&#8217;s stock. </span><span style="Background-color:#FFFFFF;">Based on the fair value adjustments made by management, the fair value of the</span><span style="Background-color:#FFFFFF;"> shares issued was </span><span style="Background-color:#FFFFFF;">determined to be $</span><span style="Background-color:#FFFFFF;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000924" name="us-gaap:StockIssued1" contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxPharmingAgreementsMember_20210701_20210701" decimals="-5" scale="6">4.1</ix:nonFraction></span><span style="Background-color:#FFFFFF;"> million with the excess proceeds of $</span><span style="Background-color:#FFFFFF;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000925" name="ortx:ExcessProceedsFromFairValueOfSharesIssuedAllocatedToCollaborationAgreement" contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxPharmingAgreementsMember_20210701_20210701" decimals="-5" scale="6">3.4</ix:nonFraction></span><span style="Background-color:#FFFFFF;"> million being allocation to the Collaboration</span><span style="Background-color:#FFFFFF;"> Agreement.</span><span style="font-size:12pt;color:#000000;"> </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company recognizes revenue under Accounting Standards Codification (&#8220;ASC&#8221;) 606,&#160;</span><span style="font-style:italic;">Revenue from Contracts with Customer </span><span style="Background-color:#FFFFFF;">(&#8220;ASC 606&#8221;). </span>The Company has concluded that the conveyance of the license for the HAE program and the provision of research, development, and manufacturing services for the HAE program represent a series of distinct services that are accounted for as a single performance obligation within the Collaboration Agreement. The Company determined that the transaction price includes: the non-refundable up-front payment of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000926" name="ortx:ProceedsFromNonRefundableUpfrontPayment" contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxStrategicCollaborationAgreementWithPharmingMember_20210701_20210701" decimals="-5" scale="6">10.0</ix:nonFraction>&#160;million, the $<ix:nonFraction unitRef="U_iso4217USD" id="F_000927" name="ortx:ProceedsFromPremiumSharesIssued" contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxSharePurchaseAgreementWithPharmingMember_20210701_20210701" decimals="-5" scale="6">3.4</ix:nonFraction> million in premium associated with the SPA, and the variable consideration for estimated reimbursement payments at agreed upon contractual rates to be received from Pharming for the Company&#8217;s on-going research, development, and manufacturing services. The potential future variable consideration is associated with the reimbursement for research, development, and manufacturing services provided by the Company to Pharming at agreed upon contractual rates which is the only remaining unsatisfied performance obligation. The milestone payments included in the Collaboration Agreement are fully constrained, as a result of the uncertainty regarding whether any of the associated milestones will be achieved and therefore,<span style="Background-color:#FFFFFF;"> the Company determined that it could not assert that it was probable that a significant reversal in the amount of cumulative revenue recognized will not occur.</span> The total estimated cost of the research and development services reflect the nature of the services to be performed and the Company&#8217;s best estimate of the length of time required to perform the services. <span style="Background-color:#FFFFFF;">The Company re-evaluates the transaction price as of the end of each reporting period</span>.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company also considered the existence of any significant financing component within the Pharming Agreements given their upfront payment structure. Based upon this assessment, the Company concluded that the up-front payments were provided for valid business reasons and not for the purpose of providing financing. Accordingly, the Company has concluded that the upfront payment structure of the Pharming Agreements does not result in the existence of a significant financing component.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes revenue associated with the performance obligation as the research, development and manufacturing services are provided using an input method, based on the cumulative costs incurred compared to the total estimated costs expected to be incurred to satisfy the performance obligation. The transfer of control to the customer occurs over the time period that the research, development and manufacturing services are to be provided by the Company, and this cost-to-cost method is, in management&#8217;s judgment, the best measure of progress towards satisfying the performance obligation. Reimbursement for research, development, and manufacturing services are recognized as the costs are incurred consistent with the cost-to-cost method.&#160;The Company's continuing obligations to provide research, development, and manufacturing services is based on the results of such efforts, and the estimated costs associated with the remaining efforts required to complete the performance obligations may change, which may materially impact revenue recognition. The Company regularly evaluates and, when necessary, updates the costs associated with the remaining effort under the Collaboration Agreement. Accordingly, revenue may fluctuate from period to period due to revisions to estimated costs, resulting in a change in the measure of progress for the performance obligation, or if the transaction price changes due to inclusion of any milestone payments that become unconstrained.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000363" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" contextRef="C_0001748907_20210101_20211231" escape="true">
<p style="Background-color:#FFFFFF;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes research and development costs incurred and collaboration revenue recognized in connection with the Company&#8217;s performance under the Collaboration Agreement:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reimbursement revenue</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000928" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001748907_srtProductOrServiceAxis_ortxReimbursementRevenueMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20210101_20211231" decimals="-3" scale="3">843</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.3%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upfront and milestone payment revenue</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000929" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001748907_srtProductOrServiceAxis_ortxUpfrontAndMilestonePaymentRevenueMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20210101_20211231" decimals="-3" scale="3">132</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.8%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.42%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000930" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20210101_20211231" decimals="-3" scale="3">975</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric>
<p style="Background-color:#FFFFFF;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had $<ix:nonFraction unitRef="U_iso4217USD" id="F_000931" name="us-gaap:ContractWithCustomerAssetNetCurrent" contextRef="C_0001748907_us-gaapBalanceSheetLocationAxis_us-gaapAccountsReceivableMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20211231" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000932" name="us-gaap:ContractWithCustomerAssetNetCurrent" contextRef="C_0001748907_us-gaapBalanceSheetLocationAxis_us-gaapAccountsReceivableMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20201231" decimals="-5" scale="6">0.8</ix:nonFraction></ix:nonFraction> million and nil due from Pharming included in accounts receivable as of December 31, 2021 and December 31, 2020, respectively.</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-32</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000308_dcnt_34cb226a-9fd9-46dc-b82c-bba42afbd1b3">
<p style="Background-color:#FFFFFF;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, the Company had contract liabilities of $</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000933" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20211231" decimals="-5" scale="6">12.9</ix:nonFraction></span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million, which is classified as either current or long-term deferred revenue in the</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> c</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">onsolidated balance sheet</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> based on the period over which this is expected to be recognized. The deferred revenue balance represents the portion of the upfront payments received </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">related to the performance obligation </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">remains</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> partially unsatisfied as of</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> December 31</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, 2021</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></ix:continuation><ix:nonNumeric id="F_000310" name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="C_0001748907_20210101_20211231" escape="true" continuedAt="F_000310_dcnt_271afbbf-6f53-4b4b-a63c-28bb8cf93d3b">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">17. Income Taxes </p><ix:nonNumeric id="F_000364" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" contextRef="C_0001748907_20210101_20211231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components of net loss before income taxes for the years ended December 31, 2021 and 2020 are as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.K.</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000934" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="C_0001748907_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">147,337</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000935" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="C_0001748907_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">155,614</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-U.K.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000936" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="C_0001748907_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,581</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000937" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="C_0001748907_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,904</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss before income taxes</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000938" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_0001748907_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">143,756</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000939" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_0001748907_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">152,710</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p><ix:nonNumeric id="F_000365" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" contextRef="C_0001748907_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The provision for (benefit from) income taxes for the years ended December&#160;31, 2021 and 2020 are as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current (benefit) provision</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal&#8212;United States</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000940" name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="C_0001748907_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,025</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000941" name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="C_0001748907_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,107</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State&#8212;United States</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000942" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="C_0001748907_20210101_20211231" decimals="-3" scale="3">334</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000943" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="C_0001748907_20200101_20201231" decimals="-3" scale="3">189</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other foreign</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000944" name="ortx:CurrentOtherTaxExpenseBenefit" contextRef="C_0001748907_20210101_20211231" decimals="-3" scale="3">388</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000945" name="ortx:CurrentOtherTaxExpenseBenefit" contextRef="C_0001748907_20200101_20201231" decimals="-3" scale="3">230</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United Kingdom</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current (benefit) provision</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000946" name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="C_0001748907_20210101_20211231" decimals="-3" sign="-" scale="3">303</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000947" name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="C_0001748907_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,526</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred provision (benefit)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal&#8212;United States</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000948" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="C_0001748907_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,099</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000949" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="C_0001748907_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,774</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State&#8212;United States</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000950" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="C_0001748907_20210101_20211231" decimals="-3" sign="-" scale="3">312</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000951" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="C_0001748907_20200101_20201231" decimals="-3" sign="-" scale="3">103</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United Kingdom</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other foreign</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000952" name="us-gaap:DeferredOtherTaxExpenseBenefit" contextRef="C_0001748907_20210101_20211231" decimals="-3" scale="3">344</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000953" name="us-gaap:DeferredOtherTaxExpenseBenefit" contextRef="C_0001748907_20200101_20201231" decimals="-3" sign="-" scale="3">380</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred provision (benefit)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000954" name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="C_0001748907_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,131</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000955" name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="C_0001748907_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">2,257</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total provision (benefit) for income taxes</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000956" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0001748907_20210101_20211231" decimals="-3" scale="3">828</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000957" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0001748907_20200101_20201231" decimals="-3" sign="-" scale="3">731</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p><ix:nonNumeric id="F_000366" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" contextRef="C_0001748907_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents a reconciliation of income tax expense (benefit) computed at the UK statutory income tax rate to the effective income tax rate as reflected in the consolidated financial statements: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income taxes at United Kingdom statutory rate</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000958" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="C_0001748907_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">27,313</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000959" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="C_0001748907_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">29,015</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000960" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="C_0001748907_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">59,691</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000961" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="C_0001748907_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">29,302</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reduction in research expense for credits granted</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000962" name="ortx:IncomeTaxReconciliationReductionInResearchExpenseForCreditsGranted" contextRef="C_0001748907_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,674</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000963" name="ortx:IncomeTaxReconciliationReductionInResearchExpenseForCreditsGranted" contextRef="C_0001748907_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,435</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in tax rates</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000964" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" contextRef="C_0001748907_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">38,785</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000965" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" contextRef="C_0001748907_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">8,105</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax credits</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000966" name="us-gaap:IncomeTaxReconciliationTaxCredits" contextRef="C_0001748907_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,232</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000967" name="us-gaap:IncomeTaxReconciliationTaxCredits" contextRef="C_0001748907_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,369</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. Deduction for foreign derived intangible income</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000968" name="ortx:IncomeTaxReconciliationDomesticDeductionForDerivedIntangibleIncome" contextRef="C_0001748907_20210101_20211231" decimals="-3" scale="3">196</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000969" name="ortx:IncomeTaxReconciliationDomesticDeductionForDerivedIntangibleIncome" contextRef="C_0001748907_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,254</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Permanent differences, including share-based compensation deduction shortfalls</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000970" name="ortx:IncomeTaxReconciliationPermanentDifferencesIncludingShareBasedCompensationDeductionShortfalls" contextRef="C_0001748907_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,863</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000971" name="ortx:IncomeTaxReconciliationPermanentDifferencesIncludingShareBasedCompensationDeductionShortfalls" contextRef="C_0001748907_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,265</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. state income taxes</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000972" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="C_0001748907_20210101_20211231" decimals="-3" scale="3">17</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000973" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="C_0001748907_20200101_20201231" decimals="-3" scale="3">68</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign rate differential</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000974" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" contextRef="C_0001748907_20210101_20211231" decimals="-3" scale="3">109</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000975" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" contextRef="C_0001748907_20200101_20201231" decimals="-3" sign="-" scale="3">58</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total provision (benefit) for income taxes</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000976" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0001748907_20210101_20211231" decimals="-3" scale="3">828</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000977" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0001748907_20200101_20201231" decimals="-3" sign="-" scale="3">731</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s income tax expense for the year ended December 31, 2021, compared to the year ended December 31, 2020, increased primarily related to shortfalls related to share-based compensation that is not deductible for tax purposes and a reduction of the U.S. deduction for foreign derived intangible income (&#8220;FDII&#8221;), offset by an increase in the benefit from U.S. federal research and development tax credits.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-33</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000310_dcnt_271afbbf-6f53-4b4b-a63c-28bb8cf93d3b" continuedAt="F_000310_dcnt_65bf876b-7092-49c9-b881-c50950cc2344">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During 2021, the U.K. Government announced that from April 1, 2023, the corporation tax rate would increase to <ix:nonFraction unitRef="U_xbrlipure" id="F_000978" name="ortx:CorporationTaxRatePercentage" contextRef="C_0001748907_srtStatementGeographicalAxis_countryGB_20210101_20211231" decimals="2" scale="-2">25</ix:nonFraction>%. This new law was enacted on June 10, 2021. The overall effect of the change was an increase in net deferred tax assets by $<ix:nonFraction unitRef="U_iso4217USD" id="F_000979" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" contextRef="C_0001748907_srtStatementGeographicalAxis_countryGB_20210101_20211231" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000980" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="C_0001748907_srtStatementGeographicalAxis_countryGB_20210101_20211231" decimals="-5" scale="6">38.8</ix:nonFraction></ix:nonFraction> million and an increase in valuation allowance by an equal amount.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for income taxes in accordance with ASC Topic 740. Deferred income tax assets and liabilities are determined based upon temporary differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.<ix:nonNumeric id="F_000367" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" contextRef="C_0001748907_20210101_20211231" escape="true" continuedAt="F_000367_cnt_1"> The following table presents the principal components of the Company&#8217;s deferred tax assets and liabilities as of December&#160;31, 2021 and 2020:</ix:nonNumeric> </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000367_cnt_1">
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforwards</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000981" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">126,563</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000982" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="C_0001748907_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">75,502</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000983" name="ortx:DeferredTaxAssetsAmortization" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">25,206</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000984" name="ortx:DeferredTaxAssetsAmortization" contextRef="C_0001748907_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">22,599</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development credits</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000985" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,449</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000986" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="C_0001748907_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,564</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share-based compensation</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000987" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,353</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000988" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="C_0001748907_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,400</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accruals</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000989" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" contextRef="C_0001748907_20211231" decimals="-3" scale="3">798</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000990" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" contextRef="C_0001748907_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,001</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease liability</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000991" name="ortx:DeferredTaxAssetsLeaseLiability" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,444</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000992" name="ortx:DeferredTaxAssetsLeaseLiability" contextRef="C_0001748907_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,805</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000993" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,022</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000994" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" contextRef="C_0001748907_20201231" decimals="-3" scale="3">523</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000995" name="us-gaap:DeferredTaxAssetsOther" contextRef="C_0001748907_20201231" decimals="-3" scale="3">3</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000996" name="us-gaap:DeferredTaxAssetsGross" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">171,835</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000997" name="us-gaap:DeferredTaxAssetsGross" contextRef="C_0001748907_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">115,397</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000998" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">161,573</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000999" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_0001748907_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">103,890</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fixed assets and right-of-use asset</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_001000" name="ortx:DeferredTaxLiabilitiesFixedAssetsAndRightOfUseAsset" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,176</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_001001" name="ortx:DeferredTaxLiabilitiesFixedAssetsAndRightOfUseAsset" contextRef="C_0001748907_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,288</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other non-current assets (net deferred tax assets and liabilities)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001002" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,086</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001003" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="C_0001748907_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,219</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;For the years ended December 31, 2021 and 2020, the Company had cumulative tax-effected UK net operating loss carryforwards of approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_001004" name="us-gaap:OperatingLossCarryforwards" contextRef="C_0001748907_srtStatementGeographicalAxis_countryGB_20211231" decimals="-5" scale="6">126.6</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_001005" name="us-gaap:OperatingLossCarryforwards" contextRef="C_0001748907_srtStatementGeographicalAxis_countryGB_20201231" decimals="-5" scale="6">75.1</ix:nonFraction> million, respectively. UK losses not surrendered may be carried forward indefinitely, subject to numerous utilization criteria and restrictions and are fully offset by a valuation allowance.&#160;&#160;For the years ended December 31, 2021 and 2020, the Company also had U.S. federal orphan drug tax credits of $<ix:nonFraction unitRef="U_iso4217USD" id="F_001006" name="us-gaap:TaxCreditCarryforwardAmount" contextRef="C_0001748907_srtStatementGeographicalAxis_countryUS_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_ortxOrphanDrugTaxCreditMember_20211231" decimals="-5" scale="6">0.6</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_001007" name="us-gaap:TaxCreditCarryforwardAmount" contextRef="C_0001748907_srtStatementGeographicalAxis_countryUS_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_ortxOrphanDrugTaxCreditMember_20201231" decimals="-6" scale="6">0</ix:nonFraction>, respectively, and U.S. state research and development tax credits of $<ix:nonFraction unitRef="U_iso4217USD" id="F_001008" name="us-gaap:TaxCreditCarryforwardAmount" contextRef="C_0001748907_srtStatementGeographicalAxis_countryUS_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20211231" decimals="-5" scale="6">2.4</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_001009" name="us-gaap:TaxCreditCarryforwardAmount" contextRef="C_0001748907_srtStatementGeographicalAxis_countryUS_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20201231" decimals="-5" scale="6">2.0</ix:nonFraction> million.&#160;&#160;The U.S. federal orphan drug tax credits expire in <ix:nonNumeric id="F_001010" name="ortx:TaxCreditCarryforwardExpirationYear" contextRef="C_0001748907_srtStatementGeographicalAxis_countryUS_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20210101_20211231">2041</ix:nonNumeric>, while the U.S. state research and development credits may be carried forward indefinitely and are offset by a valuation allowance.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In measuring the Company&#8217;s deferred tax assets, the Company considers all available evidence, both positive and negative, to determine whether, based on the weight of that evidence, a valuation allowance is needed for all or some portion of the deferred tax assets. Significant judgment is required in considering the relative impact of the negative and positive evidence, and weight given to each category of evidence is commensurate with the extent to which it can be objectively verified. The more negative evidence that exists, the more positive evidence is necessary, and the more difficult it is to support a conclusion that a valuation allowance is not needed. Additionally, the Company utilizes the "more likely than not" criteria established in FASB ASC Topic 740 to determine whether the future tax benefit from the deferred tax assets should be recognized. As a result, the Company has established valuation allowances on the deferred tax assets in jurisdictions that have incurred net operating losses and in which it is more likely than not that such losses will not be utilized in the foreseeable future.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of each reporting date, the Company considers new evidence, both positive and negative, that could impact the Company&#8217;s view with regard to future realization of our deferred tax assets. Management has considered the Company&#8217;s history of cumulative net losses in the UK, along with estimated future taxable income and has concluded that it is more likely than not that the Company will not realize the benefits of its UK deferred tax assets and U.S. state research and development tax credits. Accordingly, the Company has maintained a full valuation allowance against these net deferred tax assets as of December 31, 2021 and 2020, respectively.&#160;&#160;</p><ix:nonNumeric id="F_000368" name="us-gaap:SummaryOfValuationAllowanceTextBlock" contextRef="C_0001748907_20210101_20211231" escape="true" continuedAt="F_000368_dcnt_c5d92d2d-ccfd-489f-acf8-af4b787a405f"></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-34</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000310_dcnt_65bf876b-7092-49c9-b881-c50950cc2344"><ix:continuation id="F_000368_dcnt_c5d92d2d-ccfd-489f-acf8-af4b787a405f">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in the valuation allowance for deferred tax assets during the years ended December 31, 2021 and 2020 related primarily to the increase in UK net operating loss carryforwards as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance as of beginning of year</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_001011" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_0001748907_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">103,890</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_001012" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_0001748907_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">70,153</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increases recorded to income tax provision</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_001013" name="ortx:DeferredTaxAssetsValuationAllowanceIncreasesRecordedToIncomeTaxProvision" contextRef="C_0001748907_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">59,691</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_001014" name="ortx:DeferredTaxAssetsValuationAllowanceIncreasesRecordedToIncomeTaxProvision" contextRef="C_0001748907_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">29,302</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effect of foreign currency translation</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001015" name="ortx:DeferredTaxAssetsValuationAllowanceEffectOfForeignCurrencyTranslation" contextRef="C_0001748907_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,008</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_001016" name="ortx:DeferredTaxAssetsValuationAllowanceEffectOfForeignCurrencyTranslation" contextRef="C_0001748907_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">4,435</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance as of end of year</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_001017" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">161,573</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_001018" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_0001748907_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">103,890</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company applies the authoritative guidance on accounting for and disclosure of uncertainty in tax positions, which requires the Company to determine whether a tax position of the Company is more likely than not to be sustained upon examination, including resolution of any related appeals of litigation processes, based on the technical merits of the position. For tax positions meeting the more likely than not threshold, the tax amount recognized in the financial statements is reduced by the largest benefit that has a greater than fifty percent likelihood of being realized upon the ultimate settlement with the relevant taxing authority.&#160;There were no material uncertain tax positions as of December 31, 2021 and 2020. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company will recognize interest and penalties related to uncertain tax positions in income tax expense. As of December 31, 2021, and 2020, the Company had <ix:nonFraction unitRef="U_iso4217USD" id="F_001019" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" contextRef="C_0001748907_20211231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_001020" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" contextRef="C_0001748907_20201231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> accrued interest or penalties related to uncertain tax positions and no amounts have been recognized in the Company&#8217;s statement of operations.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company and its subsidiaries file income tax returns in the UK, the U.S., and various foreign jurisdictions. Generally, the tax years <ix:nonNumeric id="F_001021" name="us-gaap:OpenTaxYear" contextRef="C_0001748907_us-gaapTaxPeriodAxis_us-gaapEarliestTaxYearMember_20210101_20211231">2017</ix:nonNumeric> through <ix:nonNumeric id="F_001022" name="us-gaap:OpenTaxYear" contextRef="C_0001748907_us-gaapTaxPeriodAxis_us-gaapLatestTaxYearMember_20210101_20211231">2021</ix:nonNumeric> remain open to examination by the major taxing jurisdictions to which the Company is subject. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the federal, state, or foreign tax authorities, if such tax attributes are utilized in a future period. </p></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p><ix:nonNumeric id="F_000311" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="C_0001748907_20210101_20211231" escape="true" continuedAt="F_000311_dcnt_4221c293-41fc-4221-b87e-0648e9e8fa68">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">18. Commitments and Contingencies </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Lease commitments</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company leases office and laboratory space and has an embedded lease at AGC. Refer to Note 11, <span style="font-style:italic;">Leases</span>, for further information on the terms of the lease agreements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Manufacturing and technology development master agreement with AGC</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">On July 2, 2020, the Company entered into the AGC Agreement, pursuant to which AGC will develop, manufacture and supply certain viral vectors and conduct cell processing activities for certain Company development and commercial programs. Under the terms of the AGC Agreement, the Company is obligated to pay AGC for a minimum product manufacturing commitment, dedicated manufacturing and development resources, and for a lease component associated with the right of use of exclusive manufacturing suites within AGC&#8217;s existing facilities. <ix:nonNumeric id="F_000369" name="srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock" contextRef="C_0001748907_20210101_20211231" escape="true" continuedAt="F_000369_cnt_1">The following table outlines the annual commitments associated with the contract, as of December 31, 2021:</ix:nonNumeric></span></p><ix:continuation id="F_000369_cnt_1" continuedAt="F_000369_dcnt_79f8e352-a49c-4a1b-a480-10aa7621aace">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Due in:</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Product manufacturing commitments (1)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Dedicated manufacturing and development resources (2)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exclusive transduction suites (3)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total AGC Commitment</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001023" name="ortx:ManufacturingCommitmentsAmountDueInNextTwelveMonths" contextRef="C_0001748907_us-gaapSupplyCommitmentAxis_ortxProductManufacturingCommitmentsMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,627</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001024" name="ortx:ManufacturingCommitmentsAmountDueInNextTwelveMonths" contextRef="C_0001748907_us-gaapSupplyCommitmentAxis_ortxDedicatedManufacturingAndDevelopmentResourcesMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,379</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001025" name="ortx:ManufacturingCommitmentsAmountDueInNextTwelveMonths" contextRef="C_0001748907_us-gaapSupplyCommitmentAxis_ortxExclusiveTransductionSuitesMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,626</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001026" name="ortx:ManufacturingCommitmentsAmountDueInNextTwelveMonths" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">13,632</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001027" name="ortx:ManufacturingCommitmentsAmountDueInYearTwo" contextRef="C_0001748907_us-gaapSupplyCommitmentAxis_ortxProductManufacturingCommitmentsMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,051</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001028" name="ortx:ManufacturingCommitmentsAmountDueInYearTwo" contextRef="C_0001748907_us-gaapSupplyCommitmentAxis_ortxDedicatedManufacturingAndDevelopmentResourcesMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,831</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001029" name="ortx:ManufacturingCommitmentsAmountDueInYearTwo" contextRef="C_0001748907_us-gaapSupplyCommitmentAxis_ortxExclusiveTransductionSuitesMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,079</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001030" name="ortx:ManufacturingCommitmentsAmountDueInYearTwo" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">13,961</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001031" name="ortx:ManufacturingCommitmentsAmountDueInYearThree" contextRef="C_0001748907_us-gaapSupplyCommitmentAxis_ortxProductManufacturingCommitmentsMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,051</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001032" name="ortx:ManufacturingCommitmentsAmountDueInYearThree" contextRef="C_0001748907_us-gaapSupplyCommitmentAxis_ortxDedicatedManufacturingAndDevelopmentResourcesMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,831</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001033" name="ortx:ManufacturingCommitmentsAmountDueInYearThree" contextRef="C_0001748907_us-gaapSupplyCommitmentAxis_ortxExclusiveTransductionSuitesMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,079</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001034" name="ortx:ManufacturingCommitmentsAmountDueInYearThree" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">13,961</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001035" name="ortx:ManufacturingCommitmentsAmountDueInYearFour" contextRef="C_0001748907_us-gaapSupplyCommitmentAxis_ortxProductManufacturingCommitmentsMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,525</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001036" name="ortx:ManufacturingCommitmentsAmountDueInYearFour" contextRef="C_0001748907_us-gaapSupplyCommitmentAxis_ortxDedicatedManufacturingAndDevelopmentResourcesMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,915</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001037" name="ortx:ManufacturingCommitmentsAmountDueInYearFour" contextRef="C_0001748907_us-gaapSupplyCommitmentAxis_ortxExclusiveTransductionSuitesMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,539</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001038" name="ortx:ManufacturingCommitmentsAmountDueInYearFour" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,979</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2026</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total manufacturing commitments</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001039" name="ortx:ManufacturingCommitments" contextRef="C_0001748907_us-gaapSupplyCommitmentAxis_ortxProductManufacturingCommitmentsMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">10,254</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001040" name="ortx:ManufacturingCommitments" contextRef="C_0001748907_us-gaapSupplyCommitmentAxis_ortxDedicatedManufacturingAndDevelopmentResourcesMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">27,956</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001041" name="ortx:ManufacturingCommitments" contextRef="C_0001748907_us-gaapSupplyCommitmentAxis_ortxExclusiveTransductionSuitesMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">10,323</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001042" name="ortx:ManufacturingCommitments" contextRef="C_0001748907_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">48,533</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">*Tabular disclosure above has been translated to U.S. Dollar, from Euro, using an exchange rate of &#8364;1.00 to $<ix:nonFraction unitRef="U_xbrlipure" id="F_001043" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" contextRef="C_0001748907_20211231" decimals="2">1.13</ix:nonFraction>.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-35</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000311_dcnt_4221c293-41fc-4221-b87e-0648e9e8fa68"><ix:continuation id="F_000369_dcnt_79f8e352-a49c-4a1b-a480-10aa7621aace">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">(1) The minimum product manufacturing commitments may be increased to the mid-seven figures per contract year upon achievement of certain milestones.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">(2) The Company may increase or decrease the usage of dedicated development services on a rolling basis with between six and 12-months&#8217; prior written notice to AGC. The above table assumes continued usage of dedicated development services at current rates.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">(3) Refer to Note 11 for further information on the embedded operating lease agreement</span></p></ix:continuation>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The AGC Agreement has an initial term of&#160;<ix:nonNumeric id="F_001044" name="ortx:InitialTermOfAgreement" contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxManufacturingAndTechnologyDevelopmentMasterAgreementMember_20210101_20211231" format="ixt-sec:durwordsen">five years</ix:nonNumeric>, beginning on the Effective Date and ending&#160;<ix:nonNumeric id="F_001045" name="ortx:AgreementMaturityDate" contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxManufacturingAndTechnologyDevelopmentMasterAgreementMember_20210101_20211231" format="ixt:datemonthdayyearen">July 2, 2025</ix:nonNumeric>. The AGC Agreement may be extended for an additional&#160;<ix:nonNumeric id="F_001046" name="ortx:AgreementExtensionTerm" contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxManufacturingAndTechnologyDevelopmentMasterAgreementMember_20210101_20211231" format="ixt-sec:durwordsen">two years</ix:nonNumeric>&#160;by mutual agreement of the Company and AGC. The Company has the right to terminate the AGC Agreement at its discretion upon 12-month&#8217;s prior written notice to AGC, and beginning no earlier than July 2, 2022, AGC has the right to terminate the AGC Agreement at its discretion upon 24-month&#8217;s prior written notice to the Company. Each party may terminate the AGC Agreement upon prior notice to the other party for an uncured material breach that the breaching party does not cure within the notice period.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Other funding commitments</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has entered into several license agreements (see Note 15). In connection with these agreements the Company is required to make milestone payments and annual license maintenance payments or royalties on future sales of specified products. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Consulting Agreement</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the Company entered into a consulting agreement with non-employee advisor whereby the Company is obligated to make cash payments of $<ix:nonFraction unitRef="U_iso4217USD" id="F_001047" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" contextRef="C_0001748907_srtTitleOfIndividualAxis_ortxNonEmployeeAdvisorMember_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_ortxConsultingAgreementMember_20191231" decimals="-5" scale="6">0.1</ix:nonFraction> million per year and to issue up to <ix:nonFraction unitRef="U_xbrlishares" id="F_001048" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001748907_srtTitleOfIndividualAxis_ortxNonEmployeeAdvisorMember_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_ortxConsultingAgreementMember_20191231" decimals="INF" format="ixt:numdotdecimal">91,034</ix:nonFraction> ordinary shares, which vest annually over a <span style="-sec-ix-hidden:F_001050">four-year</span> period, and <ix:nonFraction unitRef="U_xbrlishares" id="F_001049" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001748907_srtTitleOfIndividualAxis_ortxNonEmployeeAdvisorMember_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_ortxConsultingAgreementMember_us-gaapTypeOfArrangementAxis_ortxClinicalDevelopmentAndRegulatoryMilestoneMember_20191231" decimals="INF" format="ixt:numdotdecimal">92,035</ix:nonFraction> ordinary shares upon attainment of certain clinical development and regulatory milestones. In December 2021 and 2020, the Company issued <ix:nonFraction unitRef="U_xbrlishares" id="F_001051" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001748907_srtTitleOfIndividualAxis_ortxNonEmployeeAdvisorMember_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_ortxConsultingAgreementMember_us-gaapTypeOfArrangementAxis_ortxClinicalDevelopmentAndRegulatoryMilestoneMember_20201231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_001052" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001748907_srtTitleOfIndividualAxis_ortxNonEmployeeAdvisorMember_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_ortxConsultingAgreementMember_us-gaapTypeOfArrangementAxis_ortxClinicalDevelopmentAndRegulatoryMilestoneMember_20211231" decimals="INF" format="ixt:numdotdecimal">22,758</ix:nonFraction></ix:nonFraction> ordinary shares associated with the service condition.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the years ended December 31, 2021 and 2020, the Company recorded $<ix:nonFraction unitRef="U_iso4217USD" id="F_001053" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001748907_srtTitleOfIndividualAxis_ortxNonEmployeeAdvisorMember_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_ortxConsultingAgreementMember_20210101_20211231" decimals="-5" scale="6">0.3</ix:nonFraction> million and <span><span style="color:#000000;">$</span><ix:nonFraction unitRef="U_iso4217USD" id="F_001054" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001748907_srtTitleOfIndividualAxis_ortxNonEmployeeAdvisorMember_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_ortxConsultingAgreementMember_20200101_20201231" decimals="-5" scale="6">0.3</ix:nonFraction></span> million in research and development expense associated with the share-based awards with service conditions. <span style="color:#000000;">During the years ended December 31, 2021 and 2020, </span><ix:nonFraction unitRef="U_iso4217USD" id="F_001055" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001748907_srtTitleOfIndividualAxis_ortxNonEmployeeAdvisorMember_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_ortxConsultingAgreementMember_20210101_20211231" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_001056" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001748907_srtTitleOfIndividualAxis_ortxNonEmployeeAdvisorMember_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_ortxConsultingAgreementMember_20200101_20201231" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> expense was recorded associated with the performance-based conditions.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Legal proceedings </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;letter-spacing:-0.15pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is not a party to any litigation and does not have contingency reserves established for any litigation liabilities. </p></ix:continuation><ix:nonNumeric id="F_000312" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" contextRef="C_0001748907_20210101_20211231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">19. Benefit Plans</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company makes contributions to private defined contribution pension plans on behalf of its employees. The Company matches its employee contributions up to <ix:nonFraction unitRef="U_xbrlipure" id="F_001059" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" contextRef="C_0001748907_20210101_20211231" decimals="INF" format="ixt-sec:numwordsen" scale="-2">six</ix:nonFraction> percent of each employee&#8217;s annual salary based on the jurisdiction the employees are located. The Company paid $<ix:nonFraction unitRef="U_iso4217USD" id="F_001057" name="us-gaap:DefinedContributionPlanCostRecognized" contextRef="C_0001748907_20210101_20211231" decimals="-5" scale="6">1.7</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_001058" name="us-gaap:DefinedContributionPlanCostRecognized" contextRef="C_0001748907_20200101_20201231" decimals="-5" scale="6">1.6</ix:nonFraction> million, in matching contributions for the years ended December&#160;31, 2021 and 2020, respectively.</p></ix:nonNumeric><ix:nonNumeric id="F_000313" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" contextRef="C_0001748907_20210101_20211231" escape="true" continuedAt="F_000313_dcnt_9ebdb1c7-d9fe-43fe-88f2-41e50457478a">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">20. Related-party Transactions </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GSK</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2018, the Company completed the GSK Agreement with subsidiaries of GSK (See Note 14). As consideration under the agreement the Company paid an upfront fee of $<ix:nonFraction unitRef="U_iso4217USD" id="F_001060" name="ortx:LicenseUpfrontFeeAndRelatedExpensesPaid" contextRef="C_0001748907_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ortxGSKMember_20180401_20180430" decimals="-5" scale="6">14.2</ix:nonFraction> million, purchased inventory of $<ix:nonFraction unitRef="U_iso4217USD" id="F_001061" name="ortx:InventoryPurchase" contextRef="C_0001748907_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ortxGSKMember_20180430" decimals="-5" scale="6">6.9</ix:nonFraction> million, paid $<ix:nonFraction unitRef="U_iso4217USD" id="F_001062" name="ortx:AssetAcquisitionTransactionCosts" contextRef="C_0001748907_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ortxGSKMember_20180401_20180430" decimals="-5" scale="6">0.8</ix:nonFraction> million in transaction costs, and issued <ix:nonFraction unitRef="U_xbrlishares" id="F_001063" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" contextRef="C_0001748907_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ortxGSKMember_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20180430" decimals="INF" format="ixt:numdotdecimal">12,455,252</ix:nonFraction> convertible preferred shares valued at $<ix:nonFraction unitRef="U_iso4217USD" id="F_001064" name="us-gaap:PreferredStockValue" contextRef="C_0001748907_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ortxGSKMember_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20180430" decimals="-5" scale="6">93.4</ix:nonFraction> million. Additionally, as part of the GSK Agreement, the Company obtained, and is responsible for maintaining the commercial availability of Strimvelis. The Company recorded a loss provision of $<ix:nonFraction unitRef="U_iso4217USD" id="F_001065" name="us-gaap:ProvisionForLossOnContracts" contextRef="C_0001748907_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ortxGSKMember_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20180430" decimals="-5" scale="6">18.4</ix:nonFraction> million associated with the agreement, as the costs to maintain Strimvelis are expected to significantly exceed revenues. The issuance of the convertible preferred shares made GSK a principal shareholder in the Company. As of June 16, 2021, GSK no longer had a right to nominate and appoint a designee to the Company&#8217;s board of directors, and GSK is no longer considered a related party.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, the Company had accounts payable and accrued expenses due to GSK of <span>$<ix:nonFraction unitRef="U_iso4217USD" id="F_001066" name="us-gaap:AccountsPayableRelatedPartiesCurrent" contextRef="C_0001748907_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ortxGSKMember_20201231" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_001067" name="ortx:AccruedExpensesRelatedPartyCurrent" contextRef="C_0001748907_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ortxGSKMember_20201231" decimals="-5" scale="6">0.1</ix:nonFraction></ix:nonFraction></span> million. During the year-ended December 31, 2020, the Company entered into a global license agreement with GSK for use of their lentiviral stable cell line technology whereby the Company recorded $<ix:nonFraction unitRef="U_iso4217USD" id="F_001068" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001748907_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ortxGSKMember_us-gaapTypeOfArrangementAxis_ortxGSKAssetPurchaseAndLicenseAgreementMember_20200101_20201231" decimals="-5" scale="6">1.2</ix:nonFraction> million of in-process research and development expense </p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-36</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000313_dcnt_9ebdb1c7-d9fe-43fe-88f2-41e50457478a">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">associated with upfront payments made to GSK. During the year-ended December 31, 2020, the Company made </span><span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001069" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="C_0001748907_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ortxGSKMember_20200101_20201231" decimals="-5" sign="-" format="ixt:numdotdecimal" scale="6">5.8</ix:nonFraction></span></span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million in payments on accounts payable due to GSK associated with </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">milestones, clinical inventory, and royalties</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></ix:continuation><ix:nonNumeric id="F_000314" name="us-gaap:SubsequentEventsTextBlock" contextRef="C_0001748907_20210101_20211231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">21. Subsequent events </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 30, 2022, the Company announced a proposed reduction of its workforce of approximately <ix:nonFraction unitRef="U_xbrlipure" id="F_001070" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" contextRef="C_0001748907_srtStatementGeographicalAxis_countryGB_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220330_20220330" decimals="2" scale="-2">30</ix:nonFraction>%, subject to a consultation process with certain employees in the United Kingdom. The Company estimates that it will incur aggregate charges of approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_001071" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" contextRef="C_0001748907_srtStatementGeographicalAxis_countryGB_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220330" decimals="-5" scale="6">2.5</ix:nonFraction> million in the first and second quarters of 2022 as a result of the restructuring, consisting of one-time cash expenditures for severance and employee termination-related costs.<span style="color:#000000;font-size:12pt;"> </span>The Company also announced that it would discontinue its investment in and seek alternatives for OTL-102 for treatment of X-CGD, OTL-103 for treatment of WAS and Strimvelis. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-37</p></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.19
<SEQUENCE>2
<FILENAME>ortx-ex1019_562.htm
<DESCRIPTION>EX-10.19
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
ortx-ex1019_562.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.19</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 30, 2022</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Frank Thomas</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">Re: <font style="text-decoration:underline;">First Amendment to the Transitional Services Agreement</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dear Frank:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As we have discussed, this First Amendment to the Transitional Services Agreement (the &#8220;<font style="text-decoration:underline;">Amendment</font>&#8221;) confirms the agreement between you, Orchard Therapeutics plc (the &#8220;<font style="text-decoration:underline;">Parent</font>&#8221;) and Orchard Therapeutics North America (the &#8220;<font style="text-decoration:underline;">U.S. Subsidiary</font>&#8221;, and together with the Parent, the &#8220;<font style="text-decoration:underline;">Company</font>&#8221;), to amend the Transitional Services Agreement dated November 3, 2021 (the &#8220;<font style="text-decoration:underline;">Agreement</font>&#8221;) to reflect, among other terms, that the mutually agreeable effective date of your resignation without Good Reason from the Company is December 31, 2022 (or such other date consistent with the terms of the Agreement as revised herein).&nbsp;&nbsp;The Agreement is attached hereto as <font style="text-decoration:underline;">Exhibit A</font> to this Amendment. Capitalized terms not otherwise defined herein shall have the respective meanings ascribed to such terms in the Agreement.&nbsp;&nbsp;For good and valuable consideration, the receipt of which is hereby acknowledged, you and the Company hereby agree as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The definition of &#8220;Date of Termination&#8221; is hereby amended and restated in its entirety to read as follows: The actual last day of your employment is referred to herein as &#8220;</font><font style="text-decoration:underline;color:#000000;">Date of Termination</font><font style="color:#000000;">.&#8221;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Section 1 of the Agreement is hereby amended and restated in its entirety to read as follows:</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.85%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">1.<font style="margin-left:36pt;">Conditions</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To receive the benefits set forth in this Agreement, you must satisfy each of the following &#8220;<font style="text-decoration:underline;">Conditions</font>&#8221;: (i) enter into, not revoke and comply with this Agreement; (ii)&#160;not be terminated by the Company for Cause or resign without the Chief Executive Officer&#8217;s written approval prior to December 31, 2022; (iii) work cooperatively to the reasonable satisfaction of the Chief Executive Officer during the Transition Period; and (iv) for purposes of the Health Benefits, the Extended Vesting Period, the Cash Payments, and the Extended Exercise Period (as such capitalized terms are defined below), enter into the certificate attached hereto as Exhibit B, which updates the release of claims set forth in Section 7 of this Agreement (the &#8220;<font style="text-decoration:underline;">Certificate</font>&#8221;), within the timeframe set forth therein.&nbsp;&nbsp;The Company agrees that if for any reason it believes you are not meeting your obligations under Section (iii) herein it will notify you in writing detailing the reasons you are not complying with this obligation and provide you with a reasonable time to cure.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">3.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Section 2 of the Agreement is hereby amended and restated in its entirety to read as follows:</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.85%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">2.<font style="margin-left:36pt;"></font>Transition Period </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(a)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">If you satisfy the Conditions, your employment with the Company will continue, along with the compensation and benefits specified below, until December 31, 2022, unless you are sooner terminated by the Company for Cause, you resign or you and the Company agree in writing to extend your employment.&nbsp;&nbsp;During the Transition Period, you will continue to serve as the President and Chief Operating Officer and provide services for the Company on a full-time basis, unless otherwise requested by the Chief Executive Officer.&nbsp;&nbsp;The Company anticipates that you will focus on transitional duties and working with the Company to hire a new Chief Financial Officer during the Transition Period, although you may be required to perform other reasonable duties as requested by the Company.&nbsp;&nbsp;For the avoidance of doubt, Good Reason shall not apply during the Transition Period, and you hereby waive any right to terminate your employment for Good Reason during the Transition Period. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(b)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">During the Transition Period, you will (i) continue to be paid your Base Salary, subject to an increase in the base salary rate in an amount determined by the Board of Directors of the Parent (or the Compensation Committee thereof) effective at the time that other executive team members receive base salary rate increases, (ii) remain eligible to participate in the Company&#8217;s group employee benefit plans and (iii) continue to vest in the stock options and any other stock-based equity awards granted to you by the Company (collectively, the &#8220;</font><font style="text-decoration:underline;color:#000000;">Equity Awards</font><font style="color:#000000;">&#8221;), consistent with the applicable equity incentive plan(s) and the applicable equity award agreement(s) governing the terms of such equity awards (collectively, the &#8220;</font><font style="text-decoration:underline;color:#000000;">Equity Documents</font><font style="color:#000000;">&#8221;). You acknowledge and agree that you received your 2021 bonus (the &#8220;</font><font style="text-decoration:underline;color:#000000;">2021 Bonus</font><font style="color:#000000;">&#8221;), in an amount equal to the greater of (i) the Target Bonus or (ii) the bonus based on corporate performance.&nbsp;&nbsp;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(c)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Subject to approval by the Board of Directors of the Parent (or the Compensation Committee thereof), the Company shall grant you options to purchase shares of the Company&#8217;s common stock at the stock&#8217;s then fair market value and/or restricted stock units in the Company (the &#8220;</font><font style="text-decoration:underline;color:#000000;">New Award</font><font style="color:#000000;">&#8221;). The New Award shall be subject to the terms of, and contingent upon your execution of, applicable equity award agreement(s) and the applicable equity incentive plan(s) governing the terms of the New Award. For the avoidance of doubt, such equity award agreement(s) and equity incentive plan(s) are Equity Documents as defined herein. Further, for the avoidance of doubt, the New Award is an Equity Award as defined herein. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(d)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Subject to approval by the Board of Directors of the Parent (or the Compensation Committee thereof), and notwithstanding anything to the contrary in the Equity Documents, if you satisfy the Conditions then all Equity Awards subject to time-based vesting shall continue to vest until April 1, 2023 (the &#8220;Extended Vesting Period&#8221;).  Any remaining unvested Equity Awards shall then be terminated and forfeited immediately following the Extended Vesting Period. Solely for purposes of the Equity Documents, you will continue to have a service relationship with the Company during the Extended Vesting Period and you agree to remain available to provide professional support to the Company on an as needed basis.&nbsp;&nbsp;Except as set forth herein, the terms of the Equity Documents shall continue in full force in all respects.&nbsp;&nbsp;</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(e)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">If the Company terminates your employment for Cause, or if you fail to satisfy any of the Conditions, your employment will end immediately and you will cease vesting as of the Date of Termination or as otherwise set forth herein, you shall be entitled to the Accrued Obligations and you shall have no right to the Health Benefits, the Extended Vesting Period, the Cash Payments, the Extended Exercise Period or any other post-employment compensation or benefits from the Company.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">4.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Section 5 of the Agreement is hereby amended and restated in its entirety to read as follows:</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.85%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">5.<font style="margin-left:36pt;"></font>Cash Incentive Compensation</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.85%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(a)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">If you are employed by the Company on October 1, 2022 or if you are terminated by the Company without Cause prior to that date and have satisfied the Conditions, including, without limitation, signing the Certificate, you will receive a cash payment equal to 25% of your then current Base Salary, which will be paid to you no later than October 31, 2022 (the &#8220;</font><font style="text-decoration:underline;color:#000000;">2022 Cash Payment</font><font style="color:#000000;">&#8221;).&nbsp;&nbsp;For purposes of the above calculation, if the Company terminates you without Cause prior to October 1, 2022 and you have satisfied the Conditions, your Base Salary as of the last day of your employment shall be used. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(b)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">If you satisfy the Conditions, including, without limitation, signing the Certificate, then you will receive a cash payment equal to 25% of your then current Base Salary at the time that the Company pays its executives their annual incentive compensation for calendar year 2022, which will be no later than March 15, 2023 (the &#8220;</font><font style="text-decoration:underline;color:#000000;">2023 Cash Payment</font><font style="color:#000000;">&#8221;) (together, the 2022 Cash Payment and 2023 Cash Payment are referred to as the &#8220;</font><font style="text-decoration:underline;color:#000000;">Cash Payments</font><font style="color:#000000;">&#8221;).</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">5.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Section 6 of the Agreement is hereby amended and restated in its entirety to read as follows:</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">6. &nbsp;&nbsp;Extended Exercise Period</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk97627814"></a>If you satisfy the Conditions, including, without limitation, signing the Certificate, then subject to the approval of the Board of Directors of the Parent (or the Compensation Committee thereof) and notwithstanding anything to the contrary in Equity Documents, the Company shall extend the exercise period with respect to the vested shares of your stock options as of the Effective Date of the Certificate until the earlier of (A) April 1, 2024 or (B) the expiration date of the applicable stock option (the &#8220;<font style="text-decoration:underline;">Extended Exercise Period</font><a name="_Hlk97627814"></a>&#8221;).&nbsp;&nbsp;You are advised to consult with your tax advisor regarding the tax impact of the Extended Exercise Period.&nbsp;&nbsp;Except as set forth herein, the terms of the Equity Documents shall continue in full force in all respects.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">6.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Section 14(a) of the Agreement is hereby amended and restated in its entirety to read as follows:</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(a)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Relief</font><font style="color:#000000;">.&nbsp;&nbsp;In the event that you fail to comply with any of your obligations under this Agreement (including the Continuing Obligations), then in addition to any other legal or equitable remedies it may have for such breach, the Company shall have the right to terminate your employment (if you are still employed) and, to the extent applicable, terminate the Health Benefits, the Extended Vesting Period, eligibility for the Cash Payments, the Extended Exercise Period and any other benefits provided under this Agreement other than the Accrued Obligations, and, if applicable, seek repayment of such benefits.&nbsp;&nbsp;Any such consequences of a breach by you of your obligations under this Agreement will not affect the release in Section 7 or your continuing obligations under this Agreement.&nbsp;&nbsp;Further, you agree that it would be difficult to measure any harm caused to the Company that might result from any breach by you of any of the Continuing Obligations and that, in any event, money damages would be an inadequate remedy for any such breach.&nbsp;&nbsp;Accordingly, you agree that if you breach, the Company shall be entitled, in addition to all other remedies it may have, to specific performance and other injunctive relief, without the posting of a bond, and that you will be obligated to pay the Company&#8217;s costs of enforcement of the Continuing Obligations, including reasonable attorneys&#8217; fees and expenses.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">7.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Exhibit B of the Agreement is hereby amended and restated in its entirety in Exhibit B to this Amendment.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">8.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">This Amendment shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts, without regard to the conflicts of law principles.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">9.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Except as specifically provided herein, this Amendment does not amend or modify or otherwise affect any other provisions of the Agreement, and the Agreement, as specifically amended by this Amendment, is hereby ratified and confirmed by you and the Company and remains in full force and effect.&nbsp;&nbsp;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">10.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">This Amendment may be executed in any number of counterparts, each of which when so executed and delivered shall be taken to be an original, but all of which together shall constitute one and the same document.&nbsp;&nbsp;Electronic and pdf signatures shall be deemed to be of equal force and effect as originals.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[Remainder of page intentionally left blank.]</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IN WITNESS WHEREOF, the undersigned have executed this Amendment as of the dates set forth below.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">PARENT </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ORCHARD THERAPEUTICS PLC</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By: <font style="text-decoration:underline;">/s/ Bobby Gaspar</font><font style="text-decoration:underline;margin-left:36pt;"></font><font style="text-decoration:underline;margin-left:72pt;"></font><font style="text-decoration:underline;margin-left:108pt;"></font><font style="text-decoration:underline;margin-left:144pt;"></font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name: Bobby Gaspar</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title: Chief Executive Officer</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 30, 2022</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-size:11.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">U.S. SUBSIDIARY </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ORCHARD THERAPEUTICS NORTH AMERICA</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-size:14pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By: <font style="text-decoration:underline;">/s/ Bobby Gaspar</font><font style="text-decoration:underline;margin-left:36pt;"></font><font style="text-decoration:underline;margin-left:72pt;"></font><font style="text-decoration:underline;margin-left:108pt;"></font><font style="text-decoration:underline;margin-left:144pt;"></font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name: Bobby Gaspar</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title: Chief Executive Officer</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 30, 2022</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This is a legal document.&nbsp;&nbsp;Your signature will commit you to its terms.&nbsp;&nbsp;<font style="color:#000000;">The Company advises you to consult with an attorney before signing this Agreement.&nbsp;&nbsp;</font>By signing below, you acknowledge that you have carefully read and fully understand all of the provisions of this Agreement and that you are knowingly and voluntarily entering into this Agreement.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">/s/ Frank Thomas</font><font style="text-decoration:underline;margin-left:36pt;"></font><font style="text-decoration:underline;margin-left:72pt;"></font><font style="text-decoration:underline;margin-left:108pt;"></font><font style="text-decoration:underline;margin-left:144pt;"></font><font style="margin-left:180pt;"></font><font style="text-decoration:underline;">March 30, 2022</font><font style="text-decoration:underline;margin-left:36pt;"></font><font style="text-decoration:underline;margin-left:72pt;"></font><font style="text-decoration:underline;margin-left:108pt;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Frank Thomas<font style="margin-left:36pt;">  Date </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="margin-left:108pt;"></font><font style="font-weight:bold;margin-left:144pt;"></font><font style="font-weight:bold;margin-left:180pt;"></font><font style="font-weight:bold;margin-left:216pt;"></font><font style="font-weight:bold;margin-left:252pt;"></font>&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9.5pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Exhibit A</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Transitional Services Agreement</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:9.5pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[<font style="font-style:italic;">Filed as Exhibit 10.1 on the Company&#8217;s Form 10-Q filed with the SEC on November 4, 2021</font>]</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:9.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;"><br /></font></p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Exhibit B</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9.5pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Certificate Updating the Release of Claims</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Frank Thomas, hereby acknowledge and certify that I entered into a Transitional Services Agreement (the &#8220;<font style="text-decoration:underline;">Transitional Services Agreement</font>&#8221;) with <font style="color:#000000;">Orchard Therapeutics plc (the &#8220;</font><font style="text-decoration:underline;color:#000000;">Parent</font><font style="color:#000000;">&#8221;) and Orchard Therapeutics North America (the &#8220;</font><font style="text-decoration:underline;color:#000000;">U.S. Subsidiary</font><font style="color:#000000;">&#8221;, and together with the Parent, the &#8220;</font><font style="text-decoration:underline;color:#000000;">Company</font><font style="color:#000000;">&#8221;)</font> in connection with the ending of my employment, as amended by the First Amendment to the Transitional Services Agreement (the &#8220;<font style="text-decoration:underline;">First Amendment to the Transitional Services Agreement</font>&#8221;, and together with the Transitional Services Agreement, the &#8220;<font style="text-decoration:underline;">Agreement</font>&#8221;).&nbsp;&nbsp;Capitalized terms used herein and not otherwise defined have the meanings ascribed to such terms in the Agreement.&nbsp;&nbsp;Pursuant to the Agreement, and provided that I have satisfied the Conditions, I am required to execute this certificate, which updates the release of claims set forth in Section 7 of the Transitional Services Agreement (this &#8220;<font style="text-decoration:underline;">Certificate</font>&#8221;), in order to be eligible for the Health Benefits, the Extended Vesting Period, the Cash Payments, and the Extended Exercise Period.&nbsp;&nbsp;<font style="font-weight:bold;">I understand that I may not sign this Certificate until on or after the Date of Termination and that I must return it to the Company within seven days after the Date of Termination as set forth below</font>.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, therefore, agree as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">A copy of this Certificate was attached to the Agreement as Exhibit B.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">In consideration of the benefits contained in the Agreement, including but not limited to the Health Benefits, the Extended Vesting Period , the Cash Payements, and the Extended Exercise Period, for which I become eligible only if I sign this Certificate, I hereby extend the release of claims set forth in Section 7 of the Agreement to any and all Claims that arose after the date I signed the Agreement through the date I signed this Certificate, subject to all other exclusions and terms set forth in the Agreement.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">3.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">I have carefully read and fully understand all of the provisions of this Certificate, I knowingly and voluntarily agree to all of the terms set forth in this Certificate, and I acknowledge that in entering into this Certificate, I am not relying on any representation, promise or inducement made by the Company or its representatives with the exception of those promises contained in this Certificate and the Agreement. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">4.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">To receive the Health Benefits, the Extended Vesting Period, the Cash Payments, and the Extended Exercise Period, I must execute the unmodified Certificate via DocuSign so that it is received by the Company within seven days following the Date of Termination.&nbsp;&nbsp;If I do not sign the Certificate, my employment will end and I will not be entitled to the Health Benefits, the Extended Vesting Period, the Cash Payments, and the Extended Exercise Period set forth in the Agreement. This Certificate shall become effective on the date that the Company receives the executed copy (the &#8220;</font><font style="text-decoration:underline;color:#000000;">Effective Date of the Certificate</font><font style="color:#000000;">&#8221;). </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">5.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">I agree that this Certificate is part of the Agreement.&nbsp;&nbsp;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">____________________________________<font style="margin-left:36pt;">__________________________________</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Frank Thomas<font style="margin-left:36pt;">  Date </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="margin-left:108pt;"></font><font style="font-weight:bold;margin-left:144pt;"></font><font style="font-weight:bold;margin-left:180pt;"></font><font style="font-weight:bold;margin-left:216pt;"></font><font style="font-weight:bold;margin-left:252pt;"></font>&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>3
<FILENAME>ortx-ex211_7.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
ortx-ex211_7.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 21.1</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:11pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Subsidiaries</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:51%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk93488042"></a>Name of Subsidiary</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:48%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Jurisdiction of Incorporation or Organization</p></td>
</tr>
<tr>
<td valign="top"  style="width:51%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:48%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:51%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Orchard Therapeutics (Europe) Limited</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">England and Wales</p></td>
</tr>
<tr>
<td valign="top"  style="width:51%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:51%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Orchard Therapeutics North America</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">California (United States)</p></td>
</tr>
<tr>
<td valign="top"  style="width:51%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:51%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Orchard Therapeutics (Netherlands) B.V.</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Netherlands</p></td>
</tr>
<tr>
<td valign="top"  style="width:51%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:51%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Orchard Therapeutics (France) SAS</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">France</p></td>
</tr>
<tr>
<td valign="top"  style="width:51%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:51%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Orchard Therapeutics (Italy) S.r.l</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Italy</p></td>
</tr>
<tr>
<td valign="top"  style="width:51%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:51%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Orchard Therapeutics (Germany) GmbH</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Germany</p></td>
</tr>
<tr>
<td valign="top"  style="width:51%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:51%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Orchard Therapeutics (Switzerland) GmbH</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Switzerland</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>ortx-ex231_6.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
ortx-ex231_6.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Georgia;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:right;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-family:Georgia;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_1fob9te"></a>Exhibit 23.1</p>
<p style="text-align:center;margin-bottom:24pt;margin-top:24pt;text-indent:0%;font-family:Georgia;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Georgia;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_3znysh7"></a><a name="_2et92p0"></a>We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-228067, 333-230432, 333-241646, and 333-258446) and Form S-3 (No. 333-234439) of <font style="color:#auto;">Orchard Therapeutics plc of our report dated March</font><font style="font-weight:bold;color:#auto;"> </font><font style="color:#auto;">30, 2022 </font>relating to the financial statements, which appears in this Form 10-K. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Georgia;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ PricewaterhouseCoopers LLP </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Georgia;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Boston, Massachusetts</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Georgia;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 30, 2022</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Georgia;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</a></p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>ortx-ex311_8.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
ortx-ex311_8.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.1</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Bobby Gaspar, certify that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="_Hlk33469136"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"><a name="_Hlk33469136"></a>I have reviewed this Annual Report on Form 10-K of Orchard Therapeutics plc;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">3.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">4.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.03%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.03%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.03%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.03%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.03%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.03%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.03%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.03%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">5.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.03%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.03%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.03%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.03%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.03%;text-indent:-5.03%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 30, 2022</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Bobby Gaspar</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Bobby Gaspar</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>ortx-ex312_10.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
ortx-ex312_10.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.2</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Frank E. Thomas, certify that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">I have reviewed this Annual Report on Form 10-K of Orchard Therapeutics plc;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">3.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">4.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.03%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.03%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.03%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.03%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.03%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.03%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.03%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.03%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.03%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.03%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.03%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.03%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.03%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 30, 2022</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Frank E. Thomas</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Frank E. Thomas</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Operating Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>ortx-ex321_9.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
ortx-ex321_9.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 32.1</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Annual Report on Form 10-K of Orchard Therapeutics plc (the &#8220;Company&#8221;) for the period ending December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:-4.86%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 30, 2022</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Bobby Gaspar</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Bobby Gaspar</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>ortx-ex322_11.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
ortx-ex322_11.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 32.2</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Annual Report on Form 10-K of Orchard Therapeutics plc (the &#8220;Company&#8221;) for the period ending December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:-4.86%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 30, 2022</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Frank E. Thomas</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Frank E. Thomas</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Operating Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>geajuovwk5do000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 geajuovwk5do000002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ([!8<# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M2CS2.QU/7O#/AYO+O;FU@D_YYJF]_P#OE037//\ %OPS&^W[)J&S^^+=<?\
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M:A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MK>U;P_J\WC+X=W4>GSM!86X6ZD"\0G:O#>E &IJGQ%U#^W=4TWP[X<DU9=)
M^W3?:%B"'GA0?O'@_D:EN?BGI4/@&T\41VTTINW\B"S&-[2Y(*Y]L'FN"U+P
M?+H_CG7[K5?"&H:]8:C<&XM9K&9E*%B25(5AW..?3BM?Q!X.O;OX=Z-+X?\
M#SZ?<:;??;1I4LN]R,G/)/)Z'% &IJOC7Q?_ ,(IK$DWA"ZTZZBM]\<@N%8*
MI!R^?5>N.M9&@>)M3U;X/:I+XDTFXN;**Q=OM;W(!O/F.1QRN/7VKIX-7\0>
M,]"UNPN?#%SI$<EB\<3W4@S)*P(P!@<>]<MH,'B*;X0:OX5N?#5[;75K9.D3
MN/\ CX9F)PH]: -V#QSIWA7X<^&I+'2IY)=0C6*QT])=S$^['MR.<=Q5S0/B
M'>77BR/PUXAT"71M1GB,ML#,)%E R2,CO@'\C7*:GX4\0Q>#O 6I6>ER7%_H
M!5Y[$D*Y!*D\'O\ */SK3TZRU[QG\3]+\2W^AW&C:;I-NRHER1YDSL&'Y?-^
MGO0 LGQ>U"9]7BTSPI<WLFE7,J7+K*!&D2' 8G'WCAOEQV[UT#?$%9?AW!XL
ML-(NKSS2JFSBY=3NVGD \ ]\>E<_X*\/ZO86GC]+K3YX6OKJ=K4.N/-!#X*^
MO4?G4OA4^(_!WP>M!;Z!-=:M%*P-D^58*TAYQUZ4 >EVLQN+2&<QM&9(U<H_
M5<C.#[BI:BMI));2&2:+RI716>/.=A(Y'X5+0 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 <S<?\C4WX?^@447'_ "-3?A_Z!10!
M-K__ ",MM](__0C705S^O_\ (RVWTC_]"-=!0 45S7C_ ,0'PQX(U/4XY EP
MD>R ]_,8[5Q],Y_"N/\ A3XE\07&MZMX=\4W+S:C!%%=1^8 &",HR.!VW+^=
M 'JM%<;KWQ/\-^'M<_LB[EN9;E #.;>$R+;CU<CH.G3/6N4^&/C V/PUUSQ!
MKM[>7D%KJD@WLYE<(5B "[CTRW3W- 'KM%< OQD\''4ULWO)XXG4E;QX"("0
M.0&ZY[=,>]:'A?XD^'_%NJSZ;I[745U$OF*ES%Y?FI_>7GIR.N#STH Z^BO-
M?!WBJPTOP-K6NW>N:GJ]G:7[I)+<0@2)]P;5&XY'S ]1U/ K0M?BYX4O-=MM
M+AN+DFY8)%<F B%G/\(;USQTQ[T =U17#P7R-\8+RS_MR^+1Z:)6TXQ_Z.HR
MHW!L]>0>G?K4EC\3]"U+5DLK.WU.:!YO(2_2T)MF?T#]>O?&* .THKR;PQ\8
M1K'C6]TJYLYQ9RS)%8%+4B1<\'S?FX_*NAN?BOX;MM9?2#]LDODO39/%'#G:
MP(!<\_<R<9Z^U '<45P%Q\8?#5M=E)(=4^Q"3RCJ(LS]FW9P?FSG]*S/&?Q8
M_P"$<\9Z7IEM;O-9-\]ZXMRS.K %?*.X \'F@#U*BO/;C6[?4/B/X5,.M:G:
MB^L&N(]-\C$<JE7;,A)^5L \8/W1TJ[KOQ1\/:#JDVFNM]>W-N,W(LK<R" ?
M[9R /PS0!VM%<O=_$#P_:>%(/$OVEYM,FD6)9(DR0Q.,$'&,8.:HZ7\5?"^L
M>(X]%M9[@33'%O/)"5BG/HC'D].X /:@#MJ*QX_$^DR^*)?#B7).J10^>\/E
MM@+Q_%C'<=^];% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%4=3OA9V_P N/-?A1Z>] %?5=2,1^S6YS*>"1V]OK5K1]$%N%N;D;ICRJG^'
M_P"O46@Z7@?;KA29&YC![>]=!0 4444 <_XUUQO#OA&_U&/_ %RQ[(?9VX!_
M G/X5\ZZ=.58RR,6=CN+$\DGO7L'QN=E\$6X7.&OXPV/38Y_F!7AD,^U1S0>
M3CY-S2.L2^+85<ECP .]=!'X!\3:A;B9+-(E;D":0*Q_#M^-4?AHD!U'4M9N
M4$L>DV;W*IZL!D'\@?TJWJ^H3:ZT>MW-INOK.)9KK2IW8)+!C/FQ<\#'7'3K
M2,*=&/+S2ZF_XAT[5M2TNUTG4?"UTUO;VPCCN;5HY9(Y0.&4;AE3C!4XKRW7
M_ ^L:%HL>I:E'%;I+*8U@>0>;C'WMH/3\<BNU\57/_"/^#-%O]$U35;::_=G
M$<MR^1%R<;2<<949'4#/>O+]1U*]U.?S[^[GN9<8WS.6('IS0:UG&^NY]"_"
M/Q'+K_@J..Z8O=6#FV=R?OJ.5/\ WR0/PKO:\4_9_=B?$*8.P& @^YWY_D*]
MKIGJ4I.4$V%9FJZ/'J";TPEP.C=C[&M.B@T.,M;F2VF-K<@J5.!GM6HCM&VY
M&(/J*LZWI8O8#-$O^D(.,?Q#TK&T^Z,B^3)]].F>XH WH=2(P)ES_M"KZ2)(
MN48,/:L"GH[(VY6(/J* -ZBL^'4#@"49_P!H5>21)!E&!% #J*** "BBB@ H
MHHH **** "BBB@ HK%/BW04U2;3)=3@@O86VO%,=ASU&">#P1TK95@RAE(*D
M9!!ZT"4D]A:***!A1110 54U.,S:5=1CJT3#]*MTA (((R#0P/)HJN1TNIZ>
MVF:E+;D'R\YC)[KVIL9KSY*SL9,L+TI3TI%-#&H$0R54EJU(>*HSNJ*S,P51
MR23@"J0SMO!,6W2YY3_',0/H /\ $UTU<WH>L:%9:5;VPUK3V<#+8N5^\>3W
MK>AO+:Y_U%Q#+_N.&_E7?!6BD6FGL34445104444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 44A(49) 'J:J37ZKQ&-Q]>U %LL%&6( '<U3
MFU%$RL0W'U[50EFDE/SL3[=JBH =<73,I>9_E'/M67!!/K5YM7*PKU/91_C2
M3&34;U;2#D9QGM[GZ5UEE9Q6-LL,0X'4]R?6@!;2TALX!%"N%'4]R?4U/110
M 5XQ\:=;D?4M/T.-\0QI]IE4?Q,<A<_0 _G7L]?-OQ7=Q\3-1WCY0D.SZ>6O
M]<T'+C)-4G8I6EV(HP :M-?;EQFN92X('6G_ &LCO2/#L7[RYSGFLB9]Q-$U
MP9#Z5 QS04D-CNI["\@O;5REQ;R++&P[,IR*^N-!U1=;T"PU-  +J!9<*> 2
M.1^=?(,I^4U].?"=F;X8Z*7Z[) /IYKX_2F>I@6]4=G1110>@<[K&BE";RR!
M5E^9D7^8IVEZD+N/RY"!,HY_VO>N@KF-:T]K&X6_M1M4G+ ?PG_ T ;%%5[.
MZ6\MEE7KT8>AJQ0 445'/,EO;R3R'$<:EV..@ R: )**XJQ^*&@7<=O--#J5
ME:W!"PW5W:,L+D]/G&0,^IQ6Y=^(([3Q7IN@FW=I+Z&6990W"A,9!'OF@#9H
MHHH ***S]<U5-#T*^U22)I4M(6E**<%L#.,T :%%5=-O5U+2K.^1"BW,"3!2
M<E0R@X_6JNGZ_9:GJ^J:9;^9]HTUT2?<N%RRY&#WXH U**QXO$NFRZQJNF&1
MHYM+C26Y>08159=P(/TZUFZ;X_TG5;VW@M[75!!<MLM[Q[)U@E/;#=@>Q(%
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M@<F@#Q_P_K-IX<^-OB>SU0RP2ZK)$+/]TQ$I/3&![]3QP:M_#2(+X]^(UR(
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M+[:;R+[.DR2,!C> WW6QW[T <5J'B'Q"G@.\MAJLG]IZ?XA735O@,&5 X +
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MQ*V-SN#\K'!(P,#BIO%NJZWIES<31>)M#TR&--]O:W$6Z2; S\Q+#&3Q\HH
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M6 0O=!\2L<8+Y_O'K7F_@K1Q;^#?$5X-0U"0K-J,/DR3[HSAF&XKC[W'7ZT
M>B>']83Q!X?L=7BB:%+N(2K&QR5SVS6E7B=C::OHGP>T[Q1;^(K\7%I!#+%:
M*RBW\K>%V%,<\'J3UKH_%'B">?QY_83RZS#86EDMQ(-)C8RRR.2!N8#*J .W
M4F@#TFJ6JZM8:)ITNH:E<I;VL0RTC_H!ZGV%<YX"OM5N(M4MM0346MK>YQ97
M&H1>7-+$PSAN!DJ<C/?(JCX^5+GQ;X(LKK_CRDU%Y'4GAG2,F,'\: -73/'V
MDZGJ4-C]GU*TDN#BW:\LWB28XSA2>^!T.*@N/B/I%OJ5]9_8M6E%E,89YX+)
MI(T<8R,KD\9]*[ @'J.E<5\/_P#D(>,O^P_-_P"@1T =#:^(M(OM";6K2]CG
MT]$9VFC!. !DY&,Y'IC-96G>/M(U#5X-,>#4;*>YS]F-[:M$L^.2%)[XYP<5
MC^#Q]F^(_CBSL@!9J]O-Y8.$6=T;<?8G S]!6=K]QK"^,_#=WXMLK:UTF"[V
MVK:?,9A]I883S2P4A?3"_4T >@ZYK=CX=T>?5-1D,=M".=HRS$\!0.Y)I-%U
MNSUW0K?6+,N+2XC,B&1<, "0<C\#7GWB;Q%HVK^+;RQU/4;2WL="B9HXIY0I
MN+QE.#@]0@Z?[3>U:'PR-AK7PNTVQCN]\EO$5F6"=D:-BS8#;2#T/0T =Y97
MEOJ-C;WMK)YEO<1K+$^"-RL,@X/(X/>IZR?#>B+H&A6=AYKRR0P1Q2.TKLI*
MJ!E0Q.T>PQ7'Z!;:EXWAU'6I/$.J6&+V6"R@M) L<*1MM!92/G)(R<_I0!Z-
M6+XF\11>&K&VNI;=YEGNXK4*C 8+G /X5Q.KZ]<WWCO4])N+G78[#3((0J:/
M$Q:21P27=E&0..!T/-9>KWFK77@&Q75UNS)!XC@B@FO(O+EFA#Y1V'K@X/TH
M ]*MO$,5SXMO_#XMW66SMH[AI2PVL')& /;%;5<+I7_)9_$/_8,MOYFK_P 0
M'UJ/0(GT879VW49O!98\\V^?G\O/\6* .KHKR_5];MX/A7K5]X>UW4IY89H@
M6NY&\^V8R1JR'< PXSUSU/.*W/&>I7ME_P (G]EN9(OM.L6T,VQL>8C=5/J#
M0!VE<QJ'BZ:'Q4- TW1;G49XXTFNI$E2-8$8X!^8C<>"<"L"WL]6\1?$'Q+:
MR>(-0L],TZ6W,4%I($8NT2G[Q!^7@\=R:IZ9H:I\6/$;G6-2B%O:V]QO-SP<
M[SA^.4&.!Z4 >I45XWJ'B!=+FTB_T37_ !#J)DU"&&>6[C;[).CMA@,J%'L5
M_6NHG%_XI\?:QI)U>^T_3M(@@_=V,@C>624,VXM@G "XQ0!WE%>:>)M3U#2-
M1T#PO)J>K3I+'-/=7EG#FZE13\BC:..OS,.>.V:T?!-]J;:_JEBZ:Q+HXBCE
MM9]5B*R(_(=-Q +#H1GIS0!W5%%% !1110 4444 <S<?\C4WX?\ H%%%Q_R-
M3?A_Z!10!-K_ /R,MM](_P#T(UT%<_K_ /R,MM](_P#T(UT% '+^+O"T^N2:
M?J6F7BV6LZ9*9+6=UW(01AD8?W2*QM3T+QCXFN](BU>+1;2UT[4([UI+::21
MY2@(P%*C ^8]2:]!HH XO4/#>JV/BZ\U_1;?3[U;^%$NK2]<Q_.G"NCA6QQP
M01VZT_6= UK7O#$-G/%IMK=IJ$-QY=N[&-8TD5B-Q4$M@'L!TKL:* .:\0:!
M=ZIXG\-:E \(ATR>62<.Q#$-&5&WCGGUQ63:^'O$'AZ_U)=+LM(U'3[V[>ZC
M%W*T4D#/RPX1@RYY'0\UW=% '&^)?#NMZK9>'[NT.GKJNE72W+1$LD#\$,H.
M"0.?2K4>B:G<^,=-UV]6TC$6F2VL\44C-B1W5OE)497"GDX^E=15'2]7L=:M
MY9[";S8XIG@<["N'0X8<CU[T <AH>@^+O"]G_86EG29=*CG8VUU<22>;%$6S
MM*!<,PR0#N'TJ&?PAKD/B+Q!=VEOH]TFKX\N[O"WFVHV;2H4*=P[@;A7H=-=
MUC1G=@JJ,DGH!0!Y]!X&U2/PMX-TQI;7S]%O8KBY(=MK*N[.TXY/(ZXK=T;P
M]=6'C'Q)JMPT+6NIBW$2J26&Q2&W#&._J:W;#4+35+*.]L+F.XMI1E)8VRK=
MN#5F@#RSX:Z$T'BS7IEF\W2](FETW31V0,YDD'U!*KGV]J]*ELX6BE\N&)9'
M1@&"@')'K5;1&T=K%_[$^R_91,X;[* %\S/SYQWSUK2) &2< =2: //X_!.I
MK\&V\(F6U_M VYBW[V\K)?=UQG&/:MKQ/X?N]9N_#LML\*KIVHQW4WF,02B@
MY"X!R?RKILY&110!Q3:'XCT/Q/JVIZ"-/N[356226VO)7B,4JKMW*55L@C&1
MQTJC/\/;^Y\)W,,M_;_V_/J8U8W 0^4LX(PN.NP*-OZUZ'10!P<^@>+-:\3>
M']5U1M*MK?3)V=K:VD=RV4*EMQ4=\87' SR:M)X4OUTCQE:&2W\S6KB>6V.X
MX4/$J#=QQR#TS795GVVMV%WK-[I,,Y:]LD1YX]A&T/G;SC!Z=J .;U/PEJ%Y
MH/A*QCDMQ+I%U:37!9CAEB4!MO')],XHU3PUJMKXPG\1:+%87GVNV6"ZL[US
M&"4SM='"M@X.,$5TNL:S8Z#8?;M1F,5N)$CW!"WS,P51@>Y%7Z .,USPUJ_B
M3PH;6Y&GZ?J<-VEW:?9BSQ(R$%0Q(!.>02 .HXJM/H/BS6O$?A_5-5;2[:#3
M+@R-;6TCN7RC*7W%1[87'<\FN\HH *XJ71/$FC>*=5U30%TZZM=5V/-;WDKQ
MF*55V[U*J<@C&1QTKIM8UFQT'3S?:C,8K<.D98(6^9F"C@<]2*OT <1J7AC6
MVUC2_$5NVFW6KPVAM;V"<,D,ZD[OD(#%2&SU!XJ?4M'U[7?!NMZ9=6FE6-Q>
M0&.WCMY6=02.2[;1^B_G7844 <J_AR]/BW0=562#R=/T^6VE!8[B[!<$#'(^
M4]Q65?>&?$&OZ[H]YJ=GH]G+IMVL[:A9RNTTJ+_RS *C:K=""Q_&N_HH ***
M* "BBB@ I&^Z?I2TC?<;Z4 9/A<9N;I_]D#\R:H?%/09M>\#W*6R;[BT<7,:
M 9+;<Y ]]I-:'A<XGNE]E_F:Z6@F45)-,^6O#7CK4O#&EW5IIL5O'+<.K&Y,
M8,B@=5Y[?7ISZUZ?X=US7=>LI]1TSQ1B&WMFDGM[RWC>2.0<X. ,H1DAAZ8Q
M7._$GX77-C=S:UH%NTUG(2\]LG+1$]2H[K[#I]*XK1O%=WI'A_5-'MH8D_M#
M"RSXQ(%&05^AR?S/K0>:N>E+EEL=+=_&#Q7=6[1)):6Y/'F0P_-^I-<'/)+<
M3233.TDLC%G=CDL3U)J1(\TL@1 !G+'@*.232.=N<W[SN9UP=B^]?4?PV\./
MX8\#V-G,/]*E!N)^,8=^<?@,#\*X#X:?#"Y-_#XA\00&%(2'M+.11N+=G?TQ
MV'7//&.?;*9Z6&HN"NPHHHH.H*S?$&D)KWAZ_P!*D;:+J%HPV,[3V/X'!K2H
MH!JZL?*>@:]J'@?7+HK:6YOHE>W(GCW>4W3(]_YUZ#X.\7:]XHNH[1?$K6NI
M&3+1RV\;1R1]R@P/F']TGD=*VOB?\-'U]FUO1D4:DJXF@&!]H Z$'^\!Q[UX
M]X?UJ\\'^(#=&R3[9"CQB.Y0@QL1C./44'EN,Z,[7]T[O6?BMXJTS4[W3%EL
M)#;RM"+@6Y!;!QG&XC]*\\U75+_6KY[W4;F2XN'X+N>@]!Z#V%1.[W4\D\K%
MY)&+NQ[DG)-*R(BY8@#WI&$Y3F]7H49.!FO9?@-X?>.#4?$4\6//Q;6S,.2@
M.7(]B<#_ (#7&>#?A[J'C.\25TDM='5AYMR1@R#^['GJ??H/TKZ2L;&WTVP@
ML;2(16\"".-%Z!1TIG;A:+7O,R_%"_Z!"WI+C]#5:T.;6+_=%6O%!_XET2^L
MH_D:J6@Q:1?[HH.XLBG"FBG"@!XIXI@IXH >*<*:*<* 'RSBST^XNB,^6A;'
MK@5Y-+*\TKRR,6=R68GN37J6J(9?#]ZB]?*;I],UY57FX]OF2,:NYK>&K-;W
M7K:.10T:DNP/L,_SQ72>(8M?U#4'AL(YEM8@!E9 @<XR3R1GT_"L7P9(J>(8
MP?XXV4?7&?Z5=\2:UJMEKLD,5PT<2[3&H P00/SYS44W%4+N^KZ"5N4P-274
MHI4AU(S[T'R"5B>/8U1KNO&N)-%L9I%"SF0<>F5)(_/%<+6%>').U[DR5F=5
MK$2^(/A-?1R_-);PE@QZAH_F'Z#'XU\[U]&V/^C?#76)7'RO%.1G_<V_S%>6
M>&/A9KOB!1<7"_V=9GI).IW-]$Z_GBO7HMNG%LY<53E.4>5:V.%HK=\8>''\
M*^(Y]+:1I455>.5EQO4CKCZY'X5A5H<$HN+LPKTSX2>#/[6U/^W+Z(_8K1OW
M((XEE']%Z_7'O7)Z+X4NM359IB8+<G@D?,P]A7J=K<W-KID.G6TK0VD*;%CC
M^48]_7-9RJQB=F%P[<N>:T/1;W6;"P!\Z==X_@7EC^%<S?\ BNZN/DM$\A/[
MQY8_X5@+'4RQUA*M)['IN0GS2.7=BS,<DDY)-3*M*JU(!6#9  4$4X"E(I 0
M,M0.E6R*C9:8%C3]>OM-VH&$L*\>6_8>Q[5TUCXGL+S"R/\ 9Y/[LG0_0UQC
M1U"\=;0JRB4I'J2LKJ&4AE/0@TM>76][>6#9M;B2/N0#P?PZ5T&F^,F5EBU&
M/()QYR#I]1_A6\:T7N6I'8T4R*6.>)98G5T89#*<@T^MAF;JWA_2==B$>IZ?
M!<@#"LZ?,OT/45YWKWP3L+C=+H=X]H__ #QG^=/P/4?K7JU%!E.C"I\2/EC7
MO!6O^'&8W]A)Y*_\O$7SQGWR.GXXJS\.M*36/'>F6\O^J20SL/78"P'XD 5]
M.L RE6 *D8((ZU@V?@S0M.UY=9L+);6Z"LA$7RHP;K\O0?AB@Y/J*4TXO0YO
MQM>/-JZVV3Y<"#C_ &CR3_*N9K<\7(4\1W!/\04C\A6'7AUVW5E?N;RW.IT'
MQ!.LNG:7!$D47F8D<<E\G]*/'?\ R&+?_KW'_H35D>'_ /D8+'_KL*U_'?\
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MZCK5QJ=Y+9-:3>=&%0@NK#:HX51M^[SDDG-=910!Q%KX)US2HOL&C>+9K/2
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M9>*--6TNVEB>*036]Q"VV2&0=&4^M;-1"Y@-T;431_: F\Q;AN"YQG'7&>]
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M>-6.!NXVYSV!-:] 'GG_  K;4IM.T_3+SQ9//8:;-#):0BT1<+&1M#D'+<#
M/&.N*UM9\'WEQK[ZYH6N2Z1?SQ+#<_N%FCF5?NDJ>C#)YKK:S-)URTUF;48K
M990VGW36DWF*!EU )QSR.10!C7_@N:ZL],DAUV[CUK3BYBU.1%D9]YRZNG *
MGL.V!6EH.F:S8F>36-=.IR28"*MLL*1@9Z 9))SU)[5-K^OVGARPCO+U9FCD
MGCMP(E!.YS@=2.*U* "BBB@ HHHH **** .9N/\ D:F_#_T"BBX_Y&IOP_\
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M. RAOQ(S^-=2-!\2Z)XFUF]T+^SI[/5V65ENY'1K>4+M+ *#O!P.,CZUGQ>
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M[RWUQ<#RR2-KN6&<@<X/-8&D>&O$'A:VFTK3=-T;4=/$SO:SW4S1R1(Q)"N
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M3A316=XAUZQ\,Z4]_J$@48Q'$#\\K>BC_.*!-J*NS66ZMX9$@GEC1ISLC5V
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MP(S^M 'E]SXKO-&U32)+?QG'KC7%_':W=JMLJQ;7)!*,HX(/N:V;N[\2ZO\
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MM1@ ^5FA9A"3^+?D/>O4Z "BBB@ HHHH YFX_P"1J;\/_0**+C_D:F_#_P!
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M'<>2,XST'-03Z=KFE_$RXUJSTK^T-/U&TBMY'2X2-K=D;DD,02,'/&37;T4
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !69K%B;
MF'SHQ^]C';N*TZ* *VAZI]KA\B9OW\8[_P 0KD/C-H#ZKX2CU"",O/ILAD(
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M1CA"Q&<X/7'X"KTFDZOJ?B/PSK5Y!:VS6"78N88YS)CS%55VG:-W3GI7544
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M/4KA;:.:SN&<PRL"55P0,YP>1Z4K>+-=U+6-3@\/Z-;75GI4WD7$D]P8WFD
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M <$]!["@"]IVEVFE0-#9Q%$9M[9<L2?4DG-7*JV]WYC^7( 'QP1T;_ ^U6J
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M/45Z?I5W]NTNWN/XF0;OJ.#^M;T'NBHERBBBN@H**** "BBB@ HHHH ****
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M[IH<_;9AP#^[!_G6/:V[7U]' O&X\GT'<UUFJ:I8>'-'>[O)!%;0J  .K'L
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MHM_^!=Z8_P 2_"J7QMCJ).'\LS")C%N_W\8Q[]*YBRAGN/%?Q"AM03.]OMC
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M %U3_P!%I71VWW!3 M#I0>E Z4'I2 @>JTE67JO)VI@4KF9K?RY%ZB6,?@6
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M(_2MBVO;:\3?;3QRCOL;./KZ5V*2>QI<GHHHJ@"BBB@ HHHH **** "BBB@
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M-. V:GEFW&JSM04CUGX<W5KX[\+7G@S76,CV8$MI+_&J=,@^JDX^AQ7$^*O
M&N>$KAC<0-<V1)V74*DIC_:_NGZT_P"&%X]G\2])*-@3,\+#U#*>/SQ^5?4+
M*&4JP!4]01UIGKTZ<:]-.6Y\=1,K=Q5C]V@RSJ/QKZ<U#P%X5U.0R76A69<]
M6C3RR?J5QDT:?X$\*Z7*);30K-9%^Z[IYA'T+9Q01]2=]SP'PWX%UKQA.!9P
M-;6/\=[.A"8_V1_$?I^8KJ?'<ECX8LK/P1H;;+>-1-?,#\\KGD!SW/?'NOI7
MNRJJ*%10J@8  P!7RSXJOGN_&^LW$ARQNW3\%.T?H*!8B*HTK1W9K6$Z6\0
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M2(K]S]TE /PW?XUGA&_:I$T_B*C JQ!Z@XI*?*<S.1W8FF5H4%%%% !1110
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M%NM7CT^6R^S2365QYXM;K_5SC&,'Z9XXKEO$%]97_@*YC6P72FM]4B@NX8R
M(Y Z[B&7 /!!S1&%[!8]'BO+6>5XH;F&21/OHC@E?J.U,DU"RAG$$MY;I,>D
M;2J&/X9S7%:[INFZ/KGA.31K:"WN'O!#^X !DA*G=N(Y88YR<^M4?$$EOJ>D
M>(9M/\.Z>UO"\T<]_<2A96E7[S*-I/!Z9(IJ"86/299HH(S)-(D<:]6=@ /Q
M--AN8+B'SH9XY(O[Z."OYBN"EV:K>^!K;5");6>R:=TE.5FF$2%=V>O4GFI/
M'%K;:7X?^SZ1!;P)>:C"EXB-L0@_WL?=!PH.!_.ER:I!8[:&^M+A7:"Z@E$?
MWRD@;;]<=*Y&R\0Z[J#:=Y"1C[=J$LD8:(@K8*>&;T8\8]<BBR\/ZK'XETW4
M/L&C:=!"LD<RV3MF=&7A2-H!P<$5VH51C"@8&!QVHTCY@([K&C.[!549+,<
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M*Q]7_P!1^%;#=*Q]6_U/X4 >'>)?^2B>&?\ L(P_^C%KZ/KYP\2_\E$\,_\
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MI&:-!R4#1,X'X;J]+$48E,HC42$;2^.2/3-*D4<>[8BKO;<V!C)]3[TU,+G
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MZR@?+,@/XC@_TK)C/%<-16DT9,L"D;I2+0U9B()#3])C\W7+-/\ IJ#^7/\
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MPI)LYH@$8(R*  !@# KI?^$;M_\ GO+^E'_"-V__ #WE_2L?83)Y6<R% S@
M9ZX%&!C&!73?\(W;_P#/>7]*/^$;M_\ GO+^E'L)ARLYDJ"02 2.AQ2UTO\
MPC=O_P ]Y?TH_P"$;M_^>\OZ4>PF'*SFJ*Z7_A&[?_GO+^E'_"-V_P#SWE_2
MCV$PY6<U172_\(W;_P#/>7]*/^$;M_\ GO+^E'L)ARLYJBNE_P"$;M_^>\OZ
M4?\ "-V__/>7]*/83#E9S5%=+_PC=O\ \]Y?TH_X1NW_ .>\OZ4>PF'*SFJ*
MZ7_A&[?_ )[R_I1_PC=O_P ]Y?TH]A,.5G-45TO_  C=O_SWE_2C_A&[?_GO
M+^E'L)ARLYJBNE_X1NW_ .>\OZ4?\(W;_P#/>7]*/83#E9S5%=+_ ,(W;_\
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M2BL[0=436]!L=2CQBXA5R!V/<?@<BM&F?0)IJZ"BBB@84444 %%%% !1110
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M1PQYSMC0*/R%1'3;%KG[2UE;F?.?,,2[OSQFNO\ ^$;M_P#GO+^E'_"-V_\
MSWE_2CV%0.5G)S65I<2I+-;0R2)]UWC!*_0FGBW@6$PK#&(FSE HVG/7BNI_
MX1NW_P">\OZ4?\(W;_\ />7]*/85 Y6<E%8VEN$$-K#&$)*!(P-I(P2/2IR
MRE6 (/!![UTW_"-V_P#SWE_2C_A&[?\ Y[R_I1["8<K.2M["SLV9K:T@A9OO
M&.,+G\J;-IMC<3B::SMY)1T=X@6_/%=?_P (W;_\]Y?TH_X1NW_Y[R_I1["H
M'*SE_)B\X3>6GFA=H?:,@>F?2H)M-L;B<336=O)*.CO$"WYXKK_^$;M_^>\O
MZ4?\(W;_ //>7]*/85 Y6<I<6EO=Q>5<P131_P!V1 P_(T?9;<VWV8P1>1C'
ME[!MQ].E=7_PC=O_ ,]Y?TH_X1NW_P">\OZ4>PJ!RLY2.SMHA$([>)!%GR]J
M ;,]<>F:;/86=S*LL]I!+(OW6>,,1^)KK?\ A&[?_GO+^E'_  C=O_SWE_2C
MV%0.5G+O#%+L\R-'V-N3<H.T^H]#088FF68QH95!"N5Y /4 UU'_  C=O_SW
ME_2C_A&[?_GO+^E'L)ARLYJBNE_X1NW_ .>\OZ4?\(W;_P#/>7]*/83#E9S5
M%=+_ ,(W;_\ />7]*/\ A&[?_GO+^E'L)ARLYJBNE_X1NW_Y[R_I1_PC=O\
M\]Y?TH]A,.5G-45TO_"-V_\ SWE_2C_A&[?_ )[R_I1["8<K.8L_^0RGX_\
MH-%=-%X:MXKH7 GE+#L<8Z8HKL@K129:V+-YK5M97T=I(DID?&"H&.3CUJY]
MH3T:N6U__D9;;Z1_^A&N@JAEG[0GHU'VA/1JK44 6?M">C4?:$]&JM10!9^T
M)Z-1]H3T:JU% %G[0GHU'VA/1JK44 6?M">C4?:$]&JM10!9^T)Z-1]H3T:J
MU% %G[0GHU'VA/1JK44 6?M">C4?:$]&JM10!9^T)Z-1]H3T:JU% %G[0GHU
M'VA/1JK44 6?M">C4?:$]&JM10!9^T)Z-1]H3T:JU% %G[0GHU'VA/1JK44
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M_O*:N17=M/Q%/&Y]%8$UCPZ1HM]'NM+A95_O0S!Q_6F2^%UQF"Y8,.@<?U%
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MA9PDB2YB4CJ-PS^55CKVG#_EOGZ*:I1^%H /WMQ(Q_V0!5I?#NG@<H[?5S0
M-XAT\*2'=B.P7DU'_P )-8_W)_\ OD?XU*?#VG'_ )9,/^!FH9/#-DWW'E3\
M<TFF [_A)+/_ )YS_P#?(_QH_P"$CL_^><__ 'R/\:S[CPQ,G-O.K^S#::R[
MBTN[,XGA91_>QD?G6<E46S)=SI/^$CL_^><__?(_QH_X2.S_ .><_P#WR/\
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M7,44?6)AS,Z?_A([/_GG/_WR/\:/^$CL_P#GG/\ ]\C_ !KF**/K$PYF=/\
M\)'9_P#/.?\ [Y'^-'_"1V?_ #SG_P"^1_C7,44?6)AS,Z?_ (2.S_YYS_\
M?(_QH_X2.S_YYS_]\C_&N8HH^L3#F9T__"1V?_/.?_OD?XT?\)'9_P#/.?\
M[Y'^-<Q11]8F',SI_P#A([/_ )YS_P#?(_QH_P"$CL_^><__ 'R/\:YBBCZQ
M,.9G3_\ "1V?_/.?_OD?XT?\)'9_\\Y_^^1_C7,44?6)AS,Z?_A([/\ YYS_
M /?(_P :/^$CL_\ GG/_ -\C_&N8HH^L3#F9T_\ PD=G_P \Y_\ OD?XT?\
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M** "BBB@ HHHH **** &V?\ R&4_'_T&BBS_ .0RGX_^@T5Z-/X$:K8TM?\
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M6!J[IOQ0\*ZC*L7V\VLC' %TAC'Y]/UH,U7I-V4D7O'U[)I_@+6KB)MKBV9
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MXD/H,;1^K"OI#4=4L=)M3<ZA=Q6T(XW2-C)]!ZGV%,[\+I2U+=%<+<_%CPY
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M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!MG_P AE/Q_]!HHL_\
MD,I^/_H-%>C3^!&JV-+7_P#D9;;Z1_\ H1KH*Y_7_P#D9;;Z1_\ H1KH*L9Y
MA\5-<U4ZMH'A+1[Q[*;5Y<37$?WECR!@'MW/&.F*O:9X"'@N[.N6GB#5[F.V
M@E>YM;F;>EQA#C_=(.#GGI57XH^&M:N]2T+Q/X?MA=WVD2EFM\\NF0>/7IC'
MO4L/B[Q+XDCFT_\ X0G4-.MY+2<7$]V=N&\MMJH"!NRVT?C0!1TOXOWVM6,E
M_IW@^\EL[>WDDN9_/PB2(I;8&V\\ <\?>Z>NM>?%&RM?AU8^*TL6F>]=88;)
M9?F,I)!7=CMM;G';WJ;X3Z5=:9\--/L-3LI+><&;S8)TVM@R-C(/J"*\LT#P
MU>CXL1^#"2^C:/?R:F%)SM0JI3]=@_$F@#U'7OB'/I^M1:!H^@SZOK9@$]Q;
M12A5MU('WGP>>1^8]:-*^)EMJ7AS6[]],GM=1T5&-WI\SC<",\!L=#@\X_"L
M'4;?6_!WQ6U'Q)!H-[K&F:I;+&?L*[Y(F&W@K_P'\C[8K-M-$U=?#GQ!\4:O
M8/ISZM;N8;20_.J 'EO3M^M &DWQJDCL+'5Y?"=_'H<[+'+?&081SU"C'S <
MC/&<5M^*_B;%X;UVRTJWTF;4I;^T%Q:FWDYD8L0J 8Z'&<Y_ UYE#=>*/$GP
MHTOPA9>%;MEGV;-1ZP&(/N!S_"<C!R>@/K7<W7AK4+7XO^#)H;2>;3M.TMK>
M6[$9V*5CE4;CV)ROYT :M_\ $2[LX](L(O#MQ/XDU&$S'2Q*%\A1G)=R.!P<
M<=JDTSXE6=SHNMW>I6$^GWNB _;;)F#LOIM;@,#^']:Y?XC>%KM_B%8>(VT?
M4-6TIK7[/<PZ=(RSQD%L$;2"1R.,]C5[P[IFE6FB^(;RQ\"ZU&D\2));:E(W
MG7J\[@%9FQ@>_- &]X5\:ZGKL7VW4?#CZ9I3VINH;TW2R*5&.&  (.#G\#6*
MWQ=E%J-:'A>\/ACSA%_:1F4-C.W?Y>,XSQU_PKG/"_AG5)/$6J6FAZ?KFD>&
M+K3Y8GM]7!7$S @;!DG ..>3C/-9&B^%X+#1/[(\0^ _%%[J*,5W6DS_ &64
M9R"2'"K^ /3- 'I?BSXFQ>&M=L=*ATF?49;^T\^V-O)S(Y8A4"X[XSG/X&GZ
M%\0KC4/%MOX;U;0I=*O9[/[5'YD^XL>ZXVCT;G/\)K-U/P_>)\:/"%W::=/_
M &59:=)"TP4LD6$E"J6]>5Z^M,^+&C:P+W0?$_AVQFNM3TV9D9($+,T;#N!R
M0#D?\"- &K;_ !-L'D\437-H\.FZ!((GNQ)N\]\E=JK@<Y&.IZBJNG?$ZZ.H
MZ7%KGAJYTFRU9@MC=-.)-Q.-H=0 5R"/\\U@6WP]U.7X$3Z.L+1ZS=O]NDBD
MX9I-X.UL]]J@<]ZI>'=#TN>ZT:"\\!>*$U&"6(RS7,T@M8F&,N&9^0,9QCVH
M [#6_B9+9>*KC0M&\.WFLR62"2^>!POE#V&#N.#TX]*S/@-()O!VK2J"%?69
MF (YYCBJDJ>(O!7Q-\1W]MX:OM7M-8"O!+;#(5QT#'^$9)SGVK;^#FCZIHGA
MK5K;5[*2TN7U::38ZX# I&-RGNN0<'OB@#T6BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** *6J7)MK%V4X9OE7\:7PY9^39FY8?/+TS_ ':S
M=8+7.HP6B>PQ[FMC7=2C\.^&;S4" 5M+<LB^K 84?B<"@3=E=G&_$#Q])IL[
M:%HSXOR/W]P,'R >P_VB/R^O3S^TL$):>Y<R3.<L[G+,?4DUS5G=O-<RW5P^
M^:5S(['NQ.2:V5U#Y<9H/ Q%:565WL6[R. *0%%5'\*?:?"E_K[W"0Q02+'$
MC#_6L>H'YC]:W[7P5XAU:T%U';I!"PW*UP^S(]<=:Z6'1O$&G>%8= N?#L6H
M6WGEKAH[E271LYV@X*L"00?:@NC0D]9)VL><>"_B%J'A"]2">22YT=CB2W)R
M8Q_>3/3Z=#47Q"\,KI.I)K6F9ET/5/\ 2+>51\J%N2F>WJ/;Z5-KOPYU33=/
MO]4E"VMA ?W2WDBI-(">@521G\>>U=/\'+^TUS2-4\'ZM$+F!1]HBCDY&PD!
M@.XPQ4\?WJ#IIQE->RJ?(XSP!?71\16^DHL=Q9ZBXAN;:=L1NOK[,.H(YJ]\
M4+^VU+QY>-:%6CA582R]&91\WZDC\*WO$GP5U&QF-UX;N1<Q;LB"5MDB?1NA
M_0UQTG@WQ7;2$3>'=29L\F. R GZKFD3*E4C#DL87ED]J@G&Q>Y)X '4FNTL
M?A]XNU%PD6B2VX/_ "TNR(P/P//Z5ZEX+^%-CX=N(]2U.5=0U->4.W$4)_V1
MW/N?R%,=+#2;U.=\,11_"KP4U_J$8?7M7(:.U/!0#[H/? SD^YQ7.E[O7KUM
M1U:X:>=N06^Z@]%'855\::\^O>.+V9F/D6SFW@4]E4X)_$Y/XU%#?;5 !XH,
M,35<GR+9&K/%;HF HJOI?A;_ (2*6](GCM;>T@::6>0?*O!P#]<?D#6CI7AS
M6O$4)FL;;]QG'G2-M4GV/?\ "NGT/0O%/AC3=1BATJTOVNPNTBX4J,9R&4CD
M$$CK030HRDTY)V/)M"\3ZKX0U/[3IEQ^[W?O8&.8Y1[C^O6OH&PUFQ\<>$UU
M'3_OK]Z(_>BD Y0_YYXKRK5OAGJ5]?375E9'2K+RC+*-0E14B;&2JLI.5]"0
M,=ZJ?![7Y='\;?V2[[K745,94'($JY*L/PR/?(]*#MPTITY<D]F>N:7,9(3&
M3RG3Z5HBLMX_L.O21#A&;CZ'D5J"@]$>*<0&4JP!!&"#WIHIPH ^?OB!X4;P
MUK9D@7_0+HEX2!]P]T_#^5<C7T[XAT*V\1Z+-IUSP'&4DQDQL.C"OF_5M+NM
M%U.?3[Q-D\+8/H1V(]B.:1XV+H>SE=;,I5K^&_$-YX8UN'4K,Y9#B2,G D3N
MIK(HH.5-IW1];:'K=EXATB'4K"3?#*.1W1NZGT(K1KYE\!^-;CPAJVYMTFG3
MD"XA'_H2^X_6OI*QOK;4K&&]LYEFMYEW(Z]"*9[>'KJK'S+%%%%!T!1110 4
M444 %%%% ''>-?\ CYLO]UOYBN>2NE\:KS9/_O#^5<RE<5;XV9RW)JB?I4G:
MHGZ5F(U_"!QKK#/6%A^HKO*X+P@,Z\?:%C^HKO:[*/PFD=@HHHK485@>,#C1
M5]YE'Z&M^N?\8_\ (%3VF7^1J*GPL3V.+CZ5..E5X^E3@\5PF8QZ6PYU:TQ_
MSV3^8I'-2Z0OF:[9+_TV4_D<TX[C1Z91117H&@4444 %%%% !1110 4444 %
M%%% !7*^._&,'A#13*-LE_."MM"3U/=C[#_ 5NZK?MIFEW%XEK/=/$A988$+
M.Y[  5\M^(]>O_$>M3W^HL?-8[5CZ"-1T4#VH.7%5_91LMV9]W=3WUW+=7,K
M2SRL7=V.22:AHHI'C!7HGPTT5H[K^WIHU/E$K;!UR-W0O^'0>_TKE?#.@2Z_
MJJP#<MO'\TT@'0>GU->U00QVT$<$*!(XU"JHZ "L*U3ET6YUX6CS/G?0L33R
MW#[Y9&=O4FHZ**X[W/2"D6-[BXC@099B *6M/PW;>;?O.1\L2\?4_P"36^'C
M>5^Q45J=/;0);6\<*#"H,5+117::!1110 4444 %>=Z?8^#6\9W5J/,N+J1G
M CF4&$-U8#U/7K7HE>2K\/\ 4Y_%DRS[HK%I7<7*,,D')&.^:3&A?B'H.CZ0
M++^S[7R)[EVW!7)7 QV/3DCIZ5/X=>SB417$[0*%PK!<C/O6;XT\*IX<2QN8
MKN>X21RK&8_=(P1CZ\_E5"&Y.P8-2RUL>H^?!)8E() \4DZ0HZ*>>,GZFN>U
MO3]MO-<6=RMS'"?WH PR>_N/>JV@WUG=6#Z==S".19O/A+/L5SC&TMVS5\"Z
MMDU3^T8$$LFGRMN60,JIP%10.@R?TIB.$N'W U4TBW^UZ_;V7VB2W2Z<1.\9
MYP3T_/%;^J>&KBRTI=02[MIXBBR.JOAE#=#@]1GBN8TJWBU#7;>VGG$$,DBH
M\I8#:/J:0ST+6?AMI5II_P!JCU*6WC@4M.\J[]P]@,8-=;X7UO3=8TQ4TYI=
MEJJQ%95PPP.#^.*X_5_A[IUE8,RZTR3N,0+<RJJR-V7GUK4^'?AS4-$AO9M0
MB\EYRJK&2"<+GGCZU74E[%_Q)9^5<I=(,+)PW^\/_K?RK(!R,UV6KV_VG3)D
MQEE&]?J*XN,\8]*PQ$;QYC.:T'T445QF84444 9?AW6D\0Z#:ZJD+0K< D1L
MV2N"1U_"LQ?&EM_PC,>L-:2[IKEK6"V1@6DD#LH / YVD^PKGO >G>(9O!6F
MR6>O0VUNR-LB:Q#E?G;^+=S4_A?08?$'PXAL;J9TD2[FECN(OE:.197PX_7\
MZU<8IOU'9'4Z/JFIWTTL6I:'+IS*NY6,ZRHX],C&#[8K+/C"\O)9&T/P_<ZE
M9Q.4>Z$JQ*Y!P?+!^_CUXJBNHZ_:7%_X:U*2*\N)--EGLKV%-K28&W#KV;)Z
MBM7X?O _@/2# 1M$&UL=F!.[]<TFDE<#>L[K[9917)AF@\Q=WE3KM=/8CL:G
MKD?&.EWMY>Z;>16 U2QMM_VBP\W87R!AQV8CG@^M;'AJZTZ[T&WETN*2*T&Y
M5BDSNC(8AE.2<$'/%2UI<1K9HKBM<72=2\07-H-$N=8OH(D\Y1-LC@4\C&Y@
M QSG@9]ZP#+=W/PET]7N9XYO[02 2[\N@%P5'/<@ ?E34+CL>J49K@/%6GQ>
M&/#5O9:-#*O]HW\-O<,)R'D!!S\Y/!;;@GW-2:5I&JV?BBPN;+01I-CM>.]4
M7JR+*NWY3M!^\&QSUYHY%:]PL=W1D>M<G\0;B6'0[2*-I")[Z&*2&$GS)T))
M9%QW./;@&L_PYHEO_P )C/JEEI%U8Z?':JL27*-&3,2=Q5">!M./K24?=N%M
M#O,T5Y%I=IJ?B3P]-J/]@/<ZC>/(\>H#4 C0MN.T(I.5"X Q[5NW&G7.J^*]
M LM8EE60Z0[7D<,FT2N&3*DKVSSQZ53IV>X6/0*,UYM'-+X<E\;VFFLZ6]G;
M)/;1%BPB9D).W/3GG\*K6FB:L]AI5UIFAO!>J\4SZB=15FG4X+[QGY@P)X[4
M>S\PL>B0ZO:3ZS<Z4C-]JMXUDD!7@!NG-.LKF[GFNUN;+[.D4VR%_,#><F/O
M8[?2N+L="TR7XI:SYEJ"4@AN$^=N'))+=?6JMYJ-U8>&_&L]O,T<HU?RED!_
MU:MY2DCTP":.1/1>06/2LT9%<_9^&-%T(?;;=)(&B@9991,QWKCDMSR>,YKA
M-2:TBL--U?1-%O;2/[9"8]2EG^:96;!W L6(;/>DH)[!8[W^W9O^$NO-'\I/
M*@L%N@_.XL6(Q].*E\*ZQ+KWANSU.>-(Y)PQ*)T&&(_I6+_S4[5/^P,G_H;5
MSFGF73_A_P"%_$$)/_$MG;SP#UAD<J_]*KE37W!8]6HKD]#WZMXTUG6"Y-K:
MA=.MQG@E?FD/YD#\_2D^)&__ (1!A'(\;&Z@ =#@C]XO(J.7WDA6.MS17G>K
M>%[&S\4>'K2SFN[=-0,\5ZR7#[KA43?\Q)ZDCDC'!-6-,C7P]XPU^QTY62S3
M3DNTM]Q95DY'&>F:?(K:,=CO,BBO-=/T&QU'X>'7;J:6359;9[HWWG,'C<9(
MP<\ 8QCVJ2"9_%6N>';#5PS6S:,M_)"&*K-*V!DX/(&,@>]')YA8Z>'7;F7Q
M'K.EI;)(+&VCEBPV&D9@?E)Z#H*AUGQ#?Z;HNFRK81IJ=_/%;K;RR92-W]6'
M4#VKFK'3H=(\0^,[6U>7R4TZ,H'D+% 5<[03S@=JJZCIEG>^&_ 4]S#YDLLM
MG [%CED*Y(Z^]7RQO_78+'?:?=:R;Q;74;" *(=[W5O,2A?<0%"D ],'-:V:
MX= --^(=U#:J5BM]"!CCR2!ASCK7,Z=INK:SX5BOK;199=5N!Y\>K?VBH</N
MST[*.FVIY$]0L>O5CZ3J\NH:OK-F\:*EA.D2,O5@R!N?SKG'LT\0^/9M/UG=
M)!9:=%(MMO(0R,?F?@\XZ58\$62:=K/B>TBEEECBO(U5I7W-CRQ@$]\=/PI<
MJ286.SHHHJ!!1110 4444 %%%% !1110 VS_ .0RGX_^@T46?_(93\?_ $&B
MO1I_ C5;&EK_ /R,MM](_P#T(UT%<_K_ /R,MM](_P#T(UT%6,**JZAJ=AI-
MJ;G4;VWLX <>9<2A%SZ9/>H--U_1M8=TTO5K"]=!N=;:Y20J/4A2<4 :-<_H
MW@_3=$U_5=;@>XEO=3;=,\SA@HSG:N ,#\^@J];^(=%NM2?3;?5[&:^0D-;1
MW"-(,=?E!SQWJ2XUK2K26XBN=3LX9+:,2SI).JF)#T9@3P#ZF@"]5/5M,@UG
M2+O3;DN(+J)HI"APP!&#@^M26-_9ZG:)=V%U#=6[_=EAD#J?Q%58/$.BW6I/
MIMOJ]C+?(2&MDN$:0$=?E!SQWH 70M&MO#VAVFDV;2-;VJ;(S*06(SGD@#U]
M*T:XZ_\ B3H.G>-4\-W-S!&QA,DEV]Q&L43<_NV)/#<=#ZBK<&LZK)\0;C22
M^EG2TLQ,H6X!NMQ(Y*9R%Y/.,=.: .FHK-G\0:+;:FFFSZM8Q7SD!;9[A!(<
M]/ESGFFZCXET+2+A8-2UFPLYF&1'<7"(Q'K@GI0!J45POQ#\6:AX>B\/R:5+
M"4O]0C@D9E#AHV]/\:(_%M\/B]?>'IY8(])M]+^U990"K97)+>F": .ZHJG%
MJVG3::=2BU"UDL I8W23*8@!U.[.,#ZU/;7,%Y;1W-K/'/!*NZ.6)PRN/4$<
M$4 2T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M(>%)]J ,33?]*\2/(W.PL1^' K.^,#NOP[N]N<&:(-CTW"M7PRNZ]N9#U"X_
M,_\ UJF\=:,^O^"]4T^(9F:'?$,]74[@/QQC\:"*B;@TCYA@FVJ.:ZWP!!;Z
MIXTT^VN]K0[BY5NC%02!^>*Q/"5[H-CJ,D_B&QGNXHXR8H4. 9!T##T_S@UZ
M-I>L:=X@LA/:>!-)N8?/6!X8I@LL18X4M\G )[C]*1XU*DG)-OY#-;UN?6+V
M./5/+L)_,>32;I_^/>158CRY >.V,]N_!J/Q%/9VOPVM]8LK5]*U"]O.!%*1
MTSN*8/W#MR/KQVJ6_P#%7A#08KC0[GPA<K)#*)&M)9P\:R8R""6. 0>PYKS_
M ,5^*KSQ5?QSSQI!;P)Y=O;1?<B7V]_\*9M.:BG=W;,:]U"\OB&N[N>X(Z&6
M0MC\ZZ_X,.P^)407HUI*&^G!_F!7#/P*]5^ VAM/JVIZ_(&$<$8M8>.&9CN8
M_@ O_?5(6%BW43/=Z***9ZX4C?<;Z4M% 'QZDS>=(SY#%R6SZYK1L&^U7UM;
M%]HEE6/=Z9(&:FU[3(M \=WEAJ4,PM([HL5C(#-"QR"I/'W37?Z;K_A_4'N+
M+P]X-TZYCMDW)%<O_I%P!U*@J<GVSFD>'[&\VI.QJ^*M17[3?:!+:O'X=T](
M(VN;;E[=G3<KD#[R<X(]O6J?A3[#+;:R=2@@E.CVC*-0M& CF0C<I)7^,8X(
MYY(/-+-KWAKPI=Q3ZAX,GL+F[M\A+:X#QR1MU#+N"D>Q%<=XD\=QZAI']B:%
MID>DZ26W2(AR\O\ O'T_/ZTSHE*,9<S>O;\CE;O5]1O8_+NK^ZG3^[)*S#\B
M:F\(NZ^._#Y0$M_:, X]"X!_3-9;"NI^%FDRZO\ $;3RB%HK(FZE;LH7[O\
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M1R:V:<I75AMG :?H6F2_%#6B]L"8X8+A/G;AR22>OK^%1:/X:L-;U'Q5+?\
MG2JNI2I'$)654.Q3O !^]R.3Z5U5[X8L[W7(M7%Q>6UTBA'-O+L690<A7&.1
M^56]/TBVTU[YH-^;VX:XEW-GYB #CT' IN>FC"YYJ-5U*\\#>$;4F:Y-]<&.
M=5G\MIE7=A"YZ9P/RKI/#NE:G8^)S/%HS:5I<EL4E@^UK*ID!&U@H/!QD&M=
M?!^DCP[!HA25K:W;="_F8DC;)(8,.A&:FTGP^FE7#3G4M2O9&78/MEQO"CV
M ';K3<U9V"YD?$I/,\([/,,>Z[MQO4\K^\'(K/UC2;7POK7ARZTHS1SW%ZMK
M<;I6<W",.2^3R1US77ZUHUGKVG&QOE9K<NKE5.,E3D#Z<5G:=X.TW3M1BO1-
M>W+P BV2ZN#(MN#Q\@/MQDY-*,DE8$S&T;1K+Q3<ZY?:PLEQ+'J$UI$AE8"W
M1"  H!X/?/O6)%>W5_X>T'2+F^F>VN-7DLY+@2$--"A;:-PYYP!79WW@W3[R
M_GO(KJ_LGN>;A;2X,:S'U8>ON,58N_"ND76B0Z1]F,-K 0T'DL5:)AT96ZY]
MZ?.@N<V_A^PTKXAZ3!9^8EM<6=T&MC(61.%!*@],YY^E9?VZYM/"MSX.69VU
M(:@--C;/S>0YW!_^^-P_"NST_P (Z=I^I0:D);NXOHD9#<7$V]W#8&&^F. ,
M=3ZUFQ:$]S\4;C6I+-HX+:S2..5NDLISEA]%.*%)=1W.M@A2VMXH(QB.) BC
MT &!7+^$"KZWXK=O]=_:>UO]P(NW^M=97-6&FWFG>.M4N$B+:?J,$<ID!X29
M/E(_$$&H6S)-MK&Q12[6D&%D,_\ JQ]_J7_WO>O,K&UU7Q?8W6I3:(MS)?.X
MM;J>^V1VJ E5VHO((QG.,DUZOU&#7,V_@FQL[C=::AJEO:^9YGV**Z*P@DY/
M&,XSVS3A*PTSF/%-W/X2FT2XM;O[5JMO9&WN]^2&BP )7 S@!^>>N2*[GP_I
M,>D:6L2SO<S2GSI[ASDRNW5OIZ#TIB>&M.5M3>1'GEU(%;B25LL4(QL'HH["
MKNG6,>F:;;V,+R/% @C1I6W-@=,FB4DU8&SC+G64\-^,?$TT[G9+8P7$49.=
M[C*!0/4D@56.DW-I:>$]&N9G:]O-0-]=G=U* R,/H"0*ZV^\+:7J7B"UUJZB
M:2ZM4V1@M\G!)!([D$DBK<VDVT^LVVJR&0W%M$\40W?* V-QQZ\"GSH+G%R:
MT= NO%UJA9[J2ZB:SBSR\LZ *![;E)I(M++:MI'@V6>;[%:6)O+W;(5-S(6Q
M@D<[<Y./?%=6WAC3'\3#7WC=KT($&6^08! ;'K@D9]Z9K'ABSUB\AO3/=V=[
M$AC6YLY?+<H?X3P01^%/G07,+0K*&Q^(&KZ;IZ%=+6RC,T&XM&LK'C@]"5S7
M9):V\4BR1P1JZH(U95 (0?PCV]JJZ/HMEH=JT%FCYD;?++(Y=Y6_O,QZFM"H
ME*[$SD=-)3XHZVB?<>PMV?\ W@2!^F:ZZN<\-V%TNJ:WJ]] 89KVY"1(W40Q
MC:GY\G\:Z.B6X,****D HHHH **** "BBB@!MG_R&4_'_P!!HHL_^0RGX_\
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MXQF@\"O6E5E=[%J]C@"D!:IZCX4*>#QXADGCC22?RHH6',@YR1^(/Y&NDM_
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M/W49_P#9C]>/:N^TO2-/T6T%KIMI%;0C^&,=?<GJ3]:NTSTZ.#C#66K$
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M*^&7B&R\/>()KV_O9H(!;/B.,9$S#HI_I[^E?0]CJ=KJD)C(4.P(>)^<CO\
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M/XAE$UO"95MUB7RY%5N=YQDDX-=U9V>N%Y?[3U&TEB:(HL=M;&,9/\1+,Q_
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M7C]B,BH/L.LV?$$CLO;:W]#0!U=%<NNH:]#P\#O_ +T7^%/_ +;U?I]A&?\
MKD_^- '2T5S!U+79N$MF0G^[$?ZTT6>O7AQ+(Z*>[/@?D* .@N=0M;3_ %TZ
MJ?[N<G\JQ+GQ%+.WDV$+;CP&(R?P%26_A>,'=<SL_JJ#'ZULV]G;VBX@A5/4
M@<G\: ,&ST&:YD^T:B[9)SLS\Q^I[5T444<,:QQ($1>@ I]% !1110 4444
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MY1D?EUK:@N8+E=T,J./]D]*@NM+L[S)FA&\_QKP:R)?#$B-NM;K!'3?P?S%
M'1T5RWE^(+7A6D8#N"'_ )T\:MK<?#6F['K"W]* .FHKF3K6KD?+8CZB%_\
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MF_[]FC['=?\ /M-_W[-%F!!14_V.Z_Y]IO\ OV:/L=U_S[3?]^S19@045/\
M8[K_ )]IO^_9H^QW7_/M-_W[-%F!!14_V.Z_Y]IO^_9H^QW7_/M-_P!^S19@
M045/]CNO^?:;_OV:/L=U_P ^TW_?LT68$%%3_8[K_GVF_P"_9H^QW7_/M-_W
M[-%F!!14_P!CNO\ GVF_[]FC['=?\^TW_?LT68$%%3_8[K_GVF_[]FC['=?\
M^TW_ '[-%F!!14_V.Z_Y]IO^_9H^QW7_ #[3?]^S19@045/]CNO^?:;_ +]F
MC['=?\^TW_?LT68$%%3_ &.Z_P"?:;_OV:/L=U_S[3?]^S19@5K/_D,I^/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** ,VRUNVOM6OM-C259[/'F;P &SZ<_P"%03^((Q?7
MUA9VL]U=VL/F,$ V9QPN<YR?I7,W^J1^'O&^KW4AYELE:-?[[\ #\ZKZGI\N
MD^!3'.3_ &AJMPAG;N2QW;3]/ZFN=U79^5R;G?:?-<7%A!-=6_V>=UR\6<[#
MZ59K@IM-35O'$>FO)(MI8V"I(L;%=P_NY'8Y&?I546]AJ5UK$U_,\6GZ.!;V
MD(E*["H(#?7*\>M5[5]@YCM-?U8:'HL]^8_,,> J9QN)(']:NVDKSV<$TB!'
MDC5F4'."1G%>8K$[>#-'LR6:74]0WMGDD;L9/Z&O3YH@]I)".A0K^F*<)N3N
M"=R6BO*=.N'U/PY8^%[=B9Y;M_._Z9Q*V23^?Z5->17WB#6-0@CL1=6-B?LT
M2/=B)(-O&\C.3TJ?;W6B#F/4*@O;VWT^SDN[J3RX(AEVP3C\JX22WO/-T+PM
M=:BSQRHTMQ+&Y_>+R50-U(P,4GBS0]*T_P /P6UB&_>WJK&#,6",>&QS[=_>
MFZKLVEL',=_!-'<6\<\1W1R*'4X(R",C@U)7!:CI\-IJFE^%K"1[.SN=TUR4
MD.Z3C[N2>^W]:K6CPZ%K7B!-+=_[-MK,LR[RR+-@8&?7.?UH]JT]4',>C45R
M/@GP_#:Z59:E<;WO'C+(6<XC1CG '3G.?QIFMYUKQE;:#/,Z6*0&::-&V^:>
MP)]*KG?*FUN.^AV-%<%J-A;IJ.E^%[*XECTVX+SS8E)++_<!].#533!9Z?JO
MB*_L)&:STZT,4 9RP#'G )[;@?SJ?:V=K"YCTBBO-;?2HM)\ -J\S2/?26[+
M$6<XC60XP!TZ'.?>GZEX7BM/ GVT^9+?K!&6D=R=JY!V@= !1[65MNEPYF>C
MUGZ=>WMW<WJ7-@UM%#)LA=FSYHYY_E^=<I:W:^(/$$&I@[K'2;3>S]C*5R0/
MI_2L39++X*M(5)%QK&I;AD=LXS^8%)U>J#F/5J*\[\F/0/&<S6LDTGV?37N+
MIGD+&5@#U_2LJ_M;8>#UUN[NY)-8OV.QA*?NDD%<?W<=:'6:OIL',>LU4CU.
MTEU.;3HY=UU"@>1-I^4'ISC'>ETZW%IIEK;?\\HE3\A7#>%M(TM]1U?5Y(?E
ML[IC =[?(%R2>O/XU<I--)=1MG5Z-K9U:_U.!80D5G-Y2N&SO/.?ITK8KR)M
M,0^![G6[F24SW%SOMT#D!"6P3CN3@_E6IJKZGK&NKI/V1KZ&RMH_.MS<B$.Y
M4$NQSDXSVK.-9I:HE2/2:*P?".F76EZ-Y-S<I-ND+(L;EUC7^Z">N*WJWB[J
M[+04444P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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1** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>geajuovwk5do000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 geajuovwk5do000001.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" ,." P# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M .A3Q%_X(RW_ .>?K_3T\'_6S ?\^,9_X#1_^7>O]/3^HJBOY=?^&[/VLO\
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M]/ZBJ*_EU_X;L_:R_P"BRZU_X)?"/_S/4?\ #=G[67_19=:_\$OA'_YGJ/\
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M\5=0M-PFM?A=\/?$&HPEU)&RVUKQ;'X.\.7V['RRV.LW,!!!\T!E)^)/%O\
MP=&?LRV7FCP)^S?\</$I4L(O^$KUCP-X+$N,[2QT?4_'WEA^#T=E!Y7(Q7J4
MLBS>LDX9?B$GLZD%1O\ ^#G3/VS)/HQ^/W$,(5<O\*>+:5.JE*G/-\%3X=4X
MO:47Q!6RR\7NI;-:IM:G]/\ 17\BMQ_P=56:W&VT_84O9[7<?W\_[24=M/LS
MPQMH_@)=H&(Y*_:L#IO/4=_X6_X.F?@_=R1CQM^R5\1O#L1QYK>&?B7X=\7R
MH/XO+BU7POX(64CL&FA#<9*YXW?#.=Q5W@7;RKX63^Y5VW]Q]17^AI])7#TO
M;5/#+$N%KVH\3<%8BI;RHX?B2K6;UV4+^1_5717X$_#K_@Y#_P""=?C.2&'Q
M2?C?\)F=E26Y\:_#JRU;3X2S8WB3X<^)_'.HR1#J6_LM) .L0Z5^HGP2_;N_
M8Y_:->WM?@O^TA\)_&^K70C:#PS;^*K+1_&4BR[O+/\ PA7B(Z1XM4,59<OH
MJ@,-APW%<%?+,PPJ;KX+$TXK><J4W!?]OI.'7^8_+>*?!GQ9X*I5,3Q3X=<8
M9-@J2;J9CB<BQ\LK@ENY9I0HULO7_A3MKL?65%%%<)^9A1110 4444 %%%%
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M\1)-X^^%_A&3P;/*55/#@\1:5KMK"Q)23^T=4U+6M/U&2--I,,>E6 G((66
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;7]\U%?P2_#K_@XI_P""EG[$7QXU?X&_\%#_ (>:#\6[7X:?%6\L/V@M$O\
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M,/\ R;GB+_ND?^KW+#Q>(?\ D3XS_N7_ /4J@?B_1117\-GYB%%%% !1110
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M?_3D3^KZBBBO]&#]@"OR)_X+O_\ **7]JC_NA_\ ZT?\(*_7:OR)_P""[_\
MRBE_:H_[H?\ ^M'_  @KFQG^YXO_ +!J_P#Z:D?'>(G_ ";_ (Z_[([B;_U2
M8X^1/^#8W_DPOXM_]G=^/?\ U37P"K^C&OYSO^#8W_DPOXM_]G=^/?\ U37P
M"K^C&L\N_P!QPW_7J/ZGC^#_ /R;+@S_ +$U+_T[5"BBBNT_20HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***\X^+7Q>^&7
MP(\ >(?BE\8/&N@_#[P!X6M#>:WXF\178M;&V4G9!;01HLMWJ6IWTQ6UTS1]
M,MKS5=5O9(;+3;*ZNYHH7J,93E&$(RE*348QBG*4I-V2BE=MMZ))7;V.C"83
M%X_%8? X'"XC&XW&5Z6&PF#PE&IB<5BL37G&G1P^'P]&,ZM>O6J2C3I4J4)5
M*DY1C"+DTCT>ORS_ &W?^"P'[''[#W]I>&_%OC%_B5\7K)9(U^$'PQDLM<\1
M:?>+A5A\8ZLUQ'H'@E8W>)[FTUB^/B,6DGVNP\.:E&-I_GB_;1_X+8?M3_MV
M^/G_ &7?^"=?A#X@>$?"7BB]NO#UMK/A2RN9/C?\3K9RT$]W#=Z4\K?#3PHT
M&^[N/[,O(M7M],CDO_$/B?3M-EU'1;/ZM_81_P"#;WP]I9TSXH?M]^))/&?B
M>XE35#\#?!>NW">'K2X>;[0T7Q!\?Z?+%J?B*[?<1?Z5X.NM-T^"Z5C'XMUZ
MSE:,_34LEPF I0Q.>XAT7-<]++J#4L556G\1I_NT]FDXI:J56G-.)_9V3?1T
MX%\+,FP'&/TH.*:^03QU%8S)?";ABI1Q?'&=4D[Q_M.I";AE6'FXRIUH0J4*
M=)R]ABL]RK,8/"'Q#X^_X+ _\%6_^"B/BZ]^&W[%OPW\2_#/P_<2>2=(^!VA
MWOB'QE:6%QYP@N?&7QAU6RCC\+H#C9KFCK\.[*-HT2>9R2S]W\(O^#<7]LGX
MZ:L/'W[87[0FB_#_ %+67BN-8@EU/5_CC\4[L ;Y8=<U235]-\-)=,\DBI>0
M>-/$H1M\DENY;8W]D7PV^%OPV^#GA+3? ?PH\!^$_ASX,TB-8]/\->#-!TWP
M]H\!")&TYL],M[>*:\G"*UU?7 EO+R7,]U/-,S2'O:F?$<L/%TLHP6&RZEM[
M14XU<3-;7G4FG%MK^>-22_Y^/KAF/TP,9PKAJN1^ /AUP?X0Y)RNBLTIY;A<
M_P",,?3C[D*V8YKF-&IAJ\YP2DX8[#9OB:,GRQS*JHJ3_ ?X2_\ !N#_ ,$]
M? 4%L_CU/BW\:]10K)=-XM\=2>%]'EE4@D6NG?#JQ\)ZE;VQ(X@NM?U%]ORR
M7$@SG[P\)_\ !*'_ ()P^#(8H-(_8Z^"=XD.WRV\6>&3X]F!3!4O<>.;KQ%<
M2," 2TDKL3R2<FOMWQAX\\#_  \TE]>\?^,_"G@;0X]WF:SXP\1:1X9TF/8-
MS[]1UJ\LK-=BD,VZ8;0<G KX5\;?\%;?^";7P_EF@U_]L/X/WDD#O'*/!VJZ
MC\1E61&*.GF?#W3/%$;,K*5*HS'(K@^NYYCFW&OF.([QHRKN"\E3H^XO111^
M4R\1/I)>)M6K/"\3^+G%?/*2J87A_$\38C Q;>L899D*C@**OIR4\-!1T222
M2/;K?]AC]B>TA%O;_L?_ ++T4(4+Y8^ ?PJ*[1T!W>%"3CW)KB/$7_!-3_@G
MYXI60:M^QI^SBK2JRO/I'PG\(>&[O# @[+SPYIFE74;<\-',C*>5((!KY3NO
M^"^'_!*VUN#;_P##2=Y<88KY]M\'/C?+;\'&X2?\*[7*GJ"%Z=J]$\*_\%IO
M^"87C"2&'3/VL_!UA--C"^)_#'Q&\'Q(3C_77?BGP;I%C$!GEGN@JC)+#!PO
MJ^>T_?5#-H=>94\7&WG=+02X0^DWEC6-APUXZ8&2]_ZU2RGCVA.%DI<SK4Z$
M90LK.\I(\F^)O_! ;_@F9\15N)-.^#WB7X7ZC<(RMJ?PV^(_BZTDB8DD20:5
MXNO_ !CX:A=<\"/0Q'@ &,@"ORD^.O\ P:ZWMK%=:K^R_P#M."6ZA$DMAX3^
M-/AY[%Y)8]LEMYGQ \#)<(LI92N%^'<,8<I)YT2A@/ZD?A?^TA^SY\;8HY?@
M]\<?A+\4/,C\T0^ OB%X4\57:(,Y\^QT;5;R\MF7!WQW$$4B?Q**]IK6CGF=
M8*7+];Q%UO3Q2]MIV:KQE**>WNN+[,]?(?I-?2-\.\:L-+C[BR=3#M1K91QM
M&>?KV?6A4H\34,7C<+"5N5O"UL+525HU(V/X.9?B3_P7-_X)'3!O&2_$'Q3\
M&M%<1[_&.?CO\#)M.C\MH8H?$UK>ZCJGP^LY=K+!I]MKO@/5'Q*'LPI(/[,?
ML6_\'&'[,GQQGTOP7^TSHLG[,_Q!NFCM5\2W-Y-K_P '=5NSO7?)XB^SPZQX
M(,Q02-%XFL+G0=.C;_3/&3E<G^BF>""Z@FM;J&*YMKF*2"XMYXTF@G@F0QS0
MS0R!HY8I8V9)(W5D=&*L"I(K\-_VXO\ @@I^R%^U3!K'BWX6:7;_ +-'QBNA
M<7<>O_#_ $FW7X>Z_J+B>4#Q7\.(9++2H!<W,K27.K>$)?#FI-/(U[J2ZXT8
MM).Y9GE&9ODS7 QPE:6GU_ +DM)V]ZK2M)R[RE+V\GM&,=S]0H^-/@'XT/\
ML_QU\-,)P)Q'B_=CXI>%U&>!<,3/3ZUGN0\F,J8NG=*6(Q-:'$F(DFX8;"X-
M?OH?MWH^LZ1XBTK3M=\/ZKINNZ'J]G!J&DZSH]]:ZGI6J6%U&LUK?:=J-E+/
M:7MG<Q,LL%S;32PS1LKQNRD&M*OX&/#7Q4_X*??\$%?BA9^#?'6EW7B[X!:Q
MK-RMCX;U2_U'Q%\!OB+$6^U:A?\ P\\3BW6\\"^+WMQ+<W$,-KHVNQR""]\6
M>$M9TQ+."?\ KT_82_X*+?LZ?\% ? <GB7X/Z^VF^--#L[67Q_\ "7Q'+;6_
MCGP3<3[(S/+:QN8M=\-373>3IOBO2/-TVZ+1VU\FE:R+K1[3@S'):^"IQQ5&
MI#&X"IK3Q="THI-V2JQ3E[-W]V]Y0YO=YE.\%^6^+OT<.)?#?+,/QKP]FN7^
M(WA9F?+4ROC[AEQQ&$I4ZM3V5*EGN$H5<4\IQ'M6L.ZOM\3@'B7'"/&4\>YX
M*E]YT445XI_.04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 13PQ7,,UO/&LL$\4D,T3C*212H4DC<=U=&*L.X
M)%?SL:W8?%#_ ()Z?M&WWB+1M%FU?P9?_P!HV^ERW?V@:3XP\%7T\,YT^XU*
M-)6MM5LWAL'U!PAFTW7+.VNI+6]TJ2R75_Z+*Y[Q/X2\+^-=(GT'Q?X>T;Q-
MHMP5>;3-<TZUU.R:1 PCF6"[BE2.XBW,8;B,)/"QW12(W-?#<;<'3XIHY;BL
M!F$\HS[(\5+&9/F4(>TC2J3]FZU"O3NN:C7]C2<FN9PE3C>%6E*K0J^9F>7/
M'1HSI5GA\5A9^TP]9*ZBW;FC)=8RY8W[-*ZE%RC+\G/&O_!5SP_<>%+J#X>_
M#K6H/&UY:M;V<^OW=G/HVE7LT95+N&&T0W.M_9I"#';7$6D+,VUW\Q%:VEQ_
M^";_ ,!/&.H>,=6_:3\?VUU!#>VVIIX2FU%'%]KVKZX)(-5\1122XEEL8-/N
M-0L6N662/4;O4W\NX^T:7?15\[_L$^!O!GBO]J77M%\3^%M#\0Z/IGA[Q#J-
MAI>LZ=;ZEIUM?66H:8;2Z6RNUEMI);<LQB\Z.5$8B15$B1NG]$,4<<,<<,,:
M10Q(D4442+''''&H5(XT4!41% 5$4!54   "OS;P_P OSKC_ !67<:<69PL;
M1X?QN)H91E-#"TL-1CCZ"HRECJ[HPIQDU/V=6$8P<Y5:5)NK3HTW0J>-E-+$
MYM.CF6/Q"J1PE6<</0C3C"*JQ4'[67*DG9V:5KN48^\HKE;Z***_H(^L"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K^>/\ X*&?
MM'_M4^ /VH[GPQX5\9^-? /A+1;;PS=?#C3O"\UW8:;XLBOM(T^:_P!3OX8D
M-MXQE?Q'<:EI$FGZE!?:?:-816"6!F26YN_W.^,WQ7\-_ _X8>,/BKXN2\ET
M'P=IL=]=6VGQQR7U]<W=[:Z5I6FV:S210BYU/5K^QT^&2>6*WBDN5EGD2%'8
M?''[)/[??@?]K/QKJW@>[^'-QX%\6Z%I=UXF\/)?:S9^*K34]+L[RTLKZ6UU
M'^Q=$FTO6+<WMC.]BEK.DMM]HDBOY!9N&PK\LN6E[5TYR::M>[M?1V:W>VJN
MUI>S.K#\T.>O[%5:<4XRNTDF^5W5TVVEO9.R=W8^WOAGJ?BK6OAQX UCQUIR
M:/XVU7P5X6U+Q?I,<3P)IGB>^T.QNM>T]8'+/;BSU26ZM_(9W,/E^49)-F]O
MYW_%O[47[:%G^VOJ'ARR\2^-(]8M?BU+X:T;X1H;U?!U]X;_ +?^RZ;IK^&5
M1;&]TS4?#XAN&\4M;G49+*=]?@U:%RMVG]*]5C9VANUOS:6QODA^SK>&"(W:
MVY9G\A;@KYRP[V9_*#A-S,VW))IU*<IJ"524.5IMK[5N]FM>J_(BE6C3E-RI
M1FIII1>BC=WTNGITMIZF/XMO-<T_PIXFO_#%A%JOB2Q\/:U>>'M,G+"'4=<M
MM-N9M)L)BK(PBO+]+>WD*NK!)#AE/(_GL_8;_:8_:T\;_M;:)X:\3^,O''C/
M2M?O]?7XD^%O$9N9-%\-Z;9V-^]W?P:/) EEX(ET;58[2*"#2[;2(9;PPZ)-
M"XO?(;^C2J\5G:037%S!:V\-Q>&,W=Q%!''-=&%66(W$J*'G,2LRQF5F**S!
M< FG4IN<J<E-Q4'=I+XM5OJNUM4]']Y2K*G"K%TXS=2-E)[QW[I][Z6U2U[?
M/_[67BSXC^!OV=/BOXK^$MM-<^/]%\.)<Z&;:S74+JQADU33[;7-8M+)X;B.
MYN]"\/3:KK5I%+;W$+7%A'YT$T>Z-OQM_8,_;7^)?AC4?BEXC_:$^(_BSQ-\
M%]"\+_VE>Z[XIEU3Q1J&F^/-1US3+7PYX>\-7DRW>H2WOB"TGULQ^&H9TT^"
MRTR?5]NG:?I%Y.?Z&J^7?VJ_V8]"_:9^#]Y\,3JJ>#;R'Q#8>+_#^M6>F175
MK9^(]/@OK(3:EID4UB;ZVOM.U34K&Y*74$\3W,5ZK3-:BVFFK3J.2J0F[PB[
M4_LR?GJM]G?=):K=51JTU%TJE-6J27-5^U".FWNMZ6;5FK-MV>Q\+?M3_MT7
M7Q)_9=U+QU^R=XA\1:=<Z7XYT3P[\4;Y=+FTSQKX!\.ZMINLW6G7S")KJ/2K
M+7=4T^VT^'Q/I][/%$ZW&FP74%])-]E] _X)7_%?XW?%/X7>/9OBQJ^O>*]"
MT'Q'I5CX%\8^)I;J^UC5&GLKU_$VDR:W=[KG6K;1)H='FBN[J:[NX;C5[NTE
MNVB@M[>V]9_8D_8HMOV3M$\;G6?%D'CCQ1\0&TF#5YK;3)-/T.PTC1%U(6FF
M6EK=7%U-?/<RZM>3:A>70@65/LMK#9PK;S37GW9!;P6L,=O:P0VUO$NR*"")
M(88EZ[8XHU5$7)/"J!STI0A5<X5:DG%\K4J:^&^J75K56;7\RW*JU:,83HTH
M*4>=2C5?Q=&U;E3TUBG?X>G4_'G_ (*N_&;X]?"Z#X66'PU\1^)_ W@K7DUR
M;7?%'A*ZO-(O[SQ'8S67V#1+OQ!IYBO--ACT]Y[VVL8;NU&L>9>M,EW'I>+?
M[&_8,\=_%3XC_LS>!O%7Q?-[=>)KN;6+>PUK4[?[+JGB/PU:7\D.AZYJ$?E0
M>9/<P![>._,0?5K2UMM7DDN9;Y[J?Z^NK2UOH'MKVUM[RVD*F2WNH8[B!RC!
MT+Q2J\;%7577*G:RAA@@&IP H"J JJ %4#   P  .  . !P!5JFU5E4YY-25
ME#HMM=_+LMWJ9RK)T(4O9Q4HR;=3J]_*]];.[>B6G;^?O_@I5^T/^TY\._VB
M[#PQX2\9^,_A[X&L-!\/ZGX(3PK=W>D6?BRYN;96UO4-2FM%0>(9;?6GN-&D
MT:_DO=.M8+&SD&G1S7TTUU^VOP2UOQKXE^#_ ,,O$'Q'T\Z7X\UGP/X:U+Q;
M8FU^PO!KMYI5M/?^=8!(QIUQ+,[37&FA$&GSR266U?(Q7I$]I:730/<VMO</
M:S+<6S3P1S-;SI]V>!I%8PS+_#)&5<=F%6*(4Y1J5)N<I*;TB]H_B_1:*R_
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MC]C[]J0_"T?\%J(_BH?B4/V?OBR?  ^& _X**'QN?B.?&(\)?\(Z/ 8\%_\
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MN?QOX*@U23Q5H_SU^UM,W@[Q[\//V;+2S\0Z3X:_9=^ OPP^$'@ZT\=+9?\
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MK'Q6\;^ OBAX7MX]9\5^-]>\%R^'_!6A:OKL7PFUG6;Z]^(5#Q5_REU^)/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%6R+-:7M*U6A@7B*D:&#JU:M:.&K3H89XK$X7'9+CLR_2"BBBOGS^3@HHHH
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MJZ?M)>R35.ZY4[WV5]VWO>UW>UKA1115F84444 %%%% !1110 4444 %%%%
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MV5-8;"N=58?VDNOHHHKE/RL**** "BBB@ HHHH **** "BBB@ HHHH ****
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MM1U/5KJVTVRMY[R>*%OXZO\ @M'_ ,%I/^"E_P"R9_P4%_;-^"'[/W[2G_"
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M1=%_\+?PC_\ +>OZ5J*/^("<%_\ 07Q#_P"%V!_^=@?ZJY;_ ,_,9_X-I?\
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M.638V,8QBM7*3:22U;=D?$?_  ;&_P#)A?Q;_P"SN_'O_JFO@%7]&-?Y]?\
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M ,Q,/FI+\XH_1Z?C/X7U;<O&.6*]W^\AC:.SMK[;"PL^R=FUJM#^C^O\X/\
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MM74VEYT^;CC(]/\ $?7WSS6;5_Z_J_:W5'C5Z%KM+U_I=?/Y^GJ-G>= 3_\
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M>,K>72Y+B:YT_3[W5'T#Q1HWF#"6T5Z%ATN^6,/.!J*WNERA66)--0!I7I^
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MMW-:RZA#/_94>CWD-C);)>FVCB^Q:2&@F6&7^H2OP$^%W_*4*^_[*_\ &/\
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MK]//^":.EVWQ*\,?M@? >XU:WT8_$KX0:?+:ZE=H9K;37MO^$E\/SZI/;B:
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M1K[P]XET"[-AK6B:E&L5[I]V(XYO)G5'DC.^&:*>&6&22&:"6.:&22*16+]
M\0ZSX:U*TUGP_JNH:-JEA.ES9:CIMW/97MG<1AA'<6US;/'-!/&'?RYH726(
ML6B=6YKUK]J_Q'#XJ_:<^/&N6LRSVTWQ,\0Z=;3(=R2P>'I(O#:.A[HW]D$K
MCMBO!5;N/Q%?*9E1I8#-<PPV#K5*E#!9CBZ&%Q$FE5J4<-BJE/#UW*GRQ52<
M*<*G-3Y4I.\.72W#6BJ->K"$FXTZTXTYM^\U";4)-JWO62=]-?DW^R7[.O\
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M_M2P+<SQO-<75[,C/]FLS9V-]>QVVRUAB33H"L']&OQ,_P"2;_$'_L2/%?\
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M6<3^1/%,$,;[J&TK7:5W97ZOLO,6O;;4U****8!1110 4444 %%%% !1110
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MMIZSQ.T<JD]]6;HW&CZ4 ,#^S;'_ -)8JTJP;N[FZ5DD%%%%(84444 %%%%
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M\7]%'_$Q/_5'_P#FP?\ X##_ %O_ .I?_P"7?_WJ?V@45_%_11_Q,3_U1_\
MYL'_ . P_P!;_P#J7_\ EW_]ZG]H%%?Q?T4?\3$_]4?_ .;!_P#@,/\ 6_\
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M"?@'\8/%EK-N*&.Z\/?#[Q#JMJP88*L+BTCVD'(;%;YS.6)SK&ZW;Q<J"?\
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M_P )5X8_Z&/0?_!OI_\ \D5V4G^ZI?\ 7N'_ *3'_-'!73]O6T?\6IT_OO\
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MX)&7W_U_2?R>MF_EHRZ/;\O7R[=C[*_8:^-%I\#OVE_A[XKUJZ2T\*Z[/<^
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M*M=;U"#XE7[?;-3>)GTB"P@O/[0L5DUF%_['BDOA\:?MI?M%>#/',OA7X ?
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MUSXW?&CQ?<OJ?B/XR_%/Q#=2-O>ZO?B1XKNU+,2?E6+6?LT0X^5(HXU4#"J
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M7^$GPQ^%_P 2[ :/>W]KXDTR;PC\0?#%TVMZ-ID.J7&I>'Y-7T+5?TV_;?\
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MI/A:_P#"_BG6M'TWPYX[\$ZGXA_F)_:U_91_:H_9>UB+P)^U3::[;?$GXL?
M'X5_&7P!:>)=<UK5O%FF?!CQG\,=.\'?"OP+XCTCQ7'8>-O &N_!NW\ ZI\
M]2^&GBO1="F\":E\*;SP[X7L[[X?V7A#7]8_T!/@G_P;*?\ !,[X1?$+3/'G
MB>T^-O[0]EH\=K/I_P -_CUXW\(ZO\,7US3_ !#X?\0:=KNN^&?AU\.?AI/X
MUBMUT.YT#4/ _CK5/$WPK\5^&?$GB+2/&W@'Q-'<:=)I?Z@_MN?\$^OV6/\
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M&!Q#=7.AZ/IUP@&R2TO9X7RDA5OY4=(1H]-MLR"621KB:64*JF23SWM][;0
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M_C:OZ%:_GJ_X*I?\G'^'O^R2>&O_ %)_&U?CWCE_R0E7_L:Y=_Z55/GN)_\
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M;R:,>5 =7\!R^"SIT<NV:]N-%U^=#*+>8Q_S$5][E^)6,P6%Q"=Y5*,.9_\
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M8J.FM&&993G> K-7C%UZ4;IU$G^Q%%%%?,'\7!1110 4444 8/BK_D6/$?\
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M9^&W@6#P3XIO;?3O&/V3QM\>?$OQMU_P=/)I6KWEGHNB?!/X:Z_X'\9:A/\
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M&H^$_A]_PG/B"&YT'P9_PF>O6UAX<_X2S6[>?2/#O]I?VQJ4,MG9S(WZ6?\
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M/*CU"^M+&27=]WRDNYH7DSVV!L]JM%64(Q!VR*'C;JLB'HZ,/E=3V925/8T
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MC8J*2Q/[Y45(U6.;=LB4Q6TEJ7,HY6B@+GU#H7B*QUR!'@D43%-S19P<@#S
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M^$ >W>XN;^^G\P)_9VOQ6_\ 9K:7&T;M<7E]%8:@D2DP:-=3R6EO=?%VK_\
M!3S]H36;V\U/PEX%\$Z9X>M%$ZVMQI.LZO+! =Y+:EJ1UFS%TG!43VEKI*OY
M9/EQL2J^+?M/_!;P'X7_ &N8/A1X.T^X\*^%]7UOP;8/YEU+?V]D?$]EHMY>
M7EJ^H-)*;.SEU:4O'=7%P5CMW4S;%54_HE\$> O"/PY\,:=X.\&Z%8:)X?TR
MV2VALK2"-?/Q&$ENK^7;YE_?W9!EOKV[:6YNYG>6>1W<FO.R6KXD\<9AG&4X
MGBS#</0X3Q#RS'8K)L#SU,SS&%;$4_;-2J86IR6P\N=PGA:#3IJ&"YIS=/'#
M2SG,ZV(P\\?#!K S]C5J8:E=UJRE)<VLJ;M:#NTX1V2IZOE^&OV6/V_O#GQP
MUN#P#X[T>U\#^/[IA#I+VTTQ\/\ B"Z" M90I>R2W>C:E))NBL;.YN]0AOG1
M8%OH=0NK#3KK]%:_GW_X*+_#CPW\'/C;X1\;?#:*W\*ZCXETV'Q+<V&BI'9K
MIWB.QU2\C_MS3K>$+%I_VUK:WN(TMX47^U8-0O@QEG(C_<_X7^)[WQO\-/AY
MXSU&U6RU#Q=X&\)>)[^S165+2\U_0-/U6ZME5\.JP3W;Q*K@, @#<YK[;P^X
MBSO$9CQ'PCQ+B*6/SCAFO04<SH4U3CC\%B8<U*=:$(QA&O3BZ4FU&,IQK1A.
M,JM&K6J^EE.,Q,ZV,R_&SC5Q&"E"U:*Y55I35XN222YTN5MZ-J:3O*,I2[FB
MBBOU(]P**** "BBB@ HHHH **** "BBB@#P_]I+XNW'P(^!_Q#^+-IHRZ_>^
M#]'M[FPTF1IDM[K4-2U73]$T]KU[<&==/MKS4X+O43$4D%C!<;9H3B9/S\_8
M _;X^)W[2/Q*\2_#+XG:!X:^T0^%]0\8:'KOA33;_3%LXM.U32[&[TK5;2YU
M#5(I;:1=8MSI]^)+:6&2W-K=M?37L,L/ZOZWHFC^)='U/P_XATNPUO0M:L;K
M3-7TC5+6&^T[4].O87M[NROK.X22"YMKF%WBFAE1D=&*L"#7E/PD_9T^"?P*
M?6)OA/\ #S1?!USKY7^U[ZT?4+_4;R))6GCLSJ6L7NHW\.G1S.98M-M[B'3X
MY C);*8T*Y2C5=2$HS2@OBC;?_.ZTUMRVNKW9O"=)4:D94W*K)^Y/I%:>=U9
MW>B=[V=CVJBBBM3 **** "O'_CG\#O /[0_P]U'X:_$:TO9]#O;JUU&VO-*N
MDL=9T75['S19:OI%W+!=P0WUO'/<0#[59WEI-;7-Q;75K/!-)&WL%?(?[;G[
M1>O?LQ? ^Y^(7A;0K'7?$>H^)=(\):,NK1W4VC:7=ZM:ZI?-J^K064UK<7%K
M;6VDW$$,"WEFLVH75C')/L9HI9FXJ$G/X4GS:7NNUNMRZ:G*<%#2;DN5WM9]
M'<Z#]F?]DWX6?LJZ'KNE?#O^WM1O_%-S8W/B+Q)XIO;*^UO4AIJ7*Z=9!M-T
MW2=/M=.T]KZ^>TMK>Q23?=S/=W%W+LD7Z<K\V_\ @GC^V+X[_:FTGXAZ9\1=
M#T:U\0_#^7PY.FO>'+.ZL-,U;3_$HUI(;>]L;B[OEM=4M)M#N'$EM.EM>VTX
MV6EM)92R77Z25-)PE3BZ:M#6RM:UFT].][W[O74JLJD:LE5=ZBMS.][WBFM?
M2WIL%%%%:&04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !6!KM[JT"16NCZ4NH7-XDX\ZY8+I]J$>WC_ -+7>C2ETN))
MUA,ENDL%I=HMS]K^R6EYOT4FFU9-Q\U:Z]+IKRV&G9WM?R=[?@>7^#SJ/A6Z
M;PKKS6@@N6^UZ%=6SS&!C,(_MED6N(XY&<WLCL9W,TDU],TUZ]E)K6BV$O\
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MN:&0,'3D@<.D<@# !T$L4,P1E$T,,N^)+%%%-??Y]SYD**** "BBB@ HHHH
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MX@>Y77?#.I8O-4U>?0[5T8RPJS6JHT=Q<V*(HCE!D0U2^">@^"!X_P#@Y?\
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M]WF>G/RN^J9SXG"T,92]CB:?M*3E&7*Y3C[T=G>$HO3UL^I^//\ PZ-\._\
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M-5PU26)R>N\)4>L\--N6%J];6?-R7U2NI);0=+XEU?ACQA\*?CWX)N9]"O\
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MLUY?U_7_  >J_9S6ZOO@5\*YKAI))1X1L[<.RDO)!97%W96SG[QYM;>'&>@
MY(KV?[(>Q/Y?_6%? G[.6M>,?BAI/@*U\2:_9_#SX3?"6RATCR+#Q$OARY^*
MGB*QE\W3[>^FFN;.[;2='MC =:MK*<V%[=$0,&FO)X[3]&(D@NHQ<6T\%S#)
M\R3VTT=Q X/.8Y8&:)A_N-@>U7!1E%:=$ON2NTO7[_N%+=][L_93_@DG^U#/
MHFMW?[+/C;42VC>(IM0\0?!^ZNYCMTSQ&$DOO$G@B-G)VVOB&".?7]$MP=J:
MS:ZK;0KOU:)!^_5?P_:3JFL>&-9T?Q)X?OY])\0>'=4L-<T/5;9V2YT[5])N
MHK[3KV%UVG=;W4$<FW.V15:-MR,RG^Q/]G#XU:7^T-\%/ ?Q:TY8(+GQ'I?D
M>)=,@8%=$\9:2_\ 9_BG2"HY2.#5(I;FR4_>TR[L91D2 TI1MML_P$>W4445
M(!1110 4Y6*LK*2"K!@1P00<@CW!IM% 'U5H?EC2K..(YBMUDM8R<_ZNTFDM
MDZY/W8AW-:U<KX+E>7P[9O)G<9KXG/</>W$JGZ%7!'KG/>NJK![OU9NMEZ(*
M***0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHKXXE_X*'?L(VWB34O"&H?M@?LY:1XDT?4
MK_1]5TG7?B]X)T&XT_5M+NI+'4-+O&UG6+&&#4+6]BEM9+.25;C[1&\2QLZE
M:F4X0MSRC&^W-)1OZ7:N<6,S++LN]E_:&/P6!]O)PH_7,50PWMI1MS1I>WJ0
M]I*/-&ZA=KF5UJC['HKC?!7Q&^'WQ)TZ75_AUX[\&^/M)@D2*;5/!7B?1/%6
MG0RR*S)'+>Z%?7]M'(ZJS(CRAF56(! -=E5)W5UJGLUJCJIU:=:$:M&I"K3F
MKPJ4Y1G":[QG%N,EYIM!11106%%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% 'SU^U#^R]\'OVP?@YXF^!_QN\-Q^(/"/B&,36M
MW!Y5OK_A3Q!;13)I7BWPEJDD-PVD>(]':>4VMT(IK:ZM9KS2=5M-0T74=2TZ
M[_B4\5^$/VY?^#?+]J2/Q/X5O9?'/P%\=:DMI::I+!?)\+?C;X5LY9KI/#GB
MFRBDN/\ A#?B;H=E)=36A69]9T&Z:\OM$N_$?A&^U*/6O[\*\W^+?P@^&7QX
M^'_B'X6?&#P3H/Q \ >*;0VFM^&O$-H+JRN54[X+JWD5H[O3=4L9@MUI>L:9
M<6>JZ5>QQ7NFWEK=PQ3)[.59O/ *IAJ]-8K+L1IB,)/5:VO4I7TC45E?5*?+
M&[C*,*D/Z(\$/'S&>&$,SX1XGRBEQQX2\57H\6<#YAR5*5JOLXSS?(Y5W[/!
M9O15*C-I2I4<<\/A_:5<)C<-E^:9=\N?L+_\%#OV=/V_?A^OBOX.^)$LO&.D
M6%I/X_\ A+K]Q;6_CSP)=S[8G:]L$?&L>'9KLM#I7BW25ETG4 4@N#INL)>Z
M/9?==?Q*_MH?\$4OVJ?V$?B _P"U%_P3K\7_ ! \7>$/#%[=>(;71_"5Y<Q_
M&_X86R$SSVB6>E)$WQ,\)B'?:7']F64VJW&F226'B/PO?Z;%J&M7GUA^PA_P
M<A>'-6.F?##]OKPW)X*\46\J:7_PO'P7H5S)X<O;A)A;F7Q_X!L(IM4\.7B;
M2U_JO@^VU/3I[MF$?A/P_91,X[<5D4<12>-R2K]=PKUGAK_[9AI/5TY4W:52
MWV4E[1KX8U8KVLOT+C;Z,6"XIRC$>(_T:LY?B3P14;K8[A*$T^/>#ZM1.<LM
MQF53Y,7F<:+4HX>,*4<UJTN25##9MAHO-Z_ZI?MW_P#!&#]BW]O%]4\5^*_"
M$WPJ^--\LDO_  N;X616.B^(-4OFVLL_CC0Y+=_#WCH.R1)=7VK6<7BAK2,6
M=AXGTV+!'\DW[5__  ;A_MY? 2XU#6/A!8:#^U)X#MS)+!?_  ZE31?B!!:(
M7VMJOPV\07<=]->,%799>#-8\;2-O4LZ$.J_Z OPW^*/PW^,7A+3?'GPI\=^
M$_B+X,UB-9-.\3>#->TWQ#H]QE$D:'[;IEQ<10W< D5;JQG,5Y9RY@NH(9E:
M,=Y7%@\[S'+_ -TI^TIP=G0Q,92Y+:<L7>-6G9:**DH)Z\ES\ZX ^D9XN>%$
MED<,?/,\KRZ;PL^&.+L-B<5#+_8ODEA<-4G4PN;Y5[&TH1P='%T\)1G=SP<G
M=/\ Q\O'WPO^)7PIUZ?PM\3_ (?>-?AWXFMBXN/#WCCPOK?A76X?+;:YETO7
M+*QOD"L0"S0 <KSR,\.K%>#T_E7^POXT^'_@+XD:0_A_XA^"/"/CW09=WF:)
MXT\-:-XITB3> K[]-URROK-]Z@*VZ$[@ #D5\$>.?^"/O_!,OXAS33^(/V-/
M@Y92W#.\I\%Z7JGPV5G=BSN(OAUJWA:)6+,261%.37T-'BZ@TO;X2M"2WE1G
M"HGZ*?LFO+WG;:[W7]6</_3SX=J4H1XGX"SO UDDJE7(<SP.;4JDM+RIT,PA
MDLZ*;N_9RQ-?ET7M):M_Y<E*"0<BO]*"Z_X-]?\ @D]=7'VC_AFK4;?YBWD6
MOQI^.<5N,]A&?B,Y"CL W'K7HWA/_@B#_P $LO!LD,VF?LB^#M0FA((;Q5XL
M^)GC*)R.GG6?BKQMJ]A*/57M2IZ%2*ZGQ=E]M*&,<O\ KW12^?[][];)^72W
MU]7Z=OA1"E>CPYX@5JMM(3RWAZC&]MI5/]9JEM=+QA)^1_F5V-A?ZG=6UEIU
MC=WU[>3);VMI9V\US<W,\AVQPV\$*/)-+(>$CC5F8\ $\5^I?[,?_!%K_@HE
M^U)/I]WX9^ GB#X;^#[[:[>/OC9'/\,/#D5JT@1;VUL=>M5\7Z_:299HKCPM
MX7UZ-T1GR$VLW^CG\*_V9_V=/@9%'%\&?@1\(/A7Y4?E"?P!\.?"7A2\=#G/
MGW^BZ39WMR[;CODN;B61\G<QKV^O/Q/&%62:PF$C3[5*\W4?K[."@D_6<EY/
MK^5<5_3WS>M1JX?@C@7!9;4DG&&9\2YC5S2<4].>GE67TLNI4JL=X>US'&4;
M_'1FKI_S8_L1_P#!ME^S#\"I])\;?M1:_+^TY\0+,Q74?A.2RF\._!C2;M=S
M".?0//EUWQT;=BJ^;XCO[#0-0C#)?^#&#8']'>BZ+HWAO2=-T#P[I.F:#H6C
MV=OIVD:+HMA:Z7I.E:?:1K#:V&FZ;8Q06=C9VT*K%;VMK#%!#&JI&BJ *O3S
MP6L$US<S16]M;Q23W%Q/(D,$$$*&26::60K'%%%&K/)([*B(I9B%!-?AU^W%
M_P %Z?V0OV58-8\)?"[5;?\ :7^,=LMS:1>'OA_JUNWP^T#4D$\2GQ9\1X4O
M-*E%M<Q-'<Z3X0B\2:HD\9LM1_L,R"[C\!RS7/*Z7[_&5%M%*U*DF[7LN6C1
MB]$Y/E3TNVS^8I5_'#Z2G%-+#07$?'V;QE>EA</3C1R3(Z->2BZKITUA,@X>
MP<G&,:N+K_4Z=:48NO7JU7=_L1\4_BQ\-O@AX$U_XF_%OQKX?^'_ ("\,6C7
MFM^)_$M_'8:=:1](H(RVZ>^U&\EVVVFZ5I\-UJFJ7DD-EIUG=7<T4#_Q3_M]
M_P#!4O\ :*_X*J_$JU_8P_8;\&>-+7X0^)M8.DC2M*B-IXZ^-/V.;>^L>-;B
M.=+3PA\-K%8CJO\ 8=]?V^GV]E"?$/CK45:"VTSPUYEX<^%W_!3_ /X+U?%"
MS\8^.-3NO"/P!T;6KHV/B+5+#4?#GP&^',2L+34+'X?>&1.U[X[\81VYEMKB
M:*ZUK7I':"R\5>+-&TM[.:W_ *\_V$?^"='[.G_!/WP')X:^$&@OJ?C77;.U
MA\?_ !;\216]QXY\:W$&R5K>2ZC3RM!\,PW2^=IOA32/*TVV*17-^^K:S]IU
MBZ]F-++^'+5<1*GF&<+6EAH-O#X.?2=65DW4CI);337N1A[M<_HS!9%X5?1%
MA'.>+<5D_BK](&C!5<EX0R^K+$\)>'N/LG0Q^>XJT)8C-<')JM3A.%''0JJF
MLNP6 OA^)8_-?_!*+_@DS\/?^">G@AO%OBE])\>?M.^--)CMO''CZ&%IM+\(
MZ;.8KB;P#\.VNX8KFVT2*=(CKFO20VNI^+KZVAN+J"QTNUTO1]/_ &(HHKYG
M%8JOC:\\1B:CJ5:CUD]DEI&,4M(QBM(Q6B1_&'&_&_$_B)Q-F?%W%^:5LVSS
M-:WM,1B:MHTZ5.*Y:&#P>'A:E@\#A*7+1PF$H1A1H4HJ,8WYFRBBBN<^4"BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "OAO]H;]@SX0_&];S6])M8_AYX[E$DJZ[H-G$-*U.Y99"#KNA1F"WF:661I
M9[[3I-/OYIRMQ?2:D(Q;M]R5S/BSQGX2\!Z1+K_C/Q'HWA?1H76-M1UO4+?3
M[=IGSY=O"UQ(AN+J4@B&UMQ+<3-\L43MQ7BY]D^1YUEU;#<083!XK 1C*I.6
M,Y:<<-:/O5Z>)<H5,).,;_OZ56E.*NN=)LYL5A\-B:,H8NG3G22;;J62AWDI
MW3IM+[491:76Q_,Q^S?\ ;G]H#XPGX4:MXNFTC2M!L=1U6]O$MY;Z26QTV\@
M\^UL+=YH$6YN7O7\N:>5([=I)+C;,4^RW']$'P:_9X^%'P'TH:=\/O#%M9WT
ML"0:CXEOECO?$VKJK&0B]U5HHVC@:1FE&GV$5EID<K-)%9)(SLWXB_L&>/?!
M7A']J/7M=\4^*-%\/:-J?AWQ#I]CJNL7B:?IT]Y>7VFFV@-Y<^7;VYE$;E9+
MJ2"+*[3('9%;^B.&:&YABN+>6.>WGCCF@GA=989H95#Q2Q2H622.1&5XY$8J
MZD,I((-?C?@9DV02R;$YNL+@Z^>4LRQ6'>*FXU\7A<)"%&.'5*$I2^JQJ)U%
M[6E"G*O&\93G""C'YWA?#X5X:>(Y*<L5&M.'.VIU(4U&/(DFW[-.\M4HN2W;
M21)1117[\?5A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110!\^?M6:-\3O$'[/'Q6T;X.7%[;?$:^\-&+P^VF7)L]4F1+^REUNQTF[6
M2)[?5M1\/1ZMI^ERQ30SI?W-NT$T4P21?RI_X)5?##]I'P5\3_'NH^-?#/C[
MP5\,I_"][:ZMIOCG2M;T&WUCQLVLZ:^FW.EZ5KD-I/<ZI8V\6MKJ.JVUN\5O
M%-+8WLWVFZMD7]S[V^L]-L[O4=1N[73]/L+::\OKZ]GBM;.SM+:-IKBZN[J=
MXX+>VMX4>6:>9TBBC5G=E521P/P]^,/PK^+$>IR_#3X@^$?'*Z-,L&K#PSKE
MAJLFG/(TBP-=PVLSS0P7)AF^QW+H+:\6*1K66948C&=.,JM.;DU*-[1OI*VN
MV_7WK;JR9T0K2C0JTU!.,VG*=G[NVC>W3W;[-MH](HHHK8YPHHHH *CFABN(
MI8)XHYX)XWAFAF198IHI%*212QN&22.1&*.CJ5=258$$BI*^&/\ @HEX1^,?
MC?\ 9HUW0O@M;ZWJ&M/K^BW/BC1/#9G.O^(/!$,6H#5M)TNWM2+V_EDU&31K
MN[TRRWW.I:;9WMDD%TLSVLTSDXQE))RLF[+=VZ?U^)<(\\XQYE'FDES/97>_
M]6]4?;.G:9INCV<.G:1I]CI6GVX86]CIUI!8V< 9B["&VM8XH(@S,68(BY8D
MGDDU>K\D/^"3_P .OCQ\/_!?Q+C^*&A^*_"?@C4]1\/2^!/#'C*RU'2=0AU.
M)-8;Q-JNF:'JL=O>Z9IFH17&B+)-):Q6^K7$"W%IN^SW$L_ZWTJ<G.$9.+A=
M?"]UK;LM'NM%I8=6'LZDH*2GRM>\MG=)]WJKV>KU3"BBBK,PHHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **QM&URRUM;\V?F!M,U&?2[R.4*'BO+=(GEC.QW4E!,J/ACLF26%L/$X&)\
M0?$=_P"%/"M_KFFPVL]W:W.E0I'>QS2VQ2^U:QL)2Z03VTI98KES&1,H$H0L
M'7*-+DE%RW23=UKHMQJ+<E&VK:2^>QVE%%8T>MP2Z[/H4=O<O+;6(O)[Q1 U
ME%(9(!]@E83_ &B*],-S;7<:/;"&6VE+1S,\4J(VTK7TN[+S?;\ 2;O9;*[\
MEM?\39HHHIB"BBB@ HHHH **** "BBB@ HHHH ^:O&08:W<9[RWY'T_M?4O_
M *]<I7:^/1C7YT"D>4'C8E<!GEGEO\@_Q?N[Z+)]<CJ*XJMULO1?D8/1M=F%
M%%%,04444 >:?&;XGZ5\%?A/\0OBOK(1[+P'X6U+7HK9R!_:&J11BWT+2E!^
M^^JZY<:=IX4<D7)('!K^,?5]9UCQ5KNM>)_$-Y+J/B#Q+K&I>(==OY6+R7FK
MZS>S:AJ-PS'YL27=Q*R+_ FV-<!5%?OS_P %B?BL^A_"[X:?!JPN?+N_B+XG
MN?%WB"%'P[>&? JQ)IT,@!!,-[XFU2VGVM\KOHAZ[#C^?RV7)'N?\_RK6"TO
M\@.8\92>/(-,CM_A_P"$_#GB;5+P213MXM\0MH6@V$! 7==0VMEJ&I:J\VXA
M;2UBMXMJMYUVFY(V^"_C'<^.M!N+#P-J_P *_P!F'Q?\3_%K20:/X2\!^"M:
MUWQII%M+&X;7;L-#9VVG);$H;:XU*XB,DO\ I31/:P2S+]W_ !%\'>._'%GI
M6@>$OB#+\--&GGN9/%VOZ-8B\\8W5D(X5LM)\-3S-%::0MP[7,NI:JTANTCB
MMK>TB*R3M7%_L^?#/0/A#X1\<W4.A:[KWCJU\9>*[+Q9J[V\6L>._$6FV>J2
M3>&C;3W4UK)J%I?>%I])U>WMK.=$U*\NKIDCN+U1"D3;;TV[_);:;Z]?T*32
MUZ]M>]]?2W3<^"?!G[(_[4_@;'C#PGK6@^$?$J6;K_9MKXN2/5[FV8"633[]
MDT^Z\.S[R@+VE]>36BSJK&6-DWK[!^P5^T_\1-4_:L\">'OB=KLWC+0?$.E^
M-?"</A>YM= T[2M0\2ZMH%Y8Z*FK7]IIBQ6UD]X)+,W]Q*+!+B[@,LH217KN
M?BI^T78_%_3U^#/[/+ZWJWC_ ,<R3Z+K>JWVAZMX>M_ GAJ,^5XFO]3?5(+:
MZMKR*W\RQN#''FPCDN%$AU![&"3W+X7?!;P/\&/#L.A^%-.A:_DMH8]<\3W,
M,;:WX@N50&66YN2IDMK#S 39Z3;&.RM(MBB.2<23O,8W:49-15FU>Z>SM;;U
M>VVG0IO3WDKO9;/_ #M^>O0_</2['7+2X\37^G-/<MX TS5]3\16B^#;73(I
MO"EMIUO>:/I=MK0\MKG1_" F6.6[M7D6>:>.W>-))(@_NOQ@^'SZG;_M'?$;
MP^-)FUS]G[PQX!^+?AOPKK5W?:5X<UG0Y_ FLKXDT;3[[2X;I_#.O7BZ5YFA
MZV^EZQI/]ID0:WI<EM=-J-A\#?\ !-C5-9^+_C']N?38;S4=?T/X._LI:CX-
MU;6=0U&_U&"P\??$2YN-<TSP?I(N)YH(IM.\-^!;[4M<"#='-=Z9:*%>&?/Z
MIZ!I.I?$%_VB?!FA1V]SK?Q;_85T.?PY;71?[+J'B&+1_$ND:3;SE")/*GU+
M6+"VE>)A(B2E@=RBK;3NEK;KNMX]]-UK;2]WNV1U^[^F_P"K+3H?Q5?MH?M;
M?'C7/BSI.LZ3HWQ ^#7A?2/">G^%=#TSQ1K&D>-I_$DMMJ.JZO?Z]?>)(M,E
MT#4;RXN=5:SM+;3CYMGI5A917.Z;>$\JT?X=?M1_M1>"[3Q#J7CC2KSP@U]=
M?V5IVN:S!I-K?ZAIDSVLTYT?P]I$D(>VG#Q03ZL%D1LR6\:QLDK_ *">#-:\
M(?&[X9Z=?7^CVFJZ'KUH]EK_ (9URWCN7TC7;!S9:YH6HPL-UMJNBZC'-;?:
M8##<+MAO+62-9HVKYXT*ZC_8S\=ZEI>MG6KO]GGXBW'V[P_K,<,^L7/@7Q?%
M"//TK48H0;F:&\LT,7GQHUQ?VEO97JQSW=CJ*M#C:SE.3@[7L[);6OW739="
MT^R7,O+>V_9W/!? 7ASQS\$O$ME\.?B+\,_@=IE[XBN[@^$_B-\6_#]SKGAZ
M[OW*&/1+7QGH[75E%%.^YK.'4K>T>SN':*Z:!)XR/T9^'=E\:=$N8M(\;?#W
MX2:?X>F^>/6OA=K=SIL=JS)F.>X\+:II<$=Y;S *GVC3K]9T#*ZVUP@(&UI7
MB7X7?'CX?ZZ]_HU_KGPOO+*\%YJGB;P_<:3I.J6]G',;S4?#R:CY.JS2Z5Y4
MCV^LVUE;I%>1[+"[FE61!Y9^S[\&_B1\--'\"ZE;_$K7KWPIK&CK/XO^%?CN
MW-[_ ,(^M]!//IMSX/U6-C=:-J=@#IIU#1+J%;*427UM+(EQ%"5(WBU9MK36
MZTU6C6[6^WW6L2W??1_/R^YZ6U/I2Y@ !X_SG_/KT^AK]?/^"0?QJ?1/'?CW
MX :M=D:9XWTZ3Q]X-BE?Y(/%7ANWBMO$ME;AN%;6/#1M]0:-.9)/#K-@EB:_
M)&[QSZ<YQ]1_2NH^#WQ*O?@W\7_AM\4]/=TF\"^,='UZZ5"1]IT>*Y%OX@LG
M ^^E]H5QJ-FR'(83<C@5JKRB_E^"7ZDG]H=%1075I?6]M?Z?,MQI^H6UM?Z?
M<*<K<6%]!'=V5PI'!6>VFBE4C@AP:EK( HHHH **** /I7P40?#UB5Z!%4_[
MZ1QI*>/659#Z\Y(!X'5USWA:T^PZ);6W=)[_ #[YO[G:?Q7:1[5T-82W?JS=
M;+T7Y!7\]7_!5+_DX_P]_P!DD\-?^I/XVK^A6OYZO^"J7_)Q_A[_ +))X:_]
M2?QM7X[XY?\ )"5?^QKEW_I54^?XG_Y%<O\ K_1_.1^:E%%%?Q@?G 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5]
M[_\ !-;_ ).K\+_]BQXT_P#3%/7P17WO_P $UO\ DZOPO_V+'C3_ -,4]?6\
M!?\ ):\*?]C_ "O_ -2Z1WY7_P C+ ?]A=#_ -.1/Z2:***_T#/UD*_EG^*'
M_!LEX7^(GC/Q[XZM_P!LCQ)H^L^./%_B/Q<T=[\$]-URSL+GQ)KMWK5U;2I%
M\4-%N=0$7VR6W2?[59N[A+ATP&@;^IBBN?$86ABE%5Z?M%!MQ]Z<;-V3^"4>
MRW^1\IQ5P/PMQM2PE'B?*HYI3P$Z\\)&6+Q^$]C/$1IPK24L#BL+*3G&E37O
MN7+RWARMMO\ SN8/@'\4?^"8'_!6/X%_!7PM\9+K6]=T[XK_  #@OO&?A2QU
M#PA;>)?!_P 2O$OAK^U?#6M^'YM4U9)].O\ 2;^XTW5]*N[_ %*PND;>&9EC
M:/\ T1J_AP_X*J_\IZOA!_V47]C3_P!//@VO[CZX,KA&E4Q]*":IT\2XPC=N
MR2:W;;V2NV[OJ?E'@=@,/DV;>*N19>JM+*LHXREA<NPDZ]:O##4(?6Z2C&5:
M=2;DZ=*E&=24I5*GLX.I.3BF%%%%>N?T$%%%% !17\>__!UY^V?I7AKX=_!/
M]A?PYK.N67B;QA?VO[2_QD.E:_XHT#38OA3X9;Q?X-^&/A/Q7H\.@Q>%OB+X
M>\??$2W\6^.(K"7Q;/<> ?%?[/7A77=5\(2W7B+P7XATKX)_X-=_C]J7P%_;
MW^,G[*/Q*T-OAYK'[2_PVGT.Y\*^,_!7C>R^*>E_M!?LN7WBSQ/8?"[48(T2
MP\ '1?AUXH_:2U'X@V/Q T2QG7Q/X$\->'+#7M%U]E\-^+OIUPS6?#DL_P#K
M*YXR]HLO]C^\>!^L+"?7?:>UOR_6'*/)["WLXNK[3ENE\1B>-L/A^+\/PL\%
M*5*JJ-&OFWM^6CALRQ6&Q.,PF72H>P?/4Q&'P\90FL1%J5:$72LN9_W_ %%?
M!O\ P4+_ ."A_P %O^":OP?\&?&OXZ>&/BCXK\*^.?BOI/P>TG3_ (3:+X3U
MWQ!;^)M9\$>/_'UK?:C:^,/&W@33H="CT?X<:Y;3W-MJMWJ"ZE=:5#'IDMK/
M=WEC^1FB?\'4?["/B?5=/\/>%OV<?V]O%7BG7=;L?#7A3PAX8^$?P8\0^+/&
M?B/5[VWTK0/#WA'P[I'[1-YJNNZ]XDUF[M=%\.Z):6S:KK.JW-K9V-G+)=VO
MG>7A\ES7%X6>.PV!KUL)35:53$0BO90CAXJ=9RDVE%4XM2=^FU[,]O'\2Y%E
M>,I9?F&:87"8VM&C.CAJLFJU6.(JRH4?9Q46YNI5A*$8QO*\6VDDV?TRT5^$
MO[7'_!Q!^P'^R#\>?%_[//B"R^-?QA\7_#X0Z=X[U[X%>&_AUXI\#^%/&R7F
MHVFN_#2_U_Q;\5? DU[XY\&FRMD\:V>A:=JVB^&M6U$^#]0UV/QWX=\;>%O"
MWUK^P-_P5@_8U_X*.0ZOI?P!\::YI?Q/\,Z!)XK\6_!#XFZ$OA+XI^'?"P\4
M:AX6M_$B6MGJ&O>#O&&AO=6^CWNJ:E\./&7C2V\&6_C3P'I_Q ?PEXC\7:1H
M4Y7R;-<-@Z>88C+\71P550<,34HSC3:J6]G)MJ\(U+KV<IJ,:G-'D<N:-W0X
MDR'$YG4R:AF^ K9I2<XU,%3Q%.593I*]6FDG:=6DK^UI0<JE/EJ<\8^SGR_I
M+17\^7QQ_P"#F/\ X)G?!WQ]?>!?#6H_&C]H>WTM;R#4?'_P#\$^%-9^&ZZQ
MIVO:WH5]H^C^)_B)\0OAH?&4"C1X=<TSQGX$L?%'PT\4>'->T+6/"'C?7X+J
MZ6R^LO\ @GU_P64_8W_X*1>+?$WPV^"$OQ5\(_%?PMH.O^-+OX:?%GP#_8NM
MWOPZ\.7W@#1=0^(&G^)O!FL^/?AG_8S>)_B-HOAFUT'4/'FG_$"?4+/6-1'@
MM?#-K;:_>WB<BSC"82..Q.6XNAA)<EJ]2C*,$JG\-S^U3C-V495%%.4HQOS3
MBGGA^*>'<7F4LHPV<Y?7S*$JD'A*>(A*JZE&[JTX?9J5*:4N>G3E*<>2I>*]
MG/E_5NBOYU_B]_P<[?\ !.'X5?%#QU\-=+T7]H7XR67@?79/#Z?%/X-^$OA9
MX@^%/C2ZM;6U?4]0\ >(O$GQF\(ZKXE\.V&JRWNA0>)T\/6OA_Q+<:3<Z]X+
MU'Q-X)U'PYXKUS[H_P"">'_!77]D7_@I;<^/] ^!M[XW\&?$3X=>7J6J_"?X
MQZ9X5\,_$/6/ \J:1;CXF^%--\*^,_'&D>(_ MIX@U>+PCKMY8:XVM^$O$?]
ME0^,-"T#3?&OPZU3QB8K(LXP6%CC<7EN+P^%ER?OJM&481]I94^>ZO3YVU&/
MM%&\G&*]Z23>%XIX=QV8RRG"9SE^(S&#J1>$I8B$JDI4=:L*=GRU:E-*3G3I
M2G.,85).*5.;C^H%%%?YRO\ P<1?\%$]5_:Y_:OU#X!?#W7OB5H_P0_94U7Q
ME\,O$'PS\967AS0_#FJ_M2?#KXF_%CP!\0/BKI<7A?6=>NO%.A7OA&W\+>'O
M 6L>,KNVUGPYIC>,DT3PEX.D\9^+W\4]/#N08CB''/"4INA2ITIUL1B%2=;V
M4(QER)4E.G[2=2:4(1]I!7;?-HD^3B_BG"<(Y1/,\13^L574IT,)@_:J@\57
MJ22<%6=.JJ<:=/GK5)^SFU3IRY82=D?Z-5%?R5_\$4OBC_P2N_8._8M^.W[:
MFB?'?]H/P=X'\<?$_P""_P"S)\8_$7[3_A?P/I<WBSXY_"[P/-XTM9_@!\&/
M@._Q5\;1Z%XHM/CYXA\0W/A2Y\9?%;Q1X6\(>$-9UG6]1B\*?#_Q3X\U7UX_
M\'7G_!/46GVD? []MAIOLWG_ -GCX?? 3[69?*\S['O;]I06'VG?^XW&]%IY
MO/VKR?WU$N&\TJXG'4LNP./QU' UZF'G7^IRHR=2EI4@Z7M*J56+33HPJU9K
MW7;WHHRH\:9)2R_+,7G.8Y5E-?-*"Q%'#+,8XJ#HRJ3A3JTZ_L,-*="<8INO
M/#TJ49\]/F;@Y/\ IVHK\S_%W_!6[]BW2/V&/'__  4.^'GC;7OCQ^SS\-?%
MOA_P+XI'PH\/&W^(VF^+_$'Q.\%?"R+P[JG@#XJ7WPPUCPOK%EJ?Q!\+>*IM
M-\:GPS?:C\.M7TCQUX<M]<T#Q'X5N=>_+D_\'7W_  3O5KKS?@M^VG!!:*KM
M=S?#WX$I;R*8S+*8S_PT>9 MN@7SI)HHHMS;8I)3'.(N7"9'FV.I5:V$R_$5
MJ5&K.A6G&%E2JTX>TJ0J<S7(X0UES62ND]6D>AF'%'#V5.@LPS?!87ZUAXXK
M"\]6ZQ&'G*,(5J$H*2JPG*<>5TW+FB^=7@G)?T[45P?PK\>?\+2^&'PX^)P\
M&^//AU_PL;P'X0\=_P#"OOBIX=/A#XG^!/\ A+_#VG>(/^$-^(_A(W=^?"_C
MSPQ_:']B>+_#IO[TZ)XAL=1TTW=S]F\Y^\KRCW@HHHH **** "BBB@ HHHH
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M;AS2FN:5O<YI*_Q."G\4.8_?BBBBOZ(/K@HHHH **** "BBB@ HHHH ****
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M?"OPMT'7/!_CA;3QCX^TJ-+3PI8W%U\3OAW\3?$WQ-H_CKXF^/?'OA_PI8>
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M3_@YU^)O@CXU_P#!+#]B_P",OPRUL^)?AM\6_P!JSX*_$WX?>(SIFL:*=?\
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MSHX?$RP\9T[Q<8/DDZ;5_P"B*BBBOST_8PHHHH **** "BBB@ HHHH ****
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MM?K<****^M.\**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MK) 5DVO&S96W=+@RQ2<(DD-TMA&X;):*Z<*O5EM_M":0]S\,_'FH6T8-U#X
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M'C3_ -,4]?!%?>__  36_P"3J_"__8L>-/\ TQ3U];P%_P EKPI_V/\ *_\
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M\1S9E@\/1Q>)PWLJZ]GA\0VJ-3VTJ:H3YVG[M.K*<?M1B?<5%%%<9Z(4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %?GUXL_X)E?LM^-/%7B7QCKF
ME>-9-:\6>(-9\3:P]MXPN[>W?5->U&YU34'@MUMBL$+7=U,8H5)$2%4!(7-?
MH+14RA"=N>*E;:ZO:Y<*DZ=W"4H7WL[7MJ?FU_PZE_9'_P"@/X[_ /"VO?\
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /\ +V_X.';2PO\
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M_P"S_P##33OAQI&J)XYBL? OC#X3V&A2VNN?J'\"OV>_^"E__! O]D_]I_\
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MBE_B-X+\?KIOB'0_!GPVU?P_8?$#PEXPTCQ3X8_;CX=_&;]E_P#;3_X)G?\
M!2'XY>!/^"-_@?\ 8OUSP!^PC^VSJOPU_:/\+_!OX*M\-];LM1_9Z^*/PTU'
M3_A7\<+/X=?"#Q_J_P 0+ZZ/Q<\'^.-&^'?@+Q#X2\(>&O#MYI?C_P"(ND:S
MX^T/P5J'I<25%'#XFG/ 8NK@I8_+O[)QM3$Y5++\)^^@Z;RBEAZ=+$NA7PRE
M2K1C+$*"LZKA-N4O)X#HU9YSDU5YM@,+GE.682SS +!9]_;N/B^>.)I9[5Q%
M:O@&Z4Y4ZV%J3I8>,6H>P?-%Q7YI_P#!JM_RE$^)G_9A?QN_]:&_9%K\T_\
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MX<\1W5I(T6GW?B+PWHFN7-D7?[1!;Z5=:K8WD]I#!:75E$J6TD2JX(QD9/\
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MP$#)2^C,17[\>.*Z/1OVV/C1X*V:=XVTO0]=DC"@#Q9HU]X5UME(&UI9[/\
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M+I@OO"V1\)/V+]7^ '_!MY^WI^UAXV.MZ3XE_;;\4_L9:EX5\-ZDM_I]E9?
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M6,>HN%W+;:'9R?VAKMU)C[L4&DVEV2Y^7>47JR@_TM:>(([VS AQ:6\T)\A
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M9=:N=,"SGPI<>$9?$DOQ"+*MA_PA#^)/[2 TS[6*^J/VP_\ A/?^&XOVQ_\
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MG4/"GB:S\)W.GZWXS\*62R>"_A1%/XQU7P9'KEQH%I8>+K[7])L-.U_XB0>
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M/XC^&_@/X+_#SX@^/_&WA[P1X5UBYOEOOBAXF\+?#GQY97?CWQ9X-\4_#_\
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M (U^&][\/_!EKXSO=0\3Z[H6KVNH6]UK=GH@LK6/2HXYHYTENUG,LN(S&A4
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M?A[^Q)^QC\(_&&B?$+X4_LB_LP_#'Q]X:-^?#GCCX>_ /X5>"_&&@'5=)O\
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MB-6EBL+*.&PU.57$5H1Q>'H.O"C2C*I4=!5.2$7)I)7.&_X**_\ !>3]CO\
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M:Y)J>G6'V#XB^)!J>E6ECK-PVDW>HSZ%IGUG\"_^#H#]BCX@?!/XB_$#XO\
MP]^)WP<^*7PPT70M?U+X*Z7J/@SQY=?$BQ\1?$NV\!1VWP*\::WK/PQT_P >
MZ]X4TG6O#'CCQ_X9\4Z-\-_$.F^';SQ/J/@O3?B#H/@#Q9XAL?>J\'<34*5.
MM4RC$<E6=.$%"5"K44JTHQIJI1I59UJ5Y246ZL(*#=IN.I\KA_$;@G%5ZV'H
M\081U*%.M5J.I3Q5"DX8>$JE5TL17H4Z&(<81E*,:%2I*HDW34C^EBBOS)_X
M)S?\%6_V>/\ @IU_PN/_ (4)X-^-'A'_ (4C_P *]_X2O_A;WAWP/H/]H?\
M"RO^$X_L+_A'O^$,^(OC[[7]D_X0'6/[6_M+^R?(^TZ9]C^W^==?8_F/]L?_
M (."/V-/V(?VC_B-^R_\5_AG^TWX@\??#'_A$/[>U?X>^#/A7JW@^[_X33P)
MX7^(6E_V1J'B3XS^$]:N/L^B^+-.M=0^V^']/\K5(;V&W^U6D<%[<\%/(<XJ
MXZMEE/+\1+'X>FJU?"J,?:TZ4E2:G)<UK-5Z+T?_ "\B>K5XJX=H97AL[JYM
MA(95C*TL/AL=*4O85J\77C*G!\MW)2PN(3O%?PI>5_W2HK^5?]K?_@Z8^!GP
M0^.?BKX6?L\_ )?VJ_ ?@Y8M)OOC;I_QNM_ASX/\3>,+>XO(]?M?AS;V_P *
M_B./&?@320ME9Z;\24U72]+\8:HFLW?A+3-7\"P>%O'?C/\ 3G]A[_@K[\"_
MVKOV%OB/^W3\5-'3]EKP%\%/&_B[P)\8+?QCXK@\9Z%X?U7P]I_A'7](D\)^
M)=)T+1-<\</XLT/XA^!M-T+0+?P'I'C'6?B-JUU\/?"WAKQ/=CPYJWBG3$<.
M9WA,'A\PQ&7UJ>%Q4Z4*$W*E*I.==7HQ^KPJ2Q$)5/L*=*+D[):M7QP?&/#.
M/S'%Y3@\WP];'8&G7JXJG&->-&E3PS2Q$_K<Z4<'.-&_[R5.O-1LV](RM^M]
M%?QY^/\ _@[A^'^G>,-8L_A7^P[XS\8_#^'^SCX>\2_$/X[:'\,_&>I>;I-A
M-JPUOP+X9^&'Q<T+06L=<DU/3M/^P?$?Q*NIZ59V.LW#:3=ZC<:%I?7_  +_
M .#LKX(>+OB'I_A_]H7]E+QK\#OAUJ2V=FWQ*\#?$^#XZ7'AW5+[7M$T\ZCX
MI\#?\*T^&&M+X(T?0KO7O$7B#5O!EWXX\;I_8EIH_AGX:^*K_60=/[I\%<44
MZ#Q$LHK>S4/:-1JX6=91M?\ W>%>6(YDMX>RYT]'&Z:/,I>)7 ];%K!0X@PW
MMY5/91<J&.IX=SYN56QE3"QP?*WM4]O[-K52:U/ZW:_$#XS?\%Y/V._"W[2W
M[-7[*_[.^MZ%^UA\0?CG^T'\*_@WXR\1_#;QB(/A5\)O#'Q.U'PII=GXYM?B
M?9^&_$_A'XMZVESXUT?^SO!7PZU&_P!,#Z/XVTKQOX]^'WB7P_IN@^(_M;_@
MH)_P4$^#7_!-WX->&?CC\<?#/Q.\5>$_%7Q.T;X4:?I_PHT;PKKGB*'Q%KGA
M7QIXOM+V]M/%_C3P+IL>BQZ;X%U>"XN(-7N+Y+ZXTZ*+3IK>:YN;3_+Q_9,^
M*_AWX#_M4_LS_''Q?9:UJ/A/X,_M _!GXK^*-/\ #=M8WGB*_P##OP[^(WAO
MQ?K=EH-IJ>HZ/IMUK5UINCW,&EV^H:OI=C/?/!%=ZC8V[27,7J\(<)0SO#8_
M'XR&(]AAZ3C@:=-J$,9B7"OS1E4^.U"<*5X0Y'*56/OJ*<9>!XA>(%3AG&93
ME675<']:Q==2S2K64JE3+L$JF%]G.-)VI<V*IU*_+4J>TC"-"=J3E*,H?Z^]
M?R5_LW_\'2'_  T%^T/\!?@+_P ,,_\ "(_\+N^-'PN^$/\ PE?_  TU_;__
M  C'_"RO'&A>#/\ A(?["_X9\T7^VO[%_MK^TO[)_MC2?[1^S?8_[3L/.^U1
M?L]_P3F_X*M_L\?\%.O^%Q_\*$\&_&CPC_PI'_A7O_"5_P#"WO#O@?0?[0_X
M65_PG']A?\(]_P (9\1?'WVO[)_P@.L?VM_:7]D^1]ITS[']O\ZZ^Q_S5_LF
M?M'?\&XFN?M4_LSZ)\#OV!/VM?!OQKUC]H'X,Z7\'_%_B3QEXINO#OA7XI:A
M\1O#=I\/_$FO6UQ^VKXJM[C1=#\63:1J>J03^%_$D,UC:SQRZ#K",VGW&.1Y
M/0I+/<-G7#^9XW&8.AAI4EAFX_V?*K0Q-95,4HX["IQJQ]C4A[N(]VE/W8WM
M/HXHXCQ5=\+8SAKBW),LR[,<5C85GC8J?]KPH8K!8=TL"YY7CVIT)_6:-3W\
M)[]>G[\[*5/^XJBBOYH_VSO^#G?]CKX :^W@K]FGP=K'[9?B?2];?3O$_B/P
M]XI_X5=\%M/MK"_\6Z-K<7AKXG:IX2\8ZI\0M9L]4T+0;[1]0\&^ =3^$WB_
MP?XKMO$WACXO:E+8/HUW\ME^5YAFU;ZOEV$JXJJES25-+EA%NRE4J2<:=*+>
MBE4G%-Z)W/N\WSS*<APWUO.,?A\!0<N6$JTGSU9K5PHTH*=:M-+5QI4YR2U:
M2U/Z7**_C:\/?\'=&@W/B+P_;>*_V"M7T7PG<ZYI-OXJUKP]^TK9>)_$6C>&
MIK^WCUW5O#WA?4O@5X1TSQ-KFG:6UU>:3X>U+Q?X2L-:OX;?3;SQ/H-O<R:K
M:?TV?L<?MS?LS_MW_"[2_BA^SI\2-%\4))H6@ZQXR^'MUJ6C6_Q7^$=YX@GU
MRQL_#GQ:\"66J:EJ7@S69-4\+^*-/TRZG>Z\->,(_#^H:_X!\0^+?"4FG^(;
MWLS/AS.\FA&KF67U</2G)1553HUZ7,]5&57#U*M.$G9\L9RBY6=D[,\[(^,>
M&>(ZDZ.39M0QE>G%SEAW3Q&&Q'(K*4XT,91P]:I"+:YITX2C&ZYFKJ_US17Y
MD_\ !1G_ (*M_L\?\$Q?^%.?\+[\&_&CQ=_PN[_A87_"*?\ "H?#O@?7O[/_
M .%:_P#"#_V[_P )#_PF?Q%\ _9/M?\ PGVC_P!D_P!F_P!K>?\ 9M3^V?8/
M)M?MGR/\:O\ @X@_8H^%'[)OP=_:4TSP_P#$[Q5XN_:(T7XDZO\ !S]G:YB\
M&:'\4/L/P]\6?$#X<KXO^+5SIOBSQ7X?^&7POUWXD> +KPOIWBVTO?&OB35(
MKR\U'P?X!\8S>#?'VF>%\\/D.<8JCA<1ALOQ-:AC:TJ&%JP@G&M5A[;GC%WT
MY/J]9SE+EA%4IRE))7-L7Q5P[@,3C\'C,WP>&Q668>&*QU&K-QGAZ%3ZO[.<
MUR^\ZCQ>&5.$.:<Y5Z<8Q<I6/WNHK^-OPY_P=T:!<^(?#]MXN_8*UC1/"ESK
M>DP>*=:\.?M*67BGQ#HWAR:_MX]<U7P_X8U/X%^#M-\2ZWIVEM=7FD^']1\7
M>$[#6K^&WTV\\3:#;W,FJVG]0_[('[7_ ,"_VY?@7X6_:"_9]\4_\)#X,\0[
M]/U?2-12ULO&7P]\96-K9W.O_#KXBZ!;7FH#P[XU\."_LGO;)+V_TK5=*O\
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MO3%L?[=NM+:^M+_Q1?V%HO\ ;JVDZPPR&6SCD\F#Q>BO#J^)G%-;%\+XR=7
MJIP=G-#.N'J5++\/A\+E]7"UL#7PF"IX7#JE0_LW#5L!"I1PO(FI5\4Y59^V
M?+YN*S;%8O+L3E,HX:AEV+KX/$U<+A<-2P\/K."P^8X:&(3IQ4G6K0S3%NO.
M<IN;=&$/9T:%*E#K?B'KUGXM^)7Q2\9:='<PZ9XW^*OQ/\<Z5!>I%'?V^D^-
M?'OB+Q3I5OJ$4$US;Q:C;Z?J]M#J$-M=7=M%>)/';7=W L=Q)Z3??$_0+G]D
MSX)_ >.SU@>+_AO\1/CKXNUS47M[(>&[O3?B=\5_'/CK0(-)O%U!M3GOK32/
M$UA;:O'>:/8P6^HPW<-E<ZA;1PWEQX317S6'X@S'#91GV24I4E@.)*^58C,X
MRI)U9U,FQE7'8)T:E[T5&O6FZB2?M(VB[)"J9KBZN<YAGTW3_M#,\/G>&Q4E
M!*DZ7$%2G4S'DI7M"4I4X^R:;]DKI7N%%%%>(>:%%%% !1110 5][_\ !-;_
M ).K\+_]BQXT_P#3%/7P17WO_P $UO\ DZOPO_V+'C3_ -,4]?6\!?\ ):\*
M?]C_ "O_ -2Z1WY7_P C+ ?]A=#_ -.1/Z2:***_T#/UD**** /X</\ @JK_
M ,IZOA!_V47]C3_T\^#:_N/K^'#_ (*J_P#*>KX0?]E%_8T_]//@VO[CZ\K+
MO]XS+_L+?_MQ^$^$7_)6^,W_ &757_TO'A1117JG[L%>6_'+XN>&_@!\%/C#
M\>/&5EK>I>$/@G\+?B#\7/%6G>&;:PO/$FH>&_AOX3U?QEKEEX?L]5U+1M,N
MM;NM,T:Z@TFVU'6-*L)[^2WBO-2L;=I+J+U*BJ@XJ<'.+G!2BYP4N1SBFG**
MG:7*Y*Z4N5\M[V=K$R4G&2BU&3BU&3CS*,FM).-US)/6UU?:ZW/\I+]IS]J_
MPQ^W1_P4&\7_ !__ &J/B'\>+O\ 9X\1_%SQ'#I"^%_"_@36_C+X%_97T;Q7
MXGU;X6?!_P"'_@W4O&/ACX7>%/$%MX5N]-\.ZCJA\0ZSHNA>,/$/B_XO:Y8?
M&+Q7<:[8>/OZB_@=_P %S/\ @E__ ,$KO@%X _9"\'_#[]OCQIX)^%WPT\(?
M&70]=\4>$_V>?$/BN[\._M:>!="_;;TC3M4U/2OBW\.](N-8T+1/VAK'PY?6
MMIX9T^RTW4=*N-)M]5\2VUE%XMUO\MOV ?\ E:+\5_\ 9]__  4\_P#46_;!
MKX,_X.+59_\ @J]_P4051EF/P5 '3)/[$?[.F.3@?G7[#F]'!9MBZ.4SH8BC
MA,MX4J9KAJ,,5>C&LL-0^K1C2C0IJ+HQYXU)\TOK'.GR4N2TOYTR:MF>0X7B
M3B:.+PF*S/$<<2X>Q&*JY?:M.B\?AUBY^VEBJO)AZR=-T,(H6PCIWC7JII1_
MO<_X*.?\%:/V<_\ @F%J'P4TWX^>"_C7XNG^/%E\4+_P@_P@\.>!=?BTZ'X2
MW'PUMO$:^)&\9_$?P ]G)>O\4_#YT0:8FL+<I9ZR;]]--O9+J'Y/?\%./^"Z
M7@?6O^"6OP[^*/[+$G[1'P?^(_[>UE\9_"WP \;7&A> -#\2?#O3/V<OVA?!
MWPF_:"F\7:MH_P 0O$EWX%USQ5X2N_%UC\*?%/PZD\3>)]*N]1TSQ);ZO\.?
M$^GZ?JNE?)/_  =[*W_"4?\ !.%\?*/#W[:B$_[3ZG^QXRC'7D(QSC QR1D9
MP]&_Y4XG_P"QUUG_ -?"7U?+Y5EF74:?!F85L-/$3S/.,1AL52G5M2FJ6+IX
M?#/DE3J1<*4YQJ5:3BUB(PE1E*"FY1_0LXSK.*V:\:9+A<93P=++>%Z.8X.O
M'#^TK4:]2%2>(?-&K2FY3I0E"E)3BZ$YQK14G!1E\_\ _!'S_@O#^S?_ ,$\
M?V>OBWX _:G\-?M/?%7XJ_&[]KOQ?\;+_P ;> M&\!^.?[;NOB;X%^$WAB]U
M?QGXD^(OQ@\$^(]2\8ZKXN\&>)-=\2W\UEJTE\NJ6NIS:M?ZG>W]O:_U8?\
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M_P )+_PBW_)2/&OC#^R_[+_X3#Q%_P @;^SOMO\ :/\ Q,?M?V2Q^S?YDO\
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MC3PM'$X.O6JT:$(4J3J3R''NHU3IQC&//.E"K.R]ZKS3=W)G]GE%%%?DA_0
M4444 %%%% !1110 4444 %%%% '\P?\ P5@_Y.TOO^R>^"__ $#4J^K_ /@B
MS_Q[?M'_ /7?X2?^B_B77RA_P5@_Y.TOO^R>^"__ $#4J^K_ /@BS_Q[?M'_
M /7?X2?^B_B77FT_]]E_BJ?DSV*O_(O7_7NC_P"E0/W-HHHKTCQPHHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** *M]?66F65WJ6I7EKI^G:?;
M3WM_?WUQ%:65E9VL337-W=W5P\<%M;6\*/+//-(D442-)(ZJI(X'X>_&'X5_
M%B/4Y/AI\0O"/CD:-,L&JKX9URPU673WD:186NX;69YH8+DQ2_9+ET%M=B-V
MMI951B.-_:?^%>N_&WX!_$SX6^&=7@T+7_%NA16NDZA=O-%9&\L=4T_5X]/U
M":"*>>#3M8_L\Z/J-Q%;W,D%E?3S);7#((7_ #C_ ."<_P"Q'\<?@!\4?%/Q
M(^*L>F>&+&7PCJ/A#3O#NGZ[IVN7>NS:AJ^D7_\ :EU)I$]Y86NEV<6CE[:*
M:Y34Y;FZA+6UK%!.D^4IU%4A%4W*$E[TOY?\K;Z[WTV9O"G3E1J3E449Q=HP
MTO+;IN[ZK3:UV?LM1116I@%%%% !7PO_ ,%$_"'QB\;_ +-.N:'\%X-<U#6V
M\0:-=>*-$\--<?V_X@\$PPZBNK:3IEM:,MYJ,DFHRZ-=W6EV@DN-1T^SO+1+
M>Z\TVTWW16%XF\4>'/!FA:CXG\7:[I/AGP[I$'VG5-<UV_M=+TNP@+I$KW5[
M>20V\7F321P1*SAIIY8H8E>61$:9I2C*+;2::;6C2[W+IR<9PDES.,DU%J]V
MGHK>9^5G_!)_X<_'CX?^#?B6GQ0T3Q9X3\$:GJ'AZ3P)X8\96>I:3?PZG$FL
MOXFU;3-"U6.WO=+TW4(KC15DG>VBM]7N(%N+7?\ 9II9OUPKAOA_\3/A_P#%
M70_^$E^''C#0/&FA+<O9RZCX?U&#4(;>\C1))+.[6)C+9W:1RQ2M:W<<,XBE
MCD,>R1&/<U-**A",8MR26DF[WOKTTMVMT^\JM.52K.<H\DFU>-FK62776^EW
MYA1116AD%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0Z!(QN+&&:4*FF7\47F2N_FH3 5<."A(X+][E[M:>35TUHK]-'^96GFE]_\
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M^3%%?67[/OP(^%GB;P!\/OC_ /M)?&FP^#WP?^)^D>-;SX8^!M,M+#7OBO\
M%O1-)\1Z3I/A[XP^#=4\/:GXSL(?A->Z3/9^)=/FL? _C"Y\3^&?B5\/-<U;
M6?AE*D>B^++'QL^!WP.T[P7\3_C;^SI^T%I?Q"^%?P=T+PK??%7P=XLT:\T/
MXC_#'3M2N?$#7WQ3\1ZK?0^&A=_"S4[6W@BM=3F^'?AW1?"X\#?$?6+SQUXH
MM-*\0V/P_P"+,/#;BG+,+C:V)H8)XS*\"LRSG),/F.%Q.?Y+@/;4J4L5FF4T
M*D\3A*5'ZQA9XIR4OJ4<52CC%0K0Q%*CQX3)L=C:>&G1C353'TIU\KPM6K"E
MB\WI0E5BIY7AYM3QOMGA\4\(J2;QWU:<<$L14J8>%;Y%HKV']F+X-^(_VFO$
M'[:WP]\*K:CXB_!?]F+X5?$GX!VMS?PZ1H'B#XP_%+4OVG-"TO1_B9?7<-VT
MG@-=8^#_ ((65="D\.:M9VFH^)Y9=:N#<:9_9/TY\,?@!^QW\8='T+X7_#;]
MK)?&G[2_BW2?&FL>#-5TOPAXHLO@'XQD\&:RNHW^D>$_$6H>$$T_Q1:7?@V1
MG\+^)M ^)&H7/Q%\.:5XA^/'@#P;KOP[T#7/#FE=M'PHXOQ&$P&+H4LMJSS7
M)Z.=Y5@(YGA8YEF>$JX#%9G*.!P,Y0K8BOA\%@ZM?%P@G#"P=.=>I"$G**PF
M48K&4J.(A/#4L-6Q\<L>)Q.(AAZ%''588*IA</6JU+1A5QT,;?!07-+$?4\<
MH*^':E\!45]E_"_X.?LV>"9=;\.?MQ?'#_A4/Q:L;[PU9ZQ\(_AQ._C)?@Y'
MXIU_5E\--\:/BYH/A#QW\-]'U_7O >I_#[Q_XO\ #?VG1=)^"/AC5F\7^*_'
M'BGX<>)/#GCE/GWX\?"_6/V?OCYXZ^ ?B;5M+UW5_"WASP%X[T'7=*L]6T]?
M%/P\\?V>L:=H_BF^TJ]MI[#PU?R^/O WQ1\*'PM8>*_&5Q:6'@_3_$%_JUNG
MB>RTZU\;/>!.(>'LNI9MCJ.#K8">+EE^(Q.79C@\QI8#,X8?#8J>68Z>$JU(
M4<=3HXJE*I1C*I[*Z]I**JX=UKED>94\/CJ]2C&G++*>%Q&882=6DL;A,'CZ
MZP^!QU?#*3G#"8VI.A]5JO\ C0Q-&I"+@YN'FU%?9_P*^ 7P6LOAK\-?BC^V
MA\6=2^$%W\>/AQH?Q*^&/P9\#:-J>O\ C?P?X4U*_P!3U#3];^*/C#3?#?CC
M14UGQ5X0UOP+N\#V'A;2+#P9XOT7XA:/HGQ)^,.GVCZGX;Y3X]?![X/^&OAT
M/V@/V>_C':?%#X'1_%6+X.^*_P#A)X$\'>-OA3XXO8]%TCPWI/B^U\20^%;O
M5F\<>++^SM_#*IX3\+ZSJ6G_ !#^$%_X3\/^.O"/C%?'\?=G7AIQ3D5+-98N
MEEM?%9 \/'B'+,NS; 9AFF0O$5:6'BLTP6%KU*M#DQ6(P^&J\GM>2K6A+6BJ
ME6"PV2XW%0A*DJ'M*V!J9GA<-4Q%&GBL9@:.&EC9XG"T)RC.M3^J0JXBG9)U
MZ=)_5U5G4H1J_+=%%%? 'DA1110 5][_ /!-;_DZOPO_ -BQXT_],4]?!%?>
M_P#P36_Y.K\+_P#8L>-/_3%/7UO 7_):\*?]C_*__4ND=^5_\C+ ?]A=#_TY
M$_I)HHHK_0,_60HHHH _AP_X*J_\IZOA!_V47]C3_P!//@VO[CZ_AP_X*J_\
MIZOA!_V47]C3_P!//@VO[CZ\K+O]XS+_ +"W_P"W'X3X1?\ )6^,W_9=5?\
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MRKYOBE+$5%5CC\14I577P]6#C.BZ=6C3G3BFXJSC)3A*47_$W^T'_P $"?\
M@LO^USH7@*3]IS]N/]GKXMZ_\$?#7A/X:?![2O%?CGXPZOIL/@-[#Q WCCQ#
MXC\5I\#=*U2Z^)TVH:'\-;;5_&?B'PU\0/'_ ,;;6YO-2^)7Q-TNZ^%WA'3_
M !A^MWPN_P""/GQ.NO\ @AYI/_!*/XM?&/P+X'^(D_B+7M8U[XL_#G0=?^*W
M@O3K9_VW]6_:JT>WTG1/$[_!O7-:EU'PR=,\):J]X^@+HNMWNH7UG_;UEI=L
M-7_?:BC%\29GBU@%*6&H+*\1+%8".%PE##4\-4<Z=1*G2IP5+DA.G&48N#3E
MS2GSRE)LR[@[)LMKYAB::QV)KYK@E@,QK9AF&*QU7&4%S)NM6Q%2=9U)0E[-
MRC4BHTXQA",%%'\?G["__!!+_@H+\#T\??LZ?M"?M#?L_>(/^"?W[1>D^,K/
M]I?X)^ =?\0>/]=OO$DGPI\8^'_A9\4?A)I/QI_9JNO"7P_^+?P\^*<OPM^(
M5EX\\/WGAK5;J_\ A9X#U#Q%_P )<OP^\(>'[?QKX+?\$!O^"RG[''B/XX2_
ML<?MN?L[_#S1_BOX:\2?##5M9M_'GQA\$ZQX\^'B:IJ1\&>(-?\ #=O\!OB'
MIOPW^)VG:==W%_X>\7^"O$6O>//@S?\ BGQEI7PU^)\UIK>N:MXB_MHHKI?%
MV:NIC)NGESCCITZV(HRRW"5,/+%4G)PQBHU:<X?6KR;E6DI.I)0=13<(M<,/
M#[((4,OH0JYS!Y7/$/ 8FGG./I8O"X?%4J=*O@*.)I585*>!G"FE]7@XJ'-5
M]G*"K55/^/3_ ()R_P#!N]^UG^Q#_P %&_@+^T]XG^,?[.OCOX)_!'Q?\:IM
M_A_4_B5HOQ0\3^%_&?P-^,?PD\&:FO@/4/AU=^$]"UVXO?'?AW6/$WAW_A:F
MLZ=X?M$UJUTKQ3XIFL+&35^6O?\ @W:_;6N/^"G]K^VLGQ0_9;'PLA_X*7V_
M[9;Z _C7XLCX@'X81?M='X^-H*Z4/@DWAT^/3X./]FKI9\5CP\?$O^AGQ0-+
M_P")S7]FE%<];B7-<17S'$5:E*57-,'# XN7LHKGH4XPC'E5_<J6IQO-;N[M
MJ=6'X)R'"X/+L#0I8B&&RK.XY_@H?69R=/'PE.4>:4KRG0BYM>RDW=6O)[GY
M$_\ !8+_ ()6>%/^"GWP,T72M.\1)X%_:*^"\/C#6/V>_&VK:AK"^!O[3\76
M^@'Q5\/_ (E:/IT.I[_!/Q D\(>%8+SQAI&A:GXW^'>J:+I/B;PY;>(M%B\7
M_#;XA?C[X*_X)(?\' &E?";X.?LOR?\ !3;X9?##]G;X8ZUX>L-*E^$/Q/\
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MY?DK_@UO_9P_:'_9]_X;G_X7W\!?C1\$?^$N_P"&9?\ A%/^%O?"WQQ\-?\
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MG6C.=*^E5RO*7\47_!;G_@@3\4=8^*'CK]LC]A7PGK_Q/L_B;KGC?XE?M _
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M6HH.O7=&D\OJN,)3J*>'JPG5?+[2/,Y4G^[/_!HB?^4A'_=I_P#[\M7Y^?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%8MSXC
MT.TG:VN-2MEG1S'+&A:;R) GF%+EH5D6V<1_O"MPT9$?SD;.:N2ZIIT-I'?R
M7UHME-Y8ANO/C:&=I3B%+>16*SR3'Y88X2[RL0L:LQ I<T=5=76^JT]>WS':
M6FCUVT>OIW+4TT5O%+//+'!!!&\TTTKK'%#%&I>2661R$CCC12[NQ"JH+,0
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M;_PGW_"@O@#_ ,*J_P"2H?\ #N#X<_\ "M_^0-_R/O\ PA?BK_A#_P#D8_\
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MTE'K%^MOD[,_A8JS965YJ5Y::=IUI<W^H7]S!96-C902W5Y>WEU*D%K:6EM
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M8/A)^QEH$GB#0[/QGX>^''Q?T_XA?''QW8+?:--H/P<F\1_'+7=$L_!WP_\
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M ,AY_P!69R_V3F?_ $ XK_P5+_+^ODS\^Z*_03_AV9^U)_T"O!?_ (6%G_\
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M/VC/@3\:OV?/&U_KVE>#/CM\)?B/\&O%VI^%;K3['Q/IWACXG^#M9\$Z_?\
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M.L;KPAKGZK?MM?$7XK_\%_/^"H%E8_L<?#/4D2_^$G@;X6_#&'QYI47@[4/
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M=V=M<+\#O$GB+QMI?A7Q!=Z<=)\/Z[X*\$:3X775/&&A1?M 77QP:'6_%_P
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M*:VN$66..5!)&VR6..5-LB(PV$1(T2.-%CCC541$4*B(H"JB*H"JJJ %4
M  8IU% 7"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MR*;+XC^$?&_@F&(N.LVNZOX>3PM&B]'D.O&-3U; )'Z1_#SXM?"SXN:0NO\
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M.7-)-7E=N]TFG=ZWL]>ST"BBBK,@HHHH **** "BBB@ HHHH **** "BBB@
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MI-I<_OIGCC426L"[O,5*]Q\%VEEIVEW-II^GQ:7%_:UTWV&,*&MY'CM@897
M!EFAQY,DSDEF0D8&T#S_ ,%_$&PT+5_''B:>"\N;GQKXCNHM'-FK,[:!X+)\
M*Z7&%4[S'=WUGJMZFT%6\\,,L:3;D_R7]?F-67I9+\5H?-G@KQ!^TC\6'UOP
MY\-_#%W\+-"OYV&N^-_B%.+6[TVWO,^=<Z7X/CC^WW.L2H9?(4;K1"$,LT3+
MYB>Q>$/@E=_!G6K'PS\,)]6\2>)M=M[C5=:U:^:"77_%&IP1M/J%_J+2RI#Y
M*H9);:S\XQV<>Y(GEF>667OK'0/C(VL7'BK0_!7B*,>(RTD>[3SY<MOO(B,Z
MS20R0$8WJ]RL.Y6WKNC8,?I?X0?"_P 2Z-K-SX\\?SPMXDN+&73M*TFWE2=-
M(L[DJ;N:ZFB9X#>W"(L"06[RI!$9C),\L@6,M9\S:;M;IV6EEHE^BLWJ%^FW
MI?7UN3?!?P!XRT/4-9\8>/9HTUO5]/@TJQTJ.6*=].L$N5NYY+J2W9[:.>XE
MCA5+:&28QHCO/()'6-/H*BBI$%7+ R_:X5@&9I2]O$.F7N8VMU&>V3)C\:IU
M<TZ00ZA83'I%>6LASZ).C'^5 'UA$_F11R#I)&CC'HZAOZU)6;HTGFZ/I4O7
MS-.LGSUY:VB)Y'N:TJYSH"BBB@#P[XE:<(;Z.^1%"S^67<N2SO+&T?EI&>%C
M@^Q&9V7AI;XE@&.6\PKW;XEP0MID%S(O[U/-M[<XS^]EFL[AQ[?Z-9W#?@:\
M)K:/PHQE\3'QR/$Z2Q.T<D;K)'(A(9'0AD=2.C*P!![$ UZIH'Q%-K#;V>I1
M;HXE2(3?,=L:B3YMT:R2851#%% 8)6.&=[I5VHOE%%-I/="3:V/JW3M7L-4C
M22TG1]XR$W(6X +A2C/'(8]P$GE/((V^1RK@K6G7R;8:C=Z;.D]K(497#E#D
MQN5#*"R@J0P1Y%26-DGAWLT$L3G>/>/"/BZ'6H4MKEPE\GRG=@&0_,54D8#L
MR*2DJJHD*NKI'($\[.4+:K5&D9WT>C_ [JBBBH+"BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KC/B)\0_!?PF\"^
M+/B7\1O$6G>$O O@?0M0\2>*?$>JRF*QTK1],@:XNKB38KS3RE5$5K9VL4][
M?W<D%E8V]Q>7$$$G9U_&#_P7C_;G\:?M0?'CPY_P38_9H_M#Q1I6A^-]"T'X
MBV/AF3SKKXE?&ZZU&"ST3X>PF*1(KG2? &H7$$-];W%PEK)X]>[_ +1MH)_!
M>E7Y]+*LNGF>+A03Y*44ZN)K.R5&A%KGE=Z<SNHPOIS23E:"DU^Q^!GA%F7C
M/QY@N%\/7>6Y)A*-3.>+L_GR1H9#PU@I0>/QLJE:U".)J\\,)@(5FJ4L77IU
M,0X82EB:U+Y3^-GQ7_:?_P""_?[;^E?"?X30:EX4^ O@V^O9O">F:FL[>&OA
ME\/(+N&SUKXM_$9+*8VVH^-=?C>W2'3X;EB+F[TCP1H5XT8N]<O_ .T#]CG]
MCGX+?L/_  7T+X+_  6T%++3[-8K[Q5XJOHH'\5?$+Q4UO'#J'BSQ9J,4:&[
MU"[,?EVEI&$TW1-.2VTC1[:TTZUAA7Q'_@F1_P $_?!/_!/C]G72/AYI\>GZ
MO\5O%T>G^)?C9X[MX]TOB/QA]E8)HNFW<D<=S_PA_@U+FYTCPO;.ENDP?4O$
M,UE::KXAU1#]^^)?$OA_P9X=UWQ=XLUK3/#?A?PQI&HZ_P"(O$&M7D&G:1HF
MB:1:2W^J:KJ=_=/';6=A864$UU=W,\B10P1/([!5)KMSC,XXEPR_ )TLLPK5
M.A2A=?6)QT=>HEK-RE=TU*\O><Y?O)RM^@_2 \:,%QE4RSPI\+<-/)?!G@BI
M#+.&LGP,:L)\48^A.5.?$F:0LJ^-K8W$SK5LNABE/$R>(JYCBXK,\PQ,::^(
M_$?A_P 'Z!K/BKQ9KFD^&?#/AW3;S6=?\0Z]J-II&BZ+I.GP/<WVIZKJE_+!
M96%A9V\<D]S=W4T4$$2,\CJH)K^-3_@I[_P<5>)?$M[XD^"'[ M_<^%O"MO-
M/I.O?M'36SV_BKQ*$+PW4?PMTV^B63PGHL@W)%XMU.V7Q9>!EN-&M/"DEK#?
MZA\"_P#!8C_@L=XT_;K\9ZK\'/@SJFL>$?V2O"6KF+3M/C-SI>K_ !FU73+@
M^1XU\;09BN8M CN(A=>#?!EVJII\8M]>U^W;Q*UK:>&_PC5L\=_YU]#DG#<*
M,88K,8*I6:4J>&FDX4D[-.K%Z3J=X2O"&TE*?P?UG]&_Z'V5Y%ALOXV\6\NH
MYIQ#7C2Q>5<'8VG&MEF10DE4HUL^PTTZ>99NTTWEU=3R_+;N&)I8O'-?V?O:
MSKVM>)]6U'7_ !'J^IZ]KVKWEQJ.K:SK-]=:GJNIW]W*TUU?:AJ%[+/=WEW<
MS.\UQ<W$LDTTKM)([.Q8YE5\D5,K9^M?8IV]-K=++;TMT['^AU-J,8PBE!0C
M&,(Q2C&,8I1C&,59)1BDE%*R2LE;13*W8_@:DJO4BMV/X&K3MYQ?X>3_ *\T
M=,97]?ZU1*"0:F!R,BH*])\&_#O4/$@COKR9M+T=R-LQCWW=XH//V.!L*(SR
M!=3$1YSY:388!N2@KR=H]'^2\_7[^XZV,HX2DZV(J*G".EW=N3>T8QBG*<G_
M "Q3=DWLG;S[..>GO4JNI[C/UK[1\-^!/!6C*GDZ':7=P,$WFJ(NI7#,!C=B
MX4V\1[X@@C'H#7J]DE@JB,6.GJG0(MC:"/'3&P1!,8&!QC^G.\4D](-^KMU]
M';K^!\W7XWHT9-4,!6KP[U*T*#?FHQIU]'TNTWLTGHOS;5RI#(Q!'0J<$?B*
M_?'_ ()M?\%V_CU^R+=:!\,OCM=:Y\>?V=H&CL5L=4OA>?$SX>6+,D:3^!_$
MNJ3AM4TC3XA^[\$^([MM+$,4%EH.J>$XO/EN/BW4O '@+Q)&R:KX7TEI'&#=
M65NNF7J$_P 276GBWDR#R/-\Q,\,A' ^=?B!^SSJ6BV\^M>"KBYUW38%>:YT
MB=$.MV<2 L[VQA"QZK#&H)98XH;U5&?L\XW.,:\,'F%+ZOC**G"72?V)-)<U
M.HGS4Y]I)IM:.\6T?.\3X3PY\6,EJ\(\?9#AL=E^*;]A#,8Q4L'BIQY(XS*L
MUHN&)RO'Q3Y88JC/"SE&]&4ZE.I4HS_T_O@)^T!\(OVG?A?X<^,?P0\:Z7X[
M\ ^)X"]EJNG,\=Q8WL21M>Z)KNF7"Q:CH/B#2VECCU/1-5MK74+-WC:6#RIH
M9).O^(_PX\"_%[P-XH^&?Q-\*Z/XV\!^,])N-$\3^%]>M5N],U;3KG:6CEC)
M62&>"5(KNPO[62"_TR_M[74=.N;6^M;>XB_S2_\ @G=_P48^-'_!/;XMV_C+
MP)>3^(/ASX@NK*V^*GPEU&^FA\.^-]%AD*M/"-LZ:)XMTJ*2>3P[XHMK:6ZT
MVX>2UO(-2T.]U;1M1_T<_P!FO]I#X4?M8_!OP?\ '/X,>(8_$'@KQA9"5%D\
MJ'6/#^KP!$U?PMXFT^.:<Z5XCT*Z8VFI632RPO\ N;_3[F^TF]T_4+O\WSG)
M:^3UHU:<IU,+.?[C$+2=.:]Y4ZCC;EJQM>$U95%%RBHM2A#_ !^^D7]'#B;Z
M/G$.$SG*<9CLSX(Q^/C/ACBJBW0S#*LPHMXJAE6;U<*J<<'G.&5)U\!C\/["
MAFE*A/&8..&Q%#&8' _Q.?M>?LP?M$?\$*/VP?!W[2'[-^N:QJOP+\3:W=P^
M"-<U(37>FWVE73K?>(?@/\78+0VT%])-I]L9=.NS]C_X2#3[&V\6>')=+\4>
M'+^/PS_91^Q5^V)\*_VY/@%X5^._PJNO*M-55M*\7^$[JYBN-;^'_CBP@MY-
M=\'ZYY:Q;I[)KF"[TV_^SV\6MZ%>Z5K=O!#!J"0Q^B_M%?L^_##]J7X-^./@
M9\8-!BU_P/X[TF33KZ,")=1TB_C(GTCQ)H-W+%,-.\0^'=2CMM6T:^$4JPWM
MK&MQ!<VDEQ:S?Q&_LN?%CXO?\$*/^"CWB?X&?&B]OK[X%>,M3TK0_'TMK;W0
MT?Q5\-]6O+K_ (5Y\<_#-CNG)U+PRMQ=7-_96K:C<10CQSX$+RZU&+RQ[TX\
M1X&2DE_;6 I<T)*R>.PT6KQ:ZU8M[;*HTU:-6?L_U2C7P_TP_#/%8?%TZ$?I
M'^%V3/$X+%TX4Z5;Q0X/PLDJN&JP@HJKG>$J5$HQY>6.9XBA.@Z6%SW'1RS^
M]ZBJ>G:CI^L:?8:MI-]::GI6J6=KJ.F:EI]Q%>6&H:??0)<V=]97=N\D%U:7
M=M+'/;7$$CPSPR)+&[(RL;E?(G\"2C*,G&47&46XRC)-2C).S33U33T:>J>C
M"BBB@04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110!X-^T]\*M<^-WP$^)?PM\-:Q!H.O>+M#AM=
M*U&[::.R^UV.J:?JZ6&H2V\5Q/#IVL#3SI&HSPV]S+!97T\R6UPR"%_SH_X)
MV?L/_&[]GSXH^*?B1\4VTGP]8S>$;[PCIOA[2M<M-;N=<FU'5-'U%M2O'TXS
MV5MIMBFDXMXY9UU&:\G1C!;V\,GVG]:/&WC3PQ\.O">O^./&FKV^@^%O#&G3
MZKK>K7*S216EG !DK#;QS7-S<2R-';VEG:PSW=Y=2PVMK!-<31QMX!^S]^V1
M\#/VEM4UW0?AIKNIMX@\/VK:E=Z%XATB;1M2N=&6ZCLCK6G(\D\%[IZ7,]K%
M<>7<?:[)KRS%]:VQNH0^,X4G5IRE*U1?"N:U[-O;KK?;?9W.B%2M&A4C"-Z3
M?ORY6[-I+XNFB6][>5SZGHHHK8YPHHHH *PO$WBCPYX,T+4?$_B[7=)\,^'=
M(@^TZIKFNW]KI>EV$!=(E>ZO;R2&WB\R:2.")6<--/+%#$KRR(C;M?&G[=W[
M/_C/]I#X"7G@/P#J=G9>)M.\3Z+XLLK#4;IK#3O$:Z1!J5K-H-W>B.5+4S1Z
MF=0L9)X_LIU73K"*ZFM+>22\MYFVHR<8\S2;2[OM_7R+IJ,IQC.7+%R2<NR?
M7_@O1;L^DOA_\3/A_P#%70_^$E^''C#0/&FA+<O9RZCX?U&#4(;>\C1))+.[
M6)C+9W:1RQ2M:W<<,XBECD,>R1&/<U^8W_!-S]DOXI_LT:-\2M4^*=QI^GZG
MX\N?#<%AX2TO58=7BTVV\-?VYOU34KRR:737OM1?61%:PV4TYMK.U9KF=I;H
M6UG^G-*G*4H1E./+)[QUTU??576MGM>PZL80J2C3ESP35I=]$WMH[.ZNM[7"
MBBBK,PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH I:CI]MJME<:?>(7M[E K[3MD1E99(IH7',4]O,D<]
MO*OS131QR(0R UQT/AGQ;:V@T^V\;J+.,)%;M<>'HKB_BM8]B+ ;[^U(C(QC
M5E:X,(G#/OA:'8BCOJ*EP4G=W3M:Z<HNW9N+5UZ[?,I2:[6O>S2:OZ-/_@]3
M'T+1;70--ATZU>:8)\\]U<OYMU=SE51I[B0\L^Q(XD'W8H(H8(PL42*-BBBF
MDDDDK)))+LEHD)MMMO5O=A1113$%%%% !5>ZNX+*![BYD$<:=^K,W9$4<N[=
M%502?IFJ>KZM:Z-9F]NR5B$D<(.V0J'E;:ID,4<KI&HW/(RQR,%4B..24I&_
M@/B3Q;>ZZ[1 F*S5W*)C:[J<A0RAW$2;,!XU=VE<N9II8Q!%;U&+EZ$RE;U[
M?YECQ;XJGUNX>W@D*6*'8$1@4D56#!=P_P!8N]$DD8$QR2I'Y>Z."&63C&CD
M149T95D7=&S*0'4'&Y"1\RYXR,C-=GX5\)7.LW"S7$;16:;')=#B16 978-@
M&,KAHT/-QE#M^S%Y1T'Q$CL;*&STZV58WA%M-L &^1)CJ0DED8 %I/,B4ECS
M^];  :M;I-17_#+^O\S.S:<G_P /T/*:***9(5WGP]MY9=<AE0XCC<1SC&=R
M-;W=U&/;%Q90MGL5'K7!UZI\,;>8WL]QG_1S%<AAC_EXMOL:Q'/48BU"X&.^
MX^E*7POT''XEZGME%%%8&X4444 ?/OQ#N?-UN>#M;SG'_;33M*S].8SU_E7
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M!0 H P @4 *J@8 50  HP  -N ./Z)]'_P"#8CXB:19Q6D7[9_PW9$+LS?\
M"H=;S(\C%F8_\7'P2?E7.!PHP!TKI(/^#:CXBPXS^V3\.6QZ?"36Q^I^(QZ=
MO>NF7$&42=OKJMT3I8CKY>QW>[MN>[FGTJ? ;&UG)>(F%<(7C2A_8/%ME'2\
MK?V!HYM*3>^R^RC\DOV%OV6-;_;7_:%\/? 71?%]CX#.I>'O$WBO5?%E_I$^
MO)IFC>&+:V>X6VT>WOM+;4+Z\O+^PM+>.74K&")9IKF6=C"MM-PGQD^'&I_
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M'"5,W>"C&*PUDZBBBOGS^4@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M2BJE>K"E!R:;45*I*,>9I-I7NTF^C/IRBOG?QS^UY^R=\,-!^'7BKXE?M/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[S6FGJH8G"9QG>)4E?12E/ X=76KY$NA_<'1117S1_' 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!F:UHND>(](U+0-?TNPUK0]9LKG3=6TC5+2"^TW4M/O(F@NK*^L[E)+>Y
MM;B%WBFAFC>.1&*LI!KRWX4_L]?!;X'OJ\WPI^'>@>#;G7O+&KWNGI=W.H7D
M4+%XK1M0U*ZOKV*PCD)ECTZ">*Q2;]\MN)/GK!_:L\:^/_AU^SO\5O&WPNLV
MO/'/A[PR;W1=EDFHO81M?V5OJ^N1V,L4\%U)X=T.?4M?C@N8)[5WTU1=036_
MFQ-^7?\ P2^_:4_:+^+7Q4\;>$OB#XGUWX@^!K?PA=>(+O5]>C2YE\,>(?[7
MTZ#3(+75TMT:.+6K>ZU2--!EE:,QZ?\ ;--BM8=.OEGQG4A&K3@X-RE\,N5.
MV_7?IK;9:LZ(4JDJ%2I&:4(NTH<S7-:SVVZJU]W?L?N/1116QSA1110 5\@_
MMO?M%>(/V8_@=<_$'PIH=CK?B34?$ND>$M&&K174^C:7=:K;:G?/J^JV]G-:
MSW%M;VFD7,%O MY:))J5U8K+*T9:";Z^KE?&W@?PA\1_#.J>#/'?AW2_%7A?
M6HDAU/1=8MENK*Y$4J7$$FUL/#<VMS%%=6=Y;O%=V=U%%<VLT,\4<BS-2<9*
M+Y9--)]F73<8SBYQYHJ2<H]UU7_ Z['P'_P3N_;#\>?M2:/\0]+^(VC:1#XB
M^'\OAR=/$'AZSFT_3M6T_P 2C6DAM[VQEN;J.UU2SFT.X<2VTL=O?6UP-MI;
MR64LEU^DU>:?"[X.?##X*:%<>&OA9X+T?P9H]W>-J%[;Z7'.\]_>LHC^TZAJ
M%[-=:C?RQQ*L,#7EW/\ 9X%6"W\N%0@]+I4U.,(J<N:2WEWU=NU[*ROUM<=6
M4)U)2IQY(-JT>VB3VT5W=V6U[!1115F84444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !7\MW_  =I?\F!?LU?]GY^ O\ UF7]K"OZD:_G _X.>/@;
M\:_C[^Q#^S[X3^!/P>^*7QJ\4Z+^VKX*\5:QX:^$OP^\6_$?Q!I/A>T_9X_:
M:T2Z\2:GHW@[2-9U&PT&VUG7]"TBXUBZMHM/AU/6M)L)+A;K4;.*;V^&IQI\
M0Y+.<HPA#-,%*4YM1C&*Q%-N4I.R22U;;LD>'Q/&=3AKB&$(RG.>1YM"$(1<
MI3E+ 8A1C&*3<I2;222;;:25S^"7X:#XH_LYWWP4_;>\*GP%KDGAW]I6^O\
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M>$]3^'UUXGU#X@>"/$&JZ_\ $B^^+7@+QA<MX7GL_P!RO^"'O_!+OXN?%O\
M9_\ ^"O'[,/[6_P*^-G[//A_]I#X;?L?Z/\ #CQ7\8?A%\4O 5O!\0?ASKG[
M2WC+PEX]\-Z9K$_PTN?B"WP;^)0^&?CG7?"%CXFM-*UA8](\->+Y4T#Q1+;W
MOFW_  3KM_\ @IW_ ,$1?VA?VL? TW_!,OXU_M8:)\0K;X?^$?$FO?"3PC\8
MKKP9K6J?"R[\4:Y\-_'?PJ^-/A;X4>/_  MXC\":UX9^+/B]]=\/W_@NW\70
MZO?>'M*\0S_#;Q=X$\<^ ]2Y,)C,,L1Q;3P=JV9U<_E7A##YQ2R7$8G QJ2Y
M?89A44H3ITJO/.M14HJ<)KFDTXPGWXO+\:\G\.JN-C*ADV%R;%TL7+%</U^(
ML+@LPJPBJ,\=DU.4)R=6G>CAZTX5/85.9QA&4N8_,#_@F7_P5E^(7_!-;0OV
ME_"TGC?XJ:?X?_: ^ /Q"\,?"'PM\/=!\ ^./"?@;]NK6-+\-Z3\$_CUJ^A_
M%&^LM-TC0/#&EZ9X@T?QU?Z-8:_/XVTBT\"V'C;X>^/[7P7X0M_"OUA_P0Y_
MX)L_#7_@J]\:_P!K[Q7^U+\3OBEJ&G_"KP?X?U;6HM"UE9/'_P 0_BS^U*/C
M98V7Q:\2?$[Q2/$U]=:Q\-=5^'^N?$&+3=4T+7/^%A_$O5?"^J^/M3U3P3H'
MC+X>_%#^GS]FG5?^"B'_  52_8U_:>^!G_!1G]C?X5?LP>$/C/\ "WQQX7^%
MWQ.UKP[K]OKUAXQU!G\.^ ];G_8X^)VM>)_'=EK?P5^(?A?4/C)8_$'QQ\4O
MA%>W][%\&[GX2^%M3CDU/XJ:%_-Y^QUX3_X+,?\ !%O]H[]I+P_\+?V(OB=\
M<=,\5>&KCX?^.(O#7P#^+GQ>^"/Q!\0^$= \5:Q^S]\8OA[\4_AUX7L-;U?1
M?!VM_$"ZUG5/"UAK&A77BKP;XG\<_"SQ_P"'_AS\8K'1/$OP>YYXZKC8<3QR
MF>#RG/*V8X&M56'S;"+V^$HT8PKSPN9+ZI1ES8A2Q.)49TY)U9PJI5)RA+LI
MY70RZ/ ]7.HYAG_"F&IYVO\ :N'L?"&#Q.,<9X".,R2;Q^(EAX1<Z6!E*G6I
MJ"BZ7[OD;_,3X!?"G_A0W_!7/]G?X$G78?%4GP._X*U_!#X+W'BRWT+_ (1B
M'Q;>?";]NSPK\/;WQ9'X;_M?Q = 7Q/=^&YM=&BOK^NRZ8-0%E+K.J20O?3_
M +J_MK_LE?\ !'NP_P""GWQ0^+W[7/\ P5HUGQAI/BCXR:G\4OBU^S;HGPK^
M)_QF\763:?J&L^%-6_9W\4_M1?!^\\<Z9X#T[P1X\\%77@(_# ^"_#?Q<^$W
MP!T3PQ\)].D\(:O%X.^,!_"GX!-\5O\ A[G^SLOQ[:5OCTG_  5K^"-M\=9+
ME?",<]S\;[7]NSPO!\7[IT\ +'X##W?Q%A\3W9'@F*'PF1*7\.P0:0;2)/N[
M3?\ @G?^W?\ L'_\%"M-^(WQY_8#^.?_  4P\"^#?&WQE\2:I/JGPZOOBYX0
M_:XT+Q=IWQ=^&7A[XK_%#6_#VA_M0:'X;\8^+?$&HV/[0%]X&^)+^(_B7HFM
M1Z!<^*;:QU34].\2GTL;"=3.:DUFM2ABEPMER4,OQ>!P-?,W4J3=3ZIC\9!T
M<-",HQK.5-0J2A*/(XI,\G 3I4.'<RIT^'X8G /Q-S*U/-L#F>-PV24:.$P7
MU>>8Y3E\XXO%>R@OJLL/5<J2GS4JT:LI1IS^._V+/BSI'@?_ (+ _LQ?$S]E
MVQU'X7_#[Q%_P43\$^#?A'H.OV6F^(O$/A7]G']H'X]CX-2> ==;Q/>^/$/B
M*[_9T^)>I^ _$&M1^(-?UK2]5OK[6?#_ (QGUNSTSQ./)?VTO%WC?X=_\%+O
MVN_B5\-/$1\(_$3X7_\ !3/]I#XH>!/%*Z9I&M/X>\8?#?\ ;1\=>-O#>LQ:
M/XAT[6/#^J3:;K&A6=W#IVO:3JFBWDL26^JZ=>V$EQ;2_6?P5_8F_;G^'_[>
M_P"SO\>_B%_P3S_:*^$W@#0?VT?V;?VJ/&^A_!/]D#XUW_PL^&7P[UGXW?#O
M]H_Q'HWPV\"?#KPKX]U/1/#OP\\(:U>:18_![37UOQ_\.[G0+GX3:YHD?C_P
MOJN@P>T^*?\ @GW^UOXQ_P""RFO^)?%G[$'[17BO]G[QE_P6$UOQ'XQU_P 2
M?LT?$G7_ (-^*O@%XJ_;]O=7\4:_XEU35?!5WX)UOX1>(OA?J-_JNN:OJ<]S
MX.U3P'>W>H7UQ/H%Q+,^E?'9;3S;,\97=#%X:IP=AYU:<,92K+&SA6][#O&1
MTKU)JFJ<ZBC[25/]Y[.SBGEA\NS67#N%P&#AB,'C(^+N'K8"K/*J^"C@L/7P
M47A,?_9=3GE@\'2K2=;ZK*<H4+2H3FY1;?W=_P &SO[(/[.W[4_Q>^./[9'Q
M]\6:]\;/VE_@!\3/#7B+P]\/O']AK_B#3/#_ (G^(Z:KXL\/_M5^-O&_B1M2
M@^+/Q6\0>-O#_P 0;3P7:ZEJ=WJGPR\6^"=7^+_B:TUGQWXI^#WBWP%'^VO^
MR5_P1[L/^"GWQ0^+W[7/_!6C6?&&D^*/C)J?Q2^+7[-NB?"OXG_&;Q=9-I^H
M:SX4U;]G?Q3^U%\'[SQSIG@/3O!'CSP5=> C\,#X+\-_%SX3? '1/#'PGTZ3
MPAJ\7@[XP'Y2^%W[(O[?O_!'_P#X*NS>-_@7^S)^V!\?_@=\#/BU>>%[_P 5
M?"GX,?&CXI:=\>?V0/B38:5JFI^&KK7?"'AKX1> OB;\6M#^&?B'0M6N=(FN
M=-^$^@?M@_#+2+J>'4-"\#6TTO":;_P3O_;O_8/_ ."A6F_$;X\_L!_'/_@I
MAX%\&^-OC+XDU2?5/AU??%SPA^UQH7B[3OB[\,O#WQ7^*&M^'M#_ &H-#\-^
M,?%OB#4;']H"^\#?$E_$?Q+T36H] N?%-M8ZIJ>G>)3YBA+$9[FV/H9W75+'
M93AL3EE+!8S 8'%U\)7<?^$^CBL4IT,NEE\X)5*<%"NX<M1N,ZDV_8<O[/X4
MP.3XOANAB<7EG%53#YWBLPP6:YC@%BHNK5I<0XO!X&4<7F]',*35.+J3J4'*
M,J,H2I^PHR^._P!BSXLZ1X'_ ."P/[,7Q,_9=L=1^%_P^\1?\%$_!/@WX1Z#
MK]EIOB+Q#X5_9Q_:!^/8^#4G@'76\3WOCQ#XBN_V=/B7J?@/Q!K4?B#7]:TO
M5;Z^UGP_XQGUNSTSQ.(?C;\-- ^-?_!9KXN_!/Q5>ZWI?ACXV?\ !7SXD_!;
MQ'J_AB?3+7Q/HWA_XN_MWZ_\.-=U?PU=:UI6O:/:^(=-T?Q/>W>C7&K:'K.F
M1:A%;MJ.DZG9>?8S^O\ P5_8F_;G^'_[>_[._P >_B%_P3S_ &BOA-X T']M
M']FW]JCQOH?P3_9 ^-=_\+/AE\.]9^-WP[_:/\1Z-\-O GPZ\*^/=3T3P[\/
M/"&M7FD6/P>TU];\?_#NYT"Y^$VN:)'X_P#"^JZ#!] :E^PY^VL__!;^Q^+*
M?L??M2/\+$_X+46GQ4?XEI^S]\66^'Z_#!?^"@C>-&^([>,AX2/AU? :^#O^
M*L;Q@=2'AX>&O^)Z=1_LO_2J[\=F%*CC<ZQF%Q=&%6KP9AI4<11QE.O.6(52
M<%*GBXM>WQ%/E355)5'RPJJ,;Q9Y6!RJMB,GR[+,5@J\\-+Q=HRJ8:IEE? 4
M_P"R,3A*-Y/+9\[P&"K0E5B\/*<H8;FG1G-RA*_M7_!Q/_P27_9X_88L_P!G
MCXV_LH?"W7_ 'PC^*=WXN^"_Q?TN]^)VL>-?"FF_$C3],;QK\*'T+2_B-XE\
M2?$R+7?B#X,M?C./%%UIFKZEX L=.^%7A='TSPCXDUF>\\>>1?\ !8K_ (*?
M>(?VS?V+?^"67@/5]9\>S:Q)\!=5_:)_:4U3QCX%^&'AO1OB/\<O!WB?QY^R
M1;_$/PY<^#;F\O-%%MXX^#G[66O1>&M"T_P5X1N? /Q<^'>IWOA\Z];IX9^'
M7]O'_!47]F/5/VQ?^"?O[4_[/?ARR\0ZKXT\8?#*ZU_X;:#X9USPOX:U+Q3\
M6/A=J^D_%GX3>#KC7O&D9\+Z9H/C'XD^!_"WA?Q7<ZO=:- /"VKZPD7B7PM<
MO!XDTK_.,_X)$?LJVW[8?_!1;]E_X27/AQ-<^'\WQ%LOC-\:4U#X:'XH^"KK
MX5_!C3HO'VO:!\4O#MW-;:%9^ OB[>>&O"O[/NHZUXKED\/6>K?%?P_:76C^
M*+Z_L?">O>1D..HXO*(Y[F%:5?'\(RS"HG7E*K4QG]ITY3R]UZLVYSFLP=6-
M-REHTGS:M'T7&&68C*<[GD>1X:GA,!XA8++LHE#"TJ=&A@<3EF*HT<75A0IQ
MA3IT99)6G"<817,U*34E'W?TS_X*T^-?&'[%'_!/[_@G7_P1T2T\>>%/$FF?
M!#PU^V+^UK8>(O$&C:LDOQ!^*WQ!^)?B>R^#%CXH^&_BRW\'>-O WP[^/R_&
MW6+GP[K7@_Q+H]F_@+]FWQ=X6^(GB7Q+X:UO7+CZ;A_X(3_LR-_P0G3]LU_'
M'C;_ (:<?]E=?^"A1^)0@F_X1]/!K? T?&;_ (9?7X9_V_\ V"?""^#?^))_
MPLAKX_$@_%K/Q*_M(?#+'[.X_4__ (.$O^"3GQH_;Z\/_!#XV?LK^&/ OB;X
MW_!E/$/@7QAX'NX?"7@WQY\6_AIXVUKPU=>'O[-^+'BC5]!T1H?@?KUMXJ\2
M:9\/_&FJZ=HEWH?Q,^)^O^$]?L/&MI:>"?BA^**?M@_\%L(?^"70_P""=?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MVE3BX0C%R<VEK)[O6_X;+R0ZLU4J2G&"@I/2*V6B3V2W>KTW844459F%%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M)'_\$C/!O[ ?@]/B3\2$TGQI^U1XRTD0>(O$D*I>Z/\ #32+Y%>Y\$>!KB1
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M@KJ#6.GV%O/=7=S=3RW.JWMQ>ZA<-!YJBSMX+*W%O-->?=M?%?[''[:/AO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-/[%?[)'[133S_&_]G#X-_$G4KC)?Q!XD\!>'Y_%2EE96:#Q;!96_B:U8JS
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M_@#X=UR,26=H=5\-? #X90NS/'>^(-2<7-YX^\=QV$@,:%=>\3R?:9WT;2=
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M%&$JDE%2<8N3C%J*<HINUVEJ?J=17^?5^R!_P46_X.-?V]+SXE:?^R?\8?\
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M,4G*23_9.BOY./V(?^"S'Q7^.'_!,'_@I'\8/C'^T]\&?#_[;_A"T_;=\?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:JB( JJ  *GHHKS#\9;;;;;;;;;=VVWJVV]VWNPHHHH$%%%% !1110 4444
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M_P FD?;OB%_PN?\ Y,,_X\_^%/?$7_A O^2._P#%S/\ DK/_  @'_(J?O?\
MH,_\4U_;5?S\?\$X?%?_  6/_P""8&I_&_5?@'_P3<^-GBZX^/EE\++#Q@GQ
M?_8\_:EU^'38?A'/\2I_#;>&E\%W'@![.2]?XI^(!KAU2365N5L]&%@FFFWO
M3J'[3?L\?\%9_P#@N]\0OV@_@'\/_BQ_P3/_ .$'^%/CWXW_  D\$_%'QO\
M\,:?MC>&?^$,^&_BWX@^'?#_ ([\7?\ "2>)?B/>^&_#O_",^%-1U;6_[?\
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MW3M.O](_X0[3?%%GX UGS[+XM_$&'[?X@\*ZKJ<7_"0>9#>QRZ5HCZ;\8_\
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M\F^K82G.I3YJ=6E92A+#2G3]J_;%_P"#?G7_ -D#_@E;^U1?^'OVLOC;\?\
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M!IV:?9GUE15:RG^U6=I<_P#/Q;03_P#?Z))/_9JLUSFX4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_8NJ_P#JAS0_L\HHHK\K/W<**** "BBB@ HHHH **** /XVOVL_^3H/VAO\
MLL_Q)_\ 4MU6OZZOA;_R3+X=?]B)X1_]1_3Z_D5_:S_Y.@_:&_[+/\2?_4MU
M6OZZOA;_ ,DR^'7_ &(GA'_U']/K@PG\2OZK_P!*D>ECOX6&_P +_P#28'=T
M445WGFA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /P,_X+I_\ !67XT?\
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MQJK^Z3_@L=^SW\8/VJO^"<'[1GP$^ OA#_A//BQX\_X5%_PBGA3^W_"_A?\
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M-RC7]CC(3J>UISI4ZD*5:G*$I_<_AK]DG_@UZ\6:_P"&O#>E?\%)OVO+:_\
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MF?;/)^WVOF_K5_P70^&_Q$^+G_!+#]J/X>_"CP%XT^)WC[Q!_P *2_L'P/\
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M/"5Z>+A1_<PC-T57@ZV(JN"5"FHRYOT"_P"#H?X#_P#"R?\ @G5I7QCT[3?
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M_P#^?ODON-/[.PW\V,_\..8?_-7DON/A7_AG+]K+_H^G6O\ PQGA'_YJJ/\
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MZU_X8SPC_P#-51_PSE^UE_T?3K7_ (8SPC_\U5?=5%'^IF2_\_>(O_$QXO\
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MIUK_ ,,9X1_^:JONJBC_ %,R7_G[Q%_XF/%__P _?)?<']G8;^;&?^'',/\
MYJ\E]Q\*_P##.7[67_1].M?^&,\(_P#S54?\,Y?M9?\ 1].M?^&,\(__ #55
M]U44?ZF9+_S]XB_\3'B__P"?ODON#^SL-_-C/_#CF'_S5Y+[CX5_X9R_:R_Z
M/IUK_P ,9X1_^:JC_AG+]K+_ */IUK_PQGA'_P":JONJBC_4S)?^?O$7_B8\
M7_\ S]\E]P?V=AOYL9_X<<P_^:O)?<?"O_#.7[67_1].M?\ AC/"/_S54?\
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MUK_PQGA'_P":JC_AG+]K+_H^G6O_  QGA'_YJJ^ZJ*/]3,E_Y^\1?^)CQ?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *S=,T;1]%BFAT;2=-TF&XGDNKB+3
M+"UL(I[J4YEN9H[6*)99Y3S),X:1SRS$UX;^U;HOQ,\1?L[?%?1/@]/>0?$3
M4/#+0Z =-N/LFIW$0O[*77+#2KH/$T&JZEX=CU;3],ECEAF2_NK<P313;)%_
M*;_@E/\ "O\ :,\#?%#Q[J7C'PKX[\#_  RG\+7MGJVF^-M(UKP];ZSXT_M?
M2_[,N-+TG6H+.:ZU33[6VUB._P!6M[=XK:W>33[N;S[JVC7*51QJ0A[.4N;[
M:VC^'S>JLK;F\*2E1J5?:*/(TN1[RV\U;>RT=VGMN?N[1116I@%%%% !7P[_
M ,%#/B=\6/A+^S=K'BSX027>GZX?$>A:5KOB*PM([N^\+>%+]+\:AK5J)H+F
M"VE?4(=)T8W\D):QCU>2ZMY;>\BM[F+[BIDL<<T<D,T:2PRH\4L4J+)')'(I
M5XY$8%71U)5T8%64D$$&IG%RC**;BVFE);KSZ?FBX24)QDXJ2C)-Q>SMT>C_
M "?HS\G_ /@E=\;_ (Y_&'PM\4(/BKK.L>,?#OA?4O#D/A/QAKRB74GU'48=
M7EU_0'U=D6;6DL8(-&OQ]H>>ZTO^T1'-</;WUC#;?K'5#3+'3--L;>TT:SL+
M#3(XP;2VTRWM[6Q2)_G4V\-HB6ZQONW@Q*%;.X9SFK]*G%PA&+DYM+63W>M_
MPV7DAU9JI4E.,%!2>D5LM$GLEN]7INPHHHJS,**** "BBB@ KX(_8H_Y'/\
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M!$]Q@# )NI](DN2W^V9MV><YKR/Q]_P1F_X)H?$2UGM]3_94\$^'YI5Q%?>
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M83$T9N%;#XG#5X4ZU"O2G%PJ4JL(5(33C**::"BBBI.4**** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7\"^'O"\\/BJ?QA\._Z=?CA\!OB7^TK_ ,&ROPI^$_PATK^W_B#<_P#!._\
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M:F6U\4^.-8^'GASXD07_ .TYXJ\)^*K[[1JNE>"[KPSX(^'7[3/C+]H;7O\
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M@^ULDD9-87@;]G7XZZ0HNY?@'\7&NY&58I&\ ZX5A0D N-]J#YC,3EB!@#C
MZ_N7\./BEXI^)O[$WPP\9Z=_P4,\8?LG:;^SFFH>!_'EKH?AO6_$MCJ/AOQ!
MJ$%QX!UJ_@T:WN;B/RK83:9%<E?LZL?+=Q(5%<]X7^,D6M:E9V6G?\%W/&&L
M3*4G>SA^&/C'S)X(G0NN7TY2#(2(_4AN_%?-4\TQ,>>G.,9N$W!N4,0[6LE?
MV5&>KC:6]O>>]M/YFPGBYQJL%CLKQV R_&XG)LQS++,PQ$LD\1\56D\)BJCP
M\L37R#@K'97&>)P$\'C>6ABYP]CB:;;3DTOBW7OV==4\!?L]ZU\9?&,/BWPQ
MXEL?B!H'@S1_"GB72YM*34H-3TJ2_O[TPW*K<,UL\>V)U^0+N!W9R/%[*^CN
M86MK@)+#("C)( Z$$8(=7!5L]3D<CI@YK[P_X*<?%;Q!HVA?!S]G/Q'\6]7^
M-'BO3[S4_BUXR\<:U;26&H/::\/*\%:3<6$P2>RC71YI9X;>X5)E7)=0Q 'Y
MD:3J^0N7SQWR?3]._P"5>AA)U:N'5:HE^\G)Q2NK03C&'+=1:YK.2ND[-75N
M5'U7 V+SC/N&J>>9NX<^:8_'8K+XT8UX4:>54ZL,)@7AUB\-A,6J%=8:IC:,
ML7AZ6(=/%1<XI6BO3O@9\<_&O[&/Q[\(?$[X<:A-IMC-JJK<Z:MPT6GRRNX^
MW:->1[O*;2=;MO,CF20-';EO/C43*K5_3%_P4"\%>!/VQOV2O /[<_POL([C
M6?"VAVS^/+.R0/JEUX+NGCLO$FD3Q1$S3:UX4U%_M6@F5M]NLZWZ*H"$?R,?
M&C4(I?#D>6'F_P!HVK0L"=PD6/)*D<DX'7OUZ=?Z3O\ @@C\;$^)7@+XM?LN
M^+KM+W1_%OA;4-9TBQGQ.L=[):/HWBUECE+ (;>?2YXP@ 66#?PVTURYM3E2
MIX?-:2?ML'*/M6E;VN&DU&I3DUJVHMN[UC:3T;/B_'C(Z^4Y1PQXZ9-2E#B7
MP_S"A0SZI2?LZN?<'8FM##9G@,7.%I5G2PV)G5HU9<SPRAB:T?WLHRC^KG_!
M*;]HW4?C#\#+KX<^,-1.H>/?@G=6?A>ZOI7_ 'FN^$Y[5+CPIJ\&]GFN8X=,
M:#3KN]9F\R\A*L0W7]2Z_EW_ .":+:W\%OV\(/A5';ZA'8ZU#\9/@OK+75RT
MB2VGPDM[SQGX6U%XR3OFU"UD94G/SF&W"$[5 ']1%?&9Q0A0QLG3M[.O".(@
MDK)*IS*5DM$G.,W%=(M(_P Z_I#\+Y?PSXE8ZKDZI+*.*,#A>*\NA1BJ=&-/
M,ZN*H8OV--)*EAZF:8''UL+2BN6GA:E&$=$@HHHKRC\."BBB@ KX(_X)R_\
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M_-%PW^7ZH]"HHHK$U"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_1!\/,LRR?O899QX68S-J]2C9*#>/\1,VS#&8IRC9^VI."J7YX+6YU%GKO\
MP<??"2V-QJ/A#]D']IQ+="\]M'=:+H&I7,:*2XLWL]<^!EJMRP&8MUM,I?:/
MLTF=A9!_P6Z^.'[/][;Z7_P4%_X)X?&_X%Z>;B"UG^)G@"&X\4^"9Y9I!"9+
M:+7K72M$DAAEW-(ND_$;Q%=-%M,-M-(R))W_ ,//^#CC_@F]XUN;:U\0ZQ\8
MOA5Y[QQO=^._AH=0L8'D8*#*_P .-=\?78B4D%Y?L(5%RS!5!-?JU\&_VGOV
M7OVK= O3\&/C!\+?C)I5Q9NFM:#HFNZ3J^I6]C<1JLD'B3P;>E-=TR&>.55>
MWUS1K42(^UHV!Q6%=U**;S+AVE"G?6KAZ>)P+7^&I3G/#7\I4I+NCYSBFMG&
M04Y5?&3Z(^1Y9E4G&,\\X4R?B[PUKT92O'FPV;Y7C<SX0E55^:%'$Y)B*4I)
M<U-IZ<S^S)^W-^RG^V%I1U']GWXS>%/'%_!:K=ZGX0-Q-H7CW1(CP\FK^"->
MAT[Q+:VT<H>#^TETZ729Y8W%IJ%P@#GZRK\6/VK/^"('[,'QFU5OBC^SQ<:K
M^QO^T+I5U)K7AKXB?!-KCP_X<&OJMP]O=:KX'TB\TFRTYC/<2/)JG@6[\(:Q
MYLIN+NXU-4^R2_,WPH_X*3?M6_\ !/[XF>'_ -F?_@K3X7?4O!FN7XT7X7?M
MK>#K%[_PGXAM85CB@D\9MI]C:KJ\4*-&-3U&'2M'\>Z&I@O/%/A368-2/B./
MD>78?&1E/*:TZM2*<I9?B5&.-44KMT)0M2Q:2NVJ:A525_9,^$J^$G"OB!A,
M3F?@5Q#F.>9GA</5QF/\*^+:6$P7B'A\-0@ZF(K\-XG M9-QYAJ%.%6K4I95
M#+\]IT(1D\BJ.5U_2!167HFN:+XFT;2O$7AS5],U_P /Z[I]GJ^B:YHM]:ZI
MI&L:5J%O'=6&IZ7J5C+/9W]A>VLL5S:7EK-+;W,$B2PR/&ZL=2O&=UHU9K1I
M]#^>IPG3G*G4A*%2$I0G"<7&<)Q;C*,HR2<91DFI1:33335PHHHH)/YYO^"
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MSJ96S]?\\BJ:L1]*F!Z$?G7V]S_16G4_KOYKS_KTNJV>#U_G7Z>_\$S/VS?
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M:[XH?3;71F\1ZQ9SSV^I:XVD6+/9:6VJWD<U\=/M'>WLS.;>%FCC4U^BP&
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7M?BW:SX/^'7B>[C\0:#X8MXY$#:1=^)0;+Q/X@T^VCL8=/M!X6\)_V98_\
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M+#ITL,I5JV<\(0H/_9,5AH*K/$9)AXK 9AA/:4,%A,)B8PP&:_J5^P)^U?\
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MB@ HHHH *^"/V*/^1S_;,_[.I^(W_IUOJ^]Z^"/V*/\ D<_VS/\ LZGXC?\
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MKCLOG3X;H9]FLLOQ>(PLJD\=C,!E=.A5J8>K3;]EBGB[1ES*\9-+JO\ 6_\
MV$_B3XU^,O[$/[&_Q?\ B3K/_"1_$3XK?LJ_L\_$GQ]XA_L[2='_ +>\:>.?
MA'X0\3^*=:_LG0;'2]#TO^U-<U2^OO[.T73-.TFR\_[-IUC:6<4-O']55^5O
M[*]A\>M7_P""+G[)FB_LNZEX+T']H/7?^"='[,F@?";Q3\0M9FT/PCX(\7:[
M^S]X TBR^(&ISQ?#;XNQZI-\/X[V?QII/A34/A]KFC>-]9T+3_!NNSZ#HNNW
M_B/2/Y,_A3_P;Z?\%!_VAO&?Q@^,O_!2GXOM^REX9\+_  ]LO&?BW]H;X\_$
MWP/^TWXX\77/AO2+;39#XGUG2?CK<P:9X2^&OPW\)3R>,_B%\2OBCHZ^'=,L
M?!.D>&-(\6Z))XHU;X??G&3Y5E^/I8BOF.=X?*:=&=.E3IO#U<;B\14J;>RP
M=&<*LJ4=I5(<_+)I2BE[Q^P9MGN<9;1RFCE/#>-XBQ6-P_M*DXXNEE^"PT:5
M"$Y2Q>8XF%2C2JU?>=*%11]JXM>T]I*G"?\ H/45_F+?\$+/V[?B9^RW^WC^
MRWX(;XA_%O3?V>?V@_B]I_PF^(WP0\/WEOJ/A#Q+XX_:&TG1OA5\.O%NM> _
M$VIV7AO1O$?AKXI0?!C4/%7Q)T%;#XFZ9\.O!FM>%=*OM=T+4-4\">)OHG_@
MM'^W_P#M0_MY_MZ?$/\ 8C^$NO>.K3X+^$?CK:_LB_#/]GC3M5T_X=:=\9/C
M-HGQ2\+>!M1UKXK+<^.G\%>.K[7?VC?"ML_P;U_Q]K>B^$O ?@33/ ?B*'P[
M\./&>J?%#6M>]B?!6)IYUB\LJ8[#T\)@L$\RQ&9SIS5.G@$KNJZ',W[56E>B
MJKBE"4O;.*N_!H^)F"J\,QSYY9BOKE3-O[!HY-2K4ZU6OF[C&<</1Q481A.B
MZ<XS]O[%/>,:,IN$9_Z,%%?YNG[6O_!$W_@H;_P3E\5?L\>/OV>M2^-7QT^(
M/BOX=^)=9UOQ[^Q'\/OC\?&G[/WQ-L-#L_#/Q(\)Z?XS^&VDS>)[;PKX@\/_
M !!GT/X:_$47G@+Q=\4]&B^)%AJ7PN\%VVB26^M_T<_\%1-;_:;U[_@W+^(U
MW^V7X(/@#]J&R\+_ +-GASXSZ.WBCX?>+GUKQ=X1_:_^#?A63XCR:G\*+2Q^
M'.GR?%W3M&L/BM)X1\(6RZ/X!?QFW@6&6Y?PY)<R\>(X=PD<9DM+ 9WALQPF
M<XJEA:>(IT94<3AI3Q,,-.=?+ZM;VT81E*3IN4X*IR2BW3O!R]3+^+LQK4,_
M6;<,8[)<?D6!J8^6'J8F&-P.+IQPT\1"G0S;#T%AO;24$ITU"I*"ES1]JZ=:
M%/\ I2HK_):_8*_X)T?M#_\ !17XTZI\-_V=?"FD"[T3PY_;/Q(^+/C:?5-%
M^%OPST)(=5?PQ!XW\4Z7HWB'48-3\:ZW9W.A>"?"?AS0?$'BOQ%>QZSK\6A+
MX*\$^/\ Q7X1_:W]K/X[_M6?\$0/V//@[_P2T\ _&?Q[I/[2GQ#N?B%^T]\9
M_C'X$\9Z;XG^$O@3X,_%G7_BY\(?"?P%_9BN/&WPTT/XC> /^$ANO!#?'+Q[
MXET&R^'OBWX<?&Z?7_$O@#QKXHC^*NKGP3Z6+X)C2S##91@<YPV/S.KB9T\1
MAHX>5&."PT:<JWUK$5%6K6?LO9N5!0YN>IR0G4:BY^'E7B;/&99C<^S'AO&9
M5D.$P#Q%/,I8N&(6-QJQ%'"++\'1^JX?VDIXBI.G3Q#JQI_NI.K&C[RA_?Q1
M7^>-\)?^#>+]L?\ :R_8IO\ ]NB\^+VB:S\?_C=HMU\>OAG\"_%EQ#XD\2?'
M3PEX[_LWQKIGBWQM\?M4\<?V'X7^*7QCTC5]=\9>'='\3:9KNG7%]J_@RW^+
MGQ$^&VL^)?'J_#'U7_@W*_X*P_$?P#^T-X'_ &)?CW\8M7\5?LZ?&[0=-\&?
ML]/\0]=M]2M_@Y\6/#WAO1--^%7@#P9XP\9^,-(E\&_"+XA^"O#4OPQ\*_"+
M0]/\56LWQBN/@]I'PK\)>#KKQI\3=1\5\6-X8PT<!C,?D^=X?.89;*$<QI4\
M+5PM2A&;<55I>TG46)H<RE^^IM0E",IP<E&5N_+N.\9/,<KP/$'#&,X=I9\W
M#)<95QV'QU/$U;*5.ABZ=*E2J8"O6C.G&G1JJ=1U9J$HQ@I5(_WR45_D/_L8
M?#/]I+X\?'OP5^S?^RGXKUOPO\5?VE=$\4?!2\@L?B5JWPO\,>)OAIK/AVY\
M7?%/1/BEJ^DW<4FN_"BP\$^"M5\8^.O"#Z5XNNO$6D^%&L_#O@;QGXO_ .$=
M\.:C]X?M[?L'?M._\$/OVK_@CXW\#_&87UQ>+J'Q!_9E_:1\$V>F^$O$=UKG
M@VPT+1OBKX<\0_#34]8\8RZ#<Z"_CFPT#Q/X?UJX\:?##XI_"_Q]IVE:C?Z_
M'KWQ,^&O@_V,1P%AJ6/JY1#B/"SS9TG6P>"G@JU+ZQ"-/G:JUE6JTL--\M1Q
MIIUZDJ4%6Y5%M1\/#^*N.KY;///]3<:\DP>*>%S3,*6:8:I]5DJL*:EA\-/#
M4:^-BH5*4JLE&A2HSG[.=7W7-_V-?\'!?[9/[2/[$'[&_P +?BM^R]\1O^%8
M>/O$?[4'@[X=ZSKW_"(> _&GVSP=JOPE^-OB:_T?^R_B'X7\6:+;^?KGA'P]
M>_VA:Z=!JD7]G_9H;Z.TN[ZWN<;_ (-X/VU/VF?VZ/V0OCG\4?VI_B5_PM+Q
MUX._:Y\6_##PYKG_  AO@#P3_9W@;3/@3^SQXRL=#_LSX=>%?".CWGD>)/'7
MBK4O[3O]/NM8E_M3['-J$EA8Z=:VGY ?\%=OVO\ Q7^WE_P0%_85_:I\=^#-
M \ ^-OB1^V);Z9XN\-^%-0U#4/"Z^)/AEX8_;(^$NM:[X<_M4/JNE:%XOU'P
M+<>+M(\,ZG?Z]J/A&PURW\+7WBKQ==:/+XGU?\,OV3_^";'QD_:M_8+_ &X_
MVNM&^(Q\)_"G]B)O%?Q&\/\ @SQ3/-J_A#XD^,],^%OA;Q]^U%8^%X].\47F
MJ_#+QUH'P*\ _!&^AU6X^&EWX?\ C-KMS\.O!-_XOT"T\%ZYXB\'O"Y'EV*X
M5RYX[$83)ZSSO$X6MCZF#=?%U)_O:=+!KV*56K^\7,U4K0HTH4YU)27*DXQO
M$^;T./ZRR?"YCQ#A<3P=A\9@<GH9@L)@7.KBL/7_ +0G]9F\-AW]5C.FJT:%
M3$5)UJ>'A%NL[?ZG=%?Y]W_!M!^W/\4/A[^W'X0_8T\8_$SXJ^(O@?\ '?X8
M_%+PO\+?A(VH6_B/X;^ /C!X'CUK]H./QCIUAXCU6.?X9:/J/@O0_CU:>)%^
M&=NH\?\ COQKX2O/'GA[6SHVD^*/!GVM_P %C?\ @FQ_P6E_;N_;&U6U\,:=
MI'B_]DC4M=\ _P#"G?#-I^TGX<L/@9\&;'2Y?$/@&/QS\1? WB+2_AUXPF^)
MRV6L>+?BO\2/$?A#X0_&;Q;X<\'_ !-_X5!\/?B%\7K+P7I'ART\"IPU3PF>
M8S*,QS?"8"C@J7MY8^K&4HUJ4J5*M3C0PZFIU<1.G5NJ"G?FA.$)U)>S53ZC
M!\;U,SX4PO$>4Y!F&98K%8A8..3X:<95*6*5:5";K8OV;A3P<)14Y8QT+0IU
M(3JTJ257V7]G=%?Y8W_!0G]E'6O^"2G[9FA?"7X)_M;^(/'/Q1\(_"KP_P"/
M[_XO?":+4O@7X^^$OB?XFK\0_"U]\/?M?@KXG^+_ !1X3\4W/POCTOQ'?2KX
MFT'5]1\!?%G16?2%T#7;._UK^K_XS?\ !9[XA^"?^"!O[./[;W@:]\17W[3/
MQ_L?"O[,^F?$3Q?\/O $UEIW[1?@^?X@^#/CY\8=:\&:'KNF>#-/T._O/@'\
M:/%'PB33M UO0AXIUGX5KXQ^$4'A"Y\7>%-&VS'A.IAZN2QR['0S/#Y])PP-
M=X>K@GS*5*+=:C5=2=.E:K&:J-MN$9R<$E'FSR;CR.,EQ'0SO*JF0XWAC#K%
MYCAUCL/FE/ZLZ,ZS=/$X:%.G.M&,$I48Q?O3A&,Y3YX0_IZHK_,D_P""<G_!
M'?\ :2_X*T^'?VE/CE:_%'PSX4T/PYJ?C731\1/BOJ&I^.=9^.'[5&O:?I?Q
M"U+PAXQ:SO\ 4O&6C:+J=GXTTWQ3\7?C=XCL?$VL0WWC?0IO"?@?XOZQ<^.X
MO!/Y%_M92_&W_A-/C]I_[27B?Q]XN^/?AC7O&O@+XMZM\3_B#<_%7QQ;^.?A
MM-<_#W7/#FM_$"X\1^+U\2GP;<^&#X0T^[T_Q1KNA0:7H=E8^'-2N- M=,8>
MB^"L'*6:T\-Q%A\37R;!XFOCZ$,!6C4IXG#I/ZM!SKJG5I-QK0J8FG.3H581
MISH<TVH>(_$_'T\-E6.Q/!^,PN7YYF&'PF4XRKFF'=/$4*]1P=>M3I8:I6PE
M;DY:U##5*;IXNDJTZ.*Y:2E4_P!D^BOX"O\ @XA_X*Z_&_Q=^T1\8?V+/@Y\
M2(_ ?[-OP&6[\(?$S5O@[\09[O5/C[XMUGX=6T7Q6\*?$[7O#<]BEMX0^'5Q
MXF\6?!;Q%\!6N[[2I/&_AOQGJGQ2EU[6X_"/A;X4_&O_  4%_P""3_[6_P#P
M1RL_V=_VC-#^.J7D?C&&/P3=_&+X$^*?$_PI\:?!C]H;Q%X$\97'BGX;>%]6
MM=;T;X@ZQX0\1_#NR\;P>#OB]X<7PY>>)M&TKQSHGQ"\"?"R2\\(V/C_ )L'
MP;"O0RY8O.<-@,RSBA]9RS+JF&KU?;4I+FI2KXJG+DPWMH^]34J=1R3Y8J51
M2IQ]'-?$*O@\;G%/+.&\7G.6\.3C#/LTI8[#898.:7-6CAL+5A*IC98:*G[9
M0G2]G*G-SY:*59_Z7]%?C_\ \$//V^?'/_!0O]A71?B;\6]]Y\;/A3\0_%/P
M&^,7BBV\,:3X2T#QYXL\*:1X6\9:!XY\/Z3HVL:C9+)XA^&7Q!\ 7'CF6TTG
MP5HH^*T?Q MO!_@;PWX&MO"]L_[ 5\;7HU<-6K8>M%PK4*M2C5@]7"I2FX3B
MVKJ\91:T=M-#]!P.-P^8X+"9AA)^TPV-PU'%8>;5G*CB*<:M-N.\9<LES1>L
M97B]4%?G?_P5&^&E]\1/V0_&=[I,-Q/K'PRUGPW\5K"&R0O?W0\$ZBFHW5C:
MA069KJVWAT!4.B')X K]$*H:KIEEK6F:AI&I01W6GZI9W-A>V\JJ\<UK=PO!
M/&ZL"I#1NPY!]:>'K/#UZ-=*[I5(5+;7Y9)M?-:?,^KX2X@K\*\3Y!Q)AX*K
M5R/-\!F:HMVC7AA,13JU</)](8BE&=&?]V;/Y[_^">Z:-^T7^R-^U-^R%?RB
M6^\[6O%G@X:E(ADN8OB+8?\ "2Z7/;H3EK'P[XG2SL+@C"P3B2(G<#C^*K]H
M;X<:Y\+_ (H^)_#&NV<]CJ.F:MJ&FWEO/ T#QWVF7<MC?B1' (,UU%)/$&PS
M0R(X!4AJ_JE$WB+_ ()@_MX1&^BN!\.8+ZYA@G'FE/$7P)\7:DUXZQ33$Q3:
MCX"U6>74=9F 9H8FBMTVB("HO^"Y?_!/*V^)GA^']MCX"VD6N^'?$VF:=K?C
MR+1$^T) UW90MIWCB&.(.S:=JUFT%IK+J FGRQ1SNB/.U?<87$0P>8<_-?!Y
MK"%6C4TY5B.6*G"3=DI5%RSMO=J&K3M_I-PGQ1EO WBE]>6+4N /''!8#B#A
MS.)2Y<+2XICAL/2S'!XB=^2CB\SOAL=4A)\T,36IX&SKPJJG_'D#D?SKLO >
MG+K'BO1-.F4O!)>I),!_SSA!EQ]"RJ#GCGM7(7=I<Z?=3V=U$\%S;2-%-%(I
M5E=#AE(/OT]1@UTG@_Q)_P (OK,>KBT6\:.">$0NQ0!IT"[]PYRG)'K7T553
M5.;I:MQ?+K;5K35Z>C?S\_Z]KU*TL)B%A]<2\/45%*22E.5-\DHRORV;::=[
M;-.VI_6U)\*_VA/"7[+?[-'PP^''[%'[-/[0OA?7/"C?%OQU/\;/$GA>":S\
M>>)I-^GFSTW4/$>DW)-II+-"MR\,D95E2,X3 \VL?A9^UC8WEK>6_P#P25_X
M)XVDL$R.+BW\0>!HYXE)VR-&P\;Y#>4S@<<9K^?+]IK]J/Q!^T5\0="\:0VF
MI>!K30?AUX)^']IH.F:]?M9K#X.TPZ>-04).BK)J!9IY4"@JYY+'FOG_ /X2
M7Q-V\3>(OPUO4O\ Y)KY^CE&*G#G=6G!S<I.G)5').3;LW&K:ZO9-K;==#^?
M<C\'.)*F ]MC<TX>PF-S"OC,QQ^&KY;Q96K4\3F.)JXJM2Q%;+?$' 8*O*DJ
MJH*I0PE&$J=*"44HJ_\ 0-_P59^&'CG5/V:_A3\4/B5\*O!OPD\<_"_Q[>_#
MR#PI\/M6TO5_"]E\-_$>GMJVB1VCZ7J&I):+9ZA:+;I;SW)($C21@*QS_/N#
MT(KZMB_:TU.7]F[XD_L]ZGX<?5U\?:[X%UZ'Q1J&K75S=:'<^#+::U;[-!,[
MAFU..4"4@C:% .3S7R/'(5X/3W[?3^5>OE5*OAJ,\/66D*C]F]E.,O>DTFVT
MDW9/I;Y+]D\*LDSKA7(,3D&<>Q<<#G&-EEE;#*=/#UL!C(T<<YT:-;'9EB</
M"&.Q.-I1IXK&UJS<'-RY9P-2(-,Z1HI:21U144$LS,P4!0.223T&37]C7_!"
MCX+P?!+X(_&+]K+QO#!8:3H7AC4-&\/7M]_HRO)I=FVJ^);B*9P%DMK^9M*T
M^&16V/.60,6&%_G>_P"">W[%OQ"_;!^-?AKPIX7TRZ72DNXKS5]=>W8Z?H6C
MPS*+_7+V9D,21VD6];.)R3>WQCM54ELC^I/_ (*5_%#P%^SA^S_\/?V!?A&Z
M10/H>C'XBP:>P^UQ>"[:5)8M)NC$PFCUSXA:X=MB=^Y9S!'@1.@7ASFJL1.E
ME-"7-4Q,H2Q#C_RYPT9*4W.VTI6Y8I_$W;1M7_(OI$<2RXOQO#W@5P]6=?-N
M*\;A<7Q74PKYY9)P?@:]/%9CB<3R:4ZN*A26'PM&;C+$.4Z"2E6H1J>._P#!
M+G1M;^,7[;#_ !=N$U:*#PMIOQ4^+^MF\YMX]6^-?VGPSIVARL"P6\TO2UCG
MCMBP:.UN-^,$X_J%K\W_ /@F-^S5J'P"^ <>O^+[$6GQ*^,%W;>./%L#1LDF
MEVDUHD/AO0O+E'FVLFFZ-]FCO;;*H+WS"4#+D_I!7Q6;XB&(QL_9V]E1C&A3
M:=TU3;<G%]8^TE/D_N<K/\XOI \78'BWQ)S*>4.E+)N'L+A^&,JG0:E0J8?+
M*F(JXJIAYQTJ86>:8S,'@YKX\&\.^H4445Y9^)A1110 5\$?\$Y?^2":W_V5
MOX@_^E.GU][U\$?\$Y?^2":W_P!E;^(/_I3I]?)YE_R6/"W_ &*>*O\ TOAX
M\^M_R,L!_P!@^/\ SP9][T445]8>@%%%% !1110!D:^Y30M88 DC3+X #J6-
MM(H ]R2 *^7;F0RW-Q*>3)/+(3ZEY&;^M?2?BW41IVC32Y7>[H$#AC&WE-]H
M>.3:"56X6$VB.<*)[B%6/S 'YEK6&WS_ $1G4>R_K^M IZ#+H/5U'YD"F4^,
MA9(V.<*ZDXZX# G&>]69GU)X><R:'I,A.3)8V\A(& 2\88D#L"3D>U;-8_A]
M&BT/2H6QOAL;>!\=/,A0128Z<;T;'M6Q7.;K9>B"BBB@84444 %%%% !1110
M!X/\21C4T./O3S_II^CBO-Z](^)$BMJBQ@_/'/-O'IOT_1V7\P#7F];K9>B_
M(QE\3]0KV3X8.!%<)GYGDO6*_P"S$NDA3^<S=J\;KT3X=7ZVVK>2[,!,IB&6
M18D6Y:)&8AL,\LEW%IL$2H20LDK%2 652UB_ZVU"+]Y?UOH>^4445B;!1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7\W?
M_!4;[7^W#_P47_8M_P"":>GSW$_PR\,78_:)_:-ALY76WFTJRMM3N;/1=1EB
MD273[Z#P1I&LZ;I=RJNHOOBQHTI5FB0)_2)7\ZG_  2SLF^.?_!4'_@JW^UC
MJR+>/X7^(,'[.W@;4Y"9A)X<T;Q%J>AW'V,MN6!!H'P@\!R#RF#-%J#!@!(^
M_P!C*7[#Z]C_ +6!P<G1?;$XF<,+1EZT_:SJKLX)]#^@? ::X;7B9XJ.T<7X
M:\ 8VOPY5:<GA^,^,<?@^"N',9"-G%U<L6=9CG%!NWL\1EM&JK.GS1_8/]L3
M]I#P=^Q5^RK\6OC_ *W96":1\*/!+R>&?#:!+"RUGQ/=-;>'? '@^VCMA']D
MM-8\3W^B:,[6D9_LW3II[Q(O)LV _P K;XH_$[QK\9?B/XV^*_Q%UR[\2>./
MB%XFUGQ=XIUN];=-J&LZY?3:A>RJ@_=VUNLT[1VEE;K':6-JD-G9PPVL$42?
MV3?\'4_Q[O-!^$7[-7[-^E7LD2?$/QEXI^*GBR&"3RVDTWX?:=9^'O"]G> '
M=-9:CJ7C/7+Y86!C-[X<M9SF2WC*_P 2JMC@]/Y5]?PI@XT<#+%RC^]Q<Y6D
MUJJ-*3A&*OJN:HJDG;22Y+_"F?W?]!_@3#9!X;XKCG$4HRSKCK,,5[/$SC>K
M2R#)L56R_#8:,I7E%8C-*.98S$2@U'$0^H2J*3PU*2NJW<?Y]C5A'X]CU'I]
M/\\U05B.1_\ KJ=6[C_/L:^I/[CIU+V_JW_ [?U;^JGXL^!OV!_V@?\ @G!_
MP2__ &AOVP_C=\<OA-'X6^#OB#]F+1;SX/\ @.S\=V5WK7PMURYTNXTKQ4UQ
MHNJRZ-J*VOAZYU#1(V>%=2T^6]FC1Q:%J^._#_PB_P""&&G^;+I_[;W[9NZ=
ME5V/P#TUB5BSM7/_  A,N!N8MP5R0,C(R?=/^"''[1?A+Q_\,OC9_P $[OB-
M\/?@9\6?%7B6?6OCU^QSX1_:2\.67BCX5:G\=M&\*W.GZ]X$U2&]BEN-*N?$
M>CVD&J:%J6F&&XTZ%/'4T:W=S?QZ;J'NT/CO]N.U>2!O^#<C]EN)H99(G%K^
MROJ1AWHY1S#/#++!/&64E)X))()TQ+$[QLKM\;%UL)B<3A95L5!0K5*E.,<5
MAJ%-TJTO:0<5B*<^9)MP;>\HNUM3^')8KB#@WB#B_@:KQ!QCEE#*^(,SS?)Z
M%'Q"\->$\GQ'#?%>:8_/LIJY5A>,,AKX[%4\)4KXS*L;6AB\33CF67XE?N%*
M%(YS]D+]GS_@DI\3?VF/@7X-^$'[5W[6_CKXC7/Q*\,Z[X5\*ZU\%=-T?1-;
MOO!5ZOC>6UUW5CX+M?[+T/[%X=N9-7OQ<6[6U@D\B2I)L8?$7[>WQ1LOB;^W
M/^U;XTTJ]COM)O?C9XMT72KR)]\-UIW@J2W\"VMQ$P.&AG3PUYL+ X*.IZ$5
M^U&C?M*>(OV0_P!D;XQ?M<_M ?\ !/G]E;]B+X_W5U?_  ;_ &/?"?@+X4VG
M@[XS^)/'GB30M0M/$?C+43>+/J.D> O#VGWL>I7+6RVTFK:?H>N6UY+%!JWA
MY-6_E/TS5II&\VYNI;NYF=YKF[N',EQ=W4[M+<W5RYY>XN9GDFG=N9)9'<Y+
M&N[+E4KXBOB)3K3ITJ:PM.5:K1K<TW)5*[A.A3IP<%RT8MJ_OJ:YKQLOJO"7
M"YKQ'Q9Q3Q;C,9GV.RS)<LH<$Y5B<\SWAKB2&*S&OC*>=<35<JS3A7*LKRNM
ME^&6'X<P,ZE+ZY_PIT<SPTL0IX2I1I_1&EZID*=V,8SST_SZUXY^T?IMO>Z%
MX=\2(@%Y87[Z-/*N TEE?0S7=NKGJ1;W-K,8_P"[]JDQP<#=TS4\;2&]/\^_
M^?2N&^.6O1MX6T?2 X,]]JXO0F1E;?3[::-GQ_=,UW&@)ZX<#H17M4DXUH>M
MODUK_P /_P %']$9%1JT<^RZ=&ZDJ\E)+2]*5*:JI^2IN3U>C2[19_6__P &
MV?[;]_\ %7X/>,OV._'VL27_ (L^!=LOBWX73WMP9;V_^$NLZDEIJVA(9))+
MB:+P%XKO[06TLK!(='\9:/HMC%%8Z#&B]S_P63T&_P#V1/VH?V,/^"IO@&SN
M(6\#>/M.^#/Q^MM+BD,OB7P%K-MJDMB;FWMRL<MS>^#I_B%X3DU.^CN#'=R^
M!X8R'TVQCK^77_@CY\>+OX ?\%$_V9O%"WTEGHWB[Q[8?";Q3$'*6MWH7Q5S
MX&S?@?>M-*U76M+\1#/RQ76C6T[<1<_W>_\ !5_X06WQN_X)W_M6^#Y+07=]
MI/PKUGXCZ&JJ#<+KGPI>#XD:>MHQP8[B\?PP^F94@R07T\#9CF=6^0S.C#+>
M(J%7EMA<R7)B8;1<,2WA\7%]_B]OY3DK;'\"^-'#V5^$'TN>',[AAH0X'\8J
M"P?%N71M3P5;+^,JN(X1X\PM2%E&?/\ 6(<3\LKPIYABZ,X<GL*:C]_Z9J=A
MK6FZ?K&DW<&H:7JUC::GIM_:N);:]T^_MX[JSN[>1>)(+FWECFB<</&ZL.#5
MZOS>_P""1'Q6NOC)_P $W_V4/%M_=-=ZEIGPY;X=:A++(9;HS?";Q!K7PQA>
M\=BSFZN;'PG:7LCR$O,+E9R2)0Q_2&OCL31EAL17P\OBH5JM&3[NE.4&_FXG
M^?/%_#V(X1XLXGX4Q<N?%<,\0YUP_B)VY?:5LGS'$Y=4J)=%.>'<UY-6/SA_
MX*I?L6+^W'^R'XV^&VA0PK\5_!\T/Q+^"NHO(EM)%\0O#%K=FWT-KQFB%M:^
M,='NM5\*RRS3I9V-YJFGZW<K*VCPJ.,_X)(?MS_\-G?LT6-CX[N)K']H_P"!
M<EI\,OC[X9U9)+3Q#_PD&DI/I^D^-[[3KE(+R >-;73+FXU,36EHMGXQT[Q9
MI$5M';Z;;R3?JC7\YO\ P42_9M^,W[#W[13?\%8/V(M$DUA1&\?[9/P-L%GB
MTKQYX,FEMIO$7CJ.QL8I7$-[%9P7_C*]L[2XNO#GB73M,^)[6.I0CQA<0>G@
M94\;AI956G&G5]HZ^75INT(8B:C&IA9R>D:>+48\LKI0KP@W=3D?LOAGB\L\
M1N#\5X'\08["9;F[S6MQ'X09]F-:-#!8'BW&4:.&S;@O,,75?)@\HXYH8;!Q
MPE>4Z6'P/$V"R^M54J>.Q+/R _X.%?\ @D]K'P:^(?B/]NCX">&I+KX,?$K6
M?[1^-OAO1+,N/A?\2=:N\7?C#[/ "T'@KXAZI<?:[FZ,;6VA>-[R\LIKBWLO
M$GAO3K?^6<'(R*_UEOV:/VF?V>OV_P#]GZ+X@?#NYT?QOX!\::1=^&?'_@#Q
M/9Z=?ZAX>OM0T_[/XD^'GQ%\,7)O+9+D6MU);7-K<I=:1KVE7$6I:7<:EHNH
M6MW/_)1_P5/_ .#=+QY\/-8\2_'3]@;1=0\?_#2[DN-8U_\ 9\AFGU#X@^!F
MD=YKK_A737+R77C[PO'N;[)H!EF\<Z6@AM;6/Q>LDUY8_29-G7LK9;F5Z&(H
M/V,)UO<4E'W52K.5N2I&R49R:C-)7DII.?\ 6_T?OI$?V0X>$7C%.MPSQ7PU
M5_L/+\USU2P<:ZP;6&I9-GU3$\JP&:X*,8T,/C<2X87,<-"G&O6ACXQJ9G_*
M/&Y!4\94@C(!!(.0"#D'W!!##@@]_J+]KW]K3XG?MK?&_5_CY\7++PGIOC'6
M/#G@[PO-IW@C2[W1O#=KIO@KP[9>'=.^PV&HZIK5Y%+=16;W]]YFHS1&]N[@
M6L=K9K;VL'S/JNDZKH6I7VC:WIE_H^KZ7=W%AJ6E:I9SV&HZ??6DK075G>V5
MU'%<6MU;3(\,]O-&DL,J-'(BNK**BMV/X'_/>OJ^2#J0JRBG.$91IS:NX1J<
MKE'TER1UZI+Y?W']1R[$YA@<XJ86C5S' 8/'8/ 8UQYJN&P>:SP%;'4J$[V5
M+&3RW 3JV5Y?5J5G:_-;!Z$?G7I/PA^)_B3X+?%7X:?&+P:-//B_X4^/O"/Q
M&\,IJUM+>:5)K_@O7[#Q%I,6J6D-Q:376FS7VG017]M#=6LL]J\L4=S [+*O
MF"L1]*F!Z$?G6S2G&49)-234HO5--6:]'_6IZ]2G1Q>'KX/%4X5\-BJ-7#XB
MC47-3K4*\)4ZM*:V<:E.4H23TE%M,]H^//QH\4_M%?&OXI_';QO9Z)I_B_XN
M>.?$/C[Q%8>&[2YL- L]5\17\M_=6NCVEY>:C>0V%NTGE6ZWFH7UXZ()+J[N
M;AY9G\K1\<$_0^G_ -;_ #TJDA+G !+>@Z\<Y'L.I]._K7[^?\$S_P#@@[^T
M)^V+J?A_XE?'73M?^ 7[-K217\FKZS8'3_B1\1;%'5UL_ 'A?5;?SK#3=1BX
M3QSXALTT-+>>*^T*P\6^7/91\U?$87+\.IUZD*%&G%1BGN^5:0IP^*<K+2,4
MV]WI=G@<2<9<%>%G"\,SXCS3 <.</Y5A:>#P5*I+]Y6AA*$:>'R[*<%#FQ6/
MQ:HPA"EA,+3JU>2//-1I0G4AY)_P1V_X)B^)O^"@OQTM-:\7:9J>E_LR?"S5
MM/U+XL^*E6>SB\2W<)CO[#X6>&K]/+:;7O$D8B.MW-C,LOA7PO//K$]Q;ZG>
M>&;/6?[W_P!K/]I3X5_L(_LQ>+_C'XHM=-TSPO\ #GPY:Z%X#\$:8+?2E\1^
M)/L?]F>!?AYX:L[>+9;+>SV]O:[;*TEAT'P]9ZEK,MNNF:/=-'N>&/#'[-7[
M!'[.2:1H\/A+X&_L^_!KP[-=W=U=3-;:=IUHC![W5=5OIC<:IXB\4>(-1EWS
MW,S:GXD\4Z_?1P0KJ&J7L$$OX#_#3PUX^_X+J_M7Z5\>_B9X;UWPC_P31_9M
M\2WD'PE^'^OQO:2?'SQK87")=:CK=FKO;7\%Y+;PGQG=1O=Z=X>T&.'X;:!<
M7.MZIXR\2P_"8C$O.\3+&XKGH9/@'JF_>G=IJC3Z2Q>*Y8IJ+:I4TI2?+#FG
M_F/Q7QC7^DGQGC/$3CCZ[PO]'_PO;]K3G*,<9C_;3A6I<-Y6XU(TL=QYQO4H
M8?#RI86K.AD65PABL16EALN6)QWU[_P1*_9F^(&A> /BA^W9^T/%+<_M%?MO
M>(9OB%<27]N\%WX=^%M]?W&M>&K*UMIGG;2;?QA>7K>*(M-M9S9P^$[?X?V(
M@MI](D@C_="HX8HK>**""*."""-(88846.*&*-0D<44:!4CCC10B(@"JH"J
M !4E?/XW%3QN)JXF:4?:27)3C\-*G!*%*E#^[3IQC!=TKO5L_E/Q$XWS#Q%X
MQSOB[,:%'!SS/$4XX'+,+I@LER? T*6 R7(\!%1@HX+)\JPV$R_#6A%RIX=5
M)KVDYME?S=?\%!;8_MZ_\%7?V2O^"?Q)U+X.? #3#^T=^T1I8*RV&H71M8M7
ML= UVS(<M!<>&QX6\+V=VGDR6T/QCU+# A''](M?SM?\$>+1_C5^VY_P53_;
M#U=5N[C6_CB_P6\#ZD1YLD/A#PYKFMW$MA]I(#,H\->'_A5'Y2@(BV$751%C
MNRI^PAF&/^W@\(XT'UCB<7..&IS7G3ISK5(]I036Q^E^!E3_ %9P'BKXIQ]W
M'>'_  )6PG#5:-O:83B_C['X?@W*,PI7T5?*\MS'/<UP\K-T\3@:-:-G31^I
MW_!0O]K31_V'?V/_ (P?M!7*64VM^%?#RZ-\.=$NE!M];^)'B61-"\$::]JC
M1R7&FVFJW46LZ[!;%9HO#6D:S<Q%?L^X?Y9?B[QAXE\>^+/$OCGQCK-_XC\6
M>,-=U;Q-XFU_5)S<ZEK6O:[?SZGJ^JW]PP!GO=0O[JXN[J4@>9-,[X&[C^OC
M_@ZQ^/-Y#;?LM?LRZ==LEC=MXL^-_BZR$I N)[<_\(-X N/*7&X6Z2?$A&+D
M@FXCV %&-?QNJV.#T_E7V/"N#C0R_P"LN*]KBYRES6U5*G)PA'T<E.?GS*^R
M/[^^A-P)A>&?"W_6^K1C_;/'F/Q.+GB)17M:6293BL1EN68.[5XTYXFCF.8M
MQ:5:.-P_.FZ%-QO*V.1T_G4Q.Z-U'\2LH]B01_7G\ZI*V/I_GD5.K8Y'3^=?
M3-733V:M]Y_:E.I?3^EY>G]>G]9G[=7P_P#^";?QP^'_ .P=^UA^UU^T%^T-
M\)?$GQO_ &-/A7H&B6WPI^&^G^-_"VL7OPOTZ"U\9?;-3ET/59;7Q)HVO>*_
M[*U*P>Y 6V@L9DB5Y)2WP_X?^$W_  0TTZ$KI_[;W[9NV>0RL3\ M-)9E&P9
M;_A")>$ ( WE<LW')%?5G_!(_P#:)TSX]?L3?%3]C*^^ _[/7[2W[2G[,L'B
MOXU?LA_#/]I+PCIWBWP]XZ\#Z_J5KK'Q3^'?@YKXQW.F>-M/U ZIJ&D+:WEO
M%J9\4Z/'?1)H7AW5M0T_M;/X@_MP*B ?\&Y/[,,([*G[*>KVX4'D?*[?+UY!
MQ@Y[@@?'4IUL+4JX2=?%0]A4G&$%B\)0I^QD^>E*$<12G>/)))ZNTU-*3LS^
M$\!B^(>$,5GO .(XBXRR]\)9UCL'@,-'Q(\+N%<LK</8[%5LSX8Q>4Y?Q9P_
M5S"I@GDV*PN%KUEBL92IYK@\RPT:ZGAIT8>E_P#!,_X+_P#!+K5OVN_ASXK^
M '[3W[37Q$\>?!_3O%OQ>_L+Q_\ ";3O"?@J'0O"_AV]TW5-7\2Z^/"6FOI]
MGIK>(+6:V"7D,ESJ7V*V!99'5OPI\8?$!O'WQ$^(/CXR%AXZ^('C;QHA))8Q
M>*_%&JZ_#G/\7E:@G'?&."*_?#]H[]I/4?V5?^">'B35?B!^R%^S?^Q;^V3^
MV=!XJ^$'@3X;_!/X?6G@KXB>%/V>UEL;3X@^,OB7,Z3:I8/J"Q7=IH&C":V@
MAO\ 7?"%](LNHV6K0:3_ #,Z3J2HL:(0JJJHJCA0J@ * .@  &/X<?0UZ&61
MJ5JF)Q4Y591?L\+1=:I2JR<:#G*K*-2A3ITY0=6HXQE%/WJ<M91L??>#V"S3
M/<SXRXVS#%9YC<)7EEO!V15\]S?(<]K5Z'#&)S?$9UC,OS3AK+,KRG&936SG
M-ZN!PU;#TZZGB,IQDHXFK3]GR_1>EZI]TAO3O^A_J*^9/VC=-@@\2Z%XBME$
M<NMZ9)#>%0,27FCR11),_'S2/97%K$Q;.Y;=<Y.<^K:9J>-I#>F1GK_]?_T+
MZY%>*_'O6X[W4?#>F1MNDT^PO+R<==AU&:%(4/HQCLC)CKMD4]"*]J@FJT;7
M^U?_ ,!_SM^#6A_0_"U.K0X@PTZ?-%.GB8UN7K2]C*2OY>VC2?;F47W1_?S_
M ,$1?VVKW]LO]B[PZ/&>K-JGQ@^!MW;_  J^(UU=3&;4M=M-/L(IO WC6]+M
M)/--XB\-JNGZGJ-S(T^K>*?#GB:_8(LR*/C_ ,<6H_X)\_\ !<OX?^--* T7
MX%_\%+/#MSX5\5V:-]GTF#XVKJ%I9F\M[4*(I=6O?'DG@O5;G4)Y?,0_%KQ8
M(U5&"2?CM_P;3?'6\\ ?MP>)?@Y/>%- ^/GPMUZQ73RY59_&7PY63QMH%\1N
M"R/8^&+7Q[:1(5+?\3>1E*X8-^[?_!Q#X&O9?V.?AY\??#;_ &#QM^S5\?\
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MKX(_8H_Y'/\ ;,_[.I^(W_IUOJ^2SK_DI^#/^O\ GW_JGJ'GXG_?LM_Q8O\
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M=^%GQB_;$^&/BGP/\5]*^,?POBT+X@_!KQ5I?PP\5>%O'D'Q#\ V_AV/XK?
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MKXS6:04)9/A^#L)P_AZCJKZQ*OA<3@I1YZ*5U%T</)N=[<VG4_A(_P""!/\
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M7AN/6K)YXP%NK=-P;:6)6,,=Z!5:0LBLWF11J?M46(RCSPV3V_SO+&\,CQ2
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MX*M? ?X4?MA_$OQY^V5\#_%G[/-YK7A/XO> ?V>O'GB[P3\./V\K+P%X?O\
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M$<2<!\/8=K]]FF(XJ\$,LI4J=O>J2QE?.:KA%+5SPL.=;PLS[$_90_X(T?\
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MY^5^O8;Q#C&K3I)1I5)-I25Y).RWN]TMM;='U"BBBMCF"BBB@ HHHH ****
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M3:M9T\ JD<'!I1BDXT$TDDGH@HHHKD/A0HHHH **** "BBB@ KX(_P""<O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MM.CB)Y-C,8Y8_#^QJ)5%B,HSRMBHXR$E&5*.8X2FH?NZO+\M YY%3!Q@ECC
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N:\9>#_#'Q"\(^)_
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MZV6YOB)>PPL:D]5@<VK8?$4936'HU\QY)8B?\X@(QQ_^JIE;/!Z_SKTGXF?
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M/]3Q7$<L//\ >8;(<KPOM,JX2R^JO:T<!/%9ABG/&9G55(HHHKRC\,"BBB@
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M%-Q7_P"'2C_\Q?U?TL?47_T&X_\ \'Q_^5^7]79\*_VI_P %'O\ H6_V2?\
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M_HIN*_\ PZ4?_F+^K^ECZB_^@W'_ /@^/_ROR_J[/A7^U/\ @H]_T+?[)/\
MW_\ B?\ _+^C^U/^"CW_ $+?[)/_ '_^)_\ \OZ^ZJ*/]5I?]%-Q7_X=*/\
M\Q?U?TL?47_T&X__ ,'Q_P#E?E_5V?"O]J?\%'O^A;_9)_[_ /Q/_P#E_1_:
MG_!1[_H6_P!DG_O_ /$__P"7]?=5%'^JTO\ HIN*_P#PZ4?_ )B_J_I8^HO_
M *#<?_X/C_\ *_+^KL^%?[4_X*/?]"W^R3_W_P#B?_\ +^C^U/\ @H]_T+?[
M)/\ W_\ B?\ _+^ONJBC_5:7_13<5_\ ATH__,7]7]+'U%_]!N/_ /!\?_E?
ME_5V?"O]J?\ !1[_ *%O]DG_ +__ !/_ /E_1_:G_!1[_H6_V2?^_P#\3_\
MY?U]U44?ZK2_Z*;BO_PZ4?\ YB_J_I8^HO\ Z#<?_P"#X_\ ROR_J[/A7^U/
M^"CW_0M_LD_]_P#XG_\ R_H_M3_@H]_T+?[)/_?_ .)__P OZ^ZJ*/\ 5:7_
M $4W%?\ X=*/_P Q?U?TL?47_P!!N/\ _!\?_E?E_5V?"O\ :G_!1[_H6_V2
M?^__ ,3_ /Y?T?VI_P %'O\ H6_V2?\ O_\ $_\ ^7]?=5%'^JTO^BFXK_\
M#I1_^8OZOZ6/J+_Z#<?_ .#X_P#ROR_J[/A7^U/^"CW_ $+?[)/_ '_^)_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)K!UJ^%R:+E>EE-)Q@XE%%%>6?BH4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
4* "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>ortx-20211231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-03-30T03:21:51.4998028+00:00 -->
<!-- Version            : 5.0.1.728 -->
<!-- Package ID         : 1b558024b59f49cabedb23f437fea13f -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ortx="http://www.orchard-tx.com/20211231" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.orchard-tx.com/20211231" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" namespace="http://xbrl.sec.gov/country/2021" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/currency/2021/currency-2021.xsd" namespace="http://xbrl.sec.gov/currency/2021" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" namespace="http://xbrl.sec.gov/dei/2021q4" />
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" namespace="http://www.xbrl.org/dtr/type/2020-01-21" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/exch/2021/exch-2021.xsd" namespace="http://xbrl.sec.gov/exch/2021" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/negated" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/net" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2021/naics-2021.xsd" namespace="http://xbrl.sec.gov/naics/2021" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/sic/2021/sic-2021.xsd" namespace="http://xbrl.sec.gov/sic/2021" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" namespace="http://fasb.org/srt/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd" namespace="http://fasb.org/srt-roles/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" namespace="http://fasb.org/srt-types/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" namespace="http://xbrl.sec.gov/stpr/2021" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" namespace="http://fasb.org/us-gaap/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd" namespace="http://fasb.org/us-roles/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" namespace="http://fasb.org/us-types/2021-01-31" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType id="TemplateLink" roleURI="http://www.orchard-tx.com/20211231/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ortx-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation Links, all" xlink:type="simple" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ortx-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ortx-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ortx-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" id="Role_StatementConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" id="Role_StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>100020 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>100030 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity" id="Role_StatementConsolidatedStatementsOfShareholdersEquity">
        <link:definition>100040 - Statement - Consolidated Statements of Shareholders&apos; Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquityParenthetical" id="Role_StatementConsolidatedStatementsOfShareholdersEquityParenthetical">
        <link:definition>100050 - Statement - Consolidated Statements of Shareholders&apos; Equity (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" id="Role_StatementConsolidatedStatementsOfCashFlows">
        <link:definition>100060 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentation" id="Role_DisclosureNatureOfBusinessAndBasisOfPresentation">
        <link:definition>100070 - Disclosure - Nature of Business and Basis of Presentation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>100080 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecurities" id="Role_DisclosureFairValueMeasurementsAndMarketableSecurities">
        <link:definition>100090 - Disclosure - Fair Value Measurements and Marketable Securities</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRevenueRecognition" id="Role_DisclosureRevenueRecognition">
        <link:definition>100100 - Disclosure - Revenue Recognition</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssets" id="Role_DisclosurePrepaidExpensesAndOtherCurrentAssets">
        <link:definition>100110 - Disclosure - Prepaid Expenses and Other Current Assets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipment" id="Role_DisclosurePropertyAndEquipment">
        <link:definition>100120 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIntangibleAssetsNet" id="Role_DisclosureIntangibleAssetsNet">
        <link:definition>100130 - Disclosure - Intangible Assets, Net</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureOtherAssets" id="Role_DisclosureOtherAssets">
        <link:definition>100140 - Disclosure - Other Assets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherLiabilities" id="Role_DisclosureAccruedExpensesAndOtherLiabilities">
        <link:definition>100150 - Disclosure - Accrued Expenses and Other Liabilities</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRestructuringCharges" id="Role_DisclosureRestructuringCharges">
        <link:definition>100160 - Disclosure - Restructuring Charges</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeases" id="Role_DisclosureLeases">
        <link:definition>100170 - Disclosure - Leases</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayable" id="Role_DisclosureNotesPayable">
        <link:definition>100180 - Disclosure - Notes Payable</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareholdersEquityAndConvertiblePreferredShares" id="Role_DisclosureShareholdersEquityAndConvertiblePreferredShares">
        <link:definition>100190 - Disclosure - Shareholders&apos; Equity and Convertible Preferred Shares</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensation" id="Role_DisclosureShareBasedCompensation">
        <link:definition>100200 - Disclosure - Share-based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLicenseAndResearchAgreements" id="Role_DisclosureLicenseAndResearchAgreements">
        <link:definition>100210 - Disclosure - License and Research Agreements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCollaborationAgreementWithPharmingGroupNV" id="Role_DisclosureCollaborationAgreementWithPharmingGroupNV">
        <link:definition>100220 - Disclosure - Collaboration Agreement with Pharming Group N.V.</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100230 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>100240 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureBenefitPlans" id="Role_DisclosureBenefitPlans">
        <link:definition>100250 - Disclosure - Benefit Plans</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactions" id="Role_DisclosureRelatedPartyTransactions">
        <link:definition>100260 - Disclosure - Related-Party Transactions</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSubsequentEvents" id="Role_DisclosureSubsequentEvents">
        <link:definition>100270 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100280 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>100290 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesTables" id="Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesTables">
        <link:definition>100300 - Disclosure - Fair Value Measurements and Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" id="Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables">
        <link:definition>100310 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentTables" id="Role_DisclosurePropertyAndEquipmentTables">
        <link:definition>100320 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIntangibleAssetsNetTables" id="Role_DisclosureIntangibleAssetsNetTables">
        <link:definition>100330 - Disclosure - Intangible Assets, Net (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureOtherAssetsTables" id="Role_DisclosureOtherAssetsTables">
        <link:definition>100340 - Disclosure - Other Assets (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherLiabilitiesTables" id="Role_DisclosureAccruedExpensesAndOtherLiabilitiesTables">
        <link:definition>100350 - Disclosure - Accrued Expenses and Other Liabilities (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRestructuringChargesTables" id="Role_DisclosureRestructuringChargesTables">
        <link:definition>100360 - Disclosure - Restructuring Charges (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesTables" id="Role_DisclosureLeasesTables">
        <link:definition>100370 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableTables" id="Role_DisclosureNotesPayableTables">
        <link:definition>100380 - Disclosure - Notes Payable (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationTables" id="Role_DisclosureShareBasedCompensationTables">
        <link:definition>100390 - Disclosure - Share-based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCollaborationAgreementWithPharmingGroupNVTables" id="Role_DisclosureCollaborationAgreementWithPharmingGroupNVTables">
        <link:definition>100400 - Disclosure - Collaboration Agreement with Pharming Group N.V. (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>100410 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" id="Role_DisclosureCommitmentsAndContingenciesTables">
        <link:definition>100420 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" id="Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails">
        <link:definition>100430 - Disclosure - Nature of Business and Basis of Presentation - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>100440 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails">
        <link:definition>100450 - Disclosure - Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails">
        <link:definition>100460 - Disclosure - Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfChangesInLossProvisionDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfChangesInLossProvisionDetails">
        <link:definition>100470 - Disclosure - Summary of Significant Accounting Policies - Schedule of Changes in Loss Provision (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfAmountsRecognizedToOffsetResearchAndDevelopmentExpenseDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfAmountsRecognizedToOffsetResearchAndDevelopmentExpenseDetails">
        <link:definition>100480 - Disclosure - Summary of Significant Accounting Policies - Summary of Amounts recognized to Offset Research and Development Expense (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSecuritiesExcludedInComputationOfDilutedNetLossPerOrdinaryShareDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesSecuritiesExcludedInComputationOfDilutedNetLossPerOrdinaryShareDetails">
        <link:definition>100490 - Disclosure - Summary of Significant Accounting Policies - Securities Excluded in the Computation of Diluted Net Loss Per Ordinary Share (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAdditionalInformationDetails" id="Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesAdditionalInformationDetails">
        <link:definition>100500 - Disclosure - Fair Value Measurements and Marketable Securities - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesScheduleOfCashEquivalentsAndMarketableSecuritiesDetails" id="Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesScheduleOfCashEquivalentsAndMarketableSecuritiesDetails">
        <link:definition>100510 - Disclosure - Fair Value Measurements and Marketable Securities - Schedule of Cash Equivalents and Marketable Securities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesScheduleOfLevel2CashEquivalentsAndMarketableSecuritiesDetails" id="Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesScheduleOfLevel2CashEquivalentsAndMarketableSecuritiesDetails">
        <link:definition>100520 - Disclosure - Fair Value Measurements and Marketable Securities - Schedule of Level 2 Cash Equivalents and Marketable Securities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesScheduleOfAvailableForSaleMarketableDebtSecuritiesByContractualMaturityDetails" id="Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesScheduleOfAvailableForSaleMarketableDebtSecuritiesByContractualMaturityDetails">
        <link:definition>100530 - Disclosure - Fair Value Measurements and Marketable Securities - Schedule of Available-for-Sale Marketable Debt Securities by contractual Maturity (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails" id="Role_DisclosureRevenueRecognitionAdditionalInformationDetails">
        <link:definition>100540 - Disclosure - Revenue Recognition - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" id="Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails">
        <link:definition>100550 - Disclosure - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" id="Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails">
        <link:definition>100560 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails" id="Role_DisclosurePropertyAndEquipmentAdditionalInformationDetails">
        <link:definition>100570 - Disclosure - Property and Equipment - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfIntangibleAssetsNetOfAccumulatedAmortizationDetails" id="Role_DisclosureIntangibleAssetsNetScheduleOfIntangibleAssetsNetOfAccumulatedAmortizationDetails">
        <link:definition>100580 - Disclosure - Intangible Assets, Net - Schedule of Intangible Assets Net of Accumulated Amortization (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIntangibleAssetsNetAdditionalInformationDetails" id="Role_DisclosureIntangibleAssetsNetAdditionalInformationDetails">
        <link:definition>100590 - Disclosure - Intangible Assets, Net - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfEstimatedFutureAmortizationForIntangibleAssetsDetails" id="Role_DisclosureIntangibleAssetsNetScheduleOfEstimatedFutureAmortizationForIntangibleAssetsDetails">
        <link:definition>100600 - Disclosure - Intangible Assets, Net - Schedule of Estimated Future Amortization For Intangible Assets (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureOtherAssetsScheduleOfOtherAssetsDetails" id="Role_DisclosureOtherAssetsScheduleOfOtherAssetsDetails">
        <link:definition>100610 - Disclosure - Other Assets - Schedule of Other Assets (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" id="Role_DisclosureAccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails">
        <link:definition>100620 - Disclosure - Accrued Expenses and Other Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRestructuringChargesAdditionalInformationDetails" id="Role_DisclosureRestructuringChargesAdditionalInformationDetails">
        <link:definition>100630 - Disclosure - Restructuring Charges - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRestructuringChargesSummaryOfCashRestructuringChargesDetails" id="Role_DisclosureRestructuringChargesSummaryOfCashRestructuringChargesDetails">
        <link:definition>100640 - Disclosure - Restructuring Charges - Summary of Cash Restructuring Charges (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRestructuringChargesSummaryOfImpairmentOfLongLivedAssetsDetails" id="Role_DisclosureRestructuringChargesSummaryOfImpairmentOfLongLivedAssetsDetails">
        <link:definition>100650 - Disclosure - Restructuring Charges - Summary of Impairment of Long Lived Assets (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" id="Role_DisclosureLeasesAdditionalInformationDetails">
        <link:definition>100660 - Disclosure - Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfLeaseCostUnderOperatingLeasesDetails" id="Role_DisclosureLeasesSummaryOfLeaseCostUnderOperatingLeasesDetails">
        <link:definition>100670 - Disclosure - Leases - Summary of Lease Cost Under Operating Leases (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumBaseRentCommitmentsUnderOperatingLeasesDetails" id="Role_DisclosureLeasesScheduleOfFutureMinimumBaseRentCommitmentsUnderOperatingLeasesDetails">
        <link:definition>100680 - Disclosure - Leases - Schedule of Future Minimum Base Rent Commitments Under Operating Leases (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumBaseRentCommitmentsUnderOperatingLeasesDetails2" id="Role_DisclosureLeasesScheduleOfFutureMinimumBaseRentCommitmentsUnderOperatingLeasesDetails2">
        <link:definition>100690 - Disclosure - Leases - Schedule of Future Minimum Base Rent Commitments Under Operating Leases (Details)2</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumBaseRentCommitmentsUnderOperatingLeasesParentheticalDetails" id="Role_DisclosureLeasesScheduleOfFutureMinimumBaseRentCommitmentsUnderOperatingLeasesParentheticalDetails">
        <link:definition>100700 - Disclosure - Leases - Schedule of Future Minimum Base Rent Commitments Under Operating Leases (Parenthetical) (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" id="Role_DisclosureNotesPayableAdditionalInformationDetails">
        <link:definition>100710 - Disclosure - Notes Payable - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableSummaryOfNotesPayableDetails" id="Role_DisclosureNotesPayableSummaryOfNotesPayableDetails">
        <link:definition>100720 - Disclosure - Notes Payable - Summary of Notes Payable (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableSummaryOfFuturePrincipalPaymentsDueDetails" id="Role_DisclosureNotesPayableSummaryOfFuturePrincipalPaymentsDueDetails">
        <link:definition>100730 - Disclosure - Notes Payable - Summary of Future Principal Payments Due (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableSummaryOfFuturePrincipalPaymentsDueDetails2" id="Role_DisclosureNotesPayableSummaryOfFuturePrincipalPaymentsDueDetails2">
        <link:definition>100740 - Disclosure - Notes Payable - Summary of Future Principal Payments Due (Details)2</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareholdersEquityAndConvertiblePreferredSharesAdditionalInformationDetails" id="Role_DisclosureShareholdersEquityAndConvertiblePreferredSharesAdditionalInformationDetails">
        <link:definition>100750 - Disclosure - Shareholders&apos; Equity and Convertible Preferred Shares - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails" id="Role_DisclosureShareBasedCompensationAdditionalInformationDetails">
        <link:definition>100760 - Disclosure - Share-based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAssumptionsUsedInBlackScholesOptionPricingModelDetails" id="Role_DisclosureShareBasedCompensationAssumptionsUsedInBlackScholesOptionPricingModelDetails">
        <link:definition>100770 - Disclosure - Share-based Compensation - Assumptions Used in Black-Scholes Option Pricing Model (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfOptionActivityDetails" id="Role_DisclosureShareBasedCompensationSummaryOfOptionActivityDetails">
        <link:definition>100780 - Disclosure - Share-based Compensation - Summary of Option Activity (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfAwardActivityDetails" id="Role_DisclosureShareBasedCompensationSummaryOfAwardActivityDetails">
        <link:definition>100790 - Disclosure - Share-based Compensation - Summary of Award Activity (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails" id="Role_DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails">
        <link:definition>100800 - Disclosure - Share-based Compensation - Share-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetails" id="Role_DisclosureLicenseAndResearchAgreementsAdditionalInformationDetails">
        <link:definition>100810 - Disclosure - License and Research Agreements - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCollaborationAgreementWithPharmingGroupNVAdditionalInformationDetails" id="Role_DisclosureCollaborationAgreementWithPharmingGroupNVAdditionalInformationDetails">
        <link:definition>100820 - Disclosure - Collaboration Agreement with Pharming Group N.V. - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCollaborationAgreementWithPharmingGroupNVSummaryOfResearchAndDevelopmentCostsIncurredAndCollaborationRevenueRecognizedDetails" id="Role_DisclosureCollaborationAgreementWithPharmingGroupNVSummaryOfResearchAndDevelopmentCostsIncurredAndCollaborationRevenueRecognizedDetails">
        <link:definition>100830 - Disclosure - Collaboration Agreement with Pharming Group N.V. - Summary of Research and Development Costs Incurred and Collaboration Revenue Recognized (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfNetLossBeforeIncomeTaxesDetails" id="Role_DisclosureIncomeTaxesScheduleOfComponentsOfNetLossBeforeIncomeTaxesDetails">
        <link:definition>100840 - Disclosure - Income Taxes - Schedule of Components of Net Loss Before Income Taxes (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDetails" id="Role_DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDetails">
        <link:definition>100850 - Disclosure - Income Taxes - Schedule of Provision for (Benefit from) Income Taxes (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetails" id="Role_DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetails">
        <link:definition>100860 - Disclosure - Income Taxes - Schedule of Reconciliation of Income Tax Expense (Benefit) (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" id="Role_DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>100870 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesTaxesDetails" id="Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesTaxesDetails">
        <link:definition>100880 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities Taxes (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfChangesInValuationAllowanceForDeferredTaxAssetsRelatedPrimarilyToIncreaseInUKNetOperatingLossCarryforwardsDetails" id="Role_DisclosureIncomeTaxesScheduleOfChangesInValuationAllowanceForDeferredTaxAssetsRelatedPrimarilyToIncreaseInUKNetOperatingLossCarryforwardsDetails">
        <link:definition>100890 - Disclosure - Income Taxes - Schedule of Changes in Valuation Allowance for Deferred Tax Assets Related Primarily to Increase in U.K. Net Operating Loss Carryforwards (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfAnnualCommitmentsAssociatedWithContractDetails" id="Role_DisclosureCommitmentsAndContingenciesScheduleOfAnnualCommitmentsAssociatedWithContractDetails">
        <link:definition>100900 - Disclosure - Commitments and Contingencies - Schedule of Annual Commitments Associated with the Contract (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfAnnualCommitmentsAssociatedWithContractParentheticalDetails" id="Role_DisclosureCommitmentsAndContingenciesScheduleOfAnnualCommitmentsAssociatedWithContractParentheticalDetails">
        <link:definition>100910 - Disclosure - Commitments and Contingencies - Schedule of Annual Commitments Associated with the Contract (Parenthetical) (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" id="Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>100920 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureBenefitPlansAdditionalInformationDetails" id="Role_DisclosureBenefitPlansAdditionalInformationDetails">
        <link:definition>100930 - Disclosure - Benefit Plans - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" id="Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
        <link:definition>100940 - Disclosure - Related Party Transactions - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" id="Role_DisclosureSubsequentEventsAdditionalInformationDetails">
        <link:definition>100950 - Disclosure - Subsequent Events - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="ortx_MarketableSecuritiesFairValueDisclosure" name="MarketableSecuritiesFairValueDisclosure" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ortx_UnamortizedPortionOfFinalPayment" name="UnamortizedPortionOfFinalPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ortx_IncomeTaxReconciliationReductionInResearchExpenseForCreditsGranted" name="IncomeTaxReconciliationReductionInResearchExpenseForCreditsGranted" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ortx_IncomeTaxReconciliationDomesticDeductionForDerivedIntangibleIncome" name="IncomeTaxReconciliationDomesticDeductionForDerivedIntangibleIncome" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ortx_IncomeTaxReconciliationPermanentDifferencesIncludingShareBasedCompensationDeductionShortfalls" name="IncomeTaxReconciliationPermanentDifferencesIncludingShareBasedCompensationDeductionShortfalls" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ortx_ResearchAndDevelopmentTaxCreditReceivableCurrent" name="ResearchAndDevelopmentTaxCreditReceivableCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ortx_AccruedExpensesAndOtherCurrentLiabilities" name="AccruedExpensesAndOtherCurrentLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ortx_CommonStockSharesAuthorizedNominalAmount" name="CommonStockSharesAuthorizedNominalAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ortx_CollaborationMember" name="CollaborationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ortx_StockIssuedDuringPeriodSharesAsPartOfConsultingAgreement" name="StockIssuedDuringPeriodSharesAsPartOfConsultingAgreement" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ortx_StockIssuedDuringPeriodValueAsPartOfConsultingAgreement" name="StockIssuedDuringPeriodValueAsPartOfConsultingAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ortx_StockIssuedDuringPeriodSharesAsPartOfCollaborationAgreement" name="StockIssuedDuringPeriodSharesAsPartOfCollaborationAgreement" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ortx_StockIssuedDuringPeriodValueAsPartOfCollaborationAgreement" name="StockIssuedDuringPeriodValueAsPartOfCollaborationAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ortx_NonCashInterestExpense" name="NonCashInterestExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ortx_AmortizationOfProvisionOnLossContract" name="AmortizationOfProvisionOnLossContract" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ortx_NonCashConsiderationForLicensesAndMilestones" name="NonCashConsiderationForLicensesAndMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ortx_AmortizationOfPremiumOnMarketableSecurities" name="AmortizationOfPremiumOnMarketableSecurities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ortx_UnrealizedForeignCurrencyAndOtherNonCashAdjustments" name="UnrealizedForeignCurrencyAndOtherNonCashAdjustments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ortx_IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable" name="IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ortx_IncreaseDecreaseInOperatingRightOfUseAssets" name="IncreaseDecreaseInOperatingRightOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ortx_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesAndOtherOperatingLiabilities" name="IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesAndOtherOperatingLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ortx_IncreaseDecreaseInOperatingLeaseLiabilities" name="IncreaseDecreaseInOperatingLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ortx_ReceiptOfFundsFromConstructionDeposit" name="ReceiptOfFundsFromConstructionDeposit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ortx_PaymentOfTaxesOnRestrictedStockVesting" name="PaymentOfTaxesOnRestrictedStockVesting" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ortx_ProceedsFromIssuanceOfSharesAsPartOfCollaborationAgreement" name="ProceedsFromIssuanceOfSharesAsPartOfCollaborationAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ortx_IntangibleAssetsAndPropertyAndEquipmentInAccountsPayableAndAccruedExpenses" name="IntangibleAssetsAndPropertyAndEquipmentInAccountsPayableAndAccruedExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ortx_EmployeeEquityPlanProceedsReceived" name="EmployeeEquityPlanProceedsReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ortx_PrepaidExpensesAndOtherCurrentAssetsTextBlock" name="PrepaidExpensesAndOtherCurrentAssetsTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ortx_ShareholdersEquityAndConvertiblePreferredSharesAbstract" name="ShareholdersEquityAndConvertiblePreferredSharesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ortx_LicenseAndResearchArrangementsAbstract" name="LicenseAndResearchArrangementsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ortx_CollaborativeArrangementAbstract" name="CollaborativeArrangementAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ortx_ResearchContractCostsAndAccrualsPolicyTextBlock" name="ResearchContractCostsAndAccrualsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ortx_StrimvelisLossProvisionPolicyTextBlock" name="StrimvelisLossProvisionPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ortx_ResearchAndDevelopmentIncomeTaxCreditsPolicyTextBlock" name="ResearchAndDevelopmentIncomeTaxCreditsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ortx_PropertyPlantAndEquipmentUsefulLifeTableTextBlock" name="PropertyPlantAndEquipmentUsefulLifeTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ortx_ScheduleOfChangesInLossProvisionTableTextBlock" name="ScheduleOfChangesInLossProvisionTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ortx_ScheduleOfIntangibleAssetsNetOfAccumulatedAmortizationTableTextBlock" name="ScheduleOfIntangibleAssetsNetOfAccumulatedAmortizationTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ortx_ClosingPriceOfShareDate" name="ClosingPriceOfShareDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ortx_PaymentsOfOtherIssuanceCosts" name="PaymentsOfOtherIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ortx_NetProceedsFromIssuanceOfPrivatePlacement" name="NetProceedsFromIssuanceOfPrivatePlacement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ortx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" name="OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ortx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" name="OrganizationConsolidationAndPresentationOfFinancialStatementsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ortx_SecuritiesPurchaseAgreementMember" name="SecuritiesPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ortx_NonVotingOrdinarySharesMember" name="NonVotingOrdinarySharesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ortx_SummaryOfSignificantAccountingPoliciesAbstract" name="SummaryOfSignificantAccountingPoliciesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ortx_SummaryOfSignificantAccountingPoliciesLineItems" name="SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ortx_SummaryOfSignificantAccountingPoliciesTable" name="SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ortx_GBAndEuropeanUnionMember" name="GBAndEuropeanUnionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ortx_FremontLeaseAgreementMember" name="FremontLeaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ortx_IncreaseDecreaseInEscrowDeposit" name="IncreaseDecreaseInEscrowDeposit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ortx_LabEquipmentMember" name="LabEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ortx_OfficeAndComputerEquipmentMember" name="OfficeAndComputerEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ortx_AssetAcquisitionLiabilityAssumed" name="AssetAcquisitionLiabilityAssumed" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ortx_AssetAcquisitionLiabilityProvision" name="AssetAcquisitionLiabilityProvision" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ortx_AssetAcquisitionLiabilityAmortizationOfLossProvision" name="AssetAcquisitionLiabilityAmortizationOfLossProvision" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ortx_IncreaseDecreaseInAssetAcquisitionLiabilityEffectOfForeignExchangeTranslation" name="IncreaseDecreaseInAssetAcquisitionLiabilityEffectOfForeignExchangeTranslation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ortx_AssetAcquisitionLiabilityAssumedCurrent" name="AssetAcquisitionLiabilityAssumedCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ortx_AssetAcquisitionLiabilityAssumedNonCurrent" name="AssetAcquisitionLiabilityAssumedNonCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ortx_AdditionalIncomeTaxCredits" name="AdditionalIncomeTaxCredits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ortx_ResearchAndDevelopmentTaxCreditReceivable" name="ResearchAndDevelopmentTaxCreditReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ortx_IncrementalPercentageOfTaxableProfits" name="IncrementalPercentageOfTaxableProfits" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ortx_UnvestedSharesFromSharePlanAndConsultingAgreementMember" name="UnvestedSharesFromSharePlanAndConsultingAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ortx_CashEquivalentsAbstract" name="CashEquivalentsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ortx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsAmortizedCost" name="AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsAmortizedCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ortx_GeneralPaymentTermsMaximum" name="GeneralPaymentTermsMaximum" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ortx_PrepaidExternalResearchAndDevelopmentExpenses" name="PrepaidExternalResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ortx_ConstructionDepositsCurrent" name="ConstructionDepositsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ortx_OfficeAndITEquipmentMember" name="OfficeAndITEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ortx_OtherNonCurrentAssets" name="OtherNonCurrentAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ortx_ConstructionDepositsLongTerm" name="ConstructionDepositsLongTerm" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ortx_AccruedExternalResearchAndDevelopmentExpensesCurrent" name="AccruedExternalResearchAndDevelopmentExpensesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ortx_AccruedMilestonePaymentsCurrent" name="AccruedMilestonePaymentsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ortx_ProductLiabilityCurrentPortion" name="ProductLiabilityCurrentPortion" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ortx_MenloParkCaliforniaMember" name="MenloParkCaliforniaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ortx_FremontCaliforniaMember" name="FremontCaliforniaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ortx_ImpairmentOfConstructionInProcess" name="ImpairmentOfConstructionInProcess" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ortx_ImpairmentOfLaboratoryEquipment" name="ImpairmentOfLaboratoryEquipment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ortx_OperatingLeaseRightOfUseAssetFairValue" name="OperatingLeaseRightOfUseAssetFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ortx_OperatingLeaseDurationForFreeRent" name="OperatingLeaseDurationForFreeRent" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ortx_OperatingLeasesLineItems" name="OperatingLeasesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ortx_OperatingLeasesTable" name="OperatingLeasesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ortx_OfficeSpaceMenloParkLeaseAgreementMember" name="OfficeSpaceMenloParkLeaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ortx_LaboratorySpaceMenloParkLeaseAgreementMember" name="LaboratorySpaceMenloParkLeaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ortx_OfficeAndLaboratorySpaceMenloParkLeaseAgreementMember" name="OfficeAndLaboratorySpaceMenloParkLeaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ortx_FiveYearsLeaseTermTerminatesInJanuaryTwoThousandTwentyThreeMember" name="FiveYearsLeaseTermTerminatesInJanuaryTwoThousandTwentyThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ortx_OfficeSpaceLondonUnitedKingdomLeaseAgreementMember" name="OfficeSpaceLondonUnitedKingdomLeaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ortx_RentalLabSpaceMember" name="RentalLabSpaceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ortx_LeaseTermTerminatesInSeptemberTwoThousandTwentyTwoMember" name="LeaseTermTerminatesInSeptemberTwoThousandTwentyTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ortx_OfficeSpaceBostonUnitedStatesLeaseAgreementMember" name="OfficeSpaceBostonUnitedStatesLeaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ortx_LeaseTermTerminatesInSeptemberTwoThousandTwentySixMember" name="LeaseTermTerminatesInSeptemberTwoThousandTwentySixMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ortx_BostonAndLondonOfficeSpaceLeaseAgreementsMember" name="BostonAndLondonOfficeSpaceLeaseAgreementsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ortx_FremontSubleaseAgreementMember" name="FremontSubleaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ortx_GSKAgreementMember" name="GSKAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ortx_OperatingLeasesCommencedTerm" name="OperatingLeasesCommencedTerm" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ortx_ReductionOfStandbyLetterOfCreditAmountPercentage" name="ReductionOfStandbyLetterOfCreditAmountPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ortx_TenantImprovementAllowance" name="TenantImprovementAllowance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ortx_LesseeOperatingLeaseExtendedTerm" name="LesseeOperatingLeaseExtendedTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ortx_LeaseComponentManufacturingCommitmentAmount" name="LeaseComponentManufacturingCommitmentAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ortx_FixedLeaseCost" name="FixedLeaseCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ortx_OperatingLeaseRightOfUseAssetValueExchangeForLeaseLiabilities" name="OperatingLeaseRightOfUseAssetValueExchangeForLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ortx_OperatingLeaseLiabilityPaymentsDueNet" name="OperatingLeaseLiabilityPaymentsDueNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ortx_OperatingLeaseLiabilityPaymentsDueYearOne" name="OperatingLeaseLiabilityPaymentsDueYearOne" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ortx_OperatingLeaseLiabilityPaymentsDueYearTwo" name="OperatingLeaseLiabilityPaymentsDueYearTwo" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ortx_OperatingLeaseLiabilityPaymentsDueYearThree" name="OperatingLeaseLiabilityPaymentsDueYearThree" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ortx_OperatingLeaseLiabilityPaymentsDueYearFour" name="OperatingLeaseLiabilityPaymentsDueYearFour" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ortx_OperatingLeaseLiabilityPaymentsDueYearFive" name="OperatingLeaseLiabilityPaymentsDueYearFive" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ortx_OperatingLeaseLiabilityPaymentsDueAfterYearFive" name="OperatingLeaseLiabilityPaymentsDueAfterYearFive" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ortx_OperatingLeaseLiabilitiesPaymentsDueNetAbstract" name="OperatingLeaseLiabilitiesPaymentsDueNetAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ortx_TheFirstTrancheTermLoanMember" name="TheFirstTrancheTermLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ortx_TheSecondTrancheTermLoanMember" name="TheSecondTrancheTermLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ortx_TheThirdTrancheTermLoanMember" name="TheThirdTrancheTermLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ortx_LondonInterbankOfferedRateFloorMember" name="LondonInterbankOfferedRateFloorMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ortx_TermLoanMember" name="TermLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ortx_LineOfCreditFacilityInterestPaymentsTerm" name="LineOfCreditFacilityInterestPaymentsTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ortx_LineOfCreditFacilityAmortizationTerm" name="LineOfCreditFacilityAmortizationTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ortx_LineOfCreditFacilityPercentageOfFinalPayment" name="LineOfCreditFacilityPercentageOfFinalPayment" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ortx_LineOfCreditFacilityCovenantsMinimumCashAllowed" name="LineOfCreditFacilityCovenantsMinimumCashAllowed" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ortx_LongTermDebtBeforeAccretionIssuanceCostsNet" name="LongTermDebtBeforeAccretionIssuanceCostsNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ortx_LongTermDebtBeforeAccretionIssuanceCostsNetCurrent" name="LongTermDebtBeforeAccretionIssuanceCostsNetCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ortx_LongTermDebtBeforeAccretionIssuanceCostsNetNoncurrent" name="LongTermDebtBeforeAccretionIssuanceCostsNetNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ortx_AccretionRelatedToFinalPayment" name="AccretionRelatedToFinalPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ortx_NumberOfOrdinaryVotingRights" name="NumberOfOrdinaryVotingRights" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ortx_OxfordBioMedicaLicenseDevelopmentAndSupplyAgreementMember" name="OxfordBioMedicaLicenseDevelopmentAndSupplyAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ortx_ConsultingAgreementMember" name="ConsultingAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ortx_NonEmployeeAdvisorMember" name="NonEmployeeAdvisorMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ortx_SharePurchaseAgreementWithPharmingMember" name="SharePurchaseAgreementWithPharmingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ortx_ProceedsFromPremiumSharesIssued" name="ProceedsFromPremiumSharesIssued" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ortx_TwoThousandAndEighteenShareOptionAndIncentivePlanMember" name="TwoThousandAndEighteenShareOptionAndIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ortx_TwoThousandAndEighteenEmployeeSharePurchasePlanMember" name="TwoThousandAndEighteenEmployeeSharePurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ortx_TwoThousandAndTwentyInducementEquityPlanMember" name="TwoThousandAndTwentyInducementEquityPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ortx_LibmeldyMember" name="LibmeldyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ortx_TimeBasedRestrictedShareUnitsMember" name="TimeBasedRestrictedShareUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ortx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeEquityPlanProceedsReceivedAfterYearEnd" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeEquityPlanProceedsReceivedAfterYearEnd" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ortx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ortx_NumberOfLateStageClinicalGeneTherapyPrograms" name="NumberOfLateStageClinicalGeneTherapyPrograms" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ortx_NumberOfEarlierStageClinicalGeneTherapyProgram" name="NumberOfEarlierStageClinicalGeneTherapyProgram" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ortx_NumberOfAdditionalEarlierStageDevelopmentPrograms" name="NumberOfAdditionalEarlierStageDevelopmentPrograms" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ortx_GSKAssetPurchaseAndLicenseAgreementMember" name="GSKAssetPurchaseAndLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ortx_TelethonOSRLicenseAgreementsMember" name="TelethonOSRLicenseAgreementsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ortx_UCLBAndUCLATechnologyMember" name="UCLBAndUCLATechnologyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ortx_UCLBTechnologyAndManufacturingTechnologyMember" name="UCLBTechnologyAndManufacturingTechnologyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ortx_UCLBLicenseAgreementMember" name="UCLBLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ortx_UCLBAndUCLALicenseAgreementMember" name="UCLBAndUCLALicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ortx_AssetAcquisitionUpfrontPayment" name="AssetAcquisitionUpfrontPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ortx_AssetAcquisitionNumberOfSharesIssuedForAcquisition" name="AssetAcquisitionNumberOfSharesIssuedForAcquisition" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ortx_AssetAcquisitionValueOfEquityInstrumentsIssued" name="AssetAcquisitionValueOfEquityInstrumentsIssued" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ortx_AssetAcquisitionInventoryPurchaseLiability" name="AssetAcquisitionInventoryPurchaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ortx_AssetAcquisitionTransactionCosts" name="AssetAcquisitionTransactionCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ortx_AssetAcquisitionInProcessResearchAndDevelopmentExpense" name="AssetAcquisitionInProcessResearchAndDevelopmentExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ortx_PaymentOfTieredRoyaltyMaximumPercentage" name="PaymentOfTieredRoyaltyMaximumPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="ortx_MilestonePaymentsPayableUponAchievementOfCertainSalesMilestones" name="MilestonePaymentsPayableUponAchievementOfCertainSalesMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ortx_UpfrontPaymentDescription" name="UpfrontPaymentDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ortx_UpfrontAndMilestonePayments" name="UpfrontAndMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ortx_InProcessResearchAndDevelopmentExpenseForUpfrontAndMilestonePayments" name="InProcessResearchAndDevelopmentExpenseForUpfrontAndMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ortx_MilestonePaymentsPayableUponAchievementOfCertainDevelopmentRegulatoryAndCommercialMilestones" name="MilestonePaymentsPayableUponAchievementOfCertainDevelopmentRegulatoryAndCommercialMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ortx_PaymentsToAcquireClinicalData" name="PaymentsToAcquireClinicalData" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ortx_UpfrontCashPayment" name="UpfrontCashPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ortx_PotentialPaymentForAchievementOfSpecifiedMilestones" name="PotentialPaymentForAchievementOfSpecifiedMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ortx_MilestonePayment" name="MilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ortx_NumberOfMilestonesMet" name="NumberOfMilestonesMet" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ortx_MilestonePaymentsReceivable" name="MilestonePaymentsReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ortx_StrategicCollaborationAgreementWithPharmingMember" name="StrategicCollaborationAgreementWithPharmingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ortx_PharmingAgreementsMember" name="PharmingAgreementsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ortx_ProceedsFromUpfrontPayment" name="ProceedsFromUpfrontPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ortx_ProceedsFromUpfrontPaymentsAttributedToEquitySold" name="ProceedsFromUpfrontPaymentsAttributedToEquitySold" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ortx_ProceedsFromUpfrontPaymentsAttributedToResearchActivities" name="ProceedsFromUpfrontPaymentsAttributedToResearchActivities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ortx_ExcessProceedsFromFairValueOfSharesIssuedAllocatedToCollaborationAgreement" name="ExcessProceedsFromFairValueOfSharesIssuedAllocatedToCollaborationAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ortx_ProceedsFromNonRefundableUpfrontPayment" name="ProceedsFromNonRefundableUpfrontPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ortx_ReimbursementRevenueMember" name="ReimbursementRevenueMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ortx_UpfrontAndMilestonePaymentRevenueMember" name="UpfrontAndMilestonePaymentRevenueMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ortx_CurrentOtherTaxExpenseBenefit" name="CurrentOtherTaxExpenseBenefit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ortx_CorporationTaxRatePercentage" name="CorporationTaxRatePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ortx_OrphanDrugTaxCreditMember" name="OrphanDrugTaxCreditMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ortx_DeferredTaxAssetsAmortization" name="DeferredTaxAssetsAmortization" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ortx_DeferredTaxAssetsLeaseLiability" name="DeferredTaxAssetsLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ortx_DeferredTaxLiabilitiesFixedAssetsAndRightOfUseAsset" name="DeferredTaxLiabilitiesFixedAssetsAndRightOfUseAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ortx_TaxCreditCarryforwardExpirationYear" name="TaxCreditCarryforwardExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ortx_DeferredTaxAssetsValuationAllowanceIncreasesRecordedToIncomeTaxProvision" name="DeferredTaxAssetsValuationAllowanceIncreasesRecordedToIncomeTaxProvision" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ortx_DeferredTaxAssetsValuationAllowanceEffectOfForeignCurrencyTranslation" name="DeferredTaxAssetsValuationAllowanceEffectOfForeignCurrencyTranslation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ortx_ManufacturingCommitmentsAmountDueInNextTwelveMonths" name="ManufacturingCommitmentsAmountDueInNextTwelveMonths" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ortx_ManufacturingCommitmentsAmountDueInYearTwo" name="ManufacturingCommitmentsAmountDueInYearTwo" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ortx_ManufacturingCommitmentsAmountDueInYearThree" name="ManufacturingCommitmentsAmountDueInYearThree" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ortx_ManufacturingCommitmentsAmountDueInYearFour" name="ManufacturingCommitmentsAmountDueInYearFour" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ortx_ManufacturingCommitmentsAmountDueInYearFive" name="ManufacturingCommitmentsAmountDueInYearFive" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ortx_ManufacturingCommitmentsAmountDueThereafter" name="ManufacturingCommitmentsAmountDueThereafter" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ortx_ManufacturingCommitments" name="ManufacturingCommitments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ortx_ProductManufacturingCommitmentsMember" name="ProductManufacturingCommitmentsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ortx_DedicatedManufacturingAndDevelopmentResourcesMember" name="DedicatedManufacturingAndDevelopmentResourcesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ortx_ExclusiveTransductionSuitesMember" name="ExclusiveTransductionSuitesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ortx_InitialTermOfAgreement" name="InitialTermOfAgreement" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ortx_AgreementMaturityDate" name="AgreementMaturityDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ortx_AgreementExtensionTerm" name="AgreementExtensionTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ortx_ManufacturingAndTechnologyDevelopmentMasterAgreementMember" name="ManufacturingAndTechnologyDevelopmentMasterAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ortx_ClinicalDevelopmentAndRegulatoryMilestoneMember" name="ClinicalDevelopmentAndRegulatoryMilestoneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ortx_InventoryPurchase" name="InventoryPurchase" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ortx_LicenseUpfrontFeeAndRelatedExpensesPaid" name="LicenseUpfrontFeeAndRelatedExpensesPaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ortx_GSKMember" name="GSKMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ortx_AccruedExpensesRelatedPartyCurrent" name="AccruedExpensesRelatedPartyCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>12
<FILENAME>ortx-20211231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-03-30T03:21:51.4998028+00:00 -->
<!-- Version            : 5.0.1.728 -->
<!-- Package ID         : 1b558024b59f49cabedb23f437fea13f -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="ortx-20211231.xsd#TemplateLink" roleURI="http://www.orchard-tx.com/20211231/role/TemplateLink" />
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:href="ortx-20211231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets">
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ResearchAndDevelopmentTaxCreditReceivableCurrent" xlink:type="locator" xlink:label="ortx_ResearchAndDevelopmentTaxCreditReceivableCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecurities" xlink:type="locator" xlink:label="us-gaap_MarketableSecurities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:type="locator" xlink:label="us-gaap_NotesPayableCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_AccruedExpensesAndOtherCurrentLiabilities" xlink:type="locator" xlink:label="ortx_AccruedExpensesAndOtherCurrentLiabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:type="locator" xlink:label="us-gaap_LongTermNotesPayable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LongTermNotesPayable" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="ortx_AccruedExpensesAndOtherCurrentLiabilities" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRevenueCurrent" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="10160.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_NotesPayableCurrent" order="10170.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="10180.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsNoncurrent" order="10190.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10200.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10210.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" order="10220.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="10230.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10240.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10250.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_MarketableSecurities" order="10260.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="10270.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10280.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="ortx_ResearchAndDevelopmentTaxCreditReceivableCurrent" order="10290.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="ortx-20211231.xsd#Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses" xlink:type="locator" xlink:label="us-gaap_CostsAndExpenses" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:type="locator" xlink:label="us-gaap_InterestExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10060.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_NonoperatingIncomeExpense" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInterest" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpense" order="10100.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_CostsAndExpenses" order="10130.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="10160.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="ortx-20211231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
    <link:loc xlink:href="ortx-20211231.xsd#ortx_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:type="locator" xlink:label="ortx_IncreaseDecreaseInOperatingLeaseLiabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="locator" xlink:label="ortx_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesAndOtherOperatingLiabilities" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_IncreaseDecreaseInOperatingRightOfUseAssets" xlink:type="locator" xlink:label="ortx_IncreaseDecreaseInOperatingRightOfUseAssets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable" xlink:type="locator" xlink:label="ortx_IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_UnrealizedForeignCurrencyAndOtherNonCashAdjustments" xlink:type="locator" xlink:label="ortx_UnrealizedForeignCurrencyAndOtherNonCashAdjustments" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_AmortizationOfPremiumOnMarketableSecurities" xlink:type="locator" xlink:label="ortx_AmortizationOfPremiumOnMarketableSecurities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_NonCashConsiderationForLicensesAndMilestones" xlink:type="locator" xlink:label="ortx_NonCashConsiderationForLicensesAndMilestones" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_AmortizationOfProvisionOnLossContract" xlink:type="locator" xlink:label="ortx_AmortizationOfProvisionOnLossContract" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_NonCashInterestExpense" xlink:type="locator" xlink:label="ortx_NonCashInterestExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:type="locator" xlink:label="us-gaap_AssetImpairmentCharges" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ReceiptOfFundsFromConstructionDeposit" xlink:type="locator" xlink:label="ortx_ReceiptOfFundsFromConstructionDeposit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ProceedsFromIssuanceOfSharesAsPartOfCollaborationAgreement" xlink:type="locator" xlink:label="ortx_ProceedsFromIssuanceOfSharesAsPartOfCollaborationAgreement" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_PaymentOfTaxesOnRestrictedStockVesting" xlink:type="locator" xlink:label="ortx_PaymentOfTaxesOnRestrictedStockVesting" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockPlans" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockPlans" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="ortx_PaymentOfTaxesOnRestrictedStockVesting" order="10070.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="ortx_ProceedsFromIssuanceOfSharesAsPartOfCollaborationAgreement" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="10100.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="10120.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit" order="10130.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="ortx_ReceiptOfFundsFromConstructionDeposit" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets" order="10150.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="10160.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="10170.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="10180.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="10190.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AssetImpairmentCharges" order="10200.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="ortx_NonCashInterestExpense" order="10210.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="ortx_AmortizationOfProvisionOnLossContract" order="10220.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="ortx_NonCashConsiderationForLicensesAndMilestones" order="10230.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="10240.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="ortx_AmortizationOfPremiumOnMarketableSecurities" order="10250.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="ortx_UnrealizedForeignCurrencyAndOtherNonCashAdjustments" order="10260.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="10270.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="ortx_IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable" order="10280.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10290.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="ortx_IncreaseDecreaseInOperatingRightOfUseAssets" order="10300.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="ortx_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesAndOtherOperatingLiabilities" order="10310.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="10320.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" order="10330.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="ortx_IncreaseDecreaseInOperatingLeaseLiabilities" order="10340.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesScheduleOfCashEquivalentsAndMarketableSecuritiesDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesScheduleOfCashEquivalentsAndMarketableSecuritiesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesScheduleOfCashEquivalentsAndMarketableSecuritiesDetails">
    <link:loc xlink:href="ortx-20211231.xsd#ortx_MarketableSecuritiesFairValueDisclosure" xlink:type="locator" xlink:label="ortx_MarketableSecuritiesFairValueDisclosure" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="ortx_MarketableSecuritiesFairValueDisclosure" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesScheduleOfLevel2CashEquivalentsAndMarketableSecuritiesDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesScheduleOfLevel2CashEquivalentsAndMarketableSecuritiesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesScheduleOfLevel2CashEquivalentsAndMarketableSecuritiesDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="10010.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" order="10030.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="10040.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesScheduleOfAvailableForSaleMarketableDebtSecuritiesByContractualMaturityDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesScheduleOfAvailableForSaleMarketableDebtSecuritiesByContractualMaturityDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesScheduleOfAvailableForSaleMarketableDebtSecuritiesByContractualMaturityDetails">
    <link:loc xlink:href="ortx-20211231.xsd#ortx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsAmortizedCost" xlink:type="locator" xlink:label="ortx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsAmortizedCost" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:to="ortx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsAmortizedCost" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="ortx-20211231.xsd#Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NontradeReceivablesCurrent" xlink:type="locator" xlink:label="us-gaap_NontradeReceivablesCurrent" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ConstructionDepositsCurrent" xlink:type="locator" xlink:label="ortx_ConstructionDepositsCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValueAddedTaxReceivableCurrent" xlink:type="locator" xlink:label="us-gaap_ValueAddedTaxReceivableCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" xlink:label="us-gaap_InventoryNet" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_PrepaidExternalResearchAndDevelopmentExpenses" xlink:type="locator" xlink:label="ortx_PrepaidExternalResearchAndDevelopmentExpenses" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="ortx_PrepaidExternalResearchAndDevelopmentExpenses" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_InventoryNet" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_ValueAddedTaxReceivableCurrent" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="ortx_ConstructionDepositsCurrent" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_NontradeReceivablesCurrent" order="10060.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:href="ortx-20211231.xsd#Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10020.00" priority="2" use="optional" weight="-1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfIntangibleAssetsNetOfAccumulatedAmortizationDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureIntangibleAssetsNetScheduleOfIntangibleAssetsNetOfAccumulatedAmortizationDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfIntangibleAssetsNetOfAccumulatedAmortizationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="10020.00" priority="2" use="optional" weight="-1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfEstimatedFutureAmortizationForIntangibleAssetsDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureIntangibleAssetsNetScheduleOfEstimatedFutureAmortizationForIntangibleAssetsDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfEstimatedFutureAmortizationForIntangibleAssetsDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" order="10060.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureOtherAssetsScheduleOfOtherAssetsDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureOtherAssetsScheduleOfOtherAssetsDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureOtherAssetsScheduleOfOtherAssetsDetails">
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ConstructionDepositsLongTerm" xlink:type="locator" xlink:label="ortx_ConstructionDepositsLongTerm" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_OtherNonCurrentAssets" xlink:type="locator" xlink:label="ortx_OtherNonCurrentAssets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:type="locator" xlink:label="us-gaap_DeferredFinanceCostsNoncurrentNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_DepositsAssetsNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_DeferredFinanceCostsNoncurrentNet" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="ortx_OtherNonCurrentAssets" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="ortx_ConstructionDepositsLongTerm" order="10050.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureAccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails">
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ProductLiabilityCurrentPortion" xlink:type="locator" xlink:label="ortx_ProductLiabilityCurrentPortion" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_AccruedMilestonePaymentsCurrent" xlink:type="locator" xlink:label="ortx_AccruedMilestonePaymentsCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_AccruedExternalResearchAndDevelopmentExpensesCurrent" xlink:type="locator" xlink:label="ortx_AccruedExternalResearchAndDevelopmentExpensesCurrent" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_AccruedExpensesAndOtherCurrentLiabilities" xlink:type="locator" xlink:label="ortx_AccruedExpensesAndOtherCurrentLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ortx_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="ortx_AccruedExternalResearchAndDevelopmentExpensesCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ortx_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ortx_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="ortx_AccruedMilestonePaymentsCurrent" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ortx_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ortx_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ortx_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="ortx_ProductLiabilityCurrentPortion" order="10060.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRestructuringChargesSummaryOfImpairmentOfLongLivedAssetsDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureRestructuringChargesSummaryOfImpairmentOfLongLivedAssetsDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRestructuringChargesSummaryOfImpairmentOfLongLivedAssetsDetails">
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ImpairmentOfLaboratoryEquipment" xlink:type="locator" xlink:label="ortx_ImpairmentOfLaboratoryEquipment" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ImpairmentOfConstructionInProcess" xlink:type="locator" xlink:label="ortx_ImpairmentOfConstructionInProcess" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseImpairmentLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:type="locator" xlink:label="us-gaap_AssetImpairmentCharges" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_OperatingLeaseImpairmentLoss" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="ortx_ImpairmentOfConstructionInProcess" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="ortx_ImpairmentOfLaboratoryEquipment" order="10030.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfLeaseCostUnderOperatingLeasesDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureLeasesSummaryOfLeaseCostUnderOperatingLeasesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfLeaseCostUnderOperatingLeasesDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome" xlink:type="locator" xlink:label="us-gaap_SubleaseIncome" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost" xlink:type="locator" xlink:label="us-gaap_VariableLeaseCost" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseImpairmentLoss" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_FixedLeaseCost" xlink:type="locator" xlink:label="ortx_FixedLeaseCost" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost" xlink:type="locator" xlink:label="us-gaap_LeaseCost" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="ortx_FixedLeaseCost" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseImpairmentLoss" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_VariableLeaseCost" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_SubleaseIncome" order="10040.00" priority="2" use="optional" weight="-1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumBaseRentCommitmentsUnderOperatingLeasesDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureLeasesScheduleOfFutureMinimumBaseRentCommitmentsUnderOperatingLeasesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumBaseRentCommitmentsUnderOperatingLeasesDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter" xlink:type="locator" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears" xlink:type="locator" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears" xlink:type="locator" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:type="locator" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:type="locator" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:type="locator" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceived" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_OperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="locator" xlink:label="ortx_OperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_OperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="locator" xlink:label="ortx_OperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_OperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="ortx_OperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_OperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="ortx_OperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_OperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="ortx_OperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_OperatingLeaseLiabilityPaymentsDueYearOne" xlink:type="locator" xlink:label="ortx_OperatingLeaseLiabilityPaymentsDueYearOne" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_OperatingLeaseLiabilityPaymentsDueNet" xlink:type="locator" xlink:label="ortx_OperatingLeaseLiabilityPaymentsDueNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ortx_OperatingLeaseLiabilityPaymentsDueNet" xlink:to="ortx_OperatingLeaseLiabilityPaymentsDueYearOne" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ortx_OperatingLeaseLiabilityPaymentsDueNet" xlink:to="ortx_OperatingLeaseLiabilityPaymentsDueYearTwo" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ortx_OperatingLeaseLiabilityPaymentsDueNet" xlink:to="ortx_OperatingLeaseLiabilityPaymentsDueYearThree" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ortx_OperatingLeaseLiabilityPaymentsDueNet" xlink:to="ortx_OperatingLeaseLiabilityPaymentsDueYearFour" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ortx_OperatingLeaseLiabilityPaymentsDueNet" xlink:to="ortx_OperatingLeaseLiabilityPaymentsDueYearFive" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ortx_OperatingLeaseLiabilityPaymentsDueNet" xlink:to="ortx_OperatingLeaseLiabilityPaymentsDueAfterYearFive" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="10160.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="10170.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="10180.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumBaseRentCommitmentsUnderOperatingLeasesDetails2" xlink:href="ortx-20211231.xsd#Role_DisclosureLeasesScheduleOfFutureMinimumBaseRentCommitmentsUnderOperatingLeasesDetails2" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumBaseRentCommitmentsUnderOperatingLeasesDetails2">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableSummaryOfNotesPayableDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureNotesPayableSummaryOfNotesPayableDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableSummaryOfNotesPayableDetails">
    <link:loc xlink:href="ortx-20211231.xsd#ortx_LongTermDebtBeforeAccretionIssuanceCostsNetCurrent" xlink:type="locator" xlink:label="ortx_LongTermDebtBeforeAccretionIssuanceCostsNetCurrent" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_LongTermDebtBeforeAccretionIssuanceCostsNet" xlink:type="locator" xlink:label="ortx_LongTermDebtBeforeAccretionIssuanceCostsNet" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_AccretionRelatedToFinalPayment" xlink:type="locator" xlink:label="ortx_AccretionRelatedToFinalPayment" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_LongTermDebtBeforeAccretionIssuanceCostsNetNoncurrent" xlink:type="locator" xlink:label="ortx_LongTermDebtBeforeAccretionIssuanceCostsNetNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:type="locator" xlink:label="us-gaap_LongTermDebtNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="ortx_LongTermDebtBeforeAccretionIssuanceCostsNetNoncurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="ortx_AccretionRelatedToFinalPayment" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ortx_LongTermDebtBeforeAccretionIssuanceCostsNet" xlink:to="ortx_LongTermDebtBeforeAccretionIssuanceCostsNetCurrent" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ortx_LongTermDebtBeforeAccretionIssuanceCostsNet" xlink:to="ortx_LongTermDebtBeforeAccretionIssuanceCostsNetNoncurrent" order="10040.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableSummaryOfFuturePrincipalPaymentsDueDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureNotesPayableSummaryOfFuturePrincipalPaymentsDueDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableSummaryOfFuturePrincipalPaymentsDueDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" order="10060.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableSummaryOfFuturePrincipalPaymentsDueDetails2" xlink:href="ortx-20211231.xsd#Role_DisclosureNotesPayableSummaryOfFuturePrincipalPaymentsDueDetails2" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableSummaryOfFuturePrincipalPaymentsDueDetails2">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:type="locator" xlink:label="us-gaap_LongTermDebtNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:type="locator" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_UnamortizedPortionOfFinalPayment" xlink:type="locator" xlink:label="ortx_UnamortizedPortionOfFinalPayment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:type="locator" xlink:label="us-gaap_LongTermDebtCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_LongTermDebtCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="ortx_UnamortizedPortionOfFinalPayment" order="10020.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_UnamortizedDebtIssuanceExpense" order="10030.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_LongTermDebtNoncurrent" order="10040.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfNetLossBeforeIncomeTaxesDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureIncomeTaxesScheduleOfComponentsOfNetLossBeforeIncomeTaxesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfNetLossBeforeIncomeTaxesDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_CurrentOtherTaxExpenseBenefit" xlink:type="locator" xlink:label="ortx_CurrentOtherTaxExpenseBenefit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredOtherTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredOtherTaxExpenseBenefit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredOtherTaxExpenseBenefit" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="ortx_CurrentOtherTaxExpenseBenefit" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="10100.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_IncomeTaxReconciliationPermanentDifferencesIncludingShareBasedCompensationDeductionShortfalls" xlink:type="locator" xlink:label="ortx_IncomeTaxReconciliationPermanentDifferencesIncludingShareBasedCompensationDeductionShortfalls" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_IncomeTaxReconciliationDomesticDeductionForDerivedIntangibleIncome" xlink:type="locator" xlink:label="ortx_IncomeTaxReconciliationDomesticDeductionForDerivedIntangibleIncome" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCredits" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_IncomeTaxReconciliationReductionInResearchExpenseForCreditsGranted" xlink:type="locator" xlink:label="ortx_IncomeTaxReconciliationReductionInResearchExpenseForCreditsGranted" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="ortx_IncomeTaxReconciliationReductionInResearchExpenseForCreditsGranted" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits" order="10050.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="ortx_IncomeTaxReconciliationDomesticDeductionForDerivedIntangibleIncome" order="10060.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="ortx_IncomeTaxReconciliationPermanentDifferencesIncludingShareBasedCompensationDeductionShortfalls" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" order="10090.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesTaxesDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesTaxesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesTaxesDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_DeferredTaxAssetsLeaseLiability" xlink:type="locator" xlink:label="ortx_DeferredTaxAssetsLeaseLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_DeferredTaxAssetsAmortization" xlink:type="locator" xlink:label="ortx_DeferredTaxAssetsAmortization" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_DeferredTaxLiabilitiesFixedAssetsAndRightOfUseAsset" xlink:type="locator" xlink:label="ortx_DeferredTaxLiabilitiesFixedAssetsAndRightOfUseAsset" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10020.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="ortx_DeferredTaxLiabilitiesFixedAssetsAndRightOfUseAsset" order="10030.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="ortx_DeferredTaxAssetsAmortization" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="ortx_DeferredTaxAssetsLeaseLiability" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="10110.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfAnnualCommitmentsAssociatedWithContractDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureCommitmentsAndContingenciesScheduleOfAnnualCommitmentsAssociatedWithContractDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfAnnualCommitmentsAssociatedWithContractDetails">
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ManufacturingCommitmentsAmountDueThereafter" xlink:type="locator" xlink:label="ortx_ManufacturingCommitmentsAmountDueThereafter" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ManufacturingCommitmentsAmountDueInYearFive" xlink:type="locator" xlink:label="ortx_ManufacturingCommitmentsAmountDueInYearFive" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ManufacturingCommitmentsAmountDueInYearFour" xlink:type="locator" xlink:label="ortx_ManufacturingCommitmentsAmountDueInYearFour" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ManufacturingCommitmentsAmountDueInYearThree" xlink:type="locator" xlink:label="ortx_ManufacturingCommitmentsAmountDueInYearThree" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ManufacturingCommitmentsAmountDueInYearTwo" xlink:type="locator" xlink:label="ortx_ManufacturingCommitmentsAmountDueInYearTwo" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ManufacturingCommitmentsAmountDueInNextTwelveMonths" xlink:type="locator" xlink:label="ortx_ManufacturingCommitmentsAmountDueInNextTwelveMonths" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ManufacturingCommitments" xlink:type="locator" xlink:label="ortx_ManufacturingCommitments" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ortx_ManufacturingCommitments" xlink:to="ortx_ManufacturingCommitmentsAmountDueInNextTwelveMonths" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ortx_ManufacturingCommitments" xlink:to="ortx_ManufacturingCommitmentsAmountDueInYearTwo" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ortx_ManufacturingCommitments" xlink:to="ortx_ManufacturingCommitmentsAmountDueInYearThree" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ortx_ManufacturingCommitments" xlink:to="ortx_ManufacturingCommitmentsAmountDueInYearFour" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ortx_ManufacturingCommitments" xlink:to="ortx_ManufacturingCommitmentsAmountDueInYearFive" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ortx_ManufacturingCommitments" xlink:to="ortx_ManufacturingCommitmentsAmountDueThereafter" order="10060.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>13
<FILENAME>ortx-20211231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-03-30T03:21:51.4998028+00:00 -->
<!-- Version            : 5.0.1.728 -->
<!-- Package ID         : 1b558024b59f49cabedb23f437fea13f -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:roleRef xlink:type="simple" xlink:href="ortx-20211231.xsd#TemplateLink" roleURI="http://www.orchard-tx.com/20211231/role/TemplateLink" />
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="ortx-20211231.xsd#Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:type="locator" xlink:label="us-gaap_InterestExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses" xlink:type="locator" xlink:label="us-gaap_CostsAndExpenses" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfCostGoodOrServiceExtensibleList" xlink:type="locator" xlink:label="us-gaap_TypeOfCostGoodOrServiceExtensibleList" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingCostsAndExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_CollaborationMember" xlink:type="locator" xlink:label="ortx_CollaborationMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember" xlink:type="locator" xlink:label="us-gaap_ProductMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10170.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_2" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ortx_CollaborationMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingCostsAndExpensesAbstract" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_TypeOfCostGoodOrServiceExtensibleList" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="10620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpenses" order="10660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="10740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="10820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpense" order="10860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="10900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="10940.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="10980.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="11020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="11060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="11100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="11140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" order="11180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="11260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="11300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="11340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="11380.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#eedm" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" />
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity" xlink:href="ortx-20211231.xsd#Role_StatementConsolidatedStatementsOfShareholdersEquity" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_StockIssuedDuringPeriodSharesAsPartOfCollaborationAgreement" xlink:type="locator" xlink:label="ortx_StockIssuedDuringPeriodSharesAsPartOfCollaborationAgreement" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_StockIssuedDuringPeriodValueAsPartOfCollaborationAgreement" xlink:type="locator" xlink:label="ortx_StockIssuedDuringPeriodValueAsPartOfCollaborationAgreement" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_StockIssuedDuringPeriodSharesAsPartOfConsultingAgreement" xlink:type="locator" xlink:label="ortx_StockIssuedDuringPeriodSharesAsPartOfConsultingAgreement" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_StockIssuedDuringPeriodValueAsPartOfConsultingAgreement" xlink:type="locator" xlink:label="ortx_StockIssuedDuringPeriodValueAsPartOfConsultingAgreement" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:type="locator" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" xlink:type="locator" xlink:label="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="10620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="10640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" order="10760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" order="10780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="10900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ortx_StockIssuedDuringPeriodValueAsPartOfConsultingAgreement" order="11040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ortx_StockIssuedDuringPeriodSharesAsPartOfConsultingAgreement" order="11060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" order="11180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="11200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ortx_StockIssuedDuringPeriodValueAsPartOfCollaborationAgreement" order="11600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ortx_StockIssuedDuringPeriodSharesAsPartOfCollaborationAgreement" order="11620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="11740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss" order="11880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="12020.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_NetProceedsFromIssuanceOfPrivatePlacement" xlink:type="locator" xlink:label="ortx_NetProceedsFromIssuanceOfPrivatePlacement" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockTransactionDate" xlink:type="locator" xlink:label="us-gaap_SaleOfStockTransactionDate" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_PaymentsOfOtherIssuanceCosts" xlink:type="locator" xlink:label="ortx_PaymentsOfOtherIssuanceCosts" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ClosingPriceOfShareDate" xlink:type="locator" xlink:label="ortx_ClosingPriceOfShareDate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_NonVotingOrdinarySharesMember" xlink:type="locator" xlink:label="ortx_NonVotingOrdinarySharesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_SecuritiesPurchaseAgreementMember" xlink:type="locator" xlink:label="ortx_SecuritiesPurchaseAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:type="locator" xlink:label="ortx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:type="locator" xlink:label="ortx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ortx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="ortx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ortx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ortx_SecuritiesPurchaseAgreementMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ortx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_2" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ortx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_2" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="ortx_NonVotingOrdinarySharesMember" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ortx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ortx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ortx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ortx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="ortx_ClosingPriceOfShareDate" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ortx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ortx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="ortx_PaymentsOfOtherIssuanceCosts" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ortx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_SaleOfStockTransactionDate" order="10580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ortx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="ortx_NetProceedsFromIssuanceOfPrivatePlacement" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ortx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_NetIncomeLoss" order="10650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ortx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ortx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" order="10730.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleDescription" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleDescription" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_IncrementalPercentageOfTaxableProfits" xlink:type="locator" xlink:label="ortx_IncrementalPercentageOfTaxableProfits" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ResearchAndDevelopmentTaxCreditReceivableCurrent" xlink:type="locator" xlink:label="ortx_ResearchAndDevelopmentTaxCreditReceivableCurrent" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ResearchAndDevelopmentTaxCreditReceivable" xlink:type="locator" xlink:label="ortx_ResearchAndDevelopmentTaxCreditReceivable" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_AdditionalIncomeTaxCredits" xlink:type="locator" xlink:label="ortx_AdditionalIncomeTaxCredits" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_AssetAcquisitionLiabilityAssumedNonCurrent" xlink:type="locator" xlink:label="ortx_AssetAcquisitionLiabilityAssumedNonCurrent" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_AssetAcquisitionLiabilityAssumedCurrent" xlink:type="locator" xlink:label="ortx_AssetAcquisitionLiabilityAssumedCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForLossOnContracts" xlink:type="locator" xlink:label="us-gaap_ProvisionForLossOnContracts" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_IncreaseDecreaseInEscrowDeposit" xlink:type="locator" xlink:label="ortx_IncreaseDecreaseInEscrowDeposit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EscrowDeposit" xlink:type="locator" xlink:label="us-gaap_EscrowDeposit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCollateralForBorrowedSecurities" xlink:type="locator" xlink:label="us-gaap_CashCollateralForBorrowedSecurities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:type="locator" xlink:label="us-gaap_ProceedsFromLinesOfCredit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember" xlink:type="locator" xlink:label="us-gaap_ProductMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:type="locator" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_FremontLeaseAgreementMember" xlink:type="locator" xlink:label="ortx_FremontLeaseAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermAxis" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_GBAndEuropeanUnionMember" xlink:type="locator" xlink:label="ortx_GBAndEuropeanUnionMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US" xlink:type="locator" xlink:label="country_US" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_GB" xlink:type="locator" xlink:label="country_GB" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_SummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="ortx_SummaryOfSignificantAccountingPoliciesTable" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="ortx_SummaryOfSignificantAccountingPoliciesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ortx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="ortx_SummaryOfSignificantAccountingPoliciesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ortx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_StatementGeographicalAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_GB" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="ortx_GBAndEuropeanUnionMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ortx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_LeaseContractualTermAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain_2" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="ortx_FremontLeaseAgreementMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ortx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_2" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ortx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_2" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ortx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_ProductOrServiceAxis" order="10640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" order="10690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ortx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk" order="10740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ortx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="10790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ortx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ortx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10980.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ortx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProceedsFromLinesOfCredit" order="11130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ortx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CashCollateralForBorrowedSecurities" order="11170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ortx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_EscrowDeposit" order="11240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ortx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="ortx_IncreaseDecreaseInEscrowDeposit" order="11280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ortx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProvisionForLossOnContracts" order="11350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ortx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="ortx_AssetAcquisitionLiabilityAssumedCurrent" order="11400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ortx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="ortx_AssetAcquisitionLiabilityAssumedNonCurrent" order="11440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ortx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="ortx_AdditionalIncomeTaxCredits" order="11510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ortx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="ortx_ResearchAndDevelopmentTaxCreditReceivable" order="11560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ortx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="ortx_ResearchAndDevelopmentTaxCreditReceivableCurrent" order="11600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ortx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="ortx_IncrementalPercentageOfTaxableProfits" order="11670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ortx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="11720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ortx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" order="11790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ortx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" order="11810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ortx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleDescription" order="11830.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_OfficeAndComputerEquipmentMember" xlink:type="locator" xlink:label="ortx_OfficeAndComputerEquipmentMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_LabEquipmentMember" xlink:type="locator" xlink:label="ortx_LabEquipmentMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="ortx_LabEquipmentMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="ortx_OfficeAndComputerEquipmentMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="10320.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfAmountsRecognizedToOffsetResearchAndDevelopmentExpenseDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfAmountsRecognizedToOffsetResearchAndDevelopmentExpenseDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfAmountsRecognizedToOffsetResearchAndDevelopmentExpenseDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCredits" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxCreditsAndAdjustments" xlink:type="locator" xlink:label="us-gaap_IncomeTaxCreditsAndAdjustments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_GB" xlink:type="locator" xlink:label="country_GB" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_SummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="ortx_SummaryOfSignificantAccountingPoliciesTable" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="ortx_SummaryOfSignificantAccountingPoliciesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ortx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="ortx_SummaryOfSignificantAccountingPoliciesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ortx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_StatementGeographicalAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_GB" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ortx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ortx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ortx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_IncomeTaxCreditsAndAdjustments" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ortx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ortx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="10460.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSecuritiesExcludedInComputationOfDilutedNetLossPerOrdinaryShareDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesSecuritiesExcludedInComputationOfDilutedNetLossPerOrdinaryShareDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSecuritiesExcludedInComputationOfDilutedNetLossPerOrdinaryShareDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_UnvestedSharesFromSharePlanAndConsultingAgreementMember" xlink:type="locator" xlink:label="ortx_UnvestedSharesFromSharePlanAndConsultingAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AwardTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="ortx_UnvestedSharesFromSharePlanAndConsultingAgreementMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10140.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesScheduleOfCashEquivalentsAndMarketableSecuritiesDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesScheduleOfCashEquivalentsAndMarketableSecuritiesDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesScheduleOfCashEquivalentsAndMarketableSecuritiesDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_MarketableSecuritiesFairValueDisclosure" xlink:type="locator" xlink:label="ortx_MarketableSecuritiesFairValueDisclosure" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_CashEquivalentsAbstract" xlink:type="locator" xlink:label="ortx_CashEquivalentsAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:type="locator" xlink:label="us-gaap_USTreasuryAndGovernmentMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10030.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="10060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CommercialPaperMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USTreasuryAndGovernmentMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="ortx_CashEquivalentsAbstract" order="10620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ortx_CashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="10780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_MarketableSecuritiesAbstract" order="11100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="ortx_MarketableSecuritiesFairValueDisclosure" order="11260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" order="11580.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesScheduleOfLevel2CashEquivalentsAndMarketableSecuritiesDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesScheduleOfLevel2CashEquivalentsAndMarketableSecuritiesDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesScheduleOfLevel2CashEquivalentsAndMarketableSecuritiesDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:type="locator" xlink:label="us-gaap_USTreasuryAndGovernmentMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10050.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USTreasuryAndGovernmentMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CommercialPaperMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="10660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" order="10780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="10900.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:href="ortx-20211231.xsd#Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_OfficeAndITEquipmentMember" xlink:type="locator" xlink:label="ortx_OfficeAndITEquipmentMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_LabEquipmentMember" xlink:type="locator" xlink:label="ortx_LabEquipmentMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10030.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="ortx_LabEquipmentMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="ortx_OfficeAndITEquipmentMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10500.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfIntangibleAssetsNetOfAccumulatedAmortizationDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureIntangibleAssetsNetScheduleOfIntangibleAssetsNetOfAccumulatedAmortizationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfIntangibleAssetsNetOfAccumulatedAmortizationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember" xlink:type="locator" xlink:label="us-gaap_LicenseMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="10030.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_LicenseMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="10300.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRestructuringChargesAdditionalInformationDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureRestructuringChargesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRestructuringChargesAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseImpairmentLoss" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_OperatingLeaseRightOfUseAssetFairValue" xlink:type="locator" xlink:label="ortx_OperatingLeaseRightOfUseAssetFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ImpairmentOfConstructionInProcess" xlink:type="locator" xlink:label="ortx_ImpairmentOfConstructionInProcess" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges" xlink:type="locator" xlink:label="us-gaap_RestructuringCharges" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:type="locator" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_FremontCaliforniaMember" xlink:type="locator" xlink:label="ortx_FremontCaliforniaMember" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_MenloParkCaliforniaMember" xlink:type="locator" xlink:label="ortx_MenloParkCaliforniaMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanDomain" xlink:type="locator" xlink:label="us-gaap_RestructuringPlanDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanDomain" xlink:type="locator" xlink:label="us-gaap_RestructuringPlanDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanAxis" xlink:type="locator" xlink:label="us-gaap_RestructuringPlanAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:type="locator" xlink:label="us-gaap_RestructuringCostAndReserveLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringPlanAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RestructuringPlanAxis" xlink:to="us-gaap_RestructuringPlanDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RestructuringPlanAxis" xlink:to="us-gaap_RestructuringPlanDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringPlanDomain" xlink:to="ortx_MenloParkCaliforniaMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringPlanDomain" xlink:to="ortx_FremontCaliforniaMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="srt_RangeAxis" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringCharges" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="ortx_ImpairmentOfConstructionInProcess" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate" order="10610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="ortx_OperatingLeaseRightOfUseAssetFairValue" order="10660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_OperatingLeaseImpairmentLoss" order="10700.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureLeasesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails">
    <link:loc xlink:href="ortx-20211231.xsd#ortx_OperatingLeaseRightOfUseAssetValueExchangeForLeaseLiabilities" xlink:type="locator" xlink:label="ortx_OperatingLeaseRightOfUseAssetValueExchangeForLeaseLiabilities" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_LeaseComponentManufacturingCommitmentAmount" xlink:type="locator" xlink:label="ortx_LeaseComponentManufacturingCommitmentAmount" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_LesseeOperatingLeaseExtendedTerm" xlink:type="locator" xlink:label="ortx_LesseeOperatingLeaseExtendedTerm" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_IncreaseDecreaseInEscrowDeposit" xlink:type="locator" xlink:label="ortx_IncreaseDecreaseInEscrowDeposit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EscrowDeposit" xlink:type="locator" xlink:label="us-gaap_EscrowDeposit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecurityDeposit" xlink:type="locator" xlink:label="us-gaap_SecurityDeposit" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_TenantImprovementAllowance" xlink:type="locator" xlink:label="ortx_TenantImprovementAllowance" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:type="locator" xlink:label="us-gaap_ProceedsFromLinesOfCredit" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ReductionOfStandbyLetterOfCreditAmountPercentage" xlink:type="locator" xlink:label="ortx_ReductionOfStandbyLetterOfCreditAmountPercentage" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_OperatingLeasesCommencedTerm" xlink:type="locator" xlink:label="ortx_OperatingLeasesCommencedTerm" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome" xlink:type="locator" xlink:label="us-gaap_SubleaseIncome" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_OperatingLeaseDurationForFreeRent" xlink:type="locator" xlink:label="ortx_OperatingLeaseDurationForFreeRent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRent" xlink:type="locator" xlink:label="us-gaap_PaymentsForRent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_GSKAgreementMember" xlink:type="locator" xlink:label="ortx_GSKAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="locator" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_FremontSubleaseAgreementMember" xlink:type="locator" xlink:label="ortx_FremontSubleaseAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_FremontLeaseAgreementMember" xlink:type="locator" xlink:label="ortx_FremontLeaseAgreementMember" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_BostonAndLondonOfficeSpaceLeaseAgreementsMember" xlink:type="locator" xlink:label="ortx_BostonAndLondonOfficeSpaceLeaseAgreementsMember" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_LeaseTermTerminatesInSeptemberTwoThousandTwentySixMember" xlink:type="locator" xlink:label="ortx_LeaseTermTerminatesInSeptemberTwoThousandTwentySixMember" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_OfficeSpaceBostonUnitedStatesLeaseAgreementMember" xlink:type="locator" xlink:label="ortx_OfficeSpaceBostonUnitedStatesLeaseAgreementMember" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_LeaseTermTerminatesInSeptemberTwoThousandTwentyTwoMember" xlink:type="locator" xlink:label="ortx_LeaseTermTerminatesInSeptemberTwoThousandTwentyTwoMember" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_RentalLabSpaceMember" xlink:type="locator" xlink:label="ortx_RentalLabSpaceMember" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_OfficeSpaceLondonUnitedKingdomLeaseAgreementMember" xlink:type="locator" xlink:label="ortx_OfficeSpaceLondonUnitedKingdomLeaseAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_FiveYearsLeaseTermTerminatesInJanuaryTwoThousandTwentyThreeMember" xlink:type="locator" xlink:label="ortx_FiveYearsLeaseTermTerminatesInJanuaryTwoThousandTwentyThreeMember" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_OfficeAndLaboratorySpaceMenloParkLeaseAgreementMember" xlink:type="locator" xlink:label="ortx_OfficeAndLaboratorySpaceMenloParkLeaseAgreementMember" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_LaboratorySpaceMenloParkLeaseAgreementMember" xlink:type="locator" xlink:label="ortx_LaboratorySpaceMenloParkLeaseAgreementMember" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_OfficeSpaceMenloParkLeaseAgreementMember" xlink:type="locator" xlink:label="ortx_OfficeSpaceMenloParkLeaseAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermAxis" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_OperatingLeasesTable" xlink:type="locator" xlink:label="ortx_OperatingLeasesTable" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_OperatingLeasesLineItems" xlink:type="locator" xlink:label="ortx_OperatingLeasesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ortx_OperatingLeasesLineItems" xlink:to="ortx_OperatingLeasesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ortx_OperatingLeasesTable" xlink:to="us-gaap_LeaseContractualTermAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="ortx_OfficeSpaceMenloParkLeaseAgreementMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="ortx_LaboratorySpaceMenloParkLeaseAgreementMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="ortx_OfficeAndLaboratorySpaceMenloParkLeaseAgreementMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="ortx_FiveYearsLeaseTermTerminatesInJanuaryTwoThousandTwentyThreeMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ortx_OperatingLeasesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="ortx_OfficeSpaceLondonUnitedKingdomLeaseAgreementMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="ortx_RentalLabSpaceMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="ortx_LeaseTermTerminatesInSeptemberTwoThousandTwentyTwoMember" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="ortx_OfficeSpaceBostonUnitedStatesLeaseAgreementMember" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="ortx_LeaseTermTerminatesInSeptemberTwoThousandTwentySixMember" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="ortx_BostonAndLondonOfficeSpaceLeaseAgreementsMember" order="10830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="ortx_FremontLeaseAgreementMember" order="10910.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ortx_OperatingLeasesTable" xlink:to="srt_RangeAxis" order="11020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="11050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="11070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="11090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="ortx_FremontSubleaseAgreementMember" order="11330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ortx_OperatingLeasesTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="11440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="11470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember" order="11490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="ortx_GSKAgreementMember" order="11550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ortx_OperatingLeasesLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="11760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ortx_OperatingLeasesLineItems" xlink:to="us-gaap_PaymentsForRent" order="11880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ortx_OperatingLeasesLineItems" xlink:to="ortx_OperatingLeaseDurationForFreeRent" order="11940.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ortx_OperatingLeasesLineItems" xlink:to="us-gaap_SubleaseIncome" order="12220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ortx_OperatingLeasesLineItems" xlink:to="ortx_OperatingLeasesCommencedTerm" order="12270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ortx_OperatingLeasesLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="12380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ortx_OperatingLeasesLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="12420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ortx_OperatingLeasesLineItems" xlink:to="ortx_ReductionOfStandbyLetterOfCreditAmountPercentage" order="12530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ortx_OperatingLeasesLineItems" xlink:to="us-gaap_ProceedsFromLinesOfCredit" order="12550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ortx_OperatingLeasesLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="12660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ortx_OperatingLeasesLineItems" xlink:to="ortx_TenantImprovementAllowance" order="12680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ortx_OperatingLeasesLineItems" xlink:to="us-gaap_SecurityDeposit" order="12850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ortx_OperatingLeasesLineItems" xlink:to="us-gaap_EscrowDeposit" order="12890.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ortx_OperatingLeasesLineItems" xlink:to="ortx_IncreaseDecreaseInEscrowDeposit" order="12930.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ortx_OperatingLeasesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="13000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ortx_OperatingLeasesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="13040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ortx_OperatingLeasesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" order="13060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ortx_OperatingLeasesLineItems" xlink:to="ortx_LesseeOperatingLeaseExtendedTerm" order="13080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ortx_OperatingLeasesLineItems" xlink:to="ortx_LeaseComponentManufacturingCommitmentAmount" order="13100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ortx_OperatingLeasesLineItems" xlink:to="ortx_OperatingLeaseRightOfUseAssetValueExchangeForLeaseLiabilities" order="13300.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumBaseRentCommitmentsUnderOperatingLeasesParentheticalDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureLeasesScheduleOfFutureMinimumBaseRentCommitmentsUnderOperatingLeasesParentheticalDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumBaseRentCommitmentsUnderOperatingLeasesParentheticalDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyExchangeRateTranslation1" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_EUR" xlink:type="locator" xlink:label="currency_EUR" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_GBP" xlink:type="locator" xlink:label="currency_GBP" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_AllCurrenciesDomain" xlink:type="locator" xlink:label="currency_AllCurrenciesDomain" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_AllCurrenciesDomain" xlink:type="locator" xlink:label="currency_AllCurrenciesDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CurrencyAxis" xlink:type="locator" xlink:label="srt_CurrencyAxis" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_OperatingLeasesTable" xlink:type="locator" xlink:label="ortx_OperatingLeasesTable" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_OperatingLeasesLineItems" xlink:type="locator" xlink:label="ortx_OperatingLeasesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ortx_OperatingLeasesLineItems" xlink:to="ortx_OperatingLeasesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ortx_OperatingLeasesTable" xlink:to="srt_CurrencyAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_GBP" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_EUR" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ortx_OperatingLeasesLineItems" xlink:to="us-gaap_ForeignCurrencyExchangeRateTranslation1" order="10140.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureNotesPayableAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCovenantDescription" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentCovenantDescription" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_LineOfCreditFacilityCovenantsMinimumCashAllowed" xlink:type="locator" xlink:label="ortx_LineOfCreditFacilityCovenantsMinimumCashAllowed" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateDescription" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDescription" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLinesOfCredit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityPeriodicPaymentInterest" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityPeriodicPaymentInterest" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_LineOfCreditFacilityPercentageOfFinalPayment" xlink:type="locator" xlink:label="ortx_LineOfCreditFacilityPercentageOfFinalPayment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityFrequencyOfPayments" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityFrequencyOfPayments" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_LineOfCreditFacilityAmortizationTerm" xlink:type="locator" xlink:label="ortx_LineOfCreditFacilityAmortizationTerm" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_LineOfCreditFacilityInterestPaymentsTerm" xlink:type="locator" xlink:label="ortx_LineOfCreditFacilityInterestPaymentsTerm" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityCovenantTerms" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityCovenantTerms" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAndCash" xlink:type="locator" xlink:label="us-gaap_InvestmentsAndCash" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:type="locator" xlink:label="us-gaap_ProceedsFromLinesOfCredit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityInitiationDate1" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityInitiationDate1" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_TermLoanMember" xlink:type="locator" xlink:label="ortx_TermLoanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodThreeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_LondonInterbankOfferedRateFloorMember" xlink:type="locator" xlink:label="ortx_LondonInterbankOfferedRateFloorMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain" xlink:type="locator" xlink:label="us-gaap_VariableRateDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain" xlink:type="locator" xlink:label="us-gaap_VariableRateDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis" xlink:type="locator" xlink:label="us-gaap_VariableRateAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_TheThirdTrancheTermLoanMember" xlink:type="locator" xlink:label="ortx_TheThirdTrancheTermLoanMember" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_TheSecondTrancheTermLoanMember" xlink:type="locator" xlink:label="ortx_TheSecondTrancheTermLoanMember" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_TheFirstTrancheTermLoanMember" xlink:type="locator" xlink:label="ortx_TheFirstTrancheTermLoanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="ortx_TheFirstTrancheTermLoanMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="ortx_TheSecondTrancheTermLoanMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="ortx_TheThirdTrancheTermLoanMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_RangeAxis" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_VariableRateAxis" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain_2" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableRateDomain" xlink:to="ortx_LondonInterbankOfferedRateFloorMember" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodAxis" order="10640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain_2" order="10650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain" order="10670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" order="10690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodThreeMember" order="10710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="10820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain_2" order="10830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="10850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="ortx_TermLoanMember" order="10870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityInitiationDate1" order="10920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" order="10940.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromLinesOfCredit" order="11050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" order="11070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InvestmentsAndCash" order="11130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityCovenantTerms" order="11170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" order="11240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="ortx_LineOfCreditFacilityInterestPaymentsTerm" order="11260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="ortx_LineOfCreditFacilityAmortizationTerm" order="11280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityFrequencyOfPayments" order="11300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="ortx_LineOfCreditFacilityPercentageOfFinalPayment" order="11320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityPeriodicPaymentInterest" order="11340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RepaymentsOfLinesOfCredit" order="11360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityInterestRateDescription" order="11380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="ortx_LineOfCreditFacilityCovenantsMinimumCashAllowed" order="11640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCovenantDescription" order="11680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebt" order="11730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod" order="11770.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareholdersEquityAndConvertiblePreferredSharesAdditionalInformationDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureShareholdersEquityAndConvertiblePreferredSharesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareholdersEquityAndConvertiblePreferredSharesAdditionalInformationDetails">
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ProceedsFromPremiumSharesIssued" xlink:type="locator" xlink:label="ortx_ProceedsFromPremiumSharesIssued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_NetProceedsFromIssuanceOfPrivatePlacement" xlink:type="locator" xlink:label="ortx_NetProceedsFromIssuanceOfPrivatePlacement" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockTransactionDate" xlink:type="locator" xlink:label="us-gaap_SaleOfStockTransactionDate" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_PaymentsOfOtherIssuanceCosts" xlink:type="locator" xlink:label="ortx_PaymentsOfOtherIssuanceCosts" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ClosingPriceOfShareDate" xlink:type="locator" xlink:label="ortx_ClosingPriceOfShareDate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValueOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockValueOutstanding" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_NumberOfOrdinaryVotingRights" xlink:type="locator" xlink:label="ortx_NumberOfOrdinaryVotingRights" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsCommonStock" xlink:type="locator" xlink:label="us-gaap_DividendsCommonStock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:type="locator" xlink:label="us-gaap_CommonStockVotingRights" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_SharePurchaseAgreementWithPharmingMember" xlink:type="locator" xlink:label="ortx_SharePurchaseAgreementWithPharmingMember" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_NonVotingOrdinarySharesMember" xlink:type="locator" xlink:label="ortx_NonVotingOrdinarySharesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_SecuritiesPurchaseAgreementMember" xlink:type="locator" xlink:label="ortx_SecuritiesPurchaseAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_NonEmployeeAdvisorMember" xlink:type="locator" xlink:label="ortx_NonEmployeeAdvisorMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ConsultingAgreementMember" xlink:type="locator" xlink:label="ortx_ConsultingAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_OxfordBioMedicaLicenseDevelopmentAndSupplyAgreementMember" xlink:type="locator" xlink:label="ortx_OxfordBioMedicaLicenseDevelopmentAndSupplyAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ortx_OxfordBioMedicaLicenseDevelopmentAndSupplyAgreementMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="ortx_ConsultingAgreementMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_TitleOfIndividualAxis" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_2" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="ortx_NonEmployeeAdvisorMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ortx_SecuritiesPurchaseAgreementMember" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="ortx_NonVotingOrdinarySharesMember" order="10630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ortx_SharePurchaseAgreementWithPharmingMember" order="10710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockVotingRights" order="10800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DividendsCommonStock" order="10840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="ortx_NumberOfOrdinaryVotingRights" order="10880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockValueOutstanding" order="10920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="11030.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="11150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="11190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="ortx_ClosingPriceOfShareDate" order="11210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="11270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="ortx_PaymentsOfOtherIssuanceCosts" order="11290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockTransactionDate" order="11310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="ortx_NetProceedsFromIssuanceOfPrivatePlacement" order="11330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="11380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="11420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="ortx_ProceedsFromPremiumSharesIssued" order="11440.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureShareBasedCompensationAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:type="locator" xlink:label="ortx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeEquityPlanProceedsReceivedAfterYearEnd" xlink:type="locator" xlink:label="ortx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeEquityPlanProceedsReceivedAfterYearEnd" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain" xlink:type="locator" xlink:label="us-gaap_VestingDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain" xlink:type="locator" xlink:label="us-gaap_VestingDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis" xlink:type="locator" xlink:label="us-gaap_VestingAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:type="locator" xlink:label="srt_ChiefExecutiveOfficerMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_TimeBasedRestrictedShareUnitsMember" xlink:type="locator" xlink:label="ortx_TimeBasedRestrictedShareUnitsMember" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_LibmeldyMember" xlink:type="locator" xlink:label="ortx_LibmeldyMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:type="locator" xlink:label="us-gaap_PerformanceSharesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_TwoThousandAndTwentyInducementEquityPlanMember" xlink:type="locator" xlink:label="ortx_TwoThousandAndTwentyInducementEquityPlanMember" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_TwoThousandAndEighteenEmployeeSharePurchasePlanMember" xlink:type="locator" xlink:label="ortx_TwoThousandAndEighteenEmployeeSharePurchasePlanMember" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_TwoThousandAndEighteenShareOptionAndIncentivePlanMember" xlink:type="locator" xlink:label="ortx_TwoThousandAndEighteenShareOptionAndIncentivePlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="ortx_TwoThousandAndEighteenShareOptionAndIncentivePlanMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="ortx_TwoThousandAndEighteenEmployeeSharePurchasePlanMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="ortx_TwoThousandAndTwentyInducementEquityPlanMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ortx_LibmeldyMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="ortx_TimeBasedRestrictedShareUnitsMember" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain_2" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" order="10690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="10710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="10730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="10780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="10820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ortx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeEquityPlanProceedsReceivedAfterYearEnd" order="10860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10930.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="11000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="11040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="11080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="11150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ortx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" order="11170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" order="11190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" order="11260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="11280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="11300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="11320.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAssumptionsUsedInBlackScholesOptionPricingModelDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureShareBasedCompensationAssumptionsUsedInBlackScholesOptionPricingModelDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAssumptionsUsedInBlackScholesOptionPricingModelDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10420.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfAwardActivityDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureShareBasedCompensationSummaryOfAwardActivityDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfAwardActivityDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_TimeBasedRestrictedShareUnitsMember" xlink:type="locator" xlink:label="ortx_TimeBasedRestrictedShareUnitsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:type="locator" xlink:label="us-gaap_PerformanceSharesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="ortx_TimeBasedRestrictedShareUnitsMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="10730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="10810.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10140.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureLicenseAndResearchAgreementsAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetails">
    <link:loc xlink:href="ortx-20211231.xsd#ortx_NumberOfMilestonesMet" xlink:type="locator" xlink:label="ortx_NumberOfMilestonesMet" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_MilestonePayment" xlink:type="locator" xlink:label="ortx_MilestonePayment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_PotentialPaymentForAchievementOfSpecifiedMilestones" xlink:type="locator" xlink:label="ortx_PotentialPaymentForAchievementOfSpecifiedMilestones" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentForAdministrativeFees" xlink:type="locator" xlink:label="us-gaap_PaymentForAdministrativeFees" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_PaymentsToAcquireClinicalData" xlink:type="locator" xlink:label="ortx_PaymentsToAcquireClinicalData" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_UpfrontCashPayment" xlink:type="locator" xlink:label="ortx_UpfrontCashPayment" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_MilestonePaymentsPayableUponAchievementOfCertainDevelopmentRegulatoryAndCommercialMilestones" xlink:type="locator" xlink:label="ortx_MilestonePaymentsPayableUponAchievementOfCertainDevelopmentRegulatoryAndCommercialMilestones" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_InProcessResearchAndDevelopmentExpenseForUpfrontAndMilestonePayments" xlink:type="locator" xlink:label="ortx_InProcessResearchAndDevelopmentExpenseForUpfrontAndMilestonePayments" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_UpfrontAndMilestonePayments" xlink:type="locator" xlink:label="ortx_UpfrontAndMilestonePayments" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_UpfrontPaymentDescription" xlink:type="locator" xlink:label="ortx_UpfrontPaymentDescription" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_MilestonePaymentsPayableUponAchievementOfCertainSalesMilestones" xlink:type="locator" xlink:label="ortx_MilestonePaymentsPayableUponAchievementOfCertainSalesMilestones" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_PaymentOfTieredRoyaltyMaximumPercentage" xlink:type="locator" xlink:label="ortx_PaymentOfTieredRoyaltyMaximumPercentage" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_AssetAcquisitionInProcessResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="ortx_AssetAcquisitionInProcessResearchAndDevelopmentExpense" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_AssetAcquisitionTransactionCosts" xlink:type="locator" xlink:label="ortx_AssetAcquisitionTransactionCosts" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_AssetAcquisitionInventoryPurchaseLiability" xlink:type="locator" xlink:label="ortx_AssetAcquisitionInventoryPurchaseLiability" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_AssetAcquisitionLiabilityAssumed" xlink:type="locator" xlink:label="ortx_AssetAcquisitionLiabilityAssumed" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_AssetAcquisitionValueOfEquityInstrumentsIssued" xlink:type="locator" xlink:label="ortx_AssetAcquisitionValueOfEquityInstrumentsIssued" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_AssetAcquisitionNumberOfSharesIssuedForAcquisition" xlink:type="locator" xlink:label="ortx_AssetAcquisitionNumberOfSharesIssuedForAcquisition" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_AssetAcquisitionUpfrontPayment" xlink:type="locator" xlink:label="ortx_AssetAcquisitionUpfrontPayment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_NumberOfAdditionalEarlierStageDevelopmentPrograms" xlink:type="locator" xlink:label="ortx_NumberOfAdditionalEarlierStageDevelopmentPrograms" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_NumberOfEarlierStageClinicalGeneTherapyProgram" xlink:type="locator" xlink:label="ortx_NumberOfEarlierStageClinicalGeneTherapyProgram" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_NumberOfLateStageClinicalGeneTherapyPrograms" xlink:type="locator" xlink:label="ortx_NumberOfLateStageClinicalGeneTherapyPrograms" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_OxfordBioMedicaLicenseDevelopmentAndSupplyAgreementMember" xlink:type="locator" xlink:label="ortx_OxfordBioMedicaLicenseDevelopmentAndSupplyAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_UCLBAndUCLALicenseAgreementMember" xlink:type="locator" xlink:label="ortx_UCLBAndUCLALicenseAgreementMember" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_UCLBLicenseAgreementMember" xlink:type="locator" xlink:label="ortx_UCLBLicenseAgreementMember" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_UCLBTechnologyAndManufacturingTechnologyMember" xlink:type="locator" xlink:label="ortx_UCLBTechnologyAndManufacturingTechnologyMember" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_UCLBAndUCLATechnologyMember" xlink:type="locator" xlink:label="ortx_UCLBAndUCLATechnologyMember" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_TelethonOSRLicenseAgreementsMember" xlink:type="locator" xlink:label="ortx_TelethonOSRLicenseAgreementsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_GSKAssetPurchaseAndLicenseAgreementMember" xlink:type="locator" xlink:label="ortx_GSKAssetPurchaseAndLicenseAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ortx_GSKAssetPurchaseAndLicenseAgreementMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ortx_TelethonOSRLicenseAgreementsMember" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ortx_UCLBAndUCLATechnologyMember" order="10630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ortx_UCLBTechnologyAndManufacturingTechnologyMember" order="10650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ortx_UCLBLicenseAgreementMember" order="10670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ortx_UCLBAndUCLALicenseAgreementMember" order="10690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10890.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ortx_OxfordBioMedicaLicenseDevelopmentAndSupplyAgreementMember" order="10950.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ortx_NumberOfLateStageClinicalGeneTherapyPrograms" order="11020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ortx_NumberOfEarlierStageClinicalGeneTherapyProgram" order="11040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ortx_NumberOfAdditionalEarlierStageDevelopmentPrograms" order="11060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred" order="11110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ortx_AssetAcquisitionUpfrontPayment" order="11150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ortx_AssetAcquisitionNumberOfSharesIssuedForAcquisition" order="11190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ortx_AssetAcquisitionValueOfEquityInstrumentsIssued" order="11230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ortx_AssetAcquisitionLiabilityAssumed" order="11270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ortx_AssetAcquisitionInventoryPurchaseLiability" order="11310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ortx_AssetAcquisitionTransactionCosts" order="11350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ortx_AssetAcquisitionInProcessResearchAndDevelopmentExpense" order="11390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ortx_PaymentOfTieredRoyaltyMaximumPercentage" order="11530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ortx_MilestonePaymentsPayableUponAchievementOfCertainSalesMilestones" order="11550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ortx_UpfrontPaymentDescription" order="11670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ortx_UpfrontAndMilestonePayments" order="11730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ortx_InProcessResearchAndDevelopmentExpenseForUpfrontAndMilestonePayments" order="11790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ortx_MilestonePaymentsPayableUponAchievementOfCertainDevelopmentRegulatoryAndCommercialMilestones" order="11850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ortx_UpfrontCashPayment" order="11940.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="12060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ortx_PaymentsToAcquireClinicalData" order="12120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_PaymentForAdministrativeFees" order="12210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ortx_PotentialPaymentForAchievementOfSpecifiedMilestones" order="12250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="12320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ortx_MilestonePayment" order="12470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ortx_NumberOfMilestonesMet" order="12550.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCollaborationAgreementWithPharmingGroupNVAdditionalInformationDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureCollaborationAgreementWithPharmingGroupNVAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCollaborationAgreementWithPharmingGroupNVAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ProceedsFromNonRefundableUpfrontPayment" xlink:type="locator" xlink:label="ortx_ProceedsFromNonRefundableUpfrontPayment" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ExcessProceedsFromFairValueOfSharesIssuedAllocatedToCollaborationAgreement" xlink:type="locator" xlink:label="ortx_ExcessProceedsFromFairValueOfSharesIssuedAllocatedToCollaborationAgreement" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssued1" xlink:type="locator" xlink:label="us-gaap_StockIssued1" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ProceedsFromUpfrontPaymentsAttributedToResearchActivities" xlink:type="locator" xlink:label="ortx_ProceedsFromUpfrontPaymentsAttributedToResearchActivities" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ProceedsFromUpfrontPaymentsAttributedToEquitySold" xlink:type="locator" xlink:label="ortx_ProceedsFromUpfrontPaymentsAttributedToEquitySold" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ProceedsFromUpfrontPayment" xlink:type="locator" xlink:label="ortx_ProceedsFromUpfrontPayment" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ProceedsFromPremiumSharesIssued" xlink:type="locator" xlink:label="ortx_ProceedsFromPremiumSharesIssued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_MilestonePaymentsReceivable" xlink:type="locator" xlink:label="ortx_MilestonePaymentsReceivable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:type="locator" xlink:label="us-gaap_ProceedsFromCollaborators" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementMember" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_PharmingAgreementsMember" xlink:type="locator" xlink:label="ortx_PharmingAgreementsMember" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_SharePurchaseAgreementWithPharmingMember" xlink:type="locator" xlink:label="ortx_SharePurchaseAgreementWithPharmingMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_StrategicCollaborationAgreementWithPharmingMember" xlink:type="locator" xlink:label="ortx_StrategicCollaborationAgreementWithPharmingMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ortx_StrategicCollaborationAgreementWithPharmingMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ortx_SharePurchaseAgreementWithPharmingMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ortx_PharmingAgreementsMember" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" order="10650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="10660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="10690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_AccountsReceivableMember" order="10710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromCollaborators" order="10800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ortx_MilestonePaymentsReceivable" order="10820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="10870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10890.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10910.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ortx_ProceedsFromPremiumSharesIssued" order="10930.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ortx_ProceedsFromUpfrontPayment" order="11000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ortx_ProceedsFromUpfrontPaymentsAttributedToEquitySold" order="11020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ortx_ProceedsFromUpfrontPaymentsAttributedToResearchActivities" order="11040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssued1" order="11090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ortx_ExcessProceedsFromFairValueOfSharesIssuedAllocatedToCollaborationAgreement" order="11110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ortx_ProceedsFromNonRefundableUpfrontPayment" order="11160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNetCurrent" order="11230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="11300.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCollaborationAgreementWithPharmingGroupNVSummaryOfResearchAndDevelopmentCostsIncurredAndCollaborationRevenueRecognizedDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureCollaborationAgreementWithPharmingGroupNVSummaryOfResearchAndDevelopmentCostsIncurredAndCollaborationRevenueRecognizedDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCollaborationAgreementWithPharmingGroupNVSummaryOfResearchAndDevelopmentCostsIncurredAndCollaborationRevenueRecognizedDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_UpfrontAndMilestonePaymentRevenueMember" xlink:type="locator" xlink:label="ortx_UpfrontAndMilestonePaymentRevenueMember" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ReimbursementRevenueMember" xlink:type="locator" xlink:label="ortx_ReimbursementRevenueMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ortx_ReimbursementRevenueMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ortx_UpfrontAndMilestonePaymentRevenueMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10240.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OpenTaxYear" xlink:type="locator" xlink:label="us-gaap_OpenTaxYear" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_TaxCreditCarryforwardExpirationYear" xlink:type="locator" xlink:label="ortx_TaxCreditCarryforwardExpirationYear" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_CorporationTaxRatePercentage" xlink:type="locator" xlink:label="ortx_CorporationTaxRatePercentage" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LatestTaxYearMember" xlink:type="locator" xlink:label="us-gaap_LatestTaxYearMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarliestTaxYearMember" xlink:type="locator" xlink:label="us-gaap_EarliestTaxYearMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:type="locator" xlink:label="us-gaap_TaxPeriodDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:type="locator" xlink:label="us-gaap_TaxPeriodDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:type="locator" xlink:label="us-gaap_TaxPeriodAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember" xlink:type="locator" xlink:label="us-gaap_ResearchMember" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_OrphanDrugTaxCreditMember" xlink:type="locator" xlink:label="ortx_OrphanDrugTaxCreditMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US" xlink:type="locator" xlink:label="country_US" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_GB" xlink:type="locator" xlink:label="country_GB" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="srt_StatementGeographicalAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_GB" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_2" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_2" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="ortx_OrphanDrugTaxCreditMember" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_TaxPeriodAxis" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain_2" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_EarliestTaxYearMember" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_LatestTaxYearMember" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="ortx_CorporationTaxRatePercentage" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" order="10580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="10650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="10690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="ortx_TaxCreditCarryforwardExpirationYear" order="10770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" order="10840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OpenTaxYear" order="10910.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfAnnualCommitmentsAssociatedWithContractDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureCommitmentsAndContingenciesScheduleOfAnnualCommitmentsAssociatedWithContractDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfAnnualCommitmentsAssociatedWithContractDetails">
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ManufacturingCommitments" xlink:type="locator" xlink:label="ortx_ManufacturingCommitments" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ManufacturingCommitmentsAmountDueThereafter" xlink:type="locator" xlink:label="ortx_ManufacturingCommitmentsAmountDueThereafter" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ManufacturingCommitmentsAmountDueInYearFive" xlink:type="locator" xlink:label="ortx_ManufacturingCommitmentsAmountDueInYearFive" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ManufacturingCommitmentsAmountDueInYearFour" xlink:type="locator" xlink:label="ortx_ManufacturingCommitmentsAmountDueInYearFour" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ManufacturingCommitmentsAmountDueInYearThree" xlink:type="locator" xlink:label="ortx_ManufacturingCommitmentsAmountDueInYearThree" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ManufacturingCommitmentsAmountDueInYearTwo" xlink:type="locator" xlink:label="ortx_ManufacturingCommitmentsAmountDueInYearTwo" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ManufacturingCommitmentsAmountDueInNextTwelveMonths" xlink:type="locator" xlink:label="ortx_ManufacturingCommitmentsAmountDueInNextTwelveMonths" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ExclusiveTransductionSuitesMember" xlink:type="locator" xlink:label="ortx_ExclusiveTransductionSuitesMember" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_DedicatedManufacturingAndDevelopmentResourcesMember" xlink:type="locator" xlink:label="ortx_DedicatedManufacturingAndDevelopmentResourcesMember" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ProductManufacturingCommitmentsMember" xlink:type="locator" xlink:label="ortx_ProductManufacturingCommitmentsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplyCommitmentArrangementMember" xlink:type="locator" xlink:label="us-gaap_SupplyCommitmentArrangementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplyCommitmentArrangementMember" xlink:type="locator" xlink:label="us-gaap_SupplyCommitmentArrangementMember_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplyCommitmentAxis" xlink:type="locator" xlink:label="us-gaap_SupplyCommitmentAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsTable" xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsLineItems" xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsTable" order="10070.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_SupplyCommitmentAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SupplyCommitmentAxis" xlink:to="us-gaap_SupplyCommitmentArrangementMember_2" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SupplyCommitmentAxis" xlink:to="us-gaap_SupplyCommitmentArrangementMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="ortx_ProductManufacturingCommitmentsMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="ortx_DedicatedManufacturingAndDevelopmentResourcesMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="ortx_ExclusiveTransductionSuitesMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="ortx_ManufacturingCommitmentsAmountDueInNextTwelveMonths" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="ortx_ManufacturingCommitmentsAmountDueInYearTwo" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="ortx_ManufacturingCommitmentsAmountDueInYearThree" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="ortx_ManufacturingCommitmentsAmountDueInYearFour" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="ortx_ManufacturingCommitmentsAmountDueInYearFive" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="ortx_ManufacturingCommitmentsAmountDueThereafter" order="10620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="ortx_ManufacturingCommitments" order="10700.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_AgreementExtensionTerm" xlink:type="locator" xlink:label="ortx_AgreementExtensionTerm" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_AgreementMaturityDate" xlink:type="locator" xlink:label="ortx_AgreementMaturityDate" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_InitialTermOfAgreement" xlink:type="locator" xlink:label="ortx_InitialTermOfAgreement" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ClinicalDevelopmentAndRegulatoryMilestoneMember" xlink:type="locator" xlink:label="ortx_ClinicalDevelopmentAndRegulatoryMilestoneMember" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_NonEmployeeAdvisorMember" xlink:type="locator" xlink:label="ortx_NonEmployeeAdvisorMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ConsultingAgreementMember" xlink:type="locator" xlink:label="ortx_ConsultingAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ManufacturingAndTechnologyDevelopmentMasterAgreementMember" xlink:type="locator" xlink:label="ortx_ManufacturingAndTechnologyDevelopmentMasterAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsTable" xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsLineItems" xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ortx_ManufacturingAndTechnologyDevelopmentMasterAgreementMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="ortx_ConsultingAgreementMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="srt_TitleOfIndividualAxis" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="ortx_NonEmployeeAdvisorMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ortx_ClinicalDevelopmentAndRegulatoryMilestoneMember" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="ortx_InitialTermOfAgreement" order="10680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="ortx_AgreementMaturityDate" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="ortx_AgreementExtensionTerm" order="10720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" order="10770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="10950.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="11010.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="11100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="11140.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_AccruedExpensesRelatedPartyCurrent" xlink:type="locator" xlink:label="ortx_AccruedExpensesRelatedPartyCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForLossOnContracts" xlink:type="locator" xlink:label="us-gaap_ProvisionForLossOnContracts" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_AssetAcquisitionTransactionCosts" xlink:type="locator" xlink:label="ortx_AssetAcquisitionTransactionCosts" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_InventoryPurchase" xlink:type="locator" xlink:label="ortx_InventoryPurchase" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_LicenseUpfrontFeeAndRelatedExpensesPaid" xlink:type="locator" xlink:label="ortx_LicenseUpfrontFeeAndRelatedExpensesPaid" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_GSKAssetPurchaseAndLicenseAgreementMember" xlink:type="locator" xlink:label="ortx_GSKAssetPurchaseAndLicenseAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_GSKMember" xlink:type="locator" xlink:label="ortx_GSKMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="ortx_GSKMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ortx_GSKAssetPurchaseAndLicenseAgreementMember" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ortx_LicenseUpfrontFeeAndRelatedExpensesPaid" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ortx_InventoryPurchase" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ortx_AssetAcquisitionTransactionCosts" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_PreferredStockValue" order="10580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ProvisionForLossOnContracts" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrent" order="10650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ortx_AccruedExpensesRelatedPartyCurrent" order="10670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10710.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureSubsequentEventsAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:type="locator" xlink:label="us-gaap_RestructuringAndRelatedCostExpectedCost1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:type="locator" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_GB" xlink:type="locator" xlink:label="country_GB" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_StatementGeographicalAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_GB" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostExpectedCost1" order="10200.00" priority="2" use="optional" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>14
<FILENAME>ortx-20211231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-03-30T03:21:51.5007884+00:00 -->
<!-- Version            : 5.0.1.728 -->
<!-- Package ID         : 1b558024b59f49cabedb23f437fea13f -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#axisDefault" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_MarketableSecuritiesFairValueDisclosure" xlink:type="locator" xlink:label="ortx_MarketableSecuritiesFairValueDisclosure" />
    <link:label xml:lang="en-US" xlink:label="ortx_MarketableSecuritiesFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Marketable securities fair value disclosure.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_MarketableSecuritiesFairValueDisclosure" xlink:to="ortx_MarketableSecuritiesFairValueDisclosure_lbl" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_UnamortizedPortionOfFinalPayment" xlink:type="locator" xlink:label="ortx_UnamortizedPortionOfFinalPayment" />
    <link:label xml:lang="en-US" xlink:label="ortx_UnamortizedPortionOfFinalPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Unamortized portion of final payment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_UnamortizedPortionOfFinalPayment" xlink:to="ortx_UnamortizedPortionOfFinalPayment_lbl" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_IncomeTaxReconciliationReductionInResearchExpenseForCreditsGranted" xlink:type="locator" xlink:label="ortx_IncomeTaxReconciliationReductionInResearchExpenseForCreditsGranted" />
    <link:label xml:lang="en-US" xlink:label="ortx_IncomeTaxReconciliationReductionInResearchExpenseForCreditsGranted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax reconciliation reduction in research expense for credits granted.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_IncomeTaxReconciliationReductionInResearchExpenseForCreditsGranted" xlink:to="ortx_IncomeTaxReconciliationReductionInResearchExpenseForCreditsGranted_lbl" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_IncomeTaxReconciliationDomesticDeductionForDerivedIntangibleIncome" xlink:type="locator" xlink:label="ortx_IncomeTaxReconciliationDomesticDeductionForDerivedIntangibleIncome" />
    <link:label xml:lang="en-US" xlink:label="ortx_IncomeTaxReconciliationDomesticDeductionForDerivedIntangibleIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax reconciliation domestic deduction for derived intangible income.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_IncomeTaxReconciliationDomesticDeductionForDerivedIntangibleIncome" xlink:to="ortx_IncomeTaxReconciliationDomesticDeductionForDerivedIntangibleIncome_lbl" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_IncomeTaxReconciliationPermanentDifferencesIncludingShareBasedCompensationDeductionShortfalls" xlink:type="locator" xlink:label="ortx_IncomeTaxReconciliationPermanentDifferencesIncludingShareBasedCompensationDeductionShortfalls" />
    <link:label xml:lang="en-US" xlink:label="ortx_IncomeTaxReconciliationPermanentDifferencesIncludingShareBasedCompensationDeductionShortfalls_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax reconciliation permanent differences including share-based compensation deduction shortfalls.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_IncomeTaxReconciliationPermanentDifferencesIncludingShareBasedCompensationDeductionShortfalls" xlink:to="ortx_IncomeTaxReconciliationPermanentDifferencesIncludingShareBasedCompensationDeductionShortfalls_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well Known Seasoned Issuer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:type="locator" xlink:label="dei_EntityPublicFloat" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityPublicFloat_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityPublicFloat_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:type="locator" xlink:label="dei_DocumentAnnualReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentAnnualReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentAnnualReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:type="locator" xlink:label="dei_EntityAddressCountry" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCountry_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Country</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCountry_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Country</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Icfr Auditor Attestation Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:type="locator" xlink:label="dei_AuditorFirmId" />
    <link:label xml:lang="en-US" xlink:label="dei_AuditorFirmId_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Firm ID</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AuditorFirmId_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm Id</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:type="locator" xlink:label="dei_AuditorName" />
    <link:label xml:lang="en-US" xlink:label="dei_AuditorName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AuditorName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:type="locator" xlink:label="dei_AuditorLocation" />
    <link:label xml:lang="en-US" xlink:label="dei_AuditorLocation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AuditorLocation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ResearchAndDevelopmentTaxCreditReceivableCurrent" xlink:type="locator" xlink:label="ortx_ResearchAndDevelopmentTaxCreditReceivableCurrent" />
    <link:label xml:lang="en-US" xlink:label="ortx_ResearchAndDevelopmentTaxCreditReceivableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development tax credit receivable, current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_ResearchAndDevelopmentTaxCreditReceivableCurrent" xlink:to="ortx_ResearchAndDevelopmentTaxCreditReceivableCurrent_lbl" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_AccruedExpensesAndOtherCurrentLiabilities" xlink:type="locator" xlink:label="ortx_AccruedExpensesAndOtherCurrentLiabilities" />
    <link:label xml:lang="en-US" xlink:label="ortx_AccruedExpensesAndOtherCurrentLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of accrued expenses and other current liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="ortx_AccruedExpensesAndOtherCurrentLiabilities_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents At Carrying Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecurities" xlink:type="locator" xlink:label="us-gaap_MarketableSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecurities" xlink:to="us-gaap_MarketableSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable Net Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense And Other Assets Current</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_ResearchAndDevelopmentTaxCreditReceivableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development tax credit receivable</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_ResearchAndDevelopmentTaxCreditReceivableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Tax Credit Receivable Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-current assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Noncurrent [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use-assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Right Of Use Asset</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Net</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash And Cash Equivalents Noncurrent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets Net Excluding Goodwill</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Noncurrent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total non-current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Noncurrent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and shareholders&#8217; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Current</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_AccruedExpensesAndOtherCurrentLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_AccruedExpensesAndOtherCurrentLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Expenses And Other Current Liabilities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:type="locator" xlink:label="us-gaap_NotesPayableCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NotesPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Notes payable, current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NotesPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Notes Payable Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:type="locator" xlink:label="us-gaap_LongTermNotesPayable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermNotesPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Notes payable, long-term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermNotesPayable" xlink:to="us-gaap_LongTermNotesPayable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermNotesPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Notes Payable</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue, net of current portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue Noncurrent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities, net of current portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Noncurrent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other long-term liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities Noncurrent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 18)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shareholders&#8217; equity:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ordinary shares, &#163;0.10 par value, authority to allot up to a maximum nominal value of &#163;13,023,851.50 of shares at December 31, 2021 and 2020, respectively; 125,674,095 and 98,283,603 shares issued and outstanding at December 31, 2021 and 2020, respectively.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income Loss Net Of Tax</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings Accumulated Deficit</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total shareholders&#8217; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and shareholders&#8217; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_CommonStockSharesAuthorizedNominalAmount" xlink:type="locator" xlink:label="ortx_CommonStockSharesAuthorizedNominalAmount" />
    <link:label xml:lang="en-US" xlink:label="ortx_CommonStockSharesAuthorizedNominalAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock shares authorized nominal amount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_CommonStockSharesAuthorizedNominalAmount" xlink:to="ortx_CommonStockSharesAuthorizedNominalAmount_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ordinary Shares, Par Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Par Or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_CommonStockSharesAuthorizedNominalAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ordinary Shares, Authorized</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_CommonStockSharesAuthorizedNominalAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Authorized Nominal Amount</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ordinary Shares, Issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Issued</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ordinary Shares, Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Product Or Service [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Products And Services [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember" xlink:type="locator" xlink:label="us-gaap_ProductMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProductMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product Sales, Net [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductMember" xlink:to="us-gaap_ProductMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProductMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Product [Member]</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_CollaborationMember" xlink:type="locator" xlink:label="ortx_CollaborationMember" />
    <link:label xml:lang="en-US" xlink:label="ortx_CollaborationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_CollaborationMember" xlink:to="ortx_CollaborationMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_CollaborationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration Revenue [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_CollaborationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total revenues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Contract With Customer Excluding Assessed Tax</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingCostsAndExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Costs and operating expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_OperatingCostsAndExpensesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Costs And Expenses [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of product sales</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cost Of Goods And Services Sold</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfCostGoodOrServiceExtensibleList" xlink:type="locator" xlink:label="us-gaap_TypeOfCostGoodOrServiceExtensibleList" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfCostGoodOrServiceExtensibleList_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Type of Cost, Good or Service [Extensible List]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfCostGoodOrServiceExtensibleList" xlink:to="us-gaap_TypeOfCostGoodOrServiceExtensibleList_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfCostGoodOrServiceExtensibleList_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Cost Good Or Service Extensible List</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Selling, general and administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Selling General And Administrative Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses" xlink:type="locator" xlink:label="us-gaap_CostsAndExpenses" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CostsAndExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total costs and operating expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CostsAndExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Costs And Expenses</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income Loss</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other (expense) income:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income Expense [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income Interest</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:type="locator" xlink:label="us-gaap_InterestExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other (expense) income, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other (expense) income, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss before income tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Income tax (expense) benefit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense Benefit</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss attributable to ordinary shareholders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share attributable to ordinary shareholders, basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic And Diluted</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average number of ordinary shares outstanding, basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Share Outstanding Basic And Diluted</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive income (loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Tax [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign currency translation adjustment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized loss on marketable debt securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other comprehensive income (loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Net Of Tax</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total comprehensive loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Net Of Tax</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_StockIssuedDuringPeriodSharesAsPartOfConsultingAgreement" xlink:type="locator" xlink:label="ortx_StockIssuedDuringPeriodSharesAsPartOfConsultingAgreement" />
    <link:label xml:lang="en-US" xlink:label="ortx_StockIssuedDuringPeriodSharesAsPartOfConsultingAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares as part of consulting agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_StockIssuedDuringPeriodSharesAsPartOfConsultingAgreement" xlink:to="ortx_StockIssuedDuringPeriodSharesAsPartOfConsultingAgreement_lbl" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_StockIssuedDuringPeriodValueAsPartOfConsultingAgreement" xlink:type="locator" xlink:label="ortx_StockIssuedDuringPeriodValueAsPartOfConsultingAgreement" />
    <link:label xml:lang="en-US" xlink:label="ortx_StockIssuedDuringPeriodValueAsPartOfConsultingAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period value as part of consulting agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_StockIssuedDuringPeriodValueAsPartOfConsultingAgreement" xlink:to="ortx_StockIssuedDuringPeriodValueAsPartOfConsultingAgreement_lbl" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_StockIssuedDuringPeriodSharesAsPartOfCollaborationAgreement" xlink:type="locator" xlink:label="ortx_StockIssuedDuringPeriodSharesAsPartOfCollaborationAgreement" />
    <link:label xml:lang="en-US" xlink:label="ortx_StockIssuedDuringPeriodSharesAsPartOfCollaborationAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares as part of collaboration agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_StockIssuedDuringPeriodSharesAsPartOfCollaborationAgreement" xlink:to="ortx_StockIssuedDuringPeriodSharesAsPartOfCollaborationAgreement_lbl" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_StockIssuedDuringPeriodValueAsPartOfCollaborationAgreement" xlink:type="locator" xlink:label="ortx_StockIssuedDuringPeriodValueAsPartOfCollaborationAgreement" />
    <link:label xml:lang="en-US" xlink:label="ortx_StockIssuedDuringPeriodValueAsPartOfCollaborationAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period value as part of collaboration agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_StockIssuedDuringPeriodValueAsPartOfCollaborationAgreement" xlink:to="ortx_StockIssuedDuringPeriodValueAsPartOfCollaborationAgreement_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Stockholders Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Equity Components [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ordinary Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income (loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Share Based Compensation</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of share options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Stock Options Exercised</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of share options, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Stock Options Exercised</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of ESPP shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Employee Stock Purchase Plan</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of ESPP shares, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Employee Stock Purchase Plans</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" xlink:type="locator" xlink:label="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of restricted share units, net of shares withheld for taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" xlink:to="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Value Shares Issued Net Of Tax Withholdings</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:type="locator" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of restricted share units, net of shares withheld for taxes, shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:to="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Shares Issued Net Of Shares For Tax Withholdings</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of voting and non-voting ordinary shares, net of issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value New Issues</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of voting and non-voting ordinary shares, net of issuance costs, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares New Issues</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_StockIssuedDuringPeriodValueAsPartOfConsultingAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ordinary shares issued as part of consulting agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_StockIssuedDuringPeriodValueAsPartOfConsultingAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value As Part Of Consulting Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_StockIssuedDuringPeriodSharesAsPartOfConsultingAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ordinary shares issued as part of consulting agreement, Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_StockIssuedDuringPeriodSharesAsPartOfConsultingAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares As Part Of Consulting Agreement</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ordinary shares issued as part of license agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Issued For Services</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ordinary shares issued as part of license agreements, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Issued For Services</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_StockIssuedDuringPeriodValueAsPartOfCollaborationAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ordinary shares issued as part of collaboration agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_StockIssuedDuringPeriodValueAsPartOfCollaborationAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value As Part Of Collaboration Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_StockIssuedDuringPeriodSharesAsPartOfCollaborationAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ordinary shares issued as part of collaboration agreement, Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_StockIssuedDuringPeriodSharesAsPartOfCollaborationAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares As Part Of Collaboration Agreement</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized gain (loss) on marketable debt securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities Unrealized Gain Loss</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance, Shares</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of voting and non-voting ordinary shares, issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Stock Issued Issuance Costs</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_NonCashInterestExpense" xlink:type="locator" xlink:label="ortx_NonCashInterestExpense" />
    <link:label xml:lang="en-US" xlink:label="ortx_NonCashInterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-cash interest expense.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_NonCashInterestExpense" xlink:to="ortx_NonCashInterestExpense_lbl" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_AmortizationOfProvisionOnLossContract" xlink:type="locator" xlink:label="ortx_AmortizationOfProvisionOnLossContract" />
    <link:label xml:lang="en-US" xlink:label="ortx_AmortizationOfProvisionOnLossContract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Amortization of provision on loss contract.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_AmortizationOfProvisionOnLossContract" xlink:to="ortx_AmortizationOfProvisionOnLossContract_lbl" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_NonCashConsiderationForLicensesAndMilestones" xlink:type="locator" xlink:label="ortx_NonCashConsiderationForLicensesAndMilestones" />
    <link:label xml:lang="en-US" xlink:label="ortx_NonCashConsiderationForLicensesAndMilestones_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-cash consideration for licenses and milestones.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_NonCashConsiderationForLicensesAndMilestones" xlink:to="ortx_NonCashConsiderationForLicensesAndMilestones_lbl" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_AmortizationOfPremiumOnMarketableSecurities" xlink:type="locator" xlink:label="ortx_AmortizationOfPremiumOnMarketableSecurities" />
    <link:label xml:lang="en-US" xlink:label="ortx_AmortizationOfPremiumOnMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Amortization of premium on marketable securities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_AmortizationOfPremiumOnMarketableSecurities" xlink:to="ortx_AmortizationOfPremiumOnMarketableSecurities_lbl" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_UnrealizedForeignCurrencyAndOtherNonCashAdjustments" xlink:type="locator" xlink:label="ortx_UnrealizedForeignCurrencyAndOtherNonCashAdjustments" />
    <link:label xml:lang="en-US" xlink:label="ortx_UnrealizedForeignCurrencyAndOtherNonCashAdjustments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Unrealized foreign currency and other non-cash adjustments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_UnrealizedForeignCurrencyAndOtherNonCashAdjustments" xlink:to="ortx_UnrealizedForeignCurrencyAndOtherNonCashAdjustments_lbl" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable" xlink:type="locator" xlink:label="ortx_IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable" />
    <link:label xml:lang="en-US" xlink:label="ortx_IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) in research and development tax credit receivable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable" xlink:to="ortx_IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable_lbl" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_IncreaseDecreaseInOperatingRightOfUseAssets" xlink:type="locator" xlink:label="ortx_IncreaseDecreaseInOperatingRightOfUseAssets" />
    <link:label xml:lang="en-US" xlink:label="ortx_IncreaseDecreaseInOperatingRightOfUseAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in operating leases, right-of-use-assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_IncreaseDecreaseInOperatingRightOfUseAssets" xlink:to="ortx_IncreaseDecreaseInOperatingRightOfUseAssets_lbl" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="locator" xlink:label="ortx_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesAndOtherOperatingLiabilities" />
    <link:label xml:lang="en-US" xlink:label="ortx_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in accounts payable and accrued liabilities and other operating liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="ortx_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:type="locator" xlink:label="ortx_IncreaseDecreaseInOperatingLeaseLiabilities" />
    <link:label xml:lang="en-US" xlink:label="ortx_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in operating lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:to="ortx_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ReceiptOfFundsFromConstructionDeposit" xlink:type="locator" xlink:label="ortx_ReceiptOfFundsFromConstructionDeposit" />
    <link:label xml:lang="en-US" xlink:label="ortx_ReceiptOfFundsFromConstructionDeposit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Receipt of funds from construction deposit.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_ReceiptOfFundsFromConstructionDeposit" xlink:to="ortx_ReceiptOfFundsFromConstructionDeposit_lbl" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_PaymentOfTaxesOnRestrictedStockVesting" xlink:type="locator" xlink:label="ortx_PaymentOfTaxesOnRestrictedStockVesting" />
    <link:label xml:lang="en-US" xlink:label="ortx_PaymentOfTaxesOnRestrictedStockVesting_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment of taxes on restricted stock vesting.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_PaymentOfTaxesOnRestrictedStockVesting" xlink:to="ortx_PaymentOfTaxesOnRestrictedStockVesting_lbl" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ProceedsFromIssuanceOfSharesAsPartOfCollaborationAgreement" xlink:type="locator" xlink:label="ortx_ProceedsFromIssuanceOfSharesAsPartOfCollaborationAgreement" />
    <link:label xml:lang="en-US" xlink:label="ortx_ProceedsFromIssuanceOfSharesAsPartOfCollaborationAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance of shares as part of collaboration agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_ProceedsFromIssuanceOfSharesAsPartOfCollaborationAgreement" xlink:to="ortx_ProceedsFromIssuanceOfSharesAsPartOfCollaborationAgreement_lbl" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_IntangibleAssetsAndPropertyAndEquipmentInAccountsPayableAndAccruedExpenses" xlink:type="locator" xlink:label="ortx_IntangibleAssetsAndPropertyAndEquipmentInAccountsPayableAndAccruedExpenses" />
    <link:label xml:lang="en-US" xlink:label="ortx_IntangibleAssetsAndPropertyAndEquipmentInAccountsPayableAndAccruedExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Intangible assets and property and equipment in accounts payable and accrued expenses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_IntangibleAssetsAndPropertyAndEquipmentInAccountsPayableAndAccruedExpenses" xlink:to="ortx_IntangibleAssetsAndPropertyAndEquipmentInAccountsPayableAndAccruedExpenses_lbl" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_EmployeeEquityPlanProceedsReceived" xlink:type="locator" xlink:label="ortx_EmployeeEquityPlanProceedsReceived" />
    <link:label xml:lang="en-US" xlink:label="ortx_EmployeeEquityPlanProceedsReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee equity plan proceeds received.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_EmployeeEquityPlanProceedsReceived" xlink:to="ortx_EmployeeEquityPlanProceedsReceived_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss attributable to ordinary shareholders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Profit Loss</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation Depletion And Amortization</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:type="locator" xlink:label="us-gaap_AssetImpairmentCharges" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of long-lived assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Asset Impairment Charges</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_NonCashInterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash interest expense</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_NonCashInterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Non Cash Interest Expense</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_AmortizationOfProvisionOnLossContract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of provision on loss contract</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_AmortizationOfProvisionOnLossContract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amortization Of Provision On Loss Contract</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_NonCashConsiderationForLicensesAndMilestones_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash consideration for licenses and milestones</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_NonCashConsiderationForLicensesAndMilestones_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Non Cash Consideration For Licenses And Milestones</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Expense Benefit</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_AmortizationOfPremiumOnMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of premium on marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_AmortizationOfPremiumOnMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amortization Of Premium On Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_UnrealizedForeignCurrencyAndOtherNonCashAdjustments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unrealized foreign currency and other non-cash adjustments</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_UnrealizedForeignCurrencyAndOtherNonCashAdjustments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrealized Foreign Currency And Other Non Cash Adjustments</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accounts receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Receivable</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Research and development tax credit receivable</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Research And Development Tax Credit Receivable</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses, other current assets, and other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Prepaid Deferred Expense And Other Assets</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_IncreaseDecreaseInOperatingRightOfUseAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leases, right-of-use-assets</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_IncreaseDecreaseInOperatingRightOfUseAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Right Of Use Assets</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable, accrued expenses, and other current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Payable And Accrued Liabilities And Other Operating Liabilities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Contract With Customer Liability</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other long-term liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Other Noncurrent Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Lease Liabilities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from sales and maturities of marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Sale And Maturity Of Marketable Securities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Available For Sale Securities Debt</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment of construction deposit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit" xlink:to="us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Restricted Certificates Of Deposit</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_ReceiptOfFundsFromConstructionDeposit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Receipt of funds from construction deposit</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_ReceiptOfFundsFromConstructionDeposit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Receipt Of Funds From Construction Deposit</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payments on intangible assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Intangible Assets</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Property Plant And Equipment</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash (used in) provided by investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from modification of credit facility, net of debt issuance costs paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Debt</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockPlans" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from employee equity plans</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockPlans" xlink:to="us-gaap_ProceedsFromStockPlans_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Stock Plans</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_PaymentOfTaxesOnRestrictedStockVesting_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment of taxes on restricted stock vesting</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_PaymentOfTaxesOnRestrictedStockVesting_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payment Of Taxes On Restricted Stock Vesting</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_ProceedsFromIssuanceOfSharesAsPartOfCollaborationAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of shares as part of collaboration agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_ProceedsFromIssuanceOfSharesAsPartOfCollaborationAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Shares As Part Of Collaboration Agreement</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the issuance of ordinary shares in private placement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Private Placement</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment of placement agent fees and offering costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments Of Stock Issuance Costs</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effect of exchange rate changes on cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net increase in cash, cash equivalents and restricted cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents, and restricted cash &#8212;beginning of year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents, and restricted cash &#8212;end of year</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of non-cash investing and financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Investing And Financing Items [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_IntangibleAssetsAndPropertyAndEquipmentInAccountsPayableAndAccruedExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets and property and equipment in accounts payable and accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_IntangibleAssetsAndPropertyAndEquipmentInAccountsPayableAndAccruedExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets And Property And Equipment In Accounts Payable And Accrued Expenses</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssued1" xlink:type="locator" xlink:label="us-gaap_StockIssued1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssued1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued in consideration of license agreements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssued1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued1</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_EmployeeEquityPlanProceedsReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee equity plan proceeds received after year-end</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_EmployeeEquityPlanProceedsReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Equity Plan Proceeds Received</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of cash flow information</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease assets obtained in exchange for new operating lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Right Of Use Asset Obtained In Exchange For Operating Lease Liability</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Paid Net</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaidNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes Paid Net</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="locator" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated By Reference [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nature of Business and Basis of Presentation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Description And Basis Of Presentation [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements and Marketable Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Contract With Customer [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Contract With Customer [Text Block]</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:type="locator" xlink:label="ortx_PrepaidExpensesAndOtherCurrentAssetsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="ortx_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid expenses and other current assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:to="ortx_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense And Other Assets Current [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid Expenses and Other Current Assets</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expenses And Other Current Assets [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill And Intangible Assets Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible Assets, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrentDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrentDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrentDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Noncurrent Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrentDisclosureAbstract" xlink:to="us-gaap_OtherAssetsNoncurrentDisclosureAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_OtherAssetsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsDisclosureTextBlock" xlink:to="us-gaap_OtherAssetsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities And Other Liabilities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Expenses and Other Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Accrued Liabilities And Other Liabilities Disclosure Current [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring And Related Activities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_RestructuringAndRelatedActivitiesAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring Charges</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring And Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Leases [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Notes Payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ShareholdersEquityAndConvertiblePreferredSharesAbstract" xlink:type="locator" xlink:label="ortx_ShareholdersEquityAndConvertiblePreferredSharesAbstract" />
    <link:label xml:lang="en-US" xlink:label="ortx_ShareholdersEquityAndConvertiblePreferredSharesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Shareholders equity and convertible preferred shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_ShareholdersEquityAndConvertiblePreferredSharesAbstract" xlink:to="ortx_ShareholdersEquityAndConvertiblePreferredSharesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_ShareholdersEquityAndConvertiblePreferredSharesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shareholders Equity And Convertible Preferred Shares [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shareholders&apos; Equity and Convertible Preferred Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Share Based Payments [Text Block]</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_LicenseAndResearchArrangementsAbstract" xlink:type="locator" xlink:label="ortx_LicenseAndResearchArrangementsAbstract" />
    <link:label xml:lang="en-US" xlink:label="ortx_LicenseAndResearchArrangementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License and research arrangements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_LicenseAndResearchArrangementsAbstract" xlink:to="ortx_LicenseAndResearchArrangementsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_LicenseAndResearchArrangementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License And Research Arrangements [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License and Research Arrangements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_CollaborativeArrangementAbstract" xlink:type="locator" xlink:label="ortx_CollaborativeArrangementAbstract" />
    <link:label xml:lang="en-US" xlink:label="ortx_CollaborativeArrangementAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborative arrangement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_CollaborativeArrangementAbstract" xlink:to="ortx_CollaborativeArrangementAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_CollaborativeArrangementAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Compensation And Retirement Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Benefit Plans</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pension And Other Postretirement Benefits Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transactions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principles of consolidation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of estimates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Use Of Estimates</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of credit risk</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Credit Risk</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign currency</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Transactions And Translations Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment information</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities Policy</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash and construction deposits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Restricted Cash And Cash Equivalents Policy</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets Finite Lived Policy</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of long-lived assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Or Disposal Of Long Lived Assets Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense Policy</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ResearchContractCostsAndAccrualsPolicyTextBlock" xlink:type="locator" xlink:label="ortx_ResearchContractCostsAndAccrualsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="ortx_ResearchContractCostsAndAccrualsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research contract costs and accruals.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_ResearchContractCostsAndAccrualsPolicyTextBlock" xlink:to="ortx_ResearchContractCostsAndAccrualsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_ResearchContractCostsAndAccrualsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research contract costs and accruals</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_ResearchContractCostsAndAccrualsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research Contract Costs And Accruals Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Compensation Related Costs Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Leases Policy [Text Block]</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_StrimvelisLossProvisionPolicyTextBlock" xlink:type="locator" xlink:label="ortx_StrimvelisLossProvisionPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="ortx_StrimvelisLossProvisionPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Strimvelis loss provision.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_StrimvelisLossProvisionPolicyTextBlock" xlink:to="ortx_StrimvelisLossProvisionPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_StrimvelisLossProvisionPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Strimvelis loss provision</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_StrimvelisLossProvisionPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Strimvelis Loss Provision Policy [Text Block]</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ResearchAndDevelopmentIncomeTaxCreditsPolicyTextBlock" xlink:type="locator" xlink:label="ortx_ResearchAndDevelopmentIncomeTaxCreditsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="ortx_ResearchAndDevelopmentIncomeTaxCreditsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development income tax credits.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_ResearchAndDevelopmentIncomeTaxCreditsPolicyTextBlock" xlink:to="ortx_ResearchAndDevelopmentIncomeTaxCreditsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_ResearchAndDevelopmentIncomeTaxCreditsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">United Kingdom Research and development income tax credits</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_ResearchAndDevelopmentIncomeTaxCreditsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Income Tax Credits Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product sales</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Contract With Customer Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Recognition Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recent accounting pronouncements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Restricted Cash And Cash Equivalents [Text Block]</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_PropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:type="locator" xlink:label="ortx_PropertyPlantAndEquipmentUsefulLifeTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="ortx_PropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Property, plant and equipment useful life.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_PropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:to="ortx_PropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_PropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Estimated Useful Lives of Property and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_PropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Useful Life Table [Text Block]</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ScheduleOfChangesInLossProvisionTableTextBlock" xlink:type="locator" xlink:label="ortx_ScheduleOfChangesInLossProvisionTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="ortx_ScheduleOfChangesInLossProvisionTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of changes in loss provision.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_ScheduleOfChangesInLossProvisionTableTextBlock" xlink:to="ortx_ScheduleOfChangesInLossProvisionTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_ScheduleOfChangesInLossProvisionTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Changes in Loss Provision [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_ScheduleOfChangesInLossProvisionTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Changes In Loss Provision Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock" xlink:type="locator" xlink:label="us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Amounts Recognized to Offset Research and Development Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock" xlink:to="us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Tax Credit Carryforwards [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Securities Excluded in the Computation of Diluted Net Loss Per Ordinary Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Cash Equivalents and Marketable Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Cash Cash Equivalents And Short Term Investments Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Cash Equivalents and Marketable Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Available For Sale Securities Reconciliation Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="locator" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Available-for-Sale Debt Marketable Securities by contractual Maturity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investments Classified By Contractual Maturity Date Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Prepaid Expenses and Other Current Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Property and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Text Block]</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ScheduleOfIntangibleAssetsNetOfAccumulatedAmortizationTableTextBlock" xlink:type="locator" xlink:label="ortx_ScheduleOfIntangibleAssetsNetOfAccumulatedAmortizationTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="ortx_ScheduleOfIntangibleAssetsNetOfAccumulatedAmortizationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of intangible assets net of accumulated amortization.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_ScheduleOfIntangibleAssetsNetOfAccumulatedAmortizationTableTextBlock" xlink:to="ortx_ScheduleOfIntangibleAssetsNetOfAccumulatedAmortizationTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_ScheduleOfIntangibleAssetsNetOfAccumulatedAmortizationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Intangible Assets Net of Accumulated Amortization</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_ScheduleOfIntangibleAssetsNetOfAccumulatedAmortizationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Intangible Assets Net Of Accumulated Amortization Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Estimated Future Amortization For Intangible Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Scheduleof Finite Lived Intangible Assets Future Amortization Expense Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Other Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" xlink:to="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Other Assets Noncurrent [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued Expenses and Other Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Accrued Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Cash Restructuring Charges</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Restructuring And Related Costs [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DetailsOfImpairmentOfLongLivedAssetsHeldAndUsedByAssetTextBlock" xlink:type="locator" xlink:label="us-gaap_DetailsOfImpairmentOfLongLivedAssetsHeldAndUsedByAssetTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DetailsOfImpairmentOfLongLivedAssetsHeldAndUsedByAssetTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Impairment of Long Lived Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DetailsOfImpairmentOfLongLivedAssetsHeldAndUsedByAssetTextBlock" xlink:to="us-gaap_DetailsOfImpairmentOfLongLivedAssetsHeldAndUsedByAssetTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DetailsOfImpairmentOfLongLivedAssetsHeldAndUsedByAssetTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Details Of Impairment Of Long Lived Assets Held And Used By Asset [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Lease Cost Under Operating Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Cost Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Future Minimum Base Rent Commitments Under Operating Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Maturity Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Notes Payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Debt Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Future Principal Payments Due</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Maturities Of Long Term Debt Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assumptions Used in Black-Scholes Option Pricing Model</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Payment Award Employee Stock Purchase Plan Valuation Assumptions Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Option Activity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Award Activity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Restricted Stock Units Award Activity Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Research and Development Costs Incurred and Collaboration Revenue Recognized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Components of Net Loss Before Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Income Before Income Tax Domestic And Foreign Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Provision for (Benefit from) Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Components Of Income Tax Expense Benefit Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Reconciliation of Income Tax Expense (Benefit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:type="locator" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Changes in Valuation Allowance for Deferred Tax Assets Related Primarily to Increase in U.K. Net Operating Loss Carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:to="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Valuation Allowance [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:type="locator" xlink:label="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Annual Commitments Associated with the Contract</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:to="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contractual Obligation Fiscal Year Maturity Schedule Table [Text Block]</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ClosingPriceOfShareDate" xlink:type="locator" xlink:label="ortx_ClosingPriceOfShareDate" />
    <link:label xml:lang="en-US" xlink:label="ortx_ClosingPriceOfShareDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Closing price of share date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_ClosingPriceOfShareDate" xlink:to="ortx_ClosingPriceOfShareDate_lbl" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_PaymentsOfOtherIssuanceCosts" xlink:type="locator" xlink:label="ortx_PaymentsOfOtherIssuanceCosts" />
    <link:label xml:lang="en-US" xlink:label="ortx_PaymentsOfOtherIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments of other issuance costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_PaymentsOfOtherIssuanceCosts" xlink:to="ortx_PaymentsOfOtherIssuanceCosts_lbl" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_NetProceedsFromIssuanceOfPrivatePlacement" xlink:type="locator" xlink:label="ortx_NetProceedsFromIssuanceOfPrivatePlacement" />
    <link:label xml:lang="en-US" xlink:label="ortx_NetProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Net proceeds from issuance of private placement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_NetProceedsFromIssuanceOfPrivatePlacement" xlink:to="ortx_NetProceedsFromIssuanceOfPrivatePlacement_lbl" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:type="locator" xlink:label="ortx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" />
    <link:label xml:lang="en-US" xlink:label="ortx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization consolidation and presentation of financial statements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="ortx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_lbl" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:type="locator" xlink:label="ortx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" />
    <link:label xml:lang="en-US" xlink:label="ortx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization consolidation and presentation of financial statements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="ortx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization Consolidation And Presentation Of Financial Statements [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Arrangement [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Arrangements And Nonarrangement Transactions [Member]</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_SecuritiesPurchaseAgreementMember" xlink:type="locator" xlink:label="ortx_SecuritiesPurchaseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="ortx_SecuritiesPurchaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Securities purchase agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_SecuritiesPurchaseAgreementMember" xlink:to="ortx_SecuritiesPurchaseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_SecuritiesPurchaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Securities Purchase Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_SecuritiesPurchaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Securities Purchase Agreement [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary Sale Of Stock [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Name Of Transaction [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Private Placement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Private Placement [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Class Of Stock [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Domain]</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_NonVotingOrdinarySharesMember" xlink:type="locator" xlink:label="ortx_NonVotingOrdinarySharesMember" />
    <link:label xml:lang="en-US" xlink:label="ortx_NonVotingOrdinarySharesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-voting ordinary shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_NonVotingOrdinarySharesMember" xlink:to="ortx_NonVotingOrdinarySharesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_NonVotingOrdinarySharesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-voting Ordinary Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_NonVotingOrdinarySharesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Non Voting Ordinary Shares [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization Consolidation And Presentation Of Financial Statements [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase price per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_ClosingPriceOfShareDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Closing price of share date</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_ClosingPriceOfShareDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Closing Price Of Share Date</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Placement agent fees</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_PaymentsOfOtherIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_PaymentsOfOtherIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments Of Other Issuance Costs</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockTransactionDate" xlink:type="locator" xlink:label="us-gaap_SaleOfStockTransactionDate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockTransactionDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Private placement, transaction date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockTransactionDate" xlink:to="us-gaap_SaleOfStockTransactionDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockTransactionDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Transaction Date</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_NetProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from private placement</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_NetProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Proceeds From Issuance Of Private Placement</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated deficit</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, cash equivalents and marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents And Short Term Investments</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_SummaryOfSignificantAccountingPoliciesAbstract" xlink:type="locator" xlink:label="ortx_SummaryOfSignificantAccountingPoliciesAbstract" />
    <link:label xml:lang="en-US" xlink:label="ortx_SummaryOfSignificantAccountingPoliciesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_SummaryOfSignificantAccountingPoliciesAbstract" xlink:to="ortx_SummaryOfSignificantAccountingPoliciesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_SummaryOfSignificantAccountingPoliciesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Abstract]</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="ortx_SummaryOfSignificantAccountingPoliciesLineItems" />
    <link:label xml:lang="en-US" xlink:label="ortx_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="ortx_SummaryOfSignificantAccountingPoliciesLineItems_lbl" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_SummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="ortx_SummaryOfSignificantAccountingPoliciesTable" />
    <link:label xml:lang="en-US" xlink:label="ortx_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="ortx_SummaryOfSignificantAccountingPoliciesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Geographical [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Geographical [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_GB" xlink:type="locator" xlink:label="country_GB" />
    <link:label xml:lang="en-US" xlink:label="country_GB_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">United Kingdom</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_GB" xlink:to="country_GB_lbl" />
    <link:label xml:lang="en-US" xlink:label="country_GB_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">UNITED KINGDOM</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US" xlink:type="locator" xlink:label="country_US" />
    <link:label xml:lang="en-US" xlink:label="country_US_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">US</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl" />
    <link:label xml:lang="en-US" xlink:label="country_US_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">UNITED STATES</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_GBAndEuropeanUnionMember" xlink:type="locator" xlink:label="ortx_GBAndEuropeanUnionMember" />
    <link:label xml:lang="en-US" xlink:label="ortx_GBAndEuropeanUnionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">GB and European Union.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_GBAndEuropeanUnionMember" xlink:to="ortx_GBAndEuropeanUnionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_GBAndEuropeanUnionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">United Kingdom and European Union</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_GBAndEuropeanUnionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">G B And European Union [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Contractual Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Contractual Term [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseContractualTermDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Contractual Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="us-gaap_LeaseContractualTermDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseContractualTermDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Contractual Term [Domain]</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_FremontLeaseAgreementMember" xlink:type="locator" xlink:label="ortx_FremontLeaseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="ortx_FremontLeaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Fremont lease agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_FremontLeaseAgreementMember" xlink:to="ortx_FremontLeaseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_FremontLeaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fremont Lease Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_FremontLeaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fremont Lease Agreement [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:type="locator" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid Expenses and Other Current Assets [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expenses And Other Current Assets [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of significant off-balance sheet risk</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk" xlink:to="us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Credit Risk Financial Instruments Off Balance Sheet Risk</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign currency transaction gain (loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Transaction Gain Loss Before Tax</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Right-of-use assets</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:type="locator" xlink:label="us-gaap_ProceedsFromLinesOfCredit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromLinesOfCredit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from lines of credit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLinesOfCredit" xlink:to="us-gaap_ProceedsFromLinesOfCredit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromLinesOfCredit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Lines Of Credit</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCollateralForBorrowedSecurities" xlink:type="locator" xlink:label="us-gaap_CashCollateralForBorrowedSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCollateralForBorrowedSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash collateral associated with corporate credit cards and other leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCollateralForBorrowedSecurities" xlink:to="us-gaap_CashCollateralForBorrowedSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCollateralForBorrowedSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Collateral For Borrowed Securities</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cash and cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total cash, cash equivalents and restricted cash shown in the statement of cash flows</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_IncreaseDecreaseInEscrowDeposit" xlink:type="locator" xlink:label="ortx_IncreaseDecreaseInEscrowDeposit" />
    <link:label xml:lang="en-US" xlink:label="ortx_IncreaseDecreaseInEscrowDeposit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) in escrow deposit.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_IncreaseDecreaseInEscrowDeposit" xlink:to="ortx_IncreaseDecreaseInEscrowDeposit_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EscrowDeposit" xlink:type="locator" xlink:label="us-gaap_EscrowDeposit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EscrowDeposit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Escrow Deposit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EscrowDeposit" xlink:to="us-gaap_EscrowDeposit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EscrowDeposit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Escrow Deposit</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_IncreaseDecreaseInEscrowDeposit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase Decrease In Escrow Deposit</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_IncreaseDecreaseInEscrowDeposit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Escrow Deposit</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment By Type [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Type [Domain]</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_LabEquipmentMember" xlink:type="locator" xlink:label="ortx_LabEquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="ortx_LabEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lab equipment member.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_LabEquipmentMember" xlink:to="ortx_LabEquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_LabEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lab Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_LabEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lab Equipment [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and Fixtures</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Furniture And Fixtures [Member]</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_OfficeAndComputerEquipmentMember" xlink:type="locator" xlink:label="ortx_OfficeAndComputerEquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="ortx_OfficeAndComputerEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Office and computer equipment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_OfficeAndComputerEquipmentMember" xlink:to="ortx_OfficeAndComputerEquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_OfficeAndComputerEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office and Computer Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_OfficeAndComputerEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Office And Computer Equipment [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment useful life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Useful Life</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment useful life, term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Estimated Useful Lives</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForLossOnContracts" xlink:type="locator" xlink:label="us-gaap_ProvisionForLossOnContracts" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProvisionForLossOnContracts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liability associated with the loss contract</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForLossOnContracts" xlink:to="us-gaap_ProvisionForLossOnContracts_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProvisionForLossOnContracts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Provision For Loss On Contracts</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_AssetAcquisitionLiabilityAssumed" xlink:type="locator" xlink:label="ortx_AssetAcquisitionLiabilityAssumed" />
    <link:label xml:lang="en-US" xlink:label="ortx_AssetAcquisitionLiabilityAssumed_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Asset acquisition liability assumed.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_AssetAcquisitionLiabilityAssumed" xlink:to="ortx_AssetAcquisitionLiabilityAssumed_lbl" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_AssetAcquisitionLiabilityProvision" xlink:type="locator" xlink:label="ortx_AssetAcquisitionLiabilityProvision" />
    <link:label xml:lang="en-US" xlink:label="ortx_AssetAcquisitionLiabilityProvision_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Asset acquisition liability provision.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_AssetAcquisitionLiabilityProvision" xlink:to="ortx_AssetAcquisitionLiabilityProvision_lbl" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_AssetAcquisitionLiabilityAmortizationOfLossProvision" xlink:type="locator" xlink:label="ortx_AssetAcquisitionLiabilityAmortizationOfLossProvision" />
    <link:label xml:lang="en-US" xlink:label="ortx_AssetAcquisitionLiabilityAmortizationOfLossProvision_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Asset acquisition liability amortization of loss provision.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_AssetAcquisitionLiabilityAmortizationOfLossProvision" xlink:to="ortx_AssetAcquisitionLiabilityAmortizationOfLossProvision_lbl" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_IncreaseDecreaseInAssetAcquisitionLiabilityEffectOfForeignExchangeTranslation" xlink:type="locator" xlink:label="ortx_IncreaseDecreaseInAssetAcquisitionLiabilityEffectOfForeignExchangeTranslation" />
    <link:label xml:lang="en-US" xlink:label="ortx_IncreaseDecreaseInAssetAcquisitionLiabilityEffectOfForeignExchangeTranslation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) in asset acquisition liability, effect of foreign exchange translation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_IncreaseDecreaseInAssetAcquisitionLiabilityEffectOfForeignExchangeTranslation" xlink:to="ortx_IncreaseDecreaseInAssetAcquisitionLiabilityEffectOfForeignExchangeTranslation_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_AssetAcquisitionLiabilityAssumed_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at beginning of period</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_AssetAcquisitionLiabilityAssumed_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition Liability Assumed</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_AssetAcquisitionLiabilityProvision_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Provisions</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_AssetAcquisitionLiabilityProvision_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition Liability Provision</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_AssetAcquisitionLiabilityAmortizationOfLossProvision_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Amortization of loss provision</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_AssetAcquisitionLiabilityAmortizationOfLossProvision_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition Liability Amortization Of Loss Provision</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_IncreaseDecreaseInAssetAcquisitionLiabilityEffectOfForeignExchangeTranslation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign currency translation</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_IncreaseDecreaseInAssetAcquisitionLiabilityEffectOfForeignExchangeTranslation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Asset Acquisition Liability Effect Of Foreign Exchange Translation</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_AssetAcquisitionLiabilityAssumed_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at end of period</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_AssetAcquisitionLiabilityAssumedCurrent" xlink:type="locator" xlink:label="ortx_AssetAcquisitionLiabilityAssumedCurrent" />
    <link:label xml:lang="en-US" xlink:label="ortx_AssetAcquisitionLiabilityAssumedCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Asset acquisition liability assumed current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_AssetAcquisitionLiabilityAssumedCurrent" xlink:to="ortx_AssetAcquisitionLiabilityAssumedCurrent_lbl" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_AssetAcquisitionLiabilityAssumedNonCurrent" xlink:type="locator" xlink:label="ortx_AssetAcquisitionLiabilityAssumedNonCurrent" />
    <link:label xml:lang="en-US" xlink:label="ortx_AssetAcquisitionLiabilityAssumedNonCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Asset acquisition liability assumed non current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_AssetAcquisitionLiabilityAssumedNonCurrent" xlink:to="ortx_AssetAcquisitionLiabilityAssumedNonCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_AssetAcquisitionLiabilityAssumedCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Strimvelis loss provision current</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_AssetAcquisitionLiabilityAssumedCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition Liability Assumed Current</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_AssetAcquisitionLiabilityAssumedNonCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Strimvelis loss provision non current</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_AssetAcquisitionLiabilityAssumedNonCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition Liability Assumed Non Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at beginning of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Amount</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxCreditsAndAdjustments" xlink:type="locator" xlink:label="us-gaap_IncomeTaxCreditsAndAdjustments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxCreditsAndAdjustments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recognition of credit claims as offset to research and development expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxCreditsAndAdjustments" xlink:to="us-gaap_IncomeTaxCreditsAndAdjustments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxCreditsAndAdjustments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Credits And Adjustments</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCredits" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Receipt of credit claims</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCredits" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Tax Credits</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Foreign currency translation</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at end of period</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_AdditionalIncomeTaxCredits" xlink:type="locator" xlink:label="ortx_AdditionalIncomeTaxCredits" />
    <link:label xml:lang="en-US" xlink:label="ortx_AdditionalIncomeTaxCredits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional income tax credits.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_AdditionalIncomeTaxCredits" xlink:to="ortx_AdditionalIncomeTaxCredits_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_AdditionalIncomeTaxCredits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional income tax credits</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_AdditionalIncomeTaxCredits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Income Tax Credits</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ResearchAndDevelopmentTaxCreditReceivable" xlink:type="locator" xlink:label="ortx_ResearchAndDevelopmentTaxCreditReceivable" />
    <link:label xml:lang="en-US" xlink:label="ortx_ResearchAndDevelopmentTaxCreditReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development tax credit receivable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_ResearchAndDevelopmentTaxCreditReceivable" xlink:to="ortx_ResearchAndDevelopmentTaxCreditReceivable_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_ResearchAndDevelopmentTaxCreditReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax incentive receivable</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_ResearchAndDevelopmentTaxCreditReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Tax Credit Receivable</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_ResearchAndDevelopmentTaxCreditReceivableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Tax incentive receivable, current</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_IncrementalPercentageOfTaxableProfits" xlink:type="locator" xlink:label="ortx_IncrementalPercentageOfTaxableProfits" />
    <link:label xml:lang="en-US" xlink:label="ortx_IncrementalPercentageOfTaxableProfits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Incremental percentage of taxable profits.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_IncrementalPercentageOfTaxableProfits" xlink:to="ortx_IncrementalPercentageOfTaxableProfits_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_IncrementalPercentageOfTaxableProfits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Incremental percentage of taxable profits</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_IncrementalPercentageOfTaxableProfits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Incremental Percentage Of Taxable Profits</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Sales of strimvelis</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Option [Member]</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_UnvestedSharesFromSharePlanAndConsultingAgreementMember" xlink:type="locator" xlink:label="ortx_UnvestedSharesFromSharePlanAndConsultingAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="ortx_UnvestedSharesFromSharePlanAndConsultingAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Unvested shares from share plan and consulting agreement member.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_UnvestedSharesFromSharePlanAndConsultingAgreementMember" xlink:to="ortx_UnvestedSharesFromSharePlanAndConsultingAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_UnvestedSharesFromSharePlanAndConsultingAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested Shares from Share Plan and Consulting Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_UnvestedSharesFromSharePlanAndConsultingAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unvested Shares From Share Plan And Consulting Agreement [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common shares attributable to anti-dilutive shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, accounting standards update, adopted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Change In Accounting Principle Accounting Standards Update Adopted</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, accounting standards update, adoption date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Change In Accounting Principle Accounting Standards Update Adoption Date</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleDescription" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleDescription" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">New accounting pronouncement or change in accounting principle, description</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleDescription" xlink:to="us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleDescription_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncement Or Change In Accounting Principle Description</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of financial assets transfers between level 1 to level 2</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:to="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Level1 To Level2 Transfers Amount</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of financial assets transfers between level 2 to level 1</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:to="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Level2 To Level1 Transfers Amount</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_CashEquivalentsAbstract" xlink:type="locator" xlink:label="ortx_CashEquivalentsAbstract" />
    <link:label xml:lang="en-US" xlink:label="ortx_CashEquivalentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash equivalents.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_CashEquivalentsAbstract" xlink:to="ortx_CashEquivalentsAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Fair Value Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Asset Class [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Bonds</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial Paper</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Paper [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:type="locator" xlink:label="us-gaap_USTreasuryAndGovernmentMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_USTreasuryAndGovernmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Government Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasuryAndGovernmentMember" xlink:to="us-gaap_USTreasuryAndGovernmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_USTreasuryAndGovernmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">U S Treasury And Government [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Fair Value Hierarchy Level [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Fair Value Hierarchy [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level1 [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level2 [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level3 [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_CashEquivalentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_CashEquivalentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Fair Value Disclosure</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_MarketableSecuritiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_MarketableSecuritiesFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_MarketableSecuritiesFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities Fair Value Disclosure</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Fair Value Disclosure</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized Cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Amortized Cost Basis</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross Unrealized Gains</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gross Unrealized Losses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit Losses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sale Allowance For Credit Loss</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Securities</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsAmortizedCost" xlink:type="locator" xlink:label="ortx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsAmortizedCost" />
    <link:label xml:lang="en-US" xlink:label="ortx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsAmortizedCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Available for sale securities debt maturities after one through three years amortized cost.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsAmortizedCost" xlink:to="ortx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsAmortizedCost_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturities in one year or less</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Maturities Within One Year Amortized Cost</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsAmortizedCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturities between one and three years</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsAmortizedCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Maturities After One Through Three Years Amortized Cost</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_GeneralPaymentTermsMaximum" xlink:type="locator" xlink:label="ortx_GeneralPaymentTermsMaximum" />
    <link:label xml:lang="en-US" xlink:label="ortx_GeneralPaymentTermsMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">General payment terms maximum.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_GeneralPaymentTermsMaximum" xlink:to="ortx_GeneralPaymentTermsMaximum_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_GeneralPaymentTermsMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General payment terms, maximum</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_GeneralPaymentTermsMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General Payment Terms Maximum</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_PrepaidExternalResearchAndDevelopmentExpenses" xlink:type="locator" xlink:label="ortx_PrepaidExternalResearchAndDevelopmentExpenses" />
    <link:label xml:lang="en-US" xlink:label="ortx_PrepaidExternalResearchAndDevelopmentExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid external research and development expenses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_PrepaidExternalResearchAndDevelopmentExpenses" xlink:to="ortx_PrepaidExternalResearchAndDevelopmentExpenses_lbl" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ConstructionDepositsCurrent" xlink:type="locator" xlink:label="ortx_ConstructionDepositsCurrent" />
    <link:label xml:lang="en-US" xlink:label="ortx_ConstructionDepositsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Construction deposits, current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_ConstructionDepositsCurrent" xlink:to="ortx_ConstructionDepositsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_PrepaidExternalResearchAndDevelopmentExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid external research and development expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_PrepaidExternalResearchAndDevelopmentExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid External Research And Development Expenses</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" xlink:label="us-gaap_InventoryNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventories</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Net</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other prepayments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Prepaid Expense Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValueAddedTaxReceivableCurrent" xlink:type="locator" xlink:label="us-gaap_ValueAddedTaxReceivableCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValueAddedTaxReceivableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">VAT receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValueAddedTaxReceivableCurrent" xlink:to="us-gaap_ValueAddedTaxReceivableCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValueAddedTaxReceivableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Value Added Tax Receivable Current</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_ConstructionDepositsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Construction deposit - current</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_ConstructionDepositsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Construction Deposits Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NontradeReceivablesCurrent" xlink:type="locator" xlink:label="us-gaap_NontradeReceivablesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NontradeReceivablesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-trade receivables</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NontradeReceivablesCurrent" xlink:to="us-gaap_NontradeReceivablesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NontradeReceivablesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nontrade Receivables Current</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total prepaid expenses and other current assets</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_OfficeAndITEquipmentMember" xlink:type="locator" xlink:label="ortx_OfficeAndITEquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="ortx_OfficeAndITEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Office and IT equipment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_OfficeAndITEquipmentMember" xlink:to="ortx_OfficeAndITEquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_OfficeAndITEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office and IT Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_OfficeAndITEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Office And I T Equipment [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Construction-In-Progress</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Construction In Progress [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Gross</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: accumulated depreciation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation Depletion And Amortization Property Plant And Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property and equipment, net</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Depreciation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Depreciation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Depreciation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Finite Lived Intangible Assets [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Finite Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets by Major Class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets By Major Class [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets, Major Class Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Major Class Name [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember" xlink:type="locator" xlink:label="us-gaap_LicenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LicenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Intangibles</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseMember" xlink:to="us-gaap_LicenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LicenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite Lived Intangible Assets [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible Assets, Cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Gross</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Intangible Assets, Accumulated Amortized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Accumulated Amortization</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Intangible Assets, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Net</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible asset, useful life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Asset Useful Life</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of intangible assets</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Amortization Expense Next Twelve Months</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Amortization Expense Year Two</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Amortization Expense Year Three</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Amortization Expense Year Four</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Amortization Expense Year Five</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Amortization Expense After Year Five</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_OtherNonCurrentAssets" xlink:type="locator" xlink:label="ortx_OtherNonCurrentAssets" />
    <link:label xml:lang="en-US" xlink:label="ortx_OtherNonCurrentAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Other non-current assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_OtherNonCurrentAssets" xlink:to="ortx_OtherNonCurrentAssets_lbl" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ConstructionDepositsLongTerm" xlink:type="locator" xlink:label="ortx_ConstructionDepositsLongTerm" />
    <link:label xml:lang="en-US" xlink:label="ortx_ConstructionDepositsLongTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Construction deposits long-term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_ConstructionDepositsLongTerm" xlink:to="ortx_ConstructionDepositsLongTerm_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Liabilities Net</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_DepositsAssetsNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deposits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deposits Assets Noncurrent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:type="locator" xlink:label="us-gaap_DeferredFinanceCostsNoncurrentNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredFinanceCostsNoncurrentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred financing costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:to="us-gaap_DeferredFinanceCostsNoncurrentNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredFinanceCostsNoncurrentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Finance Costs Noncurrent Net</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_OtherNonCurrentAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other non-current assets</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_OtherNonCurrentAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Non Current Assets</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_ConstructionDepositsLongTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Construction deposits - long-term</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_ConstructionDepositsLongTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Construction Deposits Long Term</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other assets</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_AccruedExternalResearchAndDevelopmentExpensesCurrent" xlink:type="locator" xlink:label="ortx_AccruedExternalResearchAndDevelopmentExpensesCurrent" />
    <link:label xml:lang="en-US" xlink:label="ortx_AccruedExternalResearchAndDevelopmentExpensesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued external research and development expenses current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_AccruedExternalResearchAndDevelopmentExpensesCurrent" xlink:to="ortx_AccruedExternalResearchAndDevelopmentExpensesCurrent_lbl" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_AccruedMilestonePaymentsCurrent" xlink:type="locator" xlink:label="ortx_AccruedMilestonePaymentsCurrent" />
    <link:label xml:lang="en-US" xlink:label="ortx_AccruedMilestonePaymentsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued milestone payments current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_AccruedMilestonePaymentsCurrent" xlink:to="ortx_AccruedMilestonePaymentsCurrent_lbl" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ProductLiabilityCurrentPortion" xlink:type="locator" xlink:label="ortx_ProductLiabilityCurrentPortion" />
    <link:label xml:lang="en-US" xlink:label="ortx_ProductLiabilityCurrentPortion_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Product liability, current portion.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_ProductLiabilityCurrentPortion" xlink:to="ortx_ProductLiabilityCurrentPortion_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_AccruedExternalResearchAndDevelopmentExpensesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued external research and development expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_AccruedExternalResearchAndDevelopmentExpensesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued External Research And Development Expenses Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued payroll and related expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Related Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_AccruedMilestonePaymentsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_AccruedMilestonePaymentsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Milestone Payments Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued professional fees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_ProductLiabilityCurrentPortion_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Strimvelis liability - current portion</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_ProductLiabilityCurrentPortion_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Product Liability Current Portion</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_AccruedExpensesAndOtherCurrentLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued expenses and other current liabilities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Restructuring And Related Costs [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Restructuring And Related Costs [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanAxis" xlink:type="locator" xlink:label="us-gaap_RestructuringPlanAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestructuringPlanAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring Plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringPlanAxis" xlink:to="us-gaap_RestructuringPlanAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestructuringPlanAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Plan [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanDomain" xlink:type="locator" xlink:label="us-gaap_RestructuringPlanDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestructuringPlanDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring Plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringPlanDomain" xlink:to="us-gaap_RestructuringPlanDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestructuringPlanDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Plan [Domain]</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_MenloParkCaliforniaMember" xlink:type="locator" xlink:label="ortx_MenloParkCaliforniaMember" />
    <link:label xml:lang="en-US" xlink:label="ortx_MenloParkCaliforniaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Menlo park, California.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_MenloParkCaliforniaMember" xlink:to="ortx_MenloParkCaliforniaMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_MenloParkCaliforniaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Menlo Park, California</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_MenloParkCaliforniaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Menlo Park California [Member]</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_FremontCaliforniaMember" xlink:type="locator" xlink:label="ortx_FremontCaliforniaMember" />
    <link:label xml:lang="en-US" xlink:label="ortx_FremontCaliforniaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Fremont, California.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_FremontCaliforniaMember" xlink:to="ortx_FremontCaliforniaMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_FremontCaliforniaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fremont, California</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_FremontCaliforniaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fremont California [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:type="locator" xlink:label="us-gaap_RestructuringCostAndReserveLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestructuringCostAndReserveLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring Cost And Reserve [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringCostAndReserveLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestructuringCostAndReserveLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Cost And Reserve [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:type="locator" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of positions eliminated, percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring And Related Cost Number Of Positions Eliminated Period Percent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve" xlink:type="locator" xlink:label="us-gaap_RestructuringReserve" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestructuringReserve_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at beginning of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringReserve" xlink:to="us-gaap_RestructuringReserve_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestructuringReserve_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Reserve</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges" xlink:type="locator" xlink:label="us-gaap_RestructuringCharges" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestructuringCharges_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Charged to expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCharges" xlink:to="us-gaap_RestructuringCharges_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestructuringCharges_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Charges</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRestructuring" xlink:type="locator" xlink:label="us-gaap_PaymentsForRestructuring" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsForRestructuring_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payments made</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRestructuring" xlink:to="us-gaap_PaymentsForRestructuring_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsForRestructuring_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments For Restructuring</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestructuringReserve_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at end of period</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestructuringCharges_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restructuring costs</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ImpairmentOfConstructionInProcess" xlink:type="locator" xlink:label="ortx_ImpairmentOfConstructionInProcess" />
    <link:label xml:lang="en-US" xlink:label="ortx_ImpairmentOfConstructionInProcess_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Impairment of construction in process.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_ImpairmentOfConstructionInProcess" xlink:to="ortx_ImpairmentOfConstructionInProcess_lbl" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ImpairmentOfLaboratoryEquipment" xlink:type="locator" xlink:label="ortx_ImpairmentOfLaboratoryEquipment" />
    <link:label xml:lang="en-US" xlink:label="ortx_ImpairmentOfLaboratoryEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Impairment of laboratory equipment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_ImpairmentOfLaboratoryEquipment" xlink:to="ortx_ImpairmentOfLaboratoryEquipment_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseImpairmentLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseImpairmentLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseImpairmentLoss" xlink:to="us-gaap_OperatingLeaseImpairmentLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseImpairmentLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Impairment Loss</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_ImpairmentOfConstructionInProcess_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Construction-in-progress</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_ImpairmentOfConstructionInProcess_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Of Construction In Process</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_ImpairmentOfLaboratoryEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory equipment, Asset write-downs</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_ImpairmentOfLaboratoryEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Of Laboratory Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Charge included in research and development expense</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_ImpairmentOfConstructionInProcess_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Construction-in-process, impairment charges</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Undiscounted cash flow estimate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Undiscounted Excess Amount</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Discount rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Discount Rate</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_OperatingLeaseRightOfUseAssetFairValue" xlink:type="locator" xlink:label="ortx_OperatingLeaseRightOfUseAssetFairValue" />
    <link:label xml:lang="en-US" xlink:label="ortx_OperatingLeaseRightOfUseAssetFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating Lease Right Of Use Asset Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_OperatingLeaseRightOfUseAssetFairValue" xlink:to="ortx_OperatingLeaseRightOfUseAssetFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_OperatingLeaseRightOfUseAssetFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of ROU asset</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_OperatingLeaseRightOfUseAssetFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Right Of Use Asset Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseImpairmentLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Right of use asset, impairment charge</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_OperatingLeaseDurationForFreeRent" xlink:type="locator" xlink:label="ortx_OperatingLeaseDurationForFreeRent" />
    <link:label xml:lang="en-US" xlink:label="ortx_OperatingLeaseDurationForFreeRent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease duration for free rent.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_OperatingLeaseDurationForFreeRent" xlink:to="ortx_OperatingLeaseDurationForFreeRent_lbl" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_OperatingLeasesLineItems" xlink:type="locator" xlink:label="ortx_OperatingLeasesLineItems" />
    <link:label xml:lang="en-US" xlink:label="ortx_OperatingLeasesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating leases line items.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_OperatingLeasesLineItems" xlink:to="ortx_OperatingLeasesLineItems_lbl" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_OperatingLeasesTable" xlink:type="locator" xlink:label="ortx_OperatingLeasesTable" />
    <link:label xml:lang="en-US" xlink:label="ortx_OperatingLeasesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating leases table.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_OperatingLeasesTable" xlink:to="ortx_OperatingLeasesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_OperatingLeasesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Leases [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_OperatingLeasesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases [Table]</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_OfficeSpaceMenloParkLeaseAgreementMember" xlink:type="locator" xlink:label="ortx_OfficeSpaceMenloParkLeaseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="ortx_OfficeSpaceMenloParkLeaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Office space menlo park lease agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_OfficeSpaceMenloParkLeaseAgreementMember" xlink:to="ortx_OfficeSpaceMenloParkLeaseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_OfficeSpaceMenloParkLeaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office Space Menlo Park Lease Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_OfficeSpaceMenloParkLeaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Office Space Menlo Park Lease Agreement [Member]</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_LaboratorySpaceMenloParkLeaseAgreementMember" xlink:type="locator" xlink:label="ortx_LaboratorySpaceMenloParkLeaseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="ortx_LaboratorySpaceMenloParkLeaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Laboratory space menlo park lease agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_LaboratorySpaceMenloParkLeaseAgreementMember" xlink:to="ortx_LaboratorySpaceMenloParkLeaseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_LaboratorySpaceMenloParkLeaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory Space Menlo Park Lease Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_LaboratorySpaceMenloParkLeaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Laboratory Space Menlo Park Lease Agreement [Member]</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_OfficeAndLaboratorySpaceMenloParkLeaseAgreementMember" xlink:type="locator" xlink:label="ortx_OfficeAndLaboratorySpaceMenloParkLeaseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="ortx_OfficeAndLaboratorySpaceMenloParkLeaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Office and laboratory space menlo park lease agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_OfficeAndLaboratorySpaceMenloParkLeaseAgreementMember" xlink:to="ortx_OfficeAndLaboratorySpaceMenloParkLeaseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_OfficeAndLaboratorySpaceMenloParkLeaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office and Laboratory Space Menlo Park Lease Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_OfficeAndLaboratorySpaceMenloParkLeaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Office And Laboratory Space Menlo Park Lease Agreement [Member]</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_FiveYearsLeaseTermTerminatesInJanuaryTwoThousandTwentyThreeMember" xlink:type="locator" xlink:label="ortx_FiveYearsLeaseTermTerminatesInJanuaryTwoThousandTwentyThreeMember" />
    <link:label xml:lang="en-US" xlink:label="ortx_FiveYearsLeaseTermTerminatesInJanuaryTwoThousandTwentyThreeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Five years lease term terminates in January two thousand twenty three.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_FiveYearsLeaseTermTerminatesInJanuaryTwoThousandTwentyThreeMember" xlink:to="ortx_FiveYearsLeaseTermTerminatesInJanuaryTwoThousandTwentyThreeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_FiveYearsLeaseTermTerminatesInJanuaryTwoThousandTwentyThreeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Five Years Lease Term Terminates In January 2023 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_FiveYearsLeaseTermTerminatesInJanuaryTwoThousandTwentyThreeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Five Years Lease Term Terminates In January Two Thousand Twenty Three [Member]</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_OfficeSpaceLondonUnitedKingdomLeaseAgreementMember" xlink:type="locator" xlink:label="ortx_OfficeSpaceLondonUnitedKingdomLeaseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="ortx_OfficeSpaceLondonUnitedKingdomLeaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Office space london united kingdom lease agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_OfficeSpaceLondonUnitedKingdomLeaseAgreementMember" xlink:to="ortx_OfficeSpaceLondonUnitedKingdomLeaseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_OfficeSpaceLondonUnitedKingdomLeaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office Space London United Kingdom Lease Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_OfficeSpaceLondonUnitedKingdomLeaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Office Space London United Kingdom Lease Agreement [Member]</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_RentalLabSpaceMember" xlink:type="locator" xlink:label="ortx_RentalLabSpaceMember" />
    <link:label xml:lang="en-US" xlink:label="ortx_RentalLabSpaceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Rental lab space.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_RentalLabSpaceMember" xlink:to="ortx_RentalLabSpaceMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_RentalLabSpaceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rental Lab Space [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_RentalLabSpaceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Rental Lab Space [Member]</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_LeaseTermTerminatesInSeptemberTwoThousandTwentyTwoMember" xlink:type="locator" xlink:label="ortx_LeaseTermTerminatesInSeptemberTwoThousandTwentyTwoMember" />
    <link:label xml:lang="en-US" xlink:label="ortx_LeaseTermTerminatesInSeptemberTwoThousandTwentyTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease term terminates in September two thousand twenty two.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_LeaseTermTerminatesInSeptemberTwoThousandTwentyTwoMember" xlink:to="ortx_LeaseTermTerminatesInSeptemberTwoThousandTwentyTwoMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_LeaseTermTerminatesInSeptemberTwoThousandTwentyTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Term Terminates in September 2022 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_LeaseTermTerminatesInSeptemberTwoThousandTwentyTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Term Terminates In September Two Thousand Twenty Two [Member]</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_OfficeSpaceBostonUnitedStatesLeaseAgreementMember" xlink:type="locator" xlink:label="ortx_OfficeSpaceBostonUnitedStatesLeaseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="ortx_OfficeSpaceBostonUnitedStatesLeaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Office space boston united states lease agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_OfficeSpaceBostonUnitedStatesLeaseAgreementMember" xlink:to="ortx_OfficeSpaceBostonUnitedStatesLeaseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_OfficeSpaceBostonUnitedStatesLeaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office Space Boston Lease Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_OfficeSpaceBostonUnitedStatesLeaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Office Space Boston United States Lease Agreement [Member]</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_LeaseTermTerminatesInSeptemberTwoThousandTwentySixMember" xlink:type="locator" xlink:label="ortx_LeaseTermTerminatesInSeptemberTwoThousandTwentySixMember" />
    <link:label xml:lang="en-US" xlink:label="ortx_LeaseTermTerminatesInSeptemberTwoThousandTwentySixMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease term terminates in September two thousand twenty six.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_LeaseTermTerminatesInSeptemberTwoThousandTwentySixMember" xlink:to="ortx_LeaseTermTerminatesInSeptemberTwoThousandTwentySixMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_LeaseTermTerminatesInSeptemberTwoThousandTwentySixMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Term Terminates in September 2026 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_LeaseTermTerminatesInSeptemberTwoThousandTwentySixMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Term Terminates In September Two Thousand Twenty Six [Member]</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_BostonAndLondonOfficeSpaceLeaseAgreementsMember" xlink:type="locator" xlink:label="ortx_BostonAndLondonOfficeSpaceLeaseAgreementsMember" />
    <link:label xml:lang="en-US" xlink:label="ortx_BostonAndLondonOfficeSpaceLeaseAgreementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Boston and London office space lease agreements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_BostonAndLondonOfficeSpaceLeaseAgreementsMember" xlink:to="ortx_BostonAndLondonOfficeSpaceLeaseAgreementsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_BostonAndLondonOfficeSpaceLeaseAgreementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Boston and London Office Space Lease Agreements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_BostonAndLondonOfficeSpaceLeaseAgreementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Boston And London Office Space Lease Agreements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Maximum [Member]</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_FremontSubleaseAgreementMember" xlink:type="locator" xlink:label="ortx_FremontSubleaseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="ortx_FremontSubleaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Fremont sublease agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_FremontSubleaseAgreementMember" xlink:to="ortx_FremontSubleaseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_FremontSubleaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fremont Sublease Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_FremontSubleaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fremont Sublease Agreement [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="locator" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Long-Term Liabilities [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_GSKAgreementMember" xlink:type="locator" xlink:label="ortx_GSKAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="ortx_GSKAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">GSK agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_GSKAgreementMember" xlink:to="ortx_GSKAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_GSKAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">G S K Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_GSKAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">G S K Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_OperatingLeasesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Leases [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_OperatingLeasesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leases expiration term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Date1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRent" xlink:type="locator" xlink:label="us-gaap_PaymentsForRent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsForRent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual rental payment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsForRent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments For Rent</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_OperatingLeaseDurationForFreeRent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease duration for free rent</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_OperatingLeaseDurationForFreeRent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Duration For Free Rent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome" xlink:type="locator" xlink:label="us-gaap_SubleaseIncome" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubleaseIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sublease income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubleaseIncome" xlink:to="us-gaap_SubleaseIncome_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubleaseIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sublease Income</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_OperatingLeasesCommencedTerm" xlink:type="locator" xlink:label="ortx_OperatingLeasesCommencedTerm" />
    <link:label xml:lang="en-US" xlink:label="ortx_OperatingLeasesCommencedTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating leases commenced term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_OperatingLeasesCommencedTerm" xlink:to="ortx_OperatingLeasesCommencedTerm_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_OperatingLeasesCommencedTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leases Commenced term</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_OperatingLeasesCommencedTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Commenced Term</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel">Operating lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ReductionOfStandbyLetterOfCreditAmountPercentage" xlink:type="locator" xlink:label="ortx_ReductionOfStandbyLetterOfCreditAmountPercentage" />
    <link:label xml:lang="en-US" xlink:label="ortx_ReductionOfStandbyLetterOfCreditAmountPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Reduction of standby letter of credit amount percentage.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_ReductionOfStandbyLetterOfCreditAmountPercentage" xlink:to="ortx_ReductionOfStandbyLetterOfCreditAmountPercentage_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_ReductionOfStandbyLetterOfCreditAmountPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reduction of standby letter of credit amount percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_ReductionOfStandbyLetterOfCreditAmountPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Reduction Of Standby Letter Of Credit Amount Percentage</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_TenantImprovementAllowance" xlink:type="locator" xlink:label="ortx_TenantImprovementAllowance" />
    <link:label xml:lang="en-US" xlink:label="ortx_TenantImprovementAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Tenant improvement allowance.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_TenantImprovementAllowance" xlink:to="ortx_TenantImprovementAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating lease, liability, noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_TenantImprovementAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tenant improvements allowance</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_TenantImprovementAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tenant Improvement Allowance</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecurityDeposit" xlink:type="locator" xlink:label="us-gaap_SecurityDeposit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SecurityDeposit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security deposit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SecurityDeposit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Deposit</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_IncreaseDecreaseInEscrowDeposit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Increase decrease in escrow deposit</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_LesseeOperatingLeaseExtendedTerm" xlink:type="locator" xlink:label="ortx_LesseeOperatingLeaseExtendedTerm" />
    <link:label xml:lang="en-US" xlink:label="ortx_LesseeOperatingLeaseExtendedTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease extended term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_LesseeOperatingLeaseExtendedTerm" xlink:to="ortx_LesseeOperatingLeaseExtendedTerm_lbl" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_LeaseComponentManufacturingCommitmentAmount" xlink:type="locator" xlink:label="ortx_LeaseComponentManufacturingCommitmentAmount" />
    <link:label xml:lang="en-US" xlink:label="ortx_LeaseComponentManufacturingCommitmentAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease component manufacturing commitment amount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_LeaseComponentManufacturingCommitmentAmount" xlink:to="ortx_LeaseComponentManufacturingCommitmentAmount_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Term Of Contract</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee, operating lease, option to extend</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Option To Extend</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee, operating Lease, existence of option to extend [true false]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Existence Of Option To Extend</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_LesseeOperatingLeaseExtendedTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease extended term</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_LesseeOperatingLeaseExtendedTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Extended Term</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_LeaseComponentManufacturingCommitmentAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease component manufacturing suites commitment amount per contract year</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_LeaseComponentManufacturingCommitmentAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Component Manufacturing Commitment Amount</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_FixedLeaseCost" xlink:type="locator" xlink:label="ortx_FixedLeaseCost" />
    <link:label xml:lang="en-US" xlink:label="ortx_FixedLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Fixed lease cost.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_FixedLeaseCost" xlink:to="ortx_FixedLeaseCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_FixedLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fixed lease cost</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_FixedLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fixed Lease Cost</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseImpairmentLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel">Impairment of right-of-use assets</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost" xlink:type="locator" xlink:label="us-gaap_VariableLeaseCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable lease cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Variable Lease Cost</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubleaseIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Sublease income</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost" xlink:type="locator" xlink:label="us-gaap_LeaseCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Cost</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating cash flows used for operating leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Payments</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average remaining lease term (years)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Weighted Average Remaining Lease Term1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average discount rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Weighted Average Discount Rate Percent</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_OperatingLeaseRightOfUseAssetValueExchangeForLeaseLiabilities" xlink:type="locator" xlink:label="ortx_OperatingLeaseRightOfUseAssetValueExchangeForLeaseLiabilities" />
    <link:label xml:lang="en-US" xlink:label="ortx_OperatingLeaseRightOfUseAssetValueExchangeForLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease right of use asset value exchange for lease liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_OperatingLeaseRightOfUseAssetValueExchangeForLeaseLiabilities" xlink:to="ortx_OperatingLeaseRightOfUseAssetValueExchangeForLeaseLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_OperatingLeaseRightOfUseAssetValueExchangeForLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, right-of-use asset obtained in exchange for lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_OperatingLeaseRightOfUseAssetValueExchangeForLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Right Of Use Asset Value Exchange For Lease Liabilities</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_OperatingLeaseLiabilityPaymentsDueNet" xlink:type="locator" xlink:label="ortx_OperatingLeaseLiabilityPaymentsDueNet" />
    <link:label xml:lang="en-US" xlink:label="ortx_OperatingLeaseLiabilityPaymentsDueNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease liability payments due net.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_OperatingLeaseLiabilityPaymentsDueNet" xlink:to="ortx_OperatingLeaseLiabilityPaymentsDueNet_lbl" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_OperatingLeaseLiabilityPaymentsDueYearOne" xlink:type="locator" xlink:label="ortx_OperatingLeaseLiabilityPaymentsDueYearOne" />
    <link:label xml:lang="en-US" xlink:label="ortx_OperatingLeaseLiabilityPaymentsDueYearOne_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease liability payments due year one.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_OperatingLeaseLiabilityPaymentsDueYearOne" xlink:to="ortx_OperatingLeaseLiabilityPaymentsDueYearOne_lbl" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_OperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="ortx_OperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:label xml:lang="en-US" xlink:label="ortx_OperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease liability payments due year two.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_OperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="ortx_OperatingLeaseLiabilityPaymentsDueYearTwo_lbl" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_OperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="ortx_OperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:label xml:lang="en-US" xlink:label="ortx_OperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease liability payments due year three.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_OperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="ortx_OperatingLeaseLiabilityPaymentsDueYearThree_lbl" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_OperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="ortx_OperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:label xml:lang="en-US" xlink:label="ortx_OperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease liability payments due year four.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_OperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="ortx_OperatingLeaseLiabilityPaymentsDueYearFour_lbl" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_OperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="locator" xlink:label="ortx_OperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:label xml:lang="en-US" xlink:label="ortx_OperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease liability payments due year five.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_OperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="ortx_OperatingLeaseLiabilityPaymentsDueYearFive_lbl" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_OperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="locator" xlink:label="ortx_OperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:label xml:lang="en-US" xlink:label="ortx_OperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease liability payments due after year five</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_OperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="ortx_OperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross lease payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liabilities Payments Due [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Next Twelve Months</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Two</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Three</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Four</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Five</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due After Year Five</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total future minimum lease payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: imputed interest</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total operating lease payments</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract" xlink:type="locator" xlink:label="us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross sublease receipts</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract" xlink:to="us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessor Operating Lease Payments Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">2022</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessor Operating Lease Payments To Be Received Next Twelve Months</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:type="locator" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">2023</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessor Operating Lease Payments To Be Received Two Years</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:type="locator" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">2024</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessor Operating Lease Payments To Be Received Three Years</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears" xlink:type="locator" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">2025</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessor Operating Lease Payments To Be Received Four Years</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears" xlink:type="locator" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">2026</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessor Operating Lease Payments To Be Received Five Years</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter" xlink:type="locator" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Thereafter</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessor Operating Lease Payments To Be Received Thereafter</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:type="locator" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceived" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total future minimum lease payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceived_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessor Operating Lease Payments To Be Received</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_OperatingLeaseLiabilitiesPaymentsDueNetAbstract" xlink:type="locator" xlink:label="ortx_OperatingLeaseLiabilitiesPaymentsDueNetAbstract" />
    <link:label xml:lang="en-US" xlink:label="ortx_OperatingLeaseLiabilitiesPaymentsDueNetAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease liabilities payments due net.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_OperatingLeaseLiabilitiesPaymentsDueNetAbstract" xlink:to="ortx_OperatingLeaseLiabilitiesPaymentsDueNetAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_OperatingLeaseLiabilitiesPaymentsDueNetAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net lease payments</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_OperatingLeaseLiabilitiesPaymentsDueNetAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liabilities Payments Due Net [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_OperatingLeaseLiabilityPaymentsDueYearOne_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_OperatingLeaseLiabilityPaymentsDueYearOne_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Payments Due Year One</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_OperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_OperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Payments Due Year Two</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_OperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_OperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Payments Due Year Three</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_OperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_OperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Payments Due Year Four</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_OperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_OperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Payments Due Year Five</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_OperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_OperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Payments Due After Year Five</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_OperatingLeaseLiabilityPaymentsDueNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total future minimum lease payments</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_OperatingLeaseLiabilityPaymentsDueNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Payments Due Net</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CurrencyAxis" xlink:type="locator" xlink:label="srt_CurrencyAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_CurrencyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Currency</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CurrencyAxis" xlink:to="srt_CurrencyAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_CurrencyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Currency [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_AllCurrenciesDomain" xlink:type="locator" xlink:label="currency_AllCurrenciesDomain" />
    <link:label xml:lang="en-US" xlink:label="currency_AllCurrenciesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">All Currencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_AllCurrenciesDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="currency_AllCurrenciesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">All Currencies [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_GBP" xlink:type="locator" xlink:label="currency_GBP" />
    <link:label xml:lang="en-US" xlink:label="currency_GBP_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">GBP</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_GBP" xlink:to="currency_GBP_lbl" />
    <link:label xml:lang="en-US" xlink:label="currency_GBP_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">G B P</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_EUR" xlink:type="locator" xlink:label="currency_EUR" />
    <link:label xml:lang="en-US" xlink:label="currency_EUR_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Euro</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_EUR" xlink:to="currency_EUR_lbl" />
    <link:label xml:lang="en-US" xlink:label="currency_EUR_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">E U R</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyExchangeRateTranslation1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ForeignCurrencyExchangeRateTranslation1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease translation rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:to="us-gaap_ForeignCurrencyExchangeRateTranslation1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ForeignCurrencyExchangeRateTranslation1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Exchange Rate Translation1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Name [Domain]</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_TheFirstTrancheTermLoanMember" xlink:type="locator" xlink:label="ortx_TheFirstTrancheTermLoanMember" />
    <link:label xml:lang="en-US" xlink:label="ortx_TheFirstTrancheTermLoanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Term loans available in the first tranche.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_TheFirstTrancheTermLoanMember" xlink:to="ortx_TheFirstTrancheTermLoanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_TheFirstTrancheTermLoanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial Term Loan</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_TheFirstTrancheTermLoanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">The First Tranche Term Loan [Member]</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_TheSecondTrancheTermLoanMember" xlink:type="locator" xlink:label="ortx_TheSecondTrancheTermLoanMember" />
    <link:label xml:lang="en-US" xlink:label="ortx_TheSecondTrancheTermLoanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Term loans available in the second tranch.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_TheSecondTrancheTermLoanMember" xlink:to="ortx_TheSecondTrancheTermLoanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_TheSecondTrancheTermLoanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Second Tranche (Term Loan Available from July 1, 2022 to July 1, 2023)</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_TheSecondTrancheTermLoanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">The Second Tranche Term Loan [Member]</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_TheThirdTrancheTermLoanMember" xlink:type="locator" xlink:label="ortx_TheThirdTrancheTermLoanMember" />
    <link:label xml:lang="en-US" xlink:label="ortx_TheThirdTrancheTermLoanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Term loans available in the third tranch.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_TheThirdTrancheTermLoanMember" xlink:to="ortx_TheThirdTrancheTermLoanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_TheThirdTrancheTermLoanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Third Tranche (Term Loan Available from July 1, 2023 to July 1, 2024)</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_TheThirdTrancheTermLoanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">The Third Tranche Term Loan [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis" xlink:type="locator" xlink:label="us-gaap_VariableRateAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VariableRateAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VariableRateAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Variable Rate [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain" xlink:type="locator" xlink:label="us-gaap_VariableRateDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VariableRateDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_VariableRateDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VariableRateDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Variable Rate [Domain]</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_LondonInterbankOfferedRateFloorMember" xlink:type="locator" xlink:label="ortx_LondonInterbankOfferedRateFloorMember" />
    <link:label xml:lang="en-US" xlink:label="ortx_LondonInterbankOfferedRateFloorMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">London interbank offered rate floor.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_LondonInterbankOfferedRateFloorMember" xlink:to="ortx_LondonInterbankOfferedRateFloorMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_LondonInterbankOfferedRateFloorMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LIBOR</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_LondonInterbankOfferedRateFloorMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">London Interbank Offered Rate Floor [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument, Redemption, Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Redemption Period [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument, Redemption, Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Redemption Period [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Second Tranche (Term Loan Available from July 1, 2022 to July 1, 2023)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodTwoMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Redemption Period Two [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodThreeMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodThreeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">TThird Tranche (Term Loan Available from July 1, 2023 to July 1, 2024)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodThreeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodThreeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Redemption Period Three [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term Debt, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Longterm Debt Type [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term Debt, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Longterm Debt Type [Domain]</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_TermLoanMember" xlink:type="locator" xlink:label="ortx_TermLoanMember" />
    <link:label xml:lang="en-US" xlink:label="ortx_TermLoanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Term loan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_TermLoanMember" xlink:to="ortx_TermLoanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_TermLoanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term Loan</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_TermLoanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Term Loan [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityInitiationDate1" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityInitiationDate1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityInitiationDate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Line of credit facility agreement date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityInitiationDate1" xlink:to="us-gaap_LineOfCreditFacilityInitiationDate1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityInitiationDate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Line Of Credit Facility Initiation Date1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit facility maximum borrowings</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Line Of Credit Facility Maximum Borrowing Capacity</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit facility, remaining borrowings</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Line Of Credit Facility Remaining Borrowing Capacity</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAndCash" xlink:type="locator" xlink:label="us-gaap_InvestmentsAndCash" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentsAndCash_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalent investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsAndCash" xlink:to="us-gaap_InvestmentsAndCash_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentsAndCash_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investments And Cash</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityCovenantTerms" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityCovenantTerms" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityCovenantTerms_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Line of Credit Facility, Covenant Terms</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityCovenantTerms" xlink:to="us-gaap_LineOfCreditFacilityCovenantTerms_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityCovenantTerms_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Line Of Credit Facility Covenant Terms</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_LineOfCreditFacilityInterestPaymentsTerm" xlink:type="locator" xlink:label="ortx_LineOfCreditFacilityInterestPaymentsTerm" />
    <link:label xml:lang="en-US" xlink:label="ortx_LineOfCreditFacilityInterestPaymentsTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Line of credit facility interest payments term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_LineOfCreditFacilityInterestPaymentsTerm" xlink:to="ortx_LineOfCreditFacilityInterestPaymentsTerm_lbl" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_LineOfCreditFacilityAmortizationTerm" xlink:type="locator" xlink:label="ortx_LineOfCreditFacilityAmortizationTerm" />
    <link:label xml:lang="en-US" xlink:label="ortx_LineOfCreditFacilityAmortizationTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Line of credit facility straight-line amortization term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_LineOfCreditFacilityAmortizationTerm" xlink:to="ortx_LineOfCreditFacilityAmortizationTerm_lbl" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_LineOfCreditFacilityPercentageOfFinalPayment" xlink:type="locator" xlink:label="ortx_LineOfCreditFacilityPercentageOfFinalPayment" />
    <link:label xml:lang="en-US" xlink:label="ortx_LineOfCreditFacilityPercentageOfFinalPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Line of credit facility percentage of final payment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_LineOfCreditFacilityPercentageOfFinalPayment" xlink:to="ortx_LineOfCreditFacilityPercentageOfFinalPayment_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, annual interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Basis Spread On Variable Rate1</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_LineOfCreditFacilityInterestPaymentsTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Line of credit facility interest payments term</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_LineOfCreditFacilityInterestPaymentsTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Line Of Credit Facility Interest Payments Term</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_LineOfCreditFacilityAmortizationTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Line of credit facility amortization term</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_LineOfCreditFacilityAmortizationTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Line Of Credit Facility Amortization Term</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityFrequencyOfPayments" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityFrequencyOfPayments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityFrequencyOfPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Line of credit facility, frequency of payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityFrequencyOfPayments" xlink:to="us-gaap_LineOfCreditFacilityFrequencyOfPayments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityFrequencyOfPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Line Of Credit Facility Frequency Of Payments</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_LineOfCreditFacilityPercentageOfFinalPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Line of credit facility, percentage of final payment</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_LineOfCreditFacilityPercentageOfFinalPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Line Of Credit Facility Percentage Of Final Payment</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityPeriodicPaymentInterest" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityPeriodicPaymentInterest" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityPeriodicPaymentInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Final payment amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityPeriodicPaymentInterest" xlink:to="us-gaap_LineOfCreditFacilityPeriodicPaymentInterest_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityPeriodicPaymentInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Line Of Credit Facility Periodic Payment Interest</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLinesOfCredit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RepaymentsOfLinesOfCredit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repayment of line of credit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLinesOfCredit" xlink:to="us-gaap_RepaymentsOfLinesOfCredit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RepaymentsOfLinesOfCredit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Repayments Of Lines Of Credit</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateDescription" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDescription" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Line of credit facility interest rate description</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityInterestRateDescription" xlink:to="us-gaap_LineOfCreditFacilityInterestRateDescription_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Line Of Credit Facility Interest Rate Description</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_LineOfCreditFacilityCovenantsMinimumCashAllowed" xlink:type="locator" xlink:label="ortx_LineOfCreditFacilityCovenantsMinimumCashAllowed" />
    <link:label xml:lang="en-US" xlink:label="ortx_LineOfCreditFacilityCovenantsMinimumCashAllowed_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Line of credit facility covenants minimum cash allowed.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_LineOfCreditFacilityCovenantsMinimumCashAllowed" xlink:to="ortx_LineOfCreditFacilityCovenantsMinimumCashAllowed_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_LineOfCreditFacilityCovenantsMinimumCashAllowed_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Line of credit facility minimum cash financial covenant</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_LineOfCreditFacilityCovenantsMinimumCashAllowed_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Line Of Credit Facility Covenants Minimum Cash Allowed</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCovenantDescription" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentCovenantDescription" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentCovenantDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Line of credit facility covenants description</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCovenantDescription" xlink:to="us-gaap_DebtInstrumentCovenantDescription_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentCovenantDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Covenant Description</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_LongTermDebtBeforeAccretionIssuanceCostsNet" xlink:type="locator" xlink:label="ortx_LongTermDebtBeforeAccretionIssuanceCostsNet" />
    <link:label xml:lang="en-US" xlink:label="ortx_LongTermDebtBeforeAccretionIssuanceCostsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Long term debt before accretion issuance costs net.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_LongTermDebtBeforeAccretionIssuanceCostsNet" xlink:to="ortx_LongTermDebtBeforeAccretionIssuanceCostsNet_lbl" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_LongTermDebtBeforeAccretionIssuanceCostsNetCurrent" xlink:type="locator" xlink:label="ortx_LongTermDebtBeforeAccretionIssuanceCostsNetCurrent" />
    <link:label xml:lang="en-US" xlink:label="ortx_LongTermDebtBeforeAccretionIssuanceCostsNetCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Long term debt before accretion issuance costs net current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_LongTermDebtBeforeAccretionIssuanceCostsNetCurrent" xlink:to="ortx_LongTermDebtBeforeAccretionIssuanceCostsNetCurrent_lbl" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_LongTermDebtBeforeAccretionIssuanceCostsNetNoncurrent" xlink:type="locator" xlink:label="ortx_LongTermDebtBeforeAccretionIssuanceCostsNetNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="ortx_LongTermDebtBeforeAccretionIssuanceCostsNetNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Long term debt before accretion issuance costs net noncurrent.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_LongTermDebtBeforeAccretionIssuanceCostsNetNoncurrent" xlink:to="ortx_LongTermDebtBeforeAccretionIssuanceCostsNetNoncurrent_lbl" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_AccretionRelatedToFinalPayment" xlink:type="locator" xlink:label="ortx_AccretionRelatedToFinalPayment" />
    <link:label xml:lang="en-US" xlink:label="ortx_AccretionRelatedToFinalPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accretion related to final payment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_AccretionRelatedToFinalPayment" xlink:to="ortx_AccretionRelatedToFinalPayment_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermNotesAndLoansAbstract" xlink:type="locator" xlink:label="us-gaap_LongTermNotesAndLoansAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermNotesAndLoansAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Notes And Loans [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermNotesAndLoansAbstract" xlink:to="us-gaap_LongTermNotesAndLoansAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_LongTermDebtBeforeAccretionIssuanceCostsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Notes payable, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_LongTermDebtBeforeAccretionIssuanceCostsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Before Accretion Issuance Costs Net</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_LongTermDebtBeforeAccretionIssuanceCostsNetCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: current portion</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_LongTermDebtBeforeAccretionIssuanceCostsNetCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Before Accretion Issuance Costs Net Current</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_LongTermDebtBeforeAccretionIssuanceCostsNetNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Notes payable, net of current portion</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_LongTermDebtBeforeAccretionIssuanceCostsNetNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Before Accretion Issuance Costs Net Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_AccretionRelatedToFinalPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accretion related to final payment</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_AccretionRelatedToFinalPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accretion Related To Final Payment</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:type="locator" xlink:label="us-gaap_LongTermDebtNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Notes payable, long term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Noncurrent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtByMaturityAbstract" xlink:type="locator" xlink:label="us-gaap_LongTermDebtByMaturityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtByMaturityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt By Maturity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtByMaturityAbstract" xlink:to="us-gaap_LongTermDebtByMaturityAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Maturities Repayments Of Principal In Next Twelve Months</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Maturities Repayments Of Principal In Year Two</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Maturities Repayments Of Principal In Year Three</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Maturities Repayments Of Principal In Year Four</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Maturities Repayments Of Principal In Year Five</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Maturities Repayments Of Principal After Year Five</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Carrying Amount</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:type="locator" xlink:label="us-gaap_LongTermDebtCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less current portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtCurrent" xlink:to="us-gaap_LongTermDebtCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Current</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_UnamortizedPortionOfFinalPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less unamortized portion of final payment</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_UnamortizedPortionOfFinalPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unamortized Portion Of Final Payment</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:type="locator" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less unamortized debt issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnamortizedDebtIssuanceExpense" xlink:to="us-gaap_UnamortizedDebtIssuanceExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unamortized Debt Issuance Expense</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Notes payable, long term</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestExpenseDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, interest expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestExpenseDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense Debt</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, effective annual interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Interest Rate During Period</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_NumberOfOrdinaryVotingRights" xlink:type="locator" xlink:label="ortx_NumberOfOrdinaryVotingRights" />
    <link:label xml:lang="en-US" xlink:label="ortx_NumberOfOrdinaryVotingRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of ordinary voting rights.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_NumberOfOrdinaryVotingRights" xlink:to="ortx_NumberOfOrdinaryVotingRights_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Stock By Class [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Stock By Class [Table]</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_OxfordBioMedicaLicenseDevelopmentAndSupplyAgreementMember" xlink:type="locator" xlink:label="ortx_OxfordBioMedicaLicenseDevelopmentAndSupplyAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="ortx_OxfordBioMedicaLicenseDevelopmentAndSupplyAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Oxford BioMedica license development and supply agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_OxfordBioMedicaLicenseDevelopmentAndSupplyAgreementMember" xlink:to="ortx_OxfordBioMedicaLicenseDevelopmentAndSupplyAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_OxfordBioMedicaLicenseDevelopmentAndSupplyAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Oxford BioMedica License, Development and Supply Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_OxfordBioMedicaLicenseDevelopmentAndSupplyAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Oxford Bio Medica License Development And Supply Agreement [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Indefinite-lived Intangible Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Indefinite Lived Intangible Assets By Major Class [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Indefinite-lived Intangible Assets, Major Class Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Indefinite Lived Intangible Assets Major Class Name [Domain]</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ConsultingAgreementMember" xlink:type="locator" xlink:label="ortx_ConsultingAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="ortx_ConsultingAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Consulting Agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_ConsultingAgreementMember" xlink:to="ortx_ConsultingAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_ConsultingAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consulting Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_ConsultingAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Consulting Agreement [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Title Of Individual [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Title Of Individual With Relationship To Entity [Domain]</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_NonEmployeeAdvisorMember" xlink:type="locator" xlink:label="ortx_NonEmployeeAdvisorMember" />
    <link:label xml:lang="en-US" xlink:label="ortx_NonEmployeeAdvisorMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-employee advisor.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_NonEmployeeAdvisorMember" xlink:to="ortx_NonEmployeeAdvisorMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_NonEmployeeAdvisorMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Advisor</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_NonEmployeeAdvisorMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Non Employee Advisor [Member]</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_SharePurchaseAgreementWithPharmingMember" xlink:type="locator" xlink:label="ortx_SharePurchaseAgreementWithPharmingMember" />
    <link:label xml:lang="en-US" xlink:label="ortx_SharePurchaseAgreementWithPharmingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share purchase agreement with pharming.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_SharePurchaseAgreementWithPharmingMember" xlink:to="ortx_SharePurchaseAgreementWithPharmingMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_SharePurchaseAgreementWithPharmingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Purchase Agreement with Pharming</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_SharePurchaseAgreementWithPharmingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Purchase Agreement With Pharming [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Stock [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:type="locator" xlink:label="us-gaap_CommonStockVotingRights" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ordinary shares voting rights description</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockVotingRights" xlink:to="us-gaap_CommonStockVotingRights_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Voting Rights</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsCommonStock" xlink:type="locator" xlink:label="us-gaap_DividendsCommonStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DividendsCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ordinary shares dividends declared</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsCommonStock" xlink:to="us-gaap_DividendsCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DividendsCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Dividends Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_NumberOfOrdinaryVotingRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of ordinary voting rights</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_NumberOfOrdinaryVotingRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Ordinary Voting Rights</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValueOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockValueOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValueOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ordinary shares maximum nominal value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValueOutstanding" xlink:to="us-gaap_CommonStockValueOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValueOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Value Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of ordinary shares issued and sold</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Nominal value of shares issued and sold</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ProceedsFromPremiumSharesIssued" xlink:type="locator" xlink:label="ortx_ProceedsFromPremiumSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="ortx_ProceedsFromPremiumSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from premium shares issued..</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_ProceedsFromPremiumSharesIssued" xlink:to="ortx_ProceedsFromPremiumSharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total consideration</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock consideration</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_ProceedsFromPremiumSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Premium consideration</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_ProceedsFromPremiumSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Premium Shares Issued</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_TwoThousandAndEighteenShareOptionAndIncentivePlanMember" xlink:type="locator" xlink:label="ortx_TwoThousandAndEighteenShareOptionAndIncentivePlanMember" />
    <link:label xml:lang="en-US" xlink:label="ortx_TwoThousandAndEighteenShareOptionAndIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">2018 Share Option And Incentive Plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_TwoThousandAndEighteenShareOptionAndIncentivePlanMember" xlink:to="ortx_TwoThousandAndEighteenShareOptionAndIncentivePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_TwoThousandAndEighteenShareOptionAndIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2018 Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_TwoThousandAndEighteenShareOptionAndIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Eighteen Share Option And Incentive Plan [Member]</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_TwoThousandAndEighteenEmployeeSharePurchasePlanMember" xlink:type="locator" xlink:label="ortx_TwoThousandAndEighteenEmployeeSharePurchasePlanMember" />
    <link:label xml:lang="en-US" xlink:label="ortx_TwoThousandAndEighteenEmployeeSharePurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">2018 Employee Share Purchase Plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_TwoThousandAndEighteenEmployeeSharePurchasePlanMember" xlink:to="ortx_TwoThousandAndEighteenEmployeeSharePurchasePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_TwoThousandAndEighteenEmployeeSharePurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2018 ESPP</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_TwoThousandAndEighteenEmployeeSharePurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Eighteen Employee Share Purchase Plan [Member]</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_TwoThousandAndTwentyInducementEquityPlanMember" xlink:type="locator" xlink:label="ortx_TwoThousandAndTwentyInducementEquityPlanMember" />
    <link:label xml:lang="en-US" xlink:label="ortx_TwoThousandAndTwentyInducementEquityPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">2020 Inducement Equity Plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_TwoThousandAndTwentyInducementEquityPlanMember" xlink:to="ortx_TwoThousandAndTwentyInducementEquityPlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_TwoThousandAndTwentyInducementEquityPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inducement Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_TwoThousandAndTwentyInducementEquityPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Twenty Inducement Equity Plan [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:type="locator" xlink:label="us-gaap_PerformanceSharesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PerformanceSharesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Performance-based Restricted Share Units ("RSUs")</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PerformanceSharesMember" xlink:to="us-gaap_PerformanceSharesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PerformanceSharesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Performance Shares [Member]</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_LibmeldyMember" xlink:type="locator" xlink:label="ortx_LibmeldyMember" />
    <link:label xml:lang="en-US" xlink:label="ortx_LibmeldyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Libmeldy.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_LibmeldyMember" xlink:to="ortx_LibmeldyMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_LibmeldyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Libmeldy</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_LibmeldyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Libmeldy [Member]</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_TimeBasedRestrictedShareUnitsMember" xlink:type="locator" xlink:label="ortx_TimeBasedRestrictedShareUnitsMember" />
    <link:label xml:lang="en-US" xlink:label="ortx_TimeBasedRestrictedShareUnitsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Time-based restricted share units.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_TimeBasedRestrictedShareUnitsMember" xlink:to="ortx_TimeBasedRestrictedShareUnitsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_TimeBasedRestrictedShareUnitsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Time-based Restricted Share Units</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_TimeBasedRestrictedShareUnitsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Time Based Restricted Share Units [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:type="locator" xlink:label="srt_ChiefExecutiveOfficerMember" />
    <link:label xml:lang="en-US" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Chief Executive Officer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Chief Executive Officer [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis" xlink:type="locator" xlink:label="us-gaap_VestingAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VestingAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VestingAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain" xlink:type="locator" xlink:label="us-gaap_VestingDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VestingDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VestingDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Achievement of At Least Three of Four Milestones</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Award Tranche One [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining shares available for issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise price of option</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Per Share Weighted Average Price Of Shares Purchased</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award vesting period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum term of option</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, minimum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (in years)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, minimum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Options, Outstanding at December 31, 2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options, Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Options, Exercised</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Options, Forfeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Options, Outstanding and expected to vest at December 31, 2021</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options, Exercisable as of December 31, 2021</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Exercise Price per Share, Outstanding at December 31, 2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price per Share, Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price per Share, Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price per Share, Forfeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Exercise Price per Share, Outstanding and expected to vest at December 31,2021</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price per Share, Exercisable as of December 31,2021</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Life, Outstanding at December 31, 2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Life, Outstanding and expected to vest at December 31, 2021</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Life, Exercisable as of December 31, 2021</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Exercisable as of December 31, 2021</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeEquityPlanProceedsReceivedAfterYearEnd" xlink:type="locator" xlink:label="ortx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeEquityPlanProceedsReceivedAfterYearEnd" />
    <link:label xml:lang="en-US" xlink:label="ortx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeEquityPlanProceedsReceivedAfterYearEnd_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award employee equity plan proceeds received after year end.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeEquityPlanProceedsReceivedAfterYearEnd" xlink:to="ortx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeEquityPlanProceedsReceivedAfterYearEnd_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total intrinsic value of share options exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total proceeds from share options exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeEquityPlanProceedsReceivedAfterYearEnd_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee equity plan proceeds received after year end</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeEquityPlanProceedsReceivedAfterYearEnd_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Employee Equity Plan Proceeds Received After Year End</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant date fair value of share options granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares vested</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Remaining performance based share units outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Compensation cost recognized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Allocated Share Based Compensation Expense</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:type="locator" xlink:label="ortx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="ortx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award grant date fair value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:to="ortx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total grant date fair value</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Grant Date Fair Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting rights</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PerformanceSharesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Performance-based RSUs</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">RSUs, Unvested at December 31, 2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">RSUs, Vested</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">RSUs, Forfeited</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">RSUs, Unvested at December 31, 2021</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Grant Date Fair Value per share, Unvested at December 31, 2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value per Share, Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value per share, Vested</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value per share, Forfeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Grant Date Fair Value per Share, Unvested at December 31, 2021</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and Development</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Selling General and Administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Selling General And Administrative Expenses [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total share-based compensation</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested options outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total unrecognized compensation cost of stock option and time-based RSUs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Compensation cost expected to be recognized weighted average period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total unrecognized compensation cost of performance-based RSUs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_NumberOfLateStageClinicalGeneTherapyPrograms" xlink:type="locator" xlink:label="ortx_NumberOfLateStageClinicalGeneTherapyPrograms" />
    <link:label xml:lang="en-US" xlink:label="ortx_NumberOfLateStageClinicalGeneTherapyPrograms_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of late-stage clinical gene therapy programs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_NumberOfLateStageClinicalGeneTherapyPrograms" xlink:to="ortx_NumberOfLateStageClinicalGeneTherapyPrograms_lbl" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_NumberOfEarlierStageClinicalGeneTherapyProgram" xlink:type="locator" xlink:label="ortx_NumberOfEarlierStageClinicalGeneTherapyProgram" />
    <link:label xml:lang="en-US" xlink:label="ortx_NumberOfEarlierStageClinicalGeneTherapyProgram_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of earlier stage clinical gene therapy program.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_NumberOfEarlierStageClinicalGeneTherapyProgram" xlink:to="ortx_NumberOfEarlierStageClinicalGeneTherapyProgram_lbl" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_NumberOfAdditionalEarlierStageDevelopmentPrograms" xlink:type="locator" xlink:label="ortx_NumberOfAdditionalEarlierStageDevelopmentPrograms" />
    <link:label xml:lang="en-US" xlink:label="ortx_NumberOfAdditionalEarlierStageDevelopmentPrograms_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of additional earlier-stage development programs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_NumberOfAdditionalEarlierStageDevelopmentPrograms" xlink:to="ortx_NumberOfAdditionalEarlierStageDevelopmentPrograms_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_GSKAssetPurchaseAndLicenseAgreementMember" xlink:type="locator" xlink:label="ortx_GSKAssetPurchaseAndLicenseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="ortx_GSKAssetPurchaseAndLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">GSK Asset Purchase And License Agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_GSKAssetPurchaseAndLicenseAgreementMember" xlink:to="ortx_GSKAssetPurchaseAndLicenseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_GSKAssetPurchaseAndLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">GSK Asset Purchase and License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_GSKAssetPurchaseAndLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">G S K Asset Purchase And License Agreement [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_TelethonOSRLicenseAgreementsMember" xlink:type="locator" xlink:label="ortx_TelethonOSRLicenseAgreementsMember" />
    <link:label xml:lang="en-US" xlink:label="ortx_TelethonOSRLicenseAgreementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Telethon-OSR license agreements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_TelethonOSRLicenseAgreementsMember" xlink:to="ortx_TelethonOSRLicenseAgreementsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_TelethonOSRLicenseAgreementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Telethon O S R License Agreements</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_TelethonOSRLicenseAgreementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Telethon O S R License Agreements [Member]</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_UCLBAndUCLATechnologyMember" xlink:type="locator" xlink:label="ortx_UCLBAndUCLATechnologyMember" />
    <link:label xml:lang="en-US" xlink:label="ortx_UCLBAndUCLATechnologyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">UCLB and UCLA technology.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_UCLBAndUCLATechnologyMember" xlink:to="ortx_UCLBAndUCLATechnologyMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_UCLBAndUCLATechnologyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">UCLB/UCLA Technology</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_UCLBAndUCLATechnologyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">U C L B And U C L A Technology [Member]</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_UCLBTechnologyAndManufacturingTechnologyMember" xlink:type="locator" xlink:label="ortx_UCLBTechnologyAndManufacturingTechnologyMember" />
    <link:label xml:lang="en-US" xlink:label="ortx_UCLBTechnologyAndManufacturingTechnologyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">UCLB technology and manufacturing technology.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_UCLBTechnologyAndManufacturingTechnologyMember" xlink:to="ortx_UCLBTechnologyAndManufacturingTechnologyMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_UCLBTechnologyAndManufacturingTechnologyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">UCLB Technology and Manufacturing Technology</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_UCLBTechnologyAndManufacturingTechnologyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">U C L B Technology And Manufacturing Technology [Member]</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_UCLBLicenseAgreementMember" xlink:type="locator" xlink:label="ortx_UCLBLicenseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="ortx_UCLBLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">UCLB license agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_UCLBLicenseAgreementMember" xlink:to="ortx_UCLBLicenseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_UCLBLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">UCLB License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_UCLBLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">U C L B License Agreement [Member]</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_UCLBAndUCLALicenseAgreementMember" xlink:type="locator" xlink:label="ortx_UCLBAndUCLALicenseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="ortx_UCLBAndUCLALicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">UCLB and UCLA license agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_UCLBAndUCLALicenseAgreementMember" xlink:to="ortx_UCLBAndUCLALicenseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_UCLBAndUCLALicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">UCLB/UCLA License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_UCLBAndUCLALicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">U C L B And U C L A License Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_OxfordBioMedicaLicenseDevelopmentAndSupplyAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Oxford BioMedica License, Development and Supply Agreement</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_NumberOfLateStageClinicalGeneTherapyPrograms_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of earlier stage clinical gene therapy program</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_NumberOfLateStageClinicalGeneTherapyPrograms_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Late Stage Clinical Gene Therapy Programs</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_NumberOfEarlierStageClinicalGeneTherapyProgram_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of earlier stage clinical gene therapy program</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_NumberOfEarlierStageClinicalGeneTherapyProgram_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Earlier Stage Clinical Gene Therapy Program</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_NumberOfAdditionalEarlierStageDevelopmentPrograms_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of additional earlier-stage development programs</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_NumberOfAdditionalEarlierStageDevelopmentPrograms_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Additional Earlier Stage Development Programs</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_AssetAcquisitionUpfrontPayment" xlink:type="locator" xlink:label="ortx_AssetAcquisitionUpfrontPayment" />
    <link:label xml:lang="en-US" xlink:label="ortx_AssetAcquisitionUpfrontPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Asset acquisition upfront payment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_AssetAcquisitionUpfrontPayment" xlink:to="ortx_AssetAcquisitionUpfrontPayment_lbl" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_AssetAcquisitionNumberOfSharesIssuedForAcquisition" xlink:type="locator" xlink:label="ortx_AssetAcquisitionNumberOfSharesIssuedForAcquisition" />
    <link:label xml:lang="en-US" xlink:label="ortx_AssetAcquisitionNumberOfSharesIssuedForAcquisition_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Asset acquisition number of shares issued for acquisition.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_AssetAcquisitionNumberOfSharesIssuedForAcquisition" xlink:to="ortx_AssetAcquisitionNumberOfSharesIssuedForAcquisition_lbl" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_AssetAcquisitionValueOfEquityInstrumentsIssued" xlink:type="locator" xlink:label="ortx_AssetAcquisitionValueOfEquityInstrumentsIssued" />
    <link:label xml:lang="en-US" xlink:label="ortx_AssetAcquisitionValueOfEquityInstrumentsIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Asset acquisition value of equity instruments issued.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_AssetAcquisitionValueOfEquityInstrumentsIssued" xlink:to="ortx_AssetAcquisitionValueOfEquityInstrumentsIssued_lbl" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_AssetAcquisitionInventoryPurchaseLiability" xlink:type="locator" xlink:label="ortx_AssetAcquisitionInventoryPurchaseLiability" />
    <link:label xml:lang="en-US" xlink:label="ortx_AssetAcquisitionInventoryPurchaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Asset acquisition inventory purchase liability.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_AssetAcquisitionInventoryPurchaseLiability" xlink:to="ortx_AssetAcquisitionInventoryPurchaseLiability_lbl" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_AssetAcquisitionTransactionCosts" xlink:type="locator" xlink:label="ortx_AssetAcquisitionTransactionCosts" />
    <link:label xml:lang="en-US" xlink:label="ortx_AssetAcquisitionTransactionCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Asset acquisition transaction costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_AssetAcquisitionTransactionCosts" xlink:to="ortx_AssetAcquisitionTransactionCosts_lbl" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_AssetAcquisitionInProcessResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="ortx_AssetAcquisitionInProcessResearchAndDevelopmentExpense" />
    <link:label xml:lang="en-US" xlink:label="ortx_AssetAcquisitionInProcessResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Asset acquisition in-process research and development expense.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_AssetAcquisitionInProcessResearchAndDevelopmentExpense" xlink:to="ortx_AssetAcquisitionInProcessResearchAndDevelopmentExpense_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total consideration</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition Consideration Transferred</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_AssetAcquisitionUpfrontPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront payment</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_AssetAcquisitionUpfrontPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition Upfront Payment</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_AssetAcquisitionNumberOfSharesIssuedForAcquisition_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued for asset acquisition</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_AssetAcquisitionNumberOfSharesIssuedForAcquisition_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition Number Of Shares Issued For Acquisition</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_AssetAcquisitionValueOfEquityInstrumentsIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate value of shares issued for asset acquisition</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_AssetAcquisitionValueOfEquityInstrumentsIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition Value Of Equity Instruments Issued</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_AssetAcquisitionLiabilityAssumed_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining liability</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_AssetAcquisitionInventoryPurchaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory purchase liability</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_AssetAcquisitionInventoryPurchaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition Inventory Purchase Liability</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_AssetAcquisitionTransactionCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction costs</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_AssetAcquisitionTransactionCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition Transaction Costs</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_AssetAcquisitionInProcessResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">In-process research and development expense</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_AssetAcquisitionInProcessResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition In Process Research And Development Expense</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_PaymentOfTieredRoyaltyMaximumPercentage" xlink:type="locator" xlink:label="ortx_PaymentOfTieredRoyaltyMaximumPercentage" />
    <link:label xml:lang="en-US" xlink:label="ortx_PaymentOfTieredRoyaltyMaximumPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment of tiered royalty, maximum percentage.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_PaymentOfTieredRoyaltyMaximumPercentage" xlink:to="ortx_PaymentOfTieredRoyaltyMaximumPercentage_lbl" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_MilestonePaymentsPayableUponAchievementOfCertainSalesMilestones" xlink:type="locator" xlink:label="ortx_MilestonePaymentsPayableUponAchievementOfCertainSalesMilestones" />
    <link:label xml:lang="en-US" xlink:label="ortx_MilestonePaymentsPayableUponAchievementOfCertainSalesMilestones_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payments payable upon achievement of certain sales milestones.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_MilestonePaymentsPayableUponAchievementOfCertainSalesMilestones" xlink:to="ortx_MilestonePaymentsPayableUponAchievementOfCertainSalesMilestones_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_PaymentOfTieredRoyaltyMaximumPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment of tiered royalty, maximum percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_PaymentOfTieredRoyaltyMaximumPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payment Of Tiered Royalty Maximum Percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_MilestonePaymentsPayableUponAchievementOfCertainSalesMilestones_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payments payable upon achievement of certain sales milestones</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_MilestonePaymentsPayableUponAchievementOfCertainSalesMilestones_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payments Payable Upon Achievement Of Certain Sales Milestones</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_UpfrontPaymentDescription" xlink:type="locator" xlink:label="ortx_UpfrontPaymentDescription" />
    <link:label xml:lang="en-US" xlink:label="ortx_UpfrontPaymentDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront payment Description</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_UpfrontPaymentDescription" xlink:to="ortx_UpfrontPaymentDescription_lbl" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_UpfrontAndMilestonePayments" xlink:type="locator" xlink:label="ortx_UpfrontAndMilestonePayments" />
    <link:label xml:lang="en-US" xlink:label="ortx_UpfrontAndMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront and milestone payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_UpfrontAndMilestonePayments" xlink:to="ortx_UpfrontAndMilestonePayments_lbl" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_InProcessResearchAndDevelopmentExpenseForUpfrontAndMilestonePayments" xlink:type="locator" xlink:label="ortx_InProcessResearchAndDevelopmentExpenseForUpfrontAndMilestonePayments" />
    <link:label xml:lang="en-US" xlink:label="ortx_InProcessResearchAndDevelopmentExpenseForUpfrontAndMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">In-process research and development expense for upfront and milestone payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_InProcessResearchAndDevelopmentExpenseForUpfrontAndMilestonePayments" xlink:to="ortx_InProcessResearchAndDevelopmentExpenseForUpfrontAndMilestonePayments_lbl" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_MilestonePaymentsPayableUponAchievementOfCertainDevelopmentRegulatoryAndCommercialMilestones" xlink:type="locator" xlink:label="ortx_MilestonePaymentsPayableUponAchievementOfCertainDevelopmentRegulatoryAndCommercialMilestones" />
    <link:label xml:lang="en-US" xlink:label="ortx_MilestonePaymentsPayableUponAchievementOfCertainDevelopmentRegulatoryAndCommercialMilestones_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payments payable upon achievement of certain development regulatory and commercial milestones.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_MilestonePaymentsPayableUponAchievementOfCertainDevelopmentRegulatoryAndCommercialMilestones" xlink:to="ortx_MilestonePaymentsPayableUponAchievementOfCertainDevelopmentRegulatoryAndCommercialMilestones_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_UpfrontPaymentDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront payment description</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_UpfrontPaymentDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Payment Description</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_UpfrontAndMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront and milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_UpfrontAndMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Upfront And Milestone Payments</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_InProcessResearchAndDevelopmentExpenseForUpfrontAndMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">In-process research and development expense for upfront and milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_InProcessResearchAndDevelopmentExpenseForUpfrontAndMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">In Process Research And Development Expense For Upfront And Milestone Payments</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_MilestonePaymentsPayableUponAchievementOfCertainDevelopmentRegulatoryAndCommercialMilestones_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payments payable upon achievement of certain development regulatory and commercial milestones</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_MilestonePaymentsPayableUponAchievementOfCertainDevelopmentRegulatoryAndCommercialMilestones_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payments Payable Upon Achievement Of Certain Development Regulatory And Commercial Milestones</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_PaymentsToAcquireClinicalData" xlink:type="locator" xlink:label="ortx_PaymentsToAcquireClinicalData" />
    <link:label xml:lang="en-US" xlink:label="ortx_PaymentsToAcquireClinicalData_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments to acquire clinical data.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_PaymentsToAcquireClinicalData" xlink:to="ortx_PaymentsToAcquireClinicalData_lbl" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_UpfrontCashPayment" xlink:type="locator" xlink:label="ortx_UpfrontCashPayment" />
    <link:label xml:lang="en-US" xlink:label="ortx_UpfrontCashPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront cash payment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_UpfrontCashPayment" xlink:to="ortx_UpfrontCashPayment_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_UpfrontCashPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront cash payments</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_UpfrontCashPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Cash Payment</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Ordinary shares issued</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_PaymentsToAcquireClinicalData_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments to acquire clinical data</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_PaymentsToAcquireClinicalData_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Clinical Data</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_PotentialPaymentForAchievementOfSpecifiedMilestones" xlink:type="locator" xlink:label="ortx_PotentialPaymentForAchievementOfSpecifiedMilestones" />
    <link:label xml:lang="en-US" xlink:label="ortx_PotentialPaymentForAchievementOfSpecifiedMilestones_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Potential payment for achievement of specified milestones.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_PotentialPaymentForAchievementOfSpecifiedMilestones" xlink:to="ortx_PotentialPaymentForAchievementOfSpecifiedMilestones_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentForAdministrativeFees" xlink:type="locator" xlink:label="us-gaap_PaymentForAdministrativeFees" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentForAdministrativeFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual administration fee</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentForAdministrativeFees" xlink:to="us-gaap_PaymentForAdministrativeFees_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentForAdministrativeFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payment For Administrative Fees</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_PotentialPaymentForAchievementOfSpecifiedMilestones_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments upon achievement of specified regulatory milestones</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_PotentialPaymentForAchievementOfSpecifiedMilestones_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Potential Payment For Achievement Of Specified Milestones</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_MilestonePayment" xlink:type="locator" xlink:label="ortx_MilestonePayment" />
    <link:label xml:lang="en-US" xlink:label="ortx_MilestonePayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_MilestonePayment" xlink:to="ortx_MilestonePayment_lbl" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_NumberOfMilestonesMet" xlink:type="locator" xlink:label="ortx_NumberOfMilestonesMet" />
    <link:label xml:lang="en-US" xlink:label="ortx_NumberOfMilestonesMet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of milestones met.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_NumberOfMilestonesMet" xlink:to="ortx_NumberOfMilestonesMet_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_MilestonePayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Milestone payment</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_MilestonePayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payment</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_NumberOfMilestonesMet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of milestones met</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_NumberOfMilestonesMet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Milestones Met</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_MilestonePaymentsReceivable" xlink:type="locator" xlink:label="ortx_MilestonePaymentsReceivable" />
    <link:label xml:lang="en-US" xlink:label="ortx_MilestonePaymentsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payments receivable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_MilestonePaymentsReceivable" xlink:to="ortx_MilestonePaymentsReceivable_lbl" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_StrategicCollaborationAgreementWithPharmingMember" xlink:type="locator" xlink:label="ortx_StrategicCollaborationAgreementWithPharmingMember" />
    <link:label xml:lang="en-US" xlink:label="ortx_StrategicCollaborationAgreementWithPharmingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Strategic collaboration agreement with pharming.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_StrategicCollaborationAgreementWithPharmingMember" xlink:to="ortx_StrategicCollaborationAgreementWithPharmingMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_StrategicCollaborationAgreementWithPharmingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Strategic Collaboration Agreement with Pharming</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_StrategicCollaborationAgreementWithPharmingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Strategic Collaboration Agreement With Pharming [Member]</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_PharmingAgreementsMember" xlink:type="locator" xlink:label="ortx_PharmingAgreementsMember" />
    <link:label xml:lang="en-US" xlink:label="ortx_PharmingAgreementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Pharming agreements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_PharmingAgreementsMember" xlink:to="ortx_PharmingAgreementsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_PharmingAgreementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pharming Agreements</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_PharmingAgreementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pharming Agreements [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementMember" xlink:to="us-gaap_CollaborativeArrangementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts Receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:type="locator" xlink:label="us-gaap_ProceedsFromCollaborators" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromCollaborators_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash upfront payment received</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromCollaborators" xlink:to="us-gaap_ProceedsFromCollaborators_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromCollaborators_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Collaborators</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_MilestonePaymentsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payments receivable</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_MilestonePaymentsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payments Receivable</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel">Issuance of ordinary shares</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ProceedsFromUpfrontPayment" xlink:type="locator" xlink:label="ortx_ProceedsFromUpfrontPayment" />
    <link:label xml:lang="en-US" xlink:label="ortx_ProceedsFromUpfrontPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from upfront payment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_ProceedsFromUpfrontPayment" xlink:to="ortx_ProceedsFromUpfrontPayment_lbl" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ProceedsFromUpfrontPaymentsAttributedToEquitySold" xlink:type="locator" xlink:label="ortx_ProceedsFromUpfrontPaymentsAttributedToEquitySold" />
    <link:label xml:lang="en-US" xlink:label="ortx_ProceedsFromUpfrontPaymentsAttributedToEquitySold_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from upfront payments attributed to equity sold.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_ProceedsFromUpfrontPaymentsAttributedToEquitySold" xlink:to="ortx_ProceedsFromUpfrontPaymentsAttributedToEquitySold_lbl" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ProceedsFromUpfrontPaymentsAttributedToResearchActivities" xlink:type="locator" xlink:label="ortx_ProceedsFromUpfrontPaymentsAttributedToResearchActivities" />
    <link:label xml:lang="en-US" xlink:label="ortx_ProceedsFromUpfrontPaymentsAttributedToResearchActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from upfront payments attributed to research activities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_ProceedsFromUpfrontPaymentsAttributedToResearchActivities" xlink:to="ortx_ProceedsFromUpfrontPaymentsAttributedToResearchActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_ProceedsFromUpfrontPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total upfront payments</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_ProceedsFromUpfrontPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Upfront Payment</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_ProceedsFromUpfrontPaymentsAttributedToEquitySold_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront payments attributed to equity sold</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_ProceedsFromUpfrontPaymentsAttributedToEquitySold_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Upfront Payments Attributed To Equity Sold</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_ProceedsFromUpfrontPaymentsAttributedToResearchActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront payments attributed to research activities</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_ProceedsFromUpfrontPaymentsAttributedToResearchActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Upfront Payments Attributed To Research Activities</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ExcessProceedsFromFairValueOfSharesIssuedAllocatedToCollaborationAgreement" xlink:type="locator" xlink:label="ortx_ExcessProceedsFromFairValueOfSharesIssuedAllocatedToCollaborationAgreement" />
    <link:label xml:lang="en-US" xlink:label="ortx_ExcessProceedsFromFairValueOfSharesIssuedAllocatedToCollaborationAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Excess proceeds from fair value of shares issued allocated to collaboration agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_ExcessProceedsFromFairValueOfSharesIssuedAllocatedToCollaborationAgreement" xlink:to="ortx_ExcessProceedsFromFairValueOfSharesIssuedAllocatedToCollaborationAgreement_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssued1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares issued as part of license agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_ExcessProceedsFromFairValueOfSharesIssuedAllocatedToCollaborationAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Excess proceeds from fair value of shares issued allocated to collaboration agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_ExcessProceedsFromFairValueOfSharesIssuedAllocatedToCollaborationAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Excess Proceeds From Fair Value Of Shares Issued Allocated To Collaboration Agreement</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ProceedsFromNonRefundableUpfrontPayment" xlink:type="locator" xlink:label="ortx_ProceedsFromNonRefundableUpfrontPayment" />
    <link:label xml:lang="en-US" xlink:label="ortx_ProceedsFromNonRefundableUpfrontPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from non-refundable upfront payment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_ProceedsFromNonRefundableUpfrontPayment" xlink:to="ortx_ProceedsFromNonRefundableUpfrontPayment_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_ProceedsFromNonRefundableUpfrontPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-refundable up-front payment</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_ProceedsFromNonRefundableUpfrontPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Non Refundable Upfront Payment</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ReimbursementRevenueMember" xlink:type="locator" xlink:label="ortx_ReimbursementRevenueMember" />
    <link:label xml:lang="en-US" xlink:label="ortx_ReimbursementRevenueMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Reimbursement revenue.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_ReimbursementRevenueMember" xlink:to="ortx_ReimbursementRevenueMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_ReimbursementRevenueMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reimbursement Revenue</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_ReimbursementRevenueMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Reimbursement Revenue [Member]</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_UpfrontAndMilestonePaymentRevenueMember" xlink:type="locator" xlink:label="ortx_UpfrontAndMilestonePaymentRevenueMember" />
    <link:label xml:lang="en-US" xlink:label="ortx_UpfrontAndMilestonePaymentRevenueMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront and milestone payment revenue.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_UpfrontAndMilestonePaymentRevenueMember" xlink:to="ortx_UpfrontAndMilestonePaymentRevenueMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_UpfrontAndMilestonePaymentRevenueMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront and Milestone Payment Revenue</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_UpfrontAndMilestonePaymentRevenueMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Upfront And Milestone Payment Revenue [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetNetCurrent" xlink:to="us-gaap_ContractWithCustomerAssetNetCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Asset Net Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Noncurrent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.K.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Loss From Continuing Operations Before Income Taxes Domestic</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-U.K.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Loss From Continuing Operations Before Income Taxes Foreign</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_CurrentOtherTaxExpenseBenefit" xlink:type="locator" xlink:label="ortx_CurrentOtherTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="ortx_CurrentOtherTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Current other tax expense benefit.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_CurrentOtherTaxExpenseBenefit" xlink:to="ortx_CurrentOtherTaxExpenseBenefit_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current (benefit) provision</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Income Tax Expense Benefit Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal&#8212;United States</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Federal Tax Expense Benefit</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State&#8212;United States</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current State And Local Tax Expense Benefit</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_CurrentOtherTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other foreign</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_CurrentOtherTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Other Tax Expense Benefit</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">United Kingdom</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Foreign Tax Expense Benefit</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current (benefit) provision</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Income Tax Expense Benefit</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred provision (benefit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Expense Benefit Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal&#8212;United States</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Federal Income Tax Expense Benefit</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State&#8212;United States</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred State And Local Income Tax Expense Benefit</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">United Kingdom</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Foreign Income Tax Expense Benefit</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredOtherTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredOtherTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredOtherTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other foreign</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOtherTaxExpenseBenefit" xlink:to="us-gaap_DeferredOtherTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredOtherTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Other Tax Expense Benefit</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred provision (benefit)</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total provision (benefit) for income taxes</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income taxes at United Kingdom statutory rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_IncomeTaxReconciliationReductionInResearchExpenseForCreditsGranted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reduction in research expense for credits granted</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_IncomeTaxReconciliationReductionInResearchExpenseForCreditsGranted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Reduction In Research Expense For Credits Granted</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in tax rates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Change In Enacted Tax Rate</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Tax credits</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_IncomeTaxReconciliationDomesticDeductionForDerivedIntangibleIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">U.S. Deduction for foreign derived intangible income</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_IncomeTaxReconciliationDomesticDeductionForDerivedIntangibleIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Domestic Deduction For Derived Intangible Income</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_IncomeTaxReconciliationPermanentDifferencesIncludingShareBasedCompensationDeductionShortfalls_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Permanent differences, including share-based compensation deduction shortfalls</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_IncomeTaxReconciliationPermanentDifferencesIncludingShareBasedCompensationDeductionShortfalls_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Permanent Differences Including Share Based Compensation Deduction Shortfalls</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. state income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation State And Local Income Taxes</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign rate differential</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Foreign Income Tax Rate Differential</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_CorporationTaxRatePercentage" xlink:type="locator" xlink:label="ortx_CorporationTaxRatePercentage" />
    <link:label xml:lang="en-US" xlink:label="ortx_CorporationTaxRatePercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Corporation tax rate percentage.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_CorporationTaxRatePercentage" xlink:to="ortx_CorporationTaxRatePercentage_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Loss Carryforwards [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Country [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">State And Local Jurisdiction [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Name [Domain]</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_OrphanDrugTaxCreditMember" xlink:type="locator" xlink:label="ortx_OrphanDrugTaxCreditMember" />
    <link:label xml:lang="en-US" xlink:label="ortx_OrphanDrugTaxCreditMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Orphan Drug Tax Credit.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_OrphanDrugTaxCreditMember" xlink:to="ortx_OrphanDrugTaxCreditMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_OrphanDrugTaxCreditMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Orphan Drug</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_OrphanDrugTaxCreditMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Orphan Drug Tax Credit [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember" xlink:type="locator" xlink:label="us-gaap_ResearchMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:type="locator" xlink:label="us-gaap_TaxPeriodAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxPeriodAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxPeriodAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Period [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:type="locator" xlink:label="us-gaap_TaxPeriodDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxPeriodDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_TaxPeriodDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxPeriodDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Period [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarliestTaxYearMember" xlink:type="locator" xlink:label="us-gaap_EarliestTaxYearMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarliestTaxYearMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Earliest Tax Year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarliestTaxYearMember" xlink:to="us-gaap_EarliestTaxYearMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarliestTaxYearMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earliest Tax Year [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LatestTaxYearMember" xlink:type="locator" xlink:label="us-gaap_LatestTaxYearMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LatestTaxYearMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Latest Tax Year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LatestTaxYearMember" xlink:to="us-gaap_LatestTaxYearMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LatestTaxYearMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Latest Tax Year [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Loss Carryforwards [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_CorporationTaxRatePercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporation tax rate percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_CorporationTaxRatePercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Corporation Tax Rate Percentage</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in net deferred tax assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Deferred Income Taxes</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance Deferred Tax Asset Change In Amount</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_DeferredTaxAssetsAmortization" xlink:type="locator" xlink:label="ortx_DeferredTaxAssetsAmortization" />
    <link:label xml:lang="en-US" xlink:label="ortx_DeferredTaxAssetsAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets amortization.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_DeferredTaxAssetsAmortization" xlink:to="ortx_DeferredTaxAssetsAmortization_lbl" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_DeferredTaxAssetsLeaseLiability" xlink:type="locator" xlink:label="ortx_DeferredTaxAssetsLeaseLiability" />
    <link:label xml:lang="en-US" xlink:label="ortx_DeferredTaxAssetsLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets lease liability.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_DeferredTaxAssetsLeaseLiability" xlink:to="ortx_DeferredTaxAssetsLeaseLiability_lbl" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_DeferredTaxLiabilitiesFixedAssetsAndRightOfUseAsset" xlink:type="locator" xlink:label="ortx_DeferredTaxLiabilitiesFixedAssetsAndRightOfUseAsset" />
    <link:label xml:lang="en-US" xlink:label="ortx_DeferredTaxLiabilitiesFixedAssetsAndRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liabilities fixed assets and right of use asset.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_DeferredTaxLiabilitiesFixedAssetsAndRightOfUseAsset" xlink:to="ortx_DeferredTaxLiabilitiesFixedAssetsAndRightOfUseAsset_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:type="locator" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Components Of Deferred Tax Assets [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_DeferredTaxAssetsAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_DeferredTaxAssetsAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Amortization</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development credits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Credit Carryforwards Research</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accruals</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Deferred Expense Reserves And Accruals</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_DeferredTaxAssetsLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liability</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_DeferredTaxAssetsLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Lease Liability</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Property Plant And Equipment</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Other</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Gross</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Valuation Allowance</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_DeferredTaxLiabilitiesFixedAssetsAndRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Fixed assets and right-of-use asset</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_DeferredTaxLiabilitiesFixedAssetsAndRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Fixed Assets And Right Of Use Asset</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other non-current assets (net deferred tax assets and liabilities)</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_TaxCreditCarryforwardExpirationYear" xlink:type="locator" xlink:label="ortx_TaxCreditCarryforwardExpirationYear" />
    <link:label xml:lang="en-US" xlink:label="ortx_TaxCreditCarryforwardExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax credit carryforward expiration year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_TaxCreditCarryforwardExpirationYear" xlink:to="ortx_TaxCreditCarryforwardExpirationYear_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credits carryforward, amount</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_TaxCreditCarryforwardExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforward expiration year</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_TaxCreditCarryforwardExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Expiration Year</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_DeferredTaxAssetsValuationAllowanceIncreasesRecordedToIncomeTaxProvision" xlink:type="locator" xlink:label="ortx_DeferredTaxAssetsValuationAllowanceIncreasesRecordedToIncomeTaxProvision" />
    <link:label xml:lang="en-US" xlink:label="ortx_DeferredTaxAssetsValuationAllowanceIncreasesRecordedToIncomeTaxProvision_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets valuation allowance increases recorded to income tax provision.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_DeferredTaxAssetsValuationAllowanceIncreasesRecordedToIncomeTaxProvision" xlink:to="ortx_DeferredTaxAssetsValuationAllowanceIncreasesRecordedToIncomeTaxProvision_lbl" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_DeferredTaxAssetsValuationAllowanceEffectOfForeignCurrencyTranslation" xlink:type="locator" xlink:label="ortx_DeferredTaxAssetsValuationAllowanceEffectOfForeignCurrencyTranslation" />
    <link:label xml:lang="en-US" xlink:label="ortx_DeferredTaxAssetsValuationAllowanceEffectOfForeignCurrencyTranslation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets valuation allowance effect of foreign currency translation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_DeferredTaxAssetsValuationAllowanceEffectOfForeignCurrencyTranslation" xlink:to="ortx_DeferredTaxAssetsValuationAllowanceEffectOfForeignCurrencyTranslation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel">Valuation allowance as of beginning of year</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_DeferredTaxAssetsValuationAllowanceIncreasesRecordedToIncomeTaxProvision_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increases recorded to income tax provision</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_DeferredTaxAssetsValuationAllowanceIncreasesRecordedToIncomeTaxProvision_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Valuation Allowance Increases Recorded To Income Tax Provision</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_DeferredTaxAssetsValuationAllowanceEffectOfForeignCurrencyTranslation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effect of foreign currency translation</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_DeferredTaxAssetsValuationAllowanceEffectOfForeignCurrencyTranslation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Valuation Allowance Effect Of Foreign Currency Translation</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel">Valuation allowance as of end of year</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest or penalties related to uncertain tax positions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OpenTaxYear" xlink:type="locator" xlink:label="us-gaap_OpenTaxYear" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OpenTaxYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax year open to examination</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OpenTaxYear" xlink:to="us-gaap_OpenTaxYear_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OpenTaxYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Open Tax Year</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ManufacturingCommitmentsAmountDueInNextTwelveMonths" xlink:type="locator" xlink:label="ortx_ManufacturingCommitmentsAmountDueInNextTwelveMonths" />
    <link:label xml:lang="en-US" xlink:label="ortx_ManufacturingCommitmentsAmountDueInNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Manufacturing commitments amount due in next twelve months.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_ManufacturingCommitmentsAmountDueInNextTwelveMonths" xlink:to="ortx_ManufacturingCommitmentsAmountDueInNextTwelveMonths_lbl" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ManufacturingCommitmentsAmountDueInYearTwo" xlink:type="locator" xlink:label="ortx_ManufacturingCommitmentsAmountDueInYearTwo" />
    <link:label xml:lang="en-US" xlink:label="ortx_ManufacturingCommitmentsAmountDueInYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Manufacturing commitments amount due in year two.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_ManufacturingCommitmentsAmountDueInYearTwo" xlink:to="ortx_ManufacturingCommitmentsAmountDueInYearTwo_lbl" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ManufacturingCommitmentsAmountDueInYearThree" xlink:type="locator" xlink:label="ortx_ManufacturingCommitmentsAmountDueInYearThree" />
    <link:label xml:lang="en-US" xlink:label="ortx_ManufacturingCommitmentsAmountDueInYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Manufacturing commitments amount Due In year three.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_ManufacturingCommitmentsAmountDueInYearThree" xlink:to="ortx_ManufacturingCommitmentsAmountDueInYearThree_lbl" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ManufacturingCommitmentsAmountDueInYearFour" xlink:type="locator" xlink:label="ortx_ManufacturingCommitmentsAmountDueInYearFour" />
    <link:label xml:lang="en-US" xlink:label="ortx_ManufacturingCommitmentsAmountDueInYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Manufacturing commitments amount due in year four.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_ManufacturingCommitmentsAmountDueInYearFour" xlink:to="ortx_ManufacturingCommitmentsAmountDueInYearFour_lbl" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ManufacturingCommitmentsAmountDueInYearFive" xlink:type="locator" xlink:label="ortx_ManufacturingCommitmentsAmountDueInYearFive" />
    <link:label xml:lang="en-US" xlink:label="ortx_ManufacturingCommitmentsAmountDueInYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Manufacturing commitments amount due in year five.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_ManufacturingCommitmentsAmountDueInYearFive" xlink:to="ortx_ManufacturingCommitmentsAmountDueInYearFive_lbl" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ManufacturingCommitmentsAmountDueThereafter" xlink:type="locator" xlink:label="ortx_ManufacturingCommitmentsAmountDueThereafter" />
    <link:label xml:lang="en-US" xlink:label="ortx_ManufacturingCommitmentsAmountDueThereafter_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Manufacturing commitments amount due thereafter.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_ManufacturingCommitmentsAmountDueThereafter" xlink:to="ortx_ManufacturingCommitmentsAmountDueThereafter_lbl" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ManufacturingCommitments" xlink:type="locator" xlink:label="ortx_ManufacturingCommitments" />
    <link:label xml:lang="en-US" xlink:label="ortx_ManufacturingCommitments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Manufacturing commitments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_ManufacturingCommitments" xlink:to="ortx_ManufacturingCommitments_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsTable" xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherCommitmentsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Commitments [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_OtherCommitmentsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherCommitmentsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Commitments [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplyCommitmentAxis" xlink:type="locator" xlink:label="us-gaap_SupplyCommitmentAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplyCommitmentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supply Commitment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplyCommitmentAxis" xlink:to="us-gaap_SupplyCommitmentAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplyCommitmentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Supply Commitment [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplyCommitmentArrangementMember" xlink:type="locator" xlink:label="us-gaap_SupplyCommitmentArrangementMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplyCommitmentArrangementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supply Commitment Arrangement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="us-gaap_SupplyCommitmentArrangementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplyCommitmentArrangementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Supply Commitment Arrangement [Member]</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ProductManufacturingCommitmentsMember" xlink:type="locator" xlink:label="ortx_ProductManufacturingCommitmentsMember" />
    <link:label xml:lang="en-US" xlink:label="ortx_ProductManufacturingCommitmentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Product manufacturing commitments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_ProductManufacturingCommitmentsMember" xlink:to="ortx_ProductManufacturingCommitmentsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_ProductManufacturingCommitmentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product Manufacturing Commitments</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_ProductManufacturingCommitmentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Product Manufacturing Commitments [Member]</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_DedicatedManufacturingAndDevelopmentResourcesMember" xlink:type="locator" xlink:label="ortx_DedicatedManufacturingAndDevelopmentResourcesMember" />
    <link:label xml:lang="en-US" xlink:label="ortx_DedicatedManufacturingAndDevelopmentResourcesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Dedicated manufacturing and development resources.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_DedicatedManufacturingAndDevelopmentResourcesMember" xlink:to="ortx_DedicatedManufacturingAndDevelopmentResourcesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_DedicatedManufacturingAndDevelopmentResourcesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dedicated Manufacturing and Development Resources</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_DedicatedManufacturingAndDevelopmentResourcesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Dedicated Manufacturing And Development Resources [Member]</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ExclusiveTransductionSuitesMember" xlink:type="locator" xlink:label="ortx_ExclusiveTransductionSuitesMember" />
    <link:label xml:lang="en-US" xlink:label="ortx_ExclusiveTransductionSuitesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Exclusive transduction suites.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_ExclusiveTransductionSuitesMember" xlink:to="ortx_ExclusiveTransductionSuitesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_ExclusiveTransductionSuitesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exclusive Transduction Suites</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_ExclusiveTransductionSuitesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Exclusive Transduction Suites [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsLineItems" xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherCommitmentsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Commitments [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherCommitmentsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Commitments [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_ManufacturingCommitmentsAmountDueInNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_ManufacturingCommitmentsAmountDueInNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Manufacturing Commitments Amount Due In Next Twelve Months</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_ManufacturingCommitmentsAmountDueInYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_ManufacturingCommitmentsAmountDueInYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Manufacturing Commitments Amount Due In Year Two</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_ManufacturingCommitmentsAmountDueInYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_ManufacturingCommitmentsAmountDueInYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Manufacturing Commitments Amount Due In Year Three</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_ManufacturingCommitmentsAmountDueInYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_ManufacturingCommitmentsAmountDueInYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Manufacturing Commitments Amount Due In Year Four</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_ManufacturingCommitmentsAmountDueInYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_ManufacturingCommitmentsAmountDueInYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Manufacturing Commitments Amount Due In Year Five</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_ManufacturingCommitmentsAmountDueThereafter_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_ManufacturingCommitmentsAmountDueThereafter_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Manufacturing Commitments Amount Due Thereafter</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_ManufacturingCommitments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total manufacturing commitments</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_ManufacturingCommitments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Manufacturing Commitments</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ForeignCurrencyExchangeRateTranslation1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Exchange rate, Euro to U.S. Dollar</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_InitialTermOfAgreement" xlink:type="locator" xlink:label="ortx_InitialTermOfAgreement" />
    <link:label xml:lang="en-US" xlink:label="ortx_InitialTermOfAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Initial term of agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_InitialTermOfAgreement" xlink:to="ortx_InitialTermOfAgreement_lbl" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_AgreementMaturityDate" xlink:type="locator" xlink:label="ortx_AgreementMaturityDate" />
    <link:label xml:lang="en-US" xlink:label="ortx_AgreementMaturityDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Agreement maturity date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_AgreementMaturityDate" xlink:to="ortx_AgreementMaturityDate_lbl" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_AgreementExtensionTerm" xlink:type="locator" xlink:label="ortx_AgreementExtensionTerm" />
    <link:label xml:lang="en-US" xlink:label="ortx_AgreementExtensionTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Agreement extension term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_AgreementExtensionTerm" xlink:to="ortx_AgreementExtensionTerm_lbl" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ManufacturingAndTechnologyDevelopmentMasterAgreementMember" xlink:type="locator" xlink:label="ortx_ManufacturingAndTechnologyDevelopmentMasterAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="ortx_ManufacturingAndTechnologyDevelopmentMasterAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Manufacturing and technology development master agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_ManufacturingAndTechnologyDevelopmentMasterAgreementMember" xlink:to="ortx_ManufacturingAndTechnologyDevelopmentMasterAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_ManufacturingAndTechnologyDevelopmentMasterAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_ManufacturingAndTechnologyDevelopmentMasterAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Manufacturing And Technology Development Master Agreement [Member]</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ClinicalDevelopmentAndRegulatoryMilestoneMember" xlink:type="locator" xlink:label="ortx_ClinicalDevelopmentAndRegulatoryMilestoneMember" />
    <link:label xml:lang="en-US" xlink:label="ortx_ClinicalDevelopmentAndRegulatoryMilestoneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Clinical development and regulatory milestone.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_ClinicalDevelopmentAndRegulatoryMilestoneMember" xlink:to="ortx_ClinicalDevelopmentAndRegulatoryMilestoneMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_ClinicalDevelopmentAndRegulatoryMilestoneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical Development And Regulatory Milestone</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_ClinicalDevelopmentAndRegulatoryMilestoneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Clinical Development And Regulatory Milestone [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_InitialTermOfAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial term of agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_InitialTermOfAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Initial Term Of Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_AgreementMaturityDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Agreement maturity date</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_AgreementMaturityDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Agreement Maturity Date</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_AgreementExtensionTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Agreement extension term</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_AgreementExtensionTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Agreement Extension Term</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Due To Related Parties Current And Noncurrent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares, issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Capital Shares Reserved For Future Issuance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares, vest</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contribution expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanCostRecognized" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Cost Recognized</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum annual contribution employer matches per employee, percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Employer Matching Contribution Percent</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_InventoryPurchase" xlink:type="locator" xlink:label="ortx_InventoryPurchase" />
    <link:label xml:lang="en-US" xlink:label="ortx_InventoryPurchase_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Inventory purchase.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_InventoryPurchase" xlink:to="ortx_InventoryPurchase_lbl" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_LicenseUpfrontFeeAndRelatedExpensesPaid" xlink:type="locator" xlink:label="ortx_LicenseUpfrontFeeAndRelatedExpensesPaid" />
    <link:label xml:lang="en-US" xlink:label="ortx_LicenseUpfrontFeeAndRelatedExpensesPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License upfront fee and related expenses paid.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_LicenseUpfrontFeeAndRelatedExpensesPaid" xlink:to="ortx_LicenseUpfrontFeeAndRelatedExpensesPaid_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions By Related Party [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Domain]</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_GSKMember" xlink:type="locator" xlink:label="ortx_GSKMember" />
    <link:label xml:lang="en-US" xlink:label="ortx_GSKMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">GSK</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_GSKMember" xlink:to="ortx_GSKMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ortx_GSKMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">GSK</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_GSKMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">G S K [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_LicenseUpfrontFeeAndRelatedExpensesPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License upfront fee</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_LicenseUpfrontFeeAndRelatedExpensesPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Upfront Fee And Related Expenses Paid</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_InventoryPurchase_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory purchased</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_InventoryPurchase_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Purchase</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Ordinary shares Issuable Upon Conversion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock Shares Issued Upon Conversion</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock, Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Value</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProvisionForLossOnContracts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Loss provision associated with contract</link:label>
    <link:loc xlink:href="ortx-20211231.xsd#ortx_AccruedExpensesRelatedPartyCurrent" xlink:type="locator" xlink:label="ortx_AccruedExpensesRelatedPartyCurrent" />
    <link:label xml:lang="en-US" xlink:label="ortx_AccruedExpensesRelatedPartyCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued expenses related party current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ortx_AccruedExpensesRelatedPartyCurrent" xlink:to="ortx_AccruedExpensesRelatedPartyCurrent_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Due to related party transactions, accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Related Parties Current</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_AccruedExpensesRelatedPartyCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Due to related party transactions, accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="ortx_AccruedExpensesRelatedPartyCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Expenses Related Party Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payments on accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Payable</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:type="locator" xlink:label="us-gaap_RestructuringAndRelatedCostExpectedCost1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestructuringAndRelatedCostExpectedCost1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated aggregate restructuring charges in first half of 2022</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:to="us-gaap_RestructuringAndRelatedCostExpectedCost1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestructuringAndRelatedCostExpectedCost1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring And Related Cost Expected Cost1</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>15
<FILENAME>ortx-20211231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-03-30T03:21:51.5007884+00:00 -->
<!-- Version            : 5.0.1.728 -->
<!-- Package ID         : 1b558024b59f49cabedb23f437fea13f -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/role/TemplateLink" xlink:href="ortx-20211231.xsd#TemplateLink" xlink:type="simple" />
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="ortx-20211231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="locator" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:type="locator" xlink:label="dei_AuditorLocation" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:type="locator" xlink:label="dei_AuditorName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:type="locator" xlink:label="dei_AuditorFirmId" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:type="locator" xlink:label="dei_EntityAddressCountry" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:type="locator" xlink:label="dei_DocumentAnnualReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:type="locator" xlink:label="dei_EntityPublicFloat" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCountry" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="11250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="11270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="11290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="11310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="11330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="11350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:href="ortx-20211231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:type="locator" xlink:label="us-gaap_LongTermNotesPayable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:type="locator" xlink:label="us-gaap_NotesPayableCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_AccruedExpensesAndOtherCurrentLiabilities" xlink:type="locator" xlink:label="ortx_AccruedExpensesAndOtherCurrentLiabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrentAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ResearchAndDevelopmentTaxCreditReceivableCurrent" xlink:type="locator" xlink:label="ortx_ResearchAndDevelopmentTaxCreditReceivableCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecurities" xlink:type="locator" xlink:label="us-gaap_MarketableSecurities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecurities" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="ortx_ResearchAndDevelopmentTaxCreditReceivableCurrent" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrent" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="11020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="11060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="11140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="11220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="ortx_AccruedExpensesAndOtherCurrentLiabilities" order="11260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="11300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="11340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_NotesPayableCurrent" order="11380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="11420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LongTermNotesPayable" order="11460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="11500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="11540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="11580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="11620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="11660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="11700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="11780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="11820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="11860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="11900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="11940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="11980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:href="ortx-20211231.xsd#Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_CommonStockSharesAuthorizedNominalAmount" xlink:type="locator" xlink:label="ortx_CommonStockSharesAuthorizedNominalAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="ortx_CommonStockSharesAuthorizedNominalAmount" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="ortx-20211231.xsd#Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:type="locator" xlink:label="us-gaap_InterestExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses" xlink:type="locator" xlink:label="us-gaap_CostsAndExpenses" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfCostGoodOrServiceExtensibleList" xlink:type="locator" xlink:label="us-gaap_TypeOfCostGoodOrServiceExtensibleList" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingCostsAndExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_CollaborationMember" xlink:type="locator" xlink:label="ortx_CollaborationMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember" xlink:type="locator" xlink:label="us-gaap_ProductMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ortx_CollaborationMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingCostsAndExpensesAbstract" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_TypeOfCostGoodOrServiceExtensibleList" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpenses" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpense" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="11250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="11290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="11330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="11370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity" xlink:href="ortx-20211231.xsd#Role_StatementConsolidatedStatementsOfShareholdersEquity" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_StockIssuedDuringPeriodSharesAsPartOfCollaborationAgreement" xlink:type="locator" xlink:label="ortx_StockIssuedDuringPeriodSharesAsPartOfCollaborationAgreement" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_StockIssuedDuringPeriodValueAsPartOfCollaborationAgreement" xlink:type="locator" xlink:label="ortx_StockIssuedDuringPeriodValueAsPartOfCollaborationAgreement" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_StockIssuedDuringPeriodSharesAsPartOfConsultingAgreement" xlink:type="locator" xlink:label="ortx_StockIssuedDuringPeriodSharesAsPartOfConsultingAgreement" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_StockIssuedDuringPeriodValueAsPartOfConsultingAgreement" xlink:type="locator" xlink:label="ortx_StockIssuedDuringPeriodValueAsPartOfConsultingAgreement" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:type="locator" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" xlink:type="locator" xlink:label="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ortx_StockIssuedDuringPeriodValueAsPartOfConsultingAgreement" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ortx_StockIssuedDuringPeriodSharesAsPartOfConsultingAgreement" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="11190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ortx_StockIssuedDuringPeriodValueAsPartOfCollaborationAgreement" order="11590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ortx_StockIssuedDuringPeriodSharesAsPartOfCollaborationAgreement" order="11610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="11730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss" order="11870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="12010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_li0l2" order="12150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_li0l2" order="12170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquityParenthetical" xlink:href="ortx-20211231.xsd#Role_StatementConsolidatedStatementsOfShareholdersEquityParenthetical" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquityParenthetical">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="ortx-20211231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaidNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_EmployeeEquityPlanProceedsReceived" xlink:type="locator" xlink:label="ortx_EmployeeEquityPlanProceedsReceived" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssued1" xlink:type="locator" xlink:label="us-gaap_StockIssued1" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_IntangibleAssetsAndPropertyAndEquipmentInAccountsPayableAndAccruedExpenses" xlink:type="locator" xlink:label="ortx_IntangibleAssetsAndPropertyAndEquipmentInAccountsPayableAndAccruedExpenses" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ProceedsFromIssuanceOfSharesAsPartOfCollaborationAgreement" xlink:type="locator" xlink:label="ortx_ProceedsFromIssuanceOfSharesAsPartOfCollaborationAgreement" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_PaymentOfTaxesOnRestrictedStockVesting" xlink:type="locator" xlink:label="ortx_PaymentOfTaxesOnRestrictedStockVesting" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockPlans" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ReceiptOfFundsFromConstructionDeposit" xlink:type="locator" xlink:label="ortx_ReceiptOfFundsFromConstructionDeposit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:type="locator" xlink:label="ortx_IncreaseDecreaseInOperatingLeaseLiabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="locator" xlink:label="ortx_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesAndOtherOperatingLiabilities" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_IncreaseDecreaseInOperatingRightOfUseAssets" xlink:type="locator" xlink:label="ortx_IncreaseDecreaseInOperatingRightOfUseAssets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable" xlink:type="locator" xlink:label="ortx_IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_UnrealizedForeignCurrencyAndOtherNonCashAdjustments" xlink:type="locator" xlink:label="ortx_UnrealizedForeignCurrencyAndOtherNonCashAdjustments" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_AmortizationOfPremiumOnMarketableSecurities" xlink:type="locator" xlink:label="ortx_AmortizationOfPremiumOnMarketableSecurities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_NonCashConsiderationForLicensesAndMilestones" xlink:type="locator" xlink:label="ortx_NonCashConsiderationForLicensesAndMilestones" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_AmortizationOfProvisionOnLossContract" xlink:type="locator" xlink:label="ortx_AmortizationOfProvisionOnLossContract" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_NonCashInterestExpense" xlink:type="locator" xlink:label="ortx_NonCashInterestExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:type="locator" xlink:label="us-gaap_AssetImpairmentCharges" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AssetImpairmentCharges" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ortx_NonCashInterestExpense" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ortx_AmortizationOfProvisionOnLossContract" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ortx_NonCashConsiderationForLicensesAndMilestones" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ortx_AmortizationOfPremiumOnMarketableSecurities" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ortx_UnrealizedForeignCurrencyAndOtherNonCashAdjustments" order="10870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="ortx_IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="11070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="ortx_IncreaseDecreaseInOperatingRightOfUseAssets" order="11110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="ortx_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesAndOtherOperatingLiabilities" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="11190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" order="11230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="ortx_IncreaseDecreaseInOperatingLeaseLiabilities" order="11270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="11310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="11350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="11430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="11470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit" order="11510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="ortx_ReceiptOfFundsFromConstructionDeposit" order="11550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets" order="11590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="11630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="11670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="11710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" order="11790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockPlans" order="11830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ortx_PaymentOfTaxesOnRestrictedStockVesting" order="11870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ortx_ProceedsFromIssuanceOfSharesAsPartOfCollaborationAgreement" order="11910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="11950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="11990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="12030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="12070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="12110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="12150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_li0l2" order="12190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="12230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="ortx_IntangibleAssetsAndPropertyAndEquipmentInAccountsPayableAndAccruedExpenses" order="12310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_StockIssued1" order="12350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="ortx_EmployeeEquityPlanProceedsReceived" order="12390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="12430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="12510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="12550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaidNet" order="12590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentation" xlink:href="ortx-20211231.xsd#Role_DisclosureNatureOfBusinessAndBasisOfPresentation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentation">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="ortx-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecurities" xlink:href="ortx-20211231.xsd#Role_DisclosureFairValueMeasurementsAndMarketableSecurities" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecurities">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRevenueRecognition" xlink:href="ortx-20211231.xsd#Role_DisclosureRevenueRecognition" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRevenueRecognition">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssets" xlink:href="ortx-20211231.xsd#Role_DisclosurePrepaidExpensesAndOtherCurrentAssets" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssets">
    <link:loc xlink:href="ortx-20211231.xsd#ortx_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:type="locator" xlink:label="ortx_PrepaidExpensesAndOtherCurrentAssetsTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="ortx_PrepaidExpensesAndOtherCurrentAssetsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipment" xlink:href="ortx-20211231.xsd#Role_DisclosurePropertyAndEquipment" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipment">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIntangibleAssetsNet" xlink:href="ortx-20211231.xsd#Role_DisclosureIntangibleAssetsNet" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIntangibleAssetsNet">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureOtherAssets" xlink:href="ortx-20211231.xsd#Role_DisclosureOtherAssets" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureOtherAssets">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_OtherAssetsDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrentDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrentDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsNoncurrentDisclosureAbstract" xlink:to="us-gaap_OtherAssetsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherLiabilities" xlink:href="ortx-20211231.xsd#Role_DisclosureAccruedExpensesAndOtherLiabilities" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherLiabilities">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRestructuringCharges" xlink:href="ortx-20211231.xsd#Role_DisclosureRestructuringCharges" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRestructuringCharges">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeases" xlink:href="ortx-20211231.xsd#Role_DisclosureLeases" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeases">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayable" xlink:href="ortx-20211231.xsd#Role_DisclosureNotesPayable" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayable">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareholdersEquityAndConvertiblePreferredShares" xlink:href="ortx-20211231.xsd#Role_DisclosureShareholdersEquityAndConvertiblePreferredShares" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareholdersEquityAndConvertiblePreferredShares">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ShareholdersEquityAndConvertiblePreferredSharesAbstract" xlink:type="locator" xlink:label="ortx_ShareholdersEquityAndConvertiblePreferredSharesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_ShareholdersEquityAndConvertiblePreferredSharesAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensation" xlink:href="ortx-20211231.xsd#Role_DisclosureShareBasedCompensation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensation">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLicenseAndResearchAgreements" xlink:href="ortx-20211231.xsd#Role_DisclosureLicenseAndResearchAgreements" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLicenseAndResearchAgreements">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_LicenseAndResearchArrangementsAbstract" xlink:type="locator" xlink:label="ortx_LicenseAndResearchArrangementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_LicenseAndResearchArrangementsAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCollaborationAgreementWithPharmingGroupNV" xlink:href="ortx-20211231.xsd#Role_DisclosureCollaborationAgreementWithPharmingGroupNV" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCollaborationAgreementWithPharmingGroupNV">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_CollaborativeArrangementAbstract" xlink:type="locator" xlink:label="ortx_CollaborativeArrangementAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_CollaborativeArrangementAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxes" xlink:href="ortx-20211231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxes">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingencies" xlink:href="ortx-20211231.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingencies">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureBenefitPlans" xlink:href="ortx-20211231.xsd#Role_DisclosureBenefitPlans" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureBenefitPlans">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactions" xlink:href="ortx-20211231.xsd#Role_DisclosureRelatedPartyTransactions" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactions">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSubsequentEvents" xlink:href="ortx-20211231.xsd#Role_DisclosureSubsequentEvents" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSubsequentEvents">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="ortx-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ResearchAndDevelopmentIncomeTaxCreditsPolicyTextBlock" xlink:type="locator" xlink:label="ortx_ResearchAndDevelopmentIncomeTaxCreditsPolicyTextBlock" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_StrimvelisLossProvisionPolicyTextBlock" xlink:type="locator" xlink:label="ortx_StrimvelisLossProvisionPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ResearchContractCostsAndAccrualsPolicyTextBlock" xlink:type="locator" xlink:label="ortx_ResearchContractCostsAndAccrualsPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesPolicy" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ortx_ResearchContractCostsAndAccrualsPolicyTextBlock" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ortx_StrimvelisLossProvisionPolicyTextBlock" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ortx_ResearchAndDevelopmentIncomeTaxCreditsPolicyTextBlock" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:href="ortx-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock" xlink:type="locator" xlink:label="us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ScheduleOfChangesInLossProvisionTableTextBlock" xlink:type="locator" xlink:label="ortx_ScheduleOfChangesInLossProvisionTableTextBlock" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_PropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:type="locator" xlink:label="ortx_PropertyPlantAndEquipmentUsefulLifeTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ortx_PropertyPlantAndEquipmentUsefulLifeTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ortx_ScheduleOfChangesInLossProvisionTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesTables" xlink:href="ortx-20211231.xsd#Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="locator" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" xlink:href="ortx-20211231.xsd#Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentTables" xlink:href="ortx-20211231.xsd#Role_DisclosurePropertyAndEquipmentTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIntangibleAssetsNetTables" xlink:href="ortx-20211231.xsd#Role_DisclosureIntangibleAssetsNetTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIntangibleAssetsNetTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ScheduleOfIntangibleAssetsNetOfAccumulatedAmortizationTableTextBlock" xlink:type="locator" xlink:label="ortx_ScheduleOfIntangibleAssetsNetOfAccumulatedAmortizationTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="ortx_ScheduleOfIntangibleAssetsNetOfAccumulatedAmortizationTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureOtherAssetsTables" xlink:href="ortx-20211231.xsd#Role_DisclosureOtherAssetsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureOtherAssetsTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrentDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrentDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsNoncurrentDisclosureAbstract" xlink:to="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherLiabilitiesTables" xlink:href="ortx-20211231.xsd#Role_DisclosureAccruedExpensesAndOtherLiabilitiesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherLiabilitiesTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRestructuringChargesTables" xlink:href="ortx-20211231.xsd#Role_DisclosureRestructuringChargesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRestructuringChargesTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DetailsOfImpairmentOfLongLivedAssetsHeldAndUsedByAssetTextBlock" xlink:type="locator" xlink:label="us-gaap_DetailsOfImpairmentOfLongLivedAssetsHeldAndUsedByAssetTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_DetailsOfImpairmentOfLongLivedAssetsHeldAndUsedByAssetTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesTables" xlink:href="ortx-20211231.xsd#Role_DisclosureLeasesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableTables" xlink:href="ortx-20211231.xsd#Role_DisclosureNotesPayableTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationTables" xlink:href="ortx-20211231.xsd#Role_DisclosureShareBasedCompensationTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCollaborationAgreementWithPharmingGroupNVTables" xlink:href="ortx-20211231.xsd#Role_DisclosureCollaborationAgreementWithPharmingGroupNVTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCollaborationAgreementWithPharmingGroupNVTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_CollaborativeArrangementAbstract" xlink:type="locator" xlink:label="ortx_CollaborativeArrangementAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_CollaborativeArrangementAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:href="ortx-20211231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:type="locator" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_SummaryOfValuationAllowanceTextBlock" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" xlink:href="ortx-20211231.xsd#Role_DisclosureCommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables">
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:type="locator" xlink:label="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_NetProceedsFromIssuanceOfPrivatePlacement" xlink:type="locator" xlink:label="ortx_NetProceedsFromIssuanceOfPrivatePlacement" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockTransactionDate" xlink:type="locator" xlink:label="us-gaap_SaleOfStockTransactionDate" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_PaymentsOfOtherIssuanceCosts" xlink:type="locator" xlink:label="ortx_PaymentsOfOtherIssuanceCosts" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ClosingPriceOfShareDate" xlink:type="locator" xlink:label="ortx_ClosingPriceOfShareDate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:type="locator" xlink:label="ortx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_NonVotingOrdinarySharesMember" xlink:type="locator" xlink:label="ortx_NonVotingOrdinarySharesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_SecuritiesPurchaseAgreementMember" xlink:type="locator" xlink:label="ortx_SecuritiesPurchaseAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:type="locator" xlink:label="ortx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="ortx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ortx_SecuritiesPurchaseAgreementMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="ortx_NonVotingOrdinarySharesMember" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="ortx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="ortx_ClosingPriceOfShareDate" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="ortx_PaymentsOfOtherIssuanceCosts" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_SaleOfStockTransactionDate" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="ortx_NetProceedsFromIssuanceOfPrivatePlacement" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_NetIncomeLoss" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleDescription" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleDescription" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_IncrementalPercentageOfTaxableProfits" xlink:type="locator" xlink:label="ortx_IncrementalPercentageOfTaxableProfits" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ResearchAndDevelopmentTaxCreditReceivableCurrent" xlink:type="locator" xlink:label="ortx_ResearchAndDevelopmentTaxCreditReceivableCurrent" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ResearchAndDevelopmentTaxCreditReceivable" xlink:type="locator" xlink:label="ortx_ResearchAndDevelopmentTaxCreditReceivable" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_AdditionalIncomeTaxCredits" xlink:type="locator" xlink:label="ortx_AdditionalIncomeTaxCredits" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_AssetAcquisitionLiabilityAssumedNonCurrent" xlink:type="locator" xlink:label="ortx_AssetAcquisitionLiabilityAssumedNonCurrent" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_AssetAcquisitionLiabilityAssumedCurrent" xlink:type="locator" xlink:label="ortx_AssetAcquisitionLiabilityAssumedCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForLossOnContracts" xlink:type="locator" xlink:label="us-gaap_ProvisionForLossOnContracts" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_IncreaseDecreaseInEscrowDeposit" xlink:type="locator" xlink:label="ortx_IncreaseDecreaseInEscrowDeposit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EscrowDeposit" xlink:type="locator" xlink:label="us-gaap_EscrowDeposit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCollateralForBorrowedSecurities" xlink:type="locator" xlink:label="us-gaap_CashCollateralForBorrowedSecurities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:type="locator" xlink:label="us-gaap_ProceedsFromLinesOfCredit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="ortx_SummaryOfSignificantAccountingPoliciesLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember" xlink:type="locator" xlink:label="us-gaap_ProductMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:type="locator" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_FremontLeaseAgreementMember" xlink:type="locator" xlink:label="ortx_FremontLeaseAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermAxis" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_GBAndEuropeanUnionMember" xlink:type="locator" xlink:label="ortx_GBAndEuropeanUnionMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US" xlink:type="locator" xlink:label="country_US" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_GB" xlink:type="locator" xlink:label="country_GB" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_SummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="ortx_SummaryOfSignificantAccountingPoliciesTable" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_SummaryOfSignificantAccountingPoliciesAbstract" xlink:type="locator" xlink:label="ortx_SummaryOfSignificantAccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_SummaryOfSignificantAccountingPoliciesAbstract" xlink:to="ortx_SummaryOfSignificantAccountingPoliciesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_StatementGeographicalAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_GB" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="ortx_GBAndEuropeanUnionMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_LeaseContractualTermAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="ortx_FremontLeaseAgreementMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_ProductOrServiceAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="ortx_SummaryOfSignificantAccountingPoliciesLineItems" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProceedsFromLinesOfCredit" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CashCollateralForBorrowedSecurities" order="11160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_EscrowDeposit" order="11230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="ortx_IncreaseDecreaseInEscrowDeposit" order="11270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProvisionForLossOnContracts" order="11340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="ortx_AssetAcquisitionLiabilityAssumedCurrent" order="11390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="ortx_AssetAcquisitionLiabilityAssumedNonCurrent" order="11430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="ortx_AdditionalIncomeTaxCredits" order="11500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="ortx_ResearchAndDevelopmentTaxCreditReceivable" order="11550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="ortx_ResearchAndDevelopmentTaxCreditReceivableCurrent" order="11590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="ortx_IncrementalPercentageOfTaxableProfits" order="11660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="11710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" order="11780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" order="11800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleDescription" order="11820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_SummaryOfSignificantAccountingPoliciesAbstract" xlink:type="locator" xlink:label="ortx_SummaryOfSignificantAccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_SummaryOfSignificantAccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_SummaryOfSignificantAccountingPoliciesAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_SummaryOfSignificantAccountingPoliciesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_OfficeAndComputerEquipmentMember" xlink:type="locator" xlink:label="ortx_OfficeAndComputerEquipmentMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_LabEquipmentMember" xlink:type="locator" xlink:label="ortx_LabEquipmentMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="ortx_LabEquipmentMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="ortx_OfficeAndComputerEquipmentMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfChangesInLossProvisionDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfChangesInLossProvisionDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfChangesInLossProvisionDetails">
    <link:loc xlink:href="ortx-20211231.xsd#ortx_AssetAcquisitionLiabilityAssumed" xlink:type="locator" xlink:label="ortx_AssetAcquisitionLiabilityAssumed_li0l2" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_IncreaseDecreaseInAssetAcquisitionLiabilityEffectOfForeignExchangeTranslation" xlink:type="locator" xlink:label="ortx_IncreaseDecreaseInAssetAcquisitionLiabilityEffectOfForeignExchangeTranslation" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_AssetAcquisitionLiabilityAmortizationOfLossProvision" xlink:type="locator" xlink:label="ortx_AssetAcquisitionLiabilityAmortizationOfLossProvision" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_AssetAcquisitionLiabilityProvision" xlink:type="locator" xlink:label="ortx_AssetAcquisitionLiabilityProvision" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_AssetAcquisitionLiabilityAssumed" xlink:type="locator" xlink:label="ortx_AssetAcquisitionLiabilityAssumed" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_SummaryOfSignificantAccountingPoliciesAbstract" xlink:type="locator" xlink:label="ortx_SummaryOfSignificantAccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_SummaryOfSignificantAccountingPoliciesAbstract" xlink:to="ortx_AssetAcquisitionLiabilityAssumed" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_SummaryOfSignificantAccountingPoliciesAbstract" xlink:to="ortx_AssetAcquisitionLiabilityProvision" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_SummaryOfSignificantAccountingPoliciesAbstract" xlink:to="ortx_AssetAcquisitionLiabilityAmortizationOfLossProvision" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_SummaryOfSignificantAccountingPoliciesAbstract" xlink:to="ortx_IncreaseDecreaseInAssetAcquisitionLiabilityEffectOfForeignExchangeTranslation" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_SummaryOfSignificantAccountingPoliciesAbstract" xlink:to="ortx_AssetAcquisitionLiabilityAssumed_li0l2" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfAmountsRecognizedToOffsetResearchAndDevelopmentExpenseDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfAmountsRecognizedToOffsetResearchAndDevelopmentExpenseDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfAmountsRecognizedToOffsetResearchAndDevelopmentExpenseDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCredits" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxCreditsAndAdjustments" xlink:type="locator" xlink:label="us-gaap_IncomeTaxCreditsAndAdjustments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="ortx_SummaryOfSignificantAccountingPoliciesLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_GB" xlink:type="locator" xlink:label="country_GB" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_SummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="ortx_SummaryOfSignificantAccountingPoliciesTable" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_SummaryOfSignificantAccountingPoliciesAbstract" xlink:type="locator" xlink:label="ortx_SummaryOfSignificantAccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_SummaryOfSignificantAccountingPoliciesAbstract" xlink:to="ortx_SummaryOfSignificantAccountingPoliciesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_StatementGeographicalAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_GB" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="ortx_SummaryOfSignificantAccountingPoliciesLineItems" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_IncomeTaxCreditsAndAdjustments" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount_li0l2" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSecuritiesExcludedInComputationOfDilutedNetLossPerOrdinaryShareDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesSecuritiesExcludedInComputationOfDilutedNetLossPerOrdinaryShareDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSecuritiesExcludedInComputationOfDilutedNetLossPerOrdinaryShareDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_UnvestedSharesFromSharePlanAndConsultingAgreementMember" xlink:type="locator" xlink:label="ortx_UnvestedSharesFromSharePlanAndConsultingAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_SummaryOfSignificantAccountingPoliciesAbstract" xlink:type="locator" xlink:label="ortx_SummaryOfSignificantAccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_SummaryOfSignificantAccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="ortx_UnvestedSharesFromSharePlanAndConsultingAgreementMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAdditionalInformationDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesScheduleOfCashEquivalentsAndMarketableSecuritiesDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesScheduleOfCashEquivalentsAndMarketableSecuritiesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesScheduleOfCashEquivalentsAndMarketableSecuritiesDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_MarketableSecuritiesFairValueDisclosure" xlink:type="locator" xlink:label="ortx_MarketableSecuritiesFairValueDisclosure" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_CashEquivalentsAbstract" xlink:type="locator" xlink:label="ortx_CashEquivalentsAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:type="locator" xlink:label="us-gaap_USTreasuryAndGovernmentMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CommercialPaperMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USTreasuryAndGovernmentMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10050.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="ortx_CashEquivalentsAbstract" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_CashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_MarketableSecuritiesAbstract" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="ortx_MarketableSecuritiesFairValueDisclosure" order="11250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" order="11570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesScheduleOfLevel2CashEquivalentsAndMarketableSecuritiesDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesScheduleOfLevel2CashEquivalentsAndMarketableSecuritiesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesScheduleOfLevel2CashEquivalentsAndMarketableSecuritiesDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:type="locator" xlink:label="us-gaap_USTreasuryAndGovernmentMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="10070.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USTreasuryAndGovernmentMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CommercialPaperMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesScheduleOfAvailableForSaleMarketableDebtSecuritiesByContractualMaturityDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureFairValueMeasurementsAndMarketableSecuritiesScheduleOfAvailableForSaleMarketableDebtSecuritiesByContractualMaturityDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesScheduleOfAvailableForSaleMarketableDebtSecuritiesByContractualMaturityDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsAmortizedCost" xlink:type="locator" xlink:label="ortx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsAmortizedCost" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="ortx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsAmortizedCost" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureRevenueRecognitionAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails">
    <link:loc xlink:href="ortx-20211231.xsd#ortx_GeneralPaymentTermsMaximum" xlink:type="locator" xlink:label="ortx_GeneralPaymentTermsMaximum" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="ortx_GeneralPaymentTermsMaximum" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="ortx-20211231.xsd#Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NontradeReceivablesCurrent" xlink:type="locator" xlink:label="us-gaap_NontradeReceivablesCurrent" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ConstructionDepositsCurrent" xlink:type="locator" xlink:label="ortx_ConstructionDepositsCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValueAddedTaxReceivableCurrent" xlink:type="locator" xlink:label="us-gaap_ValueAddedTaxReceivableCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" xlink:label="us-gaap_InventoryNet" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_PrepaidExternalResearchAndDevelopmentExpenses" xlink:type="locator" xlink:label="ortx_PrepaidExternalResearchAndDevelopmentExpenses" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="ortx_PrepaidExternalResearchAndDevelopmentExpenses" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_ValueAddedTaxReceivableCurrent" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="ortx_ConstructionDepositsCurrent" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_NontradeReceivablesCurrent" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:href="ortx-20211231.xsd#Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_OfficeAndITEquipmentMember" xlink:type="locator" xlink:label="ortx_OfficeAndITEquipmentMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_LabEquipmentMember" xlink:type="locator" xlink:label="ortx_LabEquipmentMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="ortx_LabEquipmentMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="ortx_OfficeAndITEquipmentMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails" xlink:href="ortx-20211231.xsd#Role_DisclosurePropertyAndEquipmentAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_Depreciation" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfIntangibleAssetsNetOfAccumulatedAmortizationDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureIntangibleAssetsNetScheduleOfIntangibleAssetsNetOfAccumulatedAmortizationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfIntangibleAssetsNetOfAccumulatedAmortizationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember" xlink:type="locator" xlink:label="us-gaap_LicenseMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_LicenseMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIntangibleAssetsNetAdditionalInformationDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureIntangibleAssetsNetAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIntangibleAssetsNetAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfEstimatedFutureAmortizationForIntangibleAssetsDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureIntangibleAssetsNetScheduleOfEstimatedFutureAmortizationForIntangibleAssetsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfEstimatedFutureAmortizationForIntangibleAssetsDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureOtherAssetsScheduleOfOtherAssetsDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureOtherAssetsScheduleOfOtherAssetsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureOtherAssetsScheduleOfOtherAssetsDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ConstructionDepositsLongTerm" xlink:type="locator" xlink:label="ortx_ConstructionDepositsLongTerm" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_OtherNonCurrentAssets" xlink:type="locator" xlink:label="ortx_OtherNonCurrentAssets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:type="locator" xlink:label="us-gaap_DeferredFinanceCostsNoncurrentNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_DepositsAssetsNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrentDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrentDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsNoncurrentDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsNoncurrentDisclosureAbstract" xlink:to="us-gaap_DepositsAssetsNoncurrent" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsNoncurrentDisclosureAbstract" xlink:to="us-gaap_DeferredFinanceCostsNoncurrentNet" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsNoncurrentDisclosureAbstract" xlink:to="ortx_OtherNonCurrentAssets" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsNoncurrentDisclosureAbstract" xlink:to="ortx_ConstructionDepositsLongTerm" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsNoncurrentDisclosureAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureAccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails">
    <link:loc xlink:href="ortx-20211231.xsd#ortx_AccruedExpensesAndOtherCurrentLiabilities" xlink:type="locator" xlink:label="ortx_AccruedExpensesAndOtherCurrentLiabilities" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ProductLiabilityCurrentPortion" xlink:type="locator" xlink:label="ortx_ProductLiabilityCurrentPortion" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_AccruedMilestonePaymentsCurrent" xlink:type="locator" xlink:label="ortx_AccruedMilestonePaymentsCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_AccruedExternalResearchAndDevelopmentExpensesCurrent" xlink:type="locator" xlink:label="ortx_AccruedExternalResearchAndDevelopmentExpensesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="ortx_AccruedExternalResearchAndDevelopmentExpensesCurrent" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="ortx_AccruedMilestonePaymentsCurrent" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="ortx_ProductLiabilityCurrentPortion" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="ortx_AccruedExpensesAndOtherCurrentLiabilities" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRestructuringChargesAdditionalInformationDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureRestructuringChargesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRestructuringChargesAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseImpairmentLoss" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_OperatingLeaseRightOfUseAssetFairValue" xlink:type="locator" xlink:label="ortx_OperatingLeaseRightOfUseAssetFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ImpairmentOfConstructionInProcess" xlink:type="locator" xlink:label="ortx_ImpairmentOfConstructionInProcess" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges" xlink:type="locator" xlink:label="us-gaap_RestructuringCharges" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:type="locator" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:type="locator" xlink:label="us-gaap_RestructuringCostAndReserveLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_FremontCaliforniaMember" xlink:type="locator" xlink:label="ortx_FremontCaliforniaMember" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_MenloParkCaliforniaMember" xlink:type="locator" xlink:label="ortx_MenloParkCaliforniaMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanDomain" xlink:type="locator" xlink:label="us-gaap_RestructuringPlanDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanAxis" xlink:type="locator" xlink:label="us-gaap_RestructuringPlanAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringPlanAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringPlanAxis" xlink:to="us-gaap_RestructuringPlanDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringPlanDomain" xlink:to="ortx_MenloParkCaliforniaMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringPlanDomain" xlink:to="ortx_FremontCaliforniaMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="srt_RangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringCostAndReserveLineItems" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringCharges" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="ortx_ImpairmentOfConstructionInProcess" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="ortx_OperatingLeaseRightOfUseAssetFairValue" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_OperatingLeaseImpairmentLoss" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRestructuringChargesSummaryOfCashRestructuringChargesDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureRestructuringChargesSummaryOfCashRestructuringChargesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRestructuringChargesSummaryOfCashRestructuringChargesDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve" xlink:type="locator" xlink:label="us-gaap_RestructuringReserve_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRestructuring" xlink:type="locator" xlink:label="us-gaap_PaymentsForRestructuring" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges" xlink:type="locator" xlink:label="us-gaap_RestructuringCharges" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve" xlink:type="locator" xlink:label="us-gaap_RestructuringReserve" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_RestructuringReserve" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_RestructuringCharges" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_PaymentsForRestructuring" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_RestructuringReserve_li0l2" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRestructuringChargesSummaryOfImpairmentOfLongLivedAssetsDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureRestructuringChargesSummaryOfImpairmentOfLongLivedAssetsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRestructuringChargesSummaryOfImpairmentOfLongLivedAssetsDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:type="locator" xlink:label="us-gaap_AssetImpairmentCharges" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ImpairmentOfLaboratoryEquipment" xlink:type="locator" xlink:label="ortx_ImpairmentOfLaboratoryEquipment" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ImpairmentOfConstructionInProcess" xlink:type="locator" xlink:label="ortx_ImpairmentOfConstructionInProcess" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseImpairmentLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseImpairmentLoss" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="ortx_ImpairmentOfConstructionInProcess" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="ortx_ImpairmentOfLaboratoryEquipment" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_AssetImpairmentCharges" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureLeasesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails">
    <link:loc xlink:href="ortx-20211231.xsd#ortx_OperatingLeaseRightOfUseAssetValueExchangeForLeaseLiabilities" xlink:type="locator" xlink:label="ortx_OperatingLeaseRightOfUseAssetValueExchangeForLeaseLiabilities" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_LeaseComponentManufacturingCommitmentAmount" xlink:type="locator" xlink:label="ortx_LeaseComponentManufacturingCommitmentAmount" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_LesseeOperatingLeaseExtendedTerm" xlink:type="locator" xlink:label="ortx_LesseeOperatingLeaseExtendedTerm" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_IncreaseDecreaseInEscrowDeposit" xlink:type="locator" xlink:label="ortx_IncreaseDecreaseInEscrowDeposit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EscrowDeposit" xlink:type="locator" xlink:label="us-gaap_EscrowDeposit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecurityDeposit" xlink:type="locator" xlink:label="us-gaap_SecurityDeposit" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_TenantImprovementAllowance" xlink:type="locator" xlink:label="ortx_TenantImprovementAllowance" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:type="locator" xlink:label="us-gaap_ProceedsFromLinesOfCredit" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ReductionOfStandbyLetterOfCreditAmountPercentage" xlink:type="locator" xlink:label="ortx_ReductionOfStandbyLetterOfCreditAmountPercentage" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_OperatingLeasesCommencedTerm" xlink:type="locator" xlink:label="ortx_OperatingLeasesCommencedTerm" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome" xlink:type="locator" xlink:label="us-gaap_SubleaseIncome" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_OperatingLeaseDurationForFreeRent" xlink:type="locator" xlink:label="ortx_OperatingLeaseDurationForFreeRent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRent" xlink:type="locator" xlink:label="us-gaap_PaymentsForRent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_OperatingLeasesLineItems" xlink:type="locator" xlink:label="ortx_OperatingLeasesLineItems" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_GSKAgreementMember" xlink:type="locator" xlink:label="ortx_GSKAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="locator" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_FremontSubleaseAgreementMember" xlink:type="locator" xlink:label="ortx_FremontSubleaseAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_FremontLeaseAgreementMember" xlink:type="locator" xlink:label="ortx_FremontLeaseAgreementMember" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_BostonAndLondonOfficeSpaceLeaseAgreementsMember" xlink:type="locator" xlink:label="ortx_BostonAndLondonOfficeSpaceLeaseAgreementsMember" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_LeaseTermTerminatesInSeptemberTwoThousandTwentySixMember" xlink:type="locator" xlink:label="ortx_LeaseTermTerminatesInSeptemberTwoThousandTwentySixMember" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_OfficeSpaceBostonUnitedStatesLeaseAgreementMember" xlink:type="locator" xlink:label="ortx_OfficeSpaceBostonUnitedStatesLeaseAgreementMember" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_LeaseTermTerminatesInSeptemberTwoThousandTwentyTwoMember" xlink:type="locator" xlink:label="ortx_LeaseTermTerminatesInSeptemberTwoThousandTwentyTwoMember" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_RentalLabSpaceMember" xlink:type="locator" xlink:label="ortx_RentalLabSpaceMember" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_OfficeSpaceLondonUnitedKingdomLeaseAgreementMember" xlink:type="locator" xlink:label="ortx_OfficeSpaceLondonUnitedKingdomLeaseAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_FiveYearsLeaseTermTerminatesInJanuaryTwoThousandTwentyThreeMember" xlink:type="locator" xlink:label="ortx_FiveYearsLeaseTermTerminatesInJanuaryTwoThousandTwentyThreeMember" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_OfficeAndLaboratorySpaceMenloParkLeaseAgreementMember" xlink:type="locator" xlink:label="ortx_OfficeAndLaboratorySpaceMenloParkLeaseAgreementMember" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_LaboratorySpaceMenloParkLeaseAgreementMember" xlink:type="locator" xlink:label="ortx_LaboratorySpaceMenloParkLeaseAgreementMember" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_OfficeSpaceMenloParkLeaseAgreementMember" xlink:type="locator" xlink:label="ortx_OfficeSpaceMenloParkLeaseAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermAxis" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_OperatingLeasesTable" xlink:type="locator" xlink:label="ortx_OperatingLeasesTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="ortx_OperatingLeasesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_OperatingLeasesTable" xlink:to="us-gaap_LeaseContractualTermAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="ortx_OfficeSpaceMenloParkLeaseAgreementMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="ortx_LaboratorySpaceMenloParkLeaseAgreementMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="ortx_OfficeAndLaboratorySpaceMenloParkLeaseAgreementMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="ortx_FiveYearsLeaseTermTerminatesInJanuaryTwoThousandTwentyThreeMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_OperatingLeasesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="ortx_OfficeSpaceLondonUnitedKingdomLeaseAgreementMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="ortx_RentalLabSpaceMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="ortx_LeaseTermTerminatesInSeptemberTwoThousandTwentyTwoMember" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="ortx_OfficeSpaceBostonUnitedStatesLeaseAgreementMember" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="ortx_LeaseTermTerminatesInSeptemberTwoThousandTwentySixMember" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="ortx_BostonAndLondonOfficeSpaceLeaseAgreementsMember" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="ortx_FremontLeaseAgreementMember" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_OperatingLeasesTable" xlink:to="srt_RangeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="11060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="ortx_FremontSubleaseAgreementMember" order="11320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_OperatingLeasesTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="11460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember" order="11480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="ortx_GSKAgreementMember" order="11540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_OperatingLeasesTable" xlink:to="ortx_OperatingLeasesLineItems" order="11740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_OperatingLeasesLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="11750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_OperatingLeasesLineItems" xlink:to="us-gaap_PaymentsForRent" order="11870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_OperatingLeasesLineItems" xlink:to="ortx_OperatingLeaseDurationForFreeRent" order="11930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_OperatingLeasesLineItems" xlink:to="us-gaap_SubleaseIncome" order="12210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_OperatingLeasesLineItems" xlink:to="ortx_OperatingLeasesCommencedTerm" order="12260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_OperatingLeasesLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="12370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_OperatingLeasesLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="12410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_OperatingLeasesLineItems" xlink:to="ortx_ReductionOfStandbyLetterOfCreditAmountPercentage" order="12520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_OperatingLeasesLineItems" xlink:to="us-gaap_ProceedsFromLinesOfCredit" order="12540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_OperatingLeasesLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="12650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_OperatingLeasesLineItems" xlink:to="ortx_TenantImprovementAllowance" order="12670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_OperatingLeasesLineItems" xlink:to="us-gaap_SecurityDeposit" order="12840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_OperatingLeasesLineItems" xlink:to="us-gaap_EscrowDeposit" order="12880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_OperatingLeasesLineItems" xlink:to="ortx_IncreaseDecreaseInEscrowDeposit" order="12920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_OperatingLeasesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="12990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_OperatingLeasesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="13030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_OperatingLeasesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" order="13050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_OperatingLeasesLineItems" xlink:to="ortx_LesseeOperatingLeaseExtendedTerm" order="13070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_OperatingLeasesLineItems" xlink:to="ortx_LeaseComponentManufacturingCommitmentAmount" order="13090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_OperatingLeasesLineItems" xlink:to="ortx_OperatingLeaseRightOfUseAssetValueExchangeForLeaseLiabilities" order="13290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfLeaseCostUnderOperatingLeasesDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureLeasesSummaryOfLeaseCostUnderOperatingLeasesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfLeaseCostUnderOperatingLeasesDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost" xlink:type="locator" xlink:label="us-gaap_LeaseCost" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome" xlink:type="locator" xlink:label="us-gaap_SubleaseIncome" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost" xlink:type="locator" xlink:label="us-gaap_VariableLeaseCost" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseImpairmentLoss" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_FixedLeaseCost" xlink:type="locator" xlink:label="ortx_FixedLeaseCost" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="ortx_FixedLeaseCost" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseImpairmentLoss" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_VariableLeaseCost" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_SubleaseIncome" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCost" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumBaseRentCommitmentsUnderOperatingLeasesDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureLeasesScheduleOfFutureMinimumBaseRentCommitmentsUnderOperatingLeasesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumBaseRentCommitmentsUnderOperatingLeasesDetails">
    <link:loc xlink:href="ortx-20211231.xsd#ortx_OperatingLeaseLiabilityPaymentsDueNet" xlink:type="locator" xlink:label="ortx_OperatingLeaseLiabilityPaymentsDueNet" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_OperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="locator" xlink:label="ortx_OperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_OperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="locator" xlink:label="ortx_OperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_OperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="ortx_OperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_OperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="ortx_OperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_OperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="ortx_OperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_OperatingLeaseLiabilityPaymentsDueYearOne" xlink:type="locator" xlink:label="ortx_OperatingLeaseLiabilityPaymentsDueYearOne" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_OperatingLeaseLiabilitiesPaymentsDueNetAbstract" xlink:type="locator" xlink:label="ortx_OperatingLeaseLiabilitiesPaymentsDueNetAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:type="locator" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceived" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter" xlink:type="locator" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears" xlink:type="locator" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears" xlink:type="locator" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:type="locator" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:type="locator" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract" xlink:type="locator" xlink:label="us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceived" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="ortx_OperatingLeaseLiabilitiesPaymentsDueNetAbstract" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_OperatingLeaseLiabilitiesPaymentsDueNetAbstract" xlink:to="ortx_OperatingLeaseLiabilityPaymentsDueYearOne" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_OperatingLeaseLiabilitiesPaymentsDueNetAbstract" xlink:to="ortx_OperatingLeaseLiabilityPaymentsDueYearTwo" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_OperatingLeaseLiabilitiesPaymentsDueNetAbstract" xlink:to="ortx_OperatingLeaseLiabilityPaymentsDueYearThree" order="10870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_OperatingLeaseLiabilitiesPaymentsDueNetAbstract" xlink:to="ortx_OperatingLeaseLiabilityPaymentsDueYearFour" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_OperatingLeaseLiabilitiesPaymentsDueNetAbstract" xlink:to="ortx_OperatingLeaseLiabilityPaymentsDueYearFive" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_OperatingLeaseLiabilitiesPaymentsDueNetAbstract" xlink:to="ortx_OperatingLeaseLiabilityPaymentsDueAfterYearFive" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_OperatingLeaseLiabilitiesPaymentsDueNetAbstract" xlink:to="ortx_OperatingLeaseLiabilityPaymentsDueNet" order="10950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumBaseRentCommitmentsUnderOperatingLeasesParentheticalDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureLeasesScheduleOfFutureMinimumBaseRentCommitmentsUnderOperatingLeasesParentheticalDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumBaseRentCommitmentsUnderOperatingLeasesParentheticalDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyExchangeRateTranslation1" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_OperatingLeasesLineItems" xlink:type="locator" xlink:label="ortx_OperatingLeasesLineItems" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_EUR" xlink:type="locator" xlink:label="currency_EUR" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_GBP" xlink:type="locator" xlink:label="currency_GBP" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_AllCurrenciesDomain" xlink:type="locator" xlink:label="currency_AllCurrenciesDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CurrencyAxis" xlink:type="locator" xlink:label="srt_CurrencyAxis" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_OperatingLeasesTable" xlink:type="locator" xlink:label="ortx_OperatingLeasesTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="ortx_OperatingLeasesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_OperatingLeasesTable" xlink:to="srt_CurrencyAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_GBP" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_EUR" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_OperatingLeasesTable" xlink:to="ortx_OperatingLeasesLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_OperatingLeasesLineItems" xlink:to="us-gaap_ForeignCurrencyExchangeRateTranslation1" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureNotesPayableAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCovenantDescription" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentCovenantDescription" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_LineOfCreditFacilityCovenantsMinimumCashAllowed" xlink:type="locator" xlink:label="ortx_LineOfCreditFacilityCovenantsMinimumCashAllowed" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateDescription" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDescription" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLinesOfCredit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityPeriodicPaymentInterest" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityPeriodicPaymentInterest" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_LineOfCreditFacilityPercentageOfFinalPayment" xlink:type="locator" xlink:label="ortx_LineOfCreditFacilityPercentageOfFinalPayment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityFrequencyOfPayments" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityFrequencyOfPayments" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_LineOfCreditFacilityAmortizationTerm" xlink:type="locator" xlink:label="ortx_LineOfCreditFacilityAmortizationTerm" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_LineOfCreditFacilityInterestPaymentsTerm" xlink:type="locator" xlink:label="ortx_LineOfCreditFacilityInterestPaymentsTerm" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityCovenantTerms" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityCovenantTerms" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAndCash" xlink:type="locator" xlink:label="us-gaap_InvestmentsAndCash" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:type="locator" xlink:label="us-gaap_ProceedsFromLinesOfCredit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityInitiationDate1" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityInitiationDate1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_TermLoanMember" xlink:type="locator" xlink:label="ortx_TermLoanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodThreeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_LondonInterbankOfferedRateFloorMember" xlink:type="locator" xlink:label="ortx_LondonInterbankOfferedRateFloorMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain" xlink:type="locator" xlink:label="us-gaap_VariableRateDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis" xlink:type="locator" xlink:label="us-gaap_VariableRateAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_TheThirdTrancheTermLoanMember" xlink:type="locator" xlink:label="ortx_TheThirdTrancheTermLoanMember" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_TheSecondTrancheTermLoanMember" xlink:type="locator" xlink:label="ortx_TheSecondTrancheTermLoanMember" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_TheFirstTrancheTermLoanMember" xlink:type="locator" xlink:label="ortx_TheFirstTrancheTermLoanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="ortx_TheFirstTrancheTermLoanMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="ortx_TheSecondTrancheTermLoanMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="ortx_TheThirdTrancheTermLoanMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_RangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_VariableRateAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateDomain" xlink:to="ortx_LondonInterbankOfferedRateFloorMember" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodThreeMember" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="ortx_TermLoanMember" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityInitiationDate1" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromLinesOfCredit" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" order="11060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InvestmentsAndCash" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityCovenantTerms" order="11160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" order="11230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="ortx_LineOfCreditFacilityInterestPaymentsTerm" order="11250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="ortx_LineOfCreditFacilityAmortizationTerm" order="11270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityFrequencyOfPayments" order="11290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="ortx_LineOfCreditFacilityPercentageOfFinalPayment" order="11310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityPeriodicPaymentInterest" order="11330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RepaymentsOfLinesOfCredit" order="11350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityInterestRateDescription" order="11370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="ortx_LineOfCreditFacilityCovenantsMinimumCashAllowed" order="11630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCovenantDescription" order="11670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebt" order="11720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod" order="11760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableSummaryOfNotesPayableDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureNotesPayableSummaryOfNotesPayableDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableSummaryOfNotesPayableDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:type="locator" xlink:label="us-gaap_LongTermDebtNoncurrent" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_AccretionRelatedToFinalPayment" xlink:type="locator" xlink:label="ortx_AccretionRelatedToFinalPayment" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_LongTermDebtBeforeAccretionIssuanceCostsNetNoncurrent" xlink:type="locator" xlink:label="ortx_LongTermDebtBeforeAccretionIssuanceCostsNetNoncurrent" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_LongTermDebtBeforeAccretionIssuanceCostsNetCurrent" xlink:type="locator" xlink:label="ortx_LongTermDebtBeforeAccretionIssuanceCostsNetCurrent" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_LongTermDebtBeforeAccretionIssuanceCostsNet" xlink:type="locator" xlink:label="ortx_LongTermDebtBeforeAccretionIssuanceCostsNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermNotesAndLoansAbstract" xlink:type="locator" xlink:label="us-gaap_LongTermNotesAndLoansAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermNotesAndLoansAbstract" xlink:to="ortx_LongTermDebtBeforeAccretionIssuanceCostsNet" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermNotesAndLoansAbstract" xlink:to="ortx_LongTermDebtBeforeAccretionIssuanceCostsNetCurrent" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermNotesAndLoansAbstract" xlink:to="ortx_LongTermDebtBeforeAccretionIssuanceCostsNetNoncurrent" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermNotesAndLoansAbstract" xlink:to="ortx_AccretionRelatedToFinalPayment" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermNotesAndLoansAbstract" xlink:to="us-gaap_LongTermDebtNoncurrent" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableSummaryOfFuturePrincipalPaymentsDueDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureNotesPayableSummaryOfFuturePrincipalPaymentsDueDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableSummaryOfFuturePrincipalPaymentsDueDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:type="locator" xlink:label="us-gaap_LongTermDebtNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:type="locator" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_UnamortizedPortionOfFinalPayment" xlink:type="locator" xlink:label="ortx_UnamortizedPortionOfFinalPayment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:type="locator" xlink:label="us-gaap_LongTermDebtCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtByMaturityAbstract" xlink:type="locator" xlink:label="us-gaap_LongTermDebtByMaturityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtByMaturityAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtByMaturityAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtByMaturityAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtByMaturityAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtByMaturityAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtByMaturityAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtByMaturityAbstract" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtByMaturityAbstract" xlink:to="us-gaap_LongTermDebtCurrent" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtByMaturityAbstract" xlink:to="ortx_UnamortizedPortionOfFinalPayment" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtByMaturityAbstract" xlink:to="us-gaap_UnamortizedDebtIssuanceExpense" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtByMaturityAbstract" xlink:to="us-gaap_LongTermDebtNoncurrent" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareholdersEquityAndConvertiblePreferredSharesAdditionalInformationDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureShareholdersEquityAndConvertiblePreferredSharesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareholdersEquityAndConvertiblePreferredSharesAdditionalInformationDetails">
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ProceedsFromPremiumSharesIssued" xlink:type="locator" xlink:label="ortx_ProceedsFromPremiumSharesIssued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_NetProceedsFromIssuanceOfPrivatePlacement" xlink:type="locator" xlink:label="ortx_NetProceedsFromIssuanceOfPrivatePlacement" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockTransactionDate" xlink:type="locator" xlink:label="us-gaap_SaleOfStockTransactionDate" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_PaymentsOfOtherIssuanceCosts" xlink:type="locator" xlink:label="ortx_PaymentsOfOtherIssuanceCosts" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ClosingPriceOfShareDate" xlink:type="locator" xlink:label="ortx_ClosingPriceOfShareDate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValueOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockValueOutstanding" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_NumberOfOrdinaryVotingRights" xlink:type="locator" xlink:label="ortx_NumberOfOrdinaryVotingRights" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsCommonStock" xlink:type="locator" xlink:label="us-gaap_DividendsCommonStock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:type="locator" xlink:label="us-gaap_CommonStockVotingRights" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_SharePurchaseAgreementWithPharmingMember" xlink:type="locator" xlink:label="ortx_SharePurchaseAgreementWithPharmingMember" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_NonVotingOrdinarySharesMember" xlink:type="locator" xlink:label="ortx_NonVotingOrdinarySharesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_SecuritiesPurchaseAgreementMember" xlink:type="locator" xlink:label="ortx_SecuritiesPurchaseAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_NonEmployeeAdvisorMember" xlink:type="locator" xlink:label="ortx_NonEmployeeAdvisorMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ConsultingAgreementMember" xlink:type="locator" xlink:label="ortx_ConsultingAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_OxfordBioMedicaLicenseDevelopmentAndSupplyAgreementMember" xlink:type="locator" xlink:label="ortx_OxfordBioMedicaLicenseDevelopmentAndSupplyAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ShareholdersEquityAndConvertiblePreferredSharesAbstract" xlink:type="locator" xlink:label="ortx_ShareholdersEquityAndConvertiblePreferredSharesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_ShareholdersEquityAndConvertiblePreferredSharesAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ortx_OxfordBioMedicaLicenseDevelopmentAndSupplyAgreementMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="ortx_ConsultingAgreementMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_TitleOfIndividualAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="ortx_NonEmployeeAdvisorMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ortx_SecuritiesPurchaseAgreementMember" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="ortx_NonVotingOrdinarySharesMember" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ortx_SharePurchaseAgreementWithPharmingMember" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockVotingRights" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DividendsCommonStock" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="ortx_NumberOfOrdinaryVotingRights" order="10870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockValueOutstanding" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="11020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="11140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_li0l2" order="11160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="11180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="ortx_ClosingPriceOfShareDate" order="11200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="11260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="ortx_PaymentsOfOtherIssuanceCosts" order="11280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockTransactionDate" order="11300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="ortx_NetProceedsFromIssuanceOfPrivatePlacement" order="11320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="11370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="11410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="ortx_ProceedsFromPremiumSharesIssued" order="11430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureShareBasedCompensationAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:type="locator" xlink:label="ortx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeEquityPlanProceedsReceivedAfterYearEnd" xlink:type="locator" xlink:label="ortx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeEquityPlanProceedsReceivedAfterYearEnd" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain" xlink:type="locator" xlink:label="us-gaap_VestingDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis" xlink:type="locator" xlink:label="us-gaap_VestingAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:type="locator" xlink:label="srt_ChiefExecutiveOfficerMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_TimeBasedRestrictedShareUnitsMember" xlink:type="locator" xlink:label="ortx_TimeBasedRestrictedShareUnitsMember" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_LibmeldyMember" xlink:type="locator" xlink:label="ortx_LibmeldyMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:type="locator" xlink:label="us-gaap_PerformanceSharesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_TwoThousandAndTwentyInducementEquityPlanMember" xlink:type="locator" xlink:label="ortx_TwoThousandAndTwentyInducementEquityPlanMember" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_TwoThousandAndEighteenEmployeeSharePurchasePlanMember" xlink:type="locator" xlink:label="ortx_TwoThousandAndEighteenEmployeeSharePurchasePlanMember" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_TwoThousandAndEighteenShareOptionAndIncentivePlanMember" xlink:type="locator" xlink:label="ortx_TwoThousandAndEighteenShareOptionAndIncentivePlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="ortx_TwoThousandAndEighteenShareOptionAndIncentivePlanMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="ortx_TwoThousandAndEighteenEmployeeSharePurchasePlanMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="ortx_TwoThousandAndTwentyInducementEquityPlanMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ortx_LibmeldyMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="ortx_TimeBasedRestrictedShareUnitsMember" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ortx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeEquityPlanProceedsReceivedAfterYearEnd" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="11070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="11140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ortx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" order="11160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" order="11180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" order="11250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="11270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="11290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="11310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAssumptionsUsedInBlackScholesOptionPricingModelDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureShareBasedCompensationAssumptionsUsedInBlackScholesOptionPricingModelDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAssumptionsUsedInBlackScholesOptionPricingModelDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfOptionActivityDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureShareBasedCompensationSummaryOfOptionActivityDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfOptionActivityDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="11110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="11310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="11410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="11510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="11710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfAwardActivityDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureShareBasedCompensationSummaryOfAwardActivityDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfAwardActivityDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_TimeBasedRestrictedShareUnitsMember" xlink:type="locator" xlink:label="ortx_TimeBasedRestrictedShareUnitsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:type="locator" xlink:label="us-gaap_PerformanceSharesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="ortx_TimeBasedRestrictedShareUnitsMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_li0l2" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_li0l2" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureLicenseAndResearchAgreementsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetails">
    <link:loc xlink:href="ortx-20211231.xsd#ortx_NumberOfMilestonesMet" xlink:type="locator" xlink:label="ortx_NumberOfMilestonesMet" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_MilestonePayment" xlink:type="locator" xlink:label="ortx_MilestonePayment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_PotentialPaymentForAchievementOfSpecifiedMilestones" xlink:type="locator" xlink:label="ortx_PotentialPaymentForAchievementOfSpecifiedMilestones" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentForAdministrativeFees" xlink:type="locator" xlink:label="us-gaap_PaymentForAdministrativeFees" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_PaymentsToAcquireClinicalData" xlink:type="locator" xlink:label="ortx_PaymentsToAcquireClinicalData" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_UpfrontCashPayment" xlink:type="locator" xlink:label="ortx_UpfrontCashPayment" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_MilestonePaymentsPayableUponAchievementOfCertainDevelopmentRegulatoryAndCommercialMilestones" xlink:type="locator" xlink:label="ortx_MilestonePaymentsPayableUponAchievementOfCertainDevelopmentRegulatoryAndCommercialMilestones" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_InProcessResearchAndDevelopmentExpenseForUpfrontAndMilestonePayments" xlink:type="locator" xlink:label="ortx_InProcessResearchAndDevelopmentExpenseForUpfrontAndMilestonePayments" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_UpfrontAndMilestonePayments" xlink:type="locator" xlink:label="ortx_UpfrontAndMilestonePayments" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_UpfrontPaymentDescription" xlink:type="locator" xlink:label="ortx_UpfrontPaymentDescription" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_MilestonePaymentsPayableUponAchievementOfCertainSalesMilestones" xlink:type="locator" xlink:label="ortx_MilestonePaymentsPayableUponAchievementOfCertainSalesMilestones" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_PaymentOfTieredRoyaltyMaximumPercentage" xlink:type="locator" xlink:label="ortx_PaymentOfTieredRoyaltyMaximumPercentage" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_AssetAcquisitionInProcessResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="ortx_AssetAcquisitionInProcessResearchAndDevelopmentExpense" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_AssetAcquisitionTransactionCosts" xlink:type="locator" xlink:label="ortx_AssetAcquisitionTransactionCosts" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_AssetAcquisitionInventoryPurchaseLiability" xlink:type="locator" xlink:label="ortx_AssetAcquisitionInventoryPurchaseLiability" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_AssetAcquisitionLiabilityAssumed" xlink:type="locator" xlink:label="ortx_AssetAcquisitionLiabilityAssumed" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_AssetAcquisitionValueOfEquityInstrumentsIssued" xlink:type="locator" xlink:label="ortx_AssetAcquisitionValueOfEquityInstrumentsIssued" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_AssetAcquisitionNumberOfSharesIssuedForAcquisition" xlink:type="locator" xlink:label="ortx_AssetAcquisitionNumberOfSharesIssuedForAcquisition" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_AssetAcquisitionUpfrontPayment" xlink:type="locator" xlink:label="ortx_AssetAcquisitionUpfrontPayment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_NumberOfAdditionalEarlierStageDevelopmentPrograms" xlink:type="locator" xlink:label="ortx_NumberOfAdditionalEarlierStageDevelopmentPrograms" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_NumberOfEarlierStageClinicalGeneTherapyProgram" xlink:type="locator" xlink:label="ortx_NumberOfEarlierStageClinicalGeneTherapyProgram" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_NumberOfLateStageClinicalGeneTherapyPrograms" xlink:type="locator" xlink:label="ortx_NumberOfLateStageClinicalGeneTherapyPrograms" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_OxfordBioMedicaLicenseDevelopmentAndSupplyAgreementMember" xlink:type="locator" xlink:label="ortx_OxfordBioMedicaLicenseDevelopmentAndSupplyAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_UCLBAndUCLALicenseAgreementMember" xlink:type="locator" xlink:label="ortx_UCLBAndUCLALicenseAgreementMember" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_UCLBLicenseAgreementMember" xlink:type="locator" xlink:label="ortx_UCLBLicenseAgreementMember" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_UCLBTechnologyAndManufacturingTechnologyMember" xlink:type="locator" xlink:label="ortx_UCLBTechnologyAndManufacturingTechnologyMember" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_UCLBAndUCLATechnologyMember" xlink:type="locator" xlink:label="ortx_UCLBAndUCLATechnologyMember" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_TelethonOSRLicenseAgreementsMember" xlink:type="locator" xlink:label="ortx_TelethonOSRLicenseAgreementsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_GSKAssetPurchaseAndLicenseAgreementMember" xlink:type="locator" xlink:label="ortx_GSKAssetPurchaseAndLicenseAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ortx_GSKAssetPurchaseAndLicenseAgreementMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ortx_TelethonOSRLicenseAgreementsMember" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ortx_UCLBAndUCLATechnologyMember" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ortx_UCLBTechnologyAndManufacturingTechnologyMember" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ortx_UCLBLicenseAgreementMember" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ortx_UCLBAndUCLALicenseAgreementMember" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ortx_OxfordBioMedicaLicenseDevelopmentAndSupplyAgreementMember" order="10940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="11000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ortx_NumberOfLateStageClinicalGeneTherapyPrograms" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ortx_NumberOfEarlierStageClinicalGeneTherapyProgram" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ortx_NumberOfAdditionalEarlierStageDevelopmentPrograms" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ortx_AssetAcquisitionUpfrontPayment" order="11140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ortx_AssetAcquisitionNumberOfSharesIssuedForAcquisition" order="11180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ortx_AssetAcquisitionValueOfEquityInstrumentsIssued" order="11220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ortx_AssetAcquisitionLiabilityAssumed" order="11260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ortx_AssetAcquisitionInventoryPurchaseLiability" order="11300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ortx_AssetAcquisitionTransactionCosts" order="11340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ortx_AssetAcquisitionInProcessResearchAndDevelopmentExpense" order="11380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ortx_PaymentOfTieredRoyaltyMaximumPercentage" order="11520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ortx_MilestonePaymentsPayableUponAchievementOfCertainSalesMilestones" order="11540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ortx_UpfrontPaymentDescription" order="11660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ortx_UpfrontAndMilestonePayments" order="11720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ortx_InProcessResearchAndDevelopmentExpenseForUpfrontAndMilestonePayments" order="11780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ortx_MilestonePaymentsPayableUponAchievementOfCertainDevelopmentRegulatoryAndCommercialMilestones" order="11840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ortx_UpfrontCashPayment" order="11930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="12050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ortx_PaymentsToAcquireClinicalData" order="12110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_PaymentForAdministrativeFees" order="12200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ortx_PotentialPaymentForAchievementOfSpecifiedMilestones" order="12240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="12310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ortx_MilestonePayment" order="12460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ortx_NumberOfMilestonesMet" order="12540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCollaborationAgreementWithPharmingGroupNVAdditionalInformationDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureCollaborationAgreementWithPharmingGroupNVAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCollaborationAgreementWithPharmingGroupNVAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ProceedsFromNonRefundableUpfrontPayment" xlink:type="locator" xlink:label="ortx_ProceedsFromNonRefundableUpfrontPayment" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ExcessProceedsFromFairValueOfSharesIssuedAllocatedToCollaborationAgreement" xlink:type="locator" xlink:label="ortx_ExcessProceedsFromFairValueOfSharesIssuedAllocatedToCollaborationAgreement" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssued1" xlink:type="locator" xlink:label="us-gaap_StockIssued1" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ProceedsFromUpfrontPaymentsAttributedToResearchActivities" xlink:type="locator" xlink:label="ortx_ProceedsFromUpfrontPaymentsAttributedToResearchActivities" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ProceedsFromUpfrontPaymentsAttributedToEquitySold" xlink:type="locator" xlink:label="ortx_ProceedsFromUpfrontPaymentsAttributedToEquitySold" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ProceedsFromUpfrontPayment" xlink:type="locator" xlink:label="ortx_ProceedsFromUpfrontPayment" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ProceedsFromPremiumSharesIssued" xlink:type="locator" xlink:label="ortx_ProceedsFromPremiumSharesIssued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_MilestonePaymentsReceivable" xlink:type="locator" xlink:label="ortx_MilestonePaymentsReceivable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:type="locator" xlink:label="us-gaap_ProceedsFromCollaborators" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementMember" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_PharmingAgreementsMember" xlink:type="locator" xlink:label="ortx_PharmingAgreementsMember" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_SharePurchaseAgreementWithPharmingMember" xlink:type="locator" xlink:label="ortx_SharePurchaseAgreementWithPharmingMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_StrategicCollaborationAgreementWithPharmingMember" xlink:type="locator" xlink:label="ortx_StrategicCollaborationAgreementWithPharmingMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_CollaborativeArrangementAbstract" xlink:type="locator" xlink:label="ortx_CollaborativeArrangementAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_CollaborativeArrangementAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ortx_StrategicCollaborationAgreementWithPharmingMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ortx_SharePurchaseAgreementWithPharmingMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ortx_PharmingAgreementsMember" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_AccountsReceivableMember" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromCollaborators" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ortx_MilestonePaymentsReceivable" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveTerseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ortx_ProceedsFromPremiumSharesIssued" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ortx_ProceedsFromUpfrontPayment" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ortx_ProceedsFromUpfrontPaymentsAttributedToEquitySold" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ortx_ProceedsFromUpfrontPaymentsAttributedToResearchActivities" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssued1" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ortx_ExcessProceedsFromFairValueOfSharesIssuedAllocatedToCollaborationAgreement" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ortx_ProceedsFromNonRefundableUpfrontPayment" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNetCurrent" order="11220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="11290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCollaborationAgreementWithPharmingGroupNVSummaryOfResearchAndDevelopmentCostsIncurredAndCollaborationRevenueRecognizedDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureCollaborationAgreementWithPharmingGroupNVSummaryOfResearchAndDevelopmentCostsIncurredAndCollaborationRevenueRecognizedDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCollaborationAgreementWithPharmingGroupNVSummaryOfResearchAndDevelopmentCostsIncurredAndCollaborationRevenueRecognizedDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_UpfrontAndMilestonePaymentRevenueMember" xlink:type="locator" xlink:label="ortx_UpfrontAndMilestonePaymentRevenueMember" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ReimbursementRevenueMember" xlink:type="locator" xlink:label="ortx_ReimbursementRevenueMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_CollaborativeArrangementAbstract" xlink:type="locator" xlink:label="ortx_CollaborativeArrangementAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ortx_CollaborativeArrangementAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ortx_ReimbursementRevenueMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ortx_UpfrontAndMilestonePaymentRevenueMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfNetLossBeforeIncomeTaxesDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureIncomeTaxesScheduleOfComponentsOfNetLossBeforeIncomeTaxesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfNetLossBeforeIncomeTaxesDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredOtherTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredOtherTaxExpenseBenefit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_CurrentOtherTaxExpenseBenefit" xlink:type="locator" xlink:label="ortx_CurrentOtherTaxExpenseBenefit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="ortx_CurrentOtherTaxExpenseBenefit" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredOtherTaxExpenseBenefit" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_IncomeTaxReconciliationPermanentDifferencesIncludingShareBasedCompensationDeductionShortfalls" xlink:type="locator" xlink:label="ortx_IncomeTaxReconciliationPermanentDifferencesIncludingShareBasedCompensationDeductionShortfalls" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_IncomeTaxReconciliationDomesticDeductionForDerivedIntangibleIncome" xlink:type="locator" xlink:label="ortx_IncomeTaxReconciliationDomesticDeductionForDerivedIntangibleIncome" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCredits" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_IncomeTaxReconciliationReductionInResearchExpenseForCreditsGranted" xlink:type="locator" xlink:label="ortx_IncomeTaxReconciliationReductionInResearchExpenseForCreditsGranted" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="ortx_IncomeTaxReconciliationReductionInResearchExpenseForCreditsGranted" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="ortx_IncomeTaxReconciliationDomesticDeductionForDerivedIntangibleIncome" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="ortx_IncomeTaxReconciliationPermanentDifferencesIncludingShareBasedCompensationDeductionShortfalls" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OpenTaxYear" xlink:type="locator" xlink:label="us-gaap_OpenTaxYear" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_TaxCreditCarryforwardExpirationYear" xlink:type="locator" xlink:label="ortx_TaxCreditCarryforwardExpirationYear" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_CorporationTaxRatePercentage" xlink:type="locator" xlink:label="ortx_CorporationTaxRatePercentage" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LatestTaxYearMember" xlink:type="locator" xlink:label="us-gaap_LatestTaxYearMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarliestTaxYearMember" xlink:type="locator" xlink:label="us-gaap_EarliestTaxYearMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:type="locator" xlink:label="us-gaap_TaxPeriodDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:type="locator" xlink:label="us-gaap_TaxPeriodAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember" xlink:type="locator" xlink:label="us-gaap_ResearchMember" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_OrphanDrugTaxCreditMember" xlink:type="locator" xlink:label="ortx_OrphanDrugTaxCreditMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US" xlink:type="locator" xlink:label="country_US" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_GB" xlink:type="locator" xlink:label="country_GB" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwardsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="srt_StatementGeographicalAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_GB" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="ortx_OrphanDrugTaxCreditMember" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_TaxPeriodAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_EarliestTaxYearMember" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_LatestTaxYearMember" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="ortx_CorporationTaxRatePercentage" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="ortx_TaxCreditCarryforwardExpirationYear" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OpenTaxYear" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesTaxesDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesTaxesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesTaxesDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_DeferredTaxLiabilitiesFixedAssetsAndRightOfUseAsset" xlink:type="locator" xlink:label="ortx_DeferredTaxLiabilitiesFixedAssetsAndRightOfUseAsset" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_DeferredTaxAssetsLeaseLiability" xlink:type="locator" xlink:label="ortx_DeferredTaxAssetsLeaseLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_DeferredTaxAssetsAmortization" xlink:type="locator" xlink:label="ortx_DeferredTaxAssetsAmortization" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:type="locator" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="ortx_DeferredTaxAssetsAmortization" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="ortx_DeferredTaxAssetsLeaseLiability" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="ortx_DeferredTaxLiabilitiesFixedAssetsAndRightOfUseAsset" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfChangesInValuationAllowanceForDeferredTaxAssetsRelatedPrimarilyToIncreaseInUKNetOperatingLossCarryforwardsDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureIncomeTaxesScheduleOfChangesInValuationAllowanceForDeferredTaxAssetsRelatedPrimarilyToIncreaseInUKNetOperatingLossCarryforwardsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfChangesInValuationAllowanceForDeferredTaxAssetsRelatedPrimarilyToIncreaseInUKNetOperatingLossCarryforwardsDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_li0l2" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_DeferredTaxAssetsValuationAllowanceEffectOfForeignCurrencyTranslation" xlink:type="locator" xlink:label="ortx_DeferredTaxAssetsValuationAllowanceEffectOfForeignCurrencyTranslation" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_DeferredTaxAssetsValuationAllowanceIncreasesRecordedToIncomeTaxProvision" xlink:type="locator" xlink:label="ortx_DeferredTaxAssetsValuationAllowanceIncreasesRecordedToIncomeTaxProvision" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="ortx_DeferredTaxAssetsValuationAllowanceIncreasesRecordedToIncomeTaxProvision" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="ortx_DeferredTaxAssetsValuationAllowanceEffectOfForeignCurrencyTranslation" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_li0l2" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfAnnualCommitmentsAssociatedWithContractDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureCommitmentsAndContingenciesScheduleOfAnnualCommitmentsAssociatedWithContractDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfAnnualCommitmentsAssociatedWithContractDetails">
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ManufacturingCommitments" xlink:type="locator" xlink:label="ortx_ManufacturingCommitments" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ManufacturingCommitmentsAmountDueThereafter" xlink:type="locator" xlink:label="ortx_ManufacturingCommitmentsAmountDueThereafter" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ManufacturingCommitmentsAmountDueInYearFive" xlink:type="locator" xlink:label="ortx_ManufacturingCommitmentsAmountDueInYearFive" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ManufacturingCommitmentsAmountDueInYearFour" xlink:type="locator" xlink:label="ortx_ManufacturingCommitmentsAmountDueInYearFour" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ManufacturingCommitmentsAmountDueInYearThree" xlink:type="locator" xlink:label="ortx_ManufacturingCommitmentsAmountDueInYearThree" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ManufacturingCommitmentsAmountDueInYearTwo" xlink:type="locator" xlink:label="ortx_ManufacturingCommitmentsAmountDueInYearTwo" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ManufacturingCommitmentsAmountDueInNextTwelveMonths" xlink:type="locator" xlink:label="ortx_ManufacturingCommitmentsAmountDueInNextTwelveMonths" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsLineItems" xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsLineItems" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ExclusiveTransductionSuitesMember" xlink:type="locator" xlink:label="ortx_ExclusiveTransductionSuitesMember" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_DedicatedManufacturingAndDevelopmentResourcesMember" xlink:type="locator" xlink:label="ortx_DedicatedManufacturingAndDevelopmentResourcesMember" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ProductManufacturingCommitmentsMember" xlink:type="locator" xlink:label="ortx_ProductManufacturingCommitmentsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplyCommitmentArrangementMember" xlink:type="locator" xlink:label="us-gaap_SupplyCommitmentArrangementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplyCommitmentAxis" xlink:type="locator" xlink:label="us-gaap_SupplyCommitmentAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsTable" xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OtherCommitmentsTable" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_SupplyCommitmentAxis" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplyCommitmentAxis" xlink:to="us-gaap_SupplyCommitmentArrangementMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="ortx_ProductManufacturingCommitmentsMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="ortx_DedicatedManufacturingAndDevelopmentResourcesMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="ortx_ExclusiveTransductionSuitesMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_OtherCommitmentsLineItems" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="ortx_ManufacturingCommitmentsAmountDueInNextTwelveMonths" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="ortx_ManufacturingCommitmentsAmountDueInYearTwo" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="ortx_ManufacturingCommitmentsAmountDueInYearThree" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="ortx_ManufacturingCommitmentsAmountDueInYearFour" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="ortx_ManufacturingCommitmentsAmountDueInYearFive" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="ortx_ManufacturingCommitmentsAmountDueThereafter" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="ortx_ManufacturingCommitments" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfAnnualCommitmentsAssociatedWithContractParentheticalDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureCommitmentsAndContingenciesScheduleOfAnnualCommitmentsAssociatedWithContractParentheticalDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfAnnualCommitmentsAssociatedWithContractParentheticalDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyExchangeRateTranslation1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ForeignCurrencyExchangeRateTranslation1" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_AgreementExtensionTerm" xlink:type="locator" xlink:label="ortx_AgreementExtensionTerm" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_AgreementMaturityDate" xlink:type="locator" xlink:label="ortx_AgreementMaturityDate" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_InitialTermOfAgreement" xlink:type="locator" xlink:label="ortx_InitialTermOfAgreement" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsLineItems" xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsLineItems" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ClinicalDevelopmentAndRegulatoryMilestoneMember" xlink:type="locator" xlink:label="ortx_ClinicalDevelopmentAndRegulatoryMilestoneMember" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_NonEmployeeAdvisorMember" xlink:type="locator" xlink:label="ortx_NonEmployeeAdvisorMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ConsultingAgreementMember" xlink:type="locator" xlink:label="ortx_ConsultingAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_ManufacturingAndTechnologyDevelopmentMasterAgreementMember" xlink:type="locator" xlink:label="ortx_ManufacturingAndTechnologyDevelopmentMasterAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsTable" xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OtherCommitmentsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ortx_ManufacturingAndTechnologyDevelopmentMasterAgreementMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="ortx_ConsultingAgreementMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="srt_TitleOfIndividualAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="ortx_NonEmployeeAdvisorMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ortx_ClinicalDevelopmentAndRegulatoryMilestoneMember" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_OtherCommitmentsLineItems" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="ortx_InitialTermOfAgreement" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="ortx_AgreementMaturityDate" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="ortx_AgreementExtensionTerm" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="10940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="11000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureBenefitPlansAdditionalInformationDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureBenefitPlansAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureBenefitPlansAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanCostRecognized" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_AccruedExpensesRelatedPartyCurrent" xlink:type="locator" xlink:label="ortx_AccruedExpensesRelatedPartyCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForLossOnContracts" xlink:type="locator" xlink:label="us-gaap_ProvisionForLossOnContracts" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_AssetAcquisitionTransactionCosts" xlink:type="locator" xlink:label="ortx_AssetAcquisitionTransactionCosts" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_InventoryPurchase" xlink:type="locator" xlink:label="ortx_InventoryPurchase" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_LicenseUpfrontFeeAndRelatedExpensesPaid" xlink:type="locator" xlink:label="ortx_LicenseUpfrontFeeAndRelatedExpensesPaid" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_GSKAssetPurchaseAndLicenseAgreementMember" xlink:type="locator" xlink:label="ortx_GSKAssetPurchaseAndLicenseAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="ortx-20211231.xsd#ortx_GSKMember" xlink:type="locator" xlink:label="ortx_GSKMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="ortx_GSKMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ortx_GSKAssetPurchaseAndLicenseAgreementMember" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ortx_LicenseUpfrontFeeAndRelatedExpensesPaid" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ortx_InventoryPurchase" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ortx_AssetAcquisitionTransactionCosts" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_PreferredStockValue" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ProvisionForLossOnContracts" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrent" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ortx_AccruedExpensesRelatedPartyCurrent" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:href="ortx-20211231.xsd#Role_DisclosureSubsequentEventsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:type="locator" xlink:label="us-gaap_RestructuringAndRelatedCostExpectedCost1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:type="locator" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_GB" xlink:type="locator" xlink:label="country_GB" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_StatementGeographicalAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_GB" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostExpectedCost1" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696132496904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 15, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ORCHARD THERAPEUTICS PLC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001748907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,834,611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 544<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">X0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">108 Cannon Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">London<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">EC4N 6EU<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">(0) 203 808-8286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">00-0000000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">GB<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">American Depositary Shares,
each representing one ordinary share, nominal value &#163;0.10 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ORTX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">PricewaterhouseCoopers LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Boston, Massachusetts<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Portions of the Registrant&#8217;s definitive proxy statement for its 2022 Annual General Meeting are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated.</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<p style="border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696131116552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 55,912<span></span>
</td>
<td class="nump">$ 55,135<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="nump">164,195<span></span>
</td>
<td class="nump">136,813<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">1,480<span></span>
</td>
<td class="nump">878<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">23,011<span></span>
</td>
<td class="nump">13,365<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_ResearchAndDevelopmentTaxCreditReceivableCurrent', window );">Research and development tax credit receivable</a></td>
<td class="nump">30,723<span></span>
</td>
<td class="nump">17,344<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">275,321<span></span>
</td>
<td class="nump">223,535<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use-assets</a></td>
<td class="nump">24,316<span></span>
</td>
<td class="nump">29,815<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">4,767<span></span>
</td>
<td class="nump">4,781<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash</a></td>
<td class="nump">4,266<span></span>
</td>
<td class="nump">4,266<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">4,149<span></span>
</td>
<td class="nump">3,076<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">9,590<span></span>
</td>
<td class="nump">15,464<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="nump">47,088<span></span>
</td>
<td class="nump">57,402<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">322,409<span></span>
</td>
<td class="nump">280,937<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">10,008<span></span>
</td>
<td class="nump">8,823<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_AccruedExpensesAndOtherCurrentLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">24,318<span></span>
</td>
<td class="nump">28,943<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
<td class="nump">346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">7,335<span></span>
</td>
<td class="nump">8,934<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Notes payable, current</a></td>
<td class="nump">786<span></span>
</td>
<td class="nump">4,861<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">42,793<span></span>
</td>
<td class="nump">51,561<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Notes payable, long-term</a></td>
<td class="nump">32,086<span></span>
</td>
<td class="nump">20,204<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">12,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">19,278<span></span>
</td>
<td class="nump">24,168<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">5,783<span></span>
</td>
<td class="nump">6,570<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">112,459<span></span>
</td>
<td class="nump">102,503<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 18)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary shares, &#163;0.10 par value, authority to allot up to a maximum nominal value of &#163;13,023,851.50 of shares at December 31, 2021 and 2020, respectively; 125,674,095 and 98,283,603 shares issued and outstanding at December 31, 2021 and 2020, respectively.</a></td>
<td class="nump">16,253<span></span>
</td>
<td class="nump">12,507<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">940,675<span></span>
</td>
<td class="nump">771,194<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">3,246<span></span>
</td>
<td class="nump">373<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(750,224)<span></span>
</td>
<td class="num">(605,640)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders&#8217; equity</a></td>
<td class="nump">209,950<span></span>
</td>
<td class="nump">178,434<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders&#8217; equity</a></td>
<td class="nump">$ 322,409<span></span>
</td>
<td class="nump">$ 280,937<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_AccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_AccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_ResearchAndDevelopmentTaxCreditReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development tax credit receivable, current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_ResearchAndDevelopmentTaxCreditReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696131181768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - GBP (&#163;)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement Of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary Shares, Par Value</a></td>
<td class="nump">&#163; 0.10<span></span>
</td>
<td class="nump">&#163; 0.10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_CommonStockSharesAuthorizedNominalAmount', window );">Ordinary Shares, Authorized</a></td>
<td class="nump">&#163; 13,023,851.50<span></span>
</td>
<td class="nump">&#163; 13,023,851.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary Shares, Issued</a></td>
<td class="nump">125,674,095<span></span>
</td>
<td class="nump">98,283,603<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary Shares, Outstanding</a></td>
<td class="nump">125,674,095<span></span>
</td>
<td class="nump">98,283,603<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_CommonStockSharesAuthorizedNominalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock shares authorized nominal amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_CommonStockSharesAuthorizedNominalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696130844584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 1,675<span></span>
</td>
<td class="nump">$ 2,595<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpensesAbstract', window );"><strong>Costs and operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of product sales</a></td>
<td class="nump">226<span></span>
</td>
<td class="nump">$ 857<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfCostGoodOrServiceExtensibleList', window );">Type of Cost, Good or Service [Extensible List]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Product Sales, Net [Member]<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">86,977<span></span>
</td>
<td class="nump">$ 93,730<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">54,905<span></span>
</td>
<td class="nump">64,986<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and operating expenses</a></td>
<td class="nump">142,108<span></span>
</td>
<td class="nump">159,573<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(140,433)<span></span>
</td>
<td class="num">(156,978)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other (expense) income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">412<span></span>
</td>
<td class="nump">3,185<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(2,497)<span></span>
</td>
<td class="num">(2,328)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (expense) income, net</a></td>
<td class="num">(1,238)<span></span>
</td>
<td class="nump">3,411<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other (expense) income, net</a></td>
<td class="num">(3,323)<span></span>
</td>
<td class="nump">4,268<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before income tax</a></td>
<td class="num">(143,756)<span></span>
</td>
<td class="num">(152,710)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (expense) benefit</a></td>
<td class="num">(828)<span></span>
</td>
<td class="nump">731<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to ordinary shareholders</a></td>
<td class="num">$ (144,584)<span></span>
</td>
<td class="num">$ (151,979)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share attributable to ordinary shareholders, basic and diluted</a></td>
<td class="num">$ (1.17)<span></span>
</td>
<td class="num">$ (1.53)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average number of ordinary shares outstanding, basic and diluted</a></td>
<td class="nump">123,963,762<span></span>
</td>
<td class="nump">99,445,874<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract', window );"><strong>Other comprehensive income (loss)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">$ 3,124<span></span>
</td>
<td class="num">$ (1,485)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on marketable debt securities</a></td>
<td class="num">(251)<span></span>
</td>
<td class="num">(184)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive income (loss)</a></td>
<td class="nump">2,873<span></span>
</td>
<td class="num">(1,669)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="num">(141,711)<span></span>
</td>
<td class="num">(153,648)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product Sales, Net [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">700<span></span>
</td>
<td class="nump">$ 2,595<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ortx_CollaborationMember', window );">Collaboration Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfCostGoodOrServiceExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates type of cost from product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123410239&amp;loc=SL49130690-203046-203046<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfCostGoodOrServiceExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ortx_CollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ortx_CollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696132721864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Shareholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Ordinary Shares</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 299,193<span></span>
</td>
<td class="nump">$ 12,331<span></span>
</td>
<td class="nump">$ 738,481<span></span>
</td>
<td class="nump">$ 2,042<span></span>
</td>
<td class="num">$ (453,661)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Shares at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,923,729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="nump">27,962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of share options</a></td>
<td class="nump">3,465<span></span>
</td>
<td class="nump">$ 149<span></span>
</td>
<td class="nump">3,316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of share options, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,154,441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of ESPP shares</a></td>
<td class="nump">671<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of ESPP shares, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_StockIssuedDuringPeriodValueAsPartOfConsultingAgreement', window );">Ordinary shares issued as part of consulting agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_StockIssuedDuringPeriodSharesAsPartOfConsultingAgreement', window );">Ordinary shares issued as part of consulting agreement, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Ordinary shares issued as part of license agreement</a></td>
<td class="nump">791<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Ordinary shares issued as part of license agreements, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(1,485)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,485)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized gain (loss) on marketable debt securities</a></td>
<td class="num">(184)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(184)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(151,979)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(151,979)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">178,434<span></span>
</td>
<td class="nump">$ 12,507<span></span>
</td>
<td class="nump">771,194<span></span>
</td>
<td class="nump">373<span></span>
</td>
<td class="num">(605,640)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,283,603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="nump">22,536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of share options</a></td>
<td class="nump">$ 2,739<span></span>
</td>
<td class="nump">$ 224<span></span>
</td>
<td class="nump">2,515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of share options, Shares</a></td>
<td class="nump">1,727,254<span></span>
</td>
<td class="nump">1,727,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of ESPP shares</a></td>
<td class="nump">$ 564<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
<td class="nump">534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of ESPP shares, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">232,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings', window );">Vesting of restricted share units, net of shares withheld for taxes</a></td>
<td class="num">(392)<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="num">(401)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings', window );">Vesting of restricted share units, net of shares withheld for taxes, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of voting and non-voting ordinary shares, net of issuance costs</a></td>
<td class="nump">143,645<span></span>
</td>
<td class="nump">$ 3,310<span></span>
</td>
<td class="nump">140,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of voting and non-voting ordinary shares, net of issuance costs, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,115,755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_StockIssuedDuringPeriodValueAsPartOfConsultingAgreement', window );">Ordinary shares issued as part of consulting agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_StockIssuedDuringPeriodSharesAsPartOfConsultingAgreement', window );">Ordinary shares issued as part of consulting agreement, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_StockIssuedDuringPeriodValueAsPartOfCollaborationAgreement', window );">Ordinary shares issued as part of collaboration agreement</a></td>
<td class="nump">4,135<span></span>
</td>
<td class="nump">$ 170<span></span>
</td>
<td class="nump">3,965<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_StockIssuedDuringPeriodSharesAsPartOfCollaborationAgreement', window );">Ordinary shares issued as part of collaboration agreement, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,227,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">3,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized gain (loss) on marketable debt securities</a></td>
<td class="num">(251)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(251)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(144,584)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(144,584)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 209,950<span></span>
</td>
<td class="nump">$ 16,253<span></span>
</td>
<td class="nump">$ 940,675<span></span>
</td>
<td class="nump">$ 3,246<span></span>
</td>
<td class="num">$ (750,224)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Shares at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,674,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_StockIssuedDuringPeriodSharesAsPartOfCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares as part of collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_StockIssuedDuringPeriodSharesAsPartOfCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_StockIssuedDuringPeriodSharesAsPartOfConsultingAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares as part of consulting agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_StockIssuedDuringPeriodSharesAsPartOfConsultingAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_StockIssuedDuringPeriodValueAsPartOfCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value as part of collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_StockIssuedDuringPeriodValueAsPartOfCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_StockIssuedDuringPeriodValueAsPartOfConsultingAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value as part of consulting agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_StockIssuedDuringPeriodValueAsPartOfConsultingAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after value of shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696130545880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Shareholders' Equity (Parenthetical)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement Of Stockholders Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Sale of voting and non-voting ordinary shares, issuance costs</a></td>
<td class="nump">$ 6,355<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696129326424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss attributable to ordinary shareholders</a></td>
<td class="num">$ (144,584)<span></span>
</td>
<td class="num">$ (151,979)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">2,327<span></span>
</td>
<td class="nump">2,004<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">22,536<span></span>
</td>
<td class="nump">27,962<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_NonCashInterestExpense', window );">Non-cash interest expense</a></td>
<td class="nump">392<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_AmortizationOfProvisionOnLossContract', window );">Amortization of provision on loss contract</a></td>
<td class="num">(1,037)<span></span>
</td>
<td class="num">(2,413)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_NonCashConsiderationForLicensesAndMilestones', window );">Non-cash consideration for licenses and milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">791<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="nump">1,131<span></span>
</td>
<td class="num">(2,257)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_AmortizationOfPremiumOnMarketableSecurities', window );">Amortization of premium on marketable securities</a></td>
<td class="nump">1,514<span></span>
</td>
<td class="nump">770<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_UnrealizedForeignCurrencyAndOtherNonCashAdjustments', window );">Unrealized foreign currency and other non-cash adjustments</a></td>
<td class="nump">9,687<span></span>
</td>
<td class="num">(3,674)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(624)<span></span>
</td>
<td class="nump">582<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable', window );">Research and development tax credit receivable</a></td>
<td class="num">(13,920)<span></span>
</td>
<td class="nump">11,674<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses, other current assets, and other assets</a></td>
<td class="num">(5,209)<span></span>
</td>
<td class="num">(5,070)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_IncreaseDecreaseInOperatingRightOfUseAssets', window );">Operating leases, right-of-use-assets</a></td>
<td class="nump">5,938<span></span>
</td>
<td class="nump">5,863<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accounts payable, accrued expenses, and other current liabilities</a></td>
<td class="num">(9,452)<span></span>
</td>
<td class="num">(12,278)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">13,122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other long-term liabilities</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">2,570<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_IncreaseDecreaseInOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="num">(6,952)<span></span>
</td>
<td class="num">(6,969)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(125,097)<span></span>
</td>
<td class="num">(126,274)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from sales and maturities of marketable securities</a></td>
<td class="nump">234,732<span></span>
</td>
<td class="nump">281,433<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable securities</a></td>
<td class="num">(263,878)<span></span>
</td>
<td class="num">(113,262)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit', window );">Payment of construction deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_ReceiptOfFundsFromConstructionDeposit', window );">Receipt of funds from construction deposit</a></td>
<td class="nump">216<span></span>
</td>
<td class="nump">1,876<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Payments on intangible assets</a></td>
<td class="num">(887)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(2,348)<span></span>
</td>
<td class="num">(2,668)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(32,165)<span></span>
</td>
<td class="nump">157,379<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from modification of credit facility, net of debt issuance costs paid</a></td>
<td class="nump">7,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from employee equity plans</a></td>
<td class="nump">3,303<span></span>
</td>
<td class="nump">3,936<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_PaymentOfTaxesOnRestrictedStockVesting', window );">Payment of taxes on restricted stock vesting</a></td>
<td class="num">(392)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_ProceedsFromIssuanceOfSharesAsPartOfCollaborationAgreement', window );">Proceeds from issuance of shares as part of collaboration agreement</a></td>
<td class="nump">4,135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from the issuance of ordinary shares in private placement</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of placement agent fees and offering costs</a></td>
<td class="num">(6,355)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">158,066<span></span>
</td>
<td class="nump">3,936<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Effect of exchange rate changes on cash</a></td>
<td class="num">(27)<span></span>
</td>
<td class="nump">1,043<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash, cash equivalents and restricted cash</a></td>
<td class="nump">777<span></span>
</td>
<td class="nump">36,084<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents, and restricted cash &#8212;beginning of year</a></td>
<td class="nump">59,401<span></span>
</td>
<td class="nump">23,317<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents, and restricted cash &#8212;end of year</a></td>
<td class="nump">60,178<span></span>
</td>
<td class="nump">59,401<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_IntangibleAssetsAndPropertyAndEquipmentInAccountsPayableAndAccruedExpenses', window );">Intangible assets and property and equipment in accounts payable and accrued expenses</a></td>
<td class="nump">2,589<span></span>
</td>
<td class="nump">3,096<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Shares issued in consideration of license agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">791<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_EmployeeEquityPlanProceedsReceived', window );">Employee equity plan proceeds received after year-end</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Lease assets obtained in exchange for new operating lease liabilities</a></td>
<td class="nump">552<span></span>
</td>
<td class="nump">17,486<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">2,103<span></span>
</td>
<td class="nump">1,828<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for taxes</a></td>
<td class="nump">$ 1,651<span></span>
</td>
<td class="nump">$ 1,007<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_AmortizationOfPremiumOnMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization of premium on marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_AmortizationOfPremiumOnMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_AmortizationOfProvisionOnLossContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization of provision on loss contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_AmortizationOfProvisionOnLossContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_EmployeeEquityPlanProceedsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee equity plan proceeds received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_EmployeeEquityPlanProceedsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in accounts payable and accrued liabilities and other operating liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_IncreaseDecreaseInOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in operating lease liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_IncreaseDecreaseInOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_IncreaseDecreaseInOperatingRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in operating leases, right-of-use-assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_IncreaseDecreaseInOperatingRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in research and development tax credit receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_IntangibleAssetsAndPropertyAndEquipmentInAccountsPayableAndAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intangible assets and property and equipment in accounts payable and accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_IntangibleAssetsAndPropertyAndEquipmentInAccountsPayableAndAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_NonCashConsiderationForLicensesAndMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-cash consideration for licenses and milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_NonCashConsiderationForLicensesAndMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_NonCashInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-cash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_NonCashInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_PaymentOfTaxesOnRestrictedStockVesting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment of taxes on restricted stock vesting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_PaymentOfTaxesOnRestrictedStockVesting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_ProceedsFromIssuanceOfSharesAsPartOfCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of shares as part of collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_ProceedsFromIssuanceOfSharesAsPartOfCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_ReceiptOfFundsFromConstructionDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Receipt of funds from construction deposit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_ReceiptOfFundsFromConstructionDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_UnrealizedForeignCurrencyAndOtherNonCashAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrealized foreign currency and other non-cash adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_UnrealizedForeignCurrencyAndOtherNonCashAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123371682&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from temporary investment with specific maturity and interest rate that are prohibited for current use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696239494376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Nature of Business and Basis of Presentation</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1. Nature of Business and Basis of Presentation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Orchard Therapeutics plc (the &#8220;Company&#8221;) is a global gene therapy company dedicated to transforming the lives of people affected by severe diseases through the development of innovative, potentially curative gene therapies. The Company&#8217;s&#160;<span style="font-style:italic;">ex vivo</span>&#160;autologous hematopoietic stem cell (&#8220;HSC&#8221;) gene therapy approach utilizes genetically modified blood stem cells and seeks to correct the underlying cause of disease in a single administration. The Company&#8217;s gene therapy product candidate pipeline spans multiple therapeutic areas where the disease burden on children, families and caregivers is immense and current treatment options are limited or do not exist.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is a public limited company incorporated pursuant to the laws of England and Wales. The Company has American Depositary Shares (&#8220;ADSs&#8221;) registered with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) and has been listed on the Nasdaq Global Select Market since October 31, 2018. The Company&#8217;s ADSs each represent one ordinary share of the Company.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2020, the Company received standard marketing authorization from the European Commission for Libmeldy&#8482; (<span style="color:#000000;">atidarsagene autotemcel</span>), for the treatment of early onset metachromatic leukodystrophy (&#8220;MLD&#8221;), characterized by biallelic mutations in the&#160;<span style="font-style:italic;">arylsulfatase-A</span>&#160;(<span style="font-style:italic;">ARSA</span>) gene leading to a reduction of the ARSA enzymatic activity in children with (i) late infantile or early juvenile forms, without clinical manifestations of the disease, or (ii) the early juvenile form, with early clinical manifestations of the disease, who still have the ability to walk independently and before the onset of cognitive decline.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February 9, 2021, the Company issued and sold (i) 20,900,321 ordinary shares, nominal value &#163;0.10 per share, at a purchase price of $6.22 per share (the &#8220;Purchase Price&#8221;), which was the closing sale price of the Company&#8217;s ADSs on the Nasdaq Global Select Market on February 4, 2021, and (ii) 3,215,434 non-voting ordinary shares, nominal value &#163;0.10 per share, at the Purchase Price (together (i) and (ii) the &#8220;Private Placement&#8221;). The Private Placement resulted in net proceeds to the Company of $143.6 million after deducting placement agent fees of $6.0 million and other issuance costs of $0.4 million. The ordinary shares and non-voting ordinary shares were sold pursuant to a securities purchase agreement entered into between the Company and the purchasers named therein on February 4, 2021.&#160;&#160;At December 31, 2021, all outstanding non-voting shares have been converted to voting ordinary shares.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s business is subject to risks and uncertainties common to development-stage companies in the biotechnology industry. There can be no assurance that the Company&#8217;s research and development will be successfully completed, that adequate protection for the Company&#8217;s technology will be obtained, that any products developed will obtain necessary government regulatory approval or that any products, if approved, will be commercially viable. The Company operates in an environment of rapid technological innovation and substantial competition from pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees, consultants and service providers. Even if the Company&#8217;s product development efforts are successful in gaining regulatory approval, it is uncertain when, if ever, the Company will realize significant revenue from product sales. &#160;<span style="Background-color:#FFFFFF;">The future developments of the COVID-19 pandemic may also directly or indirectly impact the Company&#8217;s business, including impacts due to&#160;quarantines, border closures, increased border controls, travel restrictions, shelter-in-place orders and shutdowns, business closures, cancellations of public gatherings and other measures.</span> </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. Through December&#160;31, 2021, the Company funded its operations primarily with proceeds from the sale of convertible preferred shares, and ADSs in the IPO and follow-on offering. The Company has incurred recurring losses since its inception, including net losses of $144.6 million and $152.0 million for the years ended December&#160;31, 2021 and 2020, respectively. As of December&#160;31, 2021, the Company had an accumulated deficit of $750.2 million. The Company expects to continue to generate operating losses for the foreseeable future. The Company expects that its cash, cash equivalents, and marketable securities on hand as of December&#160;31, 2021 of $220.1 million will be sufficient to fund its operations and capital expenditure requirements for at least the next twelve months. <span style="Background-color:#FFFFFF;">The Company will seek additional funding through private or public equity financings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into collaborations or other arrangements. The terms of any financing may adversely affect the holdings or the rights of the Company's stockholders.&#160;</span>The future viability of the Company is dependent on its ability to raise additional capital to finance its </p>
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">operations. If the Company is unable to obtain funding, the Company will be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects, or the Company may be unable to continue operations. Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Basis of presentation </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and include the accounts of the Company and its wholly owned subsidiaries, after elimination of all intercompany accounts and transactions. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts reported are based in thousands, except percentages, per share amounts or as otherwise noted. As a result, certain totals may not sum due to rounding.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696130452152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2. Summary of Significant Accounting Policies </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Principles of consolidation</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of estimates </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual for research and development expenses, the research and development tax credit receivable, share-based compensation, collaboration agreement milestones, operating lease assets and liabilities, and income taxes. Estimates are periodically reviewed in light of changes in circumstances, facts and experience.<span style="Background-color:#FFFFFF;"> Actual results could differ from the Company&#8217;s estimates.</span>&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of credit risk </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has no significant off-balance sheet risk, such as foreign currency contracts, options contracts, or other foreign hedging arrangements. Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents, marketable securities, and receivables. The Company maintains deposits in accredited financial institutions in excess of federally insured limits. The Company deposits its cash in financial institutions that it believes have high credit quality and has not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships or entities for which it has a receivable. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Foreign currency</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The financial statements of the Company&#8217;s subsidiaries with functional currencies other than the U.S. Dollar are translated into U.S. Dollars using period-end exchange rates for assets and liabilities, historical exchange rates for shareholders&#8217; equity and weighted average exchange rates for operating results. Translation gains and losses are included in accumulated other comprehensive income (loss) in shareholders&#8217; equity. Foreign currency transaction gains and losses are included in other income (expense), net in the results of operations.</span><span style="color:#000000;">  The Company recorded realized and unrealized foreign currency transaction losses of $1.2 million, and gains of $3.4 million for the years ended December 31, 2021, and 2020, respectively, which is included in other income (expense) in the statements of operations and comprehensive loss. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Segment information</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company operates in a single segment, focusing on researching, developing and commercializing potentially curative gene therapies.&#160;&#160;Consistent with its operational structure, its chief operating decision maker manages and allocates resources at a global, consolidated level. Therefore, results of the Company's operations are reported on a consolidated basis for purposes of segment reporting.&#160;&#160;All material long-lived assets of the Company reside in the United States or United Kingdom. The Company had property and equipment of $3.6 million and $1.2 million located in the United Kingdom and United States, respectively, as of December 31, 2021. </span>The Company had property and equipment of $3.7 million and $1.1 million located in the United Kingdom and United States, respectively, as of December 31, 2020.&#160;The Company had right-of-use assets in the United States and United Kingdom and European Union of $12.5 million and $11.8 million, respectively, as of December 31, 2021. The Company had right-of-use assets in the United States and United Kingdom and European Union of $14.2 million and $15.6 million, respectively, as of December 31, 2020.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash equivalents </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid investments purchased with original maturities of 90 days or less at the date of acquisition to be cash equivalents. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Marketable securities</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities consist of investments with original maturities greater than ninety days at the date of acquisition. The Company has classified its investments with maturities beyond one year as short term, based on their highly liquid nature and because such marketable securities represent the investment of cash that is available for current operations. The Company considers its investment portfolio of investments as&#160;available-for-sale.&#160;Accordingly, these investments are recorded at fair value, which is based on quoted market prices or other observable inputs. Unrealized gains and losses are recorded as a component of other comprehensive income (loss). Realized gains and losses are determined on a specific identification basis and are included in other income (loss). Amortization and accretion of discounts and premiums is also recorded in other income (loss).</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">When the fair value is below the amortized cost of the asset an estimate of expected credit losses is made, the estimate is limited to the amount by which fair value is less than amortized cost. The credit-related impairment amount is recognized in the consolidated statements of operations; the remaining impairment amount and unrealized gains are reported as a component of accumulated other comprehensive income (loss) in shareholders&#8217; equity. Credit losses are recognized through the use of an allowance for credit losses account and subsequent improvements in expected credit losses are recognized as a reversal of the allowance account. If the Company has the intent to sell the security or it is more likely than not that the Company will be required to sell the security prior to recovery of its amortized cost basis the allowance for credit loss is written off and the excess of the amortized cost basis of the asset over its fair value is recorded in the consolidated statements of operation.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Restricted cash and construction deposits</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents that are restricted as to withdrawal or use under the terms of certain contractual agreements are recorded as restricted cash on our consolidated balance sheet. The Company has an outstanding letter of credit for $3.0 million associated with a lease, and is required to hold this amount in a standalone bank account at December 31, 2021 and 2020. The Company is also contractually required to maintain a cash collateral account associated with corporate credit cards and other leases in the amount of <span>$1.3</span> million at December 31, 2021 and 2020. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company includes the restricted cash balance in cash and cash equivalents when reconciling beginning-of-period and end-of-period total amounts shown on the consolidated statements of cash flows. The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported in the consolidated balance sheet that sum to the total of the amounts reported in the consolidated statement of cash flows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,912</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,135</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,266</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,266</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash, cash equivalents and restricted cash shown in the statement of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; cash flows</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60,178</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59,401</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company also has <span style="color:#000000;">$7.9 million in an escrow account associated with the construction of the Company&#8217;s leased facility in Fremont, California, which the Company has ceased construction and build-out, and has subleased the facility to a third-party who intends to perform construction and build-out of the facility. </span>Subject to the terms of the lease and reduction provisions, this escrow amount may be decreased to nil over time upon qualifying construction expenditures, or will be returned in late 2022 to the extent funds are not used. The Company deposited $10.0 million into the account in the first quarter of 2020 and has received $2.1 million in receipts from the escrow funds for work performed to date. Of the $7.9 million remaining in the escrow account, the entire balance is classified within other prepaid expenses and other current assets on the consolidated balance sheets based on the timing of when the Company expects to receive the cash from the escrow agent.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Inventory</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventory is stated at the lower of cost or estimated net realizable value with cost determined on a first-in, first-out basis. Inventory costs include raw materials, third-party contract manufacturing, third-party packaging services, and freight. Raw and intermediate materials that may be utilized for either research and development or commercial purposes are classified as inventory. Amounts in inventory that are used for research and development purposes are charged to research and development expense when the product enters the research and development process and can no longer be used for commercial purposes and, therefore, does not have an &#8220;alternative future use&#8221; as defined in authoritative guidance. The Company performs an assessment of the recoverability of capitalized inventory during each reporting period and, if needed, writes down any excess and obsolete inventory to its estimated net realizable value in the period it is identified. If they occur, such impairment charges are recorded as a component of cost of goods sold in the consolidated statements of operations and comprehensive income (loss). Inventory is included in prepaid expenses and other current assets on the consolidated balance sheets and the amount was not significant as of December&#160;31, 2021.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the initial date that regulatory approval is received, costs related to the production of inventory are recorded as research and development expense on the Company&#8217;s consolidated statements of operations and comprehensive income (loss) in the period incurred. In connection with the acquisition of Strimvelis in April 2018, and with the EMA approval of Libmeldy in December 2020, the Company subsequently began capitalizing inventory manufactured or purchased after these dates.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Intangible assets, net</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Intangible assets, net consist milestones associated with the Company&#8217;s approved products, net of accumulated amortization. The Company amortizes its intangible assets using the straight-line method over their estimated economic lives and periodically reviews for impairment. The Company has not recognized any impairment charges related to intangible assets to date.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Property and equipment </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are recorded at cost and depreciated or amortized using the straight-line method over the following estimated useful lives. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated useful&#160;&#160;life</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lab equipment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5-10 years</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shorter of lease term or estimated useful life</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4 years</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Office and computer equipment</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3-5 years</p></td>
</tr>
</table></div>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Repairs and maintenance expenditures, which are not considered improvements and do not extend the useful life of property and equipment, are expensed as incurred. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts, and any resulting gain or loss is included in the consolidated statements of operations and other comprehensive loss. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Impairment of long-lived assets </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-lived assets consist of property and equipment and operating lease right-of-use assets. Long-lived assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or </p>
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">economic trends and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset group for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset group to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of an asset group are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset group over its fair value, as determined in accordance with the related accounting literature</span><span style="color:#000000;">. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research and development costs </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including salaries, share-based compensation and benefits, facilities costs, depreciation, third-party license fees, certain milestone payments, and external costs of outside vendors engaged to conduct clinical development activities and clinical trials, the purchase of in-process research and development assets, as well as costs to develop a manufacturing process, perform analytical testing and manufacture clinical trial materials. Non-refundable prepayments for goods or services that will be used or rendered for future research and development activities are recorded as prepaid expenses. Such amounts are recognized as an expense as the goods are delivered or the related services are performed, or until it is no longer expected that the goods will be delivered, or the services rendered. In addition, funding from research grants is recognized as an offset to research and development expense on the basis of costs incurred on the research program. Royalties to third parties associated with our research grants will be accrued when they become probable.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research contract costs and accruals </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has entered into various research and development contracts. These agreements are cancelable, and related costs are recorded as research and development expenses as incurred. When billing terms under these contracts do not coincide with the timing of when the work is performed, the Company is required to make estimates of outstanding obligations as of period end to those third parties. Any accrual estimates are based on a number of factors, including the Company&#8217;s knowledge of the progress towards completion of the research and development activities, invoicing to date under the contracts, communication from the research institution or other companies of any actual costs incurred during the period that have not yet been invoiced, and the costs included in the contracts. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the expense. Actual results could differ from the estimates made by the Company. The historical accrual estimates made by the Company have not been materially different from the actual costs.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Share-based compensation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company measures share-based awards granted to employees, consultants and directors based on the fair value of the shares and options on the date of the grant and recognizes compensation expense for those awards over the requisite service period, which is the vesting period of the respective award. Forfeitures are accounted for as they occur. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Comprehensive loss </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Comprehensive loss is composed of net loss and other comprehensive income (loss). Other comprehensive income (loss) consists of unrealized gains and losses on marketable securities and foreign currency translation gains and losses.</span><span style="color:#000000;"> &#160;&#160;</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Leases</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determines if an arrangement is a lease at contract inception. Operating lease assets represent a right to use an underlying asset for the lease term and operating lease liabilities represent an obligation to make lease payments arising from the lease. Operating lease liabilities with a term greater than one year and their corresponding right-of-use assets are recognized on the balance sheet at the commencement date of the lease based on the present value of lease payments over the expected lease term. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received. The Company made an accounting policy election to not record a right-of-use asset or lease liability for leases with a term of one year or less. To date, the Company has not identified any material short-term leases, either individually or in the aggregate.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">As&#160;the Company&#8217;s&#160;leases do not provide an implicit rate,&#160;the Company utilized the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term as the lease an amount equal to the lease payments in a similar economic environment. The Company estimated the incremental borrowing rate based on the </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Company&#8217;s currently outstanding credit facility as inputs to the analysis to calculate a spread, adjusted for factors that reflect the profile of secured borrowing over the expected term of the lease.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The components of a lease should be split into three categories: lease components (e.g., land, building, etc.), non-lease components (e.g., common area maintenance, utilities, performance of manufacturing services, purchase of inventory, etc.), and non-components (e.g., property taxes, insurance, etc.). Then the fixed contract consideration (including any related to non-components) must be allocated based on fair values to the lease components and non-lease components. Although separation of lease and non-lease components is required, certain accounting policy elections are available to entities. Entities can elect accounting policies that would not separate lease and non-lease components. Rather, they would account for each lease component and the related non-lease&#160;component together as a single component. The Company has elected&#160;not to apply the accounting policy with respect to its lease of manufacturing space at a contract manufacturing organization, the Company has allocated the consideration between the lease and non-lease components of the contract&#160;based on the respective fair values of the lease and non-lease components.&#160;The&#160;Company calculated the fair value of the lease&#160;and non-lease&#160;components&#160;using financial information readily available as part of its master services arrangement&#160;and other representative data&#160;indicative of fair value.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company accounts for sublease income on a straight-line basis over the respective lease period and records an unbilled rent receivable for sublease income incurred but not yet paid. The Company periodically performs a collectability assessment associated with any unbilled rent receivables. The Company recognizes the sublease income as a reduction to the related operating expense associated with the head lease.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Strimvelis loss provision</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of the GSK transaction, the Company is required to maintain commercial availability of Strimvelis in the European Union until such time that an alternative gene therapy is available (see Note 15). Strimvelis is not currently expected to generate sufficient cash flows to overcome the costs of maintaining the product and certain regulatory commitments; therefore, the Company initially recorded a liability associated with the loss contract of $18.4&#160;million in 2018. The Company recognizes the amortization of the loss provision on a diminishing balance basis based on the actual net loss incurred associated with the Strimvelis program and the expected future net losses to be generated until such time as Strimvelis is no longer commercially available. The amortization of the provision is recorded as a credit to research and development expense. The Company has made an estimate of the expected future losses associated with Strimvelis and will adjust this estimate as facts and circumstances change regarding the commercial availability and costs of maintaining and selling Strimvelis. The Company does not update the accrued loss provision for any subsequent adjustment of the future losses, however, the timing of recognizing the amortization of what was originally recorded is adjusted for the updated future losses. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table below outlines the changes to the Strimvelis loss provision for the periods ended December 31, 2021 and 2020:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.84%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.96%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.84%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at beginning of period</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,482</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,790</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provisions</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.06%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.06%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization of loss provision</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.06%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,037</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.06%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,413</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign currency translation</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.84%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.84%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.22%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at end of period</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.84%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,419</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.84%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,482</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, $0.7 million of the Strimvelis loss provision was classified as current, and $2.7 million was classified as non-current. As of December 31, 2020, $0.9 million of the Strimvelis loss provision was classified as current, and $3.6 million was classified as non-current.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">United Kingdom Research and development income tax credits </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a company that carries out research and development activities, the Company is able to submit tax credit claims from two UK research and development tax relief programs, the SME program and the RDEC program depending on eligibility. Qualifying expenditures largely comprise employment costs for research staff, consumables and certain internal overhead costs incurred as part of research projects for which the Company does not receive income.<span style="color:#000000;"> </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each reporting period, management evaluates which tax relief programs the Company is expected to be eligible for and records a reduction to research and development expense for the portion of the expense that it expects to qualify under the </p>
<p style="margin-bottom:0pt;margin-top:12pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">programs, that it plans to submit a claim for, and it has reasonable assurance that the amount will ultimately be realized. </span><span style="color:#000000;">Based on criteria established by HM Revenue and Customs (&#8220;HMRC&#8221;), management of the Company expects a proportion of expenditures being undertaken in relation to its pipeline research, clinical trials management and manufacturing development activities to be eligible for the research and development tax relief programs for the year ended December 31, 2021. </span><span style="Background-color:#FFFFFF;">The Company has qualified under the more favorable SME regime for the year ended December 31, 2020 and expects to qualify under the SME regime for the year ending December 31, 2021.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The RDEC and SME credits are not dependent on the Company generating future taxable income or on the ongoing tax status or tax position of the Company. The Company has assessed its research and development activities and expenditures to determine whether the nature of the activities and expenditures will qualify for credit under the tax relief programs and whether the claims will ultimately be realized based on the allowable reimbursable expense criteria established by the UK government which are subject to interpretation. At each period end, the Company estimates the reimbursement available to the Company based on available information at the time.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes credits from the research and development incentives when the relevant expenditure has been incurred and there is reasonable assurance that the reimbursement will be received.&#160;Such credits are accounted for as reductions in research and development expense. The following table outlines the changes to the research and development tax credit receivable, including amount recognized as an offset to research and development expense during the years ended December 31, 2021 and 2020:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.98%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.18%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at beginning of period</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,344</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,644</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.18%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recognition of credit claims as offset to research and development expense</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,920</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,130</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.18%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Receipt of credit claims</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(33,771</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.18%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign currency translation</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(541</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,341</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.18%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at end of period</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,723</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,344</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">During the year ended December 31, 2020, the Company recorded $4.8&#160;million of additional tax credits related to a change in estimate associated with its UK research and development tax credit receivable claim for fiscal year 2019. The change in estimate was based on the results of a tax credit&#160;analysis&#160;associated with the Company&#8217;s qualified projects and research and development expenditures completed during the third quarter to finalize the 2019 UK tax return.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, the Company&#8217;s tax credit receivable from the UK was $30.7 million, all of which was classified as current. As of December&#160;31, 2020, the Company&#8217;s tax incentive receivable from the UK was $17.3 million, all of which was classified as current.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Income taxes </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is primarily subject to corporation taxes in the United Kingdom and the United States. The calculation of the Company&#8217;s tax provision involves the application of both United Kingdom and United States tax law and requires judgement and estimates. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for income taxes in accordance with ASC Topic 740, <span style="font-style:italic;">Accounting for Income Taxes</span>, which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. The Company determines its deferred tax assets and liabilities based on differences between financial reporting and tax bases of assets and liabilities, which are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are provided if, based upon the weight of available evidence, it is more likely than not that some or all of the net deferred tax assets will not be realized. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for uncertainty in income taxes by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed as the amount of benefit to recognize in the consolidated financial statements. The amount of benefits that may be used is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate, as well as the related net interest and penalties. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Product sales</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s product sales in 2021 and 2020 consist of sales of Strimvelis, which is distributed exclusively at the San Raffaele Hospital in Milan, Italy. San Raffaele Hospital will purchase and pay for Strimvelis and submit a claim to the payer. The Company&#8217;s contracted sales with San Raffaele Hospital contain a single performance obligation and the Company recognizes revenue from product sales when the Company has satisfied its performance obligation by transferring control of Strimvelis to San Raffaele Hospital. Control of the product generally transfers upon the completion of the scheduled Strimvelis treatment. The Company&#8217;s product sales represent total net product sales of Strimvelis. The Company evaluated the variable consideration under Accounting Standards Codification (ASC) 606,&#160;<span style="font-style:italic;">Revenue from Contracts with Customers</span>, and there is currently no variable consideration included in the transaction price for Strimvelis. Costs to manufacture and deliver the product and those associated with administering the therapy are included in cost of product sales. As the product is sold in direct relation to a scheduled treatment, the Company estimates that there is limited risk of product return, including the risk of product expiration. During the years ended December 31, 2021 and 2020, the Company has $0.7 and $2.6 million in sales of Strimvelis, respectively.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Collaboration revenue</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The terms of the Company&#8217;s collaboration agreements may include consideration such as&#160;non-refundable license fees, funding of research and development services, payments due upon the achievement of clinical and preclinical performance-<span style="color:#000000;">based development milestones, regulatory milestones, manufacturing services, sales-based milestones and royalties on product sales.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company first evaluates collaboration arrangements to determine whether the arrangement (or part of the arrangement) represents a collaborative arrangement pursuant to ASC Topic 808,&#160;<span style="font-style:italic;">Collaborative Arrangements</span>, based on the risks and rewards and activities of the parties pursuant to the contractual arrangement. The Company accounts for any collaborative arrangement or elements within the contract that are deemed to be a collaborative arrangement, and not<span style="font-size:12pt;"> </span>a customer relationship, in accordance with ASC&#160;808. Through December&#160;31, 2021, the Company entered into one agreement with Pharming Group N.V. (the &#8220;Pharming Agreement&#8221;, see Note 16) that is accounted for pursuant to ASC 606.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:9pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine the appropriate amount of revenue to be recognized for arrangements determined to be within the scope of ASC&#160;606, the Company performs the following five steps: (i)&#160;identification of the contract(s) with the customer, (ii)&#160;identification of the promised goods or services in the contract and determination of whether the promised goods or services are performance obligations, (iii)&#160;measurement of the transaction price, (iv)&#160;allocation of the transaction price to the performance obligations, and (v)&#160;recognition of revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect consideration it is entitled to in exchange for the goods or services it transfers to the customer.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company recognizes the&#160;</span>transaction&#160;<span style="Background-color:#FFFFFF;">price allocated to upfront license payments as revenue upon delivery of the license to the customer and resulting ability of the customer to use and benefit from the license, if the license is determined to be distinct from the other performance obligations identified in the contract. If the license is considered to not be distinct from other performance obligations, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied (i)&#160;at a point in time, but only for licenses determined to be distinct from other performance obligations in the contract, or (ii)&#160;over time, and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from license payments. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Pharming Agreement entitles the Company to additional payments upon the achievement of performance-based milestones. These milestones are generally categorized into three types: development milestones, regulatory milestones, and sales-based milestones.&#160;The Company is also eligible to receive from Pharming tiered royalty payments on worldwide net sales. The Company evaluates whether it is probable that the consideration associated with each milestone will not be subject to a significant reversal in the cumulative amount of revenue recognized. Amounts that meet this threshold are included in the transaction price using the most likely amount method, whereas amounts that do not meet this threshold are considered constrained and excluded from the transaction price until they meet this threshold.&#160;Milestones tied to regulatory approval, and therefore not within the Company&#8217;s control, are considered constrained until such approval is received. Upfront and ongoing development milestones per the collaboration agreements are not subject to refund if the development activities are not successful. At the end of each subsequent reporting period, the Company&#160;</span>re-evaluates<span style="Background-color:#FFFFFF;">&#160;the probability of a significant reversal of the cumulative revenue recognized for the milestones, and, if necessary, adjusts the estimate of the overall transaction price. Any such adjustments are recorded on a cumulative&#160;</span>catch-up <span style="Background-color:#FFFFFF;">basis, which would affect revenues from collaborators in </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">the period of adjustment. The Company may enter into an agreement that includes sales-based milestone payments and royalties in exchange for a license of intellectual property. The Company considers the underlying facts and circumstances of these agreements, noting whether the future payments are contingent upon future sales and whether they are dependent on a third party&#8217;s ability to successfully commercialize a product using the licensed intellectual property. The Company also considers whether the license is the only, or predominant, item to which the milestone payments and royalties relate. If the Company concludes the license is the predominant item in the agreement, therefore the primary driver of value, the Company excludes sales-based milestone payments and royalties from the transaction price until the sale occurs (or, if later, until the underlying performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied). Currently, the Company has not recognized any royalty revenue resulting from the </span><span style="Background-color:#FFFFFF;">Pharming </span><span style="Background-color:#FFFFFF;">Agreement.</span></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ASC 606 requires the Company to allocate the arrangement consideration on a relative standalone selling price basis for each performance obligation after determining the transaction price of the contract and identifying the performance obligations to which that amount should be allocated. The relative standalone selling price is defined in ASC 606 as the price at which an entity would sell a promised good or service separately to a customer. If other observable transactions in which the Company has sold the same performance obligation separately are not available, the Company is required to estimate the standalone selling price of each performance obligation. Key assumptions to determine the standalone selling price may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Whenever the Company determines that a contract should be accounted for as a combined performance obligation, which is recognized over time, it will utilize the&#160;cost-to-cost&#160;input method. Revenue will be recognized over time using the&#160;cost-to-cost&#160;input method, based on the total estimated costs to fulfill the obligations. The Company will recognize revenue as services are delivered. Significant management judgment is required in determining the estimate of total costs required under an arrangement and the period over which the Company is expected to complete its performance obligations under an arrangement.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Consideration that does not meet the requirements to satisfy the above revenue recognition criteria is a contract liability and is recorded as deferred revenue in the consolidated balance sheets. Short-term deferred revenue consists of amounts that are expected to be recognized as revenue in the next 12 months. Amounts that the Company expects will not be recognized within the next 12 months are classified as long-term deferred revenue.</span></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied, either at a point in time or over time. In particular, for the Company&#8217;s collaborations with Pharming, revenue attributable to research services is recognized as those services are provided, based on the costs incurred to date.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Net loss per share </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share is computed by dividing the net loss by the weighted average number of ordinary shares outstanding for the period. Diluted net loss is computed by adjusting net loss based on the potential impact of dilutive securities. Diluted net loss per share is computed by dividing the diluted net loss by the weighted average number of ordinary shares outstanding for the period, including potential dilutive ordinary shares. For purpose of this calculation, outstanding options and unvested restricted shares are considered potential dilutive ordinary shares. Since the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share for all periods as the inclusion of all potential ordinary share equivalents outstanding would have been anti-dilutive. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following securities, presented based on amounts outstanding at each period end, are considered to be ordinary share equivalents, but were not included in the computation of diluted net loss per ordinary share because to do so would have been anti-dilutive: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share options</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,042,781</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,071,555</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested shares from share plan and consulting agreement</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">512,908</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">816,316</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,555,689</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,887,871</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recent accounting pronouncements</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<span style="color:#000000;">In November 2021, the FASB issued ASU No. 2020-10,&#160;</span><span style="font-style:italic;color:#000000;">Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance</span><span style="color:#000000;">, which requires increased transparency in the disclosures about government assistant in the notes to the financial statements. This ASU is effective for the Company beginning January 1, 2022, and interim periods within that year, with early adoption permitted. The Company does not expect this amendment to have a significant effect on its financial statement disclosures. </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696130435816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements and Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements and Marketable Securities</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3. Fair Value Measurements and Marketable Securities</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables present information about the Company&#8217;s financial assets that have been measured at fair value as of December 31, 2021 and 2020, and indicate the fair value of the hierarchy of the valuation inputs utilized to determine such fair value. In general, fair values determined by Level&#160;1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Fair value determined by Level&#160;2 inputs utilize observable inputs other than Level&#160;1 prices, such as quoted prices for similar assets or liabilities, quoted market prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities. Fair values determined by Level&#160;3 inputs are unobservable data points for the asset or liability, and include situations where there is little, if any, market activity for the asset or liability. During the years ended December 31, 2021 and 2020, there were no transfers between Level&#160;1 and Level&#160;2 financial assets.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the Company&#8217;s cash equivalents and marketable securities as of December 31, 2021:</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements as of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021 Using:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,085</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,085</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,321</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,321</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,198</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,198</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash equivalents</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,085</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,519</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,604</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94,794</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94,794</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69,401</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69,401</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total marketable securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">164,195</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">164,195</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,085</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">184,714</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">205,799</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the Company&#8217;s cash equivalents and marketable securities as of December 31, 2020:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements as of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020 Using:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,650</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,650</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,001</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,001</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,999</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,999</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash equivalents</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,650</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,000</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,650</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US government securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,997</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,997</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93,358</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93,358</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,458</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,458</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total marketable securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">136,813</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">136,813</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,650</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">142,813</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">149,463</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying amount reflected in the consolidated balance sheets for research and development tax incentive receivable, trade receivables, other receivables, accounts payable, and accrued expenses approximate fair value due to their short-term maturities. The carrying value of the Company&#8217;s outstanding notes payable approximates fair value (a Level 2 fair value measurement), reflecting interest rates currently available to the Company.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Marketable Securities</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the Company&#8217;s cash equivalents and marketable securities as of December 31, 2021:</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.58%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="18" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.3%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements as of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021 Using:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.58%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Credit Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.58%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.12%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102,224</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.12%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.12%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(109</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.36%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.12%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102,115</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.58%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82,657</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(58</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82,599</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.58%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">184,881</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(167</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">184,714</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the Company&#8217;s cash equivalents and marketable securities as of December 31, 2020:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="18" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.36%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements as of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020 Using:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Credit Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.54%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,000</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,996</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.54%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96,259</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">133</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(32</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96,360</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.54%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,469</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,457</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.54%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">142,728</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">134</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(49</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">142,813</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the Company&#8217;s available-for-sale marketable debt securities by contractual maturity, as of December 31, 2021 and 2020:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.2%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maturities in one year or less</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">172,575</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132,056</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.2%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maturities between one and three years</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,139</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,757</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.2%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">184,714</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">142,813</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696130431944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue From Contract With Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue Recognition</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4. Product sales</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the years ended December 31, 2021 and 2020, the Company recorded sales for one commercial-stage therapy, Strimvelis, for the treatment of ADA-SCID. Strimvelis is c<span style="Background-color:#FFFFFF;color:#000000;">urrently distributed exclusively at the San Raffaele Hospital in Milan, Italy. San Raffaele Hospital will purchase and pay for Strimvelis and submit a claim to the payer. The Company&#8217;s contracted sales with San Raffaele Hospital contain a single performance obligation and the Company recognizes revenue from product sales when the Company has satisfied its performance obligation by transferring control of Strimvelis to San Raffaele Hospital. Control of the product generally transfers upon the completion of the scheduled Strimvelis treatment. The Company&#8217;s product sales represent total net product sales of Strimvelis. The Company evaluated the variable consideration under Accounting Standards Codification (ASC) 606,&#160;</span><span style="font-style:italic;Background-color:#FFFFFF;color:#000000;">Revenue from Contracts with Customers</span><span style="Background-color:#FFFFFF;color:#000000;">, and there is currently no variable consideration included in the transaction price for Strimvelis. Costs to manufacture and deliver the product and those associated with administering the therapy are included in cost of product sales. As the product is sold in direct relation to a scheduled treatment, the Company estimates that there is limited risk of product return, including the risk of product expiration.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payment terms and conditions generally require payment for Strimvelis sales within 60 days of treatment. Strimvelis is currently distributed exclusively at the San Raffaele Hospital, and there is currently no variable consideration included in the transaction price of Strimvelis.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696130631160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expense And Other Assets Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_PrepaidExpensesAndOtherCurrentAssetsTextBlock', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5. Prepaid expenses and other current assets</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets consist of the following:</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.32%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid external research and development expenses</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,438</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,421</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventories</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,016</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">665</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other prepayments</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,128</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,930</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">VAT receivable</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,169</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,780</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction deposit - current</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,909</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,552</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-trade receivables</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,351</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,017</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total prepaid expenses and other current assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,011</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,365</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_PrepaidExpensesAndOtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid expenses and other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_PrepaidExpensesAndOtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696130563960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">6. Property and equipment </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment consist of the following: </p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.32%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lab equipment</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,937</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,114</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,450</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,522</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">303</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">304</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Office and IT equipment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,023</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">763</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction-in-progress</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">211</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">302</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,924</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,005</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: accumulated depreciation</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,157</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,224</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,767</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,781</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation expense for the years ended December&#160;31, 2021 and 2020 was $2.2 million and $2.0 million, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696130643832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill And Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets, Net</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7. Intangible assets, net</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets, net of accumulated amortization, consisted of the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.06%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.32%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated Amortization</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-top:solid 0.75pt #000000;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Net</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-top:solid 0.75pt #000000;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated Amortization</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Net</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.64%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License intangibles</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,329</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(180</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,149</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,076</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,076</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.64%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,329</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(180</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,149</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,076</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,076</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License intangibles consist of capitalized milestone payments or accruals of payments the Company has deemed probable upon receiving regulatory approval of Libmeldy in the EU. The license intangibles are being amortized on a straight-line basis over the remaining useful life of the related patents of approximately twelve years. For year ended December 31, 2021, amortization of intangible assets totaled $0.2 million. For the year ended December 31, 2020, amortization of intangible assets was nil. The effect of foreign currency translation on the net carrying value of intangible assets during 2021 was not material.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the estimated future amortization for intangible assets for the next five years and thereafter:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">364</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">364</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">364</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">364</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2026</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">364</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,329</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,149</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696130458920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrentDisclosureAbstract', window );"><strong>Other Assets Noncurrent Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsDisclosureTextBlock', window );">Other Assets</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">8. Other assets</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets consist of the following:</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,086</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,219</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deposits</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,404</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,144</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred financing costs</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">693</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">975</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other non-current assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,407</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,554</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction deposits - long-term</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,572</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,590</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,464</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrentDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrentDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696130614856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued Liabilities And Other Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses and Other Liabilities</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9. Accrued expenses and other liabilities </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses and other current liabilities consisted of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued external research and development expenses</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,273</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,878</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued payroll and related expenses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,521</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,881</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued milestone payments</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,058</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,252</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued professional fees</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">854</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">791</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued other</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,941</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,225</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Strimvelis liability - current portion</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">671</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">916</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accrued expenses and other current liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,318</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,943</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696130647896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Charges<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring And Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring Charges</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">10. Restructuring charges</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2020<span style="Background-color:#FFFFFF;color:#000000;">, the Company committed to a new strategic plan and restructuring intended to enable the Company to advance its corporate strategy while reducing overall operating expenses, including ceasing construction and build-out of its Fremont, California manufacturing facility, closing its office in Menlo Park, California, reducing its workforce by approximately&#160;25% across the Company, eliminating a number of future positions expected to be recruited in 2020 and 2021, reducing its investment in the future development for certain programs, and other cost-saving measures (collectively, the &#8220;Restructuring&#8221;). The workforce reductions took place primarily during the second and third quarters of 2020, and concluded in the fourth quarter of 2020.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Cash restructuring charges</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Accrued restructuring and severance costs are included in Accrued expenses and other current liabilities in the consolidated balance sheet. Activity for the fiscal year is summarized as follows:</span></p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.06%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at beginning of period</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Charged to expense</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.06%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,854</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.2%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payments made</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,848</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.2%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at end of period</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.7%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">There were no restructuring costs during the year ended December 31, 2021.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Impairment of long-lived assets</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">During the second quarter of 2020, the Company also took the following non-cash charges to research and development expense associated with the impairment of construction-in-process associated with the Fremont manufacturing facility, partial impairment of the right-of-use asset for the Fremont manufacturing facility lease (the &#8220;Fremont ROU asset&#8221;), and a write-down of laboratory equipment from the Company&#8217;s Menlo Park, CA facility:</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Asset write-down</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease right-of-use asset</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,605</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction-in-progress</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,285</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">760</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Charge included in research and development expense</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,650</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company assessed the Fremont construction-in-process for impairment in May 2020 upon the Restructuring. The construction-in-process related to design costs, and was determined to have no potential future value, and an impairment charge of $2.3&#160;million was taken for the full value of the construction-in-process asset.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">&#160;</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company assessed the Fremont ROU asset for impairment in May 2020 upon the Restructuring when the carrying value of the asset was $13.8&#160;million. The Fremont ROU asset represented the asset group for the impairment assessment. Upon failing the first step of the long-lived asset impairment model where the undiscounted cash flows were less than the carrying value of the Fremont ROU asset, the Company performed the second step by comparing the fair value of the Fremont ROU asset to its carrying value. The fair value of the Fremont ROU asset is a non-recurring fair value measurement that was measured using a probability-weighted discounted cash flow approach, which estimated the present value of potential sublease income to be generated by the facility, less costs incurred to sublease the facility. The significant assumptions inherent in estimating the various probability weighted scenarios included the undiscounted forecasted sublease income less costs incurred, which included assumptions of the expected income and timing of entering into a future sublease, and a market-participant discount rate that reflects a potential discount rate. The Company selected the assumptions used in the fair value estimate using current market data associated with the potential sublease income and market participant discount rates. The undiscounted cash flows utilized in the fair value estimate ranged from $11.7&#160;million to $19.1&#160;million to be generated over the remainder of the lease term. The market-participant discount rate utilized in the fair value estimate was&#160;4.6%. These assumptions represent level 3 inputs of the fair value hierarchy (see Note 3).</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">&#160;</span></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">As of the assessment date, the fair value of the Fremont ROU asset was $11.2&#160;million, and the Company recorded a $2.6&#160;million impairment charge related to the asset. The remaining carrying value of the Fremont ROU asset is being amortized over the remaining lease term on a straight-line basis. In December 2020, the Company executed a sublease for the Fremont manufacturing facility with an unrelated third-party for the remaining lease term (see Note 11). No further impairment was necessary as a result of the sublease. The occurrence of a triggering event for the Fremont ROU asset in future periods could result in additional impairment charges if the estimated fair value of the asset is determined to be lower than the carrying value.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -URI http://asc.fasb.org/topic&amp;trid=2175745<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696130646232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">11. Leases</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Operating leases</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2017 and January 2019, the Company entered into lease agreements for office and laboratory space in Menlo Park, California, United States. The leases terminated in <span style="-sec-ix-hidden:F_000618"><span style="-sec-ix-hidden:F_000619">December 2020</span></span>. The combined annual rental payments, including variable payments, under both leases with the same landlord were <span style="-sec-ix-hidden:F_000620">nil</span> in 2021 and $1.9 million in 2020. The Company was provided with one month of free rent in connection with the first lease. The lease agreement included annual rent escalation provisions. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2018 and December 2018, the Company entered into lease agreements for office space in London, United Kingdom, both of which terminate in <span style="-sec-ix-hidden:F_000623"><span style="-sec-ix-hidden:F_000624">January 2023</span></span>. The combined annual rental payments, including variable payments, under the lease agreements were $1.8 million in 2021 and $1.7 million in 2020. The Company also rented lab spaces in London in 2021, for which it made $0.2 million in payments in 2021.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2018, the Company entered into a lease agreement for office space in Boston, Massachusetts, United States, which terminates in <span style="-sec-ix-hidden:F_000628">September 2022</span>. The annual rental payments, including variable payments, were $0.4 million in 2021 and </p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020. The lease agreement includes annual rent escalation provisions.</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> The Company has subleased the space in</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> August 2021, and rec</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ognized</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> $</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.1</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million in sublease income in 2021.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2019, the Company entered into a lease agreement for office space in Boston, Massachusetts, United States, which commences for accounting purposes in <span style="-sec-ix-hidden:F_000631">January 2020</span>. The lease terminates in <span style="-sec-ix-hidden:F_000632">September 2026</span>. The annual rental payments, including variable payments, were $1.1 million and $0.9 million in 2021 and 2020, respectively. The lease agreement includes annual rent escalation provisions.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, the carrying value of the operating lease right-of-use assets in Boston and London was $4.1 million and the lease liabilities was $4.3 million. As of December 31, 2020, the carrying value of the operating lease right-of-use assets in Boston and London was $<span style="color:#000000;">5.4</span> million and the lease liabilities was $<span style="color:#000000;">5.7</span> million.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Fremont operating lease and sublease agreements</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2018, the Company leased manufacturing, laboratory, and office space in Fremont, California (the &#8220;Fremont facility&#8221; and the &#8220;Head Lease&#8221;) which terminates in <span style="-sec-ix-hidden:F_000639">May 2030</span>. In May 2020, the Company committed to a restructuring plan (see Note 10) whereby we ceased construction and build-out of the Fremont facility. I<span style="color:#000000;">n December 2020, the Company entered into a sublease agreement (the &#8220;Sublease&#8221;) with an unrelated third-party (the &#8220;subtenant&#8221;) whereby the Company subleased the entire Fremont facility to the subtenant. The Company accounts for the Head Lease and Sublease as two separate contracts. Both the Head Lease and Sublease were determined to be operating leases.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Head Lease annual rental payments, including variable payments, were $3.1 million in 2021 and 2020. The Head Lease includes annual rent escalation provisions. The Company was provided with 8 months of free rent. Subject to the terms of the Head Lease agreement, the Company executed a $3.0 million letter of credit upon signing the lease, which may be reduced by 25% subject to reduction requirements specified therein. This amount is classified as restricted cash on the consolidated balance sheets. <span style="color:#808080;"> </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, the carrying value of the Fremont Head Lease right-of-use asset was $9.5 million and the lease liability was $13.1 million. <span style="color:#000000;">The Head Lease provides for up to $5.3 million in tenant improvement allowances to be reimbursed to the Company by the landlord. These tenant improvement allowances have been included in the calculation of the operating lease liability and is currently expected to be received in 2022. The Company continues to assess the expected receipt of the tenant improvement allowances and may remeasure the right-of-use asset and liability from time to time as facts and circumstances may change</span>.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Sublease commenced in December 2020 and is in force for the remainder of the Head Lease term, through May 2030. The Sublease provides for 12 months of free rent until December 2021. The sublease provides for an initial annual cash base rent of $2.2 million, with annual rent escalation provisions. The subtenant is also responsible for paying all operating expenses associated with the Head Lease. The Sublease also includes pass-through of up to $5.3 million in tenant improvement allowances to the subtenant, subject to the Company being reimbursed for the allowances per the terms of the Head Lease. The Subtenant provided the Company with a $2.6 million security deposit, which may be converted to a letter of credit upon providing evidence of $2.6 million in construction expenditures. The Company accounts for the security deposit within other long-term liabilities.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has $7.9 million in an escrow account associated with construction on the Fremont facility, for which the Company has ceased construction and build-out. Subject to the terms of the Head Lease and reduction provisions, this amount may be returned to the Company upon qualifying construction expenditure, or will be returned in late 2022 (the &#8220;Sunset Date&#8221;) to the extent construction expenses have not been incurred. The Company deposited $10.0 million into the account in the first quarter of 2020 and has received $2.1 million in receipts from the escrow funds for costs incurred to date. The escrow balance is all classified within other current assets on the consolidated balance sheets based on the timing of when the Company expects funds to be returned from the escrow agent. Future receipts from the escrow deposit will be dependent upon the timing of the subtenant construction spend through the Sunset Date.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Embedded operating lease arrangement</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company is party to a manufacturing agreement for research and development and commercial production&#160;with AGC Biologics, S.p.A. (formerly MolMed S.p.A.) (&#8220;AGC&#8221;) pursuant to which AGC will develop, manufacture and supply certain viral vectors and conduct cell processing activities for certain Company development and commercial programs.&#160;&#160;A manufacturing agreement with AGC was novated to the Company as part of the GSK Agreement (see Note 15).&#160;&#160;On July 2, 2020 (the &#8220;Effective Date&#8221;), the Company entered into a new manufacturing and technology development master agreement with AGC (the &#8220;AGC Agreement&#8221;) which superseded the novated agreement.</span><span style="color:#000000;"> </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determined that the AGC Agreement contains an embedded lease as it includes provision of manufacturing suites designated for the Company&#8217;s exclusive use during the term of the agreement.&#160;<span style="Background-color:#FFFFFF;">The AGC Agreement has an initial term of&#160;five years, beginning on the Effective Date and ending July 2, 2025.&#160;The agreement may be extended for an additional&#160;two years&#160;by mutual agreement of the Company and AGC</span>. The AGC Agreement contains payments associated with lease and non-lease components. The contractual annual rental payments associated with the lease that are considered a lease component amount to &#8364;2.7&#160;million per contract year. The non-lease components of the agreement consist of minimum manufacturing purchase requirements and dedicated manufacturing and development services (see Note 18).</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, the carrying value of the embedded operating lease right-of-use asset was $10.7 million and the lease liability was $9.3 million. <span style="color:#000000;">As of December 31, 2020, the carrying value of the embedded operating lease right-of-use asset was $13.9 million and the lease liability was $13.1 million. </span><span style="Background-color:#FFFFFF;color:#000000;">The Company may terminate the AGC Agreement and the use of the exclusive manufacturing suites, with 12-months&#8217; notice, and beginning no earlier than July 2, 2022. AGC may terminate the AGC Agreement with 24-months&#8217; notice. The AGC Agreement provides for an option to reserve one additional exclusive manufacturing suite any time prior to January 1, 2022 for a one-time option fee plus annual rental fee. The AGC Agreement extends until&#160;July 2, 2025.</span></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Summary of all lease costs recognized under ASC 842</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our facility leases described above generally contain customary provisions allowing the landlords to terminate the leases if we fail to remedy a breach of any of our obligations under any such lease within specified time periods, or upon our bankruptcy or insolvency. The leases do not include any restrictions or covenants that had to be accounted for under the lease guidance. The following table contains a summary of the lease-related costs recognized within operating expenses, and other information pertaining to the Company&#8217;s operating leases as of December 31, 2021 and 2020:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fixed lease cost</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,701</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,593</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Impairment of right-of-use assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,781</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Variable lease cost</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,696</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,131</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sublease income</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,746</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(181</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.24%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease cost</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,651</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,324</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other information</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; Operating cash flows used for operating leases</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,989</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,447</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; Weighted-average remaining lease term (years)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000677">6.0</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000678">6.6</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; Weighted-average discount rate</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.7</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.6</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fixed lease cost represents the ASC 842 rent expense associated with the amortization of our right-of-use assets and lease liabilities. Impairment of right-of-use assets relates to discrete impairment charges taken when, in the Company&#8217;s estimation, the fair value of a right-of-use asset is below the carrying value. Variable lease cost are the amounts owed by the Company to a lessor that are not fixed, such as reimbursement for common area maintenance and utilities costs, and are not included in the calculation of the Company&#8217;s operating lease right of use assets or operating lease liabilities and are expensed when incurred. Sublease income represents the straight-line recognition of base rent sublease income over the term of the Sublease, and recognition of pass-through operating expense costs per the terms of the Sublease.</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31, 2021, the Company obtained right of use assets valued at $0.6 million in exchange for </p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">lease liabilities of $0.6 million. During the year ended December 31, 2020 the Company obtained $17.5 million in right of use assets in exchange for $17.5 million in lease liabilities.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, future minimum base rent commitments under ASC 842 under the Company&#8217;s property leases were as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.08%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Due in:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross lease payments</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross sublease receipts</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Net lease payments</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,326</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,334</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,992</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,773</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,246</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,527</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,799</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,313</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,486</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,361</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,382</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,979</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2026</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,720</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,454</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,266</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.08%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,332</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,960</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,372</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total future minimum lease payments</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,311</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20,689</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,622</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.08%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: imputed interest</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14,698</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.84%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.84%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.08%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating lease payments</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,613</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.84%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.84%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*Tabular disclosure above for leases denominated in GBP have been translated at a rate of &#163;1.00 to $1.35, and leases denominated in Euro have been translated at a rate of &#8364;1.00 to $1.13. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696130928200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Notes Payable</a></td>
<td class="text">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">12. Notes Payable</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In<span style="color:#000000;"> <span style="-sec-ix-hidden:F_000710">May 2019</span>, the Company entered into a senior term facilities agreement, which was amended in April 2020 (the &#8220;Original Credit Facility&#8221;) with MidCap Financial (Ireland) Limited (&#8220;MidCap Financial&#8221;), as agent, and additional lenders from time to time (together with MidCap Financial, the &#8220;Lenders&#8221;), to borrow up to $75.0 million in term loans.</span> </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2021, the Company amended and restated the Original Credit Facility (the &#8220;Amended Credit Facility&#8221;). Under the Amended Credit Facility, the Lenders agreed to make term loans available to the Company in the aggregate amount of $100.0 million, including increasing the principal on the initial term loan to $33.0 million, from $25.0 million. To date, the Company has borrowed $33.0 million under the amended initial term loan. The remaining $67.0 million under the Amended Credit Facility may be drawn down in the form of a second and third term loan, <span style="Background-color:#FFFFFF;">the second term loan being a $33.0&#160;million term loan available no earlier than July 1, 2022&#160;&#160;and no later than July 1, 2023 upon certain regulatory approvals and evidence of the Company having $100&#160;million in cash and cash equivalent investments; and the third term loan being a $34.0&#160;million term loan available no earlier than July 1, 2023 and no later than July 1, 2024 upon evidence of the Company having $100&#160;million in cash and cash equivalent investments and attaining a pre-specified trailing 12-month revenue target.</span><span style="color:#000000;">&#160;&#160;&#160;&#160;&#160;</span><span style="Background-color:#FFFFFF;"> </span><span style="color:#000000;">&#160;&#160;&#160;&#160;</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to execution of the Amended Credit Facility, each term loan under the Original Credit Facility bore interest at an annual rate equal to 6.0% plus LIBOR. The Company was required to make interest-only payments on the term loan for all payment dates prior to 24 months following the date of the Original Credit Facility, unless the third tranche was drawn, in which case for all payment dates prior to 36 months following the date of the Original Credit Facility. The term loans prior to the Amended Credit Facility were to begin amortizing on either the&#160;24-month&#160;or the&#160;36-month&#160;anniversary of the Original Credit Facility (as applicable), with equal monthly payments of principal plus interest to be made by the Borrower to the Lenders in consecutive monthly installments until the loan maturity date. In addition, a final payment of 4.5% was due on the loan maturity date. The Company accrued the final payment amount of $1.1 million associated with the first term loan of the Original Credit Facility, to outstanding debt by charges to interest expense using the effective-interest method from the date of issuance through the date of the Amended Credit Facility. Upon execution of the Amended Credit Facility, the Company was required to make a payment of $0.5 million for the accrued final payment associated with the Original Credit Facility, which was netted against proceeds from the additional initial term loan.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each term loan under the Amended Credit Facility bears interest at an annual rate equal to 5.95% plus LIBOR. The Company is required to make interest-only payments on the term loan for 18 months following the date of the Amended Credit Facility, unless the Company is eligible for the second tranche, in which case the Company may elect to make interest-only payments for <span>30 months</span> following the date of the Amended Credit Facility. The term loans under to the Amended Credit Facility begin amortizing on either the&#160;18-month&#160;or the&#160;30-month&#160;anniversary of the Amended Credit Facility (as applicable), with equal monthly payments of principal plus interest to be made by the Company to the Lenders in consecutive monthly installments until the loan maturity date. In addition, a final payment of 3.5% is due on the loan maturity date. The Company is accruing the final payment amount of $1.2 million associated with the first term loan of the Amended Credit Facility, to outstanding </p>
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">debt by charges to interest expense using the effective-interest method from the date of issuance through the loan maturity date.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Amended Credit Facility includes affirmative and negative covenants. The affirmative covenants include, among others, covenants requiring the Company to maintain their legal existence and governmental approvals, deliver certain financial reports, maintain insurance coverage, maintain property, pay taxes, satisfy certain requirements regarding accounts and comply with laws and regulations. The negative covenants include, among others, restrictions on the Company transferring collateral, incurring additional indebtedness, engaging in mergers or acquisitions, paying dividends or making other distributions, making investments, creating liens, amending material agreements and organizational documents, selling assets, changing the nature of the business and undergoing a change in control, in some cases subject to certain exceptions. The Company is also subject to an ongoing minimum cash financial covenant in which the Company must maintain unrestricted cash in an amount not less than $20.0&#160;million following the utilization of the second term loan and not less than $35.0&#160;million following the utilization of the third term loan.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, and December 31, 2020, notes payable consist of the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notes payable, net of issuance costs</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,669</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,659</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: current portion</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(786</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,861</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notes payable, net of current portion</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,883</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,798</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accretion related to final payment</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">203</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">406</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notes payable, long term</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,086</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,204</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, the future principal payments due are as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Minimum</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Payments</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">786</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,429</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,429</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,429</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2026</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,082</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,155</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less current portion</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(786</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less unamortized portion of final payment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(952</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less unamortized debt issuance costs</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(331</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notes payable, long term</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,086</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the years ended December 31, 2021 and 2020, the Company recognized $2.5 million and $2.3 million of interest expense related to the term loan, respectively. The effective annual interest rate as of December 31, 2021 on the outstanding debt under the Term Loan was approximately 8.4%.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696130641592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity and Convertible Preferred Shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_ShareholdersEquityAndConvertiblePreferredSharesAbstract', window );"><strong>Shareholders Equity And Convertible Preferred Shares [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Shareholders' Equity and Convertible Preferred Shares</a></td>
<td class="text">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">13. Shareholders&#8217; Equity and Convertible Preferred Shares </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Ordinary shares </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, and 2020, each holder of ordinary shares and ADSs is entitled to one vote per ordinary share and to receive dividends when and if such dividends are recommended by the board of directors and declared by the shareholders.&#160;&#160;As of&#160;December 31, 2021, and 2020, the Company has not declared any dividends.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 20</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, and 20</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, the Company had authority to allot ordinary shares up to a maximum nominal value of &#163;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,023,851.50</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> with a nominal value of &#163;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.10</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> per share.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Ordinary share issuances</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2020, the Company issued 75,413 ordinary shares to Oxford BioMedica pursuant to the terms of our license agreement (see Note 15).</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2020, the Company issued 22,758 ordinary shares pursuant to a consulting agreement (see Note 18) with a non-employee advisor.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2021, the Company issued and sold (i) 20,900,321 ordinary shares, nominal value &#163;0.10 per share, at a purchase price of $6.22 per share (the &#8220;Purchase Price&#8221;), which was the closing sale price of the Company&#8217;s ADSs on the Nasdaq Global Select Market on February 4, 2021, and (ii) 3,215,434 non-voting ordinary shares, nominal value &#163;0.10 per share, at the Purchase Price (together (i) and (ii) the &#8220;Private Placement&#8221;). The Private Placement resulted in net proceeds to the Company of $143.6 million after deducting placement agent fees of $6.0 million and other issuance costs of $0.4 million. The ordinary shares and non-voting ordinary shares were sold pursuant to a securities purchase agreement entered into between the Company and the purchasers named therein on February 4, 2021. All non-voting ordinary shares have been converted to ordinary shares as of December 31, 2021.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In July 2021 the Company issued 1,227,738 ordinary shares to Pharming Group N.V. for total consideration of $7.5 million. The consideration is payment for the fair value of ordinary shares with a fair value of $4.1 million plus a $3.4 million premium on the fair value of the Company&#8217;s ordinary shares, which was allocated to the license and collaboration agreement (see Note 16).</span></p>
<p style="Background-color:#FFFFFF;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In December 2021, the Company issued 22,758 ordinary shares pursuant to a consulting agreement (see Note 18) with a non-employee advisor</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_ShareholdersEquityAndConvertiblePreferredSharesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shareholders equity and convertible preferred shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_ShareholdersEquityAndConvertiblePreferredSharesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696130584264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-based Compensation</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">14. Share-based Compensation </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company maintains&#160;four&#160;equity compensation plans; the Orchard Therapeutics Limited Employee Share Option Plan with Non-Employee Sub-Plan and U.S. Sub-Plan (the &#8220;2016 Plan&#8221;), the Orchard Therapeutics plc 2018 Share Option and Incentive Plan (the &#8220;2018 Plan&#8221;), the 2018 Employee Share Purchase Plan (the &#8220;ESPP&#8221;), and the 2020 Inducement Equity Plan (the &#8220;Inducement Plan&#8221;). <span style="color:#000000;">The number of shares of common stock that may be issued under the 2018 Plan is subject to increase by the number of shares forfeited under any options forfeited and not exercised under the 2018 Plan or 2016 Plan. </span>The board of directors has determined not to make any further awards under the 2016 plan. As of December 31, 2021, 6,934,474 shares remained available for grant under the 2018 Plan, 721,500 remained available under the Inducement Plan, and 1,197,399 shares remained available for grant under the ESPP.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the Company&#8217;s IPO, the Company granted options to United States employees and non-employees at exercise prices deemed by the board of directors to be equal to the fair value of the ordinary share at the time of grant, and granted options to United Kingdom and European Union employees and non-employees at an exercise price equal to the par value of the ordinary shares of &#163;0.00001. After the IPO, options are now granted at exercise prices equal to the fair value of the Company&#8217;s ordinary shares on the grant date for all employees. The vesting period is determined by the board of directors, which is generally four years. An option&#8217;s maximum term is <span style="-sec-ix-hidden:F_000797">ten&#160;years</span>. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Share options</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of each stock option award is determined on the date of grant using the Black-Scholes option-pricing model. <span style="Background-color:#FFFFFF;color:#000000;">The risk-free interest rate is based on a U.S. treasury instrument whose term is consistent with the expected term of the stock options. The expected term of the Company&#8217;s options has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain-vanilla&#8221; options. The expected volatility is based on the historical volatility of a representative group of companies with similar characteristics to the Company, including those in the early stages of product development with a similar and therapeutic focus. For these analyses, the Company selects companies with comparable characteristics to its own including enterprise value, risk profiles, position within the industry, and with historical share price information sufficient to meet the expected term of the options. </span>The relevant data used to determine the value of stock option awards are as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.96%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="4" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.96%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.96%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.12%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000798">0.5 - 1.3%</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000799">0.3 - 1.7%</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.96%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.12%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.3 - 6.1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.5 - 6.1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.96%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.12%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000806">74.2 - 78.7%</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000807">70.7 - 75.2%</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.96%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend rate</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.12%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes option activity under the plans for the year ended December 31, 2021:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise Price</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">per Share</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Life (Years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,895,643</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.96</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000824">7.16</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91,133</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,489,856</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.75</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,727,254</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.59</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,357,505</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.30</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding and expected to vest at December 31, 2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,300,740</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.57</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000825">7.83</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,842</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable, as of December 31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,880,668</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.90</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000826">6.59</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,685</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate intrinsic value of options is calculated as the difference between the exercise price of the options and the fair value of the Company&#8217;s ordinary shares for those options that had exercise prices lower than the fair value of the Company&#8217;s ordinary shares. During the years ended December 31, 2021 and 2020, the total intrinsic value of share options exercised was $7.4 million and $5.0 million, respectively. During the years ended December 31, 2021 and 2020, the total proceeds to the Company from share options exercised was $2.7 million and $3.9 million, respectively. As of December 31, 2021, and 2020, there was $<span style="-sec-ix-hidden:F_000834">nil</span> and $0.2 million in employee equity plan proceeds received after year-end, respectively.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted average grant date fair value of the options granted during the years ended December&#160;31, 2021 and 2020 was $3.10 per share and $7.22 per share, respectively.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Restricted Share Units</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Performance-based share units</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company has issued performance-based restricted share units (&#8220;RSUs&#8221;) to certain executives and members of its senior management, with vesting linked to the achievement of three specific regulatory and research and development milestones and one market condition based upon the volume weighted-average price (&#8220;VWAP&#8221;) of the Company&#8217;s ADSs for a certain period. Upon achievement of any of the aforementioned milestones, one third of the RSUs will vest, and the award will become fully vested upon achievement of three of the four performance conditions.&#160; 89,667 performance-based share units vested during the years ended December 31, 2021. At December 31, 2021, the remaining 179,333 performance-based share units outstanding under the scheme were cancelled.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The fair value associated with the performance-based conditions is recognized when achievement of the milestones becomes probable, if at all. In the fourth quarter of 2020, the Company determined that a performance milestone was probable upon </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">approval of Libmeldy by the E</span><span style="Background-color:#FFFFFF;">uropean </span><span style="Background-color:#FFFFFF;">C</span><span style="Background-color:#FFFFFF;">ommission in December 2020</span><span style="Background-color:#FFFFFF;">, and recognized $</span><span style="Background-color:#FFFFFF;">1.2</span><span style="Background-color:#FFFFFF;"> million in compensation cost. </span><span style="Background-color:#FFFFFF;">The shares associated with recognition of this performance milestone vested and were issued in January 2021.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">CEO Award</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company granted&#160;195,000&#160;performance-based RSUs with a total grant date fair value of $1.4 million to its Chief Executive Officer, Bobby Gaspar, M.D., Ph.D., in April 2020.&#160;&#160;The award vests on January 2, 2024 as to 1/3 of the award for each of the first three to occur of four milestones, if each such milestone is achieved by the Company on or before December 31, 2023&#160;and Dr. Gaspar remains continuously employed with the Company through January 2, 2024. The milestones relate to achievement of specific clinical and regulatory milestones. No performance-based share unit performance conditions associated with the CEO award were deemed probable and none vested during the year ended December 31, 2021. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Time-based restricted share units</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Time-based restricted share units vest in equal annual installments over a <span style="-sec-ix-hidden:F_000844">three-year</span> period.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes restricted share unit award activity for the year-end December 31, 2021:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Performance-based RSUs</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Time-based RSUs</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted Average Grant Date Fair Value per Share</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested at December 31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">464,000</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">180,000</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.75</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,500</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.94</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(89,667</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(41,667</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.94</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.08%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(179,333</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(62,500</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.32</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.08%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested at December 31, 2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">195,000</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">123,333</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.41</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Share-based compensation </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share-based compensation expense related to share options, restricted share unit awards, and the employee stock purchase plan was classified in the consolidated statements of operations and comprehensive loss as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,214</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,679</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,322</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,283</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,536</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,962</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had 9,420,072 unvested options outstanding as of December&#160;31, 2021. As of December 31, 2021, total unrecognized compensation cost related to unvested stock option grants and time-based RSUs was approximately $37.1 million. This amount is expected to be recognized over a weighted average period of approximately 2.77 years. As of December 31, 2021, the total unrecognized compensation cost related to performance-based RSUs is a maximum of $1.4 million, the timing of recognition will be dependent upon achievement of milestones. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696130646232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Research Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_LicenseAndResearchArrangementsAbstract', window );"><strong>License And Research Arrangements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">License and Research Arrangements</a></td>
<td class="text">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">15. License and Research Arrangements </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GSK asset purchase and license agreement </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2018, the Company completed an asset purchase and license agreement (the &#8220;GSK Agreement&#8221;) with subsidiaries of GSK to acquire a portfolio of autologous <span style="font-style:italic;">ex vivo</span> gene therapy assets and licenses, for rare diseases and option rights on three additional programs in preclinical development from Telethon Foundation and San Raffaele Hospital (&#8220;Telethon-OSR&#8221;). The portfolio of programs and options acquired consisted of: </p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:2.63%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td style="width:5.26%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;color:#000000;">Two</span> late-stage clinical gene therapy programs in ongoing registrational trials for MLD and WAS; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:2.63%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td style="width:5.26%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;color:#000000;">One</span> earlier stage clinical gene therapy program for TDT; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:2.63%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td style="width:5.26%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;color:#000000;">Strimvelis, the first autologous </span><span style="font-style:italic;font-size:10pt;color:#000000;">ex vivo</span><span style="font-size:10pt;color:#000000;"> gene therapy for ADA-SCID which was approved for marketing by the European Medicines Agency in 2016; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:2.63%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td style="width:5.26%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;color:#000000;">Option rights exercisable upon completion of clinical proof of concept studies for three additional earlier-stage development programs, which option rights have all subsequently lapsed. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounted for the GSK Agreement as an asset acquisition, since the asset purchase and licensing arrangement did not meet the definition of a business pursuant to ASC&#160;805, Business Combinations. Total consideration was &#163;94.2&#160;million ($133.6&#160;million at the acquisition date), which included an upfront payment of &#163;10.0&#160;million ($14.2&#160;million at the acquisition date) and 12,455,252 convertible preferred shares of the Company issued to GSK at an aggregate value of &#163;65.8&#160;million ($93.4&#160;million at the acquisition date), a loss contract on the Strimvelis program valued at &#163;12.9 million ($18.4 million), an inventory purchase liability valued at &#163;4.9&#160;million ($6.9&#160;million) and transaction costs of &#163;0.6 million ($0.8 million). The Company allocated &#163;94.2&#160;million ($133.6&#160;million) to in-process research and development expense (based on the fair value of the underlying programs in development). The convertible preferred shares were converted to ordinary shares as part of our IPO in November 2018.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is required to use commercially reasonable efforts to obtain a Priority Review Voucher (&#8220;PRV&#8221;) from the United States Food and Drug Administration for each of the programs for MLD, WAS and TDT, the first of which GSK retained beneficial ownership over. GSK also has an option to acquire, at a price pursuant to an agreed upon formula, any PRV granted to the Company thereafter for MLD, WAS and TDT. If GSK does not exercise this option to purchase any PRV, the Company may sell the PRV to a third party and must share any proceeds in excess of a specified sale price equally with GSK. For accounting purposes, as of December 31, 2021, the Company does not consider the attainment of a PRV from the United States Food and Drug Administration to be probable.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of the GSK Agreement the Company is required to use its best endeavors to make Strimvelis commercially available in the European Union until such time as an alternative gene therapy is commercially available for patients in Italy, and at all times at the San Raffaele Hospital in Milan, provided that a minimum number of patients continue to be treated at this site. Strimvelis is not currently expected to generate sufficient cash flows to overcome the costs of maintaining the product and certain regulatory commitments; therefore, the Company recorded a liability associated with the loss contract of &#163;12.9 million ($18.4 million at the acquisition date) associated with the loss expected due to this obligation. This liability is being amortized over the remaining period of expected sales of Strimvelis as a credit to research and development expenses (see Note 2).</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company will pay GSK non-refundable royalties and milestone payments in relation to the gene therapy programs. The Company will pay a flat mid-single digit percentage royalty on the combined annual net sales of ADA-SCID products, which includes Strimvelis. The Company will also pay tiered royalty rates at a percentage beginning in the mid-teens up to twenty percent for the MLD and WAS products, upon marketing approval, calculated as percentages of aggregate cumulative net sales of the MLD and WAS products, respectively. The Company will pay a tiered royalty at a percentage from the high single-digits to low double-digit for the TDT product, upon marketing approval, calculated as percentages of aggregate annual net sales of the TDT product. These royalties owed to GSK are in addition to any royalties owed to other third parties under various license agreements for the GSK programs. In aggregate, the Company may pay up to &#163;90.0 million in milestone payments upon achievement of certain sales milestones applicable to GSK. The Company&#8217;s royalty obligations with respect to MLD and WAS may be deferred for a certain period in the interest of prioritizing available capital to develop each product. The Company&#8217;s royalty obligations are subject to reduction on a product-by-product basis in the event of market control by biosimilars and will expire in April 2048. Other than Strimvelis, these royalty and milestone payments were not determined to be probable and estimable at the date of the acquisition and are not included as part of consideration. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company and GSK also separately executed a Transition Services Agreement (&#8220;TSA&#8221;) as well as an Inventory Sale Agreement, in April 2018. The TSA outlined several activities that the Company had requested GSK to assist with during the transition period, including but not limited to utilizing GSK to sell, market and distribute Strimvelis, and assist with regulatory, clinical and non-clinical activities for the other non-commercialized products which were ongoing at the date of the GSK Agreement. The TSA expired in December 2018. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Company&#8217;s entering into the GSK Agreement, GSK assigned rights and obligations to certain contracts, which include among others, the original license agreement with Telethon-OSR and an ongoing manufacturing agreement (see Note 18). </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Telethon-OSR research and development collaboration and license agreements</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Company&#8217;s entering into the GSK Agreement, the Company also&#160;acquired and assumed agreements with Telethon Foundation and San Raffaele Hospital, together referred to as Telethon-OSR, for the research, development and commercialization of autologous <span style="font-style:italic;">ex vivo</span> gene therapies for ADA-SCID, WAS, MLD, TDT, as well as options over three additional earlier-stage development programs. The Company&#8217;s options under the agreement with Telethon-OSR with respect to the earlier-stage programs have lapsed.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As consideration for the licenses, the Company will be required to make payments to Telethon-OSR upon achievement of certain product development milestones. Additionally, the Company will be required to pay to Telethon-OSR a tiered mid-single to low-double digit royalty percentage on annual sales of licensed products covered by patent rights on a country-by-country basis, as well as a low double-digit percentage of sublicense income received from any certain third-party sublicenses of the collaboration programs. These royalties are in addition to those payable to GSK under the GSK Agreement. The Company may pay up to an aggregate of approximately &#8364;31.0 million ($35.0 million at December 31, 2021) in milestone payments upon achievement of certain product development milestones for the program.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2019, the Company entered into a license agreement with Telethon-OSR, under which Telethon-OSR granted to the Company an exclusive worldwide license for the research, development, manufacture and commercialization of Telethon-OSR&#8217;s <span style="font-style:italic;">ex vivo</span> autologous HSC lentiviral based gene therapy for the treatment of mucopolysaccharidosis type I (&#8220;MPS-I&#8221;), including the Hurler variant. To date, Telethon-OSR received &#8364;17.0 million in upfront and milestone payments from the Company upon entering into the agreement and shortly thereafter, resulting in $19.4 million in in-process research and development expense. The Company is also required to make milestone payments contingent upon certain development, regulatory and commercial milestones are achieved and may pay up to &#8364;28.0 million ($31.7 million at December 31, 2021). Additionally, the Company will be required to pay Telethon a tiered mid-single to low-double digit royalty percentage on annual net sales of licensed products. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">UCLB/UCLA License Agreement </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, and amended in July 2017, the Company completed the UCLB/UCLA license agreement, under which the Company has been granted exclusive and non-exclusive, sublicensable licenses under certain intellectual property rights controlled by UCLB and UCLA to develop and commercialize gene therapy products in certain fields and territories. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In exchange for these rights, in 2016, the Company made upfront cash payments consisting of $0.8 million for the license to the joint UCLB/UCLA technology and $1.1 million for the license to the UCLB technology and manufacturing technology. The Company also issued an aggregate of 4,665,384 ordinary shares to UCLB, of which 1,224,094, and 3,441,290 ordinary shares were issued in 2017 and 2016, respectively. The Company recorded research and development expense based on the fair value of the ordinary shares as of the time the agreement was executed or modified. The Company was also obligated to make an additional cash payment for clinical data. In 2017, the Company paid $0.8 million in relation to clinical data acquired. The Company recorded the payments to research and development expense. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the UCLB/UCLA License Agreement, the Company is also obligated to pay an annual administration fee of $0.1 million on the first, second and third anniversary of the agreement date. Additionally, the Company may become obligated to make payments to the parties of up to an aggregate of &#163;19.9 million ($26.8 million at December 31, 2021) upon the achievement of specified regulatory milestones as well as royalties ranging from low to mid-single-digit percentage on net sales of the applicable gene therapy product. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recorded nil and $0.1 million of research and development costs in respect of the UCLB/UCLA license agreement associated with the annual administrative fee for the years ended December 31, 2021 and 2020.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2021, the Company terminated the license to its OTL-101 program for ADA-SCID, which was granted pursuant to the UCLB/UCLA license agreement. <span style="color:#000000;">Except for the termination of such license, the UCLB/UCLA license agreement continues in full force and effect.</span> </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless terminated earlier by either party, the UCLB/UCLA license agreement will expire on the 25<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup> anniversary of the agreement. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Oxford BioMedica license, development and supply agreement </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In November 2016, and as amended in June 2017, May&#160;2018, July 2018, September 2018, May 2019 and April 2020</span><span style="color:#000000;">, the Company entered into an arrangement with Oxford BioMedica whereby Oxford BioMedica granted an exclusive intellectual property license to the Company for the purposes of research, development, and commercialization of collaboration products, and will provide process development services, and manufacture clinical and commercial GMP-grade lentiviral vectors to the Company (&#8220;Oxford BioMedica Agreement&#8221;). As part of the consideration to rights and licenses granted under the Oxford BioMedica Agreement, the Company issued 588,220 ordinary shares to Oxford BioMedica. The Company is also obligated to make certain development milestone payments in the form of issuance of additional ordinary shares if the milestones are achieved. In November 2017, the first milestone was achieved, and the Company was committed to issue another 150,826 ordinary shares, and issued these shares in 2018. In September 2018, the second and fourth milestones were achieved, and the Company issued 150,826 ordinary shares. In April 2020, the fifth milestone was deemed to have been met upon execution of the amended agreement in April 2020, and the Company issued 75,413 ordinary shares to Oxford BioMedica with a total value of $0.8 million, which was expensed to research and development expense. No milestones were met during the year ended December 31, 2021.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company may also pay low single-digit percentage royalties on annual net sales of collaborated product generated under the Oxford BioMedica Agreement. <span style="font-size:12pt;">&#160;</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">16. Collaboration agreement with Pharming Group N.V.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Overview</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 1, 2021, the Company entered into a strategic collaboration with Pharming Group N.V. (&#8220;Pharming&#8221;) to research, develop, manufacture, and commercialize OTL-105, an investigational&#160;<span style="font-style:italic;">ex vivo</span>&#160;autologous HSC gene therapy for the treatment of hereditary angioedema (HAE), a life-threatening rare disorder that causes recurring swelling attacks in the face, throat, extremities and abdomen (the &#8220;Collaboration Agreement&#8221;).</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the Collaboration Agreement, Pharming was granted worldwide rights to OTL-105 and will be responsible for clinical development, regulatory filings and commercialization of the investigational gene therapy, including associated costs. The Company will lead the completion of IND-enabling activities and oversee manufacturing of OTL-105 during preclinical and clinical development, which will be funded by Pharming. In addition, both the Company and Pharming will explore the application of non-toxic conditioning regimen for use with OTL-105 administration.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company received an upfront payment of $10.0&#160;million in cash from Pharming. The Company is also eligible to receive up to $189.5&#160;million in development, regulatory and sales milestones as well as mid-single to low double-digit percentage royalty payments on future worldwide sales.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Share Purchase Agreement</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company also entered into a Share Purchase Agreement with Pharming on July 1, 2021 (the &#8220;SPA&#8221;), pursuant to which the Company issued 1,227,738 ordinary shares to Pharming for total consideration of $7.5 million. The consideration is payment for the fair value of ordinary shares with a fair value of $4.1 million plus a $3.4 million premium on the fair value of the Company&#8217;s ordinary shares</span>.</p>
<p style="Background-color:#FFFFFF;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The &#8220;Collaboration Agreement&#8221; and the &#8220;SPA&#8221; are referred to together as the &#8220;Pharming Agreements.&#8221;</span></p>
<p style="Background-color:#FFFFFF;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Accounting Analysis</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">At the commencement of the arrangement, two units of accounting were identified, which are the issuance of&#160;1,227,738 of the Company&#8217;s ordinary shares as part of the SPA, and the license and collaboration agreement, which conveys the license and provides for the Company to provide research, development, manufacturing services for OTL-105. The Pharming Agreements were entered into concurrently as part of a single commercial objective, and the Company considers them a </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">single arrangement for accounting purposes. The total upfront payments of $</span><span style="Background-color:#FFFFFF;">17.5</span><span style="Background-color:#FFFFFF;"> million </span><span style="Background-color:#FFFFFF;">are</span><span style="Background-color:#FFFFFF;"> </span><span style="Background-color:#FFFFFF;">comprise</span><span style="Background-color:#FFFFFF;">d of</span><span style="Background-color:#FFFFFF;"> $</span><span style="Background-color:#FFFFFF;">4.1&#160;</span><span style="Background-color:#FFFFFF;">million attributed to the equity sold to Pharming and $</span><span style="Background-color:#FFFFFF;">13.4&#160;</span><span style="Background-color:#FFFFFF;">million attributed to the Collaboration Agreement. In determining the fair value of the common stock issued to Pharming as part of the SPA, the Company used an option pricing valuation model to take into consideration certain holding period restrictions on the shares. The fair value of the Company&#8217;s common shares was considered a level 2 fair value measurement within the fair value hierarchy. </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The most significant assumptions within the model are the Company&#8217;s stock price, the term of the restrictions and the stock price volatility, which is based upon historical volatility of the Company&#8217;s stock. </span><span style="Background-color:#FFFFFF;">Based on the fair value adjustments made by management, the fair value of the</span><span style="Background-color:#FFFFFF;"> shares issued was </span><span style="Background-color:#FFFFFF;">determined to be $</span><span style="Background-color:#FFFFFF;">4.1</span><span style="Background-color:#FFFFFF;"> million with the excess proceeds of $</span><span style="Background-color:#FFFFFF;">3.4</span><span style="Background-color:#FFFFFF;"> million being allocation to the Collaboration</span><span style="Background-color:#FFFFFF;"> Agreement.</span><span style="font-size:12pt;color:#000000;"> </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company recognizes revenue under Accounting Standards Codification (&#8220;ASC&#8221;) 606,&#160;</span><span style="font-style:italic;">Revenue from Contracts with Customer </span><span style="Background-color:#FFFFFF;">(&#8220;ASC 606&#8221;). </span>The Company has concluded that the conveyance of the license for the HAE program and the provision of research, development, and manufacturing services for the HAE program represent a series of distinct services that are accounted for as a single performance obligation within the Collaboration Agreement. The Company determined that the transaction price includes: the non-refundable up-front payment of $10.0&#160;million, the $3.4 million in premium associated with the SPA, and the variable consideration for estimated reimbursement payments at agreed upon contractual rates to be received from Pharming for the Company&#8217;s on-going research, development, and manufacturing services. The potential future variable consideration is associated with the reimbursement for research, development, and manufacturing services provided by the Company to Pharming at agreed upon contractual rates which is the only remaining unsatisfied performance obligation. The milestone payments included in the Collaboration Agreement are fully constrained, as a result of the uncertainty regarding whether any of the associated milestones will be achieved and therefore,<span style="Background-color:#FFFFFF;"> the Company determined that it could not assert that it was probable that a significant reversal in the amount of cumulative revenue recognized will not occur.</span> The total estimated cost of the research and development services reflect the nature of the services to be performed and the Company&#8217;s best estimate of the length of time required to perform the services. <span style="Background-color:#FFFFFF;">The Company re-evaluates the transaction price as of the end of each reporting period</span>.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company also considered the existence of any significant financing component within the Pharming Agreements given their upfront payment structure. Based upon this assessment, the Company concluded that the up-front payments were provided for valid business reasons and not for the purpose of providing financing. Accordingly, the Company has concluded that the upfront payment structure of the Pharming Agreements does not result in the existence of a significant financing component.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes revenue associated with the performance obligation as the research, development and manufacturing services are provided using an input method, based on the cumulative costs incurred compared to the total estimated costs expected to be incurred to satisfy the performance obligation. The transfer of control to the customer occurs over the time period that the research, development and manufacturing services are to be provided by the Company, and this cost-to-cost method is, in management&#8217;s judgment, the best measure of progress towards satisfying the performance obligation. Reimbursement for research, development, and manufacturing services are recognized as the costs are incurred consistent with the cost-to-cost method.&#160;The Company's continuing obligations to provide research, development, and manufacturing services is based on the results of such efforts, and the estimated costs associated with the remaining efforts required to complete the performance obligations may change, which may materially impact revenue recognition. The Company regularly evaluates and, when necessary, updates the costs associated with the remaining effort under the Collaboration Agreement. Accordingly, revenue may fluctuate from period to period due to revisions to estimated costs, resulting in a change in the measure of progress for the performance obligation, or if the transaction price changes due to inclusion of any milestone payments that become unconstrained.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes research and development costs incurred and collaboration revenue recognized in connection with the Company&#8217;s performance under the Collaboration Agreement:</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.8%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.76%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.8%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.8%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reimbursement revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.42%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">843</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.3%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.8%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upfront and milestone payment revenue</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.8%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.42%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">975</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had $0.8 million and nil due from Pharming included in accounts receivable as of December 31, 2021 and December 31, 2020, respectively.</p>
<p style="Background-color:#FFFFFF;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, the Company had contract liabilities of $</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.9</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million, which is classified as either current or long-term deferred revenue in the</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> c</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">onsolidated balance sheet</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> based on the period over which this is expected to be recognized. The deferred revenue balance represents the portion of the upfront payments received </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">related to the performance obligation </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">remains</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> partially unsatisfied as of</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> December 31</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, 2021</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_LicenseAndResearchArrangementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License and research arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_LicenseAndResearchArrangementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696130617016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreement with Pharming Group N.V.<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_CollaborativeArrangementAbstract', window );"><strong>Collaborative Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">License and Research Arrangements</a></td>
<td class="text">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">15. License and Research Arrangements </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GSK asset purchase and license agreement </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2018, the Company completed an asset purchase and license agreement (the &#8220;GSK Agreement&#8221;) with subsidiaries of GSK to acquire a portfolio of autologous <span style="font-style:italic;">ex vivo</span> gene therapy assets and licenses, for rare diseases and option rights on three additional programs in preclinical development from Telethon Foundation and San Raffaele Hospital (&#8220;Telethon-OSR&#8221;). The portfolio of programs and options acquired consisted of: </p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:2.63%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td style="width:5.26%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;color:#000000;">Two</span> late-stage clinical gene therapy programs in ongoing registrational trials for MLD and WAS; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:2.63%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td style="width:5.26%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;color:#000000;">One</span> earlier stage clinical gene therapy program for TDT; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:2.63%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td style="width:5.26%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;color:#000000;">Strimvelis, the first autologous </span><span style="font-style:italic;font-size:10pt;color:#000000;">ex vivo</span><span style="font-size:10pt;color:#000000;"> gene therapy for ADA-SCID which was approved for marketing by the European Medicines Agency in 2016; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:2.63%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td style="width:5.26%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;color:#000000;">Option rights exercisable upon completion of clinical proof of concept studies for three additional earlier-stage development programs, which option rights have all subsequently lapsed. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounted for the GSK Agreement as an asset acquisition, since the asset purchase and licensing arrangement did not meet the definition of a business pursuant to ASC&#160;805, Business Combinations. Total consideration was &#163;94.2&#160;million ($133.6&#160;million at the acquisition date), which included an upfront payment of &#163;10.0&#160;million ($14.2&#160;million at the acquisition date) and 12,455,252 convertible preferred shares of the Company issued to GSK at an aggregate value of &#163;65.8&#160;million ($93.4&#160;million at the acquisition date), a loss contract on the Strimvelis program valued at &#163;12.9 million ($18.4 million), an inventory purchase liability valued at &#163;4.9&#160;million ($6.9&#160;million) and transaction costs of &#163;0.6 million ($0.8 million). The Company allocated &#163;94.2&#160;million ($133.6&#160;million) to in-process research and development expense (based on the fair value of the underlying programs in development). The convertible preferred shares were converted to ordinary shares as part of our IPO in November 2018.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is required to use commercially reasonable efforts to obtain a Priority Review Voucher (&#8220;PRV&#8221;) from the United States Food and Drug Administration for each of the programs for MLD, WAS and TDT, the first of which GSK retained beneficial ownership over. GSK also has an option to acquire, at a price pursuant to an agreed upon formula, any PRV granted to the Company thereafter for MLD, WAS and TDT. If GSK does not exercise this option to purchase any PRV, the Company may sell the PRV to a third party and must share any proceeds in excess of a specified sale price equally with GSK. For accounting purposes, as of December 31, 2021, the Company does not consider the attainment of a PRV from the United States Food and Drug Administration to be probable.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of the GSK Agreement the Company is required to use its best endeavors to make Strimvelis commercially available in the European Union until such time as an alternative gene therapy is commercially available for patients in Italy, and at all times at the San Raffaele Hospital in Milan, provided that a minimum number of patients continue to be treated at this site. Strimvelis is not currently expected to generate sufficient cash flows to overcome the costs of maintaining the product and certain regulatory commitments; therefore, the Company recorded a liability associated with the loss contract of &#163;12.9 million ($18.4 million at the acquisition date) associated with the loss expected due to this obligation. This liability is being amortized over the remaining period of expected sales of Strimvelis as a credit to research and development expenses (see Note 2).</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company will pay GSK non-refundable royalties and milestone payments in relation to the gene therapy programs. The Company will pay a flat mid-single digit percentage royalty on the combined annual net sales of ADA-SCID products, which includes Strimvelis. The Company will also pay tiered royalty rates at a percentage beginning in the mid-teens up to twenty percent for the MLD and WAS products, upon marketing approval, calculated as percentages of aggregate cumulative net sales of the MLD and WAS products, respectively. The Company will pay a tiered royalty at a percentage from the high single-digits to low double-digit for the TDT product, upon marketing approval, calculated as percentages of aggregate annual net sales of the TDT product. These royalties owed to GSK are in addition to any royalties owed to other third parties under various license agreements for the GSK programs. In aggregate, the Company may pay up to &#163;90.0 million in milestone payments upon achievement of certain sales milestones applicable to GSK. The Company&#8217;s royalty obligations with respect to MLD and WAS may be deferred for a certain period in the interest of prioritizing available capital to develop each product. The Company&#8217;s royalty obligations are subject to reduction on a product-by-product basis in the event of market control by biosimilars and will expire in April 2048. Other than Strimvelis, these royalty and milestone payments were not determined to be probable and estimable at the date of the acquisition and are not included as part of consideration. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company and GSK also separately executed a Transition Services Agreement (&#8220;TSA&#8221;) as well as an Inventory Sale Agreement, in April 2018. The TSA outlined several activities that the Company had requested GSK to assist with during the transition period, including but not limited to utilizing GSK to sell, market and distribute Strimvelis, and assist with regulatory, clinical and non-clinical activities for the other non-commercialized products which were ongoing at the date of the GSK Agreement. The TSA expired in December 2018. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Company&#8217;s entering into the GSK Agreement, GSK assigned rights and obligations to certain contracts, which include among others, the original license agreement with Telethon-OSR and an ongoing manufacturing agreement (see Note 18). </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Telethon-OSR research and development collaboration and license agreements</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Company&#8217;s entering into the GSK Agreement, the Company also&#160;acquired and assumed agreements with Telethon Foundation and San Raffaele Hospital, together referred to as Telethon-OSR, for the research, development and commercialization of autologous <span style="font-style:italic;">ex vivo</span> gene therapies for ADA-SCID, WAS, MLD, TDT, as well as options over three additional earlier-stage development programs. The Company&#8217;s options under the agreement with Telethon-OSR with respect to the earlier-stage programs have lapsed.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As consideration for the licenses, the Company will be required to make payments to Telethon-OSR upon achievement of certain product development milestones. Additionally, the Company will be required to pay to Telethon-OSR a tiered mid-single to low-double digit royalty percentage on annual sales of licensed products covered by patent rights on a country-by-country basis, as well as a low double-digit percentage of sublicense income received from any certain third-party sublicenses of the collaboration programs. These royalties are in addition to those payable to GSK under the GSK Agreement. The Company may pay up to an aggregate of approximately &#8364;31.0 million ($35.0 million at December 31, 2021) in milestone payments upon achievement of certain product development milestones for the program.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2019, the Company entered into a license agreement with Telethon-OSR, under which Telethon-OSR granted to the Company an exclusive worldwide license for the research, development, manufacture and commercialization of Telethon-OSR&#8217;s <span style="font-style:italic;">ex vivo</span> autologous HSC lentiviral based gene therapy for the treatment of mucopolysaccharidosis type I (&#8220;MPS-I&#8221;), including the Hurler variant. To date, Telethon-OSR received &#8364;17.0 million in upfront and milestone payments from the Company upon entering into the agreement and shortly thereafter, resulting in $19.4 million in in-process research and development expense. The Company is also required to make milestone payments contingent upon certain development, regulatory and commercial milestones are achieved and may pay up to &#8364;28.0 million ($31.7 million at December 31, 2021). Additionally, the Company will be required to pay Telethon a tiered mid-single to low-double digit royalty percentage on annual net sales of licensed products. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">UCLB/UCLA License Agreement </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, and amended in July 2017, the Company completed the UCLB/UCLA license agreement, under which the Company has been granted exclusive and non-exclusive, sublicensable licenses under certain intellectual property rights controlled by UCLB and UCLA to develop and commercialize gene therapy products in certain fields and territories. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In exchange for these rights, in 2016, the Company made upfront cash payments consisting of $0.8 million for the license to the joint UCLB/UCLA technology and $1.1 million for the license to the UCLB technology and manufacturing technology. The Company also issued an aggregate of 4,665,384 ordinary shares to UCLB, of which 1,224,094, and 3,441,290 ordinary shares were issued in 2017 and 2016, respectively. The Company recorded research and development expense based on the fair value of the ordinary shares as of the time the agreement was executed or modified. The Company was also obligated to make an additional cash payment for clinical data. In 2017, the Company paid $0.8 million in relation to clinical data acquired. The Company recorded the payments to research and development expense. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the UCLB/UCLA License Agreement, the Company is also obligated to pay an annual administration fee of $0.1 million on the first, second and third anniversary of the agreement date. Additionally, the Company may become obligated to make payments to the parties of up to an aggregate of &#163;19.9 million ($26.8 million at December 31, 2021) upon the achievement of specified regulatory milestones as well as royalties ranging from low to mid-single-digit percentage on net sales of the applicable gene therapy product. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recorded nil and $0.1 million of research and development costs in respect of the UCLB/UCLA license agreement associated with the annual administrative fee for the years ended December 31, 2021 and 2020.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2021, the Company terminated the license to its OTL-101 program for ADA-SCID, which was granted pursuant to the UCLB/UCLA license agreement. <span style="color:#000000;">Except for the termination of such license, the UCLB/UCLA license agreement continues in full force and effect.</span> </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless terminated earlier by either party, the UCLB/UCLA license agreement will expire on the 25<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup> anniversary of the agreement. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Oxford BioMedica license, development and supply agreement </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In November 2016, and as amended in June 2017, May&#160;2018, July 2018, September 2018, May 2019 and April 2020</span><span style="color:#000000;">, the Company entered into an arrangement with Oxford BioMedica whereby Oxford BioMedica granted an exclusive intellectual property license to the Company for the purposes of research, development, and commercialization of collaboration products, and will provide process development services, and manufacture clinical and commercial GMP-grade lentiviral vectors to the Company (&#8220;Oxford BioMedica Agreement&#8221;). As part of the consideration to rights and licenses granted under the Oxford BioMedica Agreement, the Company issued 588,220 ordinary shares to Oxford BioMedica. The Company is also obligated to make certain development milestone payments in the form of issuance of additional ordinary shares if the milestones are achieved. In November 2017, the first milestone was achieved, and the Company was committed to issue another 150,826 ordinary shares, and issued these shares in 2018. In September 2018, the second and fourth milestones were achieved, and the Company issued 150,826 ordinary shares. In April 2020, the fifth milestone was deemed to have been met upon execution of the amended agreement in April 2020, and the Company issued 75,413 ordinary shares to Oxford BioMedica with a total value of $0.8 million, which was expensed to research and development expense. No milestones were met during the year ended December 31, 2021.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company may also pay low single-digit percentage royalties on annual net sales of collaborated product generated under the Oxford BioMedica Agreement. <span style="font-size:12pt;">&#160;</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">16. Collaboration agreement with Pharming Group N.V.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Overview</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 1, 2021, the Company entered into a strategic collaboration with Pharming Group N.V. (&#8220;Pharming&#8221;) to research, develop, manufacture, and commercialize OTL-105, an investigational&#160;<span style="font-style:italic;">ex vivo</span>&#160;autologous HSC gene therapy for the treatment of hereditary angioedema (HAE), a life-threatening rare disorder that causes recurring swelling attacks in the face, throat, extremities and abdomen (the &#8220;Collaboration Agreement&#8221;).</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the Collaboration Agreement, Pharming was granted worldwide rights to OTL-105 and will be responsible for clinical development, regulatory filings and commercialization of the investigational gene therapy, including associated costs. The Company will lead the completion of IND-enabling activities and oversee manufacturing of OTL-105 during preclinical and clinical development, which will be funded by Pharming. In addition, both the Company and Pharming will explore the application of non-toxic conditioning regimen for use with OTL-105 administration.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company received an upfront payment of $10.0&#160;million in cash from Pharming. The Company is also eligible to receive up to $189.5&#160;million in development, regulatory and sales milestones as well as mid-single to low double-digit percentage royalty payments on future worldwide sales.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Share Purchase Agreement</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company also entered into a Share Purchase Agreement with Pharming on July 1, 2021 (the &#8220;SPA&#8221;), pursuant to which the Company issued 1,227,738 ordinary shares to Pharming for total consideration of $7.5 million. The consideration is payment for the fair value of ordinary shares with a fair value of $4.1 million plus a $3.4 million premium on the fair value of the Company&#8217;s ordinary shares</span>.</p>
<p style="Background-color:#FFFFFF;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The &#8220;Collaboration Agreement&#8221; and the &#8220;SPA&#8221; are referred to together as the &#8220;Pharming Agreements.&#8221;</span></p>
<p style="Background-color:#FFFFFF;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Accounting Analysis</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">At the commencement of the arrangement, two units of accounting were identified, which are the issuance of&#160;1,227,738 of the Company&#8217;s ordinary shares as part of the SPA, and the license and collaboration agreement, which conveys the license and provides for the Company to provide research, development, manufacturing services for OTL-105. The Pharming Agreements were entered into concurrently as part of a single commercial objective, and the Company considers them a </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">single arrangement for accounting purposes. The total upfront payments of $</span><span style="Background-color:#FFFFFF;">17.5</span><span style="Background-color:#FFFFFF;"> million </span><span style="Background-color:#FFFFFF;">are</span><span style="Background-color:#FFFFFF;"> </span><span style="Background-color:#FFFFFF;">comprise</span><span style="Background-color:#FFFFFF;">d of</span><span style="Background-color:#FFFFFF;"> $</span><span style="Background-color:#FFFFFF;">4.1&#160;</span><span style="Background-color:#FFFFFF;">million attributed to the equity sold to Pharming and $</span><span style="Background-color:#FFFFFF;">13.4&#160;</span><span style="Background-color:#FFFFFF;">million attributed to the Collaboration Agreement. In determining the fair value of the common stock issued to Pharming as part of the SPA, the Company used an option pricing valuation model to take into consideration certain holding period restrictions on the shares. The fair value of the Company&#8217;s common shares was considered a level 2 fair value measurement within the fair value hierarchy. </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The most significant assumptions within the model are the Company&#8217;s stock price, the term of the restrictions and the stock price volatility, which is based upon historical volatility of the Company&#8217;s stock. </span><span style="Background-color:#FFFFFF;">Based on the fair value adjustments made by management, the fair value of the</span><span style="Background-color:#FFFFFF;"> shares issued was </span><span style="Background-color:#FFFFFF;">determined to be $</span><span style="Background-color:#FFFFFF;">4.1</span><span style="Background-color:#FFFFFF;"> million with the excess proceeds of $</span><span style="Background-color:#FFFFFF;">3.4</span><span style="Background-color:#FFFFFF;"> million being allocation to the Collaboration</span><span style="Background-color:#FFFFFF;"> Agreement.</span><span style="font-size:12pt;color:#000000;"> </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company recognizes revenue under Accounting Standards Codification (&#8220;ASC&#8221;) 606,&#160;</span><span style="font-style:italic;">Revenue from Contracts with Customer </span><span style="Background-color:#FFFFFF;">(&#8220;ASC 606&#8221;). </span>The Company has concluded that the conveyance of the license for the HAE program and the provision of research, development, and manufacturing services for the HAE program represent a series of distinct services that are accounted for as a single performance obligation within the Collaboration Agreement. The Company determined that the transaction price includes: the non-refundable up-front payment of $10.0&#160;million, the $3.4 million in premium associated with the SPA, and the variable consideration for estimated reimbursement payments at agreed upon contractual rates to be received from Pharming for the Company&#8217;s on-going research, development, and manufacturing services. The potential future variable consideration is associated with the reimbursement for research, development, and manufacturing services provided by the Company to Pharming at agreed upon contractual rates which is the only remaining unsatisfied performance obligation. The milestone payments included in the Collaboration Agreement are fully constrained, as a result of the uncertainty regarding whether any of the associated milestones will be achieved and therefore,<span style="Background-color:#FFFFFF;"> the Company determined that it could not assert that it was probable that a significant reversal in the amount of cumulative revenue recognized will not occur.</span> The total estimated cost of the research and development services reflect the nature of the services to be performed and the Company&#8217;s best estimate of the length of time required to perform the services. <span style="Background-color:#FFFFFF;">The Company re-evaluates the transaction price as of the end of each reporting period</span>.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company also considered the existence of any significant financing component within the Pharming Agreements given their upfront payment structure. Based upon this assessment, the Company concluded that the up-front payments were provided for valid business reasons and not for the purpose of providing financing. Accordingly, the Company has concluded that the upfront payment structure of the Pharming Agreements does not result in the existence of a significant financing component.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes revenue associated with the performance obligation as the research, development and manufacturing services are provided using an input method, based on the cumulative costs incurred compared to the total estimated costs expected to be incurred to satisfy the performance obligation. The transfer of control to the customer occurs over the time period that the research, development and manufacturing services are to be provided by the Company, and this cost-to-cost method is, in management&#8217;s judgment, the best measure of progress towards satisfying the performance obligation. Reimbursement for research, development, and manufacturing services are recognized as the costs are incurred consistent with the cost-to-cost method.&#160;The Company's continuing obligations to provide research, development, and manufacturing services is based on the results of such efforts, and the estimated costs associated with the remaining efforts required to complete the performance obligations may change, which may materially impact revenue recognition. The Company regularly evaluates and, when necessary, updates the costs associated with the remaining effort under the Collaboration Agreement. Accordingly, revenue may fluctuate from period to period due to revisions to estimated costs, resulting in a change in the measure of progress for the performance obligation, or if the transaction price changes due to inclusion of any milestone payments that become unconstrained.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes research and development costs incurred and collaboration revenue recognized in connection with the Company&#8217;s performance under the Collaboration Agreement:</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.8%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.76%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.8%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.8%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reimbursement revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.42%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">843</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.3%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.8%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upfront and milestone payment revenue</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.8%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.42%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">975</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had $0.8 million and nil due from Pharming included in accounts receivable as of December 31, 2021 and December 31, 2020, respectively.</p>
<p style="Background-color:#FFFFFF;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, the Company had contract liabilities of $</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.9</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million, which is classified as either current or long-term deferred revenue in the</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> c</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">onsolidated balance sheet</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> based on the period over which this is expected to be recognized. The deferred revenue balance represents the portion of the upfront payments received </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">related to the performance obligation </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">remains</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> partially unsatisfied as of</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> December 31</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, 2021</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_CollaborativeArrangementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_CollaborativeArrangementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696130476568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">17. Income Taxes </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components of net loss before income taxes for the years ended December 31, 2021 and 2020 are as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.K.</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(147,337</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(155,614</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-U.K.</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,581</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,904</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss before income taxes</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(143,756</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(152,710</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The provision for (benefit from) income taxes for the years ended December&#160;31, 2021 and 2020 are as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current (benefit) provision</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal&#8212;United States</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,025</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,107</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State&#8212;United States</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">334</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">189</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other foreign</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">388</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">230</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United Kingdom</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current (benefit) provision</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(303</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,526</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred provision (benefit)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal&#8212;United States</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,099</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,774</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State&#8212;United States</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(312</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(103</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United Kingdom</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other foreign</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">344</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(380</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred provision (benefit)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,131</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,257</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total provision (benefit) for income taxes</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">828</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(731</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents a reconciliation of income tax expense (benefit) computed at the UK statutory income tax rate to the effective income tax rate as reflected in the consolidated financial statements: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income taxes at United Kingdom statutory rate</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27,313</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(29,015</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59,691</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,302</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reduction in research expense for credits granted</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,674</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,435</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in tax rates</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(38,785</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,105</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax credits</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,232</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,369</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. Deduction for foreign derived intangible income</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(196</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,254</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Permanent differences, including share-based compensation deduction shortfalls</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,863</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,265</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. state income taxes</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign rate differential</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(58</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total provision (benefit) for income taxes</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">828</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(731</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s income tax expense for the year ended December 31, 2021, compared to the year ended December 31, 2020, increased primarily related to shortfalls related to share-based compensation that is not deductible for tax purposes and a reduction of the U.S. deduction for foreign derived intangible income (&#8220;FDII&#8221;), offset by an increase in the benefit from U.S. federal research and development tax credits.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During 2021, the U.K. Government announced that from April 1, 2023, the corporation tax rate would increase to 25%. This new law was enacted on June 10, 2021. The overall effect of the change was an increase in net deferred tax assets by $38.8 million and an increase in valuation allowance by an equal amount.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for income taxes in accordance with ASC Topic 740. Deferred income tax assets and liabilities are determined based upon temporary differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The following table presents the principal components of the Company&#8217;s deferred tax assets and liabilities as of December&#160;31, 2021 and 2020: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforwards</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">126,563</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75,502</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,206</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,599</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development credits</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,449</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,564</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share-based compensation</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,353</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,400</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accruals</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">798</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,001</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease liability</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,444</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,805</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">523</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">171,835</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115,397</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(161,573</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(103,890</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fixed assets and right-of-use asset</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,176</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,288</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other non-current assets (net deferred tax assets and liabilities)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,086</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,219</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;For the years ended December 31, 2021 and 2020, the Company had cumulative tax-effected UK net operating loss carryforwards of approximately $126.6 million and $75.1 million, respectively. UK losses not surrendered may be carried forward indefinitely, subject to numerous utilization criteria and restrictions and are fully offset by a valuation allowance.&#160;&#160;For the years ended December 31, 2021 and 2020, the Company also had U.S. federal orphan drug tax credits of $0.6 million and $0, respectively, and U.S. state research and development tax credits of $2.4 million and $2.0 million.&#160;&#160;The U.S. federal orphan drug tax credits expire in 2041, while the U.S. state research and development credits may be carried forward indefinitely and are offset by a valuation allowance.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In measuring the Company&#8217;s deferred tax assets, the Company considers all available evidence, both positive and negative, to determine whether, based on the weight of that evidence, a valuation allowance is needed for all or some portion of the deferred tax assets. Significant judgment is required in considering the relative impact of the negative and positive evidence, and weight given to each category of evidence is commensurate with the extent to which it can be objectively verified. The more negative evidence that exists, the more positive evidence is necessary, and the more difficult it is to support a conclusion that a valuation allowance is not needed. Additionally, the Company utilizes the "more likely than not" criteria established in FASB ASC Topic 740 to determine whether the future tax benefit from the deferred tax assets should be recognized. As a result, the Company has established valuation allowances on the deferred tax assets in jurisdictions that have incurred net operating losses and in which it is more likely than not that such losses will not be utilized in the foreseeable future.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of each reporting date, the Company considers new evidence, both positive and negative, that could impact the Company&#8217;s view with regard to future realization of our deferred tax assets. Management has considered the Company&#8217;s history of cumulative net losses in the UK, along with estimated future taxable income and has concluded that it is more likely than not that the Company will not realize the benefits of its UK deferred tax assets and U.S. state research and development tax credits. Accordingly, the Company has maintained a full valuation allowance against these net deferred tax assets as of December 31, 2021 and 2020, respectively.&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in the valuation allowance for deferred tax assets during the years ended December 31, 2021 and 2020 related primarily to the increase in UK net operating loss carryforwards as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance as of beginning of year</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(103,890</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(70,153</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increases recorded to income tax provision</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(59,691</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(29,302</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effect of foreign currency translation</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,008</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,435</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance as of end of year</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(161,573</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(103,890</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company applies the authoritative guidance on accounting for and disclosure of uncertainty in tax positions, which requires the Company to determine whether a tax position of the Company is more likely than not to be sustained upon examination, including resolution of any related appeals of litigation processes, based on the technical merits of the position. For tax positions meeting the more likely than not threshold, the tax amount recognized in the financial statements is reduced by the largest benefit that has a greater than fifty percent likelihood of being realized upon the ultimate settlement with the relevant taxing authority.&#160;There were no material uncertain tax positions as of December 31, 2021 and 2020. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company will recognize interest and penalties related to uncertain tax positions in income tax expense. As of December 31, 2021, and 2020, the Company had no accrued interest or penalties related to uncertain tax positions and no amounts have been recognized in the Company&#8217;s statement of operations.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company and its subsidiaries file income tax returns in the UK, the U.S., and various foreign jurisdictions. Generally, the tax years 2017 through 2021 remain open to examination by the major taxing jurisdictions to which the Company is subject. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the federal, state, or foreign tax authorities, if such tax attributes are utilized in a future period. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696130487592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">18. Commitments and Contingencies </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Lease commitments</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company leases office and laboratory space and has an embedded lease at AGC. Refer to Note 11, <span style="font-style:italic;">Leases</span>, for further information on the terms of the lease agreements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Manufacturing and technology development master agreement with AGC</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">On July 2, 2020, the Company entered into the AGC Agreement, pursuant to which AGC will develop, manufacture and supply certain viral vectors and conduct cell processing activities for certain Company development and commercial programs. Under the terms of the AGC Agreement, the Company is obligated to pay AGC for a minimum product manufacturing commitment, dedicated manufacturing and development resources, and for a lease component associated with the right of use of exclusive manufacturing suites within AGC&#8217;s existing facilities. The following table outlines the annual commitments associated with the contract, as of December 31, 2021:</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.88%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Due in:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Product manufacturing commitments (1)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Dedicated manufacturing and development resources (2)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exclusive transduction suites (3)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total AGC Commitment</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,627</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,379</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,626</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,632</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,051</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,831</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,079</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,961</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,051</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,831</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,079</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,961</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,525</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,915</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,539</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,979</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2026</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.88%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total manufacturing commitments</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,254</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,956</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,323</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,533</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">*Tabular disclosure above has been translated to U.S. Dollar, from Euro, using an exchange rate of &#8364;1.00 to $1.13.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">(1) The minimum product manufacturing commitments may be increased to the mid-seven figures per contract year upon achievement of certain milestones.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">(2) The Company may increase or decrease the usage of dedicated development services on a rolling basis with between six and 12-months&#8217; prior written notice to AGC. The above table assumes continued usage of dedicated development services at current rates.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">(3) Refer to Note 11 for further information on the embedded operating lease agreement</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The AGC Agreement has an initial term of&#160;five years, beginning on the Effective Date and ending&#160;July 2, 2025. The AGC Agreement may be extended for an additional&#160;two years&#160;by mutual agreement of the Company and AGC. The Company has the right to terminate the AGC Agreement at its discretion upon 12-month&#8217;s prior written notice to AGC, and beginning no earlier than July 2, 2022, AGC has the right to terminate the AGC Agreement at its discretion upon 24-month&#8217;s prior written notice to the Company. Each party may terminate the AGC Agreement upon prior notice to the other party for an uncured material breach that the breaching party does not cure within the notice period.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Other funding commitments</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has entered into several license agreements (see Note 15). In connection with these agreements the Company is required to make milestone payments and annual license maintenance payments or royalties on future sales of specified products. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Consulting Agreement</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the Company entered into a consulting agreement with non-employee advisor whereby the Company is obligated to make cash payments of $0.1 million per year and to issue up to 91,034 ordinary shares, which vest annually over a <span style="-sec-ix-hidden:F_001050">four-year</span> period, and 92,035 ordinary shares upon attainment of certain clinical development and regulatory milestones. In December 2021 and 2020, the Company issued 22,758 ordinary shares associated with the service condition.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the years ended December 31, 2021 and 2020, the Company recorded $0.3 million and <span><span style="color:#000000;">$</span>0.3</span> million in research and development expense associated with the share-based awards with service conditions. <span style="color:#000000;">During the years ended December 31, 2021 and 2020, </span>no expense was recorded associated with the performance-based conditions.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Legal proceedings </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;letter-spacing:-0.15pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is not a party to any litigation and does not have contingency reserves established for any litigation liabilities. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696130927368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Compensation And Retirement Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Benefit Plans</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">19. Benefit Plans</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company makes contributions to private defined contribution pension plans on behalf of its employees. The Company matches its employee contributions up to six percent of each employee&#8217;s annual salary based on the jurisdiction the employees are located. The Company paid $1.7 million and $1.6 million, in matching contributions for the years ended December&#160;31, 2021 and 2020, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696130575256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">20. Related-party Transactions </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">GSK</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2018, the Company completed the GSK Agreement with subsidiaries of GSK (See Note 14). As consideration under the agreement the Company paid an upfront fee of $14.2 million, purchased inventory of $6.9 million, paid $0.8 million in transaction costs, and issued 12,455,252 convertible preferred shares valued at $93.4 million. Additionally, as part of the GSK Agreement, the Company obtained, and is responsible for maintaining the commercial availability of Strimvelis. The Company recorded a loss provision of $18.4 million associated with the agreement, as the costs to maintain Strimvelis are expected to significantly exceed revenues. The issuance of the convertible preferred shares made GSK a principal shareholder in the Company. As of June 16, 2021, GSK no longer had a right to nominate and appoint a designee to the Company&#8217;s board of directors, and GSK is no longer considered a related party.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, the Company had accounts payable and accrued expenses due to GSK of <span>$0.1</span> million. During the year-ended December 31, 2020, the Company entered into a global license agreement with GSK for use of their lentiviral stable cell line technology whereby the Company recorded $1.2 million of in-process research and development expense </p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">associated with upfront payments made to GSK. During the year-ended December 31, 2020, the Company made </span><span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.8</span></span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million in payments on accounts payable due to GSK associated with </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">milestones, clinical inventory, and royalties</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696130587608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">21. Subsequent events </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 30, 2022, the Company announced a proposed reduction of its workforce of approximately 30%, subject to a consultation process with certain employees in the United Kingdom. The Company estimates that it will incur aggregate charges of approximately $2.5 million in the first and second quarters of 2022 as a result of the restructuring, consisting of one-time cash expenditures for severance and employee termination-related costs.<span style="color:#000000;font-size:12pt;"> </span>The Company also announced that it would discontinue its investment in and seek alternatives for OTL-102 for treatment of X-CGD, OTL-103 for treatment of WAS and Strimvelis. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696129028296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of consolidation</a></td>
<td class="text">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Principles of consolidation</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of estimates </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual for research and development expenses, the research and development tax credit receivable, share-based compensation, collaboration agreement milestones, operating lease assets and liabilities, and income taxes. Estimates are periodically reviewed in light of changes in circumstances, facts and experience.<span style="Background-color:#FFFFFF;"> Actual results could differ from the Company&#8217;s estimates.</span>&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of credit risk</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of credit risk </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has no significant off-balance sheet risk, such as foreign currency contracts, options contracts, or other foreign hedging arrangements. Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents, marketable securities, and receivables. The Company maintains deposits in accredited financial institutions in excess of federally insured limits. The Company deposits its cash in financial institutions that it believes have high credit quality and has not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships or entities for which it has a receivable. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign currency</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Foreign currency</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The financial statements of the Company&#8217;s subsidiaries with functional currencies other than the U.S. Dollar are translated into U.S. Dollars using period-end exchange rates for assets and liabilities, historical exchange rates for shareholders&#8217; equity and weighted average exchange rates for operating results. Translation gains and losses are included in accumulated other comprehensive income (loss) in shareholders&#8217; equity. Foreign currency transaction gains and losses are included in other income (expense), net in the results of operations.</span><span style="color:#000000;">  The Company recorded realized and unrealized foreign currency transaction losses of $1.2 million, and gains of $3.4 million for the years ended December 31, 2021, and 2020, respectively, which is included in other income (expense) in the statements of operations and comprehensive loss. </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment information</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Segment information</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company operates in a single segment, focusing on researching, developing and commercializing potentially curative gene therapies.&#160;&#160;Consistent with its operational structure, its chief operating decision maker manages and allocates resources at a global, consolidated level. Therefore, results of the Company's operations are reported on a consolidated basis for purposes of segment reporting.&#160;&#160;All material long-lived assets of the Company reside in the United States or United Kingdom. The Company had property and equipment of $3.6 million and $1.2 million located in the United Kingdom and United States, respectively, as of December 31, 2021. </span>The Company had property and equipment of $3.7 million and $1.1 million located in the United Kingdom and United States, respectively, as of December 31, 2020.&#160;The Company had right-of-use assets in the United States and United Kingdom and European Union of $12.5 million and $11.8 million, respectively, as of December 31, 2021. The Company had right-of-use assets in the United States and United Kingdom and European Union of $14.2 million and $15.6 million, respectively, as of December 31, 2020.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash equivalents</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash equivalents </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid investments purchased with original maturities of 90 days or less at the date of acquisition to be cash equivalents. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable securities</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Marketable securities</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities consist of investments with original maturities greater than ninety days at the date of acquisition. The Company has classified its investments with maturities beyond one year as short term, based on their highly liquid nature and because such marketable securities represent the investment of cash that is available for current operations. The Company considers its investment portfolio of investments as&#160;available-for-sale.&#160;Accordingly, these investments are recorded at fair value, which is based on quoted market prices or other observable inputs. Unrealized gains and losses are recorded as a component of other comprehensive income (loss). Realized gains and losses are determined on a specific identification basis and are included in other income (loss). Amortization and accretion of discounts and premiums is also recorded in other income (loss).</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">When the fair value is below the amortized cost of the asset an estimate of expected credit losses is made, the estimate is limited to the amount by which fair value is less than amortized cost. The credit-related impairment amount is recognized in the consolidated statements of operations; the remaining impairment amount and unrealized gains are reported as a component of accumulated other comprehensive income (loss) in shareholders&#8217; equity. Credit losses are recognized through the use of an allowance for credit losses account and subsequent improvements in expected credit losses are recognized as a reversal of the allowance account. If the Company has the intent to sell the security or it is more likely than not that the Company will be required to sell the security prior to recovery of its amortized cost basis the allowance for credit loss is written off and the excess of the amortized cost basis of the asset over its fair value is recorded in the consolidated statements of operation.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted cash and construction deposits</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Restricted cash and construction deposits</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents that are restricted as to withdrawal or use under the terms of certain contractual agreements are recorded as restricted cash on our consolidated balance sheet. The Company has an outstanding letter of credit for $3.0 million associated with a lease, and is required to hold this amount in a standalone bank account at December 31, 2021 and 2020. The Company is also contractually required to maintain a cash collateral account associated with corporate credit cards and other leases in the amount of <span>$1.3</span> million at December 31, 2021 and 2020. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company includes the restricted cash balance in cash and cash equivalents when reconciling beginning-of-period and end-of-period total amounts shown on the consolidated statements of cash flows. The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported in the consolidated balance sheet that sum to the total of the amounts reported in the consolidated statement of cash flows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,912</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,135</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,266</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,266</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash, cash equivalents and restricted cash shown in the statement of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; cash flows</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60,178</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59,401</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company also has <span style="color:#000000;">$7.9 million in an escrow account associated with the construction of the Company&#8217;s leased facility in Fremont, California, which the Company has ceased construction and build-out, and has subleased the facility to a third-party who intends to perform construction and build-out of the facility. </span>Subject to the terms of the lease and reduction provisions, this escrow amount may be decreased to nil over time upon qualifying construction expenditures, or will be returned in late 2022 to the extent funds are not used. The Company deposited $10.0 million into the account in the first quarter of 2020 and has received $2.1 million in receipts from the escrow funds for work performed to date. Of the $7.9 million remaining in the escrow account, the entire balance is classified within other prepaid expenses and other current assets on the consolidated balance sheets based on the timing of when the Company expects to receive the cash from the escrow agent.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Inventory</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventory is stated at the lower of cost or estimated net realizable value with cost determined on a first-in, first-out basis. Inventory costs include raw materials, third-party contract manufacturing, third-party packaging services, and freight. Raw and intermediate materials that may be utilized for either research and development or commercial purposes are classified as inventory. Amounts in inventory that are used for research and development purposes are charged to research and development expense when the product enters the research and development process and can no longer be used for commercial purposes and, therefore, does not have an &#8220;alternative future use&#8221; as defined in authoritative guidance. The Company performs an assessment of the recoverability of capitalized inventory during each reporting period and, if needed, writes down any excess and obsolete inventory to its estimated net realizable value in the period it is identified. If they occur, such impairment charges are recorded as a component of cost of goods sold in the consolidated statements of operations and comprehensive income (loss). Inventory is included in prepaid expenses and other current assets on the consolidated balance sheets and the amount was not significant as of December&#160;31, 2021.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the initial date that regulatory approval is received, costs related to the production of inventory are recorded as research and development expense on the Company&#8217;s consolidated statements of operations and comprehensive income (loss) in the period incurred. In connection with the acquisition of Strimvelis in April 2018, and with the EMA approval of Libmeldy in December 2020, the Company subsequently began capitalizing inventory manufactured or purchased after these dates.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible assets</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Intangible assets, net</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Intangible assets, net consist milestones associated with the Company&#8217;s approved products, net of accumulated amortization. The Company amortizes its intangible assets using the straight-line method over their estimated economic lives and periodically reviews for impairment. The Company has not recognized any impairment charges related to intangible assets to date.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and equipment</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Property and equipment </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are recorded at cost and depreciated or amortized using the straight-line method over the following estimated useful lives. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated useful&#160;&#160;life</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lab equipment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5-10 years</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shorter of lease term or estimated useful life</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4 years</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Office and computer equipment</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3-5 years</p></td>
</tr>
</table></div>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Repairs and maintenance expenditures, which are not considered improvements and do not extend the useful life of property and equipment, are expensed as incurred. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts, and any resulting gain or loss is included in the consolidated statements of operations and other comprehensive loss. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of long-lived assets</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Impairment of long-lived assets </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-lived assets consist of property and equipment and operating lease right-of-use assets. Long-lived assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or </p>
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">economic trends and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset group for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset group to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of an asset group are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset group over its fair value, as determined in accordance with the related accounting literature</span><span style="color:#000000;">. </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development costs</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research and development costs </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including salaries, share-based compensation and benefits, facilities costs, depreciation, third-party license fees, certain milestone payments, and external costs of outside vendors engaged to conduct clinical development activities and clinical trials, the purchase of in-process research and development assets, as well as costs to develop a manufacturing process, perform analytical testing and manufacture clinical trial materials. Non-refundable prepayments for goods or services that will be used or rendered for future research and development activities are recorded as prepaid expenses. Such amounts are recognized as an expense as the goods are delivered or the related services are performed, or until it is no longer expected that the goods will be delivered, or the services rendered. In addition, funding from research grants is recognized as an offset to research and development expense on the basis of costs incurred on the research program. Royalties to third parties associated with our research grants will be accrued when they become probable.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_ResearchContractCostsAndAccrualsPolicyTextBlock', window );">Research contract costs and accruals</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research contract costs and accruals </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has entered into various research and development contracts. These agreements are cancelable, and related costs are recorded as research and development expenses as incurred. When billing terms under these contracts do not coincide with the timing of when the work is performed, the Company is required to make estimates of outstanding obligations as of period end to those third parties. Any accrual estimates are based on a number of factors, including the Company&#8217;s knowledge of the progress towards completion of the research and development activities, invoicing to date under the contracts, communication from the research institution or other companies of any actual costs incurred during the period that have not yet been invoiced, and the costs included in the contracts. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the expense. Actual results could differ from the estimates made by the Company. The historical accrual estimates made by the Company have not been materially different from the actual costs.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Share-based compensation</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Share-based compensation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company measures share-based awards granted to employees, consultants and directors based on the fair value of the shares and options on the date of the grant and recognizes compensation expense for those awards over the requisite service period, which is the vesting period of the respective award. Forfeitures are accounted for as they occur. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive loss</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Comprehensive loss </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Comprehensive loss is composed of net loss and other comprehensive income (loss). Other comprehensive income (loss) consists of unrealized gains and losses on marketable securities and foreign currency translation gains and losses.</span><span style="color:#000000;"> &#160;&#160;</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Leases</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determines if an arrangement is a lease at contract inception. Operating lease assets represent a right to use an underlying asset for the lease term and operating lease liabilities represent an obligation to make lease payments arising from the lease. Operating lease liabilities with a term greater than one year and their corresponding right-of-use assets are recognized on the balance sheet at the commencement date of the lease based on the present value of lease payments over the expected lease term. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received. The Company made an accounting policy election to not record a right-of-use asset or lease liability for leases with a term of one year or less. To date, the Company has not identified any material short-term leases, either individually or in the aggregate.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">As&#160;the Company&#8217;s&#160;leases do not provide an implicit rate,&#160;the Company utilized the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term as the lease an amount equal to the lease payments in a similar economic environment. The Company estimated the incremental borrowing rate based on the </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Company&#8217;s currently outstanding credit facility as inputs to the analysis to calculate a spread, adjusted for factors that reflect the profile of secured borrowing over the expected term of the lease.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The components of a lease should be split into three categories: lease components (e.g., land, building, etc.), non-lease components (e.g., common area maintenance, utilities, performance of manufacturing services, purchase of inventory, etc.), and non-components (e.g., property taxes, insurance, etc.). Then the fixed contract consideration (including any related to non-components) must be allocated based on fair values to the lease components and non-lease components. Although separation of lease and non-lease components is required, certain accounting policy elections are available to entities. Entities can elect accounting policies that would not separate lease and non-lease components. Rather, they would account for each lease component and the related non-lease&#160;component together as a single component. The Company has elected&#160;not to apply the accounting policy with respect to its lease of manufacturing space at a contract manufacturing organization, the Company has allocated the consideration between the lease and non-lease components of the contract&#160;based on the respective fair values of the lease and non-lease components.&#160;The&#160;Company calculated the fair value of the lease&#160;and non-lease&#160;components&#160;using financial information readily available as part of its master services arrangement&#160;and other representative data&#160;indicative of fair value.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company accounts for sublease income on a straight-line basis over the respective lease period and records an unbilled rent receivable for sublease income incurred but not yet paid. The Company periodically performs a collectability assessment associated with any unbilled rent receivables. The Company recognizes the sublease income as a reduction to the related operating expense associated with the head lease.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_StrimvelisLossProvisionPolicyTextBlock', window );">Strimvelis loss provision</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Strimvelis loss provision</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of the GSK transaction, the Company is required to maintain commercial availability of Strimvelis in the European Union until such time that an alternative gene therapy is available (see Note 15). Strimvelis is not currently expected to generate sufficient cash flows to overcome the costs of maintaining the product and certain regulatory commitments; therefore, the Company initially recorded a liability associated with the loss contract of $18.4&#160;million in 2018. The Company recognizes the amortization of the loss provision on a diminishing balance basis based on the actual net loss incurred associated with the Strimvelis program and the expected future net losses to be generated until such time as Strimvelis is no longer commercially available. The amortization of the provision is recorded as a credit to research and development expense. The Company has made an estimate of the expected future losses associated with Strimvelis and will adjust this estimate as facts and circumstances change regarding the commercial availability and costs of maintaining and selling Strimvelis. The Company does not update the accrued loss provision for any subsequent adjustment of the future losses, however, the timing of recognizing the amortization of what was originally recorded is adjusted for the updated future losses. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table below outlines the changes to the Strimvelis loss provision for the periods ended December 31, 2021 and 2020:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.84%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.96%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.84%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at beginning of period</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,482</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,790</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provisions</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.06%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.06%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization of loss provision</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.06%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,037</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.06%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,413</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign currency translation</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.84%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.84%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.22%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at end of period</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.84%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,419</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.84%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,482</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, $0.7 million of the Strimvelis loss provision was classified as current, and $2.7 million was classified as non-current. As of December 31, 2020, $0.9 million of the Strimvelis loss provision was classified as current, and $3.6 million was classified as non-current.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_ResearchAndDevelopmentIncomeTaxCreditsPolicyTextBlock', window );">United Kingdom Research and development income tax credits</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">United Kingdom Research and development income tax credits </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a company that carries out research and development activities, the Company is able to submit tax credit claims from two UK research and development tax relief programs, the SME program and the RDEC program depending on eligibility. Qualifying expenditures largely comprise employment costs for research staff, consumables and certain internal overhead costs incurred as part of research projects for which the Company does not receive income.<span style="color:#000000;"> </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each reporting period, management evaluates which tax relief programs the Company is expected to be eligible for and records a reduction to research and development expense for the portion of the expense that it expects to qualify under the </p>
<p style="margin-bottom:0pt;margin-top:12pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">programs, that it plans to submit a claim for, and it has reasonable assurance that the amount will ultimately be realized. </span><span style="color:#000000;">Based on criteria established by HM Revenue and Customs (&#8220;HMRC&#8221;), management of the Company expects a proportion of expenditures being undertaken in relation to its pipeline research, clinical trials management and manufacturing development activities to be eligible for the research and development tax relief programs for the year ended December 31, 2021. </span><span style="Background-color:#FFFFFF;">The Company has qualified under the more favorable SME regime for the year ended December 31, 2020 and expects to qualify under the SME regime for the year ending December 31, 2021.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The RDEC and SME credits are not dependent on the Company generating future taxable income or on the ongoing tax status or tax position of the Company. The Company has assessed its research and development activities and expenditures to determine whether the nature of the activities and expenditures will qualify for credit under the tax relief programs and whether the claims will ultimately be realized based on the allowable reimbursable expense criteria established by the UK government which are subject to interpretation. At each period end, the Company estimates the reimbursement available to the Company based on available information at the time.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes credits from the research and development incentives when the relevant expenditure has been incurred and there is reasonable assurance that the reimbursement will be received.&#160;Such credits are accounted for as reductions in research and development expense. The following table outlines the changes to the research and development tax credit receivable, including amount recognized as an offset to research and development expense during the years ended December 31, 2021 and 2020:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.98%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.18%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at beginning of period</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,344</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,644</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.18%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recognition of credit claims as offset to research and development expense</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,920</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,130</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.18%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Receipt of credit claims</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(33,771</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.18%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign currency translation</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(541</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,341</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.18%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at end of period</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,723</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,344</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">During the year ended December 31, 2020, the Company recorded $4.8&#160;million of additional tax credits related to a change in estimate associated with its UK research and development tax credit receivable claim for fiscal year 2019. The change in estimate was based on the results of a tax credit&#160;analysis&#160;associated with the Company&#8217;s qualified projects and research and development expenditures completed during the third quarter to finalize the 2019 UK tax return.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, the Company&#8217;s tax credit receivable from the UK was $30.7 million, all of which was classified as current. As of December&#160;31, 2020, the Company&#8217;s tax incentive receivable from the UK was $17.3 million, all of which was classified as current.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Income taxes </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is primarily subject to corporation taxes in the United Kingdom and the United States. The calculation of the Company&#8217;s tax provision involves the application of both United Kingdom and United States tax law and requires judgement and estimates. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for income taxes in accordance with ASC Topic 740, <span style="font-style:italic;">Accounting for Income Taxes</span>, which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. The Company determines its deferred tax assets and liabilities based on differences between financial reporting and tax bases of assets and liabilities, which are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are provided if, based upon the weight of available evidence, it is more likely than not that some or all of the net deferred tax assets will not be realized. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for uncertainty in income taxes by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed as the amount of benefit to recognize in the consolidated financial statements. The amount of benefits that may be used is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate, as well as the related net interest and penalties. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Product sales</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Product sales</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s product sales in 2021 and 2020 consist of sales of Strimvelis, which is distributed exclusively at the San Raffaele Hospital in Milan, Italy. San Raffaele Hospital will purchase and pay for Strimvelis and submit a claim to the payer. The Company&#8217;s contracted sales with San Raffaele Hospital contain a single performance obligation and the Company recognizes revenue from product sales when the Company has satisfied its performance obligation by transferring control of Strimvelis to San Raffaele Hospital. Control of the product generally transfers upon the completion of the scheduled Strimvelis treatment. The Company&#8217;s product sales represent total net product sales of Strimvelis. The Company evaluated the variable consideration under Accounting Standards Codification (ASC) 606,&#160;<span style="font-style:italic;">Revenue from Contracts with Customers</span>, and there is currently no variable consideration included in the transaction price for Strimvelis. Costs to manufacture and deliver the product and those associated with administering the therapy are included in cost of product sales. As the product is sold in direct relation to a scheduled treatment, the Company estimates that there is limited risk of product return, including the risk of product expiration. During the years ended December 31, 2021 and 2020, the Company has $0.7 and $2.6 million in sales of Strimvelis, respectively.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Collaboration Revenue</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Collaboration revenue</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The terms of the Company&#8217;s collaboration agreements may include consideration such as&#160;non-refundable license fees, funding of research and development services, payments due upon the achievement of clinical and preclinical performance-<span style="color:#000000;">based development milestones, regulatory milestones, manufacturing services, sales-based milestones and royalties on product sales.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company first evaluates collaboration arrangements to determine whether the arrangement (or part of the arrangement) represents a collaborative arrangement pursuant to ASC Topic 808,&#160;<span style="font-style:italic;">Collaborative Arrangements</span>, based on the risks and rewards and activities of the parties pursuant to the contractual arrangement. The Company accounts for any collaborative arrangement or elements within the contract that are deemed to be a collaborative arrangement, and not<span style="font-size:12pt;"> </span>a customer relationship, in accordance with ASC&#160;808. Through December&#160;31, 2021, the Company entered into one agreement with Pharming Group N.V. (the &#8220;Pharming Agreement&#8221;, see Note 16) that is accounted for pursuant to ASC 606.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:9pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine the appropriate amount of revenue to be recognized for arrangements determined to be within the scope of ASC&#160;606, the Company performs the following five steps: (i)&#160;identification of the contract(s) with the customer, (ii)&#160;identification of the promised goods or services in the contract and determination of whether the promised goods or services are performance obligations, (iii)&#160;measurement of the transaction price, (iv)&#160;allocation of the transaction price to the performance obligations, and (v)&#160;recognition of revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect consideration it is entitled to in exchange for the goods or services it transfers to the customer.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company recognizes the&#160;</span>transaction&#160;<span style="Background-color:#FFFFFF;">price allocated to upfront license payments as revenue upon delivery of the license to the customer and resulting ability of the customer to use and benefit from the license, if the license is determined to be distinct from the other performance obligations identified in the contract. If the license is considered to not be distinct from other performance obligations, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied (i)&#160;at a point in time, but only for licenses determined to be distinct from other performance obligations in the contract, or (ii)&#160;over time, and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from license payments. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Pharming Agreement entitles the Company to additional payments upon the achievement of performance-based milestones. These milestones are generally categorized into three types: development milestones, regulatory milestones, and sales-based milestones.&#160;The Company is also eligible to receive from Pharming tiered royalty payments on worldwide net sales. The Company evaluates whether it is probable that the consideration associated with each milestone will not be subject to a significant reversal in the cumulative amount of revenue recognized. Amounts that meet this threshold are included in the transaction price using the most likely amount method, whereas amounts that do not meet this threshold are considered constrained and excluded from the transaction price until they meet this threshold.&#160;Milestones tied to regulatory approval, and therefore not within the Company&#8217;s control, are considered constrained until such approval is received. Upfront and ongoing development milestones per the collaboration agreements are not subject to refund if the development activities are not successful. At the end of each subsequent reporting period, the Company&#160;</span>re-evaluates<span style="Background-color:#FFFFFF;">&#160;the probability of a significant reversal of the cumulative revenue recognized for the milestones, and, if necessary, adjusts the estimate of the overall transaction price. Any such adjustments are recorded on a cumulative&#160;</span>catch-up <span style="Background-color:#FFFFFF;">basis, which would affect revenues from collaborators in </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">the period of adjustment. The Company may enter into an agreement that includes sales-based milestone payments and royalties in exchange for a license of intellectual property. The Company considers the underlying facts and circumstances of these agreements, noting whether the future payments are contingent upon future sales and whether they are dependent on a third party&#8217;s ability to successfully commercialize a product using the licensed intellectual property. The Company also considers whether the license is the only, or predominant, item to which the milestone payments and royalties relate. If the Company concludes the license is the predominant item in the agreement, therefore the primary driver of value, the Company excludes sales-based milestone payments and royalties from the transaction price until the sale occurs (or, if later, until the underlying performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied). Currently, the Company has not recognized any royalty revenue resulting from the </span><span style="Background-color:#FFFFFF;">Pharming </span><span style="Background-color:#FFFFFF;">Agreement.</span></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ASC 606 requires the Company to allocate the arrangement consideration on a relative standalone selling price basis for each performance obligation after determining the transaction price of the contract and identifying the performance obligations to which that amount should be allocated. The relative standalone selling price is defined in ASC 606 as the price at which an entity would sell a promised good or service separately to a customer. If other observable transactions in which the Company has sold the same performance obligation separately are not available, the Company is required to estimate the standalone selling price of each performance obligation. Key assumptions to determine the standalone selling price may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Whenever the Company determines that a contract should be accounted for as a combined performance obligation, which is recognized over time, it will utilize the&#160;cost-to-cost&#160;input method. Revenue will be recognized over time using the&#160;cost-to-cost&#160;input method, based on the total estimated costs to fulfill the obligations. The Company will recognize revenue as services are delivered. Significant management judgment is required in determining the estimate of total costs required under an arrangement and the period over which the Company is expected to complete its performance obligations under an arrangement.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Consideration that does not meet the requirements to satisfy the above revenue recognition criteria is a contract liability and is recorded as deferred revenue in the consolidated balance sheets. Short-term deferred revenue consists of amounts that are expected to be recognized as revenue in the next 12 months. Amounts that the Company expects will not be recognized within the next 12 months are classified as long-term deferred revenue.</span></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied, either at a point in time or over time. In particular, for the Company&#8217;s collaborations with Pharming, revenue attributable to research services is recognized as those services are provided, based on the costs incurred to date.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net loss per share</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Net loss per share </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share is computed by dividing the net loss by the weighted average number of ordinary shares outstanding for the period. Diluted net loss is computed by adjusting net loss based on the potential impact of dilutive securities. Diluted net loss per share is computed by dividing the diluted net loss by the weighted average number of ordinary shares outstanding for the period, including potential dilutive ordinary shares. For purpose of this calculation, outstanding options and unvested restricted shares are considered potential dilutive ordinary shares. Since the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share for all periods as the inclusion of all potential ordinary share equivalents outstanding would have been anti-dilutive. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following securities, presented based on amounts outstanding at each period end, are considered to be ordinary share equivalents, but were not included in the computation of diluted net loss per ordinary share because to do so would have been anti-dilutive: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share options</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,042,781</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,071,555</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested shares from share plan and consulting agreement</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">512,908</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">816,316</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,555,689</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,887,871</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent accounting pronouncements</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recent accounting pronouncements</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<span style="color:#000000;">In November 2021, the FASB issued ASU No. 2020-10,&#160;</span><span style="font-style:italic;color:#000000;">Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance</span><span style="color:#000000;">, which requires increased transparency in the disclosures about government assistant in the notes to the financial statements. This ASU is effective for the Company beginning January 1, 2022, and interim periods within that year, with early adoption permitted. The Company does not expect this amendment to have a significant effect on its financial statement disclosures. </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_ResearchAndDevelopmentIncomeTaxCreditsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development income tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_ResearchAndDevelopmentIncomeTaxCreditsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_ResearchContractCostsAndAccrualsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research contract costs and accruals.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_ResearchContractCostsAndAccrualsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_StrimvelisLossProvisionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Strimvelis loss provision.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_StrimvelisLossProvisionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155638-234783<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124437754&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696132609416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported in the consolidated balance sheet that sum to the total of the amounts reported in the consolidated statement of cash flows:
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,912</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,135</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,266</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,266</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash, cash equivalents and restricted cash shown in the statement of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; cash flows</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60,178</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59,401</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_PropertyPlantAndEquipmentUsefulLifeTableTextBlock', window );">Schedule of Estimated Useful Lives of Property and Equipment</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are recorded at cost and depreciated or amortized using the straight-line method over the following estimated useful lives. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated useful&#160;&#160;life</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lab equipment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5-10 years</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shorter of lease term or estimated useful life</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4 years</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Office and computer equipment</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3-5 years</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_ScheduleOfChangesInLossProvisionTableTextBlock', window );">Schedule of Changes in Loss Provision [Table Text Block]</a></td>
<td class="text">The following table below outlines the changes to the Strimvelis loss provision for the periods ended December 31, 2021 and 2020:
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.84%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.96%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.84%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at beginning of period</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,482</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,790</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provisions</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.06%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.06%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization of loss provision</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.06%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,037</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.06%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,413</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign currency translation</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.84%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.84%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.22%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at end of period</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.84%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,419</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.84%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,482</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock', window );">Summary of Amounts Recognized to Offset Research and Development Expense</a></td>
<td class="text">The following table outlines the changes to the research and development tax credit receivable, including amount recognized as an offset to research and development expense during the years ended December 31, 2021 and 2020:
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.98%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.18%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at beginning of period</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,344</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,644</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.18%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recognition of credit claims as offset to research and development expense</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,920</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,130</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.18%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Receipt of credit claims</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(33,771</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.18%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign currency translation</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(541</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,341</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.18%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at end of period</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,723</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,344</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Securities Excluded in the Computation of Diluted Net Loss Per Ordinary Share</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following securities, presented based on amounts outstanding at each period end, are considered to be ordinary share equivalents, but were not included in the computation of diluted net loss per ordinary share because to do so would have been anti-dilutive: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share options</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,042,781</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,071,555</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested shares from share plan and consulting agreement</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">512,908</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">816,316</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,555,689</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,887,871</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_PropertyPlantAndEquipmentUsefulLifeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Property, plant and equipment useful life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_PropertyPlantAndEquipmentUsefulLifeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_ScheduleOfChangesInLossProvisionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of changes in loss provision.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_ScheduleOfChangesInLossProvisionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of tax credit carryforwards available to reduce future taxable income, including amounts, expiration dates, limitations on use and the related deferred tax assets and valuation allowances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696134569304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements and Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Schedule of Cash Equivalents and Marketable Securities</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the Company&#8217;s cash equivalents and marketable securities as of December 31, 2021:</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements as of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021 Using:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,085</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,085</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,321</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,321</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,198</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,198</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash equivalents</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,085</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,519</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,604</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94,794</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94,794</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69,401</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69,401</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total marketable securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">164,195</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">164,195</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,085</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">184,714</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">205,799</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the Company&#8217;s cash equivalents and marketable securities as of December 31, 2020:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements as of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020 Using:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,650</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,650</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,001</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,001</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,999</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,999</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash equivalents</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,650</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,000</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,650</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US government securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,997</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,997</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93,358</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93,358</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,458</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,458</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total marketable securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">136,813</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">136,813</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,650</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">142,813</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">149,463</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Schedule of Cash Equivalents and Marketable Securities</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the Company&#8217;s cash equivalents and marketable securities as of December 31, 2021:</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.58%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="18" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.3%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements as of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021 Using:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.58%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Credit Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.58%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.12%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102,224</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.12%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.12%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(109</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.36%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.12%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102,115</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.58%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82,657</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(58</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82,599</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.58%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">184,881</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(167</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">184,714</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the Company&#8217;s cash equivalents and marketable securities as of December 31, 2020:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="18" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.36%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements as of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020 Using:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Credit Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.54%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,000</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,996</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.54%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96,259</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">133</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(32</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96,360</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.54%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,469</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,457</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.54%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">142,728</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">134</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(49</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">142,813</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Schedule of Available-for-Sale Debt Marketable Securities by contractual Maturity</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the Company&#8217;s available-for-sale marketable debt securities by contractual maturity, as of December 31, 2021 and 2020:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.2%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maturities in one year or less</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">172,575</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132,056</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.2%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maturities between one and three years</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,139</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,757</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.2%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">184,714</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">142,813</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696130931256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expense And Other Assets Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of Prepaid Expenses and Other Current Assets</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets consist of the following:</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.32%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid external research and development expenses</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,438</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,421</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventories</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,016</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">665</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other prepayments</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,128</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,930</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">VAT receivable</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,169</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,780</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction deposit - current</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,909</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,552</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-trade receivables</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,351</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,017</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total prepaid expenses and other current assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,011</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,365</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696130632280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment consist of the following: </p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.32%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lab equipment</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,937</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,114</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,450</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,522</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">303</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">304</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Office and IT equipment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,023</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">763</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction-in-progress</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">211</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">302</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,924</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,005</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: accumulated depreciation</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,157</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,224</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,767</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,781</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696130546760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill And Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_ScheduleOfIntangibleAssetsNetOfAccumulatedAmortizationTableTextBlock', window );">Schedule of Intangible Assets Net of Accumulated Amortization</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets, net of accumulated amortization, consisted of the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.06%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.32%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated Amortization</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-top:solid 0.75pt #000000;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Net</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-top:solid 0.75pt #000000;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated Amortization</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Net</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.64%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License intangibles</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,329</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(180</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,149</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,076</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,076</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.64%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,329</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(180</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,149</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,076</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,076</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Estimated Future Amortization For Intangible Assets</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the estimated future amortization for intangible assets for the next five years and thereafter:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">364</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">364</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">364</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">364</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2026</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">364</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,329</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,149</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_ScheduleOfIntangibleAssetsNetOfAccumulatedAmortizationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of intangible assets net of accumulated amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_ScheduleOfIntangibleAssetsNetOfAccumulatedAmortizationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696130654520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrentDisclosureAbstract', window );"><strong>Other Assets Noncurrent Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock', window );">Schedule of Other Assets</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets consist of the following:</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,086</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,219</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deposits</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,404</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,144</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred financing costs</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">693</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">975</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other non-current assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,407</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,554</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction deposits - long-term</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,572</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,590</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,464</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrentDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrentDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696130604664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued Liabilities And Other Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses and Other Liabilities</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses and other current liabilities consisted of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued external research and development expenses</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,273</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,878</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued payroll and related expenses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,521</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,881</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued milestone payments</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,058</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,252</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued professional fees</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">854</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">791</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued other</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,941</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,225</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Strimvelis liability - current portion</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">671</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">916</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accrued expenses and other current liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,318</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,943</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696130595800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Charges (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring And Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Summary of Cash Restructuring Charges</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Accrued restructuring and severance costs are included in Accrued expenses and other current liabilities in the consolidated balance sheet. Activity for the fiscal year is summarized as follows:</span></p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.06%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at beginning of period</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.2%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Charged to expense</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.06%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,854</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.2%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payments made</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,848</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.2%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at end of period</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.7%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DetailsOfImpairmentOfLongLivedAssetsHeldAndUsedByAssetTextBlock', window );">Summary of Impairment of Long Lived Assets</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">During the second quarter of 2020, the Company also took the following non-cash charges to research and development expense associated with the impairment of construction-in-process associated with the Fremont manufacturing facility, partial impairment of the right-of-use asset for the Fremont manufacturing facility lease (the &#8220;Fremont ROU asset&#8221;), and a write-down of laboratory equipment from the Company&#8217;s Menlo Park, CA facility:</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Asset write-down</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease right-of-use asset</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,605</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction-in-progress</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,285</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">760</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Charge included in research and development expense</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,650</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DetailsOfImpairmentOfLongLivedAssetsHeldAndUsedByAssetTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for impairment of long-lived assets held and used by an entity which includes a description of the impaired long-lived asset and facts and circumstances leading to the impairment, aggregate amount of the impairment loss and where the loss is located in the income statement, method(s) for determining fair value, and the segment in which the impaired long-lived asset is reported.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DetailsOfImpairmentOfLongLivedAssetsHeldAndUsedByAssetTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696130925144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Summary of Lease Cost Under Operating Leases</a></td>
<td class="text">The following table contains a summary of the lease-related costs recognized within operating expenses, and other information pertaining to the Company&#8217;s operating leases as of December 31, 2021 and 2020:
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fixed lease cost</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,701</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,593</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Impairment of right-of-use assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,781</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Variable lease cost</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,696</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,131</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sublease income</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,746</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(181</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.24%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease cost</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,651</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,324</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other information</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; Operating cash flows used for operating leases</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,989</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,447</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; Weighted-average remaining lease term (years)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000677">6.0</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000678">6.6</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; Weighted-average discount rate</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.7</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.6</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Base Rent Commitments Under Operating Leases</a></td>
<td class="text">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, future minimum base rent commitments under ASC 842 under the Company&#8217;s property leases were as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.08%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Due in:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross lease payments</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross sublease receipts</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Net lease payments</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,326</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,334</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,992</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,773</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,246</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,527</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,799</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,313</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,486</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,361</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,382</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,979</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2026</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,720</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,454</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,266</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.08%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,332</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,960</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,372</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total future minimum lease payments</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,311</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20,689</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,622</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.08%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: imputed interest</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14,698</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.84%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.84%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.08%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating lease payments</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,613</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.84%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.84%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696130435256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Summary of Notes Payable</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, and December 31, 2020, notes payable consist of the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notes payable, net of issuance costs</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,669</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,659</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: current portion</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(786</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,861</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notes payable, net of current portion</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,883</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,798</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accretion related to final payment</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">203</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">406</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notes payable, long term</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,086</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,204</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Summary of Future Principal Payments Due</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, the future principal payments due are as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Minimum</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Payments</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">786</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,429</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,429</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,429</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2026</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,082</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,155</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less current portion</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(786</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less unamortized portion of final payment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(952</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less unamortized debt issuance costs</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(331</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notes payable, long term</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,086</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696131172776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock', window );">Assumptions Used in Black-Scholes Option Pricing Model</a></td>
<td class="text">The relevant data used to determine the value of stock option awards are as follows:
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.96%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="4" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.96%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.96%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.12%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000798">0.5 - 1.3%</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000799">0.3 - 1.7%</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.96%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.12%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.3 - 6.1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.5 - 6.1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.96%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.12%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000806">74.2 - 78.7%</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000807">70.7 - 75.2%</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.96%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend rate</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.12%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Option Activity</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes option activity under the plans for the year ended December 31, 2021:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise Price</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">per Share</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Life (Years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,895,643</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.96</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000824">7.16</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91,133</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,489,856</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.75</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,727,254</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.59</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,357,505</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.30</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding and expected to vest at December 31, 2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,300,740</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.57</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000825">7.83</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,842</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable, as of December 31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,880,668</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.90</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000826">6.59</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,685</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Summary of Award Activity</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes restricted share unit award activity for the year-end December 31, 2021:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Performance-based RSUs</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Time-based RSUs</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted Average Grant Date Fair Value per Share</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested at December 31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">464,000</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">180,000</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.75</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,500</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.94</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(89,667</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(41,667</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.94</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.08%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(179,333</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(62,500</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.32</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.08%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested at December 31, 2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">195,000</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">123,333</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.41</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Share-based Compensation Expense</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share-based compensation expense related to share options, restricted share unit awards, and the employee stock purchase plan was classified in the consolidated statements of operations and comprehensive loss as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,214</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,679</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,322</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,283</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,536</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,962</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696130585928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreement with Pharming Group N.V. (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_CollaborativeArrangementAbstract', window );"><strong>Collaborative Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Summary of Research and Development Costs Incurred and Collaboration Revenue Recognized</a></td>
<td class="text">
<p style="Background-color:#FFFFFF;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes research and development costs incurred and collaboration revenue recognized in connection with the Company&#8217;s performance under the Collaboration Agreement:</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.8%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.76%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.8%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.8%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reimbursement revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.42%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">843</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.3%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.8%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upfront and milestone payment revenue</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.8%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.42%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">975</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_CollaborativeArrangementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_CollaborativeArrangementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696129323176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Components of Net Loss Before Income Taxes</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components of net loss before income taxes for the years ended December 31, 2021 and 2020 are as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.K.</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(147,337</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(155,614</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-U.K.</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,581</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,904</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss before income taxes</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(143,756</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(152,710</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Provision for (Benefit from) Income Taxes</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The provision for (benefit from) income taxes for the years ended December&#160;31, 2021 and 2020 are as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current (benefit) provision</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal&#8212;United States</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,025</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,107</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State&#8212;United States</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">334</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">189</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other foreign</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">388</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">230</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United Kingdom</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current (benefit) provision</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(303</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,526</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred provision (benefit)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal&#8212;United States</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,099</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,774</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State&#8212;United States</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(312</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(103</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United Kingdom</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other foreign</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">344</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(380</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred provision (benefit)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,131</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,257</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total provision (benefit) for income taxes</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">828</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(731</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Reconciliation of Income Tax Expense (Benefit)</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents a reconciliation of income tax expense (benefit) computed at the UK statutory income tax rate to the effective income tax rate as reflected in the consolidated financial statements: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income taxes at United Kingdom statutory rate</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27,313</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(29,015</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59,691</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,302</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reduction in research expense for credits granted</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,674</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,435</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in tax rates</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(38,785</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,105</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax credits</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,232</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,369</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. Deduction for foreign derived intangible income</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(196</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,254</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Permanent differences, including share-based compensation deduction shortfalls</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,863</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,265</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. state income taxes</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign rate differential</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(58</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total provision (benefit) for income taxes</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">828</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(731</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"> The following table presents the principal components of the Company&#8217;s deferred tax assets and liabilities as of December&#160;31, 2021 and 2020:
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforwards</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">126,563</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75,502</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,206</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,599</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development credits</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,449</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,564</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share-based compensation</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,353</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,400</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accruals</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">798</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,001</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease liability</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,444</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,805</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">523</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">171,835</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115,397</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(161,573</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(103,890</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fixed assets and right-of-use asset</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,176</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,288</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other non-current assets (net deferred tax assets and liabilities)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,086</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,219</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SummaryOfValuationAllowanceTextBlock', window );">Schedule of Changes in Valuation Allowance for Deferred Tax Assets Related Primarily to Increase in U.K. Net Operating Loss Carryforwards</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in the valuation allowance for deferred tax assets during the years ended December 31, 2021 and 2020 related primarily to the increase in UK net operating loss carryforwards as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance as of beginning of year</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(103,890</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(70,153</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increases recorded to income tax provision</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(59,691</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(29,302</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effect of foreign currency translation</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,008</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,435</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance as of end of year</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(161,573</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(103,890</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfValuationAllowanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfValuationAllowanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696130654520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock', window );">Schedule of Annual Commitments Associated with the Contract</a></td>
<td class="text">The following table outlines the annual commitments associated with the contract, as of December 31, 2021:
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.88%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Due in:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Product manufacturing commitments (1)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Dedicated manufacturing and development resources (2)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exclusive transduction suites (3)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total AGC Commitment</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,627</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,379</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,626</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,632</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,051</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,831</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,079</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,961</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,051</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,831</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,079</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,961</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,525</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,915</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,539</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,979</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2026</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.88%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total manufacturing commitments</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,254</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,956</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,323</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,533</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">*Tabular disclosure above has been translated to U.S. Dollar, from Euro, using an exchange rate of &#8364;1.00 to $1.13.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">(1) The minimum product manufacturing commitments may be increased to the mid-seven figures per contract year upon achievement of certain milestones.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">(2) The Company may increase or decrease the usage of dedicated development services on a rolling basis with between six and 12-months&#8217; prior written notice to AGC. The above table assumes continued usage of dedicated development services at current rates.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">(3) Refer to Note 11 for further information on the embedded operating lease agreement</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 303<br> -Paragraph (a)<br> -Subparagraph (5)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696126120520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business and Basis of Presentation - Additional Information (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 09, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 28, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>&#163; / shares</div>
</th>
<th class="th">
<div>Feb. 28, 2021 </div>
<div>&#163; / shares</div>
</th>
<th class="th">
<div>Feb. 28, 2021 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Feb. 09, 2021 </div>
<div>&#163; / shares</div>
</th>
<th class="th">
<div>Feb. 09, 2021 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>&#163; / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary Shares, Par Value | &#163; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 0.10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Placement agent fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(144,584)<span></span>
</td>
<td class="num">$ (151,979)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,224<span></span>
</td>
<td class="nump">$ 605,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents and marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 220,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ortx_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_NetProceedsFromIssuanceOfPrivatePlacement', window );">Net proceeds from private placement</a></td>
<td class="nump">$ 143,600<span></span>
</td>
<td class="nump">$ 143,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ortx_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of voting and non-voting ordinary shares, net of issuance costs, Shares | shares</a></td>
<td class="nump">20,900,321<span></span>
</td>
<td class="nump">20,900,321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary Shares, Par Value | &#163; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Purchase price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_ClosingPriceOfShareDate', window );">Closing price of share date</a></td>
<td class="text">Feb.  04,  2021<span></span>
</td>
<td class="text">Feb.  04,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Placement agent fees</a></td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_PaymentsOfOtherIssuanceCosts', window );">Other issuance costs</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockTransactionDate', window );">Private placement, transaction date</a></td>
<td class="text">Feb.  04,  2021<span></span>
</td>
<td class="text">Feb.  04,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ortx_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement | Private Placement | Non-voting Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of voting and non-voting ordinary shares, net of issuance costs, Shares | shares</a></td>
<td class="nump">3,215,434<span></span>
</td>
<td class="nump">3,215,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary Shares, Par Value | &#163; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_ClosingPriceOfShareDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Closing price of share date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_ClosingPriceOfShareDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_NetProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net proceeds from issuance of private placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_NetProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization consolidation and presentation of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_PaymentsOfOtherIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments of other issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_PaymentsOfOtherIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockTransactionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the subsidiary or equity investee issued or sold stock, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockTransactionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ortx_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ortx_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ortx_NonVotingOrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ortx_NonVotingOrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696125831608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk', window );">Description of significant off-balance sheet risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company has no significant off-balance sheet risk, such as foreign currency contracts, options contracts, or other foreign hedging arrangements.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency transaction gain (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,200)<span></span>
</td>
<td class="nump">$ 3,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,767<span></span>
</td>
<td class="nump">4,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,316<span></span>
</td>
<td class="nump">29,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from lines of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCollateralForBorrowedSecurities', window );">Cash collateral associated with corporate credit cards and other leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForLossOnContracts', window );">Liability associated with the loss contract</a></td>
<td class="nump">$ 18,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_AssetAcquisitionLiabilityAssumedCurrent', window );">Strimvelis loss provision current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_AssetAcquisitionLiabilityAssumedNonCurrent', window );">Strimvelis loss provision non current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700<span></span>
</td>
<td class="nump">3,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_ResearchAndDevelopmentTaxCreditReceivableCurrent', window );">Tax incentive receivable, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,723<span></span>
</td>
<td class="nump">17,344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales of strimvelis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,675<span></span>
</td>
<td class="nump">2,595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in accounting principle, accounting standards update, adopted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Change in accounting principle, accounting standards update, adoption date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan.  01,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleDescription', window );">New accounting pronouncement or change in accounting principle, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">ASU No. 2020-10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product Sales, Net [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales of strimvelis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="nump">2,595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=ortx_FremontLeaseAgreementMember', window );">Fremont Lease Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from lines of credit</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EscrowDeposit', window );">Escrow Deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,900<span></span>
</td>
<td class="nump">7,900<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_IncreaseDecreaseInEscrowDeposit', window );">Increase Decrease In Escrow Deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100<span></span>
</td>
<td class="num">(2,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=ortx_FremontLeaseAgreementMember', window );">Fremont Lease Agreement [Member] | Prepaid Expenses and Other Current Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EscrowDeposit', window );">Escrow Deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_GB', window );">United Kingdom</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,600<span></span>
</td>
<td class="nump">3,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_ResearchAndDevelopmentTaxCreditReceivable', window );">Tax incentive receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_ResearchAndDevelopmentTaxCreditReceivableCurrent', window );">Tax incentive receivable, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_IncrementalPercentageOfTaxableProfits', window );">Incremental percentage of taxable profits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_GB', window );">United Kingdom | Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency transaction gain (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (541)<span></span>
</td>
<td class="nump">1,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_AdditionalIncomeTaxCredits', window );">Additional income tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500<span></span>
</td>
<td class="nump">14,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=ortx_GBAndEuropeanUnionMember', window );">United Kingdom and European Union</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,800<span></span>
</td>
<td class="nump">$ 15,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_AdditionalIncomeTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional income tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_AdditionalIncomeTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_AssetAcquisitionLiabilityAssumedCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset acquisition liability assumed current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_AssetAcquisitionLiabilityAssumedCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_AssetAcquisitionLiabilityAssumedNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset acquisition liability assumed non current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_AssetAcquisitionLiabilityAssumedNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_IncreaseDecreaseInEscrowDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in escrow deposit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_IncreaseDecreaseInEscrowDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_IncrementalPercentageOfTaxableProfits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Incremental percentage of taxable profits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_IncrementalPercentageOfTaxableProfits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_ResearchAndDevelopmentTaxCreditReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development tax credit receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_ResearchAndDevelopmentTaxCreditReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_ResearchAndDevelopmentTaxCreditReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development tax credit receivable, current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_ResearchAndDevelopmentTaxCreditReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCollateralForBorrowedSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of cash collateral held for borrowed securities, for which the cash is restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCollateralForBorrowedSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether accounting standards update was adopted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121483254&amp;loc=SL120254523-199619<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S65<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124359872&amp;loc=SL124427846-239511<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120254519-210437<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123341672&amp;loc=SL120154346-209984<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122150657&amp;loc=SL122150809-237846<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)<br><br>Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 33: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date accounting standards update was adopted, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S65<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124359872&amp;loc=SL124427846-239511<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122150657&amp;loc=SL122150809-237846<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123341672&amp;loc=SL120154346-209984<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121483254&amp;loc=SL120254523-199619<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120254519-210437<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of financial instruments, excluding certain derivatives, with off-balance sheet credit risk (for example, standby letters of credit or financial guarantees), including (1) information about the (shared) activity, region or economic characteristic that identifies the concentration, (2) the face or contract amount of the instrument, (3) the nature and terms of the instrument, including the market risk, cash requirements and accounting policies for it, (4) the maximum amount of loss due to credit risk that would be incurred if the counterparties failed completely to perform according to the terms of the contracts, and any security or collateral that proved to be of no value, (5) the entity's policy of requiring collateral or other security to support financial instruments subject to credit risk, information about access to collateral or other security, and a brief description of the security supporting those financial instruments, and (6) the policy of entering into and a brief description of master netting arrangements to mitigate the credit risk, and the extent to which such arrangements would reduce the maximum amount of loss due to credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EscrowDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EscrowDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure related to a new accounting pronouncement or a change in accounting principle, including the nature and reason for the change and the effect of the change on prior periods and the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=SL108384541-122693<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=124437754&amp;loc=d3e765-108305<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124437754&amp;loc=d3e725-108305<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=d3e31137-122693<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForLossOnContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cumulative provision for contract losses not offset against related costs accumulated on the balance sheet.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 35<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123355788&amp;loc=d3e57777-111642<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForLossOnContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=ortx_FremontLeaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=ortx_FremontLeaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_GB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_GB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=ortx_GBAndEuropeanUnionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=ortx_GBAndEuropeanUnionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696135977192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_SummaryOfSignificantAccountingPoliciesAbstract', window );"><strong>Summary Of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 55,912<span></span>
</td>
<td class="nump">$ 55,135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash</a></td>
<td class="nump">4,266<span></span>
</td>
<td class="nump">4,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Total cash, cash equivalents and restricted cash shown in the statement of cash flows</a></td>
<td class="nump">$ 60,178<span></span>
</td>
<td class="nump">$ 59,401<span></span>
</td>
<td class="nump">$ 23,317<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_SummaryOfSignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_SummaryOfSignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696131096968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Property and Equipment (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property and equipment useful life, term</a></td>
<td class="text">Shorter of lease term or estimated useful life<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment useful life</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Lab Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Office and Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Lab Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment useful life</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Office and Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123364984&amp;loc=d3e1205-110223<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ortx_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=ortx_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ortx_OfficeAndComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=ortx_OfficeAndComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696132627096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Changes in Loss Provision (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_SummaryOfSignificantAccountingPoliciesAbstract', window );"><strong>Summary Of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_AssetAcquisitionLiabilityAssumed', window );">Balance at beginning of period</a></td>
<td class="nump">$ 4,482<span></span>
</td>
<td class="nump">$ 6,790<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_AssetAcquisitionLiabilityAmortizationOfLossProvision', window );">Amortization of loss provision</a></td>
<td class="num">(1,037)<span></span>
</td>
<td class="num">(2,413)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_IncreaseDecreaseInAssetAcquisitionLiabilityEffectOfForeignExchangeTranslation', window );">Foreign currency translation</a></td>
<td class="num">(26)<span></span>
</td>
<td class="nump">105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_AssetAcquisitionLiabilityAssumed', window );">Balance at end of period</a></td>
<td class="nump">$ 3,419<span></span>
</td>
<td class="nump">$ 4,482<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_AssetAcquisitionLiabilityAmortizationOfLossProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset acquisition liability amortization of loss provision.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_AssetAcquisitionLiabilityAmortizationOfLossProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_AssetAcquisitionLiabilityAssumed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset acquisition liability assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_AssetAcquisitionLiabilityAssumed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_IncreaseDecreaseInAssetAcquisitionLiabilityEffectOfForeignExchangeTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in asset acquisition liability, effect of foreign exchange translation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_IncreaseDecreaseInAssetAcquisitionLiabilityEffectOfForeignExchangeTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_SummaryOfSignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_SummaryOfSignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696132659368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Amounts recognized to Offset Research and Development Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCredits', window );">Receipt of credit claims</a></td>
<td class="num">$ (2,232)<span></span>
</td>
<td class="num">$ (1,369)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency translation</a></td>
<td class="num">(1,200)<span></span>
</td>
<td class="nump">3,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_GB', window );">United Kingdom | Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Balance at beginning of period</a></td>
<td class="nump">17,344<span></span>
</td>
<td class="nump">28,644<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxCreditsAndAdjustments', window );">Recognition of credit claims as offset to research and development expense</a></td>
<td class="nump">13,920<span></span>
</td>
<td class="nump">21,130<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCredits', window );">Receipt of credit claims</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33,771)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency translation</a></td>
<td class="num">(541)<span></span>
</td>
<td class="nump">1,341<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Balance at end of period</a></td>
<td class="nump">$ 30,723<span></span>
</td>
<td class="nump">$ 17,344<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxCreditsAndAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A credit or adjustment for government or taxing authority authorized decrease in taxes owed as a result of meeting certain tax policy conditions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxCreditsAndAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_GB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_GB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696125130648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Securities Excluded in the Computation of Diluted Net Loss Per Ordinary Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common shares attributable to anti-dilutive shares</a></td>
<td class="nump">14,555,689<span></span>
</td>
<td class="nump">11,887,871<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common shares attributable to anti-dilutive shares</a></td>
<td class="nump">14,042,781<span></span>
</td>
<td class="nump">11,071,555<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ortx_UnvestedSharesFromSharePlanAndConsultingAgreementMember', window );">Unvested Shares from Share Plan and Consulting Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common shares attributable to anti-dilutive shares</a></td>
<td class="nump">512,908<span></span>
</td>
<td class="nump">816,316<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ortx_UnvestedSharesFromSharePlanAndConsultingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ortx_UnvestedSharesFromSharePlanAndConsultingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696130471912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements and Marketable Securities - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount', window );">Fair value of financial assets transfers between level 1 to level 2</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount', window );">Fair value of financial assets transfers between level 2 to level 1</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696125930984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements and Marketable Securities - Schedule of Cash Equivalents and Marketable Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_CashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">$ 41,604<span></span>
</td>
<td class="nump">$ 12,650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_MarketableSecuritiesFairValueDisclosure', window );">Total marketable securities</a></td>
<td class="nump">164,195<span></span>
</td>
<td class="nump">136,813<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">205,799<span></span>
</td>
<td class="nump">149,463<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_CashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">21,085<span></span>
</td>
<td class="nump">6,650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">21,085<span></span>
</td>
<td class="nump">6,650<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_CashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">20,519<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_MarketableSecuritiesFairValueDisclosure', window );">Total marketable securities</a></td>
<td class="nump">164,195<span></span>
</td>
<td class="nump">136,813<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">184,714<span></span>
</td>
<td class="nump">142,813<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_CashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">21,085<span></span>
</td>
<td class="nump">6,650<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_CashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">21,085<span></span>
</td>
<td class="nump">6,650<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_CashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">7,321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_MarketableSecuritiesFairValueDisclosure', window );">Total marketable securities</a></td>
<td class="nump">94,794<span></span>
</td>
<td class="nump">93,358<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Bonds | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_CashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">7,321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_MarketableSecuritiesFairValueDisclosure', window );">Total marketable securities</a></td>
<td class="nump">94,794<span></span>
</td>
<td class="nump">93,358<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_CashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">13,198<span></span>
</td>
<td class="nump">2,999<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_MarketableSecuritiesFairValueDisclosure', window );">Total marketable securities</a></td>
<td class="nump">69,401<span></span>
</td>
<td class="nump">40,458<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_CashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">13,198<span></span>
</td>
<td class="nump">2,999<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_MarketableSecuritiesFairValueDisclosure', window );">Total marketable securities</a></td>
<td class="nump">$ 69,401<span></span>
</td>
<td class="nump">40,458<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Government Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_CashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_MarketableSecuritiesFairValueDisclosure', window );">Total marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,997<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Government Securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_CashEquivalentsAbstract', window );"><strong>Cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_MarketableSecuritiesFairValueDisclosure', window );">Total marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,997<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_CashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_CashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_MarketableSecuritiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Marketable securities fair value disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_MarketableSecuritiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696131264056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements and Marketable Securities - Schedule of Level 2 Cash Equivalents and Marketable Securities (Details) - Level 2 - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 184,881<span></span>
</td>
<td class="nump">$ 142,728<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">134<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(167)<span></span>
</td>
<td class="num">(49)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">184,714<span></span>
</td>
<td class="nump">142,813<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">U.S. Government Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,996<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Corporate Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">102,224<span></span>
</td>
<td class="nump">96,259<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">133<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(109)<span></span>
</td>
<td class="num">(32)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">102,115<span></span>
</td>
<td class="nump">96,360<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">82,657<span></span>
</td>
<td class="nump">43,469<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(58)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 82,599<span></span>
</td>
<td class="nump">$ 43,457<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696132655880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements and Marketable Securities - Schedule of Available-for-Sale Marketable Debt Securities by contractual Maturity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Maturities in one year or less</a></td>
<td class="nump">$ 172,575<span></span>
</td>
<td class="nump">$ 132,056<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsAmortizedCost', window );">Maturities between one and three years</a></td>
<td class="nump">12,139<span></span>
</td>
<td class="nump">10,757<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis', window );">Total</a></td>
<td class="nump">$ 184,714<span></span>
</td>
<td class="nump">$ 142,813<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Available for sale securities debt maturities after one through three years amortized cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=d3e62586-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696224043736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue From Contract With Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_GeneralPaymentTermsMaximum', window );">General payment terms, maximum</a></td>
<td class="text">60 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_GeneralPaymentTermsMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>General payment terms maximum.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_GeneralPaymentTermsMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696129119064">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expense And Other Assets Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_PrepaidExternalResearchAndDevelopmentExpenses', window );">Prepaid external research and development expenses</a></td>
<td class="nump">$ 2,438<span></span>
</td>
<td class="nump">$ 1,421<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">2,016<span></span>
</td>
<td class="nump">665<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other prepayments</a></td>
<td class="nump">6,128<span></span>
</td>
<td class="nump">4,930<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValueAddedTaxReceivableCurrent', window );">VAT receivable</a></td>
<td class="nump">1,169<span></span>
</td>
<td class="nump">2,780<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_ConstructionDepositsCurrent', window );">Construction deposit - current</a></td>
<td class="nump">7,909<span></span>
</td>
<td class="nump">1,552<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NontradeReceivablesCurrent', window );">Non-trade receivables</a></td>
<td class="nump">3,351<span></span>
</td>
<td class="nump">2,017<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other current assets</a></td>
<td class="nump">$ 23,011<span></span>
</td>
<td class="nump">$ 13,365<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_ConstructionDepositsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Construction deposits, current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_ConstructionDepositsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_PrepaidExternalResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid external research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_PrepaidExternalResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NontradeReceivablesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of amounts currently receivable other than from customers. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NontradeReceivablesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValueAddedTaxReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValueAddedTaxReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696130889960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">$ 10,924<span></span>
</td>
<td class="nump">$ 9,005<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(6,157)<span></span>
</td>
<td class="num">(4,224)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">4,767<span></span>
</td>
<td class="nump">4,781<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ortx_LabEquipmentMember', window );">Lab Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">5,937<span></span>
</td>
<td class="nump">5,114<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">2,450<span></span>
</td>
<td class="nump">2,522<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">303<span></span>
</td>
<td class="nump">304<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ortx_OfficeAndITEquipmentMember', window );">Office and IT Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">2,023<span></span>
</td>
<td class="nump">763<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction-In-Progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">$ 211<span></span>
</td>
<td class="nump">$ 302<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ortx_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=ortx_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ortx_OfficeAndITEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=ortx_OfficeAndITEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696130414600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 2.2<span></span>
</td>
<td class="nump">$ 2.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696129124824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets, Net - Schedule of Intangible Assets Net of Accumulated Amortization (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible Assets, Cost</a></td>
<td class="nump">$ 4,329<span></span>
</td>
<td class="nump">$ 3,076<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible Assets, Accumulated Amortized</a></td>
<td class="num">(180)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible Assets, Net</a></td>
<td class="nump">4,149<span></span>
</td>
<td class="nump">3,076<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseMember', window );">License Intangibles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible Assets, Cost</a></td>
<td class="nump">4,329<span></span>
</td>
<td class="nump">3,076<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible Assets, Accumulated Amortized</a></td>
<td class="num">(180)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible Assets, Net</a></td>
<td class="nump">$ 4,149<span></span>
</td>
<td class="nump">$ 3,076<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696135987192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill And Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible asset, useful life</a></td>
<td class="text">12 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Amortization of intangible assets</a></td>
<td class="nump">$ 180<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696129130472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets, Net - Schedule of Estimated Future Amortization For Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill And Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2023</a></td>
<td class="nump">364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2024</a></td>
<td class="nump">364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2025</a></td>
<td class="nump">364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2026</a></td>
<td class="nump">364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">2,329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible Assets, Net</a></td>
<td class="nump">$ 4,149<span></span>
</td>
<td class="nump">$ 3,076<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696130889128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Assets - Schedule of Other Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrentDisclosureAbstract', window );"><strong>Other Assets Noncurrent Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Deferred tax assets</a></td>
<td class="nump">$ 4,086<span></span>
</td>
<td class="nump">$ 5,219<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Deposits</a></td>
<td class="nump">1,404<span></span>
</td>
<td class="nump">1,144<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNoncurrentNet', window );">Deferred financing costs</a></td>
<td class="nump">693<span></span>
</td>
<td class="nump">975<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_OtherNonCurrentAssets', window );">Other non-current assets</a></td>
<td class="nump">3,407<span></span>
</td>
<td class="nump">1,554<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_ConstructionDepositsLongTerm', window );">Construction deposits - long-term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,572<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Total other assets</a></td>
<td class="nump">$ 9,590<span></span>
</td>
<td class="nump">$ 15,464<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_ConstructionDepositsLongTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Construction deposits long-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_ConstructionDepositsLongTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_OtherNonCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other non-current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_OtherNonCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNoncurrentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNoncurrentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrentDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrentDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696125035704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued Liabilities And Other Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_AccruedExternalResearchAndDevelopmentExpensesCurrent', window );">Accrued external research and development expenses</a></td>
<td class="nump">$ 9,273<span></span>
</td>
<td class="nump">$ 8,878<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued payroll and related expenses</a></td>
<td class="nump">8,521<span></span>
</td>
<td class="nump">11,881<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_AccruedMilestonePaymentsCurrent', window );">Accrued milestone payments</a></td>
<td class="nump">2,058<span></span>
</td>
<td class="nump">2,252<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">854<span></span>
</td>
<td class="nump">791<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued other</a></td>
<td class="nump">2,941<span></span>
</td>
<td class="nump">4,225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_ProductLiabilityCurrentPortion', window );">Strimvelis liability - current portion</a></td>
<td class="nump">671<span></span>
</td>
<td class="nump">916<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_AccruedExpensesAndOtherCurrentLiabilities', window );">Total accrued expenses and other current liabilities</a></td>
<td class="nump">$ 24,318<span></span>
</td>
<td class="nump">$ 28,943<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_AccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_AccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_AccruedExternalResearchAndDevelopmentExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued external research and development expenses current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_AccruedExternalResearchAndDevelopmentExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_AccruedMilestonePaymentsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued milestone payments current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_AccruedMilestonePaymentsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_ProductLiabilityCurrentPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Product liability, current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_ProductLiabilityCurrentPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696126257000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Charges - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost And Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,854,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_ImpairmentOfConstructionInProcess', window );">Construction-in-process, impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,285,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use-assets</a></td>
<td class="nump">$ 29,815,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,316,000<span></span>
</td>
<td class="nump">29,815,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Undiscounted cash flow estimate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,698,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Right of use asset, impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,605,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,781,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=ortx_MenloParkCaliforniaMember', window );">Menlo Park, California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost And Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Number of positions eliminated, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=ortx_FremontCaliforniaMember', window );">Fremont, California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost And Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_ImpairmentOfConstructionInProcess', window );">Construction-in-process, impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use-assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_OperatingLeaseRightOfUseAssetFairValue', window );">Fair value of ROU asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Right of use asset, impairment charge</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=ortx_FremontCaliforniaMember', window );">Fremont, California | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost And Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Undiscounted cash flow estimate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=ortx_FremontCaliforniaMember', window );">Fremont, California | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost And Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Undiscounted cash flow estimate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_ImpairmentOfConstructionInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Impairment of construction in process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_ImpairmentOfConstructionInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_OperatingLeaseRightOfUseAssetFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease Right Of Use Asset Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_OperatingLeaseRightOfUseAssetFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from impairment of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 25<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123399704&amp;loc=SL77918431-209957<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=ortx_MenloParkCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=ortx_MenloParkCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=ortx_FremontCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=ortx_FremontCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696126453400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Charges - Summary of Cash Restructuring Charges (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring And Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Balance at beginning of period</a></td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Charged to expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,854,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments made</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,848,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Balance at end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696132578696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Charges - Summary of Impairment of Long Lived Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring And Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Operating lease right-of-use asset</a></td>
<td class="nump">$ 2,605<span></span>
</td>
<td class="nump">$ 2,781<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_ImpairmentOfConstructionInProcess', window );">Construction-in-progress</a></td>
<td class="nump">2,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_ImpairmentOfLaboratoryEquipment', window );">Laboratory equipment, Asset write-downs</a></td>
<td class="nump">760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Charge included in research and development expense</a></td>
<td class="nump">$ 5,650<span></span>
</td>
<td class="nump">$ 5,650<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_ImpairmentOfConstructionInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Impairment of construction in process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_ImpairmentOfConstructionInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_ImpairmentOfLaboratoryEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Impairment of laboratory equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_ImpairmentOfLaboratoryEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from impairment of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 25<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123399704&amp;loc=SL77918431-209957<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696122690632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Details)<br> $ in Thousands, &#8364; in Millions</strong></div></th>
<th class="th" colspan="6">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2019</div></th>
<th class="th"><div>Jan. 31, 2019</div></th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Jan. 31, 2018</div></th>
<th class="th"><div>Nov. 30, 2017</div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_OperatingLeasesLineItems', window );"><strong>Operating Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Operating leases expiration term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul.  02,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,746<span></span>
</td>
<td class="nump">$ 181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use-assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,316<span></span>
</td>
<td class="nump">29,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from lines of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease, liability, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,278<span></span>
</td>
<td class="nump">24,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_OperatingLeaseRightOfUseAssetValueExchangeForLeaseLiabilities', window );">Operating lease, right-of-use asset obtained in exchange for lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="nump">17,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ortx_RentalLabSpaceMember', window );">Rental Lab Space [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_OperatingLeasesLineItems', window );"><strong>Operating Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Annual rental payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=ortx_OfficeSpaceMenloParkLeaseAgreementMember', window );">Office Space Menlo Park Lease Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_OperatingLeasesLineItems', window );"><strong>Operating Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Operating leases expiration term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_OperatingLeaseDurationForFreeRent', window );">Operating lease duration for free rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=ortx_LaboratorySpaceMenloParkLeaseAgreementMember', window );">Laboratory Space Menlo Park Lease Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_OperatingLeasesLineItems', window );"><strong>Operating Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Operating leases expiration term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=ortx_OfficeAndLaboratorySpaceMenloParkLeaseAgreementMember', window );">Office and Laboratory Space Menlo Park Lease Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_OperatingLeasesLineItems', window );"><strong>Operating Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Annual rental payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=ortx_FiveYearsLeaseTermTerminatesInJanuaryTwoThousandTwentyThreeMember', window );">Five Years Lease Term Terminates In January 2023 [Member] | Office Space London United Kingdom Lease Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_OperatingLeasesLineItems', window );"><strong>Operating Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Operating leases expiration term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Annual rental payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=ortx_LeaseTermTerminatesInSeptemberTwoThousandTwentyTwoMember', window );">Lease Term Terminates in September 2022 [Member] | Office Space Boston Lease Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_OperatingLeasesLineItems', window );"><strong>Operating Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Operating leases expiration term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Sep. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Annual rental payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=ortx_LeaseTermTerminatesInSeptemberTwoThousandTwentySixMember', window );">Lease Term Terminates in September 2026 [Member] | Office Space Boston Lease Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_OperatingLeasesLineItems', window );"><strong>Operating Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Operating leases expiration term</a></td>
<td class="text">Sep. 30,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Annual rental payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_OperatingLeasesCommencedTerm', window );">Operating leases Commenced term</a></td>
<td class="text">Jan. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=ortx_BostonAndLondonOfficeSpaceLeaseAgreementsMember', window );">Boston and London Office Space Lease Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_OperatingLeasesLineItems', window );"><strong>Operating Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use-assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,100<span></span>
</td>
<td class="nump">4,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,400<span></span>
</td>
<td class="nump">5,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=ortx_FremontLeaseAgreementMember', window );">Fremont Lease Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_OperatingLeasesLineItems', window );"><strong>Operating Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Operating leases expiration term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May 31,  2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Annual rental payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,100<span></span>
</td>
<td class="nump">3,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_OperatingLeaseDurationForFreeRent', window );">Operating lease duration for free rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use-assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_ReductionOfStandbyLetterOfCreditAmountPercentage', window );">Reduction of standby letter of credit amount percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from lines of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease, liability, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EscrowDeposit', window );">Escrow Deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,900<span></span>
</td>
<td class="nump">7,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_IncreaseDecreaseInEscrowDeposit', window );">Increase decrease in escrow deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,100)<span></span>
</td>
<td class="nump">2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=ortx_FremontLeaseAgreementMember', window );">Fremont Lease Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_OperatingLeasesLineItems', window );"><strong>Operating Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_TenantImprovementAllowance', window );">Tenant improvements allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=ortx_FremontSubleaseAgreementMember', window );">Fremont Sublease Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_OperatingLeasesLineItems', window );"><strong>Operating Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Annual rental payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_OperatingLeaseDurationForFreeRent', window );">Operating lease duration for free rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=ortx_FremontSubleaseAgreementMember', window );">Fremont Sublease Agreement | Other Long-Term Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_OperatingLeasesLineItems', window );"><strong>Operating Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=ortx_FremontSubleaseAgreementMember', window );">Fremont Sublease Agreement | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_OperatingLeasesLineItems', window );"><strong>Operating Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_TenantImprovementAllowance', window );">Tenant improvements allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=ortx_GSKAgreementMember', window );">G S K Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_OperatingLeasesLineItems', window );"><strong>Operating Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Operating leases expiration term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul.  02,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use-assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,700<span></span>
</td>
<td class="nump">$ 13,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease, liability, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,300<span></span>
</td>
<td class="nump">$ 13,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Lessee, operating lease, option to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The agreement may be extended for an additional&#160;two years&#160;by mutual agreement of the Company and AGC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Lessee, operating Lease, existence of option to extend [true false]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_LesseeOperatingLeaseExtendedTerm', window );">Operating lease extended term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_LeaseComponentManufacturingCommitmentAmount', window );">Lease component manufacturing suites commitment amount per contract year | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_IncreaseDecreaseInEscrowDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in escrow deposit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_IncreaseDecreaseInEscrowDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_LeaseComponentManufacturingCommitmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease component manufacturing commitment amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_LeaseComponentManufacturingCommitmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_LesseeOperatingLeaseExtendedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease extended term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_LesseeOperatingLeaseExtendedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_OperatingLeaseDurationForFreeRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease duration for free rent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_OperatingLeaseDurationForFreeRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_OperatingLeaseRightOfUseAssetValueExchangeForLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease right of use asset value exchange for lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_OperatingLeaseRightOfUseAssetValueExchangeForLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_OperatingLeasesCommencedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating leases commenced term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_OperatingLeasesCommencedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_OperatingLeasesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating leases line items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_OperatingLeasesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_ReductionOfStandbyLetterOfCreditAmountPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction of standby letter of credit amount percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_ReductionOfStandbyLetterOfCreditAmountPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_TenantImprovementAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tenant improvement allowance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_TenantImprovementAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EscrowDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EscrowDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash payments to lessor's for use of assets under operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ortx_RentalLabSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=ortx_RentalLabSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=ortx_OfficeSpaceMenloParkLeaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=ortx_OfficeSpaceMenloParkLeaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=ortx_LaboratorySpaceMenloParkLeaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=ortx_LaboratorySpaceMenloParkLeaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=ortx_OfficeAndLaboratorySpaceMenloParkLeaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=ortx_OfficeAndLaboratorySpaceMenloParkLeaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=ortx_FiveYearsLeaseTermTerminatesInJanuaryTwoThousandTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=ortx_FiveYearsLeaseTermTerminatesInJanuaryTwoThousandTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ortx_OfficeSpaceLondonUnitedKingdomLeaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=ortx_OfficeSpaceLondonUnitedKingdomLeaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=ortx_LeaseTermTerminatesInSeptemberTwoThousandTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=ortx_LeaseTermTerminatesInSeptemberTwoThousandTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ortx_OfficeSpaceBostonUnitedStatesLeaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=ortx_OfficeSpaceBostonUnitedStatesLeaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=ortx_LeaseTermTerminatesInSeptemberTwoThousandTwentySixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=ortx_LeaseTermTerminatesInSeptemberTwoThousandTwentySixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=ortx_BostonAndLondonOfficeSpaceLeaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=ortx_BostonAndLondonOfficeSpaceLeaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=ortx_FremontLeaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=ortx_FremontLeaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=ortx_FremontSubleaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=ortx_FremontSubleaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=ortx_GSKAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=ortx_GSKAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696130874440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Summary of Lease Cost Under Operating Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_FixedLeaseCost', window );">Fixed lease cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,701<span></span>
</td>
<td class="nump">$ 7,593<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Impairment of right-of-use assets</a></td>
<td class="nump">$ 2,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,781<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,696<span></span>
</td>
<td class="nump">2,131<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,746)<span></span>
</td>
<td class="num">(181)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,651<span></span>
</td>
<td class="nump">12,324<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows used for operating leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,989<span></span>
</td>
<td class="nump">$ 8,447<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.70%<span></span>
</td>
<td class="nump">8.60%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_FixedLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fixed lease cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_FixedLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from impairment of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 25<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123399704&amp;loc=SL77918431-209957<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696126109304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Future Minimum Base Rent Commitments Under Operating Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Gross lease payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 7,326<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">6,773<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">6,799<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">5,361<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2026</a></td>
<td class="nump">3,720<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">11,332<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">41,311<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(14,698)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease payments</a></td>
<td class="nump">26,613<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract', window );"><strong>Gross sublease receipts</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths', window );">2022</a></td>
<td class="num">(2,334)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears', window );">2023</a></td>
<td class="num">(2,246)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears', window );">2024</a></td>
<td class="num">(2,313)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears', window );">2025</a></td>
<td class="num">(2,382)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears', window );">2026</a></td>
<td class="num">(2,454)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter', window );">Thereafter</a></td>
<td class="num">(8,960)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived', window );">Total future minimum lease payments</a></td>
<td class="num">(20,689)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_OperatingLeaseLiabilitiesPaymentsDueNetAbstract', window );"><strong>Net lease payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_OperatingLeaseLiabilityPaymentsDueYearOne', window );">2022</a></td>
<td class="nump">4,992<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_OperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">4,527<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_OperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">4,486<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_OperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">2,979<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_OperatingLeaseLiabilityPaymentsDueYearFive', window );">2026</a></td>
<td class="nump">1,266<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_OperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">2,372<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_OperatingLeaseLiabilityPaymentsDueNet', window );">Total future minimum lease payments</a></td>
<td class="nump">$ 20,622<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_OperatingLeaseLiabilitiesPaymentsDueNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease liabilities payments due net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_OperatingLeaseLiabilitiesPaymentsDueNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_OperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease liability payments due after year five</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_OperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_OperatingLeaseLiabilityPaymentsDueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease liability payments due net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_OperatingLeaseLiabilityPaymentsDueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_OperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease liability payments due year five.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_OperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_OperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease liability payments due year four.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_OperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_OperatingLeaseLiabilityPaymentsDueYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease liability payments due year one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_OperatingLeaseLiabilityPaymentsDueYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_OperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease liability payments due year three.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_OperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_OperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease liability payments due year two.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_OperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payments to be received by lessor for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696132653160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Future Minimum Base Rent Commitments Under Operating Leases (Parenthetical) (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_OperatingLeasesLineItems', window );"><strong>Operating Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">Lease translation rate</a></td>
<td class="nump">1.13<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_GBP', window );">GBP</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_OperatingLeasesLineItems', window );"><strong>Operating Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">Lease translation rate</a></td>
<td class="nump">1.35<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_EUR', window );">Euro</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_OperatingLeasesLineItems', window );"><strong>Operating Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">Lease translation rate</a></td>
<td class="nump">1.13<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_OperatingLeasesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating leases line items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_OperatingLeasesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyExchangeRateTranslation1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Foreign exchange rate used to translate amounts denominated in functional currency to reporting currency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6897108&amp;loc=SL6897125-166521<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32618-110901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyExchangeRateTranslation1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_GBP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_GBP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_EUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_EUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696125565560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>May 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInitiationDate1', window );">Line of credit facility agreement date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May 31,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility maximum borrowings</a></td>
<td class="nump">$ 100,000,000.0<span></span>
</td>
<td class="nump">$ 75,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from lines of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Credit facility, remaining borrowings</a></td>
<td class="nump">$ 67,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_LineOfCreditFacilityInterestPaymentsTerm', window );">Line of credit facility interest payments term</a></td>
<td class="text">18 months<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_LineOfCreditFacilityAmortizationTerm', window );">Line of credit facility amortization term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityFrequencyOfPayments', window );">Line of credit facility, frequency of payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">monthly payments<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_LineOfCreditFacilityPercentageOfFinalPayment', window );">Line of credit facility, percentage of final payment</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityPeriodicPaymentInterest', window );">Final payment amount</a></td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Repayment of line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateDescription', window );">Line of credit facility interest rate description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Prior to execution of the Amended Credit Facility, each term loan under the Original Credit Facility bore interest at an annual rate equal to 6.0% plus LIBOR. The Company was required to make interest-only payments on the term loan for all payment dates prior to 24 months following the date of the Original Credit Facility, unless the third tranche was drawn, in which case for all payment dates prior to 36 months following the date of the Original Credit Facility. The term loans prior to the Amended Credit Facility were to begin amortizing on either the&#160;24-month&#160;or the&#160;36-month&#160;anniversary of the Original Credit Facility (as applicable), with equal monthly payments of principal plus interest to be made by the Borrower to the Lenders in consecutive monthly installments until the loan maturity date. In addition, a final payment of 4.5% was due on the loan maturity date.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCovenantDescription', window );">Line of credit facility covenants description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company is also subject to an ongoing minimum cash financial covenant in which the Company must maintain unrestricted cash in an amount not less than $20.0&#160;million following the utilization of the second term loan and not less than $35.0&#160;million following the utilization of the third term loan<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=ortx_TermLoanMember', window );">Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Debt instrument, interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Debt instrument, effective annual interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=ortx_LondonInterbankOfferedRateFloorMember', window );">LIBOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, annual interest rate</a></td>
<td class="nump">5.95%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_LineOfCreditFacilityAmortizationTerm', window );">Line of credit facility amortization term</a></td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Second Tranche (Term Loan Available from July 1, 2022 to July 1, 2023)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_LineOfCreditFacilityCovenantsMinimumCashAllowed', window );">Line of credit facility minimum cash financial covenant</a></td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | TThird Tranche (Term Loan Available from July 1, 2023 to July 1, 2024)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_LineOfCreditFacilityCovenantsMinimumCashAllowed', window );">Line of credit facility minimum cash financial covenant</a></td>
<td class="nump">$ 35,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_LineOfCreditFacilityAmortizationTerm', window );">Line of credit facility amortization term</a></td>
<td class="text">30 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ortx_TheFirstTrancheTermLoanMember', window );">Initial Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility maximum borrowings</a></td>
<td class="nump">$ 33,000,000.0<span></span>
</td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from lines of credit</a></td>
<td class="nump">33,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ortx_TheSecondTrancheTermLoanMember', window );">Second Tranche (Term Loan Available from July 1, 2022 to July 1, 2023)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility maximum borrowings</a></td>
<td class="nump">$ 33,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCovenantTerms', window );">Line of Credit Facility, Covenant Terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">upon certain regulatory approvals and evidence of the Company having $100&#160;million in cash and cash equivalent investments<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_LineOfCreditFacilityInterestPaymentsTerm', window );">Line of credit facility interest payments term</a></td>
<td class="text">30 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ortx_TheSecondTrancheTermLoanMember', window );">Second Tranche (Term Loan Available from July 1, 2022 to July 1, 2023) | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAndCash', window );">Cash and cash equivalent investments</a></td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ortx_TheThirdTrancheTermLoanMember', window );">Third Tranche (Term Loan Available from July 1, 2023 to July 1, 2024)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility maximum borrowings</a></td>
<td class="nump">$ 34,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCovenantTerms', window );">Line of Credit Facility, Covenant Terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">upon evidence of the Company having $100&#160;million in cash and cash equivalent investments and attaining a pre-specified trailing 12-month revenue target<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_LineOfCreditFacilityInterestPaymentsTerm', window );">Line of credit facility interest payments term</a></td>
<td class="text">30 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ortx_TheThirdTrancheTermLoanMember', window );">Third Tranche (Term Loan Available from July 1, 2023 to July 1, 2024) | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAndCash', window );">Cash and cash equivalent investments</a></td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_LineOfCreditFacilityAmortizationTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line of credit facility straight-line amortization term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_LineOfCreditFacilityAmortizationTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_LineOfCreditFacilityCovenantsMinimumCashAllowed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line of credit facility covenants minimum cash allowed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_LineOfCreditFacilityCovenantsMinimumCashAllowed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_LineOfCreditFacilityInterestPaymentsTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line of credit facility interest payments term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_LineOfCreditFacilityInterestPaymentsTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_LineOfCreditFacilityPercentageOfFinalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line of credit facility percentage of final payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_LineOfCreditFacilityPercentageOfFinalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCovenantDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of minimum financial levels (for example, tangible net worth and working capital) and achievement of certain financial ratios (for example, working capital ratio and debt service coverage ratio), and adherence to certain clauses which generally require or restrict certain actions (for example, entering into a debt arrangement with equal or greater seniority, and selling or discontinuing a certain business segment or material subsidiary) to be in compliance with the covenant clauses of the debt agreement. May also include a discussion of the adverse consequences that would result if the entity violates or fails to satisfy the covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCovenantDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAndCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of investments and unrestricted cash as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAndCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCovenantTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the conditions for borrowing under the credit facility including the nature of any restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCovenantTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityFrequencyOfPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the frequency of periodic payments, which may be presented in a variety of ways (for example, monthly, quarterly, annually).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityFrequencyOfPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityInitiationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the credit facility first became available, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityInitiationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityInterestRateDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of interest rate for borrowing under credit facility. Includes, but is not limited to, terms and method for determining interest rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityInterestRateDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityPeriodicPaymentInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payment applied to interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityPeriodicPaymentInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=ortx_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=ortx_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=ortx_LondonInterbankOfferedRateFloorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=ortx_LondonInterbankOfferedRateFloorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ortx_TheFirstTrancheTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ortx_TheFirstTrancheTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ortx_TheSecondTrancheTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ortx_TheSecondTrancheTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ortx_TheThirdTrancheTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ortx_TheThirdTrancheTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696132609704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Notes Payable - Summary of Notes Payable (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesAndLoansAbstract', window );"><strong>Long Term Notes And Loans [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_LongTermDebtBeforeAccretionIssuanceCostsNet', window );">Notes payable, net of issuance costs</a></td>
<td class="nump">$ 32,669<span></span>
</td>
<td class="nump">$ 24,659<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_LongTermDebtBeforeAccretionIssuanceCostsNetCurrent', window );">Less: current portion</a></td>
<td class="num">(786)<span></span>
</td>
<td class="num">(4,861)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_LongTermDebtBeforeAccretionIssuanceCostsNetNoncurrent', window );">Notes payable, net of current portion</a></td>
<td class="nump">31,883<span></span>
</td>
<td class="nump">19,798<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_AccretionRelatedToFinalPayment', window );">Accretion related to final payment</a></td>
<td class="nump">203<span></span>
</td>
<td class="nump">406<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Notes payable, long term</a></td>
<td class="nump">$ 32,086<span></span>
</td>
<td class="nump">$ 20,204<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_AccretionRelatedToFinalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accretion related to final payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_AccretionRelatedToFinalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_LongTermDebtBeforeAccretionIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long term debt before accretion issuance costs net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_LongTermDebtBeforeAccretionIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_LongTermDebtBeforeAccretionIssuanceCostsNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long term debt before accretion issuance costs net current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_LongTermDebtBeforeAccretionIssuanceCostsNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_LongTermDebtBeforeAccretionIssuanceCostsNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long term debt before accretion issuance costs net noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_LongTermDebtBeforeAccretionIssuanceCostsNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesAndLoansAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesAndLoansAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696132497176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Notes Payable - Summary of Future Principal Payments Due (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByMaturityAbstract', window );"><strong>Long Term Debt By Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2023</a></td>
<td class="nump">9,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2024</a></td>
<td class="nump">9,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2025</a></td>
<td class="nump">9,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2026</a></td>
<td class="nump">5,082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total</a></td>
<td class="nump">34,155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less current portion</a></td>
<td class="num">(786)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_UnamortizedPortionOfFinalPayment', window );">Less unamortized portion of final payment</a></td>
<td class="num">(952)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnamortizedDebtIssuanceExpense', window );">Less unamortized debt issuance costs</a></td>
<td class="num">(331)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Notes payable, long term</a></td>
<td class="nump">$ 32,086<span></span>
</td>
<td class="nump">$ 20,204<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_UnamortizedPortionOfFinalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unamortized portion of final payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_UnamortizedPortionOfFinalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtByMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtByMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnamortizedDebtIssuanceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnamortizedDebtIssuanceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696123482760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity and Convertible Preferred Shares - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 01, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 09, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 28, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>VotingRight</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>VotingRight</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>GBP (&#163;) </div>
<div>&#163; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 28, 2021 </div>
<div>&#163; / shares</div>
</th>
<th class="th">
<div>Feb. 28, 2021 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Feb. 09, 2021 </div>
<div>&#163; / shares</div>
</th>
<th class="th">
<div>Feb. 09, 2021 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>GBP (&#163;) </div>
<div>&#163; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2018 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Ordinary shares voting rights description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">each holder of ordinary shares and ADSs is entitled to one vote per ordinary share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStock', window );">Ordinary shares dividends declared</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_NumberOfOrdinaryVotingRights', window );">Number of ordinary voting rights | VotingRight</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary Shares, Par Value | &#163; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary Shares, Issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,674,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,283,603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Nominal value of shares issued and sold | &#163; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Placement agent fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,355,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Total consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 143,645,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ortx_ConsultingAgreementMember', window );">Consulting Agreement | Advisor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary Shares, Issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ortx_OxfordBioMedicaLicenseDevelopmentAndSupplyAgreementMember', window );">Oxford BioMedica License, Development and Supply Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary Shares, Issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">588,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,413<span></span>
</td>
<td class="nump">150,826<span></span>
</td>
<td class="nump">150,826<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ortx_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_NetProceedsFromIssuanceOfPrivatePlacement', window );">Net proceeds from private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 143,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 143,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ortx_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary Shares, Par Value | &#163; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of ordinary shares issued and sold | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,900,321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,900,321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Nominal value of shares issued and sold | &#163; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Purchase price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_ClosingPriceOfShareDate', window );">Closing price of share date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb.  04,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb.  04,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Placement agent fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_PaymentsOfOtherIssuanceCosts', window );">Other issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockTransactionDate', window );">Private placement, transaction date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb.  04,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb.  04,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ortx_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement | Private Placement | Non-voting Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary Shares, Par Value | &#163; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of ordinary shares issued and sold | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,215,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,215,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Nominal value of shares issued and sold | &#163; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ortx_SharePurchaseAgreementWithPharmingMember', window );">Share Purchase Agreement with Pharming</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of ordinary shares issued and sold | shares</a></td>
<td class="nump">1,227,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,227,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Total consideration</a></td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Common stock consideration</a></td>
<td class="nump">4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_ProceedsFromPremiumSharesIssued', window );">Premium consideration</a></td>
<td class="nump">$ 3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValueOutstanding', window );">Ordinary shares maximum nominal value | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 13,023,851.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 13,023,851.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_ClosingPriceOfShareDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Closing price of share date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_ClosingPriceOfShareDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_NetProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net proceeds from issuance of private placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_NetProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_NumberOfOrdinaryVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of ordinary voting rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_NumberOfOrdinaryVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_PaymentsOfOtherIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments of other issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_PaymentsOfOtherIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_ProceedsFromPremiumSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from premium shares issued..</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_ProceedsFromPremiumSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockTransactionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the subsidiary or equity investee issued or sold stock, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockTransactionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ortx_ConsultingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ortx_ConsultingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ortx_NonEmployeeAdvisorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ortx_NonEmployeeAdvisorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ortx_OxfordBioMedicaLicenseDevelopmentAndSupplyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ortx_OxfordBioMedicaLicenseDevelopmentAndSupplyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ortx_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ortx_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ortx_NonVotingOrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ortx_NonVotingOrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ortx_SharePurchaseAgreementWithPharmingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ortx_SharePurchaseAgreementWithPharmingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696124991192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation - Additional Information (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>&#163; / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased', window );">Exercise price of option | &#163; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 0.00001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Maximum term of option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Total intrinsic value of share options exercised | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,400<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Total proceeds from share options exercised | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700<span></span>
</td>
<td class="nump">3,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeEquityPlanProceedsReceivedAfterYearEnd', window );">Employee equity plan proceeds received after year end | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value of share options granted | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.10<span></span>
</td>
<td class="nump">$ 7.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation cost recognized | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,536<span></span>
</td>
<td class="nump">$ 27,962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Unvested options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,420,072<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation cost of stock option and time-based RSUs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Compensation cost expected to be recognized weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 9 months 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Total unrecognized compensation cost of performance-based RSUs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance-based Restricted Share Units ("RSUs")</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of shares vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Remaining performance based share units outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">179,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance-based Restricted Share Units ("RSUs") | Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares granted</a></td>
<td class="nump">195,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue', window );">Total grant date fair value | $</a></td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance-based Restricted Share Units ("RSUs") | Chief Executive Officer | Achievement of At Least Three of Four Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Vesting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The award vests on January 2, 2024 as to 1/3 of the award for each of the first three to occur of four milestones, if each such milestone is achieved by the Company on or before December 31, 2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance-based Restricted Share Units ("RSUs") | Libmeldy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation cost recognized | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ortx_TimeBasedRestrictedShareUnitsMember', window );">Time-based Restricted Share Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of shares vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Remaining performance based share units outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ortx_TwoThousandAndEighteenShareOptionAndIncentivePlanMember', window );">2018 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Remaining shares available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,934,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ortx_TwoThousandAndEighteenEmployeeSharePurchasePlanMember', window );">2018 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Remaining shares available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,197,399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ortx_TwoThousandAndTwentyInducementEquityPlanMember', window );">Inducement Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Remaining shares available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">721,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeEquityPlanProceedsReceivedAfterYearEnd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award employee equity plan proceeds received after year end.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeEquityPlanProceedsReceivedAfterYearEnd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share weighted-average price paid for shares purchased on open market for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ortx_LibmeldyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ortx_LibmeldyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ortx_TimeBasedRestrictedShareUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ortx_TimeBasedRestrictedShareUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ortx_TwoThousandAndEighteenShareOptionAndIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ortx_TwoThousandAndEighteenShareOptionAndIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ortx_TwoThousandAndEighteenEmployeeSharePurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ortx_TwoThousandAndEighteenEmployeeSharePurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ortx_TwoThousandAndTwentyInducementEquityPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ortx_TwoThousandAndTwentyInducementEquityPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696132501608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation - Assumptions Used in Black-Scholes Option Pricing Model (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">74.20%<span></span>
</td>
<td class="nump">70.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">78.70%<span></span>
</td>
<td class="nump">75.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696131269384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation - Summary of Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding at December 31, 2020</a></td>
<td class="nump">13,895,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted</a></td>
<td class="nump">8,489,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options, Exercised</a></td>
<td class="num">(1,727,254)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Options, Forfeited</a></td>
<td class="num">(3,357,505)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding and expected to vest at December 31, 2021</a></td>
<td class="nump">17,300,740<span></span>
</td>
<td class="nump">13,895,643<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options, Exercisable as of December 31, 2021</a></td>
<td class="nump">7,880,668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share, Outstanding at December 31, 2020</a></td>
<td class="nump">$ 7.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share, Granted</a></td>
<td class="nump">4.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share, Exercised</a></td>
<td class="nump">1.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share, Forfeited</a></td>
<td class="nump">10.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share, Outstanding and expected to vest at December 31,2021</a></td>
<td class="nump">6.57<span></span>
</td>
<td class="nump">$ 7.96<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share, Exercisable as of December 31,2021</a></td>
<td class="nump">$ 6.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life, Outstanding at December 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 1 month 28 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Life, Outstanding and expected to vest at December 31, 2021</a></td>
<td class="text">7 years 9 months 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Life, Exercisable as of December 31, 2021</a></td>
<td class="text">6 years 7 months 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding</a></td>
<td class="nump">$ 2,842<span></span>
</td>
<td class="nump">$ 91,133<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable as of December 31, 2021</a></td>
<td class="nump">$ 2,685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696125855240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation - Summary of Award Activity (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value per share, Unvested at December 31, 2020 | $ / shares</a></td>
<td class="nump">$ 8.75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value per Share, Granted | $ / shares</a></td>
<td class="nump">4.94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value per share, Vested | $ / shares</a></td>
<td class="nump">9.94<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value per share, Forfeited | $ / shares</a></td>
<td class="nump">10.32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value per Share, Unvested at December 31, 2021 | $ / shares</a></td>
<td class="nump">$ 6.41<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance-based RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">RSUs, Unvested at December 31, 2020</a></td>
<td class="nump">464,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">RSUs, Vested</a></td>
<td class="num">(89,667)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">RSUs, Forfeited</a></td>
<td class="num">(179,333)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">RSUs, Unvested at December 31, 2021</a></td>
<td class="nump">195,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ortx_TimeBasedRestrictedShareUnitsMember', window );">Time-based Restricted Share Units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">RSUs, Unvested at December 31, 2020</a></td>
<td class="nump">180,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares granted</a></td>
<td class="nump">47,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">RSUs, Vested</a></td>
<td class="num">(41,667)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">RSUs, Forfeited</a></td>
<td class="num">(62,500)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">RSUs, Unvested at December 31, 2021</a></td>
<td class="nump">123,333<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ortx_TimeBasedRestrictedShareUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ortx_TimeBasedRestrictedShareUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696135682328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation - Share-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation</a></td>
<td class="nump">$ 22,536<span></span>
</td>
<td class="nump">$ 27,962<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation</a></td>
<td class="nump">9,214<span></span>
</td>
<td class="nump">11,679<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation</a></td>
<td class="nump">$ 13,322<span></span>
</td>
<td class="nump">$ 16,283<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696123512136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Research Agreements - Additional Information (Details)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="6">12 Months Ended</th>
<th class="th" colspan="2">32 Months Ended</th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 30, 2018 </div>
<div>USD ($) </div>
<div>Program </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 30, 2018 </div>
<div>GBP (&#163;) </div>
<div>Program </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>Milestone</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>GBP (&#163;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2018 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 30, 2018 </div>
<div>GBP (&#163;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_AssetAcquisitionLiabilityAssumed', window );">Remaining liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,419,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,482,000<span></span>
</td>
<td class="nump">$ 6,790,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,419,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,674,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,283,603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,674,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,674,095<span></span>
</td>
<td class="nump">125,674,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 86,977,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 93,730,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ortx_GSKAssetPurchaseAndLicenseAgreementMember', window );">GSK Asset Purchase and License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_NumberOfLateStageClinicalGeneTherapyPrograms', window );">Number of earlier stage clinical gene therapy program | Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_NumberOfEarlierStageClinicalGeneTherapyProgram', window );">Number of earlier stage clinical gene therapy program | Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_NumberOfAdditionalEarlierStageDevelopmentPrograms', window );">Number of additional earlier-stage development programs | Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Total consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 133,600,000<span></span>
</td>
<td class="nump">&#163; 94,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_AssetAcquisitionUpfrontPayment', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,200,000<span></span>
</td>
<td class="nump">10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_AssetAcquisitionLiabilityAssumed', window );">Remaining liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 12,900,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_AssetAcquisitionInventoryPurchaseLiability', window );">Inventory purchase liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,900,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_AssetAcquisitionTransactionCosts', window );">Transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_AssetAcquisitionInProcessResearchAndDevelopmentExpense', window );">In-process research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 133,600,000<span></span>
</td>
<td class="nump">&#163; 94,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_PaymentOfTieredRoyaltyMaximumPercentage', window );">Payment of tiered royalty, maximum percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_MilestonePaymentsPayableUponAchievementOfCertainSalesMilestones', window );">Milestone payments payable upon achievement of certain sales milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 90,000,000.0<span></span>
</td>
<td class="nump">&#8364; 31.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_UpfrontPaymentDescription', window );">Upfront payment description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In May 2019, the Company entered into a license agreement with Telethon-OSR, under which Telethon-OSR granted to the Company an exclusive worldwide license for the research, development, manufacture and commercialization of Telethon-OSR&#8217;s ex vivo autologous HSC lentiviral based gene therapy for the treatment of mucopolysaccharidosis type I (&#8220;MPS-I&#8221;), including the Hurler variant. To date, Telethon-OSR received &#8364;17.0 million in upfront and milestone payments from the Company upon entering into the agreement and shortly thereafter, resulting in $19.4 million in in-process research and development expense.<span></span>
</td>
<td class="text">In May 2019, the Company entered into a license agreement with Telethon-OSR, under which Telethon-OSR granted to the Company an exclusive worldwide license for the research, development, manufacture and commercialization of Telethon-OSR&#8217;s ex vivo autologous HSC lentiviral based gene therapy for the treatment of mucopolysaccharidosis type I (&#8220;MPS-I&#8221;), including the Hurler variant. To date, Telethon-OSR received &#8364;17.0 million in upfront and milestone payments from the Company upon entering into the agreement and shortly thereafter, resulting in $19.4 million in in-process research and development expense.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ortx_GSKAssetPurchaseAndLicenseAgreementMember', window );">GSK Asset Purchase and License Agreement | Convertible Preferred Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_AssetAcquisitionNumberOfSharesIssuedForAcquisition', window );">Shares issued for asset acquisition | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,455,252<span></span>
</td>
<td class="nump">12,455,252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_AssetAcquisitionValueOfEquityInstrumentsIssued', window );">Aggregate value of shares issued for asset acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 93,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 65,800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ortx_TelethonOSRLicenseAgreementsMember', window );">Telethon O S R License Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_UpfrontAndMilestonePayments', window );">Upfront and milestone payments | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 17.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_InProcessResearchAndDevelopmentExpenseForUpfrontAndMilestonePayments', window );">In-process research and development expense for upfront and milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_MilestonePaymentsPayableUponAchievementOfCertainDevelopmentRegulatoryAndCommercialMilestones', window );">Milestone payments payable upon achievement of certain development regulatory and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 28.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ortx_UCLBAndUCLATechnologyMember', window );">UCLB/UCLA Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_UpfrontCashPayment', window );">Upfront cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ortx_UCLBTechnologyAndManufacturingTechnologyMember', window );">UCLB Technology and Manufacturing Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_UpfrontCashPayment', window );">Upfront cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ortx_UCLBLicenseAgreementMember', window );">UCLB License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,224,094<span></span>
</td>
<td class="nump">3,441,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,665,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ortx_UCLBAndUCLALicenseAgreementMember', window );">UCLB/UCLA License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_PaymentsToAcquireClinicalData', window );">Payments to acquire clinical data</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentForAdministrativeFees', window );">Annual administration fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_PotentialPaymentForAchievementOfSpecifiedMilestones', window );">Payments upon achievement of specified regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,800,000<span></span>
</td>
<td class="nump">&#163; 19,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ortx_OxfordBioMedicaLicenseDevelopmentAndSupplyAgreementMember', window );">Oxford BioMedica License, Development and Supply Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares issued | shares</a></td>
<td class="nump">75,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">588,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">588,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">588,220<span></span>
</td>
<td class="nump">588,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,826<span></span>
</td>
<td class="nump">150,826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_NumberOfMilestonesMet', window );">Number of milestones met | Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ortx_OxfordBioMedicaLicenseDevelopmentAndSupplyAgreementMember', window );">Oxford BioMedica License, Development and Supply Agreement | Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_MilestonePayment', window );">Milestone payment</a></td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_AssetAcquisitionInProcessResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset acquisition in-process research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_AssetAcquisitionInProcessResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_AssetAcquisitionInventoryPurchaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset acquisition inventory purchase liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_AssetAcquisitionInventoryPurchaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_AssetAcquisitionLiabilityAssumed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset acquisition liability assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_AssetAcquisitionLiabilityAssumed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_AssetAcquisitionNumberOfSharesIssuedForAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset acquisition number of shares issued for acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_AssetAcquisitionNumberOfSharesIssuedForAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_AssetAcquisitionTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset acquisition transaction costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_AssetAcquisitionTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_AssetAcquisitionUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset acquisition upfront payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_AssetAcquisitionUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_AssetAcquisitionValueOfEquityInstrumentsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset acquisition value of equity instruments issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_AssetAcquisitionValueOfEquityInstrumentsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_InProcessResearchAndDevelopmentExpenseForUpfrontAndMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In-process research and development expense for upfront and milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_InProcessResearchAndDevelopmentExpenseForUpfrontAndMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_MilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_MilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_MilestonePaymentsPayableUponAchievementOfCertainDevelopmentRegulatoryAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payments payable upon achievement of certain development regulatory and commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_MilestonePaymentsPayableUponAchievementOfCertainDevelopmentRegulatoryAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_MilestonePaymentsPayableUponAchievementOfCertainSalesMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payments payable upon achievement of certain sales milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_MilestonePaymentsPayableUponAchievementOfCertainSalesMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_NumberOfAdditionalEarlierStageDevelopmentPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional earlier-stage development programs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_NumberOfAdditionalEarlierStageDevelopmentPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_NumberOfEarlierStageClinicalGeneTherapyProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of earlier stage clinical gene therapy program.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_NumberOfEarlierStageClinicalGeneTherapyProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_NumberOfLateStageClinicalGeneTherapyPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of late-stage clinical gene therapy programs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_NumberOfLateStageClinicalGeneTherapyPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_NumberOfMilestonesMet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of milestones met.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_NumberOfMilestonesMet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_PaymentOfTieredRoyaltyMaximumPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment of tiered royalty, maximum percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_PaymentOfTieredRoyaltyMaximumPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_PaymentsToAcquireClinicalData">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments to acquire clinical data.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_PaymentsToAcquireClinicalData</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_PotentialPaymentForAchievementOfSpecifiedMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential payment for achievement of specified milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_PotentialPaymentForAchievementOfSpecifiedMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_UpfrontAndMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront and milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_UpfrontAndMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_UpfrontCashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront cash payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_UpfrontCashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_UpfrontPaymentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront payment Description</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_UpfrontPaymentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9215-128498<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 55<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6829253&amp;loc=SL6831962-166255<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123385561&amp;loc=d3e9135-128495<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9212-128498<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForAdministrativeFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount paid to managing member or general partner, affiliate of managing member or general partner, or affiliate of limited liability company (LLC) or limited partnership (LP) for administrative services provided to the LLC or LP, for example, but not limited to, salaries, rent, or overhead costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForAdministrativeFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ortx_GSKAssetPurchaseAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ortx_GSKAssetPurchaseAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ortx_TelethonOSRLicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ortx_TelethonOSRLicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ortx_UCLBAndUCLATechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ortx_UCLBAndUCLATechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ortx_UCLBTechnologyAndManufacturingTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ortx_UCLBTechnologyAndManufacturingTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ortx_UCLBLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ortx_UCLBLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ortx_UCLBAndUCLALicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ortx_UCLBAndUCLALicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ortx_OxfordBioMedicaLicenseDevelopmentAndSupplyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ortx_OxfordBioMedicaLicenseDevelopmentAndSupplyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696122554744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreement with Pharming Group N.V. - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 01, 2021</div></th>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Total consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 143,645,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Shares issued as part of license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 791,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ortx_StrategicCollaborationAgreementWithPharmingMember', window );">Strategic Collaboration Agreement with Pharming</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Cash upfront payment received</a></td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_ProceedsFromNonRefundableUpfrontPayment', window );">Non-refundable up-front payment</a></td>
<td class="nump">10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ortx_StrategicCollaborationAgreementWithPharmingMember', window );">Strategic Collaboration Agreement with Pharming | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_MilestonePaymentsReceivable', window );">Milestone payments receivable</a></td>
<td class="nump">189,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ortx_SharePurchaseAgreementWithPharmingMember', window );">Share Purchase Agreement with Pharming</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Total consideration</a></td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of ordinary shares</a></td>
<td class="nump">1,227,738<span></span>
</td>
<td class="nump">1,227,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Common stock consideration</a></td>
<td class="nump">$ 4,100,000<span></span>
</td>
<td class="nump">$ 4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_ProceedsFromPremiumSharesIssued', window );">Premium consideration</a></td>
<td class="nump">3,400,000<span></span>
</td>
<td class="nump">$ 3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ortx_PharmingAgreementsMember', window );">Pharming Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_ProceedsFromUpfrontPayment', window );">Total upfront payments</a></td>
<td class="nump">17,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_ProceedsFromUpfrontPaymentsAttributedToEquitySold', window );">Upfront payments attributed to equity sold</a></td>
<td class="nump">4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_ProceedsFromUpfrontPaymentsAttributedToResearchActivities', window );">Upfront payments attributed to research activities</a></td>
<td class="nump">13,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Shares issued as part of license agreement</a></td>
<td class="nump">4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_ExcessProceedsFromFairValueOfSharesIssuedAllocatedToCollaborationAgreement', window );">Excess proceeds from fair value of shares issued allocated to collaboration agreement</a></td>
<td class="nump">$ 3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_ExcessProceedsFromFairValueOfSharesIssuedAllocatedToCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess proceeds from fair value of shares issued allocated to collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_ExcessProceedsFromFairValueOfSharesIssuedAllocatedToCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_MilestonePaymentsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payments receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_MilestonePaymentsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_ProceedsFromNonRefundableUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from non-refundable upfront payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_ProceedsFromNonRefundableUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_ProceedsFromPremiumSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from premium shares issued..</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_ProceedsFromPremiumSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_ProceedsFromUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from upfront payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_ProceedsFromUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_ProceedsFromUpfrontPaymentsAttributedToEquitySold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from upfront payments attributed to equity sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_ProceedsFromUpfrontPaymentsAttributedToEquitySold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_ProceedsFromUpfrontPaymentsAttributedToResearchActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from upfront payments attributed to research activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_ProceedsFromUpfrontPaymentsAttributedToResearchActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollaborators">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from collaborators during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollaborators</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ortx_StrategicCollaborationAgreementWithPharmingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ortx_StrategicCollaborationAgreementWithPharmingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ortx_SharePurchaseAgreementWithPharmingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ortx_SharePurchaseAgreementWithPharmingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ortx_PharmingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ortx_PharmingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696130873688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreement with Pharming Group N.V. - Summary of Research and Development Costs Incurred and Collaboration Revenue Recognized (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 1,675<span></span>
</td>
<td class="nump">$ 2,595<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | Reimbursement Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">843<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | Upfront and Milestone Payment Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ortx_ReimbursementRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ortx_ReimbursementRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ortx_UpfrontAndMilestonePaymentRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ortx_UpfrontAndMilestonePaymentRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696132725640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Components of Net Loss Before Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">U.K.</a></td>
<td class="num">$ (147,337)<span></span>
</td>
<td class="num">$ (155,614)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Non-U.K.</a></td>
<td class="nump">3,581<span></span>
</td>
<td class="nump">2,904<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before income tax</a></td>
<td class="num">$ (143,756)<span></span>
</td>
<td class="num">$ (152,710)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696226960696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Provision for (Benefit from) Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current (benefit) provision</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal&#8212;United States</a></td>
<td class="num">$ (1,025)<span></span>
</td>
<td class="nump">$ 1,107<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State&#8212;United States</a></td>
<td class="nump">334<span></span>
</td>
<td class="nump">189<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_CurrentOtherTaxExpenseBenefit', window );">Other foreign</a></td>
<td class="nump">388<span></span>
</td>
<td class="nump">230<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current (benefit) provision</a></td>
<td class="num">(303)<span></span>
</td>
<td class="nump">1,526<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred provision (benefit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal&#8212;United States</a></td>
<td class="nump">1,099<span></span>
</td>
<td class="num">(1,774)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State&#8212;United States</a></td>
<td class="num">(312)<span></span>
</td>
<td class="num">(103)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOtherTaxExpenseBenefit', window );">Other foreign</a></td>
<td class="nump">344<span></span>
</td>
<td class="num">(380)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred provision (benefit)</a></td>
<td class="nump">1,131<span></span>
</td>
<td class="num">(2,257)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total provision (benefit) for income taxes</a></td>
<td class="nump">$ 828<span></span>
</td>
<td class="num">$ (731)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_CurrentOtherTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current other tax expense benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_CurrentOtherTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOtherTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other deferred income tax expense (benefit) pertaining to income (loss) from continuing operations. For example, but not limited to, acquisition-date income tax benefits or expenses recognized from changes in the acquirer's valuation allowance for its previously existing deferred tax assets resulting from a business combination and adjustments to beginning-of-year balance of a valuation allowance because of a change in circumstance causing a change in judgment about the realizability of the related deferred tax asset in future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOtherTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696126181608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Reconciliation of Income Tax Expense (Benefit) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Income taxes at United Kingdom statutory rate</a></td>
<td class="num">$ (27,313)<span></span>
</td>
<td class="num">$ (29,015)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">59,691<span></span>
</td>
<td class="nump">29,302<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_IncomeTaxReconciliationReductionInResearchExpenseForCreditsGranted', window );">Reduction in research expense for credits granted</a></td>
<td class="nump">6,674<span></span>
</td>
<td class="nump">8,435<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">Change in tax rates</a></td>
<td class="num">(38,785)<span></span>
</td>
<td class="num">(8,105)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCredits', window );">Tax credits</a></td>
<td class="num">(2,232)<span></span>
</td>
<td class="num">(1,369)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_IncomeTaxReconciliationDomesticDeductionForDerivedIntangibleIncome', window );">U.S. Deduction for foreign derived intangible income</a></td>
<td class="num">(196)<span></span>
</td>
<td class="num">(1,254)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_IncomeTaxReconciliationPermanentDifferencesIncludingShareBasedCompensationDeductionShortfalls', window );">Permanent differences, including share-based compensation deduction shortfalls</a></td>
<td class="nump">2,863<span></span>
</td>
<td class="nump">1,265<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">U.S. state income taxes</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Foreign rate differential</a></td>
<td class="nump">109<span></span>
</td>
<td class="num">(58)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total provision (benefit) for income taxes</a></td>
<td class="nump">$ 828<span></span>
</td>
<td class="num">$ (731)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_IncomeTaxReconciliationDomesticDeductionForDerivedIntangibleIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation domestic deduction for derived intangible income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_IncomeTaxReconciliationDomesticDeductionForDerivedIntangibleIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_IncomeTaxReconciliationPermanentDifferencesIncludingShareBasedCompensationDeductionShortfalls">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation permanent differences including share-based compensation deduction shortfalls.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_IncomeTaxReconciliationPermanentDifferencesIncludingShareBasedCompensationDeductionShortfalls</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_IncomeTaxReconciliationReductionInResearchExpenseForCreditsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation reduction in research expense for credits granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_IncomeTaxReconciliationReductionInResearchExpenseForCreditsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32059-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696122470584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accrued interest or penalties related to uncertain tax positions</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=us-gaap_EarliestTaxYearMember', window );">Earliest Tax Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Income tax year open to examination</a></td>
<td class="text">2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=us-gaap_LatestTaxYearMember', window );">Latest Tax Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Income tax year open to examination</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_GB', window );">United Kingdom</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_CorporationTaxRatePercentage', window );">Corporation tax rate percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes', window );">Increase in net deferred tax assets</a></td>
<td class="nump">$ 38,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase in valuation allowance</a></td>
<td class="nump">38,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">126,600,000<span></span>
</td>
<td class="nump">75,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">US | Federal | Orphan Drug</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credits carryforward, amount</a></td>
<td class="nump">600,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">US | State | Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credits carryforward, amount</a></td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_TaxCreditCarryforwardExpirationYear', window );">Tax credit carryforward expiration year</a></td>
<td class="text">2041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_CorporationTaxRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Corporation tax rate percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_CorporationTaxRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_TaxCreditCarryforwardExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax credit carryforward expiration year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_TaxCreditCarryforwardExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OpenTaxYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax year that remains open to examination under enacted tax laws, in YYYY format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OpenTaxYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:gYearListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_EarliestTaxYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_EarliestTaxYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_LatestTaxYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_LatestTaxYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_GB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_GB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=ortx_OrphanDrugTaxCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=ortx_OrphanDrugTaxCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696126072280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Deferred Tax Assets and Liabilities Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 126,563<span></span>
</td>
<td class="nump">$ 75,502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_DeferredTaxAssetsAmortization', window );">Amortization</a></td>
<td class="nump">25,206<span></span>
</td>
<td class="nump">22,599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credits</a></td>
<td class="nump">2,449<span></span>
</td>
<td class="nump">1,564<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Share-based compensation</a></td>
<td class="nump">9,353<span></span>
</td>
<td class="nump">7,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Accruals</a></td>
<td class="nump">798<span></span>
</td>
<td class="nump">1,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_DeferredTaxAssetsLeaseLiability', window );">Lease liability</a></td>
<td class="nump">6,444<span></span>
</td>
<td class="nump">6,805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">1,022<span></span>
</td>
<td class="nump">523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">171,835<span></span>
</td>
<td class="nump">115,397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(161,573)<span></span>
</td>
<td class="num">(103,890)<span></span>
</td>
<td class="num">$ (70,153)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_DeferredTaxLiabilitiesFixedAssetsAndRightOfUseAsset', window );">Fixed assets and right-of-use asset</a></td>
<td class="num">(6,176)<span></span>
</td>
<td class="num">(6,288)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Other non-current assets (net deferred tax assets and liabilities)</a></td>
<td class="nump">$ 4,086<span></span>
</td>
<td class="nump">$ 5,219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_DeferredTaxAssetsAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_DeferredTaxAssetsAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_DeferredTaxAssetsLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_DeferredTaxAssetsLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_DeferredTaxLiabilitiesFixedAssetsAndRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities fixed assets and right of use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_DeferredTaxLiabilitiesFixedAssetsAndRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696130933624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Changes in Valuation Allowance for Deferred Tax Assets Related Primarily to Increase in U.K. Net Operating Loss Carryforwards (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance as of beginning of year</a></td>
<td class="num">$ (103,890)<span></span>
</td>
<td class="num">$ (70,153)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_DeferredTaxAssetsValuationAllowanceIncreasesRecordedToIncomeTaxProvision', window );">Increases recorded to income tax provision</a></td>
<td class="num">(59,691)<span></span>
</td>
<td class="num">(29,302)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_DeferredTaxAssetsValuationAllowanceEffectOfForeignCurrencyTranslation', window );">Effect of foreign currency translation</a></td>
<td class="nump">2,008<span></span>
</td>
<td class="num">(4,435)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance as of end of year</a></td>
<td class="num">$ (161,573)<span></span>
</td>
<td class="num">$ (103,890)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_DeferredTaxAssetsValuationAllowanceEffectOfForeignCurrencyTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets valuation allowance effect of foreign currency translation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_DeferredTaxAssetsValuationAllowanceEffectOfForeignCurrencyTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_DeferredTaxAssetsValuationAllowanceIncreasesRecordedToIncomeTaxProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets valuation allowance increases recorded to income tax provision.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_DeferredTaxAssetsValuationAllowanceIncreasesRecordedToIncomeTaxProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696125783304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Annual Commitments Associated with the Contract (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_ManufacturingCommitmentsAmountDueInNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 13,632<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_ManufacturingCommitmentsAmountDueInYearTwo', window );">2023</a></td>
<td class="nump">13,961<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_ManufacturingCommitmentsAmountDueInYearThree', window );">2024</a></td>
<td class="nump">13,961<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_ManufacturingCommitmentsAmountDueInYearFour', window );">2025</a></td>
<td class="nump">6,979<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_ManufacturingCommitments', window );">Total manufacturing commitments</a></td>
<td class="nump">48,533<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplyCommitmentAxis=ortx_ProductManufacturingCommitmentsMember', window );">Product Manufacturing Commitments</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_ManufacturingCommitmentsAmountDueInNextTwelveMonths', window );">2022</a></td>
<td class="nump">2,627<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_ManufacturingCommitmentsAmountDueInYearTwo', window );">2023</a></td>
<td class="nump">3,051<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_ManufacturingCommitmentsAmountDueInYearThree', window );">2024</a></td>
<td class="nump">3,051<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_ManufacturingCommitmentsAmountDueInYearFour', window );">2025</a></td>
<td class="nump">1,525<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_ManufacturingCommitments', window );">Total manufacturing commitments</a></td>
<td class="nump">10,254<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplyCommitmentAxis=ortx_DedicatedManufacturingAndDevelopmentResourcesMember', window );">Dedicated Manufacturing and Development Resources</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_ManufacturingCommitmentsAmountDueInNextTwelveMonths', window );">2022</a></td>
<td class="nump">8,379<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_ManufacturingCommitmentsAmountDueInYearTwo', window );">2023</a></td>
<td class="nump">7,831<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_ManufacturingCommitmentsAmountDueInYearThree', window );">2024</a></td>
<td class="nump">7,831<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_ManufacturingCommitmentsAmountDueInYearFour', window );">2025</a></td>
<td class="nump">3,915<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_ManufacturingCommitments', window );">Total manufacturing commitments</a></td>
<td class="nump">27,956<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplyCommitmentAxis=ortx_ExclusiveTransductionSuitesMember', window );">Exclusive Transduction Suites</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_ManufacturingCommitmentsAmountDueInNextTwelveMonths', window );">2022</a></td>
<td class="nump">2,626<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_ManufacturingCommitmentsAmountDueInYearTwo', window );">2023</a></td>
<td class="nump">3,079<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_ManufacturingCommitmentsAmountDueInYearThree', window );">2024</a></td>
<td class="nump">3,079<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_ManufacturingCommitmentsAmountDueInYearFour', window );">2025</a></td>
<td class="nump">1,539<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_ManufacturingCommitments', window );">Total manufacturing commitments</a></td>
<td class="nump">$ 10,323<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_ManufacturingCommitments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Manufacturing commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_ManufacturingCommitments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_ManufacturingCommitmentsAmountDueInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Manufacturing commitments amount due in next twelve months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_ManufacturingCommitmentsAmountDueInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_ManufacturingCommitmentsAmountDueInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Manufacturing commitments amount due in year four.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_ManufacturingCommitmentsAmountDueInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_ManufacturingCommitmentsAmountDueInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Manufacturing commitments amount Due In year three.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_ManufacturingCommitmentsAmountDueInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_ManufacturingCommitmentsAmountDueInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Manufacturing commitments amount due in year two.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_ManufacturingCommitmentsAmountDueInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplyCommitmentAxis=ortx_ProductManufacturingCommitmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplyCommitmentAxis=ortx_ProductManufacturingCommitmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplyCommitmentAxis=ortx_DedicatedManufacturingAndDevelopmentResourcesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplyCommitmentAxis=ortx_DedicatedManufacturingAndDevelopmentResourcesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplyCommitmentAxis=ortx_ExclusiveTransductionSuitesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplyCommitmentAxis=ortx_ExclusiveTransductionSuitesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696130493608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Annual Commitments Associated with the Contract (Parenthetical) (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">Exchange rate, Euro to U.S. Dollar</a></td>
<td class="nump">1.13<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyExchangeRateTranslation1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Foreign exchange rate used to translate amounts denominated in functional currency to reporting currency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6897108&amp;loc=SL6897125-166521<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32618-110901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyExchangeRateTranslation1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696125012440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Shares, vest</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary Shares, Issued</a></td>
<td class="nump">125,674,095<span></span>
</td>
<td class="nump">98,283,603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 86,977,000<span></span>
</td>
<td class="nump">$ 93,730,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation cost recognized</a></td>
<td class="nump">$ 22,536,000<span></span>
</td>
<td class="nump">$ 27,962,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ortx_ConsultingAgreementMember', window );">Consulting Agreement | Advisor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,034<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Shares, vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary Shares, Issued</a></td>
<td class="nump">22,758<span></span>
</td>
<td class="nump">22,758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation cost recognized</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ortx_ManufacturingAndTechnologyDevelopmentMasterAgreementMember', window );">Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_InitialTermOfAgreement', window );">Initial term of agreement</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_AgreementMaturityDate', window );">Agreement maturity date</a></td>
<td class="text">Jul.  02,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_AgreementExtensionTerm', window );">Agreement extension term</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ortx_ClinicalDevelopmentAndRegulatoryMilestoneMember', window );">Clinical Development And Regulatory Milestone | Consulting Agreement | Advisor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,035<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary Shares, Issued</a></td>
<td class="nump">22,758<span></span>
</td>
<td class="nump">22,758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_AgreementExtensionTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreement extension term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_AgreementExtensionTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_AgreementMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreement maturity date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_AgreementMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_InitialTermOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial term of agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_InitialTermOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ortx_ConsultingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ortx_ConsultingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ortx_NonEmployeeAdvisorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ortx_NonEmployeeAdvisorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ortx_ManufacturingAndTechnologyDevelopmentMasterAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ortx_ManufacturingAndTechnologyDevelopmentMasterAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ortx_ClinicalDevelopmentAndRegulatoryMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ortx_ClinicalDevelopmentAndRegulatoryMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696232126872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Benefit Plans - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Compensation And Retirement Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Contribution expenses</a></td>
<td class="nump">$ 1.7<span></span>
</td>
<td class="nump">$ 1.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Maximum annual contribution employer matches per employee, percent</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696125170424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Additional Information (Details)<br> $ in Thousands, &#163; in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 30, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 30, 2018 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForLossOnContracts', window );">Loss provision associated with contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 86,977<span></span>
</td>
<td class="nump">$ 93,730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ortx_GSKAssetPurchaseAndLicenseAgreementMember', window );">GSK Asset Purchase and License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_AssetAcquisitionTransactionCosts', window );">Transaction costs</a></td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">&#163; 0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ortx_GSKMember', window );">GSK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_LicenseUpfrontFeeAndRelatedExpensesPaid', window );">License upfront fee</a></td>
<td class="nump">14,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_InventoryPurchase', window );">Inventory purchased</a></td>
<td class="nump">6,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_AssetAcquisitionTransactionCosts', window );">Transaction costs</a></td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableRelatedPartiesCurrent', window );">Due to related party transactions, accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ortx_AccruedExpensesRelatedPartyCurrent', window );">Due to related party transactions, accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Payments on accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ortx_GSKMember', window );">GSK | GSK Asset Purchase and License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ortx_GSKMember', window );">GSK | Convertible Preferred Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Ordinary shares Issuable Upon Conversion | shares</a></td>
<td class="nump">12,455,252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, Value</a></td>
<td class="nump">$ 93,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForLossOnContracts', window );">Loss provision associated with contract</a></td>
<td class="nump">$ 18,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_AccruedExpensesRelatedPartyCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses related party current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_AccruedExpensesRelatedPartyCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_AssetAcquisitionTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset acquisition transaction costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_AssetAcquisitionTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_InventoryPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventory purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_InventoryPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ortx_LicenseUpfrontFeeAndRelatedExpensesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License upfront fee and related expenses paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ortx_LicenseUpfrontFeeAndRelatedExpensesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ortx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForLossOnContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cumulative provision for contract losses not offset against related costs accumulated on the balance sheet.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 35<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123355788&amp;loc=d3e57777-111642<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForLossOnContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ortx_GSKAssetPurchaseAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ortx_GSKAssetPurchaseAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ortx_GSKMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ortx_GSKMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140696137391624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events - Additional Information (Details) - Subsequent Events - United Kingdom<br> $ in Millions</strong></div></th>
<th class="th">
<div>Mar. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Number of positions eliminated, percent</a></td>
<td class="nump">30.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Estimated aggregate restructuring charges in first half of 2022</a></td>
<td class="nump">$ 2.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedCost1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount expected to be recognized in earnings for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedCost1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_GB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_GB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>ortx-10k_20211231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2021"
  xmlns:currency="http://xbrl.sec.gov/currency/2021"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:ortx="http://www.orchard-tx.com/20211231"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="ortx-20211231.xsd" xlink:type="simple"/>
    <context id="C_0001748907_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_20220315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
        </entity>
        <period>
            <instant>2022-03-15</instant>
        </period>
    </context>
    <context id="C_0001748907_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0001748907_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_srtProductOrServiceAxis_us-gaapProductMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_srtProductOrServiceAxis_us-gaapProductMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_srtProductOrServiceAxis_ortxCollaborationMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ortx:CollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_us-gaapTypeOfArrangementAxis_ortxSecuritiesPurchaseAgreementMember_20210209_20210209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-09</startDate>
            <endDate>2021-02-09</endDate>
        </period>
    </context>
    <context id="C_0001748907_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_us-gaapTypeOfArrangementAxis_ortxSecuritiesPurchaseAgreementMember_20210209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-09</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapStatementClassOfStockAxis_ortxNonVotingOrdinarySharesMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_us-gaapTypeOfArrangementAxis_ortxSecuritiesPurchaseAgreementMember_20210209_20210209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ortx:NonVotingOrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-09</startDate>
            <endDate>2021-02-09</endDate>
        </period>
    </context>
    <context id="C_0001748907_us-gaapStatementClassOfStockAxis_ortxNonVotingOrdinarySharesMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_us-gaapTypeOfArrangementAxis_ortxSecuritiesPurchaseAgreementMember_20210209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ortx:NonVotingOrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-09</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapTypeOfArrangementAxis_ortxSecuritiesPurchaseAgreementMember_20210209_20210209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-09</startDate>
            <endDate>2021-02-09</endDate>
        </period>
    </context>
    <context id="C_0001748907_srtStatementGeographicalAxis_countryGB_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_srtStatementGeographicalAxis_countryGB_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_srtStatementGeographicalAxis_countryUS_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_srtStatementGeographicalAxis_countryUS_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_srtStatementGeographicalAxis_ortxGBAndEuropeanUnionMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ortx:GBAndEuropeanUnionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_srtStatementGeographicalAxis_ortxGBAndEuropeanUnionMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ortx:GBAndEuropeanUnionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapLeaseContractualTermAxis_ortxFremontLeaseAgreementMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ortx:FremontLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapLeaseContractualTermAxis_ortxFremontLeaseAgreementMember_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ortx:FremontLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapLeaseContractualTermAxis_ortxFremontLeaseAgreementMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ortx:FremontLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_us-gaapBalanceSheetLocationAxis_us-gaapPrepaidExpensesAndOtherCurrentAssetsMember_us-gaapLeaseContractualTermAxis_ortxFremontLeaseAgreementMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ortx:FremontLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_ortxLabEquipmentMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ortx:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_srtRangeAxis_srtMaximumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_ortxLabEquipmentMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ortx:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_ortxOfficeAndComputerEquipmentMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ortx:OfficeAndComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_srtRangeAxis_srtMaximumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_ortxOfficeAndComputerEquipmentMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ortx:OfficeAndComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_srtStatementGeographicalAxis_countryGB_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_srtStatementGeographicalAxis_countryGB_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_srtStatementGeographicalAxis_countryGB_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_srtStatementGeographicalAxis_countryGB_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_srtStatementGeographicalAxis_countryGB_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_srtStatementGeographicalAxis_countryGB_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_us-gaapAwardTypeAxis_ortxUnvestedSharesFromSharePlanAndConsultingAgreementMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ortx:UnvestedSharesFromSharePlanAndConsultingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_us-gaapAwardTypeAxis_ortxUnvestedSharesFromSharePlanAndConsultingAgreementMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ortx:UnvestedSharesFromSharePlanAndConsultingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapCommercialPaperMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapCommercialPaperMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapUSTreasuryAndGovernmentMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapUSTreasuryAndGovernmentMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapCommercialPaperMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapCommercialPaperMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapPropertyPlantAndEquipmentByTypeAxis_ortxLabEquipmentMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ortx:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapPropertyPlantAndEquipmentByTypeAxis_ortxLabEquipmentMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ortx:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapPropertyPlantAndEquipmentByTypeAxis_ortxOfficeAndITEquipmentMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ortx:OfficeAndITEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapPropertyPlantAndEquipmentByTypeAxis_ortxOfficeAndITEquipmentMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ortx:OfficeAndITEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicenseMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicenseMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapRestructuringPlanAxis_ortxMenloParkCaliforniaMember_20200501_20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ortx:MenloParkCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_20200401_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0001748907_us-gaapRestructuringPlanAxis_ortxFremontCaliforniaMember_20200501_20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ortx:FremontCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_us-gaapRestructuringPlanAxis_ortxFremontCaliforniaMember_20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ortx:FremontCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="C_0001748907_srtRangeAxis_srtMinimumMember_us-gaapRestructuringPlanAxis_ortxFremontCaliforniaMember_20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ortx:FremontCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="C_0001748907_srtRangeAxis_srtMaximumMember_us-gaapRestructuringPlanAxis_ortxFremontCaliforniaMember_20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ortx:FremontCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapRestructuringPlanAxis_ortxFremontCaliforniaMember_20201201_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">ortx:FremontCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_us-gaapLeaseContractualTermAxis_ortxOfficeSpaceMenloParkLeaseAgreementMember_20171101_20171130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ortx:OfficeSpaceMenloParkLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-11-01</startDate>
            <endDate>2017-11-30</endDate>
        </period>
    </context>
    <context id="C_0001748907_us-gaapLeaseContractualTermAxis_ortxLaboratorySpaceMenloParkLeaseAgreementMember_20190101_20190131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ortx:LaboratorySpaceMenloParkLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-01-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_us-gaapLeaseContractualTermAxis_ortxOfficeAndLaboratorySpaceMenloParkLeaseAgreementMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ortx:OfficeAndLaboratorySpaceMenloParkLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_us-gaapLeaseContractualTermAxis_ortxOfficeAndLaboratorySpaceMenloParkLeaseAgreementMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ortx:OfficeAndLaboratorySpaceMenloParkLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_us-gaapLeaseContractualTermAxis_ortxFiveYearsLeaseTermTerminatesInJanuaryTwoThousandTwentyThreeMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_ortxOfficeSpaceLondonUnitedKingdomLeaseAgreementMember_20180101_20180131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ortx:FiveYearsLeaseTermTerminatesInJanuaryTwoThousandTwentyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ortx:OfficeSpaceLondonUnitedKingdomLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_us-gaapLeaseContractualTermAxis_ortxFiveYearsLeaseTermTerminatesInJanuaryTwoThousandTwentyThreeMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_ortxOfficeSpaceLondonUnitedKingdomLeaseAgreementMember_20181201_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ortx:FiveYearsLeaseTermTerminatesInJanuaryTwoThousandTwentyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ortx:OfficeSpaceLondonUnitedKingdomLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_us-gaapLeaseContractualTermAxis_ortxFiveYearsLeaseTermTerminatesInJanuaryTwoThousandTwentyThreeMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_ortxOfficeSpaceLondonUnitedKingdomLeaseAgreementMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ortx:FiveYearsLeaseTermTerminatesInJanuaryTwoThousandTwentyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ortx:OfficeSpaceLondonUnitedKingdomLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_us-gaapLeaseContractualTermAxis_ortxFiveYearsLeaseTermTerminatesInJanuaryTwoThousandTwentyThreeMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_ortxOfficeSpaceLondonUnitedKingdomLeaseAgreementMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ortx:FiveYearsLeaseTermTerminatesInJanuaryTwoThousandTwentyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ortx:OfficeSpaceLondonUnitedKingdomLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_us-gaapPropertyPlantAndEquipmentByTypeAxis_ortxRentalLabSpaceMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ortx:RentalLabSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_us-gaapLeaseContractualTermAxis_ortxLeaseTermTerminatesInSeptemberTwoThousandTwentyTwoMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_ortxOfficeSpaceBostonUnitedStatesLeaseAgreementMember_20180301_20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ortx:LeaseTermTerminatesInSeptemberTwoThousandTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ortx:OfficeSpaceBostonUnitedStatesLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_us-gaapLeaseContractualTermAxis_ortxLeaseTermTerminatesInSeptemberTwoThousandTwentyTwoMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_ortxOfficeSpaceBostonUnitedStatesLeaseAgreementMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ortx:LeaseTermTerminatesInSeptemberTwoThousandTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ortx:OfficeSpaceBostonUnitedStatesLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_us-gaapLeaseContractualTermAxis_ortxLeaseTermTerminatesInSeptemberTwoThousandTwentyTwoMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_ortxOfficeSpaceBostonUnitedStatesLeaseAgreementMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ortx:LeaseTermTerminatesInSeptemberTwoThousandTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ortx:OfficeSpaceBostonUnitedStatesLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_us-gaapLeaseContractualTermAxis_ortxLeaseTermTerminatesInSeptemberTwoThousandTwentySixMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_ortxOfficeSpaceBostonUnitedStatesLeaseAgreementMember_20190701_20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ortx:LeaseTermTerminatesInSeptemberTwoThousandTwentySixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ortx:OfficeSpaceBostonUnitedStatesLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_us-gaapLeaseContractualTermAxis_ortxLeaseTermTerminatesInSeptemberTwoThousandTwentySixMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_ortxOfficeSpaceBostonUnitedStatesLeaseAgreementMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ortx:LeaseTermTerminatesInSeptemberTwoThousandTwentySixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ortx:OfficeSpaceBostonUnitedStatesLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_us-gaapLeaseContractualTermAxis_ortxLeaseTermTerminatesInSeptemberTwoThousandTwentySixMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_ortxOfficeSpaceBostonUnitedStatesLeaseAgreementMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ortx:LeaseTermTerminatesInSeptemberTwoThousandTwentySixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ortx:OfficeSpaceBostonUnitedStatesLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_us-gaapLeaseContractualTermAxis_ortxBostonAndLondonOfficeSpaceLeaseAgreementsMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ortx:BostonAndLondonOfficeSpaceLeaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapLeaseContractualTermAxis_ortxBostonAndLondonOfficeSpaceLeaseAgreementsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ortx:BostonAndLondonOfficeSpaceLeaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapLeaseContractualTermAxis_ortxFremontLeaseAgreementMember_20181201_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ortx:FremontLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_us-gaapLeaseContractualTermAxis_ortxFremontLeaseAgreementMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ortx:FremontLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_srtRangeAxis_srtMaximumMember_us-gaapLeaseContractualTermAxis_ortxFremontLeaseAgreementMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ortx:FremontLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_us-gaapLeaseContractualTermAxis_ortxFremontSubleaseAgreementMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ortx:FremontSubleaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_srtRangeAxis_srtMaximumMember_us-gaapLeaseContractualTermAxis_ortxFremontSubleaseAgreementMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ortx:FremontSubleaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_us-gaapBalanceSheetLocationAxis_us-gaapOtherNoncurrentLiabilitiesMember_us-gaapLeaseContractualTermAxis_ortxFremontSubleaseAgreementMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ortx:FremontSubleaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapLeaseContractualTermAxis_ortxFremontLeaseAgreementMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ortx:FremontLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapLeaseContractualTermAxis_ortxGSKAgreementMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ortx:GSKAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapLeaseContractualTermAxis_ortxGSKAgreementMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ortx:GSKAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_us-gaapLeaseContractualTermAxis_ortxGSKAgreementMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ortx:GSKAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapLeaseContractualTermAxis_ortxGSKAgreementMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ortx:GSKAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_srtCurrencyAxis_currencyGBP_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_srtCurrencyAxis_currencyEUR_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_20190501_20190531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
        </entity>
        <period>
            <startDate>2019-05-01</startDate>
            <endDate>2019-05-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_20190531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
        </entity>
        <period>
            <instant>2019-05-31</instant>
        </period>
    </context>
    <context id="C_0001748907_20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapDebtInstrumentAxis_ortxTheFirstTrancheTermLoanMember_20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ortx:TheFirstTrancheTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapDebtInstrumentAxis_ortxTheFirstTrancheTermLoanMember_20190531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ortx:TheFirstTrancheTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-31</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapDebtInstrumentAxis_ortxTheFirstTrancheTermLoanMember_20210501_20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ortx:TheFirstTrancheTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_us-gaapDebtInstrumentAxis_ortxTheSecondTrancheTermLoanMember_20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ortx:TheSecondTrancheTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapDebtInstrumentAxis_ortxTheThirdTrancheTermLoanMember_20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ortx:TheThirdTrancheTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="C_0001748907_srtRangeAxis_srtMinimumMember_us-gaapDebtInstrumentAxis_ortxTheSecondTrancheTermLoanMember_20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ortx:TheSecondTrancheTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="C_0001748907_srtRangeAxis_srtMinimumMember_us-gaapDebtInstrumentAxis_ortxTheThirdTrancheTermLoanMember_20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ortx:TheThirdTrancheTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapDebtInstrumentAxis_ortxTheSecondTrancheTermLoanMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ortx:TheSecondTrancheTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_us-gaapDebtInstrumentAxis_ortxTheThirdTrancheTermLoanMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ortx:TheThirdTrancheTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_us-gaapVariableRateAxis_ortxLondonInterbankOfferedRateFloorMember_20190501_20190531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">ortx:LondonInterbankOfferedRateFloorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-01</startDate>
            <endDate>2019-05-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_us-gaapVariableRateAxis_ortxLondonInterbankOfferedRateFloorMember_20210501_20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">ortx:LondonInterbankOfferedRateFloorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_20210501_20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_us-gaapDebtInstrumentAxis_ortxTheSecondTrancheTermLoanMember_20210501_20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ortx:TheSecondTrancheTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_us-gaapDebtInstrumentAxis_ortxTheThirdTrancheTermLoanMember_20210501_20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ortx:TheThirdTrancheTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_srtRangeAxis_srtMinimumMember_20210501_20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_srtRangeAxis_srtMaximumMember_20210501_20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_srtRangeAxis_srtMinimumMember_us-gaapDebtInstrumentRedemptionPeriodAxis_us-gaapDebtInstrumentRedemptionPeriodTwoMember_20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="C_0001748907_srtRangeAxis_srtMinimumMember_us-gaapDebtInstrumentRedemptionPeriodAxis_us-gaapDebtInstrumentRedemptionPeriodThreeMember_20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapLongtermDebtTypeAxis_ortxTermLoanMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ortx:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_us-gaapLongtermDebtTypeAxis_ortxTermLoanMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ortx:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_srtRangeAxis_srtMaximumMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_srtRangeAxis_srtMaximumMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapTypeOfArrangementAxis_ortxOxfordBioMedicaLicenseDevelopmentAndSupplyAgreementMember_20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:OxfordBioMedicaLicenseDevelopmentAndSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="C_0001748907_srtTitleOfIndividualAxis_ortxNonEmployeeAdvisorMember_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_ortxConsultingAgreementMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ortx:NonEmployeeAdvisorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ortx:ConsultingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_srtTitleOfIndividualAxis_ortxNonEmployeeAdvisorMember_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_ortxConsultingAgreementMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ortx:NonEmployeeAdvisorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ortx:ConsultingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_us-gaapTypeOfArrangementAxis_ortxSecuritiesPurchaseAgreementMember_20210201_20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="C_0001748907_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_us-gaapTypeOfArrangementAxis_ortxSecuritiesPurchaseAgreementMember_20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapStatementClassOfStockAxis_ortxNonVotingOrdinarySharesMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_us-gaapTypeOfArrangementAxis_ortxSecuritiesPurchaseAgreementMember_20210201_20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ortx:NonVotingOrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="C_0001748907_us-gaapStatementClassOfStockAxis_ortxNonVotingOrdinarySharesMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_us-gaapTypeOfArrangementAxis_ortxSecuritiesPurchaseAgreementMember_20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ortx:NonVotingOrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapTypeOfArrangementAxis_ortxSecuritiesPurchaseAgreementMember_20210201_20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="C_0001748907_us-gaapTypeOfArrangementAxis_ortxSharePurchaseAgreementWithPharmingMember_20210701_20210731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:SharePurchaseAgreementWithPharmingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_us-gaapPlanNameAxis_ortxTwoThousandAndEighteenShareOptionAndIncentivePlanMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ortx:TwoThousandAndEighteenShareOptionAndIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapPlanNameAxis_ortxTwoThousandAndEighteenEmployeeSharePurchasePlanMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ortx:TwoThousandAndEighteenEmployeeSharePurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapPlanNameAxis_ortxTwoThousandAndTwentyInducementEquityPlanMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ortx:TwoThousandAndTwentyInducementEquityPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_srtRangeAxis_srtMinimumMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_srtRangeAxis_srtMinimumMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_srtRangeAxis_srtMaximumMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_srtRangeAxis_srtMaximumMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_us-gaapAwardTypeAxis_us-gaapPerformanceSharesMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_us-gaapAwardTypeAxis_us-gaapPerformanceSharesMember_us-gaapTypeOfArrangementAxis_ortxLibmeldyMember_20201001_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:LibmeldyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_srtTitleOfIndividualAxis_srtChiefExecutiveOfficerMember_us-gaapAwardTypeAxis_us-gaapPerformanceSharesMember_20200401_20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="C_0001748907_srtTitleOfIndividualAxis_srtChiefExecutiveOfficerMember_us-gaapAwardTypeAxis_us-gaapPerformanceSharesMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheOneMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_us-gaapAwardTypeAxis_ortxTimeBasedRestrictedShareUnitsMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ortx:TimeBasedRestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_us-gaapAwardTypeAxis_us-gaapPerformanceSharesMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapAwardTypeAxis_ortxTimeBasedRestrictedShareUnitsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ortx:TimeBasedRestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapAwardTypeAxis_us-gaapPerformanceSharesMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapAwardTypeAxis_ortxTimeBasedRestrictedShareUnitsMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ortx:TimeBasedRestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_us-gaapTypeOfArrangementAxis_ortxGSKAssetPurchaseAndLicenseAgreementMember_20180401_20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:GSKAssetPurchaseAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="C_0001748907_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_us-gaapTypeOfArrangementAxis_ortxGSKAssetPurchaseAndLicenseAgreementMember_20180401_20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:GSKAssetPurchaseAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="C_0001748907_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_us-gaapTypeOfArrangementAxis_ortxGSKAssetPurchaseAndLicenseAgreementMember_20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:GSKAssetPurchaseAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-04-30</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapTypeOfArrangementAxis_ortxGSKAssetPurchaseAndLicenseAgreementMember_20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:GSKAssetPurchaseAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-04-30</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapTypeOfArrangementAxis_ortxGSKAssetPurchaseAndLicenseAgreementMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:GSKAssetPurchaseAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapTypeOfArrangementAxis_ortxGSKAssetPurchaseAndLicenseAgreementMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:GSKAssetPurchaseAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_us-gaapTypeOfArrangementAxis_ortxTelethonOSRLicenseAgreementsMember_20190501_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:TelethonOSRLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_us-gaapTypeOfArrangementAxis_ortxTelethonOSRLicenseAgreementsMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:TelethonOSRLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapTypeOfArrangementAxis_ortxUCLBAndUCLATechnologyMember_20160101_20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:UCLBAndUCLATechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_us-gaapTypeOfArrangementAxis_ortxUCLBTechnologyAndManufacturingTechnologyMember_20160101_20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:UCLBTechnologyAndManufacturingTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_us-gaapTypeOfArrangementAxis_ortxUCLBLicenseAgreementMember_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:UCLBLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapTypeOfArrangementAxis_ortxUCLBLicenseAgreementMember_20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:UCLBLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapTypeOfArrangementAxis_ortxUCLBLicenseAgreementMember_20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:UCLBLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapTypeOfArrangementAxis_ortxUCLBAndUCLALicenseAgreementMember_20170101_20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:UCLBAndUCLALicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_us-gaapTypeOfArrangementAxis_ortxUCLBAndUCLALicenseAgreementMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:UCLBAndUCLALicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_us-gaapTypeOfArrangementAxis_ortxUCLBAndUCLALicenseAgreementMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:UCLBAndUCLALicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_us-gaapTypeOfArrangementAxis_ortxOxfordBioMedicaLicenseDevelopmentAndSupplyAgreementMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:OxfordBioMedicaLicenseDevelopmentAndSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapTypeOfArrangementAxis_ortxOxfordBioMedicaLicenseDevelopmentAndSupplyAgreementMember_20181130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:OxfordBioMedicaLicenseDevelopmentAndSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-30</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapTypeOfArrangementAxis_ortxOxfordBioMedicaLicenseDevelopmentAndSupplyAgreementMember_20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:OxfordBioMedicaLicenseDevelopmentAndSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapTypeOfArrangementAxis_ortxOxfordBioMedicaLicenseDevelopmentAndSupplyAgreementMember_20200430_20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:OxfordBioMedicaLicenseDevelopmentAndSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-30</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="C_0001748907_us-gaapTypeOfArrangementAxis_ortxOxfordBioMedicaLicenseDevelopmentAndSupplyAgreementMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:OxfordBioMedicaLicenseDevelopmentAndSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_us-gaapTypeOfArrangementAxis_ortxStrategicCollaborationAgreementWithPharmingMember_20210701_20210701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:StrategicCollaborationAgreementWithPharmingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-01</endDate>
        </period>
    </context>
    <context id="C_0001748907_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_ortxStrategicCollaborationAgreementWithPharmingMember_20210701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:StrategicCollaborationAgreementWithPharmingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-01</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapTypeOfArrangementAxis_ortxSharePurchaseAgreementWithPharmingMember_20210701_20210701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:SharePurchaseAgreementWithPharmingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-01</endDate>
        </period>
    </context>
    <context id="C_0001748907_us-gaapTypeOfArrangementAxis_ortxPharmingAgreementsMember_20210701_20210701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:PharmingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-01</endDate>
        </period>
    </context>
    <context id="C_0001748907_srtProductOrServiceAxis_ortxReimbursementRevenueMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ortx:ReimbursementRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_srtProductOrServiceAxis_ortxUpfrontAndMilestonePaymentRevenueMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ortx:UpfrontAndMilestonePaymentRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_us-gaapBalanceSheetLocationAxis_us-gaapAccountsReceivableMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapBalanceSheetLocationAxis_us-gaapAccountsReceivableMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_srtStatementGeographicalAxis_countryUS_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_ortxOrphanDrugTaxCreditMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">ortx:OrphanDrugTaxCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_srtStatementGeographicalAxis_countryUS_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_ortxOrphanDrugTaxCreditMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">ortx:OrphanDrugTaxCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_srtStatementGeographicalAxis_countryUS_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_srtStatementGeographicalAxis_countryUS_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_srtStatementGeographicalAxis_countryUS_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_us-gaapTaxPeriodAxis_us-gaapEarliestTaxYearMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:EarliestTaxYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_us-gaapTaxPeriodAxis_us-gaapLatestTaxYearMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:LatestTaxYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_us-gaapSupplyCommitmentAxis_ortxProductManufacturingCommitmentsMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">ortx:ProductManufacturingCommitmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapSupplyCommitmentAxis_ortxDedicatedManufacturingAndDevelopmentResourcesMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">ortx:DedicatedManufacturingAndDevelopmentResourcesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapSupplyCommitmentAxis_ortxExclusiveTransductionSuitesMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">ortx:ExclusiveTransductionSuitesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapTypeOfArrangementAxis_ortxManufacturingAndTechnologyDevelopmentMasterAgreementMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:ManufacturingAndTechnologyDevelopmentMasterAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_srtTitleOfIndividualAxis_ortxNonEmployeeAdvisorMember_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_ortxConsultingAgreementMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ortx:NonEmployeeAdvisorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ortx:ConsultingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_srtTitleOfIndividualAxis_ortxNonEmployeeAdvisorMember_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_ortxConsultingAgreementMember_us-gaapTypeOfArrangementAxis_ortxClinicalDevelopmentAndRegulatoryMilestoneMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ortx:NonEmployeeAdvisorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ortx:ConsultingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:ClinicalDevelopmentAndRegulatoryMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_srtTitleOfIndividualAxis_ortxNonEmployeeAdvisorMember_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_ortxConsultingAgreementMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ortx:NonEmployeeAdvisorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ortx:ConsultingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_srtTitleOfIndividualAxis_ortxNonEmployeeAdvisorMember_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_ortxConsultingAgreementMember_us-gaapTypeOfArrangementAxis_ortxClinicalDevelopmentAndRegulatoryMilestoneMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ortx:NonEmployeeAdvisorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ortx:ConsultingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:ClinicalDevelopmentAndRegulatoryMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_srtTitleOfIndividualAxis_ortxNonEmployeeAdvisorMember_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_ortxConsultingAgreementMember_us-gaapTypeOfArrangementAxis_ortxClinicalDevelopmentAndRegulatoryMilestoneMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ortx:NonEmployeeAdvisorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ortx:ConsultingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:ClinicalDevelopmentAndRegulatoryMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_srtTitleOfIndividualAxis_ortxNonEmployeeAdvisorMember_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_ortxConsultingAgreementMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ortx:NonEmployeeAdvisorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ortx:ConsultingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_srtTitleOfIndividualAxis_ortxNonEmployeeAdvisorMember_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_ortxConsultingAgreementMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ortx:NonEmployeeAdvisorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ortx:ConsultingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ortxGSKMember_20180401_20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ortx:GSKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="C_0001748907_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ortxGSKMember_20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ortx:GSKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-04-30</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ortxGSKMember_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ortx:GSKMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-04-30</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ortxGSKMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ortx:GSKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001748907_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ortxGSKMember_us-gaapTypeOfArrangementAxis_ortxGSKAssetPurchaseAndLicenseAgreementMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ortx:GSKMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ortx:GSKAssetPurchaseAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ortxGSKMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ortx:GSKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001748907_srtStatementGeographicalAxis_countryGB_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220330_20220330">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-30</startDate>
            <endDate>2022-03-30</endDate>
        </period>
    </context>
    <context id="C_0001748907_srtStatementGeographicalAxis_countryGB_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220330">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001748907</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-30</instant>
        </period>
    </context>
    <unit id="U_xbrlishares">
        <measure>shares</measure>
    </unit>
    <unit id="U_iso4217USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U_iso4217GBP_xbrlishares">
        <divide>
            <unitNumerator>
                <measure>iso4217:GBP</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_iso4217GBP">
        <measure>iso4217:GBP</measure>
    </unit>
    <unit id="U_iso4217USD_xbrlishares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_xbrlipure">
        <measure>pure</measure>
    </unit>
    <unit id="U_iso4217EUR">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="U_ortxVotingRight">
        <measure>ortx:VotingRight</measure>
    </unit>
    <unit id="U_ortxProgram">
        <measure>ortx:Program</measure>
    </unit>
    <unit id="U_ortxMilestone">
        <measure>ortx:Milestone</measure>
    </unit>
    <dei:AmendmentFlag contextRef="C_0001748907_20210101_20211231" id="F_000001">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="C_0001748907_20210101_20211231" id="F_000004">FY</dei:DocumentFiscalPeriodFocus>
    <dei:CurrentFiscalYearEndDate contextRef="C_0001748907_20210101_20211231" id="F_000006">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityCentralIndexKey contextRef="C_0001748907_20210101_20211231" id="F_000007">0001748907</dei:EntityCentralIndexKey>
    <dei:EntityTaxIdentificationNumber contextRef="C_0001748907_20210101_20211231" id="F_000027">00-0000000</dei:EntityTaxIdentificationNumber>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted contextRef="C_0001748907_20211231" id="F_000449">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxGSKAgreementMember_20210101_20211231"
      id="F_000658">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <ortx:LineOfCreditFacilityAmortizationTerm
      contextRef="C_0001748907_srtRangeAxis_srtMinimumMember_20210501_20210531"
      id="F_000735">P18M</ortx:LineOfCreditFacilityAmortizationTerm>
    <ortx:LineOfCreditFacilityAmortizationTerm
      contextRef="C_0001748907_srtRangeAxis_srtMaximumMember_20210501_20210531"
      id="F_000736">P30M</ortx:LineOfCreditFacilityAmortizationTerm>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxOfficeSpaceMenloParkLeaseAgreementMember_20171101_20171130"
      id="F_000618">2020-12-31</us-gaap:LeaseExpirationDate1>
    <us-gaap:PaymentsForRent
      contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxOfficeAndLaboratorySpaceMenloParkLeaseAgreementMember_20210101_20211231"
      id="F_000620"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxFiveYearsLeaseTermTerminatesInJanuaryTwoThousandTwentyThreeMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_ortxOfficeSpaceLondonUnitedKingdomLeaseAgreementMember_20180101_20180131"
      id="F_000623">2023-01-31</us-gaap:LeaseExpirationDate1>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxLeaseTermTerminatesInSeptemberTwoThousandTwentyTwoMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_ortxOfficeSpaceBostonUnitedStatesLeaseAgreementMember_20180301_20180331"
      id="F_000628">2022-09-30</us-gaap:LeaseExpirationDate1>
    <ortx:OperatingLeasesCommencedTerm
      contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxLeaseTermTerminatesInSeptemberTwoThousandTwentySixMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_ortxOfficeSpaceBostonUnitedStatesLeaseAgreementMember_20190701_20190731"
      id="F_000631">2020-01-31</ortx:OperatingLeasesCommencedTerm>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxLeaseTermTerminatesInSeptemberTwoThousandTwentySixMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_ortxOfficeSpaceBostonUnitedStatesLeaseAgreementMember_20190701_20190731"
      id="F_000632">2026-09-30</us-gaap:LeaseExpirationDate1>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxFremontLeaseAgreementMember_20181201_20181231"
      id="F_000639">2030-05-31</us-gaap:LeaseExpirationDate1>
    <us-gaap:LineOfCreditFacilityInitiationDate1 contextRef="C_0001748907_20190501_20190531" id="F_000710">2019-05-31</us-gaap:LineOfCreditFacilityInitiationDate1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="C_0001748907_20210101_20211231" id="F_000797">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <ortx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeEquityPlanProceedsReceivedAfterYearEnd
      contextRef="C_0001748907_20211231"
      id="F_000834"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_0001748907_us-gaapAwardTypeAxis_ortxTimeBasedRestrictedShareUnitsMember_20210101_20211231"
      id="F_000844">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_0001748907_srtTitleOfIndividualAxis_ortxNonEmployeeAdvisorMember_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_ortxConsultingAgreementMember_20190101_20191231"
      id="F_001050">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxLaboratorySpaceMenloParkLeaseAgreementMember_20190101_20190131"
      id="F_000619">2020-12-31</us-gaap:LeaseExpirationDate1>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxFiveYearsLeaseTermTerminatesInJanuaryTwoThousandTwentyThreeMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_ortxOfficeSpaceLondonUnitedKingdomLeaseAgreementMember_20181201_20181231"
      id="F_000624">2023-01-31</us-gaap:LeaseExpirationDate1>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_0001748907_20211231"
      id="F_000082"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_0001748907_20201231"
      id="F_000083"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:TypeOfCostGoodOrServiceExtensibleList contextRef="C_0001748907_20200101_20201231" id="F_000111">http://fasb.org/us-gaap/2021-01-31#ProductMember</us-gaap:TypeOfCostGoodOrServiceExtensibleList>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0001748907_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_ortxLabEquipmentMember_20210101_20211231"
      id="F_000409">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0001748907_srtRangeAxis_srtMaximumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_ortxLabEquipmentMember_20210101_20211231"
      id="F_000410">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0001748907_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_ortxOfficeAndComputerEquipmentMember_20210101_20211231"
      id="F_000413">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0001748907_srtRangeAxis_srtMaximumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_ortxOfficeAndComputerEquipmentMember_20210101_20211231"
      id="F_000414">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="C_0001748907_20211231" id="F_000677">P6Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="C_0001748907_20201231" id="F_000678">P6Y7M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_0001748907_20210101_20211231"
      decimals="INF"
      id="F_000798"
      unitRef="U_xbrlipure">0.005</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_0001748907_20200101_20201231"
      decimals="INF"
      id="F_000799"
      unitRef="U_xbrlipure">0.003</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_0001748907_20210101_20211231"
      decimals="INF"
      id="F_000806"
      unitRef="U_xbrlipure">0.742</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_0001748907_20200101_20201231"
      decimals="INF"
      id="F_000807"
      unitRef="U_xbrlipure">0.707</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_0001748907_20210101_20211231"
      decimals="INF"
      id="F_000800"
      unitRef="U_xbrlipure">0.013</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_0001748907_20200101_20201231"
      decimals="INF"
      id="F_000801"
      unitRef="U_xbrlipure">0.017</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0001748907_srtRangeAxis_srtMinimumMember_20210101_20211231"
      id="F_000802">P5Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0001748907_srtRangeAxis_srtMinimumMember_20200101_20201231"
      id="F_000803">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0001748907_srtRangeAxis_srtMaximumMember_20210101_20211231"
      id="F_000804">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0001748907_srtRangeAxis_srtMaximumMember_20200101_20201231"
      id="F_000805">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_0001748907_20210101_20211231"
      decimals="INF"
      id="F_000808"
      unitRef="U_xbrlipure">0.787</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_0001748907_20200101_20201231"
      decimals="INF"
      id="F_000809"
      unitRef="U_xbrlipure">0.752</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="C_0001748907_20200101_20201231" id="F_000824">P7Y1M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="C_0001748907_20210101_20211231" id="F_000825">P7Y9M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="C_0001748907_20210101_20211231" id="F_000826">P6Y7M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <dei:DocumentType contextRef="C_0001748907_20210101_20211231" id="F_000000">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="C_0001748907_20210101_20211231" id="F_000023">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="C_0001748907_20210101_20211231" id="F_000002">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="C_0001748907_20210101_20211231" id="F_000003">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="C_0001748907_20210101_20211231" id="F_000024">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="C_0001748907_20210101_20211231" id="F_000025">001-38722</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="C_0001748907_20210101_20211231" id="F_000005">ORCHARD THERAPEUTICS PLC</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="C_0001748907_20210101_20211231" id="F_000017">X0</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1 contextRef="C_0001748907_20210101_20211231" id="F_000018">108 Cannon Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="C_0001748907_20210101_20211231" id="F_000019">London</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="C_0001748907_20210101_20211231" id="F_000020">EC4N 6EU</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry contextRef="C_0001748907_20210101_20211231" id="F_000028">GB</dei:EntityAddressCountry>
    <dei:CityAreaCode contextRef="C_0001748907_20210101_20211231" id="F_000021">44</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="C_0001748907_20210101_20211231" id="F_000022">(0) 203 808-8286</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="C_0001748907_20210101_20211231" id="F_000031">American Depositary Shares,  each representing one ordinary share, nominal value &#xa3;0.10 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="C_0001748907_20210101_20211231" id="F_000032">ORTX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="C_0001748907_20210101_20211231" id="F_000033">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="C_0001748907_20210101_20211231" id="F_000009">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="C_0001748907_20210101_20211231" id="F_000014">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="C_0001748907_20210101_20211231" id="F_000015">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="C_0001748907_20210101_20211231" id="F_000016">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="C_0001748907_20210101_20211231" id="F_000008">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="C_0001748907_20210101_20211231" id="F_000010">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="C_0001748907_20210101_20211231" id="F_000026">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="C_0001748907_20210101_20211231" id="F_000029">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany contextRef="C_0001748907_20210101_20211231" id="F_000013">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_0001748907_20210630"
      decimals="-6"
      id="F_000012"
      unitRef="U_iso4217USD">544000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_0001748907_20220315"
      decimals="INF"
      id="F_000011"
      unitRef="U_xbrlishares">125834611</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="C_0001748907_20210101_20211231" id="F_000293">
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Portions of the Registrant&#x2019;s definitive proxy statement for its 2022 Annual General Meeting are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated.&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId contextRef="C_0001748907_20210101_20211231" id="F_000030">238</dei:AuditorFirmId>
    <dei:AuditorName contextRef="C_0001748907_20210101_20211231" id="F_000034">PricewaterhouseCoopers LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="C_0001748907_20210101_20211231" id="F_000035">Boston, Massachusetts</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000036"
      unitRef="U_iso4217USD">55912000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000037"
      unitRef="U_iso4217USD">55135000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecurities
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000038"
      unitRef="U_iso4217USD">164195000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000039"
      unitRef="U_iso4217USD">136813000</us-gaap:MarketableSecurities>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000040"
      unitRef="U_iso4217USD">1480000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000041"
      unitRef="U_iso4217USD">878000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000042"
      unitRef="U_iso4217USD">23011000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000043"
      unitRef="U_iso4217USD">13365000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <ortx:ResearchAndDevelopmentTaxCreditReceivableCurrent
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000044"
      unitRef="U_iso4217USD">30723000</ortx:ResearchAndDevelopmentTaxCreditReceivableCurrent>
    <ortx:ResearchAndDevelopmentTaxCreditReceivableCurrent
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000045"
      unitRef="U_iso4217USD">17344000</ortx:ResearchAndDevelopmentTaxCreditReceivableCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000046"
      unitRef="U_iso4217USD">275321000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000047"
      unitRef="U_iso4217USD">223535000</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000048"
      unitRef="U_iso4217USD">24316000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000049"
      unitRef="U_iso4217USD">29815000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000050"
      unitRef="U_iso4217USD">4767000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000051"
      unitRef="U_iso4217USD">4781000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000052"
      unitRef="U_iso4217USD">4266000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000053"
      unitRef="U_iso4217USD">4266000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000054"
      unitRef="U_iso4217USD">4149000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000055"
      unitRef="U_iso4217USD">3076000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000056"
      unitRef="U_iso4217USD">9590000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000057"
      unitRef="U_iso4217USD">15464000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000058"
      unitRef="U_iso4217USD">47088000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000059"
      unitRef="U_iso4217USD">57402000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000060"
      unitRef="U_iso4217USD">322409000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000061"
      unitRef="U_iso4217USD">280937000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000062"
      unitRef="U_iso4217USD">10008000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000063"
      unitRef="U_iso4217USD">8823000</us-gaap:AccountsPayableCurrent>
    <ortx:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000064"
      unitRef="U_iso4217USD">24318000</ortx:AccruedExpensesAndOtherCurrentLiabilities>
    <ortx:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000065"
      unitRef="U_iso4217USD">28943000</ortx:AccruedExpensesAndOtherCurrentLiabilities>
    <us-gaap:DeferredRevenueCurrent
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000066"
      unitRef="U_iso4217USD">346000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000067"
      unitRef="U_iso4217USD">7335000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000068"
      unitRef="U_iso4217USD">8934000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000069"
      unitRef="U_iso4217USD">786000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000070"
      unitRef="U_iso4217USD">4861000</us-gaap:NotesPayableCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000071"
      unitRef="U_iso4217USD">42793000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000072"
      unitRef="U_iso4217USD">51561000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermNotesPayable
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000073"
      unitRef="U_iso4217USD">32086000</us-gaap:LongTermNotesPayable>
    <us-gaap:LongTermNotesPayable
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000074"
      unitRef="U_iso4217USD">20204000</us-gaap:LongTermNotesPayable>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000075"
      unitRef="U_iso4217USD">12519000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000076"
      unitRef="U_iso4217USD">19278000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000077"
      unitRef="U_iso4217USD">24168000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000078"
      unitRef="U_iso4217USD">5783000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000079"
      unitRef="U_iso4217USD">6570000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000080"
      unitRef="U_iso4217USD">112459000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000081"
      unitRef="U_iso4217USD">102503000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001748907_20211231"
      decimals="INF"
      id="F_000096"
      unitRef="U_iso4217GBP_xbrlishares">0.10</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001748907_20201231"
      decimals="INF"
      id="F_000097"
      unitRef="U_iso4217GBP_xbrlishares">0.10</us-gaap:CommonStockParOrStatedValuePerShare>
    <ortx:CommonStockSharesAuthorizedNominalAmount
      contextRef="C_0001748907_20211231"
      decimals="2"
      id="F_000098"
      unitRef="U_iso4217GBP">13023851.50</ortx:CommonStockSharesAuthorizedNominalAmount>
    <ortx:CommonStockSharesAuthorizedNominalAmount
      contextRef="C_0001748907_20201231"
      decimals="2"
      id="F_000099"
      unitRef="U_iso4217GBP">13023851.50</ortx:CommonStockSharesAuthorizedNominalAmount>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001748907_20211231"
      decimals="INF"
      id="F_000100"
      unitRef="U_xbrlishares">125674095</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001748907_20211231"
      decimals="INF"
      id="F_000102"
      unitRef="U_xbrlishares">125674095</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001748907_20201231"
      decimals="INF"
      id="F_000101"
      unitRef="U_xbrlishares">98283603</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001748907_20201231"
      decimals="INF"
      id="F_000103"
      unitRef="U_xbrlishares">98283603</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000084"
      unitRef="U_iso4217USD">16253000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000085"
      unitRef="U_iso4217USD">12507000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000086"
      unitRef="U_iso4217USD">940675000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000087"
      unitRef="U_iso4217USD">771194000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000088"
      unitRef="U_iso4217USD">3246000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000089"
      unitRef="U_iso4217USD">373000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000090"
      unitRef="U_iso4217USD">-750224000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000091"
      unitRef="U_iso4217USD">-605640000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000092"
      unitRef="U_iso4217USD">209950000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000093"
      unitRef="U_iso4217USD">178434000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000094"
      unitRef="U_iso4217USD">322409000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000095"
      unitRef="U_iso4217USD">280937000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001748907_srtProductOrServiceAxis_us-gaapProductMember_20210101_20211231"
      decimals="-3"
      id="F_000104"
      unitRef="U_iso4217USD">700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001748907_srtProductOrServiceAxis_us-gaapProductMember_20200101_20201231"
      decimals="-3"
      id="F_000105"
      unitRef="U_iso4217USD">2595000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001748907_srtProductOrServiceAxis_ortxCollaborationMember_20210101_20211231"
      decimals="-3"
      id="F_000106"
      unitRef="U_iso4217USD">975000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000107"
      unitRef="U_iso4217USD">1675000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000108"
      unitRef="U_iso4217USD">2595000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000109"
      unitRef="U_iso4217USD">226000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000110"
      unitRef="U_iso4217USD">857000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000112"
      unitRef="U_iso4217USD">86977000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000113"
      unitRef="U_iso4217USD">93730000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000114"
      unitRef="U_iso4217USD">54905000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000115"
      unitRef="U_iso4217USD">64986000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000116"
      unitRef="U_iso4217USD">142108000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000117"
      unitRef="U_iso4217USD">159573000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000118"
      unitRef="U_iso4217USD">-140433000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000119"
      unitRef="U_iso4217USD">-156978000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000120"
      unitRef="U_iso4217USD">412000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000121"
      unitRef="U_iso4217USD">3185000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000122"
      unitRef="U_iso4217USD">2497000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000123"
      unitRef="U_iso4217USD">2328000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000124"
      unitRef="U_iso4217USD">-1238000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000125"
      unitRef="U_iso4217USD">3411000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000126"
      unitRef="U_iso4217USD">-3323000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000127"
      unitRef="U_iso4217USD">4268000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000128"
      unitRef="U_iso4217USD">-143756000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000129"
      unitRef="U_iso4217USD">-152710000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000130"
      unitRef="U_iso4217USD">828000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000131"
      unitRef="U_iso4217USD">-731000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000132"
      unitRef="U_iso4217USD">-144584000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000133"
      unitRef="U_iso4217USD">-151979000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0001748907_20210101_20211231"
      decimals="2"
      id="F_000134"
      unitRef="U_iso4217USD_xbrlishares">-1.17</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0001748907_20200101_20201231"
      decimals="2"
      id="F_000135"
      unitRef="U_iso4217USD_xbrlishares">-1.53</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0001748907_20210101_20211231"
      decimals="0"
      id="F_000136"
      unitRef="U_xbrlishares">123963762</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0001748907_20200101_20201231"
      decimals="0"
      id="F_000137"
      unitRef="U_xbrlishares">99445874</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000138"
      unitRef="U_iso4217USD">3124000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000139"
      unitRef="U_iso4217USD">-1485000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000140"
      unitRef="U_iso4217USD">-251000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000141"
      unitRef="U_iso4217USD">-184000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000142"
      unitRef="U_iso4217USD">2873000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000143"
      unitRef="U_iso4217USD">-1669000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000144"
      unitRef="U_iso4217USD">-141711000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000145"
      unitRef="U_iso4217USD">-153648000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231"
      decimals="INF"
      id="F_000146"
      unitRef="U_xbrlishares">96923729</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231"
      decimals="-3"
      id="F_000147"
      unitRef="U_iso4217USD">12331000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231"
      decimals="-3"
      id="F_000148"
      unitRef="U_iso4217USD">738481000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231"
      decimals="-3"
      id="F_000149"
      unitRef="U_iso4217USD">2042000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231"
      decimals="-3"
      id="F_000150"
      unitRef="U_iso4217USD">-453661000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001748907_20191231"
      decimals="-3"
      id="F_000151"
      unitRef="U_iso4217USD">299193000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231"
      decimals="-3"
      id="F_000152"
      unitRef="U_iso4217USD">27962000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000153"
      unitRef="U_iso4217USD">27962000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="INF"
      id="F_000154"
      unitRef="U_xbrlishares">1154441</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="-3"
      id="F_000155"
      unitRef="U_iso4217USD">149000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231"
      decimals="-3"
      id="F_000156"
      unitRef="U_iso4217USD">3316000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000157"
      unitRef="U_iso4217USD">3465000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="INF"
      id="F_000158"
      unitRef="U_xbrlishares">107262</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="-3"
      id="F_000159"
      unitRef="U_iso4217USD">14000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231"
      decimals="-3"
      id="F_000160"
      unitRef="U_iso4217USD">657000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000161"
      unitRef="U_iso4217USD">671000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <ortx:StockIssuedDuringPeriodSharesAsPartOfConsultingAgreement
      contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="INF"
      id="F_000162"
      unitRef="U_xbrlishares">22758</ortx:StockIssuedDuringPeriodSharesAsPartOfConsultingAgreement>
    <ortx:StockIssuedDuringPeriodValueAsPartOfConsultingAgreement
      contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="-3"
      id="F_000163"
      unitRef="U_iso4217USD">3000</ortx:StockIssuedDuringPeriodValueAsPartOfConsultingAgreement>
    <ortx:StockIssuedDuringPeriodValueAsPartOfConsultingAgreement
      contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231"
      decimals="-3"
      id="F_000164"
      unitRef="U_iso4217USD">-3000</ortx:StockIssuedDuringPeriodValueAsPartOfConsultingAgreement>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="INF"
      id="F_000165"
      unitRef="U_xbrlishares">75413</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="-3"
      id="F_000166"
      unitRef="U_iso4217USD">10000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231"
      decimals="-3"
      id="F_000167"
      unitRef="U_iso4217USD">781000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000168"
      unitRef="U_iso4217USD">791000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231"
      decimals="-3"
      id="F_000169"
      unitRef="U_iso4217USD">-1485000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000170"
      unitRef="U_iso4217USD">-1485000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231"
      decimals="-3"
      id="F_000171"
      unitRef="U_iso4217USD">-184000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000172"
      unitRef="U_iso4217USD">-184000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231"
      decimals="-3"
      id="F_000173"
      unitRef="U_iso4217USD">-151979000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000174"
      unitRef="U_iso4217USD">-151979000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231"
      decimals="INF"
      id="F_000175"
      unitRef="U_xbrlishares">98283603</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231"
      decimals="-3"
      id="F_000176"
      unitRef="U_iso4217USD">12507000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231"
      decimals="-3"
      id="F_000177"
      unitRef="U_iso4217USD">771194000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231"
      decimals="-3"
      id="F_000178"
      unitRef="U_iso4217USD">373000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231"
      decimals="-3"
      id="F_000179"
      unitRef="U_iso4217USD">-605640000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000180"
      unitRef="U_iso4217USD">178434000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231"
      decimals="-3"
      id="F_000181"
      unitRef="U_iso4217USD">22536000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000182"
      unitRef="U_iso4217USD">22536000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231"
      decimals="INF"
      id="F_000183"
      unitRef="U_xbrlishares">1727254</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231"
      decimals="-3"
      id="F_000184"
      unitRef="U_iso4217USD">224000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231"
      decimals="-3"
      id="F_000185"
      unitRef="U_iso4217USD">2515000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000186"
      unitRef="U_iso4217USD">2739000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231"
      decimals="INF"
      id="F_000187"
      unitRef="U_xbrlishares">232340</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231"
      decimals="-3"
      id="F_000188"
      unitRef="U_iso4217USD">30000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231"
      decimals="-3"
      id="F_000189"
      unitRef="U_iso4217USD">534000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000190"
      unitRef="U_iso4217USD">564000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings
      contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231"
      decimals="INF"
      id="F_000191"
      unitRef="U_xbrlishares">64647</us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings>
    <us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings
      contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231"
      decimals="-3"
      id="F_000192"
      unitRef="U_iso4217USD">9000</us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings>
    <us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings
      contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231"
      decimals="-3"
      id="F_000193"
      unitRef="U_iso4217USD">-401000</us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings>
    <us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000194"
      unitRef="U_iso4217USD">-392000</us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000218"
      unitRef="U_iso4217USD">6355000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231"
      decimals="INF"
      id="F_000195"
      unitRef="U_xbrlishares">24115755</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231"
      decimals="-3"
      id="F_000196"
      unitRef="U_iso4217USD">3310000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231"
      decimals="-3"
      id="F_000197"
      unitRef="U_iso4217USD">140335000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000198"
      unitRef="U_iso4217USD">143645000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <ortx:StockIssuedDuringPeriodSharesAsPartOfConsultingAgreement
      contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231"
      decimals="INF"
      id="F_000199"
      unitRef="U_xbrlishares">22758</ortx:StockIssuedDuringPeriodSharesAsPartOfConsultingAgreement>
    <ortx:StockIssuedDuringPeriodValueAsPartOfConsultingAgreement
      contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231"
      decimals="-3"
      id="F_000200"
      unitRef="U_iso4217USD">3000</ortx:StockIssuedDuringPeriodValueAsPartOfConsultingAgreement>
    <ortx:StockIssuedDuringPeriodValueAsPartOfConsultingAgreement
      contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231"
      decimals="-3"
      id="F_000201"
      unitRef="U_iso4217USD">-3000</ortx:StockIssuedDuringPeriodValueAsPartOfConsultingAgreement>
    <ortx:StockIssuedDuringPeriodSharesAsPartOfCollaborationAgreement
      contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231"
      decimals="INF"
      id="F_000202"
      unitRef="U_xbrlishares">1227738</ortx:StockIssuedDuringPeriodSharesAsPartOfCollaborationAgreement>
    <ortx:StockIssuedDuringPeriodValueAsPartOfCollaborationAgreement
      contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231"
      decimals="-3"
      id="F_000203"
      unitRef="U_iso4217USD">170000</ortx:StockIssuedDuringPeriodValueAsPartOfCollaborationAgreement>
    <ortx:StockIssuedDuringPeriodValueAsPartOfCollaborationAgreement
      contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231"
      decimals="-3"
      id="F_000204"
      unitRef="U_iso4217USD">3965000</ortx:StockIssuedDuringPeriodValueAsPartOfCollaborationAgreement>
    <ortx:StockIssuedDuringPeriodValueAsPartOfCollaborationAgreement
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000205"
      unitRef="U_iso4217USD">4135000</ortx:StockIssuedDuringPeriodValueAsPartOfCollaborationAgreement>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210101_20211231"
      decimals="-3"
      id="F_000206"
      unitRef="U_iso4217USD">3124000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000207"
      unitRef="U_iso4217USD">3124000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210101_20211231"
      decimals="-3"
      id="F_000208"
      unitRef="U_iso4217USD">-251000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000209"
      unitRef="U_iso4217USD">-251000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20211231"
      decimals="-3"
      id="F_000210"
      unitRef="U_iso4217USD">-144584000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000211"
      unitRef="U_iso4217USD">-144584000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231"
      decimals="INF"
      id="F_000212"
      unitRef="U_xbrlishares">125674095</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231"
      decimals="-3"
      id="F_000213"
      unitRef="U_iso4217USD">16253000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20211231"
      decimals="-3"
      id="F_000214"
      unitRef="U_iso4217USD">940675000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20211231"
      decimals="-3"
      id="F_000215"
      unitRef="U_iso4217USD">3246000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001748907_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20211231"
      decimals="-3"
      id="F_000216"
      unitRef="U_iso4217USD">-750224000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000217"
      unitRef="U_iso4217USD">209950000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000219"
      unitRef="U_iso4217USD">-144584000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000220"
      unitRef="U_iso4217USD">-151979000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000221"
      unitRef="U_iso4217USD">2327000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000222"
      unitRef="U_iso4217USD">2004000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000223"
      unitRef="U_iso4217USD">22536000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000224"
      unitRef="U_iso4217USD">27962000</us-gaap:ShareBasedCompensation>
    <us-gaap:AssetImpairmentCharges
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000225"
      unitRef="U_iso4217USD">5650000</us-gaap:AssetImpairmentCharges>
    <ortx:NonCashInterestExpense
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000226"
      unitRef="U_iso4217USD">392000</ortx:NonCashInterestExpense>
    <ortx:NonCashInterestExpense
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000227"
      unitRef="U_iso4217USD">500000</ortx:NonCashInterestExpense>
    <ortx:AmortizationOfProvisionOnLossContract
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000228"
      unitRef="U_iso4217USD">-1037000</ortx:AmortizationOfProvisionOnLossContract>
    <ortx:AmortizationOfProvisionOnLossContract
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000229"
      unitRef="U_iso4217USD">-2413000</ortx:AmortizationOfProvisionOnLossContract>
    <ortx:NonCashConsiderationForLicensesAndMilestones
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000230"
      unitRef="U_iso4217USD">791000</ortx:NonCashConsiderationForLicensesAndMilestones>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000231"
      unitRef="U_iso4217USD">1131000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000232"
      unitRef="U_iso4217USD">-2257000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <ortx:AmortizationOfPremiumOnMarketableSecurities
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000233"
      unitRef="U_iso4217USD">1514000</ortx:AmortizationOfPremiumOnMarketableSecurities>
    <ortx:AmortizationOfPremiumOnMarketableSecurities
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000234"
      unitRef="U_iso4217USD">770000</ortx:AmortizationOfPremiumOnMarketableSecurities>
    <ortx:UnrealizedForeignCurrencyAndOtherNonCashAdjustments
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000235"
      unitRef="U_iso4217USD">-9687000</ortx:UnrealizedForeignCurrencyAndOtherNonCashAdjustments>
    <ortx:UnrealizedForeignCurrencyAndOtherNonCashAdjustments
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000236"
      unitRef="U_iso4217USD">3674000</ortx:UnrealizedForeignCurrencyAndOtherNonCashAdjustments>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000237"
      unitRef="U_iso4217USD">624000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000238"
      unitRef="U_iso4217USD">-582000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <ortx:IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000239"
      unitRef="U_iso4217USD">13920000</ortx:IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable>
    <ortx:IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000240"
      unitRef="U_iso4217USD">-11674000</ortx:IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000241"
      unitRef="U_iso4217USD">5209000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000242"
      unitRef="U_iso4217USD">5070000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <ortx:IncreaseDecreaseInOperatingRightOfUseAssets
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000243"
      unitRef="U_iso4217USD">5938000</ortx:IncreaseDecreaseInOperatingRightOfUseAssets>
    <ortx:IncreaseDecreaseInOperatingRightOfUseAssets
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000244"
      unitRef="U_iso4217USD">5863000</ortx:IncreaseDecreaseInOperatingRightOfUseAssets>
    <ortx:IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000245"
      unitRef="U_iso4217USD">-9452000</ortx:IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesAndOtherOperatingLiabilities>
    <ortx:IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000246"
      unitRef="U_iso4217USD">-12278000</ortx:IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000247"
      unitRef="U_iso4217USD">13122000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000248"
      unitRef="U_iso4217USD">34000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000249"
      unitRef="U_iso4217USD">2570000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <ortx:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000250"
      unitRef="U_iso4217USD">-6952000</ortx:IncreaseDecreaseInOperatingLeaseLiabilities>
    <ortx:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000251"
      unitRef="U_iso4217USD">-6969000</ortx:IncreaseDecreaseInOperatingLeaseLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000252"
      unitRef="U_iso4217USD">-125097000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000253"
      unitRef="U_iso4217USD">-126274000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000254"
      unitRef="U_iso4217USD">234732000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000255"
      unitRef="U_iso4217USD">281433000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000256"
      unitRef="U_iso4217USD">263878000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000257"
      unitRef="U_iso4217USD">113262000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireRestrictedCertificatesOfDeposit
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000258"
      unitRef="U_iso4217USD">10000000</us-gaap:PaymentsToAcquireRestrictedCertificatesOfDeposit>
    <ortx:ReceiptOfFundsFromConstructionDeposit
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000259"
      unitRef="U_iso4217USD">216000</ortx:ReceiptOfFundsFromConstructionDeposit>
    <ortx:ReceiptOfFundsFromConstructionDeposit
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000260"
      unitRef="U_iso4217USD">1876000</ortx:ReceiptOfFundsFromConstructionDeposit>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000261"
      unitRef="U_iso4217USD">887000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000262"
      unitRef="U_iso4217USD">2348000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000263"
      unitRef="U_iso4217USD">2668000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000264"
      unitRef="U_iso4217USD">-32165000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000265"
      unitRef="U_iso4217USD">157379000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000266"
      unitRef="U_iso4217USD">7375000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromStockPlans
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000267"
      unitRef="U_iso4217USD">3303000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000268"
      unitRef="U_iso4217USD">3936000</us-gaap:ProceedsFromStockPlans>
    <ortx:PaymentOfTaxesOnRestrictedStockVesting
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000269"
      unitRef="U_iso4217USD">392000</ortx:PaymentOfTaxesOnRestrictedStockVesting>
    <ortx:ProceedsFromIssuanceOfSharesAsPartOfCollaborationAgreement
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000270"
      unitRef="U_iso4217USD">4135000</ortx:ProceedsFromIssuanceOfSharesAsPartOfCollaborationAgreement>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000271"
      unitRef="U_iso4217USD">150000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000272"
      unitRef="U_iso4217USD">6355000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000273"
      unitRef="U_iso4217USD">158066000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000274"
      unitRef="U_iso4217USD">3936000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000275"
      unitRef="U_iso4217USD">-27000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000276"
      unitRef="U_iso4217USD">1043000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000277"
      unitRef="U_iso4217USD">777000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000278"
      unitRef="U_iso4217USD">36084000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000279"
      unitRef="U_iso4217USD">59401000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001748907_20191231"
      decimals="-3"
      id="F_000280"
      unitRef="U_iso4217USD">23317000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000281"
      unitRef="U_iso4217USD">60178000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000282"
      unitRef="U_iso4217USD">59401000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <ortx:IntangibleAssetsAndPropertyAndEquipmentInAccountsPayableAndAccruedExpenses
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000283"
      unitRef="U_iso4217USD">2589000</ortx:IntangibleAssetsAndPropertyAndEquipmentInAccountsPayableAndAccruedExpenses>
    <ortx:IntangibleAssetsAndPropertyAndEquipmentInAccountsPayableAndAccruedExpenses
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000284"
      unitRef="U_iso4217USD">3096000</ortx:IntangibleAssetsAndPropertyAndEquipmentInAccountsPayableAndAccruedExpenses>
    <us-gaap:StockIssued1
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000285"
      unitRef="U_iso4217USD">791000</us-gaap:StockIssued1>
    <ortx:EmployeeEquityPlanProceedsReceived
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000286"
      unitRef="U_iso4217USD">200000</ortx:EmployeeEquityPlanProceedsReceived>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000287"
      unitRef="U_iso4217USD">552000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000288"
      unitRef="U_iso4217USD">17486000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:InterestPaidNet
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000289"
      unitRef="U_iso4217USD">2103000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000290"
      unitRef="U_iso4217USD">1828000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000291"
      unitRef="U_iso4217USD">1651000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000292"
      unitRef="U_iso4217USD">1007000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="C_0001748907_20210101_20211231" id="F_000294">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;1. Nature of Business and Basis of Presentation &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Orchard Therapeutics plc (the &#x201c;Company&#x201d;) is a global gene therapy company dedicated to transforming the lives of people affected by severe diseases through the development of innovative, potentially curative gene therapies. The Company&#x2019;s&#160;&lt;span style="font-style:italic;"&gt;ex vivo&lt;/span&gt;&#160;autologous hematopoietic stem cell (&#x201c;HSC&#x201d;) gene therapy approach utilizes genetically modified blood stem cells and seeks to correct the underlying cause of disease in a single administration. The Company&#x2019;s gene therapy product candidate pipeline spans multiple therapeutic areas where the disease burden on children, families and caregivers is immense and current treatment options are limited or do not exist.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is a public limited company incorporated pursuant to the laws of England and Wales. The Company has American Depositary Shares (&#x201c;ADSs&#x201d;) registered with the U.S. Securities and Exchange Commission (the &#x201c;SEC&#x201d;) and has been listed on the Nasdaq Global Select Market since October 31, 2018. The Company&#x2019;s ADSs each represent one ordinary share of the Company.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2020, the Company received standard marketing authorization from the European Commission for Libmeldy&#x2122; (&lt;span style="color:#000000;"&gt;atidarsagene autotemcel&lt;/span&gt;), for the treatment of early onset metachromatic leukodystrophy (&#x201c;MLD&#x201d;), characterized by biallelic mutations in the&#160;&lt;span style="font-style:italic;"&gt;arylsulfatase-A&lt;/span&gt;&#160;(&lt;span style="font-style:italic;"&gt;ARSA&lt;/span&gt;) gene leading to a reduction of the ARSA enzymatic activity in children with (i) late infantile or early juvenile forms, without clinical manifestations of the disease, or (ii) the early juvenile form, with early clinical manifestations of the disease, who still have the ability to walk independently and before the onset of cognitive decline.&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On February 9, 2021, the Company issued and sold (i) 20,900,321 ordinary shares, nominal value &#xa3;0.10 per share, at a purchase price of $6.22 per share (the &#x201c;Purchase Price&#x201d;), which was the closing sale price of the Company&#x2019;s ADSs on the Nasdaq Global Select Market on February 4, 2021, and (ii) 3,215,434 non-voting ordinary shares, nominal value &#xa3;0.10 per share, at the Purchase Price (together (i) and (ii) the &#x201c;Private Placement&#x201d;). The Private Placement resulted in net proceeds to the Company of $143.6 million after deducting placement agent fees of $6.0 million and other issuance costs of $0.4 million. The ordinary shares and non-voting ordinary shares were sold pursuant to a securities purchase agreement entered into between the Company and the purchasers named therein on February 4, 2021.&#160;&#160;At December 31, 2021, all outstanding non-voting shares have been converted to voting ordinary shares.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s business is subject to risks and uncertainties common to development-stage companies in the biotechnology industry. There can be no assurance that the Company&#x2019;s research and development will be successfully completed, that adequate protection for the Company&#x2019;s technology will be obtained, that any products developed will obtain necessary government regulatory approval or that any products, if approved, will be commercially viable. The Company operates in an environment of rapid technological innovation and substantial competition from pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees, consultants and service providers. Even if the Company&#x2019;s product development efforts are successful in gaining regulatory approval, it is uncertain when, if ever, the Company will realize significant revenue from product sales. &#160;&lt;span style="Background-color:#FFFFFF;"&gt;The future developments of the COVID-19 pandemic may also directly or indirectly impact the Company&#x2019;s business, including impacts due to&#160;quarantines, border closures, increased border controls, travel restrictions, shelter-in-place orders and shutdowns, business closures, cancellations of public gatherings and other measures.&lt;/span&gt; &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accompanying consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. Through December&#160;31, 2021, the Company funded its operations primarily with proceeds from the sale of convertible preferred shares, and ADSs in the IPO and follow-on offering. The Company has incurred recurring losses since its inception, including net losses of $144.6 million and $152.0 million for the years ended December&#160;31, 2021 and 2020, respectively. As of December&#160;31, 2021, the Company had an accumulated deficit of $750.2 million. The Company expects to continue to generate operating losses for the foreseeable future. The Company expects that its cash, cash equivalents, and marketable securities on hand as of December&#160;31, 2021 of $220.1 million will be sufficient to fund its operations and capital expenditure requirements for at least the next twelve months. &lt;span style="Background-color:#FFFFFF;"&gt;The Company will seek additional funding through private or public equity financings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into collaborations or other arrangements. The terms of any financing may adversely affect the holdings or the rights of the Company's stockholders.&#160;&lt;/span&gt;The future viability of the Company is dependent on its ability to raise additional capital to finance its &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;operations. If the Company is unable to obtain funding, the Company will be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects, or the Company may be unable to continue operations. Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Basis of presentation &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and include the accounts of the Company and its wholly owned subsidiaries, after elimination of all intercompany accounts and transactions. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amounts reported are based in thousands, except percentages, per share amounts or as otherwise noted. As a result, certain totals may not sum due to rounding.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001748907_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_us-gaapTypeOfArrangementAxis_ortxSecuritiesPurchaseAgreementMember_20210209_20210209"
      decimals="INF"
      id="F_000370"
      unitRef="U_xbrlishares">20900321</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001748907_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_us-gaapTypeOfArrangementAxis_ortxSecuritiesPurchaseAgreementMember_20210209"
      decimals="INF"
      id="F_000371"
      unitRef="U_iso4217GBP_xbrlishares">0.10</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_0001748907_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_us-gaapTypeOfArrangementAxis_ortxSecuritiesPurchaseAgreementMember_20210209"
      decimals="2"
      id="F_000372"
      unitRef="U_iso4217USD_xbrlishares">6.22</us-gaap:SaleOfStockPricePerShare>
    <ortx:ClosingPriceOfShareDate
      contextRef="C_0001748907_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_us-gaapTypeOfArrangementAxis_ortxSecuritiesPurchaseAgreementMember_20210209_20210209"
      id="F_000373">2021-02-04</ortx:ClosingPriceOfShareDate>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001748907_us-gaapStatementClassOfStockAxis_ortxNonVotingOrdinarySharesMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_us-gaapTypeOfArrangementAxis_ortxSecuritiesPurchaseAgreementMember_20210209_20210209"
      decimals="INF"
      id="F_000374"
      unitRef="U_xbrlishares">3215434</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001748907_us-gaapStatementClassOfStockAxis_ortxNonVotingOrdinarySharesMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_us-gaapTypeOfArrangementAxis_ortxSecuritiesPurchaseAgreementMember_20210209"
      decimals="INF"
      id="F_000375"
      unitRef="U_iso4217GBP_xbrlishares">0.10</us-gaap:CommonStockParOrStatedValuePerShare>
    <ortx:NetProceedsFromIssuanceOfPrivatePlacement
      contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxSecuritiesPurchaseAgreementMember_20210209_20210209"
      decimals="-5"
      id="F_000379"
      unitRef="U_iso4217USD">143600000</ortx:NetProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_0001748907_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_us-gaapTypeOfArrangementAxis_ortxSecuritiesPurchaseAgreementMember_20210209_20210209"
      decimals="-5"
      id="F_000376"
      unitRef="U_iso4217USD">6000000.0</us-gaap:PaymentsOfStockIssuanceCosts>
    <ortx:PaymentsOfOtherIssuanceCosts
      contextRef="C_0001748907_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_us-gaapTypeOfArrangementAxis_ortxSecuritiesPurchaseAgreementMember_20210209_20210209"
      decimals="-5"
      id="F_000377"
      unitRef="U_iso4217USD">400000</ortx:PaymentsOfOtherIssuanceCosts>
    <us-gaap:SaleOfStockTransactionDate
      contextRef="C_0001748907_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_us-gaapTypeOfArrangementAxis_ortxSecuritiesPurchaseAgreementMember_20210209_20210209"
      id="F_000378">2021-02-04</us-gaap:SaleOfStockTransactionDate>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001748907_20210101_20211231"
      decimals="-5"
      id="F_000380"
      unitRef="U_iso4217USD">-144600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001748907_20200101_20201231"
      decimals="-5"
      id="F_000381"
      unitRef="U_iso4217USD">-152000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0001748907_20211231"
      decimals="-5"
      id="F_000382"
      unitRef="U_iso4217USD">-750200000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="C_0001748907_20211231"
      decimals="-5"
      id="F_000383"
      unitRef="U_iso4217USD">220100000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="C_0001748907_20210101_20211231" id="F_000295">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2. Summary of Significant Accounting Policies &lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Principles of consolidation&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Use of estimates &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual for research and development expenses, the research and development tax credit receivable, share-based compensation, collaboration agreement milestones, operating lease assets and liabilities, and income taxes. Estimates are periodically reviewed in light of changes in circumstances, facts and experience.&lt;span style="Background-color:#FFFFFF;"&gt; Actual results could differ from the Company&#x2019;s estimates.&lt;/span&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Concentration of credit risk &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has no significant off-balance sheet risk, such as foreign currency contracts, options contracts, or other foreign hedging arrangements. Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents, marketable securities, and receivables. The Company maintains deposits in accredited financial institutions in excess of federally insured limits. The Company deposits its cash in financial institutions that it believes have high credit quality and has not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships or entities for which it has a receivable. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Foreign currency&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The financial statements of the Company&#x2019;s subsidiaries with functional currencies other than the U.S. Dollar are translated into U.S. Dollars using period-end exchange rates for assets and liabilities, historical exchange rates for shareholders&#x2019; equity and weighted average exchange rates for operating results. Translation gains and losses are included in accumulated other comprehensive income (loss) in shareholders&#x2019; equity. Foreign currency transaction gains and losses are included in other income (expense), net in the results of operations.&lt;/span&gt;&lt;span style="color:#000000;"&gt;  The Company recorded realized and unrealized foreign currency transaction losses of $1.2 million, and gains of $3.4 million for the years ended December 31, 2021, and 2020, respectively, which is included in other income (expense) in the statements of operations and comprehensive loss. &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Segment information&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The Company operates in a single segment, focusing on researching, developing and commercializing potentially curative gene therapies.&#160;&#160;Consistent with its operational structure, its chief operating decision maker manages and allocates resources at a global, consolidated level. Therefore, results of the Company's operations are reported on a consolidated basis for purposes of segment reporting.&#160;&#160;All material long-lived assets of the Company reside in the United States or United Kingdom. The Company had property and equipment of $3.6 million and $1.2 million located in the United Kingdom and United States, respectively, as of December 31, 2021. &lt;/span&gt;The Company had property and equipment of $3.7 million and $1.1 million located in the United Kingdom and United States, respectively, as of December 31, 2020.&#160;The Company had right-of-use assets in the United States and United Kingdom and European Union of $12.5 million and $11.8 million, respectively, as of December 31, 2021. The Company had right-of-use assets in the United States and United Kingdom and European Union of $14.2 million and $15.6 million, respectively, as of December 31, 2020.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Cash equivalents &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company considers all highly liquid investments purchased with original maturities of 90 days or less at the date of acquisition to be cash equivalents. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Marketable securities&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Marketable securities consist of investments with original maturities greater than ninety days at the date of acquisition. The Company has classified its investments with maturities beyond one year as short term, based on their highly liquid nature and because such marketable securities represent the investment of cash that is available for current operations. The Company considers its investment portfolio of investments as&#160;available-for-sale.&#160;Accordingly, these investments are recorded at fair value, which is based on quoted market prices or other observable inputs. Unrealized gains and losses are recorded as a component of other comprehensive income (loss). Realized gains and losses are determined on a specific identification basis and are included in other income (loss). Amortization and accretion of discounts and premiums is also recorded in other income (loss).&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;When the fair value is below the amortized cost of the asset an estimate of expected credit losses is made, the estimate is limited to the amount by which fair value is less than amortized cost. The credit-related impairment amount is recognized in the consolidated statements of operations; the remaining impairment amount and unrealized gains are reported as a component of accumulated other comprehensive income (loss) in shareholders&#x2019; equity. Credit losses are recognized through the use of an allowance for credit losses account and subsequent improvements in expected credit losses are recognized as a reversal of the allowance account. If the Company has the intent to sell the security or it is more likely than not that the Company will be required to sell the security prior to recovery of its amortized cost basis the allowance for credit loss is written off and the excess of the amortized cost basis of the asset over its fair value is recorded in the consolidated statements of operation.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Restricted cash and construction deposits&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents that are restricted as to withdrawal or use under the terms of certain contractual agreements are recorded as restricted cash on our consolidated balance sheet. The Company has an outstanding letter of credit for $3.0 million associated with a lease, and is required to hold this amount in a standalone bank account at December 31, 2021 and 2020. The Company is also contractually required to maintain a cash collateral account associated with corporate credit cards and other leases in the amount of &lt;span&gt;$1.3&lt;/span&gt; million at December 31, 2021 and 2020. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company includes the restricted cash balance in cash and cash equivalents when reconciling beginning-of-period and end-of-period total amounts shown on the consolidated statements of cash flows. The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported in the consolidated balance sheet that sum to the total of the amounts reported in the consolidated statement of cash flows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;55,912&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;55,135&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,266&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,266&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total cash, cash equivalents and restricted cash shown in the statement of&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; cash flows&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;60,178&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;59,401&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company also has &lt;span style="color:#000000;"&gt;$7.9 million in an escrow account associated with the construction of the Company&#x2019;s leased facility in Fremont, California, which the Company has ceased construction and build-out, and has subleased the facility to a third-party who intends to perform construction and build-out of the facility. &lt;/span&gt;Subject to the terms of the lease and reduction provisions, this escrow amount may be decreased to nil over time upon qualifying construction expenditures, or will be returned in late 2022 to the extent funds are not used. The Company deposited $10.0 million into the account in the first quarter of 2020 and has received $2.1 million in receipts from the escrow funds for work performed to date. Of the $7.9 million remaining in the escrow account, the entire balance is classified within other prepaid expenses and other current assets on the consolidated balance sheets based on the timing of when the Company expects to receive the cash from the escrow agent.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Inventory&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inventory is stated at the lower of cost or estimated net realizable value with cost determined on a first-in, first-out basis. Inventory costs include raw materials, third-party contract manufacturing, third-party packaging services, and freight. Raw and intermediate materials that may be utilized for either research and development or commercial purposes are classified as inventory. Amounts in inventory that are used for research and development purposes are charged to research and development expense when the product enters the research and development process and can no longer be used for commercial purposes and, therefore, does not have an &#x201c;alternative future use&#x201d; as defined in authoritative guidance. The Company performs an assessment of the recoverability of capitalized inventory during each reporting period and, if needed, writes down any excess and obsolete inventory to its estimated net realizable value in the period it is identified. If they occur, such impairment charges are recorded as a component of cost of goods sold in the consolidated statements of operations and comprehensive income (loss). Inventory is included in prepaid expenses and other current assets on the consolidated balance sheets and the amount was not significant as of December&#160;31, 2021.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prior to the initial date that regulatory approval is received, costs related to the production of inventory are recorded as research and development expense on the Company&#x2019;s consolidated statements of operations and comprehensive income (loss) in the period incurred. In connection with the acquisition of Strimvelis in April 2018, and with the EMA approval of Libmeldy in December 2020, the Company subsequently began capitalizing inventory manufactured or purchased after these dates.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Intangible assets, net&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Intangible assets, net consist milestones associated with the Company&#x2019;s approved products, net of accumulated amortization. The Company amortizes its intangible assets using the straight-line method over their estimated economic lives and periodically reviews for impairment. The Company has not recognized any impairment charges related to intangible assets to date.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Property and equipment &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment are recorded at cost and depreciated or amortized using the straight-line method over the following estimated useful lives. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated useful&#160;&#160;life&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lab equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5-10 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shorter of lease term or estimated useful life&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Office and computer equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3-5 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Repairs and maintenance expenditures, which are not considered improvements and do not extend the useful life of property and equipment, are expensed as incurred. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts, and any resulting gain or loss is included in the consolidated statements of operations and other comprehensive loss. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Impairment of long-lived assets &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Long-lived assets consist of property and equipment and operating lease right-of-use assets. Long-lived assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;economic trends and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset group for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset group to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of an asset group are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset group over its fair value, as determined in accordance with the related accounting literature&lt;/span&gt;&lt;span style="color:#000000;"&gt;. &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Research and development costs &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including salaries, share-based compensation and benefits, facilities costs, depreciation, third-party license fees, certain milestone payments, and external costs of outside vendors engaged to conduct clinical development activities and clinical trials, the purchase of in-process research and development assets, as well as costs to develop a manufacturing process, perform analytical testing and manufacture clinical trial materials. Non-refundable prepayments for goods or services that will be used or rendered for future research and development activities are recorded as prepaid expenses. Such amounts are recognized as an expense as the goods are delivered or the related services are performed, or until it is no longer expected that the goods will be delivered, or the services rendered. In addition, funding from research grants is recognized as an offset to research and development expense on the basis of costs incurred on the research program. Royalties to third parties associated with our research grants will be accrued when they become probable.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Research contract costs and accruals &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has entered into various research and development contracts. These agreements are cancelable, and related costs are recorded as research and development expenses as incurred. When billing terms under these contracts do not coincide with the timing of when the work is performed, the Company is required to make estimates of outstanding obligations as of period end to those third parties. Any accrual estimates are based on a number of factors, including the Company&#x2019;s knowledge of the progress towards completion of the research and development activities, invoicing to date under the contracts, communication from the research institution or other companies of any actual costs incurred during the period that have not yet been invoiced, and the costs included in the contracts. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the expense. Actual results could differ from the estimates made by the Company. The historical accrual estimates made by the Company have not been materially different from the actual costs.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Share-based compensation &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company measures share-based awards granted to employees, consultants and directors based on the fair value of the shares and options on the date of the grant and recognizes compensation expense for those awards over the requisite service period, which is the vesting period of the respective award. Forfeitures are accounted for as they occur. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Comprehensive loss &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Comprehensive loss is composed of net loss and other comprehensive income (loss). Other comprehensive income (loss) consists of unrealized gains and losses on marketable securities and foreign currency translation gains and losses.&lt;/span&gt;&lt;span style="color:#000000;"&gt; &#160;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Leases&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company determines if an arrangement is a lease at contract inception. Operating lease assets represent a right to use an underlying asset for the lease term and operating lease liabilities represent an obligation to make lease payments arising from the lease. Operating lease liabilities with a term greater than one year and their corresponding right-of-use assets are recognized on the balance sheet at the commencement date of the lease based on the present value of lease payments over the expected lease term. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received. The Company made an accounting policy election to not record a right-of-use asset or lease liability for leases with a term of one year or less. To date, the Company has not identified any material short-term leases, either individually or in the aggregate.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;As&#160;the Company&#x2019;s&#160;leases do not provide an implicit rate,&#160;the Company utilized the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term as the lease an amount equal to the lease payments in a similar economic environment. The Company estimated the incremental borrowing rate based on the &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Company&#x2019;s currently outstanding credit facility as inputs to the analysis to calculate a spread, adjusted for factors that reflect the profile of secured borrowing over the expected term of the lease.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The components of a lease should be split into three categories: lease components (e.g., land, building, etc.), non-lease components (e.g., common area maintenance, utilities, performance of manufacturing services, purchase of inventory, etc.), and non-components (e.g., property taxes, insurance, etc.). Then the fixed contract consideration (including any related to non-components) must be allocated based on fair values to the lease components and non-lease components. Although separation of lease and non-lease components is required, certain accounting policy elections are available to entities. Entities can elect accounting policies that would not separate lease and non-lease components. Rather, they would account for each lease component and the related non-lease&#160;component together as a single component. The Company has elected&#160;not to apply the accounting policy with respect to its lease of manufacturing space at a contract manufacturing organization, the Company has allocated the consideration between the lease and non-lease components of the contract&#160;based on the respective fair values of the lease and non-lease components.&#160;The&#160;Company calculated the fair value of the lease&#160;and non-lease&#160;components&#160;using financial information readily available as part of its master services arrangement&#160;and other representative data&#160;indicative of fair value.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The Company accounts for sublease income on a straight-line basis over the respective lease period and records an unbilled rent receivable for sublease income incurred but not yet paid. The Company periodically performs a collectability assessment associated with any unbilled rent receivables. The Company recognizes the sublease income as a reduction to the related operating expense associated with the head lease.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Strimvelis loss provision&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As part of the GSK transaction, the Company is required to maintain commercial availability of Strimvelis in the European Union until such time that an alternative gene therapy is available (see Note 15). Strimvelis is not currently expected to generate sufficient cash flows to overcome the costs of maintaining the product and certain regulatory commitments; therefore, the Company initially recorded a liability associated with the loss contract of $18.4&#160;million in 2018. The Company recognizes the amortization of the loss provision on a diminishing balance basis based on the actual net loss incurred associated with the Strimvelis program and the expected future net losses to be generated until such time as Strimvelis is no longer commercially available. The amortization of the provision is recorded as a credit to research and development expense. The Company has made an estimate of the expected future losses associated with Strimvelis and will adjust this estimate as facts and circumstances change regarding the commercial availability and costs of maintaining and selling Strimvelis. The Company does not update the accrued loss provision for any subsequent adjustment of the future losses, however, the timing of recognizing the amortization of what was originally recorded is adjusted for the updated future losses. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table below outlines the changes to the Strimvelis loss provision for the periods ended December 31, 2021 and 2020:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.84%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.96%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.84%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at beginning of period&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,482&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,790&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Provisions&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.06%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.06%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortization of loss provision&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.06%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,037&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.06%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,413&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Foreign currency translation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.84%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(26&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.84%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;105&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.22%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at end of period&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.84%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,419&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.84%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,482&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2021, $0.7 million of the Strimvelis loss provision was classified as current, and $2.7 million was classified as non-current. As of December 31, 2020, $0.9 million of the Strimvelis loss provision was classified as current, and $3.6 million was classified as non-current.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;United Kingdom Research and development income tax credits &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As a company that carries out research and development activities, the Company is able to submit tax credit claims from two UK research and development tax relief programs, the SME program and the RDEC program depending on eligibility. Qualifying expenditures largely comprise employment costs for research staff, consumables and certain internal overhead costs incurred as part of research projects for which the Company does not receive income.&lt;span style="color:#000000;"&gt; &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Each reporting period, management evaluates which tax relief programs the Company is expected to be eligible for and records a reduction to research and development expense for the portion of the expense that it expects to qualify under the &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;programs, that it plans to submit a claim for, and it has reasonable assurance that the amount will ultimately be realized. &lt;/span&gt;&lt;span style="color:#000000;"&gt;Based on criteria established by HM Revenue and Customs (&#x201c;HMRC&#x201d;), management of the Company expects a proportion of expenditures being undertaken in relation to its pipeline research, clinical trials management and manufacturing development activities to be eligible for the research and development tax relief programs for the year ended December 31, 2021. &lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The Company has qualified under the more favorable SME regime for the year ended December 31, 2020 and expects to qualify under the SME regime for the year ending December 31, 2021.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The RDEC and SME credits are not dependent on the Company generating future taxable income or on the ongoing tax status or tax position of the Company. The Company has assessed its research and development activities and expenditures to determine whether the nature of the activities and expenditures will qualify for credit under the tax relief programs and whether the claims will ultimately be realized based on the allowable reimbursable expense criteria established by the UK government which are subject to interpretation. At each period end, the Company estimates the reimbursement available to the Company based on available information at the time.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognizes credits from the research and development incentives when the relevant expenditure has been incurred and there is reasonable assurance that the reimbursement will be received.&#160;Such credits are accounted for as reductions in research and development expense. The following table outlines the changes to the research and development tax credit receivable, including amount recognized as an offset to research and development expense during the years ended December 31, 2021 and 2020:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.98%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.18%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at beginning of period&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,344&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;28,644&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.18%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Recognition of credit claims as offset to research and development expense&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,920&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,130&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.18%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Receipt of credit claims&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(33,771&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.18%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Foreign currency translation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(541&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,341&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.18%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at end of period&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,723&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,344&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;During the year ended December 31, 2020, the Company recorded $4.8&#160;million of additional tax credits related to a change in estimate associated with its UK research and development tax credit receivable claim for fiscal year 2019. The change in estimate was based on the results of a tax credit&#160;analysis&#160;associated with the Company&#x2019;s qualified projects and research and development expenditures completed during the third quarter to finalize the 2019 UK tax return.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2021, the Company&#x2019;s tax credit receivable from the UK was $30.7 million, all of which was classified as current. As of December&#160;31, 2020, the Company&#x2019;s tax incentive receivable from the UK was $17.3 million, all of which was classified as current.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Income taxes &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is primarily subject to corporation taxes in the United Kingdom and the United States. The calculation of the Company&#x2019;s tax provision involves the application of both United Kingdom and United States tax law and requires judgement and estimates. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for income taxes in accordance with ASC Topic 740, &lt;span style="font-style:italic;"&gt;Accounting for Income Taxes&lt;/span&gt;, which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. The Company determines its deferred tax assets and liabilities based on differences between financial reporting and tax bases of assets and liabilities, which are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are provided if, based upon the weight of available evidence, it is more likely than not that some or all of the net deferred tax assets will not be realized. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for uncertainty in income taxes by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed as the amount of benefit to recognize in the consolidated financial statements. The amount of benefits that may be used is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate, as well as the related net interest and penalties. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Product sales&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s product sales in 2021 and 2020 consist of sales of Strimvelis, which is distributed exclusively at the San Raffaele Hospital in Milan, Italy. San Raffaele Hospital will purchase and pay for Strimvelis and submit a claim to the payer. The Company&#x2019;s contracted sales with San Raffaele Hospital contain a single performance obligation and the Company recognizes revenue from product sales when the Company has satisfied its performance obligation by transferring control of Strimvelis to San Raffaele Hospital. Control of the product generally transfers upon the completion of the scheduled Strimvelis treatment. The Company&#x2019;s product sales represent total net product sales of Strimvelis. The Company evaluated the variable consideration under Accounting Standards Codification (ASC) 606,&#160;&lt;span style="font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/span&gt;, and there is currently no variable consideration included in the transaction price for Strimvelis. Costs to manufacture and deliver the product and those associated with administering the therapy are included in cost of product sales. As the product is sold in direct relation to a scheduled treatment, the Company estimates that there is limited risk of product return, including the risk of product expiration. During the years ended December 31, 2021 and 2020, the Company has $0.7 and $2.6 million in sales of Strimvelis, respectively.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Collaboration revenue&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The terms of the Company&#x2019;s collaboration agreements may include consideration such as&#160;non-refundable license fees, funding of research and development services, payments due upon the achievement of clinical and preclinical performance-&lt;span style="color:#000000;"&gt;based development milestones, regulatory milestones, manufacturing services, sales-based milestones and royalties on product sales.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company first evaluates collaboration arrangements to determine whether the arrangement (or part of the arrangement) represents a collaborative arrangement pursuant to ASC Topic 808,&#160;&lt;span style="font-style:italic;"&gt;Collaborative Arrangements&lt;/span&gt;, based on the risks and rewards and activities of the parties pursuant to the contractual arrangement. The Company accounts for any collaborative arrangement or elements within the contract that are deemed to be a collaborative arrangement, and not&lt;span style="font-size:12pt;"&gt; &lt;/span&gt;a customer relationship, in accordance with ASC&#160;808. Through December&#160;31, 2021, the Company entered into one agreement with Pharming Group N.V. (the &#x201c;Pharming Agreement&#x201d;, see Note 16) that is accounted for pursuant to ASC 606.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:9pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine the appropriate amount of revenue to be recognized for arrangements determined to be within the scope of ASC&#160;606, the Company performs the following five steps: (i)&#160;identification of the contract(s) with the customer, (ii)&#160;identification of the promised goods or services in the contract and determination of whether the promised goods or services are performance obligations, (iii)&#160;measurement of the transaction price, (iv)&#160;allocation of the transaction price to the performance obligations, and (v)&#160;recognition of revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect consideration it is entitled to in exchange for the goods or services it transfers to the customer.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The Company recognizes the&#160;&lt;/span&gt;transaction&#160;&lt;span style="Background-color:#FFFFFF;"&gt;price allocated to upfront license payments as revenue upon delivery of the license to the customer and resulting ability of the customer to use and benefit from the license, if the license is determined to be distinct from the other performance obligations identified in the contract. If the license is considered to not be distinct from other performance obligations, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied (i)&#160;at a point in time, but only for licenses determined to be distinct from other performance obligations in the contract, or (ii)&#160;over time, and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from license payments. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The Pharming Agreement entitles the Company to additional payments upon the achievement of performance-based milestones. These milestones are generally categorized into three types: development milestones, regulatory milestones, and sales-based milestones.&#160;The Company is also eligible to receive from Pharming tiered royalty payments on worldwide net sales. The Company evaluates whether it is probable that the consideration associated with each milestone will not be subject to a significant reversal in the cumulative amount of revenue recognized. Amounts that meet this threshold are included in the transaction price using the most likely amount method, whereas amounts that do not meet this threshold are considered constrained and excluded from the transaction price until they meet this threshold.&#160;Milestones tied to regulatory approval, and therefore not within the Company&#x2019;s control, are considered constrained until such approval is received. Upfront and ongoing development milestones per the collaboration agreements are not subject to refund if the development activities are not successful. At the end of each subsequent reporting period, the Company&#160;&lt;/span&gt;re-evaluates&lt;span style="Background-color:#FFFFFF;"&gt;&#160;the probability of a significant reversal of the cumulative revenue recognized for the milestones, and, if necessary, adjusts the estimate of the overall transaction price. Any such adjustments are recorded on a cumulative&#160;&lt;/span&gt;catch-up &lt;span style="Background-color:#FFFFFF;"&gt;basis, which would affect revenues from collaborators in &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;the period of adjustment. The Company may enter into an agreement that includes sales-based milestone payments and royalties in exchange for a license of intellectual property. The Company considers the underlying facts and circumstances of these agreements, noting whether the future payments are contingent upon future sales and whether they are dependent on a third party&#x2019;s ability to successfully commercialize a product using the licensed intellectual property. The Company also considers whether the license is the only, or predominant, item to which the milestone payments and royalties relate. If the Company concludes the license is the predominant item in the agreement, therefore the primary driver of value, the Company excludes sales-based milestone payments and royalties from the transaction price until the sale occurs (or, if later, until the underlying performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied). Currently, the Company has not recognized any royalty revenue resulting from the &lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Pharming &lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Agreement.&lt;/span&gt;&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ASC 606 requires the Company to allocate the arrangement consideration on a relative standalone selling price basis for each performance obligation after determining the transaction price of the contract and identifying the performance obligations to which that amount should be allocated. The relative standalone selling price is defined in ASC 606 as the price at which an entity would sell a promised good or service separately to a customer. If other observable transactions in which the Company has sold the same performance obligation separately are not available, the Company is required to estimate the standalone selling price of each performance obligation. Key assumptions to determine the standalone selling price may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Whenever the Company determines that a contract should be accounted for as a combined performance obligation, which is recognized over time, it will utilize the&#160;cost-to-cost&#160;input method. Revenue will be recognized over time using the&#160;cost-to-cost&#160;input method, based on the total estimated costs to fulfill the obligations. The Company will recognize revenue as services are delivered. Significant management judgment is required in determining the estimate of total costs required under an arrangement and the period over which the Company is expected to complete its performance obligations under an arrangement.&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Consideration that does not meet the requirements to satisfy the above revenue recognition criteria is a contract liability and is recorded as deferred revenue in the consolidated balance sheets. Short-term deferred revenue consists of amounts that are expected to be recognized as revenue in the next 12 months. Amounts that the Company expects will not be recognized within the next 12 months are classified as long-term deferred revenue.&lt;/span&gt;&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied, either at a point in time or over time. In particular, for the Company&#x2019;s collaborations with Pharming, revenue attributable to research services is recognized as those services are provided, based on the costs incurred to date.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Net loss per share &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic net loss per share is computed by dividing the net loss by the weighted average number of ordinary shares outstanding for the period. Diluted net loss is computed by adjusting net loss based on the potential impact of dilutive securities. Diluted net loss per share is computed by dividing the diluted net loss by the weighted average number of ordinary shares outstanding for the period, including potential dilutive ordinary shares. For purpose of this calculation, outstanding options and unvested restricted shares are considered potential dilutive ordinary shares. Since the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share for all periods as the inclusion of all potential ordinary share equivalents outstanding would have been anti-dilutive. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following securities, presented based on amounts outstanding at each period end, are considered to be ordinary share equivalents, but were not included in the computation of diluted net loss per ordinary share because to do so would have been anti-dilutive: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Share options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,042,781&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,071,555&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested shares from share plan and consulting agreement&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;512,908&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;816,316&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,555,689&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,887,871&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Recent accounting pronouncements&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;span style="color:#000000;"&gt;In November 2021, the FASB issued ASU No. 2020-10,&#160;&lt;/span&gt;&lt;span style="font-style:italic;color:#000000;"&gt;Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance&lt;/span&gt;&lt;span style="color:#000000;"&gt;, which requires increased transparency in the disclosures about government assistant in the notes to the financial statements. This ASU is effective for the Company beginning January 1, 2022, and interim periods within that year, with early adoption permitted. The Company does not expect this amendment to have a significant effect on its financial statement disclosures. &lt;/span&gt;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="C_0001748907_20210101_20211231" id="F_000315">
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Principles of consolidation&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="C_0001748907_20210101_20211231" id="F_000316">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Use of estimates &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual for research and development expenses, the research and development tax credit receivable, share-based compensation, collaboration agreement milestones, operating lease assets and liabilities, and income taxes. Estimates are periodically reviewed in light of changes in circumstances, facts and experience.&lt;span style="Background-color:#FFFFFF;"&gt; Actual results could differ from the Company&#x2019;s estimates.&lt;/span&gt;&#160;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="C_0001748907_20210101_20211231" id="F_000317">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Concentration of credit risk &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has no significant off-balance sheet risk, such as foreign currency contracts, options contracts, or other foreign hedging arrangements. Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents, marketable securities, and receivables. The Company maintains deposits in accredited financial institutions in excess of federally insured limits. The Company deposits its cash in financial institutions that it believes have high credit quality and has not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships or entities for which it has a receivable. &lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk contextRef="C_0001748907_20210101_20211231" id="F_000384">The Company has no significant off-balance sheet risk, such as foreign currency contracts, options contracts, or other foreign hedging arrangements.</us-gaap:ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="C_0001748907_20210101_20211231" id="F_000318">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Foreign currency&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The financial statements of the Company&#x2019;s subsidiaries with functional currencies other than the U.S. Dollar are translated into U.S. Dollars using period-end exchange rates for assets and liabilities, historical exchange rates for shareholders&#x2019; equity and weighted average exchange rates for operating results. Translation gains and losses are included in accumulated other comprehensive income (loss) in shareholders&#x2019; equity. Foreign currency transaction gains and losses are included in other income (expense), net in the results of operations.&lt;/span&gt;&lt;span style="color:#000000;"&gt;  The Company recorded realized and unrealized foreign currency transaction losses of $1.2 million, and gains of $3.4 million for the years ended December 31, 2021, and 2020, respectively, which is included in other income (expense) in the statements of operations and comprehensive loss. &lt;/span&gt;&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="C_0001748907_20210101_20211231"
      decimals="-5"
      id="F_000385"
      unitRef="U_iso4217USD">-1200000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="C_0001748907_20200101_20201231"
      decimals="-5"
      id="F_000386"
      unitRef="U_iso4217USD">3400000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="C_0001748907_20210101_20211231" id="F_000319">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Segment information&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The Company operates in a single segment, focusing on researching, developing and commercializing potentially curative gene therapies.&#160;&#160;Consistent with its operational structure, its chief operating decision maker manages and allocates resources at a global, consolidated level. Therefore, results of the Company's operations are reported on a consolidated basis for purposes of segment reporting.&#160;&#160;All material long-lived assets of the Company reside in the United States or United Kingdom. The Company had property and equipment of $3.6 million and $1.2 million located in the United Kingdom and United States, respectively, as of December 31, 2021. &lt;/span&gt;The Company had property and equipment of $3.7 million and $1.1 million located in the United Kingdom and United States, respectively, as of December 31, 2020.&#160;The Company had right-of-use assets in the United States and United Kingdom and European Union of $12.5 million and $11.8 million, respectively, as of December 31, 2021. The Company had right-of-use assets in the United States and United Kingdom and European Union of $14.2 million and $15.6 million, respectively, as of December 31, 2020.&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001748907_srtStatementGeographicalAxis_countryGB_20211231"
      decimals="-5"
      id="F_000387"
      unitRef="U_iso4217USD">3600000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001748907_srtStatementGeographicalAxis_countryUS_20211231"
      decimals="-5"
      id="F_000389"
      unitRef="U_iso4217USD">1200000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001748907_srtStatementGeographicalAxis_countryGB_20201231"
      decimals="-5"
      id="F_000388"
      unitRef="U_iso4217USD">3700000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001748907_srtStatementGeographicalAxis_countryUS_20201231"
      decimals="-5"
      id="F_000390"
      unitRef="U_iso4217USD">1100000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0001748907_srtStatementGeographicalAxis_countryUS_20211231"
      decimals="-5"
      id="F_000391"
      unitRef="U_iso4217USD">12500000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0001748907_srtStatementGeographicalAxis_ortxGBAndEuropeanUnionMember_20211231"
      decimals="-5"
      id="F_000393"
      unitRef="U_iso4217USD">11800000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0001748907_srtStatementGeographicalAxis_countryUS_20201231"
      decimals="-5"
      id="F_000392"
      unitRef="U_iso4217USD">14200000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0001748907_srtStatementGeographicalAxis_ortxGBAndEuropeanUnionMember_20201231"
      decimals="-5"
      id="F_000394"
      unitRef="U_iso4217USD">15600000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="C_0001748907_20210101_20211231" id="F_000320">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Cash equivalents &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company considers all highly liquid investments purchased with original maturities of 90 days or less at the date of acquisition to be cash equivalents. &lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:MarketableSecuritiesPolicy contextRef="C_0001748907_20210101_20211231" id="F_000321">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Marketable securities&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Marketable securities consist of investments with original maturities greater than ninety days at the date of acquisition. The Company has classified its investments with maturities beyond one year as short term, based on their highly liquid nature and because such marketable securities represent the investment of cash that is available for current operations. The Company considers its investment portfolio of investments as&#160;available-for-sale.&#160;Accordingly, these investments are recorded at fair value, which is based on quoted market prices or other observable inputs. Unrealized gains and losses are recorded as a component of other comprehensive income (loss). Realized gains and losses are determined on a specific identification basis and are included in other income (loss). Amortization and accretion of discounts and premiums is also recorded in other income (loss).&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;When the fair value is below the amortized cost of the asset an estimate of expected credit losses is made, the estimate is limited to the amount by which fair value is less than amortized cost. The credit-related impairment amount is recognized in the consolidated statements of operations; the remaining impairment amount and unrealized gains are reported as a component of accumulated other comprehensive income (loss) in shareholders&#x2019; equity. Credit losses are recognized through the use of an allowance for credit losses account and subsequent improvements in expected credit losses are recognized as a reversal of the allowance account. If the Company has the intent to sell the security or it is more likely than not that the Company will be required to sell the security prior to recovery of its amortized cost basis the allowance for credit loss is written off and the excess of the amortized cost basis of the asset over its fair value is recorded in the consolidated statements of operation.&lt;/span&gt;&lt;/p&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="C_0001748907_20210101_20211231" id="F_000322">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Restricted cash and construction deposits&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents that are restricted as to withdrawal or use under the terms of certain contractual agreements are recorded as restricted cash on our consolidated balance sheet. The Company has an outstanding letter of credit for $3.0 million associated with a lease, and is required to hold this amount in a standalone bank account at December 31, 2021 and 2020. The Company is also contractually required to maintain a cash collateral account associated with corporate credit cards and other leases in the amount of &lt;span&gt;$1.3&lt;/span&gt; million at December 31, 2021 and 2020. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company includes the restricted cash balance in cash and cash equivalents when reconciling beginning-of-period and end-of-period total amounts shown on the consolidated statements of cash flows. The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported in the consolidated balance sheet that sum to the total of the amounts reported in the consolidated statement of cash flows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;55,912&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;55,135&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,266&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,266&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total cash, cash equivalents and restricted cash shown in the statement of&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; cash flows&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;60,178&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;59,401&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company also has &lt;span style="color:#000000;"&gt;$7.9 million in an escrow account associated with the construction of the Company&#x2019;s leased facility in Fremont, California, which the Company has ceased construction and build-out, and has subleased the facility to a third-party who intends to perform construction and build-out of the facility. &lt;/span&gt;Subject to the terms of the lease and reduction provisions, this escrow amount may be decreased to nil over time upon qualifying construction expenditures, or will be returned in late 2022 to the extent funds are not used. The Company deposited $10.0 million into the account in the first quarter of 2020 and has received $2.1 million in receipts from the escrow funds for work performed to date. Of the $7.9 million remaining in the escrow account, the entire balance is classified within other prepaid expenses and other current assets on the consolidated balance sheets based on the timing of when the Company expects to receive the cash from the escrow agent.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="C_0001748907_20210101_20211231"
      decimals="-5"
      id="F_000395"
      unitRef="U_iso4217USD">3000000.0</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="C_0001748907_20200101_20201231"
      decimals="-5"
      id="F_000396"
      unitRef="U_iso4217USD">3000000.0</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:CashCollateralForBorrowedSecurities
      contextRef="C_0001748907_20211231"
      decimals="-5"
      id="F_000397"
      unitRef="U_iso4217USD">1300000</us-gaap:CashCollateralForBorrowedSecurities>
    <us-gaap:CashCollateralForBorrowedSecurities
      contextRef="C_0001748907_20201231"
      decimals="-5"
      id="F_000398"
      unitRef="U_iso4217USD">1300000</us-gaap:CashCollateralForBorrowedSecurities>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock contextRef="C_0001748907_20210101_20211231" id="F_000339">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported in the consolidated balance sheet that sum to the total of the amounts reported in the consolidated statement of cash flows:
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;55,912&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;55,135&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,266&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,266&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total cash, cash equivalents and restricted cash shown in the statement of&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; cash flows&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;60,178&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;59,401&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000399"
      unitRef="U_iso4217USD">55912000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000400"
      unitRef="U_iso4217USD">55135000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000401"
      unitRef="U_iso4217USD">4266000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000402"
      unitRef="U_iso4217USD">4266000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000403"
      unitRef="U_iso4217USD">60178000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000404"
      unitRef="U_iso4217USD">59401000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EscrowDeposit
      contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxFremontLeaseAgreementMember_20211231"
      decimals="-5"
      id="F_000405"
      unitRef="U_iso4217USD">7900000</us-gaap:EscrowDeposit>
    <us-gaap:EscrowDeposit
      contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxFremontLeaseAgreementMember_20200331"
      decimals="-5"
      id="F_000406"
      unitRef="U_iso4217USD">10000000.0</us-gaap:EscrowDeposit>
    <ortx:IncreaseDecreaseInEscrowDeposit
      contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxFremontLeaseAgreementMember_20210101_20211231"
      decimals="-5"
      id="F_000407"
      unitRef="U_iso4217USD">2100000</ortx:IncreaseDecreaseInEscrowDeposit>
    <us-gaap:EscrowDeposit
      contextRef="C_0001748907_us-gaapBalanceSheetLocationAxis_us-gaapPrepaidExpensesAndOtherCurrentAssetsMember_us-gaapLeaseContractualTermAxis_ortxFremontLeaseAgreementMember_20211231"
      decimals="-5"
      id="F_000408"
      unitRef="U_iso4217USD">7900000</us-gaap:EscrowDeposit>
    <us-gaap:InventoryPolicyTextBlock contextRef="C_0001748907_20210101_20211231" id="F_000323">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Inventory&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inventory is stated at the lower of cost or estimated net realizable value with cost determined on a first-in, first-out basis. Inventory costs include raw materials, third-party contract manufacturing, third-party packaging services, and freight. Raw and intermediate materials that may be utilized for either research and development or commercial purposes are classified as inventory. Amounts in inventory that are used for research and development purposes are charged to research and development expense when the product enters the research and development process and can no longer be used for commercial purposes and, therefore, does not have an &#x201c;alternative future use&#x201d; as defined in authoritative guidance. The Company performs an assessment of the recoverability of capitalized inventory during each reporting period and, if needed, writes down any excess and obsolete inventory to its estimated net realizable value in the period it is identified. If they occur, such impairment charges are recorded as a component of cost of goods sold in the consolidated statements of operations and comprehensive income (loss). Inventory is included in prepaid expenses and other current assets on the consolidated balance sheets and the amount was not significant as of December&#160;31, 2021.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prior to the initial date that regulatory approval is received, costs related to the production of inventory are recorded as research and development expense on the Company&#x2019;s consolidated statements of operations and comprehensive income (loss) in the period incurred. In connection with the acquisition of Strimvelis in April 2018, and with the EMA approval of Libmeldy in December 2020, the Company subsequently began capitalizing inventory manufactured or purchased after these dates.&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="C_0001748907_20210101_20211231" id="F_000324">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Intangible assets, net&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Intangible assets, net consist milestones associated with the Company&#x2019;s approved products, net of accumulated amortization. The Company amortizes its intangible assets using the straight-line method over their estimated economic lives and periodically reviews for impairment. The Company has not recognized any impairment charges related to intangible assets to date.&lt;/span&gt;&lt;/p&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="C_0001748907_20210101_20211231" id="F_000325">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Property and equipment &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment are recorded at cost and depreciated or amortized using the straight-line method over the following estimated useful lives. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated useful&#160;&#160;life&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lab equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5-10 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shorter of lease term or estimated useful life&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Office and computer equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3-5 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Repairs and maintenance expenditures, which are not considered improvements and do not extend the useful life of property and equipment, are expensed as incurred. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts, and any resulting gain or loss is included in the consolidated statements of operations and other comprehensive loss. &lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <ortx:PropertyPlantAndEquipmentUsefulLifeTableTextBlock contextRef="C_0001748907_20210101_20211231" id="F_000340">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment are recorded at cost and depreciated or amortized using the straight-line method over the following estimated useful lives. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated useful&#160;&#160;life&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lab equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5-10 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shorter of lease term or estimated useful life&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Office and computer equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3-5 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</ortx:PropertyPlantAndEquipmentUsefulLifeTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives
      contextRef="C_0001748907_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20210101_20211231"
      id="F_000411">Shorter of lease term or estimated useful life</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0001748907_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20210101_20211231"
      id="F_000412">P4Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="C_0001748907_20210101_20211231" id="F_000326">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Impairment of long-lived assets &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Long-lived assets consist of property and equipment and operating lease right-of-use assets. Long-lived assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;economic trends and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset group for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset group to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of an asset group are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset group over its fair value, as determined in accordance with the related accounting literature&lt;/span&gt;&lt;span style="color:#000000;"&gt;. &lt;/span&gt;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="C_0001748907_20210101_20211231" id="F_000327">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Research and development costs &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including salaries, share-based compensation and benefits, facilities costs, depreciation, third-party license fees, certain milestone payments, and external costs of outside vendors engaged to conduct clinical development activities and clinical trials, the purchase of in-process research and development assets, as well as costs to develop a manufacturing process, perform analytical testing and manufacture clinical trial materials. Non-refundable prepayments for goods or services that will be used or rendered for future research and development activities are recorded as prepaid expenses. Such amounts are recognized as an expense as the goods are delivered or the related services are performed, or until it is no longer expected that the goods will be delivered, or the services rendered. In addition, funding from research grants is recognized as an offset to research and development expense on the basis of costs incurred on the research program. Royalties to third parties associated with our research grants will be accrued when they become probable.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <ortx:ResearchContractCostsAndAccrualsPolicyTextBlock contextRef="C_0001748907_20210101_20211231" id="F_000328">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Research contract costs and accruals &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has entered into various research and development contracts. These agreements are cancelable, and related costs are recorded as research and development expenses as incurred. When billing terms under these contracts do not coincide with the timing of when the work is performed, the Company is required to make estimates of outstanding obligations as of period end to those third parties. Any accrual estimates are based on a number of factors, including the Company&#x2019;s knowledge of the progress towards completion of the research and development activities, invoicing to date under the contracts, communication from the research institution or other companies of any actual costs incurred during the period that have not yet been invoiced, and the costs included in the contracts. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the expense. Actual results could differ from the estimates made by the Company. The historical accrual estimates made by the Company have not been materially different from the actual costs.&lt;/p&gt;</ortx:ResearchContractCostsAndAccrualsPolicyTextBlock>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="C_0001748907_20210101_20211231" id="F_000329">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Share-based compensation &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company measures share-based awards granted to employees, consultants and directors based on the fair value of the shares and options on the date of the grant and recognizes compensation expense for those awards over the requisite service period, which is the vesting period of the respective award. Forfeitures are accounted for as they occur. &lt;/p&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="C_0001748907_20210101_20211231" id="F_000330">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Comprehensive loss &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Comprehensive loss is composed of net loss and other comprehensive income (loss). Other comprehensive income (loss) consists of unrealized gains and losses on marketable securities and foreign currency translation gains and losses.&lt;/span&gt;&lt;span style="color:#000000;"&gt; &#160;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="C_0001748907_20210101_20211231" id="F_000331">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Leases&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company determines if an arrangement is a lease at contract inception. Operating lease assets represent a right to use an underlying asset for the lease term and operating lease liabilities represent an obligation to make lease payments arising from the lease. Operating lease liabilities with a term greater than one year and their corresponding right-of-use assets are recognized on the balance sheet at the commencement date of the lease based on the present value of lease payments over the expected lease term. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received. The Company made an accounting policy election to not record a right-of-use asset or lease liability for leases with a term of one year or less. To date, the Company has not identified any material short-term leases, either individually or in the aggregate.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;As&#160;the Company&#x2019;s&#160;leases do not provide an implicit rate,&#160;the Company utilized the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term as the lease an amount equal to the lease payments in a similar economic environment. The Company estimated the incremental borrowing rate based on the &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Company&#x2019;s currently outstanding credit facility as inputs to the analysis to calculate a spread, adjusted for factors that reflect the profile of secured borrowing over the expected term of the lease.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The components of a lease should be split into three categories: lease components (e.g., land, building, etc.), non-lease components (e.g., common area maintenance, utilities, performance of manufacturing services, purchase of inventory, etc.), and non-components (e.g., property taxes, insurance, etc.). Then the fixed contract consideration (including any related to non-components) must be allocated based on fair values to the lease components and non-lease components. Although separation of lease and non-lease components is required, certain accounting policy elections are available to entities. Entities can elect accounting policies that would not separate lease and non-lease components. Rather, they would account for each lease component and the related non-lease&#160;component together as a single component. The Company has elected&#160;not to apply the accounting policy with respect to its lease of manufacturing space at a contract manufacturing organization, the Company has allocated the consideration between the lease and non-lease components of the contract&#160;based on the respective fair values of the lease and non-lease components.&#160;The&#160;Company calculated the fair value of the lease&#160;and non-lease&#160;components&#160;using financial information readily available as part of its master services arrangement&#160;and other representative data&#160;indicative of fair value.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The Company accounts for sublease income on a straight-line basis over the respective lease period and records an unbilled rent receivable for sublease income incurred but not yet paid. The Company periodically performs a collectability assessment associated with any unbilled rent receivables. The Company recognizes the sublease income as a reduction to the related operating expense associated with the head lease.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <ortx:StrimvelisLossProvisionPolicyTextBlock contextRef="C_0001748907_20210101_20211231" id="F_000332">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Strimvelis loss provision&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As part of the GSK transaction, the Company is required to maintain commercial availability of Strimvelis in the European Union until such time that an alternative gene therapy is available (see Note 15). Strimvelis is not currently expected to generate sufficient cash flows to overcome the costs of maintaining the product and certain regulatory commitments; therefore, the Company initially recorded a liability associated with the loss contract of $18.4&#160;million in 2018. The Company recognizes the amortization of the loss provision on a diminishing balance basis based on the actual net loss incurred associated with the Strimvelis program and the expected future net losses to be generated until such time as Strimvelis is no longer commercially available. The amortization of the provision is recorded as a credit to research and development expense. The Company has made an estimate of the expected future losses associated with Strimvelis and will adjust this estimate as facts and circumstances change regarding the commercial availability and costs of maintaining and selling Strimvelis. The Company does not update the accrued loss provision for any subsequent adjustment of the future losses, however, the timing of recognizing the amortization of what was originally recorded is adjusted for the updated future losses. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table below outlines the changes to the Strimvelis loss provision for the periods ended December 31, 2021 and 2020:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.84%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.96%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.84%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at beginning of period&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,482&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,790&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Provisions&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.06%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.06%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortization of loss provision&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.06%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,037&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.06%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,413&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Foreign currency translation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.84%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(26&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.84%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;105&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.22%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at end of period&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.84%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,419&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.84%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,482&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2021, $0.7 million of the Strimvelis loss provision was classified as current, and $2.7 million was classified as non-current. As of December 31, 2020, $0.9 million of the Strimvelis loss provision was classified as current, and $3.6 million was classified as non-current.&lt;/p&gt;</ortx:StrimvelisLossProvisionPolicyTextBlock>
    <us-gaap:ProvisionForLossOnContracts
      contextRef="C_0001748907_20181231"
      decimals="-5"
      id="F_000415"
      unitRef="U_iso4217USD">18400000</us-gaap:ProvisionForLossOnContracts>
    <ortx:ScheduleOfChangesInLossProvisionTableTextBlock contextRef="C_0001748907_20210101_20211231" id="F_000341">The following table below outlines the changes to the Strimvelis loss provision for the periods ended December 31, 2021 and 2020:
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.84%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.96%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.84%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at beginning of period&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,482&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,790&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Provisions&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.06%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.06%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortization of loss provision&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.06%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,037&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.06%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,413&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Foreign currency translation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.84%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(26&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.84%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;105&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.22%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at end of period&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.84%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,419&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.84%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,482&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</ortx:ScheduleOfChangesInLossProvisionTableTextBlock>
    <ortx:AssetAcquisitionLiabilityAssumed
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000416"
      unitRef="U_iso4217USD">4482000</ortx:AssetAcquisitionLiabilityAssumed>
    <ortx:AssetAcquisitionLiabilityAssumed
      contextRef="C_0001748907_20191231"
      decimals="-3"
      id="F_000417"
      unitRef="U_iso4217USD">6790000</ortx:AssetAcquisitionLiabilityAssumed>
    <ortx:AssetAcquisitionLiabilityAmortizationOfLossProvision
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000418"
      unitRef="U_iso4217USD">1037000</ortx:AssetAcquisitionLiabilityAmortizationOfLossProvision>
    <ortx:AssetAcquisitionLiabilityAmortizationOfLossProvision
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000419"
      unitRef="U_iso4217USD">2413000</ortx:AssetAcquisitionLiabilityAmortizationOfLossProvision>
    <ortx:IncreaseDecreaseInAssetAcquisitionLiabilityEffectOfForeignExchangeTranslation
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000420"
      unitRef="U_iso4217USD">-26000</ortx:IncreaseDecreaseInAssetAcquisitionLiabilityEffectOfForeignExchangeTranslation>
    <ortx:IncreaseDecreaseInAssetAcquisitionLiabilityEffectOfForeignExchangeTranslation
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000421"
      unitRef="U_iso4217USD">105000</ortx:IncreaseDecreaseInAssetAcquisitionLiabilityEffectOfForeignExchangeTranslation>
    <ortx:AssetAcquisitionLiabilityAssumed
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000422"
      unitRef="U_iso4217USD">3419000</ortx:AssetAcquisitionLiabilityAssumed>
    <ortx:AssetAcquisitionLiabilityAssumed
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000423"
      unitRef="U_iso4217USD">4482000</ortx:AssetAcquisitionLiabilityAssumed>
    <ortx:AssetAcquisitionLiabilityAssumedCurrent
      contextRef="C_0001748907_20211231"
      decimals="-5"
      id="F_000424"
      unitRef="U_iso4217USD">700000</ortx:AssetAcquisitionLiabilityAssumedCurrent>
    <ortx:AssetAcquisitionLiabilityAssumedNonCurrent
      contextRef="C_0001748907_20211231"
      decimals="-5"
      id="F_000426"
      unitRef="U_iso4217USD">2700000</ortx:AssetAcquisitionLiabilityAssumedNonCurrent>
    <ortx:AssetAcquisitionLiabilityAssumedCurrent
      contextRef="C_0001748907_20201231"
      decimals="-5"
      id="F_000425"
      unitRef="U_iso4217USD">900000</ortx:AssetAcquisitionLiabilityAssumedCurrent>
    <ortx:AssetAcquisitionLiabilityAssumedNonCurrent
      contextRef="C_0001748907_20201231"
      decimals="-5"
      id="F_000427"
      unitRef="U_iso4217USD">3600000</ortx:AssetAcquisitionLiabilityAssumedNonCurrent>
    <ortx:ResearchAndDevelopmentIncomeTaxCreditsPolicyTextBlock contextRef="C_0001748907_20210101_20211231" id="F_000333">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;United Kingdom Research and development income tax credits &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As a company that carries out research and development activities, the Company is able to submit tax credit claims from two UK research and development tax relief programs, the SME program and the RDEC program depending on eligibility. Qualifying expenditures largely comprise employment costs for research staff, consumables and certain internal overhead costs incurred as part of research projects for which the Company does not receive income.&lt;span style="color:#000000;"&gt; &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Each reporting period, management evaluates which tax relief programs the Company is expected to be eligible for and records a reduction to research and development expense for the portion of the expense that it expects to qualify under the &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;programs, that it plans to submit a claim for, and it has reasonable assurance that the amount will ultimately be realized. &lt;/span&gt;&lt;span style="color:#000000;"&gt;Based on criteria established by HM Revenue and Customs (&#x201c;HMRC&#x201d;), management of the Company expects a proportion of expenditures being undertaken in relation to its pipeline research, clinical trials management and manufacturing development activities to be eligible for the research and development tax relief programs for the year ended December 31, 2021. &lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The Company has qualified under the more favorable SME regime for the year ended December 31, 2020 and expects to qualify under the SME regime for the year ending December 31, 2021.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The RDEC and SME credits are not dependent on the Company generating future taxable income or on the ongoing tax status or tax position of the Company. The Company has assessed its research and development activities and expenditures to determine whether the nature of the activities and expenditures will qualify for credit under the tax relief programs and whether the claims will ultimately be realized based on the allowable reimbursable expense criteria established by the UK government which are subject to interpretation. At each period end, the Company estimates the reimbursement available to the Company based on available information at the time.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognizes credits from the research and development incentives when the relevant expenditure has been incurred and there is reasonable assurance that the reimbursement will be received.&#160;Such credits are accounted for as reductions in research and development expense. The following table outlines the changes to the research and development tax credit receivable, including amount recognized as an offset to research and development expense during the years ended December 31, 2021 and 2020:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.98%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.18%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at beginning of period&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,344&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;28,644&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.18%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Recognition of credit claims as offset to research and development expense&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,920&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,130&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.18%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Receipt of credit claims&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(33,771&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.18%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Foreign currency translation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(541&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,341&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.18%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at end of period&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,723&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,344&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;During the year ended December 31, 2020, the Company recorded $4.8&#160;million of additional tax credits related to a change in estimate associated with its UK research and development tax credit receivable claim for fiscal year 2019. The change in estimate was based on the results of a tax credit&#160;analysis&#160;associated with the Company&#x2019;s qualified projects and research and development expenditures completed during the third quarter to finalize the 2019 UK tax return.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2021, the Company&#x2019;s tax credit receivable from the UK was $30.7 million, all of which was classified as current. As of December&#160;31, 2020, the Company&#x2019;s tax incentive receivable from the UK was $17.3 million, all of which was classified as current.&lt;/p&gt;</ortx:ResearchAndDevelopmentIncomeTaxCreditsPolicyTextBlock>
    <us-gaap:SummaryOfTaxCreditCarryforwardsTextBlock contextRef="C_0001748907_20210101_20211231" id="F_000342">The following table outlines the changes to the research and development tax credit receivable, including amount recognized as an offset to research and development expense during the years ended December 31, 2021 and 2020:
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.98%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.18%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at beginning of period&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,344&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;28,644&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.18%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Recognition of credit claims as offset to research and development expense&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,920&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,130&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.18%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Receipt of credit claims&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(33,771&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.18%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Foreign currency translation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(541&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,341&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.18%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at end of period&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,723&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,344&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:SummaryOfTaxCreditCarryforwardsTextBlock>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_0001748907_srtStatementGeographicalAxis_countryGB_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20201231"
      decimals="-3"
      id="F_000428"
      unitRef="U_iso4217USD">17344000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_0001748907_srtStatementGeographicalAxis_countryGB_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20191231"
      decimals="-3"
      id="F_000429"
      unitRef="U_iso4217USD">28644000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:IncomeTaxCreditsAndAdjustments
      contextRef="C_0001748907_srtStatementGeographicalAxis_countryGB_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20211231"
      decimals="-3"
      id="F_000430"
      unitRef="U_iso4217USD">13920000</us-gaap:IncomeTaxCreditsAndAdjustments>
    <us-gaap:IncomeTaxCreditsAndAdjustments
      contextRef="C_0001748907_srtStatementGeographicalAxis_countryGB_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231"
      decimals="-3"
      id="F_000431"
      unitRef="U_iso4217USD">21130000</us-gaap:IncomeTaxCreditsAndAdjustments>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="C_0001748907_srtStatementGeographicalAxis_countryGB_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231"
      decimals="-3"
      id="F_000432"
      unitRef="U_iso4217USD">33771000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="C_0001748907_srtStatementGeographicalAxis_countryGB_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20211231"
      decimals="-3"
      id="F_000433"
      unitRef="U_iso4217USD">-541000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="C_0001748907_srtStatementGeographicalAxis_countryGB_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231"
      decimals="-3"
      id="F_000434"
      unitRef="U_iso4217USD">1341000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_0001748907_srtStatementGeographicalAxis_countryGB_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20211231"
      decimals="-3"
      id="F_000435"
      unitRef="U_iso4217USD">30723000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_0001748907_srtStatementGeographicalAxis_countryGB_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20201231"
      decimals="-3"
      id="F_000436"
      unitRef="U_iso4217USD">17344000</us-gaap:TaxCreditCarryforwardAmount>
    <ortx:AdditionalIncomeTaxCredits
      contextRef="C_0001748907_srtStatementGeographicalAxis_countryGB_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231"
      decimals="-5"
      id="F_000437"
      unitRef="U_iso4217USD">4800000</ortx:AdditionalIncomeTaxCredits>
    <ortx:ResearchAndDevelopmentTaxCreditReceivableCurrent
      contextRef="C_0001748907_srtStatementGeographicalAxis_countryGB_20211231"
      decimals="-5"
      id="F_000439"
      unitRef="U_iso4217USD">30700000</ortx:ResearchAndDevelopmentTaxCreditReceivableCurrent>
    <ortx:ResearchAndDevelopmentTaxCreditReceivable
      contextRef="C_0001748907_srtStatementGeographicalAxis_countryGB_20201231"
      decimals="-5"
      id="F_000438"
      unitRef="U_iso4217USD">17300000</ortx:ResearchAndDevelopmentTaxCreditReceivable>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="C_0001748907_20210101_20211231" id="F_000334">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Income taxes &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is primarily subject to corporation taxes in the United Kingdom and the United States. The calculation of the Company&#x2019;s tax provision involves the application of both United Kingdom and United States tax law and requires judgement and estimates. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for income taxes in accordance with ASC Topic 740, &lt;span style="font-style:italic;"&gt;Accounting for Income Taxes&lt;/span&gt;, which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. The Company determines its deferred tax assets and liabilities based on differences between financial reporting and tax bases of assets and liabilities, which are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are provided if, based upon the weight of available evidence, it is more likely than not that some or all of the net deferred tax assets will not be realized. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for uncertainty in income taxes by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed as the amount of benefit to recognize in the consolidated financial statements. The amount of benefits that may be used is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate, as well as the related net interest and penalties. &lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <ortx:IncrementalPercentageOfTaxableProfits
      contextRef="C_0001748907_srtStatementGeographicalAxis_countryGB_20210101_20211231"
      decimals="2"
      id="F_000440"
      unitRef="U_xbrlipure">0.50</ortx:IncrementalPercentageOfTaxableProfits>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="C_0001748907_20210101_20211231" id="F_000335">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Product sales&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s product sales in 2021 and 2020 consist of sales of Strimvelis, which is distributed exclusively at the San Raffaele Hospital in Milan, Italy. San Raffaele Hospital will purchase and pay for Strimvelis and submit a claim to the payer. The Company&#x2019;s contracted sales with San Raffaele Hospital contain a single performance obligation and the Company recognizes revenue from product sales when the Company has satisfied its performance obligation by transferring control of Strimvelis to San Raffaele Hospital. Control of the product generally transfers upon the completion of the scheduled Strimvelis treatment. The Company&#x2019;s product sales represent total net product sales of Strimvelis. The Company evaluated the variable consideration under Accounting Standards Codification (ASC) 606,&#160;&lt;span style="font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/span&gt;, and there is currently no variable consideration included in the transaction price for Strimvelis. Costs to manufacture and deliver the product and those associated with administering the therapy are included in cost of product sales. As the product is sold in direct relation to a scheduled treatment, the Company estimates that there is limited risk of product return, including the risk of product expiration. During the years ended December 31, 2021 and 2020, the Company has $0.7 and $2.6 million in sales of Strimvelis, respectively.&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001748907_srtProductOrServiceAxis_us-gaapProductMember_20210101_20211231"
      decimals="-5"
      id="F_000441"
      unitRef="U_iso4217USD">700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001748907_srtProductOrServiceAxis_us-gaapProductMember_20200101_20201231"
      decimals="-5"
      id="F_000442"
      unitRef="U_iso4217USD">2600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="C_0001748907_20210101_20211231" id="F_000336">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Collaboration revenue&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The terms of the Company&#x2019;s collaboration agreements may include consideration such as&#160;non-refundable license fees, funding of research and development services, payments due upon the achievement of clinical and preclinical performance-&lt;span style="color:#000000;"&gt;based development milestones, regulatory milestones, manufacturing services, sales-based milestones and royalties on product sales.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company first evaluates collaboration arrangements to determine whether the arrangement (or part of the arrangement) represents a collaborative arrangement pursuant to ASC Topic 808,&#160;&lt;span style="font-style:italic;"&gt;Collaborative Arrangements&lt;/span&gt;, based on the risks and rewards and activities of the parties pursuant to the contractual arrangement. The Company accounts for any collaborative arrangement or elements within the contract that are deemed to be a collaborative arrangement, and not&lt;span style="font-size:12pt;"&gt; &lt;/span&gt;a customer relationship, in accordance with ASC&#160;808. Through December&#160;31, 2021, the Company entered into one agreement with Pharming Group N.V. (the &#x201c;Pharming Agreement&#x201d;, see Note 16) that is accounted for pursuant to ASC 606.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:9pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine the appropriate amount of revenue to be recognized for arrangements determined to be within the scope of ASC&#160;606, the Company performs the following five steps: (i)&#160;identification of the contract(s) with the customer, (ii)&#160;identification of the promised goods or services in the contract and determination of whether the promised goods or services are performance obligations, (iii)&#160;measurement of the transaction price, (iv)&#160;allocation of the transaction price to the performance obligations, and (v)&#160;recognition of revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect consideration it is entitled to in exchange for the goods or services it transfers to the customer.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The Company recognizes the&#160;&lt;/span&gt;transaction&#160;&lt;span style="Background-color:#FFFFFF;"&gt;price allocated to upfront license payments as revenue upon delivery of the license to the customer and resulting ability of the customer to use and benefit from the license, if the license is determined to be distinct from the other performance obligations identified in the contract. If the license is considered to not be distinct from other performance obligations, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied (i)&#160;at a point in time, but only for licenses determined to be distinct from other performance obligations in the contract, or (ii)&#160;over time, and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from license payments. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The Pharming Agreement entitles the Company to additional payments upon the achievement of performance-based milestones. These milestones are generally categorized into three types: development milestones, regulatory milestones, and sales-based milestones.&#160;The Company is also eligible to receive from Pharming tiered royalty payments on worldwide net sales. The Company evaluates whether it is probable that the consideration associated with each milestone will not be subject to a significant reversal in the cumulative amount of revenue recognized. Amounts that meet this threshold are included in the transaction price using the most likely amount method, whereas amounts that do not meet this threshold are considered constrained and excluded from the transaction price until they meet this threshold.&#160;Milestones tied to regulatory approval, and therefore not within the Company&#x2019;s control, are considered constrained until such approval is received. Upfront and ongoing development milestones per the collaboration agreements are not subject to refund if the development activities are not successful. At the end of each subsequent reporting period, the Company&#160;&lt;/span&gt;re-evaluates&lt;span style="Background-color:#FFFFFF;"&gt;&#160;the probability of a significant reversal of the cumulative revenue recognized for the milestones, and, if necessary, adjusts the estimate of the overall transaction price. Any such adjustments are recorded on a cumulative&#160;&lt;/span&gt;catch-up &lt;span style="Background-color:#FFFFFF;"&gt;basis, which would affect revenues from collaborators in &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;the period of adjustment. The Company may enter into an agreement that includes sales-based milestone payments and royalties in exchange for a license of intellectual property. The Company considers the underlying facts and circumstances of these agreements, noting whether the future payments are contingent upon future sales and whether they are dependent on a third party&#x2019;s ability to successfully commercialize a product using the licensed intellectual property. The Company also considers whether the license is the only, or predominant, item to which the milestone payments and royalties relate. If the Company concludes the license is the predominant item in the agreement, therefore the primary driver of value, the Company excludes sales-based milestone payments and royalties from the transaction price until the sale occurs (or, if later, until the underlying performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied). Currently, the Company has not recognized any royalty revenue resulting from the &lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Pharming &lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Agreement.&lt;/span&gt;&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ASC 606 requires the Company to allocate the arrangement consideration on a relative standalone selling price basis for each performance obligation after determining the transaction price of the contract and identifying the performance obligations to which that amount should be allocated. The relative standalone selling price is defined in ASC 606 as the price at which an entity would sell a promised good or service separately to a customer. If other observable transactions in which the Company has sold the same performance obligation separately are not available, the Company is required to estimate the standalone selling price of each performance obligation. Key assumptions to determine the standalone selling price may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Whenever the Company determines that a contract should be accounted for as a combined performance obligation, which is recognized over time, it will utilize the&#160;cost-to-cost&#160;input method. Revenue will be recognized over time using the&#160;cost-to-cost&#160;input method, based on the total estimated costs to fulfill the obligations. The Company will recognize revenue as services are delivered. Significant management judgment is required in determining the estimate of total costs required under an arrangement and the period over which the Company is expected to complete its performance obligations under an arrangement.&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Consideration that does not meet the requirements to satisfy the above revenue recognition criteria is a contract liability and is recorded as deferred revenue in the consolidated balance sheets. Short-term deferred revenue consists of amounts that are expected to be recognized as revenue in the next 12 months. Amounts that the Company expects will not be recognized within the next 12 months are classified as long-term deferred revenue.&lt;/span&gt;&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied, either at a point in time or over time. In particular, for the Company&#x2019;s collaborations with Pharming, revenue attributable to research services is recognized as those services are provided, based on the costs incurred to date.&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="C_0001748907_20210101_20211231" id="F_000337">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Net loss per share &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic net loss per share is computed by dividing the net loss by the weighted average number of ordinary shares outstanding for the period. Diluted net loss is computed by adjusting net loss based on the potential impact of dilutive securities. Diluted net loss per share is computed by dividing the diluted net loss by the weighted average number of ordinary shares outstanding for the period, including potential dilutive ordinary shares. For purpose of this calculation, outstanding options and unvested restricted shares are considered potential dilutive ordinary shares. Since the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share for all periods as the inclusion of all potential ordinary share equivalents outstanding would have been anti-dilutive. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following securities, presented based on amounts outstanding at each period end, are considered to be ordinary share equivalents, but were not included in the computation of diluted net loss per ordinary share because to do so would have been anti-dilutive: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Share options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,042,781&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,071,555&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested shares from share plan and consulting agreement&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;512,908&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;816,316&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,555,689&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,887,871&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="C_0001748907_20210101_20211231" id="F_000343">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following securities, presented based on amounts outstanding at each period end, are considered to be ordinary share equivalents, but were not included in the computation of diluted net loss per ordinary share because to do so would have been anti-dilutive: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Share options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,042,781&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,071,555&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested shares from share plan and consulting agreement&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;512,908&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;816,316&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,555,689&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,887,871&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001748907_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20211231"
      decimals="INF"
      id="F_000443"
      unitRef="U_xbrlishares">14042781</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001748907_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231"
      decimals="INF"
      id="F_000444"
      unitRef="U_xbrlishares">11071555</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001748907_us-gaapAwardTypeAxis_ortxUnvestedSharesFromSharePlanAndConsultingAgreementMember_20210101_20211231"
      decimals="INF"
      id="F_000445"
      unitRef="U_xbrlishares">512908</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001748907_us-gaapAwardTypeAxis_ortxUnvestedSharesFromSharePlanAndConsultingAgreementMember_20200101_20201231"
      decimals="INF"
      id="F_000446"
      unitRef="U_xbrlishares">816316</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001748907_20210101_20211231"
      decimals="INF"
      id="F_000447"
      unitRef="U_xbrlishares">14555689</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001748907_20200101_20201231"
      decimals="INF"
      id="F_000448"
      unitRef="U_xbrlishares">11887871</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="C_0001748907_20210101_20211231" id="F_000338">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Recent accounting pronouncements&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;span style="color:#000000;"&gt;In November 2021, the FASB issued ASU No. 2020-10,&#160;&lt;/span&gt;&lt;span style="font-style:italic;color:#000000;"&gt;Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance&lt;/span&gt;&lt;span style="color:#000000;"&gt;, which requires increased transparency in the disclosures about government assistant in the notes to the financial statements. This ASU is effective for the Company beginning January 1, 2022, and interim periods within that year, with early adoption permitted. The Company does not expect this amendment to have a significant effect on its financial statement disclosures. &lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementOrChangeInAccountingPrincipleDescription contextRef="C_0001748907_20210101_20211231" id="F_000451">ASU No. 2020-10</us-gaap:NewAccountingPronouncementOrChangeInAccountingPrincipleDescription>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate contextRef="C_0001748907_20211231" id="F_000450">2022-01-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="C_0001748907_20210101_20211231" id="F_000296">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;3. Fair Value Measurements and Marketable Securities&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following tables present information about the Company&#x2019;s financial assets that have been measured at fair value as of December 31, 2021 and 2020, and indicate the fair value of the hierarchy of the valuation inputs utilized to determine such fair value. In general, fair values determined by Level&#160;1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Fair value determined by Level&#160;2 inputs utilize observable inputs other than Level&#160;1 prices, such as quoted prices for similar assets or liabilities, quoted market prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities. Fair values determined by Level&#160;3 inputs are unobservable data points for the asset or liability, and include situations where there is little, if any, market activity for the asset or liability. During the years ended December 31, 2021 and 2020, there were no transfers between Level&#160;1 and Level&#160;2 financial assets.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the Company&#x2019;s cash equivalents and marketable securities as of December 31, 2021:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value Measurements as of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2021 Using:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,085&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,085&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate bonds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,321&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,321&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,198&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,198&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,085&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,519&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;41,604&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Marketable securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate bonds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;94,794&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;94,794&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;69,401&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;69,401&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total marketable securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;164,195&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;164,195&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,085&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;184,714&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;205,799&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the Company&#x2019;s cash equivalents and marketable securities as of December 31, 2020:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value Measurements as of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2020 Using:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,650&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,650&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,001&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,001&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,999&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,999&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,650&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,650&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Marketable securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;US government securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,997&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,997&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate bonds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;93,358&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;93,358&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;40,458&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;40,458&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total marketable securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;136,813&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;136,813&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,650&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;142,813&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;149,463&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The carrying amount reflected in the consolidated balance sheets for research and development tax incentive receivable, trade receivables, other receivables, accounts payable, and accrued expenses approximate fair value due to their short-term maturities. The carrying value of the Company&#x2019;s outstanding notes payable approximates fair value (a Level 2 fair value measurement), reflecting interest rates currently available to the Company.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Marketable Securities&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the Company&#x2019;s cash equivalents and marketable securities as of December 31, 2021:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="18" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.3%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value Measurements as of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2021 Using:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Credit Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.58%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate bonds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.12%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;102,224&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.12%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.12%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(109&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.36%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.12%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;102,115&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.58%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;82,657&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(58&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;82,599&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.58%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;184,881&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(167&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;184,714&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the Company&#x2019;s cash equivalents and marketable securities as of December 31, 2020:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="18" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.36%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value Measurements as of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2020 Using:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Credit Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.54%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,996&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.54%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate bonds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;96,259&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;133&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(32&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;96,360&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.54%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;43,469&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(13&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;43,457&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.54%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;142,728&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;134&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(49&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;142,813&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the Company&#x2019;s available-for-sale marketable debt securities by contractual maturity, as of December 31, 2021 and 2020:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.2%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Maturities in one year or less&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;172,575&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;132,056&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.2%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Maturities between one and three years&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,139&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,757&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.2%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;184,714&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;142,813&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000453"
      unitRef="U_iso4217USD">0</us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount>
    <us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000455"
      unitRef="U_iso4217USD">0</us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount>
    <us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000452"
      unitRef="U_iso4217USD">0</us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount>
    <us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000454"
      unitRef="U_iso4217USD">0</us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock contextRef="C_0001748907_20210101_20211231" id="F_000344">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the Company&#x2019;s cash equivalents and marketable securities as of December 31, 2021:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value Measurements as of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2021 Using:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,085&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,085&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate bonds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,321&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,321&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,198&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,198&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,085&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,519&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;41,604&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Marketable securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate bonds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;94,794&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;94,794&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;69,401&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;69,401&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total marketable securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;164,195&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;164,195&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,085&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;184,714&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;205,799&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the Company&#x2019;s cash equivalents and marketable securities as of December 31, 2020:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value Measurements as of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2020 Using:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,650&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,650&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,001&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,001&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,999&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,999&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,650&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,650&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Marketable securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;US government securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,997&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,997&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate bonds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;93,358&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;93,358&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;40,458&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;40,458&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total marketable securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;136,813&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;136,813&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,650&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;142,813&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;149,463&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20211231"
      decimals="-3"
      id="F_000456"
      unitRef="U_iso4217USD">21085000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_20211231"
      decimals="-3"
      id="F_000457"
      unitRef="U_iso4217USD">21085000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20211231"
      decimals="-3"
      id="F_000458"
      unitRef="U_iso4217USD">7321000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_20211231"
      decimals="-3"
      id="F_000459"
      unitRef="U_iso4217USD">7321000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapCommercialPaperMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20211231"
      decimals="-3"
      id="F_000460"
      unitRef="U_iso4217USD">13198000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapCommercialPaperMember_20211231"
      decimals="-3"
      id="F_000461"
      unitRef="U_iso4217USD">13198000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_0001748907_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20211231"
      decimals="-3"
      id="F_000462"
      unitRef="U_iso4217USD">21085000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_0001748907_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20211231"
      decimals="-3"
      id="F_000463"
      unitRef="U_iso4217USD">20519000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000464"
      unitRef="U_iso4217USD">41604000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <ortx:MarketableSecuritiesFairValueDisclosure
      contextRef="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20211231"
      decimals="-3"
      id="F_000465"
      unitRef="U_iso4217USD">94794000</ortx:MarketableSecuritiesFairValueDisclosure>
    <ortx:MarketableSecuritiesFairValueDisclosure
      contextRef="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_20211231"
      decimals="-3"
      id="F_000466"
      unitRef="U_iso4217USD">94794000</ortx:MarketableSecuritiesFairValueDisclosure>
    <ortx:MarketableSecuritiesFairValueDisclosure
      contextRef="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapCommercialPaperMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20211231"
      decimals="-3"
      id="F_000467"
      unitRef="U_iso4217USD">69401000</ortx:MarketableSecuritiesFairValueDisclosure>
    <ortx:MarketableSecuritiesFairValueDisclosure
      contextRef="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapCommercialPaperMember_20211231"
      decimals="-3"
      id="F_000468"
      unitRef="U_iso4217USD">69401000</ortx:MarketableSecuritiesFairValueDisclosure>
    <ortx:MarketableSecuritiesFairValueDisclosure
      contextRef="C_0001748907_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20211231"
      decimals="-3"
      id="F_000469"
      unitRef="U_iso4217USD">164195000</ortx:MarketableSecuritiesFairValueDisclosure>
    <ortx:MarketableSecuritiesFairValueDisclosure
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000470"
      unitRef="U_iso4217USD">164195000</ortx:MarketableSecuritiesFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001748907_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20211231"
      decimals="-3"
      id="F_000471"
      unitRef="U_iso4217USD">21085000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001748907_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20211231"
      decimals="-3"
      id="F_000472"
      unitRef="U_iso4217USD">184714000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000473"
      unitRef="U_iso4217USD">205799000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20201231"
      decimals="-3"
      id="F_000474"
      unitRef="U_iso4217USD">6650000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_20201231"
      decimals="-3"
      id="F_000475"
      unitRef="U_iso4217USD">6650000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapUSTreasuryAndGovernmentMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231"
      decimals="-3"
      id="F_000476"
      unitRef="U_iso4217USD">3001000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapUSTreasuryAndGovernmentMember_20201231"
      decimals="-3"
      id="F_000477"
      unitRef="U_iso4217USD">3001000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapCommercialPaperMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231"
      decimals="-3"
      id="F_000478"
      unitRef="U_iso4217USD">2999000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapCommercialPaperMember_20201231"
      decimals="-3"
      id="F_000479"
      unitRef="U_iso4217USD">2999000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_0001748907_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20201231"
      decimals="-3"
      id="F_000480"
      unitRef="U_iso4217USD">6650000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_0001748907_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231"
      decimals="-3"
      id="F_000481"
      unitRef="U_iso4217USD">6000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000482"
      unitRef="U_iso4217USD">12650000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <ortx:MarketableSecuritiesFairValueDisclosure
      contextRef="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapUSTreasuryAndGovernmentMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231"
      decimals="-3"
      id="F_000483"
      unitRef="U_iso4217USD">2997000</ortx:MarketableSecuritiesFairValueDisclosure>
    <ortx:MarketableSecuritiesFairValueDisclosure
      contextRef="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapUSTreasuryAndGovernmentMember_20201231"
      decimals="-3"
      id="F_000484"
      unitRef="U_iso4217USD">2997000</ortx:MarketableSecuritiesFairValueDisclosure>
    <ortx:MarketableSecuritiesFairValueDisclosure
      contextRef="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231"
      decimals="-3"
      id="F_000485"
      unitRef="U_iso4217USD">93358000</ortx:MarketableSecuritiesFairValueDisclosure>
    <ortx:MarketableSecuritiesFairValueDisclosure
      contextRef="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_20201231"
      decimals="-3"
      id="F_000486"
      unitRef="U_iso4217USD">93358000</ortx:MarketableSecuritiesFairValueDisclosure>
    <ortx:MarketableSecuritiesFairValueDisclosure
      contextRef="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapCommercialPaperMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231"
      decimals="-3"
      id="F_000487"
      unitRef="U_iso4217USD">40458000</ortx:MarketableSecuritiesFairValueDisclosure>
    <ortx:MarketableSecuritiesFairValueDisclosure
      contextRef="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapCommercialPaperMember_20201231"
      decimals="-3"
      id="F_000488"
      unitRef="U_iso4217USD">40458000</ortx:MarketableSecuritiesFairValueDisclosure>
    <ortx:MarketableSecuritiesFairValueDisclosure
      contextRef="C_0001748907_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231"
      decimals="-3"
      id="F_000489"
      unitRef="U_iso4217USD">136813000</ortx:MarketableSecuritiesFairValueDisclosure>
    <ortx:MarketableSecuritiesFairValueDisclosure
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000490"
      unitRef="U_iso4217USD">136813000</ortx:MarketableSecuritiesFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001748907_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20201231"
      decimals="-3"
      id="F_000491"
      unitRef="U_iso4217USD">6650000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001748907_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231"
      decimals="-3"
      id="F_000492"
      unitRef="U_iso4217USD">142813000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000493"
      unitRef="U_iso4217USD">149463000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock contextRef="C_0001748907_20210101_20211231" id="F_000345">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the Company&#x2019;s cash equivalents and marketable securities as of December 31, 2021:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="18" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.3%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value Measurements as of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2021 Using:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Credit Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.58%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate bonds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.12%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;102,224&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.12%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.12%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(109&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.36%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.12%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;102,115&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.58%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;82,657&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(58&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;82,599&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.58%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;184,881&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(167&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;184,714&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the Company&#x2019;s cash equivalents and marketable securities as of December 31, 2020:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="18" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.36%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value Measurements as of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2020 Using:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Credit Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.54%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,996&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.54%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate bonds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;96,259&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;133&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(32&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;96,360&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.54%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;43,469&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(13&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;43,457&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.54%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;142,728&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;134&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(49&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;142,813&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20211231"
      decimals="-3"
      id="F_000494"
      unitRef="U_iso4217USD">102224000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20211231"
      decimals="-3"
      id="F_000497"
      unitRef="U_iso4217USD">109000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20211231"
      decimals="-3"
      id="F_000500"
      unitRef="U_iso4217USD">102115000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapCommercialPaperMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20211231"
      decimals="-3"
      id="F_000495"
      unitRef="U_iso4217USD">82657000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapCommercialPaperMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20211231"
      decimals="-3"
      id="F_000498"
      unitRef="U_iso4217USD">58000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapCommercialPaperMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20211231"
      decimals="-3"
      id="F_000501"
      unitRef="U_iso4217USD">82599000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001748907_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20211231"
      decimals="-3"
      id="F_000496"
      unitRef="U_iso4217USD">184881000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0001748907_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20211231"
      decimals="-3"
      id="F_000499"
      unitRef="U_iso4217USD">167000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001748907_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20211231"
      decimals="-3"
      id="F_000502"
      unitRef="U_iso4217USD">184714000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapUSTreasuryAndGovernmentMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231"
      decimals="-3"
      id="F_000503"
      unitRef="U_iso4217USD">3000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapUSTreasuryAndGovernmentMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231"
      decimals="-3"
      id="F_000510"
      unitRef="U_iso4217USD">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapUSTreasuryAndGovernmentMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231"
      decimals="-3"
      id="F_000514"
      unitRef="U_iso4217USD">2996000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231"
      decimals="-3"
      id="F_000504"
      unitRef="U_iso4217USD">96259000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231"
      decimals="-3"
      id="F_000507"
      unitRef="U_iso4217USD">133000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231"
      decimals="-3"
      id="F_000511"
      unitRef="U_iso4217USD">32000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231"
      decimals="-3"
      id="F_000515"
      unitRef="U_iso4217USD">96360000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapCommercialPaperMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231"
      decimals="-3"
      id="F_000505"
      unitRef="U_iso4217USD">43469000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapCommercialPaperMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231"
      decimals="-3"
      id="F_000508"
      unitRef="U_iso4217USD">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapCommercialPaperMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231"
      decimals="-3"
      id="F_000512"
      unitRef="U_iso4217USD">13000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001748907_us-gaapFairValueByAssetClassAxis_us-gaapCommercialPaperMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231"
      decimals="-3"
      id="F_000516"
      unitRef="U_iso4217USD">43457000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001748907_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231"
      decimals="-3"
      id="F_000506"
      unitRef="U_iso4217USD">142728000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001748907_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231"
      decimals="-3"
      id="F_000509"
      unitRef="U_iso4217USD">134000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0001748907_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231"
      decimals="-3"
      id="F_000513"
      unitRef="U_iso4217USD">49000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001748907_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231"
      decimals="-3"
      id="F_000517"
      unitRef="U_iso4217USD">142813000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock contextRef="C_0001748907_20210101_20211231" id="F_000346">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the Company&#x2019;s available-for-sale marketable debt securities by contractual maturity, as of December 31, 2021 and 2020:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.2%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Maturities in one year or less&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;172,575&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;132,056&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.2%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Maturities between one and three years&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,139&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,757&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.2%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;184,714&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;142,813&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000518"
      unitRef="U_iso4217USD">172575000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000519"
      unitRef="U_iso4217USD">132056000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <ortx:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsAmortizedCost
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000520"
      unitRef="U_iso4217USD">12139000</ortx:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsAmortizedCost>
    <ortx:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsAmortizedCost
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000521"
      unitRef="U_iso4217USD">10757000</ortx:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000522"
      unitRef="U_iso4217USD">184714000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000523"
      unitRef="U_iso4217USD">142813000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="C_0001748907_20210101_20211231" id="F_000297">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;4. Product sales&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the years ended December 31, 2021 and 2020, the Company recorded sales for one commercial-stage therapy, Strimvelis, for the treatment of ADA-SCID. Strimvelis is c&lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;urrently distributed exclusively at the San Raffaele Hospital in Milan, Italy. San Raffaele Hospital will purchase and pay for Strimvelis and submit a claim to the payer. The Company&#x2019;s contracted sales with San Raffaele Hospital contain a single performance obligation and the Company recognizes revenue from product sales when the Company has satisfied its performance obligation by transferring control of Strimvelis to San Raffaele Hospital. Control of the product generally transfers upon the completion of the scheduled Strimvelis treatment. The Company&#x2019;s product sales represent total net product sales of Strimvelis. The Company evaluated the variable consideration under Accounting Standards Codification (ASC) 606,&#160;&lt;/span&gt;&lt;span style="font-style:italic;Background-color:#FFFFFF;color:#000000;"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;, and there is currently no variable consideration included in the transaction price for Strimvelis. Costs to manufacture and deliver the product and those associated with administering the therapy are included in cost of product sales. As the product is sold in direct relation to a scheduled treatment, the Company estimates that there is limited risk of product return, including the risk of product expiration.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Payment terms and conditions generally require payment for Strimvelis sales within 60 days of treatment. Strimvelis is currently distributed exclusively at the San Raffaele Hospital, and there is currently no variable consideration included in the transaction price of Strimvelis.&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <ortx:GeneralPaymentTermsMaximum contextRef="C_0001748907_20210101_20211231" id="F_000524">P60D</ortx:GeneralPaymentTermsMaximum>
    <ortx:PrepaidExpensesAndOtherCurrentAssetsTextBlock contextRef="C_0001748907_20210101_20211231" id="F_000298">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;5. Prepaid expenses and other current assets&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid expenses and other current assets consist of the following:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.32%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid external research and development expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,438&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,421&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inventories&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,016&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;665&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other prepayments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,128&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,930&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;VAT receivable&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,169&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,780&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Construction deposit - current&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,909&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,552&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-trade receivables&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,351&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,017&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total prepaid expenses and other current assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,011&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,365&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</ortx:PrepaidExpensesAndOtherCurrentAssetsTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="C_0001748907_20210101_20211231" id="F_000347">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid expenses and other current assets consist of the following:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.32%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid external research and development expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,438&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,421&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inventories&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,016&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;665&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other prepayments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,128&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,930&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;VAT receivable&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,169&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,780&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Construction deposit - current&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,909&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,552&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-trade receivables&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,351&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,017&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total prepaid expenses and other current assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,011&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,365&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <ortx:PrepaidExternalResearchAndDevelopmentExpenses
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000525"
      unitRef="U_iso4217USD">2438000</ortx:PrepaidExternalResearchAndDevelopmentExpenses>
    <ortx:PrepaidExternalResearchAndDevelopmentExpenses
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000526"
      unitRef="U_iso4217USD">1421000</ortx:PrepaidExternalResearchAndDevelopmentExpenses>
    <us-gaap:InventoryNet
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000527"
      unitRef="U_iso4217USD">2016000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000528"
      unitRef="U_iso4217USD">665000</us-gaap:InventoryNet>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000529"
      unitRef="U_iso4217USD">6128000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000530"
      unitRef="U_iso4217USD">4930000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:ValueAddedTaxReceivableCurrent
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000531"
      unitRef="U_iso4217USD">1169000</us-gaap:ValueAddedTaxReceivableCurrent>
    <us-gaap:ValueAddedTaxReceivableCurrent
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000532"
      unitRef="U_iso4217USD">2780000</us-gaap:ValueAddedTaxReceivableCurrent>
    <ortx:ConstructionDepositsCurrent
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000533"
      unitRef="U_iso4217USD">7909000</ortx:ConstructionDepositsCurrent>
    <ortx:ConstructionDepositsCurrent
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000534"
      unitRef="U_iso4217USD">1552000</ortx:ConstructionDepositsCurrent>
    <us-gaap:NontradeReceivablesCurrent
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000535"
      unitRef="U_iso4217USD">3351000</us-gaap:NontradeReceivablesCurrent>
    <us-gaap:NontradeReceivablesCurrent
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000536"
      unitRef="U_iso4217USD">2017000</us-gaap:NontradeReceivablesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000537"
      unitRef="U_iso4217USD">23011000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000538"
      unitRef="U_iso4217USD">13365000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="C_0001748907_20210101_20211231" id="F_000299">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;6. Property and equipment &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment consist of the following: &lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.32%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lab equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,937&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,114&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,450&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,522&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;303&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;304&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Office and IT equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;763&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Construction-in-progress&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;211&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;302&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,924&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,005&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: accumulated depreciation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,157&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,224&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,767&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,781&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Depreciation expense for the years ended December&#160;31, 2021 and 2020 was $2.2 million and $2.0 million, respectively.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="C_0001748907_20210101_20211231" id="F_000348">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment consist of the following: &lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.32%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lab equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,937&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,114&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,450&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,522&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;303&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;304&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Office and IT equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;763&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Construction-in-progress&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;211&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;302&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,924&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,005&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: accumulated depreciation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,157&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,224&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,767&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,781&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001748907_us-gaapPropertyPlantAndEquipmentByTypeAxis_ortxLabEquipmentMember_20211231"
      decimals="-3"
      id="F_000539"
      unitRef="U_iso4217USD">5937000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001748907_us-gaapPropertyPlantAndEquipmentByTypeAxis_ortxLabEquipmentMember_20201231"
      decimals="-3"
      id="F_000540"
      unitRef="U_iso4217USD">5114000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001748907_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20211231"
      decimals="-3"
      id="F_000541"
      unitRef="U_iso4217USD">2450000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001748907_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231"
      decimals="-3"
      id="F_000542"
      unitRef="U_iso4217USD">2522000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001748907_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20211231"
      decimals="-3"
      id="F_000543"
      unitRef="U_iso4217USD">303000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001748907_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20201231"
      decimals="-3"
      id="F_000544"
      unitRef="U_iso4217USD">304000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001748907_us-gaapPropertyPlantAndEquipmentByTypeAxis_ortxOfficeAndITEquipmentMember_20211231"
      decimals="-3"
      id="F_000545"
      unitRef="U_iso4217USD">2023000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001748907_us-gaapPropertyPlantAndEquipmentByTypeAxis_ortxOfficeAndITEquipmentMember_20201231"
      decimals="-3"
      id="F_000546"
      unitRef="U_iso4217USD">763000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001748907_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20211231"
      decimals="-3"
      id="F_000547"
      unitRef="U_iso4217USD">211000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001748907_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20201231"
      decimals="-3"
      id="F_000548"
      unitRef="U_iso4217USD">302000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000549"
      unitRef="U_iso4217USD">10924000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000550"
      unitRef="U_iso4217USD">9005000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000551"
      unitRef="U_iso4217USD">6157000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000552"
      unitRef="U_iso4217USD">4224000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000553"
      unitRef="U_iso4217USD">4767000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000554"
      unitRef="U_iso4217USD">4781000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="C_0001748907_20210101_20211231"
      decimals="-5"
      id="F_000555"
      unitRef="U_iso4217USD">2200000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_0001748907_20200101_20201231"
      decimals="-5"
      id="F_000556"
      unitRef="U_iso4217USD">2000000.0</us-gaap:Depreciation>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="C_0001748907_20210101_20211231" id="F_000300">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;7. Intangible assets, net&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible assets, net of accumulated amortization, consisted of the following:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.06%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.32%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accumulated Amortization&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-top:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-top:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accumulated Amortization&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.64%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;License intangibles&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,329&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(180&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,149&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,076&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,076&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.64%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,329&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(180&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,149&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,076&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,076&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;License intangibles consist of capitalized milestone payments or accruals of payments the Company has deemed probable upon receiving regulatory approval of Libmeldy in the EU. The license intangibles are being amortized on a straight-line basis over the remaining useful life of the related patents of approximately twelve years. For year ended December 31, 2021, amortization of intangible assets totaled $0.2 million. For the year ended December 31, 2020, amortization of intangible assets was nil. The effect of foreign currency translation on the net carrying value of intangible assets during 2021 was not material.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the estimated future amortization for intangible assets for the next five years and thereafter:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;364&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;364&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;364&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2025&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;364&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2026&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;364&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,329&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,149&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <ortx:ScheduleOfIntangibleAssetsNetOfAccumulatedAmortizationTableTextBlock contextRef="C_0001748907_20210101_20211231" id="F_000349">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible assets, net of accumulated amortization, consisted of the following:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.06%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.32%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accumulated Amortization&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-top:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-top:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accumulated Amortization&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.64%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;License intangibles&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,329&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(180&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,149&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,076&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,076&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.64%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,329&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(180&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,149&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,076&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,076&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</ortx:ScheduleOfIntangibleAssetsNetOfAccumulatedAmortizationTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_0001748907_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicenseMember_20211231"
      decimals="-3"
      id="F_000557"
      unitRef="U_iso4217USD">4329000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_0001748907_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicenseMember_20211231"
      decimals="-3"
      id="F_000559"
      unitRef="U_iso4217USD">180000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_0001748907_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicenseMember_20211231"
      decimals="-3"
      id="F_000561"
      unitRef="U_iso4217USD">4149000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_0001748907_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicenseMember_20201231"
      decimals="-3"
      id="F_000563"
      unitRef="U_iso4217USD">3076000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_0001748907_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicenseMember_20201231"
      decimals="-3"
      id="F_000565"
      unitRef="U_iso4217USD">3076000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000558"
      unitRef="U_iso4217USD">4329000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000560"
      unitRef="U_iso4217USD">180000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000562"
      unitRef="U_iso4217USD">4149000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000564"
      unitRef="U_iso4217USD">3076000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000566"
      unitRef="U_iso4217USD">3076000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="C_0001748907_20210101_20211231" id="F_000567">P12Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_0001748907_20211231"
      decimals="-5"
      id="F_000568"
      unitRef="U_iso4217USD">200000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="C_0001748907_20210101_20211231" id="F_000350">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the estimated future amortization for intangible assets for the next five years and thereafter:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;364&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;364&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;364&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2025&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;364&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2026&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;364&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,329&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,149&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000569"
      unitRef="U_iso4217USD">364000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000570"
      unitRef="U_iso4217USD">364000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000571"
      unitRef="U_iso4217USD">364000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000572"
      unitRef="U_iso4217USD">364000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000573"
      unitRef="U_iso4217USD">364000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000574"
      unitRef="U_iso4217USD">2329000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000575"
      unitRef="U_iso4217USD">4149000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:OtherAssetsDisclosureTextBlock contextRef="C_0001748907_20210101_20211231" id="F_000301">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;8. Other assets&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other assets consist of the following:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,086&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,219&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deposits&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,404&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,144&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred financing costs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;693&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;975&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other non-current assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,407&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,554&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Construction deposits - long-term&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,572&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total other assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,590&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,464&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:OtherAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock contextRef="C_0001748907_20210101_20211231" id="F_000351">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other assets consist of the following:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,086&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,219&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deposits&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,404&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,144&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred financing costs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;693&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;975&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other non-current assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,407&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,554&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Construction deposits - long-term&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,572&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total other assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,590&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,464&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000576"
      unitRef="U_iso4217USD">4086000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000577"
      unitRef="U_iso4217USD">5219000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000578"
      unitRef="U_iso4217USD">1404000</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000579"
      unitRef="U_iso4217USD">1144000</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:DeferredFinanceCostsNoncurrentNet
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000580"
      unitRef="U_iso4217USD">693000</us-gaap:DeferredFinanceCostsNoncurrentNet>
    <us-gaap:DeferredFinanceCostsNoncurrentNet
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000581"
      unitRef="U_iso4217USD">975000</us-gaap:DeferredFinanceCostsNoncurrentNet>
    <ortx:OtherNonCurrentAssets
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000582"
      unitRef="U_iso4217USD">3407000</ortx:OtherNonCurrentAssets>
    <ortx:OtherNonCurrentAssets
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000583"
      unitRef="U_iso4217USD">1554000</ortx:OtherNonCurrentAssets>
    <ortx:ConstructionDepositsLongTerm
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000584"
      unitRef="U_iso4217USD">6572000</ortx:ConstructionDepositsLongTerm>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000585"
      unitRef="U_iso4217USD">9590000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000586"
      unitRef="U_iso4217USD">15464000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="C_0001748907_20210101_20211231" id="F_000302">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;9. Accrued expenses and other liabilities &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued expenses and other current liabilities consisted of the following: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued external research and development expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,273&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,878&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued payroll and related expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,521&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,881&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued milestone payments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,058&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,252&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued professional fees&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;854&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;791&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,941&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,225&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Strimvelis liability - current portion&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;671&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;916&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total accrued expenses and other current liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,318&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;28,943&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="C_0001748907_20210101_20211231" id="F_000352">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued expenses and other current liabilities consisted of the following: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued external research and development expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,273&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,878&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued payroll and related expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,521&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,881&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued milestone payments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,058&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,252&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued professional fees&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;854&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;791&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,941&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,225&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Strimvelis liability - current portion&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;671&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;916&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total accrued expenses and other current liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,318&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;28,943&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <ortx:AccruedExternalResearchAndDevelopmentExpensesCurrent
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000587"
      unitRef="U_iso4217USD">9273000</ortx:AccruedExternalResearchAndDevelopmentExpensesCurrent>
    <ortx:AccruedExternalResearchAndDevelopmentExpensesCurrent
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000588"
      unitRef="U_iso4217USD">8878000</ortx:AccruedExternalResearchAndDevelopmentExpensesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000589"
      unitRef="U_iso4217USD">8521000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000590"
      unitRef="U_iso4217USD">11881000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <ortx:AccruedMilestonePaymentsCurrent
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000591"
      unitRef="U_iso4217USD">2058000</ortx:AccruedMilestonePaymentsCurrent>
    <ortx:AccruedMilestonePaymentsCurrent
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000592"
      unitRef="U_iso4217USD">2252000</ortx:AccruedMilestonePaymentsCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000593"
      unitRef="U_iso4217USD">854000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000594"
      unitRef="U_iso4217USD">791000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000595"
      unitRef="U_iso4217USD">2941000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000596"
      unitRef="U_iso4217USD">4225000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <ortx:ProductLiabilityCurrentPortion
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000597"
      unitRef="U_iso4217USD">671000</ortx:ProductLiabilityCurrentPortion>
    <ortx:ProductLiabilityCurrentPortion
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000598"
      unitRef="U_iso4217USD">916000</ortx:ProductLiabilityCurrentPortion>
    <ortx:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000599"
      unitRef="U_iso4217USD">24318000</ortx:AccruedExpensesAndOtherCurrentLiabilities>
    <ortx:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000600"
      unitRef="U_iso4217USD">28943000</ortx:AccruedExpensesAndOtherCurrentLiabilities>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock contextRef="C_0001748907_20210101_20211231" id="F_000303">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;10. Restructuring charges&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In May 2020&lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;, the Company committed to a new strategic plan and restructuring intended to enable the Company to advance its corporate strategy while reducing overall operating expenses, including ceasing construction and build-out of its Fremont, California manufacturing facility, closing its office in Menlo Park, California, reducing its workforce by approximately&#160;25% across the Company, eliminating a number of future positions expected to be recruited in 2020 and 2021, reducing its investment in the future development for certain programs, and other cost-saving measures (collectively, the &#x201c;Restructuring&#x201d;). The workforce reductions took place primarily during the second and third quarters of 2020, and concluded in the fourth quarter of 2020.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Cash restructuring charges&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Accrued restructuring and severance costs are included in Accrued expenses and other current liabilities in the consolidated balance sheet. Activity for the fiscal year is summarized as follows:&lt;/span&gt;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.06%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at beginning of period&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Charged to expense&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.06%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,854&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.2%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Payments made&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,848&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.2%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at end of period&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.7%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;There were no restructuring costs during the year ended December 31, 2021.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Impairment of long-lived assets&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;During the second quarter of 2020, the Company also took the following non-cash charges to research and development expense associated with the impairment of construction-in-process associated with the Fremont manufacturing facility, partial impairment of the right-of-use asset for the Fremont manufacturing facility lease (the &#x201c;Fremont ROU asset&#x201d;), and a write-down of laboratory equipment from the Company&#x2019;s Menlo Park, CA facility:&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Asset write-down&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease right-of-use asset&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,605&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Construction-in-progress&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,285&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;760&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Charge included in research and development expense&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,650&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:9pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The Company assessed the Fremont construction-in-process for impairment in May 2020 upon the Restructuring. The construction-in-process related to design costs, and was determined to have no potential future value, and an impairment charge of $2.3&#160;million was taken for the full value of the construction-in-process asset.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The Company assessed the Fremont ROU asset for impairment in May 2020 upon the Restructuring when the carrying value of the asset was $13.8&#160;million. The Fremont ROU asset represented the asset group for the impairment assessment. Upon failing the first step of the long-lived asset impairment model where the undiscounted cash flows were less than the carrying value of the Fremont ROU asset, the Company performed the second step by comparing the fair value of the Fremont ROU asset to its carrying value. The fair value of the Fremont ROU asset is a non-recurring fair value measurement that was measured using a probability-weighted discounted cash flow approach, which estimated the present value of potential sublease income to be generated by the facility, less costs incurred to sublease the facility. The significant assumptions inherent in estimating the various probability weighted scenarios included the undiscounted forecasted sublease income less costs incurred, which included assumptions of the expected income and timing of entering into a future sublease, and a market-participant discount rate that reflects a potential discount rate. The Company selected the assumptions used in the fair value estimate using current market data associated with the potential sublease income and market participant discount rates. The undiscounted cash flows utilized in the fair value estimate ranged from $11.7&#160;million to $19.1&#160;million to be generated over the remainder of the lease term. The market-participant discount rate utilized in the fair value estimate was&#160;4.6%. These assumptions represent level 3 inputs of the fair value hierarchy (see Note 3).&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;As of the assessment date, the fair value of the Fremont ROU asset was $11.2&#160;million, and the Company recorded a $2.6&#160;million impairment charge related to the asset. The remaining carrying value of the Fremont ROU asset is being amortized over the remaining lease term on a straight-line basis. In December 2020, the Company executed a sublease for the Fremont manufacturing facility with an unrelated third-party for the remaining lease term (see Note 11). No further impairment was necessary as a result of the sublease. The occurrence of a triggering event for the Fremont ROU asset in future periods could result in additional impairment charges if the estimated fair value of the asset is determined to be lower than the carrying value.&lt;/span&gt;&lt;/p&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
      contextRef="C_0001748907_us-gaapRestructuringPlanAxis_ortxMenloParkCaliforniaMember_20200501_20200531"
      decimals="2"
      id="F_000601"
      unitRef="U_xbrlipure">0.25</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock contextRef="C_0001748907_20210101_20211231" id="F_000353">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Accrued restructuring and severance costs are included in Accrued expenses and other current liabilities in the consolidated balance sheet. Activity for the fiscal year is summarized as follows:&lt;/span&gt;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.06%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at beginning of period&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.2%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Charged to expense&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.06%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,854&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.2%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Payments made&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,848&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.2%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at end of period&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.7%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:RestructuringCharges
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000602"
      unitRef="U_iso4217USD">1854000</us-gaap:RestructuringCharges>
    <us-gaap:PaymentsForRestructuring
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000603"
      unitRef="U_iso4217USD">1848000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserve
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000604"
      unitRef="U_iso4217USD">6000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCharges
      contextRef="C_0001748907_20210101_20211231"
      decimals="INF"
      id="F_000605"
      unitRef="U_iso4217USD">0</us-gaap:RestructuringCharges>
    <us-gaap:DetailsOfImpairmentOfLongLivedAssetsHeldAndUsedByAssetTextBlock contextRef="C_0001748907_20210101_20211231" id="F_000354">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;During the second quarter of 2020, the Company also took the following non-cash charges to research and development expense associated with the impairment of construction-in-process associated with the Fremont manufacturing facility, partial impairment of the right-of-use asset for the Fremont manufacturing facility lease (the &#x201c;Fremont ROU asset&#x201d;), and a write-down of laboratory equipment from the Company&#x2019;s Menlo Park, CA facility:&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Asset write-down&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease right-of-use asset&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,605&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Construction-in-progress&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,285&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;760&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Charge included in research and development expense&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,650&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:DetailsOfImpairmentOfLongLivedAssetsHeldAndUsedByAssetTextBlock>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="C_0001748907_20200401_20200630"
      decimals="-3"
      id="F_000606"
      unitRef="U_iso4217USD">2605000</us-gaap:OperatingLeaseImpairmentLoss>
    <ortx:ImpairmentOfConstructionInProcess
      contextRef="C_0001748907_20200401_20200630"
      decimals="-3"
      id="F_000607"
      unitRef="U_iso4217USD">2285000</ortx:ImpairmentOfConstructionInProcess>
    <ortx:ImpairmentOfLaboratoryEquipment
      contextRef="C_0001748907_20200401_20200630"
      decimals="-3"
      id="F_000608"
      unitRef="U_iso4217USD">760000</ortx:ImpairmentOfLaboratoryEquipment>
    <us-gaap:AssetImpairmentCharges
      contextRef="C_0001748907_20200401_20200630"
      decimals="-3"
      id="F_000609"
      unitRef="U_iso4217USD">5650000</us-gaap:AssetImpairmentCharges>
    <ortx:ImpairmentOfConstructionInProcess
      contextRef="C_0001748907_us-gaapRestructuringPlanAxis_ortxFremontCaliforniaMember_20200501_20200531"
      decimals="-5"
      id="F_000610"
      unitRef="U_iso4217USD">2300000</ortx:ImpairmentOfConstructionInProcess>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0001748907_us-gaapRestructuringPlanAxis_ortxFremontCaliforniaMember_20200531"
      decimals="-5"
      id="F_000611"
      unitRef="U_iso4217USD">13800000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_0001748907_srtRangeAxis_srtMinimumMember_us-gaapRestructuringPlanAxis_ortxFremontCaliforniaMember_20200531"
      decimals="-5"
      id="F_000612"
      unitRef="U_iso4217USD">11700000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_0001748907_srtRangeAxis_srtMaximumMember_us-gaapRestructuringPlanAxis_ortxFremontCaliforniaMember_20200531"
      decimals="-5"
      id="F_000613"
      unitRef="U_iso4217USD">19100000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="C_0001748907_us-gaapRestructuringPlanAxis_ortxFremontCaliforniaMember_20200531"
      decimals="3"
      id="F_000614"
      unitRef="U_xbrlipure">0.046</us-gaap:LesseeOperatingLeaseDiscountRate>
    <ortx:OperatingLeaseRightOfUseAssetFairValue
      contextRef="C_0001748907_us-gaapRestructuringPlanAxis_ortxFremontCaliforniaMember_20200531"
      decimals="-5"
      id="F_000615"
      unitRef="U_iso4217USD">11200000</ortx:OperatingLeaseRightOfUseAssetFairValue>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="C_0001748907_us-gaapRestructuringPlanAxis_ortxFremontCaliforniaMember_20200501_20200531"
      decimals="-5"
      id="F_000616"
      unitRef="U_iso4217USD">2600000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="C_0001748907_us-gaapRestructuringPlanAxis_ortxFremontCaliforniaMember_20201201_20201231"
      decimals="-6"
      id="F_000617"
      unitRef="U_iso4217USD">0</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="C_0001748907_20210101_20211231" id="F_000304">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;11. Leases&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Operating leases&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In November 2017 and January 2019, the Company entered into lease agreements for office and laboratory space in Menlo Park, California, United States. The leases terminated in &lt;span style="-sec-ix-hidden:F_000618"&gt;&lt;span style="-sec-ix-hidden:F_000619"&gt;December 2020&lt;/span&gt;&lt;/span&gt;. The combined annual rental payments, including variable payments, under both leases with the same landlord were &lt;span style="-sec-ix-hidden:F_000620"&gt;nil&lt;/span&gt; in 2021 and $1.9 million in 2020. The Company was provided with one month of free rent in connection with the first lease. The lease agreement included annual rent escalation provisions. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In January 2018 and December 2018, the Company entered into lease agreements for office space in London, United Kingdom, both of which terminate in &lt;span style="-sec-ix-hidden:F_000623"&gt;&lt;span style="-sec-ix-hidden:F_000624"&gt;January 2023&lt;/span&gt;&lt;/span&gt;. The combined annual rental payments, including variable payments, under the lease agreements were $1.8 million in 2021 and $1.7 million in 2020. The Company also rented lab spaces in London in 2021, for which it made $0.2 million in payments in 2021.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In March 2018, the Company entered into a lease agreement for office space in Boston, Massachusetts, United States, which terminates in &lt;span style="-sec-ix-hidden:F_000628"&gt;September 2022&lt;/span&gt;. The annual rental payments, including variable payments, were $0.4 million in 2021 and &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020. The lease agreement includes annual rent escalation provisions.&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; The Company has subleased the space in&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; August 2021, and rec&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ognized&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.1&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; million in sublease income in 2021.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In July 2019, the Company entered into a lease agreement for office space in Boston, Massachusetts, United States, which commences for accounting purposes in &lt;span style="-sec-ix-hidden:F_000631"&gt;January 2020&lt;/span&gt;. The lease terminates in &lt;span style="-sec-ix-hidden:F_000632"&gt;September 2026&lt;/span&gt;. The annual rental payments, including variable payments, were $1.1 million and $0.9 million in 2021 and 2020, respectively. The lease agreement includes annual rent escalation provisions.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2021, the carrying value of the operating lease right-of-use assets in Boston and London was $4.1 million and the lease liabilities was $4.3 million. As of December 31, 2020, the carrying value of the operating lease right-of-use assets in Boston and London was $&lt;span style="color:#000000;"&gt;5.4&lt;/span&gt; million and the lease liabilities was $&lt;span style="color:#000000;"&gt;5.7&lt;/span&gt; million.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Fremont operating lease and sublease agreements&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2018, the Company leased manufacturing, laboratory, and office space in Fremont, California (the &#x201c;Fremont facility&#x201d; and the &#x201c;Head Lease&#x201d;) which terminates in &lt;span style="-sec-ix-hidden:F_000639"&gt;May 2030&lt;/span&gt;. In May 2020, the Company committed to a restructuring plan (see Note 10) whereby we ceased construction and build-out of the Fremont facility. I&lt;span style="color:#000000;"&gt;n December 2020, the Company entered into a sublease agreement (the &#x201c;Sublease&#x201d;) with an unrelated third-party (the &#x201c;subtenant&#x201d;) whereby the Company subleased the entire Fremont facility to the subtenant. The Company accounts for the Head Lease and Sublease as two separate contracts. Both the Head Lease and Sublease were determined to be operating leases.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Head Lease annual rental payments, including variable payments, were $3.1 million in 2021 and 2020. The Head Lease includes annual rent escalation provisions. The Company was provided with 8 months of free rent. Subject to the terms of the Head Lease agreement, the Company executed a $3.0 million letter of credit upon signing the lease, which may be reduced by 25% subject to reduction requirements specified therein. This amount is classified as restricted cash on the consolidated balance sheets. &lt;span style="color:#808080;"&gt; &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2021, the carrying value of the Fremont Head Lease right-of-use asset was $9.5 million and the lease liability was $13.1 million. &lt;span style="color:#000000;"&gt;The Head Lease provides for up to $5.3 million in tenant improvement allowances to be reimbursed to the Company by the landlord. These tenant improvement allowances have been included in the calculation of the operating lease liability and is currently expected to be received in 2022. The Company continues to assess the expected receipt of the tenant improvement allowances and may remeasure the right-of-use asset and liability from time to time as facts and circumstances may change&lt;/span&gt;.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Sublease commenced in December 2020 and is in force for the remainder of the Head Lease term, through May 2030. The Sublease provides for 12 months of free rent until December 2021. The sublease provides for an initial annual cash base rent of $2.2 million, with annual rent escalation provisions. The subtenant is also responsible for paying all operating expenses associated with the Head Lease. The Sublease also includes pass-through of up to $5.3 million in tenant improvement allowances to the subtenant, subject to the Company being reimbursed for the allowances per the terms of the Head Lease. The Subtenant provided the Company with a $2.6 million security deposit, which may be converted to a letter of credit upon providing evidence of $2.6 million in construction expenditures. The Company accounts for the security deposit within other long-term liabilities.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has $7.9 million in an escrow account associated with construction on the Fremont facility, for which the Company has ceased construction and build-out. Subject to the terms of the Head Lease and reduction provisions, this amount may be returned to the Company upon qualifying construction expenditure, or will be returned in late 2022 (the &#x201c;Sunset Date&#x201d;) to the extent construction expenses have not been incurred. The Company deposited $10.0 million into the account in the first quarter of 2020 and has received $2.1 million in receipts from the escrow funds for costs incurred to date. The escrow balance is all classified within other current assets on the consolidated balance sheets based on the timing of when the Company expects funds to be returned from the escrow agent. Future receipts from the escrow deposit will be dependent upon the timing of the subtenant construction spend through the Sunset Date.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Embedded operating lease arrangement&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The Company is party to a manufacturing agreement for research and development and commercial production&#160;with AGC Biologics, S.p.A. (formerly MolMed S.p.A.) (&#x201c;AGC&#x201d;) pursuant to which AGC will develop, manufacture and supply certain viral vectors and conduct cell processing activities for certain Company development and commercial programs.&#160;&#160;A manufacturing agreement with AGC was novated to the Company as part of the GSK Agreement (see Note 15).&#160;&#160;On July 2, 2020 (the &#x201c;Effective Date&#x201d;), the Company entered into a new manufacturing and technology development master agreement with AGC (the &#x201c;AGC Agreement&#x201d;) which superseded the novated agreement.&lt;/span&gt;&lt;span style="color:#000000;"&gt; &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company determined that the AGC Agreement contains an embedded lease as it includes provision of manufacturing suites designated for the Company&#x2019;s exclusive use during the term of the agreement.&#160;&lt;span style="Background-color:#FFFFFF;"&gt;The AGC Agreement has an initial term of&#160;five years, beginning on the Effective Date and ending July 2, 2025.&#160;The agreement may be extended for an additional&#160;two years&#160;by mutual agreement of the Company and AGC&lt;/span&gt;. The AGC Agreement contains payments associated with lease and non-lease components. The contractual annual rental payments associated with the lease that are considered a lease component amount to &#x20ac;2.7&#160;million per contract year. The non-lease components of the agreement consist of minimum manufacturing purchase requirements and dedicated manufacturing and development services (see Note 18).&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2021, the carrying value of the embedded operating lease right-of-use asset was $10.7 million and the lease liability was $9.3 million. &lt;span style="color:#000000;"&gt;As of December 31, 2020, the carrying value of the embedded operating lease right-of-use asset was $13.9 million and the lease liability was $13.1 million. &lt;/span&gt;&lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;The Company may terminate the AGC Agreement and the use of the exclusive manufacturing suites, with 12-months&#x2019; notice, and beginning no earlier than July 2, 2022. AGC may terminate the AGC Agreement with 24-months&#x2019; notice. The AGC Agreement provides for an option to reserve one additional exclusive manufacturing suite any time prior to January 1, 2022 for a one-time option fee plus annual rental fee. The AGC Agreement extends until&#160;July 2, 2025.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Summary of all lease costs recognized under ASC 842&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Our facility leases described above generally contain customary provisions allowing the landlords to terminate the leases if we fail to remedy a breach of any of our obligations under any such lease within specified time periods, or upon our bankruptcy or insolvency. The leases do not include any restrictions or covenants that had to be accounted for under the lease guidance. The following table contains a summary of the lease-related costs recognized within operating expenses, and other information pertaining to the Company&#x2019;s operating leases as of December 31, 2021 and 2020:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fixed lease cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,701&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,593&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Impairment of right-of-use assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,781&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Variable lease cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,696&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,131&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sublease income&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,746&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(181&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.24%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total lease cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,651&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,324&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other information&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; Operating cash flows used for operating leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,989&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,447&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; Weighted-average remaining lease term (years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000677"&gt;6.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000678"&gt;6.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; Weighted-average discount rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.7&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.6&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fixed lease cost represents the ASC 842 rent expense associated with the amortization of our right-of-use assets and lease liabilities. Impairment of right-of-use assets relates to discrete impairment charges taken when, in the Company&#x2019;s estimation, the fair value of a right-of-use asset is below the carrying value. Variable lease cost are the amounts owed by the Company to a lessor that are not fixed, such as reimbursement for common area maintenance and utilities costs, and are not included in the calculation of the Company&#x2019;s operating lease right of use assets or operating lease liabilities and are expensed when incurred. Sublease income represents the straight-line recognition of base rent sublease income over the term of the Sublease, and recognition of pass-through operating expense costs per the terms of the Sublease.&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the year ended December 31, 2021, the Company obtained right of use assets valued at $0.6 million in exchange for &lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;lease liabilities of $0.6 million. During the year ended December 31, 2020 the Company obtained $17.5 million in right of use assets in exchange for $17.5 million in lease liabilities.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2021, future minimum base rent commitments under ASC 842 under the Company&#x2019;s property leases were as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.08%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Due in:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross lease payments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross sublease receipts&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net lease payments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,326&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,334&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,992&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,773&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,246&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,527&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,799&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,313&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,486&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2025&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,361&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,382&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,979&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2026&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,720&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,454&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,266&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.08%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,332&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(8,960&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,372&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total future minimum lease payments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;41,311&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(20,689&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,622&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.08%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: imputed interest&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(14,698&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.84%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.84%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.08%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total operating lease payments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;26,613&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.84%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.84%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;*Tabular disclosure above for leases denominated in GBP have been translated at a rate of &#xa3;1.00 to $1.35, and leases denominated in Euro have been translated at a rate of &#x20ac;1.00 to $1.13. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:PaymentsForRent
      contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxOfficeAndLaboratorySpaceMenloParkLeaseAgreementMember_20200101_20201231"
      decimals="-5"
      id="F_000621"
      unitRef="U_iso4217USD">1900000</us-gaap:PaymentsForRent>
    <ortx:OperatingLeaseDurationForFreeRent
      contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxOfficeSpaceMenloParkLeaseAgreementMember_20171101_20171130"
      id="F_000622">P1M</ortx:OperatingLeaseDurationForFreeRent>
    <us-gaap:PaymentsForRent
      contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxFiveYearsLeaseTermTerminatesInJanuaryTwoThousandTwentyThreeMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_ortxOfficeSpaceLondonUnitedKingdomLeaseAgreementMember_20210101_20211231"
      decimals="-5"
      id="F_000625"
      unitRef="U_iso4217USD">1800000</us-gaap:PaymentsForRent>
    <us-gaap:PaymentsForRent
      contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxFiveYearsLeaseTermTerminatesInJanuaryTwoThousandTwentyThreeMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_ortxOfficeSpaceLondonUnitedKingdomLeaseAgreementMember_20200101_20201231"
      decimals="-5"
      id="F_000626"
      unitRef="U_iso4217USD">1700000</us-gaap:PaymentsForRent>
    <us-gaap:PaymentsForRent
      contextRef="C_0001748907_us-gaapPropertyPlantAndEquipmentByTypeAxis_ortxRentalLabSpaceMember_20210101_20211231"
      decimals="-5"
      id="F_000627"
      unitRef="U_iso4217USD">200000</us-gaap:PaymentsForRent>
    <us-gaap:PaymentsForRent
      contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxLeaseTermTerminatesInSeptemberTwoThousandTwentyTwoMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_ortxOfficeSpaceBostonUnitedStatesLeaseAgreementMember_20200101_20201231"
      decimals="-5"
      id="F_000629"
      unitRef="U_iso4217USD">400000</us-gaap:PaymentsForRent>
    <us-gaap:SubleaseIncome
      contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxLeaseTermTerminatesInSeptemberTwoThousandTwentyTwoMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_ortxOfficeSpaceBostonUnitedStatesLeaseAgreementMember_20210101_20211231"
      decimals="-5"
      id="F_000630"
      unitRef="U_iso4217USD">100000</us-gaap:SubleaseIncome>
    <us-gaap:PaymentsForRent
      contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxLeaseTermTerminatesInSeptemberTwoThousandTwentySixMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_ortxOfficeSpaceBostonUnitedStatesLeaseAgreementMember_20210101_20211231"
      decimals="-5"
      id="F_000633"
      unitRef="U_iso4217USD">1100000</us-gaap:PaymentsForRent>
    <us-gaap:PaymentsForRent
      contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxLeaseTermTerminatesInSeptemberTwoThousandTwentySixMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_ortxOfficeSpaceBostonUnitedStatesLeaseAgreementMember_20200101_20201231"
      decimals="-5"
      id="F_000634"
      unitRef="U_iso4217USD">900000</us-gaap:PaymentsForRent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxBostonAndLondonOfficeSpaceLeaseAgreementsMember_20211231"
      decimals="-5"
      id="F_000635"
      unitRef="U_iso4217USD">4100000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxBostonAndLondonOfficeSpaceLeaseAgreementsMember_20201231"
      decimals="-5"
      id="F_000636"
      unitRef="U_iso4217USD">4300000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxBostonAndLondonOfficeSpaceLeaseAgreementsMember_20211231"
      decimals="-5"
      id="F_000637"
      unitRef="U_iso4217USD">5400000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxBostonAndLondonOfficeSpaceLeaseAgreementsMember_20201231"
      decimals="-5"
      id="F_000638"
      unitRef="U_iso4217USD">5700000</us-gaap:OperatingLeaseLiability>
    <us-gaap:PaymentsForRent
      contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxFremontLeaseAgreementMember_20200101_20201231"
      decimals="-5"
      id="F_000643"
      unitRef="U_iso4217USD">3100000</us-gaap:PaymentsForRent>
    <us-gaap:PaymentsForRent
      contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxFremontLeaseAgreementMember_20210101_20211231"
      decimals="-5"
      id="F_000644"
      unitRef="U_iso4217USD">3100000</us-gaap:PaymentsForRent>
    <ortx:OperatingLeaseDurationForFreeRent
      contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxFremontLeaseAgreementMember_20181201_20181231"
      id="F_000640">P8M</ortx:OperatingLeaseDurationForFreeRent>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxFremontLeaseAgreementMember_20181201_20181231"
      decimals="-5"
      id="F_000642"
      unitRef="U_iso4217USD">3000000.0</us-gaap:ProceedsFromLinesOfCredit>
    <ortx:ReductionOfStandbyLetterOfCreditAmountPercentage
      contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxFremontLeaseAgreementMember_20181201_20181231"
      decimals="2"
      id="F_000641"
      unitRef="U_xbrlipure">0.25</ortx:ReductionOfStandbyLetterOfCreditAmountPercentage>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxFremontLeaseAgreementMember_20211231"
      decimals="-5"
      id="F_000645"
      unitRef="U_iso4217USD">9500000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxFremontLeaseAgreementMember_20211231"
      decimals="-5"
      id="F_000646"
      unitRef="U_iso4217USD">13100000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <ortx:TenantImprovementAllowance
      contextRef="C_0001748907_srtRangeAxis_srtMaximumMember_us-gaapLeaseContractualTermAxis_ortxFremontLeaseAgreementMember_20210101_20211231"
      decimals="-5"
      id="F_000647"
      unitRef="U_iso4217USD">5300000</ortx:TenantImprovementAllowance>
    <ortx:OperatingLeaseDurationForFreeRent
      contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxFremontSubleaseAgreementMember_20200101_20201231"
      id="F_000648">P12M</ortx:OperatingLeaseDurationForFreeRent>
    <us-gaap:PaymentsForRent
      contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxFremontSubleaseAgreementMember_20200101_20201231"
      decimals="-5"
      id="F_000649"
      unitRef="U_iso4217USD">2200000</us-gaap:PaymentsForRent>
    <ortx:TenantImprovementAllowance
      contextRef="C_0001748907_srtRangeAxis_srtMaximumMember_us-gaapLeaseContractualTermAxis_ortxFremontSubleaseAgreementMember_20200101_20201231"
      decimals="-5"
      id="F_000650"
      unitRef="U_iso4217USD">5300000</ortx:TenantImprovementAllowance>
    <us-gaap:SecurityDeposit
      contextRef="C_0001748907_us-gaapBalanceSheetLocationAxis_us-gaapOtherNoncurrentLiabilitiesMember_us-gaapLeaseContractualTermAxis_ortxFremontSubleaseAgreementMember_20201231"
      decimals="-5"
      id="F_000651"
      unitRef="U_iso4217USD">2600000</us-gaap:SecurityDeposit>
    <us-gaap:EscrowDeposit
      contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxFremontLeaseAgreementMember_20201231"
      decimals="-5"
      id="F_000653"
      unitRef="U_iso4217USD">7900000</us-gaap:EscrowDeposit>
    <us-gaap:EscrowDeposit
      contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxFremontLeaseAgreementMember_20200331"
      decimals="-5"
      id="F_000652"
      unitRef="U_iso4217USD">10000000.0</us-gaap:EscrowDeposit>
    <ortx:IncreaseDecreaseInEscrowDeposit
      contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxFremontLeaseAgreementMember_20200101_20201231"
      decimals="-5"
      id="F_000654"
      unitRef="U_iso4217USD">-2100000</ortx:IncreaseDecreaseInEscrowDeposit>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxGSKAgreementMember_20211231"
      id="F_000655">P5Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LeaseExpirationDate1 contextRef="C_0001748907_20210101_20211231" id="F_000656">2025-07-02</us-gaap:LeaseExpirationDate1>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxGSKAgreementMember_20210101_20211231"
      id="F_000657">The agreement may be extended for an additional&#160;two years&#160;by mutual agreement of the Company and AGC</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <ortx:LesseeOperatingLeaseExtendedTerm
      contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxGSKAgreementMember_20210101_20211231"
      id="F_000659">P2Y</ortx:LesseeOperatingLeaseExtendedTerm>
    <ortx:LeaseComponentManufacturingCommitmentAmount
      contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxGSKAgreementMember_20211231"
      decimals="-5"
      id="F_000660"
      unitRef="U_iso4217EUR">2700000</ortx:LeaseComponentManufacturingCommitmentAmount>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxGSKAgreementMember_20211231"
      decimals="-5"
      id="F_000661"
      unitRef="U_iso4217USD">10700000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxGSKAgreementMember_20211231"
      decimals="-5"
      id="F_000663"
      unitRef="U_iso4217USD">9300000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxGSKAgreementMember_20201231"
      decimals="-5"
      id="F_000662"
      unitRef="U_iso4217USD">13900000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxGSKAgreementMember_20201231"
      decimals="-5"
      id="F_000664"
      unitRef="U_iso4217USD">13100000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_0001748907_us-gaapLeaseContractualTermAxis_ortxGSKAgreementMember_20200101_20201231"
      id="F_000665">2025-07-02</us-gaap:LeaseExpirationDate1>
    <us-gaap:LeaseCostTableTextBlock contextRef="C_0001748907_20210101_20211231" id="F_000355">The following table contains a summary of the lease-related costs recognized within operating expenses, and other information pertaining to the Company&#x2019;s operating leases as of December 31, 2021 and 2020:
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fixed lease cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,701&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,593&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Impairment of right-of-use assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,781&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Variable lease cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,696&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,131&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sublease income&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,746&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(181&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.24%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total lease cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,651&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,324&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other information&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; Operating cash flows used for operating leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,989&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,447&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; Weighted-average remaining lease term (years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000677"&gt;6.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000678"&gt;6.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; Weighted-average discount rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.7&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.6&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:LeaseCostTableTextBlock>
    <ortx:FixedLeaseCost
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000666"
      unitRef="U_iso4217USD">7701000</ortx:FixedLeaseCost>
    <ortx:FixedLeaseCost
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000667"
      unitRef="U_iso4217USD">7593000</ortx:FixedLeaseCost>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000668"
      unitRef="U_iso4217USD">2781000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:VariableLeaseCost
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000669"
      unitRef="U_iso4217USD">1696000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000670"
      unitRef="U_iso4217USD">2131000</us-gaap:VariableLeaseCost>
    <us-gaap:SubleaseIncome
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000671"
      unitRef="U_iso4217USD">2746000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000672"
      unitRef="U_iso4217USD">181000</us-gaap:SubleaseIncome>
    <us-gaap:LeaseCost
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000673"
      unitRef="U_iso4217USD">6651000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000674"
      unitRef="U_iso4217USD">12324000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000675"
      unitRef="U_iso4217USD">7989000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000676"
      unitRef="U_iso4217USD">8447000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_0001748907_20211231"
      decimals="3"
      id="F_000679"
      unitRef="U_xbrlipure">0.087</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_0001748907_20201231"
      decimals="3"
      id="F_000680"
      unitRef="U_xbrlipure">0.086</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <ortx:OperatingLeaseRightOfUseAssetValueExchangeForLeaseLiabilities
      contextRef="C_0001748907_20211231"
      decimals="-5"
      id="F_000681"
      unitRef="U_iso4217USD">600000</ortx:OperatingLeaseRightOfUseAssetValueExchangeForLeaseLiabilities>
    <ortx:OperatingLeaseRightOfUseAssetValueExchangeForLeaseLiabilities
      contextRef="C_0001748907_20211231"
      decimals="-5"
      id="F_000683"
      unitRef="U_iso4217USD">600000</ortx:OperatingLeaseRightOfUseAssetValueExchangeForLeaseLiabilities>
    <ortx:OperatingLeaseRightOfUseAssetValueExchangeForLeaseLiabilities
      contextRef="C_0001748907_20201231"
      decimals="-5"
      id="F_000682"
      unitRef="U_iso4217USD">17500000</ortx:OperatingLeaseRightOfUseAssetValueExchangeForLeaseLiabilities>
    <ortx:OperatingLeaseRightOfUseAssetValueExchangeForLeaseLiabilities
      contextRef="C_0001748907_20201231"
      decimals="-5"
      id="F_000684"
      unitRef="U_iso4217USD">17500000</ortx:OperatingLeaseRightOfUseAssetValueExchangeForLeaseLiabilities>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="C_0001748907_20210101_20211231" id="F_000356">
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2021, future minimum base rent commitments under ASC 842 under the Company&#x2019;s property leases were as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.08%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Due in:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross lease payments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross sublease receipts&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net lease payments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,326&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,334&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,992&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,773&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,246&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,527&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,799&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,313&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,486&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2025&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,361&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,382&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,979&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2026&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,720&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,454&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,266&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.08%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,332&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(8,960&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,372&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total future minimum lease payments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;41,311&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(20,689&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,622&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.08%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: imputed interest&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(14,698&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.84%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.84%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.08%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total operating lease payments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;26,613&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.84%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.84%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000685"
      unitRef="U_iso4217USD">7326000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000694"
      unitRef="U_iso4217USD">2334000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths>
    <ortx:OperatingLeaseLiabilityPaymentsDueYearOne
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000701"
      unitRef="U_iso4217USD">4992000</ortx:OperatingLeaseLiabilityPaymentsDueYearOne>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000686"
      unitRef="U_iso4217USD">6773000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedTwoYears
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000695"
      unitRef="U_iso4217USD">2246000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedTwoYears>
    <ortx:OperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000702"
      unitRef="U_iso4217USD">4527000</ortx:OperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000687"
      unitRef="U_iso4217USD">6799000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedThreeYears
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000696"
      unitRef="U_iso4217USD">2313000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedThreeYears>
    <ortx:OperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000703"
      unitRef="U_iso4217USD">4486000</ortx:OperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000688"
      unitRef="U_iso4217USD">5361000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedFourYears
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000697"
      unitRef="U_iso4217USD">2382000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedFourYears>
    <ortx:OperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000704"
      unitRef="U_iso4217USD">2979000</ortx:OperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000689"
      unitRef="U_iso4217USD">3720000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedFiveYears
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000698"
      unitRef="U_iso4217USD">2454000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedFiveYears>
    <ortx:OperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000705"
      unitRef="U_iso4217USD">1266000</ortx:OperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000690"
      unitRef="U_iso4217USD">11332000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedThereafter
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000699"
      unitRef="U_iso4217USD">8960000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedThereafter>
    <ortx:OperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000706"
      unitRef="U_iso4217USD">2372000</ortx:OperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000691"
      unitRef="U_iso4217USD">41311000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceived
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000700"
      unitRef="U_iso4217USD">20689000</us-gaap:LessorOperatingLeasePaymentsToBeReceived>
    <ortx:OperatingLeaseLiabilityPaymentsDueNet
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000707"
      unitRef="U_iso4217USD">20622000</ortx:OperatingLeaseLiabilityPaymentsDueNet>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000692"
      unitRef="U_iso4217USD">14698000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000693"
      unitRef="U_iso4217USD">26613000</us-gaap:OperatingLeaseLiability>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="C_0001748907_srtCurrencyAxis_currencyGBP_20211231"
      decimals="2"
      id="F_000708"
      unitRef="U_xbrlipure">1.35</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="C_0001748907_srtCurrencyAxis_currencyEUR_20211231"
      decimals="2"
      id="F_000709"
      unitRef="U_xbrlipure">1.13</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:DebtDisclosureTextBlock contextRef="C_0001748907_20210101_20211231" id="F_000305">
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;12. Notes Payable&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In&lt;span style="color:#000000;"&gt; &lt;span style="-sec-ix-hidden:F_000710"&gt;May 2019&lt;/span&gt;, the Company entered into a senior term facilities agreement, which was amended in April 2020 (the &#x201c;Original Credit Facility&#x201d;) with MidCap Financial (Ireland) Limited (&#x201c;MidCap Financial&#x201d;), as agent, and additional lenders from time to time (together with MidCap Financial, the &#x201c;Lenders&#x201d;), to borrow up to $75.0 million in term loans.&lt;/span&gt; &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In May 2021, the Company amended and restated the Original Credit Facility (the &#x201c;Amended Credit Facility&#x201d;). Under the Amended Credit Facility, the Lenders agreed to make term loans available to the Company in the aggregate amount of $100.0 million, including increasing the principal on the initial term loan to $33.0 million, from $25.0 million. To date, the Company has borrowed $33.0 million under the amended initial term loan. The remaining $67.0 million under the Amended Credit Facility may be drawn down in the form of a second and third term loan, &lt;span style="Background-color:#FFFFFF;"&gt;the second term loan being a $33.0&#160;million term loan available no earlier than July 1, 2022&#160;&#160;and no later than July 1, 2023 upon certain regulatory approvals and evidence of the Company having $100&#160;million in cash and cash equivalent investments; and the third term loan being a $34.0&#160;million term loan available no earlier than July 1, 2023 and no later than July 1, 2024 upon evidence of the Company having $100&#160;million in cash and cash equivalent investments and attaining a pre-specified trailing 12-month revenue target.&lt;/span&gt;&lt;span style="color:#000000;"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt; &lt;/span&gt;&lt;span style="color:#000000;"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prior to execution of the Amended Credit Facility, each term loan under the Original Credit Facility bore interest at an annual rate equal to 6.0% plus LIBOR. The Company was required to make interest-only payments on the term loan for all payment dates prior to 24 months following the date of the Original Credit Facility, unless the third tranche was drawn, in which case for all payment dates prior to 36 months following the date of the Original Credit Facility. The term loans prior to the Amended Credit Facility were to begin amortizing on either the&#160;24-month&#160;or the&#160;36-month&#160;anniversary of the Original Credit Facility (as applicable), with equal monthly payments of principal plus interest to be made by the Borrower to the Lenders in consecutive monthly installments until the loan maturity date. In addition, a final payment of 4.5% was due on the loan maturity date. The Company accrued the final payment amount of $1.1 million associated with the first term loan of the Original Credit Facility, to outstanding debt by charges to interest expense using the effective-interest method from the date of issuance through the date of the Amended Credit Facility. Upon execution of the Amended Credit Facility, the Company was required to make a payment of $0.5 million for the accrued final payment associated with the Original Credit Facility, which was netted against proceeds from the additional initial term loan.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Each term loan under the Amended Credit Facility bears interest at an annual rate equal to 5.95% plus LIBOR. The Company is required to make interest-only payments on the term loan for 18 months following the date of the Amended Credit Facility, unless the Company is eligible for the second tranche, in which case the Company may elect to make interest-only payments for &lt;span&gt;30 months&lt;/span&gt; following the date of the Amended Credit Facility. The term loans under to the Amended Credit Facility begin amortizing on either the&#160;18-month&#160;or the&#160;30-month&#160;anniversary of the Amended Credit Facility (as applicable), with equal monthly payments of principal plus interest to be made by the Company to the Lenders in consecutive monthly installments until the loan maturity date. In addition, a final payment of 3.5% is due on the loan maturity date. The Company is accruing the final payment amount of $1.2 million associated with the first term loan of the Amended Credit Facility, to outstanding &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;debt by charges to interest expense using the effective-interest method from the date of issuance through the loan maturity date.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The Amended Credit Facility includes affirmative and negative covenants. The affirmative covenants include, among others, covenants requiring the Company to maintain their legal existence and governmental approvals, deliver certain financial reports, maintain insurance coverage, maintain property, pay taxes, satisfy certain requirements regarding accounts and comply with laws and regulations. The negative covenants include, among others, restrictions on the Company transferring collateral, incurring additional indebtedness, engaging in mergers or acquisitions, paying dividends or making other distributions, making investments, creating liens, amending material agreements and organizational documents, selling assets, changing the nature of the business and undergoing a change in control, in some cases subject to certain exceptions. The Company is also subject to an ongoing minimum cash financial covenant in which the Company must maintain unrestricted cash in an amount not less than $20.0&#160;million following the utilization of the second term loan and not less than $35.0&#160;million following the utilization of the third term loan.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2021, and December 31, 2020, notes payable consist of the following:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Notes payable, net of issuance costs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32,669&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,659&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: current portion&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(786&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,861&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Notes payable, net of current portion&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;31,883&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19,798&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accretion related to final payment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;203&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;406&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Notes payable, long term&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32,086&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,204&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2021, the future principal payments due are as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Minimum&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Payments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;786&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,429&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,429&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2025&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,429&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2026&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,082&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;34,155&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less current portion&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(786&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less unamortized portion of final payment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(952&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less unamortized debt issuance costs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(331&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Notes payable, long term&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32,086&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the years ended December 31, 2021 and 2020, the Company recognized $2.5 million and $2.3 million of interest expense related to the term loan, respectively. The effective annual interest rate as of December 31, 2021 on the outstanding debt under the Term Loan was approximately 8.4%.&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_0001748907_20190531"
      decimals="INF"
      id="F_000711"
      unitRef="U_iso4217USD">75000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_0001748907_20210531"
      decimals="INF"
      id="F_000712"
      unitRef="U_iso4217USD">100000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_0001748907_us-gaapDebtInstrumentAxis_ortxTheFirstTrancheTermLoanMember_20210531"
      decimals="INF"
      id="F_000713"
      unitRef="U_iso4217USD">33000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_0001748907_us-gaapDebtInstrumentAxis_ortxTheFirstTrancheTermLoanMember_20190531"
      decimals="INF"
      id="F_000714"
      unitRef="U_iso4217USD">25000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="C_0001748907_us-gaapDebtInstrumentAxis_ortxTheFirstTrancheTermLoanMember_20210501_20210531"
      decimals="-5"
      id="F_000715"
      unitRef="U_iso4217USD">33000000.0</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="C_0001748907_20210531"
      decimals="-5"
      id="F_000716"
      unitRef="U_iso4217USD">67000000.0</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_0001748907_us-gaapDebtInstrumentAxis_ortxTheSecondTrancheTermLoanMember_20210531"
      decimals="INF"
      id="F_000717"
      unitRef="U_iso4217USD">33000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityCovenantTerms
      contextRef="C_0001748907_us-gaapDebtInstrumentAxis_ortxTheSecondTrancheTermLoanMember_20210101_20211231"
      id="F_000721">upon certain regulatory approvals and evidence of the Company having $100&#160;million in cash and cash equivalent investments</us-gaap:LineOfCreditFacilityCovenantTerms>
    <us-gaap:InvestmentsAndCash
      contextRef="C_0001748907_srtRangeAxis_srtMinimumMember_us-gaapDebtInstrumentAxis_ortxTheSecondTrancheTermLoanMember_20210531"
      decimals="-6"
      id="F_000719"
      unitRef="U_iso4217USD">100000000</us-gaap:InvestmentsAndCash>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_0001748907_us-gaapDebtInstrumentAxis_ortxTheThirdTrancheTermLoanMember_20210531"
      decimals="INF"
      id="F_000718"
      unitRef="U_iso4217USD">34000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityCovenantTerms
      contextRef="C_0001748907_us-gaapDebtInstrumentAxis_ortxTheThirdTrancheTermLoanMember_20210101_20211231"
      id="F_000722">upon evidence of the Company having $100&#160;million in cash and cash equivalent investments and attaining a pre-specified trailing 12-month revenue target</us-gaap:LineOfCreditFacilityCovenantTerms>
    <us-gaap:InvestmentsAndCash
      contextRef="C_0001748907_srtRangeAxis_srtMinimumMember_us-gaapDebtInstrumentAxis_ortxTheThirdTrancheTermLoanMember_20210531"
      decimals="-6"
      id="F_000720"
      unitRef="U_iso4217USD">100000000</us-gaap:InvestmentsAndCash>
    <us-gaap:LineOfCreditFacilityInterestRateDescription contextRef="C_0001748907_20210101_20211231" id="F_000730">Prior to execution of the Amended Credit Facility, each term loan under the Original Credit Facility bore interest at an annual rate equal to 6.0% plus LIBOR. The Company was required to make interest-only payments on the term loan for all payment dates prior to 24 months following the date of the Original Credit Facility, unless the third tranche was drawn, in which case for all payment dates prior to 36 months following the date of the Original Credit Facility. The term loans prior to the Amended Credit Facility were to begin amortizing on either the&#160;24-month&#160;or the&#160;36-month&#160;anniversary of the Original Credit Facility (as applicable), with equal monthly payments of principal plus interest to be made by the Borrower to the Lenders in consecutive monthly installments until the loan maturity date. In addition, a final payment of 4.5% was due on the loan maturity date.</us-gaap:LineOfCreditFacilityInterestRateDescription>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="C_0001748907_us-gaapVariableRateAxis_ortxLondonInterbankOfferedRateFloorMember_20190501_20190531"
      decimals="3"
      id="F_000723"
      unitRef="U_xbrlipure">0.060</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <ortx:LineOfCreditFacilityInterestPaymentsTerm contextRef="C_0001748907_20190501_20190531" id="F_000724">P24M</ortx:LineOfCreditFacilityInterestPaymentsTerm>
    <ortx:LineOfCreditFacilityAmortizationTerm contextRef="C_0001748907_20190501_20190531" id="F_000725">P36M</ortx:LineOfCreditFacilityAmortizationTerm>
    <us-gaap:LineOfCreditFacilityFrequencyOfPayments contextRef="C_0001748907_20210101_20211231" id="F_000726">monthly payments</us-gaap:LineOfCreditFacilityFrequencyOfPayments>
    <ortx:LineOfCreditFacilityPercentageOfFinalPayment
      contextRef="C_0001748907_20190501_20190531"
      decimals="3"
      id="F_000727"
      unitRef="U_xbrlipure">0.045</ortx:LineOfCreditFacilityPercentageOfFinalPayment>
    <us-gaap:LineOfCreditFacilityPeriodicPaymentInterest
      contextRef="C_0001748907_20190501_20190531"
      decimals="-5"
      id="F_000728"
      unitRef="U_iso4217USD">1100000</us-gaap:LineOfCreditFacilityPeriodicPaymentInterest>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="C_0001748907_20190501_20190531"
      decimals="-5"
      id="F_000729"
      unitRef="U_iso4217USD">500000</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="C_0001748907_us-gaapVariableRateAxis_ortxLondonInterbankOfferedRateFloorMember_20210501_20210531"
      decimals="4"
      id="F_000731"
      unitRef="U_xbrlipure">0.0595</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <ortx:LineOfCreditFacilityInterestPaymentsTerm contextRef="C_0001748907_20210501_20210531" id="F_000732">P18M</ortx:LineOfCreditFacilityInterestPaymentsTerm>
    <ortx:LineOfCreditFacilityInterestPaymentsTerm
      contextRef="C_0001748907_us-gaapDebtInstrumentAxis_ortxTheSecondTrancheTermLoanMember_20210501_20210531"
      id="F_000733">P30M</ortx:LineOfCreditFacilityInterestPaymentsTerm>
    <ortx:LineOfCreditFacilityInterestPaymentsTerm
      contextRef="C_0001748907_us-gaapDebtInstrumentAxis_ortxTheThirdTrancheTermLoanMember_20210501_20210531"
      id="F_000734">P30M</ortx:LineOfCreditFacilityInterestPaymentsTerm>
    <us-gaap:LineOfCreditFacilityFrequencyOfPayments contextRef="C_0001748907_20210101_20211231" id="F_000737">monthly payments</us-gaap:LineOfCreditFacilityFrequencyOfPayments>
    <ortx:LineOfCreditFacilityPercentageOfFinalPayment
      contextRef="C_0001748907_20210501_20210531"
      decimals="3"
      id="F_000738"
      unitRef="U_xbrlipure">0.035</ortx:LineOfCreditFacilityPercentageOfFinalPayment>
    <us-gaap:LineOfCreditFacilityPeriodicPaymentInterest
      contextRef="C_0001748907_20210501_20210531"
      decimals="-5"
      id="F_000739"
      unitRef="U_iso4217USD">1200000</us-gaap:LineOfCreditFacilityPeriodicPaymentInterest>
    <us-gaap:DebtInstrumentCovenantDescription contextRef="C_0001748907_20210101_20211231" id="F_000742">The Company is also subject to an ongoing minimum cash financial covenant in which the Company must maintain unrestricted cash in an amount not less than $20.0&#160;million following the utilization of the second term loan and not less than $35.0&#160;million following the utilization of the third term loan</us-gaap:DebtInstrumentCovenantDescription>
    <ortx:LineOfCreditFacilityCovenantsMinimumCashAllowed
      contextRef="C_0001748907_srtRangeAxis_srtMinimumMember_us-gaapDebtInstrumentRedemptionPeriodAxis_us-gaapDebtInstrumentRedemptionPeriodTwoMember_20210531"
      decimals="-5"
      id="F_000740"
      unitRef="U_iso4217USD">20000000.0</ortx:LineOfCreditFacilityCovenantsMinimumCashAllowed>
    <ortx:LineOfCreditFacilityCovenantsMinimumCashAllowed
      contextRef="C_0001748907_srtRangeAxis_srtMinimumMember_us-gaapDebtInstrumentRedemptionPeriodAxis_us-gaapDebtInstrumentRedemptionPeriodThreeMember_20210531"
      decimals="-5"
      id="F_000741"
      unitRef="U_iso4217USD">35000000.0</ortx:LineOfCreditFacilityCovenantsMinimumCashAllowed>
    <us-gaap:ScheduleOfDebtTableTextBlock contextRef="C_0001748907_20210101_20211231" id="F_000357">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2021, and December 31, 2020, notes payable consist of the following:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Notes payable, net of issuance costs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32,669&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,659&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: current portion&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(786&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,861&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Notes payable, net of current portion&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;31,883&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19,798&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accretion related to final payment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;203&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;406&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Notes payable, long term&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32,086&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,204&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <ortx:LongTermDebtBeforeAccretionIssuanceCostsNet
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000743"
      unitRef="U_iso4217USD">32669000</ortx:LongTermDebtBeforeAccretionIssuanceCostsNet>
    <ortx:LongTermDebtBeforeAccretionIssuanceCostsNet
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000744"
      unitRef="U_iso4217USD">24659000</ortx:LongTermDebtBeforeAccretionIssuanceCostsNet>
    <ortx:LongTermDebtBeforeAccretionIssuanceCostsNetCurrent
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000745"
      unitRef="U_iso4217USD">786000</ortx:LongTermDebtBeforeAccretionIssuanceCostsNetCurrent>
    <ortx:LongTermDebtBeforeAccretionIssuanceCostsNetCurrent
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000746"
      unitRef="U_iso4217USD">4861000</ortx:LongTermDebtBeforeAccretionIssuanceCostsNetCurrent>
    <ortx:LongTermDebtBeforeAccretionIssuanceCostsNetNoncurrent
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000747"
      unitRef="U_iso4217USD">31883000</ortx:LongTermDebtBeforeAccretionIssuanceCostsNetNoncurrent>
    <ortx:LongTermDebtBeforeAccretionIssuanceCostsNetNoncurrent
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000748"
      unitRef="U_iso4217USD">19798000</ortx:LongTermDebtBeforeAccretionIssuanceCostsNetNoncurrent>
    <ortx:AccretionRelatedToFinalPayment
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000749"
      unitRef="U_iso4217USD">203000</ortx:AccretionRelatedToFinalPayment>
    <ortx:AccretionRelatedToFinalPayment
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000750"
      unitRef="U_iso4217USD">406000</ortx:AccretionRelatedToFinalPayment>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000751"
      unitRef="U_iso4217USD">32086000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000752"
      unitRef="U_iso4217USD">20204000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock contextRef="C_0001748907_20210101_20211231" id="F_000358">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2021, the future principal payments due are as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Minimum&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Payments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;786&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,429&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,429&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2025&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,429&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2026&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,082&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;34,155&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less current portion&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(786&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less unamortized portion of final payment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(952&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less unamortized debt issuance costs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(331&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Notes payable, long term&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32,086&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000753"
      unitRef="U_iso4217USD">786000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000754"
      unitRef="U_iso4217USD">9429000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000755"
      unitRef="U_iso4217USD">9429000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000756"
      unitRef="U_iso4217USD">9429000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000757"
      unitRef="U_iso4217USD">5082000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000758"
      unitRef="U_iso4217USD">34155000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebtCurrent
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000759"
      unitRef="U_iso4217USD">786000</us-gaap:LongTermDebtCurrent>
    <ortx:UnamortizedPortionOfFinalPayment
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000760"
      unitRef="U_iso4217USD">952000</ortx:UnamortizedPortionOfFinalPayment>
    <us-gaap:UnamortizedDebtIssuanceExpense
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000761"
      unitRef="U_iso4217USD">331000</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000762"
      unitRef="U_iso4217USD">32086000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:InterestExpenseDebt
      contextRef="C_0001748907_us-gaapLongtermDebtTypeAxis_ortxTermLoanMember_20210101_20211231"
      decimals="-5"
      id="F_000763"
      unitRef="U_iso4217USD">2500000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="C_0001748907_us-gaapLongtermDebtTypeAxis_ortxTermLoanMember_20200101_20201231"
      decimals="-5"
      id="F_000764"
      unitRef="U_iso4217USD">2300000</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="C_0001748907_us-gaapLongtermDebtTypeAxis_ortxTermLoanMember_20210101_20211231"
      decimals="3"
      id="F_000765"
      unitRef="U_xbrlipure">0.084</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="C_0001748907_20210101_20211231" id="F_000306">
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;13. Shareholders&#x2019; Equity and Convertible Preferred Shares &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Ordinary shares &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2021, and 2020, each holder of ordinary shares and ADSs is entitled to one vote per ordinary share and to receive dividends when and if such dividends are recommended by the board of directors and declared by the shareholders.&#160;&#160;As of&#160;December 31, 2021, and 2020, the Company has not declared any dividends.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&#160;31, 20&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;, and 20&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;, the Company had authority to allot ordinary shares up to a maximum nominal value of &#xa3;&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,023,851.50&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; with a nominal value of &#xa3;&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.10&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; per share.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Ordinary share issuances&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In April 2020, the Company issued 75,413 ordinary shares to Oxford BioMedica pursuant to the terms of our license agreement (see Note 15).&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2020, the Company issued 22,758 ordinary shares pursuant to a consulting agreement (see Note 18) with a non-employee advisor.&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2021, the Company issued and sold (i) 20,900,321 ordinary shares, nominal value &#xa3;0.10 per share, at a purchase price of $6.22 per share (the &#x201c;Purchase Price&#x201d;), which was the closing sale price of the Company&#x2019;s ADSs on the Nasdaq Global Select Market on February 4, 2021, and (ii) 3,215,434 non-voting ordinary shares, nominal value &#xa3;0.10 per share, at the Purchase Price (together (i) and (ii) the &#x201c;Private Placement&#x201d;). The Private Placement resulted in net proceeds to the Company of $143.6 million after deducting placement agent fees of $6.0 million and other issuance costs of $0.4 million. The ordinary shares and non-voting ordinary shares were sold pursuant to a securities purchase agreement entered into between the Company and the purchasers named therein on February 4, 2021. All non-voting ordinary shares have been converted to ordinary shares as of December 31, 2021.&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;In July 2021 the Company issued 1,227,738 ordinary shares to Pharming Group N.V. for total consideration of $7.5 million. The consideration is payment for the fair value of ordinary shares with a fair value of $4.1 million plus a $3.4 million premium on the fair value of the Company&#x2019;s ordinary shares, which was allocated to the license and collaboration agreement (see Note 16).&lt;/span&gt;&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;In December 2021, the Company issued 22,758 ordinary shares pursuant to a consulting agreement (see Note 18) with a non-employee advisor&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockVotingRights contextRef="C_0001748907_20210101_20211231" id="F_000766">each holder of ordinary shares and ADSs is entitled to one vote per ordinary share</us-gaap:CommonStockVotingRights>
    <ortx:NumberOfOrdinaryVotingRights
      contextRef="C_0001748907_20210101_20211231"
      decimals="INF"
      id="F_000769"
      unitRef="U_ortxVotingRight">1</ortx:NumberOfOrdinaryVotingRights>
    <ortx:NumberOfOrdinaryVotingRights
      contextRef="C_0001748907_20200101_20201231"
      decimals="INF"
      id="F_000770"
      unitRef="U_ortxVotingRight">1</ortx:NumberOfOrdinaryVotingRights>
    <us-gaap:DividendsCommonStock
      contextRef="C_0001748907_20210101_20211231"
      decimals="0"
      id="F_000767"
      unitRef="U_iso4217USD">0</us-gaap:DividendsCommonStock>
    <us-gaap:DividendsCommonStock
      contextRef="C_0001748907_20200101_20201231"
      decimals="0"
      id="F_000768"
      unitRef="U_iso4217USD">0</us-gaap:DividendsCommonStock>
    <us-gaap:CommonStockValueOutstanding
      contextRef="C_0001748907_srtRangeAxis_srtMaximumMember_20211231"
      decimals="2"
      id="F_000771"
      unitRef="U_iso4217GBP">13023851.50</us-gaap:CommonStockValueOutstanding>
    <us-gaap:CommonStockValueOutstanding
      contextRef="C_0001748907_srtRangeAxis_srtMaximumMember_20201231"
      decimals="2"
      id="F_000772"
      unitRef="U_iso4217GBP">13023851.50</us-gaap:CommonStockValueOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001748907_20211231"
      decimals="INF"
      id="F_000773"
      unitRef="U_iso4217GBP_xbrlishares">0.10</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001748907_20201231"
      decimals="INF"
      id="F_000774"
      unitRef="U_iso4217GBP_xbrlishares">0.10</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxOxfordBioMedicaLicenseDevelopmentAndSupplyAgreementMember_20200430"
      decimals="INF"
      id="F_000775"
      unitRef="U_xbrlishares">75413</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001748907_srtTitleOfIndividualAxis_ortxNonEmployeeAdvisorMember_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_ortxConsultingAgreementMember_20201231"
      decimals="INF"
      id="F_000776"
      unitRef="U_xbrlishares">22758</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001748907_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_us-gaapTypeOfArrangementAxis_ortxSecuritiesPurchaseAgreementMember_20210201_20210228"
      decimals="INF"
      id="F_000778"
      unitRef="U_xbrlishares">20900321</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001748907_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_us-gaapTypeOfArrangementAxis_ortxSecuritiesPurchaseAgreementMember_20210228"
      decimals="2"
      id="F_000779"
      unitRef="U_iso4217GBP_xbrlishares">0.10</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_0001748907_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_us-gaapTypeOfArrangementAxis_ortxSecuritiesPurchaseAgreementMember_20210228"
      decimals="2"
      id="F_000780"
      unitRef="U_iso4217USD_xbrlishares">6.22</us-gaap:SaleOfStockPricePerShare>
    <ortx:ClosingPriceOfShareDate
      contextRef="C_0001748907_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_us-gaapTypeOfArrangementAxis_ortxSecuritiesPurchaseAgreementMember_20210201_20210228"
      id="F_000781">2021-02-04</ortx:ClosingPriceOfShareDate>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001748907_us-gaapStatementClassOfStockAxis_ortxNonVotingOrdinarySharesMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_us-gaapTypeOfArrangementAxis_ortxSecuritiesPurchaseAgreementMember_20210201_20210228"
      decimals="INF"
      id="F_000782"
      unitRef="U_xbrlishares">3215434</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001748907_us-gaapStatementClassOfStockAxis_ortxNonVotingOrdinarySharesMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_us-gaapTypeOfArrangementAxis_ortxSecuritiesPurchaseAgreementMember_20210228"
      decimals="INF"
      id="F_000783"
      unitRef="U_iso4217GBP_xbrlishares">0.10</us-gaap:CommonStockParOrStatedValuePerShare>
    <ortx:NetProceedsFromIssuanceOfPrivatePlacement
      contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxSecuritiesPurchaseAgreementMember_20210201_20210228"
      decimals="-5"
      id="F_000787"
      unitRef="U_iso4217USD">143600000</ortx:NetProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_0001748907_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_us-gaapTypeOfArrangementAxis_ortxSecuritiesPurchaseAgreementMember_20210201_20210228"
      decimals="-5"
      id="F_000784"
      unitRef="U_iso4217USD">6000000.0</us-gaap:PaymentsOfStockIssuanceCosts>
    <ortx:PaymentsOfOtherIssuanceCosts
      contextRef="C_0001748907_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_us-gaapTypeOfArrangementAxis_ortxSecuritiesPurchaseAgreementMember_20210201_20210228"
      decimals="-5"
      id="F_000785"
      unitRef="U_iso4217USD">400000</ortx:PaymentsOfOtherIssuanceCosts>
    <us-gaap:SaleOfStockTransactionDate
      contextRef="C_0001748907_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_us-gaapTypeOfArrangementAxis_ortxSecuritiesPurchaseAgreementMember_20210201_20210228"
      id="F_000786">2021-02-04</us-gaap:SaleOfStockTransactionDate>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxSharePurchaseAgreementWithPharmingMember_20210701_20210731"
      decimals="INF"
      id="F_000789"
      unitRef="U_xbrlishares">1227738</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxSharePurchaseAgreementWithPharmingMember_20210701_20210731"
      decimals="-5"
      id="F_000788"
      unitRef="U_iso4217USD">7500000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxSharePurchaseAgreementWithPharmingMember_20210701_20210731"
      decimals="-5"
      id="F_000790"
      unitRef="U_iso4217USD">4100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <ortx:ProceedsFromPremiumSharesIssued
      contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxSharePurchaseAgreementWithPharmingMember_20210701_20210731"
      decimals="-5"
      id="F_000791"
      unitRef="U_iso4217USD">3400000</ortx:ProceedsFromPremiumSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001748907_srtTitleOfIndividualAxis_ortxNonEmployeeAdvisorMember_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_ortxConsultingAgreementMember_20211231"
      decimals="INF"
      id="F_000777"
      unitRef="U_xbrlishares">22758</us-gaap:CommonStockSharesIssued>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="C_0001748907_20210101_20211231" id="F_000307">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;14. Share-based Compensation &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company maintains&#160;four&#160;equity compensation plans; the Orchard Therapeutics Limited Employee Share Option Plan with Non-Employee Sub-Plan and U.S. Sub-Plan (the &#x201c;2016 Plan&#x201d;), the Orchard Therapeutics plc 2018 Share Option and Incentive Plan (the &#x201c;2018 Plan&#x201d;), the 2018 Employee Share Purchase Plan (the &#x201c;ESPP&#x201d;), and the 2020 Inducement Equity Plan (the &#x201c;Inducement Plan&#x201d;). &lt;span style="color:#000000;"&gt;The number of shares of common stock that may be issued under the 2018 Plan is subject to increase by the number of shares forfeited under any options forfeited and not exercised under the 2018 Plan or 2016 Plan. &lt;/span&gt;The board of directors has determined not to make any further awards under the 2016 plan. As of December 31, 2021, 6,934,474 shares remained available for grant under the 2018 Plan, 721,500 remained available under the Inducement Plan, and 1,197,399 shares remained available for grant under the ESPP.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prior to the Company&#x2019;s IPO, the Company granted options to United States employees and non-employees at exercise prices deemed by the board of directors to be equal to the fair value of the ordinary share at the time of grant, and granted options to United Kingdom and European Union employees and non-employees at an exercise price equal to the par value of the ordinary shares of &#xa3;0.00001. After the IPO, options are now granted at exercise prices equal to the fair value of the Company&#x2019;s ordinary shares on the grant date for all employees. The vesting period is determined by the board of directors, which is generally four years. An option&#x2019;s maximum term is &lt;span style="-sec-ix-hidden:F_000797"&gt;ten&#160;years&lt;/span&gt;. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Share options&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair value of each stock option award is determined on the date of grant using the Black-Scholes option-pricing model. &lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;The risk-free interest rate is based on a U.S. treasury instrument whose term is consistent with the expected term of the stock options. The expected term of the Company&#x2019;s options has been determined utilizing the &#x201c;simplified&#x201d; method for awards that qualify as &#x201c;plain-vanilla&#x201d; options. The expected volatility is based on the historical volatility of a representative group of companies with similar characteristics to the Company, including those in the early stages of product development with a similar and therapeutic focus. For these analyses, the Company selects companies with comparable characteristics to its own including enterprise value, risk profiles, position within the industry, and with historical share price information sufficient to meet the expected term of the options. &lt;/span&gt;The relevant data used to determine the value of stock option awards are as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.96%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="4" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.96%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.96%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.12%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000798"&gt;0.5 - 1.3%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000799"&gt;0.3 - 1.7%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.96%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.12%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.3 - 6.1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.5 - 6.1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.96%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.12%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000806"&gt;74.2 - 78.7%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000807"&gt;70.7 - 75.2%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.96%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected dividend rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.12%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.00%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.00%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes option activity under the plans for the year ended December 31, 2021:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise Price&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;per Share&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Life (Years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,895,643&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.96&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000824"&gt;7.16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;91,133&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,489,856&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.75&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,727,254&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.59&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3,357,505&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.30&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding and expected to vest at December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,300,740&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.57&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000825"&gt;7.83&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,842&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercisable, as of December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,880,668&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.90&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000826"&gt;6.59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,685&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The aggregate intrinsic value of options is calculated as the difference between the exercise price of the options and the fair value of the Company&#x2019;s ordinary shares for those options that had exercise prices lower than the fair value of the Company&#x2019;s ordinary shares. During the years ended December 31, 2021 and 2020, the total intrinsic value of share options exercised was $7.4 million and $5.0 million, respectively. During the years ended December 31, 2021 and 2020, the total proceeds to the Company from share options exercised was $2.7 million and $3.9 million, respectively. As of December 31, 2021, and 2020, there was $&lt;span style="-sec-ix-hidden:F_000834"&gt;nil&lt;/span&gt; and $0.2 million in employee equity plan proceeds received after year-end, respectively.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The weighted average grant date fair value of the options granted during the years ended December&#160;31, 2021 and 2020 was $3.10 per share and $7.22 per share, respectively.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Restricted Share Units&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Performance-based share units&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The Company has issued performance-based restricted share units (&#x201c;RSUs&#x201d;) to certain executives and members of its senior management, with vesting linked to the achievement of three specific regulatory and research and development milestones and one market condition based upon the volume weighted-average price (&#x201c;VWAP&#x201d;) of the Company&#x2019;s ADSs for a certain period. Upon achievement of any of the aforementioned milestones, one third of the RSUs will vest, and the award will become fully vested upon achievement of three of the four performance conditions.&#160; 89,667 performance-based share units vested during the years ended December 31, 2021. At December 31, 2021, the remaining 179,333 performance-based share units outstanding under the scheme were cancelled.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The fair value associated with the performance-based conditions is recognized when achievement of the milestones becomes probable, if at all. In the fourth quarter of 2020, the Company determined that a performance milestone was probable upon &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;approval of Libmeldy by the E&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;uropean &lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;C&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;ommission in December 2020&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;, and recognized $&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;1.2&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt; million in compensation cost. &lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The shares associated with recognition of this performance milestone vested and were issued in January 2021.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;CEO Award&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The Company granted&#160;195,000&#160;performance-based RSUs with a total grant date fair value of $1.4 million to its Chief Executive Officer, Bobby Gaspar, M.D., Ph.D., in April 2020.&#160;&#160;The award vests on January 2, 2024 as to 1/3 of the award for each of the first three to occur of four milestones, if each such milestone is achieved by the Company on or before December 31, 2023&#160;and Dr. Gaspar remains continuously employed with the Company through January 2, 2024. The milestones relate to achievement of specific clinical and regulatory milestones. No performance-based share unit performance conditions associated with the CEO award were deemed probable and none vested during the year ended December 31, 2021. &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Time-based restricted share units&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Time-based restricted share units vest in equal annual installments over a &lt;span style="-sec-ix-hidden:F_000844"&gt;three-year&lt;/span&gt; period.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes restricted share unit award activity for the year-end December 31, 2021:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Performance-based RSUs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Time-based RSUs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted Average Grant Date Fair Value per Share&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;464,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;180,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.75&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;47,500&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.94&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(89,667&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(41,667&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.94&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.08%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(179,333&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(62,500&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.32&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.08%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested at December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;195,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;123,333&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.41&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Share-based compensation &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Share-based compensation expense related to share options, restricted share unit awards, and the employee stock purchase plan was classified in the consolidated statements of operations and comprehensive loss as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,214&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,679&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Selling, general and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,322&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,283&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,536&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27,962&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company had 9,420,072 unvested options outstanding as of December&#160;31, 2021. As of December 31, 2021, total unrecognized compensation cost related to unvested stock option grants and time-based RSUs was approximately $37.1 million. This amount is expected to be recognized over a weighted average period of approximately 2.77 years. As of December 31, 2021, the total unrecognized compensation cost related to performance-based RSUs is a maximum of $1.4 million, the timing of recognition will be dependent upon achievement of milestones. &lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_0001748907_us-gaapPlanNameAxis_ortxTwoThousandAndEighteenShareOptionAndIncentivePlanMember_20211231"
      decimals="INF"
      id="F_000792"
      unitRef="U_xbrlishares">6934474</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_0001748907_us-gaapPlanNameAxis_ortxTwoThousandAndTwentyInducementEquityPlanMember_20211231"
      decimals="INF"
      id="F_000794"
      unitRef="U_xbrlishares">721500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_0001748907_us-gaapPlanNameAxis_ortxTwoThousandAndEighteenEmployeeSharePurchasePlanMember_20211231"
      decimals="INF"
      id="F_000793"
      unitRef="U_xbrlishares">1197399</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased
      contextRef="C_0001748907_20211231"
      decimals="5"
      id="F_000795"
      unitRef="U_iso4217GBP_xbrlishares">0.00001</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="C_0001748907_20210101_20211231" id="F_000796">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock contextRef="C_0001748907_20210101_20211231" id="F_000359">The relevant data used to determine the value of stock option awards are as follows:
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.96%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="4" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.96%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.96%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.12%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000798"&gt;0.5 - 1.3%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000799"&gt;0.3 - 1.7%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.96%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.12%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.3 - 6.1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.5 - 6.1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.96%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.12%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000806"&gt;74.2 - 78.7%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000807"&gt;70.7 - 75.2%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.96%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected dividend rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.12%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.00%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.00%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_0001748907_20210101_20211231"
      decimals="4"
      id="F_000810"
      unitRef="U_xbrlipure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_0001748907_20200101_20201231"
      decimals="4"
      id="F_000811"
      unitRef="U_xbrlipure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="C_0001748907_20210101_20211231" id="F_000360">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes option activity under the plans for the year ended December 31, 2021:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise Price&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;per Share&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Life (Years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,895,643&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.96&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000824"&gt;7.16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;91,133&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,489,856&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.75&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,727,254&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.59&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3,357,505&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.30&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding and expected to vest at December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,300,740&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.57&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000825"&gt;7.83&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,842&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercisable, as of December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,880,668&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.90&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000826"&gt;6.59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,685&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0001748907_20201231"
      decimals="INF"
      id="F_000812"
      unitRef="U_xbrlishares">13895643</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_0001748907_20201231"
      decimals="2"
      id="F_000818"
      unitRef="U_iso4217USD_xbrlishares">7.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000827"
      unitRef="U_iso4217USD">91133000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_0001748907_20210101_20211231"
      decimals="INF"
      id="F_000813"
      unitRef="U_xbrlishares">8489856</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_0001748907_20210101_20211231"
      decimals="2"
      id="F_000819"
      unitRef="U_iso4217USD_xbrlishares">4.75</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0001748907_20210101_20211231"
      decimals="INF"
      id="F_000814"
      unitRef="U_xbrlishares">1727254</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_0001748907_20210101_20211231"
      decimals="2"
      id="F_000820"
      unitRef="U_iso4217USD_xbrlishares">1.59</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_0001748907_20210101_20211231"
      decimals="INF"
      id="F_000815"
      unitRef="U_xbrlishares">3357505</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_0001748907_20210101_20211231"
      decimals="2"
      id="F_000821"
      unitRef="U_iso4217USD_xbrlishares">10.30</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0001748907_20211231"
      decimals="INF"
      id="F_000816"
      unitRef="U_xbrlishares">17300740</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_0001748907_20211231"
      decimals="2"
      id="F_000822"
      unitRef="U_iso4217USD_xbrlishares">6.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000828"
      unitRef="U_iso4217USD">2842000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_0001748907_20211231"
      decimals="INF"
      id="F_000817"
      unitRef="U_xbrlishares">7880668</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_0001748907_20211231"
      decimals="2"
      id="F_000823"
      unitRef="U_iso4217USD_xbrlishares">6.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000829"
      unitRef="U_iso4217USD">2685000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_0001748907_20210101_20211231"
      decimals="-5"
      id="F_000830"
      unitRef="U_iso4217USD">7400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_0001748907_20200101_20201231"
      decimals="-5"
      id="F_000831"
      unitRef="U_iso4217USD">5000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_0001748907_20210101_20211231"
      decimals="-5"
      id="F_000832"
      unitRef="U_iso4217USD">2700000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_0001748907_20200101_20201231"
      decimals="-5"
      id="F_000833"
      unitRef="U_iso4217USD">3900000</us-gaap:ProceedsFromStockOptionsExercised>
    <ortx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeEquityPlanProceedsReceivedAfterYearEnd
      contextRef="C_0001748907_20201231"
      decimals="-5"
      id="F_000835"
      unitRef="U_iso4217USD">200000</ortx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeEquityPlanProceedsReceivedAfterYearEnd>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001748907_20210101_20211231"
      decimals="2"
      id="F_000836"
      unitRef="U_iso4217USD_xbrlishares">3.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001748907_20200101_20201231"
      decimals="2"
      id="F_000837"
      unitRef="U_iso4217USD_xbrlishares">7.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_0001748907_us-gaapAwardTypeAxis_us-gaapPerformanceSharesMember_20210101_20211231"
      decimals="INF"
      id="F_000838"
      unitRef="U_xbrlishares">89667</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_0001748907_us-gaapAwardTypeAxis_us-gaapPerformanceSharesMember_20210101_20211231"
      decimals="INF"
      id="F_000839"
      unitRef="U_xbrlishares">179333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001748907_us-gaapAwardTypeAxis_us-gaapPerformanceSharesMember_us-gaapTypeOfArrangementAxis_ortxLibmeldyMember_20201001_20201231"
      decimals="-5"
      id="F_000840"
      unitRef="U_iso4217USD">1200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_0001748907_srtTitleOfIndividualAxis_srtChiefExecutiveOfficerMember_us-gaapAwardTypeAxis_us-gaapPerformanceSharesMember_20200401_20200430"
      decimals="INF"
      id="F_000841"
      unitRef="U_xbrlishares">195000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <ortx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue
      contextRef="C_0001748907_srtTitleOfIndividualAxis_srtChiefExecutiveOfficerMember_us-gaapAwardTypeAxis_us-gaapPerformanceSharesMember_20200401_20200430"
      decimals="-5"
      id="F_000842"
      unitRef="U_iso4217USD">1400000</ortx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights
      contextRef="C_0001748907_srtTitleOfIndividualAxis_srtChiefExecutiveOfficerMember_us-gaapAwardTypeAxis_us-gaapPerformanceSharesMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheOneMember_20210101_20211231"
      id="F_000843">The award vests on January 2, 2024 as to 1/3 of the award for each of the first three to occur of four milestones, if each such milestone is achieved by the Company on or before December 31, 2023</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="C_0001748907_20210101_20211231" id="F_000361">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes restricted share unit award activity for the year-end December 31, 2021:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Performance-based RSUs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Time-based RSUs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted Average Grant Date Fair Value per Share&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;464,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;180,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.75&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;47,500&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.94&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(89,667&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(41,667&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.94&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.08%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(179,333&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(62,500&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.32&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.08%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested at December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;195,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;123,333&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.41&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_0001748907_us-gaapAwardTypeAxis_us-gaapPerformanceSharesMember_20201231"
      decimals="INF"
      id="F_000845"
      unitRef="U_xbrlishares">464000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_0001748907_us-gaapAwardTypeAxis_ortxTimeBasedRestrictedShareUnitsMember_20201231"
      decimals="INF"
      id="F_000846"
      unitRef="U_xbrlishares">180000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_0001748907_20201231"
      decimals="2"
      id="F_000854"
      unitRef="U_iso4217USD_xbrlishares">8.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_0001748907_us-gaapAwardTypeAxis_ortxTimeBasedRestrictedShareUnitsMember_20210101_20211231"
      decimals="INF"
      id="F_000847"
      unitRef="U_xbrlishares">47500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001748907_20210101_20211231"
      decimals="2"
      id="F_000855"
      unitRef="U_iso4217USD_xbrlishares">4.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_0001748907_us-gaapAwardTypeAxis_us-gaapPerformanceSharesMember_20210101_20211231"
      decimals="INF"
      id="F_000848"
      unitRef="U_xbrlishares">89667</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_0001748907_us-gaapAwardTypeAxis_ortxTimeBasedRestrictedShareUnitsMember_20210101_20211231"
      decimals="INF"
      id="F_000849"
      unitRef="U_xbrlishares">41667</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001748907_20210101_20211231"
      decimals="2"
      id="F_000856"
      unitRef="U_iso4217USD_xbrlishares">9.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_0001748907_us-gaapAwardTypeAxis_us-gaapPerformanceSharesMember_20210101_20211231"
      decimals="INF"
      id="F_000850"
      unitRef="U_xbrlishares">179333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_0001748907_us-gaapAwardTypeAxis_ortxTimeBasedRestrictedShareUnitsMember_20210101_20211231"
      decimals="INF"
      id="F_000851"
      unitRef="U_xbrlishares">62500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_0001748907_20210101_20211231"
      decimals="2"
      id="F_000857"
      unitRef="U_iso4217USD_xbrlishares">10.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_0001748907_us-gaapAwardTypeAxis_us-gaapPerformanceSharesMember_20211231"
      decimals="INF"
      id="F_000852"
      unitRef="U_xbrlishares">195000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_0001748907_us-gaapAwardTypeAxis_ortxTimeBasedRestrictedShareUnitsMember_20211231"
      decimals="INF"
      id="F_000853"
      unitRef="U_xbrlishares">123333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_0001748907_20211231"
      decimals="2"
      id="F_000858"
      unitRef="U_iso4217USD_xbrlishares">6.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="C_0001748907_20210101_20211231" id="F_000362">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Share-based compensation expense related to share options, restricted share unit awards, and the employee stock purchase plan was classified in the consolidated statements of operations and comprehensive loss as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,214&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,679&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Selling, general and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,322&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,283&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,536&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27,962&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001748907_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20211231"
      decimals="-3"
      id="F_000859"
      unitRef="U_iso4217USD">9214000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001748907_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231"
      decimals="-3"
      id="F_000860"
      unitRef="U_iso4217USD">11679000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001748907_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20210101_20211231"
      decimals="-3"
      id="F_000861"
      unitRef="U_iso4217USD">13322000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001748907_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20200101_20201231"
      decimals="-3"
      id="F_000862"
      unitRef="U_iso4217USD">16283000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000863"
      unitRef="U_iso4217USD">22536000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000864"
      unitRef="U_iso4217USD">27962000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="C_0001748907_20211231"
      decimals="INF"
      id="F_000865"
      unitRef="U_xbrlishares">9420072</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_0001748907_20211231"
      decimals="-5"
      id="F_000866"
      unitRef="U_iso4217USD">37100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="C_0001748907_20210101_20211231" id="F_000867">P2Y9M7D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="C_0001748907_20211231"
      decimals="-5"
      id="F_000868"
      unitRef="U_iso4217USD">1400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="C_0001748907_20210101_20211231" id="F_000308">
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;15. License and Research Arrangements &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;GSK asset purchase and license agreement &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In April 2018, the Company completed an asset purchase and license agreement (the &#x201c;GSK Agreement&#x201d;) with subsidiaries of GSK to acquire a portfolio of autologous &lt;span style="font-style:italic;"&gt;ex vivo&lt;/span&gt; gene therapy assets and licenses, for rare diseases and option rights on three additional programs in preclinical development from Telethon Foundation and San Raffaele Hospital (&#x201c;Telethon-OSR&#x201d;). The portfolio of programs and options acquired consisted of: &lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:2.63%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:5.26%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-size:10pt;color:#000000;"&gt;Two&lt;/span&gt; late-stage clinical gene therapy programs in ongoing registrational trials for MLD and WAS; &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:2.63%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:5.26%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-size:10pt;color:#000000;"&gt;One&lt;/span&gt; earlier stage clinical gene therapy program for TDT; &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:2.63%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:5.26%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-size:10pt;color:#000000;"&gt;Strimvelis, the first autologous &lt;/span&gt;&lt;span style="font-style:italic;font-size:10pt;color:#000000;"&gt;ex vivo&lt;/span&gt;&lt;span style="font-size:10pt;color:#000000;"&gt; gene therapy for ADA-SCID which was approved for marketing by the European Medicines Agency in 2016; and &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:2.63%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:5.26%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-size:10pt;color:#000000;"&gt;Option rights exercisable upon completion of clinical proof of concept studies for three additional earlier-stage development programs, which option rights have all subsequently lapsed. &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounted for the GSK Agreement as an asset acquisition, since the asset purchase and licensing arrangement did not meet the definition of a business pursuant to ASC&#160;805, Business Combinations. Total consideration was &#xa3;94.2&#160;million ($133.6&#160;million at the acquisition date), which included an upfront payment of &#xa3;10.0&#160;million ($14.2&#160;million at the acquisition date) and 12,455,252 convertible preferred shares of the Company issued to GSK at an aggregate value of &#xa3;65.8&#160;million ($93.4&#160;million at the acquisition date), a loss contract on the Strimvelis program valued at &#xa3;12.9 million ($18.4 million), an inventory purchase liability valued at &#xa3;4.9&#160;million ($6.9&#160;million) and transaction costs of &#xa3;0.6 million ($0.8 million). The Company allocated &#xa3;94.2&#160;million ($133.6&#160;million) to in-process research and development expense (based on the fair value of the underlying programs in development). The convertible preferred shares were converted to ordinary shares as part of our IPO in November 2018.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is required to use commercially reasonable efforts to obtain a Priority Review Voucher (&#x201c;PRV&#x201d;) from the United States Food and Drug Administration for each of the programs for MLD, WAS and TDT, the first of which GSK retained beneficial ownership over. GSK also has an option to acquire, at a price pursuant to an agreed upon formula, any PRV granted to the Company thereafter for MLD, WAS and TDT. If GSK does not exercise this option to purchase any PRV, the Company may sell the PRV to a third party and must share any proceeds in excess of a specified sale price equally with GSK. For accounting purposes, as of December 31, 2021, the Company does not consider the attainment of a PRV from the United States Food and Drug Administration to be probable.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As part of the GSK Agreement the Company is required to use its best endeavors to make Strimvelis commercially available in the European Union until such time as an alternative gene therapy is commercially available for patients in Italy, and at all times at the San Raffaele Hospital in Milan, provided that a minimum number of patients continue to be treated at this site. Strimvelis is not currently expected to generate sufficient cash flows to overcome the costs of maintaining the product and certain regulatory commitments; therefore, the Company recorded a liability associated with the loss contract of &#xa3;12.9 million ($18.4 million at the acquisition date) associated with the loss expected due to this obligation. This liability is being amortized over the remaining period of expected sales of Strimvelis as a credit to research and development expenses (see Note 2).&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company will pay GSK non-refundable royalties and milestone payments in relation to the gene therapy programs. The Company will pay a flat mid-single digit percentage royalty on the combined annual net sales of ADA-SCID products, which includes Strimvelis. The Company will also pay tiered royalty rates at a percentage beginning in the mid-teens up to twenty percent for the MLD and WAS products, upon marketing approval, calculated as percentages of aggregate cumulative net sales of the MLD and WAS products, respectively. The Company will pay a tiered royalty at a percentage from the high single-digits to low double-digit for the TDT product, upon marketing approval, calculated as percentages of aggregate annual net sales of the TDT product. These royalties owed to GSK are in addition to any royalties owed to other third parties under various license agreements for the GSK programs. In aggregate, the Company may pay up to &#xa3;90.0 million in milestone payments upon achievement of certain sales milestones applicable to GSK. The Company&#x2019;s royalty obligations with respect to MLD and WAS may be deferred for a certain period in the interest of prioritizing available capital to develop each product. The Company&#x2019;s royalty obligations are subject to reduction on a product-by-product basis in the event of market control by biosimilars and will expire in April 2048. Other than Strimvelis, these royalty and milestone payments were not determined to be probable and estimable at the date of the acquisition and are not included as part of consideration. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company and GSK also separately executed a Transition Services Agreement (&#x201c;TSA&#x201d;) as well as an Inventory Sale Agreement, in April 2018. The TSA outlined several activities that the Company had requested GSK to assist with during the transition period, including but not limited to utilizing GSK to sell, market and distribute Strimvelis, and assist with regulatory, clinical and non-clinical activities for the other non-commercialized products which were ongoing at the date of the GSK Agreement. The TSA expired in December 2018. &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In connection with the Company&#x2019;s entering into the GSK Agreement, GSK assigned rights and obligations to certain contracts, which include among others, the original license agreement with Telethon-OSR and an ongoing manufacturing agreement (see Note 18). &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Telethon-OSR research and development collaboration and license agreements&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In connection with the Company&#x2019;s entering into the GSK Agreement, the Company also&#160;acquired and assumed agreements with Telethon Foundation and San Raffaele Hospital, together referred to as Telethon-OSR, for the research, development and commercialization of autologous &lt;span style="font-style:italic;"&gt;ex vivo&lt;/span&gt; gene therapies for ADA-SCID, WAS, MLD, TDT, as well as options over three additional earlier-stage development programs. The Company&#x2019;s options under the agreement with Telethon-OSR with respect to the earlier-stage programs have lapsed.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As consideration for the licenses, the Company will be required to make payments to Telethon-OSR upon achievement of certain product development milestones. Additionally, the Company will be required to pay to Telethon-OSR a tiered mid-single to low-double digit royalty percentage on annual sales of licensed products covered by patent rights on a country-by-country basis, as well as a low double-digit percentage of sublicense income received from any certain third-party sublicenses of the collaboration programs. These royalties are in addition to those payable to GSK under the GSK Agreement. The Company may pay up to an aggregate of approximately &#x20ac;31.0 million ($35.0 million at December 31, 2021) in milestone payments upon achievement of certain product development milestones for the program.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In May 2019, the Company entered into a license agreement with Telethon-OSR, under which Telethon-OSR granted to the Company an exclusive worldwide license for the research, development, manufacture and commercialization of Telethon-OSR&#x2019;s &lt;span style="font-style:italic;"&gt;ex vivo&lt;/span&gt; autologous HSC lentiviral based gene therapy for the treatment of mucopolysaccharidosis type I (&#x201c;MPS-I&#x201d;), including the Hurler variant. To date, Telethon-OSR received &#x20ac;17.0 million in upfront and milestone payments from the Company upon entering into the agreement and shortly thereafter, resulting in $19.4 million in in-process research and development expense. The Company is also required to make milestone payments contingent upon certain development, regulatory and commercial milestones are achieved and may pay up to &#x20ac;28.0 million ($31.7 million at December 31, 2021). Additionally, the Company will be required to pay Telethon a tiered mid-single to low-double digit royalty percentage on annual net sales of licensed products. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;UCLB/UCLA License Agreement &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2016, and amended in July 2017, the Company completed the UCLB/UCLA license agreement, under which the Company has been granted exclusive and non-exclusive, sublicensable licenses under certain intellectual property rights controlled by UCLB and UCLA to develop and commercialize gene therapy products in certain fields and territories. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In exchange for these rights, in 2016, the Company made upfront cash payments consisting of $0.8 million for the license to the joint UCLB/UCLA technology and $1.1 million for the license to the UCLB technology and manufacturing technology. The Company also issued an aggregate of 4,665,384 ordinary shares to UCLB, of which 1,224,094, and 3,441,290 ordinary shares were issued in 2017 and 2016, respectively. The Company recorded research and development expense based on the fair value of the ordinary shares as of the time the agreement was executed or modified. The Company was also obligated to make an additional cash payment for clinical data. In 2017, the Company paid $0.8 million in relation to clinical data acquired. The Company recorded the payments to research and development expense. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the UCLB/UCLA License Agreement, the Company is also obligated to pay an annual administration fee of $0.1 million on the first, second and third anniversary of the agreement date. Additionally, the Company may become obligated to make payments to the parties of up to an aggregate of &#xa3;19.9 million ($26.8 million at December 31, 2021) upon the achievement of specified regulatory milestones as well as royalties ranging from low to mid-single-digit percentage on net sales of the applicable gene therapy product. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recorded nil and $0.1 million of research and development costs in respect of the UCLB/UCLA license agreement associated with the annual administrative fee for the years ended December 31, 2021 and 2020.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2021, the Company terminated the license to its OTL-101 program for ADA-SCID, which was granted pursuant to the UCLB/UCLA license agreement. &lt;span style="color:#000000;"&gt;Except for the termination of such license, the UCLB/UCLA license agreement continues in full force and effect.&lt;/span&gt; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unless terminated earlier by either party, the UCLB/UCLA license agreement will expire on the 25&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;th&lt;/sup&gt; anniversary of the agreement. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Oxford BioMedica license, development and supply agreement &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;In November 2016, and as amended in June 2017, May&#160;2018, July 2018, September 2018, May 2019 and April 2020&lt;/span&gt;&lt;span style="color:#000000;"&gt;, the Company entered into an arrangement with Oxford BioMedica whereby Oxford BioMedica granted an exclusive intellectual property license to the Company for the purposes of research, development, and commercialization of collaboration products, and will provide process development services, and manufacture clinical and commercial GMP-grade lentiviral vectors to the Company (&#x201c;Oxford BioMedica Agreement&#x201d;). As part of the consideration to rights and licenses granted under the Oxford BioMedica Agreement, the Company issued 588,220 ordinary shares to Oxford BioMedica. The Company is also obligated to make certain development milestone payments in the form of issuance of additional ordinary shares if the milestones are achieved. In November 2017, the first milestone was achieved, and the Company was committed to issue another 150,826 ordinary shares, and issued these shares in 2018. In September 2018, the second and fourth milestones were achieved, and the Company issued 150,826 ordinary shares. In April 2020, the fifth milestone was deemed to have been met upon execution of the amended agreement in April 2020, and the Company issued 75,413 ordinary shares to Oxford BioMedica with a total value of $0.8 million, which was expensed to research and development expense. No milestones were met during the year ended December 31, 2021.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company may also pay low single-digit percentage royalties on annual net sales of collaborated product generated under the Oxford BioMedica Agreement. &lt;span style="font-size:12pt;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;16. Collaboration agreement with Pharming Group N.V.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Overview&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On July 1, 2021, the Company entered into a strategic collaboration with Pharming Group N.V. (&#x201c;Pharming&#x201d;) to research, develop, manufacture, and commercialize OTL-105, an investigational&#160;&lt;span style="font-style:italic;"&gt;ex vivo&lt;/span&gt;&#160;autologous HSC gene therapy for the treatment of hereditary angioedema (HAE), a life-threatening rare disorder that causes recurring swelling attacks in the face, throat, extremities and abdomen (the &#x201c;Collaboration Agreement&#x201d;).&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the terms of the Collaboration Agreement, Pharming was granted worldwide rights to OTL-105 and will be responsible for clinical development, regulatory filings and commercialization of the investigational gene therapy, including associated costs. The Company will lead the completion of IND-enabling activities and oversee manufacturing of OTL-105 during preclinical and clinical development, which will be funded by Pharming. In addition, both the Company and Pharming will explore the application of non-toxic conditioning regimen for use with OTL-105 administration.&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company received an upfront payment of $10.0&#160;million in cash from Pharming. The Company is also eligible to receive up to $189.5&#160;million in development, regulatory and sales milestones as well as mid-single to low double-digit percentage royalty payments on future worldwide sales.&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Share Purchase Agreement&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The Company also entered into a Share Purchase Agreement with Pharming on July 1, 2021 (the &#x201c;SPA&#x201d;), pursuant to which the Company issued 1,227,738 ordinary shares to Pharming for total consideration of $7.5 million. The consideration is payment for the fair value of ordinary shares with a fair value of $4.1 million plus a $3.4 million premium on the fair value of the Company&#x2019;s ordinary shares&lt;/span&gt;.&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The &#x201c;Collaboration Agreement&#x201d; and the &#x201c;SPA&#x201d; are referred to together as the &#x201c;Pharming Agreements.&#x201d;&lt;/span&gt;&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Accounting Analysis&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;At the commencement of the arrangement, two units of accounting were identified, which are the issuance of&#160;1,227,738 of the Company&#x2019;s ordinary shares as part of the SPA, and the license and collaboration agreement, which conveys the license and provides for the Company to provide research, development, manufacturing services for OTL-105. The Pharming Agreements were entered into concurrently as part of a single commercial objective, and the Company considers them a &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;single arrangement for accounting purposes. The total upfront payments of $&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;17.5&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt; million &lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;are&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt; &lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;comprise&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;d of&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt; $&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;4.1&#160;&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;million attributed to the equity sold to Pharming and $&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;13.4&#160;&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;million attributed to the Collaboration Agreement. In determining the fair value of the common stock issued to Pharming as part of the SPA, the Company used an option pricing valuation model to take into consideration certain holding period restrictions on the shares. The fair value of the Company&#x2019;s common shares was considered a level 2 fair value measurement within the fair value hierarchy. &lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The most significant assumptions within the model are the Company&#x2019;s stock price, the term of the restrictions and the stock price volatility, which is based upon historical volatility of the Company&#x2019;s stock. &lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Based on the fair value adjustments made by management, the fair value of the&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt; shares issued was &lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;determined to be $&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;4.1&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt; million with the excess proceeds of $&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;3.4&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt; million being allocation to the Collaboration&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt; Agreement.&lt;/span&gt;&lt;span style="font-size:12pt;color:#000000;"&gt; &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The Company recognizes revenue under Accounting Standards Codification (&#x201c;ASC&#x201d;) 606,&#160;&lt;/span&gt;&lt;span style="font-style:italic;"&gt;Revenue from Contracts with Customer &lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;(&#x201c;ASC 606&#x201d;). &lt;/span&gt;The Company has concluded that the conveyance of the license for the HAE program and the provision of research, development, and manufacturing services for the HAE program represent a series of distinct services that are accounted for as a single performance obligation within the Collaboration Agreement. The Company determined that the transaction price includes: the non-refundable up-front payment of $10.0&#160;million, the $3.4 million in premium associated with the SPA, and the variable consideration for estimated reimbursement payments at agreed upon contractual rates to be received from Pharming for the Company&#x2019;s on-going research, development, and manufacturing services. The potential future variable consideration is associated with the reimbursement for research, development, and manufacturing services provided by the Company to Pharming at agreed upon contractual rates which is the only remaining unsatisfied performance obligation. The milestone payments included in the Collaboration Agreement are fully constrained, as a result of the uncertainty regarding whether any of the associated milestones will be achieved and therefore,&lt;span style="Background-color:#FFFFFF;"&gt; the Company determined that it could not assert that it was probable that a significant reversal in the amount of cumulative revenue recognized will not occur.&lt;/span&gt; The total estimated cost of the research and development services reflect the nature of the services to be performed and the Company&#x2019;s best estimate of the length of time required to perform the services. &lt;span style="Background-color:#FFFFFF;"&gt;The Company re-evaluates the transaction price as of the end of each reporting period&lt;/span&gt;.&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company also considered the existence of any significant financing component within the Pharming Agreements given their upfront payment structure. Based upon this assessment, the Company concluded that the up-front payments were provided for valid business reasons and not for the purpose of providing financing. Accordingly, the Company has concluded that the upfront payment structure of the Pharming Agreements does not result in the existence of a significant financing component.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognizes revenue associated with the performance obligation as the research, development and manufacturing services are provided using an input method, based on the cumulative costs incurred compared to the total estimated costs expected to be incurred to satisfy the performance obligation. The transfer of control to the customer occurs over the time period that the research, development and manufacturing services are to be provided by the Company, and this cost-to-cost method is, in management&#x2019;s judgment, the best measure of progress towards satisfying the performance obligation. Reimbursement for research, development, and manufacturing services are recognized as the costs are incurred consistent with the cost-to-cost method.&#160;The Company's continuing obligations to provide research, development, and manufacturing services is based on the results of such efforts, and the estimated costs associated with the remaining efforts required to complete the performance obligations may change, which may materially impact revenue recognition. The Company regularly evaluates and, when necessary, updates the costs associated with the remaining effort under the Collaboration Agreement. Accordingly, revenue may fluctuate from period to period due to revisions to estimated costs, resulting in a change in the measure of progress for the performance obligation, or if the transaction price changes due to inclusion of any milestone payments that become unconstrained.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes research and development costs incurred and collaboration revenue recognized in connection with the Company&#x2019;s performance under the Collaboration Agreement:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.8%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.8%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.8%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reimbursement revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.42%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;843&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.3%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.8%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Upfront and milestone payment revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;132&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.8%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.42%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;975&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company had $0.8 million and nil due from Pharming included in accounts receivable as of December 31, 2021 and December 31, 2020, respectively.&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of &lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;, the Company had contract liabilities of $&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12.9&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; million, which is classified as either current or long-term deferred revenue in the&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; c&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;onsolidated balance sheet&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;s&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; based on the period over which this is expected to be recognized. The deferred revenue balance represents the portion of the upfront payments received &lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;related to the performance obligation &lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;that &lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;remains&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; partially unsatisfied as of&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; December 31&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <ortx:NumberOfLateStageClinicalGeneTherapyPrograms
      contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxGSKAssetPurchaseAndLicenseAgreementMember_20180401_20180430"
      decimals="INF"
      id="F_000869"
      unitRef="U_ortxProgram">2</ortx:NumberOfLateStageClinicalGeneTherapyPrograms>
    <ortx:NumberOfEarlierStageClinicalGeneTherapyProgram
      contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxGSKAssetPurchaseAndLicenseAgreementMember_20180401_20180430"
      decimals="INF"
      id="F_000870"
      unitRef="U_ortxProgram">1</ortx:NumberOfEarlierStageClinicalGeneTherapyProgram>
    <ortx:NumberOfAdditionalEarlierStageDevelopmentPrograms
      contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxGSKAssetPurchaseAndLicenseAgreementMember_20180401_20180430"
      decimals="INF"
      id="F_000871"
      unitRef="U_ortxProgram">3</ortx:NumberOfAdditionalEarlierStageDevelopmentPrograms>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxGSKAssetPurchaseAndLicenseAgreementMember_20180401_20180430"
      decimals="-5"
      id="F_000872"
      unitRef="U_iso4217GBP">94200000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxGSKAssetPurchaseAndLicenseAgreementMember_20180401_20180430"
      decimals="-5"
      id="F_000873"
      unitRef="U_iso4217USD">133600000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <ortx:AssetAcquisitionUpfrontPayment
      contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxGSKAssetPurchaseAndLicenseAgreementMember_20180401_20180430"
      decimals="-5"
      id="F_000874"
      unitRef="U_iso4217GBP">10000000.0</ortx:AssetAcquisitionUpfrontPayment>
    <ortx:AssetAcquisitionUpfrontPayment
      contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxGSKAssetPurchaseAndLicenseAgreementMember_20180401_20180430"
      decimals="-5"
      id="F_000875"
      unitRef="U_iso4217USD">14200000</ortx:AssetAcquisitionUpfrontPayment>
    <ortx:AssetAcquisitionNumberOfSharesIssuedForAcquisition
      contextRef="C_0001748907_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_us-gaapTypeOfArrangementAxis_ortxGSKAssetPurchaseAndLicenseAgreementMember_20180401_20180430"
      decimals="INF"
      id="F_000876"
      unitRef="U_xbrlishares">12455252</ortx:AssetAcquisitionNumberOfSharesIssuedForAcquisition>
    <ortx:AssetAcquisitionValueOfEquityInstrumentsIssued
      contextRef="C_0001748907_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_us-gaapTypeOfArrangementAxis_ortxGSKAssetPurchaseAndLicenseAgreementMember_20180430"
      decimals="-5"
      id="F_000877"
      unitRef="U_iso4217GBP">65800000</ortx:AssetAcquisitionValueOfEquityInstrumentsIssued>
    <ortx:AssetAcquisitionValueOfEquityInstrumentsIssued
      contextRef="C_0001748907_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_us-gaapTypeOfArrangementAxis_ortxGSKAssetPurchaseAndLicenseAgreementMember_20180430"
      decimals="-5"
      id="F_000878"
      unitRef="U_iso4217USD">93400000</ortx:AssetAcquisitionValueOfEquityInstrumentsIssued>
    <ortx:AssetAcquisitionLiabilityAssumed
      contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxGSKAssetPurchaseAndLicenseAgreementMember_20180430"
      decimals="-5"
      id="F_000879"
      unitRef="U_iso4217GBP">12900000</ortx:AssetAcquisitionLiabilityAssumed>
    <ortx:AssetAcquisitionLiabilityAssumed
      contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxGSKAssetPurchaseAndLicenseAgreementMember_20180430"
      decimals="-5"
      id="F_000880"
      unitRef="U_iso4217USD">18400000</ortx:AssetAcquisitionLiabilityAssumed>
    <ortx:AssetAcquisitionInventoryPurchaseLiability
      contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxGSKAssetPurchaseAndLicenseAgreementMember_20180430"
      decimals="-5"
      id="F_000881"
      unitRef="U_iso4217GBP">4900000</ortx:AssetAcquisitionInventoryPurchaseLiability>
    <ortx:AssetAcquisitionInventoryPurchaseLiability
      contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxGSKAssetPurchaseAndLicenseAgreementMember_20180430"
      decimals="-5"
      id="F_000882"
      unitRef="U_iso4217USD">6900000</ortx:AssetAcquisitionInventoryPurchaseLiability>
    <ortx:AssetAcquisitionTransactionCosts
      contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxGSKAssetPurchaseAndLicenseAgreementMember_20180401_20180430"
      decimals="-5"
      id="F_000883"
      unitRef="U_iso4217GBP">600000</ortx:AssetAcquisitionTransactionCosts>
    <ortx:AssetAcquisitionTransactionCosts
      contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxGSKAssetPurchaseAndLicenseAgreementMember_20180401_20180430"
      decimals="-5"
      id="F_000884"
      unitRef="U_iso4217USD">800000</ortx:AssetAcquisitionTransactionCosts>
    <ortx:AssetAcquisitionInProcessResearchAndDevelopmentExpense
      contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxGSKAssetPurchaseAndLicenseAgreementMember_20180401_20180430"
      decimals="-5"
      id="F_000885"
      unitRef="U_iso4217GBP">94200000</ortx:AssetAcquisitionInProcessResearchAndDevelopmentExpense>
    <ortx:AssetAcquisitionInProcessResearchAndDevelopmentExpense
      contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxGSKAssetPurchaseAndLicenseAgreementMember_20180401_20180430"
      decimals="-5"
      id="F_000886"
      unitRef="U_iso4217USD">133600000</ortx:AssetAcquisitionInProcessResearchAndDevelopmentExpense>
    <ortx:AssetAcquisitionLiabilityAssumed
      contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxGSKAssetPurchaseAndLicenseAgreementMember_20180430"
      decimals="-5"
      id="F_000887"
      unitRef="U_iso4217GBP">12900000</ortx:AssetAcquisitionLiabilityAssumed>
    <ortx:AssetAcquisitionLiabilityAssumed
      contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxGSKAssetPurchaseAndLicenseAgreementMember_20180430"
      decimals="-5"
      id="F_000888"
      unitRef="U_iso4217USD">18400000</ortx:AssetAcquisitionLiabilityAssumed>
    <ortx:PaymentOfTieredRoyaltyMaximumPercentage
      contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxGSKAssetPurchaseAndLicenseAgreementMember_20211231"
      decimals="2"
      id="F_000889"
      unitRef="U_xbrlipure">0.20</ortx:PaymentOfTieredRoyaltyMaximumPercentage>
    <ortx:MilestonePaymentsPayableUponAchievementOfCertainSalesMilestones
      contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxGSKAssetPurchaseAndLicenseAgreementMember_20211231"
      decimals="-5"
      id="F_000890"
      unitRef="U_iso4217GBP">90000000.0</ortx:MilestonePaymentsPayableUponAchievementOfCertainSalesMilestones>
    <ortx:MilestonePaymentsPayableUponAchievementOfCertainSalesMilestones
      contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxGSKAssetPurchaseAndLicenseAgreementMember_20211231"
      decimals="-5"
      id="F_000891"
      unitRef="U_iso4217EUR">31000000.0</ortx:MilestonePaymentsPayableUponAchievementOfCertainSalesMilestones>
    <ortx:MilestonePaymentsPayableUponAchievementOfCertainSalesMilestones
      contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxGSKAssetPurchaseAndLicenseAgreementMember_20211231"
      decimals="-5"
      id="F_000892"
      unitRef="U_iso4217USD">35000000.0</ortx:MilestonePaymentsPayableUponAchievementOfCertainSalesMilestones>
    <ortx:UpfrontPaymentDescription
      contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxGSKAssetPurchaseAndLicenseAgreementMember_20210101_20211231"
      id="F_000893">In May 2019, the Company entered into a license agreement with Telethon-OSR, under which Telethon-OSR granted to the Company an exclusive worldwide license for the research, development, manufacture and commercialization of Telethon-OSR&#x2019;s ex vivo autologous HSC lentiviral based gene therapy for the treatment of mucopolysaccharidosis type I (&#x201c;MPS-I&#x201d;), including the Hurler variant. To date, Telethon-OSR received &#x20ac;17.0 million in upfront and milestone payments from the Company upon entering into the agreement and shortly thereafter, resulting in $19.4 million in in-process research and development expense.</ortx:UpfrontPaymentDescription>
    <ortx:UpfrontAndMilestonePayments
      contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxTelethonOSRLicenseAgreementsMember_20190501_20211231"
      decimals="-5"
      id="F_000894"
      unitRef="U_iso4217EUR">17000000.0</ortx:UpfrontAndMilestonePayments>
    <ortx:InProcessResearchAndDevelopmentExpenseForUpfrontAndMilestonePayments
      contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxTelethonOSRLicenseAgreementsMember_20190501_20211231"
      decimals="-5"
      id="F_000895"
      unitRef="U_iso4217USD">19400000</ortx:InProcessResearchAndDevelopmentExpenseForUpfrontAndMilestonePayments>
    <ortx:MilestonePaymentsPayableUponAchievementOfCertainDevelopmentRegulatoryAndCommercialMilestones
      contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxTelethonOSRLicenseAgreementsMember_20211231"
      decimals="-5"
      id="F_000896"
      unitRef="U_iso4217EUR">28000000.0</ortx:MilestonePaymentsPayableUponAchievementOfCertainDevelopmentRegulatoryAndCommercialMilestones>
    <ortx:MilestonePaymentsPayableUponAchievementOfCertainDevelopmentRegulatoryAndCommercialMilestones
      contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxTelethonOSRLicenseAgreementsMember_20211231"
      decimals="-5"
      id="F_000897"
      unitRef="U_iso4217USD">31700000</ortx:MilestonePaymentsPayableUponAchievementOfCertainDevelopmentRegulatoryAndCommercialMilestones>
    <ortx:UpfrontCashPayment
      contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxUCLBAndUCLATechnologyMember_20160101_20161231"
      decimals="-5"
      id="F_000898"
      unitRef="U_iso4217USD">800000</ortx:UpfrontCashPayment>
    <ortx:UpfrontCashPayment
      contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxUCLBTechnologyAndManufacturingTechnologyMember_20160101_20161231"
      decimals="-5"
      id="F_000899"
      unitRef="U_iso4217USD">1100000</ortx:UpfrontCashPayment>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxUCLBLicenseAgreementMember_20181231"
      decimals="INF"
      id="F_000900"
      unitRef="U_xbrlishares">4665384</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxUCLBLicenseAgreementMember_20171231"
      decimals="INF"
      id="F_000901"
      unitRef="U_xbrlishares">1224094</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxUCLBLicenseAgreementMember_20161231"
      decimals="INF"
      id="F_000902"
      unitRef="U_xbrlishares">3441290</us-gaap:CommonStockSharesIssued>
    <ortx:PaymentsToAcquireClinicalData
      contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxUCLBAndUCLALicenseAgreementMember_20170101_20171231"
      decimals="-5"
      id="F_000903"
      unitRef="U_iso4217USD">800000</ortx:PaymentsToAcquireClinicalData>
    <us-gaap:PaymentForAdministrativeFees
      contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxUCLBAndUCLALicenseAgreementMember_20210101_20211231"
      decimals="-5"
      id="F_000904"
      unitRef="U_iso4217USD">100000</us-gaap:PaymentForAdministrativeFees>
    <ortx:PotentialPaymentForAchievementOfSpecifiedMilestones
      contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxUCLBAndUCLALicenseAgreementMember_20210101_20211231"
      decimals="INF"
      id="F_000905"
      unitRef="U_iso4217GBP">19900000</ortx:PotentialPaymentForAchievementOfSpecifiedMilestones>
    <ortx:PotentialPaymentForAchievementOfSpecifiedMilestones
      contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxUCLBAndUCLALicenseAgreementMember_20210101_20211231"
      decimals="INF"
      id="F_000906"
      unitRef="U_iso4217USD">26800000</ortx:PotentialPaymentForAchievementOfSpecifiedMilestones>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxUCLBAndUCLALicenseAgreementMember_20200101_20201231"
      decimals="-5"
      id="F_000907"
      unitRef="U_iso4217USD">100000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxOxfordBioMedicaLicenseDevelopmentAndSupplyAgreementMember_20211231"
      decimals="INF"
      id="F_000908"
      unitRef="U_xbrlishares">588220</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxOxfordBioMedicaLicenseDevelopmentAndSupplyAgreementMember_20181130"
      decimals="INF"
      id="F_000909"
      unitRef="U_xbrlishares">150826</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxOxfordBioMedicaLicenseDevelopmentAndSupplyAgreementMember_20180930"
      decimals="INF"
      id="F_000910"
      unitRef="U_xbrlishares">150826</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxOxfordBioMedicaLicenseDevelopmentAndSupplyAgreementMember_20200430"
      decimals="INF"
      id="F_000911"
      unitRef="U_xbrlishares">75413</us-gaap:CommonStockSharesIssued>
    <ortx:MilestonePayment
      contextRef="C_0001748907_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapTypeOfArrangementAxis_ortxOxfordBioMedicaLicenseDevelopmentAndSupplyAgreementMember_20200430_20200430"
      decimals="-5"
      id="F_000912"
      unitRef="U_iso4217USD">800000</ortx:MilestonePayment>
    <ortx:NumberOfMilestonesMet
      contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxOxfordBioMedicaLicenseDevelopmentAndSupplyAgreementMember_20190101_20191231"
      decimals="INF"
      id="F_000913"
      unitRef="U_ortxMilestone">0</ortx:NumberOfMilestonesMet>
    <us-gaap:ProceedsFromCollaborators
      contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxStrategicCollaborationAgreementWithPharmingMember_20210701_20210701"
      decimals="-5"
      id="F_000914"
      unitRef="U_iso4217USD">10000000.0</us-gaap:ProceedsFromCollaborators>
    <ortx:MilestonePaymentsReceivable
      contextRef="C_0001748907_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_ortxStrategicCollaborationAgreementWithPharmingMember_20210701"
      decimals="INF"
      id="F_000915"
      unitRef="U_iso4217USD">189500000</ortx:MilestonePaymentsReceivable>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxSharePurchaseAgreementWithPharmingMember_20210701_20210701"
      decimals="INF"
      id="F_000917"
      unitRef="U_xbrlishares">1227738</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxSharePurchaseAgreementWithPharmingMember_20210701_20210701"
      decimals="-5"
      id="F_000916"
      unitRef="U_iso4217USD">7500000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxSharePurchaseAgreementWithPharmingMember_20210701_20210701"
      decimals="-5"
      id="F_000918"
      unitRef="U_iso4217USD">4100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <ortx:ProceedsFromPremiumSharesIssued
      contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxSharePurchaseAgreementWithPharmingMember_20210701_20210701"
      decimals="-5"
      id="F_000919"
      unitRef="U_iso4217USD">3400000</ortx:ProceedsFromPremiumSharesIssued>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxSharePurchaseAgreementWithPharmingMember_20210701_20210701"
      decimals="INF"
      id="F_000920"
      unitRef="U_xbrlishares">1227738</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <ortx:ProceedsFromUpfrontPayment
      contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxPharmingAgreementsMember_20210701_20210701"
      decimals="-5"
      id="F_000921"
      unitRef="U_iso4217USD">17500000</ortx:ProceedsFromUpfrontPayment>
    <ortx:ProceedsFromUpfrontPaymentsAttributedToEquitySold
      contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxPharmingAgreementsMember_20210701_20210701"
      decimals="-5"
      id="F_000922"
      unitRef="U_iso4217USD">4100000</ortx:ProceedsFromUpfrontPaymentsAttributedToEquitySold>
    <ortx:ProceedsFromUpfrontPaymentsAttributedToResearchActivities
      contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxPharmingAgreementsMember_20210701_20210701"
      decimals="-5"
      id="F_000923"
      unitRef="U_iso4217USD">13400000</ortx:ProceedsFromUpfrontPaymentsAttributedToResearchActivities>
    <us-gaap:StockIssued1
      contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxPharmingAgreementsMember_20210701_20210701"
      decimals="-5"
      id="F_000924"
      unitRef="U_iso4217USD">4100000</us-gaap:StockIssued1>
    <ortx:ExcessProceedsFromFairValueOfSharesIssuedAllocatedToCollaborationAgreement
      contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxPharmingAgreementsMember_20210701_20210701"
      decimals="-5"
      id="F_000925"
      unitRef="U_iso4217USD">3400000</ortx:ExcessProceedsFromFairValueOfSharesIssuedAllocatedToCollaborationAgreement>
    <ortx:ProceedsFromNonRefundableUpfrontPayment
      contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxStrategicCollaborationAgreementWithPharmingMember_20210701_20210701"
      decimals="-5"
      id="F_000926"
      unitRef="U_iso4217USD">10000000.0</ortx:ProceedsFromNonRefundableUpfrontPayment>
    <ortx:ProceedsFromPremiumSharesIssued
      contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxSharePurchaseAgreementWithPharmingMember_20210701_20210701"
      decimals="-5"
      id="F_000927"
      unitRef="U_iso4217USD">3400000</ortx:ProceedsFromPremiumSharesIssued>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock contextRef="C_0001748907_20210101_20211231" id="F_000363">
&lt;p style="Background-color:#FFFFFF;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes research and development costs incurred and collaboration revenue recognized in connection with the Company&#x2019;s performance under the Collaboration Agreement:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.8%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.8%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.8%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reimbursement revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.42%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;843&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.3%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.8%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Upfront and milestone payment revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;132&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.8%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.42%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;975&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001748907_srtProductOrServiceAxis_ortxReimbursementRevenueMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20210101_20211231"
      decimals="-3"
      id="F_000928"
      unitRef="U_iso4217USD">843000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001748907_srtProductOrServiceAxis_ortxUpfrontAndMilestonePaymentRevenueMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20210101_20211231"
      decimals="-3"
      id="F_000929"
      unitRef="U_iso4217USD">132000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20210101_20211231"
      decimals="-3"
      id="F_000930"
      unitRef="U_iso4217USD">975000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="C_0001748907_us-gaapBalanceSheetLocationAxis_us-gaapAccountsReceivableMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20211231"
      decimals="-5"
      id="F_000931"
      unitRef="U_iso4217USD">800000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="C_0001748907_us-gaapBalanceSheetLocationAxis_us-gaapAccountsReceivableMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20201231"
      decimals="-5"
      id="F_000932"
      unitRef="U_iso4217USD">800000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20211231"
      decimals="-5"
      id="F_000933"
      unitRef="U_iso4217USD">12900000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="C_0001748907_20210101_20211231" id="F_000310">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;17. Income Taxes &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The components of net loss before income taxes for the years ended December 31, 2021 and 2020 are as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.K.&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(147,337&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(155,614&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-U.K.&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,581&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,904&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss before income taxes&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(143,756&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(152,710&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The provision for (benefit from) income taxes for the years ended December&#160;31, 2021 and 2020 are as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current (benefit) provision&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal&#x2014;United States&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,025&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,107&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State&#x2014;United States&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;334&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;189&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other foreign&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;388&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;230&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;United Kingdom&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total current (benefit) provision&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(303&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,526&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred provision (benefit)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal&#x2014;United States&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,099&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,774&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State&#x2014;United States&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(312&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(103&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;United Kingdom&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other foreign&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;344&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(380&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred provision (benefit)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,131&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,257&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total provision (benefit) for income taxes&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;828&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(731&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table presents a reconciliation of income tax expense (benefit) computed at the UK statutory income tax rate to the effective income tax rate as reflected in the consolidated financial statements: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income taxes at United Kingdom statutory rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(27,313&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(29,015&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;59,691&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29,302&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reduction in research expense for credits granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,674&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,435&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in tax rates&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(38,785&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(8,105&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax credits&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,232&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,369&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. Deduction for foreign derived intangible income&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(196&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,254&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Permanent differences, including share-based compensation deduction shortfalls&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,863&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,265&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. state income taxes&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;68&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Foreign rate differential&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;109&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(58&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total provision (benefit) for income taxes&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;828&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(731&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s income tax expense for the year ended December 31, 2021, compared to the year ended December 31, 2020, increased primarily related to shortfalls related to share-based compensation that is not deductible for tax purposes and a reduction of the U.S. deduction for foreign derived intangible income (&#x201c;FDII&#x201d;), offset by an increase in the benefit from U.S. federal research and development tax credits.&#160;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During 2021, the U.K. Government announced that from April 1, 2023, the corporation tax rate would increase to 25%. This new law was enacted on June 10, 2021. The overall effect of the change was an increase in net deferred tax assets by $38.8 million and an increase in valuation allowance by an equal amount.&#160;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for income taxes in accordance with ASC Topic 740. Deferred income tax assets and liabilities are determined based upon temporary differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The following table presents the principal components of the Company&#x2019;s deferred tax assets and liabilities as of December&#160;31, 2021 and 2020: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;126,563&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;75,502&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortization&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25,206&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,599&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development credits&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,449&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,564&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Share-based compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,353&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,400&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accruals&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;798&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,001&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lease liability&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,444&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,805&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;523&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;171,835&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;115,397&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(161,573&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(103,890&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fixed assets and right-of-use asset&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,176&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,288&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other non-current assets (net deferred tax assets and liabilities)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,086&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,219&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160;For the years ended December 31, 2021 and 2020, the Company had cumulative tax-effected UK net operating loss carryforwards of approximately $126.6 million and $75.1 million, respectively. UK losses not surrendered may be carried forward indefinitely, subject to numerous utilization criteria and restrictions and are fully offset by a valuation allowance.&#160;&#160;For the years ended December 31, 2021 and 2020, the Company also had U.S. federal orphan drug tax credits of $0.6 million and $0, respectively, and U.S. state research and development tax credits of $2.4 million and $2.0 million.&#160;&#160;The U.S. federal orphan drug tax credits expire in 2041, while the U.S. state research and development credits may be carried forward indefinitely and are offset by a valuation allowance.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In measuring the Company&#x2019;s deferred tax assets, the Company considers all available evidence, both positive and negative, to determine whether, based on the weight of that evidence, a valuation allowance is needed for all or some portion of the deferred tax assets. Significant judgment is required in considering the relative impact of the negative and positive evidence, and weight given to each category of evidence is commensurate with the extent to which it can be objectively verified. The more negative evidence that exists, the more positive evidence is necessary, and the more difficult it is to support a conclusion that a valuation allowance is not needed. Additionally, the Company utilizes the "more likely than not" criteria established in FASB ASC Topic 740 to determine whether the future tax benefit from the deferred tax assets should be recognized. As a result, the Company has established valuation allowances on the deferred tax assets in jurisdictions that have incurred net operating losses and in which it is more likely than not that such losses will not be utilized in the foreseeable future.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of each reporting date, the Company considers new evidence, both positive and negative, that could impact the Company&#x2019;s view with regard to future realization of our deferred tax assets. Management has considered the Company&#x2019;s history of cumulative net losses in the UK, along with estimated future taxable income and has concluded that it is more likely than not that the Company will not realize the benefits of its UK deferred tax assets and U.S. state research and development tax credits. Accordingly, the Company has maintained a full valuation allowance against these net deferred tax assets as of December 31, 2021 and 2020, respectively.&#160;&#160;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Changes in the valuation allowance for deferred tax assets during the years ended December 31, 2021 and 2020 related primarily to the increase in UK net operating loss carryforwards as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation allowance as of beginning of year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(103,890&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(70,153&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Increases recorded to income tax provision&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(59,691&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(29,302&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Effect of foreign currency translation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,008&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,435&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation allowance as of end of year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(161,573&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(103,890&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company applies the authoritative guidance on accounting for and disclosure of uncertainty in tax positions, which requires the Company to determine whether a tax position of the Company is more likely than not to be sustained upon examination, including resolution of any related appeals of litigation processes, based on the technical merits of the position. For tax positions meeting the more likely than not threshold, the tax amount recognized in the financial statements is reduced by the largest benefit that has a greater than fifty percent likelihood of being realized upon the ultimate settlement with the relevant taxing authority.&#160;There were no material uncertain tax positions as of December 31, 2021 and 2020. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company will recognize interest and penalties related to uncertain tax positions in income tax expense. As of December 31, 2021, and 2020, the Company had no accrued interest or penalties related to uncertain tax positions and no amounts have been recognized in the Company&#x2019;s statement of operations.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company and its subsidiaries file income tax returns in the UK, the U.S., and various foreign jurisdictions. Generally, the tax years 2017 through 2021 remain open to examination by the major taxing jurisdictions to which the Company is subject. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the federal, state, or foreign tax authorities, if such tax attributes are utilized in a future period. &lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="C_0001748907_20210101_20211231" id="F_000364">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The components of net loss before income taxes for the years ended December 31, 2021 and 2020 are as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.K.&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(147,337&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(155,614&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-U.K.&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,581&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,904&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss before income taxes&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(143,756&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(152,710&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000934"
      unitRef="U_iso4217USD">-147337000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000935"
      unitRef="U_iso4217USD">-155614000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000936"
      unitRef="U_iso4217USD">3581000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000937"
      unitRef="U_iso4217USD">2904000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000938"
      unitRef="U_iso4217USD">-143756000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000939"
      unitRef="U_iso4217USD">-152710000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="C_0001748907_20210101_20211231" id="F_000365">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The provision for (benefit from) income taxes for the years ended December&#160;31, 2021 and 2020 are as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current (benefit) provision&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal&#x2014;United States&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,025&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,107&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State&#x2014;United States&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;334&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;189&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other foreign&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;388&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;230&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;United Kingdom&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total current (benefit) provision&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(303&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,526&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred provision (benefit)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal&#x2014;United States&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,099&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,774&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State&#x2014;United States&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(312&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(103&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;United Kingdom&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other foreign&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;344&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(380&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred provision (benefit)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,131&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,257&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total provision (benefit) for income taxes&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;828&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(731&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000940"
      unitRef="U_iso4217USD">-1025000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000941"
      unitRef="U_iso4217USD">1107000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000942"
      unitRef="U_iso4217USD">334000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000943"
      unitRef="U_iso4217USD">189000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <ortx:CurrentOtherTaxExpenseBenefit
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000944"
      unitRef="U_iso4217USD">388000</ortx:CurrentOtherTaxExpenseBenefit>
    <ortx:CurrentOtherTaxExpenseBenefit
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000945"
      unitRef="U_iso4217USD">230000</ortx:CurrentOtherTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000946"
      unitRef="U_iso4217USD">-303000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000947"
      unitRef="U_iso4217USD">1526000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000948"
      unitRef="U_iso4217USD">1099000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000949"
      unitRef="U_iso4217USD">-1774000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000950"
      unitRef="U_iso4217USD">-312000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000951"
      unitRef="U_iso4217USD">-103000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredOtherTaxExpenseBenefit
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000952"
      unitRef="U_iso4217USD">344000</us-gaap:DeferredOtherTaxExpenseBenefit>
    <us-gaap:DeferredOtherTaxExpenseBenefit
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000953"
      unitRef="U_iso4217USD">-380000</us-gaap:DeferredOtherTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000954"
      unitRef="U_iso4217USD">1131000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000955"
      unitRef="U_iso4217USD">-2257000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000956"
      unitRef="U_iso4217USD">828000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000957"
      unitRef="U_iso4217USD">-731000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="C_0001748907_20210101_20211231" id="F_000366">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table presents a reconciliation of income tax expense (benefit) computed at the UK statutory income tax rate to the effective income tax rate as reflected in the consolidated financial statements: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income taxes at United Kingdom statutory rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(27,313&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(29,015&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;59,691&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29,302&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reduction in research expense for credits granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,674&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,435&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in tax rates&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(38,785&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(8,105&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax credits&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,232&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,369&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. Deduction for foreign derived intangible income&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(196&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,254&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Permanent differences, including share-based compensation deduction shortfalls&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,863&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,265&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. state income taxes&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;68&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Foreign rate differential&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;109&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(58&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total provision (benefit) for income taxes&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;828&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(731&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000958"
      unitRef="U_iso4217USD">-27313000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000959"
      unitRef="U_iso4217USD">-29015000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000960"
      unitRef="U_iso4217USD">59691000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000961"
      unitRef="U_iso4217USD">29302000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <ortx:IncomeTaxReconciliationReductionInResearchExpenseForCreditsGranted
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000962"
      unitRef="U_iso4217USD">6674000</ortx:IncomeTaxReconciliationReductionInResearchExpenseForCreditsGranted>
    <ortx:IncomeTaxReconciliationReductionInResearchExpenseForCreditsGranted
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000963"
      unitRef="U_iso4217USD">8435000</ortx:IncomeTaxReconciliationReductionInResearchExpenseForCreditsGranted>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000964"
      unitRef="U_iso4217USD">-38785000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000965"
      unitRef="U_iso4217USD">-8105000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000966"
      unitRef="U_iso4217USD">2232000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000967"
      unitRef="U_iso4217USD">1369000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <ortx:IncomeTaxReconciliationDomesticDeductionForDerivedIntangibleIncome
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000968"
      unitRef="U_iso4217USD">196000</ortx:IncomeTaxReconciliationDomesticDeductionForDerivedIntangibleIncome>
    <ortx:IncomeTaxReconciliationDomesticDeductionForDerivedIntangibleIncome
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000969"
      unitRef="U_iso4217USD">1254000</ortx:IncomeTaxReconciliationDomesticDeductionForDerivedIntangibleIncome>
    <ortx:IncomeTaxReconciliationPermanentDifferencesIncludingShareBasedCompensationDeductionShortfalls
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000970"
      unitRef="U_iso4217USD">2863000</ortx:IncomeTaxReconciliationPermanentDifferencesIncludingShareBasedCompensationDeductionShortfalls>
    <ortx:IncomeTaxReconciliationPermanentDifferencesIncludingShareBasedCompensationDeductionShortfalls
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000971"
      unitRef="U_iso4217USD">1265000</ortx:IncomeTaxReconciliationPermanentDifferencesIncludingShareBasedCompensationDeductionShortfalls>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000972"
      unitRef="U_iso4217USD">17000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000973"
      unitRef="U_iso4217USD">68000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000974"
      unitRef="U_iso4217USD">109000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000975"
      unitRef="U_iso4217USD">-58000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_000976"
      unitRef="U_iso4217USD">828000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_000977"
      unitRef="U_iso4217USD">-731000</us-gaap:IncomeTaxExpenseBenefit>
    <ortx:CorporationTaxRatePercentage
      contextRef="C_0001748907_srtStatementGeographicalAxis_countryGB_20210101_20211231"
      decimals="2"
      id="F_000978"
      unitRef="U_xbrlipure">0.25</ortx:CorporationTaxRatePercentage>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="C_0001748907_srtStatementGeographicalAxis_countryGB_20210101_20211231"
      decimals="-5"
      id="F_000979"
      unitRef="U_iso4217USD">38800000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_0001748907_srtStatementGeographicalAxis_countryGB_20210101_20211231"
      decimals="-5"
      id="F_000980"
      unitRef="U_iso4217USD">38800000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="C_0001748907_20210101_20211231" id="F_000367"> The following table presents the principal components of the Company&#x2019;s deferred tax assets and liabilities as of December&#160;31, 2021 and 2020:
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;126,563&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;75,502&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortization&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25,206&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,599&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development credits&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,449&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,564&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Share-based compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,353&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,400&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accruals&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;798&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,001&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lease liability&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,444&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,805&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;523&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;171,835&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;115,397&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(161,573&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(103,890&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fixed assets and right-of-use asset&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,176&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,288&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other non-current assets (net deferred tax assets and liabilities)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,086&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,219&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000981"
      unitRef="U_iso4217USD">126563000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000982"
      unitRef="U_iso4217USD">75502000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <ortx:DeferredTaxAssetsAmortization
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000983"
      unitRef="U_iso4217USD">25206000</ortx:DeferredTaxAssetsAmortization>
    <ortx:DeferredTaxAssetsAmortization
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000984"
      unitRef="U_iso4217USD">22599000</ortx:DeferredTaxAssetsAmortization>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000985"
      unitRef="U_iso4217USD">2449000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000986"
      unitRef="U_iso4217USD">1564000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000987"
      unitRef="U_iso4217USD">9353000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000988"
      unitRef="U_iso4217USD">7400000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000989"
      unitRef="U_iso4217USD">798000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000990"
      unitRef="U_iso4217USD">1001000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <ortx:DeferredTaxAssetsLeaseLiability
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000991"
      unitRef="U_iso4217USD">6444000</ortx:DeferredTaxAssetsLeaseLiability>
    <ortx:DeferredTaxAssetsLeaseLiability
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000992"
      unitRef="U_iso4217USD">6805000</ortx:DeferredTaxAssetsLeaseLiability>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000993"
      unitRef="U_iso4217USD">1022000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000994"
      unitRef="U_iso4217USD">523000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000995"
      unitRef="U_iso4217USD">3000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000996"
      unitRef="U_iso4217USD">171835000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000997"
      unitRef="U_iso4217USD">115397000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_000998"
      unitRef="U_iso4217USD">161573000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_000999"
      unitRef="U_iso4217USD">103890000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <ortx:DeferredTaxLiabilitiesFixedAssetsAndRightOfUseAsset
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_001000"
      unitRef="U_iso4217USD">6176000</ortx:DeferredTaxLiabilitiesFixedAssetsAndRightOfUseAsset>
    <ortx:DeferredTaxLiabilitiesFixedAssetsAndRightOfUseAsset
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_001001"
      unitRef="U_iso4217USD">6288000</ortx:DeferredTaxLiabilitiesFixedAssetsAndRightOfUseAsset>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_001002"
      unitRef="U_iso4217USD">4086000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_001003"
      unitRef="U_iso4217USD">5219000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_0001748907_srtStatementGeographicalAxis_countryGB_20211231"
      decimals="-5"
      id="F_001004"
      unitRef="U_iso4217USD">126600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_0001748907_srtStatementGeographicalAxis_countryGB_20201231"
      decimals="-5"
      id="F_001005"
      unitRef="U_iso4217USD">75100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_0001748907_srtStatementGeographicalAxis_countryUS_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_ortxOrphanDrugTaxCreditMember_20211231"
      decimals="-5"
      id="F_001006"
      unitRef="U_iso4217USD">600000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_0001748907_srtStatementGeographicalAxis_countryUS_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_ortxOrphanDrugTaxCreditMember_20201231"
      decimals="-6"
      id="F_001007"
      unitRef="U_iso4217USD">0</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_0001748907_srtStatementGeographicalAxis_countryUS_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20211231"
      decimals="-5"
      id="F_001008"
      unitRef="U_iso4217USD">2400000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_0001748907_srtStatementGeographicalAxis_countryUS_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20201231"
      decimals="-5"
      id="F_001009"
      unitRef="U_iso4217USD">2000000.0</us-gaap:TaxCreditCarryforwardAmount>
    <ortx:TaxCreditCarryforwardExpirationYear
      contextRef="C_0001748907_srtStatementGeographicalAxis_countryUS_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20210101_20211231"
      id="F_001010">2041</ortx:TaxCreditCarryforwardExpirationYear>
    <us-gaap:SummaryOfValuationAllowanceTextBlock contextRef="C_0001748907_20210101_20211231" id="F_000368">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Changes in the valuation allowance for deferred tax assets during the years ended December 31, 2021 and 2020 related primarily to the increase in UK net operating loss carryforwards as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation allowance as of beginning of year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(103,890&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(70,153&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Increases recorded to income tax provision&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(59,691&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(29,302&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Effect of foreign currency translation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,008&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,435&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation allowance as of end of year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(161,573&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(103,890&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:SummaryOfValuationAllowanceTextBlock>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_001011"
      unitRef="U_iso4217USD">103890000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_0001748907_20191231"
      decimals="-3"
      id="F_001012"
      unitRef="U_iso4217USD">70153000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <ortx:DeferredTaxAssetsValuationAllowanceIncreasesRecordedToIncomeTaxProvision
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_001013"
      unitRef="U_iso4217USD">-59691000</ortx:DeferredTaxAssetsValuationAllowanceIncreasesRecordedToIncomeTaxProvision>
    <ortx:DeferredTaxAssetsValuationAllowanceIncreasesRecordedToIncomeTaxProvision
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_001014"
      unitRef="U_iso4217USD">-29302000</ortx:DeferredTaxAssetsValuationAllowanceIncreasesRecordedToIncomeTaxProvision>
    <ortx:DeferredTaxAssetsValuationAllowanceEffectOfForeignCurrencyTranslation
      contextRef="C_0001748907_20210101_20211231"
      decimals="-3"
      id="F_001015"
      unitRef="U_iso4217USD">2008000</ortx:DeferredTaxAssetsValuationAllowanceEffectOfForeignCurrencyTranslation>
    <ortx:DeferredTaxAssetsValuationAllowanceEffectOfForeignCurrencyTranslation
      contextRef="C_0001748907_20200101_20201231"
      decimals="-3"
      id="F_001016"
      unitRef="U_iso4217USD">-4435000</ortx:DeferredTaxAssetsValuationAllowanceEffectOfForeignCurrencyTranslation>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_001017"
      unitRef="U_iso4217USD">161573000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_0001748907_20201231"
      decimals="-3"
      id="F_001018"
      unitRef="U_iso4217USD">103890000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="C_0001748907_20211231"
      decimals="INF"
      id="F_001019"
      unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="C_0001748907_20201231"
      decimals="INF"
      id="F_001020"
      unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:OpenTaxYear
      contextRef="C_0001748907_us-gaapTaxPeriodAxis_us-gaapEarliestTaxYearMember_20210101_20211231"
      id="F_001021">2017</us-gaap:OpenTaxYear>
    <us-gaap:OpenTaxYear
      contextRef="C_0001748907_us-gaapTaxPeriodAxis_us-gaapLatestTaxYearMember_20210101_20211231"
      id="F_001022">2021</us-gaap:OpenTaxYear>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="C_0001748907_20210101_20211231" id="F_000311">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;18. Commitments and Contingencies &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Lease commitments&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company leases office and laboratory space and has an embedded lease at AGC. Refer to Note 11, &lt;span style="font-style:italic;"&gt;Leases&lt;/span&gt;, for further information on the terms of the lease agreements.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Manufacturing and technology development master agreement with AGC&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;On July 2, 2020, the Company entered into the AGC Agreement, pursuant to which AGC will develop, manufacture and supply certain viral vectors and conduct cell processing activities for certain Company development and commercial programs. Under the terms of the AGC Agreement, the Company is obligated to pay AGC for a minimum product manufacturing commitment, dedicated manufacturing and development resources, and for a lease component associated with the right of use of exclusive manufacturing suites within AGC&#x2019;s existing facilities. The following table outlines the annual commitments associated with the contract, as of December 31, 2021:&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.88%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Due in:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Product manufacturing commitments (1)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Dedicated manufacturing and development resources (2)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exclusive transduction suites (3)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total AGC Commitment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,627&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,379&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,626&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,632&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,051&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,831&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,079&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,961&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,051&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,831&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,079&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,961&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2025&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,525&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,915&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,539&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,979&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2026&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.88%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total manufacturing commitments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,254&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27,956&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,323&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;48,533&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;*Tabular disclosure above has been translated to U.S. Dollar, from Euro, using an exchange rate of &#x20ac;1.00 to $1.13.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;(1) The minimum product manufacturing commitments may be increased to the mid-seven figures per contract year upon achievement of certain milestones.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;(2) The Company may increase or decrease the usage of dedicated development services on a rolling basis with between six and 12-months&#x2019; prior written notice to AGC. The above table assumes continued usage of dedicated development services at current rates.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;(3) Refer to Note 11 for further information on the embedded operating lease agreement&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The AGC Agreement has an initial term of&#160;five years, beginning on the Effective Date and ending&#160;July 2, 2025. The AGC Agreement may be extended for an additional&#160;two years&#160;by mutual agreement of the Company and AGC. The Company has the right to terminate the AGC Agreement at its discretion upon 12-month&#x2019;s prior written notice to AGC, and beginning no earlier than July 2, 2022, AGC has the right to terminate the AGC Agreement at its discretion upon 24-month&#x2019;s prior written notice to the Company. Each party may terminate the AGC Agreement upon prior notice to the other party for an uncured material breach that the breaching party does not cure within the notice period.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Other funding commitments&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has entered into several license agreements (see Note 15). In connection with these agreements the Company is required to make milestone payments and annual license maintenance payments or royalties on future sales of specified products. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Consulting Agreement&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2019, the Company entered into a consulting agreement with non-employee advisor whereby the Company is obligated to make cash payments of $0.1 million per year and to issue up to 91,034 ordinary shares, which vest annually over a &lt;span style="-sec-ix-hidden:F_001050"&gt;four-year&lt;/span&gt; period, and 92,035 ordinary shares upon attainment of certain clinical development and regulatory milestones. In December 2021 and 2020, the Company issued 22,758 ordinary shares associated with the service condition.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the years ended December 31, 2021 and 2020, the Company recorded $0.3 million and &lt;span&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;0.3&lt;/span&gt; million in research and development expense associated with the share-based awards with service conditions. &lt;span style="color:#000000;"&gt;During the years ended December 31, 2021 and 2020, &lt;/span&gt;no expense was recorded associated with the performance-based conditions.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Legal proceedings &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;letter-spacing:-0.15pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is not a party to any litigation and does not have contingency reserves established for any litigation liabilities. &lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock contextRef="C_0001748907_20210101_20211231" id="F_000369">The following table outlines the annual commitments associated with the contract, as of December 31, 2021:
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.88%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Due in:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Product manufacturing commitments (1)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Dedicated manufacturing and development resources (2)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exclusive transduction suites (3)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total AGC Commitment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,627&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,379&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,626&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,632&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,051&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,831&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,079&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,961&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,051&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,831&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,079&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,961&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2025&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,525&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,915&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,539&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,979&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2026&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.88%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.88%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total manufacturing commitments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,254&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27,956&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,323&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;48,533&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;*Tabular disclosure above has been translated to U.S. Dollar, from Euro, using an exchange rate of &#x20ac;1.00 to $1.13.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;(1) The minimum product manufacturing commitments may be increased to the mid-seven figures per contract year upon achievement of certain milestones.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;(2) The Company may increase or decrease the usage of dedicated development services on a rolling basis with between six and 12-months&#x2019; prior written notice to AGC. The above table assumes continued usage of dedicated development services at current rates.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;(3) Refer to Note 11 for further information on the embedded operating lease agreement&lt;/span&gt;&lt;/p&gt;</srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock>
    <ortx:ManufacturingCommitmentsAmountDueInNextTwelveMonths
      contextRef="C_0001748907_us-gaapSupplyCommitmentAxis_ortxProductManufacturingCommitmentsMember_20211231"
      decimals="-3"
      id="F_001023"
      unitRef="U_iso4217USD">2627000</ortx:ManufacturingCommitmentsAmountDueInNextTwelveMonths>
    <ortx:ManufacturingCommitmentsAmountDueInNextTwelveMonths
      contextRef="C_0001748907_us-gaapSupplyCommitmentAxis_ortxDedicatedManufacturingAndDevelopmentResourcesMember_20211231"
      decimals="-3"
      id="F_001024"
      unitRef="U_iso4217USD">8379000</ortx:ManufacturingCommitmentsAmountDueInNextTwelveMonths>
    <ortx:ManufacturingCommitmentsAmountDueInNextTwelveMonths
      contextRef="C_0001748907_us-gaapSupplyCommitmentAxis_ortxExclusiveTransductionSuitesMember_20211231"
      decimals="-3"
      id="F_001025"
      unitRef="U_iso4217USD">2626000</ortx:ManufacturingCommitmentsAmountDueInNextTwelveMonths>
    <ortx:ManufacturingCommitmentsAmountDueInNextTwelveMonths
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_001026"
      unitRef="U_iso4217USD">13632000</ortx:ManufacturingCommitmentsAmountDueInNextTwelveMonths>
    <ortx:ManufacturingCommitmentsAmountDueInYearTwo
      contextRef="C_0001748907_us-gaapSupplyCommitmentAxis_ortxProductManufacturingCommitmentsMember_20211231"
      decimals="-3"
      id="F_001027"
      unitRef="U_iso4217USD">3051000</ortx:ManufacturingCommitmentsAmountDueInYearTwo>
    <ortx:ManufacturingCommitmentsAmountDueInYearTwo
      contextRef="C_0001748907_us-gaapSupplyCommitmentAxis_ortxDedicatedManufacturingAndDevelopmentResourcesMember_20211231"
      decimals="-3"
      id="F_001028"
      unitRef="U_iso4217USD">7831000</ortx:ManufacturingCommitmentsAmountDueInYearTwo>
    <ortx:ManufacturingCommitmentsAmountDueInYearTwo
      contextRef="C_0001748907_us-gaapSupplyCommitmentAxis_ortxExclusiveTransductionSuitesMember_20211231"
      decimals="-3"
      id="F_001029"
      unitRef="U_iso4217USD">3079000</ortx:ManufacturingCommitmentsAmountDueInYearTwo>
    <ortx:ManufacturingCommitmentsAmountDueInYearTwo
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_001030"
      unitRef="U_iso4217USD">13961000</ortx:ManufacturingCommitmentsAmountDueInYearTwo>
    <ortx:ManufacturingCommitmentsAmountDueInYearThree
      contextRef="C_0001748907_us-gaapSupplyCommitmentAxis_ortxProductManufacturingCommitmentsMember_20211231"
      decimals="-3"
      id="F_001031"
      unitRef="U_iso4217USD">3051000</ortx:ManufacturingCommitmentsAmountDueInYearThree>
    <ortx:ManufacturingCommitmentsAmountDueInYearThree
      contextRef="C_0001748907_us-gaapSupplyCommitmentAxis_ortxDedicatedManufacturingAndDevelopmentResourcesMember_20211231"
      decimals="-3"
      id="F_001032"
      unitRef="U_iso4217USD">7831000</ortx:ManufacturingCommitmentsAmountDueInYearThree>
    <ortx:ManufacturingCommitmentsAmountDueInYearThree
      contextRef="C_0001748907_us-gaapSupplyCommitmentAxis_ortxExclusiveTransductionSuitesMember_20211231"
      decimals="-3"
      id="F_001033"
      unitRef="U_iso4217USD">3079000</ortx:ManufacturingCommitmentsAmountDueInYearThree>
    <ortx:ManufacturingCommitmentsAmountDueInYearThree
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_001034"
      unitRef="U_iso4217USD">13961000</ortx:ManufacturingCommitmentsAmountDueInYearThree>
    <ortx:ManufacturingCommitmentsAmountDueInYearFour
      contextRef="C_0001748907_us-gaapSupplyCommitmentAxis_ortxProductManufacturingCommitmentsMember_20211231"
      decimals="-3"
      id="F_001035"
      unitRef="U_iso4217USD">1525000</ortx:ManufacturingCommitmentsAmountDueInYearFour>
    <ortx:ManufacturingCommitmentsAmountDueInYearFour
      contextRef="C_0001748907_us-gaapSupplyCommitmentAxis_ortxDedicatedManufacturingAndDevelopmentResourcesMember_20211231"
      decimals="-3"
      id="F_001036"
      unitRef="U_iso4217USD">3915000</ortx:ManufacturingCommitmentsAmountDueInYearFour>
    <ortx:ManufacturingCommitmentsAmountDueInYearFour
      contextRef="C_0001748907_us-gaapSupplyCommitmentAxis_ortxExclusiveTransductionSuitesMember_20211231"
      decimals="-3"
      id="F_001037"
      unitRef="U_iso4217USD">1539000</ortx:ManufacturingCommitmentsAmountDueInYearFour>
    <ortx:ManufacturingCommitmentsAmountDueInYearFour
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_001038"
      unitRef="U_iso4217USD">6979000</ortx:ManufacturingCommitmentsAmountDueInYearFour>
    <ortx:ManufacturingCommitments
      contextRef="C_0001748907_us-gaapSupplyCommitmentAxis_ortxProductManufacturingCommitmentsMember_20211231"
      decimals="-3"
      id="F_001039"
      unitRef="U_iso4217USD">10254000</ortx:ManufacturingCommitments>
    <ortx:ManufacturingCommitments
      contextRef="C_0001748907_us-gaapSupplyCommitmentAxis_ortxDedicatedManufacturingAndDevelopmentResourcesMember_20211231"
      decimals="-3"
      id="F_001040"
      unitRef="U_iso4217USD">27956000</ortx:ManufacturingCommitments>
    <ortx:ManufacturingCommitments
      contextRef="C_0001748907_us-gaapSupplyCommitmentAxis_ortxExclusiveTransductionSuitesMember_20211231"
      decimals="-3"
      id="F_001041"
      unitRef="U_iso4217USD">10323000</ortx:ManufacturingCommitments>
    <ortx:ManufacturingCommitments
      contextRef="C_0001748907_20211231"
      decimals="-3"
      id="F_001042"
      unitRef="U_iso4217USD">48533000</ortx:ManufacturingCommitments>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="C_0001748907_20211231"
      decimals="2"
      id="F_001043"
      unitRef="U_xbrlipure">1.13</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <ortx:InitialTermOfAgreement
      contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxManufacturingAndTechnologyDevelopmentMasterAgreementMember_20210101_20211231"
      id="F_001044">P5Y</ortx:InitialTermOfAgreement>
    <ortx:AgreementMaturityDate
      contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxManufacturingAndTechnologyDevelopmentMasterAgreementMember_20210101_20211231"
      id="F_001045">2025-07-02</ortx:AgreementMaturityDate>
    <ortx:AgreementExtensionTerm
      contextRef="C_0001748907_us-gaapTypeOfArrangementAxis_ortxManufacturingAndTechnologyDevelopmentMasterAgreementMember_20210101_20211231"
      id="F_001046">P2Y</ortx:AgreementExtensionTerm>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="C_0001748907_srtTitleOfIndividualAxis_ortxNonEmployeeAdvisorMember_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_ortxConsultingAgreementMember_20191231"
      decimals="-5"
      id="F_001047"
      unitRef="U_iso4217USD">100000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001748907_srtTitleOfIndividualAxis_ortxNonEmployeeAdvisorMember_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_ortxConsultingAgreementMember_20191231"
      decimals="INF"
      id="F_001048"
      unitRef="U_xbrlishares">91034</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001748907_srtTitleOfIndividualAxis_ortxNonEmployeeAdvisorMember_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_ortxConsultingAgreementMember_us-gaapTypeOfArrangementAxis_ortxClinicalDevelopmentAndRegulatoryMilestoneMember_20191231"
      decimals="INF"
      id="F_001049"
      unitRef="U_xbrlishares">92035</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001748907_srtTitleOfIndividualAxis_ortxNonEmployeeAdvisorMember_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_ortxConsultingAgreementMember_us-gaapTypeOfArrangementAxis_ortxClinicalDevelopmentAndRegulatoryMilestoneMember_20201231"
      decimals="INF"
      id="F_001051"
      unitRef="U_xbrlishares">22758</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001748907_srtTitleOfIndividualAxis_ortxNonEmployeeAdvisorMember_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_ortxConsultingAgreementMember_us-gaapTypeOfArrangementAxis_ortxClinicalDevelopmentAndRegulatoryMilestoneMember_20211231"
      decimals="INF"
      id="F_001052"
      unitRef="U_xbrlishares">22758</us-gaap:CommonStockSharesIssued>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001748907_srtTitleOfIndividualAxis_ortxNonEmployeeAdvisorMember_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_ortxConsultingAgreementMember_20210101_20211231"
      decimals="-5"
      id="F_001053"
      unitRef="U_iso4217USD">300000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001748907_srtTitleOfIndividualAxis_ortxNonEmployeeAdvisorMember_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_ortxConsultingAgreementMember_20200101_20201231"
      decimals="-5"
      id="F_001054"
      unitRef="U_iso4217USD">300000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001748907_srtTitleOfIndividualAxis_ortxNonEmployeeAdvisorMember_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_ortxConsultingAgreementMember_20210101_20211231"
      decimals="0"
      id="F_001055"
      unitRef="U_iso4217USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001748907_srtTitleOfIndividualAxis_ortxNonEmployeeAdvisorMember_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_ortxConsultingAgreementMember_20200101_20201231"
      decimals="0"
      id="F_001056"
      unitRef="U_iso4217USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="C_0001748907_20210101_20211231" id="F_000312">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;19. Benefit Plans&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company makes contributions to private defined contribution pension plans on behalf of its employees. The Company matches its employee contributions up to six percent of each employee&#x2019;s annual salary based on the jurisdiction the employees are located. The Company paid $1.7 million and $1.6 million, in matching contributions for the years ended December&#160;31, 2021 and 2020, respectively.&lt;/p&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="C_0001748907_20210101_20211231"
      decimals="INF"
      id="F_001059"
      unitRef="U_xbrlipure">0.06</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="C_0001748907_20210101_20211231"
      decimals="-5"
      id="F_001057"
      unitRef="U_iso4217USD">1700000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="C_0001748907_20200101_20201231"
      decimals="-5"
      id="F_001058"
      unitRef="U_iso4217USD">1600000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="C_0001748907_20210101_20211231" id="F_000313">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;20. Related-party Transactions &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;GSK&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In April 2018, the Company completed the GSK Agreement with subsidiaries of GSK (See Note 14). As consideration under the agreement the Company paid an upfront fee of $14.2 million, purchased inventory of $6.9 million, paid $0.8 million in transaction costs, and issued 12,455,252 convertible preferred shares valued at $93.4 million. Additionally, as part of the GSK Agreement, the Company obtained, and is responsible for maintaining the commercial availability of Strimvelis. The Company recorded a loss provision of $18.4 million associated with the agreement, as the costs to maintain Strimvelis are expected to significantly exceed revenues. The issuance of the convertible preferred shares made GSK a principal shareholder in the Company. As of June 16, 2021, GSK no longer had a right to nominate and appoint a designee to the Company&#x2019;s board of directors, and GSK is no longer considered a related party.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020, the Company had accounts payable and accrued expenses due to GSK of &lt;span&gt;$0.1&lt;/span&gt; million. During the year-ended December 31, 2020, the Company entered into a global license agreement with GSK for use of their lentiviral stable cell line technology whereby the Company recorded $1.2 million of in-process research and development expense &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;associated with upfront payments made to GSK. During the year-ended December 31, 2020, the Company made &lt;/span&gt;&lt;span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.8&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; million in payments on accounts payable due to GSK associated with &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;milestones, clinical inventory, and royalties&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <ortx:LicenseUpfrontFeeAndRelatedExpensesPaid
      contextRef="C_0001748907_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ortxGSKMember_20180401_20180430"
      decimals="-5"
      id="F_001060"
      unitRef="U_iso4217USD">14200000</ortx:LicenseUpfrontFeeAndRelatedExpensesPaid>
    <ortx:InventoryPurchase
      contextRef="C_0001748907_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ortxGSKMember_20180430"
      decimals="-5"
      id="F_001061"
      unitRef="U_iso4217USD">6900000</ortx:InventoryPurchase>
    <ortx:AssetAcquisitionTransactionCosts
      contextRef="C_0001748907_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ortxGSKMember_20180401_20180430"
      decimals="-5"
      id="F_001062"
      unitRef="U_iso4217USD">800000</ortx:AssetAcquisitionTransactionCosts>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="C_0001748907_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ortxGSKMember_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20180430"
      decimals="INF"
      id="F_001063"
      unitRef="U_xbrlishares">12455252</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:PreferredStockValue
      contextRef="C_0001748907_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ortxGSKMember_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20180430"
      decimals="-5"
      id="F_001064"
      unitRef="U_iso4217USD">93400000</us-gaap:PreferredStockValue>
    <us-gaap:ProvisionForLossOnContracts
      contextRef="C_0001748907_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ortxGSKMember_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20180430"
      decimals="-5"
      id="F_001065"
      unitRef="U_iso4217USD">18400000</us-gaap:ProvisionForLossOnContracts>
    <us-gaap:AccountsPayableRelatedPartiesCurrent
      contextRef="C_0001748907_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ortxGSKMember_20201231"
      decimals="-5"
      id="F_001066"
      unitRef="U_iso4217USD">100000</us-gaap:AccountsPayableRelatedPartiesCurrent>
    <ortx:AccruedExpensesRelatedPartyCurrent
      contextRef="C_0001748907_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ortxGSKMember_20201231"
      decimals="-5"
      id="F_001067"
      unitRef="U_iso4217USD">100000</ortx:AccruedExpensesRelatedPartyCurrent>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001748907_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ortxGSKMember_us-gaapTypeOfArrangementAxis_ortxGSKAssetPurchaseAndLicenseAgreementMember_20200101_20201231"
      decimals="-5"
      id="F_001068"
      unitRef="U_iso4217USD">1200000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_0001748907_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ortxGSKMember_20200101_20201231"
      decimals="-5"
      id="F_001069"
      unitRef="U_iso4217USD">-5800000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:SubsequentEventsTextBlock contextRef="C_0001748907_20210101_20211231" id="F_000314">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;21. Subsequent events &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On March 30, 2022, the Company announced a proposed reduction of its workforce of approximately 30%, subject to a consultation process with certain employees in the United Kingdom. The Company estimates that it will incur aggregate charges of approximately $2.5 million in the first and second quarters of 2022 as a result of the restructuring, consisting of one-time cash expenditures for severance and employee termination-related costs.&lt;span style="color:#000000;font-size:12pt;"&gt; &lt;/span&gt;The Company also announced that it would discontinue its investment in and seek alternatives for OTL-102 for treatment of X-CGD, OTL-103 for treatment of WAS and Strimvelis. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
      contextRef="C_0001748907_srtStatementGeographicalAxis_countryGB_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220330_20220330"
      decimals="2"
      id="F_001070"
      unitRef="U_xbrlipure">0.30</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1
      contextRef="C_0001748907_srtStatementGeographicalAxis_countryGB_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220330"
      decimals="-5"
      id="F_001071"
      unitRef="U_iso4217USD">2500000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>111
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MK&^DOEL/7G)>LJKAH@*2;2X6']'[*Q*9 9W%/YP]- ?7P"SE3HA?YN9S?K&
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MZ?LZ+Z&BNB=7(/!D(55%#89JZ>N5 EHX4,7]* A2OZ),>-G0[4U5-I2UX4S
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M-,%\"P*2\(+=6)8$)IUO8@W#?:F88%!W:J?&") !,0^3/ONAD8NCD7J+.RW
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M]>@$^#4>U!>CF3\B5*03*F(7JJ]5?P4]!SV 3FT8*O=Z1Z0W8J>LH!79*ZF
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MR5(Z =E6*K'NE#6"=5'MOME#%X@]!8@]"JA30*9"XE' G0(V%) /$ND4B*%
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M%33>P=VOB?B@>(+N-Y7] 5!+ P04    "  H07Y4'#2?*BL)  !;)0  &
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M>729\FW_+MX>#B_Y()3,-W"@3G6'+5"<OD#WP>= /E/,XK!Z)CY37')5T08
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M/GOS:I+ J_L27<T_0F0N1E?QQXW" =.3 -Z7#@ZV7VB#_E>IBW\"4$L#!!0
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M@R[ZHW<-#+TS%2@N?"/K:OCMLU7SX@9,"\INS^OOMJ;+S'H-ZHBH!$NJ&UR
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M!&0^>&;1"^Y/$AAE*8#6!G>< 4PC@]&8O1/;B.8 5T?2BYHT[(@T0-.#^6T
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M*_ER(_".VKH2MTB"';$XP9?XHV7%FDRTIJ5$<#F$M\B^][!GA8T9C3-H=V%
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M5^WNJLM[@GT(!:OYQ+0<$=^!TT(=]DA80"N[9=^T](M717,"CJ^"U=J@:J=
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M[NTHO6=JRX6F)6P0&O:&J4=5.Y[:C9&U&PEK:7# N&6!$QV4=4#[1DISVM@
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M:*>1AK(]5O0*@G$!=%]HC4?#)1C>U?4?4$L#!!0    ( "A!?E0NZ[$?O@(
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M;"OLG=I]A'T^8\=7*&'\D^RZV'$:DF)KK&KV8'30<-F-[&E?AP$@C]\ T#V
M>M^=D'=YQ2Q;S+3:$>VBD<U-?*H>C>:X=(=R;S6^Y8BSBV51Z"V4Y/H)C]F
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M#]H%X/M**7M8.('^?[+X U!+ P04    "  H07Y4EA4 IVT(  !K%@  &0
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M=*5\7!.ND9X7X/>E0Q:;+WQ ]W[Y^K]02P,$%     @ *$%^5).<"L,]#@
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M<]-7X5^32E ?/#,('0:PQTB$8CP?X!B]#(S:\3GTA@(+-+">2B0! 1W;5]I
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M[J7N(KEI[D,^5\%Z7TTG1-.$,*"S:'+>':?G]#C>/4YVC]-D AO3!,F!=%_
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M 8=1KVBZN>("KI]3DVFQ4%Q3MR\K7[S7,YCXQ\1@,/'%S\%EX(N;)?^"[.<
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M!#?NN%+E1@<F^*8%;HUM9L[>6Q];*F 2VE+G=] 2PZE%^A)S3 OF>*#F(!P
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MX\T[>[7'N*IOVT]#VLY('$ZHT&]Z3K**R&#;+\'LK,$;DC:Q87]48QP+ET!
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M&6NAZ*V 2@EJ>+OO,W0H4:K9*-*XH;1D*#QRVHHVZ7"((>Q9O,.T0-.X"D)
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M">EQ,4%BT0NJ[+48QD/J 1BFHRE!L'_31REH]* S:\ !7R6<3HYU.$A3X'T
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MO5EGL;(!(4159BB%/!OG$?+7%D&B6"%7X&]9@U#L8Y1M!*QK&S_@E!)R/I+
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M$;U0.4)M>383><7/QW(C,NC%!K!-![8D>_17H-^)%>\F;4%1NQ^J,H0][_*
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M<YJ0[4929WC3Q#$P-QY#)2XK3'&VP0'G"V/\S@@)]O^%Z4]02P,$%     @
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M0H*A",]2^%049ET)VIG[VC*J['-@!&U5XHP@K_%W@%EA88A)!"!R+F%\B^M
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M(%KUH]*C)#P[XC@)GY@F^>O@&Q4OG(AE$W1ZN:(U46^U/>]\XNAB9'".KNY
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M,N2=,%F6,T(CP/&@B!][2-W7AERLS7"7U7:+#/(I#E-AOSZ8W:/LRN<1\S"
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MK("/XN9M %E:MG;;'=BN"89*[BMT^;V5A]40S^WB?I$F!:4?4<(A9<+9=K/
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M)^Y82-?2H&>."<<[#\V)7 "1LDXU,0WR(KQ DJ**IQB6?>MCSN[XTL;M*KS
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M051V%@(9 ""E1F)1!-F(5U#439MZ_<_KM"X,[\S:;#@%=3W,=Y5+GLZ#*M'
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M+;QZL;B^>L;-%-V'MCK@D)BYWE9[^A,+EVV-#\#OVPI.3C[@!-A8G);WW?\
M4$L#!!0    ( "A!?E0&=_M2$ 8  *L/   9    >&PO=V]R:W-H965T<R]S
M:&5E=#,P+GAM;+U7WV_;-A!^UU]!>,.0 DJL'[:E9$F )$VQ >D:).F&H=@#
M+9TMHA+IDE2<[*_?'2DK=NNH?=J+1$K'N^^.'^^.IVNE/YL*P+*GII;F;%19
MNSH9CTU10</-D5J!Q#\+I1MN<:J78[/2P$NWJ*G'213-Q@T7<G1^ZK[=ZO-3
MU=I:2+C5S+1-P_7S)=1J?3:*1YL/=V)96?HP/C]=\27<@_VXNM4X&_=:2M&
M-$))IF%Q-KJ(3RYSDG<"?PI8FZTQ(T_F2GVFR>_EV2@B0%!#84D#Q]<C7$%=
MDR*$\:73.>I-TL+M\4;[.^<[^C+G!JY4_9<H;74VRD>LA 5O:WNGUK]!Y\^4
M]!6J-N[)UEXV0^&B-58UW6)$T CIW_RIB\/6@CQZ94'2+4@<;F_(H7S++3\_
MU6K--$FC-AHX5]UJ!"<D;<J]U?A7X#I[?N\W@ZD%NQ=+*1:BX-*RBZ)0K;1"
M+MFMJD4AP+"#!SZOP;PY'5LT3,O'16?DTAM)7C$2)^R]DK8R[%J64.XJ&"/B
M'G:R@7V9#&I\"\412^.0)5$2#^A+^S"D3E_ZBKY]_GZZF!NKD3;_#!B8] 8F
MSL#DM3CC:2K;&BC0=U H68A:<$=,_'+%316Z)[O^THI'7H.TAG%9HC""$(6%
MTOW?%_QARP\5L(6J\?21=Y;VD*VT>A0E^LCQ8'T-IG!@Z,G@!4SHT.@7-$Y
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MK39$.VM$<X)/U7LC.2[=H]Q;C;<<_>QTH?%]M7TE3);D\JGE:ZRX)0</;"G
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ME=H-! ^#:1OP@'APDTMCX=C%OM#QWW-.TJQ(6\6+[3O?]]UWEYSG>VU^V@H
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M<FMS:&5E=',O<VAE970S-BYX;6R55<MNVS 0O.LK"*&'%G"C=RP'M@'G4;1
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MH&P OJ^D-/N%%1A^'<O?4$L#!!0    ( "A!?E0>Z4!2Z0,  -T(   9
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M&KR$W>L&OWI 6064KZ0TNX5UL/^.FO\'4$L#!!0    ( "A!?E3%5LKL-P,
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M)06T;MP SY=:N^T"%?0?C([_!5!+ P04    "  H07Y4S8O,WC@$   5"0
M&0   'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6R-5MMNXS80?==7$&Y0; JM
M;4F^)7$,)'%Z>=@B2++M0]$'6AI9Q$JDEZ3BY.][AG*\#IID%S LBIR9<^;&
MT7QK[!=7$7GQV-3:G?<J[S>G@X'+*VJDZYL-:9R4QC;2X]6N!VYC219!J:D'
MZ7 X&312Z=YB'O9N[&)N6E\K33=6N+9II'VZI-ILSWM)[WGC5JTKSQN#Q7PC
MUW1'_O/FQN)ML+=2J(:T4T8+2^5Y[R(YO1RQ?!#X2]'6':P%>[(RY@N__%&<
M]X9,B&K*/5N0>#S0%=4U&P*-KSN;O3TD*QZNGZW_&GR'+ROIZ,K4?ZO"5^>]
M64\45,JV]K=F^SOM_!FSO=S4+OR+;2<[&?9$WCIOFITR&#1*=T_YN(O#@<+L
M+85TIY &WAU08+F47B[FUFR%96E8XT5P-6B#G-*<E#MO<:J@YQ=7IFF41Y2]
M$U(7XLIHK_2:=*[(B0_W<E63.YX//+!88Y#O[%YV=M,W[":I^ 13E1/7NJ#B
MI8$!2.Z9IL],+]-W+2XI[XLLB44Z3)-W[&5[S[-@+_L!SR_^Y_E2N;PVKK4D
M_KE8.6]1/O^^@SK:HXX"ZN@-U#MT5='6)$P)5-W*6KP@XIS)E?14H Y\)7Q%
M@1C#OY:$]\'NH5V:&HT'QX3G7(I=8[I@6G8,\L,B>(5!OF,0XY2)(Q74K,CN
MTW$:+5L22I]&-]84;>Y1HKHMH=):ACX$^) <1TLJ5!XP7LIQ!1;T@*MBP\+H
M>F=:FW,EIL?1]6->MPY-+,!&.\;AQG:M\BR1'4?WQL.=B]^N#H(:@6 :I?$D
MG4:S.)N>A/4D.HJ2+)YD*9]G418/QTDTC6=9PFM(X?1DDO#IZ-W3<93$8_QC
M(PGK["2:Q">,,P3,SS_-TB0]>_.)'.$R+3W9[XL&[]Z,+'LTC-/Q"(MT&I^,
M)]U.!O>.HM$,S++H%W1T6TLKBF\%+E<&,:V0VQ61[H);A^QX(S[W[_IBB2*2
M-A:E-8VX;JV)!1(1$B;H,:\D^D98J'!U@&XV&9TE_>&0#1PE_23K<]H%UR/N
M,-6TC=A\MU :^01"J*H< 7(=&Q\L%!\=BD2+4JW!WXD-2O&Y1L43P;MV$V[\
M2D$N5!)XY60]IA3T<:5Y@Q[H<UD%5BB7C=1/ ?,94!A$B79K!FX=QA1;*O;E
M>UBLCNR#XEIE:&$1,O8((T.YKI56Y+<<8*<>0Z4GZ<<FW)$AP=,SQ$0!<VN5
M]Q#3QL,<>XV"[@>:7::Z1D:CM@W0\G!OM2#SH_RDQV2Q-C08I#@,V;&XI1)A
M!-J?!GE,$MP<5I2MA><6,>GF/_<;?AP-O@$*( E\(, ,^UJ'4,FUI1#TUZ[+
MP<&H:LBNPT!F)UKMNZFUW]W/_(MNU'T3[SX8/DF[5MH!M83JL#\=]X3MAG#W
MXLTF#+Z5\1BC85GANX4L"^"\-/!T]\( ^R^AQ7]02P,$%     @ *$%^5-]]
MG& .!0  -!8  !D   !X;"]W;W)K<VAE971S+W-H965T-#0N>&ULS5A=;]LV
M%'WN?@7A%4,+))%(2_[H' .)T[1IM]:HU^YAV ,CT391271)*FF+_?A=2HH^
M;)F6.PS(BRU2O(>'Y+WW7'%R+^1GM69,HZ]QE*CSWEKKS0O'4<&:Q52=B0U+
MX,U2R)AJ:,J5HS:2T3 SBB.'N.[ B2E/>M-)UC>7TXE(=<03-I=(I7%,Y;=+
M%HG[\Q[N/71\X*NU-AW.=+*A*[9@^N-F+J'EE"@ACUFBN$B09,OSW@5^\9;T
MC4$VXA-G]ZKVC,Q2;H7X;!HWX7G/-8Q8Q )M("C\W;$9BR*#!#R^%*"]<DYC
M6']^0+_.%@^+N:6*S43T)P_U^KPWZJ&0+6D:Z0_B_C4K%N0;O$!$*OM%]\58
MMX>"5&D1%\; (.9)_D^_%AM1,R##/0:D,"!=#?J%07_; .\Q\ H#KZN!7QCX
MVP;>'H-!83#H:C L#(9=#4:%P:BKP;@P&'<UP.[#R;F=3<K#SITN]Y+,Q:ZH
MIM.)%/=(FO& 9QXR/\WLP;-X8D)JH26\Y6"GI^^H3B5#8HDN4P7OE$(T"=$E
M55R9WKEDBB6:9OY_BB["D)M'&J&;) ]H\^+9%=.41^HY>HH<I-84K!!/T,>$
M:W4"G?#\QUJD"K#5Q-% W$SO! 7)RYPDV4/RFMV>(7=\@HA+\,?%%7KV]'D^
M20O6K ,6&77#NK)C7;'@#/5Q ZL%Y65W%'<_RO417'[Y&0_ZOY9'T8+VZHA=
M.HSV^@BTIS:@FR,<X3"M-T>@66F]/>($K;0<",\R1DD9HR2#[^^!?R]7-.'?
M\U";B42)B(=YZP)BM1&B[Y?HFB<T"3B$Z (Z&>B?5NBOWP 4W4!3_6VAU"\I
M]3-*WEY*(<PBOZ%%ML@3-*<2?:)1RM _Z/#!7.?HPPS=J/[=U#W#$^>NON?V
M,0W:7DG;L]*>1S3(-@1!N0"_2]8>]CG*H#;UH._[[7/[Y=R^=>YW4!]%0K7.
MEUOZM?E.L>?Y(Z^Y)2_]'5ZGV,?CX;B=VJ"D-K!2NPB"-$XC<);0E",\X+J-
MY6"'Y=!W"=DF.=C=/-<?>&X[QV')<6CE.*-J?8("^$7L2\KO:)3YM1$KJ 4_
M@_[<1@PI%J02%*K]6(<[S AQL;N'V:AD-K(R6Y1SHGDJ@S44>.AB)5GF:)98
M&Y?XX\<2_MBMR@;WH#=OI @8"Q5:2A%#"PY%,[1YB+%6G7=WC@![_4'M" H-
M/SBNR;M6[N ?/RS(7?-B%?/V531GK1(X?C09'%<I'-MS^ )"R)1X=T+S9)5%
M4B*2TZ(I'C*\*C)\ B<.H[E2*9!C*!#*U':Y ,#.[4WVEP6/>N(@[MAU^P1O
M'WN'D<W55ID?VU/_?U2L5P6\5;)N#@QJ4J^$ ]N5HW14"#'8^ V3.4\@;JU:
M7A>XHWHJ/B.D2?K-H5%-UI6F8+NHS$#LC"/EI,%S<L[@]JS52>QH6:WFG?ST
MY(DIUEK+_A\':*ZP4B1LEZ2.U<0EWM4=R&0[*>_ J";)2IRP79W>ZS7X2S-J
M6TF.=J;W=CG:!S4I5OJ&Q_9]W%:.$Z0E313-;UWV>HP=M8/'_#A LXZO5)/8
M5?-H]8&^=U5.WLIA-DJ5(!+\6*2)U#YXR..0IH)'77! :WROOU74SCH,;*ZU
MDF'ROWY*O2(=OJ5N#@S*J3NU:R1SG_H[E2N>*!2Q)5BY9T-8O<RO*/.&%IOL
M9NE6:"WB[''-:,BD&0#OET+HAX:YK"HOBJ?_ E!+ P04    "  H07Y4QM!_
M$_P&  "F'P  &0   'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6R]66UOVS80
M_KS]"L+H@!9(8I.2WXHD0&*G6+:F#9IF^U#L R/1-E&)5$DZ+\!^_(Z28MH6
M17MMD2^))=V1SQWOGCN2QP]2?=4+Q@QZS#.A3SH+8XJWW:Y.%BRG^D@63,"7
MF50Y-?"HYEU=*$;34BG/NJ37&W1SRD7G]+A\=ZU.C^729%RP:X7T,L^I>CIG
MF7PXZ>#.\XM/?+XP]D7W]+B@<W;#S&UQK>"INQHEY3D3FDN!%)N==,[PVXMX
M8!5*B;\X>]!KOY$UY4[*K_;A,CWI]"PBEK'$V"$H_+MG$Y9E=B3 \:T>M+.:
MTRJN_WX>_5UI/!AS1S6;R.QOGIK%26?402F;T65F/LF'WUEM4-^.E\A,EW_1
M0RW;ZZ!DJ8W,:V5 D'-1_:>/M2/6%& <OP*I%<B60NL,4:T0;<\0MRC$M4*\
MKT*_5BA-[U:VEXZ;4D-/CY5\0,I*PVCV1^G]4AO\Q84-E!NCX"L'/7-Z4P4(
MDC-TP^>"SWA"A4%G22*7PG Q1]<RXPEG&AVBLS3E=GEIABY%%:1VL5]/F:$\
MTV] Y/9FBEZ_>H->(2[0YX5<:BI2?=PU@-7.V$UJ7.<5+M*""Z,K*<Q"HPN1
MLM2C/]FA3P(#=,%)*T^19T^=D^"(4Y8<H0@?(-+#(Q^@O=4)]JA/]U?O>=0O
MPNI75+6I;S@C6H5-5(X7[0B;C[O#YLM[T$67AN7ZG\#,\6KFN)PY;G6$3A0O
MRL"#H-5KL\O9[/".9E0D#%4LJ[C^ZENJ\!2?%PQ-9%Y0\8065",A]YCF +@V
M62 0A\0 >A*0O4HQD3RA! )1 2/J R1+X'KCE4+2+)A:Z2U8.K<>I$I1,6?
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M1E=#BIZNIYYZ8=7&#P[WRM(8XC\+FA11.P$ZSY6R3PMGH)T]9_\!4$L#!!0
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ME],(;/<"=!-GMN$2K8WC*QF&%3^::'T [Y?&N.>)OY?#,YS]!5!+ P04
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M=,-$':"^WW(N7S?J5S#=*[?%?U!+ P04    "  H07Y4:FRX0>X#  #=#P
M&0   'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6S-5UUOVS84_2N$T(<66"R1
MDF6IL TDRIH52+<@7KJ'H0^T?6T3D427I.RVO[ZDK$BR]>%DW4->;)&Z'^<>
M\AZ1XST7CW(#H-"W)$[EQ-HHM7UOVW*Q@83* =]"JM^LN$BHTD.QMN56 %WF
M3DEL$\?Q[82RU)J.\[D[,1WS3,4LA3N!9)8D5'R_@ICO)Q:VGB;NV7JCS(0]
M'6_I&F:@'K9W0H_L,LJ2)9!*QE,D8#6Q+O'[B+C&(;?XS& O:\_(E#+G_-$,
M/BXGEF,000P+94)0_;>#".+81-(XOA9!K3*G<:P_/T7_D!>OBYE3"1&/_V%+
MM9E8@866L*)9K.[Y_@\H"AJ:> L>R_P7[0M;QT*+3"J>%,X:0<+2PS_]5A!1
M<\!>AP,I',AS'=S"(6?./B#+R[JFBD['@N^1,-8ZFGG(N<F]=34L-<LX4T*_
M9=I/33]0)M!G&F> /@&5F0"]1DHBFB[1)RH>0=%Y#&@&BTPPQ4"B"S33>VF9
MZ5F^0K>P@Q@1%%&Y0;]_S=B.QF<"O+W6<RR6[W2H)_<+]#"[1F_?O$-O$$O1
MWQN>21U!CFVEBS10[451T-6A(-)1T#4L!LC%OR'B$-SB'CW?W3EVMS6U);^D
MY)?D\=SS_%Y*"9J82TW,+:-S%A_H*&A?HK]2=&]8$BQ=YU9_\E24$U=4,HG^
MO=7QT4<%B?S2@\XMT;DY.J\#W67"A6(_=/*(2]5&]L'?S_V-).RF./""0#.[
MJY/:8N:1$0E*LR-X7@G/ZX5W([B4Z$&S0.,<Y8W6I;8]$1WB#.OY7:\]^;!,
M/GQ9\EL]AM8=.6QDO\#^Z(2B%B,O;(?HEQ#]7HC5YFI#Y3<Y";P1]DYPM9AY
M),!N.[11"6W4"^UA,!N@&[X#D1I!J?5_S[8-RN#!*VRJL$07_EI316&#<M=Q
MG';"L5,IN?,_;=BHB'2\&3ORU[XD^+_OQJAPKJ<D8>AW)*WD%9/>I!$76RZH
M G3%&]^+XYB5*&+W%6XO7*DB[I?%\ZJ-6_30(82<]GZ+7>B388<LX4HZ\0NU
MLU.X<5,6L=NA/;C21=POC"_0;MS4OPOLA*=$M5BYI -FI9&X7R3[];MP/EE$
MC(>GV)IVH>_Z77I2B2P.SK16DH!8,!JC.[H%T;=W*VW$X2OL+5*)*.D7T?.]
M19K:&1!_>/JY;S'S7,_O:"U2J2SI5]GGMQ9I*B[NR%X[S?;+[0L:JXATU#+#
MX)2E%J.NHP>I!)ST'VO[^XHT#ZN!UKS3EF\QTPM86^<#.+MV]S(77WWG6>L%
M03&LM)\S&.G:Q.$N>1@HOLVO8W.N].4N?]SH^S<(8Z#?KSA73P-SPRMO]-.?
M4$L#!!0    ( "A!?E1#Y55-BP(  #,&   9    >&PO=V]R:W-H965T<R]S
M:&5E=#4T+GAM;(U574_;,!3]*U<1#R -\DT9:B-!*[0]3$(4V,.T!R>];2R<
MN+.=EO[[73LA"BPP7AI_W'-\SO%'IWNIGG2):."Y$K6>>:4QVTO?UT6)%=-G
M<HLUS:REJIBAKMKX>JN0K1RH$GX4!.=^Q7CM95,W=JNRJ6R,X#7>*M!-53%U
MN$8A]S,O]%X&[OBF-'; SZ9;ML$EFH?MK:*>W[.L>(6UYK(&A>N9=Q5>SE-;
M[PH>.>[UH W622[ED^U\7\V\P I"@86Q#(P^.YRC$):(9/SI.+U^20L<ME_8
M;YQW\I(SC7,I?O*5*6?>A0<K7+-&F#NY_X:='R>PD$*[7]AWM8$'1:.-K#HP
M*:AXW7[9<Y?# ! F[P"B#A!]%A!W@-@9;94Y6PMF6#95<@_*5A.;;;AL')K<
M\-KNXM(HFN6$,]D-XPH>F6@0?B#3C4+:(J.!U2OXP=03&I8+A"46C>*&HX93
M6-)16C4T*M=PM6-<V))3.E&G2T:C ]@"<S/$Y@<H9&T4;5[#!%4:.W. XP4!
MN- GQ/ZP7,#QT0D< :_AOI2-)BUZZAMR:S7[1>?LNG46O>-L@<49Q.$7B((H
M'('//P\/7L-]RK@/.NJ#CAQ?_/^@%UP70MJL-?RZRK7+X_<':\3]&K%;(WEG
MC2Y/FS1E)VN$ S(%4H% /1IARW?N^.R%WV7A)$HGZ=3?#:,:*8NC(#WORU[)
M37JYR6?EYFCVB*UF>_1,J;!5/RJ[Y4V'>J(P_OI&]4A5,$DGXZ+37G3ZH>A[
M:9@8TY3^F]%%,@F3-Z)&RI+H(HS?J/('5]H^IW2I-KS6M)%K @9G$^)1[1/5
M=HS<NEN>2T-OAFN6]*JCL@4TOY;2O'3LP]'_3V1_ 5!+ P04    "  H07Y4
ME?P1B!@"  "+!   &0   'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6R%5,EN
MVS 0_15"IQ9(K<5+BT 2X*5I<PA@.&AS*'J@I;%$A(M*CJ+X[T-2LNH"L7N1
M.,.9]]X,ATP[I9]-#8#D57!ILJ!&;&[#T!0U"&HFJ@%I=PY*"XK6U%5H&@VT
M]$F"ATD4+4)!F0SRU/NV.D]5BYQ)V&IB6B&H/JZ JRX+XN#DV+&J1N<(\[2A
M%3P"_FBVVEKAB%(R =(P)8F&0Q8LX]O5S,7[@)\,.G.V)JZ2O5+/SK@OLR!R
M@H!#@0Z!VM\+K(%S!V1E_!DP@Y'2)9ZO3^AWOG9;RYX:6"O^Q$JLL^!+0$HX
MT);C3G7?8:AG[O *Q8W_DJZ/G<\#4K0&E1B2K0+!9/^GKT,?SA+BQ86$9$A(
MO.Z>R*O<4*1YJE5'M(NV:&[A2_795AR3[E >4=M=9O,PW\$+R!;(#@I52>8[
M]8DLR](O*2?WLC]YM_%A T@9-Q_3$"VW0PB+@6?5\R07>.*$/"B)M2%?90GE
MOP"A%3TJ3T[*5\E5Q T4$S*-;T@2)?$5O.G8B:G'F_ZG$W=:";*V6K6=&/+$
ML"9K?PZ@R:_EWGC_[RN$LY%PY@EG%PB_@01M.]S0HYUR) A:F!MWN$RTXKT6
M7\=;1*2D1_.>LO!L0&P=E;\&AA2JE=C/RN@=;]JR'["_X?TU?:"Z8M(0#@>;
M&DT^V\'6_>CW!JK&C]M>H6V:7];VM0#M NS^02D\&8Y@?'_R-U!+ P04
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M4,\ANB.^^XEXCN=VR&>7RYU_Y3;Z5YOHU29Z)I]_F8ED6GM1>7"TY-=T)97
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ML=\/!NYZW\]F4!3UHSKH #^L\<.+\$OZ*@7G%EH"I]J6=!IXE[6[S](UJ^
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M</E6'^2YS#+!5/J+NPGP;%U@E&MO#K%'-9)RW> 8HTB6RB:02J"Q6:%A:7&
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M(@? ]W/.Q=L;>8'R]QEG_P=02P,$%     @ *$%^5/ HONAP P  V0H  !D
M  !X;"]W;W)K<VAE971S+W-H965T-C@N>&ULE99O;],Z%,:_RE'$E3:)+G^;
MM*BMM+4@0* [408O$"_<Q&TLDKC8SKI]>XZ=+.M-W8S[IHV=\SS^^=BQS^S
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M4Q\>]#Z3"G.#OK[C7#T/S-:GV[FN_P-02P,$%     @ *$%^5%7B-E%% @
M408  !D   !X;"]W;W)K<VAE971S+W-H965T-S N>&ULM57;3MM $/V5E9]
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M7L^HJK"EY-9*:A?C]T/G=5N$.NB"7;I-0SUCJ&?E]*%I@<J>?(\AWBXT>FW
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MG6#N+X3II1[8C:SY<!G]!5!+ P04    "  H07Y4$+N,A!0'   I)   &0
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M/$0-@;J(P(Y59(\%5$!NKPN$AHY;F72M9F7*N@[ ED+PI'8/ ;@(V0T-0I^
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MX_G_4O(+R1;9\_1[)B6+LX]S2M1<20W4[S/&Y/HB?42_^7?0V;]02P,$%
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M+ZQ>T,3XBWDF[5]XK,<&(XA+J7A>&VL$>5I4_^E3343+ $<#!K@VP(<&:,"
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M\SGH]T.AT0;M[IO@C9T>KK!(T>_OFA)]4\#D'X>@9B6H:04UCPBZ(_+Q8B8
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MV:#79YRKYX%Y0/6'8O /4$L#!!0    ( "A!?E0IS].+3 0  ,80   9
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MR&[CQRM6&F1+>5X<I,5/]%C2&@?(R],L#DMFT"#DT>8W_5%N1(V!C'L82,E
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M@J%>".['*4]1MDZ@Y2T.(@@QWDUG\Z/KXAF_>WL(.PHF^[(D2G%7N0A@TQZ
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MX/XM8AK8*!DQ%FL$84S0@G*%-E1DN=KJ?>I"R(B6<8WVCC?N+1Q/!G=HZ\E
MW)/A9,NZVJY6<7)9YVY2RS4Y<_*&@E?@'4J(SKDX5=53<JS6F Q=H:]5F+A5
M^&1PX$@[B2*9V3 ]G3CB[:]9*S2Y+(4.:H4.W I=[=AYJ)V67G8[8= P/._/
MVQ4\O9W70?9MWR-52P[[$VP!0/^Z#YE7Q0NTXL;(=?Z&:"Z-D4E^N6(4!KXU
M@.\74IKW&_O2J7J-.?X'4$L#!!0    ( "A!?E3--FQI$P,  #@*   9
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M6'_!)J&>X8M$KNPOK)M8SX&H4EH4#9@4%!FOG^RZ*<06P._O  0-(+@/Z.X
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MRU0+NID#AX1IE$B1WZ(3OYLE:,HR=6L4'E=+=//Z%KU&C*.'5.P4Y;&:^-K
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MN!N9;,JBK2HF6FQ=9_(DM.ESW# UK2A(:V">)T+HP\2^H&IN9W\!4$L#!!0
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M:C0^P9W71'P._*2-_XGB%U!+ P04    "  H07Y4(0K05C,$  !7$   &0
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M=/5X@87BQC_)MHV]30-2-,8JT8%1@6"R?=-=UX<#0#PZ 4@Z0/(1,#P!2#M
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M(POE[*_1($Q:D<N1A7)F"P4/K<()B+]5*2:R4'[ M6M;F%/3/%!,9*&<V4(
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MO3W^NOR^.'E[KSB[^XKAZ2]02P,$%     @ *$%^5+CD,TQ& @  C#4  !,
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M:?^/XY=G.M3=^)(OEC]AW?X$4$L! A0#%     @ *$%^5 =!36*!    L0
M !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M"  H07Y4%8O!=>X    K @  $0              @ &O    9&]C4')O<',O
M8V]R92YX;6Q02P$"% ,4    "  H07Y4F5R<(Q &  "<)P  $P
M    @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( "A!?E2@
M.(J)YP8  *L;   8              " @0T(  !X;"]W;W)K<VAE971S+W-H
M965T,2YX;6Q02P$"% ,4    "  H07Y4).U-B9\&  "T&@  &
M    @($J#P  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @
M*$%^5/@+)LYS @  C 8  !@              ("!_Q4  'AL+W=O<FMS:&5E
M=',O<VAE970S+GAM;%!+ 0(4 Q0    ( "A!?E3MTGJHJ 4  #<5   8
M          " @:@8  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4
M    "  H07Y4L6H63Y$&  "$'@  &               @(&&'@  >&PO=V]R
M:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ *$%^5*AM$GI' @  L@0
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M965T,3 N>&UL4$L! A0#%     @ *$%^5._X*&YN!   SPH  !D
M     ("!9FL  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "A!?E0NZ[$?O@(  %L&   9              "
M@>9\  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ *$%^
M5)85 *=M"   :Q8  !D              ("!VW\  'AL+W=O<FMS:&5E=',O
M<VAE970Q-RYX;6Q02P$"% ,4    "  H07Y4DYP*PST.  "%*0  &0
M        @(%_B   >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0
M   ( "A!?E2SJWG9SP@  '(8   9              " @?.6  !X;"]W;W)K
M<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ *$%^5%SWX/!.!0  WPT
M !D              ("!^9\  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q0
M2P$"% ,4    "  H07Y40Z4N0W(,  !,(0  &0              @(%^I0
M>&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( "A!?E0]PWTV
M81<  %9)   9              " @2>R  !X;"]W;W)K<VAE971S+W-H965T
M,C(N>&UL4$L! A0#%     @ *$%^5 !S/\)B%P  7TD  !D
M ("!O\D  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    "  H
M07Y4E:*6!.@,  ![(P  &0              @(%8X0  >&PO=V]R:W-H965T
M<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( "A!?E14LB5L7@<  /H1   9
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M970R.2YX;6Q02P$"% ,4    "  H07Y4!G?[4A &  "K#P  &0
M    @(&6+ $ >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    (
M "A!?E3"9#T]T 0  %@0   9              " @=TR 0!X;"]W;W)K<VAE
M971S+W-H965T,S$N>&UL4$L! A0#%     @ *$%^5#C#P83& @  %P8  !D
M             ("!Y#<! 'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"
M% ,4    "  H07Y4P80\5, "  #Q!0  &0              @('A.@$ >&PO
M=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( "A!?E1&G=;O^0(
M $D'   9              " @=@] 0!X;"]W;W)K<VAE971S+W-H965T,S0N
M>&UL4$L! A0#%     @ *$%^5 IK="V5 @  : 4  !D              ("!
M"$$! 'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    "  H07Y4
M;E4V/<L"  !&!@  &0              @('40P$ >&PO=V]R:W-H965T<R]S
M:&5E=#,V+GAM;%!+ 0(4 Q0    ( "A!?E0>Z4!2Z0,  -T(   9
M      " @=9& 0!X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%
M  @ *$%^5'H1T-A/!   4PD  !D              ("!]DH! 'AL+W=O<FMS
M:&5E=',O<VAE970S."YX;6Q02P$"% ,4    "  H07Y4Q5;*[#<#  "1!P
M&0              @(%\3P$ >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+
M 0(4 Q0    ( "A!?E0N5HA4604  'P,   9              " @>I2 0!X
M;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ *$%^5**WH"+%
M @  !P8  !D              ("!>E@! 'AL+W=O<FMS:&5E=',O<VAE970T
M,2YX;6Q02P$"% ,4    "  H07Y473.J7\8&   \$@  &0
M@(%V6P$ >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( "A!
M?E3-B\S>. 0  !4)   9              " @7-B 0!X;"]W;W)K<VAE971S
M+W-H965T-#,N>&UL4$L! A0#%     @ *$%^5-]]G& .!0  -!8  !D
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M=#0X+GAM;%!+ 0(4 Q0    ( "A!?E088T=);@,  (<*   9
M  " @9=\ 0!X;"]W;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @
M*$%^5+-7?V42 P  10D  !D              ("!/( ! 'AL+W=O<FMS:&5E
M=',O<VAE970U,"YX;6Q02P$"% ,4    "  H07Y4;@NCV4L"  "2!0  &0
M            @(&%@P$ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4
M Q0    ( "A!?E1$KGL#T 0  'X;   9              " @0>& 0!X;"]W
M;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @ *$%^5&ILN$'N P
MW0\  !D              ("!#HL! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX
M;6Q02P$"% ,4    "  H07Y40^5538L"   S!@  &0              @($S
MCP$ >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( "A!?E25
M_!&(& (  (L$   9              " @?61 0!X;"]W;W)K<VAE971S+W-H
M965T-34N>&UL4$L! A0#%     @ *$%^5%!KP.O^ @  P0@  !D
M     ("!1)0! 'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "A!?E3("\Q.AP(  $L'   9              "
M@=&B 0!X;"]W;W)K<VAE971S+W-H965T-C$N>&UL4$L! A0#%     @ *$%^
M5*EDVM2P @  C0<  !D              ("!CZ4! 'AL+W=O<FMS:&5E=',O
M<VAE970V,BYX;6Q02P$"% ,4    "  H07Y4 *.0T 0#  #T"   &0
M        @(%VJ $ >&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4 Q0
M   ( "A!?E1OL.P#500  *L1   9              " @;&K 0!X;"]W;W)K
M<VAE971S+W-H965T-C0N>&UL4$L! A0#%     @ *$%^5.+MO4F/ @  LP8
M !D              ("!/; ! 'AL+W=O<FMS:&5E=',O<VAE970V-2YX;6Q0
M2P$"% ,4    "  H07Y4X+FQR><"  !.!P  &0              @($#LP$
M>&PO=V]R:W-H965T<R]S:&5E=#8V+GAM;%!+ 0(4 Q0    ( "A!?E0V];N%
M%@D  *LQ   9              " @2&V 0!X;"]W;W)K<VAE971S+W-H965T
M-C<N>&UL4$L! A0#%     @ *$%^5/ HONAP P  V0H  !D
M ("!;K\! 'AL+W=O<FMS:&5E=',O<VAE970V."YX;6Q02P$"% ,4    "  H
M07Y4A;M>]+<#  #%#@  &0              @($5PP$ >&PO=V]R:W-H965T
M<R]S:&5E=#8Y+GAM;%!+ 0(4 Q0    ( "A!?E15XC9110(  %$&   9
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M970W-"YX;6Q02P$"% ,4    "  H07Y4A2B"8?4&  "C'P  &0
M    @(%4WP$ >&PO=V]R:W-H965T<R]S:&5E=#<U+GAM;%!+ 0(4 Q0    (
M "A!?E21<?VE/P,  %P,   9              " @8#F 0!X;"]W;W)K<VAE
M971S+W-H965T-S8N>&UL4$L! A0#%     @ *$%^5"G/TXM,!   QA   !D
M             ("!]ND! 'AL+W=O<FMS:&5E=',O<VAE970W-RYX;6Q02P$"
M% ,4    "  H07Y4>";+TZT#  !5#@  &0              @(%Y[@$ >&PO
M=V]R:W-H965T<R]S:&5E=#<X+GAM;%!+ 0(4 Q0    ( "A!?E1]8<#!Y (
M -@(   9              " @5WR 0!X;"]W;W)K<VAE971S+W-H965T-SDN
M>&UL4$L! A0#%     @ *$%^5.]L7G.>"0  @3$  !D              ("!
M>/4! 'AL+W=O<FMS:&5E=',O<VAE970X,"YX;6Q02P$"% ,4    "  H07Y4
M[OXTU:,$  #2%   &0              @(%-_P$ >&PO=V]R:W-H965T<R]S
M:&5E=#@Q+GAM;%!+ 0(4 Q0    ( "A!?E3--FQI$P,  #@*   9
M      " @2<$ @!X;"]W;W)K<VAE971S+W-H965T.#(N>&UL4$L! A0#%
M  @ *$%^5$:* UZ4 @  =@8  !D              ("!<0<" 'AL+W=O<FMS
M:&5E=',O<VAE970X,RYX;6Q02P$"% ,4    "  H07Y4G+B<!TH#  #H"@
M&0              @($\"@( >&PO=V]R:W-H965T<R]S:&5E=#@T+GAM;%!+
M 0(4 Q0    ( "A!?E32[#&JYP,  *X+   9              " @;T- @!X
M;"]W;W)K<VAE971S+W-H965T.#4N>&UL4$L! A0#%     @ *$%^5%JL(T#^
M P  PPX  !D              ("!VQ$" 'AL+W=O<FMS:&5E=',O<VAE970X
M-BYX;6Q02P$"% ,4    "  H07Y4>*X0P<8#  ! #   &0
M@($0%@( >&PO=V]R:W-H965T<R]S:&5E=#@W+GAM;%!+ 0(4 Q0    ( "A!
M?E3SL5L['P,  -0'   9              " @0T: @!X;"]W;W)K<VAE971S
M+W-H965T.#@N>&UL4$L! A0#%     @ *$%^5*[UK>^U P  #0\  !D
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M=#DS+GAM;%!+ 0(4 Q0    ( "A!?E2K$_9M1 (  -,$   9
M  " @6,O @!X;"]W;W)K<VAE971S+W-H965T.30N>&UL4$L! A0#%     @
M*$%^5*<N72QS P  ,A<   T              ( !WC$" 'AL+W-T>6QE<RYX
M;6Q02P$"% ,4    "  H07Y4EXJ[',     3 @  "P              @ %\
M-0( 7W)E;',O+G)E;'-02P$"% ,4    "  H07Y45\+5>6T&  #^/0  #P
M            @ %E-@( >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ *$%^
M5+;U/P:V @  43<  !H              ( !_SP" 'AL+U]R96QS+W=O<FMB
M;V]K+GAM;"YR96QS4$L! A0#%     @ *$%^5+CD,TQ& @  C#4  !,
M         ( ![3\" %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     &8 9@ !
)'   9$("

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>240</ContextCount>
  <ElementCount>521</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>95</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - Consolidated Statements of Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity</Role>
      <ShortName>Consolidated Statements of Shareholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - Consolidated Statements of Shareholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Shareholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070 - Disclosure - Nature of Business and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentation</Role>
      <ShortName>Nature of Business and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Fair Value Measurements and Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecurities</Role>
      <ShortName>Fair Value Measurements and Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Revenue Recognition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRevenueRecognition</Role>
      <ShortName>Revenue Recognition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Prepaid Expenses and Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssets</Role>
      <ShortName>Prepaid Expenses and Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Intangible Assets, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIntangibleAssetsNet</Role>
      <ShortName>Intangible Assets, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Other Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureOtherAssets</Role>
      <ShortName>Other Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Accrued Expenses and Other Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherLiabilities</Role>
      <ShortName>Accrued Expenses and Other Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Restructuring Charges</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRestructuringCharges</Role>
      <ShortName>Restructuring Charges</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Notes Payable</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayable</Role>
      <ShortName>Notes Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Shareholders' Equity and Convertible Preferred Shares</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareholdersEquityAndConvertiblePreferredShares</Role>
      <ShortName>Shareholders' Equity and Convertible Preferred Shares</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Share-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensation</Role>
      <ShortName>Share-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100210 - Disclosure - License and Research Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLicenseAndResearchAgreements</Role>
      <ShortName>License and Research Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Collaboration Agreement with Pharming Group N.V.</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCollaborationAgreementWithPharmingGroupNV</Role>
      <ShortName>Collaboration Agreement with Pharming Group N.V.</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureBenefitPlans</Role>
      <ShortName>Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Related-Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactions</Role>
      <ShortName>Related-Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Fair Value Measurements and Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesTables</Role>
      <ShortName>Fair Value Measurements and Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecurities</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssets</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipment</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Intangible Assets, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIntangibleAssetsNetTables</Role>
      <ShortName>Intangible Assets, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIntangibleAssetsNet</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Other Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureOtherAssetsTables</Role>
      <ShortName>Other Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureOtherAssets</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Accrued Expenses and Other Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherLiabilities</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Restructuring Charges (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRestructuringChargesTables</Role>
      <ShortName>Restructuring Charges (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRestructuringCharges</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeases</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Notes Payable (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableTables</Role>
      <ShortName>Notes Payable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayable</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Share-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationTables</Role>
      <ShortName>Share-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensation</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Collaboration Agreement with Pharming Group N.V. (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCollaborationAgreementWithPharmingGroupNVTables</Role>
      <ShortName>Collaboration Agreement with Pharming Group N.V. (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCollaborationAgreementWithPharmingGroupNV</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxes</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Nature of Business and Basis of Presentation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails</Role>
      <ShortName>Nature of Business and Basis of Presentation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Summary of Significant Accounting Policies - Schedule of Changes in Loss Provision (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfChangesInLossProvisionDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Changes in Loss Provision (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100480 - Disclosure - Summary of Significant Accounting Policies - Summary of Amounts recognized to Offset Research and Development Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfAmountsRecognizedToOffsetResearchAndDevelopmentExpenseDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Amounts recognized to Offset Research and Development Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Summary of Significant Accounting Policies - Securities Excluded in the Computation of Diluted Net Loss Per Ordinary Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSecuritiesExcludedInComputationOfDilutedNetLossPerOrdinaryShareDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Securities Excluded in the Computation of Diluted Net Loss Per Ordinary Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Fair Value Measurements and Marketable Securities - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAdditionalInformationDetails</Role>
      <ShortName>Fair Value Measurements and Marketable Securities - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>100510 - Disclosure - Fair Value Measurements and Marketable Securities - Schedule of Cash Equivalents and Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesScheduleOfCashEquivalentsAndMarketableSecuritiesDetails</Role>
      <ShortName>Fair Value Measurements and Marketable Securities - Schedule of Cash Equivalents and Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>100520 - Disclosure - Fair Value Measurements and Marketable Securities - Schedule of Level 2 Cash Equivalents and Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesScheduleOfLevel2CashEquivalentsAndMarketableSecuritiesDetails</Role>
      <ShortName>Fair Value Measurements and Marketable Securities - Schedule of Level 2 Cash Equivalents and Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>100530 - Disclosure - Fair Value Measurements and Marketable Securities - Schedule of Available-for-Sale Marketable Debt Securities by contractual Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesScheduleOfAvailableForSaleMarketableDebtSecuritiesByContractualMaturityDetails</Role>
      <ShortName>Fair Value Measurements and Marketable Securities - Schedule of Available-for-Sale Marketable Debt Securities by contractual Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>100540 - Disclosure - Revenue Recognition - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails</Role>
      <ShortName>Revenue Recognition - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>100550 - Disclosure - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails</Role>
      <ShortName>Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>100560 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment - Schedule of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>100570 - Disclosure - Property and Equipment - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails</Role>
      <ShortName>Property and Equipment - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>100580 - Disclosure - Intangible Assets, Net - Schedule of Intangible Assets Net of Accumulated Amortization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfIntangibleAssetsNetOfAccumulatedAmortizationDetails</Role>
      <ShortName>Intangible Assets, Net - Schedule of Intangible Assets Net of Accumulated Amortization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>100590 - Disclosure - Intangible Assets, Net - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIntangibleAssetsNetAdditionalInformationDetails</Role>
      <ShortName>Intangible Assets, Net - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>100600 - Disclosure - Intangible Assets, Net - Schedule of Estimated Future Amortization For Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfEstimatedFutureAmortizationForIntangibleAssetsDetails</Role>
      <ShortName>Intangible Assets, Net - Schedule of Estimated Future Amortization For Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>100610 - Disclosure - Other Assets - Schedule of Other Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureOtherAssetsScheduleOfOtherAssetsDetails</Role>
      <ShortName>Other Assets - Schedule of Other Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>100620 - Disclosure - Accrued Expenses and Other Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accrued Expenses and Other Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>100630 - Disclosure - Restructuring Charges - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRestructuringChargesAdditionalInformationDetails</Role>
      <ShortName>Restructuring Charges - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>100640 - Disclosure - Restructuring Charges - Summary of Cash Restructuring Charges (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRestructuringChargesSummaryOfCashRestructuringChargesDetails</Role>
      <ShortName>Restructuring Charges - Summary of Cash Restructuring Charges (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>100650 - Disclosure - Restructuring Charges - Summary of Impairment of Long Lived Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRestructuringChargesSummaryOfImpairmentOfLongLivedAssetsDetails</Role>
      <ShortName>Restructuring Charges - Summary of Impairment of Long Lived Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>100660 - Disclosure - Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails</Role>
      <ShortName>Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>100670 - Disclosure - Leases - Summary of Lease Cost Under Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfLeaseCostUnderOperatingLeasesDetails</Role>
      <ShortName>Leases - Summary of Lease Cost Under Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>100680 - Disclosure - Leases - Schedule of Future Minimum Base Rent Commitments Under Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumBaseRentCommitmentsUnderOperatingLeasesDetails</Role>
      <ShortName>Leases - Schedule of Future Minimum Base Rent Commitments Under Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>100700 - Disclosure - Leases - Schedule of Future Minimum Base Rent Commitments Under Operating Leases (Parenthetical) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumBaseRentCommitmentsUnderOperatingLeasesParentheticalDetails</Role>
      <ShortName>Leases - Schedule of Future Minimum Base Rent Commitments Under Operating Leases (Parenthetical) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>100710 - Disclosure - Notes Payable - Additional Information (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails</Role>
      <ShortName>Notes Payable - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>100720 - Disclosure - Notes Payable - Summary of Notes Payable (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableSummaryOfNotesPayableDetails</Role>
      <ShortName>Notes Payable - Summary of Notes Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>100730 - Disclosure - Notes Payable - Summary of Future Principal Payments Due (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableSummaryOfFuturePrincipalPaymentsDueDetails</Role>
      <ShortName>Notes Payable - Summary of Future Principal Payments Due (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>100750 - Disclosure - Shareholders' Equity and Convertible Preferred Shares - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareholdersEquityAndConvertiblePreferredSharesAdditionalInformationDetails</Role>
      <ShortName>Shareholders' Equity and Convertible Preferred Shares - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>100760 - Disclosure - Share-based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Share-based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>100770 - Disclosure - Share-based Compensation - Assumptions Used in Black-Scholes Option Pricing Model (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAssumptionsUsedInBlackScholesOptionPricingModelDetails</Role>
      <ShortName>Share-based Compensation - Assumptions Used in Black-Scholes Option Pricing Model (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>100780 - Disclosure - Share-based Compensation - Summary of Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfOptionActivityDetails</Role>
      <ShortName>Share-based Compensation - Summary of Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>100790 - Disclosure - Share-based Compensation - Summary of Award Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfAwardActivityDetails</Role>
      <ShortName>Share-based Compensation - Summary of Award Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>100800 - Disclosure - Share-based Compensation - Share-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails</Role>
      <ShortName>Share-based Compensation - Share-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>100810 - Disclosure - License and Research Agreements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetails</Role>
      <ShortName>License and Research Agreements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>100820 - Disclosure - Collaboration Agreement with Pharming Group N.V. - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCollaborationAgreementWithPharmingGroupNVAdditionalInformationDetails</Role>
      <ShortName>Collaboration Agreement with Pharming Group N.V. - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>100830 - Disclosure - Collaboration Agreement with Pharming Group N.V. - Summary of Research and Development Costs Incurred and Collaboration Revenue Recognized (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCollaborationAgreementWithPharmingGroupNVSummaryOfResearchAndDevelopmentCostsIncurredAndCollaborationRevenueRecognizedDetails</Role>
      <ShortName>Collaboration Agreement with Pharming Group N.V. - Summary of Research and Development Costs Incurred and Collaboration Revenue Recognized (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>100840 - Disclosure - Income Taxes - Schedule of Components of Net Loss Before Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfNetLossBeforeIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Schedule of Components of Net Loss Before Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>100850 - Disclosure - Income Taxes - Schedule of Provision for (Benefit from) Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Schedule of Provision for (Benefit from) Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>100860 - Disclosure - Income Taxes - Schedule of Reconciliation of Income Tax Expense (Benefit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetails</Role>
      <ShortName>Income Taxes - Schedule of Reconciliation of Income Tax Expense (Benefit) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>100870 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>100880 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesTaxesDetails</Role>
      <ShortName>Income Taxes - Schedule of Deferred Tax Assets and Liabilities Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>100890 - Disclosure - Income Taxes - Schedule of Changes in Valuation Allowance for Deferred Tax Assets Related Primarily to Increase in U.K. Net Operating Loss Carryforwards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfChangesInValuationAllowanceForDeferredTaxAssetsRelatedPrimarilyToIncreaseInUKNetOperatingLossCarryforwardsDetails</Role>
      <ShortName>Income Taxes - Schedule of Changes in Valuation Allowance for Deferred Tax Assets Related Primarily to Increase in U.K. Net Operating Loss Carryforwards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>100900 - Disclosure - Commitments and Contingencies - Schedule of Annual Commitments Associated with the Contract (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfAnnualCommitmentsAssociatedWithContractDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Annual Commitments Associated with the Contract (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>100910 - Disclosure - Commitments and Contingencies - Schedule of Annual Commitments Associated with the Contract (Parenthetical) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfAnnualCommitmentsAssociatedWithContractParentheticalDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Annual Commitments Associated with the Contract (Parenthetical) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>100920 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>100930 - Disclosure - Benefit Plans - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureBenefitPlansAdditionalInformationDetails</Role>
      <ShortName>Benefit Plans - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>100940 - Disclosure - Related Party Transactions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails</Role>
      <ShortName>Related Party Transactions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="ortx-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>100950 - Disclosure - Subsequent Events - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails</Role>
      <ShortName>Subsequent Events - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="ortx-10k_20211231.htm">ortx-10k_20211231.htm</File>
    <File>ortx-20211231.xsd</File>
    <File>ortx-20211231_cal.xml</File>
    <File>ortx-20211231_def.xml</File>
    <File>ortx-20211231_lab.xml</File>
    <File>ortx-20211231_pre.xml</File>
    <File>ortx-ex1019_562.htm</File>
    <File>ortx-ex211_7.htm</File>
    <File>ortx-ex231_6.htm</File>
    <File>ortx-ex311_8.htm</File>
    <File>ortx-ex312_10.htm</File>
    <File>ortx-ex321_9.htm</File>
    <File>ortx-ex322_11.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>geajuovwk5do000001.jpg</File>
    <File>geajuovwk5do000002.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1">http://fasb.org/srt/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="789">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>117
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ortx-10k_20211231.htm": {
   "axisCustom": 0,
   "axisStandard": 31,
   "contextCount": 240,
   "dts": {
    "calculationLink": {
     "local": [
      "ortx-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ortx-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "ortx-10k_20211231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ortx-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ortx-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "ortx-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/currency/2021/currency-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd",
      "https://xbrl.sec.gov/exch/2021/exch-2021.xsd",
      "https://xbrl.sec.gov/naics/2021/naics-2021.xsd",
      "https://xbrl.sec.gov/sic/2021/sic-2021.xsd",
      "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"
     ]
    }
   },
   "elementCount": 777,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 38,
    "http://www.orchard-tx.com/20211231": 4,
    "http://xbrl.sec.gov/dei/2021q4": 5,
    "total": 47
   },
   "keyCustom": 129,
   "keyStandard": 392,
   "memberCustom": 54,
   "memberStandard": 41,
   "nsprefix": "ortx",
   "nsuri": "http://www.orchard-tx.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100090 - Disclosure - Fair Value Measurements and Marketable Securities",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecurities",
     "shortName": "Fair Value Measurements and Marketable Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100100 - Disclosure - Revenue Recognition",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRevenueRecognition",
     "shortName": "Revenue Recognition",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ortx:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100110 - Disclosure - Prepaid Expenses and Other Current Assets",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssets",
     "shortName": "Prepaid Expenses and Other Current Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ortx:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100120 - Disclosure - Property and Equipment",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipment",
     "shortName": "Property and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100130 - Disclosure - Intangible Assets, Net",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIntangibleAssetsNet",
     "shortName": "Intangible Assets, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100140 - Disclosure - Other Assets",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureOtherAssets",
     "shortName": "Other Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100150 - Disclosure - Accrued Expenses and Other Liabilities",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherLiabilities",
     "shortName": "Accrued Expenses and Other Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100160 - Disclosure - Restructuring Charges",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRestructuringCharges",
     "shortName": "Restructuring Charges",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100170 - Disclosure - Leases",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100180 - Disclosure - Notes Payable",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayable",
     "shortName": "Notes Payable",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010 - Statement - Consolidated Balance Sheets",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20211231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:MarketableSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100190 - Disclosure - Shareholders' Equity and Convertible Preferred Shares",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareholdersEquityAndConvertiblePreferredShares",
     "shortName": "Shareholders' Equity and Convertible Preferred Shares",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100200 - Disclosure - Share-based Compensation",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensation",
     "shortName": "Share-based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100210 - Disclosure - License and Research Agreements",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLicenseAndResearchAgreements",
     "shortName": "License and Research Agreements",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100220 - Disclosure - Collaboration Agreement with Pharming Group N.V.",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCollaborationAgreementWithPharmingGroupNV",
     "shortName": "Collaboration Agreement with Pharming Group N.V.",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100230 - Disclosure - Income Taxes",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100240 - Disclosure - Commitments and Contingencies",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100250 - Disclosure - Benefit Plans",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureBenefitPlans",
     "shortName": "Benefit Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100260 - Disclosure - Related-Party Transactions",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactions",
     "shortName": "Related-Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100270 - Disclosure - Subsequent Events",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100280 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "U_iso4217GBP_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100020 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20211231",
      "decimals": "2",
      "lang": null,
      "name": "ortx:CommonStockSharesAuthorizedNominalAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217GBP",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100290 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100300 - Disclosure - Fair Value Measurements and Marketable Securities (Tables)",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesTables",
     "shortName": "Fair Value Measurements and Marketable Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ortx:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100310 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables",
     "shortName": "Prepaid Expenses and Other Current Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ortx:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100320 - Disclosure - Property and Equipment (Tables)",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentTables",
     "shortName": "Property and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ortx:ScheduleOfIntangibleAssetsNetOfAccumulatedAmortizationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100330 - Disclosure - Intangible Assets, Net (Tables)",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIntangibleAssetsNetTables",
     "shortName": "Intangible Assets, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ortx:ScheduleOfIntangibleAssetsNetOfAccumulatedAmortizationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:OtherAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100340 - Disclosure - Other Assets (Tables)",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureOtherAssetsTables",
     "shortName": "Other Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OtherAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100350 - Disclosure - Accrued Expenses and Other Liabilities (Tables)",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherLiabilitiesTables",
     "shortName": "Accrued Expenses and Other Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100360 - Disclosure - Restructuring Charges (Tables)",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRestructuringChargesTables",
     "shortName": "Restructuring Charges (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100370 - Disclosure - Leases (Tables)",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100380 - Disclosure - Notes Payable (Tables)",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableTables",
     "shortName": "Notes Payable (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100030 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100390 - Disclosure - Share-based Compensation (Tables)",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationTables",
     "shortName": "Share-based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100400 - Disclosure - Collaboration Agreement with Pharming Group N.V. (Tables)",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCollaborationAgreementWithPharmingGroupNVTables",
     "shortName": "Collaboration Agreement with Pharming Group N.V. (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100410 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100420 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "U_iso4217GBP_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100430 - Disclosure - Nature of Business and Basis of Presentation - Additional Information (Details)",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
     "shortName": "Nature of Business and Basis of Presentation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20211231",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:ConcentrationRiskCreditRisk",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100440 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:ConcentrationRiskCreditRisk",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100450 - Disclosure - Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ortx:PropertyPlantAndEquipmentUsefulLifeTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100460 - Disclosure - Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Property and Equipment (Details)",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ortx:PropertyPlantAndEquipmentUsefulLifeTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ortx:StrimvelisLossProvisionPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ortx:AssetAcquisitionLiabilityAssumed",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100470 - Disclosure - Summary of Significant Accounting Policies - Schedule of Changes in Loss Provision (Details)",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfChangesInLossProvisionDetails",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Changes in Loss Provision (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ortx:StrimvelisLossProvisionPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": "-3",
      "lang": null,
      "name": "ortx:AssetAcquisitionLiabilityAmortizationOfLossProvision",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationTaxCredits",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100480 - Disclosure - Summary of Significant Accounting Policies - Summary of Amounts recognized to Offset Research and Development Expense (Details)",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfAmountsRecognizedToOffsetResearchAndDevelopmentExpenseDetails",
     "shortName": "Summary of Significant Accounting Policies - Summary of Amounts recognized to Offset Research and Development Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_srtStatementGeographicalAxis_countryGB_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20191231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:TaxCreditCarryforwardAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100040 - Statement - Consolidated Statements of Shareholders' Equity",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity",
     "shortName": "Consolidated Statements of Shareholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100490 - Disclosure - Summary of Significant Accounting Policies - Securities Excluded in the Computation of Diluted Net Loss Per Ordinary Share (Details)",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSecuritiesExcludedInComputationOfDilutedNetLossPerOrdinaryShareDetails",
     "shortName": "Summary of Significant Accounting Policies - Securities Excluded in the Computation of Diluted Net Loss Per Ordinary Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount",
       "us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100500 - Disclosure - Fair Value Measurements and Marketable Securities - Additional Information (Details)",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAdditionalInformationDetails",
     "shortName": "Fair Value Measurements and Marketable Securities - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount",
       "us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100510 - Disclosure - Fair Value Measurements and Marketable Securities - Schedule of Cash Equivalents and Marketable Securities (Details)",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesScheduleOfCashEquivalentsAndMarketableSecuritiesDetails",
     "shortName": "Fair Value Measurements and Marketable Securities - Schedule of Cash Equivalents and Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100520 - Disclosure - Fair Value Measurements and Marketable Securities - Schedule of Level 2 Cash Equivalents and Marketable Securities (Details)",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesScheduleOfLevel2CashEquivalentsAndMarketableSecuritiesDetails",
     "shortName": "Fair Value Measurements and Marketable Securities - Schedule of Level 2 Cash Equivalents and Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100530 - Disclosure - Fair Value Measurements and Marketable Securities - Schedule of Available-for-Sale Marketable Debt Securities by contractual Maturity (Details)",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesScheduleOfAvailableForSaleMarketableDebtSecuritiesByContractualMaturityDetails",
     "shortName": "Fair Value Measurements and Marketable Securities - Schedule of Available-for-Sale Marketable Debt Securities by contractual Maturity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ortx:GeneralPaymentTermsMaximum",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100540 - Disclosure - Revenue Recognition - Additional Information (Details)",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails",
     "shortName": "Revenue Recognition - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ortx:GeneralPaymentTermsMaximum",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ortx:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ortx:PrepaidExternalResearchAndDevelopmentExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100550 - Disclosure - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details)",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails",
     "shortName": "Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ortx:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ortx:PrepaidExternalResearchAndDevelopmentExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100560 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details)",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails",
     "shortName": "Property and Equipment - Schedule of Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100570 - Disclosure - Property and Equipment - Additional Information (Details)",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails",
     "shortName": "Property and Equipment - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ortx:ScheduleOfIntangibleAssetsNetOfAccumulatedAmortizationTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100580 - Disclosure - Intangible Assets, Net - Schedule of Intangible Assets Net of Accumulated Amortization (Details)",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfIntangibleAssetsNetOfAccumulatedAmortizationDetails",
     "shortName": "Intangible Assets, Net - Schedule of Intangible Assets Net of Accumulated Amortization (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ortx:ScheduleOfIntangibleAssetsNetOfAccumulatedAmortizationTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100050 - Statement - Consolidated Statements of Shareholders' Equity (Parenthetical)",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquityParenthetical",
     "shortName": "Consolidated Statements of Shareholders' Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100590 - Disclosure - Intangible Assets, Net - Additional Information (Details)",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIntangibleAssetsNetAdditionalInformationDetails",
     "shortName": "Intangible Assets, Net - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100600 - Disclosure - Intangible Assets, Net - Schedule of Estimated Future Amortization For Intangible Assets (Details)",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfEstimatedFutureAmortizationForIntangibleAssetsDetails",
     "shortName": "Intangible Assets, Net - Schedule of Estimated Future Amortization For Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock",
       "us-gaap:OtherAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsLiabilitiesNet",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100610 - Disclosure - Other Assets - Schedule of Other Assets (Details)",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureOtherAssetsScheduleOfOtherAssetsDetails",
     "shortName": "Other Assets - Schedule of Other Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock",
       "us-gaap:OtherAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20211231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DepositsAssetsNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ortx:AccruedExternalResearchAndDevelopmentExpensesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100620 - Disclosure - Accrued Expenses and Other Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails",
     "shortName": "Accrued Expenses and Other Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ortx:AccruedExternalResearchAndDevelopmentExpensesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:RestructuringCharges",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100630 - Disclosure - Restructuring Charges - Additional Information (Details)",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRestructuringChargesAdditionalInformationDetails",
     "shortName": "Restructuring Charges - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_us-gaapRestructuringPlanAxis_ortxMenloParkCaliforniaMember_20200501_20200531",
      "decimals": "2",
      "lang": null,
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100640 - Disclosure - Restructuring Charges - Summary of Cash Restructuring Charges (Details)",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRestructuringChargesSummaryOfCashRestructuringChargesDetails",
     "shortName": "Restructuring Charges - Summary of Cash Restructuring Charges (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20200101_20201231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:PaymentsForRestructuring",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DetailsOfImpairmentOfLongLivedAssetsHeldAndUsedByAssetTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20200401_20200630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseImpairmentLoss",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100650 - Disclosure - Restructuring Charges - Summary of Impairment of Long Lived Assets (Details)",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRestructuringChargesSummaryOfImpairmentOfLongLivedAssetsDetails",
     "shortName": "Restructuring Charges - Summary of Impairment of Long Lived Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DetailsOfImpairmentOfLongLivedAssetsHeldAndUsedByAssetTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20200401_20200630",
      "decimals": "-3",
      "lang": null,
      "name": "ortx:ImpairmentOfLaboratoryEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseExpirationDate1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100660 - Disclosure - Leases - Additional Information (Details)",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
     "shortName": "Leases - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseExpirationDate1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ortx:FixedLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100670 - Disclosure - Leases - Summary of Lease Cost Under Operating Leases (Details)",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfLeaseCostUnderOperatingLeasesDetails",
     "shortName": "Leases - Summary of Lease Cost Under Operating Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ortx:FixedLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100680 - Disclosure - Leases - Schedule of Future Minimum Base Rent Commitments Under Operating Leases (Details)",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumBaseRentCommitmentsUnderOperatingLeasesDetails",
     "shortName": "Leases - Schedule of Future Minimum Base Rent Commitments Under Operating Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100060 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20211231",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ForeignCurrencyExchangeRateTranslation1",
      "reportCount": 1,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100700 - Disclosure - Leases - Schedule of Future Minimum Base Rent Commitments Under Operating Leases (Parenthetical) (Details)",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumBaseRentCommitmentsUnderOperatingLeasesParentheticalDetails",
     "shortName": "Leases - Schedule of Future Minimum Base Rent Commitments Under Operating Leases (Parenthetical) (Details)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_srtCurrencyAxis_currencyGBP_20211231",
      "decimals": "2",
      "lang": null,
      "name": "us-gaap:ForeignCurrencyExchangeRateTranslation1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210531",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100710 - Disclosure - Notes Payable - Additional Information (Details)",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails",
     "shortName": "Notes Payable - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210531",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ortx:LongTermDebtBeforeAccretionIssuanceCostsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100720 - Disclosure - Notes Payable - Summary of Notes Payable (Details)",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableSummaryOfNotesPayableDetails",
     "shortName": "Notes Payable - Summary of Notes Payable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ortx:LongTermDebtBeforeAccretionIssuanceCostsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100730 - Disclosure - Notes Payable - Summary of Future Principal Payments Due (Details)",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableSummaryOfFuturePrincipalPaymentsDueDetails",
     "shortName": "Notes Payable - Summary of Future Principal Payments Due (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockVotingRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100750 - Disclosure - Shareholders' Equity and Convertible Preferred Shares - Additional Information (Details)",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareholdersEquityAndConvertiblePreferredSharesAdditionalInformationDetails",
     "shortName": "Shareholders' Equity and Convertible Preferred Shares - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockVotingRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20211231",
      "decimals": "5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217GBP_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100760 - Disclosure - Share-based Compensation - Additional Information (Details)",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails",
     "shortName": "Share-based Compensation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20211231",
      "decimals": "5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217GBP_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100770 - Disclosure - Share-based Compensation - Assumptions Used in Black-Scholes Option Pricing Model (Details)",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAssumptionsUsedInBlackScholesOptionPricingModelDetails",
     "shortName": "Share-based Compensation - Assumptions Used in Black-Scholes Option Pricing Model (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100780 - Disclosure - Share-based Compensation - Summary of Option Activity (Details)",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfOptionActivityDetails",
     "shortName": "Share-based Compensation - Summary of Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20201231",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100790 - Disclosure - Share-based Compensation - Summary of Award Activity (Details)",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfAwardActivityDetails",
     "shortName": "Share-based Compensation - Summary of Award Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20201231",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100800 - Disclosure - Share-based Compensation - Share-based Compensation Expense (Details)",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails",
     "shortName": "Share-based Compensation - Share-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20211231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100070 - Disclosure - Nature of Business and Basis of Presentation",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentation",
     "shortName": "Nature of Business and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ortx:StrimvelisLossProvisionPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ortx:AssetAcquisitionLiabilityAssumed",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100810 - Disclosure - License and Research Agreements - Additional Information (Details)",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetails",
     "shortName": "License and Research Agreements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_us-gaapTypeOfArrangementAxis_ortxGSKAssetPurchaseAndLicenseAgreementMember_20180401_20180430",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:AssetAcquisitionConsiderationTransferred",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100820 - Disclosure - Collaboration Agreement with Pharming Group N.V. - Additional Information (Details)",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCollaborationAgreementWithPharmingGroupNVAdditionalInformationDetails",
     "shortName": "Collaboration Agreement with Pharming Group N.V. - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_us-gaapTypeOfArrangementAxis_ortxStrategicCollaborationAgreementWithPharmingMember_20210701_20210701",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:ProceedsFromCollaborators",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100830 - Disclosure - Collaboration Agreement with Pharming Group N.V. - Summary of Research and Development Costs Incurred and Collaboration Revenue Recognized (Details)",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCollaborationAgreementWithPharmingGroupNVSummaryOfResearchAndDevelopmentCostsIncurredAndCollaborationRevenueRecognizedDetails",
     "shortName": "Collaboration Agreement with Pharming Group N.V. - Summary of Research and Development Costs Incurred and Collaboration Revenue Recognized (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20210101_20211231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100840 - Disclosure - Income Taxes - Schedule of Components of Net Loss Before Income Taxes (Details)",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfNetLossBeforeIncomeTaxesDetails",
     "shortName": "Income Taxes - Schedule of Components of Net Loss Before Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100850 - Disclosure - Income Taxes - Schedule of Provision for (Benefit from) Income Taxes (Details)",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDetails",
     "shortName": "Income Taxes - Schedule of Provision for (Benefit from) Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100860 - Disclosure - Income Taxes - Schedule of Reconciliation of Income Tax Expense (Benefit) (Details)",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetails",
     "shortName": "Income Taxes - Schedule of Reconciliation of Income Tax Expense (Benefit) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100870 - Disclosure - Income Taxes - Additional Information (Details)",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
     "shortName": "Income Taxes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100880 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities Taxes (Details)",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesTaxesDetails",
     "shortName": "Income Taxes - Schedule of Deferred Tax Assets and Liabilities Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R88": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100890 - Disclosure - Income Taxes - Schedule of Changes in Valuation Allowance for Deferred Tax Assets Related Primarily to Increase in U.K. Net Operating Loss Carryforwards (Details)",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfChangesInValuationAllowanceForDeferredTaxAssetsRelatedPrimarilyToIncreaseInUKNetOperatingLossCarryforwardsDetails",
     "shortName": "Income Taxes - Schedule of Changes in Valuation Allowance for Deferred Tax Assets Related Primarily to Increase in U.K. Net Operating Loss Carryforwards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": "-3",
      "lang": null,
      "name": "ortx:DeferredTaxAssetsValuationAllowanceIncreasesRecordedToIncomeTaxProvision",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R89": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ortx:ManufacturingCommitmentsAmountDueInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100900 - Disclosure - Commitments and Contingencies - Schedule of Annual Commitments Associated with the Contract (Details)",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfAnnualCommitmentsAssociatedWithContractDetails",
     "shortName": "Commitments and Contingencies - Schedule of Annual Commitments Associated with the Contract (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ortx:ManufacturingCommitmentsAmountDueInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100080 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R90": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20211231",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ForeignCurrencyExchangeRateTranslation1",
      "reportCount": 1,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100910 - Disclosure - Commitments and Contingencies - Schedule of Annual Commitments Associated with the Contract (Parenthetical) (Details)",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfAnnualCommitmentsAssociatedWithContractParentheticalDetails",
     "shortName": "Commitments and Contingencies - Schedule of Annual Commitments Associated with the Contract (Parenthetical) (Details)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R91": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100920 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_srtTitleOfIndividualAxis_ortxNonEmployeeAdvisorMember_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis_ortxConsultingAgreementMember_20191231",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:DueToRelatedPartiesCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R92": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100930 - Disclosure - Benefit Plans - Additional Information (Details)",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureBenefitPlansAdditionalInformationDetails",
     "shortName": "Benefit Plans - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20210101_20211231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R93": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ortx:StrimvelisLossProvisionPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_20181231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProvisionForLossOnContracts",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100940 - Disclosure - Related Party Transactions - Additional Information (Details)",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
     "shortName": "Related Party Transactions - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ortxGSKMember_20180401_20180430",
      "decimals": "-5",
      "lang": null,
      "name": "ortx:LicenseUpfrontFeeAndRelatedExpensesPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R94": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_srtStatementGeographicalAxis_countryGB_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220330_20220330",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100950 - Disclosure - Subsequent Events - Additional Information (Details)",
     "role": "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
     "shortName": "Subsequent Events - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ortx-10k_20211231.htm",
      "contextRef": "C_0001748907_srtStatementGeographicalAxis_countryGB_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220330_20220330",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 95,
   "tag": {
    "country_GB": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED KINGDOM",
        "terseLabel": "United Kingdom"
       }
      }
     },
     "localname": "GB",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfAmountsRecognizedToOffsetResearchAndDevelopmentExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "US"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_AllCurrenciesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Currencies [Domain]",
        "terseLabel": "All Currencies"
       }
      }
     },
     "localname": "AllCurrenciesDomain",
     "nsuri": "http://xbrl.sec.gov/currency/2021",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumBaseRentCommitmentsUnderOperatingLeasesParentheticalDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_EUR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "E U R",
        "terseLabel": "Euro"
       }
      }
     },
     "localname": "EUR",
     "nsuri": "http://xbrl.sec.gov/currency/2021",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumBaseRentCommitmentsUnderOperatingLeasesParentheticalDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_GBP": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "G B P",
        "terseLabel": "GBP"
       }
      }
     },
     "localname": "GBP",
     "nsuri": "http://xbrl.sec.gov/currency/2021",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumBaseRentCommitmentsUnderOperatingLeasesParentheticalDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r708",
      "r709",
      "r710"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm Id",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r708",
      "r709",
      "r710"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r708",
      "r709",
      "r710"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r708",
      "r709",
      "r710"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r711"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r706"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated By Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line1",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address Country",
        "terseLabel": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r705"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r705"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r705"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r714"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r705"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r705"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r705"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r705"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r725"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well Known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r708",
      "r709",
      "r710"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Icfr Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r704"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security12b Title",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r707"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "ortx_AccretionRelatedToFinalPayment": {
     "auth_ref": [],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableSummaryOfNotesPayableDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accretion related to final payment.",
        "label": "Accretion Related To Final Payment",
        "terseLabel": "Accretion related to final payment"
       }
      }
     },
     "localname": "AccretionRelatedToFinalPayment",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableSummaryOfNotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_AccruedExpensesAndOtherCurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10140.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of accrued expenses and other current liabilities.",
        "label": "Accrued Expenses And Other Current Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Total accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedExpensesAndOtherCurrentLiabilities",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_AccruedExpensesRelatedPartyCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued expenses related party current.",
        "label": "Accrued Expenses Related Party Current",
        "terseLabel": "Due to related party transactions, accrued expenses"
       }
      }
     },
     "localname": "AccruedExpensesRelatedPartyCurrent",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_AccruedExternalResearchAndDevelopmentExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 10010.0,
       "parentTag": "ortx_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued external research and development expenses current.",
        "label": "Accrued External Research And Development Expenses Current",
        "terseLabel": "Accrued external research and development expenses"
       }
      }
     },
     "localname": "AccruedExternalResearchAndDevelopmentExpensesCurrent",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_AccruedMilestonePaymentsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 10030.0,
       "parentTag": "ortx_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued milestone payments current.",
        "label": "Accrued Milestone Payments Current",
        "terseLabel": "Accrued milestone payments"
       }
      }
     },
     "localname": "AccruedMilestonePaymentsCurrent",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_AdditionalIncomeTaxCredits": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional income tax credits.",
        "label": "Additional Income Tax Credits",
        "terseLabel": "Additional income tax credits"
       }
      }
     },
     "localname": "AdditionalIncomeTaxCredits",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_AgreementExtensionTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement extension term.",
        "label": "Agreement Extension Term",
        "terseLabel": "Agreement extension term"
       }
      }
     },
     "localname": "AgreementExtensionTerm",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ortx_AgreementMaturityDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement maturity date.",
        "label": "Agreement Maturity Date",
        "terseLabel": "Agreement maturity date"
       }
      }
     },
     "localname": "AgreementMaturityDate",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "ortx_AmortizationOfPremiumOnMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10250.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization of premium on marketable securities.",
        "label": "Amortization Of Premium On Marketable Securities",
        "terseLabel": "Amortization of premium on marketable securities"
       }
      }
     },
     "localname": "AmortizationOfPremiumOnMarketableSecurities",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_AmortizationOfProvisionOnLossContract": {
     "auth_ref": [],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10220.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization of provision on loss contract.",
        "label": "Amortization Of Provision On Loss Contract",
        "terseLabel": "Amortization of provision on loss contract"
       }
      }
     },
     "localname": "AmortizationOfProvisionOnLossContract",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_AssetAcquisitionInProcessResearchAndDevelopmentExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition in-process research and development expense.",
        "label": "Asset Acquisition In Process Research And Development Expense",
        "terseLabel": "In-process research and development expense"
       }
      }
     },
     "localname": "AssetAcquisitionInProcessResearchAndDevelopmentExpense",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_AssetAcquisitionInventoryPurchaseLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition inventory purchase liability.",
        "label": "Asset Acquisition Inventory Purchase Liability",
        "terseLabel": "Inventory purchase liability"
       }
      }
     },
     "localname": "AssetAcquisitionInventoryPurchaseLiability",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_AssetAcquisitionLiabilityAmortizationOfLossProvision": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition liability amortization of loss provision.",
        "label": "Asset Acquisition Liability Amortization Of Loss Provision",
        "negatedLabel": "Amortization of loss provision"
       }
      }
     },
     "localname": "AssetAcquisitionLiabilityAmortizationOfLossProvision",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfChangesInLossProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_AssetAcquisitionLiabilityAssumed": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition liability assumed.",
        "label": "Asset Acquisition Liability Assumed",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period",
        "terseLabel": "Remaining liability"
       }
      }
     },
     "localname": "AssetAcquisitionLiabilityAssumed",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfChangesInLossProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_AssetAcquisitionLiabilityAssumedCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition liability assumed current.",
        "label": "Asset Acquisition Liability Assumed Current",
        "terseLabel": "Strimvelis loss provision current"
       }
      }
     },
     "localname": "AssetAcquisitionLiabilityAssumedCurrent",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_AssetAcquisitionLiabilityAssumedNonCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition liability assumed non current.",
        "label": "Asset Acquisition Liability Assumed Non Current",
        "terseLabel": "Strimvelis loss provision non current"
       }
      }
     },
     "localname": "AssetAcquisitionLiabilityAssumedNonCurrent",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_AssetAcquisitionLiabilityProvision": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition liability provision.",
        "label": "Asset Acquisition Liability Provision",
        "terseLabel": "Provisions"
       }
      }
     },
     "localname": "AssetAcquisitionLiabilityProvision",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfChangesInLossProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_AssetAcquisitionNumberOfSharesIssuedForAcquisition": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition number of shares issued for acquisition.",
        "label": "Asset Acquisition Number Of Shares Issued For Acquisition",
        "terseLabel": "Shares issued for asset acquisition"
       }
      }
     },
     "localname": "AssetAcquisitionNumberOfSharesIssuedForAcquisition",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ortx_AssetAcquisitionTransactionCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition transaction costs.",
        "label": "Asset Acquisition Transaction Costs",
        "terseLabel": "Transaction costs"
       }
      }
     },
     "localname": "AssetAcquisitionTransactionCosts",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_AssetAcquisitionUpfrontPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition upfront payment.",
        "label": "Asset Acquisition Upfront Payment",
        "terseLabel": "Upfront payment"
       }
      }
     },
     "localname": "AssetAcquisitionUpfrontPayment",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_AssetAcquisitionValueOfEquityInstrumentsIssued": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition value of equity instruments issued.",
        "label": "Asset Acquisition Value Of Equity Instruments Issued",
        "terseLabel": "Aggregate value of shares issued for asset acquisition"
       }
      }
     },
     "localname": "AssetAcquisitionValueOfEquityInstrumentsIssued",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesScheduleOfAvailableForSaleMarketableDebtSecuritiesByContractualMaturityDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available for sale securities debt maturities after one through three years amortized cost.",
        "label": "Available For Sale Securities Debt Maturities After One Through Three Years Amortized Cost",
        "terseLabel": "Maturities between one and three years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsAmortizedCost",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesScheduleOfAvailableForSaleMarketableDebtSecuritiesByContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_BostonAndLondonOfficeSpaceLeaseAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boston and London office space lease agreements.",
        "label": "Boston And London Office Space Lease Agreements [Member]",
        "terseLabel": "Boston and London Office Space Lease Agreements [Member]"
       }
      }
     },
     "localname": "BostonAndLondonOfficeSpaceLeaseAgreementsMember",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ortx_CashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash equivalents.",
        "label": "Cash Equivalents [Abstract]",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsAbstract",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesScheduleOfCashEquivalentsAndMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ortx_ClinicalDevelopmentAndRegulatoryMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical development and regulatory milestone.",
        "label": "Clinical Development And Regulatory Milestone [Member]",
        "terseLabel": "Clinical Development And Regulatory Milestone"
       }
      }
     },
     "localname": "ClinicalDevelopmentAndRegulatoryMilestoneMember",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ortx_ClosingPriceOfShareDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Closing price of share date.",
        "label": "Closing Price Of Share Date",
        "terseLabel": "Closing price of share date"
       }
      }
     },
     "localname": "ClosingPriceOfShareDate",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareholdersEquityAndConvertiblePreferredSharesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "ortx_CollaborationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration.",
        "label": "Collaboration [Member]",
        "terseLabel": "Collaboration Revenue [Member]"
       }
      }
     },
     "localname": "CollaborationMember",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "domainItemType"
    },
    "ortx_CollaborativeArrangementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement.",
        "label": "Collaborative Arrangement [Abstract]"
       }
      }
     },
     "localname": "CollaborativeArrangementAbstract",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "xbrltype": "stringItemType"
    },
    "ortx_CommonStockSharesAuthorizedNominalAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock shares authorized nominal amount.",
        "label": "Common Stock Shares Authorized Nominal Amount",
        "terseLabel": "Ordinary Shares, Authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorizedNominalAmount",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_ConstructionDepositsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 10050.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Construction deposits, current.",
        "label": "Construction Deposits Current",
        "terseLabel": "Construction deposit - current"
       }
      }
     },
     "localname": "ConstructionDepositsCurrent",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_ConstructionDepositsLongTerm": {
     "auth_ref": [],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureOtherAssetsScheduleOfOtherAssetsDetails": {
       "order": 10050.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Construction deposits long-term.",
        "label": "Construction Deposits Long Term",
        "terseLabel": "Construction deposits - long-term"
       }
      }
     },
     "localname": "ConstructionDepositsLongTerm",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureOtherAssetsScheduleOfOtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_ConsultingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consulting Agreement.",
        "label": "Consulting Agreement [Member]",
        "terseLabel": "Consulting Agreement"
       }
      }
     },
     "localname": "ConsultingAgreementMember",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareholdersEquityAndConvertiblePreferredSharesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ortx_CorporationTaxRatePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporation tax rate percentage.",
        "label": "Corporation Tax Rate Percentage",
        "terseLabel": "Corporation tax rate percentage"
       }
      }
     },
     "localname": "CorporationTaxRatePercentage",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ortx_CurrentOtherTaxExpenseBenefit": {
     "auth_ref": [],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDetails": {
       "order": 10090.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current other tax expense benefit.",
        "label": "Current Other Tax Expense Benefit",
        "terseLabel": "Other foreign"
       }
      }
     },
     "localname": "CurrentOtherTaxExpenseBenefit",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_DedicatedManufacturingAndDevelopmentResourcesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dedicated manufacturing and development resources.",
        "label": "Dedicated Manufacturing And Development Resources [Member]",
        "terseLabel": "Dedicated Manufacturing and Development Resources"
       }
      }
     },
     "localname": "DedicatedManufacturingAndDevelopmentResourcesMember",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfAnnualCommitmentsAssociatedWithContractDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ortx_DeferredTaxAssetsAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesTaxesDetails": {
       "order": 10050.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets amortization.",
        "label": "Deferred Tax Assets Amortization",
        "terseLabel": "Amortization"
       }
      }
     },
     "localname": "DeferredTaxAssetsAmortization",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_DeferredTaxAssetsLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesTaxesDetails": {
       "order": 10090.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets lease liability.",
        "label": "Deferred Tax Assets Lease Liability",
        "terseLabel": "Lease liability"
       }
      }
     },
     "localname": "DeferredTaxAssetsLeaseLiability",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_DeferredTaxAssetsValuationAllowanceEffectOfForeignCurrencyTranslation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets valuation allowance effect of foreign currency translation.",
        "label": "Deferred Tax Assets Valuation Allowance Effect Of Foreign Currency Translation",
        "terseLabel": "Effect of foreign currency translation"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowanceEffectOfForeignCurrencyTranslation",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfChangesInValuationAllowanceForDeferredTaxAssetsRelatedPrimarilyToIncreaseInUKNetOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_DeferredTaxAssetsValuationAllowanceIncreasesRecordedToIncomeTaxProvision": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets valuation allowance increases recorded to income tax provision.",
        "label": "Deferred Tax Assets Valuation Allowance Increases Recorded To Income Tax Provision",
        "terseLabel": "Increases recorded to income tax provision"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowanceIncreasesRecordedToIncomeTaxProvision",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfChangesInValuationAllowanceForDeferredTaxAssetsRelatedPrimarilyToIncreaseInUKNetOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_DeferredTaxLiabilitiesFixedAssetsAndRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesTaxesDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax liabilities fixed assets and right of use asset.",
        "label": "Deferred Tax Liabilities Fixed Assets And Right Of Use Asset",
        "negatedLabel": "Fixed assets and right-of-use asset"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesFixedAssetsAndRightOfUseAsset",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_EmployeeEquityPlanProceedsReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee equity plan proceeds received.",
        "label": "Employee Equity Plan Proceeds Received",
        "terseLabel": "Employee equity plan proceeds received after year-end"
       }
      }
     },
     "localname": "EmployeeEquityPlanProceedsReceived",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_ExcessProceedsFromFairValueOfSharesIssuedAllocatedToCollaborationAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess proceeds from fair value of shares issued allocated to collaboration agreement.",
        "label": "Excess Proceeds From Fair Value Of Shares Issued Allocated To Collaboration Agreement",
        "terseLabel": "Excess proceeds from fair value of shares issued allocated to collaboration agreement"
       }
      }
     },
     "localname": "ExcessProceedsFromFairValueOfSharesIssuedAllocatedToCollaborationAgreement",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCollaborationAgreementWithPharmingGroupNVAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_ExclusiveTransductionSuitesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exclusive transduction suites.",
        "label": "Exclusive Transduction Suites [Member]",
        "terseLabel": "Exclusive Transduction Suites"
       }
      }
     },
     "localname": "ExclusiveTransductionSuitesMember",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfAnnualCommitmentsAssociatedWithContractDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ortx_FiveYearsLeaseTermTerminatesInJanuaryTwoThousandTwentyThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Five years lease term terminates in January two thousand twenty three.",
        "label": "Five Years Lease Term Terminates In January Two Thousand Twenty Three [Member]",
        "terseLabel": "Five Years Lease Term Terminates In January 2023 [Member]"
       }
      }
     },
     "localname": "FiveYearsLeaseTermTerminatesInJanuaryTwoThousandTwentyThreeMember",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ortx_FixedLeaseCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfLeaseCostUnderOperatingLeasesDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed lease cost.",
        "label": "Fixed Lease Cost",
        "terseLabel": "Fixed lease cost"
       }
      }
     },
     "localname": "FixedLeaseCost",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfLeaseCostUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_FremontCaliforniaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fremont, California.",
        "label": "Fremont California [Member]",
        "terseLabel": "Fremont, California"
       }
      }
     },
     "localname": "FremontCaliforniaMember",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRestructuringChargesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ortx_FremontLeaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fremont lease agreement.",
        "label": "Fremont Lease Agreement [Member]",
        "terseLabel": "Fremont Lease Agreement [Member]"
       }
      }
     },
     "localname": "FremontLeaseAgreementMember",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ortx_FremontSubleaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fremont sublease agreement.",
        "label": "Fremont Sublease Agreement [Member]",
        "terseLabel": "Fremont Sublease Agreement"
       }
      }
     },
     "localname": "FremontSubleaseAgreementMember",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ortx_GBAndEuropeanUnionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GB and European Union.",
        "label": "G B And European Union [Member]",
        "terseLabel": "United Kingdom and European Union"
       }
      }
     },
     "localname": "GBAndEuropeanUnionMember",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ortx_GSKAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GSK agreement.",
        "label": "G S K Agreement [Member]",
        "terseLabel": "G S K Agreement"
       }
      }
     },
     "localname": "GSKAgreementMember",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ortx_GSKAssetPurchaseAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GSK Asset Purchase And License Agreement.",
        "label": "G S K Asset Purchase And License Agreement [Member]",
        "terseLabel": "GSK Asset Purchase and License Agreement"
       }
      }
     },
     "localname": "GSKAssetPurchaseAndLicenseAgreementMember",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ortx_GSKMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GSK",
        "label": "G S K [Member]",
        "terseLabel": "GSK"
       }
      }
     },
     "localname": "GSKMember",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ortx_GeneralPaymentTermsMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "General payment terms maximum.",
        "label": "General Payment Terms Maximum",
        "terseLabel": "General payment terms, maximum"
       }
      }
     },
     "localname": "GeneralPaymentTermsMaximum",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ortx_ImpairmentOfConstructionInProcess": {
     "auth_ref": [],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRestructuringChargesSummaryOfImpairmentOfLongLivedAssetsDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_AssetImpairmentCharges",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Impairment of construction in process.",
        "label": "Impairment Of Construction In Process",
        "terseLabel": "Construction-in-progress",
        "verboseLabel": "Construction-in-process, impairment charges"
       }
      }
     },
     "localname": "ImpairmentOfConstructionInProcess",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRestructuringChargesAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRestructuringChargesSummaryOfImpairmentOfLongLivedAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_ImpairmentOfLaboratoryEquipment": {
     "auth_ref": [],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRestructuringChargesSummaryOfImpairmentOfLongLivedAssetsDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_AssetImpairmentCharges",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Impairment of laboratory equipment.",
        "label": "Impairment Of Laboratory Equipment",
        "terseLabel": "Laboratory equipment, Asset write-downs"
       }
      }
     },
     "localname": "ImpairmentOfLaboratoryEquipment",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRestructuringChargesSummaryOfImpairmentOfLongLivedAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_InProcessResearchAndDevelopmentExpenseForUpfrontAndMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In-process research and development expense for upfront and milestone payments.",
        "label": "In Process Research And Development Expense For Upfront And Milestone Payments",
        "terseLabel": "In-process research and development expense for upfront and milestone payments"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentExpenseForUpfrontAndMilestonePayments",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_IncomeTaxReconciliationDomesticDeductionForDerivedIntangibleIncome": {
     "auth_ref": [],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetails": {
       "order": 10060.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax reconciliation domestic deduction for derived intangible income.",
        "label": "Income Tax Reconciliation Domestic Deduction For Derived Intangible Income",
        "negatedLabel": "U.S. Deduction for foreign derived intangible income"
       }
      }
     },
     "localname": "IncomeTaxReconciliationDomesticDeductionForDerivedIntangibleIncome",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_IncomeTaxReconciliationPermanentDifferencesIncludingShareBasedCompensationDeductionShortfalls": {
     "auth_ref": [],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetails": {
       "order": 10070.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax reconciliation permanent differences including share-based compensation deduction shortfalls.",
        "label": "Income Tax Reconciliation Permanent Differences Including Share Based Compensation Deduction Shortfalls",
        "terseLabel": "Permanent differences, including share-based compensation deduction shortfalls"
       }
      }
     },
     "localname": "IncomeTaxReconciliationPermanentDifferencesIncludingShareBasedCompensationDeductionShortfalls",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_IncomeTaxReconciliationReductionInResearchExpenseForCreditsGranted": {
     "auth_ref": [],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax reconciliation reduction in research expense for credits granted.",
        "label": "Income Tax Reconciliation Reduction In Research Expense For Credits Granted",
        "terseLabel": "Reduction in research expense for credits granted"
       }
      }
     },
     "localname": "IncomeTaxReconciliationReductionInResearchExpenseForCreditsGranted",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10310.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in accounts payable and accrued liabilities and other operating liabilities.",
        "label": "Increase Decrease In Accounts Payable And Accrued Liabilities And Other Operating Liabilities",
        "terseLabel": "Accounts payable, accrued expenses, and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_IncreaseDecreaseInAssetAcquisitionLiabilityEffectOfForeignExchangeTranslation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in asset acquisition liability, effect of foreign exchange translation.",
        "label": "Increase Decrease In Asset Acquisition Liability Effect Of Foreign Exchange Translation",
        "terseLabel": "Foreign currency translation"
       }
      }
     },
     "localname": "IncreaseDecreaseInAssetAcquisitionLiabilityEffectOfForeignExchangeTranslation",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfChangesInLossProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_IncreaseDecreaseInEscrowDeposit": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in escrow deposit.",
        "label": "Increase Decrease In Escrow Deposit",
        "negatedLabel": "Increase decrease in escrow deposit",
        "terseLabel": "Increase Decrease In Escrow Deposit"
       }
      }
     },
     "localname": "IncreaseDecreaseInEscrowDeposit",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_IncreaseDecreaseInOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10340.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in operating lease liabilities",
        "label": "Increase Decrease In Operating Lease Liabilities",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilities",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_IncreaseDecreaseInOperatingRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10300.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in operating leases, right-of-use-assets",
        "label": "Increase Decrease In Operating Right Of Use Assets",
        "terseLabel": "Operating leases, right-of-use-assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingRightOfUseAssets",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable": {
     "auth_ref": [],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10280.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in research and development tax credit receivable.",
        "label": "Increase Decrease In Research And Development Tax Credit Receivable",
        "negatedLabel": "Research and development tax credit receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_IncrementalPercentageOfTaxableProfits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental percentage of taxable profits.",
        "label": "Incremental Percentage Of Taxable Profits",
        "terseLabel": "Incremental percentage of taxable profits"
       }
      }
     },
     "localname": "IncrementalPercentageOfTaxableProfits",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ortx_InitialTermOfAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial term of agreement.",
        "label": "Initial Term Of Agreement",
        "terseLabel": "Initial term of agreement"
       }
      }
     },
     "localname": "InitialTermOfAgreement",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ortx_IntangibleAssetsAndPropertyAndEquipmentInAccountsPayableAndAccruedExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible assets and property and equipment in accounts payable and accrued expenses.",
        "label": "Intangible Assets And Property And Equipment In Accounts Payable And Accrued Expenses",
        "terseLabel": "Intangible assets and property and equipment in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IntangibleAssetsAndPropertyAndEquipmentInAccountsPayableAndAccruedExpenses",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_InventoryPurchase": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventory purchase.",
        "label": "Inventory Purchase",
        "terseLabel": "Inventory purchased"
       }
      }
     },
     "localname": "InventoryPurchase",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_LabEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lab equipment member.",
        "label": "Lab Equipment [Member]",
        "terseLabel": "Lab Equipment"
       }
      }
     },
     "localname": "LabEquipmentMember",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ortx_LaboratorySpaceMenloParkLeaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory space menlo park lease agreement.",
        "label": "Laboratory Space Menlo Park Lease Agreement [Member]",
        "terseLabel": "Laboratory Space Menlo Park Lease Agreement [Member]"
       }
      }
     },
     "localname": "LaboratorySpaceMenloParkLeaseAgreementMember",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ortx_LeaseComponentManufacturingCommitmentAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease component manufacturing commitment amount.",
        "label": "Lease Component Manufacturing Commitment Amount",
        "terseLabel": "Lease component manufacturing suites commitment amount per contract year"
       }
      }
     },
     "localname": "LeaseComponentManufacturingCommitmentAmount",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_LeaseTermTerminatesInSeptemberTwoThousandTwentySixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease term terminates in September two thousand twenty six.",
        "label": "Lease Term Terminates In September Two Thousand Twenty Six [Member]",
        "terseLabel": "Lease Term Terminates in September 2026 [Member]"
       }
      }
     },
     "localname": "LeaseTermTerminatesInSeptemberTwoThousandTwentySixMember",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ortx_LeaseTermTerminatesInSeptemberTwoThousandTwentyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease term terminates in September two thousand twenty two.",
        "label": "Lease Term Terminates In September Two Thousand Twenty Two [Member]",
        "terseLabel": "Lease Term Terminates in September 2022 [Member]"
       }
      }
     },
     "localname": "LeaseTermTerminatesInSeptemberTwoThousandTwentyTwoMember",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ortx_LesseeOperatingLeaseExtendedTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease extended term.",
        "label": "Lessee Operating Lease Extended Term",
        "terseLabel": "Operating lease extended term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseExtendedTerm",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ortx_LibmeldyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Libmeldy.",
        "label": "Libmeldy [Member]",
        "terseLabel": "Libmeldy"
       }
      }
     },
     "localname": "LibmeldyMember",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ortx_LicenseAndResearchArrangementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License and research arrangements.",
        "label": "License And Research Arrangements [Abstract]"
       }
      }
     },
     "localname": "LicenseAndResearchArrangementsAbstract",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "xbrltype": "stringItemType"
    },
    "ortx_LicenseUpfrontFeeAndRelatedExpensesPaid": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License upfront fee and related expenses paid.",
        "label": "License Upfront Fee And Related Expenses Paid",
        "terseLabel": "License upfront fee"
       }
      }
     },
     "localname": "LicenseUpfrontFeeAndRelatedExpensesPaid",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_LineOfCreditFacilityAmortizationTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line of credit facility straight-line amortization term.",
        "label": "Line Of Credit Facility Amortization Term",
        "terseLabel": "Line of credit facility amortization term"
       }
      }
     },
     "localname": "LineOfCreditFacilityAmortizationTerm",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ortx_LineOfCreditFacilityCovenantsMinimumCashAllowed": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line of credit facility covenants minimum cash allowed.",
        "label": "Line Of Credit Facility Covenants Minimum Cash Allowed",
        "terseLabel": "Line of credit facility minimum cash financial covenant"
       }
      }
     },
     "localname": "LineOfCreditFacilityCovenantsMinimumCashAllowed",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_LineOfCreditFacilityInterestPaymentsTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line of credit facility interest payments term.",
        "label": "Line Of Credit Facility Interest Payments Term",
        "terseLabel": "Line of credit facility interest payments term"
       }
      }
     },
     "localname": "LineOfCreditFacilityInterestPaymentsTerm",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ortx_LineOfCreditFacilityPercentageOfFinalPayment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line of credit facility percentage of final payment.",
        "label": "Line Of Credit Facility Percentage Of Final Payment",
        "terseLabel": "Line of credit facility, percentage of final payment"
       }
      }
     },
     "localname": "LineOfCreditFacilityPercentageOfFinalPayment",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ortx_LondonInterbankOfferedRateFloorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "London interbank offered rate floor.",
        "label": "London Interbank Offered Rate Floor [Member]",
        "terseLabel": "LIBOR"
       }
      }
     },
     "localname": "LondonInterbankOfferedRateFloorMember",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ortx_LongTermDebtBeforeAccretionIssuanceCostsNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableSummaryOfNotesPayableDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long term debt before accretion issuance costs net.",
        "label": "Long Term Debt Before Accretion Issuance Costs Net",
        "totalLabel": "Notes payable, net of issuance costs"
       }
      }
     },
     "localname": "LongTermDebtBeforeAccretionIssuanceCostsNet",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableSummaryOfNotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_LongTermDebtBeforeAccretionIssuanceCostsNetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableSummaryOfNotesPayableDetails": {
       "order": 10030.0,
       "parentTag": "ortx_LongTermDebtBeforeAccretionIssuanceCostsNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long term debt before accretion issuance costs net current.",
        "label": "Long Term Debt Before Accretion Issuance Costs Net Current",
        "negatedLabel": "Less: current portion"
       }
      }
     },
     "localname": "LongTermDebtBeforeAccretionIssuanceCostsNetCurrent",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableSummaryOfNotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_LongTermDebtBeforeAccretionIssuanceCostsNetNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableSummaryOfNotesPayableDetails": {
       "order": 10040.0,
       "parentTag": "ortx_LongTermDebtBeforeAccretionIssuanceCostsNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long term debt before accretion issuance costs net noncurrent.",
        "label": "Long Term Debt Before Accretion Issuance Costs Net Noncurrent",
        "terseLabel": "Notes payable, net of current portion"
       }
      }
     },
     "localname": "LongTermDebtBeforeAccretionIssuanceCostsNetNoncurrent",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableSummaryOfNotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_ManufacturingAndTechnologyDevelopmentMasterAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Manufacturing and technology development master agreement.",
        "label": "Manufacturing And Technology Development Master Agreement [Member]",
        "terseLabel": "Agreement"
       }
      }
     },
     "localname": "ManufacturingAndTechnologyDevelopmentMasterAgreementMember",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ortx_ManufacturingCommitments": {
     "auth_ref": [],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfAnnualCommitmentsAssociatedWithContractDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Manufacturing commitments.",
        "label": "Manufacturing Commitments",
        "totalLabel": "Total manufacturing commitments"
       }
      }
     },
     "localname": "ManufacturingCommitments",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfAnnualCommitmentsAssociatedWithContractDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_ManufacturingCommitmentsAmountDueInNextTwelveMonths": {
     "auth_ref": [],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfAnnualCommitmentsAssociatedWithContractDetails": {
       "order": 10010.0,
       "parentTag": "ortx_ManufacturingCommitments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Manufacturing commitments amount due in next twelve months.",
        "label": "Manufacturing Commitments Amount Due In Next Twelve Months",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "ManufacturingCommitmentsAmountDueInNextTwelveMonths",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfAnnualCommitmentsAssociatedWithContractDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_ManufacturingCommitmentsAmountDueInYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfAnnualCommitmentsAssociatedWithContractDetails": {
       "order": 10050.0,
       "parentTag": "ortx_ManufacturingCommitments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Manufacturing commitments amount due in year five.",
        "label": "Manufacturing Commitments Amount Due In Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "ManufacturingCommitmentsAmountDueInYearFive",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfAnnualCommitmentsAssociatedWithContractDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_ManufacturingCommitmentsAmountDueInYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfAnnualCommitmentsAssociatedWithContractDetails": {
       "order": 10040.0,
       "parentTag": "ortx_ManufacturingCommitments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Manufacturing commitments amount due in year four.",
        "label": "Manufacturing Commitments Amount Due In Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "ManufacturingCommitmentsAmountDueInYearFour",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfAnnualCommitmentsAssociatedWithContractDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_ManufacturingCommitmentsAmountDueInYearThree": {
     "auth_ref": [],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfAnnualCommitmentsAssociatedWithContractDetails": {
       "order": 10030.0,
       "parentTag": "ortx_ManufacturingCommitments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Manufacturing commitments amount Due In year three.",
        "label": "Manufacturing Commitments Amount Due In Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "ManufacturingCommitmentsAmountDueInYearThree",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfAnnualCommitmentsAssociatedWithContractDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_ManufacturingCommitmentsAmountDueInYearTwo": {
     "auth_ref": [],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfAnnualCommitmentsAssociatedWithContractDetails": {
       "order": 10020.0,
       "parentTag": "ortx_ManufacturingCommitments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Manufacturing commitments amount due in year two.",
        "label": "Manufacturing Commitments Amount Due In Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "ManufacturingCommitmentsAmountDueInYearTwo",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfAnnualCommitmentsAssociatedWithContractDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_ManufacturingCommitmentsAmountDueThereafter": {
     "auth_ref": [],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfAnnualCommitmentsAssociatedWithContractDetails": {
       "order": 10060.0,
       "parentTag": "ortx_ManufacturingCommitments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Manufacturing commitments amount due thereafter.",
        "label": "Manufacturing Commitments Amount Due Thereafter",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "ManufacturingCommitmentsAmountDueThereafter",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfAnnualCommitmentsAssociatedWithContractDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_MarketableSecuritiesFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesScheduleOfCashEquivalentsAndMarketableSecuritiesDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable securities fair value disclosure.",
        "label": "Marketable Securities Fair Value Disclosure",
        "terseLabel": "Total marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesFairValueDisclosure",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesScheduleOfCashEquivalentsAndMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_MenloParkCaliforniaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Menlo park, California.",
        "label": "Menlo Park California [Member]",
        "terseLabel": "Menlo Park, California"
       }
      }
     },
     "localname": "MenloParkCaliforniaMember",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRestructuringChargesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ortx_MilestonePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payment.",
        "label": "Milestone Payment",
        "verboseLabel": "Milestone payment"
       }
      }
     },
     "localname": "MilestonePayment",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_MilestonePaymentsPayableUponAchievementOfCertainDevelopmentRegulatoryAndCommercialMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments payable upon achievement of certain development regulatory and commercial milestones.",
        "label": "Milestone Payments Payable Upon Achievement Of Certain Development Regulatory And Commercial Milestones",
        "terseLabel": "Milestone payments payable upon achievement of certain development regulatory and commercial milestones"
       }
      }
     },
     "localname": "MilestonePaymentsPayableUponAchievementOfCertainDevelopmentRegulatoryAndCommercialMilestones",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_MilestonePaymentsPayableUponAchievementOfCertainSalesMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments payable upon achievement of certain sales milestones.",
        "label": "Milestone Payments Payable Upon Achievement Of Certain Sales Milestones",
        "terseLabel": "Milestone payments payable upon achievement of certain sales milestones"
       }
      }
     },
     "localname": "MilestonePaymentsPayableUponAchievementOfCertainSalesMilestones",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_MilestonePaymentsReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments receivable.",
        "label": "Milestone Payments Receivable",
        "terseLabel": "Milestone payments receivable"
       }
      }
     },
     "localname": "MilestonePaymentsReceivable",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCollaborationAgreementWithPharmingGroupNVAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_NetProceedsFromIssuanceOfPrivatePlacement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net proceeds from issuance of private placement.",
        "label": "Net Proceeds From Issuance Of Private Placement",
        "terseLabel": "Net proceeds from private placement"
       }
      }
     },
     "localname": "NetProceedsFromIssuanceOfPrivatePlacement",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareholdersEquityAndConvertiblePreferredSharesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_NonCashConsiderationForLicensesAndMilestones": {
     "auth_ref": [],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10230.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-cash consideration for licenses and milestones.",
        "label": "Non Cash Consideration For Licenses And Milestones",
        "terseLabel": "Non-cash consideration for licenses and milestones"
       }
      }
     },
     "localname": "NonCashConsiderationForLicensesAndMilestones",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_NonCashInterestExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10210.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-cash interest expense.",
        "label": "Non Cash Interest Expense",
        "terseLabel": "Non-cash interest expense"
       }
      }
     },
     "localname": "NonCashInterestExpense",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_NonEmployeeAdvisorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-employee advisor.",
        "label": "Non Employee Advisor [Member]",
        "terseLabel": "Advisor"
       }
      }
     },
     "localname": "NonEmployeeAdvisorMember",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareholdersEquityAndConvertiblePreferredSharesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ortx_NonVotingOrdinarySharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-voting ordinary shares.",
        "label": "Non Voting Ordinary Shares [Member]",
        "terseLabel": "Non-voting Ordinary Shares"
       }
      }
     },
     "localname": "NonVotingOrdinarySharesMember",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareholdersEquityAndConvertiblePreferredSharesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ortx_NumberOfAdditionalEarlierStageDevelopmentPrograms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional earlier-stage development programs.",
        "label": "Number Of Additional Earlier Stage Development Programs",
        "terseLabel": "Number of additional earlier-stage development programs"
       }
      }
     },
     "localname": "NumberOfAdditionalEarlierStageDevelopmentPrograms",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ortx_NumberOfEarlierStageClinicalGeneTherapyProgram": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of earlier stage clinical gene therapy program.",
        "label": "Number Of Earlier Stage Clinical Gene Therapy Program",
        "terseLabel": "Number of earlier stage clinical gene therapy program"
       }
      }
     },
     "localname": "NumberOfEarlierStageClinicalGeneTherapyProgram",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ortx_NumberOfLateStageClinicalGeneTherapyPrograms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of late-stage clinical gene therapy programs.",
        "label": "Number Of Late Stage Clinical Gene Therapy Programs",
        "terseLabel": "Number of earlier stage clinical gene therapy program"
       }
      }
     },
     "localname": "NumberOfLateStageClinicalGeneTherapyPrograms",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ortx_NumberOfMilestonesMet": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of milestones met.",
        "label": "Number Of Milestones Met",
        "terseLabel": "Number of milestones met"
       }
      }
     },
     "localname": "NumberOfMilestonesMet",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ortx_NumberOfOrdinaryVotingRights": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of ordinary voting rights.",
        "label": "Number Of Ordinary Voting Rights",
        "terseLabel": "Number of ordinary voting rights"
       }
      }
     },
     "localname": "NumberOfOrdinaryVotingRights",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareholdersEquityAndConvertiblePreferredSharesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ortx_OfficeAndComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office and computer equipment.",
        "label": "Office And Computer Equipment [Member]",
        "terseLabel": "Office and Computer Equipment"
       }
      }
     },
     "localname": "OfficeAndComputerEquipmentMember",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ortx_OfficeAndITEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office and IT equipment.",
        "label": "Office And I T Equipment [Member]",
        "terseLabel": "Office and IT Equipment"
       }
      }
     },
     "localname": "OfficeAndITEquipmentMember",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ortx_OfficeAndLaboratorySpaceMenloParkLeaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office and laboratory space menlo park lease agreement.",
        "label": "Office And Laboratory Space Menlo Park Lease Agreement [Member]",
        "terseLabel": "Office and Laboratory Space Menlo Park Lease Agreement [Member]"
       }
      }
     },
     "localname": "OfficeAndLaboratorySpaceMenloParkLeaseAgreementMember",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ortx_OfficeSpaceBostonUnitedStatesLeaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office space boston united states lease agreement.",
        "label": "Office Space Boston United States Lease Agreement [Member]",
        "terseLabel": "Office Space Boston Lease Agreement [Member]"
       }
      }
     },
     "localname": "OfficeSpaceBostonUnitedStatesLeaseAgreementMember",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ortx_OfficeSpaceLondonUnitedKingdomLeaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office space london united kingdom lease agreement.",
        "label": "Office Space London United Kingdom Lease Agreement [Member]",
        "terseLabel": "Office Space London United Kingdom Lease Agreement [Member]"
       }
      }
     },
     "localname": "OfficeSpaceLondonUnitedKingdomLeaseAgreementMember",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ortx_OfficeSpaceMenloParkLeaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office space menlo park lease agreement",
        "label": "Office Space Menlo Park Lease Agreement [Member]",
        "terseLabel": "Office Space Menlo Park Lease Agreement [Member]"
       }
      }
     },
     "localname": "OfficeSpaceMenloParkLeaseAgreementMember",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ortx_OperatingLeaseDurationForFreeRent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease duration for free rent.",
        "label": "Operating Lease Duration For Free Rent",
        "terseLabel": "Operating lease duration for free rent"
       }
      }
     },
     "localname": "OperatingLeaseDurationForFreeRent",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ortx_OperatingLeaseLiabilitiesPaymentsDueNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease liabilities payments due net.",
        "label": "Operating Lease Liabilities Payments Due Net [Abstract]",
        "terseLabel": "Net lease payments"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueNetAbstract",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumBaseRentCommitmentsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ortx_OperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumBaseRentCommitmentsUnderOperatingLeasesDetails": {
       "order": 10060.0,
       "parentTag": "ortx_OperatingLeaseLiabilityPaymentsDueNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease liability payments due after year five",
        "label": "Operating Lease Liability Payments Due After Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumBaseRentCommitmentsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_OperatingLeaseLiabilityPaymentsDueNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumBaseRentCommitmentsUnderOperatingLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease liability payments due net.",
        "label": "Operating Lease Liability Payments Due Net",
        "totalLabel": "Total future minimum lease payments"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityPaymentsDueNet",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumBaseRentCommitmentsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_OperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumBaseRentCommitmentsUnderOperatingLeasesDetails": {
       "order": 10050.0,
       "parentTag": "ortx_OperatingLeaseLiabilityPaymentsDueNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease liability payments due year five.",
        "label": "Operating Lease Liability Payments Due Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumBaseRentCommitmentsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_OperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumBaseRentCommitmentsUnderOperatingLeasesDetails": {
       "order": 10040.0,
       "parentTag": "ortx_OperatingLeaseLiabilityPaymentsDueNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease liability payments due year four.",
        "label": "Operating Lease Liability Payments Due Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumBaseRentCommitmentsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_OperatingLeaseLiabilityPaymentsDueYearOne": {
     "auth_ref": [],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumBaseRentCommitmentsUnderOperatingLeasesDetails": {
       "order": 10010.0,
       "parentTag": "ortx_OperatingLeaseLiabilityPaymentsDueNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease liability payments due year one.",
        "label": "Operating Lease Liability Payments Due Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityPaymentsDueYearOne",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumBaseRentCommitmentsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_OperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumBaseRentCommitmentsUnderOperatingLeasesDetails": {
       "order": 10030.0,
       "parentTag": "ortx_OperatingLeaseLiabilityPaymentsDueNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease liability payments due year three.",
        "label": "Operating Lease Liability Payments Due Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumBaseRentCommitmentsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_OperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumBaseRentCommitmentsUnderOperatingLeasesDetails": {
       "order": 10020.0,
       "parentTag": "ortx_OperatingLeaseLiabilityPaymentsDueNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease liability payments due year two.",
        "label": "Operating Lease Liability Payments Due Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumBaseRentCommitmentsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_OperatingLeaseRightOfUseAssetFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease Right Of Use Asset Fair Value",
        "label": "Operating Lease Right Of Use Asset Fair Value",
        "terseLabel": "Fair value of ROU asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetFairValue",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRestructuringChargesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_OperatingLeaseRightOfUseAssetValueExchangeForLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease right of use asset value exchange for lease liabilities.",
        "label": "Operating Lease Right Of Use Asset Value Exchange For Lease Liabilities",
        "terseLabel": "Operating lease, right-of-use asset obtained in exchange for lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetValueExchangeForLeaseLiabilities",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_OperatingLeasesCommencedTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating leases commenced term.",
        "label": "Operating Leases Commenced Term",
        "terseLabel": "Operating leases Commenced term"
       }
      }
     },
     "localname": "OperatingLeasesCommencedTerm",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "ortx_OperatingLeasesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating leases line items.",
        "label": "Operating Leases [Line Items]",
        "terseLabel": "Operating Leases [Line Items]"
       }
      }
     },
     "localname": "OperatingLeasesLineItems",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumBaseRentCommitmentsUnderOperatingLeasesParentheticalDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ortx_OperatingLeasesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating leases table.",
        "label": "Operating Leases [Table]",
        "terseLabel": "Operating Leases [Table]"
       }
      }
     },
     "localname": "OperatingLeasesTable",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumBaseRentCommitmentsUnderOperatingLeasesParentheticalDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ortx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization consolidation and presentation of financial statements.",
        "label": "Organization Consolidation And Presentation Of Financial Statements [Line Items]",
        "terseLabel": "Organization Consolidation And Presentation Of Financial Statements [Line Items]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ortx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization consolidation and presentation of financial statements.",
        "label": "Organization Consolidation And Presentation Of Financial Statements [Table]",
        "terseLabel": "Organization Consolidation And Presentation Of Financial Statements [Table]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsTable",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ortx_OrphanDrugTaxCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Orphan Drug Tax Credit.",
        "label": "Orphan Drug Tax Credit [Member]",
        "terseLabel": "Orphan Drug"
       }
      }
     },
     "localname": "OrphanDrugTaxCreditMember",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ortx_OtherNonCurrentAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureOtherAssetsScheduleOfOtherAssetsDetails": {
       "order": 10040.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other non-current assets.",
        "label": "Other Non Current Assets",
        "terseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "OtherNonCurrentAssets",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureOtherAssetsScheduleOfOtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_OxfordBioMedicaLicenseDevelopmentAndSupplyAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oxford BioMedica license development and supply agreement.",
        "label": "Oxford Bio Medica License Development And Supply Agreement [Member]",
        "terseLabel": "Oxford BioMedica License, Development and Supply Agreement",
        "verboseLabel": "Oxford BioMedica License, Development and Supply Agreement"
       }
      }
     },
     "localname": "OxfordBioMedicaLicenseDevelopmentAndSupplyAgreementMember",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareholdersEquityAndConvertiblePreferredSharesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ortx_PaymentOfTaxesOnRestrictedStockVesting": {
     "auth_ref": [],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10070.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment of taxes on restricted stock vesting.",
        "label": "Payment Of Taxes On Restricted Stock Vesting",
        "negatedLabel": "Payment of taxes on restricted stock vesting"
       }
      }
     },
     "localname": "PaymentOfTaxesOnRestrictedStockVesting",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_PaymentOfTieredRoyaltyMaximumPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment of tiered royalty, maximum percentage.",
        "label": "Payment Of Tiered Royalty Maximum Percentage",
        "terseLabel": "Payment of tiered royalty, maximum percentage"
       }
      }
     },
     "localname": "PaymentOfTieredRoyaltyMaximumPercentage",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ortx_PaymentsOfOtherIssuanceCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments of other issuance costs.",
        "label": "Payments Of Other Issuance Costs",
        "terseLabel": "Other issuance costs"
       }
      }
     },
     "localname": "PaymentsOfOtherIssuanceCosts",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareholdersEquityAndConvertiblePreferredSharesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_PaymentsToAcquireClinicalData": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments to acquire clinical data.",
        "label": "Payments To Acquire Clinical Data",
        "terseLabel": "Payments to acquire clinical data"
       }
      }
     },
     "localname": "PaymentsToAcquireClinicalData",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_PharmingAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pharming agreements.",
        "label": "Pharming Agreements [Member]",
        "terseLabel": "Pharming Agreements"
       }
      }
     },
     "localname": "PharmingAgreementsMember",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCollaborationAgreementWithPharmingGroupNVAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ortx_PotentialPaymentForAchievementOfSpecifiedMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential payment for achievement of specified milestones.",
        "label": "Potential Payment For Achievement Of Specified Milestones",
        "terseLabel": "Payments upon achievement of specified regulatory milestones"
       }
      }
     },
     "localname": "PotentialPaymentForAchievementOfSpecifiedMilestones",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_PrepaidExpensesAndOtherCurrentAssetsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid expenses and other current assets.",
        "label": "Prepaid Expenses And Other Current Assets [Text Block]",
        "terseLabel": "Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsTextBlock",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ortx_PrepaidExternalResearchAndDevelopmentExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid external research and development expenses.",
        "label": "Prepaid External Research And Development Expenses",
        "terseLabel": "Prepaid external research and development expenses"
       }
      }
     },
     "localname": "PrepaidExternalResearchAndDevelopmentExpenses",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_ProceedsFromIssuanceOfSharesAsPartOfCollaborationAgreement": {
     "auth_ref": [],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10080.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of shares as part of collaboration agreement.",
        "label": "Proceeds From Issuance Of Shares As Part Of Collaboration Agreement",
        "terseLabel": "Proceeds from issuance of shares as part of collaboration agreement"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesAsPartOfCollaborationAgreement",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_ProceedsFromNonRefundableUpfrontPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from non-refundable upfront payment.",
        "label": "Proceeds From Non Refundable Upfront Payment",
        "terseLabel": "Non-refundable up-front payment"
       }
      }
     },
     "localname": "ProceedsFromNonRefundableUpfrontPayment",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCollaborationAgreementWithPharmingGroupNVAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_ProceedsFromPremiumSharesIssued": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from premium shares issued..",
        "label": "Proceeds From Premium Shares Issued",
        "terseLabel": "Premium consideration"
       }
      }
     },
     "localname": "ProceedsFromPremiumSharesIssued",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCollaborationAgreementWithPharmingGroupNVAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareholdersEquityAndConvertiblePreferredSharesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_ProceedsFromUpfrontPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from upfront payment.",
        "label": "Proceeds From Upfront Payment",
        "terseLabel": "Total upfront payments"
       }
      }
     },
     "localname": "ProceedsFromUpfrontPayment",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCollaborationAgreementWithPharmingGroupNVAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_ProceedsFromUpfrontPaymentsAttributedToEquitySold": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from upfront payments attributed to equity sold.",
        "label": "Proceeds From Upfront Payments Attributed To Equity Sold",
        "terseLabel": "Upfront payments attributed to equity sold"
       }
      }
     },
     "localname": "ProceedsFromUpfrontPaymentsAttributedToEquitySold",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCollaborationAgreementWithPharmingGroupNVAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_ProceedsFromUpfrontPaymentsAttributedToResearchActivities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from upfront payments attributed to research activities.",
        "label": "Proceeds From Upfront Payments Attributed To Research Activities",
        "terseLabel": "Upfront payments attributed to research activities"
       }
      }
     },
     "localname": "ProceedsFromUpfrontPaymentsAttributedToResearchActivities",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCollaborationAgreementWithPharmingGroupNVAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_ProductLiabilityCurrentPortion": {
     "auth_ref": [],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 10060.0,
       "parentTag": "ortx_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product liability, current portion.",
        "label": "Product Liability Current Portion",
        "terseLabel": "Strimvelis liability - current portion"
       }
      }
     },
     "localname": "ProductLiabilityCurrentPortion",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_ProductManufacturingCommitmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product manufacturing commitments.",
        "label": "Product Manufacturing Commitments [Member]",
        "terseLabel": "Product Manufacturing Commitments"
       }
      }
     },
     "localname": "ProductManufacturingCommitmentsMember",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfAnnualCommitmentsAssociatedWithContractDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ortx_PropertyPlantAndEquipmentUsefulLifeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property, plant and equipment useful life.",
        "label": "Property Plant And Equipment Useful Life Table [Text Block]",
        "terseLabel": "Schedule of Estimated Useful Lives of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLifeTableTextBlock",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ortx_ReceiptOfFundsFromConstructionDeposit": {
     "auth_ref": [],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10140.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Receipt of funds from construction deposit.",
        "label": "Receipt Of Funds From Construction Deposit",
        "terseLabel": "Receipt of funds from construction deposit"
       }
      }
     },
     "localname": "ReceiptOfFundsFromConstructionDeposit",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_ReductionOfStandbyLetterOfCreditAmountPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduction of standby letter of credit amount percentage.",
        "label": "Reduction Of Standby Letter Of Credit Amount Percentage",
        "terseLabel": "Reduction of standby letter of credit amount percentage"
       }
      }
     },
     "localname": "ReductionOfStandbyLetterOfCreditAmountPercentage",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ortx_ReimbursementRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reimbursement revenue.",
        "label": "Reimbursement Revenue [Member]",
        "terseLabel": "Reimbursement Revenue"
       }
      }
     },
     "localname": "ReimbursementRevenueMember",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCollaborationAgreementWithPharmingGroupNVSummaryOfResearchAndDevelopmentCostsIncurredAndCollaborationRevenueRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ortx_RentalLabSpaceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rental lab space.",
        "label": "Rental Lab Space [Member]",
        "terseLabel": "Rental Lab Space [Member]"
       }
      }
     },
     "localname": "RentalLabSpaceMember",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ortx_ResearchAndDevelopmentIncomeTaxCreditsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development income tax credits.",
        "label": "Research And Development Income Tax Credits Policy [Text Block]",
        "terseLabel": "United Kingdom Research and development income tax credits"
       }
      }
     },
     "localname": "ResearchAndDevelopmentIncomeTaxCreditsPolicyTextBlock",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ortx_ResearchAndDevelopmentTaxCreditReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development tax credit receivable.",
        "label": "Research And Development Tax Credit Receivable",
        "terseLabel": "Tax incentive receivable"
       }
      }
     },
     "localname": "ResearchAndDevelopmentTaxCreditReceivable",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_ResearchAndDevelopmentTaxCreditReceivableCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10290.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development tax credit receivable, current.",
        "label": "Research And Development Tax Credit Receivable Current",
        "terseLabel": "Research and development tax credit receivable",
        "verboseLabel": "Tax incentive receivable, current"
       }
      }
     },
     "localname": "ResearchAndDevelopmentTaxCreditReceivableCurrent",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_ResearchContractCostsAndAccrualsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research contract costs and accruals.",
        "label": "Research Contract Costs And Accruals Policy [Text Block]",
        "terseLabel": "Research contract costs and accruals"
       }
      }
     },
     "localname": "ResearchContractCostsAndAccrualsPolicyTextBlock",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ortx_ScheduleOfChangesInLossProvisionTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of changes in loss provision.",
        "label": "Schedule Of Changes In Loss Provision Table [Text Block]",
        "terseLabel": "Schedule of Changes in Loss Provision [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfChangesInLossProvisionTableTextBlock",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ortx_ScheduleOfIntangibleAssetsNetOfAccumulatedAmortizationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of intangible assets net of accumulated amortization.",
        "label": "Schedule Of Intangible Assets Net Of Accumulated Amortization Table [Text Block]",
        "terseLabel": "Schedule of Intangible Assets Net of Accumulated Amortization"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsNetOfAccumulatedAmortizationTableTextBlock",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIntangibleAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ortx_SecuritiesPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities purchase agreement.",
        "label": "Securities Purchase Agreement [Member]",
        "terseLabel": "Securities Purchase Agreement"
       }
      }
     },
     "localname": "SecuritiesPurchaseAgreementMember",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareholdersEquityAndConvertiblePreferredSharesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ortx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeEquityPlanProceedsReceivedAfterYearEnd": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award employee equity plan proceeds received after year end.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Employee Equity Plan Proceeds Received After Year End",
        "terseLabel": "Employee equity plan proceeds received after year end"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeEquityPlanProceedsReceivedAfterYearEnd",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award grant date fair value.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Grant Date Fair Value",
        "terseLabel": "Total grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_SharePurchaseAgreementWithPharmingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share purchase agreement with pharming.",
        "label": "Share Purchase Agreement With Pharming [Member]",
        "terseLabel": "Share Purchase Agreement with Pharming"
       }
      }
     },
     "localname": "SharePurchaseAgreementWithPharmingMember",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCollaborationAgreementWithPharmingGroupNVAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareholdersEquityAndConvertiblePreferredSharesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ortx_ShareholdersEquityAndConvertiblePreferredSharesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shareholders equity and convertible preferred shares.",
        "label": "Shareholders Equity And Convertible Preferred Shares [Abstract]"
       }
      }
     },
     "localname": "ShareholdersEquityAndConvertiblePreferredSharesAbstract",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "xbrltype": "stringItemType"
    },
    "ortx_StockIssuedDuringPeriodSharesAsPartOfCollaborationAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares as part of collaboration agreement.",
        "label": "Stock Issued During Period Shares As Part Of Collaboration Agreement",
        "terseLabel": "Ordinary shares issued as part of collaboration agreement, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAsPartOfCollaborationAgreement",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "ortx_StockIssuedDuringPeriodSharesAsPartOfConsultingAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares as part of consulting agreement.",
        "label": "Stock Issued During Period Shares As Part Of Consulting Agreement",
        "terseLabel": "Ordinary shares issued as part of consulting agreement, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAsPartOfConsultingAgreement",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "ortx_StockIssuedDuringPeriodValueAsPartOfCollaborationAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period value as part of collaboration agreement.",
        "label": "Stock Issued During Period Value As Part Of Collaboration Agreement",
        "terseLabel": "Ordinary shares issued as part of collaboration agreement"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueAsPartOfCollaborationAgreement",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_StockIssuedDuringPeriodValueAsPartOfConsultingAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period value as part of consulting agreement.",
        "label": "Stock Issued During Period Value As Part Of Consulting Agreement",
        "terseLabel": "Ordinary shares issued as part of consulting agreement"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueAsPartOfConsultingAgreement",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_StrategicCollaborationAgreementWithPharmingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Strategic collaboration agreement with pharming.",
        "label": "Strategic Collaboration Agreement With Pharming [Member]",
        "terseLabel": "Strategic Collaboration Agreement with Pharming"
       }
      }
     },
     "localname": "StrategicCollaborationAgreementWithPharmingMember",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCollaborationAgreementWithPharmingGroupNVAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ortx_StrimvelisLossProvisionPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Strimvelis loss provision.",
        "label": "Strimvelis Loss Provision Policy [Text Block]",
        "terseLabel": "Strimvelis loss provision"
       }
      }
     },
     "localname": "StrimvelisLossProvisionPolicyTextBlock",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ortx_SummaryOfSignificantAccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policies.",
        "label": "Summary Of Significant Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesAbstract",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "xbrltype": "stringItemType"
    },
    "ortx_SummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policies.",
        "label": "Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfAmountsRecognizedToOffsetResearchAndDevelopmentExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ortx_SummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policies.",
        "label": "Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfAmountsRecognizedToOffsetResearchAndDevelopmentExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ortx_TaxCreditCarryforwardExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax credit carryforward expiration year.",
        "label": "Tax Credit Carryforward Expiration Year",
        "terseLabel": "Tax credit carryforward expiration year"
       }
      }
     },
     "localname": "TaxCreditCarryforwardExpirationYear",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "ortx_TelethonOSRLicenseAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Telethon-OSR license agreements.",
        "label": "Telethon O S R License Agreements [Member]",
        "terseLabel": "Telethon O S R License Agreements"
       }
      }
     },
     "localname": "TelethonOSRLicenseAgreementsMember",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ortx_TenantImprovementAllowance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tenant improvement allowance.",
        "label": "Tenant Improvement Allowance",
        "terseLabel": "Tenant improvements allowance"
       }
      }
     },
     "localname": "TenantImprovementAllowance",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_TermLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term loan.",
        "label": "Term Loan [Member]",
        "terseLabel": "Term Loan"
       }
      }
     },
     "localname": "TermLoanMember",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ortx_TheFirstTrancheTermLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term loans available in the first tranche.",
        "label": "The First Tranche Term Loan [Member]",
        "terseLabel": "Initial Term Loan"
       }
      }
     },
     "localname": "TheFirstTrancheTermLoanMember",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ortx_TheSecondTrancheTermLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term loans available in the second tranch.",
        "label": "The Second Tranche Term Loan [Member]",
        "terseLabel": "Second Tranche (Term Loan Available from July 1, 2022 to July 1, 2023)"
       }
      }
     },
     "localname": "TheSecondTrancheTermLoanMember",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ortx_TheThirdTrancheTermLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term loans available in the third tranch.",
        "label": "The Third Tranche Term Loan [Member]",
        "terseLabel": "Third Tranche (Term Loan Available from July 1, 2023 to July 1, 2024)"
       }
      }
     },
     "localname": "TheThirdTrancheTermLoanMember",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ortx_TimeBasedRestrictedShareUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Time-based restricted share units.",
        "label": "Time Based Restricted Share Units [Member]",
        "terseLabel": "Time-based Restricted Share Units"
       }
      }
     },
     "localname": "TimeBasedRestrictedShareUnitsMember",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfAwardActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ortx_TwoThousandAndEighteenEmployeeSharePurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2018 Employee Share Purchase Plan.",
        "label": "Two Thousand And Eighteen Employee Share Purchase Plan [Member]",
        "terseLabel": "2018 ESPP"
       }
      }
     },
     "localname": "TwoThousandAndEighteenEmployeeSharePurchasePlanMember",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ortx_TwoThousandAndEighteenShareOptionAndIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2018 Share Option And Incentive Plan.",
        "label": "Two Thousand And Eighteen Share Option And Incentive Plan [Member]",
        "terseLabel": "2018 Plan"
       }
      }
     },
     "localname": "TwoThousandAndEighteenShareOptionAndIncentivePlanMember",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ortx_TwoThousandAndTwentyInducementEquityPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 Inducement Equity Plan.",
        "label": "Two Thousand And Twenty Inducement Equity Plan [Member]",
        "terseLabel": "Inducement Plan"
       }
      }
     },
     "localname": "TwoThousandAndTwentyInducementEquityPlanMember",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ortx_UCLBAndUCLALicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "UCLB and UCLA license agreement.",
        "label": "U C L B And U C L A License Agreement [Member]",
        "terseLabel": "UCLB/UCLA License Agreement"
       }
      }
     },
     "localname": "UCLBAndUCLALicenseAgreementMember",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ortx_UCLBAndUCLATechnologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "UCLB and UCLA technology.",
        "label": "U C L B And U C L A Technology [Member]",
        "terseLabel": "UCLB/UCLA Technology"
       }
      }
     },
     "localname": "UCLBAndUCLATechnologyMember",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ortx_UCLBLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "UCLB license agreement.",
        "label": "U C L B License Agreement [Member]",
        "terseLabel": "UCLB License Agreement"
       }
      }
     },
     "localname": "UCLBLicenseAgreementMember",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ortx_UCLBTechnologyAndManufacturingTechnologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "UCLB technology and manufacturing technology.",
        "label": "U C L B Technology And Manufacturing Technology [Member]",
        "terseLabel": "UCLB Technology and Manufacturing Technology"
       }
      }
     },
     "localname": "UCLBTechnologyAndManufacturingTechnologyMember",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ortx_UnamortizedPortionOfFinalPayment": {
     "auth_ref": [],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableSummaryOfFuturePrincipalPaymentsDueDetails2": {
       "order": 10020.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unamortized portion of final payment.",
        "label": "Unamortized Portion Of Final Payment",
        "negatedLabel": "Less unamortized portion of final payment"
       }
      }
     },
     "localname": "UnamortizedPortionOfFinalPayment",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableSummaryOfFuturePrincipalPaymentsDueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_UnrealizedForeignCurrencyAndOtherNonCashAdjustments": {
     "auth_ref": [],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10260.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrealized foreign currency and other non-cash adjustments.",
        "label": "Unrealized Foreign Currency And Other Non Cash Adjustments",
        "negatedLabel": "Unrealized foreign currency and other non-cash adjustments"
       }
      }
     },
     "localname": "UnrealizedForeignCurrencyAndOtherNonCashAdjustments",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_UnvestedSharesFromSharePlanAndConsultingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unvested shares from share plan and consulting agreement member.",
        "label": "Unvested Shares From Share Plan And Consulting Agreement [Member]",
        "terseLabel": "Unvested Shares from Share Plan and Consulting Agreement"
       }
      }
     },
     "localname": "UnvestedSharesFromSharePlanAndConsultingAgreementMember",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSecuritiesExcludedInComputationOfDilutedNetLossPerOrdinaryShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ortx_UpfrontAndMilestonePaymentRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront and milestone payment revenue.",
        "label": "Upfront And Milestone Payment Revenue [Member]",
        "terseLabel": "Upfront and Milestone Payment Revenue"
       }
      }
     },
     "localname": "UpfrontAndMilestonePaymentRevenueMember",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCollaborationAgreementWithPharmingGroupNVSummaryOfResearchAndDevelopmentCostsIncurredAndCollaborationRevenueRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ortx_UpfrontAndMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront and milestone payments.",
        "label": "Upfront And Milestone Payments",
        "terseLabel": "Upfront and milestone payments"
       }
      }
     },
     "localname": "UpfrontAndMilestonePayments",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_UpfrontCashPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront cash payment.",
        "label": "Upfront Cash Payment",
        "terseLabel": "Upfront cash payments"
       }
      }
     },
     "localname": "UpfrontCashPayment",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ortx_UpfrontPaymentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront payment Description",
        "label": "Upfront Payment Description",
        "terseLabel": "Upfront payment description"
       }
      }
     },
     "localname": "UpfrontPaymentDescription",
     "nsuri": "http://www.orchard-tx.com/20211231",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ChiefExecutiveOfficerMember": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Person with designation of chief executive officer.",
        "label": "Chief Executive Officer [Member]",
        "terseLabel": "Chief Executive Officer"
       }
      }
     },
     "localname": "ChiefExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock": {
     "auth_ref": [
      "r713"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation.",
        "label": "Contractual Obligation Fiscal Year Maturity Schedule Table [Text Block]",
        "terseLabel": "Schedule of Annual Commitments Associated with the Contract"
       }
      }
     },
     "localname": "ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_CurrencyAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by currency.",
        "label": "Currency [Axis]",
        "terseLabel": "Currency"
       }
      }
     },
     "localname": "CurrencyAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumBaseRentCommitmentsUnderOperatingLeasesParentheticalDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r301",
      "r338",
      "r410",
      "r411",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r671",
      "r674",
      "r701",
      "r702"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upper limit of the provided range.",
        "label": "Maximum [Member]",
        "terseLabel": "Maximum",
        "verboseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCollaborationAgreementWithPharmingGroupNVAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRestructuringChargesAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAssumptionsUsedInBlackScholesOptionPricingModelDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareholdersEquityAndConvertiblePreferredSharesAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r301",
      "r338",
      "r410",
      "r411",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r671",
      "r674",
      "r701",
      "r702"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lower limit of the provided range.",
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCollaborationAgreementWithPharmingGroupNVAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRestructuringChargesAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAssumptionsUsedInBlackScholesOptionPricingModelDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareholdersEquityAndConvertiblePreferredSharesAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r203",
      "r384",
      "r387",
      "r608",
      "r670",
      "r672"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by product and service, or group of similar products and similar services.",
        "label": "Product Or Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCollaborationAgreementWithPharmingGroupNVSummaryOfResearchAndDevelopmentCostsIncurredAndCollaborationRevenueRecognizedDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r203",
      "r384",
      "r387",
      "r608",
      "r670",
      "r672"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product or service, or a group of similar products or similar services.",
        "label": "Products And Services [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCollaborationAgreementWithPharmingGroupNVSummaryOfResearchAndDevelopmentCostsIncurredAndCollaborationRevenueRecognizedDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r301",
      "r338",
      "r390",
      "r410",
      "r411",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r671",
      "r674",
      "r701",
      "r702"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Range [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCollaborationAgreementWithPharmingGroupNVAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRestructuringChargesAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAssumptionsUsedInBlackScholesOptionPricingModelDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareholdersEquityAndConvertiblePreferredSharesAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r301",
      "r338",
      "r390",
      "r410",
      "r411",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r671",
      "r674",
      "r701",
      "r702"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Range [Member]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCollaborationAgreementWithPharmingGroupNVAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRestructuringChargesAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAssumptionsUsedInBlackScholesOptionPricingModelDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareholdersEquityAndConvertiblePreferredSharesAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r204",
      "r205",
      "r384",
      "r388",
      "r673",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r715",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Geographical area.",
        "label": "Segment Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfAmountsRecognizedToOffsetResearchAndDevelopmentExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r204",
      "r205",
      "r384",
      "r388",
      "r673",
      "r684",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r715",
      "r716"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by geographical components.",
        "label": "Statement Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfAmountsRecognizedToOffsetResearchAndDevelopmentExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r207",
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by title of individual or nature of relationship to individual or group of individuals.",
        "label": "Title Of Individual [Axis]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareholdersEquityAndConvertiblePreferredSharesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of individual, or nature of relationship to individual or group of individuals.",
        "label": "Title Of Individual With Relationship To Entity [Domain]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareholdersEquityAndConvertiblePreferredSharesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "Accounts Payable Accrued Liabilities And Other Liabilities Disclosure Current [Text Block]",
        "terseLabel": "Accrued Expenses and Other Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r48",
      "r588"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10130.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableRelatedPartiesCurrent": {
     "auth_ref": [
      "r48",
      "r137",
      "r581",
      "r583"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable Related Parties Current",
        "terseLabel": "Due to related party transactions, accounts payable"
       }
      }
     },
     "localname": "AccountsPayableRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r686"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCollaborationAgreementWithPharmingGroupNVAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r7",
      "r33",
      "r208",
      "r209"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10270.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable Net Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities And Other Liabilities [Abstract]"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r13",
      "r14",
      "r52"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 10040.0,
       "parentTag": "ortx_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees Current",
        "terseLabel": "Accrued professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r46",
      "r253"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation Depletion And Amortization Property Plant And Equipment",
        "negatedLabel": "Less: accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r36",
      "r69",
      "r70",
      "r71",
      "r657",
      "r681",
      "r682"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10060.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income Loss Net Of Tax",
        "terseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r68",
      "r71",
      "r79",
      "r80",
      "r81",
      "r140",
      "r141",
      "r142",
      "r507",
      "r677",
      "r678",
      "r727"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r34",
      "r451",
      "r588"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10050.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid In Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r140",
      "r141",
      "r142",
      "r448",
      "r449",
      "r450",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid In Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r353",
      "r361"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments To Additional Paid In Capital Stock Issued Issuance Costs",
        "terseLabel": "Sale of voting and non-voting ordinary shares, issuance costs"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquityParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r414",
      "r441",
      "r453"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share Based Compensation Expense",
        "terseLabel": "Compensation cost recognized",
        "verboseLabel": "Total share-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount",
        "terseLabel": "Common shares attributable to anti-dilutive shares"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSecuritiesExcludedInComputationOfDilutedNetLossPerOrdinaryShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSecuritiesExcludedInComputationOfDilutedNetLossPerOrdinaryShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Arrangements And Nonarrangement Transactions [Member]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCollaborationAgreementWithPharmingGroupNVAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCollaborationAgreementWithPharmingGroupNVSummaryOfResearchAndDevelopmentCostsIncurredAndCollaborationRevenueRecognizedDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareholdersEquityAndConvertiblePreferredSharesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionConsiderationTransferred": {
     "auth_ref": [
      "r493",
      "r494",
      "r495",
      "r496"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.",
        "label": "Asset Acquisition Consideration Transferred",
        "terseLabel": "Total consideration"
       }
      }
     },
     "localname": "AssetAcquisitionConsiderationTransferred",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r113",
      "r250"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRestructuringChargesSummaryOfImpairmentOfLongLivedAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10200.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Impairment of long-lived assets",
        "totalLabel": "Charge included in research and development expense"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRestructuringChargesSummaryOfImpairmentOfLongLivedAssetsDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r132",
      "r186",
      "r195",
      "r201",
      "r223",
      "r285",
      "r286",
      "r287",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r296",
      "r297",
      "r502",
      "r508",
      "r528",
      "r586",
      "r588",
      "r627",
      "r654"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r9",
      "r11",
      "r65",
      "r132",
      "r223",
      "r285",
      "r286",
      "r287",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r296",
      "r297",
      "r502",
      "r508",
      "r528",
      "r586",
      "r588"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10180.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r521"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesScheduleOfCashEquivalentsAndMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets Fair Value Disclosure",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesScheduleOfCashEquivalentsAndMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Fair Value Disclosure [Abstract]"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNoncurrent": {
     "auth_ref": [
      "r18",
      "r19",
      "r20",
      "r21",
      "r22",
      "r23",
      "r24",
      "r25",
      "r132",
      "r223",
      "r285",
      "r286",
      "r287",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r296",
      "r297",
      "r502",
      "r508",
      "r528",
      "r586"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10190.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.",
        "label": "Assets Noncurrent",
        "totalLabel": "Total non-current assets"
       }
      }
     },
     "localname": "AssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Noncurrent [Abstract]",
        "terseLabel": "Non-current assets:"
       }
      }
     },
     "localname": "AssetsNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r218"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesScheduleOfLevel2CashEquivalentsAndMarketableSecuritiesDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesScheduleOfLevel2CashEquivalentsAndMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r219"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesScheduleOfLevel2CashEquivalentsAndMarketableSecuritiesDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax",
        "negatedLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesScheduleOfLevel2CashEquivalentsAndMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r215",
      "r230"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesScheduleOfLevel2CashEquivalentsAndMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Debt Securities Amortized Cost Basis",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesScheduleOfLevel2CashEquivalentsAndMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis": {
     "auth_ref": [
      "r220",
      "r222",
      "r645"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesScheduleOfAvailableForSaleMarketableDebtSecuritiesByContractualMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.",
        "label": "Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesScheduleOfAvailableForSaleMarketableDebtSecuritiesByContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "auth_ref": [
      "r221"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesScheduleOfAvailableForSaleMarketableDebtSecuritiesByContractualMaturityDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Available For Sale Securities Debt Maturities Within One Year Amortized Cost",
        "terseLabel": "Maturities in one year or less"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesScheduleOfAvailableForSaleMarketableDebtSecuritiesByContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r213",
      "r216",
      "r230",
      "r632"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesScheduleOfLevel2CashEquivalentsAndMarketableSecuritiesDetails": {
       "order": 10040.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Securities Debt Securities",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesScheduleOfLevel2CashEquivalentsAndMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r416",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfAwardActivityDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSecuritiesExcludedInComputationOfDilutedNetLossPerOrdinaryShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCollaborationAgreementWithPharmingGroupNVAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r512",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCollaborationAgreementWithPharmingGroupNVAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r4",
      "r139",
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description And Basis Of Presentation [Text Block]",
        "terseLabel": "Nature of Business and Basis of Presentation"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r5",
      "r43",
      "r115"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
       "weight": 1.0
      },
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10250.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash And Cash Equivalents At Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesScheduleOfCashEquivalentsAndMarketableSecuritiesDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash And Cash Equivalents Fair Value Disclosure",
        "terseLabel": "Total cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesScheduleOfCashEquivalentsAndMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r17",
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash And Cash Equivalents Policy [Text Block]",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r17",
      "r116",
      "r626"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash And Cash Equivalents Restricted Cash And Cash Equivalents Policy",
        "terseLabel": "Restricted cash and construction deposits"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r43"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash Cash Equivalents And Short Term Investments",
        "terseLabel": "Cash, cash equivalents and marketable securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r107",
      "r115",
      "r121"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash \u2014end of year",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash \u2014beginning of year",
        "totalLabel": "Total cash, cash equivalents and restricted cash shown in the statement of cash flows"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r107",
      "r539"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCollateralForBorrowedSecurities": {
     "auth_ref": [
      "r633",
      "r662"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of cash collateral held for borrowed securities, for which the cash is restricted as to withdrawal or usage.",
        "label": "Cash Collateral For Borrowed Securities",
        "terseLabel": "Cash collateral associated with corporate credit cards and other leases"
       }
      }
     },
     "localname": "CashCollateralForBorrowedSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": {
     "auth_ref": [
      "r0",
      "r1",
      "r140",
      "r141",
      "r143",
      "r211",
      "r212",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r284",
      "r445",
      "r446",
      "r447",
      "r479",
      "r514",
      "r515",
      "r516",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r556",
      "r576",
      "r610",
      "r611",
      "r675",
      "r676",
      "r726"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether accounting standards update was adopted.",
        "label": "Change In Accounting Principle Accounting Standards Update Adopted",
        "terseLabel": "Change in accounting principle, accounting standards update, adopted"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": {
     "auth_ref": [
      "r0",
      "r1",
      "r140",
      "r141",
      "r148",
      "r211",
      "r212",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r284",
      "r445",
      "r446",
      "r447",
      "r479",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r556",
      "r576",
      "r610",
      "r611",
      "r675",
      "r676",
      "r726"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format.",
        "label": "Change In Accounting Principle Accounting Standards Update Adoption Date",
        "terseLabel": "Change in accounting principle, accounting standards update, adoption date"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r129",
      "r132",
      "r155",
      "r156",
      "r157",
      "r159",
      "r161",
      "r168",
      "r169",
      "r170",
      "r223",
      "r285",
      "r290",
      "r291",
      "r292",
      "r296",
      "r297",
      "r336",
      "r337",
      "r341",
      "r345",
      "r528",
      "r712"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class Of Stock [Domain]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareholdersEquityAndConvertiblePreferredSharesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class Of Stock [Line Items]",
        "terseLabel": "Class Of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareholdersEquityAndConvertiblePreferredSharesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r497",
      "r498",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "License and Research Arrangements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCollaborationAgreementWithPharmingGroupNV",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLicenseAndResearchAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCollaborationAgreementWithPharmingGroupNVAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCollaborationAgreementWithPharmingGroupNVSummaryOfResearchAndDevelopmentCostsIncurredAndCollaborationRevenueRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]",
        "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCollaborationAgreementWithPharmingGroupNVAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCollaborationAgreementWithPharmingGroupNVSummaryOfResearchAndDevelopmentCostsIncurredAndCollaborationRevenueRecognizedDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial Paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesScheduleOfCashEquivalentsAndMarketableSecuritiesDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesScheduleOfLevel2CashEquivalentsAndMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r57",
      "r279",
      "r636",
      "r661"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10020.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments And Contingencies",
        "terseLabel": "Commitments and contingencies (Note 18)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments And Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r276",
      "r277",
      "r278",
      "r280",
      "r687"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments And Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock Capital Shares Reserved For Future Issuance",
        "terseLabel": "Shares, issued"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r140",
      "r141",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Ordinary Shares"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock Par Or Stated Value Per Share",
        "terseLabel": "Ordinary Shares, Par Value",
        "verboseLabel": "Nominal value of shares issued and sold"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareholdersEquityAndConvertiblePreferredSharesAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock Shares Issued",
        "terseLabel": "Ordinary Shares, Issued",
        "verboseLabel": "Ordinary shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareholdersEquityAndConvertiblePreferredSharesAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r32",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock Shares Outstanding",
        "terseLabel": "Ordinary Shares, Outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r32",
      "r588"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10040.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock Value",
        "terseLabel": "Ordinary shares, \u00a30.10 par value, authority to allot up to a maximum nominal value of \u00a313,023,851.50 of shares at December 31, 2021 and 2020, respectively; 125,674,095 and 98,283,603 shares issued and outstanding at December 31, 2021 and 2020, respectively."
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockValueOutstanding": {
     "auth_ref": [
      "r32"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.",
        "label": "Common Stock Value Outstanding",
        "terseLabel": "Ordinary shares maximum nominal value"
       }
      }
     },
     "localname": "CommonStockValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareholdersEquityAndConvertiblePreferredSharesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockVotingRights": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.",
        "label": "Common Stock Voting Rights",
        "terseLabel": "Ordinary shares voting rights description"
       }
      }
     },
     "localname": "CommonStockVotingRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareholdersEquityAndConvertiblePreferredSharesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation And Retirement Disclosure [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.",
        "label": "Compensation Related Costs Policy [Text Block]",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components Of Deferred Tax Assets [Abstract]",
        "terseLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r74",
      "r76",
      "r77",
      "r87",
      "r641",
      "r667"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income Net Of Tax",
        "totalLabel": "Total comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income Policy Policy [Text Block]",
        "terseLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r173",
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk Credit Risk",
        "terseLabel": "Concentration of credit risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk": {
     "auth_ref": [
      "r527",
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of financial instruments, excluding certain derivatives, with off-balance sheet credit risk (for example, standby letters of credit or financial guarantees), including (1) information about the (shared) activity, region or economic characteristic that identifies the concentration, (2) the face or contract amount of the instrument, (3) the nature and terms of the instrument, including the market risk, cash requirements and accounting policies for it, (4) the maximum amount of loss due to credit risk that would be incurred if the counterparties failed completely to perform according to the terms of the contracts, and any security or collateral that proved to be of no value, (5) the entity's policy of requiring collateral or other security to support financial instruments subject to credit risk, information about access to collateral or other security, and a brief description of the security supporting those financial instruments, and (6) the policy of entering into and a brief description of master netting arrangements to mitigate the credit risk, and the extent to which such arrangements would reduce the maximum amount of loss due to credit risk.",
        "label": "Concentration Risk Credit Risk Financial Instruments Off Balance Sheet Risk",
        "terseLabel": "Description of significant off-balance sheet risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r123",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation Policy [Text Block]",
        "terseLabel": "Principles of consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction In Progress [Member]",
        "terseLabel": "Construction-In-Progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetNetCurrent": {
     "auth_ref": [
      "r364",
      "r366",
      "r385"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.",
        "label": "Contract With Customer Asset Net Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCollaborationAgreementWithPharmingGroupNVAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r364",
      "r365",
      "r385"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract With Customer Liability Noncurrent",
        "terseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCollaborationAgreementWithPharmingGroupNVAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [
      "r336",
      "r337",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Convertible Preferred Stock [Member]",
        "terseLabel": "Convertible Preferred Shares"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "auth_ref": [
      "r30",
      "r31",
      "r348",
      "r354",
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.",
        "label": "Convertible Preferred Stock Shares Issued Upon Conversion",
        "verboseLabel": "Ordinary shares Issuable Upon Conversion"
       }
      }
     },
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r391",
      "r406",
      "r683"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate Bonds"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesScheduleOfCashEquivalentsAndMarketableSecuritiesDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesScheduleOfLevel2CashEquivalentsAndMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r90",
      "r608"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 10140.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost Of Goods And Services Sold",
        "terseLabel": "Cost of product sales"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 10130.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs And Expenses",
        "totalLabel": "Total costs and operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r133",
      "r475",
      "r484"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDetails": {
       "order": 10070.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal Tax Expense Benefit",
        "terseLabel": "Federal\u2014United States"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r133",
      "r475"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDetails": {
       "order": 10100.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense Benefit",
        "terseLabel": "United Kingdom"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r133",
      "r475",
      "r484",
      "r486"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense Benefit",
        "totalLabel": "Total current (benefit) provision"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense Benefit Continuing Operations [Abstract]",
        "terseLabel": "Current (benefit) provision"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r133",
      "r475",
      "r484"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDetails": {
       "order": 10080.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current State And Local Tax Expense Benefit",
        "terseLabel": "State\u2014United States"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r128",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r315",
      "r322",
      "r323",
      "r325",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Notes Payable"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r26",
      "r27",
      "r28",
      "r131",
      "r138",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r305",
      "r311",
      "r312",
      "r313",
      "r314",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r328",
      "r329",
      "r330",
      "r331",
      "r554",
      "r628",
      "r629",
      "r653"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument Basis Spread On Variable Rate1",
        "terseLabel": "Debt instrument, annual interest rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r28",
      "r326",
      "r629",
      "r653"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableSummaryOfFuturePrincipalPaymentsDueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableSummaryOfFuturePrincipalPaymentsDueDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Debt Instrument Carrying Amount",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableSummaryOfFuturePrincipalPaymentsDueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentCovenantDescription": {
     "auth_ref": [
      "r28",
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of minimum financial levels (for example, tangible net worth and working capital) and achievement of certain financial ratios (for example, working capital ratio and debt service coverage ratio), and adherence to certain clauses which generally require or restrict certain actions (for example, entering into a debt arrangement with equal or greater seniority, and selling or discontinuing a certain business segment or material subsidiary) to be in compliance with the covenant clauses of the debt agreement. May also include a discussion of the adverse consequences that would result if the entity violates or fails to satisfy the covenants.",
        "label": "Debt Instrument Covenant Description",
        "terseLabel": "Line of credit facility covenants description"
       }
      }
     },
     "localname": "DebtInstrumentCovenantDescription",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "auth_ref": [
      "r54",
      "r318",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average effective interest rate during the reporting period.",
        "label": "Debt Instrument Interest Rate During Period",
        "terseLabel": "Debt instrument, effective annual interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r55",
      "r131",
      "r138",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r305",
      "r311",
      "r312",
      "r313",
      "r314",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r328",
      "r329",
      "r330",
      "r331",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument Name [Domain]",
        "terseLabel": "Debt Instrument, Name"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "auth_ref": [
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about timing of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument Redemption Period [Axis]",
        "terseLabel": "Debt Instrument, Redemption, Period"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "auth_ref": [
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features.",
        "label": "Debt Instrument Redemption Period [Domain]",
        "terseLabel": "Debt Instrument, Redemption, Period"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodThreeMember": {
     "auth_ref": [
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period three representing third most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument Redemption Period Three [Member]",
        "terseLabel": "TThird Tranche (Term Loan Available from July 1, 2023 to July 1, 2024)"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodThreeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": {
     "auth_ref": [
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument Redemption Period Two [Member]",
        "terseLabel": "Second Tranche (Term Loan Available from July 1, 2022 to July 1, 2023)"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r55",
      "r131",
      "r138",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r305",
      "r311",
      "r312",
      "r313",
      "r314",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r324",
      "r328",
      "r329",
      "r330",
      "r331",
      "r354",
      "r358",
      "r359",
      "r360",
      "r551",
      "r552",
      "r554",
      "r555",
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Debt Instrument [Table]",
        "terseLabel": "Debt Instrument [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": {
     "auth_ref": [
      "r217",
      "r230",
      "r231",
      "r232"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesScheduleOfLevel2CashEquivalentsAndMarketableSecuritiesDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities Available For Sale Allowance For Credit Loss",
        "terseLabel": "Credit Losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesScheduleOfLevel2CashEquivalentsAndMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.",
        "label": "Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Text Block]",
        "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r133",
      "r476",
      "r484"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal Income Tax Expense Benefit",
        "terseLabel": "Federal\u2014United States"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsNoncurrentNet": {
     "auth_ref": [
      "r47",
      "r553"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureOtherAssetsScheduleOfOtherAssetsDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Deferred Finance Costs Noncurrent Net",
        "terseLabel": "Deferred financing costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsNoncurrentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureOtherAssetsScheduleOfOtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r133",
      "r476",
      "r484"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDetails": {
       "order": 10050.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Foreign Income Tax Expense Benefit",
        "terseLabel": "United Kingdom"
       }
      }
     },
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r113",
      "r133",
      "r476",
      "r484",
      "r485",
      "r486"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      },
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10240.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense Benefit",
        "terseLabel": "Deferred income taxes",
        "totalLabel": "Total deferred provision (benefit)"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense Benefit Continuing Operations [Abstract]",
        "terseLabel": "Deferred provision (benefit)"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredOtherTaxExpenseBenefit": {
     "auth_ref": [
      "r133",
      "r477",
      "r483"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDetails": {
       "order": 10060.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other deferred income tax expense (benefit) pertaining to income (loss) from continuing operations. For example, but not limited to, acquisition-date income tax benefits or expenses recognized from changes in the acquirer's valuation allowance for its previously existing deferred tax assets resulting from a business combination and adjustments to beginning-of-year balance of a valuation allowance because of a change in circumstance causing a change in judgment about the realizability of the related deferred tax asset in future periods.",
        "label": "Deferred Other Tax Expense Benefit",
        "terseLabel": "Other foreign"
       }
      }
     },
     "localname": "DeferredOtherTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueCurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10150.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Deferred Revenue Current",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredRevenueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueNoncurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10100.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Deferred Revenue Noncurrent",
        "terseLabel": "Deferred revenue, net of current portion"
       }
      }
     },
     "localname": "DeferredRevenueNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r133",
      "r476",
      "r484"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDetails": {
       "order": 10040.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred State And Local Income Tax Expense Benefit",
        "terseLabel": "State\u2014United States"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r466"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesTaxesDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r468"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureOtherAssetsScheduleOfOtherAssetsDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets Liabilities Net",
        "terseLabel": "Deferred tax assets",
        "totalLabel": "Other non-current assets (net deferred tax assets and liabilities)"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesTaxesDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureOtherAssetsScheduleOfOtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r473",
      "r474"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesTaxesDetails": {
       "order": 10040.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r473",
      "r474"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesTaxesDetails": {
       "order": 10110.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "auth_ref": [],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesTaxesDetails": {
       "order": 10100.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Assets Property Plant And Equipment",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r471",
      "r473",
      "r474"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesTaxesDetails": {
       "order": 10060.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets Tax Credit Carryforwards Research",
        "terseLabel": "Research and development credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r473",
      "r474"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesTaxesDetails": {
       "order": 10070.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "auth_ref": [
      "r473",
      "r474"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesTaxesDetails": {
       "order": 10080.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.",
        "label": "Deferred Tax Assets Tax Deferred Expense Reserves And Accruals",
        "terseLabel": "Accruals"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r467"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesTaxesDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets Valuation Allowance",
        "negatedLabel": "Valuation allowance",
        "negatedPeriodEndLabel": "Valuation allowance as of end of year",
        "negatedPeriodStartLabel": "Valuation allowance as of beginning of year"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfChangesInValuationAllowanceForDeferredTaxAssetsRelatedPrimarilyToIncreaseInUKNetOperatingLossCarryforwardsDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r409"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan Cost Recognized",
        "terseLabel": "Contribution expenses"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.",
        "label": "Defined Contribution Plan Employer Matching Contribution Percent",
        "terseLabel": "Maximum annual contribution employer matches per employee, percent"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DepositsAssetsNoncurrent": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureOtherAssetsScheduleOfOtherAssetsDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.",
        "label": "Deposits Assets Noncurrent",
        "terseLabel": "Deposits"
       }
      }
     },
     "localname": "DepositsAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureOtherAssetsScheduleOfOtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r113",
      "r251"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "verboseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r113",
      "r184"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10180.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation Depletion And Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DetailsOfImpairmentOfLongLivedAssetsHeldAndUsedByAssetTextBlock": {
     "auth_ref": [
      "r255",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for impairment of long-lived assets held and used by an entity which includes a description of the impaired long-lived asset and facts and circumstances leading to the impairment, aggregate amount of the impairment loss and where the loss is located in the income statement, method(s) for determining fair value, and the segment in which the impaired long-lived asset is reported.",
        "label": "Details Of Impairment Of Long Lived Assets Held And Used By Asset [Text Block]",
        "terseLabel": "Summary of Impairment of Long Lived Assets"
       }
      }
     },
     "localname": "DetailsOfImpairmentOfLongLivedAssetsHeldAndUsedByAssetTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRestructuringChargesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Disclosure Of Compensation Related Costs Share Based Payments [Text Block]",
        "terseLabel": "Share-based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DividendsCommonStock": {
     "auth_ref": [
      "r361",
      "r648"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).",
        "label": "Dividends Common Stock",
        "terseLabel": "Ordinary shares dividends declared"
       }
      }
     },
     "localname": "DividendsCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareholdersEquityAndConvertiblePreferredSharesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Country [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r137",
      "r288",
      "r290",
      "r291",
      "r295",
      "r296",
      "r297",
      "r580",
      "r635",
      "r664"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.",
        "label": "Due To Related Parties Current And Noncurrent",
        "terseLabel": "Cash payments"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarliestTaxYearMember": {
     "auth_ref": [
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earliest identified tax year.",
        "label": "Earliest Tax Year [Member]",
        "terseLabel": "Earliest Tax Year"
       }
      }
     },
     "localname": "EarliestTaxYearMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share Basic And Diluted",
        "terseLabel": "Net loss per share attributable to ordinary shareholders, basic and diluted"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r162",
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share Policy [Text Block]",
        "terseLabel": "Net loss per share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r539"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10040.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations",
        "terseLabel": "Effect of exchange rate changes on cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 10020.0,
       "parentTag": "ortx_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee Related Liabilities Current",
        "terseLabel": "Accrued payroll and related expenses"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]",
        "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r442"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized",
        "terseLabel": "Total unrecognized compensation cost of stock option and time-based RSUs"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1",
        "terseLabel": "Compensation cost expected to be recognized weighted average period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r442"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options",
        "terseLabel": "Total unrecognized compensation cost of performance-based RSUs"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Share options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSecuritiesExcludedInComputationOfDilutedNetLossPerOrdinaryShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r2",
      "r79",
      "r80",
      "r81",
      "r140",
      "r141",
      "r142",
      "r145",
      "r150",
      "r152",
      "r167",
      "r229",
      "r353",
      "r361",
      "r448",
      "r449",
      "r450",
      "r480",
      "r481",
      "r519",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r546",
      "r677",
      "r678",
      "r679",
      "r727"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EscrowDeposit": {
     "auth_ref": [
      "r634",
      "r688"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy.",
        "label": "Escrow Deposit",
        "terseLabel": "Escrow Deposit"
       }
      }
     },
     "localname": "EscrowDeposit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Abstract]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesScheduleOfCashEquivalentsAndMarketableSecuritiesDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesScheduleOfLevel2CashEquivalentsAndMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r521",
      "r522",
      "r523",
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesScheduleOfCashEquivalentsAndMarketableSecuritiesDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesScheduleOfLevel2CashEquivalentsAndMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount": {
     "auth_ref": [
      "r523"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.",
        "label": "Fair Value Assets Level1 To Level2 Transfers Amount",
        "terseLabel": "Fair value of financial assets transfers between level 1 to level 2"
       }
      }
     },
     "localname": "FairValueAssetsLevel1ToLevel2TransfersAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount": {
     "auth_ref": [
      "r523"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.",
        "label": "Fair Value Assets Level2 To Level1 Transfers Amount",
        "terseLabel": "Fair value of financial assets transfers between level 2 to level 1"
       }
      }
     },
     "localname": "FairValueAssetsLevel2ToLevel1TransfersAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain]",
        "terseLabel": "Asset Class"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesScheduleOfCashEquivalentsAndMarketableSecuritiesDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesScheduleOfLevel2CashEquivalentsAndMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r521",
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Fair Value By Asset Class [Axis]",
        "terseLabel": "Asset Class"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesScheduleOfCashEquivalentsAndMarketableSecuritiesDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesScheduleOfLevel2CashEquivalentsAndMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r313",
      "r328",
      "r329",
      "r391",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r406",
      "r522",
      "r592",
      "r593",
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value By Fair Value Hierarchy Level [Axis]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesScheduleOfCashEquivalentsAndMarketableSecuritiesDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesScheduleOfLevel2CashEquivalentsAndMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements and Marketable Securities"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r313",
      "r391",
      "r393",
      "r398",
      "r406",
      "r522",
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value Inputs Level1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesScheduleOfCashEquivalentsAndMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r313",
      "r328",
      "r329",
      "r391",
      "r393",
      "r398",
      "r406",
      "r522",
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value Inputs Level2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesScheduleOfCashEquivalentsAndMarketableSecuritiesDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesScheduleOfLevel2CashEquivalentsAndMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r313",
      "r328",
      "r329",
      "r391",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r406",
      "r522",
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value Inputs Level3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesScheduleOfCashEquivalentsAndMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r313",
      "r328",
      "r329",
      "r391",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r406",
      "r592",
      "r593",
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Measurements Fair Value Hierarchy [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesScheduleOfCashEquivalentsAndMarketableSecuritiesDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesScheduleOfLevel2CashEquivalentsAndMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite Lived Intangible Asset Useful Life",
        "terseLabel": "Intangible asset, useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIntangibleAssetsNetAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r243"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfIntangibleAssetsNetOfAccumulatedAmortizationDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite Lived Intangible Assets Accumulated Amortization",
        "negatedLabel": "Intangible Assets, Accumulated Amortized",
        "terseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIntangibleAssetsNetAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfIntangibleAssetsNetOfAccumulatedAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfEstimatedFutureAmortizationForIntangibleAssetsDetails": {
       "order": 10060.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite Lived Intangible Assets Amortization Expense After Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfEstimatedFutureAmortizationForIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r244"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfEstimatedFutureAmortizationForIntangibleAssetsDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite Lived Intangible Assets Amortization Expense Next Twelve Months",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfEstimatedFutureAmortizationForIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r244"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfEstimatedFutureAmortizationForIntangibleAssetsDetails": {
       "order": 10050.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite Lived Intangible Assets Amortization Expense Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfEstimatedFutureAmortizationForIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r244"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfEstimatedFutureAmortizationForIntangibleAssetsDetails": {
       "order": 10040.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite Lived Intangible Assets Amortization Expense Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfEstimatedFutureAmortizationForIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r244"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfEstimatedFutureAmortizationForIntangibleAssetsDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite Lived Intangible Assets Amortization Expense Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfEstimatedFutureAmortizationForIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r244"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfEstimatedFutureAmortizationForIntangibleAssetsDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite Lived Intangible Assets Amortization Expense Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfEstimatedFutureAmortizationForIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r238",
      "r240",
      "r243",
      "r246",
      "r609",
      "r612"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite Lived Intangible Assets By Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfIntangibleAssetsNetOfAccumulatedAmortizationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r243",
      "r612"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfIntangibleAssetsNetOfAccumulatedAmortizationDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite Lived Intangible Assets Gross",
        "terseLabel": "Intangible Assets, Cost"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfIntangibleAssetsNetOfAccumulatedAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfIntangibleAssetsNetOfAccumulatedAmortizationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r238",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite Lived Intangible Assets Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfIntangibleAssetsNetOfAccumulatedAmortizationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r243",
      "r609"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfEstimatedFutureAmortizationForIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfIntangibleAssetsNetOfAccumulatedAmortizationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite Lived Intangible Assets Net",
        "totalLabel": "Intangible Assets, Net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfEstimatedFutureAmortizationForIntangibleAssetsDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfIntangibleAssetsNetOfAccumulatedAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyExchangeRateTranslation1": {
     "auth_ref": [
      "r547",
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign exchange rate used to translate amounts denominated in functional currency to reporting currency.",
        "label": "Foreign Currency Exchange Rate Translation1",
        "terseLabel": "Lease translation rate",
        "verboseLabel": "Exchange rate, Euro to U.S. Dollar"
       }
      }
     },
     "localname": "ForeignCurrencyExchangeRateTranslation1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfAnnualCommitmentsAssociatedWithContractParentheticalDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumBaseRentCommitmentsUnderOperatingLeasesParentheticalDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r535",
      "r536",
      "r537",
      "r538"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain Loss Before Tax",
        "terseLabel": "Foreign currency transaction gain (loss)",
        "verboseLabel": "Foreign currency translation"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfAmountsRecognizedToOffsetResearchAndDevelopmentExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions And Translations Policy [Text Block]",
        "terseLabel": "Foreign currency"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture And Fixtures [Member]",
        "terseLabel": "Furniture and Fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill And Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r248",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment Or Disposal Of Long Lived Assets Policy [Text Block]",
        "terseLabel": "Impairment of long-lived assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r134",
      "r487"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfNetLossBeforeIncomeTaxesDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income Loss From Continuing Operations Before Income Taxes Domestic",
        "terseLabel": "U.K."
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfNetLossBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r84",
      "r186",
      "r194",
      "r197",
      "r200",
      "r202",
      "r625",
      "r638",
      "r643",
      "r668"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfNetLossBeforeIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 10050.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest",
        "totalLabel": "Net loss before income tax"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfNetLossBeforeIncomeTaxesDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r134",
      "r487"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfNetLossBeforeIncomeTaxesDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income Loss From Continuing Operations Before Income Taxes Foreign",
        "terseLabel": "Non-U.K."
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfNetLossBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r256",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfAmountsRecognizedToOffsetResearchAndDevelopmentExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfAmountsRecognizedToOffsetResearchAndDevelopmentExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxCreditsAndAdjustments": {
     "auth_ref": [
      "r114"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A credit or adjustment for government or taxing authority authorized decrease in taxes owed as a result of meeting certain tax policy conditions.",
        "label": "Income Tax Credits And Adjustments",
        "terseLabel": "Recognition of credit claims as offset to research and development expense"
       }
      }
     },
     "localname": "IncomeTaxCreditsAndAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfAmountsRecognizedToOffsetResearchAndDevelopmentExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r135",
      "r461",
      "r464",
      "r470",
      "r482",
      "r488",
      "r490",
      "r491",
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r136",
      "r151",
      "r152",
      "r185",
      "r459",
      "r483",
      "r489",
      "r669"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 10060.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense Benefit",
        "negatedLabel": "Income tax (expense) benefit",
        "totalLabel": "Total provision (benefit) for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r78",
      "r457",
      "r458",
      "r464",
      "r465",
      "r469",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax Policy [Text Block]",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r460"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [
      "r456",
      "r460"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetails": {
       "order": 10040.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.",
        "label": "Income Tax Reconciliation Change In Enacted Tax Rate",
        "terseLabel": "Change in tax rates"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r460"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetails": {
       "order": 10090.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).",
        "label": "Income Tax Reconciliation Foreign Income Tax Rate Differential",
        "terseLabel": "Foreign rate differential"
       }
      }
     },
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r460"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate",
        "terseLabel": "Income taxes at United Kingdom statutory rate"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r460"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetails": {
       "order": 10080.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).",
        "label": "Income Tax Reconciliation State And Local Income Taxes",
        "terseLabel": "U.S. state income taxes"
       }
      }
     },
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCredits": {
     "auth_ref": [
      "r460"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetails": {
       "order": 10050.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Income Tax Reconciliation Tax Credits",
        "negatedLabel": "Receipt of credit claims",
        "negatedTerseLabel": "Tax credits"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfAmountsRecognizedToOffsetResearchAndDevelopmentExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r117"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid Net",
        "terseLabel": "Cash paid for taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r112"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase Decrease In Accounts Payable",
        "negatedLabel": "Payments on accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r112"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10270.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase Decrease In Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r112",
      "r602"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10320.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase Decrease In Contract With Customer Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": {
     "auth_ref": [
      "r112"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.",
        "label": "Increase Decrease In Deferred Income Taxes",
        "terseLabel": "Increase in net deferred tax assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10330.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase Decrease In Other Noncurrent Liabilities",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r112"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10290.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase Decrease In Prepaid Deferred Expense And Other Assets",
        "negatedLabel": "Prepaid expenses, other current assets, and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r239",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite Lived Intangible Assets By Major Class [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareholdersEquityAndConvertiblePreferredSharesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r239",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite Lived Intangible Assets Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareholdersEquityAndConvertiblePreferredSharesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Intangible Assets, Net"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIntangibleAssetsNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "auth_ref": [
      "r124",
      "r242",
      "r605",
      "r606",
      "r607",
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.",
        "label": "Intangible Assets Finite Lived Policy",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r237",
      "r241"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10230.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets Net Excluding Goodwill",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r83",
      "r183",
      "r550",
      "r553",
      "r642"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 10100.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r94",
      "r319",
      "r327",
      "r330",
      "r331"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense Debt",
        "terseLabel": "Debt instrument, interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r104",
      "r109",
      "r117"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid Net",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r6",
      "r61",
      "r588"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory Net",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r16",
      "r62",
      "r125",
      "r166",
      "r233",
      "r234",
      "r235",
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory Policy [Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r92",
      "r182"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 10090.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsAndCash": {
     "auth_ref": [
      "r663"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of investments and unrestricted cash as of the balance sheet date.",
        "label": "Investments And Cash",
        "terseLabel": "Cash and cash equivalent investments"
       }
      }
     },
     "localname": "InvestmentsAndCash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified By Contractual Maturity Date Table [Text Block]",
        "terseLabel": "Schedule of Available-for-Sale Debt Marketable Securities by contractual Maturity"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LatestTaxYearMember": {
     "auth_ref": [
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Latest identified tax year.",
        "label": "Latest Tax Year [Member]",
        "terseLabel": "Latest Tax Year"
       }
      }
     },
     "localname": "LatestTaxYearMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseContractualTermAxis": {
     "auth_ref": [
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Axis]",
        "terseLabel": "Lease Contractual Term"
       }
      }
     },
     "localname": "LeaseContractualTermAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseContractualTermDomain": {
     "auth_ref": [
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Domain]",
        "terseLabel": "Lease Contractual Term"
       }
      }
     },
     "localname": "LeaseContractualTermDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r571",
      "r573"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfLeaseCostUnderOperatingLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease Cost",
        "totalLabel": "Total lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfLeaseCostUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease Cost Table [Text Block]",
        "terseLabel": "Summary of Lease Cost Under Operating Leases"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseExpirationDate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format.",
        "label": "Lease Expiration Date1",
        "terseLabel": "Operating leases expiration term"
       }
      }
     },
     "localname": "LeaseExpirationDate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee Leases Policy [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments.",
        "label": "Lessee Operating Lease Discount Rate",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRestructuringChargesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": {
     "auth_ref": [
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether lessee has option to extend operating lease.",
        "label": "Lessee Operating Lease Existence Of Option To Extend",
        "terseLabel": "Lessee, operating Lease, existence of option to extend [true false]"
       }
      }
     },
     "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee Operating Lease Liability Maturity Table [Text Block]",
        "terseLabel": "Schedule of Future Minimum Base Rent Commitments Under Operating Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r572"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumBaseRentCommitmentsUnderOperatingLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumBaseRentCommitmentsUnderOperatingLeasesDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee Operating Lease Liability Payments Due",
        "totalLabel": "Total future minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumBaseRentCommitmentsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r572"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumBaseRentCommitmentsUnderOperatingLeasesDetails": {
       "order": 10180.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due After Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumBaseRentCommitmentsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r572"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumBaseRentCommitmentsUnderOperatingLeasesDetails": {
       "order": 10130.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Next Twelve Months",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumBaseRentCommitmentsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r572"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumBaseRentCommitmentsUnderOperatingLeasesDetails": {
       "order": 10170.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumBaseRentCommitmentsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r572"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumBaseRentCommitmentsUnderOperatingLeasesDetails": {
       "order": 10160.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumBaseRentCommitmentsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r572"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumBaseRentCommitmentsUnderOperatingLeasesDetails": {
       "order": 10150.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumBaseRentCommitmentsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r572"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumBaseRentCommitmentsUnderOperatingLeasesDetails": {
       "order": 10140.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumBaseRentCommitmentsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r572"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumBaseRentCommitmentsUnderOperatingLeasesDetails2": {
       "order": 10010.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee Operating Lease Liability Undiscounted Excess Amount",
        "negatedLabel": "Less: imputed interest",
        "terseLabel": "Undiscounted cash flow estimate"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumBaseRentCommitmentsUnderOperatingLeasesDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRestructuringChargesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "auth_ref": [
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.",
        "label": "Lessee Operating Lease Option To Extend",
        "terseLabel": "Lessee, operating lease, option to extend"
       }
      }
     },
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee Operating Lease Term Of Contract",
        "terseLabel": "Operating lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessor Operating Lease Payments Fiscal Year Maturity [Abstract]",
        "terseLabel": "Gross sublease receipts"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsFiscalYearMaturityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumBaseRentCommitmentsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceived": {
     "auth_ref": [
      "r575"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumBaseRentCommitmentsUnderOperatingLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payments to be received by lessor for operating lease.",
        "label": "Lessor Operating Lease Payments To Be Received",
        "negatedTotalLabel": "Total future minimum lease payments"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceived",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumBaseRentCommitmentsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears": {
     "auth_ref": [
      "r575"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumBaseRentCommitmentsUnderOperatingLeasesDetails": {
       "order": 10110.0,
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payment to be received by lessor for operating lease in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessor Operating Lease Payments To Be Received Five Years",
        "negatedLabel": "2026"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceivedFiveYears",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumBaseRentCommitmentsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears": {
     "auth_ref": [
      "r575"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumBaseRentCommitmentsUnderOperatingLeasesDetails": {
       "order": 10100.0,
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payment to be received by lessor for operating lease in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessor Operating Lease Payments To Be Received Four Years",
        "negatedLabel": "2025"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceivedFourYears",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumBaseRentCommitmentsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths": {
     "auth_ref": [
      "r575"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumBaseRentCommitmentsUnderOperatingLeasesDetails": {
       "order": 10070.0,
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payment to be received by lessor for operating lease in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessor Operating Lease Payments To Be Received Next Twelve Months",
        "negatedLabel": "2022"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumBaseRentCommitmentsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter": {
     "auth_ref": [
      "r575"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumBaseRentCommitmentsUnderOperatingLeasesDetails": {
       "order": 10120.0,
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payment to be received by lessor for operating lease after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessor Operating Lease Payments To Be Received Thereafter",
        "negatedLabel": "Thereafter"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceivedThereafter",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumBaseRentCommitmentsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears": {
     "auth_ref": [
      "r575"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumBaseRentCommitmentsUnderOperatingLeasesDetails": {
       "order": 10090.0,
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payment to be received by lessor for operating lease in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessor Operating Lease Payments To Be Received Three Years",
        "negatedLabel": "2024"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceivedThreeYears",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumBaseRentCommitmentsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears": {
     "auth_ref": [
      "r575"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumBaseRentCommitmentsUnderOperatingLeasesDetails": {
       "order": 10080.0,
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payment to be received by lessor for operating lease in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessor Operating Lease Payments To Be Received Two Years",
        "negatedLabel": "2023"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceivedTwoYears",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumBaseRentCommitmentsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r51",
      "r132",
      "r196",
      "r223",
      "r285",
      "r286",
      "r287",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r296",
      "r297",
      "r503",
      "r508",
      "r509",
      "r528",
      "r586",
      "r587"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10010.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r39",
      "r132",
      "r223",
      "r528",
      "r588",
      "r631",
      "r659"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities And Stockholders Equity",
        "totalLabel": "Total liabilities and shareholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities And Stockholders Equity [Abstract]",
        "terseLabel": "Liabilities and shareholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r53",
      "r132",
      "r223",
      "r285",
      "r286",
      "r287",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r296",
      "r297",
      "r503",
      "r508",
      "r509",
      "r528",
      "r586",
      "r587",
      "r588"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10080.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]",
        "terseLabel": "License Intangibles"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfIntangibleAssetsNetOfAccumulatedAmortizationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityCovenantTerms": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the conditions for borrowing under the credit facility including the nature of any restrictions.",
        "label": "Line Of Credit Facility Covenant Terms",
        "terseLabel": "Line of Credit Facility, Covenant Terms"
       }
      }
     },
     "localname": "LineOfCreditFacilityCovenantTerms",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityFrequencyOfPayments": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the frequency of periodic payments, which may be presented in a variety of ways (for example, monthly, quarterly, annually).",
        "label": "Line Of Credit Facility Frequency Of Payments",
        "terseLabel": "Line of credit facility, frequency of payments"
       }
      }
     },
     "localname": "LineOfCreditFacilityFrequencyOfPayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityInitiationDate1": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date the credit facility first became available, in YYYY-MM-DD format.",
        "label": "Line Of Credit Facility Initiation Date1",
        "terseLabel": "Line of credit facility agreement date"
       }
      }
     },
     "localname": "LineOfCreditFacilityInitiationDate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_LineOfCreditFacilityInterestRateDescription": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of interest rate for borrowing under credit facility. Includes, but is not limited to, terms and method for determining interest rate.",
        "label": "Line Of Credit Facility Interest Rate Description",
        "terseLabel": "Line of credit facility interest rate description"
       }
      }
     },
     "localname": "LineOfCreditFacilityInterestRateDescription",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r49"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line Of Credit Facility Maximum Borrowing Capacity",
        "terseLabel": "Credit facility maximum borrowings"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityPeriodicPaymentInterest": {
     "auth_ref": [
      "r49"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the required periodic payment applied to interest.",
        "label": "Line Of Credit Facility Periodic Payment Interest",
        "terseLabel": "Final payment amount"
       }
      }
     },
     "localname": "LineOfCreditFacilityPeriodicPaymentInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {
     "auth_ref": [
      "r49"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).",
        "label": "Line Of Credit Facility Remaining Borrowing Capacity",
        "terseLabel": "Credit facility, remaining borrowings"
       }
      }
     },
     "localname": "LineOfCreditFacilityRemainingBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtByMaturityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Debt By Maturity [Abstract]"
       }
      }
     },
     "localname": "LongTermDebtByMaturityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableSummaryOfFuturePrincipalPaymentsDueDetails2": {
       "order": 10010.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long Term Debt Current",
        "negatedLabel": "Less current portion"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableSummaryOfFuturePrincipalPaymentsDueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": {
     "auth_ref": [
      "r138",
      "r282",
      "r317"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableSummaryOfFuturePrincipalPaymentsDueDetails": {
       "order": 10060.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long Term Debt Maturities Repayments Of Principal After Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableSummaryOfFuturePrincipalPaymentsDueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r138",
      "r282",
      "r317"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableSummaryOfFuturePrincipalPaymentsDueDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long Term Debt Maturities Repayments Of Principal In Next Twelve Months",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableSummaryOfFuturePrincipalPaymentsDueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "auth_ref": [
      "r138",
      "r282",
      "r317"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableSummaryOfFuturePrincipalPaymentsDueDetails": {
       "order": 10050.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long Term Debt Maturities Repayments Of Principal In Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableSummaryOfFuturePrincipalPaymentsDueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r138",
      "r282",
      "r317"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableSummaryOfFuturePrincipalPaymentsDueDetails": {
       "order": 10040.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long Term Debt Maturities Repayments Of Principal In Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableSummaryOfFuturePrincipalPaymentsDueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r138",
      "r282",
      "r317"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableSummaryOfFuturePrincipalPaymentsDueDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long Term Debt Maturities Repayments Of Principal In Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableSummaryOfFuturePrincipalPaymentsDueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r138",
      "r282",
      "r317"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableSummaryOfFuturePrincipalPaymentsDueDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long Term Debt Maturities Repayments Of Principal In Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableSummaryOfFuturePrincipalPaymentsDueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableSummaryOfFuturePrincipalPaymentsDueDetails2": {
       "order": 10040.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      },
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableSummaryOfNotesPayableDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long Term Debt Noncurrent",
        "terseLabel": "Notes payable, long term",
        "totalLabel": "Notes payable, long term"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableSummaryOfFuturePrincipalPaymentsDueDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableSummaryOfNotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermNotesAndLoansAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Notes And Loans [Abstract]"
       }
      }
     },
     "localname": "LongTermNotesAndLoansAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermNotesPayable": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10090.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.",
        "label": "Long Term Notes Payable",
        "terseLabel": "Notes payable, long-term"
       }
      }
     },
     "localname": "LongTermNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Longterm Debt Type [Axis]",
        "terseLabel": "Long-term Debt, Type"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r55",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Longterm Debt Type [Domain]",
        "terseLabel": "Long-term Debt, Type"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecurities": {
     "auth_ref": [
      "r637"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10260.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security.",
        "label": "Marketable Securities",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities [Abstract]",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesScheduleOfCashEquivalentsAndMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r646"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities Policy",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MarketableSecuritiesUnrealizedGainLoss": {
     "auth_ref": [
      "r88"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in marketable security.",
        "label": "Marketable Securities Unrealized Gain Loss",
        "terseLabel": "Unrealized gain (loss) on marketable debt securities"
       }
      }
     },
     "localname": "MarketableSecuritiesUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesScheduleOfCashEquivalentsAndMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10030.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided By Used In Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10020.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided By Used In Investing Activities",
        "totalLabel": "Net cash (used in) provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r107",
      "r111",
      "r114"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10010.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided By Used In Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r3",
      "r72",
      "r75",
      "r81",
      "r85",
      "r114",
      "r132",
      "r144",
      "r146",
      "r147",
      "r148",
      "r149",
      "r151",
      "r152",
      "r158",
      "r186",
      "r194",
      "r197",
      "r200",
      "r202",
      "r223",
      "r285",
      "r286",
      "r287",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r296",
      "r297",
      "r520",
      "r528",
      "r639",
      "r665"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 10010.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income Loss",
        "totalLabel": "Net loss attributable to ordinary shareholders",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleDescription": {
     "auth_ref": [
      "r143",
      "r148",
      "r153",
      "r154",
      "r164",
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure related to a new accounting pronouncement or a change in accounting principle, including the nature and reason for the change and the effect of the change on prior periods and the current period.",
        "label": "New Accounting Pronouncement Or Change In Accounting Principle Description",
        "terseLabel": "New accounting pronouncement or change in accounting principle, description"
       }
      }
     },
     "localname": "NewAccountingPronouncementOrChangeInAccountingPrincipleDescription",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements Policy Policy [Text Block]",
        "terseLabel": "Recent accounting pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing And Financing Items [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash investing and financing activities"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 10080.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income Expense",
        "totalLabel": "Total other (expense) income, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income Expense [Abstract]",
        "terseLabel": "Other (expense) income:"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NontradeReceivablesCurrent": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 10060.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of amounts currently receivable other than from customers. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.",
        "label": "Nontrade Receivables Current",
        "terseLabel": "Non-trade receivables"
       }
      }
     },
     "localname": "NontradeReceivablesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableCurrent": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10170.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.",
        "label": "Notes Payable Current",
        "terseLabel": "Notes payable, current"
       }
      }
     },
     "localname": "NotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OpenTaxYear": {
     "auth_ref": [
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax year that remains open to examination under enacted tax laws, in YYYY format.",
        "label": "Open Tax Year",
        "terseLabel": "Income tax year open to examination"
       }
      }
     },
     "localname": "OpenTaxYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearListItemType"
    },
    "us-gaap_OperatingCostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Costs And Expenses [Abstract]",
        "terseLabel": "Costs and operating expenses"
       }
      }
     },
     "localname": "OperatingCostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r186",
      "r194",
      "r197",
      "r200",
      "r202"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 10070.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income Loss",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseImpairmentLoss": {
     "auth_ref": [
      "r557"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfLeaseCostUnderOperatingLeasesDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      },
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRestructuringChargesSummaryOfImpairmentOfLongLivedAssetsDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_AssetImpairmentCharges",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from impairment of right-of-use asset from operating lease.",
        "label": "Operating Lease Impairment Loss",
        "positiveLabel": "Impairment of right-of-use assets",
        "terseLabel": "Operating lease right-of-use asset",
        "verboseLabel": "Right of use asset, impairment charge"
       }
      }
     },
     "localname": "OperatingLeaseImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfLeaseCostUnderOperatingLeasesDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRestructuringChargesAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRestructuringChargesSummaryOfImpairmentOfLongLivedAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Liabilities Payments Due [Abstract]",
        "terseLabel": "Gross lease payments"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumBaseRentCommitmentsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r559"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumBaseRentCommitmentsUnderOperatingLeasesDetails2": {
       "order": 10020.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease Liability",
        "positiveLabel": "Operating lease liabilities",
        "terseLabel": "Total operating lease payments"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumBaseRentCommitmentsUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r559"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10160.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease Liability Current",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r559"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10110.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease Liability Noncurrent",
        "terseLabel": "Operating lease liabilities, net of current portion",
        "verboseLabel": "Operating lease, liability, noncurrent"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r560",
      "r567"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease Payments",
        "terseLabel": "Operating cash flows used for operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfLeaseCostUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r558"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10200.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease Right Of Use Asset",
        "terseLabel": "Operating lease right-of-use-assets",
        "verboseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRestructuringChargesAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r570",
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease Weighted Average Discount Rate Percent",
        "terseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfLeaseCostUnderOperatingLeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r569",
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease Weighted Average Remaining Lease Term1",
        "terseLabel": "Weighted-average remaining lease term (years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfLeaseCostUnderOperatingLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r471"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization Consolidation And Presentation Of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r13",
      "r14",
      "r15",
      "r52"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 10050.0,
       "parentTag": "ortx_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities Current",
        "terseLabel": "Accrued other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets.",
        "label": "Other Assets Disclosure [Text Block]",
        "terseLabel": "Other Assets"
       }
      }
     },
     "localname": "OtherAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureOtherAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureOtherAssetsScheduleOfOtherAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10240.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets Noncurrent",
        "terseLabel": "Other assets",
        "totalLabel": "Total other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureOtherAssetsScheduleOfOtherAssetsDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrentDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets Noncurrent Disclosure [Abstract]"
       }
      }
     },
     "localname": "OtherAssetsNoncurrentDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Other Commitments [Line Items]",
        "terseLabel": "Other Commitments [Line Items]"
       }
      }
     },
     "localname": "OtherCommitmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfAnnualCommitmentsAssociatedWithContractDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about obligations resulting from other commitments.",
        "label": "Other Commitments [Table]",
        "terseLabel": "Other Commitments [Table]"
       }
      }
     },
     "localname": "OtherCommitmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfAnnualCommitmentsAssociatedWithContractDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 10030.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax",
        "terseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r73",
      "r76",
      "r79",
      "r80",
      "r82",
      "r86",
      "r353",
      "r540",
      "r545",
      "r546",
      "r640",
      "r666"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 10020.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income Loss Net Of Tax",
        "totalLabel": "Total other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income Loss Tax [Abstract]",
        "terseLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r67",
      "r69"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 10040.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax",
        "terseLabel": "Unrealized loss on marketable debt securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10120.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Other Long-Term Liabilities [Member]"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 10110.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income Expense",
        "terseLabel": "Other (expense) income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "auth_ref": [
      "r8",
      "r10",
      "r236"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Other Prepaid Expense Current",
        "terseLabel": "Other prepayments"
       }
      }
     },
     "localname": "OtherPrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentForAdministrativeFees": {
     "auth_ref": [
      "r105",
      "r579"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount paid to managing member or general partner, affiliate of managing member or general partner, or affiliate of limited liability company (LLC) or limited partnership (LP) for administrative services provided to the LLC or LP, for example, but not limited to, salaries, rent, or overhead costs.",
        "label": "Payment For Administrative Fees",
        "terseLabel": "Annual administration fee"
       }
      }
     },
     "localname": "PaymentForAdministrativeFees",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRent": {
     "auth_ref": [
      "r110"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash payments to lessor's for use of assets under operating leases.",
        "label": "Payments For Rent",
        "terseLabel": "Annual rental payment"
       }
      }
     },
     "localname": "PaymentsForRent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRestructuring": {
     "auth_ref": [
      "r105",
      "r262"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.",
        "label": "Payments For Restructuring",
        "negatedLabel": "Payments made"
       }
      }
     },
     "localname": "PaymentsForRestructuring",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRestructuringChargesSummaryOfCashRestructuringChargesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10100.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments Of Stock Issuance Costs",
        "negatedLabel": "Payment of placement agent fees and offering costs",
        "terseLabel": "Placement agent fees"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareholdersEquityAndConvertiblePreferredSharesAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r96",
      "r97",
      "r214"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10120.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments To Acquire Available For Sale Securities Debt",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10150.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments To Acquire Intangible Assets",
        "negatedLabel": "Payments on intangible assets"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10160.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments To Acquire Property Plant And Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10130.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow from temporary investment with specific maturity and interest rate that are prohibited for current use.",
        "label": "Payments To Acquire Restricted Certificates Of Deposit",
        "negatedLabel": "Payment of construction deposit"
       }
      }
     },
     "localname": "PaymentsToAcquireRestrictedCertificatesOfDeposit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r390",
      "r392",
      "r398",
      "r399",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Pension And Other Postretirement Benefits Disclosure [Text Block]",
        "terseLabel": "Benefit Plans"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureBenefitPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance-based Restricted Share Units (\"RSUs\")",
        "verboseLabel": "Performance-based RSUs"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfAwardActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r416",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r31",
      "r588"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock Value",
        "verboseLabel": "Preferred stock, Value"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r9",
      "r41",
      "r42"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10280.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense And Other Assets Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Total prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense And Other Assets Current [Abstract]"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.",
        "label": "Prepaid Expenses And Other Current Assets [Member]",
        "terseLabel": "Prepaid Expenses and Other Current Assets [Member]"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement"
       }
      }
     },
     "localname": "PrivatePlacementMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareholdersEquityAndConvertiblePreferredSharesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromCollaborators": {
     "auth_ref": [
      "r108"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received from collaborators during the current period.",
        "label": "Proceeds From Collaborators",
        "terseLabel": "Cash upfront payment received"
       }
      }
     },
     "localname": "ProceedsFromCollaborators",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCollaborationAgreementWithPharmingGroupNVAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r100"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds From Issuance Of Common Stock",
        "terseLabel": "Common stock consideration"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCollaborationAgreementWithPharmingGroupNVAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareholdersEquityAndConvertiblePreferredSharesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10050.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.",
        "label": "Proceeds From Issuance Of Debt",
        "terseLabel": "Proceeds from modification of credit facility, net of debt issuance costs paid"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10090.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.",
        "label": "Proceeds From Issuance Of Private Placement",
        "terseLabel": "Proceeds from the issuance of ordinary shares in private placement"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "auth_ref": [
      "r101",
      "r131"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Proceeds From Lines Of Credit",
        "terseLabel": "Proceeds from lines of credit"
       }
      }
     },
     "localname": "ProceedsFromLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10110.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds From Sale And Maturity Of Marketable Securities",
        "terseLabel": "Proceeds from sales and maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r100",
      "r444"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds From Stock Options Exercised",
        "terseLabel": "Total proceeds from share options exercised"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10060.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds From Stock Plans",
        "terseLabel": "Proceeds from employee equity plans"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product Sales, Net [Member]"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r3",
      "r72",
      "r75",
      "r81",
      "r106",
      "r132",
      "r144",
      "r151",
      "r152",
      "r186",
      "r194",
      "r197",
      "r200",
      "r202",
      "r223",
      "r285",
      "r286",
      "r287",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r296",
      "r297",
      "r501",
      "r505",
      "r506",
      "r510",
      "r511",
      "r520",
      "r528",
      "r643"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10170.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Profit Loss",
        "terseLabel": "Net loss attributable to ordinary shareholders"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property Plant And Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r46",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property Plant And Equipment By Type [Axis]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r258",
      "r689",
      "r690",
      "r691"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property Plant And Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).",
        "label": "Property Plant And Equipment Estimated Useful Lives",
        "terseLabel": "Property and equipment useful life, term"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r45",
      "r252"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property Plant And Equipment Gross",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property Plant And Equipment [Line Items]",
        "terseLabel": "Property Plant And Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r21",
      "r22",
      "r254",
      "r588",
      "r647",
      "r660"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10210.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property Plant And Equipment Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "verboseLabel": "Property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r44",
      "r254",
      "r689",
      "r690"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property Plant And Equipment Policy [Text Block]",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r21",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property Plant And Equipment [Text Block]",
        "terseLabel": "Schedule of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r21",
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property Plant And Equipment Type [Domain]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property Plant And Equipment Useful Life",
        "terseLabel": "Property and equipment useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ProvisionForLossOnContracts": {
     "auth_ref": [
      "r363"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cumulative provision for contract losses not offset against related costs accumulated on the balance sheet.",
        "label": "Provision For Loss On Contracts",
        "terseLabel": "Liability associated with the loss contract",
        "verboseLabel": "Loss provision associated with contract"
       }
      }
     },
     "localname": "ProvisionForLossOnContracts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r400",
      "r579",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r400",
      "r579",
      "r583",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party Transactions By Related Party [Axis]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r577",
      "r578",
      "r580",
      "r584",
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfLinesOfCredit": {
     "auth_ref": [
      "r102",
      "r131"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Repayments Of Lines Of Credit",
        "terseLabel": "Repayment of line of credit"
       }
      }
     },
     "localname": "RepaymentsOfLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r455",
      "r604",
      "r703"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 10150.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research And Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research And Development Expense [Member]",
        "terseLabel": "Research and Development Expense",
        "verboseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfAmountsRecognizedToOffsetResearchAndDevelopmentExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research And Development Expense Policy",
        "terseLabel": "Research and development costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research [Member]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "auth_ref": [
      "r12",
      "r25",
      "r115",
      "r121",
      "r685"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
       "weight": 1.0
      },
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10220.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash And Cash Equivalents Noncurrent",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.",
        "label": "Restricted Stock Shares Issued Net Of Shares For Tax Withholdings",
        "terseLabel": "Vesting of restricted share units, net of shares withheld for taxes, shares"
       }
      }
     },
     "localname": "RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after value of shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.",
        "label": "Restricted Stock Value Shares Issued Net Of Tax Withholdings",
        "terseLabel": "Vesting of restricted share units, net of shares withheld for taxes"
       }
      }
     },
     "localname": "RestrictedStockValueSharesIssuedNetOfTaxWithholdings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring And Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r260",
      "r262",
      "r265",
      "r274",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.",
        "label": "Restructuring And Related Activities Disclosure [Text Block]",
        "terseLabel": "Restructuring Charges"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRestructuringCharges"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringAndRelatedCostExpectedCost1": {
     "auth_ref": [
      "r261",
      "r264",
      "r271",
      "r273"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost.",
        "label": "Restructuring And Related Cost Expected Cost1",
        "terseLabel": "Estimated aggregate restructuring charges in first half of 2022"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostExpectedCost1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).",
        "label": "Restructuring And Related Cost Number Of Positions Eliminated Period Percent",
        "terseLabel": "Number of positions eliminated, percent"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRestructuringChargesAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r113",
      "r259",
      "r268",
      "r271"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "terseLabel": "Charged to expense",
        "verboseLabel": "Restructuring costs"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRestructuringChargesAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRestructuringChargesSummaryOfCashRestructuringChargesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost And Reserve [Line Items]",
        "terseLabel": "Restructuring Cost And Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRestructuringChargesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringPlanAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by individual restructuring plan.",
        "label": "Restructuring Plan [Axis]",
        "terseLabel": "Restructuring Plan"
       }
      }
     },
     "localname": "RestructuringPlanAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRestructuringChargesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringPlanDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the individual restructuring plans.",
        "label": "Restructuring Plan [Domain]",
        "terseLabel": "Restructuring Plan"
       }
      }
     },
     "localname": "RestructuringPlanDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRestructuringChargesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringReserve": {
     "auth_ref": [
      "r262",
      "r269"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.",
        "label": "Restructuring Reserve",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period"
       }
      }
     },
     "localname": "RestructuringReserve",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRestructuringChargesSummaryOfCashRestructuringChargesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r35",
      "r361",
      "r451",
      "r588",
      "r658",
      "r680",
      "r682"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10070.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings Accumulated Deficit",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r2",
      "r140",
      "r141",
      "r142",
      "r145",
      "r150",
      "r152",
      "r229",
      "r448",
      "r449",
      "r450",
      "r480",
      "r481",
      "r519",
      "r677",
      "r679"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue From Contract With Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r180",
      "r181",
      "r193",
      "r198",
      "r199",
      "r203",
      "r204",
      "r206",
      "r383",
      "r384",
      "r608"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 10120.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue From Contract With Customer Excluding Assessed Tax",
        "terseLabel": "Total revenues",
        "verboseLabel": "Sales of strimvelis"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCollaborationAgreementWithPharmingGroupNVSummaryOfResearchAndDevelopmentCostsIncurredAndCollaborationRevenueRecognizedDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r126",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue From Contract With Customer Policy [Text Block]",
        "terseLabel": "Product sales"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r386",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue From Contract With Customer [Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRevenueRecognition"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r126",
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue Recognition Policy [Text Block]",
        "terseLabel": "Collaboration Revenue"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r568",
      "r573"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right Of Use Asset Obtained In Exchange For Operating Lease Liability",
        "terseLabel": "Lease assets obtained in exchange for new operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale Of Stock Name Of Transaction [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareholdersEquityAndConvertiblePreferredSharesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale Of Stock Price Per Share",
        "terseLabel": "Purchase price per share"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareholdersEquityAndConvertiblePreferredSharesAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SaleOfStockTransactionDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date the subsidiary or equity investee issued or sold stock, in YYYY-MM-DD format.",
        "label": "Sale Of Stock Transaction Date",
        "terseLabel": "Private placement, transaction date"
       }
      }
     },
     "localname": "SaleOfStockTransactionDate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareholdersEquityAndConvertiblePreferredSharesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule Of Accrued Liabilities Table [Text Block]",
        "terseLabel": "Schedule of Accrued Expenses and Other Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSecuritiesExcludedInComputationOfDilutedNetLossPerOrdinaryShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]",
        "terseLabel": "Securities Excluded in the Computation of Diluted Net Loss Per Ordinary Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule Of Available For Sale Securities Reconciliation Table [Text Block]",
        "terseLabel": "Schedule of Cash Equivalents and Marketable Securities"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.",
        "label": "Schedule Of Cash Cash Equivalents And Short Term Investments Table [Text Block]",
        "terseLabel": "Schedule of Cash Equivalents and Marketable Securities"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]",
        "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCollaborationAgreementWithPharmingGroupNVAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCollaborationAgreementWithPharmingGroupNVSummaryOfResearchAndDevelopmentCostsIncurredAndCollaborationRevenueRecognizedDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": {
     "auth_ref": [
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions Table [Text Block]",
        "terseLabel": "Summary of Research and Development Costs Incurred and Collaboration Revenue Recognized"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCollaborationAgreementWithPharmingGroupNVTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule Of Components Of Income Tax Expense Benefit Table [Text Block]",
        "terseLabel": "Schedule of Provision for (Benefit from) Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "Schedule Of Debt Table [Text Block]",
        "terseLabel": "Summary of Notes Payable"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]",
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]",
        "terseLabel": "Schedule of Reconciliation of Income Tax Expense (Benefit)"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r414",
      "r440",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]",
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r414",
      "r440",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]",
        "terseLabel": "Share-based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r238",
      "r242",
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule Of Finite Lived Intangible Assets [Table]",
        "terseLabel": "Schedule Of Finite Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfIntangibleAssetsNetOfAccumulatedAmortizationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule Of Income Before Income Tax Domestic And Foreign Table [Text Block]",
        "terseLabel": "Schedule of Components of Net Loss Before Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule Of Maturities Of Long Term Debt Table [Text Block]",
        "terseLabel": "Summary of Future Principal Payments Due"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of noncurrent assets.",
        "label": "Schedule Of Other Assets Noncurrent [Text Block]",
        "terseLabel": "Schedule of Other Assets"
       }
      }
     },
     "localname": "ScheduleOfOtherAssetsNoncurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureOtherAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r46",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Schedule Of Property Plant And Equipment [Table]",
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r581",
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule Of Related Party Transactions By Related Party [Table]",
        "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r17",
      "r121",
      "r626",
      "r656"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Schedule Of Restricted Cash And Cash Equivalents [Text Block]",
        "terseLabel": "Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r261",
      "r262",
      "r263",
      "r264",
      "r271",
      "r272",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule Of Restructuring And Related Costs [Table]",
        "terseLabel": "Schedule Of Restructuring And Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRestructuringChargesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "auth_ref": [
      "r266",
      "r267",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.",
        "label": "Schedule Of Restructuring And Related Costs [Text Block]",
        "terseLabel": "Summary of Cash Restructuring Charges"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRestructuringChargesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r416",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAssumptionsUsedInBlackScholesOptionPricingModelDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfAwardActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Schedule Of Share Based Compensation Restricted Stock Units Award Activity Table [Text Block]",
        "terseLabel": "Summary of Award Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r421",
      "r431",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]",
        "terseLabel": "Summary of Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule Of Share Based Payment Award Employee Stock Purchase Plan Valuation Assumptions Table [Text Block]",
        "terseLabel": "Assumptions Used in Black-Scholes Option Pricing Model"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r58",
      "r129",
      "r168",
      "r169",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r341",
      "r345",
      "r351",
      "r354",
      "r355",
      "r356",
      "r358",
      "r359",
      "r360",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule Of Stock By Class [Table]",
        "terseLabel": "Schedule Of Stock By Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareholdersEquityAndConvertiblePreferredSharesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Scheduleof Finite Lived Intangible Assets Future Amortization Expense Table [Text Block]",
        "terseLabel": "Schedule of Estimated Future Amortization For Intangible Assets"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIntangibleAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecurityDeposit": {
     "auth_ref": [
      "r64"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.",
        "label": "Security Deposit",
        "terseLabel": "Security deposit"
       }
      }
     },
     "localname": "SecurityDeposit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting Policy Policy [Text Block]",
        "terseLabel": "Segment information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 10160.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling General And Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling General And Administrative Expenses [Member]",
        "terseLabel": "Selling General and Administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r112"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10190.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share Based Compensation",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1",
        "terseLabel": "Award vesting period",
        "verboseLabel": "Shares, vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights",
        "terseLabel": "Vesting rights"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period",
        "negatedLabel": "RSUs, Forfeited",
        "verboseLabel": "Remaining performance based share units outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfAwardActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value per share, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfAwardActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period",
        "terseLabel": "Number of shares granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfAwardActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value per Share, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfAwardActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number",
        "periodEndLabel": "RSUs, Unvested at December 31, 2021",
        "periodStartLabel": "RSUs, Unvested at December 31, 2020"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfAwardActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted Average Grant Date Fair Value per Share, Unvested at December 31, 2021",
        "periodStartLabel": "Weighted Average Grant Date Fair Value per share, Unvested at December 31, 2020"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfAwardActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period",
        "negatedLabel": "RSUs, Vested",
        "terseLabel": "Number of shares vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfAwardActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value per share, Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfAwardActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate",
        "terseLabel": "Expected dividend rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAssumptionsUsedInBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum",
        "terseLabel": "Expected volatility, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAssumptionsUsedInBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum",
        "terseLabel": "Expected volatility, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAssumptionsUsedInBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum",
        "terseLabel": "Risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAssumptionsUsedInBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum",
        "terseLabel": "Risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAssumptionsUsedInBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAssumptionsUsedInBlackScholesOptionPricingModelDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfAwardActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant",
        "terseLabel": "Remaining shares available for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number",
        "terseLabel": "Number of Options, Exercisable as of December 31, 2021"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price per Share, Exercisable as of December 31,2021"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r433"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value",
        "terseLabel": "Total intrinsic value of share options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period",
        "negatedLabel": "Number of Options, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross",
        "terseLabel": "Number of Options, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value of share options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r443"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r423",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number",
        "periodEndLabel": "Number of Options, Outstanding and expected to vest at December 31, 2021",
        "periodStartLabel": "Number of Options, Outstanding at December 31, 2020"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price per Share, Outstanding and expected to vest at December 31,2021",
        "periodStartLabel": "Weighted Average Exercise Price per Share, Outstanding at December 31, 2020"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased": {
     "auth_ref": [
      "r413",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share weighted-average price paid for shares purchased on open market for issuance under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Per Share Weighted Average Price Of Shares Purchased",
        "terseLabel": "Exercise price of option"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r413",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfAwardActivityDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSecuritiesExcludedInComputationOfDilutedNetLossPerOrdinaryShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price per Share, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price per Share, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price per Share, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share Based Compensation Award Tranche One [Member]",
        "terseLabel": "Achievement of At Least Three of Four Milestones"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period",
        "terseLabel": "Maximum term of option"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r437",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAssumptionsUsedInBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r443"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable as of December 31, 2021"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1",
        "terseLabel": "Weighted Average Remaining Contractual Life, Exercisable as of December 31, 2021"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-vested options outstanding.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares",
        "terseLabel": "Unvested options outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2",
        "terseLabel": "Weighted Average Remaining Contractual Life, Outstanding at December 31, 2020"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1",
        "terseLabel": "Weighted Average Remaining Contractual Life, Outstanding and expected to vest at December 31, 2021"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares Outstanding",
        "periodEndLabel": "Balance, Shares",
        "periodStartLabel": "Balance, Shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r122",
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State And Local Jurisdiction [Member]",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r30",
      "r31",
      "r32",
      "r129",
      "r132",
      "r155",
      "r156",
      "r157",
      "r159",
      "r161",
      "r168",
      "r169",
      "r170",
      "r223",
      "r285",
      "r290",
      "r291",
      "r292",
      "r296",
      "r297",
      "r336",
      "r337",
      "r341",
      "r345",
      "r353",
      "r528",
      "r712"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Statement Class Of Stock [Axis]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareholdersEquityAndConvertiblePreferredSharesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r2",
      "r60",
      "r79",
      "r80",
      "r81",
      "r140",
      "r141",
      "r142",
      "r145",
      "r150",
      "r152",
      "r167",
      "r229",
      "r353",
      "r361",
      "r448",
      "r449",
      "r450",
      "r480",
      "r481",
      "r519",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r546",
      "r677",
      "r678",
      "r679",
      "r727"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Statement Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Stockholders Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r140",
      "r141",
      "r142",
      "r167",
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssued1": {
     "auth_ref": [
      "r118",
      "r119",
      "r120"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of stock issued in noncash financing activities.",
        "label": "Stock Issued1",
        "terseLabel": "Shares issued in consideration of license agreements",
        "verboseLabel": "Shares issued as part of license agreement"
       }
      }
     },
     "localname": "StockIssued1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCollaborationAgreementWithPharmingGroupNVAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r31",
      "r32",
      "r353",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period Shares Employee Stock Purchase Plans",
        "terseLabel": "Issuance of ESPP shares, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Stock Issued During Period Shares Issued For Services",
        "terseLabel": "Ordinary shares issued as part of license agreements, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r31",
      "r32",
      "r353",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period Shares New Issues",
        "positiveTerseLabel": "Issuance of ordinary shares",
        "terseLabel": "Sale of voting and non-voting ordinary shares, net of issuance costs, Shares",
        "verboseLabel": "Number of ordinary shares issued and sold"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCollaborationAgreementWithPharmingGroupNVAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareholdersEquityAndConvertiblePreferredSharesAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r31",
      "r32",
      "r353",
      "r361",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Stock Issued During Period Shares Stock Options Exercised",
        "negatedLabel": "Number of Options, Exercised",
        "terseLabel": "Exercise of share options, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationSummaryOfOptionActivityDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r31",
      "r32",
      "r353",
      "r361"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period Value Employee Stock Purchase Plan",
        "terseLabel": "Issuance of ESPP shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Stock Issued During Period Value Issued For Services",
        "terseLabel": "Ordinary shares issued as part of license agreement"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r31",
      "r32",
      "r353",
      "r361"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period Value New Issues",
        "terseLabel": "Sale of voting and non-voting ordinary shares, net of issuance costs",
        "verboseLabel": "Total consideration"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCollaborationAgreementWithPharmingGroupNVAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareholdersEquityAndConvertiblePreferredSharesAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r31",
      "r32",
      "r361",
      "r415",
      "r432"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Stock Issued During Period Value Share Based Compensation",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r60",
      "r353",
      "r361"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period Value Stock Options Exercised",
        "terseLabel": "Exercise of share options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r32",
      "r37",
      "r38",
      "r132",
      "r210",
      "r223",
      "r528",
      "r588"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10030.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders Equity",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets",
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders Equity [Abstract]",
        "terseLabel": "Shareholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r130",
      "r337",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r349",
      "r350",
      "r352",
      "r361",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders Equity Note Disclosure [Text Block]",
        "terseLabel": "Shareholders' Equity and Convertible Preferred Shares"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareholdersEquityAndConvertiblePreferredShares"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r566",
      "r573"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfLeaseCostUnderOperatingLeasesDetails": {
       "order": 10040.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "Sublease Income",
        "negatedLabel": "Sublease income",
        "terseLabel": "Sublease income"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfLeaseCostUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r547",
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r547",
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r547",
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r547",
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r589",
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Subsidiary Sale Of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareholdersEquityAndConvertiblePreferredSharesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock": {
     "auth_ref": [
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of tax credit carryforwards available to reduce future taxable income, including amounts, expiration dates, limitations on use and the related deferred tax assets and valuation allowances.",
        "label": "Summary Of Tax Credit Carryforwards [Text Block]",
        "terseLabel": "Summary of Amounts Recognized to Offset Research and Development Expense"
       }
      }
     },
     "localname": "SummaryOfTaxCreditCarryforwardsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SummaryOfValuationAllowanceTextBlock": {
     "auth_ref": [
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.",
        "label": "Summary Of Valuation Allowance [Text Block]",
        "terseLabel": "Schedule of Changes in Valuation Allowance for Deferred Tax Assets Related Primarily to Increase in U.K. Net Operating Loss Carryforwards"
       }
      }
     },
     "localname": "SummaryOfValuationAllowanceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplyCommitmentArrangementMember": {
     "auth_ref": [
      "r29",
      "r630",
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item is intended to be populated, by the entity, with Members identifying each supply commitment about which information required or determined to be disclosed is being provided. If only one such commitment exists, this item may be used to capture such information; if multiple commitments exist, this item is the dimensional default, which will aggregate such information, as appropriate.",
        "label": "Supply Commitment Arrangement [Member]",
        "terseLabel": "Supply Commitment Arrangement"
       }
      }
     },
     "localname": "SupplyCommitmentArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfAnnualCommitmentsAssociatedWithContractDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SupplyCommitmentAxis": {
     "auth_ref": [
      "r29",
      "r630",
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by arrangements in which the entity has committed resources to supply goods or services to a customer.",
        "label": "Supply Commitment [Axis]",
        "terseLabel": "Supply Commitment"
       }
      }
     },
     "localname": "SupplyCommitmentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfAnnualCommitmentsAssociatedWithContractDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r471"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward Amount",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period",
        "terseLabel": "Tax credits carryforward, amount"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfAmountsRecognizedToOffsetResearchAndDevelopmentExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about the period subject to enacted tax laws.",
        "label": "Tax Period [Axis]",
        "terseLabel": "Tax Period"
       }
      }
     },
     "localname": "TaxPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified tax period.",
        "label": "Tax Period [Domain]",
        "terseLabel": "Tax Period"
       }
      }
     },
     "localname": "TaxPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Type Of Arrangement [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCollaborationAgreementWithPharmingGroupNVAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCollaborationAgreementWithPharmingGroupNVSummaryOfResearchAndDevelopmentCostsIncurredAndCollaborationRevenueRecognizedDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLicenseAndResearchAgreementsAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareholdersEquityAndConvertiblePreferredSharesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfCostGoodOrServiceExtensibleList": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates type of cost from product sold and service rendered.",
        "label": "Type Of Cost Good Or Service Extensible List",
        "terseLabel": "Type of Cost, Good or Service [Extensible List]"
       }
      }
     },
     "localname": "TypeOfCostGoodOrServiceExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_USTreasuryAndGovernmentMember": {
     "auth_ref": [
      "r391",
      "r644",
      "r683"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "U S Treasury And Government [Member]",
        "terseLabel": "U.S. Government Securities"
       }
      }
     },
     "localname": "USTreasuryAndGovernmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesScheduleOfCashEquivalentsAndMarketableSecuritiesDetails",
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesScheduleOfLevel2CashEquivalentsAndMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnamortizedDebtIssuanceExpense": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableSummaryOfFuturePrincipalPaymentsDueDetails2": {
       "order": 10030.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.",
        "label": "Unamortized Debt Issuance Expense",
        "negatedLabel": "Less unamortized debt issuance costs"
       }
      }
     },
     "localname": "UnamortizedDebtIssuanceExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableSummaryOfFuturePrincipalPaymentsDueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r462"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued",
        "terseLabel": "Accrued interest or penalties related to uncertain tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r171",
      "r172",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use Of Estimates",
        "terseLabel": "Use of estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r468"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance Deferred Tax Asset Change In Amount",
        "terseLabel": "Increase in valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValueAddedTaxReceivableCurrent": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 10040.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.",
        "label": "Value Added Tax Receivable Current",
        "terseLabel": "VAT receivable"
       }
      }
     },
     "localname": "ValueAddedTaxReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r565",
      "r573"
     ],
     "calculation": {
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfLeaseCostUnderOperatingLeasesDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease Cost",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfLeaseCostUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number Of Share Outstanding Basic And Diluted",
        "terseLabel": "Weighted average number of ordinary shares outstanding, basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.orchard-tx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 10
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e725-108305"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e765-108305"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(10))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(11))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aaa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120254519-210437"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(i)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123364984&loc=d3e1205-110223"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2420-110228"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(e))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "420",
   "URI": "http://asc.fasb.org/topic&trid=2175745"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S65",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "35",
   "Topic": "605",
   "URI": "http://asc.fasb.org/extlink&oid=123355788&loc=d3e57777-111642"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130533-203044"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f(1))",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32059-109318"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123385561&loc=d3e9135-128495"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9212-128498"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9215-128498"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6829253&loc=SL6831962-166255"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121483254&loc=SL120254523-199619"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6897108&loc=SL6897125-166521"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "http://asc.fasb.org/topic&trid=2175825"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123341672&loc=SL120154346-209984"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123399704&loc=SL77918431-209957"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=124258985&loc=SL77919396-209981"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(b)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(17))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.1)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(3),(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.4)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8,17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62586-112803"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62652-112803"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "(g)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1,2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.17)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(d)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r704": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r705": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r706": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r707": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r708": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r709": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r710": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r711": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r712": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r713": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "303",
   "Subparagraph": "(5)"
  },
  "r714": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r715": {
   "Footnote": "2",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r716": {
   "Footnote": "4",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "29"
  },
  "r717": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column B",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r718": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column C",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r719": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column D",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r720": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column E",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r721": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column F",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r722": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column G",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r723": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column H",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r724": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column I",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r725": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3151-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>118
<FILENAME>0001564590-22-012325-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-22-012325-xbrl.zip
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M@9J7I^.V.!KST5"^74)=!A]W2E+MHYE()T6E\TI+-$E2UGC^[;Y#MDL?YBT
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MC 0,1QYEY_]')@3]+PO^+PO^_\."=M6(7PLUH"VY)6 "EA$N18#$--24X>F
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M9$=AKL1$@[;OQ%':((@Q*G&@?8^ I-QGP+U97"(L4 P3$\WC082/0FRT7W1
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M WP:3CE_BF W&][Z.GYUK:^ICS&4EUN-%W\+$]<5'.R_^B8_3<K-PT@T\$F
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M+GQ8;?@PJ;&11WVP;<S4S"J FG>ZND&V&\CL%R HH#.>AW-#-"K]07(%"\7
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M&$X;A:P/90F&,EQ!8^9?>2@&?9R$1L["S$#])<+S TB].AD?LU@_W&OY;%&
MI<"\(?>YG)JL3%MA*8@L*$WI"=#-NG#"=%52[.[0,0Z9]H&EU@9ZNBWE(>X
M4WUYB!Z8P#\CI((#R(P,0X5=QN'Z4V>=/Q.VVJK>0Y@Y@#!>36+EF&;.OAP(
M7?Y9!?8RF$P<]&3Z8!W!6F\ Y<J=7R+V,IX?Q#-> :IO\"=V]1$]^QUY5 W@
M $)KV.>0/&GJ/):A12C89]&/A&DR8Q'4HA#G%!A.]&R6X%@?K(&GQW+VZ>)'
M?/T>&9\$%\5!_#J4 <L-,M$7=P&,I^ EL,:@$UUD[V,SYW!].]THNUO9;$N
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MJ>0]L$5#1W'$6(>_M*&EHVA2&KT=$G6@,>,/;B87UN <1]#[&#% 4P77BE_
M/*8C)G0I-:9-"!U>A>6WE,+4D[.'@?1>Y.D=4NS"%8#08_G?OI8.Q55'UZCJ
M58X*^ Q?CKT*)@+,+H*([%@((19W8;*!%/NR,^@?##$DL2 ^5FB4BK65E/9
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M*)G^JD=JYIR<#,,J_)J?/DDL]7/,+*7+T1;/<KZ2@$?>FR:PZ#8%#^UG'7^
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M=B.<\A8I:B"*O4?7CN6H&C--0#@9>2@D5<3>$;/.R!C'G5LC"%7C+K#,6UO
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M5PD7:.(/^PE9=SWLV.F+:R7^.^"_,*^)^@G/WYI%T?"]^&BNI(!WSZN1[3J
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M89XJ/G"9NCR='A*.+@]#9$^=,I(4='R>TUY)0.RK+E8O/'@O]YT)*\H72>!
M!< G HX#?7?'J2.:<8WZ\+MWQNZ.;2W5-)O-Z>N?MXU_Z!]PI,91Q51&A-XK
M>)."&)F%)VTNY]X=^^=(_.FYSXMGO7VW OZ)G_KD\#%Q(+PI\-6WT*N_E&51
MFM:(& 2",A<46.VTQ+$?](13<JKSH=_.$KH:?/4/($3XRS=.YD^+08+IB)'P
MLYK_2^,(V@&$);S"\=_BK/5QMDW9_Q![#B"@\C!K;I$]D<K^GOF;D 3_%8!)
MY*S"]ML'H:)Q^&^620>0]WBVZ3\X=>Z@K*LX]_]C0TIA1NG&"A.!N4XA=AU
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MN(V).#<)4KT??8TO5,-XH#DQ(L%L]QL/M.O#YQGQG57X2RB#OY7_F*BOVO!
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M#YWNM9(T&_S]X2'A!,RAJ6'X0>5"2YZ""[#$]Z1!OK%\H51^F*OUYHA)LOJ
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M"N7C"AETY(#KH,L=J_V<*V^KZG?N-KFJ$EI/(9(.VM:*AGOSTW0^I!J:K#T
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MJHIYX%P%$DR5)ZLG7E)D&I-?WMC6V\*2(@;BLH[B"U"&C+%&*L18EQJ;0=5
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M_.W<0]N-0Q_K"Z@R8:21=SJWHA*U]+H[?OC;,7,">^6DO-C@!((,$=SUZ]_
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M2*(5NOO&6%552$2NX[6QD%_:QRN+VH8( O<RAA _MZDPSC$V5T"?O0_9V^4
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M75_I9BS0M\D#LAPE(/JM/P]4WS&U_HQ[%FD)9^@D_;X=NCXUS+^\UN50A "
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M.3:SR9(WX<\KRZ[, =Y=B0QL5YO.N"=SH=,09@/,4:T,>:#AO(3MBS,:'5[
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M9+R0W$'"3UXC2Y$*!%$6M51\M*[93"JG,]!P(_'ZX#PM!:OXR@_A]K8Y@%S
M->UC7UM?YCW!U39T9;EW8FK!+FX^#/[IN$!S7P3X(['=+]Y5'G#!HKL*1!EB
MY2@]@4**8MFLWWF?>LW(&0>$'4QVU&GH$I")GGXT-"49?H7SI!*D6M[.W$.
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M<;Z/Y,H],HZI"<14&]4*AW>_%XLNJB827HC*1,E46HISJ[X?"$4T-MVFFK-
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MHA*Y<J:\P0:M2$;*QBEWT\QKWL-"." Q8ASZ,E?:F45O<:5K%&Z\:8+USKW
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MMN*_M4*E^JATU=+J:_<S?HIT\((+B;-AN -G ''N2LT"T"NY#U28^K2<76>
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M_Z\L#Z7N:U9LK/PZDYAZ'SK/).Z3%DOM__/A-[Q?<<?HB_?2[V)2(M"D/I@
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M2A>_"]A]"/)7&5 44^7BXAN-N=WD[L@!+@N[J3*>O*V@EI.JWJ@@D#[1>#5
M?TU?_6@%TX"< 7=OZS)>1[+/K,GKR>IN,,J^.?G!NG.SH^=WAF_PMW>%GKIU
MXAR^]W?\"NQ:B,X][!=.<#A-U2>^*TNWI&S'U38!515#^=PRENMA#^OMPIQR
M9()D+BZ83-:+BGB #/^1_98+@Q*^YG%0*$R6BV4*4;W%&EKN'W%$!2F^FI.#
M-S;5B4G7;CJ0SN-CC5/4((+W=D+,!%@CT]#/-;56*()!E2:E:*1J\UI:JB@/
M R.AV$23IH-6;0J<"D]'08/-DQJ"_;^CUYJNV>WY9=R)T.6P! 4+&!I04>>:
MTKLFP 'KDU"6;.;E(I;'8BE6K[%@3H4PGX_/LS3NS8CJW-%C3ZFMK3AS6>><
M5%V]Z<AG)L_X/LC0:^3)CI+:=4,4:F!NH4AVMDNI)?V'QKAMD[/$CXO)+!>^
M"=YOJV&O[W06&)#0%\6!=.8VLMHJ&0OQ=!,I1]#,>G5S1\CS.R4))8_^[QRU
MI5G61)TTRPN)2>F%M8^J*WFEMWINW7HUO%'YCP; 5P?A)217QT2_X8<\;J+>
MV_$;'_7*?#CZ(B?Y7?DT!@]8KEUM(=1[+U;6NR]/F(8X%D-Z%BX+T@DR4I*G
M]?F'A9,_2;P5-<X12%^Y$:,=HU$I%MX@^D%K.9O'BB<@K.4J&CFL?.(=R@<T
MO.]^G)<3EZ)D;FHTR766ZZ/ES/7F^;_316_\9UI.S=R\C?6]V\413A5?9=4K
M]UG70;QB<X>PLO9<GG2-YG,C7DT6&2*70[X4+_G4W!)*2=*T,IO)R-1(!L#"
M:#YZ8W2A1@\1YGC',2"J'403CRZTOOFZ9Z:EG>?*B!@.55V?S*):ZT845/^>
M^90E][9C$<:IP@9M56-<]?48<(&[ML'K_@&0O:XL966ZMSFYG  "QM]N&S^C
M:F!8>D_Q"GZV^R@Q#OW+U=8U6(IF1W\\&5P4/Z5YKK&IHYT\$N-=?Z.CLR5W
M1G%3I,?46FQS;J64L[;16/WM[,,R_'6+WM:65HXFT&TH9D:WCUN8'0;R]B69
M)_:W5<2I:T,0,] U&Z>F";1(!82;O.I;;K-Z<,Y><PN_ME_:UEY(7.JP%LU2
M"R%@!Q-74@OF1TJ,Q^NSUDO;VV2 (8YDU=5C $=DGG!]D^D;\TR-AS<8#[NJ
M#T-#+,\I3<C5*J[DG>.:D*N3!O^U$#I@VUKL&1KRG5^C.DZ\)!MR5K?_J^1V
MPL,!O8)"9=Z_?\TW$9[_*U&JOD:;$E)3IL>1?WA%B-?5>20Y(0%TC;:LK3?I
MDA?R):/76ZPJ\,ZRQWO9"*UB:$*_W4LA%LXG9H':^0+_4/_,21^@<)^RSI/.
M2WOL68=H^907V6F&4[)-OK6C5LE+KB^W'CO@L1B^*&]EGG-:.5-$-$%9,:!?
M"=W8)8?#R]:Q-SAQS3Z^^N?5L]?YFV,NE09N6IGRNQUZV'6@:\5C+.P0_%[-
M].12J=7)R-LH3I.G3__KFKS,:,COM1-K7@7_VD\-9WX5C\'LBU-0D1I+V?0W
MF? -2#9\U<*XD 3_S37(Q(S1?T1ZF6AST?^*]/M7ZL>_VPOE+F2BX^43#;MP
M=;U0D@HDA2^<6=.4@,2C;=PK$*C^6'7[2KL9JAF(.4^QBMJ_X$.7)PESV_PJ
M9"%/QP;Y\JZU&4XGHH'$/!:8\GO("[?XRK40GB)?")QL/H(WML A@]8%Q8F.
M,?5;Q3N+TT'&K.OC:VV0;4N:=H:F",4'4Z)_G[._Q60,=>&^FK (5-=XJ$UJ
M_2XZM,]:^JQZ(VO/S)  &Y\<1VRQ0+#[OIU:ZJWBUU42!O7LR4JA.EG<B#M/
MJR0F2Z^;YY<=D3]MN%T\!ECT6)3RZAN.FW:(*Q)6#A16$$.WCP%A8JR3!O*5
MR]=[98OZYA4I[CVI7&L.#R@_XX(=N:$M%DD$>TC;W&SV]-?R>F3=^E0;VVN#
M)R^,8X+JK'IR]Z=>$R,DU>38J5"OZ>8CH9P*_+=12SM\7<_"J4@QYDC2F]1S
M,'/&^TA.)D[HYL2D';1PI%_X_%;D)7LHQ& ,^236H(6,V"LZK2ZJ1.#?Y#&9
MW#(SH5P>WY^3K]_KPRG<08J?+?S)"]N5?*?>SZ53[A]]E.5I8AY8E=+-@)_-
MH0D\7I,8*', RG8YY_GF3&+-? QOYZ4XI:2H\A9-4:Y^DQ@(3+F'L)GLD3#'
M3G0;&=7I/M ?9+-$\'Q;V/I!:K,N29#ZJM+]KU3?G8<GNP@"_SI)=63VIO+!
M5Q->4&_]%Q\>S9\Z!J1-1P,WX)G'@#5[$8S4,>!MUFEF]R_XZI<BG"&GB>,O
MWJ,O5C^,Z3QPI@F(9@Z?^_OOME3J0\?WPKQP+^&9_H/0""'AE 5!34ZZ2!OE
M4N#(^Y-#?ED]F+APR2MW#E46SS4WGX[PRHWN+*V<L1D2?3KO@ </03P51[7]
M%0.,KV).G'SN0.9%"=H5F.W)%&%T.%6"W'*01O6G\)!"DUVIAAPQZG*+->O'
M@&N:Y4<<??"8>87)+Y--R9K;CQH3^K&YW#5PZ<,C1"V;6*GGF-Y1_@<;4&]*
MG8&*G;F8:6X>=BHA,=\\+^A'FHG/H7>-E/V<;>!NT=7=C52V+CO??_3\?& I
M+&@6K?*:P_BLHWP7KG>BQSG@N9W?WLV8*K 2 HRN-DOF,WE=8&-T\4IZ6B?F
M_XC\4<>>N11S#$":,/3(<*9A]CGX]]QL9D'UR0D-*2K[]VK=_]^;<$\HG>?G
MXL]$X+,1PO8B9G.<W"R.RR;)3$>K>W+7G+G'R#:D3I(M=[5B_$.:-][J>M="
M7XQW@=^T9"ZE@]'&G&K2@X+CTP>\-'68#SE[4X2L3'3O]SW]Y"/5A93]:L^1
M^WOW;?UEW);OIKD74[@C[>XUFAD6_.U%;.R^QX2SH/&3]EBFS?1 $=F\Z/LP
MX6"9D1(I"KOUH:DYFW0_^2I,BZH6YN><1(#IDQ%U/W(=<F7=>BRSF+*XK?W4
MLPYS T\L[\_?BM K'71A!Y[%+!*. 82 I>ZCZ13@8N$"-])',1E$LW*D5'1)
M&0:!7$-=D=]K/](-J<]D9'M"N5M\LLR@!!#NV^5WLANP,!D"X^,!;JZSNH0Y
M]>7.9&Q'TE=;!%C"P:S+:#:]>=,TR>5'J4%3X<]#]D!MZO:>Y9?=6;ZC:6&&
M0(5THB96:Z'/A:[<;Y8X&"BD-Q^(2"=^@$)U-JNO/\^.DP]^8 ^58&["NRR/
M <[A<,+(@30UCPPQ0J'229;)G/ KG9<<9J\[T^1ZMB_@YP?+5A>\BJ[8$*A8
M4/L4C",B7-9Y?%,=)%MNLMP0*[S\M=KS16%T]1I8".44AH"H:C#FLZL]<Z.;
MIJR.(DN=U+-:FJV:0R4$>Q'+=3VF#P.]U?V'SGRA#,2M#0"_KV%B@525729+
M>#AYJ=_J&-"RT 5D;Z2K4A.K;;5ICWZU6;1*+([$JV90\#,P;9I&F_=K[,(5
M'P<I^&7[>[=L8'_"F^WG[&:I:U.L,BHN]\RK07)UHL5@.VK(D>5'TXI07+5^
MK_<(=W:'F</?I9 2]P+4Q[F(/A$)R0+G+SO/ Z-KIHMD5!_LK79G2=T)2&_B
M]M?)Y'MW?5<'B%?Q=%KM+A=1C*<7CT\V=*W2J[G^(T8H8N'GV#' \35MC\!0
MC6)N#_X=((#>^)N:IM+BGSW!3=O+8M3?P/4A09/,/;CXPA%=O^L+,P@%$!5(
M>">0^M.R:&$R1#FIKI2P<_N?7#,5D_]19BUGDF6SOD,8ODZA;_P_B6H>3K(P
M&%;P=?)_/)B,]NDG W]VF/[/D*5?JBZR_QYYA-$"+N8Z?M!-P?Q]Y=!4$:MY
M[9?)PBJ00U$910'V.0IU^;81NCI/H]J3?:985E) EA3=N#G;Q^28 DFC:7#9
M9J4=N#FV#)(=8C-59\QA@'B!>XHPD V^?9!DM3(_EC!EZB6Y618VLWW%54 J
MS0VM7[14Y=IZ'_2J[IV;]<#P:&E,L9"G2F_X),0\6T9:XZ*71</UA(P/>S=-
M4=:/',<6Z/SR-+8YJ"]6Z &C#191ILC3J=0\H7F=SI%P<*I>7<ZULB_R)A0_
M^6P^6BDBT A%#DD-O_YJ:TY1F)>@DM9O&;W,1$FE4B,6A2_ I,AR49I\=.!H
M+5I^,?4/:J >N2A:'5@A(E;X]OTOR[NK>.\,M9GE]*^H5_)B/3N@P$!96F*.
M:Z&-J.\PDBJ%W!QSH;%&?BF4I3@D5FM[4[))=E8+[)T7K<L2#WZI&U?;J*YU
M*NE%AMH"8_'JN/7N-3VQ#_ KRC&*MDM\ZPU*D2;Q=7'#NZ!NF8F>R61)3@*N
M0&FK2[_N:A2/AHV,W(CRQ#'@(K4?2"HJJTA.1V8Y24Y\HPZJ=3_+5\@<-GHZ
M\/&%H=-'O$K\^,\*G933?["L/!B69'F:[+@IT&UP-V.3W@/OTJ';U\&[S#"+
M#9JLC!Q-@36S!2C'YWD97"3  Y]2<*,0-VA,'BX-KX<%4%]?\OI(^!:4&$>W
MN377C</64.%=N9P?&J[JH!AC4 BV32Y*7>T]%(1] >.SBH7)E:PZ"(X&M5M(
M>9?_:A-+XO/)=O(I2_M@\YWPT/=JFK^ EX+CP(D%L:%Q.GJJ<J1B?+;C<I]7
M6% &UHK8-5D[2_G1VT2:M[8M22[EAF>NX]VUH\UDS.N]]KV[\Y\5C?G @RLS
M:PV-QP!KB[D>B]6^>GXI;#MQITTR>FJ\1U^7,(1<0;OPAE16V^I$IN]](MD5
ML1;YP5_EB\59IW"2M6*KR-]JL)FZ=TG?GMS=5\D3ME3\0=R/MN6(P;K<& \*
M?!'6]OI'394VI]6P\!>G_]T=G V^$UGNP6>)J(=83>$=4DN_SWF]*$>$2W9Y
M.CFYLL[:S\U^^R'M1^CB'Q1IZ*Y.!RO]WCZ!N_<H(75$WQE$[5ZCI'@2+(PX
MPNJ5]FA'6Q0<L'IT&(]EN26Y5F%"GBI,DUW6=PF-,:1\H6 2>\*ZO]P3(*AF
MRODR\E[V.!?K;$FBP'Z1?1EEZ7[)!O67\W$^5WPL0QJ&DGHBS%CC>C[MAO.9
MY:;,XD!SB1'7,M,CN)O=OV&XCP&+E?,W/TUO*0K_@WEQO#YH/;P4PA.G;N,.
M#P^O<9H[<_!"HV K3R@M+6/.5Y">F['-+_'IU<#/H<:8U.YC %52.4EQ^_+#
M4E@ 63.=D2Z&M[6'"'&C.L:5O,6L;Z:%Y[&NT]9E3(KGDPX^' -</O8PG0IR
M3"4B4T^TFA?]-MGA)5E.GYKC6VX]#QWIRTW!' QY09T+CP&@\;UDA^U'K_4:
M"I8XW'W]@J8G91_?%&M7'M4.E.GM2"G\$"Q,?CH2%<E**?ILS E=,AG?D%&W
M7_3=2&3P]SRZ7M+A(:=4IZ;7AI.3-1=ML;2ZO"8CAFCZR!5KFC!)PJ<&<O63
MWG1#\ZQBX-/[?0TQ8LLCFK$<NJ=U:7(T^:?0WIB?@4&3GG\QEGF=$"9&$Q5)
M!]D]R+RGPXA7S$F;S/+5"$\GC8R(V(;E@_QLG]GY$5L5Y0A!;3G8#CQ5F&P&
M/TVU%Q_5O.")(1="8ZR_^5-3S5&8!O)D$D[WAIDOXDLS>*I!_5YU[5LC18B?
MH'A+GDF<HOLNO\$TQL,WMNAR$!(_?PSX?%1<9$G1;"6QPB]#A*ZW)W8?E1>3
M'G?$T.&E7:YN4T<9+_9G+9W[("&92<> F8]:2HD=R%D,^0G\%9P5YDYTY*0_
MHOB^KD7KDI <5)3BG-"NS=!!NJM'T#KK%WJ!T%_/;T_4;8N$OPT+XQHD2#?'
M],K<MBG_Q,CI'-]04N,O4#!M:)Q0)'P1FMHV[FR.V>I;PVO/B'4,E:V*7ON\
MNH,V[1O[2*\M\S?))K=P4_.R%Z%(55*E*R1GZ1-$;N!NVE&S;4)QG']%0GWU
M!,+4PLDTJHZ&W\?YY\N_C29OFGY>VFU3;/B>'U",1'698L=A&>Z\-D9V0Z <
ME?9P7-:0N7X , ;NCB'0B,)]_N[%T!227*R0ZCM=G@.'EJ#7#R=E.3*%%)-#
M3#BO@!1Q)=H57B4XXLI;[^?BDP5"X'T.O,*!!I679NQYCT#7)C<]I;Z5R5T
M4;9CIQ:>4&*R'GL+8NA/8/'%DW4R+0VQAM,R**D+(/6L4=O9NP615HQB^&)N
M)!LEW9Y:L9BYH7F*HOFLU9?-7GV3"/G=K$<(6G]')RQPC$C77C!L.?(P3\!-
ML0DM! WN<+P$>H[@PP\4*&P8[$ABV[D:)-5H-(XXJFXL&DT<+WDC,DO5ZJ&P
M]G(;N,5<2&[*Q<06?Y\Z: 9Z>;HYT-VON>4HL?@=)J(U8H<^JH.2+_C+<K (
M^-C$K1I!-VXAA)WBC':3#10_?/ID(&D-N_0[HA7QQ!NF'EG1<UW/"FLT9HT/
M8M2Q;+I;YJ:VJ\U5<%V,7[]H3-)48E1A%G,P D#WTDIJ'O8^CFY.=7^.&X;I
M$]MY4Y"E-K'\QO'T^ZG!X15E=VPJ)FI_3.Q9WT@<04_*B&5Z9^^^X7YD,OGV
M)5;D56T%4O)/D>F*#OCSA=- +^$HQZ9S10*=+)13#Y&U0M['@->H4K;4>.F$
MGC0CEZ;=9['FS2WLG<%;Z1J;:/ZWLOBID+MRW^ H'OHUA47?S5-R='UBN$?D
M-;I^/NC!-.R!$\^)PS1)D$8> [AX8FY!(&;2NU]PQM6_MBN\K@ZO;)OP=25[
M$W9]),C"9W.(0G!BBF?L-S^+]"J!PN9[7,[38)L0]P>VA7RZ:SGYI98<.1;]
M$G=P#IIJT9Y3%?NU66@IT]P5:\\)4V-O"2O?H*:#8'S:=&[=YK7?WKC(6]!U
M+7)H/%/H%U-VNFGD%'1JW;"3$AI5B_P1^X@BN)(J;;::K5J7FV2G[R[3T10?
M8_&VSEMSM)'5UI_G;HK.@R/A7Q&8D?%583S_ 9"Z3+NW-N))X>C.YB#^KN<3
ME.K#\PU60W6M^G 8MTF7:,U!O\4&>P6+UX:3]$]EGR)45>Y_6;A7X[)*K_D]
MJ-"]TAHBL3S3<2GD&D]V_]KZ^=1DKV"_C-F?%J85)]YUI0$"G/F^"J%35CW<
M]*"C)K_S/EIJK&K#_TH-"\ZN<+@Z+5-E[JNV#KBR14+?=BY;(:T]- L=$.E8
M"?Q)7VFJW=J2D?7VE1'/G3H86)G?&=Z:UXDAX;>FS#^AVEIR[R'9>M&4?L5[
M?0.4@<1;=UW/!/[ZX5)4S(PET!F*-Q9$SB3;?/^Q^11TZ93^YPV M/&??XA?
M5QIDZ1 MDBZMF\IJ,3\&U/"63^;^5FBGQ*; G"C\/;FI2>@PDKUC[[ST9'3E
MQ#XCX,?<FE6-"X0M.0TD.V'"ABA <S>3>][V7I*_=8L=T<E+_AFG;E]K_4N(
M9PRE 0=/;%V=PAK@GF_);6]MV=ND\=O:6B\7AN6(A.B5)/\(UL%'5?7_XMCH
M.@:<^48=HK33U'J8J@F.T8X<XO)VLL7U-@,P4!W>5P?X/5(@M+EUQ\=I[L=:
M6WY;9.$8B&NE\.BC%*'HE\*B\0:&['C@.Z:=BD6R@O%>AEXW)]$N-6'*3*G)
ML7L[_)M.I#@POM'-:KSI4]"FA%W8@O,UGLQC@/<BYCRT,:E:5W'(_GFZ5(\Q
M8?);X)V)JG=+C+*.LC6B7Z8KWWZ!VV]F:U+!1;.?!TW+"9Z]#$T;[$R,\^1S
MW?M\40MJ=?;Z4S6AWV8EOE8-%AY:2*KTSJ].S# -(K]AR/J;ON:J\$2@QY#V
M'MN#**N[=/71>J<\^_9'M[(4I_>AWP[ ZL:[_1K);R:4>&]FE(X4.S[ZDX$8
M1:N12Q?%7Y8UC06=8$2Z(OEV-*O=W& ;07^\Y/,?V\$:.EL/E1ATJD7:X=/6
MM@DY,3Q2$??Q]8[<)LL)/+E$-2:_<?#0O)!%(+DGE\C]$6O0=K[[R'[@R^BG
M":5WK,DZ4%'+H90WS^)_)-BJ%5@9MEX7+E"U>@6$8 @+CBW3ZKJAH0CH5?[F
MG7T9;?=1.EOIK;=G)_C.Y?"U>RFO7TK_O.GN6[EVE3-AP1'SV&.K?U-%NO^5
MNF;1P7G LTEH2Z)D[VB-[:6I>YA[3>[2V/O1RD;)? %--4Y^EV/X,MY/B:^E
M=9BM2E@,WLO>?U+!3OD=U3%C((S.G$P/AI1-.'=.2(AQ3F\_$$9'B-- \"Z]
MO?!!#5_B].<Z'N;5!TH0#2VM"9AK+7@X*V9^YW9C&]^Y.))4#H@P=#?59$H]
MM?%;M./C7/&47S M<BKI_.9I&@\UAH/?"\BAQ"K(T]]\N6,Y-8$.A+NXUENK
M#[VP'-@G-;6B,#$J0B1Y;S]+O'+,RL'4"L[:.>^@Z""2D:#)3C^3,FZ.&K?J
MTWP0I2U:>)?"UF3ZU3/X.GR>"M=W*QQ_C'^6/M#*$593HM:-;R1D1FN64SAB
M%3FX/7ERS\?OV<OU\-TNOA)S:# E[;W/ROKNBSK(.UC@K8*$6FE$\9*?T'VK
M/V*?T366"D60NO'0UPG%&?Y"[/OWU(6L8J+MV TWI=?&JLP*5%.:X(&.:=9Y
M"-JLCFIF99V#6:Z+N("/G, 'ZL +HN?HJTQI9:76DCG&ENO6P#!\OL!BJZ@(
M[TCGG%Y4VL8.GJCF>0($[YM8*Q(#I/XI-+<EZ[M=L7L*[@ZAV!X#W)JS^74V
M_<,BN&+>OY6XZS%M]M73-Y@2<J+2SZHSBI7R"$/&W0YGR48YQ'7M:W5U?>FU
M:SM=?\R#O,!OIY[WXOS,C3TA936_G_WV;Y#LE*$9T[G)?Q=\@+S3Y(2J&7\B
M(Z/W(WR[FCE6[$%PWV<P8]>2>0<'<.=[G,'SC>5)A)S@9&^7]>;<$P*7!;#$
M\0R4M1O(#I.O@*IUM7'%Q!,9]V9DBC\VO5+:I5S7]T$N$U8<%^;>N'9VM'OZ
M^*R$9H4)SN;N?@1WBE+ZG/)=50JEL7Y[*L:7=[Z%2-W^O#OQ;?>Z98_9P9!!
M.7>%V(>=GWZ%W*^-<F-8<P.#*%C0@V_KSG=W^['G/B@<*'DY5=E/U2+$AFJK
MVL'LFRJZSZK6?D?R,;* OMOL,+^I13)'REZXXVDJ<S5*%40PE"<? ^)D7YV:
M>HK82)O[A<](\TGH.S%Z3V-^C_UE^RN8M89-=7W/$E,$I][!8%/9Z )4 E&8
M'W8_8:&[+34^Z#L,%.A44A8"J8"F])NC4VF!1BU1TF X 8R?)RFV1//0+-D>
M4>6S D08(U1'4O@"/UV1&K:DH3/Y',7! ^7O=A#'-&J[@D!#\#_']VUK7*VP
MU5T:A)[JQ;L73@?FTGPY/B6J];BIZW:K@^(0J<,J;AUG!8:CE8Q4Z-RW!28J
MP)>3G/CV2*OZJ.L#_G77C>[5Z-1Y=6:9)?4,-RO(]0TK^5^7>#19TFH!-K-*
M3-.7#6JU?7&_/!U=*@%J+4F0VA>9_:\R_M2!!VG4=G^RR"*\!YAX/_?>^F$G
MQ]CFUG/%'+YG+6T32C)6QF.*!QWA?N[VFOA=LU?;)O*<;ZR[_)L]C&X;CXQ\
M/WU I1;0].@&%#FL7#S^?$SG&$?T/L=UCQ?;T8H$AOQSTCC*4+9OVV#26S:8
MS53"N\S>>7;UD 3R=$J;Q<^A]J8_#'*L,5M*/)AB8_M #FHLZ,/4GHQ7W_J3
MR;UDTRG^336S<:13>'B[U+I:5!IK'N2=/2F7U^3M6,*'&],9=%%&@28+_6*$
MLV_4,8!#T?&\W?HR'+5=)_P4,^%[2Q\,W1A&U#JL*9-7Q[ZM6#<1PN."J#\N
M?'U>KBB546HQ$56J^+[S#@&^VS9N&X!?.W0C%XCIE+D:#M06M6J^!8?-V<S]
M*MAV=\%7EB1,?/YG;DH_\P&=G<RQR4$^-*%"*'RX@PCV@[5IDV8TKCZMWV8L
M.%Q8T<;K2'OV@WT7VSXZ</9/S4GW,$\EU% O:K*6;"CJO<&U([S92M->7VCD
M^4PKBG/@'JT-7KBRIBF&4Q<KE:T3G,#?SPZM :]E#]6LC=H80OS](=[>9;,/
M+[&&N35Z\5C*?]7L\T#D?*K4'R'J[WJ&UT^M!ZQ6#?@]Q?F ,N>G(@2'7Q^X
M,](CN2,'VH3:$3 UYOR$+]TLT"60)'<56GXP0+.=B,G-EJJP.3<>-"=NC!IO
M.NCL# =!PCG3(V9'0OU#9;_RK [\,QL4ROS>J<:H:BJ*>^'>8\^A@Z)P8'_#
M'JA"Y@4:VSZ<.*/ GE*PGO?V<Q_9[:QI\Z8\K4_^8DVKWN'>*C.>WF(9'^TC
MT\QQ?IDJ;5ZC4P-3J#QCH\,.6D>PY,<JOH\6]FM2@6KSAPD01]"+YYPFVA[/
M_JN;I?^NQO6R?GYM5-2R33.C+7J(9*2^GL5:@8\*AQX#<-,O%!$XDO[4-;$V
MT%D$7F8$S_SJ&8;1OIUG:=@_!%['K2)E8@H*-N'BX9'GLZGJ:YI<;;X7UX<\
M;K3ZHGY968[(OTSJ!C;;<']*>< [M)'2%ZJ@K[0WI+0^HU_GT7SU&* *)YL)
M4\5].LB-/?,BC/=,%FCDDA451%(;[ CMC^0<DQ$*7XCAF_N1&ER]?A\<_%$Q
MC7K>O#7,=^7^V[ODS(T6^1%.\)DLW.K)9'53S[W!7RNOP0QYO@U*_\,5;6B"
M%6O'-_D;WQ )L\F\\<FSV+T%9-OJEC#UW%NXYT5?JK=+.76KBPC)@[Y5\CB8
MM]47Q3WT%4P^!F0(!V\D!_)Q11EMF)*_?;29*7"CV7'?#XOP]=\UTY?0;AD@
M!GL8UNPT;:U._&IZX5BT]8DGI3'ES+!+OFN"TJI50G&N:Z8;,?;;A[&TO.2E
M,%.D82=,\];EC%_F 6BOT1J':&.B5;>0[#3Z"LF1 SK>#2[+-8ZCR]>L=MXD
M;S5X->]^K5C#6TQ8'7G36?P%#AKYPRN=<ZYZE+\R?*_N$U55'!8>7.DPYZ7<
MJ#&YO/]M.COTZN)7_\! $4/UX3]/P]+:U2X#9HW.J2#7#I<.Z5=C#QRHE.!0
MTHD]C&A?G$[8=T_;B7 D?A[?4K]9,SN\*9K=PKS8QE;"ZQ:8XT;>[(\M^^2-
MLP,IUN*L?OJTGN#;!]1I[S!)J,M2=O>FH]$\+!YUHE>HC=CI3H=(,YGF@F,
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M1.Q=H;G$+RG*L'ZF2%A!=_=;Q<T;#QY>['.]M\4[$ 97<<J4VKV49"IZU'@
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M,UUR_Q>QRJ#Y5IF$Z2MTA;+KK[8!XXT^B0%CO?(1A;A/-;%4M=N]% Y.-ZI
MJOAGK;QKJ?U3YI7E$_EW< D==D:2+5(IPN=C*FQYXBLSI37X4 +.3%/&VV/
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MC>A66.W<\R[>?[GI!_">AYA_E^AZ)X"GF5C082:-@"EV8H1C%JM!NP$,D1-
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M_:W]6F;]?IRFC8O_._U[Q(H@?O_DK9",8ED@944O'Q'%8B543<6+OL37?HT
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M6$0XI2Y<A%KA*MU;*30$]C"E[_FEX98]DX[794^?WQCI+_L2>&8.&]3OSEC
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MOBR"&=-%G99EE26P-SBX%<MYO53B?IB>!SJVV^]WCG0/_&!($U:*@U]18XE
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MN]5] OIT<Q]#B;\?B&ONVS;A1C5P0C%0 )JUL;G^%BMC#\PA]INDYO42]W1
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M4>6H(47[B\.:X2_/ZEYOMB/AWFXI,1H8*V:</.[3=]%QD<P[U;A;<RIM30W
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MW-Y(W2P7['870L3V"Z89S>HK?:)5/2B$*& 5!0-8%8YZ'Q+T(')R%QE[^?)
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M*+OQ9V;=^8_K+8P2!\(.4RJCCS5,>_MDWS54NOE$X>G+T*-GC<RZ'^/D.XR
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M/T>D"+*-BDBEJ-BP?^Q4G:^^;LKUOLM6OU9K=\QY5^840I$CRZT$*WAPS'&
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MZYR_-"-'PU\;I72YV1BORA\,/X;Y?EK>MLFU"WWIK.D47/(O@V>A$:'ZO?[
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M%5X8'P[?"^E7A,F)U40,&E)ED7G>S/@UXNBM[^8!-V [V,?Y9^YW(WL_W\[
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M\.$$7 ;$7^LKXB0FKTJ;=GU@;@D"HS@7+M95@4%L>X/]X/2E7G1C4-FO^B>
MS6KW?V;_$,%=^,_LAP-[/-74.#)M1$EDKE!L<-$(,>^@/,(FT/"BV;/)K4E\
MKQ(;%EIYC('9N<)VNV^N$\"1I.!WA> .Y7Y8MSP81[O>[Y/K2*WFUYYV/])N
M0D:FY!AO70G0M=9V2IMT39OK<,_MMK/>-^GX4NZ-]?$0K5;MT_9<G#1F_<.P
MU5O#Y1_AMY_09!Y<?GI(LI_[K<7E$>KS';CLCM[VJ]S*K-OEFD<7>]@J0LDG
M/#FP1RC5SX%S>SB;D(48GB<VJ ', H)8M??^!N IZ-#5I?V"K ZF&M:>4XL
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MB\7!E\!B-U*B>><-(F">+KX*_8IOV*!*[+[$'@?%NA0,1[=P_($*JL"]IMK
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MDG[*V^V8YZ[_7.TT_V<$[M?V9-&Z,?>8V(XPMD>Y;Y[Y9C>+[-O$NHS^B7&
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M'5.H2>2T;!L[:@K;MUN!^[I;C5JU([]WYPH@]R JPKL=>Y"US3U(('+72\&
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M#4.30A&VE2#<&HQ_ >[O*3[1\*L:B!*[2K!IN5(J\MXI@G&0_VK--<OF4ME
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M#V*#\]X U3;>D:?>LB7!K)T(CL/P*-L-D.JRE0/?OL-+JW-\F*\1?B_1.$>
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MC*$]J)NP&YC$9@IX&HT$QF6PY (&D#%-B&<B@%+H0KSPEM"!'_UL1!CZX95
MXE?BPS_]ZJ7D_YH4L ;JPU=/<BF9A?"^+/+L$=":@TOV=%V+1ZMPAY)+_^!K
M966@]3@. 3UQ2%$F77M!2KPK-O@_3>^:5N%BQ5#X<NG!L4@9^ Z"XQ).:;E0
MMW+H#06(K/A'4JAP\>-S64>0'VB<IK<O_]V_"=.4A.GNC.05M?IYV(9AK-&C
MJX?4J%KSY@\YAPEW1K]^=#<]#%I^L,RIM783H'0<VQQOR-<XCSBUW<QL38B.
M\8L?O(61_@9I\G_$'86[6W1^O=C?J*Z687B)>.89^U*EY0>\G6F>75/U;(%9
MQZK_CQ#GRVQ[R>2\P "VC'N;,*WV'5S2=(Z$ZV*0/:]D,.H$FL3=PQ-PBI!4
M:#00[O5LA(AY;,T=RHARL]I__YL-V$>9^BEF  /=M\,7&T"C3A]C )<5:?2"
MZ,#?-=2]P9"V.B@YEW<W87,2S[B=-$>Q,@51OZ3J'13UF+@-G$0DMR/K"48N
M.&6"Q/1OM]I'4+$'>@I#,@IZ:;N#?@HZ;L8=6FC]N9'2A-T"\EQ'(9O06H(4
MU^<Y9TTAB+XK>Z*;(L=XC ./V0B2@(W>4/" F +XSYZ G^='K;SD8UBS6\<C
MTD@JEX*M]H^C#_-U>CP+^K*D(>NQ=A.MO,R:N1G%RV-0%"^4/*OMQ:R]1) 8
M&PXFI=G!['),XE@$7.Y7>X-M?N)W=,2(&"X>H#3D5=S1IG)IRI#=."/0^\XE
MM->?:-LY&APZ#M!? NQNIR7Z'YG]/)<0.#=.@MY]]7\3VM:<AJ_K,,#37 <-
MQP;^EI[""K$:_U#TTW"D0O"5>9S\HCTBK=M>>LG^0^RI=*,8M1@CH7GU</IA
MA6P[QY"6CU1=9-6;AH.:U+DO")6=!^10O-QY$/0M/RNS^]MEZ_-'>FRFJX4>
M_824T:ZWNW+N5^5>+[>3TY9@RU8)!K\]N0G[(J'@C?E@/EDLIRA1=D;<!&[C
M/Q)K^3!.>F)E U+7V819;-N$O<)NPMAYM#X$:(X5.XN$WJ09J4W8^!70"'<R
MG_3Z#1<A5/SUES$/M:\6;.B1H_PFK"%-<L :S0NQ(@DFI$CF^HX8$?<1TUB0
MP C&3>GQ&.D2GESFAD+&#F:=F)U6.R8#V]S35Z\!-EF43GLN395XAC^>R.V0
M&[LV#NGP%;$Y'$$:\,W%3/V:6);O##DTM(6$=LF+ORYA@%,=RLOB'?8<!GB@
M-$-HM^2S=2)B*#4*H8(.X"]S-KJ#<=)XDGJ[C5YF\^J-X2$>J5L#DYSM#=F\
M_T[9$J2]&Z _V$KC7\9= G,XR&ZX*JM:"]GI&7!O>@T!2G*/F;65:"1Q]'@Q
M,TX-T,X0)98M41IMNBG)&^.8*<NG-9_!(1XB<27N(&0S'C=2QPXR"R-UV_#A
M+&U]/EP08::PZ&DCH H<$WTK%VY[WB["@UV2V+&+FR!IT;= <N 6H15DP'<&
MS3K9S<[$&R-B5)#G>?=CLT?X\ 2Z9A?P1 9'SK?:D[JN<@ZP22_@'JNC*-09
MK[B[\F\\JEPL57HQ'@(I/OGE 0Z!T9_:3_9<=MC9DG3%T"DSS*UEZU&J_>2?
M],?\7517EPO$;V5)&38#>LA@TY?S,7:8:N=_"/;Q+PY4A:?T[_5QYJQ8(4QK
M'.M#Z_R11RZ9NS+[:VM4'$N--"P/W[I/?E[%WG_1)8&^0_3(2I74M9TQES^K
M"S)I<<.,%G@G'#28R$"[ D5GQNE*A..2(3:>8:A R+\]\&WD=!KZ)&=(;FG*
M)I-N$3?HCM@=IQ<TI9+PO41)8N=><=92K+0^+,I_] %SF+-28&7MDCOCS<:J
M=4W<X)T)UE"*Y] *B<-(C9,3%:-B_2=<05^)FTW?L#RQ)K$D'X(LCSV*?DKP
M=>EXCS[)'8@9U&"*C8I\AM$JD=4$6J_V_A> -87LSR<EKP\IT1N?>,=5D;HT
M&'.9;21(29F4&F? #V4]%"L0X',%Z7&*B[-[@;7$[UE;"1-<O:PFG+(]-]:^
MMRVR1%)0Y'\9*J)VY#O(;"ME+BO%YQ#HQ\/\02CP&8OL!<1%W.FA1+$E,,_H
M1  72/?9$G<<@)C&".+!;4(S<(*%D*<K0EK\+C"2"I9S3TUMPKH#D.GM>N5X
M3TQOB8I[/K,+!X]8[@$HO;4X30+6?K1I2-IC\4Y5UF/\S_Q'U834[B5VSYW6
MQ6C$F/[G'YF[/-[BBP+DNZUY,X2^?-Q9T_FD=!W'1,N(A6[&VMZ!E9DSCY>I
MNF;.F[!4/D:0I)?00"2:A^_[Q_Q.E:_^O+V,,R&=K6#9Q&\L7KY:ZUJ;7)/8
M8=@NGG3.*;Y9?W+D8N$F[ SF'NXY;65&&$+J,F3,E2)VD/!L,@)HC$,00@57
M1=GMI'("D?"*%2>M''?PO62\)CI,S]MU*"Q9@N#YC9C)[UBE90%N<L,R?>HR
M(U1X9OR(M^<D-D0<QGYN\PM_+__"WVM9B0CYIBSP'%J*?UR"OS+ !DO]%_[J
M"4.[Q*9@#0<K"Q9)\/<],F(FV$$\_#[2:%J"OSI.S\:,H;4F_$9+:U@OFK2D
M)1&<N5_^2-Q%$?@C&CZ+JS=A4NX_LB4%S1PSOY?]+$!42EIYN0FK97:.?4,K
M)#^MX5?J>C94)N:4JA?66)U'?_KF;O$NR\S$8'"D:EY?_Z7YR9:/OJ'-_.,R
MB7DXV=H!67(D_]W%Y\TETG$3*HZ%__@ZEAX@MH\MCF0$]1<;OCPK76^].W>>
M]'U*]->OUC?LAFTK$G"6D1&KV7-4($,&Z$D!))K8';,)4]KHD51W4BBI&[X)
MVX&$]K&_.J.#>? 5Q@H#/(^VWH3M"5U9:]F$!6[">EBKI&O/A6;_FZ&(FU&_
M7*XC7.)D5M3^:W(/DI8  '7KYE8=A;1N?IR.DD_+@8[SVC)3[CVN)4$C_S+]
M;V:=L,O.G1_8WJ?07E*NVAN8?0*N?)-P?NMQYIL#VV3(75?P_A8%#<PK^B[,
M*XO"\_ZV;G%O,U2[BRV6'"/U!I0&+?IO?,T)%0Y))#X=@V>KB@<9@ -28]%J
M^W/W,0Q^2 ./:!BO?]K^TQZ9",'Y\*[9$WRSGN"D]^LT63!U (=3)6SKC-L/
M>NG6A7)$+J>S6&L\!YF>VY:?$YN6@]F\*/%VLG K]$N D^*F!>SM=%2PYPR%
MB20C9-JM^9][9Y6 '_FL"R"E$CS:QY C(A#,1T0'/,FOAF!F/;Z.2V[S_IP2
M*9+5X^^GJP^OA\)!_XWNTCV2$J%%</]9*?G=->@37)-@\8[7P&?G]\033X,M
M0Q-(P90D^EY^7&7%HMG/#')"^_%PH)5'2C0AGN3&#!R/KO\N*_>YEZX',!)-
MUD/<[.UWM-MS0^&!3A^/U=3C6UHQ60@@",>:)"H)<1!!5!JI9=_YTYU,1Q,5
MF_GY):)7A.O$8"XBA235[K #F$AHWQHPOFJ\[D?AL'O8Z5:'^&[QH67!EM_;
M NZMMI_VC2X/+%7CFX^FWZ\\#R>_?'O\X W5'U<-#9MK\)[%%X&FBM&Q>81O
M8HUSG4G -H.+:>F40V$AAA[4M':SO,\&KOUE">6&JD']X)W&$N.0P!J7D%,D
M#Y93.?E)R=BED42#FF[#;<L;D%*:>'N44,I6*$^\#+X"O#AQ!4(SR$&4BPGP
M#N\3*_'=F;UC7TPW8>J$HP(2X)X&78F>RTKU41V-7!\A1M' 93M[X0E?WNV6
M#82&/]^$EM NX6--<)HYJS5*E.'BY@O$VZ.%5XFNHES27!D"%H'<&E0XML%D
M3-EP"YB,NQ@5L<;)IUT58'B?96@/10%Y#ZW%+?$TFH'W7- *YJBD$J^$\J68
M$X4A^05<^V4'3 \.OHIVY[!EH=/\B +2PG-A"!1;(/ 4_87!DZ;46<Z U2,N
M(H'TAW@?.-#)!AJ0LI3[S5DI=Z*2(G\#&-V>'[*\@/E/C^G'P!1D$AKA^_>B
MY9<\&J' 9<*X_01'^$]S!Q:K!S$9<P]G$7QX"F.NG/0LLXB3):'W Z.K$M=.
MF5SK4;$,)3=EG/8:-8%.<)"I<:I\7!IT\D3^H]#P<#DR![DCL(V="CG5OE9?
M%". MVFURU/-O55Y5;,S3*)6<H\_T:P'O#Y>>=Y-.F.'72[_:)[[C@'9Y!J/
MLY5G);-J>-'H]*QHQC:<E>_02DE^@3Y@WU<,3_^GVJG+GU!\\8I/OG1N8(SG
MS;X_%ZY\7'1R2J _E_[0;F+?O1[(G'1XJ^"4]9TFX8THTELKS)<5S,94[1P#
M-"L2[\ #6,$Z'[.JP4<*:L%H&N'S7"@3(0>Z=UHIO-/&I6IO>4=TYWOU%:;/
M[AF+K%?D,I@T35![M7DH858>J"S)2D%O49M0YK(D>8&VKK6Z.ZZ-T-XC'!'+
M?=F$%1-),Q](:\WNDYLP(,@=*F?QD!*QZL&(G"1D4(_*Z)DC(KM&N\=J3M7;
MC54+/9US#4\I#O)O$'/2G--RK\Y-X;_VV_W,,6[=5DC@/')B<1:O/OO^[ ,1
M.[8\DN&),G3F0"^=!;F?B@_4O VJNYAS&8AO(<\C(4V&I !,@QCAT66,%"F(
M-DF;$^< M$[$[L@3X1SWO@QXYR '*4,T?!>W;Z%MZX,GT-Y7 +E;=,S$<H-9
MR,Z"M,H@">\F]/&ZE?4ZPQT GLUXI,-1IAC-]V^LA\[\1(AEY5/^8  77G;?
M,WX@?NUTG/<ID!,Z%<)SOO-7!KK2YC_>ST<GIDA )$TRZKD)R:B90[]&W>1*
MO/)_9^\@JT:<&B?N".%)#LTY<U^>_L5: \?'"4<O[TL-S[E%?%ZC?W;MG*?1
MF2" </T52Y.>OS4#;:+I*-<1U!1X:G>-9<X_85_*+R[V'<Y"+YZJ6^E8:A^)
MNA4@B+;>[?XO^?O_U$OE-TB"9EV7,/^N(ADKI2!R$_:?T=JE31BX;PB*B9/4
M[W4V1T^<!A;@]$G_;][F$X+9F"2E4O\=NDJ#TB9$,>6;L,K_B 8?IQH-HV_^
MKZN7_'^P_5Z_OI[_R"^J)L@]ORVNA#J-C2&18L.4*O/R2NH<4(,S,V-,UI;F
MYG;]KT/HX?U.9S+V9SZIR-S&6>M#))*4=4;_!?%\F6XK"W73@:U/Z&H3QBB/
MB(T'%9<\OVAXE ;^^?*PO<"^X&3(;9W;+?FN9W4R1%2QTC)#(^XWZ#SHQ2GQ
MD97!\6\D*CW-J?9N?^^A,:#E@AWCC:SO^#LU>FZD.6OE6_F2F8+7Q]=;\KY_
MTVUF[DG<A)E+&$!"CL\1+,1=Q&ZB"U^'6W<G(,G8#\@LY\@>9[;%O:(&%]Q9
MF4JB5> V84'>MA78Z"O!E9.]Y04MJ<&YH_,OVQ*:F^LN..;,&XRZ[E5RZ-_E
M\YU1 -737[$='K4;C.2IY^19J_5.'1K^.EWUY6?]L>9)H8GU;K>J_RYKC9.1
MS/<9:"\_K4^2>8XORR"5^,NCJ!;^UHQ(;H8BTR%,Q.#"_V#*/6YKR:GR\CPR
M&W3$MGJ@W'L&?_N^?88-MK&]R3Z&9CKML&%]A5#4JZT)^"=6@Y3>J2\Y'(K<
MHGPL]>($:EKHC;1_=K?M#"TR)GK_,7YTCJVF@I$YGIJO?]4]_\S91Y7Z_29-
MA?CF<ON. :J>6K=MN/EKE#+M=FGJ;,!\ +2+Q!EB99'%LF ^9;<I5IF [5(O
M+>,LHG=PLM0\ECP=(,MBVSI&2G/(T5-COJT=P]]G3AEE*%TK67W<.O9ECU>:
M]R;,O]"#<=DH"23QCW(V8;W></$N'%G[T#LTOLQD8'*@&B0YQ5](FOUJ:KN_
M\=6EAP,!MQ\,[*X/CM(\FER9>5K[M4)6N(N=H7SZU8_9GK:O9G]^'YZI'UDS
M;)IWKONL_]6VF3!9ZZ$[X;48]6FWDW7@M?_I0L/_GUMT5L_ <VU*:)"OL>[L
MLEY@P*[.?1;B[RWE%]+E$M']P-0Z)J6Q/_1/\LUC*W\]?>=HW?MXT"A?M7.K
MB;,)-?OFY(+1@%'@HM*&Z--1D#+P]:3U;M==2M\G$D+4AZSO6^@HV+U=-C3X
M!QE80TTY ALJS<>;D=8?ONX+_NQM*!5>/75&Q]8V%Y.C\P-OD79$YBIXW//?
MZM8L6,[^)T]DY.&C K?7?@'! 0B#X-"=TC'/4E$.K)J!D(^V^[-M]5"*=Y N
MYVZP_VFTWOUZ_Z7R;'?S<^\KPA>J*Q^*8>K_O/M!Y5*3FU8-EX0NXRBC8)-]
M7179]BD#6UK^>JV<&_*L[-_"Z"^FZU_W)!W+#RC1R30+'YIW7[W\TXR%D2-Z
M@*[<5VFOX-)@46?#(AM^8ZWNH,G*]R'ERK]&3;.4;(/#-6^90%9[,V?WWEGR
M:QSA%<XB=0_J?HM[(:I&6= R[U4LWNK52[W*-RE(UNA.HWN5G&([WN>."[[\
MF?KNY):6BJ]O]K?E[R]TRYU6\TM3XLM1^$=M^:0^N$*0U>'WQP)]))D._UY_
M\)/J^A_-? ?6)&I(-2AG^M!A>[/"J6-D*<-&KZJ"L'0UOZ</ZY4+;C<WT?-C
M*?YM[-#+VO6,1Q#UP,M:B9,=)1[G:G@T99!.,EX-HTJ.+)BZ*ZM7)M2'1(?L
M.S3TY9/-!U#&V-_BKX?_.H=>!L>^$%\1U+V*TA[M:VEIN><3G%:4,G/U_NRL
M*M/6]%O_Z]V'S]9]_6<I6>80;08SM4UP#/06.H*,"WQ!6H4]1U@4,VE:-./"
M_)E@>8!&,\G_\,;,(-:W&F_6:NF\I37U\X7[!MU')G673UY_C,8D(IYCF4/W
M[LQ0DHD88*1O]@@_LJ/'?Z*W%%GD.*[QG[/'=5^^,Q49]0^;(,</W"R\/V4;
M=Y<K\^&DX5C4N,^KG]\GH)8V>F-_:RMG@8%]\&VMTT3C#'"BX*Z$*Q4_7)X9
MPE<O3@WU>&^[U- ^4M7Z8BQRWU1E;EA__H3LELR'>Y.FEHY$^4S^PQ&LN/R\
M]ZMG?%1OV^ 8^3[:]?'EQ><Z!Q_4##R1V7'PN]#WWX]3+T9FQ;]O'/D1U2IS
MY$A_2.'^U-VY"?.80(U5C!MXLAQ?X'EQO%0'("775V0*["^\^BY<N+%"VY=_
MV^G(EVQ[6^(C56J1?.2_GVI Q!QF9;IF40B%S[4,HXR*M(Z)9S>LQZ#3?Y_K
MX_:I54H7^D%.T=FO?E2?WW+97/_<'".FX)5G-"IB/%5D2GKD&5VYL0E[\-&'
M$&TJ.A5K$(EK'J2RZYOKY^O,C (;[(^<$->$WD0J$[92];.U3FW]YBMO2KD:
MZ!@V1BC@H#[?;\=H-R)33.8"0_<JWQ[WFIKZ<OSA%]_2<-'C/_(OM;P46GIX
M] O>[XE.?_KE\+<[<6\QV[Y YW4:Q\0Z@6(UBG,P]L@TRS(>JU1'^.U:Z2>-
M^#8,2BW;NV]_GKV^R9 M'RXX!VI5GJ1F('LQ"LW"1S.%]B'V+).:Z<K'?9?H
M*MB,QWN^_V!IO( IVGUM#]$@30]Y[YJ8F9U>_!L_(V(#6+<)M!>@R,DBFV(5
M@NA[@:17W&CCE72G(/&15Z^*K-M'.(JG,9#.5,CT0'2 TL>@;PL30/O1\P^L
M;_"G=X3,_U#L\='C;_0QTM2'>D*.=O^D]7HMHQH87W>=BUA6C7 X,.H5.%$X
MUL,_'5JUT!>8.."Y?P?ZZWG!N],=_QI]]TD#0@57 ,;]^1P',-0OEF=[O5#W
MU80<E:LQU+IE_\>I^O4>@6'=$P_EJ3?G3DZ5[VLD^4W'^CH 49G-P19-]7H.
M?#FJ7$%,K4_UM[GF$9,BXK%:NOG?269CJLHO(I+/_:-X7&[+VYQ0Q[3;P\,_
M.TZ8WMGX@,L:&&F,B[TM0<Q 7*+5<1$%<O:;^/[B,9"5^E1OM-VL/O#KY=E
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M<SAKZ5:R8^@3->#;;D3"1-MY09SNR*?G ";](!'+H:3@X*A!+P_0S]#F,=C
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ME:\WIU4_"%F>O<>%IV-V-R.GPD\-?R>E%$S<G&DJE?+^=8'UOK+KNPK@4WT
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M$3*7"+0^=^5\;?@(=))4ZT5-66E:QFF<F'/<RUEIRP_)+(^OOUMZT"-.1['
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M;F@Z6^#MN@D;YG,DO_5)W,I_^]084QKAD,(VP5/PU\K,!>.;L+G'DB".%Y[
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MHS@G9+Q?=/#9Y,@L14*46+FJD4J(>X^J]3;JM3(H[.YSP.5W;,+B;S-"@K-
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M:5? @?=LPM+; GKA?X#*XSRGD:>F@]OZ/%4Z-V%)C%W$R#(0P_044[?=HRN
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MPO61U*^91C49-'N%W OEITIW[5[LS_ [VW*D(?<S,NX@5DV?[KTK >=&*L9
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MF&XX-%!+DB,/1.-0_'WZ4W.*@.L\5 R5N .Q$;S15 _X[!AP9+]L9@ISG-H
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MKWJ#6^;:QZ@*D54&@?8UC@-&H997Q)J#<5]V<U\3\Z' Z3J.--R1%X_C.*9
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MRH[9S;H5GN4)\#\KVUC1[8Y^;?)^BW+UL<2/:DCU][:.:#FQJ:K5KHD5G*P
M^EW;]\=UA/)LW.?:A*&(PE,VU5:3)7\4>@?M'=KK?K01XBG^0OM<+-#ICX>5
ML!]"9")#69D%^B.5!CSVVC1A@:[C3["!Q]V+!?JPP\"QQ3\+E,("_<@>P=+F
M$UB@;WHL4/5E"K8N"+9_I!=+KL3F[FQ[K<S_C[;Y&]L#6\+NRP4M,K3NPOZ
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MM77^7?#KM>GN9D;?(R_&P;Q'(F'B1*\1"<3ZK$.T_E6T')!&\^N=Q<4&-!Q
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MEN=1;?RNZ.Q8&8(WIF<P^U2]6W=;!7G%J(R=7WZQ02HZ"79O) 5W!.9;R]N
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M&PL185REL\DDEIL@_F-6ZRE3[0>,[V5#!ZV\>R0! N[0H6WUV&-4WM%BF#I
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M@CR"J%!^U.O=P0.7B;C\7*5RIY/CP?/R\,;QAET"(=S,+UPP,^+K2&A@J.J
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M2(9S2W2UFYC@5TB[CUB@.*?#1H(J<W)1#$NN@C0;]V"CV;CF3JF6]* L]DC
M8@@*0&T5VA08IR:$1*B#!5!U(VQB%[VSSJM$B>_B!7>["7YF]]["1]R+Y(+D
M1R%ZW81IN.Y%288:;86DT%! 9,\A\@OV/+(>29'?_7<Q?BRF&W:6"5TOD@.L
MZ)>97($'?G<P(_IGZ'_H7FEZAF1$TK^U"SS],<P1"H*$$#70+_<BPV.)M)<=
MY^DB#ATT^[;/#-VQ'7@L$P+A+:/%)[+GK+\6-13&!LAU8.9 '=NE!O-&S/;_
MNXVD\:X ]IG^N7!D/%,,?AI53D%VI24O7 +DEQ;CIS$7)P*4&^#<#+OV.EH#
M4P#HI4 2PQ!)"*I6% /3ADP(AIU$7YEDP-SIQ[K=+HWIV5#2YM+BL6)$3Q9H
M#L[D*F1[Z3RP3(8#,MA(]NP^#'H/>9NV65_%T#PL94!I2'(U6FMJHQ$RLTY-
M(YD;PP$'>O<(9;H;#%EC\V/HF[3>$0Y@R0@()4// &;=4N*TS>^Y2RQ00IM1
M_=(FN,LYOJPG6_ AD!_T_NX:N2QMB%@7V*BF8UO'D-]ZN=I1DB-5J&Q6C. I
M,VWP4+X955]%N;(,E7_Z8[(H*-/N2=,Q[B*;''?E7Z"W3GN[/_6A1=KY3IMW
M#'V!DZL6MNONOA8Y4FJ^4EV_#'LQ/NQHK%K<SH(GXG;=L1+$G6+B/6?&.-MA
M8JCH?BD!]H]43"]3$?"D[3&%%WMP/ !X]P6=@[05BZ#E^$@=98%B"Y92V"GE
MS\%M7WT!((+MQI&$\ZV?T6+L7T6=_NZ4$<!,L_W)[[33[#2 ?>!K.>3EI:ZU
MZL40KV6!%/X"\EB@^R+T=A;(66+7$#^, ,X_ 9[#R*5LT><#*!).()]YO"<V
MC *WB8(N/5RT8<(%+(F(]4D#KD]390!S6;HI2A H/[B(:NW0E  BT;##E\'W
M_/]R45@:UL13U1_7EZ4C\AE$26ARKDMH4].<C<59%B@='"..8*J?73></L2K
M;7GN-3PD'B4H,D>(; ZWB:3"D['_EG1+PC7@$CH4Z&WS(3 AAB_ 'A,G[V(/
M-SQ)?"61(/4# Z%CGS5L"0"A#F/^^B=0$A2TOG+JKVXB-UJR"B@@.<O'HX^1
MV51MX2CNQI@*6@4Q(<^0<*<Y]!,YT3Y+\C1CAB!^]PK03 NB:L5MH2.HV)EC
ME--E=(X^')_>C6K@\=HZI3^!H DGPY.9D,,B@C)S>+8YNL/0BT8D06B%"+0R
M?3%>7YNA1Q<N* &J;XY#;@&\2YM*O_J7V"@*-I\F^@XP.-@!RTY8449H\*C_
MULER/+#2LW@,(X8V 80.G'T)YVG9<?6T$<I6:@,N67ZI,PO2@.ARR.P6WR)5
MAW/JR]V@3?>$113%TSFZW*Y.CU.,HBD(0=0T0V+\ (9V !+9S9L!O ?7T6J
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M-0-*3K,?Z*O3MSS:<\*Y7O&HVL-4N1,W5Z[?NR\A>:MO]NDU:$];? _D)-J
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MJ$_U^4)L!W)9P.:=LY"XK_DBO;(9XO8IK[81((*4=K-&"@%^@3,7DMZ!CLP
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M7;R0@S8A$.?5OZ0MTD!(PL8!)\:.M" *+DWUN,@T<!EA:'_FZ>W6N/L<=DW
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M"*@J+3[472,M&",D?["8Y'<IL/P'AUZ*]M74B)L:[HX*0'8G'Q((_4WQN@[
M+OY2=NH>:HIB=&@5\^0[_M$.DTMY#7T]6X829^&' D@*A?6SJ9\O["PFC7J)
M]U,\JS@CK6VQG.Z=]U-D$LKDN^\5P$53QI1NWGA*TU5VPJBZWES#$3LR[J+=
MLL\G+2/:7?6#O;_)X&I53=65-?,TE_>'U.\NWZ<HZWNQ/_? (T)M>B61^<=,
MF4!*X'U5WJ8K3ZO4+QU74,=.[")HQ+MM_7HFG_W\JC3-=:MJL,DF)__JTYCM
M/V/9WP04)KB?3"6!P*DV<[,SI&J@-]/CY+Z4 ?[F^[_:SN1MEGUOOPRSO!3P
M I1/DO6HSY1(X5<M3SX90<=5ZZ#"Q+N*K]!PI\P^>L#9%G# ,'WW[MDBB/ *
M@P^2(E <,9G8</RG4:L$PPQL07/]SZHH1_P2C'G/X$'+9:7X)%+D+GRK_LLY
MH"C4H-%V_D4+ZY^G\[.AO_]':S:0LF\ F+7WCD<)57MU:,9ZAO*O+0S[@GB%
M+UW]M?A+"LB^%@:&VXW +-(Y:O%W8<?1#7'6"1FLTAU< 28>(R"WOUO<!?3B
M?,IP_\3TTL^JC^AV6;XX@4M_.VX$X ./51(*>Q+F'-0&@C]FLM]71[BD)(37
M=7[[8[72U@N/G#D'7+#:'57][9 ML4\I$+I;LS-\/1766G?/ :+83;FYIGCI
M;4@69]2!VO>X=L%WO4<F^G4K85GS100[_%'#0A+PB(@\@W_:1^TDA%)D$(7!
M'!I?1#M*"!E8G7!XX70J<39:@F]<GBI*E&Y@Q48GM35L#W&92^VUU??%&@VD
M4U[8^#G@2N616$3]V^6N!=[1O#2"5F@92:UA[)!@TR0T Q6*G+?&/$KY+)1Y
M:G9<7IN$A;9###TH?9 DD?$*O^ RX5Z,]Y>%+I:8T@5Q2.J?CBLV'C1\\79Q
MP,+WI2IU(6E$-9BE%&>('P'NXR.FE4?@[0KCP']%^;.=/-'&./!UE$NL9A50
M!5>$Q@+T!W1J"H*SOOH8SQ3.EX'73OWD$AIYSJ"AQQ<"PNP(U#T(<2O?XI"*
M9L\;A:H9\WP)Z5I+!%(5[ZV,%;Y<Y+>37[;3%OKTS@XIR+O:X[]8%9E$T]8+
MXG%P-UCK,M%6LWQ5&39,S!*Y-N[_ASM2&"K/AA5CE^X3^]A.74 GC9HXHN.!
M;0\6_IX#?8FHW8((>V9N8D\I&72I/=WC[J3MKJ85W:M.BQ6\UG[=,.P#B9X
MDNK:8<#N648NT-W:TK_>4%-/'\BA@* '/QW]U:Z6WA"8/;=)1^M\T/TD7PDE
MHU&3.-AB.3#T0S/#(4-+[N_!.>#U'K3+;'8]+_9_MN0T4G *&$SSO?F0V7JV
M87VOPD]!?[O#U6NRW4JVRM)Q4%+<L>91O]09/8V??'QMZA'I2-%.2OOD @I-
M9:B*639GL-/DE6[&^XN[@YPZB_D<)RY6L=9^8E5R$*84X'%D#*TEOV^9S\J5
M-^1BX$KVZP>FUZ_2@ZRLALCJ8^2>"KTM+N\^M529;4VUKSIVTT+)\"B9A99J
MEQ77.@&NW2MZZE,_8[81T'',>@7P3,U6VU-%;[3O97G_8RD>?CJ!E\TL@D![
M-B$_"R7ZO+;Y9(_P[O72;JY[IC>X/S+D#(M__L;S\:B".C(?;91R1W2]?[.K
MM/J]>=+#ZY0SK0C<X*B#>[TAAQR8R9EMV9]VP^LUI_KVC0'U.#N# .ZNGUV
M:>:#P8GW*JXMAT!E4QV@C@+J)LKG$X"WF?65MB=@W<" 4OC/:527NK;C3##%
M,]HK!B4MF5;N''+I;I:<%M2L+ JX=^H2 H*ZEI]VUNWE_'?;U$VF-\GLHW7O
MO+WI,OAW[[JG\V&RO[B9R+W*TR/;1J7+ZSO<MWS_^MX\71>'_QN!T6F*196K
MKS;C_2.I+W_O/RA>\GIP+^8[]4BZN=C(B(W#3H +4&QAYO1B+?3^K[.&L$<D
MH=WR2$HXJ02-.X1T: TLH#V,$<\;?T3,?G,<RMIYJKZ**C5,OZ.;YN*BNA+-
M*R7$/&FUHDMB&<!F(_Z9W'Y:K!TJA,AJE\ &NF;H.HE7+6>\^ @QV!;6+EL2
M^W=!XW=(-2V!6!E;I?F7#_B:[GW@$6*.["HCDULX5+Q:"O4ZVE("-)"O"1XA
MKKTDWDZYN7Q)(6Q(W)VUMW]+^A1^XGZS3]A-FT8$FD/SXD+IUJ3(UZ67U"''
M%U+O[2>2^QF2?,<N06<-<]:6%":^.*<W['=5DRE,=BNS,CG_ 7&D9ANWP5&4
M!#U$OSD&)M#V5+C$S^9KG?5,'4#. 13?27>3.A%5?3W0V+\*6SPE>)=EB\E/
M5[%JZL,19&X8U*!V-$XOT)LU&@U<%F[G%7V:U.K8ED\D;AE*]OXU'1=*G.PR
MJFUH;6GZN!,[,SK*VM"8:TEFPT0J)L]6E\AOX27@T"RKHFL>,.O1SM&W,Z+9
MK/^-N/<,:FJ-WD=C145 >A-B0P0$+#0QD*,(" B1+C5'$2D1(SU(2%1Z,T<0
M4%JD2XV4@-0(!#B*]"8@I" B37:D;4GAYOSN_&?NS/UP[]S_A_LAD\ P.^_[
MK+6>M9Z]%^^"W6O";=F?;W:"MD5<!#-AQG,38O,8F7>>Q\6C/H'29]J'$:D"
M,9\NV,U>/FQ^V,DD/32Q[^2A+NP149<SE.<#X!725@616;(:P4!,EE\?S40<
MPO7A1,D1 <.R=]K]649,X]PLIMLCGRBO?QOED)$3[?I^#:_/9%F-RE,=EH;D
ML^(&UATJB97AZ-4K+((--P_N34RFR6\ZE:0O,TNZ-(]CYAWH*5LA[J=84GFE
M/DWW]@IDH L7MZ6:_ KO</LJ*RX*'W.,N9_ %=?HJ) 2%(HQ[T\[5_IG-.5'
MN2;[26$AA^3!=05*HKQ!/(,F $3+^9? ,LZT#_6\*TR[11.53NKW5\3?Z?.7
M^;RT2I9]YS[D4)VBZOF0Z]M4CZM;>>E6\A,@?MN%B"R7WO^_WP*^-B:+-/T=
ML0LA47G_4NC9<MH+'(E$WB$GUMK6J2%-OV)P!)!W':LP5'!Q][VX.*(^.GL2
M*F=XK%>G],R0:?%73"R2T$43[MN<+JK,S;J+\?)'RWIRJI"@[C;OR$":,D/J
MV>A]*($HA!?M220LNE_CRU=W;LLJY2YT6KDS]Q0K]]TX=+^AYI0+1QW\,GPU
M@F T3)8'2P *5;9 /@8KP-147;?^<&?^ Z%#GY!XHB[^5U6!+3MM%W+@Q1B%
M7H6L+5D5\9JC3*K-$59/SM$F*7/166!LAQRT@Z]'N^;X*M4!=[:NGJ](<<*Y
MZOLZ]/LV%&7;S-ZR-)]K7^W^K:$UO<P5/OSK/O"MP1&N8#U7LS+<)B\(4U#5
M6^R5-K_SX5/[J*_A5/;](HFBX/X1!Y_%4L[E-_=@5D!M]XNS]!>"?;"K_X*!
M7<=#/)FF(AY8HW8O[4L[DYNNAL(9DO<_' UQ3.SLB-'7_FFAC3'?X&:UV^7I
M!WLXER@AOY3CP1,+',DGY[T8TK$Q>CT<+>A3?$F\R.GC7G\V9^OYL2BY"VFW
M]SB-[T"(!.]""IX"HES3N!WV3C#I4@.W!D]OJ9#N8YFN?CM\?([N%6\F<'P7
MTJ=Q=\)@%P)%5,$]1/X;E^O/5^CX*67&+J1#1)3SD!_;$IC3MFV\KV J2[R;
M)BP063=PA&,P](./4$:FWRXDP5#!9]QQ]BPEP3L((>CSSR>M6E1345K?J$K1
MY)+NA6"$:-9(B7YMUW=?"?J",GO[5U&HIUS56KZ%PTI!):&H7R^U)SM#[<OE
MI($7N&2)2QR20%S/',HD0];AU86OSE9DKR-VM2ICE=8=EY+UM>ZJDI?TA@L.
MCV:?VH584#Q%GNU"Q/D$^!(/W-J%3+O,.:Z*H+T8M!>YVKI;;7)#ZC!D,:;J
MJBGA!N$C\F#=M*6794MS;>:Z-:LG,3@B9*N__T$Z#?$AN4I2B9SUB7=3:SI2
MXG;W[[JBTS?"7'^8R=H=?#D0$ICAD7LG?:!D0W 7(G"8]ZTIE*H9QSO&C3<\
MCOJ]-"L&RD:@F.BDJ3+W1.HX[WQ]^I:[(I VPY22;E#<.XC^M:EY+/VAB 28
M(J_VFE_ :C]^N0O13P\EAOZ8J][8@@^.3ZKK#^<Y*L2;.7Y151TVTRHPN7 [
M3]'A^_!W*^L68K-2:-" Q<_U%'\IS9A:BCCF<_11N"1(RF2 J>*QG8PEQCL&
M!G_@65'&XS:Q=,76A\:^=K@"N:\KYWWOJ=G=@>'DM,O,6U21HY4:.X$\O,@Z
M>-_1UBML4'S@SR+7E&F R'":#5H@S/,BV@JFW]4U+PZ4(-9Y$?H)FY[0Y0U\
MP1_#)&XWF>\;I.6^X$T#J_[U$A@K,K?M#8\XTM .%<=6LT2Z3UW8F_-D$]!_
M]#(J!7=ULL8 M=)L>5WOU:?+40E*/IX!C\7^&P@GAMDC:J'[\"A[HMUYJWBJ
MN['"]WM*L+K5UF;@J%(7-<4$3K^8=GS' ;3[4\Q6PT[SJ[0(W?V#KRY^6/K,
M>=G9D=U0FV9>9M%K;.ZP3"O=.< GAW)NJ0;\/F(ZBX[N4LLQKH#)EX+I- :-
M^NWSJ;H,Q@+A0>Q?$[_6VM467$!?ET2H;/O!C75M32&?[ZFU*'R)"8KS+#_U
M:.53\_=Z!O(">J=I>8IIO"(B8+66+,X;)+[?7J&P'NW\I"T;*H'&C$2XV&S&
M)>V%Q!;E1SPA5O3(1:4&5PRQ<Z?NBTRZ#?M.RF$XM/OUC5P1><GRA4[[B)76
M2FA.*YGF*3G(V\O-_R9R_3*P"Z%FJTO*D7G-[6_Z["5:2VJ2;RV<^$%N+'MG
M$7?RRN??0:4,.E%)KPATY/L;'#=@O4PYA-N+&]DQ?A&,CFV[,&HH@:E9.C3:
MIQG3@O+R9VH>=:5=D8]^$4D"0^_4UK<?T80],%(+*[/=TN0=UF7M(*=,>8>W
MV3K8ZZ.:[FSJ$Z]G3-"?.;D0L5T#$AC1,SW/JM";!]?"JR:]TQ7/I%'F\Y=5
M-"0,AZ0YDIT,&%P63\_&DPG1[B.KH<Z:':NF3*O7[[)^B=\&K<,\6:?@-:%.
MOTX 75V$S]=2Y!OSX.>31+XW<.366.9^Z*U@;D&;\+<9V2S&1!=1&)S]?/BX
M%+D:?,,(TXI]+LGN?:C9)N?FNKK/^T-+SOJ;FR1U2B5 GB5?:HG(7PMY=^]\
MY>QPN9.FN;^;"-4+OKG]\V;9/2BY#R;*TM?#&I@9/JG#N"1&)$4DS\S+!:^W
M;(DFM+ZZ5':!T'Q DGO=VEAR78#U^']CO,0>*L<4#&<@$W@'6;J=)'F?!5N
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M+&@G8G*$L97#- BW!]59LFUBX#VHE#=>"*M&FD3-G@*_T(3J"(<7,Q4I7N_
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M\HA6CN]R9V9Z+7T5Z312$;S,_ZM!LL]&>/EK\J&@/I09)67&+UC^RH,_W_D
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M\/M5I97S_H/^U\4RK;/?O*2^_\CXM;BJ_*71V9=3GZ'5F&EAN_Q!,S(P]\K
MS_M.VH<B[I;$49E+GV^WSX/Z <]+D[O,+V9M60=&J71DNRZ/E9JGG?L<? KW
M$AO"_< '&STYOA0!92I3$P58]T7CH1]YD@T?6,C$@H$9EU4U4Z<18R^HEA>R
M<3C%^.1<B(T0[@D8RSNRS=;TE>MT-060<P=+]^2J*/)NML@7M?8:G;ED_'A<
MH%M,W]R23'G-O*.<JW?O^>)\S)ED? YQ/P;9 Y?D6'CF@3KRJX[47*6FT2S+
MD1-Q[BC]F6\.Z\C9F5DW7VF=-?\GIVM;<W^Y9)6$QQ>\/A 0K]X5<?CL:+"9
MED56HO<O/Z9%;./G$ZC+\Y%7_SIR(?#'#5'LAX;/OZFF.Y<'-$=M/@6LJDP$
MDK0:OQ<I2=37O3J]=J9E7GU[3)F;\T^$/%;OHS4&2U/(]&HLDI-8GO/DYG%S
MCMPN5WW%<'BQ;V_ZJ6@Y\KGQ9#@ZL6N]/^=F=\#W%,)F$9#!.Y+&/L&Q:*D=
MK(+9EW/4QI0O.$].<FX-27<V67R>O_=B2E/,9^());K2'F.G'U-9DG=[[U$&
M:N73YK+!Z2[HU.\'_-I@*_[ ZHO&^\#,5[>!QT$_U=57BV),Q,^GC^>ON.;I
M=,N7>SF97Z[!'Q_F: UOH(7X*:UIG%!ER5B3<</$(@:UYUNB_38M:$<4+F+-
MT%X'FCXS-M+'@[J(JQ?.')UX7QCX&3L"G8;6Q*Z&SQ&^3E#U31))*+F&9,J#
M2M3MF$XW8'79++P<JY/RRV@7(@F-.NB4U_#TC4:PILATU$AP8E"C5'VZW->&
M#XW?N^_7E4B?/V"V/I)QJ<AFV,9_V_6N4N\:ZDR!<EOV8CF4R"(-T<Z41E/G
ML%>^^&]6USF<Q)?_*3*7>?U#O*/_,?5N3<7G-/U'+PR3S2\7'9<RE%1R$3T\
MB"F3O%>*V+%15)T@FU[\J2@Q*J7](7?*TLCMXN(6*XZA*;1)_O JV:;#YW-[
MV_C.E8]B_>]A*&EB&KX4,V+2.(BT&0UJ_!5LL8R2W7#3Z';)LE&\,\[<DBU\
MKF BJ)WB@CJ8&W8FH2/B^OBO):?\Y$JO7^=;3/-]<8HU+/<WI2[\#Z,;Y9:H
M6V-!VVS/^I)B7ZFAF<7M)^%_'9]5XHA?W[)X5&,PE'DFVNV[,8P6\[!*NWQN
M3MWY[ NS?WKRG.H^:3F$[+>0<WL;_9U\:6#_NE+KJ"8LM3TX/"@CIL>6/!)$
M>?/J?F'^@J[.KXF/;_,G+OLG$[=M4M.F)VY,\4Q][69N]F?4!LVK!D8QN?GO
MLJS$;,<O)R)RE*3EM5;5D)3_3N#[G_-K8UB;8-U0YC''B':OJ?O>M/L'M5_<
M#*'7I6]O2XF_^M?V>,"C?P\@7F&L)@)G9R^;0E,?V4A]2$XR],>DR^[_>DI%
M?5.V+A^C,=AW=NS$104H=?J-W.]#NJ71_M!TVQ\O7# I(<'8A8>+I2953R&6
M%0]#CS4'C/"4W$4CYAXVO=F%.&IXQ@1]E;'<XUIXF<G[?%LFYK)WBG_3"5OO
M1<D?$_Q4M._WI=1M$J>>U[;MD4%&-BSIBL<=N^$<_N:DZRFCHS5A8=<&U1MS
M9"7\XSXRPJ2#E@.#J_011P--]V!^=>B<%DW.#/]6X/<GRL8\8]\)]/0G-VKD
MC>1[SW]MN=R]]#8B.L=:X22!:_@UIOM'2O_WSP4G4H7'>B](XCM"5((F:LR5
MH2<(6..GF =JGJ&R=W<AZOM\=0*Z#SV4O.1Q,=).:<N^:6NQY,^E,K4E1>5N
MQ>' X(;ML%?MI7NJG6[.ZGPJOY2=U%WL"D02BDX;QXMIR=MHV1DKI$'LH4\A
MCM%8V/OT-0?4]J6'#B$AWMO&>E&%OTM?+=P?G#4KMGI[=T:0OB(LTN)@&ZY!
M P1C^K;Q$TO_:[B%0%^NEEO3MQF<5QMZP'%T.:5JNN>KW/J[I9>?Y15KD.[?
M M?J@^&WGOSXD/E_=E5MXRK.Y2?<^Y]F%E*HE\\[YS[/=\XN2"=7C<E533]F
M4_V;B#//@S!$A7@;N]^%BKY=$GN8MWG_4@["7*JD&H 9WC/MB=<->"!Y65K'
M 7U@)=Y+W[+(7<C(,O.S0Q.R?E+0_CD*J0_7?)F82>*(T[8> <)9IS$NG4^*
MT^[B VI]G4/>1* *77P;;C^P"*;H2Z66N+H:[3_X"W,W]Z>S4V)$^C_4=7&D
M-4>?++:LXM_O5_S77WH'/*M'!_J6]K^\\1&/4>F17'+7@;(0,VU]\X>,97Y.
MQ)_-A?(@FH(XF=* E%?!O%QBGG_"?'K.+L0$&TS?A<3.'@8.E#MCKG;J.T0>
M)RX7USW]%!%PLUU7/[EW '_E;\@IBW2K]K^8S7+GRAK_KST7 L.YA_R58Q^^
M#ED_M3:^;RL0_'$Z=_*[?\*R6B:0=)!VK2YNTVGS*!M/[5[Q^+VWR;F]%5G^
MO[I];MYU1[!TJ'4ZVZ5'4JI)1,/'GQ3J>';6>PA9_:EV7K#O@K@H,=,*1_4Y
M!3U?_?.]U;)OT5>.$N9[%,$B,BK^3+N@0KZK]MRO#F)M<I=_HZ_&,#)T5L7W
M#;/VLR;LBFQXZ["S3."CT^VSE)\AM]=DE3_5D"E-RO.NM]J?J<;4M-1EF%TZ
MF!6DT?S,YM.9^6Q5M0,=%5(WAW6L]N 0_<_K6_0SI!V:TE_%R]6TAU[Q&=E[
M-MWM,N)#V.%V(S3*H+/TWG[TIU^JZ3'+ZJVKV0U(+T?'KW(&/^.U\(O;ZA/H
M#!^_[Y'/ _54C<H6W/#0WSQ*N<QR268#6NG[#KYSR?NGM9"I\>A#>,3YH:H-
M6\TT/S$!N\@O6+\C*32W)1N3!;&JS$*_W[WE6*%W60J^$AK+QX>-F[0(86EM
MX8$MW.\QLX+-B9]D@MB7TO]<.U42]<M&"+$R<;6//&PF234>UVNI3[BC4?B!
M]M2!9O6!\O*V0M^%)$C/$90[=2HT[KBK%WIJ/>"$D_I8NM/1)TG'Q&/OI!@%
M/ZBJ"#BMI! CDS.!_VVQLZFP%4&<+^,ZYO\V?)O_SL?1,KS89_O1A6V=D)&;
M%Y/,SIP;/AK2F2Z)>Z_S__?_@/Y_>O'"X/0?!@_F_CM7!XO1Z!>X3Z!"^=5S
M9Y_<ZK43%FAH)R5QBED@PK0.SI\VB^18E^.%33=TD?VZG./;1/!O=-3K74A!
M*R",(P+%.,-=B*MCY4O\OW.:NY#WK^&9S<AX=L_0<U'B\+Z.Z#.9!"EZ6?E&
MCESPLFU&A=>A3V&%$62^QOH+P"H*\1> Y/6.5U,]B*[#L%!F[SC\B0_'@F74
MG9DMEOKTIEQ0_86>;.:Y NO?3]661,!SFB^\0!1;D#?!TZL+2?B?YLM:?/?5
M9(T;>/6YL5\P@<JOB\(OKCBZ62T-EA[_M>_X1!:^_9Q'@B:H++T2\G[N+JC&
M:)3?!VU+^S7_89$V$';I26I*6!6>)RAX_K]QA9?P#QLBKPZTL\$L68%/67>&
M&(V+TRN_+3X$G3[Q_;Y-.7OE=WYZVXAV2H:;4J(/[VAO7'[M6F%5*$(VK$>7
MU7FQ(,YV&2'?D^;3K\&54-6;7$DC_%[6L*C=A82]B=N%8+[SM(#_SLFZ?5-[
M9WPV!_J=0N=R:>RDPND?5JO-%,?R1L.;I6FUF^_V_/MOT2>)_CC$KZ5F/)(P
M[W'&[O/DSECP0Z[/Y*G(8G$VD<$-/H_?B3,XM''Z@S:W -].@0*.5_$2/HI2
MW&=P'ZAX$25A W4G"#&9Q3S8&!S%TDGT4^S5C-2?W_P2R5-5%Y80Q>KE^EQ'
M-9VQ!G4N"Y,*O75X)WCJ8[6;)!/0%%AG.G81XV</@/Y X%\3'&N611=/:42+
MM/=GKLREKBI7\&E_@U2HE*._A<#6G>$O0F4SRX&N4TX_'1P<]?LV5]-RDK9O
M_VFLVAMS-ZK4O/GV=ZM"-?B?P'/EZS/<+!\-5N.?C*0V6: AX9O@&S[R$N,%
M&2,=P^5OYK.-;"=-L%<)'4.EYW[D#M<MCNQ4J(3??*#E.U9B(?HLS=N\2"XA
M_53&UBK;&-]N!*?7P?=3_)#"O.XV.6X6_ $R/C.CR])J9YF.I*I?;4=*K<#4
MY@A[IOJAMUD.S>^@B>*3H#-^K\_O3N4N0?E2%YYHJ>2C57B=5K)'9T93PQ 1
ML"> JL4E[#VX 9X":"L=WR+.W(5,4YA>S^@W$ =]'$,4A<#'FGZY VY@+3PV
M.,>1*I=.+)CV%8Q  0.=4[S2B'"F@L.89K FV4??L.$H\0GV"*N^%@ADT%9H
M;$W>&+0NHQ,NP9O!7001S#U%OBE3TZ858*\-L)IO4;[4Y!YM,)^V%C\'K$ G
MZW?J2[5XBHT@(9#1ZD4]YK,35%HVY4U;*.+K[[.@"MN!<Y#['J?J ZV7JBS%
M]# ;$C?+B;+&+"O_RS^ADBV7\;#T)N5$+%3M3,A6KD+,\+B!U'2G5/5TR3.:
M)?I0EIK2L$<4]H%]=,</O<]:Y3:=?)TK'%(D:_SC4M(W^QO?4X*"7(=><!VJ
M: O;S[%"']TO^,]:I"YD&[1C#2+I#VO"LG]^O_.P5\BV&^L@KM4U7_<A\0"W
M-+;3Y+B2,=W#$9I!SY.=Z!JKM"*K8GS[8^S7SV3^*"A?DM[IKBY%HN2ZJ_'A
MY2C]MM)0;5YI^=)4SFC#5&YY*=+U\C?W)?WD3>IV1D-@<U]@H%;-YZYO"[C^
M=9F%$^Q-1>("1RC,/N?'Q77_S7[X@#_/U-$K;"3W*F$)/F @8H"_[K_2K.9B
M$;(Q-=.JCMZ4*SK4H2J:D'3JOT/MSG6K.)WK\LY/RU =4J\CM_Y/.TK00D/U
M+D1NJ6+MX@O,SL8N!,[U7YU/#WTMGX@M*%4^(L"^ >@'G_&@5-J,P2)\BDV
MQ8J,":JD(WL\9/7?F?.1W/#3PJ?B5@=V/DE@2PP=MAS;<G/6%L&MMMA]'^VI
MB)2DXX4S.1G-$CN?78R#FU&[D+U#6T@Q[/TF]^2SL5Z:G%MD3$OCUH49GV*X
M^&6/7ZWT@[,GVW\G_7ZLX[4 N7;<9F;F&\VU+RSL\C<WURLI/H570CUZANS_
M.A+W5O7$D;?G]K[='^EF1R\M#PKO':B-:%+>_A61:_^\)./NF(RA;TI&7>55
MERD['V7/X8MF)FHU/X9M7AK@WTYPY!/GG+"V?#Z>&JJ[HJ1!$<9=XB" H$,N
M_C'RVX-M)R0@*?;NRSW2-L\^GE\QM44N_"ML8HP/Q@.H+R.4%4M6DXJ@S"GN
MN^"U$XK/"D%K(+NO@6A_*UL8\ZD'>K6KVN;S&=I7ZF#*)G9P9%X'K\2]"M15
MX_;<0UE=#.S]0(FIKG-Q[JYHHV18I*V%FEXHJYO5A>>MQ<_*1';O0H3:3F(N
M+5W4)B6VB# 'CKI2.P-ZT:2?NCMV0S79SQ6OUML<^G[<D36R"SG8A$GWN[H5
MQ2UK$52Y^*D*JPP,Q%>I?UKH ]#)&3?WO_BQ;R[^'\59']XFWF>,8XAO;_#,
MXR>?E[AAJ?$_.J>W'H&YUXZK>!OJ8R5>C*[.I1Y-]9N;ESWN14S]C-2QH-K1
M.DK_+L[8+G"H(.U"4DQ_P:-A!U.[(XZWI4_:H\.%$*>!->WBW#*9[+/^.4R[
MM V;5X!><'#Y=XL\;ON0L>2Z*>OC_TX3R9M*[R;3N(UDB[\F-IJ%4$;C#ZN"
M9EQNCJF?:!L)5C?\??;YTN>=_ODS#8WD#]&S*GF9NB]NW*LHE/M-BX;73K2C
MGZV5]P$EC-EG].F<\%ZYUE^Y&:'ZT=]O5V,JY6^/5I%(]]Z_N.Y)L'J.J;!!
MT]0_I"Y40*=JN]O@8##[*L>!U="QK-/"&HAMN80.<DLW>]<:Y8?W1)<OO_S:
M*P&XF3%FA",LD"\$7RN30T?LW*YI4[+$<6[\=*I)\4%,:3(GNA#R& NF2/PF
M+<[P8 ,0/1&GL1GQ1*LQHU/Q)&]BY.W("?+8\(R<'KD\O-)&:] SK>#BXB[D
MX<@]<JQ5FQ,KYZ9)I9Z>K@KVTKS5]":MN'[2MS_.IE154M7$Y[K&<.QEU_':
MZ4=E$S.T:C;!6,*A1^]_)MG_"Z_?7I5DBDP2Z,$#5.@1[Q!]6KPV5&Q146PH
MIE)R=$<G([ALVC=TH'RI?BO0><#?#^U3Z-J.WCOK?"8S;2RA5\W$^7!;6Y5C
M]ZP $$O%'UW*/<JBQ091)#%(Y_B3HQMN]R8?553=L"FBBOD]A.GJ-%PT#O8*
M>\1RFYPQENRK&!R0"#C?9]9MKIENJ45\X*8KTZ_A_R,A)8 0/(;_N%P-0#GB
MS5N=K(55LP*.T3#OM/?4#<-3(%XS5AEQ#/.DWP]N-<8OR\22?4XVM%:G_UBZ
MZF;3[R?,H-8/]Z C_![K3+E\\CR?@2P<^T$4;!/&7@!5\EPQ*(;7\PW\0>_M
MT.1W[M.+_OWKM-F:.-[(.U_I6C=?W=\]8A47M.>_[4*\GCD(XC4D#QEHI&GK
M=:@&_$B9==L,60U74]LD]SC<SC$SSPX[,547[ITZ;1P:ZDE>X0M+I]?_3^[J
M^'MF%R+@@__T#->'W,+A]NY"QCVY%6H[+TD+^WC"&%">19I;6S%B&X((.J)]
M+0$IUV*;SYMJ.\)RJ&:0HB@B+2XL*%4.$;T*]R),H6XTL<Z6%&"NWAP/EA<Z
M..TTL:%^:NY.4WTB(M9VO"[KL(;4LG5M AH=4R*'-4KI#T@Z>73D@(J5G\G%
M!*KM(YO4&C-UET>?%*'BW<%ZJ+B[ASX'YIIF73\6Y5ITQ6)/G'72O=2 5UEF
M9[+\"M,&Z!F,MV !^PH-*\%M:%'%'J@R8]"F''9V(7RE&-5RH^W$*):6"*VN
M;%AAL)IOXQ5^-MW#1!0#4HVAK%J&.]%G%W)H%Y+LQS$MQ7N!GX=V(0QIG29%
M4AF7S_<'3K&\XG<ACS2G1WA'Y-DW0225<FB-HP(0>_0;"#\F.*+E2[JSLN!+
M0(!1THU_3GF?T4X2X^B/!?429!<-ST]P7 HP;#HAF=QWM\6X$'/5?42^.U<)
MZ.HF^L[* T&[D(A%)&#)KU3V(?G4IH*:NH6OENYN-#3$PO@_5Z 4#1 B*-I^
MF%$^)X3/F5Z$X[R>7<AAC@ S.9"Q"XG&&N?Q-R".M::+B'/^'N3)+/+41W"*
M/D_&R+P\^DTL@K2X5H@]/ZY-.AI(JQ7AB"UL50[!Z=F[$,!N( YWD<O?G;<?
M=$Z1PK_:UV:ZU\K\VR6H,.Z,#TV<@V 0010Q>A<B!?=QN]Q!VU?P'"ZUW*8X
M$D3;RQ%@&=!>;(K$;CO[55*B.*8EX-4N4=,\CETUF6O*-CJPFHO:S(2ZNIK\
M%O:R$4;:N#K4&KLP$5^Y9N':VM[O)F=F:,!Q#<2;<-A!$^!.6H8'&+JO*SBS
M0*\[%[ZOHS'&:=-'6=C>O4I'YLAPB9K=0NQ5@M9++]ZA2;8].+&EPHW#TQOQ
M=5Z=J!!\7)L$&,Q/AW^ V*?!6D33>,[I.40230+N37ON+@7&I;>=! :2L/ J
MW4[U0*82@:H$Y#8REF>@W::=ISLRLYN"TVL-2SV!C!4OELC6WD:6X^II)@54
MH<7B4<BD'1J5)&A0TL&'F2/.4HXEPZ46H>*PX%*PQ!XDLGI[IA:H< 70T88%
M[U)0Y& 0MF!$,#/"B"GP'':M;)G/!9IMZAC!;FEU1MC*+B2 0H^E !:41*(4
MWYZ[$%"M9Z63[<(Y DZR82!^ZQ_0CPW]N0L1ACFR8AG279I[7-I9 HS^1K8%
MIK?#W>"_Q\$(8'B!*8B5!U\9RH(+;D T(;Y2J_*NQS!,F_G']B_6C?KM-C\^
M(,L-?"?*X7.Z*-X;.=7S<03??HFGS1N74Z:JH6-YHJRSK4!J!URFJD6VTI<H
MJ,&QKL+JLF@=I&1#*=!Z;A<BB"%\S)R(P9T'6S=I(C10@]8UN+0]JSC<8@3O
M1$MCQ'L,]XTV7GC]Y1+5WP^F4/X@./"/8]2%/UWG,T3C/W87-D;$W+4V%R\Q
M)\&6K6T2LL\V%HXD*=,2>UDD96"I2N=27NK=@(=NYUVK7>'(N/<?SG=4G'HW
MH)!J^TI9V2'G)V/92M(@VLI+QL3F!_P"G/X&#S@@X_@!XR>XE0'4Y>J"I25\
MR)Z"^UB"G=!#6'5@^QH@\@*F3$=/E]\9YN@6<L3!S?*?> ET1=W,Z;^ [HQB
M3*0I:XR7?)<T,.=W:N1CO:(.&#['1AX K],Z*'?P[<)X>A9<"$\OI\GM0E!K
MDKQ1BGB;BJ\<OH,D .(=QO,'R6FI_!@\QCO/&RV8\TS.Z"*)8:U8-UG:F^/5
MP(0]B*_"7DNT'--2#^1)0:FMCAT[) +9P+9=7R"I39%SFT>$/\AQY!TYR:<7
M&VXRWF?M&1&P)GZE,1Q7VADB27S4L?X,?#1-G$P27M[:V8Q-"CZ(%P9%7(A;
M>F!.)8;8$^),:T?&X:1'#2_=X5QC]71I1CDV;%=CY1M!"X:?U15M>$*F]'H8
M6P&#X E>Y#N""[> XJ,IPE'GQK4I8_U'8/:,<D(L3R^Q$PGA:6#=P=,L :JA
MZ"#,O@(W0)/A+],6#&:$"Z$=A[ *E9R_FL:#$8)W4'*2$PDM\DS\<<YYUBXD
MEG><<Z]Z"&8!A.=BECY\]8<%O*'_SOY=[_&LTO[N^L-36Z"YEL>1]8X?%DNO
M//OB;*A,.R\KL[%LU2*;@*AFE?F@2S\! ]>E*S'XCM>^85.[$%_&"O9D)'7N
MN-?3%Y?/9/4PE6*C7!?_]E0-+GUWK@G9_!V]+DZ7[B""MVF (WR21C>;N,NR
M(^ZCT"OQ^PT%OV%J:-?YI'\/*C6+/<MMAJD!6]M=+T$T&TD5^ LI/@,^\@OR
M)I&6:Q8C;TO9+.L7_M/*5PU-E'K*2AH?I?#W_' A8F^#K6Q7?M X:Q-E? S/
M@9]*.38@F:WSDWB$I\QYP I.]=F)J658NFR%LA"KQ@!NO4??Z^G&VG[,>KNC
M^U[X49'G'%U6($/WHX)X)_3PQB+L9'D7?2U) "BABV,=^, U\OI[6:M%:((9
MWP=0X&D_UKA%&I 4^(V#)O.7K2G0Q2Y!0,[C]HF$LJ2@XC,OZ:_S@#=B&<#*
M,9^#PV?8S9;_G:[,XR?M]WB.A)HEF,Q:V-H'+O"O=@'0C,3ZL3*HF84[)9WE
M:XFYQ[A56IK2/C1IG"PFG$GI$D)W3D%7K^6!Z&Y#==;! @_V7TB,/-,")##=
MXRM-W[J"Q5,]=J,;:V)$"_G#H_V^E@_(Y^YE"'I^,M+LHC_67M>U*9Q!E'FP
M_@EZ/)A4(-=O]]^C8,+IA%N_'XL7&<4&J@:!.)GL?2S=2V38]+XW<X\GE>3T
M;DF/+;R>OX*=2^P*/Z=9UBMB_SF%J*TZ5*YBDLV[RDTT/+^H*,#?U4?>%Z0X
MW'-:P92![UP3Q;??X(C3:5%/A"F>Q6 BU5"2FXWWAA(\Z*.Y>R9<J-MM,".F
M&F5RA.E>0H<?0UF#D<CQNE:'';83L M)\AI?V1@0)RAQZUK<YO"Q>,!F;6J-
MZ=B)$(4>XMP ^3GWP&5NH>$YC'B76K&/W @8W@T5VH7X014PTYU/OCC#XX)6
M/3IW"J<>5><YS726H*:L2O-G+<1<EIJ"5Z,RI(:Y7H#CUEEN(P_*F]V%U%)Z
M*'QZ0L"GU!BZ3[6@TZ9;?MPR&#J/(\[]QU";QCD/>@)K3N ,L+9%8"DF ],?
MB<(M:G,SB!O 6N? (91CIC&A?55[DP+E7&T<U,")HS+/X.! 6_G;]E5#%3X\
M$;QQ'C^@GW]&\9187BO7V,88TA:.E<&1$N=78$G\+"B&ZX.*\=\C<:K@ 29I
M>FO;D65"8;K9V@/VM.?!E"CW4R#R'6VIZ0>I=""0OFK[,;3A2?0F=>< M=8P
MC37I!YN^W.T8=!'CFZT0F^/\N-NFHKHV&ATNS'HYW&I6YIN]=(YM9LM=J*U-
M"+O[>V7<]6KTQ[\9<>USIYF_%.OW5OPN \_1WV\"UIA;^"TWJ["_@:!RL_&=
MBI)SM^O>63VR]N/RW?9@/^]?>&W#*H(5/D=8?<G:[LK<[AZ80M(%J -"F,1.
MFD@+_BX)C+S%-V(\[W1Q.7- A#>&TV%1XN5M(ID#7>AC? /Q2=@/)HTJ]0U]
M4M*I*04J.X(4)LK2JP>G AHP:7M,V2C>)R1@VBP"JFQWB232R ,<R0(G5DPJ
MDY"42>S23$36/HH'2$Q\-UK:28?X#F4H,4;QPDOP1I$":[# 8HR(%6!*@$D&
MTT\#'T'-3KRTH3AVSQ#L(D"T2NV0:W$7!C_B;$ W]JG_9I.:\I.YZLJL+BC-
MOH3["H7R!+!'07(8(WP7(HE5 2^R"ICI.?Q _0M,O5ODFTF,J2+3#O%+?^FG
M;6<YSH,\63#V^EA54'Q5$"UJ1V U$NB]V92K8'0=T*X;!C+1'''*UAHWDE_7
MYCFCJ6@"_#VT!PZJQ#[#RL^AD]K.C"F/&2H@L:Y [*I_'J;9"FP&>CMIDKQS
M*)SB()];A40Z<1=9Z#AM>>C47O9'FAB2BA?;L/0UV+O0I3.N7UQ2@GGU)T&,
MZM58;Q@3ZF;3XZGWT,K)XD#2Q[_]@X&T;WB&X0LUB1(CC72DGI)-MH3:AX#1
M1Y=+=;BQFBL\B8_?P3;YO/BN^6Q[6Y$<9NU1*=1KNI2J1J6SJU%B.]WSN#O:
M]$+AF%Y3:NFUSY<*SID3WQ=HOMB%W!M(U#=]QM_4>WBM-'5@,J3'&D0";"H2
ML(;O!W49BI&D29^V4RR1:+P7=$I@[BNHK?PT>)QEL$8X!B:L;06!&:6@"%5N
M%'=B8K-2T[ZM;1P+GY/=;#:X3&5"DRE"6B+)>,")E$C9S[$/KUS$R8"3_W7!
M@*F "_4))49Y1!V+*,#@F6NK-!)';R(8+^2&<G9H+9@"8RV'.(CPT )7WRG%
MVF+C=\:/IEZDEDZ&;5WFBXMVY->LK040SP[G]>]"%'DG\>W\BMV;%#4+&<3[
M02<;MMZQVF(!!-_:$WB@EI'1V>HU%]I)F8)3G^AVHO=B]0$2(=A O),B CM9
MZ>XC!1>HFQCGX(%?"W\U@I95WB_!74C'3E6DP*!<QLH5-@K.D>+U,#_C>FCD
MTYSS"%#=N*3+%$PGUFYWI8,XRE%IWI%#LUKHN-6YDXS3C#% #KS*4^UF/1N-
MC8V-H3"?!$-7*!ME:ST/)-[-!58\D)8VD?0%'LC9^4OXOUKNOQ-M\]BF)#'1
MG2:*2-.V5[+^W5&6A)8*NW.\K/ZT<F_-%X<C+< P*R2I[&Z99QH@L0NIN:AG
MKIO:Z]4/R*@.IMUI@96<N]M88A(8$$5:10+^<(X8<@O#C3G_GVA)IM3$=LS@
M/T(/\51FP&8ZI8NKL<T,J9Y#'O&AB&EQ+[:@@+P-=4VF;CS6C'5)/90I$JF.
MNTR0<//);"NB"RI<93A&#VT,' )3G7+7>W*-^19,^"]78V*W^KB)>'JZ^[ZQ
M3:)B7X49(&W/S<?[6-IV&QX [S):Y9GP'DT!?LU$K#&F4.'"KJ#.C]_KQE*S
M>N 5MA-J"(.Z/L*19,@3(1Q7,+1T%L0NCR\RB+'(Z1Z.I/26QQC\(1)47EM%
ML W @%ZJ/BD9=A?XO(P$_=Z"7JX )8:L*<&Y [J5+\*E<.(8_3EW5J%7Q\Z#
MR#EHO*$ T!#-<0PLG_$>%!'TW>DP9B(%75L4SPQ3^B_S#HNR5:=Q7_& -7H2
MSU :B!5W!?&Z5!?-))J<[6W0&W<.5%UF(-N3]36AJ"F!+DWAF3Z_/"=0D+FZ
M$-.BQC9<TI](F$_M''_2T(47F7+SYIUKHU0#N:W?[^LMZ;7D7_EUU]F>Q3E]
MOB,_>%Z5?)$X%30/:YTHUUFX4M$^EJRKXCV,G:J+D);Q?)U4<C77]"6CE'%!
M\>3?-2OYMSN&2TQB!,33[[T;ZAJ+/N(?K1_DF>*0K2QC'*BMHJT$#=T8X!T9
MF4/*X+J@ &(-5$9R1(?486$,A)@/<3],FWV/-UZO>(IU,+G\#.483@U[#<Q@
MAFM&2O'+*32S%R^ F?Y($^;!-;MG[BUT-DU$<BP*)BE/*0]HTA@7IG(\UH)1
MB7;]L/,("IZ$K_Q+ ZX'<6N1/8HZNY"8;/RD&YZ>9\J\_1P-FHZT5P):V ?\
MWR.1,?AIOHA5[A"DT\ 4?,>_J#G6"8[S )6T>A+HA=9^X"+X:3&*0D\ERL'1
M)!'.,;[D4@,]/K:=!6F )\R(CI3!*/Z"'L;H]A"E>'*8:6=@;"*64HL[CREP
M' PRB:7C6OV8)/X613@^98M32K.QK,M,'(5A@.OLKD_//0SF@?G$>A&.5 <4
M5.)S[G-^'NYLY'/OV7K$/L*S4M87W+]P.4*BP,H3F 3L+&6?2*<D:#(E#](Q
M'CQU"D?]?205"I3Y%Q$/XCO6!>8F>\]3YU#S5P2V-'R,!&P%7W0[,F7&>@;;
M[7/,7[\;+4GJ5B6KP-PE&:\FSMLQTTJ;@I4$S@7_^'JT1)/Y<)GK]>FB4[JU
MXZG>"\?/EGJ^KNB/4<R5%U+5:VD6W'RB/2YXL3+>NO1Z"S<I3[!W>CC9>.!/
M&OL\OOTN#\[K)E:'KHJS1;%P\!D+:3G>IK_,.YRZ]9BE^*P"Q%L.[4(\9P16
M9Z^RE%<]*T UE[:1383LS\RU;D$SF,!;#+(3=\QO'P) )[38LB[/+41RG.C0
M1&LW5\Y-KAX?%R4^@2KL0AYH@BK**^)L)W":J9,WAQ#@!%2#K'#@*GV;VB=M
ME[)F!,)@@D Y?1?2I7Z5ZD 4/D&\,<3Q%TG2)B8XNLN"&7D@Q:[)S^ACIF+.
M7:#'"32=NT+"1L"'*344CCQ\#B_]/T.KO2TO;Z4"#<_:)'BSM&,</&,7(LKK
M;R+%<XP*0#8"E&6L1?F5WEELTFEE:D;#4;P>_)0&5)QS:Q!WUN5GK@XX0$_6
M_)BQ"]EKJ-0'_%B>4^Z(AREX,)'54"H)5%O@B*'HRJLN;+F?2. 6<@K:Y7X)
MS*I<1A[C0;&^((I..<97A/2!KET(E",)4)[36:_TUR(-%3@X4)0U8@J023&&
M,LL[H9%U,Q:6U<,MUOP%RH&V/7+]#6=)9Y/I;4VORS!-LI6&HMUW ;T%*M&E
MO#<A+V- /*,"YM/=>F4\1\GQP'&7[%E977F[1W;$NB15$(11Q#/L&*K?(C+N
MK1_/)QR>NV!=XK(GOJ^4?OE)8[+Y5PP3J#O']+(0^XTNOZO27V3H&^SC9"[6
M:1[$+=_J^J^ Y'OOY#[>81>V'1(,WZH!I_FBSQYTFUL3QDV$P ]MY%QFD-H'
M)G<$16)PBF0 027$*YX!$,F:N#-@U5P/[R"7R*?S7JIS50/ GI-^BF2&$/.P
MY__K/MZ%=$]M=_ !-7J'"\<-0 %;D6,<?G0_/\#[2JG9NX0S0!Y7[N'G['V@
M9^4=C#@C>N$I5A.XNM4_PCN%M0+3Z.HN-J-5'A.D@80@XC-D?71)',SB'>CE
MS@J-WB0E4P0K.>*D=B\_A>V.@:4LWJ&\.0JH1NC"Q[1I@P1^^CCS8;@.+; T
M]:/:!R!V$$5Y L9 ZA:QN>W]AZ$Z2X0]ZVPT(Q$=PY,"I#O43RUWSIY "OS,
MO0!:E'(<P;1*L/P.ZRT+&=,F_A,N9,M$_&'S^&5%C6DBW),XC9C+6'G#-^$!
MS'J7^WD0S0IT KT K\Z MI<L<2:)BCX(CM@.;R(F_Z1 8\;]/)AP1<[?P,%&
MH->-KU[#.YNDLLH;XF$6T%A/@!A+!A]Q+I?,O]1WRG$=V)/M\?A#V1L-M*)2
MNJ[PG*U(0I$)T&>073I2)!W[;NP((3W;PR;P5:;5< 36],ICWO_!W'M%-=E]
M[Z+QLZ"B(KT3I?>H- 4DGR(@($1Z"1!16D! !"1 ( K2FX* @!"E2@FA(S72
M!02D!0@M"0+2$X00(82#_WU^_W$NSLT>>^]QSL7*2'*Q\KXS\WWF\ZPUUYRL
M4?2HR*JR#E#!^Y]?YBXGVB<D&" 8:A-/3%MU9&O6K+ 6%I\2(FSF,.XI?@5G
M=0TS=&$M,(JQ-UU*J@,DC&H[?\S,\F"U 3VH4Q[[F\7DD),+4MVPJ7%7*K&&
M@HDX JP;45@6AB*8 @S8\ [LQ&JC=[0HE2>#FD0NVA DHKD05N2T3\4([\X@
M5%BS5'%1QZ\=;"4BJLN![5AP*]+U#M2,*#W,\QH'G@P?^C$LL%;W "E&J$@<
M"\H#^Y*@QY!'BR!5#]@2M;C=YFN\NV%5(;AV@3<CBJCZVJVP'):H#9$;%'3B
M3@+H0./[L?4\3*J;QG=:K [$J-[K%B4,\6.?NHTT.@P+98$+\"8P_/-#OP)Y
MP*Y'@'-2D<U@$NIU'9 W] 8]B>@:JZE2C&A?N-\Z@2+Q4I*BM909%GA_D""B
M]"&5+<Z+"..B=UCC&1;D#=TE3S-8 _,!BIAR!#@/]AJ:7%X ]: G]VC'3#;,
M*?0'F!/E@IONV_N*KE+;4"F90; M0%[70$[079:[C^,ZA R+40?W0*((EYJ(
M&!C))>;X@5A@Z3I6"ISN6OQX>05-B",P OF$B$X(O3!<8]BTQ?G<4>FI)?P-
M]5YK_4T\-L.L!\*R^\MQJ6JU/)\Z]KF[P-W K^".08*!^4RV4QX+?Y^^UDP
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MNP\B.< IW<!Y(Y^D/ZZ?.]!Y;M@D?(N&?4KO\.XY*KIZ^O;@[="A&,KM(T!
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MC9 T M^%J-(:DQ*E(\#7]SP]3\GE)CHN;O^GBX7_'RE SE@[ K0-X&_,H=K
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MY'"PV?QOG'%RM[V44/J&D)8%]Y<5CQ'N[^38YDZ3"C,Y_3-8<8/QS2E9ZMH
MO]OLC^2R.Q/EAEU!B]W9%\LS"F0'L!XW5%JSV3*$/(4\*NP=3LK[%JOVBKX[
M N@V61L*KF79^$TKW"%E?-EN=?8G3#0%B:=;3E?90RM-3)\;* [LMF#P>[]2
MR^<-[:@H0<;U2GH6"7LLGDXY-Z7! (@>4FLMR7 !,3+;^VE-H.O-B/**<LOJ
M6T-X89F56IAYID>&_[0@?9??:+S"A2G#>$+$<C#4J-B85F$ZOML(U!7*2CU]
M!(C4U'MR9?KGJJUS;WVF&U^8>'5+O-YG^(1<HUR+^NK(INCP@WA4"Y#-S7(.
M.)HV>!&K7*4R</B-PZNI)=7$.3L3+IG]3E;\6E9<7-;;4R:L<5D9G>D<S+\-
MBW5P1#0!M*'M<P1@52-NEI(P(%KX<,VW=7^%?];,*JLJZ9]R5X8K*D?];S6W
M^^&X5DSDH&[JAV,N(QZW,Q7KQ6V1JKS[X-+D!;'PYWFV!EQK&H7S30;!.OXU
M3\>@4.7,&J^D><V+5+'3[?QU:I*#I2$P\2&)NR8]!JLYL(R'<07G=X\ *:SQ
M!2#GF+)1FE)!1+%)=[S'6-)OW($0@J5CGNL(X+85*0*D^ED2HJ**J(VK3,6P
MS7&OC='V4-91+^03,I1?@5&<_BU%>]@_^!9!6H0(O3M\%R.OB-TKBM42"QUJ
M5:"_(D/XUIB*Q[@0ZIXC1VW]%$ &\[BG'T,,RNN<RJ&'68/:\\/6S=6Y[;G)
MDM=UB=)I?=*>'^/6:=>ATP.GQ+9'N[38J!/M: '8+Q&Y44U7"JZ'8-U8,U:3
M]7,,J8$1M[K>4MLA'1LL4U[F[5F0 ZI;V4M7-R[R\%?2D_AN=:.YN?EREU,Z
M9W%#4TI_3J!S:GR]6<3L]<C;G6^@CW75E)/9A43UA:_&</YR?;W?.;-HZ3 P
M:F*7YCYAZIUE(:$@H.^PHB*V?P2X1FK4U'[?H<J<_7Z-;N-L_NR]M+/*L^%"
MDFG+4V,I]MW,=]>?8;6Y6C^MCXOH(+EED]_-BQ7LZQQXZ9#8!!%JM!=T+ EC
M1=J*:9W]B, 2:=4H2H\V=2M*4U"XI]UFAY,$-10&DQ\\1.#E#L%?<U0H2Q&^
M_B@?OW351H5,PFS-9?G+H0'P/=M;<'*%VUMB_)_O 2=_ZDGJ<PR()POZPWD>
M7$]XT2O4=KYN-^D!59B)+8+"F?[$FOJQ94^-^]"FN-(GQ;""EI;.QI#HA0/=
M7>4#Z<(#3<FE56F_W<<'3Q+ +F!'(%W2N)B<$'R'WG5@[%:)!--=/7T\2^C!
MI(E8<7NY3C2'(BE9,$N)+*S(M%[\2W#O]9[N&DSU%Q+HB1&S5I"LJAQV^NVM
M8%Z03GI7:F%\?;DZR+A@$=%^_45S;75=7*"&?29^<!M\GFYD"!Z4L+H8EG.;
M>-5DA/GCNX6=,]*2$]1.^M0KI"N9(#!646(.'^T83E"Q;>H@D=3?'/YS[$ >
M2#8J;QML2H[)Z6DY\7"8 :%B.RUS-,:O1IX;A590I"OM06T\;]LJC"[B/WEQ
MVGDY>D#!G(9+$$=Q#KNV_9@\A%D[GJJ-<G7V_%P[JEC$4^#'L;N<N716C_;Z
M],0Z;7NF34@POS)RRDGG0;E<WOUUK_7FZ!'\@G'FS'3@]3+3J7[WX?>9@+A&
MGI>=#URN77#6>N!)_A(B8,-0P*#:E0(5!@8SBFN[EJ)0SP:N1^J^4Z:I*7WH
M;RC,X"YHG&W=]X!KS?KX8G4*5U#L,25KY*+HSRFTD=$-62_::PMFOUT%)+A;
MAF&+^J!IUHD85"!?6([V*3;K<OFR.MEK^OI#GD'X8J3@N7/*!3<?58RM/"Q<
M=%D9,0W=OGTI=IEA1+97:@^ZMS^($9.H$1<5=[3UB,FPQ_-99'#5IPM5:RB5
MZ)PR'1"3]ZD4>4*");;R4%6Q/&^>A&A!B]-8;Q6\KU'2%Z]L\Q:,V5B?%6_(
MM";'WK1<#$\>#7Q8:E I6Q'_SEF\0"&]?"X]V.[/XKG>6])U:>NT5>G<LI?_
M]U;#_W.<_*XE:<O_U',SX+)"7D:&;T2 !T:++P;8^2UE)I6YVOSAN1'"/X1]
MX4#;_]-/+Y%[U8.3XO^\69D8(;U<U9PD/Q51D\WYR/Z[Q9-E<Q],!Q?',Z6V
MSTOG?O[O;8TI+=ZJ&JMB=*9D\MW6.#\%$RCSU-,/J*\AI2,J-;^5/6VN9^\[
M;R],J%810_W;D#?JMS= 4D< =+3"V7V))2S_$>#'Z2 C<F!=NLD18,@P<)1Y
M$)..$S[ WZ"C^[=UA^E6NV-_# XU2P\F<<O9LWVH>4[U(X!!L56MS+W]A)VU
MOJ$ '_6W/\I&FDOT*JU.!3_^C.^^^A]5!LT1BC<LL^D>SC"U4AW\\@L4-<D]
MB.A\;B^&=K[9^_6F_Q2=77N-]NN;M<$3G2LAO5<R;]^[?@1X:7V_A;E'/H&9
M*&$,Y;GEQBZK_7]>D^9_U]@>2H2QUN 2YD\SY1E">$;M2*L,XR:UJ&-MQ1ER
MW?,3-2#*7YAUX]4S2(;31'\ J_2\4$5>H;!YDEEN"><["?XNPL/D=[8KTC6C
M?U1\BT['=R[2OTN"62S-KR.$C"ZX\#0K9PL9"Y3)/2SE98RMMBLE9>I1[QQ'
MF!F&U;@6*W,25:.WGKKP2C*N&/DO9>#G6[>)YPS:/$<KRUK0!_7(B N7+-)^
M,]E; KKK S "7FX,Y;AK_TC3C@ >NPQ95)L94H$,H4OV,'AXO\[7#KVJZ253
MT)T@'C=P#4_*Z=R"VCH,R@?A!TD,/:_VNAOM057H6)O(K!0,[<UG:(^VO4F?
MA<WPOF+ 2=AH)BLEJ1-T9O6-1R@[=2BR!LQ+AUG7:F!V(6STI =U>.60NYP3
M_4VC6PK+#T.=V6I?/M()D>*XJU+RJ-K=<,\FC8<C->UMITF\H^E%#(AO6WOP
M(=H%]3CD^@T&F,-E3@2QD3R<1).*U^1,?>)3E?_N4SBY.>Y<5'\ULJ[L$Z*[
MD/-LU3IO\Y\2<A6C([7W(1KT9Q75UHVNVNCYZDV75L11U0Q'YZ;;@#7+4<I;
ML;8/J)T<W6!^ZQZVR%9QN,^W?S)JS^!W#B!\JS:SBTF"4XPC@-8X@Q6[DWL,
MSINA'5; NJAU;;+AL>57+A8S7 [14JWT>@I9T/H"H;"A8')E"1R=<[;J;+*=
MD50T0\E+Q5[#J"9FTQ_%38>V[S_GMIF9^%/N]+.8S_FFV(S5V#.FRN/M51.O
MW6N]CJM=6_VG4F4":HJWR[VJXP\\#C-V;*@<22((DV32VF.NWX.7BO0B?@>9
MIJX>R)_FOI#.-^KEE0.2213)PH#)"\_>TPL/WV%DZY_0!9)+QV)GDX@><\9S
M/JBH%&;S\*'"N<-#*]0:A;%X*MSLG[,#=TQU+DS<T//T*EAN\*N/5.$_YG"O
M3403UT?42PXR/;<+]RP;#[D/M)**S#X9]V?<YO"<URDLWW)>WD-/;ZVCJ%E_
MBSC=.F9XYUN%F*,@HH)2]]_#RM[1MK"$#4V)TM7G]*#ISL:BKHNFAM[GVP++
M")/N5L.3<. I)#<P1H&4.&@>O/LEXMXYE$H7L@)'\>_I"N]A7$_ON)XX3ZG3
M-!P] IPM.43\+37."#E^]6)V T^"GPQ-5=.VZ<)D4$*.< 4]N+"',MJ^#WJE
M#.)?:17^0M<GL;'2+VU9C2G48OGH!AJLO4]KCP 5\*I_003KQ,]5(5ENOX\
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MK,T*I(M*%I3Y2+\C -UX-X'%9-P/%9TCUC@M'\IO='>$;;V8P[!%2P5._*;
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MP[1%]YL(H!/)_Y:[+>]#^#03OSF\!XR?5I[YYTYC5ER+#;7(<6G\3BI3ST+
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M.?C\LF1J\C:QWE@XQY*_^=,[Q IQW8;3,<<Q,$!Z%Y%"\D=(P[HVA69R_(:
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M4PT4?'Q(ZZ4[XEBUD>"[ "JY-.ROO76V)F#+EJ7KCQ1"SY\++1\4P%Z_QW.
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M81^E,!^M1IQYN=6/?ZJ;%'CM?*I:ZKH_$SY[E?\R(DSHWP\QU@>4>/^"$G'
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M1=0SII]0 9\[J.EB3'5 ,OTWQ)B?Y;8.-O(!71.BFWN+8%)M](.V+XW)_ B
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M^N\$>\B;77%96M(7O$V6KDQ_.5G=/W:OLL-U<"W\U=#!ND0./GSI4M#<V:&
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M_:2CW);4W%D =N:_ $)+6I$*VZ),W:XNS=C-)X4Z.4^%?A;!3!%CMT4P7O
MT9)O.,RXCH#S7<" 158A-E*UN'43@)7K!ZX3]^'+T(/5*78__P3:LZ/*L73%
MQ-X_07CB\[YJDII/4*XVT)&HSX='<4XVJG$LI-I*7@374K]6B75389/8IP.%
MPRY0!P\2D$E7MZ.NB6#R7U_CTWBGP#^H0!SD/\WW*B8O8M@=[??\4&PWPCYP
M+IZ^"V-+>KD@W(6#+AB/ZV%VW_ X)>Z]6W.NE);U:]E!*&!S4#U4D"O<11S&
M;!IEK'=:JX.QC=1R!Z!V4($Z$EL7*!;GUT1SI*!,W..,]Y0$X?$^!B=JNAO[
M/]N98)8_CP'U1_2$@SS4ZZE[+UHX\R.DU2+!$X8_98S)VP=%EO,/"S*%>\2"
M_S4 CS</>LD_/;R*@.SY=[CH&HCIWL<W8S>=\1 .0;$<BB+678S!_00M]@9R
M<</'6MT ^>K>"[7#W[_3 MYQ0*3*@UB["\9ZG2>3@2<ZIUPJNC(:#X F\4,I
M7G9O;K7:A>>P7C^YZ&][<J.64CQ=Y//4K1!SU'4EZ,I0U4XWG<I:!-4TU6^G
MHHQK,;D26$D^\K#8]T1B:XM=6.4PBKBR?H-^1?!Z\QP;,O4U?)$-JO&>0[1\
M_&"KQF^0O[@'R#S>(^"G8]\:3ME'_#Q!7(84WV) !'MC*$[?^*26N_H=8VLT
MQ:!1+_($X53Q+Z^+QE7>@M+O)GJ5Q&Q:.P(R00N=)#9\2),2(MA(+J2+R;RJ
M''SAXX1>\ZAS>*AGJI2TI]7*AP%:0J'=BV3ZQW<'%M<MT)^A:#6,P3_'&YD[
M.:]-=N8?:V=_YO9NP4@]J/!->Z+Q.+%DVP\KOMU"R8J8V %A<XO;7Q)V0H,@
MFBDF-=TX;F\<M\4+S5Q^0))=I".@,^T(M48,-YND9%LX#CES6RS-H=QP].]X
M$\C.OC>)M=MHR4 ?^;[>MX9=YJ#I !:G-GI.+_^.3WN/NHJ"3(^+W:;:9DD7
MT)I62B1=[L:P>S+!!@XYQE+N#/>>%%>0V:JV6:V,PE&DA;!1DKZV;'6;Z65F
MPST/Z[1VU=K8((Y]#'B#>B\??XOK-AK>9-::5?0T@'TO (($L6+(8.T2?F;5
M4)JI8RXM0H,^_I92OM>H48-GXU6.E)K G<FD(P!RC+D5*-FN6DBG%"M7&DT&
MC[9H[!Z] K#(7X8,S=1)K6?L^]?0<GB,0U,#J/A4T"SL1  AO>+^V3A$'$"\
MR5S:QUY.F=*%LLOX4J93#-"E&:-(WX/7:J7#H1QP/_HW^Q=XS7;6SI#RH@$#
M^C8*F21;.0L5L[O0LFBP _-FV) BZ1UDB>R/Z)5&)1OA!JH^9SXPN6OR\<0A
MD]*Q.$TI%]G, =[;(F#DQ;<^YQR5TVENKUU+[=:XSIWNH2DF):BVMQX)!$?.
MKYE/G^5?*5_/ETPMC.DNV]@I3ZS//:3PVCG6%"CQ,;?<VG3X,/NJE6W[?,&"
M0SNB5 2KZ^7+8WABWOW@)E^_7WA(V%<_]2XTC-,=8@B'$8X"TKF42H(+1(["
M65+%\*,^&FMN5H&=4AGHB9W..>Y4-]+HS_&)PO3Q+?*;0PL"J>.1&D? @ >-
M1AST["M2\^3*]2V,Z=R7!SIT4-@35R3[3@J>IL?_7&D6BP^&F"M5BV"(QC,;
M?XJ5CR,#2]V-#5W(ND=F4A.]YA8%;*1,\)3!D+F/'YLES?^]/IL=7L&.C@HH
M]H;\3X$=B823'%*2D@9\0&_?8#5:CG\&W!?5%.7>,&QN7T&R)E4%\.7FA-)\
MU&LM)HN,J%;JZ!US'N0E@QU,^._X)"ZZE0KA*#%U)'E+!/\6M=GWL,^-P?=9
M<[%$G2F^_JM^2U5\$@<57^V#8'K9D,U/ 1V<G40I***2X#E /[)@">\WM_O4
MS_Y(/M!Y[+-O9.8UE?;CALDZ]1=.>B3?#"]T5#CXG;W@U%"XXZ%S6 XZR*UF
MB_*AGF<VRJ"'7*A,1";0$_;DYG>?1SV%6^(_^L4]^Z':5^:<?&_1%R';I;IV
M>/B)@DYXCNIVT\J( X\VT&)P[18;J9[8305<<#(+&23XWA&Z*N$&<"CAA=A\
MLI9;H=EEVVQ,]1OZX"I^C:3$-Q\)GTB3;,7%KJ.3:K3Y>Z;T5 /B"/9^]V22
M(KE4&%X&J0;M5R>-BS/T<RIP'AV- 1Q8T;XJ$%?<0RBY1C<V2H'@V$^7#UHG
MM:2HM=3/Q>>!BN_88LY('^#Q!MN$AH!!MD:21O:TCZ]44KQ15-(7^MO!%TF.
M65/8[&ST#Y@@1W@4&N09",HLY?C!@\,U<$5B#T/%$+$;ZV7,[$W,NJ@:F:+'
M5^$8UH&C3($69YE91E.& MP!CU:&3#,-DG(#47%:(/4!WW.:MGM>?Z>E/E!;
MR:O/Y/T44T@O$:S3G"A-&IOCFXOI!F+#RL/@:C.T!RYWY:V)7<VYXI/9X6SM
M&B_J?M^1QR4WKF5::+?<2LS4^W6P^_#)KH9#H)SA1T@S(4SU(7. ([/G08K7
MPZ+"N(JE R.(75\G6XYE5M$<"TT^-'=F5I,/!.O<7 _N%<JH".Y?%3Q&BF#8
M)>=1+IIL?H)H.,_ZG: ))'D!H\QER)>ZFX!A,V0(YB I*0(C =G;0?FE4#!N
M"Q[%Q.RN5K=O%>J#6BD$XZ*@X_'5*IZ-: [FM\!<)#]-!(MO^#)&A2)+[_R]
M005&4JINF]ZA A\;7N<*?4-[IH:A!;$?:(C]X!Y>29Q*!6_6]"6YI)@:AOQF
M&;-MEDI0<0=#SG A"K[GVY0ZZ-M4GHV3X)^$(DH(M@ RL5&MA&\&;A%6<-1=
M.)GD*V2/1@;HF W@VHB(Z-/U \6C$?>D>#BAC*KX%G9BXOL'RG\Y;K/@7CJ@
M=0["1 $2G@"\!9/X"*_I-A!.D@E&_+[6$.+!]%4'6:T6QJW&SE :!]WFH,6I
M^<GLW4Z)SZC/?0V:M64@9(VZT9R*WE3#7NFO66(&;3:7!KA[4L_L;6,?_;3H
M>*Q)^73Y:P7M\\WF;O0RLJ#[KI%.CYWKI%V:BT>9C&O35YL/9%E\9L[-0D>]
M]_XKC55;,MEE0R7D.)ET@F_ '@D2IHU1[A<J'^B2%!LX4&@[>#O?Z"0FHX!1
M@/JD)MRAOR%.J<TV="5QI,BA BK"O!XLM-P=#+1$0?[<+@O$&:@8^,Z;O7=&
M*-M%5<1'6HTVVA<9D+D^QQW>C1 0'!\IWU%SBW)F2-G7?-?HMBDYL#B.;\QA
M "Y(2)>V."JVR@> )]97,M)83D#[LOK7K"D:L#R-NX\SC(_8*%-31WE2SH+D
M5H< E_I=8H/XE$&,<]'-99S>Q5XY*/,\(]NK 3#^R_P._(%YJ!)9!'N"@8P,
M#J  )W2R2_K6"R+8Y=X$64WN[(59:&;#N#$1?E[]>?RKKW8&=W?PM01YPJ/X
M+EZ_H(RNRP\:B@R:TA6\$!['3AWHKZ;&4Q4,NU*,F]U]#4'-"4CIO2FCC15?
M9PD'1M*FJ7&YZM1_ 1KI')R<PW3O5CRZV5=U,/D5'MTR;GX[Z\8%XA_-O0D_
M]BC8#8MYR;%%2X0*ZJ[E%%9.Q10?Y)KHGAA>]LXU^>2D:2BEX>2&%1W9=JYS
MCUS:K.O-3[@ULDD;9V4^I!WC5JRWD[T#^C205O4L'[,SS]J%%UKAY4)8+8G2
M%L'<I,6Q'/G/KB=BI[N;;YNJP,"><.W-"]TX?E*"U85R'!;H$-^S "?,6)EP
MAP50YP%E;UA@[TXV]<8:U?69DX"NCMJ[UF30GCVSU"K&!2#U,T1CCALT<7R.
M!!(-!PTW4@*:A0?Z(@21S/'6$^OT1*.SYA@V6A6/8Y)Z(Y?TQ=;[)8)%DVP6
M;4 Y=N_B3W"9Y]HHR"=( XR.7$U(%]Q+9"&VZPD/$TY!,[AIJE2*3&^'UW*2
MI:XG08_1;WD(G\3N((<[^#.].L@$"Z"#O4HT@I(J^8<&A#(+OD=&^.<8/3B^
MK+]8.\8S C"0]N@BA>,@HX]S>@510/1I ;71F]VMU39.CKEN;L5F4.IN\@T2
M&AVOEZ^ID>0"?;>"Z'C^4? :JWF])F;\=AV'1,[=L[)LJ.X^>@XT2'1G?XXV
MZSQN[FN?>>VDY7'=Y/G2"Q\\GH0^R=\^1&F(KW#O*==V3;ZH!;_J=M#(Q"B2
MS)719>?N^W!,>+#G%G%_5]582S0MTT9J^\SPG'NZBN7U0PAXMZJ"[L"38:\(
MBQI)+=N6 B_,)TP[!3I)X<$A%9#"F6N&*_"U!15&& 6^,I0/2K&U$B,0.R&E
MZ:4Y,HYO#XRVC7<\6-NHV+KL"OW(G_?P,E^G)]PY]#3TY3=3M]61D)V961$I
M3-L0I559-E4.']:>JP:(8,D$=8ZT7%ON+O!:0B$^NX6N _24^='PN-8IM=%R
M_34'>*L&8M2P+*GBN&>_4<ZQ^5&G@1H?T_E9IM.K=W6-56__0[F+KQ2=A[H6
M<H:-6EK+(_9EN&<MYLH*RH3*7U4_KO?0*O#!/\0Y-;88"#C73U2$NEJ$2OV&
MGY;,[?,#[VHQLQ$/?/>]>PL:U:RJUB400FCT6(Y:5Y19+QSR6%O@710P4L5@
MO?4CP1JJN /*==REB;797XBMPH/"C@%\&KLVPUR6BXG%[*I9(DY,BV"++?4:
M55?HL&HWR ]8YLPM_N#HBEW!=]=P!&J7Y[<32NO,8-^#4$7A@JE/!R7KYM2.
M.THRL^_,=7[,1KR<?GT^Q],]L=W=M_OP!OV+7T*^;]KW&0<OGDW_%<+5IX.<
MW"/_F,05P@,>LQ=F+^QX\M4&;ISIQZI-*PDR<BX\IZBUW=,S,,\=([VTX+M7
MW"\EJ.EGII:,BF^F:#'Y'I]HO^N>63;O=?LI%RY#. X%!+"7%;[Q/*J\/?%I
MIZI!2CMM.U0_:CT:\H+B.K DI@4X:7RJE-K+_:.&TFHNWA6F$^M_0&H@CLE
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M\?A6<&>L-:L-=Q-*%P/=)M4ULU3#_^P0;L'](1RT-(U^;XD$/6*R.QC2?"/
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MO6!) 1*--PVH :(LV9"_^^I3#>!3<JV(>O@G1!+BM_ #3'. 2ZXE*!Q0I\1
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M@4,<T"]K0Z9J^IH[!V0X7($AQ5.3."!UZVUKD5%VX1WBK^UH(NT"F0-BA^]
M/@PS= 287P>8E[Z#F:/?"!02 O" 3/:PDXJXM+#]) G,]B[F<JX 5CGQQVX0
MCGDA^Q@']+V4L)R;M*4JPP%A\?H<4$R2&/=;M[O#6EE9D>Q['NQ3#P39WC\1
M_E3</V_$"O-/VT4$F1ONODGF@ 9FN2R^XU,<![3#^$:89_>W8S14.: C6E'<
M"T,@'P!;]LD>>C4'E+<T1J1V[8T!R"B%D=X2D9!=:!:2 SKL\1RS4XIK*LYC
MW>C&+&X<PY#=.CD@)NLGXC[&PY68>9(#BCK5SKT,GSZ-5N)>L,"PQPQNKB
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M#%=III=&9/%9IZ:F6O>QBA3,<DL.E?K>3.]4&6 ?W-T(4]>,T XHL @HSK.
MS$3]\OD5W.S@@VP1G!"7SZT[__?[&0""S:<POQ$OI<UZL[7&,S]*J"M>@>!^
MC$/EOZ O^4HXT\2>NL:9FSH:#OOXG/3=$DNYF6Z(;QI:NU:SK!V6NI#A.!-2
M.(EH4N+OF)6G+CY34S;L8*N,!V(/ \'7GZUI%S96SDTN/7)^?F!()K1LJON/
MAKC>C.OS,?;MIKI55X_CJ\^H]2D8F/OD#YM6B#NO.VM=ZC]N\J;+J+@NM';3
MYA=,D>MJ4N8$V-I,/:I'QRB0E8,J:X/RC=9!!.'S?H=1;9]N#D&&K6+U;@%8
MN^%-4PN=T!E5^,CIS"L)ZV?K$@5<D('97]_7IMD3G9 10!A-A[31Z7,,;TB=
MZW*1HE7&2/9,P(M1H18-(V?J6JY34E=Q%F*J=K/G5*]>J&M.E'ARN,ID82=
M6C/(TECQ:/SMZ60'H^;9W<VAF8KA#<7:!8OR1?F?1G6HB3)[F7''">1W87-]
MSSO_:(+QKQ_U;+>@CS&$,7\M,NYB)D:8!AS0<,46.BV( Y*!'<2,,QG<V+TE
M"!-BL](XH#@Q#JAX]>_D0X7>O[\M1>. "*J]+?O@X#KZ,@5R[$>VZ)?5P=E%
MZ_$Z'5/%KO/10Q=9N3_MW+PTE$1B^(V!-FDII9^6%#!3E$'7!(++C$B8J&VH
M&D CYYVEI^UBVC@@09/BB;I-G=0\L=WG3>A@(XG'I[[&/5W\=K6?-AS52J[R
M*=>0JD#ZD@Y2P#0X*8F%'Z2CI4F+IVAK(20 %O& <#H50AGM>:]>2CI?ME.%
M6CPQ__XEFR[;(N/;!*X:L?WUI'BOZ@DS7P(3EO.Y2K_+>D)NIJ[V96I!%= Z
MM%6Q@2-0VV0D/-9%I&:GZ6E,[;X1BAR,+=',YB>^>[V!1W#/&@LPF]3U(5"!
MT%87*)Y@!SHW:W&5\:?W-6-A*0'\V\4%BL@<*R;6P;C^X%L.:'&:]B%(;2WT
MTJ]F:)H/,F<WBFGB(6GYK2B!+'@X8#J0C*7;N))M^;[TDN20%B41=CL_;9H;
M:EX-FRUAA\)$@ ,D04#E8<)\XYH:9+*'?A_HH48YIGGZJ&R5P7_W%@T7:VB\
M?[6^#^G01$0&S 6]RUCX<ECDU0O#%9Z/L"DENA>KL!; $0XS':@-L>MG^<#7
M&-Y+A#-/+4[4'O?,B*X?$;>COT_Y*_*.DT>(!>]"A_N'U7,A*ZZEBIA?= 6K
M7 YH75E3/LBQVQ=M*PIHDCWVN[JX=9R2SK#HWO!<_'KBJL9?BLK*\HM:3K20
M1Q;?G0A#^+/K+3/P(L_<6!+LPG]Z'0Z09O/V<$!GA1PYH.H&&@\'9!RXRYC]
MU[DX OPBERQ]BB"N6G8B=A&"4F%^.R=OP5;!X)WY@98?N;&[[5_^\9\OZ.K[
M2,Z^]-__X6=OO=FW3:O8W4E;MVS0H824KW?&>ZRW'M8(3JHE6!S&<(_=40Q^
M[.<!9N9!@O/(;='=B$W^;5=\X_,PZ3=?PN,<VCV6/2SSV+4<4)3"H+[(7?>^
M2X(-#C77AL]:GOW9\>Q[LL2#Q=ZXY(,WS#^<E%Y!6'UUC-.1T/D3)#I63Y__
M[>//V]<!#HB 7 0?FNP.JI@L=[]L$/_AE@1::/JR1^!CH9ZPM.]W)1]&*#^K
M)[PI7P[<R6B_R^2 (,#]W%BEB__!._ (<E 9?UQHR[Q^_?[KU(MW7SLK=^0U
M_JZD<];W\T,.Z%%++GZ.;%IJ5'@YX+9'FJHZ7M\ 7?V=?^(LABXZ!?_@E!A/
M232UDL16/A\@82"]U$?RN?47^#8YH$BC/T:*= Q??>E189,=S4_]85AE:MHC
MU<B?J(H]CW,'7'@3M^4-4]^(FIWO>338V5 8;C/T=1<]?6=1"!+! 3D;)W4D
M.7+W*G3KW^Y,_C=8.'&N]F@,DNUJ.S6S<TZ<K88J'&Z#_D9U?](\XK?(6EM@
M34?U#-<J\\-M[+<P1Y&V=W4DI8WK#H8VEU@)G>)5HSU:6%@HS/(**O86LQG3
M$-48GG69G86+5!1D%92;ZO6-CO:NOIB:<FQ+4OO5N_0W@%!4D-X)_A+8\H#-
M7\= >KLHT?9YUQ.I-P:^,CIKO%S$OPPY]FF/4[8[R@)M0GLJ$O979BQD%N:4
MW##V#A<"?(+S/#72)@6CF9@R)/\/=^#2;7>;^C,!!4_;.JTZK6/-?#2] ^6+
M\G N+@MJFTDM6J'OO=A5)$34UR.03@_=RYUO(J7/4.>>4 ,?A&L,G/_RG#:4
M%UW^PQVM^6*XPOM2HBP9?<=EGWR!-4/\6*+2Q8X2U_<B7KU4V[:DR3(V/X[,
M@,?-U1[,(1,G>MB\=>^ N#4B/X'O1[J/*WDCH2??N?HR#FFK?UBS1*EC*8RB
MU(-,D#-4]B?-16G?&U_L@"H_VSWX!:_#N,!N1^S+KQE<@TJ$]\_]3@!/Z,TL
M=&R+2IVD;L6X6W,CF<UH'2][O!*(LWEY["QAI)++SU!1-STI7G7\.WFV9 QR
M;G)Q'K+7;N01$:BB09%Z^]K"3];44(GM&U%L\8;WU:-HQ\K66S34@X]2!P:E
M&>IO9>ZM1LM>FA_2U<JQF_&V3? ILH/"^K%TK@T\?<D>1%!O8J.K@2(RH44V
M85Y/BKV.B,+PH&$A@=D\5)GGK:2$^7J,_ I!-GL07^'1N9LO9STRDQ\YJZ>D
M;R(@"-\^_T'7!2/?=<SN<)Z@G+A5R4RK6NJ(GT=T1[?]:(=52Z9?:2$'5/!!
M[/&EQ263Z/9;[]5* ,=Y'EXWN<CN@%.E(HJW%*R>)NF>?U6J;4$F7.@8>N7M
M\=;V;7]>GN,Q&Z\NU?8%$5BAWR0'Q#[R$/"87YFQ;4-4X=H:H8K>HM6F/N!.
M1"QL,ER<JO3YR:AO+63?UY:D>-W+KG_(6X3Y65/51^Y5'GGC+W0VBNI(GF.*
M@=E\[K2 G]_MN;QZS8-$3[W@)WT9@.>B,!]%T_AZ>RW&[08#O]$"/_I.XDI0
MZ3??6%N%-)Z$O>2;F-]B!RE6@>'&C%.R1JFN9UZ=?[5LI.P]'HLS;T:;3,J=
MV"F]_W0YM1+SCLFS>8\*?_Q^1,$=S9MR]^ND?Q+T02?*"7;\>^IRI_W8@S[Y
ML=;YTI[R@'(IQ)5U6I[H.KL3R^;[C1'H,LO=UW3X!+CN5'IS;R0"0&"$A[_+
M:1TKBDT[K_I5EL<L=1/<#@'.I3.%RTCN"Q5="0P[]'7:8='U2!/!Z%]+6.%S
MZV3S9W[^'!#_/C.:Y&<#2F3R$'ER 76A/WZ?8,]"M^)1T=M_WGR7;'0)]%OW
M62KHI%R\;0W*D7005W'65KQSTT$ GV-_VM-T-O]S2,]4S!^Q4P$OK.]B^R3%
MCSF/GO_ (^7PU>E<[MA0^U RLOL2=$9]N&37Q:LU6]RFU3@RI!4M$MMJI@*V
M_72_WB2ND))[O^A*(<)Z0@EIQI]B&%1 +!Z8L&0?08_/XX=UM1AN:)'A(&4-
M^S/UC4 J]69/X7*:>6W9"?QH.!A(L6H:WKI=_!VYDB#1*<Z3?DKE7J!.R1V3
M1VPL08")8KW&^,*?:Q). P@R[G>T/^!(=CR6CRK[LZ6Z?O3,$W5^C 9" &!\
M9/]1Z\B2^NEY\:<G079P+?_#<_[7KMFCN5D<4-]%R,34E<8H'V*<^G7?0SMW
ML*8U&9)?V?)Y'R)-&S=?O;5UI6+(\#488S_Z^A!!'2U ZZ3'^!=.7Q;-*?Z1
M;!I$:L$8_QHR0FM1-@X["W*QOFBN8;IR98Y 9_F#UWYJ4PQ3E]FN];GO-*9F
M.AFG2T!8=%2X@C'+OS)JC(I"+/SR2W0,^ABRF-, =E./FIE <3Q/+9+":U$<
MX"LG3HG5?OH4\>O<'?$2LU?OMT9O&)BZ! F+'#8S<OQ*NO>MVNG&Y"M8.7R2
M"S=HM&TV;Q6E#TGG4NFGMBY(VUF^6(\QJ$YXET-$?PD7@0&9[:+KVX]2QY_6
MUC<F<T!V]>\C*BM]:B\50-6I!$8C6K#<Y>M,-RD.\Q7VU9*^#*@ST,P3U0".
M6KI6NX: A_HHD6'M"1;+O'ASZESGQ;:A^I32Z.1CF/RYZ$H5M"K9,11U#WW9
M]7#'5=<R.Z2#1@H%2[U!!!2P;41 OJ'MC7J8K [L /,>U;G@%4*$+=P=LFA2
M"-?X(ZXS6RCM(<,,-^]S]]O%*:=+H6N_[Q"KU'/7 UMLG9@3>X/OF"#: %-(
ME1XYS 6T'% 5(4J1J3VZ->4L1_\"B.5A<@ D8J_*6=T$M8'W\'+]7;T^RP?G
M'= VF3HMVCLK"CS>!<?=KAD)['/KJ*_'ZERR^F259O_&\.OW34QP1*?99[N8
MLXWG7Y<PU</*?;:<+'WJ22>-;V9X_!1U3?_.EKW[=> @\W8K!W0+V&EG-B+V
M^U=Z**I=T+6/;A^,^WA?4^(['\*V'U9_?K;KE%!7D))UA?;6?3LG,TV))Y^&
MBC$FKVQ?,\6 UGE($@?$ASY PY+"J_?ZZ(=+ [[M'6R)D=1K#]2SEH^I)^;<
MDS)X/Z:6^74],,OO1FI"5WJYW9S7^!^^RN[F2Z._DO].*OB_/4N1[U:CR#<;
M*^M9FJJ-&V#^H)Q'X9O%8GMH@#>@^Y!'",$3WW;;RRQ1FC^NW3KUE('$,8/<
M^"7;' >A INWY"*^EZ_NI)@>$#:W>/#OR/J?(OX_F<:ZPP'1T:QJPD'VL'AA
MRSNF^EB=.5E0T%$C+R@'%6>48C!26>O>%-N[\L@[9/RFBU=WD%ZMZNH'QQZY
MYEJQL8=$[X9?>IJ4AC9E,.53&UR"*3/NMUY; >MR<+)Y9ET3(_=A6%T =K-F
M+#!,WR<_6;@Y\9/=\#W?HFJOM<[58T9(>B9&9R")C/E:P^9=XH .-U#Z,&18
M-/NT(S".:/Z"TX7DV"\YJ.U",XN\&K;';(.;$BC.+C/3SLNV"D4.4^U^)V+'
MVA0@P2;%1KK')]WEK*V>QM]>(B:TC+'#*KAX_3O52E(\,2"Y%-LH4N,0 FT@
ME'8K@0L#S?6];_U-?VD-:^,,&.H3/1D0#)Z'_+8\YA <$\@!"?T@*%77C*S?
MJ1[6O=*D3RA":D2$AIQ2967VF\(95SX;N2+=2KW&CDUW(WU_.D^Q4EQ<:<\H
M8H^A^P$Q"R"&)F>O#8G<G/"IT.STT=MBYQ3/-B9^,AE:57ZYB"<V!P6\++;+
MB5384/E>7UW?V!AY-Y<DH^E9NY.UYCZ[,/R*8G&$[Y>%F>)X,R%VQJ^*^HDI
MA*$; 7D,5<^YX^KP6-N,H.P2R@1372#I>6V"N;IG8)G?$8%[A(*268?UX3LC
MZCQCZ$S4/9D/CDB3*[]FC&2^-E2S-'!8F =Q,I0DMZ:9X[V[V+;FLKO U E"
M>I E!1V&IXS':^TA0V13#<<>F :9IW;$K;99PS;--OAAC5[!M%3 ].3T5;$O
M06IYA]H4,_$BJQNA,_5;+CZI#M8R-@'%%1KC%^LJ[B0/#T*<N1RCXO#3?Q -
MPB%6+.S; U8-;'4Y7!JS-+9+V/Y7S]>2^XG?BN8'=CD@+&8Y.V>1C)FKGJ/=
MYH"V)+&A7)ZT5?3N'UF+?UZ(;R\].* #,GO=;EA)9K\P?IBI/WL>[.<K('K#
M$V_\[*$;?$ W,.7.IOTDIUWI#9D,Z3ZYFRU.NF=XO!R9$Y<3L9L^:M6"EY,Q
M)V<%'1 3*/^AMA':V/5YL<._2(+TX6(VPE+H<0>%6"L7\UPZ,NN2-L8Z0J'?
M@AXS<VF4D"E?OPD;FXUE6K.>PGSGQ+SGJ%<V?F=/9ZM2LXD4W"DF/^L%6PTI
M)3>(MZ5!;HXQX;2]EJ=5J44=25&/&F+PAC0=&^KWO-+)%:)D$.3I+V#8=G1+
MC[_3(2G2CXGT/[#V*:&RMB3(V8/)6L/,Y\U1;_YU.[$W? Y3G]!1_\*Q4ZF'
M8<GT3R-5276D!?M)BGG)_IR8--S)]^DU.ILQ'(4R/-D!<_[68=X:9ER@K6I-
M4= :RRA=-%,$>R<7A,SEI^*\'#-CF5=Z/MCRO[I=]+SC[M%^^9&.+W9>PU&R
M4D?;C6R*%X-Z-&,+3C@^G&U&L.X5XQ)A\UG9\C3(7B-/+.8]+I[)M:('G;/G
M:<&K_HP+ +8S^QP-6E&,9,O08#%!>QT<#HT&S1T%HIQ'?56V3)%.8W4FS14F
M7,BM5);),F9_)__\24;&Y+]L"25OK\DP=,('$D@CP#9M8[ZAE8>&&I-H,Z&%
MDM.?$,0;8L7:/QF+,U!!:(_*'T6.XB?' R^72ZHY)9Q?$;_9\A-6JZR[D5ID
M5F!?&EC27V&$2!.F*/3;F)D-QOI,R,ZDQ6A60TFWO<ZI7;#VX!-V-\NR-ZNE
M'+*T%G98?/OV=EURPI11??(T/4.I@R#('@;7)*WQPV(J"+^%?P'O)UR:!A3U
MCB!..C+!0,4\/.8!8 P1DG1%:\K%Y%)=6BJ,WGTBBU+I!#7-49O1(+><E=\_
M3DM>W/XKG7M7T@P=]D!1>QYE[A/N*0>T7S NLA(M"X6@+:BP=DNR/XD#6JW"
M@8\DG5QI4AB+C YJ$6,X+1&]V'WL\2'VQ#<68;BO^ M.D="FYOVY.B"I*D&K
MJ>&IK\E$P0 J?SH5)YSYL$:BTS55L$)7_T#D@L5N>YGIS844\_B6LO2:!9]\
MK'JFE[+]FK!MKQ2$U8#A'JVH]C93RMSD!OT6]<H>7 ,#F?,&-,RGN0BHN)0Z
MX$,>?(A6HO&W&=K3W%_0P$^8-]08O[C;%/7D'MTO03ENP:Q,S .Z5WT8S]XL
M"K\NPM^S*/ 29 '!3L)1FF]4/O#?9E%4_ ^S*)S_,8NB!>+P9:M"97W<8BC(
M1^,_SZ)P5[1V/625I?@BPFI&Z_/Q>$49Y >C_,+4T1W'NM%M25TSJ0JCH0*7
M!./:5\[&@<MM00HE9:W]QU)>":?@G9*_.Y3E!<3^$HP#2Q .HP]0MZ+B"%I,
M9\"5ZM:64=C@1\I2Y9Y 4=TP$CS*16H$;11<M/RH#A>UJHX[X3T)S0RIF%YR
M4*DIF5JRV;Z(Z"M:TLY:?;CFXQITU@G6AN4*# YLD#-Q^]""K"(.R",IGJ!1
M]06"M@^=YX B8.($"?15FFE11.V,H='@%OCX# K3!I494T>&_=YN,[ZIK+)M
MGS:HMN)LZ#!TKZC1),N@7P%;5;':0JPJ6_7K66MYRTI77_/S\C69,W'9_@(7
MB;2F1*!B^87D?QD>61ZV7I#0[!,W<QGL&DQI2J@0I=_8E8I5^H8YBFG]$W9K
M@Q?U#+'70] '.P%NARI2"YO+ 40G5)S&LR9-]3.@\43B34E]QBL&-,&H():$
M.2VK/B\/V21:Y1::OZ)MD.?C4^SU*#5K-&$++V;SLR-"4;VLOGBPS+[S@9%%
MD7;BA<DU?8W4W9;?"7*"$;'9<L>N"O*:)*OB;+).-*I-QJ8:Z6O9:][9N#-3
M_F:K4Z2]DP8CE<\)N %]@AV0?3W4<,2^H@YN=.TD]QV$1U:CU5/^E%*$1YL#
M2T'[2,%4'< IZ;A<G)B5]C[/_<A]-[7]&?HAZ5R14^@67)$C<0?V1 [SP,43
M+E9Q 8)E* G"%3A4@GF5IHZ-#%R[:C04)'C,V1-ZC*9253KUPT:\LB7'*ST#
M7Q]3-+DL/I;BH=?FM*SAWYNJ6%VD.%AD8?5N*,N:5_M^@)>^L5= 9W=MLH]S
M;=J/@(Z;$<:!'@[Q2C:F@P7_!W-O'@[U&_Z/3I\6R3*6),)4DNR5?9U/"T((
MV6,JR1;30@9CILB^%:&("3%9IZPE3(SE@YCL(68KLK]'C'=F<:;ON<XY_YSS
MW^^<ZUR7<5WSS_/,\]SW\[I?K_?[?NY;]6F:=87J>BCU1ZFN5.4/NW[7H@T-
M*3I6>@<2@)SL9T7EDUQV(# S.$<2A,%3&>-S !HFS5,%I6EO9M522!HE^,2?
MP"A&9Z+>=<('8(,II*7JMIPFFU*]3R75?QXM/CR/[8*#:CC.H1$:?'F>K108
M25S68)OSOB".$/T1\N":#6A5]AUM"@X =?3!)D#?E@F+1?O2@RT9MA02 1KH
MK9[2*0G>APLO;$/C5TR\_)#42K@,:J3#:")Y!>U9/&D+L+N]7@@3Y%_>//WM
MCH9@GUMS7YIJ9FK)A3S>[VQO5RG9 $/;ROJLVI!>YFWW0<_GM/>H5P\UTTY=
MOUO7?5/E=[=;XM<8L.0</$A9W]_)VHQK92'DKKA]N)B8BP3U";P#\%+.%7 7
M,P\V[<0: Q[6L2TY3MQFCG,00.F R?$,4?:7F+S64LZ_8  ;3J(A!-%RX ,Z
M4FRAR2,\1C<CV:,G5<<^@0+ER: >DMIS,"<_CIMH4ZOW#=-5ZK_M0(IA*93Z
MC.4UMAE.-",#J] FQ!$STY3]"+P 6YDVGW<@(O9)/0D[D-KN%K21R=_0X"%[
M;'P#L?*@C(MGZ[,1-FR_+!;;7O?F^K*W)"RQO]2Z]+(%3#RQ*#!T$1Z\&9FM
MTEQ_DXHW<KI:ZBCQ<QS7LN)W9[WE]ZZ\GP9WYM+\'=KI_@XU,Y'U/NKZC4^4
M90W*+=XL.!*D' ^4POW_^)[(RA[!#)E'A'<@T^%[,68HK /3[S,A90<BU*8#
MNEI.^ &-!#KRR2P<P'4BH0N8DPTCH=6!2Z3F]#HJU]-]I"IL.ACF]74S8",E
M_T7#_M 9/^NVS)G@L"-6MS=E:<]]!:TE4U)+E&4LK+H=GGLZIF;5.:;8ZHR-
MV)K:NT@=<Q$OM[O'_W.,NV1E)YF:S3C5I]'M$'1U)*#ZB@."!.?(I;#O\KZ9
M27!;,0J80<3['<C*&2;>G-?!Q7%V\<G3 00+ <;2Y06ZM[#UV*X,!7 SF*-$
MC]:F\:E7AHD5<W>WV?X4JFW/8PP,5;!IW JW9IY,JP:E_^4/%5=03D'ELB,!
M0OS&WY[>"!)&;%A3ESV@W-$LFD%K/;O6Y:W*M$SG.(3A_2/#VE[ZWJ/;'P$I
M;DQHFHDO@1P<=+"Y)[D%05CBLPK1X@G9-F)58&3#SYEE7KJQ1N%N:(YKN8M$
MCN^3G+,Z-]^46F0TE5MDY4?:3%7<?Q7QT,-X-4(&\\#^S)>ZEK;L \_<3RH*
MQI4G/2]>N*E&O_NT:Q1OK3:;0K(H-;@Z-^NX%>JJ_[8X^;?]+;7?TJQU/C=Y
MP3G#S:C_PU$L(DEW:J5MI[WE]0(N./V7046M_ZD$1--?KFSUAM1:NRY/7?5$
MKK7Y)JIX$=[_3Y7QIFKX+7)\4 EH%W6$D#IK6M<6VS[N:F=&ILV<W3^I"Y==
M_$_TY[NA=H5_NR>U9!5/?E-\5OG;B2=(88LNY)6VX=DHWJ11QG35*PIJFB2&
M8OFZ*2<)?;=G0KO*HY[?4 R1W9=#G9KN^IGO-B=10EZY?EI'\=R<3 )\[/G'
MNR JP$G&V?A4UVKY[*)MX(J&JQIQ Q'O+0O,0N,K4 3ZFS/W:;(&I3&TD(/M
MUJ%U&#CYX,\#;G+::96.?=F1#_!)G</UBVQU:[Q!A80SBF]%RKNFE5C^NDZ-
M!YN=Q4SCQ$ULJ? G1K'M6!HE?BJ47#83Z!'PXGMG'B:FS-A6=D J:]ECL AY
M[ZW7OYZG,G=G#'UL6 .5FCB2^N=DO;K(';A_EL:O7-Q2U5@Q<6>J7<V6CO+Z
MPD8VG+NGB%Y/G!TT72[IWR.,@6';K?D\\I.W%E.SJ!I]E)L5)I2Q#]0;)9<A
MP+E)S #=-E+):9>>Z(=@J.U=_79A\Y"YIN#< ''52DXO*J5K]@0SO3R\&I7O
M,1K6ZL@*4&YN&0TI:RX,N'USV-B$K"B_;&6HG+5!>%.2S:B3O8M:).R*&9GT
M!2^6OR59M!;;Y.9-_^Z^3UQ?)K[_@&W7DD C^M\YMUB0*U!>M,4G2D]!^\_U
M ;[U[[X)]*L*Z5BIZX^7"ME5W^E(]TDML#1<OXY;O<%MY/R[ XE]AKT%$YT9
M"*(B$Q!2:/1[[8J9[^UEH/7P=6(8/2AG;(Z4\0(99S=K;P*%#V&I<XA)WBKS
M^ 3<CYPXI?ORKL(JN2M/LTZU+"*LGM<UTO34<"I$<B0\DJ?A\)\IBH>8'Z[7
MH.<LC)]2C"B]+^6HJ_YE)N:1H?)7UR(%F=X_=Q:<LSS[G!>51UR*&0ILM: ?
M&%S<]F%PEZ70LMH/F3G5*I\ GS,F3GDD<0UX4G]<>5S[[%;DC:O&[;!?4L \
M[\!O/B<=XU9J.+7S3D]L#,AL&@R\FA+H)NS_UEZF?2WV<+PQF[!B:AQ:&G.B
M:&7&]VC,$[6);-Y7&&"I]7@'(K$RP=!?MF(H@6>8^\^=K'YM11V(] /,ZG1Z
M64_2Q^G="ZLZ,LB?^S/"_.Y^/6Y<E=-^7X"I4<(YR1PO3KJ']!,I>]B"#6AV
M4Q*H>%H46V,E\-0L(97W&-,':])?><P6!&/ZMBZ-;Z9Y\OGG5%&P7T=S]I?F
MB?@UC0OT>TJ55JK3__GT]41(]&B\56>&8 3D:HU>6*J^-#,J-5P%QDIEGP=6
M$NY5NK/J:5I,RP?T]T0+=,^C2M<!3$:;RNT(LX##O>/4FI,]M#KU!+,T@LG>
M,%D=H*'$0V3DZF_A?7HK"XE%RBN*W']X@T3 "9%!J<5U7OI;^P4\Y1??X);3
MN[)<3TZZ/?&P*,#W>8R&->N2F"<_QO<>3IMPJ/^'=<22';PZVM'+E48]Z,P3
M2-G0T.J<E1Y;UEV#+CV\&RAK1RB[9AGF@_6]&W,I1&,^-3LT["C+U]#EP.?'
MX$H)JH3EQD>IK[S!NNE_[[2<88:3(E&?ZHRI69VS^\9G%7\@OMEG&+L":9N]
M9Z[UQ.^2(X4+NQI?) K^+?M>3^XD?Y-DE%6R3_"&FES%.(98B9,Q)]LR79L
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M@,8H&(,2\-NP>)B\V7'.&;".?8HC#@YI)6IP-.CPQ-,9TB##?FP'0E.L3_$
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M78W/(2_+;>Y EB;J^NC%^7.!*OJM4U9ZE/R)^:F!'<B_ZLV-1P3CBSSJF5(
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MO/GU!3!IK+7PJ\?=K!XH^)PSO&C2=4_XO?8Q #&YQ#NP0A=16S:3YY:8Z.Y
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MU 19LVBTEY7&Y,_ CX9=R'\\_2>,GF^G/Z,AA=&WP"ZV4: 1-IG>-ES/]M3
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M&9^@&ZS%>L,MW-B!)*_S!O(L\$6+/",0R_S=!3_2IL@Y!V;3@CV]<>>;@0!
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M6.];-9LI\;;\U!>L[-GX6_'E"1'YCT@S74G5!NQE!'!%:R]*DM7-S6S9S7[
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M<+\@6N6 Q?J65V.PI0.S,8UF/U?':N-F\50Q)+C<)N7Q#N1@23U1KW%\]A@
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M]M;(&$B&M#:T9D3=[2T\# D.LYU:B-,VL+QR4HOE&<?9%_7AXD6UGV]9#=3
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MX<[Y!+31T/GTX!]; M'$G5C>#4YK%O:$4/SL\)/8T#Y$2_[ &>_&SJGP096
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M:3K3S9\->P3Z8'RERRXD<,788H:WET-@6F0*??R-:?'Y5CS)U0JFS:%VP74
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MV]E+O8.:V8<\PHM.'MC>8H=R3+NH$LT=$J[?>7L9&XGTIJR<2 #12Q>_O6D
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M#A+O-)C),>W9RMLF),"L%PBT8Y:CG=)88^!.,P,A%73?Z]@HQ8))3KN.E9N
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MJ\LO[X1A8SC.Z_2=LR#9G4/M0]&<_P(LNJS_U<"I!M'%>#HL=%+!2/(=K">
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M?PZ(F")HIV[B>[1G$((#]4 .MY8?MPNY@Z"MF8,96#4.B7L2+<TSYPA?#N8
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MA:]?,H,_%X?8-<7UAB181 GN*9#4(6#QG9Z[P,R>)+P\%N78./8+DZ#?\\C
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MC-K]6W16ZT&/;,U<WT8.[Q77F&.*,_[2BA8M+6$$6 DQQQ_BX30__5MM^+$
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M1.6IX\WT^=Z?Z+N!Y5 6ZU3>[B<T_JVA!NB&X]>UK'^ZXF1^3PLB-@K?13Y
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MQCMSSK>QR,M55SM^_./F=_K6E<R9C&8J'PY9"3BI]G"A&HD_26\*FIC1K$7
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M@CM!%T7D;*DWGI?@/ U'R@M/7 VFAD3I:?,J@C)JI (-D6OXT6-0+*,'E'F
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M'PBBA;R_59V!D<*RW/K-UE#0\VB!'TES5<%O38H7P*+IR3YV0)N0S9 V4B)
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M"ALQD*JJMSB36L;?0-#UK>)]Y G(3 "S4O7'42%=CB^$CD^\/4P52.J^"UY
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M$\FN1)PK\9 9K#>9]>'<L-&M4%%HLBHV%Q(O,VB86?2> ?*-UM/.=#V1C^Z
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M@()&35!"2^.P$F6\1D+IJ[2&28#7-Z)]B#ZGI;/$^D/0*(8B$,SN2NO!<'2
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M-0BG5-C#HHRG D#L,/]>GDS=SI*?Q[XO J"7+^RZ3_CZ9C0QJ<MOY/"LBIX
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MFSJV Q>3$I!<R ,)V99O]1IOFS*^8HZ,(D94N*.O&!DIE3:L7WB@?7Y\S'P
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M_K;Z@^*M!P?ZP-SJO'_=^?A6@QKT;CX=L<\DN &"Y;,X00T-F3A:Y!!L//]
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M BR=>: ER HWU[J$!_IJ!N9G!_Q>!P 2H?Z_ 3)?;^YX'LC&3(H'HHSP;]$
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M[H#T_35 42Y5 5 I1;+"*6B=ZYZGN=,6PSTM W-IG$?W#6%[%*(W(7* '67
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MLUNC?1AI%VCCG4B/..)>E%]';*Z"QC&%KUY!F@.WB2/D._-\'QC/-FB300A
M@S#)U@(3NL.JV!Z/.3#6F]&2+K OO2V*:C>!OLP WI]'UCX9-+B*SPC&9PVC
M1PE/_+Z0U()'.EP>KUMF5:56CZX.'B!M'$T'ER;\QFU._X#V8#CH9VYX"(AG
M^R<H^C_)QX9XK<U(%404W=8R9".%<%<(YL0H"2=X<5H,BPSP,S;NP1H?VV'
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M?K2=8+6_9U3&[>ZC9/7!3L7U*-I[+D55EW>Z!J%Y -*:^>5DDG+S]Z\HK%X
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M0=G4X(YO.6MS '?_VNV!.#%I[79=VX<9HIZFPMJ"Q4$VWT57EVC-22W+.R-
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M:XT!?T;,166YK65\A'HI=WQ#3ECS(S"P+X8QB9U:^6(Q],O1S_7:-!<?M7W
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M-1"TD1:68'HR^H?3#XZPUD_4" :7Y3O[4,/*_3=KS6?L$\:0GD6WR+;%%BB
MY%HC'I%)58>NJMI]L"61THF\:PTF/Y_$=2_=\P#+U*K#&WFIC,N,HT6&0U^D
M^<L*_O*MD=Z9=/ PPQ\5*7QR8RG\;$)J@)P(@!E)JSL593X,-.S--4$QQ6<
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M78/8^=:NOV:B9""%@A6K&#T_'%O_GC>E?&^$X\ZQFX;DN;MMNT2/7D_9LML
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M;)C0)\\;XH\%;V-XB9UUC!?J4PG.[S'^1D80]2'/B).T5X"$7AN6Z'O>9X/
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MV[A['.H&#)G?V7],75E-M-E*MD_U &GS V!!(CE/\R>T]7Y?->@4?UR%Z7C
M^.^_<6I8X!1WD4S_WKX+@[3*7]3RY*>%CB_=^,T@CB*<^:&9T Y6_4 >796
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M*'\0VY.*U#NX*]ENL*[=%?5&2^7;PP^5[)K?21O!'E7_6</J5S8^;&?\8>;
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M08L"[.'.92HB_N*>V\Y2DRLVEC=KCV2Y3Z].O=R8VRUIT[I?7G)2<_;6DB#
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M\37EK>N%<4I/\\FDTOF<0&1;8R_M$Z!,C&Q2B_5U7J$5/CJ;2BZX5@D8<&R
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MHW&U[#FSFF/JIRH[<A>>%U\\WT4[RX=AC=.:? I[\?ZXS/;+2"IW'ZD)1![
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M1DIUZ'WA=,>/L)@HW%?GL:?T\)9L;JAN;3:MK\,PY"![Y8X5X75JZ%GBD:$
MRS\Q: GJHYT;0?^5-*M!AL&[$:6$EN="ZIK7,M)S:%403,>ADR/3XEP3+QYS
M' @2-!QZ6Z@]%608*6Q6+/^N@:[609OU=\6=0)=\L%"0.[\(<.[9LW52OO/U
M[B+M/GBDF61=XA":FV>*0^P@6$UVC(@(FMGPGKZ*S7DDTFRL)_/[3=PCDE.Z
MC)+]'&KPK*O5F!KH^SO.&Q=7R=W[[_D(0>9UX*386FK3K3",$%9/%C-,GRZ$
MNB*1ECU?MEX_JJFR\O>L1[.JPT!>>]YWJD4/1S*TNX8FKE@%JU0A1Y\46/.@
MI[&;ZA:;"PL9=LN1[D2/ F-V+JR:^V(_V""VMA(5O%T,*/Z__Y#T.(.MD\7]
MJ,?R\GW$3Z[*BJ2,40:+A'OQ7F29OO)]0?C#[%1ZV)YXT<KY4._E &%-..:Q
M%2<"]@Y7>D?]?MH7 R.=D_BNN06B<^B@W8FXS6:X:K>?ZN((&MAZ9V6RE!L8
MH5MW%8?^^HAX?"&I#ZO7CB/@=LJ;'Y*&V*N4;=2\Q E;\;6"F 29LY*^REY^
M1%E*>@*\NF=*[)G9HUN]KV;_$:'7MMS#<3S>$,Y@47]JU,5@*\[5TCK3OJ==
MU&W<NX:-^4A(,LI[-$UV_67R@_M-NKF$RU]7GQD.\5VC@+6GFE5R=ISGN@L7
M2X%6,AY)@>K!),+@B>GL46&C;'B*W-K$>YW-H,3(=8:9R]][S$%3W-M!FG#'
M@CV.TE@9$CF5'FDQ15P(,,]Z=RS7B.R2)_(#L]6>K(J_4I]:'QE&?Z]%WGZC
M78V==)I+=:K.)S5CV;G..FJ+/?XRTFT?YB)+W2!K$\F:UUO,V77\W][=B/C>
MP:1T^G1FQ*4(5/_UR:K_KB#4@LY(E'J? .+9X< ;K(+U)T#FF&$D,("T++SU
M7[=.[+NISLC!CPWEYSRJ#:="V>8:DZ5J:A/O2TW-)>M_Y)@;9N)%,56.&8N2
M/G:>FYZAE,_Z#//9SM>))I?1?(B(!5 ,(01A%2%3KC5 _G! ?/AL75=+?+'S
M?XHC=I10]ZQOQM,*FZ1EIQ9ZV-I!C0[EF>_21&]R\.3H$&3CQ=>=*JAC]J=K
MXZ?.H0&]^J28F20L.;]<CY62@_OG7'_5\O8(E%LTQR15RXMR72"( ;R_-/BZ
M2R=JG#[^&F!=+ Q5BL]IK%LW.=;'BA;_0Q\TW<0I1D*/6/F>I^C+J6M(] \R
M<6<;EB%ZH0!50.]7)ZONID5$ZKH3UUB=/4>#!?VED2+(?$ER$IIQ!( =H"P$
M8$(^^<Q':EKG-?0P-F&F5:?#BP+ ^KPJK:2H).QK(VW@?0>4R%";.B0=,HXN
MBC1]%=M46^*X'^TX5[9LL"@VG3T^:,!2C1S?O*G$Z%T']-YA7)*8S')>A<9U
M2>C63KZWI?>89AQGSS/7$  <H5$F$[ %EV(GE%MQQ%KRR,UYQG^_D<,0U?>R
M1?:>GA?,'& W*LJ,1I4#J)]SZ'=6CK+9OO,?6*/XN(4N.T^0;C0$/F97'KJ9
M:N&3"?T4I^*1&S-T.:#?>N!3JHZ%:Y]0(\%(AXH<E2/"\+Y8S!R0GBQBV?39
MV>2W)FV',MS[D B1@5R.8"6 AM^V_:+7R'JALBYE>NQ-^I%> ZJ[ E.A^3T!
M@N8+#$Y9@#M/*&4#=SIOHB1>[Y5+I5X,]?!:=__Z!#'!T0;R2.:'V\WIXO?T
M<D>L*$7H8G,(] XBSD-:T).!=T4V(%#QXMXKG9#7 YS9WUC8Y>9RZ,E-IV_X
M27@D9*=9>090FJO-.;@X(]?1F!P\;L.TW! ?"!;WF^Q6FR:$)XK^T]II'P[1
MOH%?D,V5+<<+8BL_9_C% W.L["!,11(8&?AHWG2I7$S@@H38M",]RATV^@PG
MT'^</]DT3\L[I=CCDTW&\TLE> +H+M?>!38\ RJM:,$3P$#M"2"5Y^*V[*"&
M.+HKOBOV7&31*4OD- U+^N:2""#F-J#W4GMO(_Q0_(%9/$WZ1UF/6<#]&J-;
M4IB4[-_GP>BU:N\H2VC ]=M>#[A/ ,,2S>,PVW-R(J1*AF4P[0WI;S0F;*<O
M)L6F"IA2!%H<B('J@2^076B@!]";K Y], ^PY5[BWH8RK'"H>Q'132C<IO[]
M^C)60(N,XR6AB(/*GU-^C\68T _8+J3F=71G><VG1^;\.#DW87L%!O+2EKEV
M4T*'J@,*8-_%#IGT\"GP*(X-5U<C?)RU2WEEL9^S@01#1,%S<$+>F4N>JR:6
MH\]<X%UV*Z.:3^54'..\I)O2&A56+F0WCY:K5J>["K%W\G9*+QR$L+\BX9XW
M+]9ULD;U[#"6Y1^L"T\,(=)N'<##/.4I;N;%-[3>F:FF=.^GAS[OK]&6)J2'
MV%U-$:>SP(&LI:^L*<F3(9F8]7-U;. K]+MEQ3;=RV7LF2> N8?%IRIF:%:M
ME/&.X\B^/F7P&F8DC:OFEZM2/X\1_FO*R]WH(?*3W#%VRT4)1HINU]%RTA*%
MCD@&:465T=@PAK)A_W_GZU*.*K/</Q<+)O C5MD)*^7I51K5>)8*2>:%;H_'
M6=FA+"H>'PB:=?<XJ(@:%:WX0;>0Z#;.E+P68*[G)33B6+;D&/-1ZP.DW=U.
M4REQHR%'))#JW[>.#UM9-$^ RM<@M0>@X-;7,L/;*V;+QXO(B%N<K1;>N24A
M/<N5[\:T!MEIQ 8+-#]L@D]9MFRM8,*266CGC]!%K12#D:N2FVT*NNB*6XNP
MQN/%BLV*MXI0#/6U^MFDU?$TA8)_<^/Y$T4,""%97DF32@H(1HYRA+#B7V$7
M?][J'*['^^T7&L/#SAD%89ZK?<V'.#A.:@P@) -^]Q*IKD2=B9Z\_#[T)X"V
MJ.7(W8?FE4TY36+JE2##<GU@V,5(M6'XG_:S B [1>H3H%Q+ETB_,U9@W2 T
MB(U/;\2T]Z?0Q([78]MP P[40K$U[E.K?%+/@4,_Z+N7)L'F '-L6O+NA29*
M6_C%K-AY1#3E72+M15FXS;Q-U[*ML%/4'1G_[:W6EUAO4OWT,(;B_PI_D&+A
M/U9+,@C@5E^_=OCFV;V2?.^ IBQW_P+BK@ W6C7"T<V=NU^[6B]:^ICOBXBC
MM&Y0_ATZ-5:&.L@SV;8W>4&9"TM5$NF^'(O5\C2/:3J3NR#L,R(H:M7>&[:.
M+A@9G)J=SJ]>%1*OFI<.5G>\:U)7T70Y5.L V<M_9RD[@/@S5?NF*:]<HH3:
MEWV16!G2U>ZLDJ*4=FLZO]74S,E;W%7[#EF?TS;3)@^Y)=WVB)#TW645P6C2
MG;F$NKIBE9(H?< 1+]!*LA1]4S].KVYN46-RWN/M#?:Z^),GER5G8OMGCT2I
MD&?V0[-U&1]/Q,_0\5<$IM& /04+PWW>Z60IT:\Y</43T?R&^:&/6Q>/IR=I
M,1X$V[H<:'21 XM^Q.YO*\Z-[I8[@#T-=ZD-1QO+W,$M:,9P=0(MNKV/WM'S
M?RTKHC,2K\KEY<MZ(!;C;<5*Z%9GGK34#?!,X,C-%%P"QYM!O8_O0'CP1GE3
MT 4F&H=D3@[[W2 (#YQ9;N49%;E*%IZ'Y K-C3O?(X#Z0&V$3)O(J\GCC@UC
M^L"I*BH&BN-SAU\BF%8</S4T+PC"A.MR<6JVFE%P%&C[7ITY=$USK_!:>YHO
M6%=#46BG_<@7=>''';!T+)CVGZO/\E9LI\4N?T2+%45#";O@)>VDV]\@Q MB
M,%[)M$3E(D;P55NC7\T3((0(;''*)L<P@\_5T3G)F0X4]M.XQ&0P8VHG%!&G
ML$IO$70L5Q"P\W'%9W8G-+FVY!S..2TOX,%%\-!2B^YSS=))%-'E/NN[C>]1
M( 4%"#/G];^M&2V=EKJ#[&[A7;#^4I:93+L61NOT0YEN-N9_[< #!9\N#7][
M!YREZO++2((4]#IIP[_TC_PF)?M:%RD)&\0=84X7<UZX[FV\U6IB*F905RY&
M!2 !M 9$F5J]V\CV^5Z15S:YW!,<4F5F:G\OYBZCF"TS%M3K O18=UTW)98Y
M,WJ([:MB+D0IT/:_:ZE?4/BB3]&37U^_T(6D/ELM+GOP2 BO,L*!0YA?_ )9
M6+^GB>;UDWE$I8I"N!*=.O1[5SOK3-@/;N6MFP1=ML7[E'-5?9'\ BEPBIG$
M&X5-:[$]E*V2>?<@^43+.'#LJ>/?XG^Z8G=V"LZ02$>CY58S ;*-IQF:)K*D
M\'K_:HU;):P\Q:DK,I##'A2,"-O'E$I+&M&_A"1)!P)9:+[U\*Y':/I&06T+
MK1NCTE[]>5=AJB./@[,:$V9M,VU;O,>+I<LWL:9C$=-#P(RU#?QHG]PBH;JG
M/2==7&2#6%R[\IH=(-JF&RWQ,CX/+S,F!#.8A'9?_RAC7<A7VL:>67[J]?AN
MH(3;=._ UPO13"I5IIZRM1+6]P_<%X%'MS=QH-G2-4[.\A(WE<N<!*T*G=0/
MQ-_R54A?$'^N5XD5K?F!S%%2+!E&'MO.0/;C\K)8D+<.%8I53DZD>?;A[FW(
M%BU95H\7U1;SQ[Q%!-+?KR0V2F4K3<@0_=OB><GD;5Q, Y>(8QK,)#%P880\
M:F$/>5,0%H6T?A:.DO"03U+OO!F/9+QX$"4KJK\C4.2B(]DAF"!A[U\6]-G8
M<Q>Q5$B>T3,,^O]_K+UE5)Q!M*[90( $ @1W2/"D P1W#^[NKHU;XTYPAP#!
M&K= XQXD:./:2'!W=^<F9\X]<^>L,[]F?GQK]:]O=557[=Y/[7>_E7Q/,2W9
MP]LT[DH*5?IM2;"/E4)J?QC/N[H!!<5*6,TZ$E7U)/)'D  [EHUR".XA5Y1S
M4'$8A#'WHF.G.(7+S]?:BP$AYJW"[@D)6_&224[RO9?2AW Y"^SB= GT(]+P
MRQ'-,-7:)GB%ZVW1$MCZYY1D74QN^PEWYRB?NC9'7; <_.28D<DHLK/@+:U\
MD;I(UL!^<76Q!<IW)TF"$R9V>9B+G1*KK[Q@\P'6NWVV3DN.[4 GM&6I*.P@
M9<X>XZQS(XP ]X.9%A(2&T<TAO)2<"YEI-VEXOLDCC*]NX5[XX"_W#/+GMA$
M4J>L+4@V PMGKVQ$]Z>^F12O]3MIZ;'D)G<2KVLB@?\[QU77!I-*<:#;O*%=
M #M7C,/J'CM9?D&"B<FMO_.N9O1JZM#_.=O4I85E=9S8<_>QW&]'?>'8_?^[
MY)'I'I&KK]E'0A'E3ATCJ%4$D5(?C$ASJE?@#4QT.E+WD2_NS+&Z3K=(.9^?
MWT\O4%)LT!#4^<(7A..G=T295I&A>WH5VQKO6S)"-G/2_N9HDV6 ^"047YN?
MNO %8+JX5_N4M\]7?$&7LF[A21SZ92'N??1;DQH5'5P7R+1KE!#:;7!W[6[X
M]1C8@]$RQ-RD5D)M,UZ1QH@,3B(9>L@OXK[NR4'-WR4@8[6FR!'4XU;Z&2#D
MG3!PB0\'M>-435V]/H&LWU]OTP+1EQ?9VY4$W':*9RKW[L4K?LSVK?C?VW7K
MR3;77L0CP')6E<>* EU&[8Z/.?S1/)@56ILS#N^_;?,5X;PS5T-%TZWDIDRV
MT=U-X:7L>>)D%!J.);:U]'_?KZVTY:GD97FO\>#!)>V/N6 57>L+F6[L?!\?
M06TD_9;(E3_=+6N-G$L>O@&?."YJ5S,#'=.Q\H7"5'Q98!OR(ZX7Z)FT5\EM
M.UU1#U$_'@?L3K996$S/MS=0_]U_@P-*\6+SL)A5#.L/J?\Q5V+B+)-Y)3@]
MP1S*/I&SN%L>>^W^^8BJUB75#H:Z[U%B>IJ5.#_7R3AR-397$0)7=.)Q6T0!
MT+P ,/F41X.V\5.2+=?__O$'UB?;)-=DV4&/YB70<>Q&5Q'VI0^.M-SM>#W8
M5*=4MOVI8/JQ,_-V=V#Y7>$QWX($_;["-5(,,15?$2;F\HH"I<0!<^<)SQS7
MI=CZ#Z<5R4\AF+$)_&X),C4!E1>$&DN)BBJ*.GCC>COV=3:*&![=W0Y%Q/DV
MS>9!NZW#SQYS"KKT21 7[?&YL77@B-OVSE=?4?7V])F/.C=##[RY72$&L';O
M[5\/2U0+2AU5K1G^&:;4TI@SOP?TBP5;249_G8;$].4*7!)ZA43/HK(]Q6[E
M:V.5(G6TH=F4Z&T7UG2T9G094)[AC2ZL9QTGFPMU6/V>0\=L)<O64YNG2 +E
M^ZBTU=<PO7\>UM2:%UWG[_=3A@B?Q'GMGK1^++8F 6<50)V+^H\;FZ3GY,)F
M_?72]9F[6MP22@7S[>TICJ5:2\W358[H>89PX=?W:#S30=O0Z3JNAIH%/;I;
M<Y78@H1XO^3M=L*ZQHEGTGW>K6@$#J+U9G0&$ZEY&)DEF9&?^CY^6/&MJN*4
MO?UFX+$<H>[0/'_/;_3,ZC?C%D6L-55TSB258>Q'P-^RE3KRG_:K1,@G#3T/
M#;0QWXSQAXZRG!C$H==VDK8<62C)W)-I<J &N(93X+,9#H%>0<PT5);8A+^Y
M=F4K>NU;959@A. I*_V?]ER(RU%$J3IA G@ICR%NR;!;[V<QZJ>9BJXV!A^&
M:=M_:H]_)F"87U\ _6.E+X!9M1? !$B?O'$1?RN].,(AK%=?4:3^#]:B$XO2
MRGDOEI@^GK('1.2AS9GV!= (IIP,X*N>#)YLJB[R:+[W"!)ZN!3J2GV@[J.\
MI%1\6/4/ 8#CU+=V!9-'_N[[VU_M'91/#Y1KTKYVZPSO V),O@Q1T A*\<4J
M"C @*2J] )2RK^:9GS!L\BKQX3X./^<\HJ0F[=^Z ST]\6P?$.TH3"YZO=7_
MJ^1E?AO(M8=#>5PE!'56?AH\!'?<(2WZHE[@]\%N_$FZL4]Q&<,FQ/%[+/[#
M=[!QK5],3Y;E&?GWH_^3>H0^5FCX^3%ANPC4JFP$DR^3HM9C=KYM^% :N=_0
MG RM(-O7KVYO'.9$Q:5N@K6C'+T3VU8VFF0O7TO?O+M,IV\[@C#9>A2H\ +X
M'#CBQ%MP7];26UKWD)JL+4(97A:UO@32PW4CI>PRU?/_M->J5.J^IG5<%/WY
M-W5E"3TQ)=1MI*_F>]YR%B\)G\P1A;?^"R#PA,*.TT:3Y@[K^YB1MY]G!>(O
M14#NR,5%7+P_[]#K^9\1Q6?D4#QE@\[Q_RKYS8)CB)>"?D:GF 9\G.ZS2:&@
MGJXTP,8I3&_L)Q#&B^VY2+0V.PP8.2-H >MFTZ%03;*=OP :?.7-\L[T0U)#
MWT^6%_UJ _(/D'[1\RF#'>BEQP)3\I*/^TT" Z6\5./P24F&D\I/S5-Q5[X<
M/-0)E3XGS\RXA=C:L>M:_3!N.#8^]GRNS]>OTHB4B#(I*N7Z<UE6ZA)4G>FK
MB+^#/6NY_F?82[0'Z_X/0$AD[ *Q:>X \NNF7"[JHTIDS"=EO4W,$W%Z+QWA
M?R-AI,7[#@B#?KUB*8'\P#>KR.]L) [=_PNGZ*B4<:AW:-LT4$4T^2T;/VVA
M U/@;:Q_+K243QJ??/2XQ(93] 4@ R'S67#_<&G<7W:I::JIP<Z?!9KK+^.%
M5M=,5QCUX?$ G_<VU9TFFTAJJ]-PH8Q9A_=VZWH+#<2*U+68JU-S3OJ8(85_
M;$CX3V5R+6/E(O!\NJGC2E;/U%\MC&/#05Z%[656M;^[A?J^G1>/3\]?G*VU
M^4NWXH(.:]YYF#FR"G16; \<&XS2_8HQ;0(^]*K&8X#[Y(^COEXJBVMU_;<>
M4ZS/9[07AC:-S*/]"T,BNX1Q.TG:57(S-]@*/U9(P_0N^WE*P:]8]C6E5CPM
M'%VN.+00%0 #'*L*\B,-SHVEXSH>4=J_IH^N%ZN9WQLR(#2^NNQUN#U:)]%O
MX>2?XM2<!9"] %B4=KW4*"AK['15/U@LG'_<S[E^ 7C,,I9;U^S?'#G1#^9O
MQ0BU=&SH.W_/E2YM,[-:4(:/53QTSJ)<B#75)D2<1RCY(F&=C3AR+'@@2T4^
MC2W1 AZY_&,LOSG,%\@+A9?\+GOG%1PIXU/,QD,^EVYN]5^-P:IHJ<GOP*:!
MBL6ZT?N<JY>LS!?0$A]S29<:N*W&@^2OJGYT@5_=B;PH*D)0G[#ZU82U>!.I
MN7PL44P,WSA#/A_=TV_IA.&&FO4QL=DE+&Z_US_ZAWLCP?T$DQ==3$'-XM*N
MW(9?[J=D<9=S-49D4$ 4B@RA^=;559#I5[<Q;_B5]$Q=2F_5+6Y6<%U'HI(;
M<11V'G(^$C_V4\;XBAD8G]ITUEKI\,^//!HS<[PK8J?^L4X6X/N&_UE][W+,
M^AO/^_B_8R!%]BG>T-68>@1#=:LZ">4V=E>^/&'X:AN(G15WX2R+$4;8FBS1
MMOKISY=L%GDX^%BB+E!\)VMJL7>]W/7HC]^ ?G#VAJ/=E4JRQU%^_QB3GF',
M/BOW-ATE3^W+@ N[VWC%7I$3"7,9;@#P$.B-8),C5AST.G3:^)5_3=-S\FKV
M:WYRNN9UCEE[Y=#L8D'3_M\I]G/7!L4K^)?*FR9I!VN@IJZ3TIT$]])/W/?I
MB4W 1]L978B36?M[!_+;X@?LRRT*,PJ'!:3LU0U2?Y(,X=JVMC/_2-NK;MNI
M,9M7SAGRG9S)U#&+._@S>_=DO&[5/ZV5!X_H<OI'8Z*9)@(C Q^YD/9UZD];
MFF+E)? B'AOF3>>_H"7TL[OD-(_.ZQ\((MM@<*F>5]9)T^K*VC0]:QO3'X<9
M?'/[UXNJWH'ZR@'7HT':Z;JC\17//C4:IQ^Y]=QI\**^SL#/ _?Y:,[$-T9!
MZN+ZW;EV/]&Q3U2M!?$B#S1YVV)SW8M66EZER#H7FB,5;1F)]-(S5-&?Z?%F
M/E,TR[]O:J%UIO:-'6BR1UOZ4>%H(]392*(;U6]+!Y^T&KR[]HJ.-< =>\_I
ME&T:^VG3@ Q"^M%4WUV%*W&PIGZ!-Z6?Z+>>'?KSZ*>8T6!P$>B^[:B^=R87
M:MA3%>$AVM'5A!Z08\ES70"UT<.L:4JKERUC)O3($_D<1UZ103;Q=5@&I9,'
MJ1"L(Y_9XI< LA086AQY*Q/'EBA;10:QSKOU6WAP4()GS8OYVJ><?_UM-]_\
M[%E(D/S[XLA0HBEU+>E@RH;W6V.JQL288R7G;@'FH-OA;HYEM&NO[6V2<E/K
M6< $A%Q%E]2;(VM]*L.T_U!JZ)W(/&"7;_J/(*489[QK!#A+_!+^ E"VEPFD
M=$I$T<+\G:G17KHVW0XWAD.9+:O@5-$]]-^ #F*C,QJOL"$V"JY\F>#IF4;S
M5<-W$2CY=G@X/;9TO_Q7#IF:540&.D]VG32O2(&5& >\&(<Z]4_#L[-E=F[T
MWW]L8O)^VVT28)EL/&[EO \-="]<V6_4% *9,[+]1&QZOR8,0#A_KK?1F/@P
MO3D%T=;'B)G4*UKTZ?6FM-;;U>1^HA1N=(CPNK:OA/V963;OG7KLV5QKODL=
M)PE3CKD20O;HK;"OR#AL"?D3A?OEMSJ1ZAAP;&E/WW:9] 40F5!?)B^Q/J.M
MC+-.HVZ>IG:6]7MC*A(KY&@TH7QOQ2IU:-HB!42*Q& &>"?X(S_+X#G0):NY
MT8Y@MDM)Q\# MAE.!?(9"G7^#1L\]SLAYU67+?L58]-#\KLEV" =G2^N5K<H
M@SXE(3XGA=LXA>;F2#_K)&RUC43*L\#P<"#1ZBPNL^0W2IG>K?$+H-X>3,ZL
MWC)5U+)P'1*#/2G*C5$?V&W:E"N//&JU9#.;KAAZJ2_C74::\9!FVOR#/+%.
M.:@[8;P**4'CLVOVH7_$3,J>-]@)88K&:F9;C%KR(CH EBC8!O17.NVRUK$K
M;+V/^=-2ESH6>HE_H?[D94I>'6V28;QF5C>KJI.MU/*K_5R'T-,M8%"*&@V
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MG6[+<VB&,"AEVB=TQ<VT-ER(397[X8+2L]IJ:.^A!>L[E*V+PP&/2TY!PN1
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M#'U[8_,70%Q#V"!K9OR7X(ZJRR+XM2F\K6R7UZTI@?%1H8]*SHX,2LKD=5Y
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ME\;$M%[,^I29F:G^(7]Z]ABKD)'JJ?.RL/(K'!A\!LUMA.>VBH2D.4H=#KT
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MI[K6Z+3W7AFQHFX#MQ@*[L1]_8U]\9^J4MB")U);TN\ZUC6_F9]61A2FT+P
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M$L)8E%2L);NM/;>PT)%"-:P<<H= @\EGELYSB1Y_&Z84)G-Z]735VS'_(93
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MT/%18Y)_J'+'KC[F+NM^&>5#B6I*^1@JE>S=K^)- 1?YK</S=VXDM=0^-)@
M@U%\3_I-M(Z>UI_$G61HRYMHSN]*34:V]J150$WOKQ;7?-+BS=OXIE6>V%03
MG8R+4)_=-"E?2^[N-5O.*:<3*3[^3G0OEY+6O_*SA^'IU];46NS:U/Z)-WH/
M</J( :($SUH.ULZ&OG(EZHDKL^P9SW&$_-4J^\*G?TB1G]_DVP=^EPBQ-%8S
ME$I!V]U$BPL"9_;BRCD1II!+C74,\)HY[&]'Z#>&XL$I)7AF/MK.K^H:*BKB
M3Y/P]5U&C,B+35? .6!:X?\.+/&?)5AT.'6):X-WM)]O,O&3&N;2E?0RBM%H
MSE2ZPK0T],"F;Z6^>.CG$VVL3Y5X9@@2UUM"D.):UMF0ZU<EOOE&:56T60H7
MW\[,8&( C9L/;EQ $SGQP@GY)___.5$H(2_]$K G:[1H'B$6X^T*VQ^1?WHY
MASM:$*4WW\E!Y0-:HE#CSE*?N!(S61?$7@2NF4T($7Z]*K'RLEI]"E$2)F8N
M-=VSW3;>X7B@O=]"Y) W]X!ESD[XHB]V<N^R:I=RG1RZ1M_FPO)L!P7O//.*
M4EH&Y_.J6DXEW?'D]>%YY$EB/?YBU:V8@)4GO@\7%"LR<QG<,+9JI/=;E,WV
MSC0*H6,;SZ+.MD,*41 >\@_>;$JQE[F*3%3OD<<ZOG(L4O6B#AOZU7M;@SPY
M ;V:\^;9R15CLA>G"IH<.6,P/?NW^G@#RSA5W".WEFX9MD]&;V1H9QN@/RL8
M=Q-/64.O45KA9\1-C G%0!SW[D4()71@Q&Z=_G2\U?"G268P.-C=^2>S^]!X
M*2?]EU]M2QX,<G!R(FS]A7M 6]&4^2;K<W/8ZC#NK!F$)XYD3;Y9QM@?&..I
M@C&Z($(*KW/)EM_IR$"+,$WM?I''):36 !3#DW?ZJT?^^%S*IYQ)5>=!K3&N
M58Y[N"4WKGB7'T!2)SO7:MR4#C(ATF,_SG)A&.;Q _ZB6DATF:5%4+:^E_$]
M *9]YM\P_$2TIG_/_M;N"=#['K _-:'6I.W,%TR7V8C.WB0)3$C709D4MN[U
MTWYLG..FFT&8DJ?==;<3[Q6SI4"\65(M$T0PG4._*Z/4Q7M68O>,ZK<.R#>S
MTSD:XAH#7HV"Q)?H2ATTD=:-9H.64J [C&:@5[8+.P_6.6#ZNUJM?PCC]G"H
MYL[$K7J#AZ*5GYQL !KT7;WU+Q^$6HU+EG9(1RIIT\3F1F? +[W?[U?!VWKT
MPP)Q/#@+,ETY,;\:R3>2HT5^AA>8Y+-D.R@(/T[&DLQV!1=[O!JYO5.\T8SP
MB-W=$.M1LY*\!=P#>HKF]Y/@Y+X"_*OH)-S 5L?3/%XD]P:TX^%>DC*7-F=W
M*9Q_)-0LT&6FUS?Z#@F>]N;S&Q=<OP"D!F\="4@R5;@ZL>&F?O>7O'WRD7/1
M4)Z_A)HNK_(!YPN3/6[XGDP5Q/)9D2^L Q2CRG>1#-IL\0HV^^%%X(V]M"#1
M<Q?Q1%,/:W?%+GQ9C1/ $^@ SPYPHBS3E07? YYS02]I[P$M8,1$7L><[3T@
M5@:T\C4CNH-;]I)<^=9>,A>U=96J\B&RV3_,&LI;DX<I%#Z,=!V^!WA CXMO
MH!@RR?-#I0<=IL6-(=*-'$&K1L"E;O"V1I^R%KO.4#02AQ]TM0VZ.P%U0Q$2
M!P_A-_D><-G[ ,8V_?P./Y6XJA80?I7C ,L]-(4L[?8T#7D%7 ??4CE!3H<@
M-QN0,'L\Q>O.CH04T)]^ \(C9Q^B[@.L^QV)Y!I0 $_1D [\P< H_ZZA)9^#
MA<K9MHS_![=1. \*X."#_&LC07]6:1Z?"2V6>9\P_K!8@!\<6V#['X8;_;-.
M[2X\S\\& T-I?]_Q+;JL?5RLKP[W@#]W@Q/R9YW3[\2 ZO'V''G_THNL/RFM
M#Z;[?W;Y?W;Y_\ NF<?4R;5OGP1[;M<KA"><9]:[_R>6B70.-H*%,?\)H]3?
M_1FP&/Q/DA3_MT2EE#6C$LI.6GY3R)<(E9_ Z6=A&ZM=U-M7KEJDT1'7JUXF
M.!E^(Z=Z#T 1?IGMYE]/ ^X#"+H] #A<K2E-YIQ8$N,$VLOE:ZQ)SU>&PH$9
MRC8 TA>. /R -2B>.D)+AD<-[#$<:6T%\X]I1DO?C9X'B6A9_'R5$(XO+GE6
MFGC^^Y7T6AK>@AE.[1%^J%/?K"$9"'?BSN1]N<K=#\[%I,3PQA)$R8?+6KDG
M)5Y:ZD2%*+\7H5,5M*.PS ]L]=?*(\M/9--7E*ABM6)G'ULS&AYEQH)R*#M_
MY/"X\B?8F,PED10UO[%"J8(.QDH\?T(X37D+]V0LA^MUW31*QU?]Q@6E6/28
M+;\*@(Y["<$O]\\+J@1%I<:;" MVYSJG"3B695[5=(M^H\#LH(S LA/DT#7-
MWXE[MZPS/V_1(NW(SCD52BW'!'G%F(Q=*H65+Z7\0UOW)DVCYZTT<1])499W
M?[_=,\$NY3_X><!O0Y0;/KCY+^1S%]AOIA*!]ZY"NS#"@>H%UW?&,9=S$K?8
MU6Z''-/?)M:RPQ6U!$5%(P8MW[CP7WM17D]-)16+Y-/IU?.29@AZI59G"E,^
M_D*\7:WS*K)E6O]%0_(/W58%)!Z! Z?JTX12SKK@C4?KB(#'4PM*/6Q71$"K
M,Q1JM98*/X6RNHIZ6;@<"?CMM2^;61?>T^W>ZZ4X[B#8DFGE]D#MCUR)/7Y@
MISZ2ZT-STKJ>_R_JVD#+=2 -10.%$_(I*/^VJ-N4'-/-:\CJC>X5W+ES6VE$
M3[S.QLH"-+E=]-'-"PS-96S;U^O@.T.2'#\I*<"2^['<)&S;C+VDU^^SNG=#
MGS=RW1Y<:NANG3_ST]V<(NKY"!_;$:9ZKGOC][\ 0R\703'&G&F+8=!=70,R
M-\) FA-.QMPC-9/;3R"8ZYGCH,Y>8*2!F^*[-1]9KY@!25U1W>^KOR"5)JK]
MXNBE\1!R\V^5-3P-H02+V3;8XZV[NJD >0 1JO<3AQ$=Z< J!3&''_A;A#7+
MAA,ES#=4W[#SK,>:A>I:"6>OU$862R75S#T?EFZM*U6NR74[H_)@_V0SS@)^
MM=>/<=0,5F91397 :0DT NXO0=?GO9(Z:+Z;\\[.ST&N^ $KD.OS:D)3?+*A
M_F"ZDO;_LC_XG\*(UBU$%=*^1%(WH8?)PBT<@-@0!&%MS\C32XKII"H=)W5N
MG:J$"-=$LVEZG!Z"W#[P KWO'B8-4P$+"W5#?>R:,RM3B<[,.=,GR?Q=\B>:
MX=D+\6H&\/$.OTY=UEJ-B.J<O.N/"S8V7BH@)6@'5\_T&!"]B7V)')XI;>-C
MS1J8JK"H!F1 HJ85<!*OFKI+)1Z$+P73Y;H;B.$/F34TQ>'<^;?%,CE5YBEZ
MHB%&GH0IZ4G;&51U1AL_:?C^,/V5#QVDBZZ$1O,E]K!Y:;= JYK$JB%D44%?
M48ZP-UKECF%N -^YH:51[I\XZ>='$.+4_WBX5K2\U)6G+N<NY)'_LM'R-2]Y
MS-:U<:>LL<HQ-:R8.P+=-??9YQ?23X9IG<NV<QC#>_(5R4JR2=D$P9K;MT:Y
M9IHUOE/7VDO:2_I?=>8]NG[V;Y^ OMO< S Y[Q0M9?9>+>"5A?Z(D;X[#7\*
M>FDOUCY'[N.YNN_N/6Q]DR"(M@@*,-LZLBQA,CK9_B"(;7C&%>)\3*E=-F7L
M[RYM2ZJ(S\8>T8;M<0^0.HO7G-<:TT]9$U(^#L+C4>E%.B0JJGXVK^_V?=:;
M4\07F\"=Q.+JHGY;>H?=K/*8K;>$H2H9&!D=]CTSF/'-/[P8+ "?_S NQR"&
M@U'9^U/94[* H?D\K";'F#IE@Y&K*0N;Q,% &!^T^G;D'K##D0=9482$F?0P
MV7^LZ-RGLF(OR:. RIOW5@VCF]A[&$Q5)7#.:+:C4T?Q8CD5?29WNP=4+:>8
MF^B^/:9&UMIG[1([?G-S2G#>D#B,K'DY\R(+Y Y(G!S703,<,RGEF/;06QM\
M1&]=,M^Q1K=@5:8Q6\(=[7/;(]5:@AA6#^AT4XW+G-4:FHN)2'WSGK$Z_)/D
M&8J;\@TW ?\<H]^(@%&Q!)*B8LIBQ?SN+24+LQV!B*_MD">:T-GR4T2>]C%>
MI*ZL8V9U$(85\^I70H(5U*H(MQ.T;='<$?4C5I:5LLK$HRT1TI<9SG9\*#)E
MK343!P;-E3^DK=F/P(!0:'=3J<*Q6K" ]*JGL7QE607Q,QS1@,\TC- F?ML(
MLZ.4->EA; 3P9X%))%MS@N7&*0JOXF+]OLI!2E-[3[Z"=FK>FODO4& #*& ]
M'-?4%562\J6S+VHJ%F06_T<JW;%J<Y&9Z6JC+/\!GT,W 8_,?*[!! LO,$S*
M#YW<3WE:=7Q>Q9+9:HVG-]50I'$+??^A.:WJ=<=JM\R-$C#-/JO$D>HF1?XK
M75T@__&MGGM>M4/L=>(#VIAI*(_J'M05Y)68-@?^EEOL7=P=WJ&_X??\:5B7
MV33&^MJE4JN\=>J,GTS0(01L4V2G-1BC_"4RG \2P"54<(QS GJQHSF49H3;
M!P'%4&')*40(@Q2FXBHB-%*#Q&SX](*;P);K6K)HG:I."G<-!+$$U50';8:^
MDMM'D5=JDGFZ^_8N 8JUS>-C9-S,K5_J,*-92UR1/Y*)\<,*Z3*S_V>).7\E
M_X./+7%6WP.N7ENV1#XXJGC#B^WS?SDL_ZOX_:^B;"N'L1K*GNVC7H2G;P.6
MMUWRIOI?*+@+R&<YBAI;S/%:0-DS<]O>9BTV*[!\):28;#Q?G_[<H0AMDB7Q
M9)^&8@'U%CR^JR,!P$#QIB_KC/A0+IZA( [ CX&YY(G!D9,3UEG!XJ_5 P8V
MW Y)1VBI\9TL%+0Q6@F;!''U-??L6+RNV^KNU(D;<V_EX259#%T7I^:4I"@.
M_N^NSNY,.%1V>8RH=(_/#Q(AWM5%@4GF(5^%/7D\6J=:C*J3/H>;[P$)U<G,
M?R96)S_F'S9#JK[':#."R#-N8:+)\77#+//N"M&5. Y/C2T+6^_<L$@]M'Y8
MF.^^&BS<FTKT8'H<AU.LGSK+.^A6?5&2*-8\]'UEEU)65 ZT2_<9D[D-E4D^
MV=]@X=79KO920CI"[F.3GY)?5S1G384WBUB"B<"PC ]TJBJUH^/RZ]Z6'O&N
M[6+S+UVMI0\"!?J1+?"?D(1/?,3/LF1_"OT>)-3K3-Q#*%YVOMSG)LY-PUHL
M6YCUWN;%@%5Y%S\_>T\ZC5)XJSC-6G5E 3.H',^,?_6F*L2<35#<W0O?NEN7
M?AQ7W!K;A#TI?CM^06\9;W:[+QG^%  ,,-!U6J3'52TN_47@"$%GT9U?^QI3
MMCYX^M;:1OX>\-U31(_=XTU9U#U@324I_8II+6I-=.==E5<QXRXF6+E\S%)V
M*,,9OXHR;(R;W1.MX )OZ);E1S7SJ#;S<!<42WCC8]PE!02/[8$V0U])FA_;
MMX_W59A:'0IN^T%O'1+1K[L8YQ-(B(]B*GFF.DS1V.F0GS,J&D[7T7@CO2X8
M,ZL;JR<L<=;&7$J8-UZKA?DQ8N>7J"(7J\*4[+ 76AFAG];AZ3.+_LB/JTC;
MZTE$R>>DHUJA -AGRJ?R;1OD8@+R3V/S\K3,KHV&TIR2TNM"L\(1@CUUI3&.
M=\3KPM,L9XT1'KU $PM#NW-,1"CQ=3!CO>%*2L?(-,JQ<8<DS)01-L?"RA1]
M601M)51"E.KEFO >_W!=':@%?U<0PX.2GB_[M;Q[*;-$TO+CR@[GPJ+'>W'\
M>$_P=%]W4H^LBRE"*JKS((KRJ:J2;[;#VY8X!&2=J$DK@U&BS8Q[A;K?H>^@
M8^:!GXP+:N.[EQJS1DZ-BN&1K?YW&!^-9YU>:K?L(_9R'.T.R@/9V: LB>N&
MG6K0WO1<J7'&]&BM<<1NG).,WRA;JP=.P9,_R-J[W@-B;3FP2U&O<'46;9!8
MH&/>'V[MD/B2M4:36YK(&;K,X D#=7+64.Z(TD5J8(F8]10P!(N3EKR"[LZ,
MP8-)SC H=**YD.CZ15*US>M(24TA@J3^X\?2<V)?0+&0'.-FR>QZJ':%];5%
MUBEOD5]5Q.CN R)S3OS;9%@)%:9.P%-)P:*MY2 A-B'Z8Y3PV>$+RPQZP,$V
M(NWX\.")\SV 4,#R+L7$0S"O7VQA/RE."5G"<0M21>IIPONQ.4AT[P&-T &Z
MS#0\.<X"/ E=L'YA^I<HMQ?@5,=6S%LF#]FUP&^CL>55;\W]'HSJ",$!49CO
MZC] 1H :\TH:UL^5W^BBUOR9"WTW\W$"1KTWK2)CI3J(8,XK2R57Y(T-B"'A
MT[N%B[*)&#KS1N[9&+S*,A4RR3_*YY[?N(BHHR4CFPGJ]Y-^A=0L<N8T-V*W
M%Y6W#=KW-T97R28W$E@[2C=VSXR]Q";!]='!"LN&A7[0$.;!>J"-7]Q4K0,X
M[P'<HJYT_1GMJ O72/P)-1G*_FIZBG\FMT[;DEH<7BKCF$YN;J]QC1S;AG^5
M.(OYT=E726LM.[N?R,)9\J5CW?U0M/-8VM-Q<]=.LD+:Z36T7^ EV(M_ZAX0
MPBDM^'9HN-.+_(2">XCHRO*D-R^#O"7^C*L ^D@V1U?@<UN[<A]#1F>R&W83
M]E@=&;H$<=,]H,DU3E;R>3"!G?WPU8;RCVI^>B$Z+0%;6'B<O?U[>1W[*OK?
MH5_2^NM_/T>4-]$;4^=LQ=F,2K+&?T$SU07L@ 4%S>MKQ@Z9.6\[\,S\-MM#
M/]<WJ]))6,?&S!SX(WC57>*Z-%L*/-[$@D%UM?&//FR7"'HK(*9%UU.<F"E%
M8N?FCO5;(E!PWESY;D>]&P\]U=5Q1M721@\!FWP5C?G"^[;A=X JL2J,>7 3
M;@Y3I%WXN&T#.-/G3X-Q=HX:KUX&LE27.V;M64V_^7R* ]ZLV7CT_#HRN#E_
M1BC)N6RC>R'+#7I<2!P07%7Z E$HK87)L/#!*:0@\Z8S58*L;EA.\\C:,G/2
MX> -FEM T#T@AD!6(VJTQQ%/2=ADPR39X(\7\.-%P\FDU(8$Q0\LH."/E!:4
M'M,ET@GF%OJ])8I(PYLGDXD=K[%/K1ZQ9"$!)O X_W,R2H5CJFDQ2IT/&WVH
ME%841O5" 9$Z8?B?+(NPMD/3 EJHD&U-HT-Q.0*E]-$WLIL#8[=MWORAZRV\
M@XYY[7-IMS1+Q)-.71<Z0FU:0\XG0,-P--M8_(51Y;V^[[-=NTC@U(,K$2"2
MU(*8C]UQ0F1_1ZACKZ%&,%)^@ON7NZ^3R.I>2I6-KOF0?F+:[*OOI20BQ:K>
M=5"\"&5QE2W]YF&4:](0Y\\TZ+=K7QE_E U)I@<Z6Q?TK$8/ZDYXX!;+K@@^
M'9II:RB)81AXE;;Y^?DZ*+)4(C.M.D+[M$@."U%XT^,&#CR/J1#SH0I;]6F=
M9.E&35NC*K]68G; )G+14YE4$O9OW^I&VK,+=L:S1>_QKQ_O,([1Y1P2::\(
M@%=_OX(2F>I2C695-]3Y3A^<@AD/%+VLDW9/T_I+15<;[P$(#37-C5W"F:]E
M!!L!V\Z_(J&?,)TX%88." 4:QCN$..#(N'P7=ZGP]FW9>N>3DMPX\^YB-CNA
MU)[$V@*7I]<@3!=[J3*7+4NA UG^2DNTY')@F!L7WEUQ+7IR.&QU_V8X\)J\
M%J?;HG@UDIH:WA:QHN]\TU[-^1LA\8#B)UJKGK1>?"(\<'_7N@RZ<YO+S.FK
M-M!^B)41+^@RO?]WA>2?&S3H*N\!$?U>H&M,_)UQQ*O"F;'I!WQF5'/]P% S
MB'<8T_[ED*';-:!+UEZ%K\9GE9G\^"!W<K-S^M7=)I1"GWQQF&@WN#G7Y9D+
MR\%^;"K%Y)%AC:]:?75]DINV 19HD6)E.S5&;0WJ7UW4+/WA&!1P^'WQ(I+^
M:^TP2P(:5#>^IUD:.Z1)>DUB:_P>L/I\@G/?E9F6$'<QI<Z:N:;PT=.#FM$'
MJDC&NG9W46U(C4Q9N>FS.#S<B-J"@)Y%O8V=(;$60!D&NN>55&]WD3#J!:@*
M,4H3)/S6,?#O,[H*S8Y0<^*WM+*=7\I%R.7HF*9A<MY@?NJ7=OV9-.CK,#?#
MSLV.G?^VJ5(8/KF#* ?Z/6?-,KD\,3.0')I@R 'I^!W3> N"=1$!0FDPL723
M:XSKEAI]W 4M,3J56D6T)0]R5V#\>984(L&RP,5>J]63W5T'+";.X^8QQ/.(
MH\W"@5=@'5Y,)KZL!7?NL@1W1ICP-'0G%&HQ&1\PMDC$6ZZ4WJ*=",T4S\OB
MJNEA>8@<BY?J7]OO31T95$7<[GF3:XW7[@L3RQX72APP.;IZT$+( _B9[)9?
M/WTU+)\%9",-/4Y670Y&TG2M-CO]DJH=^SJ1TUI%2)"[].G+YTX&E/" UT,0
M5%TCS.E@ 4EXEC3\>]QWJUGCV4J%?91 H17[6UI*--ITH>J%11=S^6I$ZTI?
M1E6J)?^GL;DEK?+7,SF&,>+K,\FEV\+$M?> 5RP'ZV-,;^&'G4BJ"0,.,B8I
MPEZ%Y#@[7E)2V[GL<2%JC86=AL6E' .A-/=,U(MY&OV#EB0M[[:'^% /"5PB
M:(0$JI)36@+E)ZMRJV\$!_@<0BN[12Q>5?F"*4,ON-P[&K[&F&8B_$]ZVAHF
M3 4DHK3,%'E2W)J.4#22B,AO1YY>?O<P+]@O]ZQ5@*_O)BK-)>5;RX[UYHCS
MZ@,>? S.%;Q,:$20I4E.V"1$=/I-;T[<"#/T<'ESG7>8#-)>/XR.,%:.[M3,
MR0W(VT\$^[-477UV]]3&[QQX1O)4LHUW.SKT5(.8]?M*V2BH0D!T!82GNT?7
MY:PI<P\P^F%,$47*@ 2<#0+<]$*$'LP-<^J1"I!,4XA%C@_7<)_84\:^D6?A
M7W\_O&)Z3=C)&";:58,DF:RB=RB:/4!. A.$UGH:UDW.K.QO:2H=0=A+M-W0
M9SISI@\>;Z1A.O9A_ E3I 'UBYQF5]V6JN$08NXR5@<@+L*IVQPF)YL0&?68
M:9 $:\5.^#T03BE,7',/P+4@E\.3M3>![S8\]J5MQ+$Z7:9V*ERQCPS/RR]L
M<.[<S\K?M35/):X?LZC^BF[H,![$@QN6,0%0HX">#NIK>0A.;")>"8675;D-
MSM\U2&2O)LJN'%I<SJ7;+Q6X.(N.;3>,IC?!"8-Q%7S50RNU!RFJ@_S95Q.N
M4%]W"^:CEDTA::2-UHK"T,7AAUN5U%'/65/1T#>Q#?SJ5L[6QRJ%4"5HX$XP
M!E_\\X3X1^^W> NC\@*;\(]Y.ITOEHA;)@^YO$L?UW2\T7; @'S[DKP]5X/$
M,KG.#5J%:<ZK542-;9Z;9L_L>[=E&]JE[D?8N*]Y"Q+\+Y#-%YHY?37E3DK^
MUC$08CTLC2ONKYL!PZP/(^A4Z>@[S1=*$'3P[LC<4&<B"_[;WYKK$8J6M%UO
M2_%3/"_:1SX\1DZVK2\%/&F2^$TT.=9NH<L+&$ *\HZ[3!!KJ1RHJNR#IGL<
MN\PVTY'=@*<DUZ#&8M,T^Z*VT%6./67Y4>=&XJR.Z&:WB0"&F*E*S%)78^_*
M"V$%%6![FBD\!]ER^1Q#7J*\,Q0T5;Z'M@727*Z&JP4ZFHLXDC6(H&/V3V-7
M4DZ3F><$B!\_35E5=T!/P^K*UW+=+"'FCZ$>K4Q)7REZ)((VY[LS$CTE.=>3
M[,*Z1I"QBC[AZTI5/SJS)FUG9PA<DCF[=N B[&3%*(DNH*G._:J#K7P/D*B-
M ?=_KZ=/7<J:WU4R;\5RE.61:YVD1C<W0+D;6Y(HX/1.]5&.3.M)G1R_)6VM
MFN8,4_IY7?5AZPG0)/C]>Y+G*-Y';%URP*7TW;S7LNX,:92A\"?GH\?X+5$A
M9%VIF6LD2:;SKQJN;]CVGFV5>LBWUDPTN;I,?=?D53%@:G[]PV.Y@!(.^XWC
M@3]A\95'EZ2>\)U5KZ_J[%M/DHP[3-LQ%YXNI[%7/ &.-!8GAMZ]SZ]+3'$9
M5"BQI(ET-00+GW=W'4FNH$PD'C)Y 5T:%6PB3:+F_>X!S"R]H=AMI]=J!2ZL
MJ[+0 "O*B>KW:O(3TS_X;?%H[R(7;M)ZE<B8.),FMCW>X4%>-.%-7W\S.#_4
M]@^?@,MC-V![8&S<)*OQZ?[6;;8$J]:9;EN)6#?XC8(-5#Q,2X6:UT-F$Z"1
M%EM+3P1C/CV__22WKB#J62V,%HSQCDL[[>TL<66759!W9M&N%\$]X%NPUAAM
M^-32V--$C0T@ ]P&>QH8P965XV*O>8Q'8TYBO6!,[A!6+7DA> ]XL7LFB-XE
M1#3N2)0Q!F.=.V 98\'+[[9[+;'Q4F)?A).N7_8]K6%?%2ON7LO+">1XKK;7
M;^??^H;QF^3KU^>EZ19<24!2%UE',M#OTJ7 NYULU!^@[53&_FIK?[>8\[-I
M556P5,5):$78!V7EH/*HPOY/:B,1[Y8*/<BG-T=O+>^B?C=,*RB]EK=[7!15
M#,* >D"EL!8X\SYI1\^FUN<,?/G6+4<_OJOYMF()5+8_]I%7W.H!+&KZ^HV2
MTW<^52Q&>:SOMY1(W^XMY(7P616'3]5\\8&,L 2Y2 !M+N4ZKM0H]3XA C[4
M').'<*?8M]G^B'[]KFRGO<5ZLJH11JB4)M<D&]T^(_3-B7(FW)2<FR6@,F9J
M($<327*,N>W/5>?(R!$K&D1)^^CC46X%7?JF;)Z#IV7&OI/NF[$W$\54RQA9
MD8LD#6D?&,5;C.# ,"N!-T56EF.FXQ$L;X#7.#?0J9:H\I::B6*#YLJ$K[4)
MSI2E'QX<G[RA",C>A:<@,O+G'$?;):X'_I_$>JEU%;P=U:!'7,HMAX0C509R
M;%41L\FU-/EI.9)SF5XQ\6&09Z3FQ1Q3!,#\DI,ZUF<8^SUS!*#\DHM&NC\1
M5S;>4;4E(V &['K[UO >0*%\D0")S"^ EPN&LPC%\.ZJK.\J^779)(2Z:6$Y
MFLM AK\@/T<.2F>S)I3,LMYQ*UV1CH>O@W,5Q/!WB/^2L]JU\!^'DK\<E<FR
MB#OUK1F)GK@T/ "UJ1X5><U]C;-UB:U<%)#0,/!!YT]M0]%C1D!U6X_)JP61
MF3V#AM6&.Y0*H\(7Z9M=:A<*%8L)E\Y*RSJ_'.T9I06*=1;#)6DR,H/!H?@[
M#_A(-7S_QLUDXNHCK,RQ=W&D=77$_8XQ!C[DP]):6(QJ-]]S*DM!AI8W,5TM
M@N$T GY,A\,[P9"_ RAF5-X<M7)<-3D5<AXIYSQ9$+KZ8FRM:,9'5\*_<.8;
M:>@>$K@B$OL9D ,#8<Z[UOY^#V22[IFX!T1KK:Z[ZI4K:*8(5CVWM":E8\M_
MIS@JYO2?U-UU*<UP9>HX93+_E(4EV_C1^Q]$HH[Z@G*ZU3LQ&T7P>X!26E<T
MTTUFN:E.5S];'QJ588OINPRO-SM\0A%,K96''D%'.K5/[-10R:"?)'9WE1".
M!VL*^)V'C[ZWEVF'WDQ9APDPI))*D\27;-=)DA:]ABY2/C;<']Y4?E//_Q13
MFMG"#9KV.)::(D) \5-$5F:J2]]UXG9U,\BR:9K F=&>E/8R'8/=_0;J!DM?
MUEA4%TIQ9@L72QK^5GF@QML]MEBIUM90(ZMT(_X8IR^O?SY6N+^@35F>#R-M
M+#X<9_42584S!%*]?W&A9Q*UR)+\\??K[<=GM\=:UWG^)4Q5.1,X1W,NP4SA
MA0@CS)&5\]=K]6$,2\RB.K4UJ;:/V27R3V)13:X31071-1"6.9JF]P SJ&+L
M$B]>U6^&WPN"WMV8CBV$4V>+AC+*XXDZL87E^#$V':A^B+6Z.[W5HQ0C_8&&
M<:JC=X\6^@LK>(RVIZJ%R!#V\J-OFI/D0_I<^PN[)6C14UVN)QVI#_2.J=-B
M[.(DV"ILEG]C(VM/BKWM.'1B2ZTO4MB_=&N(GU\'KZT+&(Z5=8H?;W$DCGCB
M*6A__>/=\E.] ,?L8RP_\\)LYA<+CSY:S#+Z@O7:*PF[8Y?AH3W%7-F-N?7F
MZLR1/J946/T  2RGZ /&5#AYRMKK)OS</N-244NKWOFWYB\WO9R0S L32,(1
M@V.TCD +JUR'2):M6/[ %M5PL1CX^OGMOAI1[AWXBR.?4$'!LBR39FP 2W)_
M8TSH/@/O66\W=@TC$Z+]Y$2#1!1^-Y1CC/O#/8.ALT3DY\G/&\3Y6GY)5NF<
MMA["7#&*\5<0YZQQ1?-W[JIX$IO]V0JWX$F$%QSD?>:'0O*11(LL'K?Q?) F
M2@W5;6C_,%9!._ZKWX#.DO)^]?A,>'=>";B;3^=P\RC)%=][DLFR]BZS8W!&
MC\*@YRME*C;,PL5L_U/CB.7FV%H4HTB]*CU' SN1OU*4C<@P/K.I+?%L9AW,
MUB%%NI.0V^]C_11K>I# )JY%^!.!4"M]5-)MGS2W-O;%A5OJ\<DCXW#KP\?>
MTJTLWMKXI)<4*%=*\G4';CFO2U"[-#UTB>"3S;%A&$5W61#,YH[GO:XH:*#W
M @3SOIZ#DCFFQ+"T8"86BZI7V3.'+K^5=8M#& ZO/HUXP2WLIQ/?XY?:E"^.
M1NYKIW62!!F,'+X-RW[KOO,YBDCRE/:#Y!=M9]Z+%>)A^%:0]3W@>>AU3FRD
MHV%>CUD1CG:6N$QG2I=\ZM-Q*(P:Z+1JB77*J19IZI28%B0@R)UUYWW)%[;>
M>[R'*O]LI&:]ZFUT#+KWNT.M6F+'H:*UYD>_U&-5(G:QIB,[:$89_64*&.<%
MCG>5=V>/" 0?A4XG@3E;2..Z+Q+-^;1FYZDN1@F8WG[]\&GA;#NMO4C3)+%R
MQE1-\ZL_7+>HBV./5D'5=&*EY3@MGHTV?,(=Q%:^$[%W$;W/PZ?(X5FXQ!4E
MK.9-DL>YSYA4O]6HE<1:F:UD\?VV;<G.\+=A[5A=(QFZ3-Q:;.66IJ_B,RO<
M;2O2*&G'\\+:Q+#) /];<\&F0=(LM9-88<ADD:N4Q%D;3?C',UT1P[%*<3'[
M"R^B48<W%_,.44^#GVH8X;Y;JMNH%4CE2%SEHJD*[I"=/),EN!@#U7PPG,A)
MVTK0*'-^U!5H<9F=GOK3L!FYF(3$V1\$]LLQH#]IP!Y:ZPKL&0^.:V_H;+CT
M/SA_ORZQD?R.+N4I$717O?54J5KN!I46Z3\Y9+JE UJ]!WR_%7D..F9.:8)C
MJW^Q*[UCJ%?2LU$_-V.,'KG<6^*<<O3=F)O[/@[K=J'V,L7>$KZ]HQ>B>AC&
M;R+?[ 0LK-)11E:@2ZQOL^*6)%3Y%D9UG8M<=+N'N\C)JRH3CQ:Y4 74BN.P
M&U85>&X[4[/#)7H>3X:Q<\$O0[ENR-YK,(U_DJZJ7=!0_01^O9OH$3SW;N8W
M.UTIU_@9"1EX=77:*C=65E7+N(%GR1XMK%OBYS# D.BB@"+A5J7$Q:E##6-J
M,(OY-L*?H5)JYC6O@$^HSV\P;;SZ[L.%1L?DE3DY%1),EEFQ3-S$XOI>BFY8
MOAE3'J*0W)T&BR(#8C/GTRZKFI.^'V'+DP'R@D6)Y>,98P*BZ_Q::G%]LGSL
M/AM,\OCV5;A#:&9%^;NQSBTD<+Q+MJNH7\S)6%WA&B\VPEO./<I;SV>8G.<\
MIRJL":85RKSI MP7M0:D"!>$Y;-1Q]&X8(FK(Y@\:V03W(6JC)[/B-;[* R&
M^*8Y\DP;:BI7U4MA51I&DU9H:>2PN\R,CJ/A3_U\E@4;<O+E^Y/0[+V3/>*6
MRJ_'F3G?=G'8S_5[2=*&ZGLJY5XB+BQ!&HM4!)H.BLPU)R][>[:\L'EW505>
M?4ETJEQSE\B)55]K"E/)\1R$,NGC+I.!7F@7T!#P\]%EIHO\=X_G42W^^:Z-
M '+R6J[G'B"2V4P,><2E1:QY#[@-K5F6N ><4>H\L;_^ET/U]N"B?#,G8MF"
M^@EKRX,5-'*CS@Q"H03!/4P>O='J (>Q<W/T:9'ZJ;E-*@9!"45;86*NX9TE
M['$'68C*U(I[D+4C]R+'P*IOZ+;9"@;V<'K1%/+-J%4U[;CEN?OKTHB(J=$%
M2HEWTYMH LX%+%PPAC&MP!)'?MXO-:'2?))\!4'8XOIR@.M$0+/RN24[IK%$
MX[B5="!+IDDVG4W;*S^_?47UY=D]IR!G T?,R<:[68,(OK1.%74!T<Q%,[G<
M^;T+]N4W;V!1J\3"8+T?I,=+WH0?1F%-@AESIMR6E%ISN;T#V024[S>\!3T9
MQ>OV[P%!?%@IZ\KPQ<&!5^7?^JCG%\3+/RX@#X,$>,BP\XMLS/F*TUY:<49=
M:XR-#<AD6*$T+$ALY-H11@^]&T\$[.87S]Z*9,Z;F>8.%ZEW>6P\J7'_AD-Z
M=F6?:MH #7)@?KNJ/U&=A/X^_@O8UB:PTVTE]0=*@9A-Z\M;C7P7-U;LOASI
MY])W'WBIOLJO9EG+'6>""):Q0Z:7R%/5*<<LSUJKC7X\@L7T,>_ZFJ V9!9T
M%9F.F^8IALA71[71&SI$TP>B3!P-L0E5"U8/$,:.+LP-D\*E&K-B:3%*!$5(
M7PGCC/[7'55_(V]6)2_2,61Y[A@[H93V9>7 @$>5+6S\I1V-S?4_$REFSA88
MU3H8&RZV1"=80!SW@*F")L<LH=:59B6YP*]? SQ$!74^K8!(#8_3@X/J.*'Q
M^DEFX>8P^&."Z[PPSAOS9AC6VJ96%OYCGZNU<@%J]_29/7:Y-9+71VOA[)^_
M8Z%$.& (@H8PW;CCBDV7*"IPYUQP)>L#AM7)B7+1F<3"\6K[VFCK[NC)N1@D
M^[B1HES-5IZ?+WC/Y5C:(>\VQJS2D((;*I\%ZE'6:SCF6Y]F'>-=.+5BPLY#
M&-7&JM'GAQXK1H[S!^O?==12[O>8Q=X#NG1?CGRN&SGR>&-7(4H7":-.%C"G
M87]&'8Z"5K;5]'#>BZ'I6.76?IA8Q/J1J]/%J&=OW/SR+7W2)S/ZQ<5*XDOY
MII8W)4?;=909L1]F;O=+$6P'0M0?";,TI4AV?R+UU3!N7YSK><^1R!69N=WZ
M?+,19S98]__*'X\$L-Z=2ZBKURIP+.YD!AN7X(5=DNQ*BP$\W*)Y4BB%1 FI
M*_<31\NLJ_6TM CGJ&,,%W>CGII9NLN$"!\O;OKG8+2/\6=V&5)P?.BA*!#P
M'-=!)I4B(/+N(:S8+CR?ZL-G>:C46)&1-FB*Z05]%T.FY,#RIKGH\J(UF)C7
MN&>ZM-DQPEE.@M(\R4IW,86',4+HQ-Y7L-DL[;M0!W--A2,=Q8^=B] L^2I]
MRH1G"]DQR'?AS[:CL#DKS9>(X3D+2GOD&*GM6T?+;YA+4'NH+"?8CUZ R_%[
M7*)[;/>(P1<TWW/!V;O4M1*!=B?W@"9/$ C&D:D8:C2PU-Q*&=,X>4XR<]M8
M=%,P?E,A-0!Z:V;]K+$T_%9('F=YC@U+$-T;(C.E]6+/B\"4?>\>\*KJ)%"3
M\:U5CE4_X=$]8+U3\5U'[A[ETNVG5)W%IOT._&ZO@'M J:K\D7!'W2 YO;#%
MBM>:C-<#]8(IS)'.=4)F\(9-RNC;_V"KY(SA"+^5KF/N1!9+94RI6;FX>X L
MX4W M=IG^C5?VB>\)[U7[!)+KW7I%:(^4FNHZ_OR^<F6FB!B5G#SB_;=9"@/
MI3AL7V 9 9> AQ!0J1YAMDM,@=2/XO9FDE6Y("X82!4Y6%U9USJ^J6\4SD7;
M>P^P(/=;(&_5[($#?8X$# JX3T9V1X#+ WPW##=I8\V)EEI2\)3,74VR9.%N
MMID=[!MP$7'01"C^QB"\R@ABZDY9F=F4N]W)!QN/C;I02%L5K<+NSPQ1G\C0
M[_/DI;RK,(_;A[?TY!TJ[#NH868CYE0<0Y3D=UQ.(_2A^;\1:I9XY8,XOW #
MPKI5?%:"=W,T\?'7-*/<L3.#&17^2*P@'0[#Y?.L2EN, \:#5K6#B8\\U @3
MTOL7UXULK]:OIY_YUS.RN@19R<UEV'>!!)05R1EQ/H7\5+!J:4BZ*?]^.WP/
MT&S4W/8@L]XTQ7X'Y!S[;ZR]=5 <;;0^. DD$SP0(#@DD$""?;A;"!X8W 8)
M@6"#Z^ A!+<  8*[,X,/-KB[,S"XR^ >=//M_=V]M[9J?WNK=KOJK:[^HZNZ
MW]/O.>=Y^SS/>9%ATGI?,Z9CRV>9(U/^%\-FME=Z*P$S,N?]IP".5W1_+5LC
MY_@\':T+DOO0\COOC>MG401/UR<BLL??([2"<%.)U0.Z//9ZY?BR5G[?CA"#
MT[.P!.Z%_;JK#([!Z031;F5_O8X3XW6,CK)7+\2Y_N^+U(W^=T[ >^J4W[;L
M:*]0<L&?3H/6UJ?&9!#VPET";!7?@4?H3!?S PC5>3S+4A%WXGM>/GJ:3\-]
M!1\*T[!C\2LN>Z1T8:O*)BF.+8GB,U@G73KCI:LMDZ:UR8[8'TG&Z5KQ41H6
M>5#M71,+_$.VK9R7C!(J4UO,^@CD])^9@<5$#?Z![N2T^L=K7_LMTCH@OE\*
MIF]Y_B9A(9Y>0W;D$YIJ&;PLA$0Y_I>)BY6WTCD$5'=?Y#A)P^OQ7*^I<DQ\
MQ-,\:(<:34;/]N0<K+-"BA2]JR83RQK%U-8;FN,\LG:==RZ/?L-?V?PC]FQ/
MKI"/+L/$L6A)QLHZ<./G,A%(W:=DSI?%DAB:TJ&=?)]![%6G6/1,R.7+4Z(Z
M>XS>/>E1I_Z3A#^/F_9RN)O%#V\8Y_Z@LM2S(^RB7O[PG4C,\OLP9GO&SL7.
ML-%\%DL'7ZPID"%KG;/;.R-1T/L7>7?7MU/MBO*1#_'E'C)F3(1MY-ZT1+IY
M<F./LW\[J+\=AM02-G7([QG_M8?3]S"SRAYL3C9X$=4[<S=!7*"ZLLG./<\8
MG]@GJXO$3Z<(MXUGVCU9F037K'''9>$<HCRTE7/ZI96@QJTX$1V*M:B"Y)(5
M(AIE.'77)/M:H&TV#^_QUF>U29HSL0< EN):Q9Q.@K=ZT 6M?O<?_'! M+5P
M[&-!IO,]^9X-PZB,M4@L=218GO-9_/ DR2O5GM$7X$2'T'VSB!Z:'T7H2@[-
M]%E2.SSI(9M; M=5@D>N2OOJJ^#9E:7'\KY:8O[,HO0VKG#R=\DX5)10LS>@
M%3!_\D@('^O4* >?4#8XJ1-4YQ0LV%-(UQ&V+6J\O/]2Z@CIW#D>7NW@/V Q
M;(IB1 #$Q-Z1.EDQV 4ASL #4)-)6[C9R?CN3'8S3Q"0\;0T9P5$ I:F&2A0
M9G)B<#WIOB<JW\R<V'.%Z7/;L)DE2=MRE+1*&/T*DBDQ'G)D'6!-B 6= "[(
M1J^(VA(:SO,6IC.'-K V>C::*234ER8R](VQH8ISQG7I6VI)(34_6><>?5_2
MF/$18S7N]*6/:UNIV7]Z#LLAQ$X8ZD]-#YCTHA_^73:ZX=I"L$N^^(;J35U=
MO9'XH'&6^E-0)F!+0O$"(Z_<E/J<Q]YR39,=XQ^!>G*TI3OMZK4O=0@W2Y]A
M$?(-6S^C2[6(SO.DY57"77X;W=N4_&K,P/\/RL] !=[(U_A- DFT^419!LIM
MU&7-DHU<8\@.8WD<%9D[9^GYB<HV_0%0U?I,>3^NC[EL30^V?"=P0\?.Q]08
M^BII,\RRX-UK$1(%;#\DE $E)2-N_I0C<B6%EGP3G)NPNWNB]0PEX$S)-(>R
M% .,B.+F."XKOU?J@[,?\.$1B]@G4XO$T3B]F(R9$Y^!QZZZ(! )J^H?'5^Y
M,5A\X[:F%;XGT%"I;:YA:A,&?N@  M$9O+5X51R8]H2X-@A!S69.05ZUK[Y/
MU'J^SEA5ZIWG=$)2OO[VM8LVOZ7ZL].("J98)P7F(J8X#<,!7G)G)?M'Z68?
M^I[;-HZ8I$\F. V)_>*>E[3==,$_)E\H7XM)/TNQ?11=")7M4)TR5CL]M+6(
M?PRZ  =0I,E)7MW6=8F),N?U9'7EONY'Q!C@_5"]#2)J*<OW4XSA"S7N?F'9
MK.ZA-I/7&R?!]:9_;:?+1L-.GN^]M>?7_(J" 5.OETG8 3&IS^48 F8"%JNJ
M1_"E\XW8^R;/P0C)CU:N+H8O1!T$1]:2Y[/C%TJ!K&LP88QZ>7D4*S.R)NSX
M34,0"7;>4]\5IL];HP&:+F+\FQ*DX/D=A'!^6EXN!T=.2VIY?/0";M[O"#KG
MGCR7YE=3W8$K-PN?>C9]TL7:>")[!+%.7^>.@[4@'URA^R3+M?WL>DENRZ[S
M0*&1'<W<2;G1_I0V;79WWFD4.BU,95/A<W4#5_>>9ZIIQ,V7FI>RU<KJ<ZK&
M/,,(!/_81A\U#C#U!-0O-"1,JS_N\V5+*?+W E@V5A[W",MELWA;O[.A]!KI
M]#&$S3YY"O<!\!RW@'EI,\\#3]WRC)5TL@9O->+$^EG%,-PI3_,SO@^!N3[T
M?7>W)3)26ANL^YO7S<_&_HV#TU/AM3F^\3&EI,!!\"&^WA+$87?5JQ%2K1IE
MNSGS1M6)K,<Q.5Y4I("]N<#NF-)D,L\*KB[]4PE * 9\G',L7L41F M;YV**
ML'L=#HF+$ ED/H<EN[MAI4]XTYOD#R 7K%]:,W+)T2[TQ3"J_R-)X[:6.B5_
M3[>]@RN)HHI(..JME,)._)B+S2\[=F6:>IR,8<E)-VS?&[[OJKY'IVC=;:'-
M:\E'3KT;'S$7E/%EN.=(Y5[1'2J4UR3L\B)B&+^E#6Y4]6Q:3VV6O:D-XQUZ
M]T6#=IY'?ACT7L..ZP'@H]WTTKKU"U1.5A@86.IR2=\L?_G);R?'::FH9T6'
MS^<U"EQ^0[OX & =5!"7;>LO-[D.:]%-N)Y$^7(@Q[,B"6KB*T5/: Y.:=**
MQ1#?K0QK'3@6K+11R0D9?AP/ .&NM*RVUC\HJY&RI\G)8KF>Z]=UBW86_I^]
M,Q(MA6BT"7/6I""NWNS[/T;!\FQC5:<@MYE.R#;0R0=2A#B]'WB)=O.X 29M
M;-D=7(U8V_)^VR+ZYN*S%\Y^HB=R"'E2;V*GXN1K_.EBF%5:YV@JJN+"PBT=
M[640PEP=-^ "_)YY[:7=15J?X5 ?8+)"P*H"V?P&:K@F)N@0S4OJD> 'B42M
M#7U:I)I8[%&H$K>/ST,Z@6]O-YZ^=(?9:+%K[_[%W+%>U"^\'' #OPDJSS*\
MB-L6NF79M/W6EH,F<#V/D$"GSX-I:@>JA'8PR7UTP(FUI"'819&5S8$AC/V@
M_X/"^O&DQ4S8CF9L9LQW.<;QA"CS[YMTL!4P@?X!=7?"P?0!TTGG11S%0MQ-
M[B69J>S1149F2D:Y[#:'H9'D,)@)WR+=R3/U_&UU'VYN+ "+*7E-+OSP8/9)
M8"IW2N/AVTY^N:3':X._'P"51-)G^?7)Y><BPJS44E,%DV\G89PD@@=[=LEO
M-8=QZ4SMNT"GL.2$4H;_6Q7K(\3_!>S_B[-L%"GA3_6_X?F46D1YZS6&$=%#
M=880M9/D+/DQ>QQYNMD.LH_8ECB@:V*MQ?K: :Y_<Y<@7V[4_G)53>,D%I)X
M5K'2)YWF) NUJP+\A+O=S "5 T\A3?,P_&BMA/H",+A:N<!@D/%1GY O5$SG
M9$?#6_B([R+8!VZ\J^V6P'^=3L9;R'3*&"KK'#>1>I%))#%V2U^Z^S<WV;A/
M @:=G2&2A>+4E!+UYL_>;]EQ*^RDYY"-SU_Y*1\S[^,4H:W+?;*G:=F93_1"
MY$PV"N=%_.M2/5<;=<4IH!PH=>4/M(\7.-0Z0]J6K,N%L#GVFWQ*W,2 G\*-
M$PV59 Q5++U#.01H*LUH3 7OB>=J -#T$(O16[%C]1YY3E)MYQB[L)[+SXE
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M!BSONXZ%R'70/1N]92:^'T$L.'60&'YRE__[V"9[_[#F9.YG26E,'7R!9CX
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M9/&&H"N'EB_7_U::8_];B,$-:KQ"V>>E[FC7/0#2O]2%BN^[4>&GFT<3%6^
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MX5$XY<HZ@@65G4R"*Y^W1;GJW2*2=-R>U^^D$O4W@ AW]-.B0P>/+8?RK)S
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M8Q-Z<H>9$CJEGUO$#;[/_)O#;IW#6<%*X0K\!A_'XGI[,6!M@2K#[7(CM@?
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M\3J:_XRNY?V]5HT,P%E;'&O4QM8U1<WN%(QYP8MR'+P)(''N^82? ?NZ_0#
M07+F[*H:OS8R%*NR0T0=+/?1 ._BU\Z'W'E5@6]6C8/%Z8^UBPCS?&@[=6+@
M'>S5W?PQ?@TSNR*>-Q/5A\%&=.,N=^;MW3@F-5._F(Y#!54? 3@+-%!\4V.2
M-+"MCH6_D:7=TR]HZ^7;]G:96!JEX/GZ;A6AF^XR#!WYA.N0L<+D(?:2Y?@&
M]]R>-WZJS\I2)JR!!>LGJIG&TO.BU%7]<IHJX%NE@:X!1;+4]H+4CO9<*YJF
M^84X=3J.'1L.VZ?QA#@/H86ZT\:W#8HL6($3S2108Z7&\L9 3KK=;M=DH8W4
M*MH65Q %6NPI:_:Q0%#U X#<LM)*__>O.9&2C'<7",UU9S"IZE..VA5; >.C
M <N7)9PSBMG1[$>MKYYXW#[YBLD@Y*7U)!!COOF*1#S'\_(*U^N7K_#_EGM"
MM&'H2OK(?R7CJ67ZB\KD.:4:QA&A=#VP=QS]1>AUNK".D.N1<=NEP*'+3\,Y
MIF!N,'B>-/0N9!=8_KH)-PRPZLH9F$XWF8_=5P0&_QY_Q\X.GWT5H_:A\.M6
M.=9W81WCKU]M"W3;OEK@=M@^?K86Z?D^"E"T_3\2EGQF]QF<8A'8$N+@0V!Q
MY;;7YOCF!](LMOZ<5@:BS5%E/=9;.[K.'=-(VT0 <.5K]_[L9ASL[N4\6($5
MK=S>L,^IJOQA5%XP!NIZQA>_UD1[?OC$.H&88P=-<LRR:^C[^;]QF3+_Y3+5
M7WV%$!:M/>OJ#V5$A![P"S#$=TMH9+37^^$:0'WGU&*-B>?F1[ =XVB>I]K_
M=-'>=KQ"%5A>>MKE/:F9CEE.T3-)&Q0I/?SD_&%FF&;%\:?@%G Z9FTLM_Y7
MRA]25V453-?8G%&UN$H15=(^[(WINK$DSO!\*I!"B'(SI539UN((3?_<2H J
M(</1PQTAF+QSE)/6GR/X'C>5QB+=,J/+Z.F$+0<O))I@5X5]BTE?F<4E3%+>
MM@SY$P<S2:/S8O60? %:?$ RF@>+K_1PFZZ@3^"Z%R7J3RK=H,@_=!M4EE9O
MFLPE,38<<5K^3&G&'IT/:;IZR933=5UJ392 =C27V <:^/&7\?L^XMM; IP%
M@<6,]6,(9Q=L5TWG.91,CQE/<D5?V^6-,"G\'F)L=N>)G3T? H/C6H? *)?"
M:DY:(RMT[&!"D8L>LM3NGXI>UG2>:I1KOG4S\20GTP2OQ#/]!0]+?1X/(3T[
M1Y2=U)_&Y1BID3W[MRD5HYC$L2L_9<31S9P2>?B%_#W*QS;MJ'=]WSDJY[V3
MR!0!4*'B 1 :.DFB2Z]<P1W>R!HL;V<JP:T4;Q+4GBY,<[8:>VATM!4,STK1
M/IHNL7JS@<!7<F&.THWRU=;V-F7.?\H:?4P490MWT1Y%BN1QQ.?USN7]J57@
MK!#/"-V93IH2^L"QOS^Z";^5@QE)CAKLHF+;.Y[0F3/<R4)>OS-BQ5B98O?&
M,3+0]C*27I!5+-O28.Y%QVW<7H::OQCR'WM^('0AB'6<ZSRFHB$WK16XJK1"
MUH!^]6=]HRFA!GZ04XGP6)=X'P4L.H,KSBL4&HO-ST?./@ >76F(56Y$T,E4
M?A<WWRB>R?UH85N<FR&EDU4N2@FFWPL#E(;IKD@QH^$RYCU)A&*!8/EQKA^J
M[R8!DY&,%%J/T_Z7*];4F.MP)0Z#)NB.:)DD)X11U=$,H;[SSJ96<RO99ZP
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MB;8VA??8GY:]I%&B4C&-WGTVY4/B:8&)*%6RFLVX+IHOV^ E^;-2UC<^8*[
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M/(7KEDSZFG3.7/<96;//9OWU2DE3:1#7LOT09ZLNUHEMJB1,XR>UW37HRB#
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MM"'7_*E8=JJEL7>;K\!7'8$*RWR-Q_<MTC)(63+M[:^N6$*.,GTMFLSZVU;
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M(J*3#2H9W^AO ]-WE*6TX9>7B:W.2LE%<9:BTF++;>Y01%SG7"08X:Q(%4*
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MC;W>_MY1C[/Z7B^]4G<T]D1_$!@_F3_3$F&_CL-MFX^-2^$PQQ3,-MK13BL
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M'B)=N8[E.M_AN+GU&_ WRQW.0JEC!5G\ ZD$8+PGK:7E:*6Q#EK)!66;@^C
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M>HIV"G30L7,'Q7\(:M@B(%A.[0 (3$F4 AW[JR"P).(?'DV9!UD/P1\<\P]
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M+<&^@G>6GXM]E^*1_\F9Y]-5^!/^7SBP'+_E_#=S0N:-.T]N9^"&/G.LSA/
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MH)$^3LR@CN;^U_$U^\OU:,9&_,PSU_%#.TAG_L<(6]Y*UB4AH3!X)BS>[F)
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MK%R*O*1]82>/2_C&7TY$XU_3!#=-@%N""T G,^3E:FP]+;R*(KSV<U58?*A
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M;& -V-W:O=]M[QJJ\M';:G1NJ5PS.<O1N'%W?WZ;GV*F5?1FHV&6W9?P_?<
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M8P:$9^IA>QG=3PG,<;W1)0:XG!ZVCD.D,SM:LV+4)*B!:GW.1ZXO N:-C?8
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MB2ZF+L-,)I0UL'M@\R "S($#;^R/$^GT RX& 6$)'"\3VF0HC<"L$J;LLA,
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M9*4%"",?^9[P!TE+.,-GMK+QD@P<DXUD;5\4?L0(IVQ!P?H>5[-=2021>]=
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M3\ 6!<8^%*:T5RDUQXK;P$7]GZEPDK)V&)BTOGH!?CN563O+-%7E,9$@%$.
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MUPR5CJXP@#@1QW8Y^<2%=PX88$=/V!+E^/- =(5D'CDW1(,0;=FL3?F.%&;
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M31"R@M%5U%TH </'?RE'0\I*F@CKIW)7V@)5'%47(/,2J2C!=/L.,$%+50W
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MAL =L2<,H 8LP,'0A,+(.-M%,B"+1TV'I6@[;U;;9ZWSBO*F2^]YGPUAZSS
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M5&&%88[%56Z*2V6%1#IA5//Y8G)GHEOR1V:'47.2_/H:E:*21C&+>X)*8S
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M,O+_1P$/+7,B-#7U),JB>7(X]E'T>!73OT!6.7(D$IRDG(<4[;P7S\^+0^U
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M8?8/>/83S8&J&++S/86L:#H-^A%M.56UAS,ZI7-O6,%I4X$<# 5W]'"M8\Z
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MF)<$ZN@ ?'U,V__HR9'0#3R*)AI_Z.C)XX>[C"0[W;Y38+JH^=K0]D12'#_
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MSCB8; [P)W AN7"J6B)8(CZN7F>Q(3O&Q0_A,;0(Z6=9JCCY>4*6/4FJ:JE
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M'<A+9_I(%WH87/G*,3M%AK6]'=R.K+6X$V9@P0F/GWKMO'[(:@'7;. @)@"
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ML8JV0O W=2H16SU9F%C_6M /ZHU4,T@I(LHXA&-_SAEN[JI5CIX<_;L0#UI
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M-PC).IO(SM+X9F5BMZ76[70;-L/;!\4Y2&W&#NQ%*>/3<B?F"<BBOL":Z-<
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M81:]L;ONLGA<2]X.;HCS[6.W7O5FHI#L@8P+E&3'1^][5D%\0F(+G_JF&SB
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M2!TK("4-7PNX2F24;OBKW&Z40X%\3DF$2K\V^D GRK)&B*%DMYXM,Z 7F=^
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M&EV@^[2_:5R]==ATM CZ4'+DT'I$6T/J5KQCZ@4):T-)^0\@0L<]#8\[W7,
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M9N[58O,FGY>UHN[$U4AIQ\G.XD)^[1^"E,KP[GI=-,:L_F+1^953<>"[7'5
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M?[^RCYZ9@5]8_B\+M27]W<'RAQI:G==<K#92U<,O]LA 4PL\T(RM:F,("6L
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MW8V. '^R8+XM:]8$H(2 \<"4X8^4,'UEE?3@)WL81*2458)\&LV,9($"B6(
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M&E/"8TKX<]^=^Y<2?ILHCOU12O@5L7Q4\&C*2C*(UJU/EM!5N805I,08V@0
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MV%FIJ*I18<*G<HEB#*AW8QN((Y*B+469W<>Y@9#R%40BQCSG FS ZTP6M-_
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M"L;-9,4>H-D"$%V#*M 2?^576H,@_'OY*\,BT<^W4K2/[T3G?;9M-_5<TV/
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M1N+9]JE8K^X)RS>!#C%E0WQ15?6-DB#+HC]Y>8G"@H+]+_TK2K9VP<\Q4IV
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M Y%,(G>E*><1(5>+\LMF?L+AR)T%/6^OR9%JKK9J<H5/HP !L3.1@2LY:-Q
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MDAG-SC4PTKAUX_XU9%CC\</ZUPQ8%C=</BZA&QV%_,I&B$#6XT<&Q&F&Y_G
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MCE.ZL3<[\Q(-:4/AFT\GEZZ;O-\Z;SE2;5W7#B5?Y516'"FV9N>DCEJKI0<
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MC?#M#D0%9:_3V& ; 8(?E&YY4 UM"+)HMY;,_*R?+Y%HP>GD8N"<\F.ZFXC
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M)K<JU01OT"ZXQG9EGNJ!3@N+KYH'RH0ABEW[THOYUSCR!DALR-/^L49%;ZC
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M"F4RW74(OHOW)7HX- ]!3YV%'+IIK#EKE7*Z!1];A[BM;C)/J[W<93[_1 ]
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M&9[CWPN W<XV4NQD0(8![Y.\&%)EI/L\\.JL;EF#M6T]*R/P]QT[ %& Y+L
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MP Y0!4@9>?%N"  !/5$'ZL9I.)TI%-4U:@EAB]#&KW@F_(0;6D%<,JTX.5A
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MNJ^M\1=5EQ7]G50J%'-H;AHXE[2]#BMA5W>7:;M>$?,6F08LE#ME<A'7A/%
ME?-KZDSK80].B[KC"*.%=K0_D9V%1MJD7M]\PQ\U13.FD\AE+3:2A(X6=2CI
M]G@_R>^C$J]'5J'TQ52A]/NI4%I)=2F+<&\!#3= 166]TDJMQ;[,L](<3'X/
M2A495J)8]=NSXY:\N76#2DC%[ +SF+&,@$A@F*$P*^MSDH,79QS]+'5?RR8U
MV"T?( I7NA99,Y02&;=PPU#9)YM8)S!%1)!![TBA4*(6>_8KZ=2OK$6B@<J2
MU8 <YL/^Q;WIE*&>M[*?P/(V=E36Y'5BS^(V=T^CF%' ^G'Y>6>Z>4F(L(GR
MA=W@@>$-!96*?G'IT2^\C1O&T1)QS7OF96*LC*?'N F^LUBCEX@^;$D(NRBD
MPI+1?PV&0<=!<6;)C_OSC?Y)GE*+$F//('5ZN>IR)<5_".>TE<),%+Y'P8=+
M.\UM^8FK, ;VC?BKG(3BA@WB0UX8@@/[!SLU*-*^ORR.-8'0\<A3V<1XCS&.
M"YF-KC>E=YXX0L7J#VP#=EL=#)G _2MZYSY.2<:K>*Q,9,W)[ #0#D>MV4<"
M_E:W04?;5ACC8Z5EEL<D^"7VHM&DR-;KV6MHS>2-^!Y2)8WE#OH3;SSUIC1+
M"A+[3! THMYA8Y3>'$W?N,/>44F4K@_L.LM2 ,I)JUY_-*>^'E4YQ<<B"?-5
MD6N(^Z#PF1\@6MDA?B,Q5GYN)Z0ML0:DXCF.^IR]#A8>7VE!1#W[)HR^PQ->
M:3,=>TC/O_KFU5PC?W4IX0&E1!NXU,OL6->I;5Y<TZ$M/*>SHG.MYKH%_N!W
M>%Y8_8TYE\^]<\G!X5L 9&!YEK[1%7&>#6$+;4Z10_S;B^]Y!:CV6#(P1Z,_
M?>44MXFH_^N_W0R]CZ^5[T?0"HIL[Y/@?^,B?I;E[SC.Q[SVQG>()D<Z\' ^
MY;]]\^[-JYOGU_87 >%;NQ72CD/N-2L2397UH^.V--K=UT2J\(C%ZC8,%+K_
M=N\;YM 6W/I*'K89664CKC)7^U'NT%+E1F^=:8O$%.#I#8IM4L 843L*X00
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M&@1$>6? QQI$>M KY\)T\<XC*S*O5E?2QI,75MF\1/*)J$6<Z7R_:,D>DM!
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M-/&\Q659U%-D^U)):1+%DRB>1/%#%\5A;J^'V+2PB QF6%7E 3-%9@N&V^N
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M&)9J*4/QE@RK\OKF&Z#8U>42X]I6(8W:BZ K2A5);W05"<8=&?Y\GC-@TD2
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M=6L<7'%/<,5RO?2/NB7QW:.#ZYD1[@"1D/[8D[1N*C84M481#W68])DMCXS
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M\!E+3KDA @*8]UNS58BF1 SA>%E2\:&9_VPOOB3R>?;%?/;LR;.G<^]9D0"
MN4M*,:NY,CHO6KZ]<N:*FB?OB.R0.^$G1:Y#S0IN#[TJL"$">Q"1@$<%]'"
MX'&R>*6Z#S9_6Q/?K)VSVA)VL3>E482"5K GGM? FY@M(: 95Z+<@[N7_$$
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M5OF_9!G"?/OC4RX(?\*!2XRGXS9%WJ)496D%?S)'CQ[1:?O897>^>EP*W!"
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M(SF Z8M>%VJ,4K_5F1V/6&#^#K&N9@M)F6G!358DM5PIR!N;LZ[0;R5UXP[
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M)LKO5EG\PA.:E,7O0ED\=/[Y<,IB6^Y6SL,(CEG[9K_33S8L[$>E/T*M N;
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M.WT'Y2539A2C-FB<U5Q&DC7\UZRN75TKYV4L+3"]Y'IV8YG.N_>N?SD;*=S
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M\N8DD!^&0+Y,_OG@T6P&*6JY69 A2]#06MI(1G2HH7DWZ2Z29DEN:?.__WT
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MQL&7*/FT,<W>HW/;48;BT(F[A2DHE $'(X0V(JK"$ 0"#H,>*X1/8/C2L ;
M0>$FPDQ8OL^1IX]^'C(P@]<NN RA0^76CRUY[O(>+HQ,*U4F@;*! *<(Y%ZQ
M I^G-D!?6Q8)5@<I/8X@ 03QT[LR&Z'G4("*,,)3QCP #[ U=@@.WQ>>RY?;
M3%"".P>+N3O(O,,4UWNDH"MP>X?\N3:VQ";O>\XB/3H:\JYQI<C:8) 9_*M:
MUP\2.V+:C=DH\9TQ"L1%H>\/4X7+:].5BSY>H=>S<559)C/;[8BI,#'!DSQ'
MB BQ&>D=W$:>-%/^')L"TX_G](=D@]$#8"JQJ-=DEH-Y@26)#^(J,B#OTV1@
MO&C'ZI=:C=$7F[ <Z1Q-68M'C(7.&#Y>N^A-5]VP60C?H7;4-CDV4&R?_NZ\
MS J]OY: U7*,KN#@:AB!I$OIT<EYMXGA0Z1,S-(9)LBE2X9Z?/@?&_OW;[!Z
M),0WSVX_^_V[$1'_&@%[KE$#+::$4;,?QV?&WM,9)D3T\#,ZR6^.4\&]K(?&
M;>DL*ER:+>;)&9'E*9$^0FC 9V>5VCL^TK\DT^<Y0&2L'9%_V4-9>#SIN0M]
M=5\3URFE,3/=6+HS0FIXO#L4,X_8&@HO"Q;[OO %=PSJN&BK<"P<C)R ,"Y&
M2J-#+=;-,N>T6)W@UE/&76"?K70T#*^E-2>MG'+&.\?T2%$>0TT2&R.I:H4F
MF\L)F47H\+[7? /ME"MSYL^KT-K/C,MJ\#R#<^ /B%<Y@,=1JS':%& K+P36
MQQ$+30&_,MOR):5/7@_;+7(-.V+DA':YKDHFSE90:]$/+.D4:6V]6/&'IL8D
MECT3IT=%6?>TGJ\I!S,QN'%@T53QFM9P-!D_))"@<>_',&1/V?2>/& \$!I2
MTA,V1-R+JFJDQQ#_PAR7F(-ES!2O^S)?,C(040"P!^"J.[>Z\X/T(F^QN&GH
M05,6LZF'Q871$(]&[_1BEUB61JJQ@C42^4B O,L?%&/0B^13N:M,<)*AP,_8
MFF',8R8HG 62)2Z %KN!>JM N]R>=KU'MHQ-Z8<JK!Q)L.,YQ&DP[?NN0H=E
M  LMDLD*A[D8V:)]BHF=C6CBM?8%;(RE#$*;8YN=[9,<QSWH]DE)#^JFM^:5
MLV6$08:0$Z$1U*"H[MS1 *2X"(+G!(-=Q;PWO%7L^1QCODJ:['M\+A'#[\$>
MK)%S^/W;[_.+U+\IF/3'!5+^32"/ZK599#:_2C!RI!$<7RK<UCNUCD[L1%,!
MXB7C,BT/6I9_UXPU5\*E=?(BOV)FFU="H4NW])75[O_C>FOWY[=W3I3TS^]A
MA[Z+4Q3V@"8YKSY?%6+0*9@9V7)TV(8#JW2 3>UXZJ!@."GM98FXXY<,A <#
MO7[HG<?X8:09?CS-<GW4S(;MK><Z#4C_=(LD4N##;^ZUPJ>V7DEA;A=OB$\A
MN3K]RC(2X@5#I8ACR421P$Y]Z/_G-DN)YC4,R-)O9_+='O65-E=T/G%0E#O6
MUQ&>0A%1FNC&GPA+!AY)^Y-BAS27C";(CK1J8VB&#.EZ/!78#--\UO\E8>I+
MP]\1)EPP$0C=/Q6$>B8 P7-"30ECZ8H/P4'".D%#2O"3X9A?%\SB]:,4:6P*
M$HI.KA@%@L4(07D*.R>G-UMZ3;Z0_5Z4PJ##NJ7>Q%-^ST8%E*G9A4B^#>]>
M$,#V[2[PHPK!"T/E#3+ D-<(*LG(4BD@89SN0_$.0D<Y=)69FD@O2*[4A! O
MN:8U3L]"9'U\%P9%[6;O$-"ZK0542\Z;@GM*-&-'VTIH(2E9 Y8]9%/61O-"
MVZ<$N)<T=.N)T,#X./UOJ.W<AF]4;Q(,+_U.X7<I0B_!X<&0_'O?AF,!J=?E
M$>!^ PVNM,V"R5T>&75-:TT @+ &%<M./M:^-4'?X%M1/H77G:O@AC6M+6M3
M=-Q04.'Q#:DD(?!JPBZ"=)*;&SP?ZU%XR<QI!9>L9.K&E S"UY5Q+0$U[/,[
MF?D]$A:4=86M"*';1]9BK]:A91-]S@':Q12OA;Y@V><039 NL6@\!)ZPLDM,
MT67!<Z;$"A-W3%-NPQM)>5IN$^K'1EI^[(G[ HV9"*T=N,B8_&$S0J)H]4[Z
MO*Z1^1^<6!M\FG2"# A_>^C23)*@V$V)7(DMDPT.S@,!O*:'_H ^+8)4 ;YC
M*I#)!'RH\!$%,ZNCM2:AGP9?A$\CEL(V<%"E_-,5GA[H=7U>2G"D76\IOZ2"
M8SD9,<;X%0.&#1XW=D9F(I3IPAX/X:Q0L,KSQ83E>.\=6[!DH6ATV:.OC;RU
MXE\H,J'L!4&JB!*QH'Z$7JI$.)P,$GN0R%:B22[/T_,CJ);'QO ":P9.1RBZ
MM';7=TQC<14],]%_B*2LJ:9.L)@:D23^>:UL:H3^]3NMXKPS(WU2A65K8$S;
MG ">B@)3E.H(^8GV 81@3-8)9MBJ=3E1I%#DG;6S5];Y]*31ZT<2[2AR91@W
M@Z/[E[#2G@9H>>F]*/9L?XG\1%,PP4FGLY,]AD^..*F C\Y1?(RAK_LZY!3"
M6J#-#<'OFAEO'_"X0.9K I=L8B#B/L?3!A6M?BKVK' VAHI;NC61"]@%EU:@
M0BT+O90NT.P)Y;1T-$;[/@+P6=FD1N'.1%'3-IVB.@ST+1Y[A-G_4'L,J+RP
M.K,'AU<ZA)@R?-N@H'S4!:043(,DY>617]?9]$0F83R[(O-8<JZ9'!0*IF*-
M)@6GV:9F@],R<&\&:Y&P%MY$7,,@U*2?)=$IM56J9)BYSVF\R,^SN6<BPL,E
M"FGX3]1C(+:[$FI$I727E7+(?9OIFF]))H., N.),BM7'YNF&?.5$L$+<8'R
M=O<.P6[$()M#6>_2JLL<\6E9$B^,]0<H?O"JX!\Z630+:EN9]S6PO=NA6^1;
M\%9"^3N8G[YFRC=O_GOQ7'\ YY2N\4BFC]/(*5/\ C\HQ/!. ,%&8B8+PC.+
MW[Y^^]W-Y\^>_2Y;X']]]NP+LFL_/G]#3XF???'L&7WV]L7;7NH"[U/5][H-
M.R^GY1_^]__ZXD]_>3'VG@@I$?[;/+Z"1/#Z._-R-!IO78D,)M7-ZS<_J-JG
M&3%F\^7=\&!$"2!24/7S_BV%ZTI_B3-(.'%4.X%SPI9/F+!TX(B&LAZ'_,C/
MT]3'O"268:1AR56ZB@\YB6(A4@NS#V6B)NLJTT?I%VAPRVADW^":]%Q%0.S&
MRHDC@B@%S^T=1_8H-'34U]3)Z%3",+U=J/52_@="$.QI[*?34U+]'L5I/%Z(
MH@+EF(Z&D+=O,JZJL(1RQ\AOF>SNO+?2:>&>J'G^YK^^QPPZ[NEOFKH[+/YV
M^S^WM!/T\[&='7Z#93]2I,6^D;HIUP\8U,75PIOY]QGS:9E, ZP7+?8-!,9.
M.+7?_)?T58[]N/]5BW_:P<$9IKDN7$L''[>GK%8:'FJ*>*(,>>$P@]]?)LQ@
M8F#/9AN>7((1B0U&%'-"X+,0^917VZ)VF,UYRD*^?=)J1QO_I9">D%OA-&,H
MH*CA?_FW%S<.8?T4 P0"-78@% _ULZ+P(]G(RAT(YZM4^&0$H*654R5KVJ C
MH+RMFH^KK/=+&X6)?!/1E21238+FH4QE8-2ZE[-:OJ\[\8IML9>I 8\M4C44
M:UB'2!703H[ID;,(JQ5K+*,$/KY?HI/V.DUK,G,C<1#>NZIS/J10T?\W5% Q
ML0^3.:H\C*;^DZ?5,D00\!$%B=A\HFT-/)@JLI![%!$0NCJ4;X.7Z'30>P]S
MNWA5-ZXF?9X<ZVVFF;'NVA4W=%!XD69#R6GP0N\_.(+NA/BPD/XW/G;@\L<+
M:Z:#>2/A)9#,0N/3D*0<YS:&4R>^\G6%-)C6[I\3G=U*Z2D3]QE&S@PSQCH(
M'LG[YY10__Q/&:MU<:^CQ=Z\=!MT1? GKHHMB0;Q__O-L]]0D"" L/#O VYH
M^;=<AW]Q0\]^\.X_]3_^ HM\W>Y@M, O\AT:^M\U!/MX;X@JZD.X#'^9)P76
M5.L(C(8C^0"S_INI:(2>_Z27_L-3)RM="D^>NAYT+JR-=X\"_M]_;]<7-$)C
M&T)>^M]Z;_UOOV@X?S,2*#]IYZV1ZI V$]_PK_GJ;ML@6>6-O J&R1_QM2:/
M 4^[/2Z>/WW^^1_^8H*)B45TO?LG&;V)&1Y=#>/CWX\MY3MI#$&A2J(W5_A5
MX[14J\S0:H;UT"[%0QNR4 ,2DPNPT%X]FM@C58,PO? _#?X/6FSX_V#4/U';
M_F1'_,G:]I\Y0K-M_R1L^[GOGX]AVY77PARLBC2QG'O)<+OU;)<O<EW-=GFV
MR[-=/G>[+,P<:(SSU8XDJXG56FN"/I-F'1*,)()W+A*B>%" '::!M,V0Q L1
M<8K\=J%<L5K%K,/=X]UFNW^1ZW:V^[/=G^W^N=O]!',KN.NH*V<(LD8A4(:7
M+A8R9GM]D>MMMM>SO9[M];G;ZXG\"4*GW!,@;=)H-24(K\'WJ IYPX #Q.'1
M3:6;GV0[*5K'_JI'*_RJ#[1@U<JZWYVJ_32955I@=,E(K5X(&HO58E.O.CI;
MY/=Y47+782?RC0U)N#6(C& R0FH=0PEB3YT$JW]V2)THC0XYEACN7=.:^@&^
M"F)L&.3"7$"J_.GFBL%E[MC9X\T>;_9XE^?QN&-T(&F#?@IAP8A5QQ8A9I 4
M'[ 9$\'Q,,H(94X=$/J0)3A&$>7N>4IL^#RX7+Q;Q>P"J&T\Y%C01LB<OH"3
MT971#0\OW7M()E^8?<M%[HW9M\R^9?8MY^Y;3-6#8$9!Z#33XPY1@3#?C[8P
M(_ZHK#WUK"A_2X$D"7LV[G!XRKG'=^28Q:((<DIBSI6D U&[H/L--D39$=DX
M2A&I2W#<!AW-ST,U&:)(V-7EFDB.EZ@9S>0->=OYH)PS?-39\5SDQID=S^QX
M9L=S[HXG/=1PQP;V2F"3"IEW=1'DB+1=?:Q9.M59Y^P4MO4*Q0.Q&89_T07&
M&VQ4^BA]LJ4K*2%H+EZ0Y'=*^E=3U_&=8U!M4@V*KR+>#L9FZ<:='B)Y-1.I
MEX51KNJ]$&(8S7'X%O7RS'[J,O?9[*=F/S7[J7/W4R-^(EIS9!8=L@!T7@].
M]X5[X$[<0:_E@@1;HCL1ST;HWX=JS#U% >R@7HVW86K ]-I8F")1 &9ZJ:E)
M-'2"U#VZYD=;3V<'<Y$;9'8PLX.9'<RY.Y@\;64G/Q#E=@8<MY'R!7F*,$=7
M1P+_GX-JT/0?^H.B79C*T<!EG'@L@56,9])F_W&1ZW_V'[/_F/W'N?L/,,-]
M-L'D,)!P<"??);8;))-K"D=D2>Q;6'0&LTS,"GYH7&3W9H)1)T2#*#3.HC,)
MZFT*8I>9 TND Q_2Y:'G<7FSVF5/XLN9*-_PW90"WG #!:H89;EA<GX>._RC
M-.),7%<+8Y' #R^S#4.4-\LBL :+3I\0-"DO#3+3WF MJ]NK-V7R]KG9YU(W
M^^PL9V<Y.\MS=Y83X'$B5"V/"U2)(30#E9PV3DC2QME7Y20FWJ#S058B^%.+
MB2#1!P1<+Q[@V[EGC,(]:JD8]R%5)G03_W#U 5$4_W(BR 4S31BYZ2>JIV]/
M"'"B\&)YI4/=BJ1)O/OL>2YRY\R>9_8\L^<Y=\^#TA5=*[IM\ ;>#<X;>/*I
M'U"@9%<<\-0P;N5C^<GR10_)!V9S?I'+<3;GLSF?S?FYF_/A00*B;63L/J77
MH">&31_"%JOY29!N#@9$5&QB=D$ZDXW'/W[*=EY7Y7#9GO,Z_9!V_KV.T&SG
MK\S.7^;^^=!V/M"]+*/"CXA,,YP*Y64+1Y)D0R"Q*,YNS$\SI/T*5/72*DFU
MBB;'XX%5,\@/J-)"B1LF.MATC>BL/EX?(4&#PZ$L5F3J)^1Z3GB/Z^"\?[D9
M.20MUC6E &,QAY5O@R;!DQ@EK-8JS#$A,_IW(UR>3KY?%(@<UUJ<X@:SA>G'
MLE1SPL.O=3%+[!!%J[#AEN6J(KT<P\HI\YB^.*FZP=W"^_/-1-B!+AY9Z<:5
MI;*!BI11/S;ULK#&J>:G4K/ZI@[[MI+B7 2=!)6Z"46,1)WLO0S\ID")O991
M-4%/F@J(C+SG5N<4R2D"T%<F8_2'6<;HUQC7$U[G(SZ5T42QXBU1RI$4;HSZ
M\W[?55P]/R7RN'A>EJ&H'V4\1?Y5MW2B932&41LWO&OG5TVQ=**)6?C%\ZK"
M ]</#A7)$XY[J[\T9B&N62$IU7*!< @Y(A*A4,E%LJKA 55SX(#1M4%U:EG
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MQZ$S[#8X-O'Y,>8&>A9N3X(OEIMGQ+IA3.4:W'O*KBQ6S@H21"L'48JO'S&
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M$AV=^31A)?BL'S"4J:.QG#"19_T:NN3/^B'UV)ZD(4B.L&ZI=$7Q"J7.1N;
M),CQZ,] NK7 BN%%SGPGC*DC21AQUL\]%M^0O\E;HCIE-H3AH8R#D93%>I#
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MH9X(;CEL!<"U&'=<?$%Z@!SEH*R"%N$LP!CO#P*,((13B:PXBV6W1FZ<M4,
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MFP#3G=25Z9HG;&+23_JJY\6*=K18QN?3BKHUX)I'L14T+,/82[2231L>&PC
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MN>VL^\/1TW$3*->"JGSEDU$I9W"B^I(^4H\E8[>ZQ\96$<:L']\AC!^U6U*
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M'4V9\^:(QI;6&S<V5_=:_C*_=57LBOCJEN]QI^]5F\%.)8XC/SBMA^"8 V4
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M0<?$9:H*0'+&<O04<X1X4M#U*K2=*\1J6A<0_BU/_V,S7&_+[J L7Z.JGUC
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MF13.^=Z?#Z-PI%=*4+-7$M$L$_]CTPX(*=<I], 9Y+:AO>@F 7V6!VP2T).
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M#-@RW#JHGT>#A M4@$&DWT@!-3W,'LPBMNS$Q+RFU:7QTK!J;8SGW>LAD(R
M9%D%]>YI4<F"7,)]9_9N+C8O\%G KM3#H<. \^/'L1$3B0;.@M!XP.N&58M1
MFK,T*A1LEZM&8) ,Z\?3QO)K&:<%GG]4WF,CN)A]GSC(X2)U/9M?I4AZVTJ:
MT:)5!=:E.AGZ=>&VCM>#CG_GU)9<4G!O+X*%+HJZ;KAP4B$'XDDW!NQK6E^V
M#TDW-9%Y.YGF;;G)K,@F<P4/+0X7!3M''H _G!\/P'DJKQ/AP5]P5%^+IR'Q
M#Q4$UTV%KA!WI\T8[$)XBXNI^F1&CN5 =3C5"QM1=0R$Y?NJ0G7O$(V!2DR/
M%Q&8^PMNJ'$T+5=1)R$"$:[F'DE<5J<DR*4.SZEM%D;RM+L,-%ZY6;E6#C_V
MCLS07I<MC3,Q1!5JMP=H)-89#6KCDIJ/QF(R*UEPLFJ\*<H*5DI3NX&"YJ3H
MFEH:@4*[P4+R+E;5Q>PE+30K*#]IQ6.!\MK2KSH27"CJHS5;!X-#;_:%E)#P
M4)G\*N3#Y]570YC?K ._F+U&#"%^$K977>'%;*.$=Q#@-Z*>U=!B@WA@575T
MQ44DJY[O.^V1&F[2T*^U[>I*NDVD1YGQA:6!,+S#I8@^:$6?V845V0UBQ/&Y
MQ%)%NO9*.JS80UD5&Z1?=?)R1[J3>\=NKEM=!;2'#L6Y8Z^''V^/IE.D'OX:
M>)KT*NC,V[*JQ'2Q [_*;N7%;.P6.S.GR<=(;VGQVT5^-WBQV,")?QW&=O/J
MUEY/76/F==KW.P_I4#(,UK#<Z4IQF"(S\CA549/54L(FHVMH)FI4[ZF R4X$
MWL**.V:W'HU2^5[.2W%;M"$&1RP(/A+%&G%AO</-A^@PR,[^YLIB4B.N*"^Z
ME^S]F"CG]_\V5HZI?W]4'V3NT,G$VM>ZK?D]-/&/LZRZ:N54$Z[Y@AV^FQ"C
M*[AL!XHFZD Q2_/45[$;7BWQ#D1JI^NZV-^Q+"./XBWE!\'>OIC]K;D-D.7E
M>NPZCTP26Q[G(V[0M7T0.A/?S-5C7\/1XV#3\%8?WM.?H*?F25'=*7/E'I]4
MUKQ+=X6*=)]YRJ3<.&)%X[H.518Q&9^B2:/W2?+\)%'UB&347V AB?0H%AW<
M6+8M>7DD")Y'?J.U$GUL.8AZ##L#__2Q4G855S?P9GD+V)4N6MHWL;":VY'L
MW=  /19#5P]V30?;Z[IZGW1_'!D4KSOI2\YXL'=9GSK_JK_I!RAP%V6 @C8M
M>X]0TWWF\SQ/T.),9SDX7O1KX(VLQ71"@H"W.:I^@0(DP[ -(T'Y_+:8)1:!
M3,K-MAA)B<XNXY(B$7/5(&&,1]F-H_NJ=X[_I;<NNW+';]?(97Q<]XP.$9?5
MB93A5<EW";9X3*NJ<?>V;FYK#1_SK#CN+1%P;@!BWT&4E\M1T0E*/[BTYM@1
MV/9T"<V^OT<DGR[$+FRV, G;($9*&/&5XGC05L477VHC;UE_M_S+&!WT:7Q-
MV,]'+.I!'CH%B%T2.AROZHBU!:O )C_I;ECP.FT&S.1;E7R5%%32>"IO@Y]4
M_&QIBFN-Z6O&6877J;&05%F;F#H\#<X%J(I;60L1;9*_'!P&&:N<A<*=AD'Y
MA61*G "##*@;&9)&.=5)"5*T1+ZRF!:WUP+IC,.VZ6O9>PXR.P]0S*1L';UH
MXFRB!"_%P^AE%0ZG;[85_>[?O1@":9^8\#F%*3%HB9H6=3ILB/P>YF_]+Q!6
MM\1TM&^& HQ#!H5=F(%$U.O,@L_L/F99V';(:-62>!-"ZB.37 72J6R\VTRC
M=L76D*7H [(< N8 ;(RQ^"O-%ME!L<;!6T_*U!]7TO6+53CQ G+('C= ;P/K
MK>,U)R3)HKV\.F*H_"3][2-B=]4GN>KN-OKQ<RO(F9O#)QZY)ASDP$DGIUDU
M!A9#GY?F5/@1]\[#GUU!TXF=EZCC_78_+M?@!" \TP8%32ZD[JP.[($A92^[
MXK?7)/B16->QD^(<U?1-5Z,X=.?Y.>;/W\>2_%H.$K>;%1)C7#60JJS,X)"=
M+B&(=7/\'3H=<>7XNX/HA1OVZUU;;A@HB:;XSW*Q(0=.^IZ3KJM"<=285[F7
MWF8UB6P+/;EN;M-6XO[^]?4_I @I5%RP4#_YYO6W\RR,X0?TS9M_/GGV]#,(
MR^\O7Z<1RL7E/W_V]"G^_.;%F_E=+_<OS=[)#_I4W_/RU>LG7_]-7F#/.U5J
MMM8RDF55UE)A;/ZU_DR?I#N_49O<-88?N#P69Q'ME:H?$$AJ)&'L8Z 6E8^A
M4 GPM:D$,P\$O[]_\ZA,^LN*4PE7UZ[J)RZYG ]:YV_#E<]T?E=+XESRPL]I
MY>@U=5G,_5^>-Z@5F?V3)#Z["W3(YR.G'.5%*68/ZXQ_IY%SR2&8!-!RM7DL
M)'SYSQ=SO@0S.^RP\-N\^$O/*YD.8GN:\7JYZ$2SS0J2@:N-UN<6T20B*Z4-
M@X"!99FE0$U-SKX+*K?3G1^]&'-</%BE\3KBKM1>)N)F@%6EEDNFOQND$7 #
M3(-^G$1QAR0U?OU)[H2C06L_0PZ9!]C$,L >XMEF:-:HG@.=(1;]N&IR&H"'
M3JX$29-P@ZR/5!G2#'NMR-!/<'<!F[5*Z1MK$'D@Y!9=>V-FD)H) X4US^_M
M(\NA__%1Y= ?C/1[F!GS(W6VA6J_3!@M.! 1PJ$FBVKZ/EEPU"'I)6VS6XG(
M*?V"\;\@!P9"2%W&%)]4MS?*=(B84P_TJ>,4BC1M[5Q?T4<J#JR,?QBESSQC
MF_-@")H<A11R:H^F]L\[Q6GC]8//A3GQ!YD[3(:;2>2M[BCK1_,;N6Q6V?T3
MLR _.M7P*'.;Y%X@\K<LVV6_X;I [D<XK>NU[%XJQ]M FZ^M&^NRLD/):9:P
M[,V>':WH;]HLMN):3YB__D:@,(:'ZC:9Q8>>OY:LK6.- 9>IX;2DGJC#%" ;
M3'G5->EEE*[('#AX9*,,4K4?$X'(W=$^U4'PHLH.$Q6X6NX* &J@WO;.1%&*
M/FG@+!6;6PHD+HLO0L":54WG[1*)[9WV N=I [MH"D4[+=Y3$A42F0N5H%+I
M;)'ML=T_'EEQON&]LH2%=J*8I6K%17%@F=\S&M5[7)X(FKRTR],.>33 .\0R
MNA!+3;F\=ZF5*"HA1[YDEV9@]>*,VP-Y)-RCTY"8OQK#I:%?2V&L<WZWQ5[\
MA?0E'&=ZEYWACG[=K24KGSU;KGKT:>STIY!I)F_,-U;[.TWN8O:B[+:]=;S0
M+)!TV=V&4%MJW@<LXB638FO#Y3DTYIWO-'BE;S'CX(F58ZUL((A8CS\U<T3B
M(5<>1JTK6V=>J'OOH(62\WME._3DLSBUG:2B;0O-^G9H$%PNPW9W1#WJ)NCC
MM7:[MRIY_RRSA2ZM=$.7X,?I5CTY*K#C/ H7LSM8%*R#CBO^CHOE[;RLQ@VK
MK%#]N#C#<U7.W!VG>Y,'<([L(FIS#&[$"5KW+15Z AK.&1Q,($5]^#.TN!JB
MJL-5LT,NC9?J5E[ >041WLY[/UY%(C%4;ACXM^ ;KHN;ICUI/_%S-LP(JK5T
M:7&/^JICRSEJBN.KZ#22FGWHN[&52=,[F=?^^;J&SRJU\O7Z<'-B7<4J7;%[
MMLXZ2D*SX^^,C:?[V2WI,8-NP_=X8TR:TNWFXYOR:5SV*C#^@RRA;O[QZWVO
M*M:4"?*%LUFCR_L&3TT>O9\Q<W;YG6\.8LS(&/M>+]@@DOEQ"3.]CV-:31R.
MU'@)+(YP)'.3XS"AV:3K-#W1\NN97#/[3#J0%IF<)\,[R[_.QV2[)O=VS RD
M!_D&Q,Q2R]^QRN6 WETU!79N=E9X<[?ND6P!&345I#*-[]H*&0LNQUA)@;A%
ME-W-DI7:'\G3.[&+=4N]F[]H$DKS/Q>SE^_A<@A(1GKUF/=XN5PVL M1"F"N
M,?=>B\VJ.E-.)K\GRK5ML],J+IV_6^.RBRN_*&#R<8]8B?*4I9X0K5U-)JJ:
MA67-%A^J'BSBG[[$_6+74J% KO=X9RZ7FU\'J1XY\3$KDN-K.VR 5M9RF/5]
MZQ1)<HOGL5>ET3:2U:E@N17RK#6C*!&;>6PUXV+"@W;^+ ^J?:5VJ=1170@^
MD52AT>_(:X'AT19;*:\J:HY^J?GDO^UB4O,1L;!B-(=R(?$,C^DV%P'U-E9+
M><0 M=.7!QDW?9M_4]"KR&2/]].NATTQ?)_S4-B-U/G2L>,[Q!_^.<)@CT=+
M'6;76Q%_)4VC%"4QD/Q9$EF.85_+E<K*SSQB102,U4(GE@PD;2SQ>!O0\Q6;
MH:+@4%27A;KNZK V6=DH1%'20H@\\7[1Z5@)VH5AFL\S1/,X?&ZP;Y+K70BR
MC PTJEI7 '9W9"T;#NEX_22G:I;7*,5233-CSNJ5U3VQ))#/N'9E\U+F)I;>
M:SN.PC3HJ([4:K*$&RO7]!5Z WO3/-AA+QPV4;=42[E.R\2NJ$)WH-1X>]CJ
M#>V81<IRKI7UI&WO7:%_QU8 'VD11(_,R#QEDKR_67&RJ.6Y'O,CFW?'TQ&)
MDLK:8RTJ=YHG<Q+!*7[TLY?S'"D^LNO=E33C9,VAF++F,EG.[+B:7D@'.Z+)
MG)&^=)9VNQC Y*64#CPVFTL^M^B$)$F8Q*2-+5[C6.Q)=U 3#F,&S1@KC^"8
ML .\XXWN=IF!YQNE$@G0(\NB?W&>6?1QR?1@Y-##3*(?14[+BMQBF)C;-R2-
M<._L3:JN5""A%,^-G73)6-B2J"CI2=$?N3X")A1%^B+@>C,4%^#U.6?!,D[H
M5V+S6'I<CI21$#]C%Q\_PFI[K'F^F(UV.OB*N9$</"KNV#U(70@)J<G"3LDI
MR'H-)+*=\&3X Y)$G'N'[3;$7.1H[%H6YI3XTPT=XCUYXIM[;;EO<Q_?-DNC
MTMJ*8H0567:*0H.596&? =EDT"5NEG!3?1H9N$LN%P OLRM;UQA_Z,^.-8EA
MY7D0M'RRX@>=Z7-3C+8TI'[I<S"?*S S%!$54]4OJP_?OR:V^=KB(AA!(6V'
M4OW!APKCW+ QJYNEC0'T@7N4G7,03>K.%8&OE-Q'TP ERT5[#P,24F.]&6;+
M$=2G^^6"&0SZU^[ZNDPX!:2=7?W'P</O425Q=F;FUUA:,CRZ$@>4Q1\'.70[
M^?NS&)Z,]1"X76*@C%= 2$Z6L0ACWDU2F-GES2!;#WKZQ0*5<!([ PG$2N-&
MU^5V+K^58-5<4D0 GA*W2T?&J1[:V1_Z;J?)U3R9&Z,E<Y=FC)U7.8+)7:']
MZ.OPES3J>:H* 6,1%+D"19H:J;!-L 6CC9CG)2E9'4J;]66;W7M'Y40V,1VD
MXC-97[E#_JHT/R_!NN%FUZP272X/3XFQLQSEX](WOY(J9_?4LAKCV=^ALD*N
M9L2-2"D\<?CK&/$YTC7ZN(HLI)[8%F,3@8IIH10]*^*CD9*X8M!$V30%THK!
M;,AN7WC/ETYOSZRLCRC_N4$@6"Q!KWYL53QH2HPW0]RY)F]^BP$?*-]B>3V/
M07V\B'5I?,GQ^*__RH+K)]29U"\NPM"[S+ I ;5(9Z@J-/-;KRN8>C:XT:L5
M2NS%0L66X0]WQ4;"J>KI#> N/:QEDW_;ZC8VW.*J> ^:!VRTA,0-QIX//S=U
M]:*8DRG$1;0#K#;Y@ZY ?) AL6X?#)_.(^;;98\[L,0'5:T^E:(*.:(JGJI2
MCY:LQ=4L%T5.M7.0G0F0]UZB5)4[7AT:T+"L]"!?>C_LT$>33Q^W5/TQ.)G4
MVUVW'/U@S"K>R-NFK1Y7+.XKF#I.XP)W7"T%_"!Y(4NIB-+SSID@2Y_T/+5I
M(EW'L65-T6-ZPG6Y*#7?'#V1E-6_"R9<XD/Q;<<]ZH2LPFX/;C]\'C!$2XGF
M6$1*3?"CG"E'SOM'_SU3,YOQ)A=C4)/F.ZK\@!C/*S[2+!'[/#8S*;=Q_M!A
MZON$ ,4"'DI1C=7:[3E]<T;%JF&&PMCBD<HK1\-^0<%1/-*FT7N/1BM1;)<Y
MU\[!F3VG;[,!S2&*(^'.44EA3?E9OS>+VBV7#)3+E!^([N'!>3^^3Q^_]RR/
MS? 3>"X\L(YV13'A)-23*0+8/PH:=SALM#CIWN4CC7 &V4ASR M>P+X;=#AI
MZ.3>$XR!<HL@X2-62W2H%%W@)@%&V'1%:* [3_PV7@^70'*AG+A"4KP:NR[B
M4#&PP_=S?-][*%KM1*>]VS&#L)@3Q>ZX*.F"WQZ#%'%&XGWP009>T3T(%=QQ
MCP4^8P@/"98BVAAB(5\<Q-G/616B+"4K-V#H,%QBI$N\ST!+20)"FAU=GK P
M5+$35<I)@)N '5RH-]=6%=3MNUV0P*@E=*),F;L4.!>TZ=]=EY'[J IN5(CB
M# X\ZO%ZJ?>H]1N,1E2GCU_F/ OI=OJ*!A1DE#N7=U\#1B_"7NY&@$T'QUY*
M,31Z,U+<P>Z[D7*['-J0#452L^1)7LQ>.<!CA^[J/!*+BUAIA\FJ^=%-/F@*
M]^C>'/14@#IN2A8KU1/JL)M4ISB!,HFG0&4.^V1P0[MLJ8J=T%30QR5<G\"K
M%>2&#CU=??ZQ+MJVN:WV S%S$+JU!R+)V0D/1VIG9Z^G>1MFA^AD0N1P $^?
MA9E9"G%(2_'%C+DE6DTE!SN1R%1Y'Q'RHBR,50L,";G"]B#A,/>",*O#X:J\
M$A3P@R(SOR.#,W&Z1E"R#LGFC9&IZ -ZS% O<1R-4,IU:)SH&/"&+8ZK[E8S
M\-'X=U_GX8W8@'8?K1FM?\&4M?#@,#3(QR0BQJXD1 0X>,E+'&4-.I8F\<YG
M+F_MT8\,2/V+IP\^??UHXJ02_<^1&>3.B\\N2;$H+M70<*<V@;MZW#(OY8K(
MH1 O6WV(C',$M+R[QJ630'LDDXB$,VH]B<#C#ZKY):D0*U8['("KA!EM3F&6
MB2/76\%Z=M*^%U&<QXSU>3Z\.+!.^&6<&CU&+E*THF*:>EL52WKW7Z$1M)(N
M,6XDA.K41EE'%AM7TKL)86?U0*@:8[.1!MN3\[*W)NY-4)X=ZPVD=ZNF)L7
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M$K,\/ 8DP&C@1BBEU*R[G0'YKC4*61<R6L%P3]2>-.N.V<LKIKC>6],]<[*
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MY-A8&_G<OWO]ZLTWEB_1I?)G2_*2<(-HRGD; *U8WVJQPH[LUK<'F>N8C%<
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M%3,(W835),3/\A!.0GP2XI,0/SLAS@B!TLGOF]T!A1BNRJ6+OQNM5U""4H9
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M%!IL&S8*#H8GZF:LJY[1>M6'NBYV\MUFO0OU;!'H/WUM'A,GI,N.ZXZ:EK_
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M"C=(7M;8^TW3!G^,;NLKFF1(\^)R<D3<^;LE#6%;UMIXE"YF?C!N<0JJ\FT
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M\N5&EMM<I!OPF &?E]?P-PS NNH:S8F \A9 :^#/RV2+SX]^-_C)2'V)&HF
M=!\ADC1E)P__B^R#.R&- K^3U1'%YLZQ170WM#]/PF; ;UWDZS_T.LEU0!L"
MPVPU>0LQFB>7]B,=%OXZ";]_-'?*[ &W"ID""ZPL ^$Q7;:.CFX'<7MVL\"_
MCHQQ 9:TVK Q?RDXS2\H1))%U]O!5],EA*=2^H#L$UQ;7$9L@;47YJR9+2H5
MC-$(%LF.F;GZ<4*.4Q"!/\E2 06!,X^+QG5Q"-C,Z]JF?(]\%=^<TKH"]8K&
M2ZQ+W,CVP:!,2,8H:-H!8NXA7^:D1+"PP9SH%U6UB;%--AV:>)(AFCN(M94)
M8C:#%OV+[*,BR-()K$=JT',5G/!H0\S447SX9V5 ]NGP-XMORII95'I]]83H
MELBI#8OBLP&8M/<#V?P:'$<Q*YR+0UX\!4M31+JAKTOD@=0@!E_;.A$\+5"]
M*?H?R:2B-&J,3;=XQ4?88LO(".:*MS*>^*)X5E.R\]/\:N#VD7F'%ER6\IH-
M+Y1B2JC>'KM\)0EA$+"T0,KX\'F4MQT.'2:=04R&FKO]E)2_?-_Y"KC_^6<\
M A \8"VEE8X.Y(%3ZOBB[X"2@V(@B08V0**%P05&N_.)Q ?L3\#0PR*^"3F[
MB-(,GT XSY6#6C<G+>@+Y*JBF4L""$1[A1DCYZ(9<22'9D09_&V$!,K:EZTA
MZ6^[8Y^2">H?&O6213?&*.+'9B9&8N4TVF6#HY^J^9<M<ZN)6>!VP#'K<;>(
M= FBFNE*/&>XR# %D)9$L7R(8#P:'PKG1-&<$H9+DQ6CSQC *)#309 Y$;2H
MX63(AC6F)DM ]IM&-QPBBU/$\T;KOC-ZV\H%NA2DJ@#05VB_"S-^%47Y$I&^
M*A!M'$02CU\;)Q0 B[Z(#VLZAB[1JY)WB(2 XP%Q &8#71K"9+D$3[MV*,T&
M/I;ZT9+!GLG8OB!.UF&=C0OB3N[D2!7-AH.O:]Y56+W)3W.1< LA0SS3,,G6
M1OO^P1Q&T;Z,V32:)*)&NZTOI(-)7*OYTA(8+)OH>@#3<W@8O:*F0$(Z4"2<
M8JO=<@N)A'EZB9,4$FIE62F&6F B6.N5WS[L?7Y[7<RF1[P&+9Y<YBK<B\>Q
M.B5JKDR-(WKD76M'3RO'^/$-JA?,E\1)4Q*CF1!?P0$!LQ4<8IZY<M.U'(_Q
M38RN)>89UM6%FLD55P?#*J$6DU&XK]5LR@GUXJ*,)@2F"Y]H('=QI GU4+-V
MQCS G*U;R2,Y(#A+3+JTG4I:?Z-T1WTP^S0,R>L.B4,P!UERDB$&NZYU3 Z=
MFNKW.LU R>09GA %]X*]G2"&FZM*GYXT(J_;B06;=W,98U[<R1Y(23$H8X?U
MYMW'X.VL1.I@U"S4@2'"#6BI4BIWSK!M"VQ\\S@:2>^78QJKK<E69BOSH\\@
M%6V"FFP66)XDSZ^JN]/4&-V "[U%#6M.J"3Y(I>2XN<FT4K!C*)1QE=-X>VT
MRN8N"KL0L!PQ/491>;&2*=Z/*5@J!*/<ST4!?+D%A+EJI0@I.CAW2L0*YA0[
MV$0Y!(XS@].KVZS"+,",$@*OU_-\X3*!IG\FV\'OAA]&:3F:33!,/=(X<^/@
M)[##)O,OBD/PE^&%MU\''BAVAZYO\S*YGY=%P0X?!=<=:Q63Y[.R3'13KA4K
ME!,N=B(RMUNU?)P2PX*WD?T/I\M.$:7H;AC,%6C,;BSLOBK0>5X;DY .L<-O
M:"C'X*\9R@,4A2Q8X?2FXD:.LBB=5.1]X1G?(H6:]57PB%E&"HI"B;9V5NH@
M3)?J%%Z *%[CY]4+U6>L4^7>K5-$YU/GK6./QPU68K$;UVEH:KDM-&4<%-_W
M4 ]S/,LR+ V %0D0V@2S)]282[$(MU;'EN9(-8/-;,%-O"HP*(NV!<HO&TUH
M,XP$/HA/;$:;0ZD70-I*RW+G0C',451 />9XCRWR, =1+-)YM]W0U6N+&'.9
MB7L1\=Q+)QR$9EW1HFDS>!YRU0'),KZ%\&T:5=-AMW8K /;&G75H5FR>@,5T
M2K&4!C?$R818B^H\)%+).V&-@*4QM=0^6XT..EJ,2_TT_ ?T?PX'-TJXJ=!]
M(K9', \W=1]M*\)1\56R* OA'!FE)^DQXR2FYGQ*H'SB&J//>7$-$O(BX96;
MQ9CB@8B+HJ2[ N[KED#6=I"Q(UZZ4++J8AQ+B&(C&.1B\9UP"SX:KE'\URR&
M_=2V^_Y\-J4&EQ,\:R<>3$805Q5Q*.4>ZV^PH8V^.A1R2[SL7CBHP]QV3L<-
M/^"U^E=1?E:-P?)OD59!-C=G@G8"/88921R&$Z%(^\%\8OD6&)(9N!%7M+.T
M@O/B$"7NS" !WZWAR,-0KL7/&KXM]"0>=J@A;T=L1GN\: *FN!Q]441M$S?$
MF[" C KK:JQ @B]AS:&V,X'E5J8JO>/%XIL\T 97D!R2)!O=H[9%<(L7K:FV
M=9/-J. <VW>QXAQ*^2-KPUOU7X=$N <KZ@.YN,;>/!$J_,T%@B1D^\K6E;;W
M\R!#D9[)K]?K9PP!DI]<(H5)$4P!:DF>*9?$7RB,H'MR\*&_SYT>::5(/T^A
M>2J"J>_\YNT6+/PD*<O+!$M2R<LG 012]H*TX%^SJN'56W7"YT(W64_@6NML
M$.%E-N)"T!'9<A?LF6O-Y2B]2C/6U_%,:\8X"J.&M/VPM:$Q\1S)FV&=1!]^
M*=<Z1K'+'?PL\1%-#5#+0%_.+@^EEXNKLKMC1/B8G.8HZ6DI?^"_YTX4CYPJ
M^%U.4KERE>0S\QCYY'K)F=\*BP.$<TS2Z4Q3:>4264'\%,D@'/N=5%R[+HH&
M.=B(L,X;KP*L*"U<1-O>&W/*)K7V%/.$5,@11E!KE131663/&!2B69;,U7W@
MLR:S[((,&ZK4H(N[-HYYJV"(NR.=,A2*4T5@Q4F&T9:DV*SJHK(4(SOP:1J!
MDN=HS).#K9+J=Q*)R9>D'*6286TE;XT% <^ZM8YMY?SRTR]8E8JG"R[UJ$R'
M7-M-MM!QGJ,I]Y':STPYYG_-P!##R)/\H9(&[D6:I16VDK(OL/9:B5QS_BVZ
MUW4TNG2<XS;)3<# ^@%<]?3[DJY?]Q*I3#/G-HN. #(R0N=R.@O#MH/W>).O
M87MA1PW<+8?!SVCPW]<6J3FKGU _,K5+B #$%J6;+@_RCFHUPQ['"$ @1=#'
M556 J.5HUBDHLJ JNA/Z:-9+*W-D2@?&$39P4(DO+DAR"[!\9]/4JC%7/T".
M>U1]I@ ^GHQ24A% .RC>+AL*N;T,)45VHQD-"D-3$Z80+1W?- /$$IR=@L;@
M=DIQM*.RY#2;J?FAXYH33LSE&.;6YC:,@2=5/5?61$M8LUSQ4>]SQ;X7^K%6
M-9&&9Q.9;;37J1"0BR>&>XYM;56WT1TY5?>1B;+#1G(.0[%C(A>N(1#$\[F
M6YE37&"$<_?JX )4':PYD=<OS'&1F7Z+E9'DA!]IBV-'V++P>,KEN'%R:<7>
MF^O ,BY,BLCT\.)0>R Q/2==&%JNU6X>E7![+!DR3D-5W<:7$7\EH@6!BXNO
MJP0*PVWR9&VA*E&LZT3*P6_5(HW2L.;)&6L-#'7;,N(2;2QM]F)-</-OTLD2
M4FCH<! VEW"W,(OUN:^D%3OXU@[IB*,=5]0J@M[HO"704=ZVR!"X<"S;]L*5
M@[IUNS@?-^9MMO@[01>^LNF+MA]4HG^4:JWR'/FEW![?'8N]+F$046$,'V0>
M(-^3RS9,^)OKAC?0Y>^T7908.X?2X<Q4AW==KP6&;B U"@AQGBC33O"4.3X$
M@HHJ4?#D)U.,S](,:$V/TX>C*[@5RG(MKEPK=^=3DZ/'3C"18N9T4T5BWJ@*
MN>R@H 2)+TTQJUMJV:!F:D*6HUE5%S&L2.F^D-2W5FT&9 ?!GS"N1O<?W"0L
M6*6KC97J>94TNS[,LMMJJVKS7BI-VJ6V^5,HJ]$-VEZL$U-M5CL;AG52,0MR
M4VYSA"B,^O(6I]*&*\$9BJ['LX7\'34V>#NGH^K78HEBF.G(1#P%KB31JG-)
M-=IJZ,8["E,-1NV?K=H,K;&C6TNV2Y!D57L]UHW]A*[X)(D,--L2\H1.K4%7
M*HWZG-S"<(X,T5H;*T3N.N6F%*&>AXK0K6 )CI$EJD:;+TUHG ^,W]Y&!EP'
M'?"S%.]?FXXKC!N*/:9U\5A+T)(HN26Q19J!D^7,,+>TAJ8?%A$@$K&4"$,+
M'BF>ZE#B:@4F?^&9',8G-7^;E*/2=WN]%9;OBAHOI+X+_@7+4*Y/M=/_KE*%
ME5,='$X:4:U6[38>AK9%T<@_Q,^;S!@Q$7S7#%9%-0ECE-63&16J4'T"Y7RZ
M/IP558780Z9&$%.B19;&G/".JK1Z 63E+C[#,>A8#*D$+HNP;(Z0A:(TIAO)
M/7]<)HE+H-MHQ 2QE"Y1'TS/48-]KH'#%9@UO<=9BO8+8^W?HD://QC.@>N0
M@8\0LR2)J"*HLAP\)L,S49P+4Q=+6;1[7*>%5ZAEEM]^G]Q+^35W2VV/KAO=
M>>^J&6;!"*:CJKJNFUC6W.PURU7+M2L.(S)(HF$ABJ(%+M)X;P.Z9+UD\KE"
M-=R&?$$'=BLN0%=;/)KG#?BO!@J##BJZ#\X#F&1-C*6U$JW+DN)VX(DVPH9S
MZ2)!P[!/%)VJL@?O2&@*.,&POITF)#"Z4<6HWRYN() -=@_"PZ/]<.?5@;KL
MIJ&P*1Q>AH>#0;AW=&#LL@5IKE:7A]B4704K#5B*8I'O;FL#SJV?<<Q5"X-7
M>WLA956QC%H:2.<_NAU\G'_5?'1^\:NN6^6SQC%KE(22I4F%T90B (] P 9(
MW&D/BF-YAJ1JIQR$HN=9H3:\<1#;6L$E/'<'"FX>*<X&L5S8-Y34\/*(H!M9
MDBL:U]T@@,YS&+U9'X2G+ITE$SC?D0%?FF;H&/"9?IS!"0QVA@=; W4A3K61
MX!C;653EP %,!>,J,2TI<] UV[<+OE^T6"N4K_(B2'WPJHP4[#PYNW,I\M=K
M/:8 7:5Q(,:#T\4Y;C#'0%I@6[?@[10&;\=!H'$7+>=+SK9SNBH7V'DQ$=X%
M3LQ",)06>RV$)1P<@1!X%>X<[75$@*C$(29"(DH+.=&<IL)"(XT54JA25$\A
MHY$:D(B8L-6OPX>=YO4M+C>E("$H ?E1KQ,>C7N+"?I++&)!WDD)+HYJ(H@)
MQ$2B1H8$7.J4[!R,!P,I.@5Z$[&GT=JM-XDC6G2WG)I#)XAP:_'\2IDI?R1\
MA&[3#YPQX;V-L"\IP4.H:JE[$?&)?&= S^D/"J)R3??  "RT\5KD['_/*>A$
MA:M2B]2"BW*;<RBG22%G5WUK]@-A2YWZ&8:I0PY9K] BN1#"R'K8V/G%Q=L1
M5P1I8U=H^O*)ENJJ+:!T8^ PLGY(0;19WLREF-A?8%JATIC<(WX,\8%V>,D2
M.S(JYU$YC,#!VGK_)0-G E4S)?NI6 D)3 B1A/.)C7"31D1:4:YD3@%O<<+U
M\GAFV%/E0$60'],XM#1IE'4:#6AJ;2<1F6TJNT2!L2>+( >*B6EAD 7!4^KF
M#0PF%U_3<R2@A3; >SBH-4NJO_1)]0U*JAL);>4"9P'S)".1WR&VHPZX/S(A
M%1''#/#H$.+!NZ*D1E)%&NXN:U1I)SIKD;BC/S. H5'R[E4V2Q"E1Q+A,T9>
M8*EXBZ\$\)4 @=&$P<#9;**2$K]&[O.=2<:5JZ/]X*!MG7-Y/5^R_9U]TXHR
M)]S)8I:/!_#)4/%:7#X9S\J<IDT(&+W:]@Z[%8I"6Z-4-5*7>TTL!?G[2(U;
MO0L@%8;:1HFN)B\4GC92 ,0*MIU1*%H?Z81A=P<_T4XT1->YFYQPM"LV&G5K
MV.JS]"8(*S'6XT"^P-IP/ \%<<+ +RLX1V>/TW(B+$@:V&##8*TCH1^KIHNH
M7:)9?=PFKK4FXF(T$X5,R4">>RVX/TOO2HOXL;N@P(8MNC-\?2[QS/,+0NH^
MDT)1'KPCDPGL;09[DOJS[(L1,QL#I)5.)\HO@'TX6H(]VW15,Y1#X@_'X+Y0
MIUV,P6&,=EP7Y6=R+9Q.>.X'PWBY!H7Y%+A/(0;*1R,JX[['"3! .1!P2A$X
M3'IAP%2_2/T*%*%'JPJAM\&PHDYX'!P62_$VXY,BAW'H0FJ8V!@IT<7)B9)B
MI;>HI\:3L;$BW3!;4<J#Y,[Q^FC7LC;V$I?=,8+-5].T9MD+5A66]H9<@$X(
M8$&95I^U'X)*I8*;)"J-K=E5QHK@X6#(,=NJKU>:0F,4S^,RFDAIU/W$!ZS)
MVGZ1XXW 76Q?$,FBMANTG4PDJ!V6@(N&: 0Q,[6&W[$G(!]C9F%DW-@RL:5'
MXOG;YYCBM&HYH%FK53$+VP"Q[1#0Q9 D!<)MRP0>6P)GCBEW1F,M?]#$7N/[
MRS?.&]M")IJC_"U6&#K@XAC:(:B_>>KP3*N1R#$4J4G=>&'[T;918V%LWK02
MS<TJPX@=V3@6<YAB($XT@U<M50:5ZT&9^@\QH IL&Y_5EX6="(5!:Z?H#WA.
M'M1$(VAGW$%.1#98U=R7,ZZ*CHA2$XR!(0ZD!;HV92;?(\[RC1) SO&!R*R3
MD:UD;U0NC'$DHE3&7,E<!HY_?=(6W),BIMJ*3X*IPD]YEY07^&]-4BJ"V^QQ
M&D6?LC4T#]XFPW*&P<G=G=T=CAS\_D]S ,&'"/T-NH7E1,M'C2U7FPY?%E]-
MJ-3ECI4,5_RH>2=^G&Y=Z ;#PODY$[H(-X>"&^#N,')]--1H47(H^^HRBBF-
MM<S06,KV_*\L>D44D.8C<T:T(]_;VNQ5^LYX4"0+_ LI$Y#0IW96$AJA-IYR
MX"]I0!'J;J0+0>"HZ"%8\:GZ#)_G4H8JUB;2M#L7%Y2B C7/G=LAF?H%5;S,
M"R!C,S8/V2HP7X8/SQ_EBM^7SEYS,TV'"ZQX()X%9&M@M/+QYVAP:5P<07XZ
MRNDNBB(V 2WK I7)59IPFQ"\=19II5JD \>XID280GE(^(P,)E.L-W_-N?!
M#,7\QN9(9"O"#TW,BG:V4IO Y1ITOFA"]<\&'0 ,K@3!FNR@& 4I,$G(>=R#
M.Z3O*B4'/EVZF'V=XW2X=]J.3U&@[ILI%O#A:"KJK8Y;!H6DS2EHK2%3+,!?
MIXC]'SIDZ'98^>8ANZ4\\\VGXC!QG94*76V*Z'H&%XGB,C@<S?Y+H[JL.4"J
M*2CEEIP8-8'1^MV=G4,V/B4LL;";0LHT>6'"*1AOD(7+Y:SFN*?5)4+7CQEJ
MCF/6#!/C$Q=,R:@^!288$80CN[I<TY5EA%/RHVP^3J]T^\[H<!HLSH5W0XH
M_<>SG6<!(DG+0&_S\Q1-;_E9GL/?P$G=632MDA_U'S\%/.M^L -RBM]0=LPT
MU\?PA_F40?+6"0T3QZ.Y+J/E1I]WYP<.ESW])QI];O,/"Z:^]_6$NCA\T9#[
MKSK.5HYC^:O4'A:_8+#\TVVK8W3]?5Z/S/-R=_?P)R>+L(")UO?^-$YO 84[
MN:'[_-MA,/G,[VU]?%>C>1@D$5:Q-IQ[&?SH-I=CMP^U2>+<);>M7H#<L.D"
M)UWS9#SZ0,$C,+%2T'AK!!1%;Y277224U)9G3G4Z':&-Q I*0$J2E/O<8JUA
MA@%.QS_M>"9N"$Q['5^Y;?@0_J?$_T'5 O\%[;.A2FAI$V!CE= #3\@KH8U0
M0GV_/T^DA$)IBQ,%(FK!-/@[=>;B&AK$SZKU=Y3H& Q4U(.(NE9J]CJ;2#B%
M,]8LRJJBX3'.NX;1(I!3*FRV/;##*/_L-<?*<;[7'%YS>,VQ@IJCHYR=&U1,
M\A%G$##:ELQ\G7,2+% NNC%3%.]3JH/0Z&Y!!7U49B'ZR33U8UB?0_TR"<#M
M!.CH"^]Z)-!&1Q^-BART4-V<%%L7<XWOY$AA0^:\#]0()=JMN:" \UL4;PT#
ME%0:C=^X(+0>4\2.QTM_8_!E&^<5:$D#0./5W\I=7Z_^O/KSZF_EU-_=T3O5
MB9H-UN; FB&GP<7AT1M'!W_3!%A#?UQ?"OK5\T[XJQ=:^F12QUB3FC%PRW-4
M"L:;:R>Y&FVHSNO;BDZ\M@7O?^$F],Q@(E,)YY[+'5II7=I37O6_/<4; +T3
M8(]F &RVZ.]-8KU5EY!R]0JU]B#8%\/<8/\XEB(Q(HR9I9M0/Z/V]3FSZRH:
MWXT5<F9^M91$# N:<C"V;>CS?HEU12C.-XG^POK;FX8G9E12JQ_6SJZ\RPO!
M#T^EN4!TG]OOZ>YFNVVQ>'=E1>Z<=U>\N^+=E;Z[*V>-(N=_PDKC8A(Z%=F"
M.<EPN[-28&X;%>*,I5@%U>@RF0BJD2VZ5B73@H\;IC'!D"3)9\$FCD;L]LRH
M+X3A'UM36ZE:CT%S<@$MU8&G_#<J76!'AD"$' 20EL_R=P$H&6,U<3*5 EVM
MDA>H/X8=>;7S-]PA*>1N!X@>YL#\T&+"^<I*[AF0K0L(L%'GMLGSW[,D^1^:
MGBEMG4Z[$ZH=VQXTQM+>X%C'#"$RC;L=^#LM?KG3X*II*<H>RGBS.-4>,:K,
M;I*B0;603NX WA<1,C2=%^QN(BUF/.]5.(9"HT[))"SH(LH)!I!/[4T"YX7D
MH(+4GV\$]@2' D3":2U&X\.M9B/L!$3@3CE9J8IVAS0Y_7!*#3Y>PJZ:.^%0
M[9QJSB>/K(W4=I[%*9;\J L#?D^WFIA:WKG1<5L5V_-RO<^"_'L:0H]Z0MX0
M6C-#:#7O3V_CMLW^NA;T"(5E)]B+1(-^0(3+6( (_DB26' P"],F%6$'A7X0
M![_RP,^2QPA(0Y&H!C'+&L F# :$W1T$;28 #XA38*=GZ .KUO-F<Z-WM!$8
MIT?0*(]"._DDF"QO=M_6[C8GG'/J'2_=_E(\R46SKA0SW$:,M:-/!P68-D7B
M/0<\7+^*)3](%AGN8=%P<4O:RMXH--KF=I)2 8&UIF@N,TL8<V*A:-3D+I6\
M\BU7/%MJ++-K#$0'7"F+1E#= )-.[@DX00CM<_,_N&F]1B-4X4E:G>H\V)(F
M)<*]R6OL*YW%+4CCQNUDQNSHDF\^VKG$W-\_AP^B\S;+R3PP\^U8B.O41G9J
MZ-ZF=G4+J +Z5@D:YSJ'@N.9*E482B)+ND$)<.S]!0]&YN%LA'%2-S#0&JAG
M=KPJ-YO%"<889=)%BV_ LW'$G,$?L4(. ?UD#D!QE<3F322O39 6*T& L1 1
M(BE-449:VB>Z8M(%&S"7"[P$$<-Z;'8J0QM/4T%67"70&#_+TST[A@_/H^DP
M_+8"W9E'/P3D)Y11ME<)S8C'T:-P*%PETXER<0O/\.QRHAX%M7F'IM?V.HD^
MYXQ)4P@L"[];T%7+@KKY"(@5SQ3>%O&/W*5+9[\(LX0(CEO&@7<">HOJFV<J
MS4K^#=@VN<:U'40:)!7HIK0#CT:E$16T,A-8,(^Z6"2E^% 2%QK,4;U=$!@&
MH6-IO-9'D%%/*)7^F,>(,3:1TIL:7!;R85-N<&+\WV;X)Y60+8,,*KA,G3 O
MBBMGWLA83LZ\F#%'TQ#Z"_\K !)W0X"%&BRZ/VR-"V34V A!A3T2J,[T%JPV
MFHM JX#CSO#"$9K%DJAGTHROV"YS0U6"RR0C:8A#)1S :03[2C*PSG_8/=CA
MM0#?9EH7\</13NNW@@G$1",1A[A?. 6-Z0TFT0^#G9U /O_"F0^7X5 (8R[$
MD8%+FA05QQL)7U2C@33]J" @P I[C(4+45<U:,NLQFATX\>@$@L0+-X?$:P6
M*.1)9<&J+-/;P1]V"8Q5 (S$0=^:0($ZQ?6"*WC7NK(D8CB[>7E-#H:1W1QF
M,P%E@^?#H-$$Y$->"&J5],X^_Y4RU]\3BOM=1I&QO-46*DJE.@;0D[(L)+ _
MXD8,MI76R8H5?=%1G6S9K@G<.X\PS^BY2QQWVP0U@0""\3.S,IN^>\.N4UWF
MV'5J'Z-[EF9DY,!N<#J7S46XJR6P$F?TCL""368Y)>LEH:(W/)2AEH+$3^!_
M,59S3X#,%*J78#;;)0[@'0&X3-'\B4V]LBU2MF"IN%=SK.>G)Z0&&J@QF'18
MXG0[S:RV%Y KX$IP"3+_.F$D5DGTD%9G")@XI*%"ZI=0)82-VW":(QI2"1UB
M+R'U>$RS]D(5Q% \[8[WIN)-W&1DADE2*QI%FB."!B)=.S/A7' %&I%$[@6]
MXZ]9?,$<"2<:P^EBM&)K$E$F3>8AC2-P2&XTC -?HN*RN+C.>602#0- A#8R
M0#%W04X*7WQ*=X'-$'W&04$& @W32]:(Y?<PP,U5 Q$;KCO&7%!'JO0@K%J)
MC(7X.<PBS"H=FW%=F S;-"FFS,HXJB)'/#V&@4.&0_50$E$:Y]K.@3G;XO5T
MGB\#]#0H$^*V6RY CE.(R(FI'58TZ(CFP$A VD$+=/)B4ZDJG!.?JUW'"*9.
M_PL9'U&??YWF>N@I+\R-/.&:/J;59_1Y,M4:=?2%[M7=(--WFPG],:5.Q&LD
M4+POE!40WYVQ)0WTY7PPL('%SP+T-N/I;H;LG_&DZ'EFWQ=9,61G%EMY\<1J
M$ 2UZYWHF B9OBF_Q8S.U$'^,QBCZCK@0;>.G-5-A3XS'/(XDJ%%)F_ :'$H
M@'5$=5W\&#Q/7W L@*)+3%/*[UO4=M*8N&Z:RR"S=<BZF.*\/H'S X52C/_W
M_SIX]1,\$QZ*SYH6P)@W+E*\6$ALY[!-IDAN_*#G-(>')D<7A,EK;Q2\]3T7
M1?!',2YP"M\N)N#!GQ1;[Z?Z$'S)&SB(K)BZGADM_OWIR9LP^!DQ.T[+HM*/
M?Z"IA\'Y93KF\#9\].?3#^<A_@6M%ZZF.)V58!2!^#D!*Q$T(_GLXO>1F@QP
M F(+U=5&T9V3>&'."@_KTAE 04P I^>BO<*%<U'L*HL^ J:NF&G\0'S9\_3J
MA=A)IK$!,Q$(5(Z6-]A'-#@+$;WH17'*NCWY$BEPGJ!OTTQPIH&FRBC1D(#Y
M@RO;#LZ18#:<=&,,M>?(;UI 9'F.5Z;RL3FF!BMC)XF"^7(H27YELU:F%@G6
M\5Q,:.T!)/,%+BT5N#AI+WC="^<1- ]SK4#)Q'>S8,MP-Y%9@$O0" <J\ZW3
M1"DU@U9\B$#+D=,S*0C3\ ?ZKL1**Y?,US:J6C0G<K*4<3\<FG#9EUH V7D\
MY9"@T6OJ%671@W&Y3,*WC@0*69 (ZK&])\M<"IW<Y:@EJXD4?3/4/9M4FF%*
M>CT-$1UGQ77%)5+3"%/@A)C)3AU?<9*\-!_9Y@'IY#FXUCA=2D+,P-3&75T3
M<*8"^+MOED&$L%!@!"(B#MHU8?JYC+N9GJ&Z)4N^I.CV#&?@M^9F_(7*&#M6
M8(51G#]%7RB?YLA+R2C)I (&M+],,:5 "(5DD# A6$]5FDYG &SX6C&R0PQ!
M5@VS1$01SD;!--2,8@N@NM*H3'5"EFI0))!A13>H8A8FF*A8+Y?GF#@1=.X[
ML:%7(_%@$(AE ((.?G*/C/=O@5#LA9!OX1A'9.3KHLQBK$G(S>"IL'VP*D/(
M?+'F2GL$C?:%FU=UR@S)7E<)$].U@-HO;1I"=APR#8\(NV?<X-_"%N?QE#UW
M@HJUKC!>,"-<:-[@K:/M5H _,$2HU2J4=>-TN(M++6:#+3@9IE*HFP>"C$"*
MKFDGL:'->3RX8^6%5"R#MD/+'/@!IR>F(\>0+8L;L&1N1$@[\SQI A*;"F:,
M!D@3GC.(ZC,I\6M4+Q-:"]W('!/]4=9OK344;<-VCPNL3V36*1*VYHF8Z>]-
MXXO1MR7TE!?MX!O6BC=DXXU-;4E.5/%+ZPZF<PY:"\ DE3>KM.K 7369@V#H
M@6*DRNO&EF]4$\,3RKH!!M^ZPR06&J#-1D%J+/3:&3KN3$CE5W(UF4GQ ZG'
M8'F@ 924)B,IV;3!X4_R'Z GL#Z-L70'SHEY+_\1GT5BJPZ]FA*'G9A<]JJS
MPVTIMO)+8]@5IF'(#FO0G^)R>6+"@0V+A^KU-2%*E)&X\QQA0L8;YVH 6^Q]
MRR13SK%WV$/*AET>_8H+IN,6Q^)QH;!F!TVQVJ6N0DY.K *7:#+ 4-PE"KOK
ME>6)F]&--B)B,?U8/"\,\S*G,Y(Z KM@V2-R=3*ZS,ETN4J+S%Q0[@% ;L#Q
M($97N0K/5(R0&\?C2;!ZQTP7XI L#CJRMY!,]8J@5A@SOFCKI#;^Y74B_&LN
MML%IIY2YN/6:&25EKD4U[FW1Q"E[*2A(Z\L;8[;*!*J4F/XZ(8?':7# Z']:
M36<Z)=IY(KOO&-)73)VN*XC3[Q#6&6_AO T?"G6L6 RED%/N$VL.APO69P:M
M(V<T19"Q<H6EY6[KB@Z,,AI110O5AXZ3F.)3SJT9J5DWXOHC33K2Y\6Y^3J#
M^&A[L-\C7_T4L9RDE.,37+P/.*<ZQ^"3\>:TD.,YC@1+0-*B.8&E&2_$:"[R
MK3;,NB1,@;$SX'O.,+I5(W>0S53+(-CMR=L3EDN+B";SP]V2X%;1CX:!TER_
M-_>\QH-("MQR'!1C [L+KV*DB+H<+H75FD_(9L]G0_32@[?R<MT=.\DFNH33
M8Z,2VYS($Z#5J6T7!E@(H+4T\ X2R%0PE5,E%3@0PYE(6=@OZ$G7'\?(6',-
M[EGQX50V)N7:>6B.H7U(IBDI$XXDXT<P5$L&67&-$0$*VW"$[ (NC8/33\.U
MF^/2)4) M,"/-2K'M5U>9G)PS(\B'<G<X/)%=-*Q+B"6_@=Y Q_>6E!I!B [
MV)C$TWC"'67\PLTWA,E2-OPA>GYD#U$W!QQRR8L!%H^F*";IL]O!<??-L831
M69'M.X2+6^H^ +LL.)P* :!#01O(;EBGZD^A3"O%)1]PBV*2RB[09ZQY\NF0
M)('4ZD^+:W:<,>I$"^;@<547H\_FD-Q]NF#2C&==ZAWB5YA2,2+8HN?@.2XG
MOVAJ8&-BD +B-"0;.THXY><%H?=05IX&W+>&1,$?@L%\^^E#SF?^++HVBO[D
MW$ 99 :,]L\J7B&%V?1V\;V.:B,=N+XCU%9)-4!L#R8\0R=1E6B>R;5<*YW7
MKF-1^XUJ1^A )3*SN[,[,$X<3I?DB+*T1L@$/?.-J%&D[7S+]8R:=YG&F?(#
MR*$%&5>1J:M*T5$/6DF*_/;A[=D)<VU:C6;D:;%&IE#4NA4R#%:SD,$/#'_
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M9\8\SB;NL>;''&X_*YVY.07F/,EFU%'%X+0/=EX&)QB:R>'*E4E2A\&O8-?
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MN2690 MEB,:S#(L"RA$78_%R-JCR^[T,HC3!.^I9D(IJ.STR<AS_9L]!L].
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M3G"8J9_S_H@ "6,N)!&KKFD?B!VO>2J.-IK9& S3Y)P4Z@[0.@QG.SCZB5Z
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M5SXIL==9^.1A>_NJK?$KFQND4#-F$2EJ3 4TY"H4.**F<NLJ0>I+;@1,U4@
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M*R/^%VSJ8/O5P=^":(BN]J]G/[__B".^9A7-$N8YQC?LZOU[QK&[O6WXO$D
MPN5(I_"'85&6Q;6!-JT7KVZ;7\-AE H==]S8?\[R!'>V%^+R^)2F19K7+HP%
M'8><*06SR+OAE A[DV/8)IHZN+O;[MMJJ81N&V-M+MUM)I2Y?PW_!,-0/ LB
MCZFT0'Z$5\&R<IF^.KIIS-*X %.8Q3-F,A?+XQ68-/?Q/G/E[KF?IQH9Z=0&
M)*66^X&\&:<8[N-)4!R]X4H&D_E"Z=L8(8@"X2T\+1CL;/W31+)O&26U@]]
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M+V#N5;;/4VPN&;S*?O;Z5;@[V.\?:?P-Z049O'[PW+^Y9/#ZX=GKP2 \?#J
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MO O@QV@GD+MF,@,-G0S5X,KAO)OL8D,=DWS5P-GAR;TTGZ%P^2]L2E;Y7>
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M(&V1L8 W-Y\!H&\$--JV3:U%2$*1#C3A"E3>DQU+).M![Y0*:]3@<_&AS>'
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M*R&![:T9-%ZUW[U:LR/]S2-9?S3X<'(&3U&G[:S9B3MK=IZ]-3M/JZ9@5YN
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M)N]G;XWYU7JV/3\ID1LI9Y3P306UP;S01_B[R$_WX93R.TJU@P4B:?2#ZZ_
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MOX6C&J^4Z!@EOK$P):E,Y.>E@:[%OLY.\9SFY$X]!C\_66EQIHCC<=E4ZF-
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M*LFP)U7(0\9L_M$V#V<V^F_@^%7UPQ# M)>[\J)U4*.NM]B^EAJN.E<T@'-
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MN=N5;ISF2P7&8D;:G=/W6Y0<7BI5TBWC=&-BZ>8"'^$2-&K\QH5[M3GEMB*
MAZA2UGCG5YDT=*,#\%D2^QR6YRK MK<T[KH12-/5@;)2TCP&R*@$@^M*4"=L
MK<396ORU<FW.$JJ3QBE-/OH:J1A;P?;SU:^Z6&P+6!A,L,P5K2%":<F,Y:P>
M\V?3>J1)C&W([.YD]ISIS'?][64'^PU*%9FVXY4^B<U-D,CP&QSAXBX6V!S
MM#,+_>OZ;/46*0=2R253TT7'.$#-*.#9NKTXS&>CP&]HN*'A6VCX61-Q9*HB
MK;YO-.]BR_X%NJ.>.XVCM$)I&X(-/U(P$<>*Z0\(M"'!A@07D>#5<Z9 CF]A
M6RDS9EV*H-')0OXJ72)L6X4DP8Q,,6>L%PVL(7^0XR2PQ<F\"PT,CLA[.(L3
M\5(9CR0.U $ 7\:)-(36PW#0:G=F9#C#S@NK8_<//:K=_O:25 !\THFG0O%E
M<AN;3%0!^H1S%E$$G )I^F.=M^+INBY+'B%N=T#-\]T>_Z8?LO0E*/5!Q78&
MU K$Z4:.+CQX&B4N&UDH'@'-R2*+OQIQWUO=5-?^13<*XL%[NN]K_?A1=!.J
M9 9O]YOM.V"<%=QVJGLPU-U('$19R3OK6S\G7:SDN# 0<WI='L"273HH? M/
M$\7>A<^J91BGMM.5F>0A,Z5]IZNB]"^A0Y8VY3:V121&NE#?\"SHB<-F5"K1
MC25H'-5,30+ "CO_!O8)(NEX(>YJUR%7@9_QXV%?=]-"4](W;YC(N.&C $&W
M9LC\K^1Y'3N]+A!K$-I1"KRET-BLTLE%9GWCWYP]]+XE2-/%$KAJY@[?!.8$
M$@#?E9Q2%)%L\6#10O\/S$ 5'-'SOV@ND3ZY_Q6 ,[KY'H":QC3,/7$@C/14
MPF,56SMS=P8#MIHEI'4U=]G MAZ6!=9VQ"D!L0ZO4F6VY#E"-"9CM.BYJ*63
M&;(B(YH4]Z? 6J=6%<;%3A7D/:&6J-)4BD"N*Y%IXHO8>^;^F^V;/^V?#4^.
MAUX/_C,XZ)\-CG_SNL?>X/B?_>'YQ_[Q.?S3.SD[&!QWS_[M#7_OGO6'\#._
M^/#WDT]'!_3=3T?GWOGO_<&9=_+YV#OO_@L^\<_!\.1LZ'6'WOD)_M$[[9Z=
M#WJ?CKIG] G\7O\?G_K'/5BS>WIZ-.AU/QSUY=,?O;/^4?<<#R1?[_;^\6DP
M'.!4MQ9N T?_?7 *QSWP#@;#TQ/^DW=R2)]><.@67*AW].F UL5%9=_!T>#\
MW_A=XF2'?8!%]ZCE#<^[YWW:XNBDUSVB<Q]U/P^7O_IWM'+BA[Q[@Z^[O/GA
MH">CBS>X*]-@JL<DE6.>=#_J2FA]-3?*3UJE+D-:\"WJ2.,$+9''4@=I.S .
M^PSC?.*(>_/<V'Z0/%N$E(RI2A)N(KLP:$H"J' N9OOP+XSHT&*<,L:UF#AP
M"/B0J-',K6D1VZZ(G$6C/#,-BZC;NY]$- :)6D<[#1B#&A:VZ=60G<VKAMP(
MR!9Z3#YJ=-"A >. M9IZ'4= W;7,$I">R"$$O &Q@M0!TD:TS _C^.N.GE B
MC:I4@.[97TKC@1J'R^.[')Y]"A;( 6QPFGEON/\N<OZ+!,T\D3D!%@"DU U0
M?K.EQQV2(<&MTO$/VXV#LZ&WAMY6I+=7NR5ZHWZ4J;?E#&V(S9"'@%N0Z[&F
M.+&;NWEODU,T8_U-6Z6R%&EY8%V3^EDB8ID+;AI;4F(:?51[2HM?>+J^Q<_*
MJ &. T(:J:*+@S+$$JJ]STRG9ND[S("F?O&L+M_V#1M7HL0N"A,70L*4?JXG
ME^G.XPK/TP)%'5M\P^-+Y@;_U.+>Z>+&WAK=(#WE:OLI9'7!XTQBZ<$<!NI*
MNGGC.#"%0TF-[89@H_$]10,.YT9<7/*\LBMV-\TP9;@\&I=C=OK]:%')--7N
M,;%_W.71 +N&,Y&AF*JY3VZ>XL(S=/N/E.PZS20P00,T:02'CZ/&70V3$T6O
M+Q7AAIBLCDI* .#MG6%JK<K!T7^I9]R@34B+P\IBV0+*7BOMY*S5?^T$63NE
M8YIG>:+8A9O%V$:7<$VW&!9ZP&,:%[1+*EZ&ZH(UDXW^[8=CJ8C*4^V$G7'C
M,#.GL,Z!;?*,;7[D-,2!M/@2IDWQ*+QI>X?R>]>K?X<M:&WQ;J*C%&X[4N09
M7FPM. @23.U32J*B1)1"]N63C]?A!&YSCXH5LI6JFH!(8.8A]I8N7>K?;(>H
M4G_]N[^G?D5WW)";L(MN"R/#1'FD=?G1V'UA)AM1RDOP%<C]$N=1:WKG2(T3
M(T.HM[T/,JC:N(?%#LO8M7T5AU<<_S'5 #5$WN+T&4##2 8\8&R)V[=:SL!/
M:*FB]D3$AR5R4/E;B8@VF3&OYDTC9"UW_>)7+[JP0+REMQ"XJLY-JP5R>3M"
M.'<O/!L%<<=CI>AE\9BI'B?/QRLU6U_A@,6T#X=_NR>>*26IVPH'==OH@C^*
MKY0>N;852.08O\U$09>5&YKT<N=\&$$3R28\8(+1R DU7C,3477(V2:7T8+B
MIL"8=1 X06MW YPHCS#^AYD*V:?5 &*'L)S\).EO_^@?.K\HOXBTD3?LS("^
M_%0V>"D#0;3WI2@6V]Z J7^%FP<,ID6N7?DJ#AY$?8&&FRX3"I5GH&H87U>
M3/T@T4*&&:N.&E-$E>0R7=HYL@2NBGYF"DZ1C[D4D (EP"@5[B+*0#^-J?TM
M4LBUHTV1&NI0*R4U4"%!5M&A5&TG^D4PJ:=WNJ9YAFN-KF:J:Y&694DZV$*<
M=[^["JRJB @/(3BCOHV1\HPKW)' Y6W-^!AZOIS;)Q2>U*>1PIA436]A\D%+
MLTB6(%:[U .?H_\+RHOB8GD1%7MP^)A'&19KB682T*Y%%RWDZIE.\0T9AV#K
M*S\($5\V6Z(=8H"FHHTOTCPJN.2^5ZOX>DOB1A1H)ER]'VY6A)M!S@*CJ?L8
MYVX(%OM+,'7+#)9HB>#0ON[2  K?FX/&B3Z)Q34RK8J,JYS-2!I'B!1ET[(Z
M4>HZBHWTC3A@_HM/*K\H=.TR>%UWA%FQA[%!?=_,)K%\^,!YGK0D7LRK$$,K
M()A)*+D@%).I8GLR#HTT;3VWC:>536[?9Z(%*N6X7,;H,C+I:9<XE'6.G^2T
MH((@%D]0';LOB6+M-%HL!2H^%4X0*J,RL#JMC>!LMS)A--54:^2]?/;N6VX.
M4<%AZE:&'%%C/:BX\9@'R/F(G3><DUH_TN=NE-64<30TVM#H+30JTT4M&8IR
M7.?&;1E=J2"8S>A@<MD$29K59P*@B@BJL&_,J59M/$$3,P< FO8P#2$WA'Q/
M0B8KC>T4<3!6["O*-X:#**9:/4Q>3STNQ%&<'@^2SS &@0L*MXU3%)-^R0B:
M^S<S,T<(=M"'"&;<3D)\WQPQ$$6[$JBEFY#UP>$"2X-/,=)Z+K& ,-#I[13<
MH!=.BT_,UDB!!=-3 ; +3I1D!1MY#(83.XGBZ12#%I@4#]P^@G]BYKE/SX.E
M#8I#'>9!Q#R\H*&U6S@R'A?B3VY3CSZJ?M"M:<B"7AY$LF=Q9(-,I&QYZDJ1
M!\:O\2DN6]6N(9&5S?;$<&S!1),*(: ET;96,3RCOK$K1<>+R8,F\^:%W/$D
M'!%[:OFL^T\JG[5)8'T?*>1O2/OE0<D45O*_JI+'K#R>=EJDH-H B!5X)6]E
M %<&[EOOJ2PZI*Z5]D*19[%E*H4<OFV"R-).<=K2;8[X@YC7XN:X4&PBT 5+
M[#'#NAZ\#EXFI7*H0(++Y?-0L99)G7'J=.AL/\>EHY6_,/:3)*#^D1E]I^PL
MO+.KWD:4,SL$WHT)V)@<#4G*D\+]V][M\^'7GD,50(9A=_\J#NJUL+C6:Y@:
MEPO57Q(TXZ5"$J2^"7TL\NN647MIP%=DB5LWND@^)S7.Z+;63TYN\:#:KR"*
MPSXW[H+<2YC+YWPXC5X5TSS$34_ 9E+3!9JT"Q5VZ/R0XM_Y3ABM3JVW/XZ8
MFP *'L;:86O;9:WB#=:9)^@8*QU<^ZR1$XQ!E8HFONCWY<"\3KW ;[7$$""O
M.1QR(F.K@Q1S):7!>8NNJC,O]UZQ')J ^--KDR)N=I4LR[;7C>1TPG6X+#P5
MJ@;U-!H'<]"Z! @$,";L .F<.L\62H(!A9G\U:3MG>0EZ(18GTCZY+&?3OS_
MM&SS"4K]E,"[>:1IY17:7D^'^R@S,&"62KO 4:A H;0)>S\257D0TJ>,%J46
M$XVI.M6!P,H,[[+T:7M]OQ1R*?%-S(MUN*83W]29%8NI.'!BDA2<Q37HASO0
M]V:KT-T";&74_/*8%F4J<JA/<0^B@L>*D(W(1&QF;9HK1$S;.'E,75AUE;)(
MM&H>Q"UVDC!4DR8I:636^V9:/-0YU/W)GSDAN<T\D]2KA8_=C0020+V7.@AX
MPVH&50GCC<VWJ0Y^HG2VM/;8+[C]TB.N<CQ[VP<'9,M#LY;XE;U/P-;X-1-0
M%-[8Y\UTNU8QH$O8Q*8RY0N2[4Y6=-O[C7_],+D1*[A7K4M7S'KX-1J&$Y9Y
MM^XL&];',(M8\)V0.<$<0\Y(HF4T-5I'0:*NXJ_21"+.Y3F1R=M6?0-4F7 R
MW!EZ$  IAM@*9:Q,R]'!V= $WI>Z)YR\#T=3V6A6Z.1H+V)]UNZQ8*?L).)Y
MG(ROU=)4YS8"?:AD!]0+3B5-C:>!4O4%V!J^8IJ4OL-ZS*6:I2K$[(#%.F(A
MT[O>341=9<*;6_E\90CKXF2*2NX7)Y47,S!+7E?'>-DJI3=N5_8.")QBY#GE
M9*XY:,=?.-TW2ED%Q2=RTL96:9)R9P,.;5[CG#+J")^8U3$-[+1..:(NL8 0
M,:IWOD/03I(6688A437UZ36MLIT566:@'FH;2A<R<C:;;C\Q!=D)"\;>DDXU
MA18R+=9-V-1!)'8ZP$B2H]'(R<,\#>@I0/!35LV9PHH=W3+()*.Z/D(_K6XK
M50&T+"@1M:(>9':8)\ILBHL4=^7$9LIC9Z^(3_E+<'9L&*#;&1G7=-TFBY \
M45F>1-R&@-3_>*X,#T!#1--MD $;*D"(NZ:@.C@Q_<\3/C".;@\EE8A=];:T
MQ647>-^T>F$2SY9'XL(:2*B',&M!",<140R#!ND&F3-":YJ'(&0OD,Q:M\%L
MD0J&W3F3Q=WI!7+T-B[LW%QESMCX3@^08R<2[0/0:O&/#Y3:Y.U4\EPWF\X_
M][WA^=G)\6]'__8^G?W6]TX^G4D_&>P&<WY2ZA?C](KQSOJ_=<],:Y;!Q]-N
M[QQ[LN 21/38CN73T#LYEB_;/C5#:E0#GUO4K*8[]#[WCXZH'8WM^^)VC.&^
M*)^.^KIA36&#6];?Y(8P=RHOVN2>,>2E$*WL'&C_5"48#O*&5L)H#6V+&G)-
MN?H),T*W*[U7+(063=]8J3*L95Q\Z 3I'?96ZV?O=J<I,GK'Z)?O63N_LG)A
M2>)12P!#?!;D-F7!V4)8[5',;N:L[IAMD\C*=[J9R3W6L!GF(]1WO$-MZFEH
MR-\OPGA$   =Z") Z0%OL8/-TR8F]X:_0,GQ<A*V!.48#*BL=!*M=<LO;,5-
M5 Z!B&+KJ"%I*1KC+P(:8X9$EE.GI, &F)-"ESU;**'/)=5G[@,+FMU@AC;7
M)1N+A':@=&9N9*9A /<W;E4=6Z;/WE9Z>*[;X'*HWH)%@[TH_"IS8$H'V4:M
MJI:&:JI(2]2$T%AM-OITT7NDRPNOJ>*:8"3E_-SIA6]&Y;&PV8AXPE5,OJ4Y
M6H"DE:+*AP<6\U B8?PJ[CVIB7C(#PF+J"<7JWZYF;'J>MG5A*K?Q[;6H%@A
M[D9\*WB.=+Z:I*5H2*$1OFZ56Y#!PKKC"?H=+F.NX$3Z3=TH5$9_\/9V;0>%
M'T3&]P73$XC^?E;U[1S0NF.V_= ='7#-VQLZE-HB2(FDG&=AA21W0RCNCF,7
MG"UY-F2HOK'SA_4MV[>%SLLUN#4I 28&B'=EHS4T/49+B@5F-T29.S^*%BSO
M4PF:+SL] H,23 )L%3B=HJLI*SK!2B"N[X4P()579E')R_L%9\W"'M@K27%2
M V3<YV*1K2+"']&;:HK(%W"?58Q\Y"0%0[\NWCB/,5* -4[P,5A*/!!U8]\(
M!3EC89&^2(@)H*<:Z-J*?.  EX+%%!31.>JJK$%5$Q,7E#H""::J" Z3+B#8
M!#S8!%06']ZI4EM8X$UWVUQ3>:$ZO,EF\;#H\G>L =W& %]7I+G384!+\"(@
MYGY <;F%00@GPT/;:\:F+.4$+:D[K6:X.9AN^S@7XWE\MCS3P0@M-9#!C<?Y
M3)K6F%ZI,E&0VKJR-F):HC!0%G(QSB4!*&W;IB8BB9 P38<<.D;M?JMN4,SK
M\+,2#*MV%3M]674I4+T+N+;G8(63+^]Z8W6BO4685##&2FO3_-WV@Z_W]]LG
MHT=",[>V[7;AQ*:INTQDPMX_V'17.')"VF0QVU_0V*;?E"Q4HY96._S8[RQI
M\%-U0Q0<PKC@3&5.*R&$Q<+3.,:T1AUJ4>H<;Q4&7P ;*SB2[J''5>IM:V+D
M<MD='GM3/6$9B_0J(H! ,V3'C7;>FY?>L?7-)E?!*=*HI!\YT';<YF038+VV
MQI\J9W#C'O4UF[J/FTR'\#.CNM=]FLX]KP"O#%C4F<K0(N0.(HM!Q('&ECK-
MGA,LJ-+U%&Y+K1&&J C)Q\I)U&$?4JDRIG0A2=6($ZZK3W(>&RKW6=3TA@0Z
MU\=XG-PRA85P"4#@C,"JGX@/G9H6+O;ZZ;+/E\]I#E2,B8N69C(IK$O,-$"H
M K8P[((23)DPRIBO&R,6<ZV0ZL@RN67=NUW7AM=*-T:VJ]UX9D '77J1J,-U
M-6F6<[QDA7J\=,N=IS*U(;LI2&<_O02QAPG?#R"R\7\3U%EX#BXK]HL^O%V@
MA]HT*8[8F6,7$:C8D6"3C6M,S75FALA $4<..RF[G&Z_F \Z:*/;@6*)UD5L
M4,8J*Q&@[!^.QN'D3Z%\X4ZCZ,JV&RY3^C+JR*97@,7U8)10N==3U#@U'@=T
M3AX+[W!1G3)2K7404<*H+NW[,<V.8O]5^+$@=JWX.G.0#HU?7C8)O.@ UWQ7
M#R Q@L)>8;KRBVZRI30L).5I#:V4G%=&%WP(XA7/V)HJ\/[ZHL0[0K62M>\&
M@/1.OJ/\88.Q';1TZC\:5#0C;CR\+!5QJMVQ)$1P4)OUM155T>IP*DE))F!.
MM>)3F-=>HZ.MFBLLP$,03XU%(R<J0]^!<XN4+"XS2)57M UUD8;1ALXQ(;=Z
ML0)S=@5YX:,+^(5E$NRO) W:SIG2+Z<S9@L#+QTK;K.EHZB9A12%PNRFHJ@0
MKZM6PMU':M4^_"*MO.#=U[JQ8\[8SJDURCH@4<:*.L8F3/2W:GLL3&PN=J)=
MFC!>M!"E-H?'N^E::]U*%;O'F59:HF^Y9NU-G--Z$D[Q64%D(@/$!#!@$(6+
M"<;C!(FV]$>INC&]+75[*)/-NB6-?Z7-,IGN/$).AGT!K53:'[/-;5)]&9[+
M,ZS/AMLMN@\]L%N;O.2=R\A13 B1;QC[8$2%-U&J/?/N H(GDBVZ%!]2E64A
M5QV548.L+/THMP!=QQNT,8Z!LL3.#*('* 8!ZFYLNSD[9ZX]IP/=56VSVM3[
M!1S_J07-7VUFT+PI\%Y:$5MTX52T"2%GS>5=+:[0'[6.%QD26L),:@ESI8CS
M>IL6@T(6+:5 4:$I5E^-O^9S-E"E"]L&6Q*G3D\::SY2ATL?#=QY$F/+:Z>.
M0GKP9I>B\Q;3*LC_RI.LW%KB'3WR=@H:1$3RN#13U''*)H4*D:#N)3CL+JYY
MY\/5QZEV#RW;%90<XN9=&&U(?5.S.<G28!Y(#,>V%-59 3Z7R=5M7=Y*ZA%D
M0RIA,2(409\%4QW%C_+92"7&U8^>>SW=UDC:I1?GNK5)3GU-0.5"Z!\")+W/
M.^_,%:E*PBIGTG 3;[WQ3JT/58@(V'R;_L#9J77.RQJ 2MM;K8JCA[&V(S@5
M0NIHB5A2/A7S90M-R44Q.-OX2".\9 55<(N. W9 CG42U48#QI/MTA.J</ J
MJ/#F2<3JN:A(H+YNLFO(Y=_E6)56$2TODN$2&\S'>V[C!M-%^C*6P=/$VD%O
M3\G7KILR)W80?,NP:R4=$+;KTH*EF*?(DU=JIM%RN979Z]M8S=FI;UM&ZZ:_
M<U,HO<CP)(^0#$FGAF!8<B/SVYV9RDQ;CN#A;L^X+5AH\$$IGP&49P[Y]MW^
M6V^+))K.,1ZB%4G1TT/!GD.S8)>P9]L=T+ZP.$B"+Y5GPF(F@F"!'!=3;E7T
M 6-2P,]H0KCA;M+0H<BGC$5F:LOJMEA:)%4)_YH+FEK$$F^R,S(JR*-2F[-
M1>>+:L4J]4W O_ .=RNGJCC4@\11\6*0A!>+;JE3MF3:.;+DNS3H_XO8Z1TX
MSKU-C3\\G9:TP4P2I?PT1NDLVH"9N4RB6E10[R*G?F^Q2=V!VY,L]J_IR7__
M>-;SYKGV9\T3G!\_5MJQ)%K&"+EN=+%MY[WZIK>"];+ AXN%G8!&Q(/V=G?^
M\+8H$\\D=)8T8W'BH%Z.F9,!-C&07,D;C;M9$A/Z8AR.XT;;%8YM%,:IX.G
MF?3L-,</@6@HL*]):<P5EN:SY"Y.,C,%@F-?-+O:#V_T1$)0D@2@I:JO6\Y%
MK0EDVC0IWF[ALDT#-%484SN$2^9FFW821L6E@#'F%4_Y;WPP29OF[-/K),@
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MV;5MWY&B!L[F);$>[JEB/KG=\BYH"@GEE2#S'1??1_<4)G6<1P"G:6WQ.K)
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M&9&+(XX,Q["M[+FSO>YG;UOE]W.<@0TX\"E"&!'28S?\:OMA\\D>("@\FW=
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MOQ#M/&?&M;?;?O6VP:TJ;E6MFV7QHD>WP1'&C_IJ]"RO;T?/1X(6&XI_827
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M$W$\[Z6!E4%D94 ;AS9^$/BM"@ ,^>U)A5X\#9'\P%-VS#M$\KQG'2)Y_B!
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M[WC=W08L'@CV->"AHX+VR:&%1+Z:SZ"UNA7: _7"VX&0<R#&L6M';.39+\R
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M7'L 4(%K=\6UC1UR[1M$B)91J]?!M84P.BH5 OM6)JQ6I=:@#<UM$'./2(D
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M*>S-@(=B$'C2L42Z_T3K,Q/_.W;CIT_TY$B$"3AS5%X8<,:0+C98(B1@ $'
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M^CP0G_S+>"!"]CZMU?C 7+U</]$3L''@E>H>4*F<%56<<*U/@<$K_0%3&C"
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MRV:C!<(D9IM$G08($[9?5A107XKF=T1@(+D^P VP_;*B@&0*W$ $!I+K ]P
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MVKO.O\91K$K$+T1\V;_ECUE5E=OV>#B6'R*<EYYSXPZ_+Y]AGC^M9=3;#30
M)F;O:  ,SU]"LR>* G(SY&9$8""Y/L -L/VRH@!NV#PW:U5SS\V0197 97S(
MI&81+2^WG/X__5#(2?ZW<-@]=WTF78-\^!\BYCU/R.76BUDD[''HQJZ(Z!7Y
M(JA!:75)44!0\\:$%^OCH-<'N &V7U84P W@!B(PD%P?X ;8?EE1 #> &XC
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M7' :!^TT0)BP_;*B@/I2-+\C @/)]0%N@.V7%04D4^ &(C"07!_@!MA^65$
M-VPLM'56WU2?H="VB3S6A#Q&S:+0NS1_#/Y;1+$<N*HB#>67H6O'PDF[F*H5
M'AG,%_&TLVG$?KKQ8" \1Q4YL9@_;E]RBG,P!W4"H_3.BP0*B%,V+SGM+-WD
M>#UUA3H<24I-D\#E0L27_>0'9T%XRQ__J1QBX"DXB-:<-NM&L]["*1IBADK4
M@X ]8?ME10'LN7F6OW1YR3/RG%U:,L^@)(AS42+ .5-JQDC42X A8?ME10$,
M^7YSBERZ12-'BGQKP:FVOZ-YWJQ733 G,2/]0 \ D";,OJ0HH.@4C>N(P$!R
M?8 ;8/ME10$)%;B!" PDUP>X ;9?5A3 #5N(;4L7[V4LMFTCD=4Z%B0R8J;U
M(9/"4_0OW7+Z;^3:4&6E#X&N/^6^(W_G'Z7?!J&<%1X^I56GTR)4=]+UU ZB
M.%(_^<NF'L(REYHD=9U_C:-8*>?1;?""0#Y7NSYIO7JLGF'G+9";1JV1W=5A
M.!QT4,=22N:SB:* .&V+HMMU[W],0C7YZ/I71$MLK;IAF@VC50A/#9]! 07P
M)6R_I"B +S>7-3:ZK"5GMEP[MZD9-1-]7JD9)U&O <:$[9<5!3#FYHRY[D4B
M.V',-Y;9KL6>9KUJU&K(.*F9*E$? OZ$[9<5!53@HK4?$1A(K@]P VR_K"@@
MMP(W$(&!Y/H -\#VRXH"N&%SW6VC.PC7T=VR4LMJ1K,.M8R:@:$+;/X87"Z6
MV^HR6^$P'K$1#W7AK5R<T=A+2G7O0Z'U;WH5[(A4<&Z@I"@@4MFB!G5Z%600
MQH^O%Z!VHROI"B_[QU-'V)WX0:(EJ9;1:K1Q[(B8E1)U'Z!.V'Y940!U;GR&
MKEI=ASEUAD^..!>[OM; D,2,D:B7 $/"]LN* AARXT845M4D1)%O+$==U=("
MO$G,1-'S%<ZZA&9/% 54G**O'Q$82*X/< -LOZPH()T"-Q"!@>3Z #? ]LN*
M K@!W$ $ALSJ,M$D=8=UF9['>T'(M2C]YM),'"(YJ.,+I7=9)%  I6]<FFE5
MK6U*,^=\(?'J3-.PK);1JF57H DG<M!.! 0*VR\K"B#0S:M/:EM4G]"AS\4:
M3;.%)J'4+)*HJP!-PO;+B@)H<G.:K-.BR3?6::[9=+O31!L$:J9+U*> 3V'[
M944!)9QH#$<$!I+K ]P VR\K"LBUP U$8""Y/L -L/VRH@!NV%R':^Q>A\M&
M/:L;)J[<(6=P:"*:/P9G02C?S&?V. R%;S\Q_6>>7I_TBKD1GZ"$OJ0H(#[!
M$1,B,)!<'^ &V'Y940 W@!N(P$!R?8 ;8/ME10'< &X@ @/)]0%N@.V7%074
MRFV^Y]5\?E'>93P0H2H,#\5 ^)'[(,Y].QB*;T$4I>KZ<2JNWZIG2CZIZSNW
M,Z6]Z_QK',5J*^Q"Q)?]6_Z856FZ;8^'8_DAPGGI.3,N4S>M.IH,$[-RHNX'
MU O;+RL*2,N0EA&!@>3Z #? ]LN* KAA\[2LE7M:A@2J3(X";37WC<&??BCD
M)/];.,R3:YA)MR ?_H>(><\3<JGU8A8)>QRZL2LB>J6]B&=04%U2%!#/X-@=
M$1A(K@]P VR_K"B &\ -1& @N3[ #;#]LJ( ;@ W$(&!Y/H -\#VRXH"2A??
M;[Y)UGZ^2?9]*J#?3*7SF<[^.W=]M5U&KQ8QTM9W-+]Q9C5,-/@@9J(?Z $
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MLWK L>WPLO</(,C^<C=:Y09UCN%C('TJDG(%U^"AW0/I4 ,L(130),75Y]*
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MW;S!.85OQ;?KA!.SA+]1_W@+X."E$U@C;(=>FL;T_QXZ$514*TXC?^IH5;!
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M,KP6TV[LT:UM=1I79E/F&]V%6G[Q:NF]*W%_;;%'NQ.-M[[[=%H'I3?[U:Z
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MHW$]2U0-3L.I/CR-L$I[P@,J61;EVBBG*4_2O,R\5 ^-->(<RP?X@Q"V& N
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M'=ZN9/+BKOJXNB]!-TW5?3<F[M.*%>,G/8X@*:]VZ3H\WPM^*C<%J&,)JO9
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MK,OIDR\[\;0:[9V;L*_,YCRGC<\Q)7MMNZ3#]@J3S:@:@^X16^(_J]?ZH>D
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M%D&I1PA(7.#+$(\_'8&N%RPN;E-2$!1 -0I#'E#1*W[?3RB+K=VX+'Q 5:K
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M(H>VWIY;D-+K]6K]P="8A-<J>VLE>%B5\]*TL=AN(G$LME\"+2VV'P_;!T?
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M^*M4>*<WNM\@V21X2IYQA"S;O=Z?K[#5L[%_=8! 4<0:!#@X)'$^_9M9!8
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M.PV&!+R-% -",1I/XF/2F/G'JS:P@=LVFBNPI.3WR! 2OV?H?*N'@?LZ,H7
M#+'UN<]OXQ]>L\A<:K>CZ5VYW+XS)6'V^JW^CN98>\6BLUAPC,VFK+]^GD8U
M!V3%GLU<'E5N+@,;8'&H?O_QJC-ZI4!N?5]K=?=K*G>&,[-/ANS^G"QL7*%!
M*MQ?]GEID$;Z-E*N=:!##EG8GS[(T&WEZ?;G<+G58,'^.?2UQ5E5&46(JQSB
M:DO G5FF:?.*BMFTDHK9:G.Z[F:N%\"WF#5"WWO7#S;HDY,++R%M-01O'5NP
M3$J>E/REGL _/-?W:Z3@_W0\#CNK%ZK]H5O.I@[*!&MUAC6"*X*K2SI9!%<U
MV/0GX/'&CO_GPRN5^HNHP1C"-<*UW;@V;'4'A&L'QIT\;EH!(\VG*'\N1_-1
MH$I]#4F6_S'Y 96KQSJKO6JZR6T\2='-^/46#MV[WMS%_&M0!HY9; S:Z4K!
M$)&NE_877(!'Q765LFBT'\!3X=QAA7.]7.'<2E+\.SX.EHGQ20(#WNJ_U7W+
M+V5Z;*20L]\5]8(Y17.93O$RO[;6T+2>,F5^VU1:K326JLA">$YX7CV?",\O
MDFT5-W8A<%%<S1&X$+A4SR<"EXMDVZ^'>XO# [U%PPAGH8TM)426R3+U F_E
MWG)8(G_07Z['A4S[B3?D(ZHF\;^IQP%"<$+PZOFD'H(/]LMXJ3>"DWNH"A_4
M5',$+@0NU?-)/7 A]_ $=XG]=GN7=[ATS+)NVO4X@'O?(78Z??(/51/YLG*S
M%&A1<DULN7=G,^X9EFZSN3[G'G4GJ9HCZH])WY;@6W.=I@2KLB;84=PB*RP3
MH\\U/*TDHRO6V-]082MIA8VTQJ _I!GL%W$,JM5BA/W*L(*P__)91=A_EO ^
M(=+UGBU")&5808AT^:PB1#I9RMA(W92Q2GW4I2/:'Y$3>A'27SA]C-#^^B&$
MT/YB6)7-+2.T)__S(IE#_B>Q@A#I*EA%_N>I<M(ZE>:D7<0M:/^FO%(EPOQ+
MR$\K9[;X^ORTC?/%CV"+UL:G%6SI=@"KBO+EP0UTNY(^8IOML%/PX>*.ARI9
MM(?VI<PPKY:&VL46#93"23+B,G<(@[.FM%5:&C#J-4:CCC*E 9OLL8WH4BLE
M52W@$/8KPPK"?L)^PG[U*]8)SM35H4?#V94?',*W:^$EX=O5'M,""7(WU2?(
MG;X;VJ"\0BNR 93,<:L<_J^)"X3VU\-+]=!^S]YJA/;DS5XT<R[:FR56$)RI
MR$OUX(R<U\JRZ[2S9-=5?2$[[*@S[^E2,%]*:2RDE<VIC?+C?@]0)N%5TWK:
M?_,=#7[/;/:7M4?P3+M[F'*06=MVGT$FF-@1\\,9+!B6X[, _GSOSN:ZLQ!V
MZ?"USPS=GS+^K] "^80-^$QW3 8?^,FCCR<'DND^<R?L'3?$H6'=3H/!P6G?
M(C4/$I=U!-M/GZ49"%\9\4JN5$K[/UZU07-P&R</&T"%Y/?HI(C?,PN]U</
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M9+V48[WDQGN>PWJ)WIHHU8\IG5J&MZ\U>GV:3JZ<=-+MMV(T)]&O.QL(-(N
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M:4:[6HD"!,67H-\)BB^&503%IX+B_0?SG1^*=^8AE%=*0%!\"1$,A9,3%.?
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M1'58IS$:$=0I)U-T(5\U!V*G&[Z;^P&\$=UOC(;1Q?L%(1]% :^<#62 %#%
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M"3KGW;YNHAJ:&ECU:T#E%S:W0Y]]^OCVZW?IM,3:$R.;'NH&+Q5\B0G;=!W
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MX])NW+3;C:Z63XY>/3*-%<,ZLJJ/,A!S-?3'&8BJ,"/+ VV#@;HT !M,#YB
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M+(?+A\-R9_I/+I8P"3T1.].?X9-^]ML&0I);;&,!W^'H>I._ZTF4<5IQI$S
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MT1KZ6!,UB<,MG+<QF4&L;CA.BGL>&7QF <^M4IP3K;&,E;.4B..H#%S^Q%P
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M>SAH%:<.[=KJXJ-A^]1W.'.(,V;.]X(WOZYNLUYRE#-M7-))>KC6==[#I-#
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M="=:J!YK(>YLQB#X_?]NOR0@6.+SW;Y_X$ZED4!H1L*JH7W#MRUL$;$BGF3
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MP%['?[S11,%O$U9Z4]I6ZT2G5SK-1G--_[[EQU>6AC'W*2RN[AF6^#S1L'<
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ME1966O@H6KA7:'DHGQ9NQEJXN;,6;K5JO?Y0J6'9Z%6N'M)[)0:O"2T/S'$
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M/10^O*P:*7M7*NSDQ/LBA+_Q%XGR;?G@VFPTCT!XW8N&R7IF7$9JW/?;^FQ
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MB0K^L=?(3#QV09W.L88DI>6R^"!SP# 5W1H$N$7EU [0[:X^>O:5GH]E*2N
M&_CA5P0H 1,^B*:XFWJ9NX-^5<748-CHKH?YJ@.4Q9Z;:?%/X339TDX?R<&R
M.$J+A8@1)0E2I4"O.I"H.$XW[<.N9;457B+8#IZ7I.B5%C<C2/7W%> @FQ%>
MLIB=(7RNS&CAF,N"+[$,G0O.A)=W3W*F[L.7V[2K0;9FHWC$;_> :J%RC4*I
M/(CZGLR@+]19D0=7 0WTTWZ:#1^5=-W85:%M<JRD7^NW2V)Y):'5!"'D$I7,
M>-_-5.AM"%T:]"H1<//60K]$<<4!T61:5P96.&PU<T*C>(BD<**%Q['S%^T
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MN6 ./\UY;/RT=\%/4@Z7I";/C:=6F9]]8$0M\2<I11H/HHHKOHJNO$EQ&U@
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MR5>1J,V"=.0Y5ID:(P0,8OBO1-4A$0$K@6T#)D!=G#_+UVXVVAO6+Y^ :^1
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M!QJ48;.+89.,Y/'\\/LRJR81EO?P)Q>5(I?QT?/ON)S\A8O)HWO[O5JO+\]
M'R45))<*RME7U%]=-"B=N(M.;)]4)Q[ TQ_4.FV5P)>.\@[EZ*LL_D&R^'''
MDIT;R*K<O1SZ4D4BKQP-RFS9I2"Q5YAALR9)\<$UL&G3R:OZVX-:?W X>T6)
M@W-7]:M<_94)X(H1OJQH4'IP)SU8&!%S0#UXR,+[0:W55&I0.HJ38#9,I3UV
MX,,X^2Y?"$MYZG+@H6(R258T* ME)PME^425Q<;7WT4JX>AY=;VFMP]7+*@8
M_]P^N4JI7YFHK1CARXH&I?%VTGC+AYCLIO$.D#5OU=J]H=)XLA&7.O9^7OA_
M:SPTM/=)>3R6PL/_X/DN,)EO/].4C]!PGVR<G\&G@<@7LU)^NAQXJ)CPDA4-
MRFK9R6H9;%()^!Z^#$+;3&3F1\]_SR7E?2(H^;V'F9#:&O94UD VZE+)<R5K
M*TGXLJ)!J;R=5-[PI"KO(&Z\WCW<@3 E%N1QXU46?0_X?V'PAPOKTBQ[/&8^
M<TT6U-!?=R*$BA9,#)_51T; +)H(RMR ][BS$M\_F( 0&!N.HQ+Q9\>GK/'P
MBHDU6=&@K)T=3OKUFYL8.XDD?9\*TOM8C#Z@%'V'0O0N(T,3N^@AD: G2. /
M>JI5OG1$*:O 4,$!1?W518-2E[NHRY8LZO(P88.>.C,O'5&J,_,2((%* '#,
M7IS?Y[/XY(NIJ2" ''BHO)"2 PW*JMG%JM$W+$W$.3WLUK5^]<"(2*YA>WGV
M&7NDKW(8LM&2K'RN?'=%_=5%@])RNVBY]E&UW)IC\6GWUH'2<K+1DBS]Z'/^
M=3RN4D X-[&2MC4S? #E=?OA'T7=/7:M2]+XH6TXYPI39>V/W3!TU5)9UFCW
M:F15<DZOK*C*#^O="UU7S6K;&T";=L<30C<WC/=]1O8>R-UORG/T<",ID17I
M2E)<D,95N% *5J%**=BC'QWH;]IW;S\-NV$'OLQ\V,/%')2FE?S(P+Y!H54Q
M",N+\,2[WJB.OGWT0L/19K[W; <H UZ-F,O&=O@3M060H39@A7VT(;ZN6HK+
M&L-/D85 +56_J[!928OJ!_G0F#>FCHO*J^;3[8VMY2T$Q1BB=UQ4'R9<,=#E
M2=PL,Z*6ROM*28GS2OS]U;'"A=*^,N)2:=_KU;X[Q#J6]S/<1OUN'<OHMUM*
M#U\$394%,WX.#8 ,?&O9SV]C/'Z*ILRWS>T D=OWC]F]Z+,PIWGV>6P),!<
MM@JVAXQ#3)B&!X8,=_[7OPR '=\$F>B#QCC+45 BA$OGS/ U!MNPM/?,9-,1
M\[5VJZ:AG5NC9@= D)86>NNN;E+#!)]1DX29#[SIPW8UGSE&R!^0MDC(?[ND
MMT(X,4+-#F!G8=QG 7F%%@X;F47^S L E(9K:08\,>[$X(UIJ70PP]JN-Z/V
M"D&F-]]\?']_3W^VWOQ4@R>. Q9JHSF\*]DDC4F$]X@PCS;VO2E_Z9C!"PP'
MEL1GG=(*+?;,'&\VQ2X383JUH<&I[S TN(*T5W%01E^9\"3F9U]#3RHNI.S-
M9RK\J;?; G 3/][2S'@"F@(\_5DWQK"CUX;S8LR#&^WG_0&\V39SP ?8HVJS
MW8B3=J(<VZWF'Y;IAG_H_98Q'HW&]=ZXVZYW1IU1W>BUS;H^&(T&YGC8MMHC
MKA_A(<RZ#1<?T.N.QH-^;U3O-X=ZO3,TA_718-"JF]WFL-LT3;W=Z6RI00ZS
M^:L0JN\C'S2Z$(I<NORSH?WB/3/?)98V7!?L!1-%&HHM$@:W( 4=C4O'-K_-
M]$!H^4*^B1FKVHL7.58J5T FKK"QOH]\QP;9QW(F5K[YXEWZ%I$R^L)\9&W@
MBA5&5N"'5-&*&_J%>4]@=$QL,*=NO]O!'R9L+_3GO[Q;'0K1$PNLKM^\U8NG
M1G]L:(\3E.J *\=XT5Z, !0*#9728*?_B%RFM9I<_^"E3$,@@]+0V'C,S# 6
M[R:?58NW+PAEEZ&^&#.?]!8 V0A >@<HOG_8WG@=EABO]"K0?_3?>_>]>-EF
M%<"'@'*]FX"YMT- ;-!<W-3OAL-%TZWC>"\&$'*\*=C.+<(O'@!V.\4EGG1_
M[4&C+**V\(4&@L#![9,]D">)YWA[FA'O3VAS]I\(-+5!FSJ5+CZ1$#ZB8:D9
M)F$R*.2V$-KXHV\1D%_L<*+=/MQIX O9IM;O-+%?MN#-C%4J6!11Y]C&R';L
MT$;3SF= %:"_I[8+-W C,9JA\&13%''^/-NR"VRQ\(4Q;I>-;1>68),=!I>&
M*+_Q^?@Z?%" DF39>Y&$X-U3(* (EQH%>#L^-I95R81L?K/Q$G#)_P)4".M
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MMOZ]JTV9 687VN 90X6ZY_;?!&5)R[Q% T06V$#> 4)$,YX-VT%?2V//\"V
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MF:813#+$-EX9"EP2UN\OQ@+?1^S1^\HH/OD%!"F0+H\+AJ"H/WFN<)Q6J/_
M#Q_MT '=?P\RZ=FV@$\2U0]/^" V?,OW*Q2[>#_<PL9H'+-?P>RS[MT0K <;
MW+W;(&!A\&[^F_%OS[]SP/E+GIF26M%:: T+.8=NDECHW;QM-HH3GI'E'00?
M1A,HB( ,#U"WP>,$+WB&?Z^+N@83,-Z"'*P'B[#&Q(GG/H2>^>>=,4/F?*"[
MOC)T59GUT?,_DLBXAQ>C:+E<J-]_^K@JU?-VV*HUV\5R6Q"AH-8,?ZYQ>-:
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M^?6_CHX^'!T)#/[@,CC"?Q^<=P='!\<'OYS\*A#>N]X7]QDYUQ<"X?'3NW?
M]NW3N_>SM^\]]PGY3R=O9F_?_#)#[O&;F=C2<+F.\/,\<7[P?F1-!'D)04&
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MH-XAPY[@1;Z_OK@*T\BL*WB)[[ G\,H0%+S$]]43+ #2O#MJQ7:_3^AQ\\K
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MUHT;T3(S/2 )/1#;]/IVTPSOZAWJ#$:TG+OD(DJ?BPO;:F<LV@DL1><%FB&
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MAYDX35S9[0H%>P4\MK\H/ G>>K)Y?4D#4+"6^XO/HA6/>M' 3C)LB),GV,C
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M)10D./SD[@Z/A/1Y^,.XO$QL/RC<7_K=972W@#'JLF1L/K=6:^/:HGX\0KZ
MV02?EZEN*@OWY?IM7Y>5/8^S,C1R-!#K0H?$F,.N9?0VO.;LBR@'.7H]&@=(
M^1!$]17/416JADC_JJ%9PD9=6?JRT?I2"!2Y.?D]J+5;'F@_'9YR4^#+:!6'
MD5O+JEJ;CHNKGR).4U/=KV*CN\Q-7)>]\-1V^)SL1\F6T<+1UZ,S=YC98=6V
MHR6?-\0!/R((\IU@SF)R.8GD?6TM-3AH</C-45K!V6EP". DB14\UR\(SZV
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M7.B2QC9:T:+D$0Q>PA]!2.V.<<B;&2H05Z^A;\'"!LK/7]_ $AK?90MOPGP
M!N<W'CBK1*YT=Z=L]*].=*#,6AIV1IMTPP=ZL\Z9E0=;JMSN?/9,^35V(-0Y
M\<B,AAR';@P#Z<:&;!:("Z-#":3N7#HTH?G4BD\YDUG(&TFA@B,IU?CN/!1[
M(E2TZ-N4AX?0"LG$<VZ!6[<-P)L(ZA3NFL#*UHY8U:0TQ8)F!/AP\ -/E))6
M<=+9N5EMU,5JHJA5O*VYT**08G3U]F0R/]KLR0:*6L5K4:Y^!4J7LQ;D::*D
MT6M4DD-0@/Z<B&KIF'AOO %G2@B'QEEF>!J-V')4 DC3<FIXY@P:%S%=:GC.
M#'[4-)A3AN?)H'&ILIZ-+K4H:!OL:YUJY\CH.HIH/)I\8*-+)HJC(A+K,+H@
M(G["5$:EE(L>]A^,O2<V\VSJ4BM)3JB I\6(+*[%(8=E)272ZFIM\[9K(=S#
MTG=)9Z F89Q3/DH1KIAL$WI]S6WNR@U((G7R19HT*GA=T<H=\9<6SPS(,+5)
M (^ZD4.]^0.,9<(+0#D\@0"&7OS*)0Q3.^9P 91GEKL[JVJ"WQUST28RV5[D
MIB$8B9?$Y_5$;[S0\N;TR96XQ+RUIOH<[O#%!1C -&QC@!>)]2G4Q0(0!GBO
M/,OF)0R2-:8% :L(MSE*[[,A<P-_!@0,F$6J)6 ,I?#^XEN\))3J*)5J:@@=
MFOEK\, D"$@8_&JY46(DNBY[X8F"+?:R4&M]PE)A1DPR#XXKG C$7V_IVA80
MPC;\(XBL,WC:<N=]+S'G-E8%H\/2HK& -K2*T7'J]@;5KD%A=(!:'9:B(8F*
M20\FX5]Q+DGY$:AH]5M!JBV'T^@0M_K,JXY1&!WE5@>F.6JE'/ON/]:[9]OP
MD9"6V*4D:#OU%M'<D*.\,N+HS';:\!/OVF"2G'8I:$W6VC1^Y[,5\</UG0O&
M(V![]4=$5Z)GF#%446&=O0;D2]J+T>FG$^"/[+MT+>5&OO],^&CGI1XC2RQZ
MK-K"4,0O6A3 8*I9@G*3@Y>^;!D<1/N]09<8]?&QUQGS7V#%#3(741656M+M
M3.1)<C Y!A(_C;>I]-,5>1%]%@1;F*EIAQJRJEU04*37])4X&PU[SPVIZ>Q;
M0.*O,!TC3KN?[E*+<@\GC+W'R2\^#!0E65(*_;!?&#>"A?>%2?7O,HE*6Y).
MM]L[1D>.V\"AM1#Q8*(U$JC@5UO3:WW4KG9UXZ5.D1H=&F[&1,1H>A-IRHAA
MT63F&IVNK(:+NE-D=."W5?!*W6VCP[_89:?ZCC$#TYL5QDA-C,SH:]U55'02
M"56^J5UKT/\BO_(3>C&I*S(GGDV+8>R)Y\&4+SX:!,RF_#*@?])PP=_R+1N9
M\-TA!P/9&NA"0DSLY(OE13.@$?G0?K&EN-C<940>80 3BU< %HZ92-%$17P:
M6Y"[AT2>9J=<"UX@(D^S2ZZ%;_Y $.V4;[$K.Z1)=L4SYJX-/.U6I5!FM?<K
MSQHE8RI@&QD :QT7L^^^Z 8.@^^YZ 00@^^TZ 8/<^^O:!F/HFG9W445Z0_\
M_Y[ ]__[_P-02P,$%     @ *$%^5/ID55U20P  G[0$ !4   !O<G1X+3(P
M,C$Q,C,Q7V1E9BYX;6SM?5MSXSB2[ON)./_!I_9E-\ZI*KLNW54=V[OA:ZUW
M7"6'[>K9>>J@*<CB%$5H>'%9\^M/ I0(2N(%"8( *&FBI]N6Q41F$D@D\O+A
MW__S918>/9,X"6CT^ZN3-\>OCDCDTW$0/?W^*DM>>XD?!*_^\S_^]__Z]__S
M^O71Q=7UMZ-3/PV>R460^"%-LIC\Z_W7?SOZG[.[FZ.;(/KQZ"7DZ(+ZV8Q$
MZ='KHVF:SG][^_;GSY]OQI,@2FB8I3!8\L:GL[='KU^O2)_'Q&-_.+KP4G+$
M__?;T;OC=^]>'[]__?[XX?C];^].?OMX\N;#Y\^?CM]]^K_'Q[\='Y<(_)%+
M<53ZWV]'']\<OSEY\^N[3Z4OWGK^#^^)'%U?E+YX\OCQ(Y#]\/CQ\^3#9]][
M)./'=^\G'][_.B'>R?M)F5,Z7\3!TS0]^E?_WSB+(&\4D3 DBZ.K(/(B/_#"
MH_N5I/_OZ#KRWQR=AN'1'7LL.;HC"8F?R?C-DFH(>OLM7"D/7DF4\%]_?U72
MWLMC'+ZA\=/;=\?'[]^NOOUJ^77VUW%:/%#^\L>W^1^+KVZ1_OF>?_?D\^?/
M;_E?BZ\F0=47@>C)V__Y>G/O3\G,>PUO-06A&2])\%O"/[RA/G^=$B(<U7Z#
M_?9Z];77[*/7)^]>OS]Y\Y*,7X'BCHYRU7FQ'].0W)')$6?_MW0Q)[^_2H+9
M/&1<\<^F,9G4<K/2$1OD(R/_+UX8OCI:$OY^=[VMV2!*WXZ#V=OE=][R!][V
MS!4,2"(VS5^/R<3+PA3'8\7C!CFF,R^(E!E>/MT[OWR<US,R>R0QDMGU1_OF
M= HD8C][)*\++>'XK210YEJ691JG+\#7NY.3=_GB_)<' M\"0W[#C<DF1TPV
M&OM3+QZ_3E_X3K!Z^BWG;/WQ*I8P)%/OA49TMLAIWZ= F&U.YY3M1L$8?AT7
M'R:CR0BTPFU7<AJ-S^EL'I,IT\XSN:%)TB;Y'8SQIZ8QUC5>5@,LWR *& &F
MHK6ODY>41&,R7A%A0EM0$V=VQ6Y(_:TYGJRFYL1+'OG\!'_CR?/FG*.W)$R3
MU2=<PZ^/3Y:F_U^6'_^Y-BILLG1&OI%T-'GP7M95&++=B,:K#T/8WD/NW[23
M>6M"D%$Z)7$%&TR3*A+)T;,JVO<('+XP^"<9_Q<-F;_Y!6PGXV\4W1,_BV%R
MD^0T#A+XTP7\&CW=DCB@8YWJZ,Z#]=EQ16,2/$7G61R#X[YXB+TH\7RV+&%5
M\M]"ODA/QW_/DI0M7=WSJ0L'UM4'7)P^)FD,#.O2QQI)(P+^E;!C!1F?PD$.
M#C;?,N9_C";W8.7)*$N9<\XF]YF7!#Z\DXL #B9B?Y"15W4$(^)?>G$$@R>P
M-CE#'>1L)65$(%@?8CIAV-]XT BS^8 PZ2]?YK 4R!F)P#=!K:9:$@8%X)8L
MIC/P=M(@RF 2"/_FC$S QA5<DN3R!98WC6'*>_'B&CRBY!N%OT8I>$[ X--U
ME)*8) I*Z(D-,],6O,><638TXW+Y/E%3N)Z(N<U"BR1ME Q-[GP**/"_]:@A
MAI])[B7DZE);2G4T[*X#%4]#@IB9=;'.!'9GJGS<"./G-$G9"76I-A37V\\:
M8?F><//]!;;!V MA_-/Q#$[[['VSR+O"6I:E:$0\%OWV8G_*_"KR3$(Z9TM5
M0:H60D:$>0 ^1Q,V4;Y0.A[%]R1^#GS0:,K.!8\AN0EPQDN2H+&U,YHP/M@J
M6'*2W,-9&;N*ZJB8M5V;ZUGIZ-=.S- J>B911E;.(AOYKT$Z/8<S-AC8^/+%
M#S-V)CM-@+>$C)$G?B7RS8)OQTK9)S ]0AB;YD[NUV7LO)W1^F>-J/\VIN/,
M3^7YK7E0A=DD3DN,PF^;3,)'JW'*2^YBF4)I9[:%P "9_O-=_VP7QOKT)9#R
M,^J?->-GK*+Y#]YCB/,G-IXTR^Y-$!%^W%5BN?3T.MLBIW(:^VN4P<E845WF
MSB33P?DS$S"BS8PL!Z/U&H9C/HE_?W5R?/+K\9OCXU='\SB@<9 N?G\%,SM+
M@",Z9[Q[;%B>*?R-A0+(2WH9<D(PW<@3^T'\/:1@N7]_E<;9UCO4JXS*3&.C
M<M:G)&U:*X5JWAVWJZ9/*2NRZV496RT%E;!A0M@39X1=L]":9"U+^MZRI.MI
M_1HQ&_8L6KO["QD_#E_&>H],B"EAO"R)B3//2NYQH8;WM@V5+C5('(8*H3^\
M<UYH^8,BE3O>%L)_=/^-*PDO&:T0>OBPFWIH"44)^3_MIORR <9"$;_LL#58
M#QD+D7_939$K8_N%U+^Z;_GD]CJ)3(P0VGTS)Y^E*NF@/K-6B/[)_86M*/I&
M.E1([/ZZ5I*X+8%=*."S^TM<20%2LKN_TN7,6Z_U)T)=[OL_&'55U"RM1&7A
MJ-T0=:.J3 CHOMV3$["UZJ\0^<1]2R<GLFI!I]#$KM@]Z5)>(;K[-@Q;\BRI
MCRZEWH7ZWKEO-GI07_=6@T*! X@>]C3_JI3AOAWJH(S&SB2A VF#].]O-U0
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MO,F4AN/KV3RFSWDH$"]'(QFE.7+C/:K.C:I'[5H0!O&*SZM*D;,KV-E"Y=(
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M>@D<W54G9Y<A#C=6]2'PH&^L.E09[':5P6XC$<E6&1PN23I<DE096T9NH,X
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MMV=[C?JRW?#L==A*W=BF!XN<VPREIS-D3\$ZD3]AE)"YE^XLRE>3PPUUFN8
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M';,;.LX>[V&^D[U:R]1[/V^A\1YZWB,[(DQ/R>]W@5C[&"9815<AZK^R><(
M4 Z@%>@7W@R;'?Z/$'&V*?-YXZ6[*V97Q6C5OVHBH#TI%R_%J@[9\(;9W84!
MS_ ,;9N7NT,PL.DQO!LV3<SY]LSKG;'A+738SJ2.ZO3NVN&5LWD0G-QC+^AM
M-%LLK0LMKF .4+&\$-A+U==ES'IA%MZ61 &H[@7-$=6%"PJ2\9 W+,OYB&;5
MYMZ/.=D3^MJ'!V?L U63!U42D':/M]JSUUW$NUU:T@=L]!SR'&=TRH%9K&F^
MHV0LZO4-D_5PSZ9AQ@LLRNS =W1'"-[^\;=A&+T*;EA#D0%CA([A88^_9$YS
MNXV;:Z)^+H;.>17T;O#J9R!7U/1N>_J[WSG3C<ZP;G!2E\49DTF_?N_19^U"
ME$S+PXX@3](LRE_Y76BRO?[G?WK[A_?_^N;[MV_ /LK!,V5[ J)#^819;[ 2
M@P@A7(+#GGT-=M%+NCOL0(9WA!+BGZ [=$[I[?N3-^_>G_SQ]V^___T;^F/.
M"$0EN( QI$W-P?NW)X BP68O\L6;$T#^9 _C,GV&Z/5?P=MWOS_YP[_\[N3-
MC[]G?_/C'T_>_?']R1_>O*_(I45![PBQ"U"'LBC)%W0+JL%EX2X;DZ:'I\PB
M-#.3IC^<\2O:R]0+/DL2UM A0C=1FEQEY]$^)1L"':<>)&%QZ;&?I(=;@C4C
M0(L'GJ89B#FO,"Q^"AZLJ+- H4!'*% FX"H#YU,H>+M_?=@=4%1"<7T3[_9D
M+02S@L3!JRS&.WB-"_I4>[.]CUZTW$27M-6=81U67B[?5@)4=VYE$4#*9 C$
MQ0PAQY;Z7AF\Z!A9<<^XA2QG#RA_5EU@LZ5E.N>OH5-&:0:3RRC/R%*GD*2^
M@-LT3C5KYTQ3LRF],D7=KW\FG$D8SJ@!'-978?@@"2^KV(&*'Y 1NYA";*[T
MB%U:Q.W.VU=F//1WL".HC.9 W.<^?.<\0GM#;G@2-$#+WROC&<Z,OHD7XQ/G
M3".Z#1V[XQ.IH9?AMJV:I6P)RR(79SPY]G>8?.8YL#/6Z%7%=S0)&K:^567@
MI?.MR/\4+/]3)?]J_G7:D#?'#:'5K3:^V$C-LS04E42ZB?)-SOJ=)BP+=P-S
M)J5A;GN8G),\Y!!YCQGP.Y$!)ZRG\I0+)80G(>S/$8_K<@5P]662*4J;''">
M'"] N'(4[9\ZSQLR1^VQX;RV8?7AQME*@P*",>"<%SSJXZ)=L9,DPZC8)N'$
MM622,U@;9Q1<Z.O%IC_<'2LL4!Q&W&,*A9E\8=,<I5HY1(N.0S0DNC.XAL0M
M4/_HPVO,28[T%S(V(^ZBA(RO^MGT,( M0W:&E;X&2=C47>XEZ;C4,CL&J9DH
MW=>9TSVFH,&*^IIEIU;SOM=]+-K]I$V^4Z;DX=)=8RJ,0R!V,J!Z/*Z8L-2,
MM#6L9,9%7DHF3+[KFB_Y$6UCDASBDFP 8?Z<QO#L)56Z@SW\67W=#M'RTN&&
M<F'I8,%H63.>A !/J2<T=:.VINDVG[,@4PQA,J=1LY0U9UY<X%V49IJ6W4?
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M4IRXC&_V,K@W1EN9W,>X1B*>KR"6M8OR7R%/4R3PH01%+5G8D<Z9T2G$.C=
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M8Z)+!"A&!7*ZB(M%_4ZRXZ+1+(Q@M3P ?4%P>:EL@VLH(W 4M(5-DX54-2!
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M9W:A5IVH1:)1E8F'YKV'_1ZQ4QKB%PFQ+82+0\Z.3+.F$65]&9Z@&W!>6=L
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MO'Q<AZ%EG.C-%R$%S6!*8H3A@\9X8UM=KPU;5 73KZ#A#MKL SH O8N?8')
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MS MZWZQ9]<2X9O?&!1T.>HVP_)957769RQO [2JI$%C3Q/$9GN4Y+0&^$^7
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M_CF<3]FRK( )VRU8V0UH"SUP^X0S^/HIRG^%Y<=#EA3ZK]N&*)C;0S]%]\&
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MD-@JK4-:7;&-'E+$6O1HWIN9)&7SJ'J4M/M9OF((RNAE\NATSNE>%2^LJ;S
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M]/,GQ$H644'J___3[YU$ ^_CKH6#UK"]Q(/'YSB;'@Z&J-C;6#_5X,&@8*+
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MQMVBD8+C)8PG:0R%SMJE?\P:F^J1.$J.^/98Y$644M%VMK/W"1DW\T2+K/^
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MDT?=G!>O+C[:VIJCBS!K!>E',3UW*U^QX*V)C[C\B V@76.JT9)Y:?&T;)$
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M^'=]'$X]MR)+F=U$Z7%+]^W'+$YWDYS9A.P$>])GX\_E*T_GWK^O2P$P#%@
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M>*C#N]KM,KQC!U]EMJ$C->8?\1#C[D5;/''(CH9.WZ 4 K@?<+F7I+^@K#Q
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M#:RK>6?%<J33AN5%F],UO+H0F+-7R+(-_2PI[Y?>9>0ESB?=Y;)FZ.KJCJ4
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ML\WX;+U=$JO2C1Z1C<B9@]E*DH0UG6.TL=S,(LT,4NDE$"*GU;3EP!*)TL+
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M9?J9$S>[<[289R,I/?4C4<2W$X3]@P\UU=ZB Y)-GX9E7B ?+6"5PBM):)P
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MY80BXA[:"Z[XU<#\)PK=1OVO3B$F/@];;ID#4$)G2*'_U=/$[=:+ERLSNSY
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M!,,DQ9@809?8W](RON3X/&2S22I^0=,EY*@/18Y V=?33IULR3V>J+1K*7P
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MT1$>0W&?8Q&'2R3L&,KWE&DA7*H(QU"WIPZ-?9N%.\3,?!-O(U! ENE8:M)
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M+"JQW?81(-8&<K&.89+K "2N\R04<"P1]3)7>2#AWHTR.2!PJQ4>2\" -+:
M4S^6IVLE^[1:(XSE_;3UEFQ2_&-I2M<:R":#<"S-Z=H=[*9;PECZTRE2X\U7
M0H.;U!'KA3GIXL#UEY?DTR6!0EWJJ2SYH;A&P/QKN:!O4$ &]9>LE/WM>F.Y
M :L-"ZQ/5D]'[BE]C^2CNUQ%\\7W, F#N2'T67]7\;=U07*:VDB14=$^2W2G
MX-B/'HFI"H&^F59O4\K5RG??23FB4M(FOSI;T[^UG:?  'K\7'6;2_X<'1&2
M.DC\-,X71R7P*53"9TB DA:XRT0I!.7R[_6S3@R%]&I*'U/O8UK 9[YXH.];
M!-7PVG/7KD__^0$1*X'^KPWT>RD9KH<U)?PQ;D,4;,DIER@M*49/9FIA$!6F
M1?YV."7RH]^_66_N.EZ+EY,L^:@[YEQ?@KG]CSIC[M'REX RG$>?=,N8:(7)
M@P^D!/=-@-;8CRXMSR7&H>]:P,:.E=]+<?,-^1Y^L((_I/FIH:!?Q-!ZY/#J
MJ)4D^ID M-YI!0'-E4UKE%*;TJ8"9/M4\3-B*FVEWT4 1'MWIL !**UG*K">
M_"7$[- ?F;.#&X\]1\]L%VF]V*S#Z;@:J=FAM4T:$C=K\K$4;A6%JM((&TNL
MK*3L.C"@]V75N7%HE5\P<,G]AC_)F+EOJNZ N/0:VF4(ZRF@L>\QX&B8+7Q5
MVD.5OB'^5&<VF"#/6Q6*LKY%#K+9\0Y*0,Y=U;S_HG(=4-81[81P$WVGZ+"#
MY8DC*/@4E0/XR4PSI"U\DL^5'%8S[9DN8-U_[<X1_,7L3$XIR2@:!<%!-#N>
M4XUP/(QWX>AI42[]AWD]Q>NU%>R(MK7"5=DOJ OY@@XUY/ OX;EH?[9(SX#T
M"T7Z_>^>^]X[U]5:.0U*O\'!'B^02533F );]&^?Z<'N!![LRA>NPYX,&^9!
M>(JL(!JD&=$*P.,K_I@>YZ#058OK+MI6#+-'EO+#FRGM#M,,DR-\[3M#M6.+
M'B1::8258FQ3@%#1:"=AS0I,1TN.,AV1\R)A3E51:!V&3;8]#NC N^L_8Y=E
M^4H%89?2F8+$!Y/:,AFH ]!Q@KX:PWMB2T$(?DT94WR4-(BE4GN4<5/0HURE
MD+NLWMAS5BT36BKS:,4)#L78%.!8>8(I>P>Y?B.,^DM$KI=[[W>0<F$M1Y$R
MYAB92[S>8)^LTC?+CQ=6_L:Q7KL1/3SB&9APFI)<'S_M7:=["537NYE0;QFQ
MUV]N2!BQ:1EW)I"><<(9Q'(#$NYMLFIG.)AIT2W$+"&PR2U"3>[VYML!>PE'
MR7]O_>N0*.37M%BJ^-VMB8Z>RF]0WBL^U)/6A.R86AH2[!Y]*K7VS\BW?&H4
M!7B+F!#V//Q**S0++WL=B1[NZGF8C&2?B69B>MXCZ>T(.>$-L7^)D81"<LR)
MU0G;(S5$I';+(W*2V]M\\119OO.RNT-11&,U$[*)!D_#,ZVE^!Z"$^YS9RG8
M3U-IB4/C-J2&(+5!8.9:/1$]0CQ^\1)]1RXDL/33@R\5P'@5!UD/[)N %B\$
M6.D"E/3'8L#$]]&GF@P]9D1OW 2Q*RM"9S#3KNQ[%8?J#E+]HH& %#]?G_XQ
M6Y+M0U<%F/%?]JF^PM-<XQ>NU.(S$*>E94H7ED<MLJ<50M$=99AN,W !@SHJ
MO4T#6L:@FD:;.AN9*)?=[$UDQEG.9="%<*9:,P=GX$[! 2BG(<75!:;EAF>^
M<X=]AUXM%BXY]AO+1ON# *2Z'%UY-RRU8NG_9]EOX:W_A#81(_K\BI]7. [)
M7>GYE8RU>W+?@-.0'T#.,.$P)0!^IUU*:20>&;C5SI&@K&-%R ^Z79'" )*W
M>3]YG6+0 7DM_[CMSDA.5+)^_R VJ(/7JK:&,&E=[AUB9T<[6ON!IHWD;[G/
M9$IPPTR(7+\3N]A17J#&FA Y.9WE;ED+[[#TU/UORX^M8'=\YFC/>JAF:S]2
MBW,U8W&2:<A >EC3^BL*CA:8NISD[6("&O@NB!^5H+?G5Z7?(WM]BBV/[FNX
M\*JCTMLTH(*JFH8*-XYP8;N:C_5!*151>/AE[[%&%5,I3X8=2TVYYLV)1<[$
M6/)3&B5+ UIC*R$GH% P6!6.)3@2 ![,]AE+>VOP[@-;OQQ),]6#!)(*;D>\
M<)F9^Q.D=(5NS*871)3Q1HA@6'2GF%X\4,955:*<A?UN8RD_*(-GN;>5E[^;
MM$EK%_I8"C:V/,ZB+RR\1)[9<':W-PL/;KRNVP2F["-LCN'G25B*/+GG>'T9
ML5%=6T?\HW&8P.N(GQF:^"Q7.?M,O7MN(/5@Y>JJGTT>MP-96QG?ET-FJ"T/
M\F%4AVCN2^!?C(-).-"U :U#)\791[.=% +QS8?MWVN#LCENDP2K"<?/83*T
MCK>0U&I(F\@Q^G4\&-W55^$NRW;A,)E9-!H,TU$J4X[09^4E]4X+(=%DM1RP
M+V9&&8"WU&&^80;0^;GR.JNG!9! *BG'RDQ+"KR9!%M\G'\8N;1JS 3/D?JH
MOMHQ:Z&T/1VP)*L!Y!!^&L_MN=YXJ*[\P+&:[%'1DA\Y9NH[F@S$P0<[H74U
M7SA6D^ OK]23(_1Y.H%EI9<X/F8Z7V!GK;&L5@[7%W7*;UC5ZB5<#,VUTCAL
M9C:/5 +:8=V\#+0/A@;N*P&MIIPBQV_D7B[!6IL<KY$;$_ RJARZD<LW%95T
M<S#/-8#91XWHO/]&NL?"Z#LYA<$!OFV*1DN-,*PJTK IZ"_P]T]$]S5R9N12
M:2WW6IOF/;.+,$%J_HG0[J&FX0%;CXB^719-/E A-CCM'J:</0S)3XQ3T)E?
M'<+S@9./C*KBJ(C=WZS I0_14MB6?#R:KCJ5Y4#>B+Z&@%GZV91DKS3)_A#>
M+AKS#<FF;89%[ APG)2;JT-Y4A*'JD3:\3Q<,]T8XN!4A02\/U-WX1Z6,U$<
MF[(-TT&DQ%&/H$&#4F5)<H0FT0R]1'#LS'35*,*N],[)\S8UB/)>/#/V"CFQ
MA^:+FS@B/TUS+2ZH&XLPP1U_H7*/C<J1!^;)43*U]I6]\FB#3)!>Q>A>K#4#
MA)J"&F1EM&<+<D1H\0Y:Q$,ASP=T.^*^ \;U\(QC0,5  ,D.>6;U6A0SG=+L
MDNM7K)IG2K%#CN>^:I09184<NRC<ETX0/X8<76W-WG!0;AT_XPNB5FQ$6YG#
MW#6B- <UQ><5"I!%97@7DRU2']2T\TI67<RZ0'Q8DR::H[M)<^*#FC33/)W-
MNDA]6--^Q=U-.J<]J"G?D_O'\RORMN@;]J-5)U,_'J-W"&[(=<GRZ()\LR(6
MO"KWVB WPM3;3[:[;,X#N;6FSA+D7+_9Y%?%.S:W'*#_R1?L0&7SW:,YJ"F"
M+^$M!QC4Y+N<]Y"G+.@"D*<]N"D+>Q!:$!_>I,4<$-*D!S7AMK:6W!@]&AO[
M+@L9"PM&=PI.Z?:YJ@E__K9N]C.?U&YOR*D0.\S\(=7LN Y=".>*8BRO^UJ!
M38P.#JV9*2Y]0)O8L&,)J]"*++L0\: +,PO'Z$;VX(JM-:9E!/ 6$56OOTXK
M?D_2J\<!5"=+3S4NM+&2SWOUE7P&=6[%=IF,ZY\C:+;D:_GX(HAT_2L3[RJ@
M;K<.]4CK1IL_9W*4U6F>">7CEW*.L_D*2C?.A3B,'.9?U GH">:C&!\.L_EI
M./JE!@\@RW'^==*!JG$NHMN5[GL^C<N77-PJA\],_U6K*.%Z5$NCF'D+*#,O
M%QKQW'\4^&SFHX!./ _> L93XKTK1 ^> #Y/(K0MH/NNZ2]FNK@T 5KE\!]/
MIX(N4+TO%IY__T6#J__T$H(?V"*M4.02D[^_[. Z-DQ*%2Z=IXXXK!L<('?I
M7[(2YO8NJVY(<^>? \L//08BJ#J:,$D%Z8(EI1QA>8%% H# MQ#9/RWQ]F<[
MG60">/8WQC9C.?O)[]??'T4XW/_]+AGZ>O$ 8HC]?I<,S3POW3)$UA\T%Q-A
ML/1[F5C&,(@*YX?\[?#LT%:6V>[>Z[97P^;Q-RIV_WZ3,>#.3S^>PCT[=-]D
M(/-*6^/I/%+:)GG_#.SWZ30/EDI)@9L$%T?&S#Y20F(?'^H?CHJ9+1_ J# S
M@0>,C[@'NV![S?=GXQ' Q[8QEK#2M19!U'M1OL<1<RO0O31S'#>9Q:V_P,&:
MC2UW\862'<I%5IAO'1;C%7J);GUB9,7TTGSKD[V"0E;3[8IU,GA 9!N"RJ2(
M4M1B$&?#7[]MD$^[]KR K.+2S[4POH_B)=ZR'E]7*+0#EXD!^24I)29U3:*2
M+VME=V/9S &840]3S\RE%:Y8/S*Q8CMR=/5<KDJXVMO><HL#(JMEHH]HDWIQ
MYXN[_7:%XM.J(=+;:B6BQ[53)W6&<MO5JB2K[% ]Y-TUYXL;EVB+=*A6)ZJ:
M:&\+=!.@/V-J)\T7,GT5A$DJ6YC9FOR3^Q=3VTF/I!8+<DQ,&9_9GLPC@]KR
M6DZP!]5X885N^$0L.,N9^UEQ\<>DB[VLAJRCV=O9R!0@1;KUJ3@@ILD6VY(-
MPW;+S'>H_H:98L=?][86>=WH"QP$^)7\X=+:D'^#52R"4M8RW9I>Q>(SJR'2
MVYI]L][82Z'J%:NFVZ-52BZ5R542*@B%R/4@YH^=+&"I?B?Z!%FA5ZFLO,.6
M_PVM7\2*:99^IF=78'])%/2:(O!,.!1_Z&NBT O[HL]_]=_WL&T?D8/6[.Z6
M7!)89*'X!I(@.H1)OF+E4^0D!S!!^&D2HS> J4%/F@@UN5L,]AWLLVO&B^7_
M,5\LR'W#H4;XC8=Q !3"@M2T-HMCSAWP3BK[6CO;T%UR_&UG$2.I.2:^/TH^
MZHZYQ'<)9&[_H\Z8>Z0/4S#6]C[IEC%(!%#A SE+;X6>5V[@T!<Z>X5D#;]Z
M*K*</2&;"+/6K-62D>7MQ@W"J#5K=51Z4)'WUEI"3E?3Z&$*[;1Z;]:S<-Q=
M[>?:&.=/O#(1>%44>H_$:Y@:;H#?])@\D:U;B=$XXO,$A%(E0D7):7JTGK#^
MP6+*TO0X/AF\:NT>'H3U<0),P(;E>(WI0)9&7!?N'/OB_-PX5,KO9+CD2LAK
M?IHI@*JNS;CTYLZK]ID90-R$QKZ3A:,Q)EE;:1<>N\CVQ<A'8P&J="Q6H'-D
M#7XP4[@(^(LQS+W-ZSF:*8!:7<7*WR[V#^$O(X&L]E5(&,&C@_K+F*S$AD=#
M810+3Y\<2+,E7D= %I_)>36O2116!DSL"[_/QH)4&VY2@]*1@/MLMBG;$%6$
M*R*>.#QCDO^"9L==2?+DES')I+NZ],D[D7!$TZM@*<*M.E#5]()7$@#61#!G
M:-%KU(265"0[AW!,&J$6PK+\AAPF0[/I%>VT@V06CMJTN<#I33EXAO?L$P /
MF/O&D3.S_JX*Y(XS'#EJ9M;8523B2K-8.79FEM-5L>.JDYQS] SOFM=RYU4F
MMW/\1J\ILE^MJ7G T1J]=JB_VU<4ON#XC5Y/R)5(R0%4V"KH1 $L_]72LC@<
MM=%O.WY1+:F)E./TZW13+?W5ZCI8'#H-U]7^"K\]Q>NU%1#[M?C#]H7?1,@.
ML?!;+=^Z4JR?T[><>^PGI2YAI9 J*$@E#\UL.T!T&1Z1E[22DJISU$1&-A4U
MG^@%6N  Y</<AF%L^3:ZQ&$4WB,@DFVH=SV3R^ZF<:EK#ETPK[$" N6(B8>9
M[]#W5+G"WO6$>M>H8A/%,@O%PQ<,;S/>%83Y0>5(&M_.M2LLB[);:ZW?DP&S
M27?S9 *S'7;"J#498APPXWHOE9K224>@!W*YLMU-OG%H*RJ%]PSA009]ZVB>
MA<EW$$7L?_>MY#T+.>RRGTK\U#$"F483)2E#N4#T@?X7^Y+%8YL):36)*4*
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M/9!_61-L@'V!Q G*'4#L)TN6'9Y$[ *9;*"B?1O VQ:5?:W))B!*@;G0"QQ
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MF*(43WP'$;6]0&Y$(_V'M(E*V#IQH']CZFE8*!_R-&R(2^7+/Q'57\2JVJ+
M6B(YO=(;:WJ5;F:G)OOBP;/\S-%!3$Y$TWWRCCO7OG@U>FW\:*]JS]Q$Z=I>
MOZ' =D/8S4" V$F<N8S??&^SZ\NM'P6N'[JV]H,FQL^P+T_$@G #]LN2*D'-
MH,/>?\6;2L(QR.>A=MQA0Y6%"!RHG>+3>)X)H<?^ '(T;'CW'0NSK>5Z--"8
M&*I,L6L!M)&'84-X_.#2)5AWHM6CNX6%LD)?Q>T5FON DF)29+5,-!6+\&J4
M!Q_J9!9:J6_OL\Z*N5VN7+0@MHP=1\3:G2\61# ""MPVDIA*W)Y\B=MG=YV<
M_D>R(XGBS!Q2WWTW@E:&%Z(EQ>6=^[)&GK,#,G3XV52VM(L)#ZEL*?PZC@+V
MF.ZG[VH2JU))8AC64EA[!Z'8DZU$G2-R):"[&5_/2<T9 &[8@P_E!.\K?E[A
M.+1\A\S_^96@LB,2/4[B\[C+"BJ#@605\'[-;E\H+_BQETC:>@K"U!7.A(V1
MN(+(3V_)P?:I]:-L+@+T]0@_Z5/?RWG-!H4>U_WO=%<IEI:/;6H:MQU44R.M
M+.*-18OF?#*+G+(>1N&1FQ%4.%G52+W'E2J"JKR8<MO-,L+2RXH.-:X24J;7
M:ZX5Z26H')4],;1Z<X-FQFW-"M/K/;?"K]'$'$M]:!!ZS7<,#MND'Z3UP\&=
M<RS%M\OOZ+AK_\-HRD9WZ3W" CXR#K39"JE3V2!4H-_<FMT:"O0;GK;>MG;<
MX4/+:(K\=BP^Q9_5<L0_FFV:=B)'IS+I799)_VAF'>&69=(;@RLX?F;KGDXM
MH[TXF[$44B^+23K&Y.B<?C+SG-:'E37?),LCX498VEO]Z501>\D78N2FIGA4
MK(H5: P5YNMB=C'?@:T+,":>%T>?3H_&52I-_QA-6?7NUD)-RA)?",/?*X9U
M*$"Y=WR-S"[LW<T:">2-\LKI9E=L4PNPWH1EOD9F5QX?IJ "9^/S0O&37M&X
M7. R%7R=IJO+D-:II&@+[RB@/$YN8-58NUDLT2I$'.?)W!K2D3@LAM5AHPB#
MUTE]W;<.6TX8O Y*_2J'+:!,;V@Q,+=*4^%,WN5@NKO EZ7#DK!\8295/Z"%
MJ:B"S%=KNJL,:+4XI:IJX;R/A ;_VB!*_(=AO$YF_SVD=[@+S[+_>+)7Y.,P
M@86^4M$^L]A!GM+B_ZV&'GA; +FY#:(T0=69S0WIPN3H592&/F8]41]9^Y\B
MX!W5>1)G9ACU'F3F\1NF(6L>D3YT)M^L-W<=KWM'MX(K8V!V_2'"G'$U[.J6
M=1-Z1L$:7L:Q(RY.;[<^NN$?-P%"MSXQ)(CA,P214,N3(1#W+ YJ>1HVQ,<V
M_H +/PK5ATOW-JQ6W\%'W3&7[ H@<_L?=<;<(UT^&&M[GW3+&*3,7^&#J6:-
MP*!3S9JI9LU4LT97OEQ!.IE>K*9<>N,2Y6%Z>9HJ!8M+=;SIQ6::T-@WQ\92
M/.9T,H9,+T<SK+=Y\)V3KY.9:N74URESO_!UFAZ,-098"/@>>1F.*8:_YQ/4
MX&S/5^K#).N&N5)'TN[#).T&LE+[K["\;L9( BN>XO7:"G;S15KZTXX('M%.
M90"%V!###I1HF,.@7SOWT_/HY6@_'U+/:Z< %\-^)THG,(^C,+)\Q_67_;68
MK&%BV"_OQ[O@(/7M$=$**V1>E]AGKMS8\O0]R;=A[R2 3[+5:-GBS-C']$>%
M_33$]5#)]4DL$WQFYSK70XJ]DY#NU2<_RVYGQ5!TRGIAEDX"X.JMTQO @BS]
M[KGOO<'LXTKO]WZZ*S%HJY+,N\-;.6^G ?E1[9'!  [D[#3@KJV@T!_6$+:&
M ;2Q$OM$ "XH^"3/L2?K(AO\)$ K; ']H!T-/BS; *Y^=8)7.KP>X&BQJMLP
MC)%S%0=Y]3S&;5A1R0J BP3UD]@O^QKM:X!#/:'2=<.?!'##DE%3C.L(8ES5
M;QH>AZ?\16R3",C("J*A/%P.;TE*Q1^/FC$[-J.#Y9#0TEU$PGQ)T/;1DD[$
M8+R[L!9Y&,6T(+VKB.SNTV'H1*(HKOUI62#W>%Y$?U(2O9V1>O\4KZ _&5>=
M+)1*;RVO&CZ=)\W+!'S &$OY\0&N%/AMC]=+GM9JD%KJT+X[Z\H1,-EW*J)
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MV'.=Q";SG8="2,)\<>/ZED\?;'))(A4PK&C W@-[U )7&CZL;BN-+W98N1#
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MW X9B>6G/#-LJO:L6-#4YAYRM*=JYNWJX0BDI4Y5A[L#NS3!F0.NP5@<:*F
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ME&)V%:*K 720]U9%2A[T@!X$0CP6P]&'_ GX)F1]+A,&TWP-^@$S24@/;IN
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MWWVAE#G>4VD<1TF.UMS32,K'"X7 _N@XLN2../ONB9BRQ(N 80,Y6G6<50-
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M0]*]XF&*CY^0,W^NL<:;KTY7-_V[E?OMJJ[M$&7_7^H@R/Z/U?\!4$L#!!0
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M/!+&(V$\.,*H/S#"X-+.2'(6P'K*$"ZQ6N!%55*Q">$:Z235++/$4;/=1 C
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M;[[YN'K5VZ3/^Q5^]"BH?#/<]LLWT/\"4$L#!!0    ( "A!?E2K3=SY&@4
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M,2YJ<&=02P$"% ,4    "  H07Y4J1&]#K^< 0#9O0$ %@
M@ ''[04 9V5A:G5O=G=K-61O,# P,# R+FIP9U!+ 0(4 Q0    ( "A!?E2*
M"7E03H(% "U81  5              "  ;J*!P!O<G1X+3$P:U\R,#(Q,3(S
M,2YH=&U02P$"% ,4    "  H07Y4)0]>!&XA  #,I0$ $0
M@ $[#0T ;W)T>"TR,#(Q,3(S,2YX<V102P$"% ,4    "  H07Y4)K0YZ;4:
M  "DR $ %0              @ '8+@T ;W)T>"TR,#(Q,3(S,5]C86PN>&UL
M4$L! A0#%     @ *$%^5/ID55U20P  G[0$ !4              ( !P$D-
M &]R='@M,C R,3$R,S%?9&5F+GAM;%!+ 0(4 Q0    ( "A!?E0,SRC%U+X
M (>'"P 5              "  46-#0!O<G1X+3(P,C$Q,C,Q7VQA8BYX;6Q0
M2P$"% ,4    "  H07Y40D*%7IAU  #Z"0D %0              @ %,3 X
M;W)T>"TR,#(Q,3(S,5]P<F4N>&UL4$L! A0#%     @ *$%^5)*[B/OH&0
M(/4  !,              ( !%\(. &]R='@M97@Q,#$Y7S4V,BYH=&U02P$"
M% ,4    "  H07Y4Q SV3HP#  #0*@  $               @ $PW X ;W)T
M>"UE>#(Q,5\W+FAT;5!+ 0(4 Q0    ( "A!?E188[8" @,  "X*   0
M          "  >K?#@!O<G1X+65X,C,Q7S8N:'1M4$L! A0#%     @ *$%^
M5..\ 3D@"0  .$L  !               ( !&N,. &]R='@M97@S,3%?."YH
M=&U02P$"% ,4    "  H07Y4X)KVE?L(  #920  $0              @ %H
M[ X ;W)T>"UE>#,Q,E\Q,"YH=&U02P$"% ,4    "  H07Y42W,)B@,%  #R
M'@  $               @ &2]0X ;W)T>"UE>#,R,5\Y+FAT;5!+ 0(4 Q0
M   ( "A!?E2K3=SY&@4  +L?   1              "  </Z#@!O<G1X+65X
@,S(R7S$Q+FAT;5!+!08     #P / ,T#   ,  \    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
